PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	FAFOURNOUX, P; NOEL, J; POUYSSEGUR, J				FAFOURNOUX, P; NOEL, J; POUYSSEGUR, J			EVIDENCE THAT NA+/H+ EXCHANGER ISOFORMS NHE1 AND NHE3 EXIST AS STABLE DIMERS IN MEMBRANES WITH A HIGH-DEGREE OF SPECIFICITY FOR HOMODIMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; MOLECULAR-CLONING; FUNCTIONAL EXPRESSION; GLUCOSE TRANSPORTERS; CYTOPLASMIC DOMAIN; LIGAND-BINDING; ANTIPORTER; PROTEIN; BAND-3; SITES	In this study, we have investigated whether members of the Na+/H+ exchanger (NHE) family are oligomers and whether such oligomeric structure is required for function. Fibroblasts overexpressing NHE1 were treated briefly at 0-degrees-C with the cross-linker disuccinimidyl suberate, then membranes were prepared and proteins analyzed by SDS-polyacrylamide gel electrophoresis. Disuccinimidyl suberate treatment converted quantitatively the immunoreactive monomeric form of NHE1 (110 kDa) to a putative dimeric form (210 kDa). Utilization of NHE1 mutant deleted of the cytoplasmic domain (DELTA515TH) demonstrates that the transmembrane domain of the antiporter is sufficient for dimerization. Moreover, coimmunoprecipitation of NHE1 and DELTA515TH, coexpressed in the same cell, formally proved the existence of dimers. This dimerization was also shown to take place with the epithelial and apically expressed NHE3 isoform, suggesting that oligomerization is a common feature of these transporters. However, coexpression of NHE1 and NHE3 in the same cells did not lead to the formation of heterodimers demonstrating an isoform specificity for the subunit interaction. The domain(s) involved in the isoform-specific dimerization is (are) likely to be confined within the transmembrane segments, as deletion of the 300 amino acids of the cytoplasmic domain did not disrupt dimerization. Exploiting the dimeric properties of the receptor tyrosine kinases and the fact that dimerization triggers kinase activity, we constructed a NHE1/insulin receptor chimera to probe NHE1 dimerization in vivo. When transfected into hamster fibroblasts, this chimera containing the N-terminal transmembrane domain of NHE1 and the cytoplasmic beta-subunit domain of the insulin receptor generates a functional transporter that is autophosphorylated on tyrosine and that presents properties of a constitutively active insulin receptor. These findings support the notion that NHE1 exists in an oligomeric state in intact cells. Finally, to test whether individual subunits of NHE1 are the minimum functional unit for Na+/H+ exchange, we coexpressed a truncated form of NHE1 (DELTA515) together with an inactive mutant of NHE1 (E2621). In spite of good expression of the inactive transporter and its capacity to dimerize with active NHE1, no dominant negative effect was observed on amiloride-sensitive Na-22+ flux. This observation would suggest that individual subunits of NHE1 function independently within the oligomeric state.			FAFOURNOUX, P (corresponding author), UNIV NICE,CNRS,CTR BIOCHIM,PARC VALROSE,F-06108 NICE 2,FRANCE.							ARONSON PS, 1986, NA H EXCHANGE INTRAC; Battey, 1986, BASIC METHODS MOL BI; BELIVEAU R, 1988, BIOCHEM BIOPH RES CO, V152, P484, DOI 10.1016/S0006-291X(88)80739-3; BURANT CF, 1992, BIOCHEMISTRY-US, V31, P10414, DOI 10.1021/bi00157a032; CASEY JR, 1991, J BIOL CHEM, V266, P15726; COUNILLON L, 1993, IN PRESS MOL PHARM; CUPPOLETTI J, 1985, J BIOL CHEM, V260, P5714; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FAFOURNOUX P, 1991, BIOCHEMISTRY-US, V30, P9510, DOI 10.1021/bi00103a018; FLIEGEL L, 1993, BIOCHEM J, V289, P101, DOI 10.1042/bj2890101; FRANCHI A, 1986, P NATL ACAD SCI USA, V83, P9388, DOI 10.1073/pnas.83.24.9388; FRANCHI A, 1986, J BIOL CHEM, V261, P4614; GEIBEL J, 1989, AM J PHYSIOL, V257, pF790, DOI 10.1152/ajprenal.1989.257.5.F790; GRINSTEIN S, 1988, NA PLUS H PLUS EXCHA; HAGGERTY JG, 1988, P NATL ACAD SCI USA, V85, P6797, DOI 10.1073/pnas.85.18.6797; JENNINGS ML, 1992, J BIOL CHEM, V267, P13964; KLINGENBERG M, 1981, NATURE, V290, P449, DOI 10.1038/290449a0; KOEPSELL H, 1986, REV PHYSIOL BIOCH P, V104, P65, DOI 10.1007/BFb0031013; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAHUE RS, 1986, J BIOL CHEM, V261, P3079; LALLEMAIN G, 1986, FEBS LETT, V197, P344, DOI 10.1016/0014-5793(86)80354-4; LEMAIRE M, 1976, BIOCHEMISTRY-US, V15, P2336, DOI 10.1021/bi00656a014; MACARA IG, 1981, BIOCHEMISTRY-US, V20, P5095, DOI 10.1021/bi00521a001; MCKENZIE FR, 1992, SIGNAL TRANSDUCTION; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; OTSU K, 1993, J BIOL CHEM, V268, P3184; OTSU K, 1989, P NATL ACAD SCI USA, V86, P4818, DOI 10.1073/pnas.86.13.4818; PESSINO A, 1991, J BIOL CHEM, V266, P20213; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; RIEDEL H, 1989, EMBO J, V8, P2943, DOI 10.1002/j.1460-2075.1989.tb08444.x; SARDET C, 1976, J MOL BIOL, V105, P383, DOI 10.1016/0022-2836(76)90100-5; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TSE CM, 1991, EMBO J, V10, P1957, DOI 10.1002/j.1460-2075.1991.tb07725.x; TSE CM, 1992, J BIOL CHEM, V267, P9340; TSE MT, 1993, J BIOL CHEM, V268, P11917; WAKABAYASHI S, 1992, REV PHYSIOL BIOCH P, V119, P157; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; WANG Z, 1993, J BIOL CHEM, V268, P11925; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZULAUF M, 1991, CRYSTALLIZATION MEMB	45	159	162	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2589	2596						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300588				2022-12-27	WOS:A1994MV43200038
J	GEROLD, P; DIECKMANNSCHUPPERT, A; SCHWARZ, RT				GEROLD, P; DIECKMANNSCHUPPERT, A; SCHWARZ, RT			GLYCOSYLPHOSPHATIDYLINOSITOLS SYNTHESIZED BY ASEXUAL ERYTHROCYTIC STAGES OF THE MALARIAL PARASITE, PLASMODIUM-FALCIPARUM - CANDIDATES FOR PLASMODIAL GLYCOSYLPHOSPHATIDYLINOSITOL MEMBRANE ANCHOR PRECURSORS AND PATHOGENICITY FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEINS; TRYPANOSOMA-BRUCEI; PHOSPHOLIPASE-C; DEVELOPMENTAL VARIATION; GLYCOLIPID PRECURSORS; MAMMALIAN-CELLS; BIOSYNTHESIS; IDENTIFICATION; MEROZOITES; ACYLATION	Plasmodium falciparum is the causative agent of malaria tropica in man. Biochemical studies were focused on the asexual, intraerythrocytic stages of P. falciparum, because of their role in the clinical phase of the disease and the possibility of propagation in a cell culture system. In this report, we describe the in-culture labeling of malarial glycolipids and the analysis of their hydrophilic moieties. They were identified as glycosylphosphatidylinositols (GPIs) by: 1) labeling with [H-3]mannose, [H-3]glucosamine, and [H-3]ethanolamine and 2) sensitivity toward glycosylphosphatidylinositol-specific phospholipase D, phospholipase A2, and nitrous acid. Malarial GPIs are shown to be unaffected by treatment with phosphatidylinositol-specific phospholipase C, regardless of prior treatment with mild base commonly used for inositol deacylation. Two candidates for putative GPI-anchor precursors to malarial membrane proteins with the structures ethanolamine-phosphate-6(Manalpha1-2)Manalpha1-2Manalpha1-6Manalpha1-4GlcN-PI (Pf(gl) alpha) and ethanolamine-phosphate-6Manalpha1-2Manalpha1-6Manalpha1-4-GlcN-PI (Pf(gl); beta) were identified.			GEROLD, P (corresponding author), PHILIPPS UNIV,ZENTRUM HYG & MED MIKROBIOL,ROBERT KOCH STR 17,D-35037 MARBURG,GERMANY.							BRAUNBRETON C, 1988, NATURE, V332, P457, DOI 10.1038/332457a0; CLAYTON CE, 1989, J BIOL CHEM, V264, P15088; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DAVITZ MA, 1987, SCIENCE, V238, P81, DOI 10.1126/science.2443973; DIECKMANNSCHUPPERT A, 1992, EUR J BIOCHEM, V205, P815, DOI 10.1111/j.1432-1033.1992.tb16846.x; DIECKMANNSCHUPPERT A, 1992, PARASITOL RES, V78, P416, DOI 10.1007/BF00931698; DOERING TL, 1990, J BIOL CHEM, V265, P611; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; Ferguson MAJ, 1991, CURR OPIN STRUC BIOL, V1, P522, DOI 10.1016/S0959-440X(05)80072-7; FIELD MC, 1991, J BIOL CHEM, V266, P8392; FIELD MC, 1992, J BIOL CHEM, V267, P5324; GEROLD P, 1992, Biochemical Society Transactions, V20, p297S; Gerold P., 1992, Biological Chemistry Hoppe-Seyler, V373, P844; GOMAN M, 1982, MOL BIOCHEM PARASIT, V5, P391, DOI 10.1016/0166-6851(82)90012-3; HALDAR K, 1985, J BIOL CHEM, V260, P4969; HALDAR K, 1986, P NATL ACAD SCI USA, V83, P8565, DOI 10.1073/pnas.83.22.8565; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HOLDER AA, 1985, NATURE, V317, P270, DOI 10.1038/317270a0; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; KRAKOW JL, 1989, MOL BIOCHEM PARASIT, V36, P263, DOI 10.1016/0166-6851(89)90174-6; KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; LOCKYER MJ, 1989, VACCINATION STRATEGI, P124; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MAYOR S, 1990, Methods (Orlando), V1, P297, DOI 10.1016/S1046-2023(05)80331-7; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MCDOWELL W, 1988, POSTTRANSLATIONAL MO; MENON AK, 1993, EMBO J, V12, P1907, DOI 10.1002/j.1460-2075.1993.tb05839.x; MENON AK, 1988, J BIOL CHEM, V263, P1970; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; PLAYFAIR JHL, 1990, IMMUNOL TODAY, V11, P25; PUOTI A, 1991, J BIOL CHEM, V266, P21051; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROSENFELD L, 1974, CARBOHYD RES, V32, P287, DOI 10.1016/S0008-6215(00)82106-0; SCHOFIELD L, 1993, J EXP MED, V177, P145, DOI 10.1084/jem.177.1.145; SCHWARZ RT, 1993, RES IMMUNOL, V144, P24, DOI 10.1016/S0923-2494(05)80092-6; SCHWARZ RT, 1986, MOL CELL BIOL, V6, P964, DOI 10.1128/MCB.6.3.964; SCHWARZ RT, 1989, BIOCHEM SOC T, V7, pS746; SCHWARZ RT, 1987, HOST PARASITIC CELLU, P275; SHARMA CB, 1974, EUR J BIOCHEM, V46, P35, DOI 10.1111/j.1432-1033.1974.tb03594.x; SMYTHE JA, 1988, P NATL ACAD SCI USA, V85, P5195, DOI 10.1073/pnas.85.14.5195; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; TOMAVO S, 1992, J BIOL CHEM, V267, P21446; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; URAKAZE M, 1992, J BIOL CHEM, V267, P6459; WALTER EI, 1990, J IMMUNOL, V144, P1030; YAMASHITA K, 1982, METHOD ENZYMOL, V83, P105	49	142	144	0	92	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2597	2606						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300589				2022-12-27	WOS:A1994MV43200039
J	LEE, SW; ELLIS, V; DICHEK, DA				LEE, SW; ELLIS, V; DICHEK, DA			CHARACTERIZATION OF PLASMINOGEN ACTIVATION BY GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED UROKINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN UROKINASE; RECEPTOR-BOUND UROKINASE; HUMAN-ENDOTHELIAL-CELLS; PRO-UROKINASE; GLYCOSYL-PHOSPHATIDYLINOSITOL; ENZYMATIC-ACTIVITY; MEMBRANE; BINDING; MONOCYTES; KINETICS	The characteristics of plasminogen activation by glycosylphosphatidylinositol (GPI)-anchored urokinase were evaluated and compared with those reported previously for receptor-bound urokinase. When expressed in cultured bovine aortic endothelial cells, GPI anchoring of single-chain urokinase plasminogen activator (scu-PA) potentiated plasmin generation as compared with GPI-anchored scu-PA that had been released into solution from the cell surface by enzymatic cleavage of the GPI anchor (''released'' scu-PA). The potentiation of plasmin generation by GPI-anchored scu-PA was inhibited in a dose-dependent manner by 6-aminohexanoic acid, a lysine analog, suggesting that the augmentation of plasmin generation by GPI-anchored scu-PA was dependent on simultaneous binding of plasminogen to the cell surface. GPI-anchored two-chain urokinase (tcu)-PA cleaved a peptide substrate at a rate equivalent to that of released urokinase. However, at a plasminogen concentration of 0.5 muM, GPI-anchored tcu-PA activated plasminogen less rapidly than did released urokinase. Modeling of kinetics of individual reactions revealed that cell-associated plasminogen activation by GPI-anchored tcu-PA was characterized by a K(m) of approximately 0.15 muM. This value of K(m) was 70-fold below that for activation of solution plasminogen by GPI-anchored urokinase. There was a concomitant decrease in V(max) for plasminogen activation by anchored tcu-PA. These alterations in kinetic parameters are similar to those reported previously for the activation of plasminogen by receptor-bound tcu-PA. In addition, GPI-anchored tcu-PA exhibited a modest resistance to plasminogen activator inhibitor 1 inactivation. The enzymatic characteristics of GPI-anchored urokinase reported here resemble closely those reported previously for receptor-bound urokinase. These data suggest that the urokinase receptor may regulate plasmin generation through a relatively nonspecific localization of urokinase to the cell Surface rather than through any intrinsic property of the urokinase receptor.	NHLBI, MOLEC HEMATOL BRANCH, BLDG 10, RM 7D-18, BETHESDA, MD 20892 USA; RIGSHOSP, FINSEN LAB, DK-2100 COPENHAGEN, DENMARK	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Rigshospitalet; University of Copenhagen			Ellis, Vincent/D-1860-2009	Ellis, Vincent/0000-0003-1956-073X; Dichek, David/0000-0002-5224-2736				BARNATHAN ES, 1990, J BIOL CHEM, V265, P2865; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; DICHEK DA, 1993, THROMB HAEMOSTASIS, V70, P198; ELLIS V, 1991, J BIOL CHEM, V266, P12752; ELLIS V, 1993, J BIOL CHEM, V268, P4806; ELLIS V, 1987, J BIOL CHEM, V262, P14998; ELLIS V, 1990, J BIOL CHEM, V265, P9904; ELLIS V, 1989, J BIOL CHEM, V264, P2185; ELLIS V, 1993, METHOD ENZYMOL, V223, P223; FERSHT A, 1985, ENZYME STRUCTURE MEC, P98; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KIRCHHEIMER JC, 1989, BLOOD, V74, P1396; LEE SW, 1992, J BIOL CHEM, V267, P13020; LISANTI MP, 1990, J MEMBRANE BIOL, V117, P1, DOI 10.1007/BF01871561; LONGSTAFF C, 1992, J BIOL CHEM, V267, P173; MANCHANDA N, 1991, J BIOL CHEM, V266, P14580; MILES LA, 1985, J BIOL CHEM, V260, P4303; NACHMAN RL, 1991, ANN NY ACAD SCI, V614, P240, DOI 10.1111/j.1749-6632.1991.tb43706.x; OSWALD RE, 1989, NATURE, V337, P579, DOI 10.1038/337579a0; PANNELL R, 1987, BLOOD, V69, P22; PETERSEN LC, 1985, BIOCHEM J, V225, P149, DOI 10.1042/bj2250149; PLOUG M, 1991, J BIOL CHEM, V266, P1926; PLOW EF, 1991, THROMB HAEMOSTASIS, V66, P32; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; SCULLY MF, 1989, ARCH BIOCHEM BIOPHYS, V268, P438, DOI 10.1016/0003-9861(89)90311-1; SOBERANO ME, 1976, BIOCHIM BIOPHYS ACTA, V445, P763, DOI 10.1016/0005-2744(76)90126-1; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; THORSEN S, 1974, SCAND J CLIN LAB INV, V34, P167, DOI 10.3109/00365517409050831; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86	31	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2411	2418						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300567				2022-12-27	WOS:A1994MV43200014
J	LUO, MJ; SMELAND, TE; SHOUKRY, K; SCHULZ, H				LUO, MJ; SMELAND, TE; SHOUKRY, K; SCHULZ, H			DELTA(3,5),DELTA(2,4)-DIENOYL-COA ISOMERASE FROM RAT-LIVER MITOCHONDRIA - PURIFICATION AND CHARACTERIZATION OF A NEW ENZYME INVOLVED IN THE BETA-OXIDATION OF UNSATURATED FATTY-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-HYDROXYACYL-COA DEHYDROGENASE; REVISED PATHWAY; HYDRATASE; PROTEIN	Mitochondrial DELTA3,5,DELTA2,4-dienoyl-CoA isomerase, which catalyzes the conversion of 3,5-octadienoyl-CoA to 2,4-octadienoyl-CoA, was purified from rat liver 370-fold at almost 30% yield by a six-step purification procedure. The final preparation appeared to be homogeneous as judged by gel electrophoresis. The molecular weights of the native enzyme and its subunit(s) were estimated to be 126,000 and 32,000, respectively. The purification of DELTA3,5,DELTA2,4-dienoyl-CoA isomerase completes the characterization of the enzymes functioning in the NADPH-dependent pathway for the beta-oxidation of unsaturated fatty acids with double bonds extending from odd-numbered carbon atoms. This novel pathway may not be operative in peroxisomes because DELTA3,5,DELTA2,4-dienoyl-CoA isomerase was only detected in mitochondria. Substrates of this pathway are 2,5-dienoyl-CoAs formed from 5-enoyl-CoAs by acyl-CoA dehydrogenase. Two sequential isomerization reactions catalyzed by DELTA3,DELTA2-enoyl-CoAs isomerase and DELTA3,5,DELTA2,4-dienoyl-CoA isomerase, respectively, convert 2,5-dienoyl-CoAs to 2,4-dienoyl-CoAs, which are reduced by NADPH-dependent 2,4-dienoyl-CoA reductase (EC 1.3.1.34) before reentering the beta-oxidation spiral.	CUNY CITY COLL, DEPT CHEM, NEW YORK, NY 10031 USA	City University of New York (CUNY) System; City College of New York (CUNY)					NCRR NIH HHS [RR 03060] Funding Source: Medline; NHLBI NIH HHS [HL 18089, HL 30847] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL018089, R01HL030847] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APPELMANS F, 1955, BIOCHEM J, V59, P438, DOI 10.1042/bj0590438; BAUDHUIN P, 1964, BIOCHEM J, V92, P179, DOI 10.1042/bj0920179; Binstock J F, 1981, Methods Enzymol, V71 Pt C, P403; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DUPLESSIS LM, 1980, LIPIDS, V14, P943; Fong J C, 1981, Methods Enzymol, V71 Pt C, P390; HAMES BD., 1981, GEL ELECTROPHORESIS, P1; HASHIMOTO T, 1990, PROG CLIN BIOL RES, V321, P137; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NADA MA, 1992, ANAL BIOCHEM, V201, P62, DOI 10.1016/0003-2697(92)90174-6; OCHOA S, 1955, METHOD ENZYMOL, V1, P735, DOI 10.1016/0076-6879(55)01128-2; OSMUNDSEN H, 1991, BIOCHIM BIOPHYS ACTA, V1085, P141, DOI 10.1016/0005-2760(91)90089-Z; OSUMI T, 1979, BIOCHEM BIOPH RES CO, V89, P580, DOI 10.1016/0006-291X(79)90669-7; PALOSAARI PM, 1990, J BIOL CHEM, V265, P2446; SCHULZ H, 1991, BIOCHIM BIOPHYS ACTA, V1081, P109, DOI 10.1016/0005-2760(91)90015-A; Schulz H, 1981, Methods Enzymol, V71 Pt C, P398; SCHULZ H, 1987, TRENDS BIOCHEM SCI, V12, P403, DOI 10.1016/0968-0004(87)90196-4; SMELAND TE, 1992, P NATL ACAD SCI USA, V89, P6674; TEINMAN H, 1965, METHOD ENZYMOL, V35, P136; THOMASON SC, 1968, J CHEM EDUC, V45, P546, DOI 10.1021/ed045p546; TSERNG KY, 1991, J BIOL CHEM, V266, P11614; YANG SY, 1986, J BIOL CHEM, V261, P5390	22	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2384	2388						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300563				2022-12-27	WOS:A1994MV43200010
J	CHANG, ZY; CHOUDHARY, A; LATHIGRA, R; QUIOCHO, FA				CHANG, ZY; CHOUDHARY, A; LATHIGRA, R; QUIOCHO, FA			THE IMMUNODOMINANT 38-KDA LIPOPROTEIN ANTIGEN OF MYCOBACTERIUM-TUBERCULOSIS IS A PHOSPHATE-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; STRUCTURAL GENE; PHOS-GENE; TRANSPORT	Several antigens of Mycobacterium tuberculosis have been identified by monoclonal antibodies and are being exploited in the development of improved vaccines and diagnostic reagents, but none has been linked to a specific function. Herein we report that the 38-kDa extra cellular lipoprotein antigen, the most potent immunogen of the mycobacteria, is a phosphate-binding protein with features very similar to those of the well characterized periplasmic phosphate-binding protein of Escherichia coli which serves as an initial receptor for active transport. This is also the first report definitely linking a function of a binding protein anchored to a membrane nd found in other that Gram-negative bacteria.	BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT BIOCHEM & MOLEC PHYSIOL,HOUSTON,TX 77030; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,MRC,TB UNIT,LONDON W12 0HS,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,MRC,RELATED INFECT UNIT,LONDON W12 0HS,ENGLAND	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Imperial College London; Imperial College London								ABOUYA YL, 1992, AM REV RESPIR DIS, V145, P617, DOI 10.1164/ajrccm/145.3.617; ANDERSEN AB, 1990, J GEN MICROBIOL, V136, P477, DOI 10.1099/00221287-136-3-477; ANDERSEN AB, 1989, INFECT IMMUN, V57, P2481, DOI 10.1128/IAI.57.8.2481-2488.1989; ANDERSEN AB, 1988, INFECT IMMUN, V56, P1344, DOI 10.1128/IAI.56.5.1344-1351.1988; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BARINAGA M, 1993, SCIENCE, V260, P750, DOI 10.1126/science.8484114; COATES ARM, 1981, LANCET, V2, P167; FURLONG CE, 1987, ESCHERICHIA COLI SAL, P768; HARBOE M, 1992, J INFECT DIS, V166, P874, DOI 10.1093/infdis/166.4.874; HASLOV K, 1990, SCAND J IMMUNOL, V31, P503, DOI 10.1111/j.1365-3083.1990.tb02798.x; JACOBS WR, 1993, SCIENCE, V260, P819, DOI 10.1126/science.8484123; JACOBSON BL, 1988, J MOL BIOL, V204, P783, DOI 10.1016/0022-2836(88)90369-5; KADIVAL GV, 1987, J IMMUNOL, V139, P2447; KUBENA BD, 1986, J BIOL CHEM, V261, P7995; LEUCKE H, 1990, NATURE, V347, P402; MAGOTA K, 1984, J BACTERIOL, V157, P909, DOI 10.1128/JB.157.3.909-917.1984; MEDVECZKY N, 1970, BIOCHIM BIOPHYS ACTA, V211, P158, DOI 10.1016/0005-2736(70)90090-8; PARDEE AB, 1966, J BIOL CHEM, V241, P3962; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SURIN BP, 1985, J BACTERIOL, V161, P189, DOI 10.1128/JB.161.1.189-198.1985; SURIN BP, 1984, J BACTERIOL, V157, P772, DOI 10.1128/JB.157.3.772-778.1984; YOUNG D, 1990, MOL BIOL MYCOBACTERI, P1; YOUNG DB, 1991, RES MICROBIOL, V142, P55, DOI 10.1016/0923-2508(91)90097-T	23	48	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1956	1958						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294447				2022-12-27	WOS:A1994MR98800063
J	HARA, E; YAMAGUCHI, T; NOJIMA, H; IDE, T; CAMPISI, J; OKAYAMA, H; ODA, K				HARA, E; YAMAGUCHI, T; NOJIMA, H; IDE, T; CAMPISI, J; OKAYAMA, H; ODA, K			ID-RELATED GENES ENCODING HELIX-LOOP-HELIX PROTEINS ARE REQUIRED FOR G(1) PROGRESSION AND ARE REPRESSED IN SENESCENT HUMAN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-DIPLOID FIBROBLASTS; CELL-CYCLE; DNA-BINDING; C-FOS; RETINOBLASTOMA PROTEIN; MAMMALIAN-CELLS; 3T3 CELLS; EXPRESSION; GROWTH; PRODUCT	Three complete cDNA clones encoding Id-related helix-loop-helix (HLH) proteins lacking a basic region were isolated from a pcD2 cDNA expression library prepared from TIG-3 human diploid fibroblasts (HDF). Of these cDNAs (Id-1H, Id-1H', and Id-2H), two (Id-IH and Id-1H') appeared to be derived by alternative RNA splicing. Id-1H and Id-2H seem to be human homologues of mouse Id-1 and Id-2, respectively, and have potential to encode 154 and 135 amino acid proteins. The Id-1H and Id-2H mRNAs were barely detectable in quiescent early passage HDF; serum coordinately induced both mRNAs, with two peaks of expression, in early and late in G1. Antisense oligomers complementary to Id-1H and Id-2H mRNA prevented early passage HDF from entering the S phase of the cell cycle. The treatment of serum-stimulated early passage cells with the antisense Id-1H oligomer completely abolished Id-1H. In senescent cells, serum barely induced the Id-1H and Id-2H mRNAs, although the levels of c-myc expression induced were similar in early passage and senescent cells. The expression levels of these Id genes vary among immortal human cell lines. Both genes were overexpressed in VA4 SV40-transformed lung fibroblasts and EJ-1 bladder carcinoma cells, while these genes were expressed at a very low level in SVts8 cells derived from SV40 tsA-transformed TIG-3 cells. SVts8 cells may acquire some function redundant to Id proteins. HT1080 fibrosarcoma cells expressed the Id-1H gene but not the Id-2H gene, suggesting these Id genes may subserve redundant functions.	SCI UNIV TOKYO,DEPT BIOL SCI & TECHNOL,NODA,CHIBA 278,JAPAN; SCI UNIV TOKYO,DEPT APPL BIOL SCI,NODA,CHIBA 278,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,TOYONAKA,OSAKA 560,JAPAN; HIROSHIMA UNIV,DEPT CELLULAR & MOLEC BIOL,HIROSHIMA 734,JAPAN; LAWRENCE BERKELEY LAB,DEPT CELL & MOLEC BIOL,BERKELEY,CA 94720	Tokyo University of Science; Tokyo University of Science; Osaka University; Hiroshima University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory					NATIONAL INSTITUTE ON AGING [R37AG009909, R01AG009909, R56AG009909] Funding Source: NIH RePORTER; NIA NIH HHS [AG09909] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BIGGS J, 1992, P NATL ACAD SCI USA, V89, P1512, DOI 10.1073/pnas.89.4.1512; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CABRERA CV, 1987, CELL, V50, P425, DOI 10.1016/0092-8674(87)90496-X; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARA E, 1991, NUCLEIC ACIDS RES, V19, P7097, DOI 10.1093/nar/19.25.7097; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; MATSUKURA M, 1987, P NATL ACAD SCI USA, V84, P7706, DOI 10.1073/pnas.84.21.7706; MATSUO M, 1982, J GERONTOL, V37, P33, DOI 10.1093/geronj/37.1.33; McCormick A, 1991, CURR OPIN CELL BIOL, V3, P230, DOI 10.1016/0955-0674(91)90144-N; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; RICHTER KH, 1991, CANCER RES, V51, P6010; RITTLING SR, 1986, P NATL ACAD SCI USA, V83, P3316, DOI 10.1073/pnas.83.10.3316; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; STANULISPRAEGER BM, 1987, MECH AGEING DEV, V38, P1, DOI 10.1016/0047-6374(87)90109-6; STEIN CA, 1988, CANCER RES, V52, P428; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; STEIN GH, 1991, P NATL ACAD SCI USA, V88, P11012, DOI 10.1073/pnas.88.24.11012; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; TSUYAMA N, 1991, CELL STRUCT FUNCT, V16, P55, DOI 10.1247/csf.16.55; WALKER MD, 1990, NUCLEIC ACIDS RES, V18, P1159, DOI 10.1093/nar/18.5.1159; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	50	279	288	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2139	2145						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294468				2022-12-27	WOS:A1994MR98800089
J	MULLIS, KG; HUYNH, M; KORNFELD, RH				MULLIS, KG; HUYNH, M; KORNFELD, RH			PURIFICATION AND KINETIC-PARAMETERS OF BOVINE LIVER N-ACETYLGLUCOSAMINE-1-PHOSPHODIESTER ALPHA-N-ACETYLGLUCOSAMINIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL-ENZYMES; RAT-LIVER; PHOSPHORYLATION; PHOSPHODIESTERASE; OLIGOSACCHARIDES; RECOGNITION; RESIDUES; PROTEINS	The enzyme N-acetyl-glucosamine phosphodiester alpha-N-acetylglucosaminidase (phosphodiester alpha-GlcNAcase) catalyzes the second step in the formation of the mannose 6-phosphate targeting signal on lysosomal enzyme oligosaccharides by removing GlcNAc residues from GlcNAc-alpha-P-mannose moieties, which are formed in the first step by UDP-N-acetyl-glucosamine:glycoprotein N-acetylglucosamine-1-phosphotransferase (GlcNAc-phosphotransferase). Phosphodiester alpha-GlcNAcase, a membrane-bound enzyme, has been purified about 3,000-fold from bovine liver to apparent homogeneity using detergent solubilization, fractionation on DEAE-cellulose, affinity chromatography on lectin-Sepharose columns, gel filtration, and sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The enzyme migrated as 129- and 121-kDa species on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Since both bands had the same amino-terminal sequence, the smaller species is presumed to be derived from the larger by proteolysis. Kinetic analysis of bovine phosphodiester alpha-GlcNAcase with enzymatically synthesized artificial and biological substrates indicates that phosphodiester alpha-GlcNAcase requires GlcNAc-alpha-P R for substrate and that when R contains the Manalpha1,2Man linkage the substrate binding is most effective. Unlike GlcNAc-phosphotransferase, bovine phosphodiester alpha-GlcNAcase does not require a protein recognition determinant on lysosomal enzyme substrates.	WASHINGTON UNIV,SCH MED,DEPT MED,660 S EUCLID AVE,BOX 8125,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOPHYS,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NCI NIH HHS [CA08759] Funding Source: Medline; NHLBI NIH HHS [T32-HL07088] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA008759, R01CA008759] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007088] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENDIAK B, 1987, J BIOL CHEM, V262, P5775; COUSO R, 1986, J BIOL CHEM, V261, P6326; HARLOW E, 1988, ANTIBODIES LABORATOR; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KRYSTAL G, 1987, ANAL BIOCHEM, V167, P86, DOI 10.1016/0003-2697(87)90136-9; LACKS SA, 1980, J BIOL CHEM, V255, P7467; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG L, 1984, J BIOL CHEM, V259, P4663; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MULLIS KC, 1993, J BIOL CHEM, V269, P1727; MULLIS KG, 1992, ANAL BIOCHEM, V205, P200, DOI 10.1016/0003-2697(92)90424-6; REITMAN ML, 1981, J BIOL CHEM, V256, P4275; SCHLOSNAGLE DC, 1974, J BIOL CHEM, V249, P7574; TABAS I, 1980, J BIOL CHEM, V255, P6633; VARKI A, 1981, J BIOL CHEM, V256, P9937; VARKI A, 1983, ARCH BIOCHEM BIOPHYS, V222, P145, DOI 10.1016/0003-9861(83)90511-8; WAHEED A, 1981, J BIOL CHEM, V256, P5717	18	9	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1718	1726						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294420				2022-12-27	WOS:A1994MR98800030
J	HENSEY, CE; HONG, F; DURFEE, T; QIAN, YW; LEE, EYHP; LEE, WH				HENSEY, CE; HONG, F; DURFEE, T; QIAN, YW; LEE, EYHP; LEE, WH			IDENTIFICATION OF DISCRETE STRUCTURAL DOMAINS IN THE RETINOBLASTOMA PROTEIN - AMINO-TERMINAL DOMAIN IS REQUIRED FOR ITS OLIGOMERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR E2F; DNA-BINDING ACTIVITY; LARGE T-ANTIGEN; GENE-PRODUCT; SUSCEPTIBILITY GENE; CELL-CYCLE; INSECT CELLS; EXPRESSION; CLONING; REGIONS	To characterize the protein product of the retinoblastoma tumor suppressor gene biochemically, a recombinant human protein was produced in an Escherichia coli expression system. The full-length protein, p110RB, and an amino-terminal truncated form, p56RB, were expressed and purified to near homogeneity by conventional chromatographic procedures. To probe, the structural organization of the retinoblastoma protein the purified proteins were subjected to partial proteolysis by trypsin, chymotrypsin, and subtilisin. Four discrete structural domains were revealed in p110RB by this method. Two of these structural domains, found in both p56RB and p110RB, were mapped to the carboxyl-terminal half of the protein and corresponded to the SV40 large T binding domains defined previously by genetic methods. In addition two distinct domains in the amino-terminal half of the protein were also defined. A potential role for these newly defined amino-terminal domains was uncovered upon analysis of the purified proteins by nondenaturing polyacrylamide gel electrophoresis. p110RB revealed multiple bands by this method, suggesting the formation of oligomeric structures by the protein, while this property was not observed for p56RB. Electron microscopy of p110RB revealed linearly extended, macromolecular structures, further supporting the formation of homologous higher order structures by the full-length retinoblastoma protein. Analysis of the interactions between retinoblastoma protein molecules using the yeast two-hybrid system confirmed that the retinoblastoma protein could self-associate and that this association was mediated by interactions between the amino- and carboxyl-terminal ends of the protein. These observations suggest that the retinoblastoma protein contains multiple structural domains with the amino-terminal domains being required for oligomerization of the full-length protein.	UNIV TEXAS, HLTH SCI CTR, CTR MOLEC MED, INST BIOTECHNOL, SAN ANTONIO, TX 78245 USA	University of Texas System; University of Texas Health San Antonio			Hong, Frank/H-1019-2015; Hensey, Carmel/L-7456-2013	Hensey, Carmel/0000-0003-3319-4094; Hong, Frank/0000-0002-6814-4671	NATIONAL CANCER INSTITUTE [R01CA058318] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY005758] Funding Source: NIH RePORTER; NCI NIH HHS [CA58318] Funding Source: Medline; NEI NIH HHS [EY05758] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BOOKSTEIN R, 1991, Critical Reviews in Oncogenesis, V2, P211; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EDWARDS GM, 1992, J BIOL CHEM, V267, P7971; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FONTANA A, 1986, BIOCHEMISTRY-US, V25, P1847, DOI 10.1021/bi00356a001; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GOODRICH D, 1991, CELL, V67, P1; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEE WH, 1991, ORIGINS OF HUMAN CANCER, P413; LEE WH, 1991, COLD SH Q B, V56, P211; OREILLY DR, 1988, J VIROL, V62, P3109, DOI 10.1128/JVI.62.9.3109-3119.1988; PATEL SS, 1993, J BIOL CHEM, V268, P10668; PRIVES C, 1991, COLD SPRING HARB SYM, V56, P227; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; ROSE GD, 1979, J MOL BIOL, V134, P447, DOI 10.1016/0022-2836(79)90363-2; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SHEW JY, 1989, ONCOGENE RES, V4, P205; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; STIRDIVANT SM, 1992, J BIOL CHEM, V267, P14846; WANG NP, 1990, CELL GROWTH DIFFER, V1, P233; WANG NP, 1990, CELL GROWTH DIFFER, V1, P429; WETLAUFE.DB, 1973, P NATL ACAD SCI USA, V70, P697, DOI 10.1073/pnas.70.3.697; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILSON JE, 1991, METHOD BIOCHEM ANAL, V35, P207	50	62	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1380	1387						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288605				2022-12-27	WOS:A1994MR22000095
J	KUNAPULI, P; ONORATO, JJ; HOSEY, MM; BENOVIC, JL				KUNAPULI, P; ONORATO, JJ; HOSEY, MM; BENOVIC, JL			EXPRESSION, PURIFICATION, AND CHARACTERIZATION OF THE G-PROTEIN-COUPLED RECEPTOR KINASE GRK5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-DEPENDENT PHOSPHORYLATION; RHODOPSIN KINASE; BETA-2-ADRENERGIC RECEPTOR; CATALYTIC SUBUNIT; AGONIST; FAMILY; TRANSLOCATION; INHIBITION; POLYANIONS	G protein-coupled receptor kinases (GRKs) such as rhodopsin kinase and the beta-adrenergic receptor kinase (betaARK) play an important role in agonist-specific phosphorylation and desensitization of G protein-coupled receptors. GRK5 is a recently identified member of the GRK family that has greater homology with rhodopsin kinase than with PARK. To further characterize the activity of GRK5, it has been overexpressed in Sf9 insect cells and purified by successive chromatography on S-Sepharose and Mono S columns. GRK5 phosphorylates the beta2-adrenergic receptor (beta2AR), m2 muscarinic cholinergic receptor, and rhodopsin in an agonist-dependent manner to maximal stoichiometries of approximately 2.5,1.5, and 1 mol of phosphate/mol of receptor, respectively, with K(m) values of approximately 0.5 muM for the beta2Ar, approximately muM for rhodopsin, and approximately 24 muM for ATP. Peptide phosphorylation studies suggest that in contrast to betaARK and rhodopsin kinase, GRK5 preferentially phosphorylates nonacidic peptides with a K(m) of approximately 1.5 mM. Heparin and dextran sulfate were found to be potent inhibitors of GRK5 with IC50 values of approximately 1 nM, thereby being at least 150-fold more potent on GRK5 than on betaARK. GRK5 can also be activated by polycations, with 10 mM polylysine promoting an approximately 2.6-fold activation. Overall, these studies demonstrate that GRK5 has unique properties that distinguish it from other members of the GRK family and that likely play an important role in modulating its mechanism of action.	NORTHWESTERN UNIV,SCH MED,DEPT PHARMACOL,CHICAGO,IL 60611; UNIV WISCONSIN,DEPT MED,NEPHROL SECT,MADISON,WI 53706	Northwestern University; University of Wisconsin System; University of Wisconsin Madison	KUNAPULI, P (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031601, R01HL045964] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL31601, HL45964] Funding Source: Medline; NIGMS NIH HHS [GM44944] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambrose Christine, 1992, Human Molecular Genetics, V1, P697, DOI 10.1093/hmg/1.9.697; BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1989, J BIOL CHEM, V264, P6707; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1993, J BIOL CHEM, V268, P19521; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BOWNDS D, 1972, NATURE-NEW BIOL, V237, P125, DOI 10.1038/newbio237125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASILL JA, 1991, P NATL ACAD SCI USA, V88, P11067; CHEN CY, 1993, J BIOL CHEM, V268, P7825; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; DAWSON TM, 1993, SCIENCE, V259, P825, DOI 10.1126/science.8381559; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; GOMEZ J, 1992, MOL BIOL RECEPTORS T, P1; HARGRAVE PA, 1992, MOL BIOL RECEPTORS T, P49; HATHAWAY GM, 1984, J BIOL CHEM, V259, P7011; KIM CM, 1993, RECEPTOR, V3, P39; KUHN H, 1972, FEBS LETT, V20, P1, DOI 10.1016/0014-5793(72)80002-4; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN WJ, 1991, J BIOL CHEM, V266, P5664; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MAYOR F, 1987, J BIOL CHEM, V262, P6468; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P8764, DOI 10.1021/bi00448a013; PALCZEWSKI K, 1988, J BIOL CHEM, V263, P14067; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; SHICHI H, 1978, J BIOL CHEM, V253, P7040; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032	38	98	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1099	1105						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288567				2022-12-27	WOS:A1994MR22000052
J	SUGIMOTO, Y; HASUMOTO, KY; NAMBA, T; IRIE, A; KATSUYAMA, M; NEGISHI, M; KAKIZUKA, A; NARUMIYA, S; ICHIKAWA, A				SUGIMOTO, Y; HASUMOTO, KY; NAMBA, T; IRIE, A; KATSUYAMA, M; NEGISHI, M; KAKIZUKA, A; NARUMIYA, S; ICHIKAWA, A			CLONING AND EXPRESSION OF A CDNA FOR MOUSE PROSTAGLANDIN-F RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBOXANE-A2 RECEPTOR; LEUKOTRIENE RECEPTORS; INOSITOL PHOSPHATES; CORPUS-LUTEUM; CORPORA-LUTEA; CELLS; STIMULATION; HYDROLYSIS; PROTEINS	A functional cDNA clone for mouse prostaglandin (PG) F receptor was isolated from a mouse cDNA library using polymerase chain reaction based on the sequence of cloned prostanoid receptors, and cross-hybridization screening. The mouse PGF receptor consists of 366 amino acid residues with putative seven transmembrane domains. The sequence revealed the highest homology to the EP1 subtype of PGE receptor and thromboxane (TX) A2 receptor. Ligand binding studies using membranes of COS cells transfected with the cDNA revealed specific [H-3]PGF2alpha binding. The binding was displaced with unlabeled PGs in the order of PGF2alpha = 9alpha,11beta-PGF2 > PGF1alpha > PGD2 > STA2 (a stable TXA2 agonist) > PGE2 > iloprost (a stable PGI2 agonist). PGF2alpha increased inositol trisphosphate formation in a concentration-dependent manner in COS cells expressing PGF receptor. RNA blot and in situ hybridization analyses demonstrated that the PGF receptor transcripts are abundantly expressed in luteal cells of corpus luteum and in a lesser amount in kidney, heart, stomach, and lung.	KYOTO UNIV,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT PHARMACOL,KYOTO 606,JAPAN	Kyoto University; Kyoto University			Sugimoto, Yukihiko/AAV-6470-2021	Sugimoto, Yukihiko/0000-0001-6973-932X				BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN RA, 1981, BRIT J PHARMACOL, V74, pP913; COLEMAN RA, 1985, PROSTAGLANDINS, V29, P363, DOI 10.1016/0090-6980(85)90096-6; COLEMAN RA, 1990, COMPREHENSIVE MED CH, V3, P643; DAVIS JS, 1987, P NATL ACAD SCI USA, V84, P3728, DOI 10.1073/pnas.84.11.3728; FARMAN N, AM J PHYSIOL, V252, pF53; FINDLAY JBC, 1986, BIOCHEM J, V238, P625, DOI 10.1042/bj2380625; FITZPATRICK TM, 1978, J PHARMACOL EXP THER, V206, P139; HALUSHKA PV, 1989, ANN REV PHARM TOXICO, V10, P213; HANSEL W, 1986, J REPROD FERTIL, V78, P755, DOI 10.1530/jrf.0.0780755; HASHIMOTO H, 1990, PROSTAGLANDINS, V40, P491, DOI 10.1016/0090-6980(90)90111-8; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HONDA A, 1993, J BIOL CHEM, V268, P7759; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; LEUNG PCK, 1986, ENDOCRINOLOGY, V119, P12, DOI 10.1210/endo-119-1-12; MENE P, 1987, BIOCHEM BIOPH RES CO, V142, P579, DOI 10.1016/0006-291X(87)90313-5; MONCADA S, 1985, PHARMACOL BASIS THER, P660; NAKAJIMA Y, 1992, J BIOL CHEM, V267, P2437; NAMBA T, 1992, BIOCHEM BIOPH RES CO, V184, P1197, DOI 10.1016/S0006-291X(05)80009-9; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; POWELL WS, 1974, EUR J BIOCHEM, V41, P103, DOI 10.1111/j.1432-1033.1974.tb03249.x; RAO CV, 1975, BIOCHEM BIOPH RES CO, V64, P416, DOI 10.1016/0006-291X(75)90269-7; RAYMOND V, 1983, BIOCHEM BIOPH RES CO, V116, P39, DOI 10.1016/0006-291X(83)90377-7; ROBERTSON RP, 1986, PROSTAG OTH LIPID M, V31, P395; Rothchild I, 1981, Recent Prog Horm Res, V37, P183; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641; WASSERMAN MA, 1975, EUR J PHARMACOL, V32, P146, DOI 10.1016/0014-2999(75)90277-0; WATABE A, 1993, J BIOL CHEM, V268, P20175	33	206	214	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1356	1360						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288601				2022-12-27	WOS:A1994MR22000091
J	SUN, M; LI, L; GAO, QS; PAUL, S				SUN, M; LI, L; GAO, QS; PAUL, S			ANTIGEN RECOGNITION BY AN ANTIBODY LIGHT-CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; BINDING; HEAVY; HYDROLYSIS; COMPLEXES; PROTEINS	A monoclonal antibody to vasoactive intestinal polypeptide (VIP) was reduced and alkylated and its light and heavy chains were purified by denaturing gel filtration. Following renaturation, the light chain displayed sequence-specific binding of VIP. The specific VIP binding activity of several fractions spanning the light chain peak recovered from the gel filtration column was constant, the light chain was electrophoretically homogeneous, the VIP binding activity was precipitated by antilight chain antibody but not anti-heavy chain antibody and the activity remained associated with a light chain fraction recovered by resolutive chromatography on a hydroxylapatite column. N-terminal amino acid sequencing of the light and heavy chain, fractions confirmed the purity of these proteins and suggested that the V(L) and V(H) regions belonged to kappa-family II and gamma-family III, respectively. The VIP-binding affinity of the light chain was only 5-fold lower than that of the parent antibody and the light chain did not bind unrelated peptides. These observations suggest that light chains display structural characteristics necessary for high affinity antigen binding.	UNIV NEBRASKA,MED CTR,DEPT ANESTHESIOL,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT INTERNAL MED,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT PATHOL,OMAHA,NE 68198	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI031268, R01AI031268] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 44126] Funding Source: Medline; NIAID NIH HHS [AI 31268] Funding Source: Medline; PHS HHS [K 02217] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BJORK I, 1971, BIOCHEMISTRY-US, V10, P1289; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; EDELMAN GM, 1963, P NATL ACAD SCI USA, V50, P753, DOI 10.1073/pnas.50.4.753; EDMUNDSO.AB, 1974, BIOCHEMISTRY-US, V13, P3816, DOI 10.1021/bi00715a031; ERHAN S, 1974, NATURE, V251, P353, DOI 10.1038/251353a0; FLEISCHMAN JB, 1963, BIOCHEM J, V88, P220, DOI 10.1042/bj0880220; FRANEK F, 1963, BIOCHEMISTRY-MOSCOW+, V28, P193; GHERARDI E, 1992, NATURE, V357, P201, DOI 10.1038/357201a0; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; HOPPER JE, 1986, CELL IMMUNOL, V101, P122, DOI 10.1016/0008-8749(86)90191-7; IOANNIDIS R A, 1989, Hematologic Pathology, V3, P169; KABAT EA, 1991, NIH913242 US DEP HLT; KING DJ, 1993, BIOCHEM J, V290, P723, DOI 10.1042/bj2900723; MEI S, 1991, J BIOL CHEM, V266, P15571; MERI S, 1992, J EXP MED, V175, P939, DOI 10.1084/jem.175.4.939; NOVOTNY J, 1989, BIOCHEMISTRY-US, V28, P4735, DOI 10.1021/bi00437a034; PAUL S, 1991, J BIOL CHEM, V266, P16128; PAUL S, 1989, SCIENCE, V244, P1158, DOI 10.1126/science.2727702; PAUL S, 1992, J BIOL CHEM, V267, P13142; PAUL S, 1989, J NEUROIMMUNOL, V23, P133, DOI 10.1016/0165-5728(89)90032-5; ROHOLT O, 1963, P NATL ACAD SCI USA, V51, P173; SCHIFFER M, 1973, BIOCHEMISTRY-US, V12, P4620, DOI 10.1021/bi00747a013; STEVENS FJ, 1981, J MOL BIOL, V147, P185, DOI 10.1016/0022-2836(81)90086-3; STEVENS FJ, 1991, BIOCHEMISTRY-US, V30, P6803, DOI 10.1021/bi00242a001; UTSUMI S, 1964, BIOCHEMISTRY-US, V3, P1329, DOI 10.1021/bi00897a024; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0; WU TT, 1993, PROTEINS, V16, P1, DOI 10.1002/prot.340160102	27	54	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					734	738						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276876				2022-12-27	WOS:A1994MR21900115
J	TEBBEY, PW; MCGOWAN, KM; STEPHENS, JM; BUTTKE, TM; PEKALA, PH				TEBBEY, PW; MCGOWAN, KM; STEPHENS, JM; BUTTKE, TM; PEKALA, PH			ARACHIDONIC-ACID DOWN-REGULATES THE INSULIN-DEPENDENT GLUCOSE-TRANSPORTER GENE (GLUT4) IN 3T3-L1 ADIPOCYTES BY INHIBITING TRANSCRIPTION AND ENHANCING MESSENGER-RNA TURNOVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; STEAROYL-COA DESATURASE; FACTOR-ALPHA; DIABETES-MELLITUS; PLASMA-MEMBRANE; RAT ADIPOCYTES; PRETRANSLATIONAL SUPPRESSION; PLATELET PHOSPHOLIPIDS; GROWTH-FACTOR; EXPRESSION	Chronic exposure of fully differentiated 3T3-L1 adipocytes to 50 muM arachidonic acid (AA) resulted in an inhibition (approximately 91%) in cellular GLUT4 mRNA content after a 48-h exposure, without similarly affecting the mRNA content of the ubiquitous glucose transporter, GLUT1. Subsequent investigations revealed that transcription of the GLUT4 gene was reduced by approximately 50% in response to AA treatment and the half-life of GLUT4 mRNA decreased from 8.0 to 4.6 h. By contrast, AA increased the accumulation of GLUT1 mRNA by 65%, by a mechanism that also involved regulation at both transcriptional and mRNA stability levels. Western blot analysis revealed that AA was specifically reducing the insulin-responsive glucose transporter (GLUT4) in both plasma and intracellular membranes. Subsequently, AA was observed to alter the ability of the GLUT4 transporter to respond to insulin and mediate a significant enhancement of glucose uptake. The results presented in this study indicate that AA can partially mimic the effects of both tumor necrosis factor-alpha and insulin which, when chronically supplied to 3T3-L1 adipocytes, also down-regulate GLUT4 gene expression. Therefore, these data may have relevance to the insulin-resistance associated with non-insulin-dependent diabetes mellitus.	E CAROLINA UNIV,SCH MED,DEPT BIOCHEM,GREENVILLE,NC 27858; E CAROLINA UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,GREENVILLE,NC 27858	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University			Stephens, Jacqueline M/R-5217-2018		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032892] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32892] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVRUCH J, 1971, BIOCHIM BIOPHYS ACTA, V233, P334, DOI 10.1016/0005-2736(71)90331-2; BALY DL, 1988, BIOCHIM BIOPHYS ACTA, V947, P571, DOI 10.1016/0304-4157(88)90008-1; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BUTTKE TM, 1989, P NATL ACAD SCI USA, V86, P6133, DOI 10.1073/pnas.86.16.6133; BUTTKE TM, 1985, NUTR REP INT, V32, P749; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CHANG DJ, 1992, BIOCHEM BIOPH RES CO, V188, P538, DOI 10.1016/0006-291X(92)91089-9; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; CLARKE SD, 1992, FASEB J, V6, P3146, DOI 10.1096/fasebj.6.13.1397836; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; CORNELIUS P, 1988, BIOCHEM J, V249, P765, DOI 10.1042/bj2490765; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; EZAKI O, 1992, AM J PHYSIOL, V263, pE94, DOI 10.1152/ajpendo.1992.263.1.E94; FLORESRIVEROS JR, 1993, P NATL ACAD SCI USA, V90, P512, DOI 10.1073/pnas.90.2.512; GARVEY WT, 1991, J CLIN INVEST, V87, P1072, DOI 10.1172/JCI115068; GARVEY WT, 1989, SCIENCE, V245, P60, DOI 10.1126/science.2662408; GLASGOW WC, 1992, J BIOL CHEM, V267, P1071; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HABENICHT AJR, 1990, NATURE, V345, P634, DOI 10.1038/345634a0; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; HIRAKI Y, 1988, J BIOL CHEM, V263, P13655; IP C, 1977, HORM METAB RES, V9, P218, DOI 10.1055/s-0028-1093540; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KAESTNER KH, 1989, J BIOL CHEM, V264, P14755; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KAHN BB, 1992, J CLIN INVEST, V89, P1367, DOI 10.1172/JCI115724; KALOFOUTIS A, 1981, DIABETOLOGIA, V21, P540; LAVAU M, 1979, J LIPID RES, V20, P8; MURER E, 1992, DIABETES, V41, P1063, DOI 10.2337/diabetes.41.9.1063; NEUFELD EJ, 1983, J CLIN INVEST, V72, P214, DOI 10.1172/JCI110959; NTAMBI JM, 1992, J BIOL CHEM, V267, P10925; OKA Y, 1988, J BIOL CHEM, V263, P13432; PEKALA P, 1983, J EXP MED, V157, P1360, DOI 10.1084/jem.157.4.1360; PELIKANOVA T, 1991, CLIN CHIM ACTA, V203, P329, DOI 10.1016/0009-8981(91)90305-V; RANDLE PJ, 1988, DIABETES METAB REV, V4, P623, DOI 10.1002/dmr.5610040702; REID T, 1991, J BIOL CHEM, V266, P16580; SELLMAYER A, 1991, J BIOL CHEM, V266, P3800; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SINHA MK, 1991, DIABETES, V40, P472, DOI 10.2337/diabetes.40.4.472; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; STEPHENS JM, 1992, J BIOL CHEM, V267, P13580; STORLIEN LH, 1987, SCIENCE, V237, P885, DOI 10.1126/science.3303333; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TAKAHASHI R, 1984, DIABETOLOGIA, V26, P134; TAKUWA N, 1988, J BIOL CHEM, V263, P9738; TAYLOR AS, 1985, BIOCHIM BIOPHYS ACTA, V883, P229; TEBBEY PW, 1992, BIOCHIM BIOPHYS ACTA, V1171, P27, DOI 10.1016/0167-4781(92)90136-N; THOIDIS G, 1993, J BIOL CHEM, V268, P11691; YANG J, 1992, BIOCHEM J, V281, P809, DOI 10.1042/bj2810809; YANG J, 1993, J BIOL CHEM, V268, P4600; YANG J, 1992, J BIOL CHEM, V267, P10393; YU NC, 1993, P NATL ACAD SCI USA, V90, P4042, DOI 10.1073/pnas.90.9.4042; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	59	81	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					639	644						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276864				2022-12-27	WOS:A1994MR21900101
J	ZAK, P; KLEIBL, K; LAVAL, F				ZAK, P; KLEIBL, K; LAVAL, F			REPAIR OF O6-METHYLGUANINE AND O4-METHYLTHYMINE BY THE HUMAN AND RAT O6-METHYLGUANINE-DNA METHYLTRANSFERASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; ESCHERICHIA-COLI; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; MAMMALIAN-CELLS; ALKYLATED DNA; CDNA CLONING; O6-ALKYLGUANINE-DNA-ALKYLTRANSFERASE; EXPRESSION; RESIDUES; SEQUENCE	In order to compare the ability of the human and rat O6-methylguanine-DNA methyltransferases (transferases) to repair in vitro O6-methylguanine (O6-MeGua) and O4-methylthymine (O4-MeThy) residues, which are two mutagenic DNA adducts formed by alkylating agents, we have purified both proteins to homogeneity. Gel electrophoresis of the proteins shows that the O4-MeThy repair is due to the transfer of the methyl group from the alkylated base to the transferase molecules. However, both proteins repair with different efficiencies the O6-MeGua and O4-MeThy residues present in alkylated DNA, poly[d(G.C)], poly(dG.dC), or in alkylated poly[d(A.T)] and poly(dA.dT), respectively. Reaction of both proteins with either methylated residues follows a second-order kinetics. The rate constants are 1 x 10(9) M-1 min-1 for both proteins acting on O6-MeGua and 4.8 x 10(6) or 1.8 x 10(5) M-1 min-1 for the rat or human protein acting on 04-MeThy, respectively. The activity of the mammalian transferases on O4-MeThy present in a poly(dA.dT) substrate is inhibited by double-stranded DNA.	INST GUSTAVE ROUSSY,RADIOCHIM ADN GRP,UNITE 247,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,INSERM,F-94805 VILLEJUIF,FRANCE	UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy								BECKER RA, 1985, CARCINOGENESIS, V6, P313, DOI 10.1093/carcin/6.2.313; BELINSKY SA, 1986, CANCER RES, V46, P1280; BOITEUX S, 1985, CARCINOGENESIS, V6, P805, DOI 10.1093/carcin/6.5.805; BOITEUX S, 1984, EMBO J, V3, P2569, DOI 10.1002/j.1460-2075.1984.tb02175.x; BRENT TP, 1988, P NATL ACAD SCI USA, V85, P1759, DOI 10.1073/pnas.85.6.1759; CHAN CL, 1993, ARCH BIOCHEM BIOPHYS, V300, P193, DOI 10.1006/abbi.1993.1027; DOLAN ME, 1985, CARCINOGENESIS, V6, P1611, DOI 10.1093/carcin/6.11.1611; DOSANJH MK, 1991, BIOCHEMISTRY-US, V30, P7027, DOI 10.1021/bi00242a031; DRINKWATER NR, 1980, BIOCHEMISTRY-US, V19, P5087, DOI 10.1021/bi00563a023; GERSON SL, 1986, CARCINOGENESIS, V7, P745, DOI 10.1093/carcin/7.5.745; HAYAKAWA H, 1990, J MOL BIOL, V213, P739, DOI 10.1016/S0022-2836(05)80260-8; KOIKE G, 1990, J BIOL CHEM, V265, P14754; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVAL F, 1977, RADIAT RES, V71, P571, DOI 10.2307/3574625; LAVAL F, 1992, INDUCED EFFECTS GENO, P39; LEFEBVRE P, 1985, CANCER RES, V46, P5701; LINDAHL T, 1982, EMBO J, V1, P1359, DOI 10.1002/j.1460-2075.1982.tb01323.x; LING-LING C, 1992, Carcinogenesis (Oxford), V13, P837, DOI 10.1093/carcin/13.5.837; LOMONOSSOFF GP, 1981, J MOL BIOL, V149, P745, DOI 10.1016/0022-2836(81)90356-9; MCCARTHY TV, 1985, NUCLEIC ACIDS RES, V13, P2683, DOI 10.1093/nar/13.8.2683; MCCARTHY TV, 1984, EMBO J, V3, P545, DOI 10.1002/j.1460-2075.1984.tb01844.x; PEGG AE, 1990, CANCER RES, V50, P6119; POTTER PM, 1987, NUCLEIC ACIDS RES, V15, P9177, DOI 10.1093/nar/15.22.9177; RAFFERTY JA, 1992, NUCLEIC ACIDS RES, V20, P1891, DOI 10.1093/nar/20.8.1891; RAHDENSTARON I, 1991, BIOCHEM BIOPH RES CO, V177, P597, DOI 10.1016/0006-291X(91)91830-6; REBECK GW, 1988, P NATL ACAD SCI USA, V85, P3039, DOI 10.1073/pnas.85.9.3039; RYDBERG B, 1990, J BIOL CHEM, V265, P9563; SAFFHILL R, 1985, BIOCHIM BIOPHYS ACTA, V823, P111, DOI 10.1016/0304-419X(85)90009-5; SASSANFAR M, 1991, J BIOL CHEM, V266, P2767; Singer B., 1983, MOL BIOL MUTAGENS CA; SWANN PF, 1990, MUTAT RES, V233, P81, DOI 10.1016/0027-5107(90)90153-U; TANO K, 1990, P NATL ACAD SCI USA, V87, P686, DOI 10.1073/pnas.87.2.686	32	62	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					730	733						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276875				2022-12-27	WOS:A1994MR21900114
J	ROTHSCHILD, KJ; MARTI, T; SONAR, S; HE, YW; RATH, P; FISCHER, W; KHORANA, HG				ROTHSCHILD, KJ; MARTI, T; SONAR, S; HE, YW; RATH, P; FISCHER, W; KHORANA, HG			ASP(96) DEPROTONATION AND TRANSMEMBRANE ALPHA-HELICAL STRUCTURAL-CHANGES IN BACTERIORHODOPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFRARED DIFFERENCE SPECTROSCOPY; SCHIFF-BASE; N-INTERMEDIATE; PROTON TRANSLOCATION; PURPLE MEMBRANE; VIBRATIONAL SPECTROSCOPY; TRANSIENT SPECTROSCOPY; PROTEIN-STRUCTURE; ASPARTIC ACID-96; PHOTOCYCLE	The M-->N transition in the photocycle of bacteriorhodopsin involves the transfer of a proton from Asp96 to the retinylidene Schiff base, possibly through a network of hydrogen-bonded amino acid residues and water molecules (Rothschild, K. J., He, Y. W., Sonar, S., Marti, T., and Khorana, H. G. (1992) J. Biol. Chem. 267, 1615-1622). A conformational change of the protein backbone is also observed during this transition. In this work, we have investigated the effects of replacing the residue Thr46, which might be part of this chain, with an aspartic acid. Both Fourier transform infrared and resonance Raman spectroscopy show that the chromophore structure of this mutant (T46D) is normal. However, N formation is accelerated and N decay is significantly slowed compared to wild-type bacteriorhodopsin. This effect causes the N intermediate to accumulate under steady-state illumination thereby facilitating spectroscopic studies under normal pH conditions. Fourier transform infrared difference spectroscopy reveals that like native bacteriorhodopsin, N formation in T46D involves deprotonation of Asp96, reprotonation of the Schiff base, and a change in the backbone secondary structure. However, in contrast to bacteriorhodopsin, bands assigned to the C=O stretch mode of the carboxylic acid group of Asp96 are upshifted by 10 cm-1 reflecting a change in the Asp96 environment and a drop in its effective pK(a) throughout the photocycle. This change in the pK(a) can directly account for changes in the photocycle kinetics and indicates that Asp96 deprotonation/protonation are the rate limiting steps in the formation and decay of the N intermediate. By studying the effects of H/D exchange, evidence is found that the backbone structural changes involve transmembrane alpha-helices. It is proposed that these structural changes serve to modulate the local environment and protonation state of Asp96 during the photocycle and are also essential for formation of the proton conducting hydrogen bonded network which functions during Schiff base reprotonation.	BOSTON UNIV,MOLEC BIOPHYS LAB,BOSTON,MA 02215; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; MIT,DEPT CHEM,CAMBRIDGE,MA 02139	Boston University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	ROTHSCHILD, KJ (corresponding author), BOSTON UNIV,DEPT PHYS,BOSTON,MA 02215, USA.		; Rothschild, Kenneth/P-6177-2018	Fischer, Wolfgang/0000-0001-7753-1828; Rothschild, Kenneth/0000-0002-2847-6671	NIAID NIH HHS [AI11479] Funding Source: Medline; NIGMS NIH HHS [GM28289] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI011479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028289, R01GM028289] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGLEY K, 1982, P NATL ACAD SCI-BIOL, V79, P4972, DOI 10.1073/pnas.79.16.4972; Bellamy L. J., 1980, INFRARED SPECTRA COM, V2, P299; BOUSCHE O, 1992, PHOTOCHEM PHOTOBIOL, V56, P1085, DOI 10.1111/j.1751-1097.1992.tb09732.x; BRAIMAN MS, 1988, BIOCHEMISTRY-US, V27, P8516, DOI 10.1021/bi00423a002; BRAIMAN MS, 1992, BIOPHYS J, V62, P56, DOI 10.1016/S0006-3495(92)81777-0; BRAIMAN MS, 1988, ANNU REV BIOPHYS BIO, V17, P541; BRAIMAN MS, 1991, J BIOL CHEM, V266, P11063; CAO Y, 1991, BIOCHEMISTRY-US, V30, P10972, DOI 10.1021/bi00109a023; CAO Y, 1993, BIOCHEMISTRY-US, V32, P1981, DOI 10.1021/bi00059a015; DUNACH M, 1990, J BIOL CHEM, V265, P16978; EARNEST TN, 1986, BIOCHEMISTRY-US, V25, P7793, DOI 10.1021/bi00372a002; EARNEST TN, 1990, BIOPHYS J, V58, P1539, DOI 10.1016/S0006-3495(90)82498-X; FODOR SPA, 1988, BIOCHEMISTRY-US, V27, P7097, DOI 10.1021/bi00418a064; GERWERT K, 1989, P NATL ACAD SCI USA, V86, P4943, DOI 10.1073/pnas.86.13.4943; HACKETT NR, 1987, J BIOL CHEM, V262, P9277; HE YW, 1993, BIOCHEMISTRY-US, V32, P2282, DOI 10.1021/bi00060a021; HOLZ M, 1989, P NATL ACAD SCI USA, V86, P2167, DOI 10.1073/pnas.86.7.2167; KHORANA HG, 1988, J BIOL CHEM, V263, P7439; KOUYAMA T, 1988, BIOCHEMISTRY-US, V27, P5855, DOI 10.1021/bi00416a006; KREBS MP, 1993, J BACTERIOL, V175, P1555, DOI 10.1128/JB.175.6.1555-1560.1993; KRIMM S, 1982, SCIENCE, V216, P407, DOI 10.1126/science.6280277; MAEDA S, 1992, SPRINGER P PHYS, V68, P68; MARTI T, 1991, J BIOL CHEM, V266, P6919; MATHIES R, 1977, J MOL BIOL, V109, P367, DOI 10.1016/S0022-2836(77)80040-5; NAKAGAWA M, 1991, J MOL STRUCT, V242, P221, DOI 10.1016/0022-2860(91)87137-7; ORMOS P, 1991, P NATL ACAD SCI USA, V88, P473, DOI 10.1073/pnas.88.2.473; OTTO H, 1989, P NATL ACAD SCI USA, V86, P9228, DOI 10.1073/pnas.86.23.9228; OTTO H, 1990, P NATL ACAD SCI USA, V87, P1018, DOI 10.1073/pnas.87.3.1018; PELTIER S, 1959, COMPT RENDU, V248, P1148; PFEFFERLE JM, 1991, BIOCHEMISTRY-US, V30, P6548, DOI 10.1021/bi00240a027; RATH P, 1993, BIOCHEMISTRY-US, V32, P2272, DOI 10.1021/bi00060a020; ROEPE P, 1987, BIOCHEMISTRY-US, V26, P6696, DOI 10.1021/bi00395a020; ROTHSCHILD KJ, 1992, J BIOL CHEM, V267, P1615; ROTHSCHILD KJ, 1982, P NATL ACAD SCI-BIOL, V79, P4045, DOI 10.1073/pnas.79.13.4045; ROTHSCHILD KJ, 1984, BIOCHEMISTRY-US, V23, P6103, DOI 10.1021/bi00320a031; ROTHSCHILD KJ, 1981, BIOCHEM BIOPH RES CO, V103, P483, DOI 10.1016/0006-291X(81)90478-2; ROTHSCHILD KJ, 1992, J BIOENERG BIOMEMBR, V24, P147, DOI 10.1007/BF00762674; ROTHSCHILD KJ, 1979, SCIENCE, V204, P311, DOI 10.1126/science.432645; ROTHSCHILD KJ, 1979, BIOPHYS J, V25, P473, DOI 10.1016/S0006-3495(79)85317-5; ROTHSCHILD KJ, 1990, J BIOL CHEM, V265, P16985; SASAKI J, 1992, J BIOL CHEM, V267, P20782; SIEBERT F, 1982, FEBS LETT, V141, P82, DOI 10.1016/0014-5793(82)80021-5; SMITH SO, 1987, J AM CHEM SOC, V109, P3108, DOI 10.1021/ja00244a038; SONAR S, 1993, BIOCHEMISTRY-US, V32, P2263, DOI 10.1021/bi00060a019; STERN LJ, 1989, J BIOL CHEM, V264, P14202; SUBRAMANIAM S, 1991, P NATL ACAD SCI USA, V88, P6873, DOI 10.1073/pnas.88.15.6873; ZIMANYI L, 1989, BIOCHEMISTRY-US, V28, P5165, DOI 10.1021/bi00438a038	48	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27046	27052						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262942				2022-12-27	WOS:A1993MM26200034
J	STEGMANN, T				STEGMANN, T			MEMBRANE FUSION-INHIBITING PEPTIDES DO NOT INHIBIT INFLUENZA-VIRUS FUSION OR THE CA2+-INDUCED FUSION OF NEGATIVELY CHARGED VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENDAI VIRUS; PHOSPHOLIPID-VESICLES; BILAYER-MEMBRANES; PHASE-TRANSITION; L-ALPHA; LIPOSOMES; KINETICS; PH; DESTABILIZATION; GLYCOPROTEINS	Short hydrophobic N-carbobenzoxy oligopeptides are known to inhibit the infectivity of several enveloped viruses. Recently, it was shown that they inhibited the fusion of Sendai virus with N-methyl-dioleoylphosphatidylethanolamine (N-methyl-DOPE) liposomes as well as the low pH-induced fusion of these liposomes with each other (Kelsey, D. R., Flanagan, T. D., Young, J. E., and Yeagle, P. L. (1990) J. Biol. Chem. 265, 12178-12183). Therefore it was concluded that the peptides inhibit membrane fusion, an important step in viral infectivity. Here, it is shown that this peptide and a series of similar peptides did not inhibit influenza virus fusion with N-methyl-DOPE or other liposomes. In fact, some peptides enhanced the overall rate of fusion of influenza virus with N-methyl-DOPE liposomes. In our hands, the peptides did not inhibit influenza infectivity in Madin-Darby canine kidney cells or influenza-induced hemolysis either. They also did not inhibit the Ca2+-induced fusion between cardiolipin or phosphatidylserine liposomes. However, the inhibitory effect of one of the peptides on the fusion of Sendai virus with N-methyl-DOPE liposomes and on N-methyl-DOPE liposome-liposome fusion could be reproduced. These data indicate that the peptides do not, as had been suggested (Yeagle, P. L., Young, J. E., Hui, S. W., and Epand, R. M. (1992) Biochemistry 31, 3177-3183), act by preventing the formation of lipid structures with small radii of curvature, such as the inverted phase intermediates that are thought to be involved in N-methyl-DOPE fusion. The results also suggest that the mechanism of inhibition of Sendai virus infection and N-methyl-DOPE fusion by the peptides may be different after all.			STEGMANN, T (corresponding author), UNIV BASEL,BIOCTR,DEPT BIOPHYS CHEM,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND.							ASANO K, 1988, BIOCHEMISTRY-US, V27, P1321, DOI 10.1021/bi00404a035; BENTZ J, 1993, VIRAL FUSION MECHANI, P163; Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; CHOPPIN PW, 1980, REV INFECT DIS, V2, P40; DOMS RW, 1986, J VIROL, V57, P603, DOI 10.1128/JVI.57.2.603-613.1986; ELLENS H, 1986, BIOCHEMISTRY-US, V25, P285, DOI 10.1021/bi00350a001; ELLENS H, 1989, BIOCHEMISTRY-US, V28, P3692, DOI 10.1021/bi00435a011; ELLENS H, 1986, BIOCHEMISTRY-US, V25, P4141, DOI 10.1021/bi00362a023; EPAND RM, 1987, J BIOL CHEM, V262, P1526; FOLCH J, 1957, J BIOL CHEM, V226, P497; GAGNE J, 1985, BIOCHEMISTRY-US, V24, P4400, DOI 10.1021/bi00337a022; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; HULL JD, 1987, VIROLOGY, V159, P690; KELSEY DR, 1990, J BIOL CHEM, V265, P12178; KELSEY DR, 1991, VIROLOGY, V182, P690, DOI 10.1016/0042-6822(91)90610-N; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MILLER FA, 1968, APPL MICROBIOL, V16, P1489, DOI 10.1128/AEM.16.10.1489-1496.1968; NICOLAIDES E, 1968, J MED CHEM, V11, P74, DOI 10.1021/jm00307a016; NORRBY E, 1971, VIROLOGY, V44, P599, DOI 10.1016/0042-6822(71)90374-6; NOVICK SL, 1988, P NATL ACAD SCI USA, V85, P7433, DOI 10.1073/pnas.85.20.7433; PAPAHADJOPOULOS D, 1975, BIOCHIM BIOPHYS ACTA, V394, P579; RICHARDSON CD, 1980, VIROLOGY, V105, P205, DOI 10.1016/0042-6822(80)90168-3; RICHARDSON CD, 1983, VIROLOGY, V131, P518, DOI 10.1016/0042-6822(83)90517-2; ROTT R, 1984, EMBO J, V3, P3329, DOI 10.1002/j.1460-2075.1984.tb02299.x; SIEGEL DP, 1986, CHEM PHYS LIPIDS, V42, P279, DOI 10.1016/0009-3084(86)90087-3; SIEGEL DP, 1986, BIOPHYS J, V49, P1171, DOI 10.1016/S0006-3495(86)83745-6; SIEGEL DP, 1984, BIOPHYS J, V45, P399, DOI 10.1016/S0006-3495(84)84164-8; SIEGEL DP, 1993, VIRAL FUSION MECHANI, P475; STEGMANN T, 1985, BIOCHEMISTRY-US, V24, P3107, DOI 10.1021/bi00334a006; STEGMANN T, 1989, BIOCHEMISTRY-US, V28, P1698, DOI 10.1021/bi00430a041; STEGMANN T, 1993, J BIOL CHEM, V268, P1716; STEGMANN T, 1986, J BIOL CHEM, V261, P966; STEGMANN T, 1993, VIRAL FUSION MECHANI, P89; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; STUBBS CD, 1989, BIOCHIM BIOPHYS ACTA, V986, P89, DOI 10.1016/0005-2736(89)90276-9; TSURUDOME M, 1992, J BIOL CHEM, V267, P20225; VERKLEIJ AJ, 1980, BIOCHIM BIOPHYS ACTA, V600, P620, DOI 10.1016/0005-2736(80)90465-4; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331; WILSCHUT J, 1992, BIOCHEMISTRY-US, V31, P2629, DOI 10.1021/bi00125a001; WILSCHUT J, 1985, BIOCHEMISTRY-US, V24, P4630, DOI 10.1021/bi00338a023; WILSCHUT J, 1993, VIRAL FUSION MECHANI, P133; WILSCHUT J, 1990, MEMBRANE FUSION, P89; YEAGLE PL, 1992, BIOCHEMISTRY-US, V31, P3177, DOI 10.1021/bi00127a019	43	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26886	26892						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262922				2022-12-27	WOS:A1993MM26200012
J	HERRMANN, J; TURCK, CW; ATCHISON, RE; HUFLEJT, ME; POULTER, L; GITT, MA; BURLINGAME, AL; BARONDES, SH; LEFFLER, H				HERRMANN, J; TURCK, CW; ATCHISON, RE; HUFLEJT, ME; POULTER, L; GITT, MA; BURLINGAME, AL; BARONDES, SH; LEFFLER, H			PRIMARY STRUCTURE OF THE SOLUBLE LACTOSE BINDING LECTIN L-29 FROM RAT AND DOG AND INTERACTION OF ITS NONCOLLAGENOUS PROLINE-RICH, GLYCINE-RICH, TYROSINE-RICH SEQUENCE WITH BACTERIAL AND TISSUE COLLAGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSE-SPECIFIC LECTIN; AMINO-ACID-SEQUENCE; MASS-SPECTROMETRY; IV COLLAGENASE; DIFFERENTIAL RECOGNITION; MONONUCLEAR PHAGOCYTES; MONOCLONAL-ANTIBODIES; ENDOGENOUS LECTIN; IGE GLYCOFORMS; MAC-2 ANTIGEN	A lactose-binding lectin from rat lung (RL-29) and a related lectin from Madin-Darby canine kidney (MDCK) cells have been analyzed with the primary goal of identifying post-translational modifications. The sequences show that RL-29 and the dog lectin are homologues of a lectin designated here as L-29 and elsewhere as CBP-35, epsilonBP, Mac-2, or L-34. RL-29 has a 140-amino-acid COOH-terminal carbohydrate-binding domain, a 20-amino-acid NH2-terminal domain, and an intervening domain consisting of 11 repeating elements rich in Pro, Gly, and Tyr (R-domain). The dog homologue has 14 repeating elements in its R-domain explaining its larger size. The sensitivity of the R-domain to bacterial collagenase allowed us to isolate the NH2-terminal domain and show that the NH2 terminus was blocked by acetylation and, in the accompanying paper (Huflejt, M. E., Turck, C. W., Lindstedt, R., Barondes, S. H., and Leffler, H. (1993) J. Biol. Chem. 268, 26712-26718), that the NH2-terminal domain is phosphorylated. In addition, we unexpectedly found an endogenous component, resembling 92-kDa type IV collagenase, that co-purified with L-29 and slowly digested the R-domain. Hence, L-29 is a substrate for bacterial and tissue collagenases even though the R-domain is non-collagenous. Moreover, the co-purification suggests a non-enzymatic interaction between 92-kDa collagenase and L-29.	UNIV CALIF SAN FRANCISCO,LANGLEY PORTER NEUROPSYCHIAT INST,DEPT PSYCHIAT,BOX 0984,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Leffler, Hakon/A-2416-2019	Leffler, Hakon/0000-0003-4482-8945; Huflejt, Malgorzata/0000-0002-2016-8367	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038627] Funding Source: NIH RePORTER; NCRR NIH HHS [RRO1614] Funding Source: Medline; NHLBI NIH HHS [HL38627] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBRANDT K, 1987, P NATL ACAD SCI USA, V84, P6859, DOI 10.1073/pnas.84.19.6859; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; BOND MD, 1984, BIOCHEMISTRY-US, V23, P3077, DOI 10.1021/bi00308a035; BRASSART D, 1992, EUR J BIOCHEM, V203, P393, DOI 10.1111/j.1432-1033.1992.tb16563.x; CERRA RF, 1985, J BIOL CHEM, V260, P10474; CHERAYIL BJ, 1990, P NATL ACAD SCI USA, V87, P7324, DOI 10.1073/pnas.87.18.7324; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; CLERCH LB, 1988, BIOCHEMISTRY-US, V27, P692, DOI 10.1021/bi00402a030; COLLIER IE, 1992, J BIOL CHEM, V267, P6776; CRITTENDEN SL, 1984, MOL CELL BIOL, V4, P1252, DOI 10.1128/MCB.4.7.1252; FALICK AM, 1989, ANAL BIOCHEM, V182, P165, DOI 10.1016/0003-2697(89)90736-7; FALICK AM, 1986, ANAL CHEM, V58, P1308, DOI 10.1021/ac00298a009; FISHER SJ, 1989, J CELL BIOL, V109, P891, DOI 10.1083/jcb.109.2.891; FLOTTE TJ, 1983, AM J PATHOL, V111, P112; FODDY L, 1990, J CELL SCI, V97, P139; FRENCH MF, 1992, J PROTEIN CHEM, V11, P83, DOI 10.1007/BF01025095; FRIGERI LG, 1992, J IMMUNOL, V148, P861; GRITZMACHER CA, 1992, BIOCHEMISTRY-US, V31, P9533, DOI 10.1021/bi00155a004; GROBELNY D, 1992, BIOCHEMISTRY-US, V31, P7152, DOI 10.1021/bi00146a017; HIRABAYASHI J, 1992, J BIOL CHEM, V267, P15485; HO MK, 1982, J IMMUNOL, V128, P1221; HSU DK, 1992, J BIOL CHEM, V267, P14167; HUFLEJT ME, 1993, J BIOL CHEM, V268, P26712; JIA SH, 1988, J BIOL CHEM, V263, P6009; LAING JG, 1989, J BIOL CHEM, V264, P1907; LEFFLER H, 1986, J BIOL CHEM, V261, P119; LEFFLER H, 1989, BIOCHEMISTRY-US, V28, P9222, DOI 10.1021/bi00449a039; LIBRACH CL, 1991, J CELL BIOL, V113, P437, DOI 10.1083/jcb.113.2.437; LINDSTEDT R, 1993, J BIOL CHEM, V268, P11750; LOTZ MM, 1993, P NATL ACAD SCI USA, V90, P3466, DOI 10.1073/pnas.90.8.3466; MASSA SM, 1993, BIOCHEMISTRY-US, V32, P260, DOI 10.1021/bi00052a033; MATSUSHIMA N, 1990, PROTEINS, V7, P125, DOI 10.1002/prot.340070204; MECHAM RP, 1989, J BIOL CHEM, V264, P16652; MEDZIHRADSZKY KF, 1992, EUR J BIOCHEM, V203, P327, DOI 10.1111/j.1432-1033.1992.tb16553.x; MOOKHTIAR KA, 1985, BIOCHEMISTRY-US, V27, P4299; MOUTSATSOS IK, 1986, J CELL BIOL, V102, P477, DOI 10.1083/jcb.102.2.477; NIBBERING PH, 1987, CELL IMMUNOL, V105, P374, DOI 10.1016/0008-8749(87)90085-2; ODA Y, 1993, J BIOL CHEM, V268, P5929; ODA Y, 1991, GENE, V99, P279; RAZ A, 1989, CANCER RES, V49, P3489; ROBERTSON MW, 1991, J IMMUNOL, V147, P3024; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; ROSE K, 1988, BIOCHEM J, V252, P191; ROSENBERG IM, 1993, J BIOL CHEM, V268, P12393; SAKAKURA Y, 1990, J BIOL CHEM, V265, P21573; Sambrook J, 1989, MOL CLONING LABORATO; SASTRY K, 1993, CURR OPIN IMMUNOL, V5, P59, DOI 10.1016/0952-7915(93)90082-4; SATO S, 1992, J BIOL CHEM, V267, P6983; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; THOLE JER, 1990, INFECT IMMUN, V58, P80, DOI 10.1128/IAI.58.1.80-87.1990; WALLS FC, 1990, BIOLOGICAL MASS SPECTROMETRY /, P197; WANG JL, 1992, BIOCHEM SOC T, V20, P269, DOI 10.1042/bst0200269; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOO HJ, 1990, J BIOL CHEM, V265, P7097; ZHANGKECK ZY, 1993, BIOCHEM J, V289, P735, DOI 10.1042/bj2890735	57	92	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26704	26711						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253805				2022-12-27	WOS:A1993MK42500101
J	BOYER, JL; GRABER, SG; WALDO, GL; HARDEN, TK; GARRISON, JC				BOYER, JL; GRABER, SG; WALDO, GL; HARDEN, TK; GARRISON, JC			SELECTIVE ACTIVATION OF PHOSPHOLIPASE-C BY RECOMBINANT G-PROTEIN ALPHA-SUBUNIT AND BETA-GAMMA-SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACULOVIRUS EXPRESSION SYSTEM; PERTUSSIS TOXIN; RECEPTOR; PURIFICATION; CELLS; STIMULATION; MEMBRANES; CALCIUM; ISOZYME	Receptor activation of phospholipase C (PLC) via G-proteins occurs by pertussis toxin-sensitive and toxin-insensitive signaling pathways. The alpha-subunits of the G(q) family are presumed to mediate the toxin-insensitive pathway, but the nature of the G-proteins mediating the toxin-sensitive pathway is not established. Recently, PLC-beta has been shown to be activated by G-protein beta subunits of mixed or undefined composition. The relative activities of G-protein subunits that might activate PLC-beta were examined using defined recombinant alpha- and betagamma-subunits obtained from the baculovirus expression system by reconstituting the purified subunits with purified bovine brain PLC-beta1 or turkey erythrocyte PLC-beta in unilamellar phospholipid vesicles. Turkey erythrocyte Galpha11 and recombinant Galpha11 and Galpha(q) obtained after expression in Sf9 cells activated both bovine brain PLC-beta1 and turkey erythrocyte PLC-beta. In contrast, under the same assay conditions, recombinant Galpha(i1), Galpha(i2), Galpha(i3), and Galpha(o) were without effect on either type of PLC. All types of betagamma-subunits tested (rbeta1gamma2, rbeta1gamma3, rbeta2gamma2, rbeta2gamma3, bovine brain betagamma or turkey erythrocyte betagamma) inhibited Galpha11-mediated activation of PLC, presumably by promotion of formation of inactive heterotrimeric G-protein. All types of betagamma-subunits also markedly stimulated the activity of turkey erythrocyte PLC-beta but did not activate bovine brain PLC-beta1. Of the four different betagamma complexes of defined composition, three stimulated PLC with similar activities whereas beta2gamma3 was less effective. The data suggest that pertussis toxin-sensitive activation of PLC is mediated by the betagamma-subunits of G-proteins acting on specific phospholipase C isoenzymes.	UNIV N CAROLINA,SCH MED,DEPT PHARMACOL,CB 7365,FAC LAB OFF BLDG,CHAPEL HILL,NC 27599; UNIV VIRGINIA,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Virginia					NIDDK NIH HHS [DK-19952] Funding Source: Medline; NIGMS NIH HHS [GM-38213, GM-29536] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019952] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029536, R01GM029536, R01GM038213] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BOYER JL, 1992, J BIOL CHEM, V267, P25451; BOYER JL, 1989, J BIOL CHEM, V264, P13917; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CAROZZI A, 1993, FEBS LETT, V315, P340, DOI 10.1016/0014-5793(93)81190-B; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRABER SG, 1992, J BIOL CHEM, V267, P1271; GRABER SG, 1992, J BIOL CHEM, V267, P13123; GRABER SG, 1993, FASEB J, V7, P499; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; MARTIN TFJ, 1989, INOSITOL LIPIDS CELL, P81; MAURICE DH, 1993, BIOCHEM J, V290, P765, DOI 10.1042/bj2900765; MEISENHELDER J, 1989, CELL, V57, P1099; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; MORIARTY TM, 1989, J BIOL CHEM, V264, P13524; MORRIS AJ, 1990, J BIOL CHEM, V265, P13501; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; NAKAMURA T, 1985, J BIOL CHEM, V260, P3584; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; PARK D, 1992, J BIOL CHEM, V267, P16048; PARK DG, 1993, J BIOL CHEM, V268, P4573; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROBISHAW JD, 1992, BIOCHEM J, V286, P677, DOI 10.1042/bj2860677; ROONEY TA, 1991, J BIOL CHEM, V266, P15068; SHAYMAN JA, 1987, J BIOL CHEM, V262, P17083; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; VAZIRI C, 1992, BIOCHEM J, V284, P917, DOI 10.1042/bj2840917; VERGHESE MW, 1985, BIOCHEM BIOPH RES CO, V127, P450, DOI 10.1016/S0006-291X(85)80181-9; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WALDO GL, 1991, MOL PHARMACOL, V40, P480; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WU DQ, 1992, J BIOL CHEM, V267, P1811	43	109	113	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2814	2819						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300614				2022-12-27	WOS:A1994MV43200068
J	RUBIN, E; PANTAZIS, P; BHARTI, A; TOPPMEYER, D; GIOVANELLA, B; KUFE, D				RUBIN, E; PANTAZIS, P; BHARTI, A; TOPPMEYER, D; GIOVANELLA, B; KUFE, D			IDENTIFICATION OF A MUTANT HUMAN TOPOISOMERASE-I WITH INTACT CATALYTIC ACTIVITY AND RESISTANCE TO 9-NITRO-CAMPTOTHECIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGETING ANTITUMOR DRUGS; TUMOR-CELL LINES; PROTEIN-KINASE-C; EUKARYOTIC TOPOISOMERASE; DNA TOPOISOMERASES; MELANOMA-CELLS; SITE TYROSINE; LUNG-CANCER; CAMPTOTHECIN; EXPRESSION	Human U-937 myeloid leukemia cells were selected for resistance to increasing concentrations of the camptothecin derivative, 9-nitro-20(S)camptothecin (9-NC). The isolated single cell clone, designated U-937/CR, was approximately 20-fold resistant to 9-NC. Analysis of topoisomerase I (topo I) gene expression in U-937/CR cells demonstrated similar mRNA levels as compared with U-937 cells. Immunoblotting with an anti-topo I serum revealed reactive proteins at 100, 75, and 67 kDa which were expressed at the same level in the parental and 9-NC-resistant clones. These cell lines also demonstrated similar levels of topo I catalytic activity as determined by assaying nuclear extracts for relaxation of supercoiled plasmid DNA. In contrast, catalytic assays performed in the presence of 9-NC demonstrated that topo I activity from U-937/CR cells was approximately 10-fold more resistant than that from U-937 cells. Nucleotide sequencing of topo I cDNAs revealed the substitution of phenylalanine (TTC) at residue 361 in U-937 cells with serine (TCC) in the 9-NC-resistant clone. Expression and partial purification of the mutant topo I protein in Escherichia coli demonstrated resistance of this enzyme to 9-NC in catalytic assays. Taken together, these findings identify a novel mutation in topo I which confers resistance to 9-NC and support the involvemenT of this region in the interaction between topo I and 9-NC.	ST JOSEPH HOSP,STEHLIN FDN CANC RES,HOUSTON,TX 77002		RUBIN, E (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CANC PHARMACOL,BOSTON,MA 02115, USA.			Bharti, Ajit/0000-0001-7972-6688	NATIONAL CANCER INSTITUTE [P01CA038493, K08CA001664] Funding Source: NIH RePORTER; NCI NIH HHS [CA38493, 1K08CA01664-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BJORNSTI MA, 1987, P NATL ACAD SCI USA, V84, P8971, DOI 10.1073/pnas.84.24.8971; BJORNSTI MA, 1989, CANCER RES, V49, P6318; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARMICHAEL J, 1987, CANCER RES, V47, P936; CHAMPOUX JJ, 1976, P NATL ACAD SCI USA, V73, P3488, DOI 10.1073/pnas.73.10.3488; CHANG JY, 1992, BIOCHEM PHARMACOL, V43, P2443, DOI 10.1016/0006-2952(92)90325-D; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; DARPA P, 1989, BIOCHIM BIOPHYS ACTA, V989, P163, DOI 10.1016/0304-419X(89)90041-3; DEFFIE AM, 1989, CANCER RES, V49, P58; EGYHAZI E, 1987, MOL CELL BIOL, V7, P4308, DOI 10.1128/MCB.7.12.4308; ENG WK, 1990, MOL PHARMACOL, V38, P471; ENG WK, 1988, MOL PHARMACOL, V34, P755; ENG WK, 1989, J BIOL CHEM, V264, P13373; GARG LC, 1987, P NATL ACAD SCI USA, V84, P3185, DOI 10.1073/pnas.84.10.3185; GIOVANELLA BC, 1973, JNCI-J NATL CANCER I, V51, P615; GIOVANELLA BC, 1989, SCIENCE, V246, P1046, DOI 10.1126/science.2555920; GIOVANELLA BC, 1972, JNCI-J NATL CANCER I, V48, P1531; HERTZBERG RP, 1990, J BIOL CHEM, V265, P19287; HERTZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629, DOI 10.1021/bi00437a018; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; JAXEL C, 1991, J BIOL CHEM, V266, P20418; KANZAWA F, 1990, CANCER RES, V50, P5919; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KHARBANDA S, 1991, CANCER RES, V51, P6636; KJELDSEN E, 1988, J BIOL CHEM, V263, P3912; KUBOTA N, 1992, BIOCHEM BIOPH RES CO, V188, P571, DOI 10.1016/0006-291X(92)91094-7; KUDINOV AR, 1992, FEBS LETT, V314, P267, DOI 10.1016/0014-5793(92)81486-6; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MADDEN KR, 1992, CANCER RES, V52, P525; MORHAM SG, 1992, J BIOL CHEM, V267, P15984; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; PANTAZIS P, 1993, CANCER RES, V53, P1577; PANTAZIS P, 1992, CANCER RES, V52, P3980; PANTAZIS P, 1993, INT J CANCER, V53, P863, DOI 10.1002/ijc.2910530526; POMMIER Y, 1990, J BIOL CHEM, V265, P9418; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; SAMUELS DS, 1992, J BIOL CHEM, V267, P11156; Schneider E, 1990, Adv Pharmacol, V21, P149, DOI 10.1016/S1054-3589(08)60342-7; SUGIMOTO Y, 1990, CANCER RES, V50, P6925; SUGIMOTO Y, 1990, CANCER RES, V50, P7962; SVEJSTRUP JQ, 1991, J MOL BIOL, V222, P669, DOI 10.1016/0022-2836(91)90503-X; TAMURA H, 1991, NUCLEIC ACIDS RES, V19, P69, DOI 10.1093/nar/19.1.69; TAN KB, 1989, J NATL CANCER I, V81, P1732, DOI 10.1093/jnci/81.22.1732; TANIZAWA A, 1992, CANCER RES, V52, P1848; TANIZAWA A, 1993, P AACR, V34, P2522; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WANI MC, 1986, J MED CHEM, V29, P2358, DOI 10.1021/jm00161a035; ZHANG H, 1990, CANCER CELL-MON REV, V2, P23; ZUMSTEIN L, 1986, J MOL BIOL, V191, P333, DOI 10.1016/0022-2836(86)90130-0	55	124	126	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2433	2439						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300570				2022-12-27	WOS:A1994MV43200017
J	ZHENG, Y; CERIONE, R; BENDER, A				ZHENG, Y; CERIONE, R; BENDER, A			CONTROL OF THE YEAST BUD-SITE ASSEMBLY GTPASE CDC42 - CATALYSIS OF GUANINE-NUCLEOTIDE EXCHANGE BY CDC24 AND STIMULATION OF GTPASE ACTIVITY BY BEM3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CELL CYCLE GENE; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; ACTIVATING PROTEIN; ESCHERICHIA-COLI; FUSION PROTEINS; BINDING PROTEIN; HUMAN HOMOLOG; IDENTIFICATION; PRODUCT	Bud emergence in Saccharomyces cerevisiae involves cell cycle-regulated reorganizations of cortical cytoskeletal elements and requires the action of the Rho (Ras homologous)-type GTPase Cdc42. As a first step toward understanding how these cytoskeletal rearrangements are controlled, we have sought to identify those proteins that regulate the binding and hydrolysis of GTP by Cdc42. Here we report that the product of the CDC24 gene, which is required for proper bud-site selection and bud emergence, can stimulate the exchange of GTP for GDP on Cdc42. Combined with previously reported genetic data, this finding suggests that the processes of bud-site selection (which requires the action of a Ras-type GTPase) and bud-site assembly might be coordinated through an activator of a Rho-type GTPase. We also report the identification of a new gene, BEM3, that is a multicopy suppressor of the temperature-sensitive lethality caused by mutations in the bud emergence gene BEM2. Bem3 and Bem2 both contain a Rho GTPase-activating protein homology domain, but only Bem3 is able to stimulate the hydrolysis of GTP on Cdc42. These studies demonstrate that Cdc24 and Bem3 have GDP-release factor activity and GTPase-activating protein activity, respectively, toward the essential bud-site assembly GTPase Cdc42.	INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405	Indiana University System; Indiana University Bloomington	ZHENG, Y (corresponding author), CORNELL UNIV,DEPT PHARMACOL,ITHACA,NY 14850, USA.		Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046271, R01GM047458, R01GM046271] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46271, GM47458] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; BENDER A, 1991, MOL CELL BIOL, V11, P1295, DOI 10.1128/MCB.11.3.1295; BENDER A, 1993, P NATL ACAD SCI USA, V90, P9926, DOI 10.1073/pnas.90.21.9926; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HART MJ, 1990, J BIOL CHEM, V265, P5990; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HART MJ, 1991, J BIOL CHEM, V266, P20840; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HOLDEN JL, 1991, J BIOL CHEM, V266, P16992; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KOLAND JG, 1990, BIOCHEM BIOPH RES CO, V166, P90, DOI 10.1016/0006-291X(90)91915-F; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIYAMOTO S, 1987, GENE, V54, P125, DOI 10.1016/0378-1119(87)90354-4; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; PARK HO, 1993, NATURE, V365, P269, DOI 10.1038/365269a0; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; RON D, 1991, NEW BIOL, V3, P372; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395	30	237	242	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2369	2372						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300560				2022-12-27	WOS:A1994MV43200006
J	HERZ, U; SCHRODER, W; LIDDELL, A; LEAVER, CJ; BRENNICKE, A; GROHMANN, L				HERZ, U; SCHRODER, W; LIDDELL, A; LEAVER, CJ; BRENNICKE, A; GROHMANN, L			PURIFICATION OF THE NADH UBIQUINONE OXIDOREDUCTASE (COMPLEX-I) OF THE RESPIRATORY-CHAIN FROM THE INNER MITOCHONDRIAL-MEMBRANE OF SOLANUM-TUBEROSUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROSPORA-CRASSA-MITOCHONDRIA; BOVINE HEART-MITOCHONDRIA; CYTOCHROME-C REDUCTASE; NAD(P)H DEHYDROGENASES; ENCODED SUBUNITS; PROTEINS; DNA; PHOSPHOLIPIDS; SEQUENCES; IMPORT	The plant NADH:ubiquinone oxidoreductase (or complex I) was isolated from potato (Solanum tuberosum) mitochondria. The multisubunit enzyme was solubilized with detergents, Triton X-100 and 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS), out of the inner mitochondrial membranes and purified by hydroxylapatite and gel filtration chromatography. The preparation was found to be virtually free of any ATPase or transhydrogenase contamination. Complex I of potato is composed of at least 32 individual subunits as detected in silver-stained sodium dodecyl sulfate-polyacrylamide gel electrophoresis and has a total molecular mass of about 900 kDa. The enzyme preparation showed an NADH:ubiquinone-2 reductase activity of 11.5 mumol x min-1 x mg-1 and is strongly inhibited by rotenone. Heterologous polyclonal antibodies against the 70- and 49-kDa subunits of the Neurospora crassa complex I and against the wheat NAD9 subunit cross-reacted specifically with the respective potato subunits. Four of the 10 NH2-terminal sequences determined show significant similarities to Neurospora or bovine complex I subunits and allow a tentative assignment of these subunits.	INST GENBIOL FORSCH BERLIN,IHNESTR 63,D-14195 BERLIN,GERMANY; FREE UNIV BERLIN,INST BIOCHEM,D-14195 BERLIN,GERMANY; UNIV OXFORD,DEPT PLANT SCI,OXFORD OX1 3RB,ENGLAND	Free University of Berlin; University of Oxford								BERGER S, 1993, PLANTA, V190, P25, DOI 10.1007/BF00195671; BONEN L, 1991, 3RD INT C PLANT MOL, P123; BRAUN HP, 1992, EUR J BIOCHEM, V208, P761, DOI 10.1111/j.1432-1033.1992.tb17245.x; CARLENOR E, 1988, PLANT PHYSIOL, V88, P3003; CHOMYN A, 1986, SCIENCE, V234, P614, DOI 10.1126/science.3764430; CHOMYN A, 1985, NATURE, V314, P592, DOI 10.1038/314592a0; FEARNLEY IM, 1991, BIOCHEM J, V278, P821, DOI 10.1042/bj2780821; FEARNLEY IM, 1989, EMBO J, V8, P655; FRIEDRICH T, 1989, EUR J BIOCHEM, V180, P173, DOI 10.1111/j.1432-1033.1989.tb14629.x; FRIEDRICH T, 1990, FEBS LETT, V265, P37, DOI 10.1016/0014-5793(90)80878-M; HACK E, 1983, EMBO J, V2, P1783, DOI 10.1002/j.1460-2075.1983.tb01658.x; HAWKESFORD MJ, 1989, PLANT PHYSIOL, V91, P1535, DOI 10.1104/pp.91.4.1535; ISE W, 1985, EMBO J, V4, P2075, DOI 10.1002/j.1460-2075.1985.tb03894.x; KIMURA T, 1989, J BIOL CHEM, V264, P3183; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETERME S, 1993, PLANT PHYSIOL, V102, P435, DOI 10.1104/pp.102.2.435; LINKE P, 1986, EUR J BIOCHEM, V158, P615, DOI 10.1111/j.1432-1033.1986.tb09799.x; MATSUSHITA K, 1987, BIOCHEMISTRY-US, V26, P7732, DOI 10.1021/bi00398a029; MOLLER IM, 1986, ANNU REV PLANT PHYS, V37, P309, DOI 10.1146/annurev.arplant.37.1.309; ODA K, 1992, J MOL BIOL, V223, P1, DOI 10.1016/0022-2836(92)90708-R; PILKINGTON SJ, 1993, BIOCHEM SOC T, V21, P26, DOI 10.1042/bst0210026; PILKINGTON SJ, 1991, BIOCHEMISTRY-US, V30, P1901, DOI 10.1021/bi00221a024; PREIS D, 1990, CURR GENET, V18, P59, DOI 10.1007/BF00321116; RAGAN CI, 1973, J BIOL CHEM, V248, P6876; RAGAN CI, 1978, BIOCHEM J, V172, P539, DOI 10.1042/bj1720539; RAGAN CI, 1976, BIOCHIM BIOPHYS ACTA, V456, P249, DOI 10.1016/0304-4173(76)90001-X; RASMUSSON AG, 1990, PLANT PHYSIOL, V94, P1012, DOI 10.1104/pp.94.3.1012; RASMUSSON AG, 1991, PHYSIOL PLANTARUM, V83, P357, DOI 10.1111/j.1399-3054.1991.tb00106.x; ROHLEN DA, 1991, FEBS LETT, V278, P75, DOI 10.1016/0014-5793(91)80087-J; SACKMANN U, 1991, EUR J BIOCHEM, V200, P463, DOI 10.1111/j.1432-1033.1991.tb16205.x; SOOLE KL, 1992, PLANT PHYSIOL, V98, P588, DOI 10.1104/pp.98.2.588; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUSCHEN G, 1990, J MOL BIOL, V213, P845, DOI 10.1016/S0022-2836(05)80268-2; VANDERPAS JC, 1991, BIOCHIM BIOPHYS ACTA, V1089, P389, DOI 10.1016/0167-4781(91)90181-K; VIDEIRA A, 1990, BIOCHEM BIOPH RES CO, V171, P1168, DOI 10.1016/0006-291X(90)90807-Y; WALKER JE, 1992, J MOL BIOL, V226, P1051, DOI 10.1016/0022-2836(92)91052-Q; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; WEISS H, 1991, EUR J BIOCHEM, V197, P563, DOI 10.1111/j.1432-1033.1991.tb15945.x; WINNING BM, 1992, PLANT J, V2, P763, DOI 10.1046/j.1365-313X.1992.t01-15-00999.x; YAGI T, 1993, BIOCHIM BIOPHYS ACTA, V1141, P1, DOI 10.1016/0005-2728(93)90182-F	40	65	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2263	2269						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294484				2022-12-27	WOS:A1994MR98800106
J	HORITA, DA; HAJDUK, PJ; GOETINCK, PF; LERNER, LE				HORITA, DA; HAJDUK, PJ; GOETINCK, PF; LERNER, LE			NMR-STUDIES OF PEPTIDES DERIVED FROM THE PUTATIVE BINDING REGIONS OF CARTILAGE PROTEINS - NO EVIDENCE FOR BINDING TO HYALURONAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINK PROTEIN; PROTEOGLYCANS; DOMAINS; ACID	Previous work has implicated sequences within the tandem repeats of cartilage link protein in the interaction of link protein with hyaluronan. This conclusion was based on competitive inhibition experiments using synthetic peptides (Goetinck, P. F., Stirpe, N. S., Tsonis, P. A., and Carlone, D. (1987) J. Cell Biol. 105, 2403-2407). Further investigation of this system using high resolution nuclear magnetic resonance, circular dichroism, and competitive inhibition with other peptides indicates that the previously observed inhibition of link protein-hyaluronan binding was not caused by peptide-hyaluronan interactions. Instead, nonspecific aggregation of the peptides with link protein is proposed to account for all of the experimental data. Consequently, there is no direct experimental evidence to support the conclusion that these sequences in the tandem repeats of link protein are responsible for the link protein-hyaluronan interaction. If these peptides do represent the hyaluronan binding regions of link protein, these results imply a highly structure-dependent interaction between link protein and hyaluronan. Conformational analysis of the peptides using two-dimensional nuclear Overhauser spectroscopy indicates that the linear peptides do not adopt any stable secondary structure. However, several residues in the disulfide-looped peptides exhibit connectivities, suggesting a relatively long-lived extended chain conformation, consistent with predictions of secondary structure based on sequence analysis.	UNIV WISCONSIN,DEPT CHEM,1101 UNIV AVE,MADISON,WI 53706; MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,BOSTON,MA 02129	University of Wisconsin System; University of Wisconsin Madison; Harvard University; Massachusetts General Hospital				Horita, David/0000-0002-9563-107X	NCRR NIH HHS [SIO RRO 4981] Funding Source: Medline; NIAMS NIH HHS [R29 AR39801] Funding Source: Medline; NICHD NIH HHS [HD 22016] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022016] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039801] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAX A, 1986, J MAGN RESON, V67, P565, DOI 10.1016/0022-2364(86)90395-1; GOETINCK PF, 1987, J CELL BIOL, V105, P2403, DOI 10.1083/jcb.105.5.2403; HASCALL VC, 1974, J BIOL CHEM, V249, P4242; HASCALL VC, 1977, J SUPRAMOL STR CELL, V7, P101, DOI 10.1002/jss.400070110; LEE KK, 1991, HPLC PEPTIDES PROTEI, P389; LYON M, 1986, BIOCHIM BIOPHYS ACTA, V881, P22, DOI 10.1016/0304-4165(86)90092-9; Maroudas A, 1986, ARTICULAR CARTILAGE, P311; NEAME PJ, 1987, J BIOL CHEM, V262, P17768; PERIN JP, 1987, J BIOL CHEM, V262, P13269; PERKINS SJ, 1989, J MOL BIOL, V206, P737, DOI 10.1016/0022-2836(89)90580-9; ROSENBERG L, 1991, J BIOL CHEM, V266, P7016; SUMMERS MF, 1986, J AM CHEM SOC, V108, P4285, DOI 10.1021/ja00275a008; TANG LH, 1979, J BIOL CHEM, V254, P523; VOLD RL, 1968, J CHEM PHYS, V48, P3831, DOI 10.1063/1.1669699; WRIGHT PE, 1988, BIOCHEMISTRY-US, V27, P7167, DOI 10.1021/bi00419a001; Wuthrich K, 1986, NMR PROTEINS NUCL AC, P117	16	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1699	1704						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294417				2022-12-27	WOS:A1994MR98800027
J	KAPELLER, R; PRASAD, KVS; JANSSEN, O; HOU, W; SCHAFFHAUSEN, BS; RUDD, CE; CANTLEY, LC				KAPELLER, R; PRASAD, KVS; JANSSEN, O; HOU, W; SCHAFFHAUSEN, BS; RUDD, CE; CANTLEY, LC			IDENTIFICATION OF 2 SH3-BINDING MOTIFS IN THE REGULATORY SUBUNIT OF PHOSPHATIDYLINOSITOL 3-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; RECEPTOR TYROSINE KINASES; SIGNAL TRANSDUCTION; SH3 DOMAINS; C-SRC; GROWTH; PI3-KINASE; EXPRESSION; P60C-SRC; BINDING	Src homology 3 (SH3) domains have been recently shown to bind to proline-rich sequences contained in 3BP1, 3BP2, and SOS. In a recent study we demonstrated that phosphatidylinositol 3-kinase (PI 3-kinase) associates with the Fyn SH3 domain. Here we show that p85, the regulatory subunit of PI 3-kinase, binds directly to the SH3 domains of Abl, Lck, Fyn, and p85 itself. An examination of p85 amino acid sequence revealed two proline-rich sequences in its N-terminal region similar to those present in 3BP1, 3BP2, and SOS. To test whether these sequences mediate the association of p85 with SH3 domains two peptides with amino acid composition corresponding to the p85alpha proline-rich sequences were synthesized and used in competition assays. Both peptides worked equally well in inhibiting the binding of PI 3-kinase activity and p85alpha to Fyn SH3 domain, whereas a control peptide had no effect. These results indicate that, as in 3BP1 and SOS, the proline-rich sequences in p85 mediate its interaction with SH3 domains. These results also suggest that the SH3 domain of p85 may ''self-associate'' with the proline-rich motifs of the same subunit as part of the PI 3-kinase regulatory mechanism.	TUFTS UNIV, SCH MED, DEPT PHYSIOL, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02111 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, BOSTON, MA 02115 USA	Tufts University; Tufts University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	KAPELLER, R (corresponding author), HARVARD UNIV, BETH ISRAEL HOSP,SCH MED,DEPT MED, DIV SIGNAL TRANSDUCT, 200 LONGWOOD AVE EQRF, BOSTON, MA 02215 USA.		Rudd, Christopher E/GOH-2021-2022; Janssen, Ottmar/N-8769-2019; Janssen, Ottmar/E-9735-2010; Cantley, Lewis C/D-1800-2014; Rudd, Christopher E/ABF-7259-2021	Rudd, Christopher E/0000-0001-5295-9019; Janssen, Ottmar/0000-0002-9612-8900; Janssen, Ottmar/0000-0002-9612-8900; Cantley, Lewis C/0000-0002-1298-7653; 	NATIONAL CANCER INSTITUTE [R01CA034722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036624, R01GM041890, R37GM041890] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA034722] Funding Source: Medline; NIGMS NIH HHS [R01 GM041890, GM 36624, GM 41890] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1991, CANCER CELL-MON REV, V3, P263; AUGER KR, 1992, J BIOL CHEM, V267, P5408; AUGER KR, 1990, METHODS INOSITIDE RE, P155; Ausubel FM, 1991, CURRENT PROTOCOLS MO; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PIWNICAWORMS H, 1990, J VIROL, V64, P61, DOI 10.1128/JVI.64.1.61-68.1990; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; PRASAD KVS, 1993, IN PRESS MOL CELL BI; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	35	133	137	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1927	1933						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294442				2022-12-27	WOS:A1994MR98800058
J	PERLMAN, JH; THAW, CN; LAAKKONEN, L; BOWERS, CY; OSMAN, R; GERSHENGORN, MC				PERLMAN, JH; THAW, CN; LAAKKONEN, L; BOWERS, CY; OSMAN, R; GERSHENGORN, MC			HYDROGEN-BONDING INTERACTION OF THYROTROPIN-RELEASING-HORMONE (TRH) WITH TRANSMEMBRANE TYROSINE-106 OF THE TRH RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MUSCARINIC CHOLINERGIC RECEPTORS; PROTEIN-COUPLED RECEPTORS; SITE-DIRECTED MUTAGENESIS; RAT PITUITARY-CELLS; MOLECULAR-BIOLOGY; NEUROKININ-1 RECEPTOR; ADRENERGIC-RECEPTORS; EXTRACELLULAR DOMAIN; ANTAGONIST BINDING; HIGH-AFFINITY	Thyrotropin-releasing hormone (TRH, pyroglutamic acid-histidine-proline-amide) binds to a seven-transmembrane-spanning, G protein-coupled receptor. We tested the hypothesis that Tyr106 of the third transmembrane helix of the TRH receptor (TRH-R) binds pyroglutamyl of TRH by mutating Tyr106 to Phe and replacing the ring carbonyl of the TRH pyroglutamyl moiety with a methylene group ([Pro1]TRH). Compared to the affinity of wild-type TRH-R for TRH, the affinities of [Phe106]TRH-R for TRH and of wild-type TRH-R for [Pro1]TRH were 100,000- and 110,000-fold lower, respectively. The affinity of [Phe106]TRH-R for [Pro1]TRH was only 16-fold lower than that for TRH, demonstrating a lack of additivity of the effects of these changes in the receptor and ligand. These data provide compelling evidence that the hydroxyl group of Tyr106 of the TRH-R binds the TRH pyroglutamyl carbonyl group. To our knowledge, this represents the highest affinity, non-covalent bond yet observed between single functional groups of a GPCR and ligand and is the first delineation of a direct binding interaction between a residue in the transmembrane core of a GPCR and a specific moiety of a peptide agonist.	CORNELL UNIV,MED CTR,COLL MED,DEPT MED,DIV MOLEC MED,1300 YORK AVE,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,NEW YORK HOSP,NEW YORK,NY 10021; CUNY MT SINAI SCH MED,DEPT PHYSIOL & BIOPHYS,NEW YORK,NY 10029; TULANE UNIV,MED CTR,DEPT MED,ENDOCRINE SECT,NEW ORLEANS,LA 70112	Cornell University; Cornell University; NewYork-Presbyterian Hospital; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Tulane University					NIDDK NIH HHS [DK 43036, DK 02101] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043036, K11DK002101] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; DELAPENA P, 1992, BIOCHEM J, V284, P891, DOI 10.1042/bj2840891; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DRUMMOND AH, 1986, J EXP BIOL, V124, P337; DRUMMOND AH, 1985, BIOCHEM BIOPH RES CO, V127, P63, DOI 10.1016/S0006-291X(85)80126-1; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; FONG TM, 1993, NATURE, V362, P350; GERSHENGORN MC, 1986, ANNU REV PHYSIOL, V48, P515; GERSHENGORN MC, 1986, ENDOCRINOLOGY, V119, P833, DOI 10.1210/endo-119-2-833; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GOREN HJ, 1977, MOL PHARMACOL, V13, P606; HOSEY MM, 1992, FASEB J, V6, P845, DOI 10.1096/fasebj.6.3.1740234; IMAI A, 1987, METHOD ENZYMOL, V141, P100; IMAI A, 1985, J BIOL CHEM, V260, P536; KAMIYA K, 1980, J CHEM SOC CHEM COMM, V10, P438; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KOSUGI S, 1992, J BIOL CHEM, V267, P24153; LIMBIRD LE, 1986, CELL SURFACE RECEPTO; LOMASNEY JW, 1991, BIOCHIM BIOPHYS ACTA, V1095, P127, DOI 10.1016/0167-4889(91)90075-9; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; METCALF G, 1989, THYROTROPIN RELEASIN; NAGAYAMA Y, 1992, MOL ENDOCRINOL, V6, P145, DOI 10.1210/me.6.2.145; NATHANS J, 1987, ANNU REV NEUROSCI, V10, P163; PERLMAN JH, 1992, J BIOL CHEM, V267, P24413; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; QUINTANA J, 1993, MOL ENDOCRINOL, V7, P767, DOI 10.1210/me.7.6.767; RAMSDELL JS, 1985, MOL CELL ENDOCRINOL, V43, P173, DOI 10.1016/0303-7207(85)90081-4; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Strader C D, 1991, Adv Exp Med Biol, V287, P209; STRADER CD, 1989, J BIOL CHEM, V264, P13572; STRAUB RE, 1990, P NATL ACAD SCI USA, V87, P9514, DOI 10.1073/pnas.87.24.9514; VENTER JC, 1989, BIOCHEM PHARMACOL, V38, P1197, DOI 10.1016/0006-2952(89)90325-0; WESS J, 1992, J BIOL CHEM, V267, P19313; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x; XIE YB, 1990, J BIOL CHEM, V265, P21411; YAMADA M, 1992, BIOCHEM BIOPH RES CO, V184, P367, DOI 10.1016/0006-291X(92)91202-2; YAMANO Y, 1992, BIOCHEM BIOPH RES CO, V187, P1426, DOI 10.1016/0006-291X(92)90461-S; ZHAO DY, 1992, ENDOCRINOLOGY, V130, P3529, DOI 10.1210/en.130.6.3529; ZHU GC, 1992, J CELL BIOCHEM, V50, P159	44	69	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1610	1613						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294406				2022-12-27	WOS:A1994MR98800012
J	HAYMAN, AR; COX, TM				HAYMAN, AR; COX, TM			PURPLE ACID-PHOSPHATASE OF THE HUMAN MACROPHAGE AND OSTEOCLAST - CHARACTERIZATION, MOLECULAR-PROPERTIES, AND CRYSTALLIZATION OF THE RECOMBINANT DI-IRON-OXO PROTEIN SECRETED BY BACULOVIRUS-INFECTED INSECT CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLOSINUS-TRICHOSPORIUM OB3B; BONE-RESORPTION; PORCINE UTEROFERRIN; METHANE MONOOXYGENASE; FREE-RADICALS; GENE-CLUSTER; SEQUENCE; EXPRESSION; CLONING; SPLEEN	The purple phosphatases catalyze hydrolysis of phosphate esters (optimum pH approximately 5) and are resistant to inhibition by dextro-rotatory tartrate; their distinctive, color is due to Fe(III)-phenolate charge-transfer transitions at their active site. Expression of human purple phosphatase, designated type 5 acid phosphatase, is restricted to osteoclasts and other activated cells of monohistiocytic lineage, but its biological role in relation to bone resorption and phagocytosis is unknown. To characterize this enzyme further, we have engineered the human type 5 acid phosphatase into a baculovirus vector expression system that enabled milligram quantities of purple protein to be purified from medium containing Sf9 host cells. The phosphatase cDNA was transcribed as a single RNA species of 1.5 kilobases as in human tissues. Tartrate-resistant acid phosphatase activity reacting with uteroferrin antisera appeared in the culture medium, from which up to 8 mg/liter was purified by two-step cation-exchange chromatography at pH 8.0. Two isoforms of approximately 36 kDa were identified by SDS-polyacrylamide electrophoresis and were converted to a single species of apparent molecular size 34 kDa upon treatment with N-glycosidase F, indicating secreted glycoforms of a single polypeptide. Mass spectroscopy showed that the mean molecular mass of the active, secreted glycoprotein was 35849 Da. The recombinant enzyme (specific activity, 190 mumol p-nitrophenol/min/mg at 37-degrees-C) contained 2 iron atoms/molecule and formed purple, monoclinic crystals. Exposure to the ferric chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, rapidly inactivated the enzyme, which was not inhibited by alpha,alpha'-bipyridyl, a ferrous chelator. That ferric iron is essential for enzymatic catalysis, was further indicated by the synergistic effects of the reductant, dithiothreitol, and bipyridyl on phosphatase activity. The recombinant purple phosphatase catalyzed the peroxidation of 5-aminophthalhydrazide (luminol), as evidenced by the induction of chemiluminescence; this reaction was inhibited by alpha,alpha'-bipyridyl at concentrations that did not inhibit phosphatase activity. The divalent iron moiety of human type 5 phosphatase may therefore participate in the generation of free radical species by fluid-phase reactions involving Fenton chemistry that are dissociated from its phosphatase function.	UNIV CAMBRIDGE, ADDENBROOKES HOSP, DEPT MED, LEVEL 5, CAMBRIDGE CB2 2QQ, ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANTANAITIS B, 1983, STRUCTURE FUNCTION I, P503; ANTANAITIS BC, 1980, J BIOL CHEM, V255, P1204; ANTANAITIS BC, 1983, J BIOL CHEM, V258, P3166; ANTANAITIS BC, 1983, ADV INORG BIOCHEM, V5, P111; Ausubel FA, 1990, CURRENT PROTOCOLS MO; BAUMBACH GA, 1984, P NATL ACAD SCI-BIOL, V81, P2985, DOI 10.1073/pnas.81.10.2985; BAX BE, 1992, BIOCHEM BIOPH RES CO, V183, P1153, DOI 10.1016/S0006-291X(05)80311-0; BECK JL, 1986, BIOCHIM BIOPHYS ACTA, V869, P61, DOI 10.1016/0167-4838(86)90310-9; BEVILACQUA MA, 1991, MOL BIOL MED, V8, P135; BOLDT DH, 1992, BLOOD, V80, pA182; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURSTONE MS, 1959, J HISTOCHEM CYTOCHEM, V7, P39, DOI 10.1177/7.1.39; CARDY DLN, 1991, MOL MICROBIOL, V5, P335, DOI 10.1111/j.1365-2958.1991.tb02114.x; CASSADY AI, 1993, IN PRESS GENE; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOY FYM, 1985, AM J MED GENET, V21, P519, DOI 10.1002/ajmg.1320210315; DAVIS JC, 1982, P NATL ACAD SCI-BIOL, V79, P4623, DOI 10.1073/pnas.79.15.4623; ECHETEBU ZO, 1987, CLIN CHEM, V33, P1832; FOX BG, 1990, BIOCHEMISTRY-US, V29, P6419, DOI 10.1021/bi00479a013; FOX BG, 1993, P NATL ACAD SCI USA, V90, P2486, DOI 10.1073/pnas.90.6.2486; GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485; GIGNAC SM, 1990, LEUKEMIA LYMPHOMA, V3, P19, DOI 10.3109/10428199009050971; GRIMES R, 1993, GENOMICS, V15, P421, DOI 10.1006/geno.1993.1079; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HAYMAN AR, 1989, BIOCHEM J, V261, P601, DOI 10.1042/bj2610601; HENLEY R, 1991, ARCH BIOCHEM BIOPHYS, V286, P238, DOI 10.1016/0003-9861(91)90035-H; JOHNSTON RB, 1978, J EXP MED, V148, P115; KETCHAM CM, 1989, J BIOL CHEM, V264, P557; KETCHAM CM, 1985, J BIOL CHEM, V260, P5768; KEY LL, 1990, BONE, V11, P115, DOI 10.1016/8756-3282(90)90058-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDERS JW, 1958, AM J CLIN PATHOL, V29, P590; LAU KHW, 1987, CLIN CHEM, V33, P458; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LI CY, 1970, J HISTOCHEM CYTOCHEM, V18, P901, DOI 10.1177/18.12.901; LORD DK, 1990, EUR J BIOCHEM, V189, P287, DOI 10.1111/j.1432-1033.1990.tb15488.x; Maniatis T, 1989, MOL CLONING; MCPHAIL LC, 1979, J CLIN INVEST, V63, P648, DOI 10.1172/JCI109347; McPherson A, 1982, PREPARATION ANAL PRO; MILLER SC, 1985, CALCIFIED TISSUE INT, V37, P526, DOI 10.1007/BF02557836; MOONGA BS, 1990, J PHYSIOL-LONDON, V429, P29, DOI 10.1113/jphysiol.1990.sp018242; MURRAY HW, 1980, J INVEST DERMATOL, V74, P285, DOI 10.1111/1523-1747.ep12543457; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; NORDLUND I, 1990, J BACTERIOL, V172, P6826, DOI 10.1128/jb.172.12.6826-6833.1990; OSDOBY P, 1987, BIOESSAYS, V7, P30, DOI 10.1002/bies.950070107; QUE L, 1990, PROG INORG CHEM, V38, P97; QUE L, 1988, ACS SYM SER, V372, P152; ROBERTS RM, 1986, FED PROC, V45, P2513; ROBERTS RM, 1984, BIOESSAYS, V1, P8, DOI 10.1002/bies.950010106; ROBINSON DB, 1980, CLIN CHEM, V26, P371; SCHINDELMEISER J, 1987, HISTOCHEMISTRY, V87, P13, DOI 10.1007/BF00518719; SCHLOSNAGLE DC, 1976, J BIOL CHEM, V251, P4680; SJOBERG BM, 1982, BIOCHEMISTRY-US, V21, P96; STENKAMP RE, 1981, NATURE, V291, P263, DOI 10.1038/291263a0; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; VINCENT JB, 1990, FEBS LETT, V263, P265, DOI 10.1016/0014-5793(90)81389-6; WHITAKER KB, 1989, CLIN CHEM, V35, P86; YAM LT, 1974, AM J MED, V56, P604, DOI 10.1016/0002-9343(74)90630-5; YAM LT, 1972, ARCH INTERN MED, V130, P248, DOI 10.1001/archinte.130.2.248; YEN KM, 1991, J BACTERIOL, V173, P5315, DOI 10.1128/jb.173.17.5315-5327.1991	61	119	127	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1294	1300						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288593				2022-12-27	WOS:A1994MR22000083
J	ISHII, K; CHEN, J; ISHII, M; KOCH, WJ; FREEDMAN, NJ; LEFKOWITZ, RJ; COUGHLIN, SR				ISHII, K; CHEN, J; ISHII, M; KOCH, WJ; FREEDMAN, NJ; LEFKOWITZ, RJ; COUGHLIN, SR			INHIBITION OF THROMBIN RECEPTOR SIGNALING BY A G-PROTEIN COUPLED RECEPTOR KINASE - FUNCTIONAL SPECIFICITY AMONG G-PROTEIN COUPLED RECEPTOR KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; RAT-BRAIN; 3T3 CELLS; FAMILY; ACTIVATION; PEPTIDES; CLONING; DESENSITIZATION; PURIFICATION; EXPRESSION	The thrombin receptor, a member of the seven membrane-spanning superfamily of G-protein coupled receptors, is activated by an irreversible proteolytic mechanism, but signaling by activated thrombin receptors shuts off soon after receptor activation. This shut-off mechanism is thought to be required for concentration-dependent responses to thrombin and an important determinant of the cell's sensitivity to thrombin. We report that the thrombin receptor is rapidly phosphorylated upon activation, consistent with the action of a G-protein-coupled receptor kinase. Moreover, the G-protein coupled receptor kinase BARK2 (beta-adrenergic receptor kinase 2) blocked signaling by thrombin receptors coexpressed in Xenopus oocytes. In this system, rhodopsin kinase was inactive and BARK1 was markedly less effective than BARK2. Thrombin receptor mutants which lacked potential serine and threonine phosphorylation sites in the receptor's cytoplasmic tail were insensitive to inhibition by exogenous BARK2 but did confer concentration-dependent responses to thrombin. Our studies demonstrate that a G-protein coupled receptor kinase can shut off thrombin receptor signaling but that additional mechanism(s) for terminating signaling exist. These studies also reveal functional specificity among G-protein coupled receptor kinases in a novel in vivo reconstitution system and show that heterologous expression of these kinases can be used to manipulate cellular responsiveness.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; DUKE UNIV,SCH MED,HOWARD HUGHES MED INST,DURHAM,NC 27706	University of California System; University of California San Francisco; Duke University; Howard Hughes Medical Institute			Lefkowitz, Robert/AAW-2649-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL043821, R01HL016037, R01HL044907, R37HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43821, HL16037, HL44907] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ambrose Christine, 1992, Human Molecular Genetics, V1, P697, DOI 10.1093/hmg/1.9.697; ARRIZA JL, 1992, J NEUROSCI, V12, P4045; ARRIZA JL, 1992, J BIOL CHEM, V267, P1422; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; COLLINS MKL, 1984, J CELL PHYSIOL, V118, P133, DOI 10.1002/jcp.1041180205; COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HUGH DT, 1992, J CLIN INVEST, V89, P1350; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; ISHII K, 1993, J BIOL CHEM, V268, P9780; KARNIK SS, 1993, P NATL ACAD SCI USA, V90, P40, DOI 10.1073/pnas.90.1.40; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LANZA F, 1991, J BIOL CHEM, V266, P10638; LIU LW, 1991, J BIOL CHEM, V266, P16977; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PRICKETT KS, 1989, BIOTECHNIQUES, V7, P580; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; ROZENGURT E, 1984, P NATL ACAD SCI-BIOL, V81, P5748, DOI 10.1073/pnas.81.18.5748; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WALZ DA, 1986, ANN NY ACAD SCI, V485	34	224	228	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1125	1130						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288570				2022-12-27	WOS:A1994MR22000056
J	KHARBANDA, S; SALEEM, A; EMOTO, Y; STONE, R; RAPP, U; KUFE, D				KHARBANDA, S; SALEEM, A; EMOTO, Y; STONE, R; RAPP, U; KUFE, D			ACTIVATION OF RAF-1 AND MITOGEN-ACTIVATED PROTEIN-KINASES DURING MONOCYTIC DIFFERENTIATION OF HUMAN MYELOID-LEUKEMIA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; TUMOR NECROSIS FACTOR; C-JUN EXPRESSION; GROWTH-FACTOR; OKADAIC ACID; MAP KINASE; GENE-EXPRESSION; FOS GENE; MOLECULAR-CLONING; INDUCTION	Treatment of human myeloid leukemia cells with 12-O-tetradecanoylphorbol-13-acetate (TPA), an activator of protein kinase C (PKC), is associated with induction of monocytic differentiation. Since PKC can act immediately upstream to the cytoplasmic Raf-1 serine/threonine protein kinase, we studied activation of Raf-1 during induction of the differentiated monocytic phenotype. The results demonstrate that Raf-1 is activated during TPA-induced monocytic differentiation of HL-60 cells. In contrast, there was little effect of TPA on this kinase in an HL-60 variant, designated HL-525, which is resistant to TPA-induced differentiation. Treatment of both HL-60 and HL-525 cells with okadaic acid, an inhibitor of serine/threonine protein phosphatases 1 and 2A, was associated with Raf-1 activation and induction of the monocytic phenotype. Since Raf-1 can activate the mitogen-activated protein (MAP) kinases, we also studied the relationship between MAP kinase activation and monocytic differentiation. Treatment of HL-60, but not HL-525, cells with TPA was associated with increased MAP kinase activity as determined by phosphorylation of myelin basic protein and the c-Jun Y peptide. Okadaic acid-induced differentiation of both HL-60 and HL-525 cells was similarly accompanied by increases in MAP kinase activity. These findings indicated that activation of Raf-1/MAP kinase signaling is associated with induction of a differentiated monocytic phenotype and that okadaic acid by-passes a defect in this cascade in TPA-treated HL-525 cells. While recent studies have shown that HL-525 cells are deficient in PKCbeta, the present results demonstrate that PKCbeta expression is up-regulated in the HL-525 variant by treatment with retinoic acid. The results also demonstrate that retinoic acid-treated HL-525 cells respond to TPA with activation of Raf-1 and MAP kinase, as well as induction of monocytic differentiation. Taken together, the results indicate that activation of Raf-1/MAP kinase signaling is associated with monocytic differentiation and that stimulation of serine/threonine protein phosphorylation by TPA or okadaic acid is sufficient for reversal of the leukemic HL-60 phenotype.	NCI,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	KHARBANDA, S (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,CLIN PHARMACOL LAB,BOSTON,MA 02115, USA.				NCI NIH HHS [CA42802] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042802] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COLLINS SJ, 1987, BLOOD, V70, P1233; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; DATTA R, 1992, BIOCHEMISTRY-US, V31, P8300, DOI 10.1021/bi00150a025; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DUNYAH SE, 1992, J CELL PHYSL, V151, P415; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GROSSO LE, 1985, CANCER RES, V45, P847; GUNJI H, 1992, J CLIN INVEST, V89, P954, DOI 10.1172/JCI115677; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HIDAKA H, 1988, J BIOL CHEM, V263, P4523; HOMMA Y, 1986, P NATL ACAD SCI USA, V83, P7316, DOI 10.1073/pnas.83.19.7316; HORIGUCHI J, 1986, BIOCHEM BIOPH RES CO, V141, P924, DOI 10.1016/S0006-291X(86)80131-0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUBERMAN E, 1979, P NATL ACAD SCI USA, V76, P1293, DOI 10.1073/pnas.76.3.1293; KHARBANDA S, 1993, CELL GROWTH DIFFER, V4, P17; KHARBANDA S, 1992, CELL GROWTH DIFFER, V3, P391; KHARBANDA S, 1991, J CLIN INVEST, V88, P571, DOI 10.1172/JCI115341; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LOTEM J, 1979, P NATL ACAD SCI USA, V76, P5158, DOI 10.1073/pnas.76.10.5158; MAKOWSKE M, 1988, J BIOL CHEM, V263, P3402; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; NAKAMURA T, 1991, CELL GROWTH DIFFER, V2, P267; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PANTAZIS P, 1986, P NATL ACAD SCI USA, V83, P6455, DOI 10.1073/pnas.83.17.6455; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RAPP UR, 1991, ONCOGENE, V6, P495; ROVERA G, 1979, SCIENCE, V204, P868, DOI 10.1126/science.286421; ROVERA G, 1982, ANN NY ACAD SCI, V397, P211, DOI 10.1111/j.1749-6632.1982.tb43428.x; SARIBAN E, 1985, NATURE, V316, P64, DOI 10.1038/316064a0; SHERMAN ML, 1990, J BIOL CHEM, V265, P3320; SOZERI O, 1992, ONCOGENE, V7, P2259; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; SZABO E, 1991, CELL GROWTH DIFFER, V2, P475; TONETTI DA, 1992, CELL GROWTH DIFFER, V3, P739; WANG AM, 1985, SCIENCE, V228, P149, DOI 10.1126/science.3856324; WILLIAM F, 1990, J BIOL CHEM, V265, P18166; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU BY, 1989, J BIOL CHEM, V264, P9000	56	114	114	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					872	878						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288641				2022-12-27	WOS:A1994MR22000019
J	RUSCH, SL; KENDALL, DA				RUSCH, SL; KENDALL, DA			TRANSPORT OF AN EXPORT-DEFECTIVE PROTEIN BY A HIGHLY HYDROPHOBIC SIGNAL PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID RESIDUES; COLI MEMBRANE-VESICLES; PROTON MOTIVE FORCE; ESCHERICHIA-COLI; INVITRO TRANSLOCATION; PRECURSOR PROTEINS; SECRETORY PROTEINS; POSITIVE CHARGE; INNER MEMBRANE; MATURE DOMAIN	We have examined the sequence constraints on the amino-terminal region of the mature portion of alkaline phosphatase that are important for its efficient transport in Escherichia coli. Using a homopolymeric sequence of serines to replace 6 residues in this region, a transport-incompetent mutant was produced. Reintroduction of residues from the native sequence which restore charge and beta-turn potential resulted in little improvement. However, by replacing the hydrophobic core of the signal peptide with a homopolymeric series of leucines, not only was transport restored but precursor processing was more efficient than for the wild type and was insensitive to disruption of the protonmotive force. Moreover, we have titrated the signal peptide with leucine to alanine substitutions (Doud, S. K., Chou, M. M., and Kendall, D. A. (1993) Bioehemistry 32,1251-1256) and determined the minimum level of hydrophobicity necessary to achieve transport of the mutant protein. The results indicate that signal peptide hydrophobicity can completely override possible requirements for negatively charged residues and strong beta-turn forming potential in the mature protein and that the polyleucine-containing signal peptide may act as a generic signal sequence for the transport of non-native proteins in E. coli.	UNIV CONNECTICUT,DEPT MOLEC & CELL BIOL,BOX U-44,STORRS,CT 06269	University of Connecticut					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037639] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37639] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON H, 1991, P NATL ACAD SCI USA, V88, P9751, DOI 10.1073/pnas.88.21.9751; ANDERSSON H, 1992, J BIOL CHEM, V267, P1491; BASSILANA M, 1992, J BIOL CHEM, V267, P25246; BOYD D, 1989, P NATL ACAD SCI USA, V86, P9446, DOI 10.1073/pnas.86.23.9446; CHOU MM, 1990, J BIOL CHEM, V265, P2873; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DANIELS CJ, 1981, P NATL ACAD SCI-BIOL, V78, P5396, DOI 10.1073/pnas.78.9.5396; DOUD SK, 1993, BIOCHEMISTRY-US, V32, P1251, DOI 10.1021/bi00056a008; DRIESSEN AJM, 1991, P NATL ACAD SCI USA, V88, P2471, DOI 10.1073/pnas.88.6.2471; DUFFAUD G, 1988, J BIOL CHEM, V263, P10224; ENEQUIST HG, 1981, EUR J BIOCHEM, V116, P227, DOI 10.1111/j.1432-1033.1981.tb05323.x; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FERENCI T, 1987, J BACTERIOL, V169, P5339, DOI 10.1128/jb.169.12.5339-5342.1987; GELLER BL, 1986, P NATL ACAD SCI USA, V83, P4219, DOI 10.1073/pnas.83.12.4219; GENNITY J, 1990, J BIOENERG BIOMEMBR, V22, P223; GOLDSTEIN J, 1990, J BACTERIOL, V172, P1225, DOI 10.1128/jb.172.3.1225-1231.1990; HIKITA C, 1992, J BIOL CHEM, V267, P12375; INOUYE M, 1980, CRC CR REV BIOCH MOL, V7, P339, DOI 10.3109/10409238009105465; INOUYE S, 1982, P NATL ACAD SCI-BIOL, V79, P3438, DOI 10.1073/pnas.79.11.3438; INOUYE S, 1986, J BIOL CHEM, V261, P970; KADONAGA JT, 1984, J BIOL CHEM, V259, P2149; KATO M, 1992, J BIOL CHEM, V267, P413; KENDALL DA, 1988, J BIOL CHEM, V263, P7261; KENDALL DA, 1986, NATURE, V321, P706, DOI 10.1038/321706a0; KUHN A, 1985, J BIOL CHEM, V260, P5914; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFORET GA, 1991, J BIOL CHEM, V266, P1326; LI P, 1988, P NATL ACAD SCI USA, V85, P7685, DOI 10.1073/pnas.85.20.7685; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LISS LR, 1985, J BACTERIOL, V164, P925, DOI 10.1128/JB.164.2.925-928.1985; MACINTYRE S, 1990, MOL GEN GENET, V221, P466; MCKNIGHT CJ, 1991, P NATL ACAD SCI USA, V88, P5799, DOI 10.1073/pnas.88.13.5799; Miller J.H., 1972, EXPT MOL GENETICS; MORENO F, 1980, NATURE, V286, P356, DOI 10.1038/286356a0; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; PUZISS JW, 1989, J BACTERIOL, V171, P2303, DOI 10.1128/jb.171.5.2303-2311.1989; RANDALL LL, 1987, ANNU REV MICROBIOL, V41, P507; RASMUSSEN BA, 1987, GENE DEV, V1, P185, DOI 10.1101/gad.1.2.185; ROSENBLATT M, 1980, P NATL ACAD SCI-BIOL, V77, P3983, DOI 10.1073/pnas.77.7.3983; RUSSEL M, 1982, CELL, V28, P177, DOI 10.1016/0092-8674(82)90387-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHULDINER S, 1975, BIOCHEMISTRY-US, V14, P5451, DOI 10.1021/bi00696a011; SUMMERS RG, 1989, J BIOL CHEM, V264, P20074; SUMMERS RG, 1989, J BIOL CHEM, V264, P20082; SUNG CY, 1992, J BIOL CHEM, V267, P997; TOMMASSEN J, 1985, EMBO J, V4, P1041, DOI 10.1002/j.1460-2075.1985.tb03736.x; VLASUK GP, 1984, J BIOL CHEM, V259, P6195; VLASUK GP, 1983, J BIOL CHEM, V258, P7141; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; VONHEIJNE G, 1986, J MOL BIOL, V192, P287, DOI 10.1016/0022-2836(86)90365-7; YAMADA H, 1989, J BIOL CHEM, V264, P18577; YAMANE K, 1988, J BIOL CHEM, V263, P19690; YAMANE K, 1987, J BIOL CHEM, V262, P2358	56	17	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1243	1248						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288586				2022-12-27	WOS:A1994MR22000075
J	AVIEZER, D; LEVY, E; SAFRAN, M; SVAHN, C; BUDDECKE, E; SCHMIDT, A; DAVID, G; VLODAVSKY, I; YAYON, A				AVIEZER, D; LEVY, E; SAFRAN, M; SVAHN, C; BUDDECKE, E; SCHMIDT, A; DAVID, G; VLODAVSKY, I; YAYON, A			DIFFERENTIAL STRUCTURAL REQUIREMENTS OF HEPARIN AND HEPARAN-SULFATE PROTEOGLYCANS THAT PROMOTE BINDING OF BASIC FIBROBLAST GROWTH-FACTOR TO ITS RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBENDOTHELIAL EXTRACELLULAR-MATRIX; SMOOTH-MUSCLE CELLS; DIMETHYL-SULFOXIDE; MOLECULAR-SIZE; SURFACE; GLYCOSAMINOGLYCANS; DEGRADATION; SEQUENCE; RELEASE; PROLIFERATION	Heparan sulfate proteoglycans (HSPG) are obligatory for receptor binding and mitogenic activity of basic fibroblast growth factor (bFGF). The capacity of various species of heparin and heparan sulfate (HS) to promote bFGF receptor binding was investigated using both Chinese hamster ovary mutant cells deficient in cell surface HSPG and a soluble bFGF receptor-alkaline phosphatase fusion protein. Highly sulfated oligosaccharides were more effective than medium and low sulfate fractions of the same size oligosaccharide. O-Sulfation in heparin was found to be critical for its capacity to promote binding of bFGF to its receptors. The highest level of bFGF-receptor binding was achieved in the presence of over-sulfated heparin fragments (% sulfur >14) regardless of whether the N-position was sulfated or acetylated. Unlike receptor binding of bFGF which requires oligosaccharides containing at least 8-10 sugar units, displacement of heparin- or HS-bound bFGF was obtained by oligosaccharides containing as little as four sugar units and by an N-sulfated, O-desulfated heparin fragment (% sulfur = 5.3). A preparation of total cell surface-derived HS induced bFGF receptor binding. A preliminary survey of several defined and affinity purified species of cell surface HSPG, including syndecan, fibroglycan, and glypican failed to identify natural HSPG that promote high affinity receptor binding of bFGF. A similar lack of activity was observed with species of HS isolated from bovine arterial tissue and characterized for their effect on vascular smooth muscle cell proliferation. Moreover, most of these species of HS inhibited in a dose-dependent manner the restoration of bFGF-receptor binding induced by heparin or by total HSPG. These results suggest the involvement of defined heparin-like oligosaccharide sequences and unique species of cell surface and extracellular matrix HS in the regulation of bFGF receptor binding and biological activity.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL; KABI PHARM,R&D CARDIOVASC,S-11287 STOCKHOLM,SWEDEN; HADASSAH HEBREW UNIV HOSP,DEPT ONCOL,IL-91120 JERUSALEM,ISRAEL; UNIV MUNSTER,INST ARTERIOSCLEROSIS RES,W-4400 MUNSTER,GERMANY; CTR HUMAN GENET,B-3000 LOUVAIN,BELGIUM	Weizmann Institute of Science; Hebrew University of Jerusalem; Hadassah University Medical Center; University of Munster								BARNER M, 1987, BLOOD, V70, P551; BASHKIN P, 1992, J CELL PHYSIOL, V151, P126, DOI 10.1002/jcp.1041510117; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BENEZRA M, 1993, IN PRESS BLOOD, V81; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BERNFIELD M, 1991, ANN NY ACAD SCI, V638, P182, DOI 10.1111/j.1749-6632.1991.tb49029.x; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CARDONCARDO C, 1990, LAB INVEST, V63, P832; CASTELLOT JJ, 1986, J CELL BIOL, V102, P1979, DOI 10.1083/jcb.102.5.1979; DAVID G, 1993, IN PRESS J CELL BIOL; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GOSPODAROWICZ D, 1976, P NATL ACAD SCI USA, V73, P4120, DOI 10.1073/pnas.73.11.4120; GOSPODAROWICZ D, 1977, EXP EYE RES, V25, P75, DOI 10.1016/0014-4835(77)90248-2; GOSPODAROWICZ D, 1978, J BIOL CHEM, V253, P3736; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOLLMANN J, 1989, ARTERIOSCLEROSIS, V9, P154, DOI 10.1161/01.ATV.9.2.154; HOOK M, 1984, ANNU REV BIOCHEM, V53, P847; INOUE Y, 1976, CARBOHYD RES, V46, P87, DOI 10.1016/S0008-6215(00)83533-8; ISHAIMICHAELI R, 1992, CELL REGUL, V31, P2080; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Lindahl U., 1989, HEPARIN, P159; LLOYD AG, 1971, BIOCHEM PHARMACOL, V20, P637, DOI 10.1016/0006-2952(71)90150-X; LORIES V, 1989, J BIOL CHEM, V264, P7009; LORTAT-JACOB H, 1991, J CLIN INVEST, V87, P878, DOI 10.1172/JCI115093; MACH H, 1993, BIOCHEMISTRY-US, V32, P5480, DOI 10.1021/bi00071a026; MOSCATELLI D, 1992, J BIOL CHEM, V267, P25803; NADER HB, 1987, P NATL ACAD SCI USA, V84, P3565, DOI 10.1073/pnas.84.11.3565; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; OGAMO A, 1985, BIOCHIM BIOPHYS ACTA, V841, P30; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SCHMIDT A, 1988, EXP CELL RES, V178, P242, DOI 10.1016/0014-4827(88)90395-3; SCHMIDT A, 1992, J BIOL CHEM, V267, P19242; SUDHALTER J, 1989, J BIOL CHEM, V264, P6892; THUNBERG L, 1980, FEBS LETT, V117, P203, DOI 10.1016/0014-5793(80)80945-8; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; VLODAVSKY I, 1993, BASEMENT MEMBRANES C, P463; VOLKIN DB, 1993, ARCH BIOCHEM BIOPHYS, V300, P30, DOI 10.1006/abbi.1993.1005; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	53	238	247	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					114	121						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276782				2022-12-27	WOS:A1994MR21900025
J	BARROW, RT; HEALEY, JF; LOLLAR, P				BARROW, RT; HEALEY, JF; LOLLAR, P			INHIBITION BY HEPARIN OF THROMBIN-CATALYZED ACTIVATION OF THE FACTOR-VIII VON-WILLEBRAND-FACTOR COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE FACTOR-VIII; HUMAN ALPHA-THROMBIN; ANTITHROMBIN-III; VONWILLEBRAND-FACTOR; FACTOR-XA; PROTEASE INACTIVATION; PROCOAGULANT ACTIVITY; TRANSIENT KINETICS; A1/A3-C1-C2 DIMER; SUBUNIT STRUCTURE	The activation of factor VIII (fVIII) by thrombin is associated with heavy chain cleavages at Arg372 and Arg740 and light chain cleavage at Arg1689. In a defined, plasma-free assay of fVIII activation and at physiological ionic strength and pH, heparin inhibited the rate of activation of either human or porcine fVIII by thrombin in either the presence or absence of von Willebrand factor (vWf). The inhibitory effect of heparin was associated with inhibition of all three thrombin-catalyzed bond cleavages. At plasma concentrations of fVIII (almost-equal-to 1 nM) and vWf (almost-equal-to 35 nM), the rate of fVIII activation was inhibited by 50% at approximately 0.1 unit/ml heparin, which is below the normal range of heparin concentrations in plasma during therapeutic anticoagulation (0.2-0.7 unit/ml). We propose that, in addition to catalyzing the inhibition of thrombin and other intrinsic pathway coagulation proteases by antithrombin, heparin functions as an anticoagulant by direct inhibition of the activation of the fVIII-vWf complex by thrombin.	EMORY UNIV, DEPT MED, DIV HEMATOL ONCOL, ATLANTA, GA 30322 USA	Emory University					NHLBI NIH HHS [R01 HL40921] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040921] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABILDGAARD U, 1968, SCAND J CLIN LAB INV, V21, P89, DOI 10.3109/00365516809076981; ALY AM, 1992, J CLIN INVEST, V89, P1382, DOI 10.1172/JCI115726; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BARUCH D, 1986, HAEMOSTASIS, V16, P71; BEGUIN S, 1988, THROMB HAEMOSTASIS, V60, P457; BJORK I, 1989, HEPARIN CHEM BIOL PR, P229; BODE W, 1992, THROMBIN STRUCTURE F, P3; Brinkhous KM, 1939, AM J PHYSIOL, V125, P683, DOI 10.1152/ajplegacy.1939.125.4.683; BROWN JE, 1980, THROMB RES, V17, P267, DOI 10.1016/0049-3848(80)90314-X; CHOPEK MW, 1986, BIOCHEMISTRY-US, V25, P3146, DOI 10.1021/bi00359a012; DUFFY EJ, 1992, J BIOL CHEM, V267, P7821; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FASS DN, 1982, BLOOD, V59, P594; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FENTON JW, 1989, ANN NY ACAD SCI, V556, P158; FENTON JW, 1977, J BIOL CHEM, V252, P3587; GRIFFITH MJ, 1979, ARCH BIOCHEM BIOPHYS, V195, P378, DOI 10.1016/0003-9861(79)90363-1; GRIFFITH MJ, 1982, J BIOL CHEM, V257, P7360; HEMKER HC, 1990, HAEMOSTASIS, V20, P81; HILLEUBANKS DC, 1990, J BIOL CHEM, V265, P17854; HILLEUBANKS DC, 1989, P NATL ACAD SCI USA, V86, P6508, DOI 10.1073/pnas.86.17.6508; HOYLAERTS M, 1984, J BIOL CHEM, V259, P5670; HULTIN MB, 1981, BLOOD, V57, P476; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1985, BIOCHEMISTRY-US, V24, P8056, DOI 10.1021/bi00348a033; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; LOLLAR P, 1984, BLOOD, V63, P1303; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1988, BLOOD, V71, P137; LOLLAR P, 1991, J BIOL CHEM, V266, P12481; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; LOLLAR P, 1987, J BIOL CHEM, V262, P17572; MARCH SC, 1974, ANAL BIOCHEM, V60, P149, DOI 10.1016/0003-2697(74)90139-0; MIHALYI E, 1968, BIOCHEMISTRY-US, V7, P208, DOI 10.1021/bi00841a026; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NESHEIM M, 1986, J BIOL CHEM, V261, P3214; NESHEIM ME, 1983, J BIOL CHEM, V258, P4708; OBRIEN DP, 1990, BLOOD, V75, P1664; OFOSU F, 1980, THROMB RES, V20, P391, DOI 10.1016/0049-3848(80)90278-9; OFOSU FA, 1989, BIOCHEM J, V257, P143, DOI 10.1042/bj2570143; OFOSU FA, 1991, HAEMOSTASIS, V21, P240; OLSON ST, 1986, J BIOL CHEM, V261, P3151; OLSON ST, 1982, J BIOL CHEM, V257, P4891; OLSON ST, 1991, J BIOL CHEM, V266, P6342; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1988, J BIOL CHEM, V263, P1698; OLSON ST, 1985, J BIOL CHEM, V260, P153; OLSON TA, 1986, ANN NY ACAD SCI, V485, P96, DOI 10.1111/j.1749-6632.1986.tb34571.x; OWEN WG, 1977, BIOCHIM BIOPHYS ACTA, V494, P182, DOI 10.1016/0005-2795(77)90146-5; PIETERS J, 1989, BLOOD, V74, P1021; PITTMAN DD, 1988, P NATL ACAD SCI USA, V85, P2429, DOI 10.1073/pnas.85.8.2429; POMERANTZ MW, 1978, BIOCHIM BIOPHYS ACTA, V535, P66, DOI 10.1016/0005-2795(78)90033-8; Roden L., 1989, HEPARIN CHEM BIOL PR, P1; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; STONE SR, 1987, EUR J BIOCHEM, V169, P373, DOI 10.1111/j.1432-1033.1987.tb13622.x; STRAUGHN W, 1966, THROMB DIATH HAEMOST, V16, P198, DOI 10.1055/s-0038-1655637; TOLLEFSEN DM, 1989, HEPARIN CHEM BIOL PR, P257; VANPUTTEN J, 1982, CLIN CHIM ACTA, V122, P261, DOI 10.1016/0009-8981(82)90285-6; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V585, P405, DOI 10.1016/0304-4165(79)90085-0; YIN ET, 1970, BIOCHIM BIOPHYS ACTA, V201, P387, DOI 10.1016/0304-4165(70)90316-8	62	24	25	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					593	598						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276857				2022-12-27	WOS:A1994MR21900094
J	THELEN, MP; ONEL, K; HOLLOMAN, WK				THELEN, MP; ONEL, K; HOLLOMAN, WK			THE REC1 GENE OF USTILAGO-MAYDIS INVOLVED IN THE CELLULAR-RESPONSE TO DNA-DAMAGE ENCODES AN EXONUCLEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III HOLOENZYME; ESCHERICHIA-COLI; EDITING EXONUCLEASE; 3'-5' EXONUCLEASE; KLENOW FRAGMENT; ACTIVE-SITE; AMINO-ACID; RECOMBINATION; SEQUENCE; ALIGNMENT	Mutation in the REC1 gene of Ustilago maydis is known to lead to a complex phenotype with alterations in DNA repair, recombination, mutagenesis, meiosis, and cell division. The predicted product of the REC1 gene is a polypeptide of 522 amino acid residues with a molecular mass of 56,866 daltons, with no overall sequence homology to any other known protein. The open reading frame of the REC1 gene placed by itself in a U. maydis expression vector was found to be sufficient to complement the rec1 mutant. Overexpression of REC1 in Escherichia coli gave rise to the anticipated 57-kDa product together with a 3'-->5' exonuclease activity. This activity was only present in cells overexpressing REC1 and its characteristics were distinguishable from the major bacterial nucleases, but it had certain enzymatic features in common with epsilon, the proofreading exonuclease subunit of E. coli DNA polymerase III holoenzyme. To facilitate isolation of the protein product from bacteria, the REC1 gene was overexpressed from a vector that fused a hexa-histidine-leader sequence onto the amino terminus, enabling the isolation of the HisREC1 product on an immobilized metal ion affinity column. The HisREC1 protein co-eluted with the novel exonuclease activity. Alignment of the amino acid sequence of the REC1 gene product with the conserved proofreading exonuclease motifs of DNA polymerases indicated significant homology.	CORNELL UNIV,MED CTR,COLL MED,DEPT MICROBIOL,NEW YORK,NY 10021	Cornell University			Thelen, Michael/C-6834-2008; Thelen, Michael P/G-2032-2014	Thelen, Michael/0000-0002-2479-5480; Thelen, Michael P/0000-0002-2479-5480	NIGMS NIH HHS [GM42482] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042482] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BLANCO L, 1992, GENE, V112, P139, DOI 10.1016/0378-1119(92)90316-H; BRENOWITZ S, 1991, J BIOL CHEM, V266, P7888; BRUTLAG D, 1972, J BIOL CHEM, V247, P241; CARTER DM, 1971, J BIOL CHEM, V246, P2502; CHASE JW, 1974, J BIOL CHEM, V249, P4545; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; ECHOLS H, 1983, P NATL ACAD SCI-BIOL, V80, P2189, DOI 10.1073/pnas.80.8.2189; FOTHERINGHAM S, 1990, GENETICS, V124, P833; FOTHERINGHAM S, 1989, MOL CELL BIOL, V9, P4052, DOI 10.1128/MCB.9.9.4052; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; FRIEDBERG EC, 1991, MOL CELLULAR BIOL YE, V1, P147; GRIEP MA, 1990, BIOCHEMISTRY-US, V29, P9006, DOI 10.1021/bi00490a018; GUPTA AP, 1984, NUCLEIC ACIDS RES, V12, P5897, DOI 10.1093/nar/12.14.5897; Haynes R.H., 1981, MOL BIOL YEAST SACCH, P371; HOLDEN DW, 1989, EMBO J, V8, P1927, DOI 10.1002/j.1460-2075.1989.tb03596.x; HOLDEN DW, 1991, CURR GENET, V20, P145, DOI 10.1007/BF00312777; HOLEN DW, 1989, NUCLEIC ACIDS RES, V17, P10489; HOLLIDAY R, 1965, MUTAT RES, V2, P557, DOI 10.1016/0027-5107(65)90022-9; HOLLIDAY R, 1976, GENET RES, V27, P413, DOI 10.1017/S0016672300016621; HOLLIDAY R, 1967, MUTAT RES, V4, P275, DOI 10.1016/0027-5107(67)90022-X; HOLLIDAY R, 1977, PHILOS T R SOC B, V277, P359, DOI 10.1098/rstb.1977.0024; HOLLOMAN WK, 1981, J BIOL CHEM, V56, P5087; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; LEHMAN IR, 1962, J BIOL CHEM, V237, P819; LEHMAN IR, 1964, J BIOL CHEM, V239, P2628; MARTINEZ HM, 1988, NUCLEIC ACIDS RES, V16, P1683, DOI 10.1093/nar/16.5.1683; MORRISON A, 1991, P NATL ACAD SCI USA, V88, P9473, DOI 10.1073/pnas.88.21.9473; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PORATH J, 1992, PROTEIN EXPRES PURIF, V3, P263, DOI 10.1016/1046-5928(92)90001-D; PUTNEY SD, 1981, P NATL ACAD SCI-BIOL, V78, P7350, DOI 10.1073/pnas.78.12.7350; RICHARDSON CC, 1964, J BIOL CHEM, V239, P251; SCHAAPER RM, 1989, GENETICS, V121, P205; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAKANO K, 1986, MOL GEN GENET, V205, P9, DOI 10.1007/BF02428026; THELEN M, 1992, J CEL LBIOCH SB, V16, P39; THOMPSON PR, 1992, THESIS AUSTR NATIONA, P99; TONEGUZZO F, 1988, BIOTECHNIQUES, V6, P460; TSUKUDA T, 1989, GENE, V85, P335, DOI 10.1016/0378-1119(89)90426-5; TSUKUDA T, 1988, MOL CELL BIOL, V8, P3703, DOI 10.1128/MCB.8.9.3703; UNRAU P, 1975, MUTAT RES, V29, P53, DOI 10.1016/0027-5107(75)90020-2; VANDESAN.JH, 1973, BIOCHEMISTRY-US, V12, P5050, DOI 10.1021/bi00749a004; WANG J, 1988, P NATL ACAD SCI USA, V85, P865, DOI 10.1073/pnas.85.3.865; WRIGHT M, 1971, J BIOL CHEM, V246, P6543	49	55	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					747	754						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276878				2022-12-27	WOS:A1994MR21900117
J	ZUTTER, MM; SANTORO, SA; PAINTER, AS; TSUNG, YL; GAFFORD, A				ZUTTER, MM; SANTORO, SA; PAINTER, AS; TSUNG, YL; GAFFORD, A			THE HUMAN ALPHA-2-INTEGRIN GENE PROMOTER - IDENTIFICATION OF POSITIVE AND NEGATIVE REGULATORY ELEMENTS IMPORTANT FOR CELL-TYPE AND DEVELOPMENTALLY RESTRICTED GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN RECEPTOR; MEGAKARYOCYTIC DIFFERENTIATION; FIBRONECTIN RECEPTOR; LAMININ RECEPTOR; MAMMALIAN-CELLS; GAMMA-GLOBIN; DNA; BINDING; SURFACE; VLA-2	The alpha2beta1 integrin serves as a collagen receptor or a collagen/laminin receptor, depending upon cell type. Expression of the integrin is regulated during normal cellular differentiation and is altered during carcinogenesis. We have previously demonstrated that increased expression of the alpha2beta1 integrin during megakaryocytic differentiation is a consequence of increased alpha2 mRNA due to transcriptional activation of the alpha2 integrin gene and that the decreased expression of the integrin in breast adenocarcinoma is due to decreased steady-state levels of alpha2 mRNA. We now report the identification and characterization of the 5'-flanking region of the alpha2 integrin gene. The 5'-untranslated region of the alpha2 mRNA extends 129 base pairs 5' to the site of translation initiation. The promoter region lacks TATA and CAAT boxes but contains an abbreviated initiator sequence and six Sp1 binding sites. Consensus binding sites for AP-1 and AP-2 complexes, a GATA box, a Pu.1 box, and two palindromic motifs with potential to bind the estrogen receptor are also present. A 961-base pair fragment of the 5'-flanking region directs both cell type- and differentiation-specific expression of a reporter gene in T47-D epithelial cells and in pluripotent hematopoietic K562 cells upon megakaryocytic differentiation.	WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA	Washington University (WUSTL)	ZUTTER, MM (corresponding author), WASHINGTON UNIV, SCH MED, DEPT PATHOL, BOX 8118, 660 S EUCLID, ST LOUIS, MO 63110 USA.							ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; AGURA ED, 1992, BLOOD, V79, P602; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BIRKENMEIER TM, 1991, J BIOL CHEM, V266, P20544; BRUTLAG DL, 1980, ANNU REV GENET, V14, P121, DOI 10.1146/annurev.ge.14.120180.001005; BURGER SR, 1992, EXP CELL RES, V202, P28, DOI 10.1016/0014-4827(92)90400-3; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CHEN HM, 1993, J BIOL CHEM, V268, P8230; COLLER BS, 1989, BLOOD, V74, P182; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; DUBAND JL, 1986, J CELL BIOL, V102, P160, DOI 10.1083/jcb.102.1.160; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAMADA H, 1982, NATURE, V298, P396, DOI 10.1038/298396a0; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HICKSTEIN DD, 1992, P NATL ACAD SCI USA, V89, P2105, DOI 10.1073/pnas.89.6.2105; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LEARY JF, 1987, LEUKEMIA RES, V11, P807, DOI 10.1016/0145-2126(87)90065-8; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOPEZCABRERA M, 1993, J BIOL CHEM, V268, P1187; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; NGUYEN VT, 1988, ANAL BIOCHEM, V171, P404, DOI 10.1016/0003-2697(88)90505-2; NISHIOKA Y, 1980, J BIOL CHEM, V255, P3691; Orkin SH, 1990, CURR OPIN CELL BIOL, V2, P1003, DOI 10.1016/0955-0674(90)90149-9; PRANDINI MH, 1988, BIOCHEM BIOPH RES CO, V156, P595, DOI 10.1016/S0006-291X(88)80884-2; PRANDINI MH, 1992, J BIOL CHEM, V267, P10370; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; ROSEN GD, 1991, P NATL ACAD SCI USA, V88, P4094, DOI 10.1073/pnas.88.10.4094; ROY RJ, 1992, NUCLEIC ACIDS RES, V20, P401, DOI 10.1093/nar/20.3.401; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO SA, 1988, BIOCHEM BIOPH RES CO, V153, P217, DOI 10.1016/S0006-291X(88)81211-7; SLIGHTOM JL, 1980, CELL, V21, P627, DOI 10.1016/0092-8674(80)90426-2; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPANOPOULOU E, 1991, MOL CELL BIOL, V11, P2216, DOI 10.1128/MCB.11.4.2216; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TARANTINO MD, 1992, BLOOD, V80, pA127; TORA L, 1988, EMBO J, V7, P3771, DOI 10.1002/j.1460-2075.1988.tb03261.x; ULRICH MJ, 1990, BLOOD, V75, P990; UZAN G, 1991, J BIOL CHEM, V266, P8932; YE RD, 1987, J BIOL CHEM, V262, P3718; ZUTTER MM, 1990, AM J PATHOL, V137, P113; ZUTTER MM, 1992, J BIOL CHEM, V267, P20233; ZUTTER MM, 1990, AM J PATHOL, V137, P863	55	105	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					463	469						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276836				2022-12-27	WOS:A1994MR21900077
J	EGNER, R; THUMM, M; STRAUB, M; SIMEON, A; SCHULLER, HJ; WOLF, DH				EGNER, R; THUMM, M; STRAUB, M; SIMEON, A; SCHULLER, HJ; WOLF, DH			TRACING INTRACELLULAR PROTEOLYTIC PATHWAYS - PROTEOLYSIS OF FATTY-ACID SYNTHASE AND OTHER CYTOPLASMIC PROTEINS IN THE YEAST SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS-INDUCED PROTEOLYSIS; MULTIFUNCTIONAL PROTEINASE; CATABOLITE INACTIVATION; METABOLIC CONDITIONS; INVIVO FUNCTION; GENETIC-CONTROL; CELL-SURVIVAL; SYNTHETASE; DEGRADATION; ENZYME	Yeast fatty acid synthase consists of two independent polypeptide strains, alpha and beta. The functional multienzyme complex, composed of six alpha- and six beta-subunits, is rather stable against proteolysis in vivo. Mutations in one of the subunits or deletion of one subunit lead to degradation of the nonmutated remaining fatty acid synthase protein. We show that the unassembled alpha-subunit of this enzyme is short-lived, and degradation depends on the presence of active cytoplasmic proteinase yscE, the yeast proteasome. The unassembled beta-subunit is degraded by a nonvacuolar proteolytic system under vegetative growth conditions. However, starvation of a vacuolar proteinase mutant strain, which lacks the alpha-subunit of fatty acid synthase, leads to appearance of the unassembled beta-subunit in isolated vacuoles. This indicates that the major vacuolar peptidases proteinase yscA and yscB are at least partly involved in degradation of the beta-subunit of fatty acid synthase. In a proteinase yscA and yscB double mutant strain wild type for fatty acid synthase both subunits of fatty acid synthase, alpha and beta, are detectable in vacuoles. In addition, under the same starvation conditions other cytoplasmic proteins are found in the vacuole of a proteinase yscA and yscB double mutant strain. The experiments in conjunction with the previous finding of the appearance of vesicles in vacuoles of starved cells (Simeon, A., van der Klei, I. J., Veenhuis, M., and Wolf, D. H. (1992) FEBS Lett. 301, 231-235) indicate that transport of these tested cytoplasmic proteins into the vacuole is an unselective bulk process induced by nutritional stress.	UNIV STUTTGART,INST BIOCHEM,PFAFFENWALDRING 55,D-70569 STUTTGART,GERMANY; UNIV ERLANGEN NURNBERG,INST MIKROBIOL & BIOCHEM,LEHRSTUHL BIOCHEM,W-8520 ERLANGEN,GERMANY	University of Stuttgart; University of Erlangen Nuremberg			Thumm, Michael/A-8033-2015	Thumm, Michael/0000-0003-3238-4857				ACHSTETTER T, 1984, J BIOL CHEM, V259, P3344; Achstetter T, 1985, Yeast, V1, P139, DOI 10.1002/yea.320010203; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BECK J, 1987, FAT SCI TECHNOL, V89, P570; BETZ H, 1976, EUR J BIOCHEM, V62, P65, DOI 10.1111/j.1432-1033.1976.tb10098.x; BURKL G, 1972, MOL GEN GENET, V119, P315, DOI 10.1007/BF00272089; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; FUNAYAMA S, 1980, EUR J BIOCHEM, V109, P61, DOI 10.1111/j.1432-1033.1980.tb04767.x; HACKENJOS WA, 1987, BIOL CHEM H-S, V368, P19, DOI 10.1515/bchm3.1987.368.1.19; HANSEN RJ, 1977, BIOCHIM BIOPHYS ACTA, V496, P103, DOI 10.1016/0304-4165(77)90119-2; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HEMMINGS BA, 1981, P NATL ACAD SCI-BIOL, V78, P435, DOI 10.1073/pnas.78.1.435; HILT W, 1993, J BIOL CHEM, V268, P3479; HILT W, 1992, MOL MICROBIOL, V6, P2437; HIRSCH HH, 1992, EUR J BIOCHEM, V207, P867, DOI 10.1111/j.1432-1033.1992.tb17118.x; Hirsch HH., 1989, MOL CELL BIOL YEASTS, P134; HOLZER H, 1976, TRENDS BIOCHEM SCI, V1, P178, DOI 10.1016/S0968-0004(76)80018-7; JONES EW, 1991, J BIOL CHEM, V266, P7963; JONES EW, 1982, GENETICS, V102, P665; KATO N, 1979, BIOCHIM BIOPHYS ACTA, V566, P1, DOI 10.1016/0005-2744(79)90242-0; KLEINSCHMIDT JA, 1988, FEBS LETT, V239, P35, DOI 10.1016/0014-5793(88)80540-4; KOBAYASHI R, 1989, ANAL BIOCHEM, V183, P9, DOI 10.1016/0003-2697(89)90162-0; KOPITZ J, 1990, J CELL BIOL, V111, P941, DOI 10.1083/jcb.111.3.941; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZ S, 1979, BIOCHEM J, V178, P769, DOI 10.1042/bj1780769; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYNEN F, 1980, EUR J BIOCHEM, V112, P431; LYNEN F, 1969, METHOD ENZYMOL, V14, P17; MECHLER B, 1987, EMBO J, V6, P2157, DOI 10.1002/j.1460-2075.1987.tb02483.x; MEYER KH, 1976, EUR J BIOCHEM, V65, P317, DOI 10.1111/j.1432-1033.1976.tb10344.x; MOHAMED AH, 1988, J BIOL CHEM, V263, P12315; MULLER M, 1981, J BIOL CHEM, V256, P723; MULLER M, 1981, J BIOL CHEM, V256, P1962; PEREA J, 1982, ARCH MICROBIOL, V132, P141, DOI 10.1007/BF00508719; PRINGLE JR, 1990, METHOD ENZYMOL, V194, P565; RENDUELES PS, 1988, FEMS MICROBIOL LETT, V54, P17; RICHTERRUOFF B, 1992, FEBS LETT, V302, P192, DOI 10.1016/0014-5793(92)80438-M; SCHULLER HJ, 1992, EUR J BIOCHEM, V203, P607, DOI 10.1111/j.1432-1033.1992.tb16590.x; SCHULLER HJ, 1992, EMBO J, V11, P107, DOI 10.1002/j.1460-2075.1992.tb05033.x; SCHWEIZER E, 1978, MOL CELL BIOCHEM, V21, P95; SCHWEIZER E, 1987, FETT WISS TECHNOL, V89, P570; SCHWEIZER M, 1986, BIOCHEM SOC T, V14, P572, DOI 10.1042/bst0140572; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SIMEON A, 1992, FEBS LETT, V301, P231, DOI 10.1016/0014-5793(92)81254-J; SPORMANN DO, 1991, EUR J BIOCHEM, V197, P399, DOI 10.1111/j.1432-1033.1991.tb15924.x; TAGESHIGE K, 1992, J CELL BIOL, V119, P301; TEICHERT U, 1989, J BIOL CHEM, V264, P16037; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERWILDEN M, 1973, Z NATURFORSCH, V280, P416; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; WIEMKEN A, 1979, ARCH MICROBIOL, V123, P23, DOI 10.1007/BF00403499; WOOLFORD CA, 1993, J BIOL CHEM, V268, P8990; YOSHIHISA T, 1988, J BIOL CHEM, V263, P5158; YOSHIHISA T, 1993, J BIOL CHEM, V268, P8990	56	74	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27269	27276						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262967				2022-12-27	WOS:A1993MM26200063
J	SHIMIZU, K; SANTOCANALE, C; ROPP, PA; LONGHESE, MP; PLEVANI, P; LUCCHINI, G; SUGINO, A				SHIMIZU, K; SANTOCANALE, C; ROPP, PA; LONGHESE, MP; PLEVANI, P; LUCCHINI, G; SUGINO, A			PURIFICATION AND CHARACTERIZATION OF A NEW DNA-POLYMERASE FROM BUDDING YEAST SACCHAROMYCES-CEREVISIAE - A PROBABLE HOMOLOG OF MAMMALIAN DNA-POLYMERASE BETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; CDC2 GENE; CLONING; SUBUNIT; TRANSFORMATION; REPLICATION; EXPRESSION; MUTATIONS; DELTA	A new DNA polymerase activity was identified and purified to near homogeneity from extracts of mitotic and meiotic cells of the yeast Saccharomyces cerevisiae. This activity increased at least 5-fold during meiosis, and it was shown to be associated with a 68-kDa polypeptide as determined by SDS-polyacrylamide gel electrophoresis. This new DNA polymerase did not have any detectable 3' --> 5' exonuclease activity and preferred small gapped DNA as a template-primer. The activity was inhibited by dideoxyribonucleoside 5'-triphosphates and N-ethylmaleimide but not by concentrations of aphidicolin which completely inhibit either DNA polymerases I (alpha), II (epsilon), or III (delta). Since no polypeptide(s) in the extensively purified DNA polymerase fractions cross-reacted with antibodies raised against yeast DNA polymerases I, II, and III, we called this enzyme DNA polymerase IV. The DNA polymerase IV activity increased at least 10-fold in a yeast strain overexpressing the gene product predicted from the YCR14C open-reading frame (identified on S. cerevisiae chromosome III and provisionally called POLX), while no activity was detected in a strain where POLX was deleted. These results strongly suggest that DNA polymerase IV is encoded by the POLX gene and is a probable homolog of mammalian DNA polymerase beta.	NIEHS,MOLEC GENET LAB,RES TRIANGLE PK,NC 27709; UNIV MILAN,DIPARTIMENTO GENET & BIOL MICROORGANISMI,I-20133 MILAN,ITALY; OSAKA UNIV,MICROBIAL DIS RES INST,DEPT MOLEC IMMUNOL,SUITA,OSAKA 565,JAPAN	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Milan; Osaka University			Pia, Maria/AAK-2693-2020	Santocanale, Corrado/0000-0003-1337-5656; Longhese, Maria Pia/0000-0003-1726-2034; PLEVANI, PAOLO/0000-0003-1869-2626				ARAKI H, 1991, NUCLEIC ACIDS RES, V19, P4867, DOI 10.1093/nar/19.18.4867; ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; ARAKI H, 1991, P NATL ACAD SCI USA, V88, P4601, DOI 10.1073/pnas.88.11.4601; BAUER GA, 1988, P NATL ACAD SCI USA, V85, P7506, DOI 10.1073/pnas.85.20.7506; BAUER GA, 1988, J BIOL CHEM, V263, P917; BORK P, 1992, PROTEIN SCI, V1, P1677, DOI 10.1002/pro.5560011216; BOULET A, 1989, EMBO J, V8, P1849, DOI 10.1002/j.1460-2075.1989.tb03580.x; BUDD M, 1987, P NATL ACAD SCI USA, V84, P2838, DOI 10.1073/pnas.84.9.2838; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; BURGERS PMJ, 1988, NUCLEIC ACIDS RES, V16, P6297, DOI 10.1093/nar/16.14.6297; Campbell JL, 1991, MOL CELLULAR BIOL YE, P41; CHANG LMS, 1977, J BIOL CHEM, V252, P1873; CHANG LMS, 1982, P NATL ACAD SCI-BIOL, V79, P758, DOI 10.1073/pnas.79.3.758; FABRE F, 1991, MOL GEN GENET, V229, P353, DOI 10.1007/BF00267455; FOURY F, 1989, J BIOL CHEM, V264, P20552; FRANCESCONI S, 1991, P NATL ACAD SCI USA, V88, P3877, DOI 10.1073/pnas.88.9.3877; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HAMATAKE RK, 1990, J BIOL CHEM, V265, P4072; HIROSE F, 1989, EXP CELL RES, V181, P169, DOI 10.1016/0014-4827(89)90191-2; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON LM, 1985, CELL, V43, P369, DOI 10.1016/0092-8674(85)90042-X; LUCCHINI G, 1987, EMBO J, V6, P737, DOI 10.1002/j.1460-2075.1987.tb04815.x; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; MORRISON A, 1989, J BACTERIOL, V171, P5659, DOI 10.1128/jb.171.10.5659-5667.1989; MORRISON A, 1993, PROG NUCLEIC ACID RE, V46, P93, DOI 10.1016/S0079-6603(08)61019-3; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; PLEVANI P, 1984, J BIOL CHEM, V259, P7534; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN R, 1983, METHOD ENZYMOL, V101, P201; Sambrook J, 1989, MOL CLONING LABORATO; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SITNEY KC, 1989, CELL, V56, P599, DOI 10.1016/0092-8674(89)90582-5; SUGINO A, 1988, P NATL ACAD SCI USA, V85, P3683, DOI 10.1073/pnas.85.11.3683; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; ZMUDZKA BZ, 1986, P NATL ACAD SCI USA, V83, P5106, DOI 10.1073/pnas.83.14.5106	36	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27148	27153						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262953				2022-12-27	WOS:A1993MM26200047
J	SOULA, M; ROTHHUT, B; CAMOIN, L; GUILLAUME, JL; STROSBERG, D; VORHERR, T; BURN, P; MEGGIO, F; FISCHER, S; FAGARD, R				SOULA, M; ROTHHUT, B; CAMOIN, L; GUILLAUME, JL; STROSBERG, D; VORHERR, T; BURN, P; MEGGIO, F; FISCHER, S; FAGARD, R			ANTI-CD3 AND PHORBOL ESTER INDUCE DISTINCT PHOSPHORYLATED SITES IN THE SH2 DOMAIN OF P56(LCK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; PROTEIN-KINASE-C; HUMAN LYMPHOCYTES-T; TYROSINE KINASE; SIGNAL TRANSDUCTION; ACTIVATION; P56LCK; COMPLEX; STIMULATION; CD4	p56lck is a protein tyrosine kinase of the Src family specifically expressed in T lymphocytes. Triggering of T cells with anti-CD3 or with phorbol 12-myristate 13-acetate (PMA) results in the appearance of slower migrating forms (shift) of p56lck. To investigate the phosphorylation sites on the shifted forms of p56lck and to assess the role of protein kinase C in this phosphorylation, Jurkat cells were treated with a selective inhibitor of this kinase (GF 109203X). This inhibitor completely reversed the shift induced by PMA but only partially reversed the one induced after triggering with anti-CD3. To analyze the shift further, p56lck was immunoprecipitated from in vivo labeled cells treated either with anti-CD3 or with PMA. Tryptic phosphopeptides were generated and analyzed by using a combination of thin layer chromatography, high reticulation polyacrylamide gel electrophoresis, reverse phase chromatography, and phosphopeptide sequencing. We identified serine 158 as a newly phosphorylated site after PMA treatment and tyrosine 192 and serine 194 in the major tryptic phosphopeptide obtained after anti-CD3 triggering. The three sites identified are located in the SH2 domain of p56lck; this suggests that their phosphorylation may regulate the interaction with other proteins or with other internal domains in p56lck.	INSERM,U332,F-75005 PARIS,FRANCE; INST COCHIN GENET MOLEC,CNRS,UNITE PROPRE RECH 0415,F-75014 PARIS,FRANCE; HOP PORT ROYAL,INSERM,U29,F-75674 PARIS 14,FRANCE; F HOFFMANN LA ROCHE & CO LTD,CH-4002 BASEL,SWITZERLAND; UNIV PADUA,DIPARTAMENTO CHIM BIOL,I-35121 PADUA,ITALY	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Roche Holding; University of Padua			Camoin, Luc/AAB-3856-2019	Camoin, Luc/0000-0002-1230-4787; Rothhut, Bernard/0000-0001-6467-8134				BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BLANKEMEYERMENGE B, 1990, TETRAHEDRON LETT, V31, P1701, DOI 10.1016/S0040-4039(00)88858-9; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CANTRELL D, 1987, NATURE, V325, P540, DOI 10.1038/325540a0; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; CASNELLIE JE, 1990, FEBS LETT, V261, P331, DOI 10.1016/0014-5793(90)80584-6; CASNELLIE JE, 1987, J BIOL CHEM, V262, P9859; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHATILA TA, 1988, J IMMUNOL, V140, P4308; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DANIELIAN S, 1989, EUR J IMMUNOL, V19, P2183, DOI 10.1002/eji.1830191202; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; FISCHER S, 1987, BIOCHEM BIOPH RES CO, V143, P819, DOI 10.1016/0006-291X(87)90322-6; GASSMANN M, 1992, EUR J IMMUNOL, V22, P283, DOI 10.1002/eji.1830220142; GAY D, 1987, NATURE, V328, P626, DOI 10.1038/328626a0; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HSI ED, 1989, J BIOL CHEM, V264, P10836; JIN YJ, 1990, P NATL ACAD SCI USA, V87, P3319, DOI 10.1073/pnas.87.9.3319; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KITAS EA, 1991, HELV CHIM ACTA, V74, P1314, DOI 10.1002/hlca.19910740621; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOYASU S, 1992, J BIOL CHEM, V267, P3375; LONDON IM, 1981, COLD SPRING HARBOR C, V8, P941; LUO K, 1990, ONCOGENE, V5, P803; MARTH JD, 1989, J IMMUNOL, V142, P2430; MEUER SC, 1983, J EXP MED, V157, P705, DOI 10.1084/jem.157.2.705; MINAMI Y, 1987, J BIOL CHEM, V262, P13342; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; PATEL MD, 1987, J BIOL CHEM, V262, P5831; PURCHIO AF, 1985, SCIENCE, V229, P1393, DOI 10.1126/science.2994221; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, J IMMUNOL, V145, P2448; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SOULA M, 1992, INT IMMUNOL, V4, P295, DOI 10.1093/intimm/4.2.295; TARR GE, 1978, ANAL BIOCHEM, V84, P121; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TSOUKAS CD, 1985, J IMMUNOL, V135, P1719; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; VANWAUWE JP, 1980, J IMMUNOL, V124, P2708; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; VEILLETTE A, 1992, ONCOGENE, V7, P971; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; VONWUSSOW P, 1981, J IMMUNOL, V127, P1197; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WEST MHP, 1984, ELECTROPHORESIS, V5, P133, DOI 10.1002/elps.1150050302; WINKLER DG, 1993, P NATL ACAD SCI USA, V90, P5176, DOI 10.1073/pnas.90.11.5176	55	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27420	27427						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262984				2022-12-27	WOS:A1993MM26200083
J	YAMAGUCHI, T; SHIRATAKI, H; KISHIDA, S; MIYAZAKI, M; NISHIKAWA, J; WADA, K; NUMATA, S; KAIBUCHI, K; TAKAI, Y				YAMAGUCHI, T; SHIRATAKI, H; KISHIDA, S; MIYAZAKI, M; NISHIKAWA, J; WADA, K; NUMATA, S; KAIBUCHI, K; TAKAI, Y			2 FUNCTIONALLY DIFFERENT DOMAINS OF RABPHILIN-3A, RAB3A P25/SMG P25A-BINDING AND PHOSPHOLIPID-BINDING AND CA2+-BINDING DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP DISSOCIATION INHIBITOR; GDP/GTP EXCHANGE PROTEIN; SMG P25A; SYNAPTIC VESICLES; REGULATORY PROTEIN; KINASE-C; GTP; TISSUE; PURIFICATION; EXPRESSION	Rabphilin-3A is a putative target molecule for rab3A p25/smg p25A, which is a member of a ras p21-related small GTP-binding protein and implicated in neurotransmitter release from the synapse. Rabphilin-3A has two copies of an internal repeat that are homologous to the C2 domains of protein kinase C, synaptotagmin, and phospholipase A2, which are known to bind to phospholipid in a Ca2+-dependent manner. In the current study, we have investigated the functional domains of rabphilin-3A by use of three recombinant proteins as follows: full rabphilin-3A (1-704 amino acids), an N-terminal fragment (1-280 amino acids), and a C-terminal fragment containing the C2 domains (281-704 amino acids). Both rabphilin-3A and the C-terminal fragment bound to phospholipid in the presence of Ca2+, but the N-terminal fragment did not bind to phospholipid. Ca-45(2+) bound to rabphilin-3A and the C-terminal fragment only in the presence of phospholipid but did not bind to the N-terminal fragment. The GTPgammaS-bound form of rab3A p25 bound to both rabphilin-3A and the N-terminal fragment but did not bind to the C-terminal fragment. These results indicate that rabphilin-3A has at least two functionally different domains, the N-terminal rab3A p25-binding and C-terminal phospholipid- and Ca2+-binding domains.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN; NATL INST PHYSIOL SCI,DEPT CELL PHYSIOL,OKAZAKI,AICHI 444,JAPAN	Kobe University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)				kishida, shosei/0000-0003-0405-851X				ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BURSTEIN E, 1989, MOL CELL BIOL, V9, P4807, DOI 10.1128/MCB.9.11.4807; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; KABCENELL AK, 1990, J BIOL CHEM, V265, P9366; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KISHIDA S, 1993, J BIOL CHEM, V268, P22259; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE AW, 1988, J CELL BIOL, V106, P51, DOI 10.1083/jcb.106.1.51; LUO JH, 1993, J BIOL CHEM, V268, P3715; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MIZOGUCHI A, 1992, BIOCHEM BIOPH RES CO, V186, P1345, DOI 10.1016/S0006-291X(05)81554-2; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; MIZOGUCHI A, 1989, BIOCHEM BIOPH RES CO, V162, P1438, DOI 10.1016/0006-291X(89)90835-8; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NONAKA H, 1991, BIOCHEM BIOPH RES CO, V174, P556, DOI 10.1016/0006-291X(91)91453-J; OGAWA Y, 1968, J BIOCHEM-TOKYO, V64, P255, DOI 10.1093/oxfordjournals.jbchem.a128887; OLOFSSON B, 1988, ONCOGENE, V3, P231; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; SALMINEN A, 1990, CELL, V265, P9366; Sambrook J, 1989, MOL CLONING LABORATO; SANO K, 1989, BIOCHEM BIOPH RES CO, V158, P377, DOI 10.1016/S0006-291X(89)80058-0; SASAKI T, 1991, MOL CELL BIOL, V11, P2909, DOI 10.1128/MCB.11.5.2909; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHIRATAKI H, 1992, J BIOL CHEM, V267, P10946; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UEDA T, 1991, BIOCHEMISTRY-US, V30, P909, DOI 10.1021/bi00218a005; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V	45	141	144	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27164	27170						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262955				2022-12-27	WOS:A1993MM26200050
J	HAYASHI, T; SEKINE, T; OKAMOTO, T				HAYASHI, T; SEKINE, T; OKAMOTO, T			IDENTIFICATION OF A NEW SERINE KINASE THAT ACTIVATES NF-KAPPA-B BY DIRECT PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR-NECROSIS-FACTOR; DNA-BINDING SUBUNIT; DEPENDENT PROTEIN-KINASE; TRANSCRIPTION FACTOR; FACTOR-ALPHA; MAP KINASE; INVITRO ACTIVATION; ONCOGENE PRODUCT; PHORBOL ESTER	A novel serine kinase, named nuclear factor kappa B (NFkappaB) kinase, has been shown to be associated with the NFkappaB.IkappaB complex in the cytosol of human primary T lymphocytes. It activates the DNA binding activity of NFkappaB by directly phosphorylating its p65 and p50 subunits. There is no evidence that it phosphorylates IkappaB. Experiments with inhibitors and antisera showed that it is distinct from other known serine kinases such as mitogen-activated protein kinase or Mos. It has an apparent molecular size of 43 kDa determined by the substrate binding assay. This kinase might have a central role in mediating various signals to NFkappaB.	NATL CANC CTR, RES INST, DIV VIROL, 5-1-1 TSUKIJI, CHUO KU, TOKYO 104, JAPAN; NATL CANC CTR, RES INST, RI LAB, CHUO KU, TOKYO 104, JAPAN	National Cancer Center - Japan; National Cancer Center - Japan								BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; CAMPBELL S, 1990, P NATL ACAD SCI USA, V87, P1243, DOI 10.1073/pnas.87.3.1243; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINTER H, 1987, EMBO J, V6, P4067, DOI 10.1002/j.1460-2075.1987.tb02752.x; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; FEUILLARD J, 1991, CYTOKINE, V3, P257, DOI 10.1016/1043-4666(91)90025-9; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; HAGIWARA M, 1987, MOL PHARMACOL, V31, P523; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JAMIESON C, 1991, J IMMUNOL, V147, P416; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KAWAMOTO S, 1984, BIOCHEM BIOPH RES CO, V125, P258, DOI 10.1016/S0006-291X(84)80362-9; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LAWRENCE DK, 1991, GENE DEV, V5, P1464; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MAEKAWA T, 1989, J BIOL CHEM, V264, P2826; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MOLITOR JA, 1991, NEW BIOL, V3, P987; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; OKAMOTO T, 1990, VIROLOGY, V177, P606, DOI 10.1016/0042-6822(90)90526-W; OKAMOTO T, 1989, AIDS RES HUM RETROV, V5, P131, DOI 10.1089/aid.1989.5.131; OKAMOTO T, 1992, INT IMMUNOL, V4, P811, DOI 10.1093/intimm/4.7.811; OSTROWSKI J, 1991, J BIOL CHEM, V266, P12722; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SAHAL D, 1991, METHOD ENZYMOL, V200, P90; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P959, DOI 10.1128/MCB.9.3.959; WATANABE N, 1991, NATURE, V352, P247, DOI 10.1038/352247a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508	50	92	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26790	26795						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253816				2022-12-27	WOS:A1993MK42500113
J	AMSTAD, P; MORET, R; CERUTTI, P				AMSTAD, P; MORET, R; CERUTTI, P			GLUTATHIONE-PEROXIDASE COMPENSATES FOR THE HYPERSENSITIVITY OF CU,ZN-SUPEROXIDE DISMUTASE OVERPRODUCERS TO OXIDANT STRESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MANGANESE-SUPEROXIDE-DISMUTASE; MOUSE EPIDERMAL-CELLS; HYDROGEN-PEROXIDE; CYTO-TOXICITY; MAMMALIAN-CELLS; EXPRESSION; GENE; DNA; ENHANCEMENT; RESISTANCE	The balance between several components of the antioxidant defenses appears to be important for the cellular resistance to oxidative stress. While Cu,Zn-superoxide dismutase (SOD) transfectants of mouse epidermal cells JB6 clone 41 were sensitized to oxidants produced by xanthine/xanthine oxidase (X/XO) consecutive transfection with catalase corrected their hypersensitivity (Amstad, P., Peskin, A., Shah, G., Mirault, M. E., Moret, R., Zbinden, I., and Cerutti, P. (1991) Biochemistry 30, 9305-9313). We studied the effect of the transfection of bovine selenoglutathione peroxidase (GPx) on the sensitivity of JB6 clone 41 and its SOD transfectants. Sensitivity to DNA strand breakage and killing by X/XO was reversely related to the activity ratios GPx over SOD. A GPx-transfectant of JB6 clone 41 cells with a GPx/SOD ratio of 3.8 was very strongly protected. The hypersensitivity of the SOD clones with GPx/SOD ratios of 0.4 was corrected or overcorrected by secondary transfection with bovine Se-GPx resulting in increased activity ratios GPx/SOD of 1 to 2.4. Our results indicate that small deviations from the physiological activity ratios of GPx/SOD have a dramatic effect on the resistance of cells to oxidant-induced damage to the genome and cell killing.			AMSTAD, P (corresponding author), SWISS INST EXPTL CANC RES,DEPT CARCINOGENESIS,CH BOVERESSES 155,CH-1066 EPALINGES,SWITZERLAND.				NCI NIH HHS [R01CA52310] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052310] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMSTAD P, 1991, BIOCHEMISTRY-US, V30, P9305, DOI 10.1021/bi00102a024; Battey, 1986, BASIC METHODS MOL BI; BLOCH CA, 1986, J BACTERIOL, V168, P795, DOI 10.1128/jb.168.2.795-798.1986; CANTONI O, 1989, EUR J BIOCHEM, V182, P209, DOI 10.1111/j.1432-1033.1989.tb14819.x; CEBALLOS I, 1988, BIOCHIM BIOPHYS ACTA, V949, P58, DOI 10.1016/0167-4781(88)90054-1; CERUTTI P, OXYRADICALS MOL BIOL; CERUTTI P, 1983, GENES PROTEINS ONCOG, P55; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; ELROYSTEIN O, 1986, EMBO J, V5, P615, DOI 10.1002/j.1460-2075.1986.tb04255.x; GRONER Y, 1990, PROG CLIN BIOL RES, V360, P233; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5299, DOI 10.1021/bi00695a011; KEDZIORA J, 1988, FREE RADICAL BIO MED, V4, P317, DOI 10.1016/0891-5849(88)90052-4; KELNER M, 1990, BIOL REACT INTERMED, V4, P305; KELNER MJ, 1990, J BIOL CHEM, V265, P10872; KOHN KW, 1976, BIOCHEMISTRY-US, V15, P4629, DOI 10.1021/bi00666a013; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; LINK EM, 1988, BIOCHEM J, V249, P391, DOI 10.1042/bj2490391; MAO GD, 1993, J BIOL CHEM, V268, P416; Mello Filho AC, 1984, BIOCHEM J, V218, P273; MIRAULT ME, 1991, J BIOL CHEM, V266, P20752; MUEHLEMATTER D, 1988, CARCINOGENESIS, V9, P239, DOI 10.1093/carcin/9.2.239; MULLENBACH GT, 1988, OXYRADICALS MOL BIOL, P313; OCHI T, 1987, P NATL ACAD SCI USA, V84, P990, DOI 10.1073/pnas.84.4.990; OMAR BA, 1990, FREE RADICAL BIO MED, V9, P473, DOI 10.1016/0891-5849(90)90124-2; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SCOTT MD, 1987, J BIOL CHEM, V262, P3640; SINET PM, 1979, LIFE SCI, V24, P29, DOI 10.1016/0024-3205(79)90276-5; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5	29	187	197	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1606	1609						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294405				2022-12-27	WOS:A1994MR98800011
J	BINZ, T; BLASI, J; YAMASAKI, S; BAUMEISTER, A; LINK, E; SUDHOF, TC; JAHN, R; NIEMANN, H				BINZ, T; BLASI, J; YAMASAKI, S; BAUMEISTER, A; LINK, E; SUDHOF, TC; JAHN, R; NIEMANN, H			PROTEOLYSIS OF SNAP-25 BY TYPE-E AND TYPE-A BOTULINAL NEUROTOXINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SYNAPTOSOMAL-ASSOCIATED PROTEIN; CLEAVAGE; PURIFICATION; SEQUENCE	Clostridial neurotoxins, tetanus toxin (TeTx) and the seven related but serologically distinct botulinal neurotoxins (BoNT/A to BoNT/G), are potent inhibitors of synaptic vesicle exocytosis in nerve endings. Recently it was reported that the light chains of clostridial neurotoxins act as zinc-dependent metalloproteases which specifically cleave synaptic target proteins such as synaptobrevin/VAMPs, HPC-1/syntaxin (BoNT/C1), and SNAP-25 (BoNT/A). We show here that BoNT/E, like BoNT/A, cleaves SNAP-25, as generated by in vitro translation or by expression in Escherichia coli. BoNT/E cleaves the Arg180-Ile181 bond. This site is different from that of BoNT/A, which cleaves SNAP-25 between the amino acid residues Gln197 and Arg198. These findings further support the view that clostridial neurotoxins have evolved from an ancestral protease recognizing the exocytotic fusion machinery of synaptic vesicles whereby individual toxins target different members of the membrane fusion complex.	FED RES CTR VIRUS DIS ANIM,DEPT MICROBIOL,POB 1149,D-72001 TUBINGEN,GERMANY; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	Yale University; Yale University; Howard Hughes Medical Institute; Yale University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Blasi, Juan/K-7943-2014	Blasi, Juan/0000-0002-0482-9444; Jahn, Reinhard/0000-0003-1542-3498				BINZ T, 1990, J BIOL CHEM, V265, P9153; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; DASGUPTA BR, 1983, TOXICON, V21, P535, DOI 10.1016/0041-0101(83)90131-9; HESS DT, 1992, J NEUROSCI, V12, P4634; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MOLGO J, 1990, J PHYSIOLOGY PARIS, V84, P152; MOLGO J, 1989, ACTA PHYSIOL SCAND, V137, P497, DOI 10.1111/j.1748-1716.1989.tb08786.x; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; POHLNER J, 1992, BIO-TECHNOL, V10, P799, DOI 10.1038/nbt0792-799; POULET S, 1992, BIOCHEM BIOPH RES CO, V183, P107, DOI 10.1016/0006-291X(92)91615-W; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATHYAMOORTHY V, 1985, J BIOL CHEM, V260, P461; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1993, J BIOL CHEM, V268, P11516; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUGII S, 1975, INFECT IMMUN, V12, P1262, DOI 10.1128/IAI.12.6.1262-1270.1975; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; [No title captured]	22	376	391	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1617	1620						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294407				2022-12-27	WOS:A1994MR98800014
J	HOFFMANN, B; STOCKL, A; SCHLAME, M; BEYER, K; KLINGENBERG, M				HOFFMANN, B; STOCKL, A; SCHLAME, M; BEYER, K; KLINGENBERG, M			THE RECONSTITUTED ADP ATP CARRIER ACTIVITY HAS AN ABSOLUTE REQUIREMENT FOR CARDIOLIPIN AS SHOWN IN CYSTEINE MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; MITOCHONDRIAL PHOSPHATE CARRIER; ADENINE-NUCLEOTIDE TRANSPORT; NUCLEAR-MAGNETIC-RESONANCE; ADP/ATP CARRIER; SPIN-LABEL; PHOSPHOLIPIDS; PROTEIN; SPECIFICITY; SPECTROSCOPY	Although the site-directed C73S mutation in the ADP/ATP carrier (AAC) AAC2 gene from Saccharomyces cerevisiae produced a glycerol-positive strain, indicating that the mutant AAC is active, on isolation and reconstitution in egg yolk phosphatidylcholine, the C73S AAC had no transport activity, whereas the wild-type AAC was fully active. Only on addition of cardiolipin was an exchange activity with the C73S AAC obtained. The AACs isolated from the other cysteine mutants did not (C244S) or only marginally (C271S) require cardiolipin for transport on reconstitution. [H-3]Carboxyatractylate binding as a measure of incorporated AAC molecules was unchanged on addition of cardiolipin in all mutants, indicating that cardiolipin does not increase the incorporation of the AAC. It also shows that cardiolipin is required only for translocation and not for binding. The activity of the C73S mutant AAC shows half-saturation with cardiolipin at 2% by weight or at 1.15 mol % in the phosphatidylcholine vesicles. Other acidic phospholipids tested such as phosphatidylserine and phosphatidic acid did not activate. Among various cardiolipin derivatives, the selectivity for cardiolipin is high. Only monolysocardiolipin still retains 12% activity. After removal of the bulk of phospholipid, the content of bound phospholipids was assayed by P-31 NMR. By unmasking with SDS, in the wild-type AAC and in the C73S AAC, 6.4 mol and only 1.3 and 2.9 mol of bound cardiolipin/mol of AAC dimer are found, respectively. Presumably, on isolation, cardiolipin is lost from the more labile C73S mutant AAC. Although the absolute requirement for cardiolipin is unique for the C73S AAC, it is concluded that in this mutant, the unmasking of the cardiolipin requirement demonstrates a general cardiolipin requirement of the wild-type AAC and of AACs from other sources.	UNIV MUNICH, INST PHYS BIOCHEM, GOETHESTR 33, D-80336 MUNICH, GERMANY	University of Munich								ABRAMOVITCH DA, 1990, BIOCHIM BIOPHYS ACTA, V1020, P34, DOI 10.1016/0005-2728(90)90090-Q; BEYER K, 1985, BIOCHEMISTRY-US, V24, P3821, DOI 10.1021/bi00336a001; BOGNER W, 1986, EUR J BIOCHEM, V161, P611, DOI 10.1111/j.1432-1033.1986.tb10485.x; BOULAY F, 1984, BIOCHEMISTRY-US, V23, P4807, DOI 10.1021/bi00315a042; BRANDOLIN G, 1980, BIOCHIM BIOPHYS ACTA, V592, P592, DOI 10.1016/0005-2728(80)90103-6; DREES M, 1988, BIOCHEMISTRY-US, V27, P8584, DOI 10.1021/bi00423a012; EBLE KS, 1990, J BIOL CHEM, V265, P19434; FRY M, 1980, BIOCHEM BIOPH RES CO, V93, P1238, DOI 10.1016/0006-291X(80)90622-1; GAWAZ M, 1990, J BIOL CHEM, V265, P14202; HAYERHARTL M, 1992, EUR J BIOCHEM, V209, P423, DOI 10.1111/j.1432-1033.1992.tb17305.x; KADENBACH B, 1982, FEBS LETT, V139, P109, DOI 10.1016/0014-5793(82)80498-5; KLINGENBERG M, 1992, DEVEL BIOCH, V29, P187; Klingenberg M, 1976, ENZYMES BIOLOGICAL M, V3, P383; KLINGENBERG M, 1991, STUDY ENZYMES, V2, P367; KNIRSCH M, 1989, FEBS LETT, V244, P427, DOI 10.1016/0014-5793(89)80577-0; KRAMER R, 1982, BIOCHIM BIOPHYS ACTA, V693, P296, DOI 10.1016/0005-2736(82)90435-7; KRAMER R, 1980, FEBS LETT, V119, P257, DOI 10.1016/0014-5793(80)80266-3; KRAMER R, 1989, BIOCHIM BIOPHYS ACTA, V974, P1, DOI 10.1016/S0005-2728(89)80160-4; Krumer R., 1992, MOL MECHANISMS BIOEN, P359, DOI DOI 10.1016/50167-7306(08)60184-2; LAWSON JE, 1990, J BIOL CHEM, V265, P14195; MENDE P, 1983, FEBS LETT, V158, P331, DOI 10.1016/0014-5793(83)80607-3; POWELL GL, 1987, BIOCHEMISTRY-US, V26, P8138, DOI 10.1021/bi00399a018; ROBINSON NC, 1982, BIOCHEMISTRY-US, V21, P184, DOI 10.1021/bi00530a031; ROBINSON NC, 1980, BIOCHEMISTRY-US, V19, P3656, DOI 10.1021/bi00557a003; SCHLAME M, 1991, EUR J BIOCHEM, V199, P459, DOI 10.1111/j.1432-1033.1991.tb16144.x; STAPPEN R, 1993, BIOCHIM BIOPHYS ACTA, V1149, P40, DOI 10.1016/0005-2736(93)90022-R; STIPANI I, 1980, BIOCHEM BIOPH RES CO, V97, P206; WOHLRAB H, 1984, BIOCHEMISTRY-US, V23, P1057, DOI 10.1021/bi00301a004; YU CA, 1975, J BIOL CHEM, V250, P1383	29	196	197	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1940	1944						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294444				2022-12-27	WOS:A1994MR98800060
J	ABE, I; PRESTWICH, GD				ABE, I; PRESTWICH, GD			ACTIVE-SITE MAPPING OF AFFINITY-LABELED RAT OXIDOSQUALENE CYCLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PEA-SEEDLINGS; SQUALENE-2,3-EPOXIDE CYCLASES; 2,3-OXIDOSQUALENE CYCLASE; PYROPHOSPHATE SYNTHETASE; SESQUITERPENE CYCLASE; DIPHOSPHATE SYNTHASE; CANDIDA-ALBICANS; PURIFICATION; GENE; CLONING	Rat liver oxidosqualene cyclase (OSC), a 78-kDa membrane-bound enzyme, was purified and labeled with the mechanism-based irreversible inhibitor, [H-3]29-methylidene-2,3-oxidosqualene (Abe, I., Bai, M., Xiao, X.-Y., and Prestwich, G. D. (1992) Biochem. Biophys. Res. Commun. 187, 32-38). A 6-kDa CNBr peptide was separated by Tricine sodium dodecyl sulfate-polyacrylamide gel electrophoresis and blotted to a polyvinylidene difluoride membrane. The sequence of the first 30 amino acids of this peptide were determined by Edman degradation and showed unexpectedly high similarity to the fungal OSC from Candida albicans (50% identity with Arg413-Val442) and to the bacterial squalene cyclase from Alicyclobacillus (formerly Bacillus) acidocaldarius (37% identity with Lys356-Leu385). Further, radioanalysis clearly established that the two adjacent Asp residues in the highly conserved region (Asp-Asp-Thr-Ala-Glu-Ala or DDTAEA) were equally labeled by the irreversible inhibitor. This result provides the first information on the structural details of the active site of OSC and shows for the first time the ancient lineage of this vertebrate enzyme to ancestral eukaryotic and prokaryotic cyclases. Interestingly, the covalently modified DDXX(D/E) sequence of rat liver OSC showed surprising similarity to the putative allylic diphosphate binding site sequence of sesquiterpene cyclases and prenyl transferases.	SUNY STONY BROOK,DEPT CHEM,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Abe, Ikuro/E-4449-2010	Abe, Ikuro/0000-0002-3640-888X	NIGMS NIH HHS [GM 44836] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044836] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE I, 1989, CHEM PHARM BULL, V37, P536; ABE I, 1989, FEBS LETT, V249, P100, DOI 10.1016/0014-5793(89)80024-9; ABE I, 1988, CHEM PHARM BULL, V36, P5031; ABE I, 1992, CHEM PHARM BULL, V40, P1755, DOI 10.1248/cpb.40.1755; ABE I, 1993, CHEM REV, V93, P2189, DOI 10.1021/cr00022a009; ABE I, 1992, BIOCHEM BIOPH RES CO, V187, P32, DOI 10.1016/S0006-291X(05)81454-8; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; BUNTEL CJ, 1992, J AM CHEM SOC, V114, P9711, DOI 10.1021/ja00050a090; COREY EJ, 1991, J AM CHEM SOC, V113, P4025, DOI 10.1021/ja00010a073; COREY EJ, 1991, J AM CHEM SOC, V113, P8172, DOI 10.1021/ja00021a056; COREY EJ, 1991, J AM CHEM SOC, V113, P8171, DOI 10.1021/ja00021a055; ESCHENMOSER A, 1955, HELV CHIM ACTA, V38, P1890, DOI 10.1002/hlca.19550380728; FACCHINI PJ, 1992, P NATL ACAD SCI USA, V89, P11088, DOI 10.1073/pnas.89.22.11088; HOHN TM, 1989, GENE, V79, P131, DOI 10.1016/0378-1119(89)90098-X; Johnson W. S., 1991, TETRAHEDRON, V47, pxi; JOHNSON WS, 1987, J AM CHEM SOC, V109, P2517, DOI 10.1021/ja00242a049; JOHNSON WS, 1987, J AM CHEM SOC, V109, P5852, DOI 10.1021/ja00253a048; JOHNSON WS, 1993, J AM CHEM SOC, V115, P504, DOI 10.1021/ja00055a021; KELLY R, 1990, GENE, V87, P177, DOI 10.1016/0378-1119(90)90299-7; KUSANO M, 1991, CHEM PHARM BULL, V39, P239; LEGENDRE N, 1993, PRACTICAL GUIDE PROT, P71; MARRERO PF, 1992, J BIOL CHEM, V267, P21873; MATH SK, 1992, P NATL ACAD SCI USA, V89, P6761, DOI 10.1073/pnas.89.15.6761; MOORE WR, 1992, J BIOL CHEM, V267, P22003; OCHS D, 1992, J BACTERIOL, V174, P298, DOI 10.1128/jb.174.1.298-302.1992; OURISSON G, 1989, PURE APPL CHEM, V61, P345, DOI 10.1351/pac198961030345; PEPINSKY RB, 1991, ANAL BIOCHEM, V195, P177, DOI 10.1016/0003-2697(91)90315-K; PROCTOR RH, 1993, J BIOL CHEM, V268, P4543; ROESSNER CA, 1993, GENE, V127, P149, DOI 10.1016/0378-1119(93)90631-C; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHEARES BT, 1989, BIOCHEMISTRY-US, V28, P8129, DOI 10.1021/bi00446a025; STORK G, 1955, J AM CHEM SOC, V77, P5068, DOI 10.1021/ja01624a038; VANTAMELEN EE, 1982, J AM CHEM SOC, V104, P6480, DOI 10.1021/ja00387a070; XIAO XY, 1991, J AM CHEM SOC, V113, P9673, DOI 10.1021/ja00025a043	34	83	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					802	804						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288628				2022-12-27	WOS:A1994MR22000005
J	CHRISTIE, KR; AWREY, DE; EDWARDS, AM; KANE, CM				CHRISTIE, KR; AWREY, DE; EDWARDS, AM; KANE, CM			PURIFIED YEAST RNA POLYMERASE-II READS THROUGH INTRINSIC BLOCKS TO ELONGATION IN RESPONSE TO THE YEAST TFIIS ANALOG, P37	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-S-II; ASCITES TUMOR-CELLS; TRANSCRIPTION ELONGATION; FACTOR-SII; ESCHERICHIA-COLI; TERNARY COMPLEXES; SACCHAROMYCES-CEREVISIAE; STIMULATORY FACTORS; STRUCTURAL-ANALYSIS; TERMINATION SITES	Saccharomyces cerevisiae has a TFIIS-related transcription elongation factor, originally called P37 (Sawadogo, M., Sentenac, A., and Fromageot, P. (1979) J. Biol. Chem. 255, 12-15; Nakanishi, T., Nakano, A., Nomura, K., Sekimizu, K., and Natori, S. (1992) J. Biol. Chem. 267, 13200-13204), which binds directly to RNA polymerase II and stimulates read-through of intrinsic blocks to elongation. To elucidate functional features of this protein:protein interaction, we tested the ability of several forms of RNA polymerase II to respond to either full-length or an amino-terminal truncation of TFIIS. The variants of the polymerase differed in the structure of the carboxyl-terminal domain of the largest subunit or lacked two of the smaller subunits. No differences in ability to recognize intrinsic blocks to elongation or to read through them in response to either form of TFIIS were detected among these variants. Furthermore, ternary complexes containing each variant form of RNA polymerase cleave the 3' end of the nascent transcripts in response to TFIIS, a reaction previously reported for mammalian and Drosophila TFIIS (Kassavetis, G. A., and Geiduschek, E. P. (1993) Science 259, 944-945) and likely to be important in TFIIS function. Thus the carboxyl-terminal domain of the largest subunit and subunits four and seven of the polymerase, required in vivo, are not required in vitro for recognition of intrinsic blocks to elongation, read-through in response to TFIIS, or TFIIS-stimulated cleavage of the nascent transcript.	UNIV CALIF BERKELEY,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720; MCMASTER UNIV,DEPT PATHOL,HAMILTON L8N 3Z5,ONTARIO,CANADA; MCMASTER UNIV,DEPT BIOCHEM,HAMILTON L8N 3Z5,ONTARIO,CANADA	University of California System; University of California Berkeley; McMaster University; McMaster University				Christie, Karen/0000-0001-5501-853X; Edwards, Aled/0000-0002-4782-6016				AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; AHN BY, 1990, MOL CELL BIOL, V10, P5433, DOI 10.1128/MCB.10.10.5433; ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ARCHAMBAULT J, 1992, MOL CELL BIOL, V12, P4142, DOI 10.1128/MCB.12.9.4142; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; CHAMBERLIN MJ, 1993, IN PRESS HARVEY LECT; CHEN HC, 1992, GENE, V116, P253, DOI 10.1016/0378-1119(92)90522-Q; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; GU WG, 1993, J BIOL CHEM, V268, P25604; GUO HL, 1993, J BIOL CHEM, V268, P18762; HAGLER J, 1993, J BIOL CHEM, V268, P2166; HIRASHIMA S, 1988, J BIOL CHEM, V263, P3858; HORIKOSHI M, 1985, J BIOL CHEM, V260, P5739; HORIKOSHI M, 1984, J BIOL CHEM, V259, P608; HORIKOSHI N, 1990, J BIOL CHEM, V265, P11854; HUBERT JC, 1983, EMBO J, V2, P2071, DOI 10.1002/j.1460-2075.1983.tb01702.x; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KANAI A, 1991, J BIOCHEM-TOKYO, V109, P674, DOI 10.1093/oxfordjournals.jbchem.a123439; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; KUHN A, 1990, NATURE, V344, P559, DOI 10.1038/344559a0; KUHN A, 1989, GENE DEV, V3, P224, DOI 10.1101/gad.3.2.224; LEE DN, 1992, J MOL BIOL, V228, P759, DOI 10.1016/0022-2836(92)90862-E; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; MARSHALL TK, 1990, NUCLEIC ACIDS RES, V18, P6293, DOI 10.1093/nar/18.21.6293; MCKUNE K, 1993, YEAST, V9, P295, DOI 10.1002/yea.320090309; NAKANISHI T, 1992, J BIOL CHEM, V267, P13200; NATORI S, 1982, MOL CELL BIOCHEM, V46, P173; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; RAPPAPORT J, 1987, J BIOL CHEM, V262, P5227; RAPPAPORT J, 1988, MOL CELL BIOL, V8, P3136, DOI 10.1128/MCB.8.8.3136; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; RICE GA, 1993, NUCLEIC ACIDS RES, V21, P113, DOI 10.1093/nar/21.1.113; SAWADOGO M, 1980, J BIOL CHEM, V255, P12; SAWADOGO M, 1981, BIOCHEMISTRY-US, V20, P3542, DOI 10.1021/bi00515a037; SAWADOGO M, 1980, BIOCHEM BIOPH RES CO, V96, P258, DOI 10.1016/0006-291X(80)91208-5; SEKIMIZU K, 1979, BIOCHEMISTRY-US, V18, P1582, DOI 10.1021/bi00575a031; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SLUDER AE, 1989, J BIOL CHEM, V264, P8963; SPENCER CA, 1990, ONCOGENE, V5, P777; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; TURNBOUGH C, 1992, TRANSCRIPTIONAL REGU, P407; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; WIELAND T, 1991, EXPERIENTIA, V47, P1186, DOI 10.1007/BF01918382; WIEST DK, 1992, J BIOL CHEM, V267, P7733; WOYCHIK NA, 1990, TRENDS BIOCHEM SCI, V15, P347, DOI 10.1016/0968-0004(90)90074-L; WOYCHIK NA, 1989, MOL CELL BIOL, V9, P2854, DOI 10.1128/MCB.9.7.2854; YOO OJ, 1991, NUCLEIC ACIDS RES, V19, P1073, DOI 10.1093/nar/19.5.1073	66	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					936	943						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288647				2022-12-27	WOS:A1994MR22000028
J	DASCHER, C; BALCH, WE				DASCHER, C; BALCH, WE			DOMINANT INHIBITORY MUTANTS OF ARF1 BLOCK ENDOPLASMIC-RETICULUM TO GOLGI TRANSPORT AND TRIGGER DISASSEMBLY OF THE GOLGI-APPARATUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING-PROTEIN; PERIPHERAL MEMBRANE-PROTEIN; SEMI-INTACT CELLS; BREFELDIN-A; PERMEABILIZED CELLS; VESICULAR TRANSPORT; GUANINE-NUCLEOTIDE; ENDOCYTIC PATHWAY; ER	Using three different trans dominant mutants of bovine ARF1 affecting GDP exchange or GTP hydrolysis we demonstrate the central role of ARF1 in controlling vesicular traffic from the endoplasmic reticulum (ER) to the Golgi apparatus and between successive Golgi compartments. Overexpression of ARF1(Q71L), a mutant likely to be restricted to the GTP-bound form, resulted in the accumulation of vesicular stomatitis virus glycoprotein in pre-Golgi intermediates, inhibited transport between successive Golgi compartments, and led to a striking association of beta-COP with pre-Golgi intermediates and the Golgi stack. In contrast, ARF1(T31N), a mutant which is likely to have a preferential affinity for GDP compared to the wild-type protein, inhibited export from the ER and triggered a brefeldin A-like phenotype, resulting in the redistribution of beta-COP from Golgi membranes to the cytosol and the collapse of the Golgi into the ER. This mutant, which may efficiently sequester an ARF-specific guanine nucleotide-exchange protein (ARF-GEF), suggests that ARF and ARF-GEF are essential for export from the ER. These results are discussed in the context of the GDP and GTP-bound forms of ARF in controlling both membrane structure and vesicular traffic through the early secretory pathway.	SCRIPPS RES INST, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042336] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 42336] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALCH WE, 1992, J BIOL CHEM, V267, P13053; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARLOWE C, 1993, J BIOL CHEM, V268, P873; BECKERS CJM, 1990, J BIOL CHEM, V265, P18298; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; DENFERT C, 1991, J CELL BIOL, V114, P663, DOI 10.1083/jcb.114.4.663; DER CJ, 1988, ONCOGENE, V3, P105; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DER CJ, 1991, CANCER CELL-MON REV, V3, P331; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GRAHAM TR, 1993, EMBO J, V12, P869, DOI 10.1002/j.1460-2075.1993.tb05727.x; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HENDRICKS LC, 1993, MOL BIOL CELL, V4, P413, DOI 10.1091/mbc.4.4.413; HLEMS BJ, 1993, J CELL BIOL, V121, P751; JOHN J, 1993, J BIOL CHEM, V268, P923; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KOSHRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264; Lippincott-Schwartz Jennifer, 1993, Trends in Cell Biology, V3, P81, DOI 10.1016/0962-8924(93)90078-F; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; OKA T, 1991, J CELL BIOL, V114, P671, DOI 10.1083/jcb.114.4.671; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; OSAWA T, 1987, ANNU REV BIOCHEM, V56, P21, DOI 10.1146/annurev.biochem.56.1.21; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P15; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STUDIER RW, 1990, METHOD ENZYMOL, V185, P60; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4638; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; WAGNER P, 1992, METHOD ENZYMOL, V219, P369; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WATERS M G, 1991, Current Opinion in Cell Biology, V3, P615, DOI 10.1016/0955-0674(91)90031-S; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WEISS O, 1989, J BIOL CHEM, V264, P21066; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P67; YAMAMOTO K, 1982, CURR OPIN CELL BIOL, V5, P613	69	349	353	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1437	1448						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288610				2022-12-27	WOS:A1994MR22000103
J	PESCINI, R; KASZUBSKA, W; WHELAN, J; DELAMARTER, JF; VANHUIJSDUIJNEN, RH				PESCINI, R; KASZUBSKA, W; WHELAN, J; DELAMARTER, JF; VANHUIJSDUIJNEN, RH			ATF-A0, A NOVEL VARIANT OF THE ATF/CREB TRANSCRIPTION FACTOR FAMILY, FORMS A DOMINANT TRANSCRIPTION INHIBITOR IN ATF-A HETERODIMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; AMP RESPONSE ELEMENT; DNA-BINDING PROTEINS; CYCLIC-AMP; GENE-TRANSCRIPTION; ACTIVATES TRANSCRIPTION; CYTOKINE INDUCTION; MESSENGER-RNA; CDNA CLONES; POU-DOMAIN	We have isolated a cDNA encoding a variant of the transcription factor ATF-a (called ATf-a0) by screening a HeLa cDNA expression library with a regulatory element of the E-selectin promoter, NF-ELAM1/deltaA. Relative to full-length ATF-a, the ATF-a0 cDNA contains a large in-frame deletion of 525 base pairs that removes the P/S/T-rich putative transactivation domain. Using reverse-transcription-polymerase chain reaction and Northern blot hybridization to characterize ATF-a0 expression, we found that putative mRNAs for ATF-a0 and ATF-a are present at varying ratios in different tissues. Full-length ATF-a is a transcriptional activator for the NF-ELAM1/deltaA site of the E-selectin promoter. In contrast, we show ATF-a0 has no measurable transactivating function on this element. Moreover, we demonstrate that co-expressed ATF-a0 and ATF-a preferentially heterodimerize. In the heterodimer ATF-a0 is a dominant inhibitor that completely blocks the transactivating activity of ATF-a. Both forms of ATF-a bind the p50 subunit of NF-kappaB as shown by affinity chromatography. ATF-a0 appears to be a splice variant similar to the one found for ATF-2, its closest homologue in structure and function. Taken together, our results suggest that ATF-a0 is an important member of the ATF family with a negative regulatory role in transactivation.	GLAXO,INST MOLEC BIOL,CHEMIN AULX,CH-1228 PLAN LES OUATES,SWITZERLAND	GlaxoSmithKline			van Huijsduijnen, Rob A.M. Hooft/B-3653-2009	van Huijsduijnen, Rob A.M. Hooft/0000-0002-2261-9424				Ausubel FM, 1988, MOL REPROD DEV; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BECKERANDRE M, 1992, EUR J BIOCHEM, V206, P401, DOI 10.1111/j.1432-1033.1992.tb16940.x; BECKERANDRE M, 1993, ABSOLUTE LEVELS MRNA, P420; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DEGROOT RP, 1992, ONCOGENE, V7, P2281; DENG TL, 1992, P NATL ACAD SCI USA, V89, P8572, DOI 10.1073/pnas.89.18.8572; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DWORETZKY SI, 1992, P NATL ACAD SCI USA, V89, P4178, DOI 10.1073/pnas.89.9.4178; Ferre F, 1992, PCR Methods Appl, V2, P1; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GEORGOPOULOS K, 1990, EMBO J, V9, P109, DOI 10.1002/j.1460-2075.1990.tb08086.x; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HOEFFLER JP, 1992, J INVEST DERMATOL, V98, pS21, DOI 10.1111/1523-1747.ep12462126; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; INAGAKI N, 1992, P NATL ACAD SCI USA, V89, P1045, DOI 10.1073/pnas.89.3.1045; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; IVASHKIV LB, 1992, NEW BIOL, V4, P360; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LARIGAN JD, 1992, DNA CELL BIOL, V11, P149, DOI 10.1089/dna.1992.11.149; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEE KAW, 1992, J CELL SCI, V103, P9; LEE MR, 1992, J IMMUNOL, V146, P1906; LI XY, 1992, J BIOL CHEM, V267, P8984; LIOU HC, 1988, SCIENCE, V242, P69, DOI 10.1126/science.3140376; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MEYER TE, 1992, NUCLEIC ACIDS RES, V20, P6106, DOI 10.1093/nar/20.22.6106; MORGAN IM, 1992, CELL PROLIFERAT, V25, P205, DOI 10.1111/j.1365-2184.1992.tb01395.x; MORRIS AE, 1992, NUCLEIC ACIDS RES, V20, P1355, DOI 10.1093/nar/20.6.1355; MURO AF, 1992, J BIOL CHEM, V267, P12767; NEHLIN JO, 1992, NUCLEIC ACIDS RES, V20, P5271, DOI 10.1093/nar/20.20.5271; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; NICOSIA A, 1992, NUCLEIC ACIDS RES, V20, P5321, DOI 10.1093/nar/20.20.5321; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUPPERT S, 1992, EMBO J, V11, P1503, DOI 10.1002/j.1460-2075.1992.tb05195.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SINGH H, 1988, CELL, V52, P414; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; VANHUIJSDUIJNEN RAMH, 1992, BIOTECHNIQUES, V12, P830; VANHUIJSDUIJNEN RH, 1992, J BIOL CHEM, V267, P22385; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WALTON KM, 1990, MOL NEUROBIOL, V4, P197, DOI 10.1007/BF02780341; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; WHELAN J, 1989, MOL CELL BIOL, V9, P3253, DOI 10.1128/MCB.9.8.3253; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	80	28	33	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1159	1165						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288576				2022-12-27	WOS:A1994MR22000062
J	RAJPUROHIT, R; LEE, SO; PARK, JO; PAIK, WK; KIM, S				RAJPUROHIT, R; LEE, SO; PARK, JO; PAIK, WK; KIM, S			ENZYMATIC METHYLATION OF RECOMBINANT HETEROGENEOUS NUCLEAR RNP PROTEIN-A1 - DUAL SUBSTRATE-SPECIFICITY FOR S-ADENOSYLMETHIONINE - HISTONE-ARGININE N-METHYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN-BASIC-PROTEIN; HELIX-DESTABILIZING PROTEIN; AMINO-ACID SEQUENCE; CALF THYMUS; BINDING-PROTEINS; COMPLEX PROTEIN-A1; MOUSE-BRAIN; PURIFICATION; UP1; RIBONUCLEOPROTEIN	We have previously reported the existence of two different molecular species of protein methylase I (S-adenosylmethionine:protein-arginine N-methyltransferase, E.C. 2.1.1.23) in calf brain, one specific for myelin basic protein and the other for histone (Ghosh, S. K., Paik, W. K., and Kim, S. (1988) J. Biol. Chem. 263, 19024-19033). In the present study, however, we report that heterogeneous ribonucleoprotein particle protein Al is most likely an in vivo substrate for the ''histone-specific protein methylase I.'' The unmethylated recombinant protein A1 has been found to be a much superior methyl acceptor for the enzyme than histone with a K(m) value two orders of magnitude lower (0.19 muM) than that for histone (21 muM). Myelin basic protein, a specific inhibitor for histone protein methylase I, exhibited a lower IC50 for protein Al methylation (IC50 = 33 muM) compared with histone methylation (IC50 = 220 muM) and competitively inhibited the former with a K(i) value of 1.3 x 10(-6) M. The extent of inhibition of protein A1 and histone methylation by the polyclonal antibodies prepared against purified ''histone protein methylase I'' was identical. Maximally, 1.08-mol methyl groups were incorporated per mol of protein A1, which was 27-fold higher than that of histone (0.04 mol/mol of histone). HPLC analysis of the enzymatically methylated amino acid residues in protein Al revealed the formation of N-monomethylarginine and N(G),N(G)-dimethylarginine. The ratio of N(G),N(G)-dimethylarginine/N(G)-monomethylarginine increased as a function of incubation period; however, N(G),N'G-dimethylarginine was not detectable. Proteolytic cleavage of the methyl-H-3-labeled recombinant protein Al by trypsin and Staphylococcus aureus V8 endoprotease indicated that, protein A1 possesses multiple sites for methylation, one of which was identified as residue 194 arginine, which coincided with the in vivo methylation site.	TEMPLE UNIV, HLTH SCI CTR,SCH MED, FELS INST CANC RES & MOLEC BIOL,3420 N BROAD ST, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NCI NIH HHS [CA 122270] Funding Source: Medline; NIADDK NIH HHS [AM09602] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM009602] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R21CA122270] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALDWIN GS, 1971, SCIENCE, V171, P579, DOI 10.1126/science.171.3971.579; BOFFA LC, 1979, BIOCHEM BIOPH RES CO, V89, P1322, DOI 10.1016/0006-291X(79)92153-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROSTOFF S, 1971, P NATL ACAD SCI USA, V68, P765, DOI 10.1073/pnas.68.4.765; CHANDERKAR LP, 1986, BIOCHEM J, V240, P471, DOI 10.1042/bj2400471; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; COBIANCHI F, 1988, J BIOL CHEM, V263, P1063; COBIANCHI F, 1986, J BIOL CHEM, V261, P3536; DELANGE RJ, 1969, J BIOL CHEM, V244, P5669; DESROSIERS R, 1988, J BIOL CHEM, V263, P4686; Dixon G. H., 1975, CIBA F S, V28, P229; DREYFUSS G, 1984, J CELL BIOL, V99, pA233, DOI 10.1083/jcb.99.6.1997; DUERRE JA, 1975, J BIOL CHEM, V250, P8457; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FAROOQUI J, 1981, J BIOL CHEM, V256, P5041; GHOSH SK, 1990, BIOCHIM BIOPHYS ACTA, V1039, P142, DOI 10.1016/0167-4838(90)90179-J; GHOSH SK, 1988, J BIOL CHEM, V263, P19024; GUPTA A, 1982, J BIOL CHEM, V257, P9677; HERRICK G, 1976, J BIOL CHEM, V251, P2124; HONDA BM, 1975, J BIOL CHEM, V250, P8681; KARN J, 1977, J BIOL CHEM, V252, P7307; KIM SD, 1984, METHOD ENZYMOL, V106, P295; KUMAR A, 1986, J BIOL CHEM, V261, P1266; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P10717, DOI 10.1021/bi00500a001; KUMAR A, 1990, J BIOL CHEM, V265, P17094; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; LISCHWE MA, 1990, PROTEIN METHYLATION, P97; MERRILL BM, 1986, J BIOL CHEM, V261, P878; MERRILL BM, 1987, INT J PEPT PROT RES, V29, P21; OLIVER CL, 1984, METHOD MOL BIOL, V2, P157; PAIK WK, 1968, J BIOL CHEM, V243, P2108; PAIK WK, 1990, PROTEIN METHYLATION, P23; PAIK WK, 1980, BIOCH SERIES MONOGRA, V1, P8; PARK GH, 1986, BIOCHIM BIOPHYS ACTA, V874, P30, DOI 10.1016/0167-4838(86)90098-1; PARK KS, 1987, J BIOL CHEM, V262, P14702; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; PINOLROMA S, 1989, J CELL BIOL, V109, P2575, DOI 10.1083/jcb.109.6.2575; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; RAJPUROHIT R, 1992, BIOCHIM BIOPHYS ACTA, V1122, P183, DOI 10.1016/0167-4838(92)90322-5; RAWAL N, 1992, BIOCHEM J, V287, P929, DOI 10.1042/bj2870929; RAWAL N, 1991, J NEUROSCI METH, V37, P133, DOI 10.1016/0165-0270(91)90123-H; REPORTER M, 1971, BIOCHEM BIOPH RES CO, V43, P644, DOI 10.1016/0006-291X(71)90663-2; RIVA S, 1986, EMBO J, V5, P2267, DOI 10.1002/j.1460-2075.1986.tb04494.x; STAHMANN MA, 1946, J BIOL CHEM, V164, P753; WILLIAMS KR, 1985, P NATL ACAD SCI USA, V82, P5666, DOI 10.1073/pnas.82.17.5666; ZAPPIA V, 1969, J BIOL CHEM, V244, P4499; 1984, 07124 WAT ASS OP MAN, P1	49	56	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1075	1082						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288564				2022-12-27	WOS:A1994MR22000049
J	SANDBRINK, R; MASTERS, CL; BEYREUTHER, K				SANDBRINK, R; MASTERS, CL; BEYREUTHER, K			BETA-A4-AMYLOID PROTEIN-PRECURSOR MESSENGER-RNA ISOFORMS WITHOUT EXON-15 ARE UBIQUITOUSLY EXPRESSED IN RAT-TISSUES INCLUDING BRAIN, BUT NOT IN NEURONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-BETA-PROTEIN; ALZHEIMERS-DISEASE; DIFFERENTIAL EXPRESSION; HIPPOCAMPAL-NEURONS; GENE; LOCALIZATION; PEPTIDE; CORTEX; APP; IDENTIFICATION	The betaA4-amyloid protein precursor (APP), the source of the betaA4-amyloid deposits found in Alzheimer brains, constitutes a family of transmembrane glycoproteins generated by alternative splicing. While exon 7 and exon 8 are well known to be alternatively spliced, APP mRNA isoforms without exon 15 were only recently identified in leukocytes and rat brain microglial cells and therefore denoted as L-APP mRNAs. In order to perform a detailed analysis of individual L-APP mRNA isoforms in perfused rat tissues, we developed a quantitative polymerase chain reaction assay from reverse transcribed RNA allowing us to analyze the alternatively spliced region in between exon 6 and 16. In all peripheral tissues examined, L-APP mRNA isoforms were detected comprising between 25% (skeletal muscle) and about 70% (aorta, pancreas) of total APP transcripts. All four possible A.PP mRNA isoforms without exon 15 were shown to exist, i.e. L-APP752, L-APP733, L-APP696, and L-APP677. L-APP expression in the central nervous system (approximately 4% of total APP mRNA) was then studied in more detail by analyzing different brain regions and tissues and primary cultured brain cells. The only cell type which was shown not to express L-APP mRNA to a detectable level is the neuronal cell. Ubiquitous expression of APP mRNAs lacking exon 15 except for neurons indicates an important function in non-neuronal cells and is especially remarkable since neurons are the primarily affected cells in Alzheimer's disease.	UNIV MELBOURNE,DEPT PATHOL,PARKVILLE,VIC 3052,AUSTRALIA	University of Melbourne	SANDBRINK, R (corresponding author), UNIV HEIDELBERG,CTR MOLEC BIOL HEIDELBERG ZMBH,NEUENHEIMER FELD 282,D-69120 HEIDELBERG,GERMANY.							AUSBUBEL FM, 1989, CURRENT PROTOCOLS MO; BANATI RB, 1993, IN PRESS GLIA, V9; BORRIELLO F, 1990, NUCLEIC ACIDS RES, V18, P5481, DOI 10.1093/nar/18.18.5481; BREWER GJ, 1989, BRAIN RES, V494, P65, DOI 10.1016/0006-8993(89)90144-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK MJ, 1985, EMBO J, V4, P113, DOI 10.1002/j.1460-2075.1985.tb02324.x; DESAUVAGE F, 1989, SCIENCE, V245, P651, DOI 10.1126/science.2569763; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; JACOBSEN JS, 1991, NEUROBIOL AGING, V12, P585, DOI 10.1016/0197-4580(91)90090-7; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; JOHNSON SA, 1988, EXP NEUROL, V102, P264, DOI 10.1016/0014-4886(88)90104-5; KANG J, 1990, BIOCHEM BIOPH RES CO, V166, P1192, DOI 10.1016/0006-291X(90)90992-V; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KANG J, 1989, NUCLEIC ACIDS RES, V17, P2130, DOI 10.1093/nar/17.5.2130; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KONIG G, 1991, MOL BRAIN RES, V9, P259, DOI 10.1016/0169-328X(91)90010-U; KONIG G, 1992, J BIOL CHEM, V267, P10804; KOO EH, 1990, NEURON, V2, P97; Krainer AR, 1988, TRANSCRIPTION SPLICI, P131; LEBLANC AC, 1991, FEBS LETT, V292, P171, DOI 10.1016/0014-5793(91)80861-V; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; MIYAZAKI K, 1993, NATURE, V362, P839, DOI 10.1038/362839a0; MONNING U, 1992, J BIOL CHEM, V267, P23950; MULLERHILL B, 1989, ANNU REV BIOCHEM, V58, P287; NEVE RL, 1990, NEURON, V5, P329, DOI 10.1016/0896-6273(90)90169-G; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; OYAMA F, 1991, J NEUROPATH EXP NEUR, V50, P560, DOI 10.1097/00005072-199109000-00004; PALMERT MR, 1988, SCIENCE, V241, P1080, DOI 10.1126/science.2457949; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; Sambrook J, 1989, MOL CLONING LABORATO; SCHUBERT D, 1988, SCIENCE, V241, P223, DOI 10.1126/science.2968652; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; SCHUBERT W, 1991, BRAIN RES, V563, P184, DOI 10.1016/0006-8993(91)91532-6; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; TANAKA S, 1988, BIOCHEM BIOPH RES CO, V157, P472, DOI 10.1016/S0006-291X(88)80273-0; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WHITSON JS, 1989, SCIENCE, V243, P1488, DOI 10.1126/science.2928783; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N	54	124	127	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1510	1517						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288617				2022-12-27	WOS:A1994MR22000112
J	SMIRNOV, MD; ESMON, CT				SMIRNOV, MD; ESMON, CT			PHOSPHATIDYLETHANOLAMINE INCORPORATION INTO VESICLES SELECTIVELY ENHANCES FACTOR VA INACTIVATION BY ACTIVATED PROTEIN-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BLOOD-COAGULATION; ENZYME COMPLEXES; MEMBRANE-BINDING; THROMBOMODULIN; PROTHROMBIN; THROMBIN	Membrane surfaces accelerate the proteolytic inactivation of factor Va by activated protein C. In most coagulation complexes, the most active membrane phospholipid is believed to be phosphatidylserine. In this study, we demonstrate that with phosphatidylserine-containing vesicles, incorporation of phosphatidylethanolamine increased the rate of factor Va inactivation approximately 10-fold at all concentrations of factor Va studied and at all vesicle concentrations at or below the optimum for prothrombin activation. In contrast, phosphatidylethanolamine had very little influence on prothrombin activation. Phosphatidylethanolamine was a critical component of vesicles for the vesicles to support activated protein C anticoagulant activity optimally in plasma. These results demonstrate that the membrane requirements for the different coagulation/anticoagulation complexes differ much more than previously appreciated.	UNIV OKLAHOMA,HLTH SCI CTR,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOLEC BIOL,OKLAHOMA CITY,OK 73190; OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA CITY,OK 73104	Howard Hughes Medical Institute; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation	SMIRNOV, MD (corresponding author), UNIV OKLAHOMA,HLTH SCI CTR,HOWARD HUGHES MED INST,DEPT PATHOL,OKLAHOMA CITY,OK 73190, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030340] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37 HL30340] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BEVERS EM, 1991, BLOOD REV, V5, P146, DOI 10.1016/0268-960X(91)90031-7; BEVERS EM, 1983, BIOCHIM BIOPHYS ACTA, V736, P57, DOI 10.1016/0005-2736(83)90169-4; ESMON CT, 1979, J BIOL CHEM, V254, P964; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON CT, 1973, THESIS WASHINGTON U; FERNLUND P, 1982, J BIOL CHEM, V257, P2170; JACKMAN RW, 1986, P NATL ACAD SCI USA, V83, P8834, DOI 10.1073/pnas.83.23.8834; LAURA R, 1980, BIOCHEMISTRY-US, V19, P4859, DOI 10.1021/bi00562a024; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1990, BLOOD, V76, P1; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4164, DOI 10.1021/bi00638a005; NESHEIM ME, 1984, J BIOL CHEM, V259, P1447; NEUENSCHWANDER PF, 1992, J BIOL CHEM, V267, P14477; OWEN WG, 1974, J BIOL CHEM, V249, P594; PEI G, 1993, J BIOL CHEM, V268, P3226; RAUCH J, 1986, J BIOL CHEM, V261, P9672; SCHWALBE RA, 1989, J BIOL CHEM, V264, P20288; TANS G, 1991, BLOOD, V77, P2641; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; TRIPLETT DA, 1993, ARCH PATHOL LAB MED, V117, P78; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; WALKER FJ, 1981, J BIOL CHEM, V256, P1128; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; WALKER FJ, 1980, J BIOL CHEM, V255, P5521	27	163	171	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					816	819						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288632				2022-12-27	WOS:A1994MR22000009
J	BOERNER, RJ; BARRY, BA				BOERNER, RJ; BARRY, BA			EPR EVIDENCE THAT THE M+ RADICAL, WHICH IS OBSERVED IN 3 SITE-DIRECTED MUTANTS OF PHOTOSYSTEM-II, IS A TYROSINE RADICAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN-RESONANCE; OXYGEN-EVOLVING SYSTEM; GALACTOSE-OXIDASE; MODEL COMPOUNDS; D1 POLYPEPTIDE; SYNECHOCYSTIS-6803; SPECTROSCOPY; CONSTANTS; CATIONS; DONOR	Isotopic labeling of Synechocystis sp. PCC 6803 and EPR spectroscopy have been used to demonstrate that photosystem II contains two redox active tyrosines, D and Z (Barry, B. A. and Babcock, G. T. (1987) Proc. Natl. Acad. Sci. U.S.A. 84, 7099-7103; Boerner, R. J. and Barry, B. A. (1993) J. Biol. Chem. 268, 17151-17154). Another organic radical, M+, has recently been observed in site-directed mutants in which a non-redox active amino acid is substituted at either the putative D or putative Z sites (Boerner, R. J., Bixby, K. A., Nguyen, A. P., Noren, G. H., Debus, R. J., and Barry, B. A. (1993) J. Biol. Chem. 268, 1817-1823; Noren, G. H., and Barry, B. A. (1992) Biochemistry 31, 3335-3342). Here, we use isotopic labeling to determine the chemical identity of M+. Upon incorporation of perdeuterated tyrosine into photosystem II, the M+ EPR signal narrows to approximately 12-13 G. Labeling with 3,5-deuterated tyrosine results in an isotropic doublet with splittings of 11 G. Our results show that M+ is a tyrosine radical with unique spectroscopic properties.	UNIV MINNESOTA, DEPT BIOCHEM, ST PAUL, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043273] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43273] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABCOCK GT, 1992, J AM CHEM SOC, V114, P3727, DOI 10.1021/ja00036a023; BABCOCK GT, 1983, BIOCHIM BIOPHYS ACTA, V723, P276, DOI 10.1016/0005-2728(83)90127-5; BARRY BA, 1987, P NATL ACAD SCI USA, V84, P7099, DOI 10.1073/pnas.84.20.7099; BARRY BA, 1990, J BIOL CHEM, V265, P20139; BARRY BA, 1988, CHEM SCRIPTA, V28A, P117; BARRY BA, 1993, PHOTOCHEM PHOTOBIOL, V57, P179, DOI 10.1111/j.1751-1097.1993.tb02275.x; BOERNER RJ, 1993, J BIOL CHEM, V268, P1817; BOERNER RJ, 1993, J BIOL CHEM, V268, P17151; DEBUS RJ, 1988, BIOCHEMISTRY-US, V27, P9071, DOI 10.1021/bi00426a001; DEBUS RJ, 1988, P NATL ACAD SCI USA, V85, P427, DOI 10.1073/pnas.85.2.427; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DIXON WT, 1976, J CHEM SOC FARAD T 2, V72, P1221, DOI 10.1039/f29767201221; DIXON WT, 1974, J CHEM SOC FARAD T 2, V70, P1713, DOI 10.1039/f29747001713; GERFEN GJ, 1993, J AM CHEM SOC, V115, P6420, DOI 10.1021/ja00067a071; HOGANSON CW, 1992, BIOCHEMISTRY-US, V31, P11874, DOI 10.1021/bi00162a028; HOLTON DM, 1979, J CHEM SOC FARAD T 2, V75, P1637, DOI 10.1039/f29797501637; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; MATTOO AK, 1993, SOC EXP BIOL SEMIN S, V53, P65, DOI 10.1017/CBO9780511600401.006; METZ JG, 1989, BIOCHEMISTRY-US, V28, P6960, DOI 10.1021/bi00443a028; MU D, 1992, J BIOL CHEM, V267, P7979; NOREN GH, 1991, BIOCHEMISTRY-US, V30, P3943, DOI 10.1021/bi00230a020; NOREN GH, 1992, BIOCHEMISTRY-US, V31, P3335, DOI 10.1021/bi00128a005; VERMAAS WFJ, 1988, P NATL ACAD SCI USA, V85, P8477, DOI 10.1073/pnas.85.22.8477; WERTZ JE, 1986, ELECTRON SPIN RESONA; WHITTAKER MM, 1990, J BIOL CHEM, V265, P9610	26	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					134	137						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276786				2022-12-27	WOS:A1994MR21900028
J	GOPALAKRISHNAN, L; SCARPULLA, RC				GOPALAKRISHNAN, L; SCARPULLA, RC			DIFFERENTIAL REGULATION OF RESPIRATORY-CHAIN SUBUNITS BY A CREB-DEPENDENT SIGNAL-TRANSDUCTION PATHWAY - ROLE OF CYCLIC-AMP IN CYTOCHROME-C AND COXIV GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ELECTRON-TRANSPORT; MESSENGER-RNAS; SOMATOSTATIN GENE; THYROID-HORMONE; PROCESSED PSEUDOGENES; COORDINATE INDUCTION; CATALYTIC SUBUNIT; RIBONUCLEIC-ACID; SKELETAL-MUSCLE; PROTEIN-KINASE	In vertebrate organisms, the molecular mechanisms by which extracellular signals regulate mitochondrial function and biogenesis are largely unknown. We have previously identified multiple cis-acting elements in both cytochrome c and cytochrome oxidase subunit IV (COXIV) genes that are likely targets for the regulated expression of respiratory chain components. We now demonstrate that cytochrome c but not COXIV mRNA is induced by cAMP through a mechanism involving transcriptional activation. Maximal induction occurs within 3 h and does not require de novo protein synthesis. The differential response of these genes is mediated by two distinct cAMP response elements (CREs) in the cytochrome c promoter region. Both elements function independently to drive cAMP-dependent expression from a heterologous promoter and within the proper cytochrome c promoter context. In addition, the binding properties of both elements to nuclear factors were characterized by competition DNase I footprinting, methylation interference footprinting, site-directed mutagenesis, and UV-induced DNA-protein cross-linking. The results are all consistent with the specific recognition of both CREs by CRE binding protein (CREB). A highly purified preparation of recombinant CREB formed a specific complex with each of the cytochrome c CREs identical to that formed with a crude nuclear fraction. In addition, the trans-activation of cytochrome c gene expression by recombinant CREB and protein kinase A in transfected cells was completely dependent on functional CREs within the promoter. These results establish that respiratory chain gene expression can be regulated directly by cAMP through a CREB-dependent signal transduction pathway.	NORTHWESTERN UNIV, SCH MED, DEPT CELL MOLEC & STRUCT BIOL, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA	Northwestern University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032525, R56GM032525] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32525-11] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BOOTH FW, 1975, ARCH BIOCHEM BIOPHYS, V167, P674, DOI 10.1016/0003-9861(75)90511-1; CHAU CMA, 1992, J BIOL CHEM, V267, P6999; CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321; CLAYTON DA, 1992, INT REV CYTOL, V141, P217, DOI 10.1016/S0074-7696(08)62067-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS MJ, 1988, P NATL ACAD SCI USA, V85, P9625, DOI 10.1073/pnas.85.24.9625; EVANS MJ, 1988, MOL CELL BIOL, V8, P35, DOI 10.1128/MCB.8.1.35; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; EWART G, 1990, BIOCHIM BIOPHYS ACTA, V1018, P223, DOI 10.1016/0005-2728(90)90253-Z; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINK JS, 1988, P NATL ACAD SCI USA, V85, P6662, DOI 10.1073/pnas.85.18.6662; GLAICHENHAUS N, 1986, EMBO J, V5, P1261, DOI 10.1002/j.1460-2075.1986.tb04355.x; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; GUPTE SS, 1988, J BIOL CHEM, V263, P5248; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.biochem.54.1.1015; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOOD DA, 1989, EUR J BIOCHEM, V179, P275, DOI 10.1111/j.1432-1033.1989.tb14551.x; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; KADOWAKI T, 1991, EXP CELL RES, V192, P243, DOI 10.1016/0014-4827(91)90182-T; KESSLER MA, 1986, ARCH BIOCHEM BIOPHYS, V251, P403, DOI 10.1016/0003-9861(86)90346-2; KU CY, 1991, MOL ENDOCRINOL, V5, P1669, DOI 10.1210/mend-5-11-1669; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; MEKALANOS JJ, 1988, METHOD ENZYMOL, V165, P169; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MUCHARDT C, 1992, EMBO J, V11, P2573, DOI 10.1002/j.1460-2075.1992.tb05322.x; MUCHARDT C, 1990, J VIROL, V64, P4296, DOI 10.1128/JVI.64.9.4296-4305.1990; MUTVEI A, 1989, ACTA ENDOCRINOL-COP, V121, P223, DOI 10.1530/acta.0.1210223; PARISI MA, 1993, MOL CELL BIOL, V13, P1951, DOI 10.1128/MCB.13.3.1951; POYTON RO, 1988, ANN NY ACAD SCI, V550, P289, DOI 10.1111/j.1749-6632.1988.tb35344.x; RIABOWOL KT, 1988, NATURE, V336, P83, DOI 10.1038/336083a0; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SCARPULLA RC, 1983, CELL, V32, P473, DOI 10.1016/0092-8674(83)90467-1; SCARPULLA RC, 1986, J BIOL CHEM, V261, P4660; SCARPULLA RC, 1984, MOL CELL BIOL, V4, P2279, DOI 10.1128/MCB.4.11.2279; SHAN B, 1990, EMBO J, V9, P4307, DOI 10.1002/j.1460-2075.1990.tb07879.x; SHORT JM, 1986, J BIOL CHEM, V261, P9721; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TORRONI A, 1990, J BIOL CHEM, V265, P20589; UHLER MD, 1987, J BIOL CHEM, V262, P15202; VANITALLIE CM, 1988, MOL ENDOCRINOL, V2, P332, DOI 10.1210/mend-2-4-332; VANITALLIE CM, 1990, ENDOCRINOLOGY, V127, P55, DOI 10.1210/endo-127-1-55; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; VIRBASIUS JV, 1990, NUCLEIC ACIDS RES, V18, P6581, DOI 10.1093/nar/18.22.6581; VIRBASIUS JV, 1988, J BIOL CHEM, V263, P6791; WILLIAMS RS, 1987, J BIOL CHEM, V262, P2764; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	55	72	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					105	113						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276781				2022-12-27	WOS:A1994MR21900024
J	AOYAGI, T; IZUMO, S				AOYAGI, T; IZUMO, S			MAPPING OF THE PRESSURE RESPONSE ELEMENT OF THE C-FOS GENE BY DIRECT DNA INJECTION INTO BEATING HEARTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC MYOCYTES; PROTOONCOGENE INDUCTION; NERVOUS-SYSTEM; MUSCLE INVIVO; CYCLIC-AMP; EXPRESSION; HYPERTROPHY; THERAPY; SIGNALS; CELLS	In vivo gene transfer into various organs of postnatal animals has recently been demonstrated. We applied this technique in order to map the promoter element of the protooncogene c-fos in the myocardium that responds to left ventricular pressure overload in vivo. Beating rat hearts were directly injected with a recombinant plasmid containing a 356-base pair upstream regulatory element of the mouse c-fos gene fused to a reporter gene. Two days after the injection, the hearts were excised and buffer-perfused. Acute pressure overload was applied for 2 h by inflating an intraventricular balloon. Pressure overload increased the myocardial reporter gene activity by 3-8-fold (p < 0.01). Deletion and point mutations in the serum response element (SRE) of the c-fos promoter resulted in loss of pressure-induced reporter gene expression, indicating that the SRE is necessary for pressure response. The SRE alone was sufficient to confer pressure responsiveness to the minimal c-fos promoter, confirming that the pressure response element coincides with the SRE. A construct containing a point mutation at the p62TCF binding site of the SRE did not respond to pressure overload or to a protein kinase C activator but retained responsiveness to a calcium ionophore. This suggests that pressure overload may activate the c-fos promoter by a protein kinase C-dependent pathway. Thus, a directly injected gene can be regulated in the host cells by a physical stimulus to the intact organ. The in vivo DNA injection technique is a useful method to study complex organ physiology at the molecular level.	BETH ISRAEL HOSP, MOLEC MED UNIT, 330 BROOKLINE AVE, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, DIV CARDIOVASC, BOSTON, MA 02215 USA; BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School								ACSADI G, 1991, NEW BIOL, V3, P71; AOYAGI T, 1991, J CARDIOVASC PHARM, V17, P647; AUSEBEL FM, 1988, CURRENT PROTOCOL MOL, P966; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CRYSTAL RG, 1992, AM J MED, V92, pS44; FRIEDMANN T, 1989, SCIENCE, V244, P1275, DOI 10.1126/science.2660259; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; KITSIS RN, 1991, P NATL ACAD SCI USA, V88, P4138, DOI 10.1073/pnas.88.10.4138; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KOMURO I, 1991, J BIOL CHEM, V266, P1265; LEINWAND LA, 1991, TRENDS CARDIOVAS MED, V1, P271, DOI 10.1016/1050-1738(91)90042-D; LIN H, 1990, CIRCULATION, V82, P2217, DOI 10.1161/01.CIR.82.6.2217; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; NABEL EG, 1991, J AM COLL CARDIOL, V17, pB189; NORDEEN SK, 1991, BIOTECHNIQUES, V6, P474; PARMACEK MS, 1992, MOL CELL BIOL, V12, P1967, DOI 10.1128/MCB.12.5.1967; PARTRIDGE TA, 1989, NATURE, V337, P176, DOI 10.1038/337176a0; RIVERA V M, 1990, New Biologist, V2, P751; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SADOSHIMA J, 1992, P NATL ACAD SCI USA, V89, P9905, DOI 10.1073/pnas.89.20.9905; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; SCHUNKERT H, 1991, P NATL ACAD SCI USA, V88, P11480, DOI 10.1073/pnas.88.24.11480; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; Treisman R, 1990, Semin Cancer Biol, V1, P47; VONHARSDORF R, 1993, CIRC RES, V72, P1688; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; WOLFF JA, 1991, BIOTECHNIQUES, V11, P474	32	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27176	27179						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262957				2022-12-27	WOS:A1993MM26200052
J	FURRIOLS, M; CHILLARON, J; MORA, C; CASTELLO, A; BERTRAN, J; CAMPS, M; TESTAR, X; VILARO, S; ZORZANO, A; PALACIN, M				FURRIOLS, M; CHILLARON, J; MORA, C; CASTELLO, A; BERTRAN, J; CAMPS, M; TESTAR, X; VILARO, S; ZORZANO, A; PALACIN, M			RBAT, RELATED TO L-CYSTINE TRANSPORT, IS LOCALIZED TO THE MICROVILLI OF PROXIMAL STRAIGHT TUBULES, AND ITS EXPRESSION IS REGULATED IN KIDNEY BY DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL BRUSH-BORDER; XENOPUS-LAEVIS OOCYTES; AMINO-ACID-TRANSPORT; RAT-KIDNEY; MEMBRANE-VESICLES; GLUTAMATE TRANSPORTER; MOLECULAR-CLONING; MESSENGER-RNA; BRAIN; CDNA	We have recently isolated a renal cDNA clone (rBAT) that induces amino acid transport in oocytes either as a component or as a specific activator of a system bo,+-like transporter. (Bertran, J., Werner, A., Moore, M. L., Stange, G., Markovich, D., Biber, J., Testar, X., Zorzano, A., Palacin, M., and Murer, H. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 5601-5605. In order to obtain additional information on the rBAT protein, we have investigated the cellular localization of rBAT and its expression during development in rat kidney. A polyclonal antibody raised against rBAT recognizes a specific protein band of approximately 90 kDa, which is highly enriched in rat renal brush border membranes. Immunofluorescence and immunoelectron microscopy studies demonstrated that rBAT is expressed in the microvilli domain of S3 epithelial cells (i.e. straight tubules). The onset of rBAT mRNA expression in kidney was detected during late fetal life. In keeping with this, induction in oocytes of L-cystine uptake due to fetal rBAT-related mRNA was approximately 10% of the induction obtained with rBAT-related mRNA from adult kidneys. rBAT mRNA levels were low in early postnatal life, and only at the end of lactation did they increase steeply, attaining approximately 50% of adult values after weaning. rBAT protein was undetectable in total membrane preparations of kidneys from fetuses and early neonates, weakly detected during lactation, and represented <15% of adult values after weaning. The postnatal expression of rBAT and its specific location in the microvilli of epithelial cells from the S3 segment of the proximal tubule coincide with postnatal maturation of cystine resorption and with the site of high affinity resorption of cystine in kidney. This is consistent with the involvement of rBAT in a bo,+-like high-affinity resorption system for cystine in the proximal straight tubule of the nephron.	UNIV BARCELONA,FAC BIOL,DEPT BIOQUIM & FISIOL,AVDA DIAGONAL 645,E-08028 BARCELONA,SPAIN	University of Barcelona			Palacín, Manuel/G-9786-2015; Wilson, Matthew H/K-3193-2013; Camps, Marta/F-6557-2016; Farré, Anna Castelló/K-9637-2015; Chillaron, Josep/ABF-7663-2021; Zorzano, Antonio/R-5479-2018; Mora, Conchi/A-8280-2010	Camps, Marta/0000-0001-5392-1792; Farré, Anna Castelló/0000-0001-8497-6251; Chillaron, Josep/0000-0003-3068-7598; Mora, Conchi/0000-0002-5644-0537; Furriols, Marc/0000-0002-0656-1912; Palacin, Manuel/0000-0002-8670-293X				Bergeron M, 1985, KIDNEY PHYSL PATHOPH, P1725; BERTRAN J, 1993, J BIOL CHEM, V268, P14842; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; BERTRAN J, 1992, BIOCHEM J, V281, P717, DOI 10.1042/bj2810717; BIBER J, 1983, PFLUG ARCH EUR J PHY, V396, P335, DOI 10.1007/BF01063939; BIEMESDERFER D, 1992, AM J PHYSIOL, V262, pF55, DOI 10.1152/ajprenal.1992.262.1.F55; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRETAUDIERE JP, 1984, METHOD ENZYMAT AN, V4, P75; BRODEHL J, 1968, PEDIATRICS, V42, P395; BULGER RE, 1988, CELL TISSUE BIOL TXB, P815; CAMPS L, 1991, J LIPID RES, V32, P1877; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOSS EI, 1993, J BIOL CHEM, V268, P7538; COICADAN L, 1980, PEDIATR RES, V14, P109, DOI 10.1203/00006450-198002000-00008; FOREMAN JW, 1980, METABOLISM, V29, P53, DOI 10.1016/0026-0495(80)90098-0; FREMEAU RT, 1992, NEURON, V8, P915, DOI 10.1016/0896-6273(92)90206-S; FURLONG TJ, 1990, AM J PHYSIOL, V258, pF321, DOI 10.1152/ajprenal.1990.258.2.F321; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P9608; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANAI Y, 1982, AM J PHYSIOL, V263, pF1087; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON L, 1975, J ULTRA MOL STRUCT R, V51, P119, DOI 10.1016/S0022-5320(75)80013-X; LARSSON L, 1975, J ULTRA MOL STRUCT R, V53, P254, DOI 10.1016/S0022-5320(75)80142-0; LIU AR, 1992, P NATL ACAD SCI USA, V89, P1214; MAGAGNIN S, 1992, J BIOL CHEM, V267, P15384; MARKOVICH D, 1993, J BIOL CHEM, V268, P1362; MCKUSICK VA, 1990, MENDELIAN INHERITANC, P1128; MCNAMARA PD, 1992, BIOCHIM BIOPHYS ACTA, V1103, P101, DOI 10.1016/0005-2736(92)90062-Q; MCNAMARA PD, 1981, BIOCHEM J, V194, P443, DOI 10.1042/bj1940443; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; OZEGOVIC B, 1982, BIOSCIENCE REP, V2, P913, DOI 10.1007/BF01114898; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Rosen K., 1990, FOCUS, V12, P23; ROSENBERG LE, 1966, J CLIN INVEST, V45, P365, DOI 10.1172/JCI105351; SCHAFER JA, 1984, PFLUG ARCH EUR J PHY, V401, P143, DOI 10.1007/BF00583874; SCRIVER CR, 1985, J PEDIATR-US, V106, P411, DOI 10.1016/S0022-3476(85)80666-1; SEGAL S, 1969, P NATL ACAD SCI USA, V63, P926, DOI 10.1073/pnas.63.3.926; SEGAL S, 1977, SCIENCE, V197, P169, DOI 10.1126/science.877548; SEGAL S, 1989, METABOLIC BASIS INHE, P2479; SILBERNAGL S, 1988, PHYSIOL REV, V68, P911, DOI 10.1152/physrev.1988.68.3.911; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; THIER SO, 1965, J CLIN INVEST, V44, P442, DOI 10.1172/JCI105157; UCHIDA S, 1992, P NATL ACAD SCI USA, V89, P8230, DOI 10.1073/pnas.89.17.8230; VANWINKLE LJ, 1988, J BIOL CHEM, V263, P3150; VOLKL H, 1982, PFLUG ARCH EUR J PHY, V395, P190, DOI 10.1007/BF00584808; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; YAN N, 1992, P NATL ACAD SCI USA, V89, P9982, DOI 10.1073/pnas.89.21.9982	52	101	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27060	27068						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262944				2022-12-27	WOS:A1993MM26200036
J	SUN, AQ; YUKSEL, KU; GRACY, RW				SUN, AQ; YUKSEL, KU; GRACY, RW			LIMITED PROTEOLYSIS OF TRIOSE-PHOSPHATE ISOMERASE AND CHARACTERIZATION OF THE CATALYTICALLY ACTIVE PEPTIDE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TRIOSEPHOSPHATE ISOMERASE; SITE MODIFICATION; PROTEINS; DISSOCIATION; DEGRADATION; QUANTITIES; REPRESSOR; SEQUENCES; ENZYME; REGION	Limited proteolysis of the triose-phosphate isomerase (EC 5.3.1.1) by subtilisin generates peptides that remain noncovalently attached and catalytically active. Edman degradation of the peptides showed that the primary proteolytic sites for yeast triose-phosphate isomerase are the Leu174-Ala175 bond followed by Ser52-Leu53. The Leu174-Ala175 site is of particular interest, since it forms part of the hinged lid that closes over the catalytic center, and this bond is only 12.2 angstrom (open) or 9.8 angstrom (closed) from the catalytic residue Glu165. The higher K(m), k(cat), and k(cat)/k(m) values exhibited by the catalytically active peptide complex suggest that the substrate is not bound as tightly to the catalytic center. In addition, increased methylglyoxal formation by the cleaved enzyme indicates that the enzyme-substrate complex is less protected from the solvent. Circular dichroic and fluorescence spectra show that the overall structure of the peptide complex is similar to the native enzyme but with local structural perturbations around the tryptophans. Also, the peptide complex is more susceptible to denaturation by guanidine and exhibits lower T(m) values, indicating a loose interaction between the fragments. Unfolding, dissociation, and refolding experiments suggest that the fragments have strong inherent secondary structural features and can reassociate into catalytically active structures.	UNIV N TEXAS, HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, 3500 CAMP BOWIE BLVD, FT WORTH, TX 76107 USA	University of North Texas System; University of North Texas Health Science Center					NATIONAL INSTITUTE ON AGING [R01AG001274, R37AG001274] Funding Source: NIH RePORTER; NIA NIH HHS [AG01274] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AHERN TJ, 1987, P NATL ACAD SCI USA, V84, P675, DOI 10.1073/pnas.84.3.675; ALBER T, 1981, PHILOS T ROY SOC B, V293, P159, DOI 10.1098/rstb.1981.0069; Anfinsen C B, 1967, Harvey Lect, V61, P95; BERGMEYER HU, 1984, METHOD ENZYMAT AN, V6, P593; BOWIE JU, 1989, BIOCHEMISTRY-US, V28, P7139, DOI 10.1021/bi00444a001; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIANG HL, 1988, J BIOL CHEM, V263, P6797; EDER J, 1992, BIOCHEMISTRY-US, V31, P3617, DOI 10.1021/bi00129a010; GOLDBERG AL, 1974, ANNU REV BIOCHEM, V43, P835, DOI 10.1146/annurev.bi.43.070174.004155; GRACY RW, 1990, PROG CLIN BIOL RES, V344, P787; HARTMAN FC, 1971, BIOCHEMISTRY-US, V10, P146, DOI 10.1021/bi00777a021; JOSEPH D, 1990, SCIENCE, V249, P1425, DOI 10.1126/science.2402636; KIM HS, 1992, J BIOL CHEM, V267, P7177; KINOSHITA CM, 1992, PROTEIN SCI, V1, P700, DOI 10.1002/pro.5560010602; KNOWLES JR, 1991, NATURE, V350, P121, DOI 10.1038/350121a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS SD, 1992, PROTEIN SCI, V1, P998, DOI 10.1002/pro.5560010805; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6619, DOI 10.1021/bi00480a010; MAIZEL JV, 1971, METHOD VIROL, V5, P180; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; POMPLIANO DL, 1990, BIOCHEMISTRY-US, V29, P3186, DOI 10.1021/bi00465a005; RICHARD JP, 1991, BIOCHEMISTRY-US, V30, P4581, DOI 10.1021/bi00232a031; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROJODOMINGUEZ A, 1990, BIOCHEMISTRY-US, V29, P8689, DOI 10.1021/bi00489a026; ROZACKY EE, 1971, ARCH BIOCHEM BIOPHYS, V146, P312, DOI 10.1016/S0003-9861(71)80069-3; SNAPKA RM, 1974, COMP BIOCHEM PHYSIOL, V49, P733, DOI 10.1016/0305-0491(74)90259-4; Speicher D.W., 1989, TECHNIQUES PROTEIN C, P24; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; SUN AQ, 1992, ARCH BIOCHEM BIOPHYS, V295, P421, DOI 10.1016/0003-9861(92)90536-6; SUN AQ, 1992, J BIOL CHEM, V267, P20168; SUN AW, 1992, ARCH BIOCHEM BIOPHYS, V293, P382, DOI 10.1016/0003-9861(92)90410-X; TASAYCO ML, 1992, SCIENCE, V255, P594, DOI 10.1126/science.1736361; WALEY SG, 1973, BIOCHEM J, V135, P165, DOI 10.1042/bj1350165; WIERENGA RK, 1991, J MOL BIOL, V220, P995, DOI 10.1016/0022-2836(91)90368-G; YUAN PM, 1981, BIOCHIM BIOPHYS ACTA, V671, P211, DOI 10.1016/0005-2795(81)90136-7; YUKSEL KU, 1986, ARCH BIOCHEM BIOPHYS, V248, P452, DOI 10.1016/0003-9861(86)90498-4	37	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26872	26878						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262920				2022-12-27	WOS:A1993MM26200010
J	ABRAMOVITZ, M; BOIE, Y; NGUYEN, T; RUSHMORE, TH; BAYNE, MA; METTERS, KM; SLIPETZ, DM; GRYGORCZYK, R				ABRAMOVITZ, M; BOIE, Y; NGUYEN, T; RUSHMORE, TH; BAYNE, MA; METTERS, KM; SLIPETZ, DM; GRYGORCZYK, R			CLONING AND EXPRESSION OF A CDNA FOR THE HUMAN PROSTANOID FP RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; PROSTAGLANDIN-F2-ALPHA RECEPTORS; HUMAN MYOMETRIUM; CORPORA-LUTEA	A cDNA clone coding for a functional human prostanoid FP receptor has been isolated from a uterus cDNA library. The human FP receptor consists of 359 amino acid residues with a predicted molecular mass of 40,060, and has the seven putative transmembrane domains characteristic of G-protein-coupled receptors. Challenge of Xenopus oocytes expressing the FP receptor with 10 nM of either prostaglandin (PG) F2alpha or the selective FP-receptor agonist fluprostenol resulted in an elevation in intracellular Ca2+. Radioreceptor binding studies using membranes prepared from mammalian COS cells transfected with the FP receptor cDNA showed that the rank order of potency for prostaglandins and prostaglandin analogs in competition for [H-3]PGF2alpha specific binding sites was as predicted for the FP receptor, with PGF2alpha almost-equal-to fluprostenol > PGD2 > PGE2 > U46619 > iloprost. In summary, we have cloned the human prostanoid FP receptor which is functionally coupled to the Ca2+ signalling pathway.	MERCK FROSST CTR THERAPEUT RES,DEPT PHARMACOL,POINTE CLAIRE H9R 4P8,PQ,CANADA	Merck & Company	ABRAMOVITZ, M (corresponding author), MERCK FROSST CTR THERAPEUT RES,DEPT MOLEC BIOL,POB 1005,POINTE CLAIRE H9R 4P8,PQ,CANADA.			Grygorczyk, Ryszard/0000-0002-9798-7651				BARNARD JW, 1992, J APPL PHYSIOL, V72, P2469, DOI 10.1152/jappl.1992.72.6.2469; BAUKNECHT T, 1981, ACTA ENDOCRINOL-COP, V98, P446, DOI 10.1530/acta.0.0980446; BLACK FM, 1990, BIOCHEM J, V266, P661, DOI 10.1042/bj2660661; CAMPBELL W B, 1990, P600; COLEMAN RA, 1981, BRIT J PHARMACOL, V74, pP913; COLEMAN RA, 1987, PROSTAGLANDINS RELAT, P267; COLEMAN RA, 1989, COMPREHENSIVE MED CH, V3, P643; Colman A., 1984, TRANSCRIPTION TRANSL, P49; CSEPLI J, 1975, PROSTAGLANDINS, V10, P689, DOI 10.1016/S0090-6980(75)80017-7; DAVIES P, 1992, INFLAMMATION BASIC P, P123; DAVIS JS, 1987, P NATL ACAD SCI USA, V84, P3728, DOI 10.1073/pnas.84.11.3728; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DONG YJ, 1986, BRIT J PHARMACOL, V87, P97, DOI 10.1111/j.1476-5381.1986.tb10161.x; DUKES M, 1974, NATURE, V250, P330, DOI 10.1038/250330a0; FREY EA, 1993, EUR J PHARM-MOLEC PH, V244, P239, DOI 10.1016/0922-4106(93)90149-4; FUNK CD, 1993, IN PRESS J BIOL CHEM, V268; GILADI E, 1991, BIOTECHNIQUES, V10, P744; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HONDA A, 1993, J BIOL CHEM, V268, P7759; HORTON EW, 1976, PHYSIOL REV, V56, P595, DOI 10.1152/physrev.1976.56.4.595; KITANAKA J, 1991, BIOCHEM BIOPH RES CO, V178, P946, DOI 10.1016/0006-291X(91)90983-E; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MARTENS GJM, 1992, PROG BRAIN RES, V92, P201, DOI 10.1016/S0079-6123(08)61176-0; MOLNAR M, 1990, AM J PHYSIOL, V258, pE740, DOI 10.1152/ajpendo.1990.258.5.E740; NAKAO A, 1993, J CELL PHYSIOL, V155, P257, DOI 10.1002/jcp.1041550206; NEUSCHAFERRUBE F, 1993, EUR J BIOCHEM, V211, P163, DOI 10.1111/j.1432-1033.1993.tb19883.x; POWELL WS, 1976, EUR J BIOCHEM, V61, P605, DOI 10.1111/j.1432-1033.1976.tb10056.x; POWELL WS, 1975, EUR J BIOCHEM, V56, P73, DOI 10.1111/j.1432-1033.1975.tb02208.x; POWELL WS, 1974, EUR J BIOCHEM, V41, P103, DOI 10.1111/j.1432-1033.1974.tb03249.x; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; RACZ P, 1993, ARCH OPHTHALMOL-CHIC, V111, P657, DOI 10.1001/archopht.1993.01090050091036; Sambrook J, 1989, MOL CLONING LABORATO; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SENIOR J, 1993, BRIT J PHARMACOL, V108, P501, DOI 10.1111/j.1476-5381.1993.tb12832.x; SENIOR J, 1992, BRIT J PHARMACOL, V107, P215, DOI 10.1111/j.1476-5381.1992.tb14489.x; STJERNSCHANTZ J, 1992, Drugs of the Future, V17, P691; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641; WATSON S, 1993, TRENDS PHARM SCI S, P31; WEILAND GA, 1981, LIFE SCI, V29, P313, DOI 10.1016/0024-3205(81)90324-6	43	244	272	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2632	2636						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300593				2022-12-27	WOS:A1994MV43200044
J	CONNOR, J; PAK, CC; SCHROIT, AJ				CONNOR, J; PAK, CC; SCHROIT, AJ			EXPOSURE OF PHOSPHATIDYLSERINE IN THE OUTER LEAFLET OF HUMAN RED-BLOOD-CELLS - RELATIONSHIP TO CELL-DENSITY, CELL AGE, AND CLEARANCE BY MONONUCLEAR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OCCURRING ANTI-BAND-3 ANTIBODIES; HUMAN-ERYTHROCYTES; TRANSBILAYER MOVEMENT; SICKLE ERYTHROCYTES; PLASMA-MEMBRANES; INVIVO; SURFACE; RECOGNITION; MACROPHAGES; PHOSPHOLIPIDS	Human red blood cells (RBC) were separated by density on self-forming Percoll gradients into five distinct populations. The transbilayer movement and equilibrium distribution of 1-oleoyl-2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)aminocaproyl)phosphatidylserine (NBD-PS) was slower in dense cells and equilibrated in the inner leaflet of these cells to a lesser degree than in light cells. Conversely, the outward movement of the lipid was slower in light cells. Assessment of endogenous PS in the cells' outer leaflet by the prothrombinase activity of externalized PS revealed an increase in its presence at the cell surface with increasing cell density. The presence of PS on the cell surface directly correlated with the propensity of the RBC to be bound by autologous monocytes. To determine whether increased cell density is associated with increased cell age, the in vivo clearance of density-separated murine RBC was monitored in syngeneic mice. The T1/2 of circulation of light cells was about twice that of dense cells. The majority of the cleared cells localized in the spleen. Studies carried out in antibody-deficient SCID mice indicated that RBC were cleared via a mechanism that was independent of antibody. These data suggest that cell age is related to cell density and that cells of increasing age and density display higher amounts of PS in their outer leaflet.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT CELL BIOL, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center					NIDDK NIH HHS [DK 41714] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041714] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLAN D, 1982, NATURE, V295, P612, DOI 10.1038/295612a0; ALLEN TM, 1988, P NATL ACAD SCI USA, V85, P8067, DOI 10.1073/pnas.85.21.8067; AMINOFF D, 1988, BLOOD CELLS, V14, P229; BARTOSZ G, 1981, BIOCHIM BIOPHYS ACTA, V644, P69, DOI 10.1016/0005-2736(81)90059-6; BARTOSZ G, 1991, GERONTOLOGY, V37, P33, DOI 10.1159/000213251; BARTOSZ G, 1984, MECH AGEING DEV, V24, P1, DOI 10.1016/0047-6374(84)90172-6; BARTOSZ G, 1990, BLOOD CELL BIOCH, V1, P45; BEVERS EM, 1983, BIOCHIM BIOPHYS ACTA, V736, P57, DOI 10.1016/0005-2736(83)90169-4; BLUMENFELD N, 1991, BLOOD, V77, P849; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; CLARK MR, 1983, BLOOD, V61, P899, DOI 10.1182/blood.V61.5.899.899; COMFURIUS P, 1990, J LIPID RES, V31, P1719; CONNOR J, 1992, J BIOL CHEM, V267, P19412; CONNOR J, 1988, BIOCHEMISTRY-US, V27, P848, DOI 10.1021/bi00403a002; CONNOR J, 1989, P NATL ACAD SCI USA, V86, P3184, DOI 10.1073/pnas.86.9.3184; DALE GL, 1990, BIOCHIM BIOPHYS ACTA, V1036, P183, DOI 10.1016/0304-4165(90)90032-R; DHERMY D, 1987, BIOCHIM BIOPHYS ACTA, V904, P201, DOI 10.1016/0005-2736(87)90369-5; DUMASWALA UJ, 1984, TRANSFUSION, V24, P490, DOI 10.1046/j.1537-2995.1984.24685066807.x; FADOK VA, 1992, J IMMUNOL, V149, P4029; FADOK VA, 1992, J IMMUNOL, V148, P2207; FRANCK PFH, 1985, J CLIN INVEST, V75, P183, DOI 10.1172/JCI111672; GALILI U, 1986, J CLIN INVEST, V77, P27, DOI 10.1172/JCI112286; GREENWALT TJ, 1988, BRIT J HAEMATOL, V68, P465, DOI 10.1111/j.1365-2141.1988.tb04237.x; HENTSCHEL WM, 1986, CLIN CHIM ACTA, V157, P33, DOI 10.1016/0009-8981(86)90315-3; HERRMANN A, 1990, BIOCHIM BIOPHYS ACTA, V1027, P41, DOI 10.1016/0005-2736(90)90045-P; JAIN SK, 1983, BRIT J HAEMATOL, V53, P247, DOI 10.1111/j.1365-2141.1983.tb02018.x; JAIN SK, 1988, BIOCHIM BIOPHYS ACTA, V937, P205, DOI 10.1016/0005-2736(88)90242-8; KAY MMB, 1983, P NATL ACAD SCI-BIOL, V80, P1631, DOI 10.1073/pnas.80.6.1631; KAY MMB, 1978, J SUPRAMOL STR CELL, V9, P555, DOI 10.1002/jss.400090409; LINDERKAMP O, 1982, BLOOD, V59, P1121; LUTZ HU, 1988, BLOOD CELLS, V14, P175; LUTZ HU, 1992, BIOCHIM BIOPHYS ACTA, V1116, P1, DOI 10.1016/0304-4165(92)90120-J; LUTZ HU, 1987, P NATL ACAD SCI USA, V84, P7368, DOI 10.1073/pnas.84.21.7368; Lutz HU, 1990, BLOOD CELL BIOCH, V1, P81; MORRISON M, 1983, BIOMED BIOCHIM ACTA, V42, pS107; MUELLER TJ, 1987, J CLIN INVEST, V79, P492, DOI 10.1172/JCI112839; NASH GB, 1980, BIORHEOLOGY, V17, P479; NASH GB, 1983, BIOPHYS J, V43, P63, DOI 10.1016/S0006-3495(83)84324-0; OPDENKAMP JAF, 1979, ANNU REV BIOCHEM, V48, P47, DOI 10.1146/annurev.bi.48.070179.000403; PIOMELLI S, 1993, AM J HEMATOL, V42, P46, DOI 10.1002/ajh.2830420110; RIFKIND JM, 1983, ARCH BIOCHEM BIOPHYS, V222, P582, DOI 10.1016/0003-9861(83)90556-8; SCHLEPPERSCHAFER J, 1983, BIOCHEM BIOPH RES CO, V115, P551, DOI 10.1016/S0006-291X(83)80180-6; SCHROIT AJ, 1985, J BIOL CHEM, V260, P5131; SCHWARTZ RS, 1985, J CLIN INVEST, V75, P1965, DOI 10.1172/JCI111913; UTSUGI T, 1991, CANCER RES, V51, P3062; VANOSS CJ, 1982, BIORHEOLOGY, V19, P725; VERKLEIJ AJ, 1973, BIOCHIM BIOPHYS ACTA, V323, P178, DOI 10.1016/0005-2736(73)90143-0; ZWAAL RFA, 1989, MOL CELL BIOCHEM, V91, P23, DOI 10.1007/BF00228075	48	262	269	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2399	2404						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300565				2022-12-27	WOS:A1994MV43200012
J	KRATZ, F; HARTMANN, M; KEPPLER, B; MESSORI, L				KRATZ, F; HARTMANN, M; KEPPLER, B; MESSORI, L			THE BINDING-PROPERTIES OF 2 ANTITUMOR RUTHENIUM(III) COMPLEXES TO APOTRANSFERRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-METABOLISM; PERSPECTIVES; TRANSFERRINS; CISPLATIN	The interaction of two ruthenium(III) complexes exhibiting high anticancer activity, namely trans-indazolium(bisindazole)tetrachlororuthenate(III) (ruind) and trans-imidazolium(bisimidazole)tetrachlororuthenate(III) (ru-im), with human serum apotransferrin has been investigated through spectroscopic and chromatographic techniques with the ultimate goal of preparing adducts with good selectivity for cancer cells. Whereas the binding of ru-im to human serum apotransferrin takes several hours, ru-ind, the less toxic complex, gives rise to a well defined 2:1 complex within a few minutes. We have ascertained that ru-ind binding occurs around the iron binding sites; binding does not occur in the absence of bicarbonate, and this anion dictates the kinetic and mechanistic characteristics of protein binding of ru-ind. The two ruthenium(III) complexes do not behave as iron(III) complexes, eg. FE(EDTA) or Fe(nitrilotriacetate), which lose their respective ligands when binding apotransferrin, but the N-heterocycles remain attached to the metal in the protein-bound species. Reversion of binding is obtained by acidification in the presence of chelators such as citrate or ATP. In comparison with cisplatin and its deactivation by serum proteins, our results indicate that other metal complexes such as ruind could use transferrin as a drug delivery system. Furthermore, the rapid protein binding of ru-ind seems to be related to a lower toxicity while still exhibiting high antitumor activity.	UNIV FLORENCE,DEPT CHEM,INORGAN & BIOINORGAN CHEM LAB,I-50121 FLORENCE,ITALY	University of Florence	KRATZ, F (corresponding author), UNIV HEIDELBERG,INST ANORGAN CHEM,NEUENHEIMER FELD 270,D-69120 HEIDELBERG,GERMANY.			Keppler, Bernhard/0000-0003-0877-1822; messori, luigi/0000-0002-9490-8014				ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; BAKER EN, 1992, J INORG BIOCHEM, V47, P147, DOI 10.1016/0162-0134(92)84061-Q; BATES GW, 1975, J BIOL CHEM, V250, P2177; CAZZOLA M, 1990, BLOOD, V75, P1903; COLE WC, 1980, CHEM-BIOL INTERACT, V30, P223, DOI 10.1016/0009-2797(80)90128-3; CRICHTON RR, 1992, BIOCHEMISTRY-US, V31, P11255, DOI 10.1021/bi00161a001; DALEYYATES PT, 1985, BIOCH MECHANISMS PLA, P121; Faulk W.P., 1990, OXIDOREDUCTION PLASM, V1, P205; HAGEN WR, 1993, IN PRESS J CHEM S DA; Keppler BK, 1989, PROGR CLIN BIOCH MED, V10, P41; KRATZ F, 1993, J INORG BIOCHEM, V49, P79, DOI 10.1016/0162-0134(93)85017-3; KRATZ F, 1992, METAL IONS BIOL MED, V2, P69; Kratz F., 1993, METAL COMPLEXES CANC, P391; KROGHJESPERSEN K, 1984, INORG CHEM, V23, P4390, DOI 10.1021/ic00193a060; Lipponer K.-G., 1992, THESIS U HEIDELBERG; MANOHARAN PT, 1973, INORG CHEM, V12, P2753, DOI 10.1021/ic50130a003; MASON SF, 1982, MOL OPTICAL ACTIVITY; PIZZO SV, 1988, J INORG BIOCHEM, V33, P67, DOI 10.1016/0162-0134(88)80035-7; TAKAHASHI K, 1985, JPN J CANCER RES, V76, P68; Trowbridge I S, 1991, BIOTECHNOLOGY PLASMA, V58, P139; Ward S. G., 1988, METAL BASED ANTITUMO, P1; WELLHONER HH, 1991, J BIOL CHEM, V266, P4309	22	198	205	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2581	2588						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300587				2022-12-27	WOS:A1994MV43200037
J	TOWNSENDNICHOLSON, A; SCHOFIELD, PR				TOWNSENDNICHOLSON, A; SCHOFIELD, PR			A THREONINE RESIDUE IN THE 7TH TRANSMEMBRANE DOMAIN OF THE HUMAN A(1)-ADENOSINE RECEPTOR MEDIATES SPECIFIC AGONIST BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							A1 ADENOSINE RECEPTOR; SITE-DIRECTED MUTAGENESIS; RAT-BRAIN MEMBRANES; MOLECULAR-CLONING; CHEMICAL MODIFICATION; EXPRESSION; ANTAGONISTS; CDNA; ADENOSINE-A1-RECEPTORS; CELLS	The A1 adenosine receptor is a member of the seven-transmembrane G protein-coupled, receptor superfamily. This receptor binds the purine nucleoside adenosine with high affinity and inhibits the activity of adenylate cyclase. We have used site-directed mutagenesis and functional expression studies to examine the role of the threonine residue, located at position 277 in transmembrane domain VII of the human A1 receptor. Mutation of Thr-277 to either serine or alanine resulted in the expression of receptors that had essentially no change in binding affinity for the A1 selective antagonist 8-cyclopentyl-1,3-dipropylxanthine. Mutation of Thr-277 to serine resulted in modest (4.4-8.6-fold) but significant increases in the observed K(i) values for three adenosine agonists, namely N-(1-methyl-2-phenethyl)adenosine (R-PIA or S-PIA) and 1-(6-amino-9H-purin-9-yl)-l-deoxy-N-ethyl-beta-L-ribofuranuronamide (NECA). However, mutation of Thr-277 to alanine resulted in no significant changes in the K(i) for R-PIA or S-PIA but did result in a highly significant 437-fold increase in the K(i) for NECA. This demonstrates that the hydroxyl moiety of Thr-277 mediates agonist but not antagonist binding and, more specifically, that this residue forms a probable molecular contact site with the 5' substitution found in NECA.			TOWNSENDNICHOLSON, A (corresponding author), GARVAN INST MED RES, 384 VICTORIA ST, DARLINGHURST, NSW 2010, AUSTRALIA.		Townsend-Nicholson, Andrea/B-8506-2009; Schofield, Peter/C-9669-2011	Schofield, Peter/0000-0003-2967-9662				BHATTACHARYA S, 1993, GENE, V128, P285, DOI 10.1016/0378-1119(93)90576-O; BRUNS RF, 1987, N-S ARCH PHARMACOL, V335, P59, DOI 10.1007/BF00165037; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHERN YJ, 1992, BIOCHEM BIOPH RES CO, V185, P304, DOI 10.1016/S0006-291X(05)90000-4; FINK JS, 1992, MOL BRAIN RES, V14, P186, DOI 10.1016/0169-328X(92)90173-9; FURLONG TJ, 1992, MOL BRAIN RES, V15, P62, DOI 10.1016/0169-328X(92)90152-2; GARRITSEN A, 1990, BIOCHEM PHARMACOL, V40, P835, DOI 10.1016/0006-2952(90)90324-E; GERWINS P, 1990, MOL PHARMACOL, V38, P660; GUAN XM, 1992, MOL PHARMACOL, V41, P695; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JACOBSON KA, 1992, MOL PHARMACOL, V42, P123; KLOTZ KN, 1988, J BIOL CHEM, V263, P17522; LIBERT F, 1991, EMBO J, V10, P1677, DOI 10.1002/j.1460-2075.1991.tb07691.x; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; LIBERT F, 1992, BIOCHEM BIOPH RES CO, V187, P919, DOI 10.1016/0006-291X(92)91285-X; LINDEN J, 1991, FASEB J, V5, P2668, DOI 10.1096/fasebj.5.12.1916091; LONDOS C, 1980, P NATL ACAD SCI-BIOL, V77, P2551, DOI 10.1073/pnas.77.5.2551; MAENHAUT C, 1990, BIOCHEM BIOPH RES CO, V173, P1169, DOI 10.1016/S0006-291X(05)80909-X; MAHAN LC, 1991, MOL PHARMACOL, V40, P1; MEYERHOF W, 1991, FEBS LETT, V284, P155, DOI 10.1016/0014-5793(91)80674-R; OKSENBERG D, 1992, NATURE, V360, P161, DOI 10.1038/360161a0; OLAH ME, 1992, J BIOL CHEM, V267, P10764; OLSSON RA, 1990, PHYSIOL REV, V70, P761, DOI 10.1152/physrev.1990.70.3.761; PIERCE KD, 1992, BIOCHEM BIOPH RES CO, V187, P86, DOI 10.1016/S0006-291X(05)81462-7; RAMKUMAR V, 1993, J BIOL CHEM, V268, P16887; REPPERT SM, 1991, MOL ENDOCRINOL, V5, P1037, DOI 10.1210/mend-5-8-1037; STEHLE JH, 1992, MOL ENDOCRINOL, V6, P384, DOI 10.1210/me.6.3.384; SURYANARAYANA S, 1991, J BIOL CHEM, V266, P15488; TOWNSENDNICHOLSON A, 1992, MOL BRAIN RES, V16, P365, DOI 10.1016/0169-328X(92)90248-A; TUCKER AL, 1992, FEBS LETT, V297, P107, DOI 10.1016/0014-5793(92)80338-H; UKENA D, 1986, FEBS LETT, V209, P122, DOI 10.1016/0014-5793(86)81096-1; WESS J, 1992, J BIOL CHEM, V267, P19313; YOON KW, 1991, J NEUROSCI, V11, P1375; ZHOU QY, 1992, P NATL ACAD SCI USA, V89, P7432, DOI 10.1073/pnas.89.16.7432	34	92	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2373	2376						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300561				2022-12-27	WOS:A1994MV43200007
J	CHNG, JLC; IBRAHIM, B				CHNG, JLC; IBRAHIM, B			TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL MECHANISMS MODULATE CREATINE-KINASE EXPRESSION DURING DIFFERENTIATION OF OSTEOBLASTIC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT OSTEO-SARCOMA; RNA POLYMERASE-II; MESSENGER-RNA; REGULATORY ELEMENTS; GROWTH CARTILAGE; PROMOTER REGION; ROS 17/2.8; BRAIN; SEQUENCES; GENE	Enhancement of energy metabolism is fundamental to the developmental programs of many cell types. This work examines the molecular mechanisms that mediate changes in energy metabolism during differentiation of osteoblastic cells. When the rat osteoblastic cell line, ROS 17/2.8, is induced to differentiate with 1,25-dihydroxyvitamin D3, expression of creatine kinase-b (ck-b), a pivotal enzyme in energy metabolism, is enhanced. Maximum enhancement occurs at 48 h of induction with 10 nM 1,25-dihydroxyvitamin D3 when creatine kinase activity is 2.1-fold over uninduced cells. This, is associated with a 2-fold increase in transcription rate and the formation of a second protein-DNA complex on the ck-b gene promoter that is supplementary to the one present in undifferentiated cells. In addition, the contribution of posttranscriptional regulatory mechanisms is suggested by (1) the increase in ck-b mRNA abundance exceeds that of transcription rate, indicating an increase in message stability, (2) the increase in ck-b mRNA precedes and exceeds that of protein activity, indicating translational modulation, and (3) RNA mobility-shift assays indicate that a cytosolic factor in ROS 17/2.8 cells interacts specifically with the highly conserved 3'-untranslated region of the ck-b mRNA. We have previously reported that such an interaction mediates translational control (Ch'ng, J. L. C., Shoemaker, D. L., Schimmel, P., and Holmes, E. W. (1990) Science 248,1003-1006). The physiological roles of these regulatory mechanisms during osteoblast differentiation are discussed.	VANDERBILT UNIV,DEPT MED,NASHVILLE,TN 37232	Vanderbilt University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044490] Funding Source: NIH RePORTER; NIDDK NIH HHS [1RO1 DK44490] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUSUBLE FM, 1991, CURRENT PROTOCOLS MO; BENFIELD PA, 1988, GENE, V63, P227, DOI 10.1016/0378-1119(88)90527-6; BESSMAN SP, 1985, ANN REV BIOCH, V54, P8314; BILLADELLO JJ, 1986, BIOCHEM BIOPH RES CO, V138, P392, DOI 10.1016/0006-291X(86)90294-9; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHNG JLC, 1989, P NATL ACAD SCI USA, V86, P10006, DOI 10.1073/pnas.86.24.10006; CHNG JLC, 1990, SCIENCE, V248, P1003, DOI 10.1126/science.2343304; DAOUK GH, 1988, J BIOL CHEM, V263, P2442; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ECKERT BS, 1980, J CELL BIOL, V86, P1, DOI 10.1083/jcb.86.1.1; FRIEDMAN DL, 1992, J BIOL CHEM, V267, P4270; FUNANAGE VL, 1992, BONE MINER, V17, P228, DOI 10.1016/0169-6009(92)90742-V; GRONOWICZ G, 1986, J BONE MINER RES, V1, P441; HAMES BD, 1984, TRANSCRIPTION TRANSL; HARRISON JR, 1989, ENDOCRINOLOGY, V125, P327, DOI 10.1210/endo-125-1-327; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HOBSON GM, 1990, MOL CELL BIOL, V10, P6533, DOI 10.1128/MCB.10.12.6533; HORLICK RA, 1990, MOL CELL BIOL, V10, P4826, DOI 10.1128/MCB.10.9.4826; KADDURAHDAOUK R, 1990, MOL CELL BIOL, V10, P1476, DOI 10.1128/MCB.10.4.1476; KATOH R, 1991, CLIN ORTHOPAEDICS, V271, P283; KELLER TCS, 1991, CELL MOTIL CYTOSKEL, V19, P169, DOI 10.1002/cm.970190305; KRUYS V, 1987, P NATL ACAD SCI USA, V84, P6030, DOI 10.1073/pnas.84.17.6030; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LEECH AR, 1978, ANAL BIOCHEM, V90, P561, DOI 10.1016/0003-2697(78)90150-1; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1494, DOI 10.1210/endo-107-5-1494; MARIMAN E, 1991, GENE, V102, P205, DOI 10.1016/0378-1119(91)90079-Q; MITCHELL MT, 1990, J BIOL CHEM, V265, P8259; MOWRY KL, 1992, SCIENCE, V255, P991, DOI 10.1126/science.1546297; RIGS BL, 1988, OSTEOPORSIS; RITCHIE ME, 1991, NUCLEIC ACIDS RES, V19, P6231, DOI 10.1093/nar/19.22.6231; SHAPIRO IM, 1992, J BONE MINER RES, V7, P493; SOMJEN D, 1989, P NATL ACAD SCI USA, V86, P3361, DOI 10.1073/pnas.86.9.3361; SOMJEN D, 1989, ENDOCRINOLOGY, V125, P1870; TAPSCOTT SJ, 1991, J CLIN INVEST, V87, P1133, DOI 10.1172/JCI115109; WALLIMANN T, 1990, PROG CLIN BIOL RES, V344, P877; YI TM, 1991, NUCLEIC ACIDS RES, V19, P3027, DOI 10.1093/nar/19.11.3027	36	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2336	2341						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294491				2022-12-27	WOS:A1994MR98800115
J	ORELLANA, A; HIRSCHBERG, CB; WEI, Z; SWIEDLER, SJ; ISHIHARA, M				ORELLANA, A; HIRSCHBERG, CB; WEI, Z; SWIEDLER, SJ; ISHIHARA, M			MOLECULAR-CLONING AND EXPRESSION OF A GLYCOSAMINOGLYCAN N-ACETYLGLUCOSAMINYL N-DEACETYLASE N-SULFOTRANSFERASE FROM A HEPARIN-PRODUCING CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; SULFATE SULFOTRANSFERASE; POLYMER-MODIFICATION; BIOSYNTHESIS; BINDING; PURIFICATION; MASTOCYTOMA; ADHESION; RECEPTOR; MUTANTS	Heparin has a higher content of N-sulfated glucosamine and L-iduronic acid than heparan sulfate. Deacetylation of N-acetylglucosamine followed by N-sulfation may be important steps differentiating the biosynthesis of these glycosaminoglycans. We have cloned, by cross-hybridization with the cDNA from rat liver heparan sulfate N-deacetylase/N-sulfotransferase, a protein from a heparin synthesizing mastocytoma derived cell line called MST. This protein, which has both N-deacetylase/N-sulfotransferase activities, has a predicted amino acid sequence homology of 70% with the above rat liver enzyme and is unique for the following reasons. 1) It was found to be encoded by a 3.8-kilobase mRNA that was unique to heparin-producing cells; 'an 8.5-kilobase mRNA encoding the rat liver enzymes has been found to occur in all mammalian cells tested on the basis of nucleic acid cross-hybridization; 2) the protein over-expressed in COS cells in its full-length transmembrane form or as a soluble secreted protein A chimera displayed ratios of N-deacetylase to N-sulfotransferase activities that were 4-8-fold higher than that observed for the enzyme found in liver that is involved in the biosynthesis of heparan sulfate. These results suggest that the MST-derived enzyme is probably unique to the production of heparin in mast cells.	GLYCOMED INC, ALAMEDA, CA 94501 USA		HIRSCHBERG, CB (corresponding author), UNIV MASSACHUSETTS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, WORCESTER, MA 01655 USA.		Orellana, Ariel/E-2166-2014; Orellana, Ariel/AAE-4866-2021	Orellana, Ariel/0000-0002-9243-808X; Orellana, Ariel/0000-0002-9243-808X; Hirschberg, Carlos/0000-0003-2299-7721	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034396] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34396] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARUFFO A, 1991, CURRENT PROTOCOL S14; BAME KJ, 1991, J BIOL CHEM, V266, P12461; BRANDAN E, 1988, J BIOL CHEM, V263, P2417; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; ISHIHARA M, 1992, ANAL BIOCHEM, V206, P400, DOI 10.1016/0003-2697(92)90385-K; ISHIHARA M, 1993, J BIOL CHEM, V268, P20091; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; KJELLEN L, 1992, ADV EXP MED BIOL, V313, P107; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEBARON RG, 1989, J BIOL CHEM, V264, P7950; LEBARON RG, 1988, J CELL BIOL, V106, P945, DOI 10.1083/jcb.106.3.945; LIDHOLT K, 1992, BIOCHEM J, V287, P21, DOI 10.1042/bj2870021; LIDHOLT K, 1989, BIOCHEM J, V261, P999, DOI 10.1042/bj2610999; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; LINDAHL U, 1989, ANN NY ACAD SCI, V556, P36; LUPA MT, 1990, DEV BIOL, V142, P31, DOI 10.1016/0012-1606(90)90148-C; Machamer C E, 1991, Trends Cell Biol, V1, P141, DOI 10.1016/0962-8924(91)90001-P; MONTGOMERY RI, 1992, P NATL ACAD SCI USA, V89, P11327, DOI 10.1073/pnas.89.23.11327; Nader H. B., 1989, HEPARIN CHEM BIOL PR, P81; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RIESENFELD J, 1982, J BIOL CHEM, V257, P421; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TYRRELL DJ, 1993, J BIOL CHEM, V268, P4684; VANN WF, 1981, EUR J BIOCHEM, V116, P359, DOI 10.1111/j.1432-1033.1981.tb05343.x; WEI Z, 1993, P NATL ACAD SCI USA, V90, P3885, DOI 10.1073/pnas.90.9.3885; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989; YANAGISHITA M, 1984, J BIOL CHEM, V259, P270; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	36	128	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2270	2276						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294485				2022-12-27	WOS:A1994MR98800107
J	POSSMAYER, FE; GRABER, P				POSSMAYER, FE; GRABER, P			THE PH(IN) AND PH(OUT) DEPENDENCE OF THE RATE OF ATP SYNTHESIS CATALYZED BY THE CHLOROPLAST H+-ATPASE, CF0F1, IN PROTEOLIPOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-PH; COUPLING FACTOR; EXTERNAL PH; SPINACH-CHLOROPLASTS; SYNTHESIS HYDROLYSIS; ACTIVATION; TRANSPORT; SYNTHASE; MEMBRANE; PHOTOPHOSPHORYLATION	The H+-ATPase from chloroplasts was isolated, purified, and reconstituted into liposomes from phosphatidylcholine/phosphatidic acid. The rate of ATP synthesis was measured after energization of the proteoliposomes by an acid-base transition as a function pH(out) and pH(in). At any given pH(out), the rate increased sigmoidally with increasing internal H+ concentration with half-maximal rates at about pH(in) 5.3 for all pH(out) values between 9.3 and 7.2. At any given pH(in), the rate decreased sigmoidally with increasing external H+ concentration with half-maximal rates at about pH(out) 7.8. The dependence on internal H+ concentration was attributed to the protonation of three monovalent groups with the same pK(in), and the dependence on external proton concentration to the deprotonation of two groups with the same pK(out). The following scheme is proposed. The first step of the reaction is the binding of three (or four) protons from the inside of the F0 part, followed by ADP and P(i) binding at the F1 part. Then, the enzyme conformation is changed, and the proton binding sites are exposed to the outside, followed by proton release from F0 and ATP release from F1. The reaction cycle is closed by changing the enzyme conformation to the form where protons can bind from the inside.	UNIV STUTTGART, INST BIOL, PFAFFENWALDRING 57, D-70550 STUTTGART, GERMANY	University of Stuttgart								ALLGYER TT, 1979, BIOCHEMISTRY-US, V18, P5348, DOI 10.1021/bi00591a014; ALTHOFF G, 1989, J MEMBRANE BIOL, V108, P263, DOI 10.1007/BF01871741; BIAUDET P, 1987, BIOCHIM BIOPHYS ACTA, V893, P544, DOI 10.1016/0005-2728(87)90106-X; BIZOUARN T, 1991, BIOCHEMISTRY-US, V30, P6847, DOI 10.1021/bi00242a007; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; DAVENPORT JW, 1986, BIOCHIM BIOPHYS ACTA, V851, P136, DOI 10.1016/0005-2728(86)90256-2; DEWEY TG, 1981, J BIOL CHEM, V256, P8941; FROMME P, 1987, Z NATURFORSCH C, V42, P1239; Gr_ aber P., 1980, PHOTOSYNTHESIS, VII; GRABER P, 1992, J BIOENERG BIOMEMBR, V24, P493, DOI 10.1007/BF00762367; GRABER P, 1977, BIOCHIM BIOPHYS ACTA, V461, P426, DOI 10.1016/0005-2728(77)90231-6; GRABER P, 1984, BER BUNSEN PHYS CHEM, V88, P599, DOI 10.1002/bbpc.19840880706; GRABER P, 1976, BIOCHIM BIOPHYS ACTA, V423, P141, DOI 10.1016/0005-2728(76)90174-2; Graber P, 1987, PROGR PHOTOSYNTHESIS, V3, P177; GRESSER MJ, 1982, J BIOL CHEM, V257, P2030; GRZESIEK S, 1988, BIOCHIM BIOPHYS ACTA, V938, P411, DOI 10.1016/0005-2736(88)90139-3; JAGENDORF AT, 1966, P NATL ACAD SCI USA, V55, P170, DOI 10.1073/pnas.55.1.170; JENCKS WP, 1989, METHOD ENZYMOL, V171, P145; JUNESCH U, 1987, BIOCHIM BIOPHYS ACTA, V893, P275, DOI 10.1016/0005-2728(87)90049-1; KETCHAM SR, 1984, J BIOL CHEM, V259, P7286; KOTHEN G, 1992, RES PHOTOSYNTHESIS, V2, P645; KRAMER DM, 1990, PHOTOSYNTH RES, V26, P213, DOI 10.1007/BF00033134; KRAMER DM, 1989, BIOCHIM BIOPHYS ACTA, V976, P28, DOI 10.1016/S0005-2728(89)80186-0; LABAHN A, 1992, FEBS LETT, V313, P177, DOI 10.1016/0014-5793(92)81439-S; Lauger P., 1991, ELECTROGENIC ION PUM; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MILLS JD, 1984, BIOCHIM BIOPHYS ACTA, V764, P93, DOI 10.1016/0005-2728(84)90145-2; MILLS JD, 1982, PHOTOSYNTHESIS, V2, P839; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; MITCHELL P, 1966, BIOL REV, V41, P445, DOI 10.1111/j.1469-185X.1966.tb01501.x; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NAGLE JF, 1983, J MEMBRANE BIOL, V74, P1, DOI 10.1007/BF01870590; NISHIMURA M, 1962, BIOCHIM BIOPHYS ACTA, V59, P177; PATERNOSTRE MT, 1988, BIOCHEMISTRY-US, V27, P2668, DOI 10.1021/bi00408a006; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PICK U, 1974, FEBS LETT, V48, P32, DOI 10.1016/0014-5793(74)81055-0; PICK U, 1979, J BIOL CHEM, V254, P2793; PORTIS AR, 1976, J BIOL CHEM, V251, P1610; RAVIZZINI RA, 1980, BIOCHIM BIOPHYS ACTA, V591, P135, DOI 10.1016/0005-2728(80)90227-3; RICHARD P, 1990, EUR J BIOCHEM, V193, P921, DOI 10.1111/j.1432-1033.1990.tb19418.x; RUMBERG B, 1980, BER BUNSEN PHYS CHEM, V84, P1055, DOI 10.1002/bbpc.19800841025; RUMBERG B, 1990, CURRENT RES PHOTOSYN, V3, P125; SCHMIDT G, 1985, BIOCHIM BIOPHYS ACTA, V808, P46, DOI 10.1016/0005-2728(85)90026-X; SCHOLL DW, 1982, MAR GEOL, V4, P105; SINGLETON WS, 1965, J AM OIL CHEM SOC, V42, P53, DOI 10.1007/BF02558256; Stein W., 2012, TRANSPORT DIFFUSION; STRELOW F, 1993, FEBS LETT, V323, P19, DOI 10.1016/0014-5793(93)81439-7; VONWALRAVEN HS, 1990, BIOCHIM BIOPHYS ACTA, V1015, P425	48	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1896	1904						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294439				2022-12-27	WOS:A1994MR98800054
J	WALZ, T; SMITH, BL; ZEIDEL, ML; ENGEL, A; AGRE, P				WALZ, T; SMITH, BL; ZEIDEL, ML; ENGEL, A; AGRE, P			BIOLOGICALLY-ACTIVE 2-DIMENSIONAL CRYSTALS OF AQUAPORIN CHIP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INTEGRAL MEMBRANE-PROTEIN; WATER CHANNELS; RECONSTITUTION; FAMILY; CDNA; MIP	Plasma membranes of several mammalian tissues are highly permeable to water due to the presence of CHIP, the 28-kDa channel-forming integral protein which is the archetypal member of the aquaporin family of water channel proteins. To define its native structure, purified red cell CHIP protein was reconstituted into lipid bilayers at a high protein-to-lipid ratio, and the resulting 3-mum diameter membrane vesicles were examined by high resolution electron microscopy. The reconstituted membranes contained highly ordered two-dimensional crystalline lattices of p422(1) symmetry in which each CHIP tetramer contained a central depression extending from the outer and inner surfaces of the membrane into the transbilayer domain of the molecule. The reconstituted membranes also exhibited extremely high osmotic water permeability, P(f) = 0.472 cm/s, corresponding to the sum of activities of all incorporated CHIP molecules. These studies report the first two-dimensional crystallization of a biologically active water channel and provide direct evidence of the structure responsible for its pore-like behavior.	UNIV BASEL, BIOCTR, ME MULLER INST HIGH RESOLUT ELECTRON MICROSCOPY, CH-4056 BASEL, SWITZERLAND; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA; UNIV PITTSBURGH, SCH MED, DIV RENAL ELECTROLYTE, PITTSBURGH, PA 15213 USA	University of Basel; Johns Hopkins University; Johns Hopkins University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh				Walz, Thomas/0000-0003-2606-2835	NHLBI NIH HHS [HL33991, HL48268] Funding Source: Medline; NIDDK NIH HHS [DK43955] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048268, R01HL033991, R37HL048268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043955] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGRE P, 1993, AM J PHYSIOL, V265, pF463; AGRE P, 1993, AM J PHYSIOL, V265, pF461, DOI 10.1152/ajprenal.1993.265.3.F461; AMBUDKAR SV, 1986, METHOD ENZYMOL, V125, P558; DENKER BM, 1988, J BIOL CHEM, V263, P15634; Finkelstein A., 1987, WATER MOVEMENT LIPID; FORD RC, 1990, EMBO J, V9, P3067, DOI 10.1002/j.1460-2075.1990.tb07503.x; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; GORIN MB, 1984, CELL, V39, P49, DOI 10.1016/0092-8674(84)90190-9; HARRIS HW, 1991, J CLIN INVEST, V88, P1, DOI 10.1172/JCI115263; HORWITZ J, 1987, BIOCHEMISTRY-US, V26, P8092, DOI 10.1021/bi00399a012; JAP BK, 1992, ULTRAMICROSCOPY, V46, P45, DOI 10.1016/0304-3991(92)90007-7; MAUREL C, 1993, EMBO J, V12, P2241, DOI 10.1002/j.1460-2075.1993.tb05877.x; MULLER SA, 1992, ULTRAMICROSCOPY, V46, P317, DOI 10.1016/0304-3991(92)90022-C; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; PAO GM, 1991, MOL MICROBIOL, V5, P33, DOI 10.1111/j.1365-2958.1991.tb01823.x; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1994, J BIOL CHEM, V269, P1668; PRESTON GM, 1993, J BIOL CHEM, V268, P17; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; SMITH BL, 1991, J BIOL CHEM, V266, P6407; VANHOEK AN, 1991, J BIOL CHEM, V266, P16633; VERKMAN AS, 1989, AM J PHYSIOL, V257, pC837, DOI 10.1152/ajpcell.1989.257.5.C837; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; ZEIDEL ML, 1994, IN PRESS BIOCHEMISTR	25	179	183	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1583	1586						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294400				2022-12-27	WOS:A1994MR98800005
J	YIM, MB; CHAE, HZ; RHEE, SG; CHOCK, PB; STADTMAN, ER				YIM, MB; CHAE, HZ; RHEE, SG; CHOCK, PB; STADTMAN, ER			ON THE PROTECTIVE MECHANISM OF THE THIOL-SPECIFIC ANTIOXIDANT ENZYME AGAINST THE OXIDATIVE DAMAGE OF BIOMACROMOLECULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN RESONANCE; PULSE-RADIOLYSIS; THIYL RADICALS; LIPID-PEROXIDATION; HYDROGEN-PEROXIDE; MOLECULAR-OXYGEN; AQUEOUS-SOLUTION; GLUTATHIONE; DITHIOTHREITOL; INACTIVATION	A thiol-specific antioxidant enzyme (TSA), which provides protection against the inactivation of other enzymes by the thiol/Fe(III)/oxygen system, was previously isolated and cloned. We investigated the mechanism by which TSA protects biomolecules from oxidative damage caused by the thiol-containing oxidation system using the spin trapping method with 5,5-dimethyl-1-pyrroline N-oxide (DMPO). Thiyl radicals from dithiothreitol (.DTT) were produced by horseradish peroxidase/H2O2 under aerobic and anaerobic conditions and by the Fe(III)/oxygen system. The formation of DMPO-.DTT radical adducts were inhibited by TSA regardless of the thiyl radical-generating conditions used. The active mutant C170S also quenched the signals of the radical adduct, whereas the inactive mutant C47S did not exert any effect. It was also found that C170S has a higher rate at the initial stage of the reaction than that of the native enzyme, although C170S failed to remove DMPO-.DTT radical adducts completely. These results indicate that only active TSA can catalyze the removal of thiyl radicals, and cysteine 47 is required for this activity. In addition, thiyl radicals react with oxygen to generate unidentified thiylperoxy species. Fe.EDTA reacts with this species to generate a reactive radical that can abstract hydrogen atom from ethanol to produce a hydroxyethyl radical. This reactive thiyl-oxygen radical is believed to be responsible for causing deleterious effects on biomolecules. Together, our data indicate that TSA protects biomolecules from oxidative damage by catalyzing the removal of thiyl radicals before they generate more reactive radicals. However, presently we cannot rule out the possibility that TSA can also use other thiol-containing species as substrates.			YIM, MB (corresponding author), NHLBI,BIOCHEM LAB,BLDG 3,RM 202,BETHESDA,MD 20892, USA.							AKHLAQ MS, 1987, INT J RADIAT BIOL, V51, P91, DOI 10.1080/09553008714550531; ASMUS KD, 1992, OXIDATIVE DAMAGE REP, P226; BAKER MZ, 1982, INT J RADIAT BIOL, V41, P595, DOI 10.1080/09553008214550691; BECKER D, 1988, INT J RADIAT BIOL, V53, P767, DOI 10.1080/09553008814551121; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; CHAN PC, 1973, J AM CHEM SOC, V95, P5504, DOI 10.1021/ja00798a012; CHATGILIALOGLU C, 1990, NATO ADV SCI I A-LIF, V197, P31; COSTA M, 1977, BIOCHEM BIOPH RES CO, V78, P596, DOI 10.1016/0006-291X(77)90221-2; DAVIES MJ, 1987, CHEM-BIOL INTERACT, V61, P177, DOI 10.1016/0009-2797(87)90038-X; GILBERT BC, 1990, NATO ADV SCI I A-LIF, V197, P135; GLATT H, 1983, SCIENCE, V220, P961, DOI 10.1126/science.6342137; HARMAN LS, 1986, J BIOL CHEM, V261, P1642; HOROWITZ PM, 1987, J BIOL CHEM, V262, P8728; ITO O, 1984, B CHEM SOC JPN, V57, P1745, DOI 10.1246/bcsj.57.1745; JANZEN EG, 1971, ACCOUNTS CHEM RES, V4, P31, DOI 10.1021/ar50037a005; JAYSON GG, 1971, INT J RADIAT BIOL RE, V19, P143, DOI 10.1080/09553007114550191; JOSEPHY PD, 1984, TETRAHEDRON LETT, V25, P1685, DOI 10.1016/S0040-4039(01)81144-8; KENNEDY CH, 1986, BIOCHEM BIOPH RES CO, V141, P1123, DOI 10.1016/S0006-291X(86)80160-7; KIM IH, 1989, P NATL ACAD SCI USA, V86, P6018, DOI 10.1073/pnas.86.16.6018; KIM K, 1985, J BIOL CHEM, V260, P5394; KIM KW, 1988, J BIOL CHEM, V263, P4704; LAI CS, 1977, BIOCHEM BIOPH RES CO, V78, P51, DOI 10.1016/0006-291X(77)91220-7; Mason RP, 1982, FREE RADICALS BIOL, V5, P161; MISRA HP, 1974, J BIOL CHEM, V249, P2151; PRUTZ WA, 1987, INT J RADIAT BIOL, V52, P677, DOI 10.1080/09553008714552191; PUNEKAR NS, 1987, J BIOL CHEM, V262, P6714; PURDIE JW, 1973, CAN J CHEM, V51, P3132, DOI 10.1139/v73-466; QUINTILIANI M, 1986, INT J RADIAT BIOL, V50, P573, DOI 10.1080/09553008614550981; REYNOLDS CH, 1980, BIOCHEM J, V185, P451, DOI 10.1042/bj1850451; ROSS D, 1985, J BIOL CHEM, V260, P5028; SCHONEICH C, 1989, BIOCHEM BIOPH RES CO, V161, P113, DOI 10.1016/0006-291X(89)91568-4; SCHONEICH C, 1990, NATO ADV SCI I A-LIF, V197, P367; SCHONEICH C, 1989, FREE RADICAL RES COM, V6, P393, DOI 10.3109/10715768909087923; SCHREIBER J, 1989, J BIOL CHEM, V264, P7936; SCHULTEFROHLINDE D, 1989, FREE RADICAL RES COM, V6, P181, DOI 10.3109/10715768909073465; SEVILLA MD, 1987, BIOCHEM BIOPH RES CO, V144, P1037, DOI 10.1016/S0006-291X(87)80068-2; SEVILLA MD, 1990, INT J RADIAT BIOL, V57, P65, DOI 10.1080/09553009014550351; SIMIC M, 1970, J AM CHEM SOC, V92, P6096, DOI 10.1021/ja00723a067; SWARTS SG, 1989, J PHYS CHEM-US, V93, P155, DOI 10.1021/j100338a034; TAMBA M, 1986, INT J RADIAT BIOL, V50, P595, DOI 10.1080/09553008614550991; TROTTA PP, 1974, J BIOL CHEM, V249, P1915; von Sonntag C., 1987, CHEM BASIS RAD BIOL, P353; Wardman P, 1988, GLUTATHIONE CONJUGAT, P43; WELLNER VP, 1984, P NATL ACAD SCI-BIOL, V81, P4732, DOI 10.1073/pnas.81.15.4732; YAMAZAKI I, 1977, FREE RADICALS BIOL, V3, P183; ZHANG N, 1991, J PHYS CHEM-US, V95, P4718, DOI 10.1021/j100165a024	46	106	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1621	1626						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294408				2022-12-27	WOS:A1994MR98800015
J	BUSH, J; RICHARDSON, J; CARDELLI, J				BUSH, J; RICHARDSON, J; CARDELLI, J			MOLECULAR-CLONING AND CHARACTERIZATION OF THE FULL-LENGTH CDNA-ENCODING THE DEVELOPMENTALLY-REGULATED LYSOSOMAL-ENZYME BETA-GLUCOSIDASE IN DICTYOSTELIUM-DISCOIDEUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED OLIGOSACCHARIDES; ALPHA-MANNOSIDASE; NUCLEOTIDE-SEQUENCE; ACID-PHOSPHATASE; GENETIC-ANALYSIS; SECRETION; PROTEIN; TRANSPORT; HOMOLOGY; TRANSCRIPTION	The developmentally regulated Dictyostelium discoideum lysosomal enzyme beta-glucosidase is synthesized as a membrane-associated glycosylated precursor polypeptide which undergoes at least two proteolytic cleavage events to generate a soluble mature lysosomally Ioealized protein. To begin to analyze the mechanisms regulating the sorting of this protein and the regulation during development of the expression of the encoding gene, we have cloned and sequenced a 2.6-kilobase (kb) cDNA which contains a complete 2463-nucleotide open reading frame coding for beta-glucosidase. Conceptual translation of this open reading frame predicts a polypeptide similar in molecular mass to the primary translation product of 94 kDa that also contains the same amino acid sequences of two V8 protease derived-peptides generated from the purified beta-glucosidase enzyme. The D. discoideum enzyme contained regions highly homologous at the amino acid sequence level to both bacterial and fungal beta-glucosidases, although these regions did not overlap. A potential cleavable signal sequence was also found in the first 21 amino acids followed by a highly polar stretch of 49 amino acids which (based on amino acid sequencing of the mature beta-glucosidase) represents a pro region for this protein. This region is similar in location, size, and charge to the D. discoideum alpha-mannosidase pro-I region (Schatzle, J., Bush, J., and Cardelli, J. (1992) J. Biol. Chem. 267, 4000-4007). Several small hydrophobic stretches of amino acids were also distributed throughout the protein; however, no obvious transmembrane region(s) were identified which might explain the observed membrane association of the precursor protein. Finally, Northern blot analysis indicated that the gene encoding this enzyme was under developmental regulation. The steady state level of a 2.7-kb beta-glucosidase mRNA decreased significantly during the aggregation stage of development, from high levels during growth, and then increased in the form of a larger size 2.8-kb mRNA during the final stages of development.	LOUISIANA STATE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,1501 KINGS HIGHWAY,SHREVEPORT,LA 71130	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport					NIDDK NIH HHS [DK 39232] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039232, R29DK039232] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUSE E, 1980, BIOCHIM BIOPHYS ACTA, V626, P459, DOI 10.1016/0005-2795(80)90142-7; BUSH JM, 1990, ARCH BIOCHEM BIOPHYS, V283, P158, DOI 10.1016/0003-9861(90)90626-A; BUSH JM, 1989, J BIOL CHEM, V264, P7630; CARDELLI JA, 1981, DEV BIOL, V82, P180, DOI 10.1016/0012-1606(81)90440-1; CARDELLI JA, 1990, J BIOL CHEM, V265, P8847; CARDELLI JA, 1985, DEV BIOL, V110, P147, DOI 10.1016/0012-1606(85)90072-7; CARDELLI JA, 1990, DEV GENET, V11, P454, DOI 10.1002/dvg.1020110522; CARDELLI JA, 1986, J CELL BIOL, V102, P1264, DOI 10.1083/jcb.102.4.1264; CARDELLI JA, 1989, J BIOL CHEM, V264, P3454; CARDELLI JA, 1987, METHOD CELL BIOL, V28, P139; Cardelli JA, 1993, ENDOSOMES LYSOSOMES, P341; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CLARKE M, 1988, DEV GENET, V9, P315, DOI 10.1002/dvg.1020090413; COSTON MB, 1969, J BACTERIOL, V100, P1208, DOI 10.1128/JB.100.3.1208-1217.1969; EBERT DL, 1990, J CELL SCI, V96, P491; FREE SJ, 1974, BIOCHIMIE, V56, P1525; FREEZE HH, 1989, J BIOL CHEM, V264, P19278; FREEZE HH, 1986, MOL CELL BIOCHEM, V72, P47; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOLUMBESKI GS, 1986, ANAL BIOCHEM, V154, P373, DOI 10.1016/0003-2697(86)90001-1; GOLUMBESKI GS, 1987, DEV BIOL, V123, P494, DOI 10.1016/0012-1606(87)90407-6; GRABNITZ F, 1989, MOL GEN GENET, V217, P70, DOI 10.1007/BF00330944; GRAHAM TR, 1988, J BIOL CHEM, V263, P16823; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KOHCHI C, 1985, NUCLEIC ACIDS RES, V13, P6273, DOI 10.1093/nar/13.17.6273; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUMAGAI A, 1991, J BIOL CHEM, V266, P1220; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LACOSTE CH, 1992, J BIOL CHEM, V267, P5942; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOOMIS WF, 1980, DEV GENET, V1, P241; LOOMIS WF, 1982, DEV DICTYOSTELIUM DI, P1; Loomis WF., 1975, DICTYOSTELIUM DISCOI; MATSUOKA K, 1991, P NATL ACAD SCI USA, V88, P834, DOI 10.1073/pnas.88.3.834; MIERENDORF RC, 1985, J CELL BIOL, V100, P1777, DOI 10.1083/jcb.100.5.1777; MIERENDORF RC, 1983, J BIOL CHEM, V258, P5878; MORANELLI F, 1986, BIOCHEM INT, V12, P905; OHMIYA K, 1990, NUCLEIC ACIDS RES, V18, P671, DOI 10.1093/nar/18.3.671; PANNELL R, 1985, J CELL BIOL, V101, P2063; RAYNAL A, 1987, CURR GENET, V12, P175, DOI 10.1007/BF00436876; RICHARDSON JM, 1988, J CELL BIOL, V107, P2097, DOI 10.1083/jcb.107.6.2097; SCHATZLE J, 1991, MOL CELL BIOL, V11, P3339, DOI 10.1128/MCB.11.6.3339; SCHATZLE J, 1993, J BIOL CHEM, V268, P19632; SCHATZLE J, 1992, J BIOL CHEM, V267, P4000; SINGLETON CK, 1989, NUCLEIC ACIDS RES, V17, P9679, DOI 10.1093/nar/17.23.9679; STEEL LF, 1987, MOL CELL BIOL, V7, P965, DOI 10.1128/MCB.7.3.965; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X	48	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1468	1476						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288612				2022-12-27	WOS:A1994MR22000106
J	SKOUFIAS, DA; COLE, DG; WEDAMAN, KP; SCHOLEY, JM				SKOUFIAS, DA; COLE, DG; WEDAMAN, KP; SCHOLEY, JM			THE CARBOXYL-TERMINAL DOMAIN OF KINESIN HEAVY-CHAIN IS IMPORTANT FOR MEMBRANE-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN KINESIN; MICROTUBULES INVITRO; SUBCELLULAR-LOCALIZATION; LIGHT-CHAINS; IDENTIFICATION; ASSOCIATION; MOTILITY; ORGANELLES; GENERATION; TRANSITION	Sea urchin kinesin is a plus end-directed microtubule-based motor consisting of two heavy chains and two light chains and is proposed to be responsible (a) for the transport of membranous organelles along microtubules in sea urchin mitotic spindles (Wright, B. D., Henson, J. H., Wedaman, K. P., Willy, P. J., Morand, J. N., and Scholey, J. M. (1 99 1) J. Cell Biol. 113, 817-833) and (b) for the radial dispersion of endoplasmic reticulum and endosomal membranes in non-mitotic cultured coelomocytes (Henson, J. H., Nesbitt, D., Wright, B. D., and Scholey, J. M. (1992) J. Cell Sci. 103, 309-320). We report here that sea urchin kinesin is indeed able to bind in a concentration-dependent and saturable manner to microsomal membranes isolated from sea urchin eggs in the presence of MgATP. The kinesin light chains may not be essential for membrane binding since kinesin containing negligible amounts of light chains binds as well as kinesin containing stoichiometric amounts of light chains. Finally, we propose that kinesin binds to membranes with the carboxyl-terminal domain of the heavy chain (amino acid residues 858-1031) since the bacterially expressed and then isolated stalk-tail fragment of kinesin heavy chain, in contrast to the stalk fragment, is able (a) to bind membranes in a concentration-dependent and saturable manner and (b) to compete with native kinesin for membrane binding. Our results support the hypothesis that the carboxyl-terminal domains of the heavy chains attach kinesin molecules to their membranous cargo in mitotic and interphase sea urchin cells.			SKOUFIAS, DA (corresponding author), UNIV CALIF DAVIS,MOLEC & CELLULAR BIOL SECT,STORER HALL,DAVIS,CA 95616, USA.		Skoufias, Dimitrios A/A-5535-2016	Skoufias, Dimitrios/0000-0001-5595-3413	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046376] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 46376] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; BRADY ST, 1991, NEURON, V7, P521, DOI 10.1016/0896-6273(91)90365-7; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; BUSTER D, 1991, J CELL SCI S, V14, P1096; CYR JL, 1991, P NATL ACAD SCI USA, V88, P10114, DOI 10.1073/pnas.88.22.10114; DECUEVAS M, 1992, J CELL BIOL, V116, P957, DOI 10.1083/jcb.116.4.957; ERICKSON HP, 1976, P NATL ACAD SCI USA, V73, P2813, DOI 10.1073/pnas.73.8.2813; GAUGER AK, 1993, J BIOL CHEM, V268, P13657; HACKNEY DD, 1992, J BIOL CHEM, V267, P8696; HACKNEY DD, 1991, BIOCHEM BIOPH RES CO, V174, P810, DOI 10.1016/0006-291X(91)91490-4; HENSON JH, 1992, J CELL SCI, V103, P309; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; INGOLD AL, 1988, J CELL BIOL, V107, P2657, DOI 10.1083/jcb.107.6.2657; JOHNSON CS, 1990, CELL MOTIL CYTOSKEL, V16, P204, DOI 10.1002/cm.970160307; KLAUSNER RD, 1981, J BIOL CHEM, V256, P5879; KOSIK KS, 1990, J BIOL CHEM, V265, P3278; KUMAR N, 1981, J BIOL CHEM, V256, P5886; KUZNETSOV SA, 1988, EMBO J, V7, P353, DOI 10.1002/j.1460-2075.1988.tb02820.x; LACY ML, 1992, J BIOL CHEM, V267, P4793; LEOPOLD PL, 1992, CELL MOTIL CYTOSKEL, V23, P19, DOI 10.1002/cm.970230104; LYE RJ, 1987, CELL, V51, P309, DOI 10.1016/0092-8674(87)90157-7; MULTIGNER L, 1992, NATURE, V360, P33, DOI 10.1038/360033a0; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; OBERDORF JA, 1986, J CELL BIOL, V102, P2205, DOI 10.1083/jcb.102.6.2205; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; SATOYOSHITAKE R, 1992, J BIOL CHEM, V267, P23930; SCHNAPP BJ, 1992, J CELL BIOL, V119, P389, DOI 10.1083/jcb.119.2.389; SCHOLEY JM, 1985, NATURE, V318, P483, DOI 10.1038/318483a0; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SCHROER TA, 1991, ANNU REV PHYSIOL, V53, P629, DOI 10.1146/annurev.ph.53.030191.003213; Skoufias DA, 1993, CURR OPIN CELL BIOL, V5, P95, DOI 10.1016/S0955-0674(05)80014-6; TOYOSHIMA I, 1992, J CELL BIOL, V118, P1121, DOI 10.1083/jcb.118.5.1121; URRUTIA R, 1991, P NATL ACAD SCI USA, V88, P6701, DOI 10.1073/pnas.88.15.6701; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; WEDAMAN KP, 1993, J MOL BIOL, V231, P155, DOI 10.1006/jmbi.1993.1267; WRIGHT BD, 1991, J CELL BIOL, V113, P817, DOI 10.1083/jcb.113.4.817; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332; YU H, 1992, J BIOL CHEM, V267, P20457	41	110	111	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1477	1485						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288613				2022-12-27	WOS:A1994MR22000107
J	URCELAY, E; BUTTA, N; CIPRES, G; MARTINREQUERO, A; AYUSO, MS; PARRILLA, R				URCELAY, E; BUTTA, N; CIPRES, G; MARTINREQUERO, A; AYUSO, MS; PARRILLA, R			FUNCTIONAL COUPLING OF NA+/H+ AND NA+/CA2+ EXCHANGERS IN THE ALPHA(1)-ADRENOCEPTOR-MEDIATED ACTIVATION OF HEPATIC-METABOLISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ADRENERGIC AGONISTS; ASCITES-TUMOR-CELLS; PERFUSED-RAT-LIVER; INTRACELLULAR PH; GROWTH-FACTOR; ALPHA-2-ADRENERGIC RECEPTORS; CA-2+ MOBILIZATION; HUMAN-PLATELETS; CALCIUM; STIMULATION	The purpose of this study was to characterize the role of ions other than Ca2+ in hepatic responses to alpha1-adrenergic stimulation. We report that the alpha1-adrenoreceptor activation of hepatic functions is accompanied by extracellular acidification and an increase in intracellular pH. These effects are dependent on extracellular Na+ concentration and are inhibited by the Na+/H+ antiporter blocker 5-(N-ethyl-N-isopropyl) amiloride under conditions that preclude antagonistic effects on agonist binding. Thus, the activation of plasma membrane Na+/H+ exchange is an essential feature of the hepatic alpha-adrenoreceptor-coupled signaling pathway. The following observations indicate that the sustained hepatic alpha1-adrenergic actions rely on a functional coupling between the plasma membrane Na+/H+ and Na+/Ca2+ exchangers, resulting in the stimulation of Ca2+ influx. 1) Inhibition of the Na+/K+-ATPase does not prevent the alpha1-adrenergic effects. However, alpha1-adrenoreceptor stimulation fails to induce intracellular alkalinization and to acidify the extracellular medium in the absence of extracellular Ca2+. 2) A non-receptor-induced increase in intracellular Na+ concentration, caused by the ionophore monensin, stimulates Ca2+ influx and increases vascular resistance. 3) Inhibition of Na+/Ca2+ exchange prevents, in a concentration-dependent manner, most of the alpha1-agonist-induced responses. 4) The actions of Ca2+-mobilizing vasoactive peptide receptors or alpha2-adrenoreceptors, which produce neither sustained extracellular acidification nor release of Ca2+, are insensitive to Na+/H+ exchange blockers.	CSIC,CTR INVEST BIOL,ENDOCRINE PHYSIOL UNIT,VELAZQUEZ 144,E-28006 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Consiglio Nazionale delle Ricerche (CNR)			Ayuso, Matilde Sánchez/B-2777-2008; Parrilla, Roberto/B-6307-2008; Martín-Requero, Angeles/K-3901-2014	Ayuso, Matilde Sánchez/0000-0003-2504-0925; Martín-Requero, Angeles/0000-0002-3416-9440; Urcelay, Elena/0000-0001-8470-8396				ALTHAUSSALZMANN M, 1980, EUR J BIOCHEM, V106, P241; BERGMEYER HU, 1975, METHODS ENZYMATIC AN; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BURNS CP, 1983, BIOCHEM BIOPH RES CO, V116, P931; BUTTA N, 1993, J BIOL CHEM, V268, P6081; BUXTON D, 1982, J BIOL CHEM, V257, P4318; CHOBANIAN MC, 1987, AM J PHYSIOL, V252, pF1073, DOI 10.1152/ajprenal.1987.252.6.F1073; CITTADINI A, 1978, J PHYSIOL-LONDON, V281, P29, DOI 10.1113/jphysiol.1978.sp012407; CONNOLLY TM, 1983, J BIOL CHEM, V258, P3907; DEHAYE JP, 1981, BIOCHEM J, V194, P949, DOI 10.1042/bj1940949; EXTON JH, 1988, FASEB J, V2, P2670, DOI 10.1096/fasebj.2.11.2456243; FABIATO A, 1978, J PHYSIOL-LONDON, V276, P233, DOI 10.1113/jphysiol.1978.sp012231; FEHLMANN M, 1981, J BIOL CHEM, V256, P7449; GARCIA ML, 1990, J BIOL CHEM, V265, P3763; GARCIASAINZ JA, 1985, P NATL ACAD SCI USA, V82, P6727, DOI 10.1073/pnas.82.20.6727; GESEK FA, 1989, AM J PHYSIOL, V257, pF623, DOI 10.1152/ajprenal.1989.257.4.F623; GIRBES T, 1983, ARCH BIOCHEM BIOPHYS, V226, P37, DOI 10.1016/0003-9861(83)90269-2; GONZALEZMANCHON C, 1988, ARCH BIOCHEM BIOPHYS, V265, P258, DOI 10.1016/0003-9861(88)90126-9; GOODHARDT M, 1986, HORMONAL CONTROL GLU, V2, P55; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HAUSSINGER D, 1987, EUR J BIOCHEM, V163, P197, DOI 10.1111/j.1432-1033.1987.tb10755.x; HO AK, 1989, J BIOL CHEM, V264, P12983; HORSTMAN DA, 1990, J BIOL CHEM, V265, P21590; HOWARD MJ, 1987, MOL PHARMACOL, V32, P53; IKEDA U, 1988, J MOL CELL CARDIOL, V20, P493, DOI 10.1016/S0022-2828(88)80076-2; IWAKURA K, 1990, EUR J PHARMACOL, V186, P29; JAGADEESH G, 1990, J PHARMACOL EXP THER, V252, P1184; LESBURG C, 1990, J PHARMACOL EXP THER, V253, P530; LYNCH CJ, 1986, J BIOL CHEM, V261, P4551; MALY K, 1990, BIOCHEM BIOPH RES CO, V167, P1206, DOI 10.1016/0006-291X(90)90652-4; MARTINREQUERO A, 1986, ARCH BIOCHEM BIOPHYS, V246, P114, DOI 10.1016/0003-9861(86)90455-8; OWEN NE, 1986, J CELL BIOL, V103, P2053, DOI 10.1083/jcb.103.5.2053; POLLOCK AS, 1986, AM J PHYSIOL, V250, pF217, DOI 10.1152/ajprenal.1986.250.2.F217; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; PUCEAT M, 1993, AM J PHYSIOL, V264, pH310, DOI 10.1152/ajpheart.1993.264.2.H310; REEVES JP, 1992, ARCH BIOCHEM BIOPHYS, V292, P329, DOI 10.1016/0003-9861(92)90001-D; REINHART PH, 1984, BIOCHEM J, V220, P43, DOI 10.1042/bj2200043; RINK TJ, 1982, J CELL BIOL, V95, P189, DOI 10.1083/jcb.95.1.189; SAZ JM, 1989, BIOCHEM BIOPH RES CO, V160, P480, DOI 10.1016/0006-291X(89)92458-3; SIFFERT W, 1987, FEBS LETT, V212, P123, DOI 10.1016/0014-5793(87)81569-7; SIFFERT W, 1987, NATURE, V325, P456, DOI 10.1038/325456a0; SIFFERT W, 1986, THROMB RES, V44, P235, DOI 10.1016/0049-3848(86)90139-8; SPENCER TL, 1976, BIOCHEM J, V154, P405, DOI 10.1042/bj1540405; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; URCELAY E, 1993, IN PRESS BIOCH BIOPH; URCELAY E, 1993, IN PRESS ENDOCRINOLO; WILLIAMSON JR, 1985, AM J PHYSIOL, V248, pC203, DOI 10.1152/ajpcell.1985.248.3.C203	48	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					860	867						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288639				2022-12-27	WOS:A1994MR22000017
J	WALKER, A; TURNBULL, JE; GALLAGHER, JT				WALKER, A; TURNBULL, JE; GALLAGHER, JT			SPECIFIC HEPARAN-SULFATE SACCHARIDES MEDIATE THE ACTIVITY OF BASIC FIBROBLAST GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR BINDING; CELL-SURFACE; RECEPTOR; DIFFERENTIATION; MOLECULES; BFGF	In a previous study, we showed that heparitinase releases a 14-saccharide sequence (Oligo-H) from heparan sulfate (HS) with the structure DELTAGlcUAbeta1,4GlcNSO3 alpha1,4[IdceA(2S)alpha1,4GlcNSO3]5alpha1,4IdceAalpha1,4GlcNAc (where IdceA(2S) represents iduronic acid 2-sulfate), which binds to basic fibroblast growth factor (bFGF) with high affinity (Turnbull, J. E., Fernig, D., Ke, Y., Wilkinson, M. C. & Gallagher, J. T. (1992) J. Biol. Chem. 267, 10337-10341). This paper describes further work on the binding properties of HS saccharides and their capacity to mediate bFGF activity in a mitogenesis assay in which responsiveness is dependent on the addition of HS or heparin. Saccharides prepared by heparinase or nitrous acid digestion and heparitinase-resistant fragments five disaccharide units (degree of polymerization (dp) = 10) or less in size were unable to activate bFGF. However, heparitinase-resistant saccharides of dp12-16 were active in the assay; the dp14 and dp16 fractions were equivalent in activity to heparin and more active than the parent HS. Saccharides of the same size and basic structure as the active fractions (greater-than-or-equal-to dp12) bound to bFGF with high relative affinity. Active saccharides were composed mainly of N-sulfated disaccharides, the predominant unit being IdceA(2S)-GlcNSO3. This was enriched at least 5-fold in the active saccharides by comparison with the original HS. In addition, the dp12 and dp14 active fractions had a notably low content of trisulfated disaccharides (IdceA(2S)-GlcNSO3(6S)) (where GlcNSO3(6S) represents N-sulfated glucosamine 6-sulfate), which are the major repeat units of heparin. The data show that sequences similar in size and basic structure to Oligo-H can mediate the mitogenic activity of bFGF. Overall, the results provide further evidence that specific HS sequences are generated biosynthetically in order to fulfill particular biological functions such as activation of bFGF.	UNIV MANCHESTER,CANC RES CAMPAIGN,DEPT MED ONCOL,MANCHESTER M13 9PL,LANCS,ENGLAND; CHRISTIE HOSP & HOLT RADIUM INST,CLIN RES DEPT,MANCHESTER M20 9BX,LANCS,ENGLAND	University of Manchester; Christie NHS Foundation Trust; Christie Hospital								GALLAGHER JT, 1992, GLYCOBIOLOGY, V2, P523, DOI 10.1093/glycob/2.6.523; GALLAGHER JT, 1992, ADV EXP MED BIOL, V313, P49; GALLAGHER JT, 1992, INT J BIOCHEM, V24, P553, DOI 10.1016/0020-711X(92)90326-V; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Klagsbrun M, 1990, CURR OPIN CELL BIOL, V2, P857, DOI 10.1016/0955-0674(90)90084-R; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; KOLSET SO, 1990, BIOCHIM BIOPHYS ACTA, V1032, P191, DOI 10.1016/0304-419X(90)90004-K; Lindahl U., 1989, HEPARIN, P159; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TURNBULL JE, 1990, BIOCHEM J, V265, P715, DOI 10.1042/bj2650715; TURNBULL JE, 1993, BIOCHEM SOC T, V21, P477, DOI 10.1042/bst0210477; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; TYRRELL DJ, 1993, J BIOL CHEM, V268, P4684; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	25	185	187	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					931	935						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288646				2022-12-27	WOS:A1994MR22000027
J	MARMIROLI, S; OGNIBENE, A; BAVELLONI, A; CINTI, C; COCCO, L; MARALDI, NM				MARMIROLI, S; OGNIBENE, A; BAVELLONI, A; CINTI, C; COCCO, L; MARALDI, NM			INTERLEUKIN-1-ALPHA STIMULATES NUCLEAR PHOSPHOLIPASE-C IN HUMAN OSTEOSARCOMA SAOS-2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SWISS 3T3 CELLS; PROTEIN-KINASE-C; SIGNAL TRANSDUCTION; INOSITOL LIPIDS; CYCLIC-AMP; RECEPTOR; DIACYLGLYCEROL; LOCALIZATION; MECHANISM; IL-1	Interleukin 1 (IL-1) is one of the most potent stimulators of bone resorption. However, the early biochemical events elicited by IL-1 receptor binding are not fully understood. Here we show that in human osteosarcoma SaOS-2 cells the treatment with IL-1alpha is able to evoke a rapid and transient increase of nuclear phospholipase C (PLC) activity. A parallel decrease of nuclear phosphatidylinositol monophosphate and phosphatidylinositol bisphosphate is observed. All these events are strictly confined to the nuclear compartment without affecting the cytoplasmatic inositol lipid pool. In addition we show that by Western blot analysis with specific monoclonal antibodies the PLC gamma is located both in the cytoplasm and in the nucleus, while PLC beta appears exclusively Iocalized in the nucleus. Moreover, the increase of PLC activity in response to IL-1alpha is completely neutralized by monoclonal antibody against the beta-form. While confirming the existence of an autonomous nuclear phosphoinositide signaling system, our data clearly indicate that in SaOS-2 cells one of the earliest events following IL-1alpha treatment is the breakdown of nuclear phosphatidylinositol monophosphate and phosphatidylinositol bisphosphate because of the activation of a specific nuclear PLC isoform.	CNR, IST CITOMORFOL NORMALE & PATOL, I-40136 BOLOGNA, ITALY; IST ORTOPED RIZZOLI, BIOL CELLULARE & MICROSCOPIA ELETTRON LAB, I-40136 BOLOGNA, ITALY; IST ANAT UMANA NORMALE, I-40126 BOLOGNA, ITALY	Consiglio Nazionale delle Ricerche (CNR); IRCCS Istituto Ortopedico Rizzoli	MARMIROLI, S (corresponding author), CNR, IST ORTOPED RIZZOLI, VIA BARBIANO 1-10, I-40136 BOLOGNA, ITALY.		Marmiroli, Sandra/J-5242-2016; Bavelloni, Alberto/E-5726-2019	Marmiroli, Sandra/0000-0001-5545-9319; Bavelloni, Alberto/0000-0002-6467-1431; Cinti, Caterina/0000-0001-8049-0369				ABRAHAM RT, 1987, J BIOL CHEM, V262, P2719; Auger K. R., 1990, METHODS INOSITIDE RE, P159; BACHS O, 1992, BIOCHIM BIOPHYS ACTA, V1113, P259, DOI 10.1016/0304-4157(92)90041-8; BANSAL VS, 1990, ANNU REV CELL BIOL, V6, P41, DOI 10.1146/annurev.cellbio.6.1.41; CAPITANI S, 1990, CELL BIOL INT REP, V14, P783, DOI 10.1016/0309-1651(90)90005-J; CAPITANI S, 1989, FEBS LETT, V254, P194, DOI 10.1016/0014-5793(89)81037-3; CAPITANI S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P193, DOI 10.1016/0005-2760(90)90303-F; CARROLL GJ, 1985, ANN RHEUM DIS, V44, P631, DOI 10.1136/ard.44.9.631; CATALDI A, 1990, FEBS LETT, V269, P465, DOI 10.1016/0014-5793(90)81216-B; COCCO L, 1988, BIOCHEM BIOPH RES CO, V154, P1266, DOI 10.1016/0006-291X(88)90276-8; COCCO L, 1987, BIOCHEM J, V248, P765, DOI 10.1042/bj2480765; CURTIS BM, 1990, J IMMUNOL, V144, P1295; CURTIS BM, 1989, P NATL ACAD SCI USA, V86, P3045, DOI 10.1073/pnas.86.9.3045; DEDHAR S, 1989, EXP CELL RES, V183, P207, DOI 10.1016/0014-4827(89)90430-8; DINARELLO CA, 1988, FASEB J, V2, P108, DOI 10.1096/fasebj.2.2.3277884; DIVECHA N, 1993, BIOCHEM J, V289, P617, DOI 10.1042/bj2890617; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GEORGILIS K, 1987, J IMMUNOL, V138, P3403; GRENFELL S, 1989, BIOCHEM J, V264, P813, DOI 10.1042/bj2640813; HEGUY A, 1991, CELL GROWTH DIFFER, V2, P311; Irvine R F, 1992, Semin Cell Biol, V3, P225, DOI 10.1016/1043-4682(92)90024-P; KILIAN PL, 1986, J IMMUNOL, V136, P4509; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTELLI AM, 1991, FEBS LETT, V283, P243, DOI 10.1016/0014-5793(91)80598-W; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; MAZZONI M, 1992, BIOCHEM BIOPH RES CO, V187, P114, DOI 10.1016/S0006-291X(05)81466-4; MICHELL R H, 1992, Current Biology, V2, P200, DOI 10.1016/0960-9822(92)90533-G; MIZEL SB, 1989, FASEB J, V3, P2379, DOI 10.1096/fasebj.3.12.2676681; PARK DG, 1993, J BIOL CHEM, V268, P3710; RAY K, 1992, BIOCHEM J, V282, P59, DOI 10.1042/bj2820059; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RODAN SB, 1990, J IMMUNOL, V145, P1231; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; SHIRAKAWA F, 1988, P NATL ACAD SCI USA, V85, P8201, DOI 10.1073/pnas.85.21.8201; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SMITH CD, 1983, J BIOL CHEM, V258, P9368; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; SUH PG, 1988, J BIOL CHEM, V263, P14497; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WIJELATH ES, 1988, BIOCHEM BIOPH RES CO, V152, P392, DOI 10.1016/S0006-291X(88)80726-5; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802; ZINI N, 1993, EXP CELL RES, V208, P257, DOI 10.1006/excr.1993.1245	43	80	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					13	16						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276785				2022-12-27	WOS:A1994MR21900004
J	PIKE, R; MCGRAW, W; POTEMPA, J; TRAVIS, J				PIKE, R; MCGRAW, W; POTEMPA, J; TRAVIS, J			LYSINE-SPECIFIC AND ARGININE-SPECIFIC PROTEINASES FROM PORPHYROMONAS-GINGIVALIS - ISOLATION, CHARACTERIZATION, AND EVIDENCE FOR THE EXISTENCE OF COMPLEXES WITH HEMAGGLUTININS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPSIN-LIKE PROTEASE; BACTEROIDES-GINGIVALIS; CULTURE SUPERNATANT; ENZYME-ACTIVITY; PURIFICATION; W50; PERIODONTITIS; VIRULENT; STRAINS; HEMIN	Porphyromonas gingivalis contains many virulence factors that have been implicated as participants in the progression of periodontal disease. lt has been shown to produce proteinases of ''trypsin-like'' specificity in a number of molecular forms, but previous work in our laboratory resulted in the purification of a major arginine-specific cysteine proteinase, gingipain, which contradicted this supposed specificity. In this study, separate proteinases with arginine and lysine specificity were isolated from a high molecular mass fraction of the P. gingivalis culture fluid. The arginine-specific enzyme was found, by amino acid sequencing studies, to be a high molecular mass form of gingipain, formed by the 50-kDa gingipain noncovalently complexed with 44-kDa binding proteins, subsequently identified as hemagglutinins. The 60-kDa lysine-specific proteinase, referred to as Lys-gingipain, was also found to have one of these hemagglutinins complexed with it in the same manner. Lys-gingipain was found to be a cysteine proteinase with optimal activity and stability at pH 8.0-8.5 and was extensively characterized in terms of its specificity and activation characteristics. The proteinase-hemagglutinin complexes may be important in the uptake of hemin, a vital metabolite for P. gingivalis, via hemagglutination and subsequent hemolysis of erythrocytes.	UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602; JAGIELLONIAN UNIV,INST MOLEC BIOL,DEPT MICROBIOL & IMMUNOL,PL-3120 KRAKOW,POLAND	University System of Georgia; University of Georgia; Jagiellonian University				Pike, Robert/0000-0002-2083-0269	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE009761] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 09761] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BICKEL M, 1985, J PERIODONTAL RES, V20, P35, DOI 10.1111/j.1600-0765.1985.tb00408.x; BIRKEDALHANSEN H, 1988, J PERIODONTAL RES, V23, P258, DOI 10.1111/j.1600-0765.1988.tb01369.x; CARMAN RJ, 1990, INFECT IMMUN, V58, P4016, DOI 10.1128/IAI.58.12.4016-4019.1990; CHEN ZX, 1991, INFECT IMMUN, V59, P2846, DOI 10.1128/IAI.59.8.2846-2850.1991; CHEN ZX, 1992, J BIOL CHEM, V267, P18896; FUJIMURA S, 1992, ORAL MICROBIOL IMMUN, V7, P212, DOI 10.1111/j.1399-302X.1992.tb00027.x; Garvey JS, 1977, METHODS IMMUNOLOGY, V3rd; GRENIER D, 1987, INFECT IMMUN, V55, P111, DOI 10.1128/IAI.55.1.111-117.1987; GRENIER D, 1987, J CLIN MICROBIOL, V25, P738, DOI 10.1128/JCM.25.4.738-740.1987; GRENIER D, 1987, INFECT IMMUN, V55, P3131, DOI 10.1128/IAI.55.12.3131-3136.1987; GRENIER D, 1989, INFECT IMMUN, V57, P95, DOI 10.1128/IAI.57.1.95-99.1989; HALKIER T, 1991, MECHANISMS BLOOD COA; HAYASHI H, 1992, ORAL MICROBIOL IMMUN, V7, P204, DOI 10.1111/j.1399-302X.1992.tb00026.x; HINODE D, 1991, INFECT IMMUN, V59, P3060, DOI 10.1128/IAI.59.9.3060-3068.1991; INOSHITA E, 1986, INFECT IMMUN, V52, P421, DOI 10.1128/IAI.52.2.421-427.1986; MARSH PD, 1989, FEMS MICROBIOL LETT, V59, P181; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCBRIDE BC, 1990, ARCH ORAL BIOL, V35, pS59, DOI 10.1016/0003-9969(90)90132-T; MCDERMID AS, 1988, INFECT IMMUN, V56, P1096, DOI 10.1128/IAI.56.5.1096-1100.1988; MCKEE AS, 1986, INFECT IMMUN, V52, P349, DOI 10.1128/IAI.52.2.349-355.1986; NISHIKATA M, 1991, BIOCHEM BIOPH RES CO, V178, P336, DOI 10.1016/0006-291X(91)91819-X; OKUDA K, 1986, INFECT IMMUN, V54, P659, DOI 10.1128/IAI.54.3.659-665.1986; Ono M, 1987, Oral Microbiol Immunol, V2, P77, DOI 10.1111/j.1399-302X.1987.tb00294.x; OTSUKA M, 1987, J PERIODONTAL RES, V22, P491, DOI 10.1111/j.1600-0765.1987.tb02060.x; SCOTT CF, 1993, J BIOL CHEM, V268, P7935; SHAGGER H, 1987, ANAL BIOCHEM, V166, P368; SHAH HN, 1992, J MED MICROBIOL, V36, P239, DOI 10.1099/00222615-36-4-239; SLOTS J, 1977, SCAND J DENT RES, V85, P114; SMALLEY JW, 1991, ORAL MICROBIOL IMMUN, V6, P202, DOI 10.1111/j.1399-302X.1991.tb00478.x; SMALLEY JW, 1989, ORAL MICROBIOL IMMUN, V4, P178, DOI 10.1111/j.1399-302X.1989.tb00249.x; SORSA T, 1987, J PERIODONTAL RES, V22, P375, DOI 10.1111/j.1600-0765.1987.tb01602.x; SUIDO H, 1987, J PERIODONTAL RES, V22, P412, DOI 10.1111/j.1600-0765.1987.tb01608.x; TSUTSUI H, 1987, INFECT IMMUN, V55, P420, DOI 10.1128/IAI.55.2.420-427.1987; UITTO VJ, 1987, J PERIODONTAL RES, V22, P58, DOI 10.1111/j.1600-0765.1987.tb01540.x; VANWINKELHOFF AJ, 1988, J CLIN PERIODONTOL, V15, P145; WHITE D, 1981, J PERIODONTAL RES, V16, P259, DOI 10.1111/j.1600-0765.1981.tb00974.x	37	309	320	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					406	411						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276827				2022-12-27	WOS:A1994MR21900069
J	WHITE, MF; KAHN, CR				WHITE, MF; KAHN, CR			THE INSULIN SIGNALING SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							KINASE DOMAIN AUTOPHOSPHORYLATION; RECEPTOR KINASE; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3'-KINASE; TRANSMEMBRANE DOMAIN; LIGAND-BINDING; PROTEIN; IRS-1; PHOSPHORYLATION; ACTIVATION		HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215	Harvard University; Harvard Medical School	WHITE, MF (corresponding author), JOSLIN DIABET CTR,DIV RES,1 JOSLIN PL,BOSTON,MA 02215, USA.		Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NIDDK NIH HHS [DK43808, DK38712, DK33201] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038712, R29DK038712, R01DK043808, R01DK033201, R55DK038712] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN AS, 1992, J BIOL CHEM, V267, P13681; ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BACKER JM, 1990, J BIOL CHEM, V265, P14828; BACKER JM, 1991, J CELL BIOL, V115, P1535, DOI 10.1083/jcb.115.6.1535; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BURGESS JW, 1992, J BIOL CHEM, V267, P10077; CANTLEY LC, 1991, CELL, V64, P231; CHEATHAM B, 1993, P NATL ACAD SCI USA, V90, P7336, DOI 10.1073/pnas.90.15.7336; CHUANG LM, 1993, MOL CELL BIOL, V13, P6653, DOI 10.1128/MCB.13.11.6653; CHUANG LM, 1993, P NATL ACAD SCI USA, V90, P5172, DOI 10.1073/pnas.90.11.5172; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; DEMEYTS P, 1990, MOL ENDOCRINOL, V4, P409, DOI 10.1210/mend-4-3-409; DOHERTY JJ, 1990, J CELL BIOL, V110, P35, DOI 10.1083/jcb.110.1.35; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FEENER EP, 1993, J BIOL CHEM, V268, P11256; FRATTALI AL, 1991, J BIOL CHEM, V266, P9829; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; IHLE JN, 1990, PROG CLIN BIOL RES, V352, P329; ISSAD T, 1991, BIOCHEM J, V275, P15, DOI 10.1042/bj2750015; KABURAGI Y, 1993, J BIOL CHEM, V268, P16610; KELLER SR, 1993, BIOCHIM BIOPHYS ACTA, V1172, P323, DOI 10.1016/0167-4781(93)90222-Y; KELLER SR, 1991, J BIOL CHEM, V266, P12817; KHAN MN, 1989, J BIOL CHEM, V264, P12931; KOETTNITZ K, 1993, EUR J IMMUNOL, V23, P988, DOI 10.1002/eji.1830230437; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEE JS, 1993, J BIOL CHEM, V268, P4092; LI CJ, IN PRESS P NATL ACAD; LONGO N, 1992, J BIOL CHEM, V267, P12416; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MEYERS MG, 1991, J BIOL CHEM, V266, P10616; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NISHIYAMA M, 1992, BIOCHEM BIOPH RES CO, V183, P280, DOI 10.1016/0006-291X(92)91640-C; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PRONK GJ, 1992, J BIOL CHEM, V267, P24058; RICE KM, 1992, J BIOL CHEM, V267, P10163; RIEDEL H, 1989, EMBO J, V8, P2943, DOI 10.1002/j.1460-2075.1989.tb08444.x; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; SCHUMACHER R, 1993, J BIOL CHEM, V268, P1087; SEINO S, 1990, DIABETES, V39, P129, DOI 10.2337/diabetes.39.2.129; SHIER P, 1989, J BIOL CHEM, V264, P14605; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STADTMAUER L, 1986, J BIOL CHEM, V261, P3402; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; THIES RS, 1989, J BIOL CHEM, V264, P12820; TRANISIJEVIK M, 1993, J BIOL CHEM, V268, P18157; VOGT B, 1991, BIOCHEM BIOPH RES CO, V177, P1013, DOI 10.1016/0006-291X(91)90639-O; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; YAMAMOTOHONDA R, 1993, J BIOL CHEM, V268, P16859	67	1355	1391	0	54	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					1	4						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276779				2022-12-27	WOS:A1994MR21900001
J	KAWASHIMA, H; YAMAMOTO, K; OSAWA, T; IRIMURA, T				KAWASHIMA, H; YAMAMOTO, K; OSAWA, T; IRIMURA, T			PURIFICATION AND CHARACTERIZATION OF UDP-GLCNAC-GAL-BETA-1-4GLC(NAC) BETA-1,3-N-ACETYLGLUCOSAMINYLTRANSFERASE (POLY-N-ACETYLLACTOSAMINE EXTENSION ENZYME) FROM CALF SERUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; LYSOSOMAL MEMBRANE-GLYCOPROTEINS; FULL-LENGTH CDNA; ACETYLGLUCOSAMINE (BETA-1-4)GALACTOSYLTRANSFERASE; LINKED OLIGOSACCHARIDES; CARBOHYDRATE STRUCTURE; PORCINE THYROGLOBULIN; BAND-3 GLYCOPROTEIN; RAT-KIDNEY; CLONING	UDP-GlcNAc:Galbeta1-4Glc(NAc) beta-1,3-N-acetylglucosaminyltransferase is involved in the initiation and the extension of poly-N-acetyllactosamine biosynthesis. This enzyme has been purified to about 125,000-fold with a 0.2% yield from calf serum. The purification was achieved by ammonium sulfate precipitation and chromatography on concanavalin A-Sepharose, DEAE-Toyopearl, SP-Toyopearl, Sephacryl S-200, AF-Blue-Toyopearl, and Mono Q columns. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis showed a single band corresponding to an apparent M(r) of 70,000. This component was specifically photoaffinity-labeled with 4-thiouridine diphosphate. Exoglycosidase digestion and methylation analysis of the reaction products demonstrated that the enzyme catalyzed the transfer of one N-acetylglucosamine to position C-3 of the terminal galactosyl residue of lactose or N-acetyllactosamine in the beta linkage. The enzyme required Mn2+ ions for its activity and showed a broad pH optimum around 7.0. Apparent K(m) values for lactose, N-acetyllactosamine, and UDP-GlcNAc were 18.2, 19.6, and 0.129 mM, respectively. Acceptor specificity was tested using several oligosaccharides. The results indicated that terminal Galbeta1-4Glc(NAc) sequences (type II chains) were preferred substrates for the enzyme. Terminal Galbeta1-3GlcNAc sequences (type I chains), Lewis X trisaccharides (Galbeta1-4(Fucalpha1-3)GlcNAc), and monosaccharides (galactose) did not serve as substrates.	UNIV TOKYO, FAC PHARMACEUT SCI, DIV CHEM TOXICOL & IMMUNOCHEM, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo								BASU M, 1984, J BIOL CHEM, V259, P2557; BENDIAK B, 1987, J BIOL CHEM, V262, P5775; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; CHEN C, 1989, BIOCHEMISTRY-US, V28, P2229, DOI 10.1021/bi00431a039; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; CLAUSEN H, 1990, J BIOL CHEM, V265, P1139; Cuatrecasas P., 1971, METHOD ENZYMOL, V22, P345; DAGOSTARO G, 1989, EUR J BIOCHEM, V183, P211, DOI 10.1111/j.1432-1033.1989.tb14915.x; ELICES MJ, 1990, CARBOHYD RES, V203, P109, DOI 10.1016/0008-6215(90)80050-D; FUKUDA M, 1981, P NATL ACAD SCI-BIOL, V78, P6299, DOI 10.1073/pnas.78.10.6299; FUKUDA M, 1979, J BIOL CHEM, V254, P3700; FUKUDA M, 1984, J BIOL CHEM, V259, P925; FUKUDA M, 1984, BIOCHIM BIOPHYS ACTA, V780, P119, DOI 10.1016/0304-419X(84)90002-7; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; HOLMES EH, 1987, J BIOL CHEM, V262, P15649; HOSOMI O, 1989, JPN J MED SCI BIOL, V42, P77, DOI 10.7883/yoken1952.42.77; IMAI Y, 1990, MOL IMMUNOL, V27, P335, DOI 10.1016/0161-5890(90)90046-3; KAWASHIMA H, 1990, GLYCOCONJUGATE J, V7, P323, DOI 10.1007/BF01073376; KETCHAM CM, 1992, J BIOL CHEM, V267, P11645; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE N, 1990, J BIOL CHEM, V265, P20476; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; MURAMATSU H, 1983, J BIOCHEM-TOKYO, V94, P799, DOI 10.1093/oxfordjournals.jbchem.a134422; MURAMATSU T, 1978, P NATL ACAD SCI USA, V75, P2315, DOI 10.1073/pnas.75.5.2315; MURAMATSU T, 1979, CELL, V18, P183, DOI 10.1016/0092-8674(79)90367-2; NAKAZAWA K, 1988, J BIOCHEM-TOKYO, V104, P165, DOI 10.1093/oxfordjournals.jbchem.a122434; NARIMATSU H, 1986, P NATL ACAD SCI USA, V83, P4720, DOI 10.1073/pnas.83.13.4720; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; NISHIKAWA Y, 1988, J BIOL CHEM, V263, P8270; OGATA SI, 1976, NATURE, V259, P580, DOI 10.1038/259580a0; PILLER F, 1983, J BIOL CHEM, V258, P2293; POWELL JT, 1976, J BIOL CHEM, V251, P3645; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SHAPER NL, 1986, P NATL ACAD SCI USA, V83, P1573, DOI 10.1073/pnas.83.6.1573; SHOREIBAH MG, 1992, J BIOL CHEM, V267, P2920; TANIGUCHI N, 1984, J BIOL CHEM, V259, P5637; TSUJI T, 1981, BIOCHEM J, V195, P691, DOI 10.1042/bj1950691; TSUJI T, 1981, J BIOL CHEM, V256, P497; VANDENEIJNDEN DH, 1988, J BIOL CHEM, V263, P12461; VANDENEIJNDEN DH, 1983, J BIOL CHEM, V258, P3435; WANG WC, 1991, J BIOL CHEM, V266, P23185; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; YAMAMOTO K, 1984, EUR J BIOCHEM, V143, P133, DOI 10.1111/j.1432-1033.1984.tb08352.x; YAMAMOTO K, 1981, BIOCHEM J, V195, P701, DOI 10.1042/bj1950701; YAMASHITA K, 1984, J BIOL CHEM, V259, P834; YATES AD, 1983, CARBOHYD RES, V120, P251, DOI 10.1016/0008-6215(83)88020-3; YAZAWA S, 1986, CARBOHYD RES, V149, P241, DOI 10.1016/S0008-6215(00)90381-1	49	25	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27118	27126						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262950				2022-12-27	WOS:A1993MM26200043
J	RICHAUD, C; MENGINLECREULX, D; POCHET, S; JOHNSON, EJ; COHEN, GN; MARLIERE, P				RICHAUD, C; MENGINLECREULX, D; POCHET, S; JOHNSON, EJ; COHEN, GN; MARLIERE, P			DIRECTED EVOLUTION OF BIOSYNTHETIC PATHWAYS - RECRUITMENT OF CYSTEINE THIOETHERS FOR CONSTRUCTING THE CELL-WALL OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; DIAMINOPIMELATE EPIMERASE; FUSOBACTERIUM-NUCLEATUM; CYTOPLASMIC STEPS; REGULATORY REGION; META GENE; PEPTIDOGLYCAN; CLONING; MUTAGENESIS; INSERTION	We report that expansion of thioether biosynthesis in Escherichia coli generates sulfur-containing amino acids that can replace meso-diaminopimelate, the essential amino acid used for cross-linking the cell wall. This was accomplished by jointly overexpressing the metB gene coding for L-cystathionine gamma-synthase and disrupting the metC gene, whose product, L-cystathionine beta-lyase, is responsible for the destruction of L-cystathionine and other L-cysteine thioethers. As a result, meso-lanthionine and L-allo-cystathionine were produced endogenously and incorporated in the peptidoglycan, thereby enabling E. coli strains auxotrophic for diaminopimelate to grow in its absence. Thus, current techniques of metabolic engineering can be applied to evolving the chemical constitution of living cells beyond its present state.	INST PASTEUR, UNITE PHYSIOL CELLULAIRE, CNRS, URA 1300, F-75724 PARIS 15, FRANCE; INST PASTEUR, UNITE CHIM ORGAN, CNRS, URA 487, F-75724 PARIS 15, FRANCE; INST PASTEUR, UNITE BIOCHIM CELLULAIRE, CNRS, URA 1129, F-75724 PARIS 15, FRANCE; UNIV PARIS 11, BIOCHIM MOLEC & CELLULAIRE LAB, CNRS, URA 1131, F-91405 ORSAY, FRANCE; TULANE UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, NEW ORLEANS, LA 70112 USA	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Tulane University				MENGIN-LECREULX, Dominique/0000-0003-3205-0275				BAILEY JE, 1991, SCIENCE, V252, P1668, DOI 10.1126/science.2047876; BELFAIZA J, 1986, P NATL ACAD SCI USA, V83, P867, DOI 10.1073/pnas.83.4.867; BOGOSIAN G, 1989, J BIOL CHEM, V264, P531; BOUVIER J, 1984, J BIOL CHEM, V259, P4829; Brown GB, 1941, J BIOL CHEM, V140, P767; BUGG TDH, 1991, BIOCHEMISTRY-US, V30, P2017, DOI 10.1021/bi00222a002; CAIRNSSMITH AG, 1982, GENETIC TAKEOVER MIN, P349; CAPARROS M, 1992, J BACTERIOL, V174, P5549; COHEN GN, 1987, ESCHERICHIA COLI SAL, P429; DAMANI LA, 1989, SULPHUR CONTAINING B, V1; DAMANI LA, 1989, SULPHUR CONTAINING A, V1; DEAN D, 1981, GENE, V15, P99, DOI 10.1016/0378-1119(81)90108-6; DEJONGE BLM, 1992, J BIOL CHEM, V267, P11248; DUCLOS B, 1989, NUCLEIC ACIDS RES, V17, P2856, DOI 10.1093/nar/17.7.2856; DWIVEDI CM, 1982, BIOCHEMISTRY-US, V21, P3064, DOI 10.1021/bi00256a005; FLAVIN M, 1975, METABOLIC PATHWAYS, V7, P457; FREDRIKSEN A, 1991, J BACTERIOL, V173, P900, DOI 10.1128/jb.173.2.900-902.1991; GUGGENHEIM S, 1969, J BIOL CHEM, V244, P3722; HOPWOOD DA, 1985, NATURE, V314, P642, DOI 10.1038/314642a0; HUANG HT, 1963, BIOCHEMISTRY-US, V2, P296, DOI 10.1021/bi00902a018; JENSEN RA, 1976, ANNU REV MICROBIOL, V30, P409, DOI 10.1146/annurev.mi.30.100176.002205; KNUSEL F, 1967, PATHOL MICROBIOL, V30, P871, DOI 10.1159/000161753; KOCH AL, 1992, J BACTERIOL, V174, P4811, DOI 10.1128/JB.174.14.4811-4819.1992; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LEMEIGNAN B, 1993, J MOL BIOL, V231, P161, DOI 10.1006/jmbi.1993.1269; LEVY S, 1988, MOL MICROBIOL, V2, P777, DOI 10.1111/j.1365-2958.1988.tb00089.x; Maniatis T., 1982, MOL CLONING; MAZEL D, 1989, NATURE, V341, P245, DOI 10.1038/341245a0; MENGINLECREULX D, 1988, J BACTERIOL, V170, P2031, DOI 10.1128/jb.170.5.2031-2039.1988; MENGINLECREULX D, 1982, J BACTERIOL, V151, P1109, DOI 10.1128/JB.151.3.1109-1117.1982; MENGINLECREULX D, 1985, J BACTERIOL, V163, P208, DOI 10.1128/JB.163.1.208-212.1985; MICHAELI S, 1984, J BACTERIOL, V160, P1158, DOI 10.1128/JB.160.3.1158-1162.1984; Mortlock R., 1992, EVOLUTION METABOLIC; NANNINGA N, 1991, MOL MICROBIOL, V5, P791, DOI 10.1111/j.1365-2958.1991.tb00751.x; PARKER B, 1988, GENE, V73, P531, DOI 10.1016/0378-1119(88)90517-3; POCHET S, 1990, NUCLEIC ACIDS RES, V18, P7127, DOI 10.1093/nar/18.23.7127; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; PRIDMORE RD, 1987, GENE, V56, P309, DOI 10.1016/0378-1119(87)90149-1; RHULAND LE, 1957, J BACTERIOL, V73, P778, DOI 10.1128/JB.73.6.778-783.1957; RICHAUD C, 1987, J BACTERIOL, V169, P1454, DOI 10.1128/jb.169.4.1454-1459.1987; RICHAUD C, 1984, J BIOL CHEM, V259, P4824; RICHAUD F, 1986, J BACTERIOL, V166, P297, DOI 10.1128/jb.166.1.297-300.1986; RICHMOND MH, 1962, BACTERIOL REV, V26, P398, DOI 10.1128/MMBR.26.4.398-420.1962; Rogers H.J., 1980, MICROBIAL CELL WALLS, P239; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; SHAPIRA SK, 1983, GENE, V25, P71, DOI 10.1016/0378-1119(83)90169-5; SIMON M, 1983, J BACTERIOL, V153, P558, DOI 10.1128/JB.153.1.558-561.1983; VASSTRAND EN, 1979, INFECT IMMUN, V25, P775, DOI 10.1128/IAI.25.3.775-780.1979; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WANNER BL, 1986, J MOL BIOL, V191, P39, DOI 10.1016/0022-2836(86)90421-3; WINANS SC, 1985, J BACTERIOL, V161, P1219, DOI 10.1128/JB.161.3.1219-1221.1985; YCAS M, 1974, J THEOR BIOL, V44, P145, DOI 10.1016/S0022-5193(74)80035-4; ZAKIN MM, 1982, MOL GEN GENET, V187, P101, DOI 10.1007/BF00384390	53	67	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26827	26835						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262915				2022-12-27	WOS:A1993MM26200004
J	FRAGA, D; HERMOLIN, J; FILLINGAME, RH				FRAGA, D; HERMOLIN, J; FILLINGAME, RH			TRANSMEMBRANE HELIX-HELIX INTERACTIONS IN F(0) SUGGESTED BY SUPPRESSOR MUTATIONS TO ALA(24)-]ASP/ASP(61)-]GLY MUTANT OF ATP SYNTHASE SUBUNIT-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F0F1-ATPASE; F1F0-ATP SYNTHASE; H+-ATPASE; A-SUBUNIT; ALPHA-SUBUNIT; PROTON PORE; F0; TRANSLOCATION; SUBSTITUTION; TOPOLOGY	A mutant of ATP synthase subunit c was isolated in which the essential aspartate was exchanged from position 61 on transmembrane helix-2 to position 24 on transmembrane helix-1 (Miller, M. J., Oldenburg, M., and Fillingame, R. H. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 4900-49041. The H+ transporting ATP synthase function of the Ala24 --> Asp/Asp61 --> Gly mutant is not optimal, and cells grow more slowly than wild type. Twenty-three third-site suppressor mutants with optimized function were isolated in this study. Ten of the optimizing mutations were located to helix-2 of subunit c, and seven of these fell in residues Phe53, Met57, and Met65. The side chains of these three residues are proposed to form a hydrophobic surface on transmembrane helix-2, which participates in the presentation or occlusion of the essential aspartate carboxyl group during proton translocation. The other 13 optimizing mutations were located to subunit a, and 10 of these fell in residues Ala217, Ile221, and Leu224. These three residues are proposed to lie on one face of a transmembrane alpha-helix that includes the essential Arg210 residue. This helix is proposed to interact with the transmembrane bihelical unit of subunit c during protonation and deprotonation of the essential Asp24 in the mutant or Asp61 in wild type.	UNIV WISCONSIN,SCH MED,DEPT BIOMOLEC CHEM,587 MED SCI BLDG,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison				Fraga, Dean/0000-0002-9933-665X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023105, R01GM023105, T32GM007133] Funding Source: NIH RePORTER; NIGMS NIH HHS [5-T32-GM07133, GM23105] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BJORBAEK C, 1990, FEBS LETT, V260, P31, DOI 10.1016/0014-5793(90)80058-Q; CAIN BD, 1988, J BIOL CHEM, V263, P6606; CAIN BD, 1989, J BIOL CHEM, V264, P3292; COX GB, 1986, BIOCHIM BIOPHYS ACTA, V849, P62, DOI 10.1016/0005-2728(86)90096-4; EYA S, 1991, ARCH BIOCHEM BIOPHYS, V284, P71, DOI 10.1016/0003-9861(91)90265-K; FILLINGAME RH, 1991, J BIOL CHEM, V266, P20934; FILLINGAME RH, 1992, ANN NY ACAD SCI, V671, P323, DOI 10.1111/j.1749-6632.1992.tb43806.x; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; GIRVIN ME, 1993, IN PRESS BIOCHEMISTR; HIGUCHI RG, 1989, NUCLEIC ACIDS RES, V17, P5865, DOI 10.1093/nar/17.14.5865; HOPPE J, 1986, BIOCHIMIE, V68, P427, DOI 10.1016/S0300-9084(86)80010-4; HOPPE J, 1980, FEBS LETT, V109, P107, DOI 10.1016/0014-5793(80)81321-4; HOPPE J, 1984, BIOCHEMISTRY-US, V23, P5610, DOI 10.1021/bi00318a035; HOPPE J, 1982, FEBS LETT, V145, P21, DOI 10.1016/0014-5793(82)81198-8; HOWITT SM, 1990, BIOCHIM BIOPHYS ACTA, V1015, P264, DOI 10.1016/0005-2728(90)90030-8; HOWITT SM, 1992, P NATL ACAD SCI USA, V89, P9799, DOI 10.1073/pnas.89.20.9799; LEWIS MJ, 1992, J BIOL CHEM, V267, P3482; LEWIS MJ, 1990, J BIOL CHEM, V265, P10541; LIGHTOWLERS RN, 1988, BIOCHIM BIOPHYS ACTA, V933, P241, DOI 10.1016/0005-2728(88)90031-X; LIGHTOWLERS RN, 1987, BIOCHIM BIOPHYS ACTA, V894, P399, DOI 10.1016/0005-2728(87)90118-6; Miller J.H., 1972, EXPT MOL GENETICS; MILLER MJ, 1990, P NATL ACAD SCI USA, V87, P4900, DOI 10.1073/pnas.87.13.4900; MOSHER ME, 1985, J BIOL CHEM, V260, P4807; MOSHER ME, 1983, J BACTERIOL, V156, P1078, DOI 10.1128/JB.156.3.1078-1092.1983; PAULE CR, 1990, THESIS U WISCONSIN M; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; VIK SB, 1992, BIOCHIM BIOPHYS ACTA, V1140, P199, DOI 10.1016/0005-2728(92)90009-Q; VIK SB, 1990, ARCH BIOCHEM BIOPHYS, V282, P125, DOI 10.1016/0003-9861(90)90095-G; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; Young A., 1991, FOCUS, V13, P137	31	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2562	2567						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300584				2022-12-27	WOS:A1994MV43200034
J	ADACHI, Y; PAVLAKIS, GN; COPELAND, TD				ADACHI, Y; PAVLAKIS, GN; COPELAND, TD			IDENTIFICATION AND CHARACTERIZATION OF SET, A NUCLEAR PHOSPHOPROTEIN ENCODED BY THE TRANSLOCATION BREAK POINT IN ACUTE UNDIFFERENTIATED LEUKEMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-I; HEMATOPOIETIC SYSTEM CELLS; FUSION MESSENGER-RNA; TRANSCRIPTION FACTOR; PROTEIN-KINASE; CDNA CLONE; RAR-ALPHA; GENE; PHOSPHORYLATION; ABL	The translocation (6;9) in acute nonlymphocytic leukemia results in the formation of a dek-can fusion gene. In a case of acute undifferentiated leukemia, the oncogene can is fused to a different gene, named set, instead of dek and is assumed to be activated. Transcripts of set encode a putative SET protein with a predicted molecular mass of 32 kDa. We identified SET as a 39-kDa protein by immunoprecipitation with rabbit antiserum against each of three synthetic peptides predicted from the open reading frame of the set gene. We confirmed this identification of SET by protein sequencing. We also observed that SET is expressed ubiquitously in various hu an cell lines. SET is phosphorylated on serine residue(s) in cultured cells and is localized predominantly in nuclei. Although the function(s) of SET and SET-CAN is not known, we propose that SET plays a key role in the mechanism of leukemogenesis. in acute undifferentiated leukemia, perhaps by activating CAN in nuclei and stimulating the transformation potential of SET-CAN. This proposed role would therefore be similar to the roles observed for BCR and DEK of the chimeric oncoproteins BCR-ABL and DEK-CAN in acute myeloid leukemia and acute nonlymphocytic leukemia, respectively.	NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, PROT STRUCT GRP, FREDERICK, MD 21702 USA; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, HUMAN RETROVIRUS SECT, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI Y, 1988, BIOL CHEM H-S, V369, P223; ADACHI Y, 1990, J CHROMATOGR-BIOMED, V530, P39, DOI 10.1016/S0378-4347(00)82300-2; ADACHI Y, 1992, J BIOL CHEM, V267, P21977; ADACHI Y, 1992, J BIOL CHEM, V267, P19373; ADACHI Y, 1991, J BIOL CHEM, V266, P3968; ADACHI Y, 1993, J BIOL CHEM, V268, P13930; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; COPELAND TD, 1986, J IMMUNOL, V137, P2945; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; EARNSHAW WC, 1987, J CELL BIOL, V105, P1479, DOI 10.1083/jcb.105.4.1479; GAZDAR AF, 1980, BLOOD, V55, P409; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; ISHII K, 1990, J CELL PHYSIOL, V143, P569, DOI 10.1002/jcp.1041430323; ISHIMI Y, 1991, J BIOL CHEM, V266, P7025; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KLEIN E, 1968, CANCER RES, V28, P1300; KROHNE G, 1980, EXP CELL RES, V129, P167, DOI 10.1016/0014-4827(80)90341-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; NOSAKA T, 1989, P NATL ACAD SCI USA, V86, P9798, DOI 10.1073/pnas.86.24.9798; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; SHIRAKAWA H, 1992, J BIOL CHEM, V267, P6641; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; WEN L, 1989, NUCLEIC ACIDS RES, V17, P1197, DOI 10.1093/nar/17.3.1197; ZHANG XT, 1989, BIOCHEM BIOPH RES CO, V164, P176, DOI 10.1016/0006-291X(89)91699-9	34	154	162	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2258	2262						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294483				2022-12-27	WOS:A1994MR98800105
J	FENG, LL; XIA, YY; WILSON, CB				FENG, LL; XIA, YY; WILSON, CB			ALTERNATIVE SPLICING OF THE NC1 DOMAIN OF THE HUMAN-ALPHA-3(IV) COLLAGEN GENE - DIFFERENTIAL EXPRESSION OF MESSENGER-RNA TRANSCRIPTS THAT PREDICT 3 PROTEIN VARIANTS WITH DISTINCT CARBOXYL REGIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR-BASEMENT-MEMBRANE; IV COLLAGEN; ALPORT SYNDROME; GOODPASTURE ANTIGEN; HEREDITARY NEPHRITIS; ALPHA-3(IV) CHAIN; SEQUENCE-ANALYSIS; IDENTIFICATION; LOCALIZATION; CLONING	Three clones of NC1 of alpha3(IV) collagen, named Q1, L5, and V, were isolated from human kidney; these predict three variant alpha3(IV) NC1 domains of 232-, 60-, and 199-amino acid residues, respectively, with unique COOH-termini. The human collagen IV gene (COL4A3) was isolated and characterized, and it was shown that the cDNA variants arose from alternative splicing by deletion of exon 4 in L5 and deletion of exon 2 in V. The mRNA transcripts were differentially expressed in fetal-and adult human kidney with Ql the major species. Exon 4L5 lacked 183 residues from the carboxyl terminus with a frameshift producing a unique 11-amino acid terminal peptide. In exon 2- V a frameshift resulted in a unique V carboxyl terminus of 53 novel peptides with a new glycosylation site. The size of recombinant proteins indicated the frameshifts and new stop codons were as predicted. The multiple forms of the alpha3(IV) NC1 region may contribute to autoimmune glomerular disease and hereditary nephritis, in which this portion of the collagen IV molecule is thought to play an important role.	Scripps Res Inst, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK020043, R01DK020043] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR00833] Funding Source: Medline; NIDDK NIH HHS [DK20043] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN GP, 1988, J VIROL, V62, P2850, DOI 10.1128/JVI.62.8.2850-2858.1988; ANAND SK, 1978, J PEDIATR-US, V92, P952, DOI 10.1016/S0022-3476(78)80372-2; BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; BRINKER JM, 1985, P NATL ACAD SCI USA, V82, P3649, DOI 10.1073/pnas.82.11.3649; BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; BUTKOWSKI RJ, 1990, J LAB CLIN MED, V115, P365; BUTKOWSKI RJ, 1985, J BIOL CHEM, V260, P3739; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROUZET J, 1990, J BACTERIOL, V172, P5980, DOI 10.1128/jb.172.10.5980-5990.1990; DION AS, 1987, J MOL BIOL, V193, P127, DOI 10.1016/0022-2836(87)90632-2; Feng Lili, 1992, Journal of the American Society of Nephrology, V3, P629; Fujinami R S, 1988, Ann N Y Acad Sci, V540, P210, DOI 10.1111/j.1749-6632.1988.tb27063.x; GARBE T, 1990, J BACTERIOL, V172, P6774, DOI 10.1128/jb.172.12.6774-6782.1990; GARY GL, 1984, P NATL ACAD SCI USA, V81, P2645; Goebel S.J., 1990, VIROLOGY, V179, P517; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; HORSFALL AC, 1992, MOL BIOL REP, V16, P139, DOI 10.1007/BF00464701; HOSTIKKA SL, 1987, FEBS LETT, V224, P297, DOI 10.1016/0014-5793(87)80473-8; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; HUDSON BG, 1989, LAB INVEST, V61, P256; HUDSON BG, 1992, KIDNEY INT, V42, P179, DOI 10.1038/ki.1992.276; HUEY B, 1993, KIDNEY INT, V44, P307, DOI 10.1038/ki.1993.245; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KALLURI R, 1991, J BIOL CHEM, V266, P24018; KEFALIDES NA, 1993, KIDNEY INT, V43, P85, DOI 10.1038/ki.1993.15; KEFALIDES NA, 1993, KIDNEY INT, V43, P94, DOI 10.1038/ki.1993.16; KIDA H, 1988, VIROLOGY, V162, P160, DOI 10.1016/0042-6822(88)90405-9; KLEPPEL MM, 1987, J CLIN INVEST, V80, P263, DOI 10.1172/JCI113057; KLEPPEL MM, 1986, J BIOL CHEM, V261, P6547; KLEPPEL MM, 1992, KIDNEY INT, V41, P1629, DOI 10.1038/ki.1992.235; MARIYAMA M, 1992, J BIOL CHEM, V267, P1253; MCCOY RC, 1982, KIDNEY INT, V21, P642, DOI 10.1038/ki.1982.72; MCCOY RC, 1976, LAB INVEST, V34, P325; MORRISON KE, 1991, AM J HUM GENET, V49, P545; NEILSON EG, 1993, J BIOL CHEM, V268, P8402; NUNN D, 1990, J BACTERIOL, V172, P2991; QUINONES S, 1992, J BIOL CHEM, V267, P19780; REES AJ, 1978, LANCET, V1, P966; SAITO A, 1991, Journal of the American Society of Nephrology, V2, P560; SIEBOLD B, 1988, EUR J BIOCHEM, V176, P617, DOI 10.1111/j.1432-1033.1988.tb14321.x; SOININEN R, 1989, J BIOL CHEM, V264, P13565; SPEAR GS, 1984, CLIN NEPHROL, V21, P3; TAYLOR TK, 1992, INT J SYST BACTERIOL, V42, P593, DOI 10.1099/00207713-42-4-593; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TRYGGVASON K, 1990, ANN NY ACAD SCI, V580, P97, DOI 10.1111/j.1749-6632.1990.tb17922.x; TURNER N, 1992, J CLIN INVEST, V89, P592, DOI 10.1172/JCI115625; WILSON CB, 1972, ANN INTERN MED, V76, P91, DOI 10.7326/0003-4819-76-1-91; XIA YY, 1993, AM J PHYSIOL, V264, pF774, DOI 10.1152/ajprenal.1993.264.5.F774; ZHOU J, 1991, GENOMICS, V9, P10, DOI 10.1016/0888-7543(91)90215-Z; ZHOU J, 1991, GENOMICS, V9, P1, DOI 10.1016/0888-7543(91)90214-Y	51	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2342	2348						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294492				2022-12-27	WOS:A1994MR98800116
J	JUMINAGA, D; ALBAUGH, SA; STEINER, RF				JUMINAGA, D; ALBAUGH, SA; STEINER, RF			THE INTERACTION OF CALMODULIN WITH REGULATORY PEPTIDES OF PHOSPHORYLASE-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN KINASE; TROPONIN-C; MELITTIN; SUBUNIT; DOMAINS	The regulatory peptides Phk13 (301-327) and Phk5 (342-367) have been synthesized and their interaction with calmodulin studied. In the case of Phk13 modified forms were also synthesized in which a tryptophan group was placed at position 4 or 21, as well as a form with tryptophan at position 4 and nitrotyrosine at position 21. From tryptic digestion, circular dichroism, and radiationless energy transfer measurements, it appears that Phk13 forms an elongated complex with calmodulin in which the peptide is in a non-helical conformation, probably bent into a hairpin-shaped structure, the connecting strand of calmodulin is extended and exposed to the action of proteolytic enzymes, and the peptide makes contact with both the N- and C-terminal half-molecules of calmodulin. In contrast, the Phk5 peptide has an alpha-helical conformation in the complex, which is relatively compact in shape.			JUMINAGA, D (corresponding author), UNIV MARYLAND,DEPT CHEM & BIOCHEM,CATONSVILLE,MD 21228, USA.							BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; CADAY CG, 1986, BIOCHEM BIOPH RES CO, V135, P419, DOI 10.1016/0006-291X(86)90011-2; CHEUNG HC, 1991, TOPICS FLUORESCENCE, V2, P128; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; GARONE L, 1990, ARCH BIOCHEM BIOPHYS, V276, P12, DOI 10.1016/0003-9861(90)90003-H; GARONE L, 1988, BIOPHYS CHEM, V32, P231; HAAS E, 1978, BIOCHEMISTRY-US, V17, P5064, DOI 10.1021/bi00616a032; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; HEIDORN DB, 1989, BIOCHEMISTRY-US, V28, P6757, DOI 10.1021/bi00442a032; JARRETT HW, 1991, J BIOL CHEM, V266, P362; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KLEE CB, 1980, ANNU REV BIOCHEM, V49, P489, DOI 10.1146/annurev.bi.49.070180.002421; LINSE S, 1986, FEBS LETT, V199, P28, DOI 10.1016/0014-5793(86)81217-0; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; RICHMAN PG, 1978, BIOCHEMISTRY-US, V17, P928, DOI 10.1021/bi00598a029; Steiner R. F., 1991, TOPICS FLUORESCENCE, V2, P1, DOI DOI 10.1007/0-306-47058-6_; STEINER RF, 1986, ARCH BIOCHEM BIOPHYS, V246, P286, DOI 10.1016/0003-9861(86)90474-1; STRASBURG GM, 1988, J BIOL CHEM, V263, P542; STRYER L, 1967, P NATL ACAD SCI USA, V58, P719, DOI 10.1073/pnas.58.2.719; STRYNADKA NCJ, 1990, PROTEINS, V7, P234, DOI 10.1002/prot.340070305; TREWHELLA J, 1990, BIOCHEMISTRY-US, V29, P9316, DOI 10.1021/bi00492a003; WATTERSON DM, 1980, J BIOL CHEM, V255, P962	24	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1660	1667						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294413				2022-12-27	WOS:A1994MR98800021
J	LINDBERG, FP; LUBLIN, DM; TELEN, MJ; VEILE, RA; MILLER, YE; DONISKELLER, H; BROWN, EJ				LINDBERG, FP; LUBLIN, DM; TELEN, MJ; VEILE, RA; MILLER, YE; DONISKELLER, H; BROWN, EJ			RH-RELATED ANTIGEN CD47 IS THE SIGNAL-TRANSDUCER INTEGRIN-ASSOCIATED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RED-CELL MEMBRANE; HUMAN-CHROMOSOMES; VACCINIA VIRUS; IDENTIFICATION; PHAGOCYTOSIS; SEQUENCE	Integrin-associated protein (LAP) is a 50-kDa membrane protein with an amino-terminal immunoglobulin domain and a carboxyl-terminal multiply membrane-spanning region. It is physically and funcitonally associated with the integrin alpha(v)beta3 vitronectin receptor and is involved in the increase in intracellular calcium concentration, which occurs upon cell adhesion to extracellular matrix. Oxidative burst in neutrophils can be induced or inhibited via LAP. Surprisingly, LAP is also expression erythrocytes, which have no known integrins. IAP has been shown to be identical to OA3, an ovarian carcinoma antigen. We now show that IAP expression is reduced on Rh(null)erythrocytes. The IAP structural gene is mapped to q13.1-2 on human chromosome 3, within a region known to contain a gene encoding the Rh-associated 1D8 antigen. By expression studies on human erythrocytes and IAP transfectants, IAP is shown to be identical to the 1D8 antigen and to CD47, a cell surface protein with broad tissue distribution, reduced in expression on Rh(null) erythrocytes. Two CD47 antibodies recognize the immunoglobulin domain of IAP, as does antibody 1D8. These studies suggest the possibility that IAP and the Rh polypeptides may share a pathway for membrane expression on erythrocytes. Furthermore, decreased expression of IAP on Rh(null) cells may contribute to the these cells' abnormal cation permeabilities. These studies demonstrate an unexpected link between integrin signal transduction and erythrocyte membrane structure.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV INFECT DIS,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT SURG,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT LAB MED,ST LOUIS,MO 63110; DUKE UNIV,MED CTR,DIV HEMATOL ONCOL,DURHAM,NC 27710; COLORADO HLTH SCI CTR,DEPT MED,DENVER,CO 80220	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Duke University; University of Colorado System; University of Colorado Anschutz Medical Campus				Telen, Marilyn/0000-0003-3809-1780	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000304] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038330] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00304] Funding Source: Medline; NIGMS NIH HHS [GM38330] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agre P, 1991, Baillieres Clin Haematol, V4, P793, DOI 10.1016/S0950-3536(06)80031-4; AGUADO B, 1992, J GEN VIROL, V73, P2887, DOI 10.1099/0022-1317-73-11-2887; AVENT N, 1988, BIOCHEM J, V251, P499, DOI 10.1042/bj2510499; AVENT ND, 1988, BIOCHEM J, V256, P1043, DOI 10.1042/bj2561043; BALLAS SK, 1984, BLOOD, V63, P1046; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; CAMPBELL IG, 1992, CANCER RES, V52, P5416; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; GRESHAM H, 1990, CLIN RES, V38, pA480; GRESHAM HD, 1989, J CELL BIOL, V108, P1935, DOI 10.1083/jcb.108.5.1935; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; MALLINSON G, 1986, BIOCHEM J, V234, P649, DOI 10.1042/bj2340649; MILLER YE, 1987, AM J HUM GENET, V4, P1061; MOORE S, 1987, BIOCHEM J, V244, P735, DOI 10.1042/bj2440735; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P221; POELS LG, 1986, JNCI-J NATL CANCER I, V76, P781; POSS MT, 1993, VOX SANG, V64, P231, DOI 10.1111/j.1423-0410.1993.tb03061.x; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SCHWARTZ MA, 1993, J BIOL CHEM, V268, P19931; SENIOR RM, 1992, J CLIN INVEST, V90, P2251, DOI 10.1172/JCI116111; SPRING FA, 1989, LEUKOCYTE TYPING, V4, P660; STURGEON P, 1970, BLOOD-J HEMATOL, V36, P310, DOI 10.1182/blood.V36.3.310.310; TELEN MJ, 1986, HUM IMMUNOL, V17, P311, DOI 10.1016/0198-8859(86)90283-1; YUNIS JJ, 1976, SCIENCE, V191, P1268, DOI 10.1126/science.1257746; ZAHAR BC, 1993, BLOOD, V82, P656; ZHOU MJ, 1993, J EXP MED, V178, P1165, DOI 10.1084/jem.178.4.1165	28	129	150	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1567	1570						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294396				2022-12-27	WOS:A1994MR98800001
J	KIM, KS; TEIXEIRA, SMR; KIRCHHOFF, LV; DONELSON, JE				KIM, KS; TEIXEIRA, SMR; KIRCHHOFF, LV; DONELSON, JE			TRANSCRIPTION AND EDITING OF CYTOCHROME OXIDASE-II RNAS IN TRYPANOSOMA-CRUZI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; KINETOPLAST DNA; MAXICIRCLE DNA; READING FRAMES; LIFE-CYCLE; GUIDE RNAS; BRUCEI; GENES; SEQUENCES; MITOCHONDRIA	The cytochrome oxidase subunit II (COII) gene is one of the maxicircle cryptogenes of kinetoplastids whose primary transcripts are sometimes modified by RNA editing to produce mature mRNAs. We determined the sequence of the COII gene in three strains of Trypanosoma cruzi (Y, Corpus Christi, and Tulahuen) and examined its developmental expression. Comparison of the RNA and DNA sequences encoding COII indicated that in the three strains of T. cruzi, four uridines are inserted in the pre-mRNA at the same positions as they are in the COII pre-mRNAs of Trypanosoma brucei, Leishmania tarentolae, and Crithidia fasciculata. The putative guide RNA (gRNA) sequence that serves as a template for the four uridine insertions is located in the 3'-untranslated region of the T cruzi COII mRNA. Analysis of editing intermediates demonstrates that the COII gRNA remains attached to the pre-mRNA while participating in the formation of chimeric RNAs. Northern blots used to investigate stage-specific expression of the COII gene revealed RNAs of 800 and 900 nucleotides, similar in size to those present in T brucei. In contrast to the differential expression observed in T. brucei, no difference occurs between the COII mRNA levels of insect and mammalian stages of T cruzi.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242; UNIV IOWA,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,MED SCI TRAINING PROGRAM,IOWA CITY,IA 52242; DEPT VET AFFAIRS MED CTR,IOWA CITY,IA 52242; HOWARD HUGHES MED INST,IOWA CITY,IA 52242	University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; Howard Hughes Medical Institute			Donelson, John E/F-5795-2010; TEIXEIRA, SANTUZA MR/I-8137-2013		NIAID NIH HHS [AI24711] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI024711] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM JM, 1988, CELL, V55, P267, DOI 10.1016/0092-8674(88)90049-9; ANDREWS NW, 1987, EXP PARASITOL, V64, P474, DOI 10.1016/0014-4894(87)90062-2; BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BENNE R, 1986, CELL, V46, P189; BENNE R, 1985, ACHIEVEMENTS PERSPEC, V2, P325; BHAT GJ, 1992, MOL BIOCHEM PARASIT, V52, P231, DOI 10.1016/0166-6851(92)90055-O; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; DECARVALHO TU, 1983, Z PARASITENKD, V69, P571; DECKER CJ, 1990, CELL, V61, P1001, DOI 10.1016/0092-8674(90)90065-M; DELACRUZ VF, 1984, J BIOL CHEM, V259, P5136; ENGMAN DM, 1987, MOL BIOCHEM PARASIT, V22, P115, DOI 10.1016/0166-6851(87)90041-7; FEAGIN JE, 1985, NUCLEIC ACIDS RES, V13, P4577, DOI 10.1093/nar/13.12.4577; FEAGIN JE, 1985, P NATL ACAD SCI USA, V82, P3380, DOI 10.1073/pnas.82.10.3380; FEAGIN JE, 1986, MOL BIOCHEM PARASIT, V20, P207, DOI 10.1016/0166-6851(86)90100-3; Fourney R.M., 1988, FOCUS, V10, P5; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HENSGENS LAM, 1984, NUCLEIC ACIDS RES, V12, P7327, DOI 10.1093/nar/12.19.7327; KIRCHHOFF LV, 1984, J IMMUNOL, V133, P2731; KIRCHHOFF LV, 1988, J BIOL CHEM, V263, P12698; Maniatis T., 1982, MOL CLONING; PIZZI T, 1957, THESIS U CHILE SANTI; POLLARD VW, 1990, CELL, V63, P783, DOI 10.1016/0092-8674(90)90144-4; SHAW JM, 1988, CELL, V53, P401, DOI 10.1016/0092-8674(88)90160-2; SILVA LHP, 1953, FOLIA CLIN BIOL, V20, P197; SIMPSON L, 1986, INT REV CYTOL, V99, P119; STUART K, 1991, TRENDS BIOCHEM SCI, V16, P68, DOI 10.1016/0968-0004(91)90027-S; STURM NR, 1990, CELL, V61, P879, DOI 10.1016/0092-8674(90)90198-N; VANDERSPEK H, 1988, EMBO J, V7, P2509, DOI 10.1002/j.1460-2075.1988.tb03098.x; VILLALTA F, 1982, J PROTOZOOL, V29, P570, DOI 10.1111/j.1550-7408.1982.tb01338.x; WILLIAMS DM, 1976, J INFECT DIS, V134, P610, DOI 10.1093/infdis/134.6.610; WOODY NC, 1955, JAMA-J AM MED ASSOC, V159, P676, DOI 10.1001/jama.1955.02960240042010a	33	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1206	1211						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288582				2022-12-27	WOS:A1994MR22000069
J	YAMAGUCHI, N; HATTORI, K; OHEDA, M; KOJIMA, T; IMAI, N; OCHI, N				YAMAGUCHI, N; HATTORI, K; OHEDA, M; KOJIMA, T; IMAI, N; OCHI, N			A NOVEL CYTOKINE EXHIBITING MEGAKARYOCYTE POTENTIATING ACTIVITY FROM A HUMAN PANCREATIC TUMOR-CELL LINE HPC-Y5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CHEMICALLY DEFINED MEDIUM; COLONY FORMATION; SERUM-FREE; INVITRO; INTERLEUKIN-11; GROWTH	Sixty-four kinds of cell lines were examined for their ability to produce megakaryocyte potentiating activity by means of conditioned media obtained from a protein-free culture system. Six human tumor cell lines were shown to produce this activity, and the cell line HPC-Y5, established from human pancreatic cancer, was shown to have the highest level of activity. The megakaryocyte potentiating factor (MPF) was purified from an HPC-Y5 conditioned medium by a combination of ion-exchange chromatography, gel filtration and reverse-phase HPLC. The purified MPF showed a megakaryocyte potentiating activity almost equal to human interleukin-6 in the presence of murine interleukin-3 in a colony formation assay with mouse bone marrow cells. The apparent molecular weight of MPF is 32,000 when determined by SDS-polyacrylamide gel electrophoresis. Glycopeptidase F digestion, and amino sugar analysis of the factor demonstrated that MPF is a glycoprotein carrying at least one N-linked sugar chain. The N-terminal amino acid sequence of MPF was determined to be Leu-Ala-Gly-Glu-Thr-Gly-Gln-Glu-Ala-Ala-Pro-Leu-Asp-Gly-Val-Leu-Ala-Asn. The same or homologous amino acid sequence has not been found in known proteins, demonstrating that MPF is a novel cytokine that has megakaryocyte potentiating activity in the murine assay system.	CHUGAI PHARMACEUT CO LTD,FUJI GOTEMBA RES LABS,KOMAKADO 1-135,GOTEMBA,SHIZUOKA 412,JAPAN; KYOTO PREFECTURAL UNIV MED,NEUROL DIS & GERIATR RES INST,DEPT CELL BIOL,KYOTO 602,JAPAN	Chugai Pharmaceutical Co., Ltd.; Roche Holding; Kyoto Prefectural University of Medicine								GORDON MS, 1992, BLOOD, V80, P302; HASEGAWA M, 1992, EUR J BIOCHEM, V210, P9, DOI 10.1111/j.1432-1033.1992.tb17384.x; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; HIRANO T, 1989, PEPTIDE GROWTH FACTO, P633; IKEBUCHI K, 1987, P NATL ACAD SCI USA, V84, P9035, DOI 10.1073/pnas.84.24.9035; IMAI N, 1990, J BIOCHEM, V107, P352, DOI 10.1093/oxfordjournals.jbchem.a123050; ISHIBASHI T, 1989, P NATL ACAD SCI USA, V86, P5953, DOI 10.1073/pnas.86.15.5953; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; METCALF D, 1991, BLOOD, V77, P2150; METCALF D, 1975, P NATL ACAD SCI USA, V72, P1744, DOI 10.1073/pnas.72.5.1744; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; QUESENBERRY PJ, 1985, BLOOD, V65, P214; ROBINSON BE, 1987, J CLIN INVEST, V79, P1648, DOI 10.1172/JCI113002; TAYRIEN G, 1987, J BIOL CHEM, V262, P3262; TERAMURA M, 1992, BLOOD, V79, P327; TURNER KJ, 1991, BLOOD, V78, pA279; VANDAMME J, 1989, ANN NY ACAD SCI, V557, P104; WILLIAMS N, 1981, BLOOD, V57, P157; WILLIAMS N, 1982, J CELL PHYSIOL, V110, P101, DOI 10.1002/jcp.1041100116; YAMAGUCHI N, 1986, CANCER RES, V46, P5353; YAMAGUCHI N, 1990, CANCER RES, V50, P7008; YAMAGUCHI N, 1990, CANCER RES, V50, P658	22	80	167	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					805	808						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288629				2022-12-27	WOS:A1994MR22000006
J	AUSONI, S; CAMPIONE, M; PICARD, A; MORETTI, P; VITADELLO, M; DENARDI, C; SCHIAFFINO, S				AUSONI, S; CAMPIONE, M; PICARD, A; MORETTI, P; VITADELLO, M; DENARDI, C; SCHIAFFINO, S			STRUCTURE AND REGULATION OF THE MOUSE CARDIAC TROPONIN-I GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHITE SKELETAL-MUSCLE; RAT MYOCARDIAL-CELLS; AMINO-ACID SEQUENCE; HEAVY-CHAIN GENE; MESSENGER-RNA; CDNA CLONE; DEVELOPMENTAL EXPRESSION; BIOLOGICAL-ACTIVITY; MAMMALIAN-CELLS; ALPHA-ACTIN	The gene coding for mouse cardiac troponin I (TnI) has been cloned and sequenced. The cardiac TnI gene contains 8 exons and has an exon-intron organization similar to the quail fast skeletal TnI gene except for the region of exons 1-3, which is highly divergent. Comparative analysis suggests that cardiac TnI exon 1 corresponds to fast TnI exons 1 and 2 and that cardiac exon 3, which codes for most of the cardiac-specific amino-terminal extension and has no counterpart in the fast gene, evolved by exon insertion/deletion. The amino acid sequence of cardiac TnI exon 4 shows limited homology (36% identity) with fast TnI exon 4 but is remarkably similar (79% identity) to the corresponding sequence of slow TnI, possibly reflecting an isoform-specific TnC-binding site. The cardiac TnI gene is one of the very few contractile protein genes expressed exclusively in cardiac muscle. To identify the regulatory sequences responsible for the cardiac-specific expression of this gene we transfected cultured cardiac and skeletal muscle cells with fragments up to 4.0 kilobases of the 5'-flanking region linked to a reporter gene. Deletion analysis reveals four major regions in the 5'-flanking sequence, a minimal promoter region, which directs expression at low level in cardiac and skeletal muscle cells, and two upstream cardiac-specific positive regions separated by a negative region.	UNIV PADUA,DEPT BIOMED SCI,VIA TRIESTE 75,I-35121 PADUA,ITALY; UNIV PADUA,CNR,MUSCLE BIOL & PHYSIOPATHOL UNIT,I-35121 PADUA,ITALY	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua			Campione, Marina/G-9001-2013	CAMPIONE, MARINA/0000-0003-0582-5303; Schiaffino, Stefano/0000-0002-5607-6421	Telethon [A.012] Funding Source: Medline	Telethon(Fondazione Telethon)		AUSONI S, 1991, DEVELOPMENT, V112, P1041; BALDWIN AS, 1985, P NATL ACAD SCI USA, V82, P8080, DOI 10.1073/pnas.82.23.8080; BARBAS JA, 1991, GENE DEV, V5, P132, DOI 10.1101/gad.5.1.132; BEALL CJ, 1991, J CELL BIOL, V114, P941, DOI 10.1083/jcb.114.5.941; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE HA, 1975, BIOCHEM J, V149, P525, DOI 10.1042/bj1490525; DAUBAS P, 1985, NUCLEIC ACIDS RES, V13, P4623, DOI 10.1093/nar/13.13.4623; Ebashi S, 1968, Prog Biophys Mol Biol, V18, P123, DOI 10.1016/0079-6107(68)90023-0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLINK IL, 1992, J BIOL CHEM, V267, P9917; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORZA L, 1993, DEV BIOL, V156, P253, DOI 10.1006/dbio.1993.1074; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GRAND RJA, 1982, BIOCHEM J, V203, P61, DOI 10.1042/bj2030061; HASTINGS KEM, 1991, J BIOL CHEM, V266, P19659; IANNELLO RC, 1991, J BIOL CHEM, V266, P3309; KOBAYASHI T, 1989, J BIOL CHEM, V264, P1551; KOPPE RI, 1989, J BIOL CHEM, V264, P14327; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; MABLY JD, 1993, J BIOL CHEM, V268, P476; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MOIR AJG, 1977, BIOCHEM J, V161, P371, DOI 10.1042/bj1610371; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P2602; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; NGAI SM, 1992, J BIOL CHEM, V267, P15715; NIKOVITS W, 1986, NUCLEIC ACIDS RES, V14, P3377, DOI 10.1093/nar/14.8.3377; ORDAHL CP, 1992, CURR TOP DEV BIOL, V26, P145, DOI 10.1016/S0070-2153(08)60444-5; PARMACEK MS, 1992, MOL CELL BIOL, V12, P1967, DOI 10.1128/MCB.12.5.1967; PERRY SV, 1986, MYOLOGY, P613; QASBA P, 1992, MOL CELL BIOL, V12, P1107, DOI 10.1128/MCB.12.3.1107; RUOQIANSHEN SK, 1991, MOL CELL BIOL, V11, P1676; SAGGIN L, 1989, J BIOL CHEM, V264, P16299; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SCHIAFFINO S, 1993, TRENDS CARDIOVAS MED, V3, P12, DOI 10.1016/1050-1738(93)90022-X; SEN A, 1988, J CLIN INVEST, V82, P1333, DOI 10.1172/JCI113735; SHENG ZL, 1992, J BIOL CHEM, V267, P25407; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; WILKINSON JM, 1978, NATURE, V271, P31, DOI 10.1038/271031a0; WINEGRAD S, 1990, P NATL ACAD SCI USA, V87, P2456, DOI 10.1073/pnas.87.7.2456; YUTZEY KE, 1989, MOL CELL BIOL, V9, P1397, DOI 10.1128/MCB.9.4.1397; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273	49	52	56	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					339	346						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276817				2022-12-27	WOS:A1994MR21900058
J	BRAXTON, BL; TLAPALSIMMONS, VL; REINHART, GD				BRAXTON, BL; TLAPALSIMMONS, VL; REINHART, GD			TEMPERATURE-INDUCED INVERSION OF ALLOSTERIC PHENOMENA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CARBAMYL-PHOSPHATE SYNTHETASE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; PHOSPHOFRUCTOKINASE; PARAMETERS; BINDING	Two instances, involving the enzymes carbamoyl-phosphate synthetase from Escherichia coli and phosphofructokinase from Bacillus stearothermophilus, respectively, are described in which increasing temperature alone causes the actions of an allosteric ligand to change from inhibition to activation. In neither case are these effects due to a change in the activation energy of the enzyme catalyzed reaction induced by the allosteric ligand. Rather, they are due to temperature-dependent changes in the extent to which the binding of allosteric ligand modifies the affinity of the enzyme for substrate. The data can be readily explained by an analysis of the apparent DELTAH and DELTAS components of the coupling free energy, which quantitatively describe the actions of allosteric ligands that act in this manner. These observations underscore the shortcomings of expecting to explain the actions of an allosteric ligand solely by the structural perturbations that accompany the binding of an allosteric ligand such as those often revealed by x-ray crystallography.	UNIV OKLAHOMA,DEPT CHEM & BIOCHEM,NORMAN,OK 73019	University of Oklahoma System; University of Oklahoma - Norman					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033216] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 33216] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3157, DOI 10.1021/bi00874a012; ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3164, DOI 10.1021/bi00874a013; ANDERSON PM, 1968, BIOCHEM BIOPH RES CO, V32, P928, DOI 10.1016/0006-291X(68)90116-2; BOETTCHER B, 1982, J BIOL CHEM, V257, P3971; Boyer, 1970, ENZYMES, P341, DOI DOI 10.1016/S1874-6047(08)60170-5; BRAXTON BL, 1992, BIOCHEMISTRY-US, V31, P2309, DOI 10.1021/bi00123a015; EVANS PR, 1979, NATURE, V279, P500, DOI 10.1038/279500a0; EVANS PR, 1981, PHILOS T ROY SOC B, V293, P53, DOI 10.1098/rstb.1981.0059; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; MEISTER A, 1978, ADV ENZYME REGUL, V16, P289; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MULLINS LS, 1991, J BIOL CHEM, V266, P8236; REINHART GD, 1989, P NATL ACAD SCI USA, V86, P4032, DOI 10.1073/pnas.86.11.4032; REINHART GD, 1983, ARCH BIOCHEM BIOPHYS, V224, P389, DOI 10.1016/0003-9861(83)90225-4; RYPNIEWSKI WR, 1989, J MOL BIOL, V207, P805, DOI 10.1016/0022-2836(89)90246-5; SCHIRMER T, 1990, NATURE, V343, P140, DOI 10.1038/343140a0; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; SYMCOX MM, 1992, ANAL BIOCHEM, V206, P394, DOI 10.1016/0003-2697(92)90384-J; Weber G, 1975, Adv Protein Chem, V29, P1, DOI 10.1016/S0065-3233(08)60410-6; WEBER G, 1972, BIOCHEMISTRY-US, V11, P864, DOI 10.1021/bi00755a028; 1992, REGULATION PROTEINS, V36	21	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					47	50						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276837				2022-12-27	WOS:A1994MR21900013
J	HSIEH, ML; TINTUT, Y; GRALLA, JD				HSIEH, ML; TINTUT, Y; GRALLA, JD			FUNCTIONAL ROLES FOR THE GLUTAMINES WITHIN THE GLUTAMINE-RICH REGION OF THE TRANSCRIPTION FACTOR-SIGMA-54	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MESSENGER-RNA; PROMOTER DNA; ACTIVATION; BINDING; DOMAINS; GLNA; INVIVO; EXPRESSION; PROTEIN	Single and multiple point mutations were introduced to change the 12 glutamine residues within a 37-amino acid region of sigma54. Multiple changes are shown to be required in order to interfere significantly with the function of this protein which is associated with enhancer-dependent bacterial transcription. Mutation of the central 4 glutamines leads to the production of less m-RNA, caused by an inability to fully open the promoter start site. DNA binding, however, is normal. Mutation of 4 other adjacent glutamines causes the promoter start site to open more readily than wild type, although this enhanced opening is not accompanied by more mRNA. The emhanced DNA melting is not caused by enhanced promoter binding, as indicated by normal protection of the polymerase-bound promoter against dimethyl sulfate attack. The results suggest that multiple glutamines play a role in transducing the melting signal from the enhancer protein to the polymerase.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			Demer, Linda L/I-5770-2013	Demer, Linda L/0000-0002-9618-6895	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007185, R01GM035754] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 07185, GM 35754] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACKMAN K, 1981, P NATL ACAD SCI-BIOL, V78, P3743, DOI 10.1073/pnas.78.6.3743; BAGA M, 1988, CELL, V52, P197, DOI 10.1016/0092-8674(88)90508-9; BIRKMANN A, 1989, MOL MICROBIOL, V3, P187, DOI 10.1111/j.1365-2958.1989.tb01807.x; BUCK M, 1992, NATURE, V358, P422, DOI 10.1038/358422a0; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DYNLACHT BD, 1989, GENE DEV, V3, P1677, DOI 10.1101/gad.3.11.1677; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GRALLA JD, 1991, CELL, V66, P415, DOI 10.1016/0092-8674(81)90001-5; HIRSCHMAN J, 1985, P NATL ACAD SCI USA, V82, P7525, DOI 10.1073/pnas.82.22.7525; JIANG Y, 1993, J BIOL CHEM, V268, P6535; KNAUS R, 1988, EMBO J, V7, P2919, DOI 10.1002/j.1460-2075.1988.tb03150.x; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; KUSTU S, 1991, TRENDS BIOCHEM SCI, V16, P397, DOI 10.1016/0968-0004(91)90163-P; MAGASANIK B, 1988, TRENDS BIOCHEM SCI, V13, P475, DOI 10.1016/0968-0004(88)90234-4; MAITY SN, 1990, P NATL ACAD SCI USA, V87, P5378, DOI 10.1073/pnas.87.14.5378; MORETT E, 1988, P NATL ACAD SCI USA, V85, P9401, DOI 10.1073/pnas.85.24.9401; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; REITZER LJ, 1985, P NATL ACAD SCI USA, V82, P1979, DOI 10.1073/pnas.82.7.1979; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; SASSEDWIGHT S, 1990, CELL, V62, P945, DOI 10.1016/0092-8674(90)90269-K; SASSEDWIGHT S, 1991, METHOD ENZYMOL, V208, P146; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SMITH GR, 1971, J BIOL CHEM, V246, P3320; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; VONGABAIN A, 1983, P NATL ACAD SCI-BIOL, V80, P653; WONG CN, 1992, J BIOL CHEM, V267, P24762	30	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					373	378						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276822				2022-12-27	WOS:A1994MR21900063
J	RONCO, LV; SILVERMAN, SL; WONG, SG; SLAMON, DJ; PARK, LS; GASSON, JC				RONCO, LV; SILVERMAN, SL; WONG, SG; SLAMON, DJ; PARK, LS; GASSON, JC			IDENTIFICATION OF CONSERVED AMINO-ACIDS IN THE HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR RECEPTOR-ALPHA SUBUNIT CRITICAL FOR FUNCTION - EVIDENCE FOR FORMATION OF A HETERODIMERIC RECEPTOR COMPLEX PRIOR TO LIGAND-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; AFFINITY INTERLEUKIN-5 RECEPTOR; HUMAN MYELOID CELLS; GM-CSF RECEPTORS; SIGNAL TRANSDUCTION; BETA-CHAIN; TYROSINE PHOSPHORYLATION; EXTRACELLULAR DOMAIN; CYTOPLASMIC REGION; EXPRESSION CLONING	A superfamily of growth factor and cytokine receptors has recently been identified, which is characterized by four spatially conserved cysteine residues, a tryptophan-serine motif (WSXWS) in the extracellular domain, and a proline-rich cytoplasmic domain. The high affinity human granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor (hGM-CSFR) consists of two subunits, alpha (hGM-CSFRalpha) and beta (hGM-CSFRbeta), both of which are members of the receptor superfamily. In this study, we prepared mutations in conserved amino acids of the receptor subunit necessary for GM-CSF binding (hGM-CSFRalpha) and analyzed mutant receptors for low affinity binding, internalization, and high affinity binding when complexed with the beta subunit. Mutations in the cytoplasmic domain did not affect GM-CSF binding or receptor internalization. Mutation of a single conserved serine residue within the WSXWS motif diminishes cell surface receptor expression but not ligand binding. Mutation of either the second or third conserved cysteine residue of hGM-CSFRalpha resulted in complete loss of low affinity binding; however, co-expression of the cysteine 2 mutant with hGM-CSFRbeta yielded a high affinity receptor complex. Since neither the cysteine 2 mutant nor the beta subunit can bind ligand alone, this result suggests that hGM-CSFRalpha and hGM-CSFRbeta exist in a preformed heterodimeric protein complex on the plasma membrane.	UNIV CALIF LOS ANGELES, SCH MED, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, DIV HEMATOL ONCOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, JONSSON COMPREHENS CANC CTR, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	RONCO, LV (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA.				NCI NIH HHS [CA09120, R01 CA40163] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040163] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALDWIN GC, 1991, BLOOD, V78, P609, DOI 10.1182/blood.V78.3.609.bloodjournal783609; BALDWIN GC, 1989, BLOOD, V73, P1033; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; CHIBA S, 1990, LEUKEMIA, V4, P29; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; DIPERSIO J, 1988, J BIOL CHEM, V263, P1834; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GASSON JC, 1986, P NATL ACAD SCI USA, V83, P669, DOI 10.1073/pnas.83.3.669; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; HARA T, 1992, EMBO J, V11, P1875, DOI 10.1002/j.1460-2075.1992.tb05239.x; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P299, DOI 10.1042/bj1130299; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OKUDA K, 1991, BLOOD, V78, P1928; QUELLE DE, 1991, P NATL ACAD SCI USA, V88, P4801, DOI 10.1073/pnas.88.11.4801; QUELLE DE, 1992, MOL CELL BIOL, V12, P4553, DOI 10.1128/MCB.12.10.4553; ROZAKISADCOCK M, 1991, J BIOL CHEM, V266, P16472; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHANAFELT AB, 1992, J BIOL CHEM, V267, P25466; TAKAKI S, 1991, EMBO J, V10, P2833, DOI 10.1002/j.1460-2075.1991.tb07832.x; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; YOSHIMURA A, 1992, J BIOL CHEM, V267, P11619; ZON LI, 1992, MOL CELL BIOL, V12, P2949, DOI 10.1128/MCB.12.7.2949	36	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					277	283						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276807				2022-12-27	WOS:A1994MR21900050
J	ZHONG, ZY; HIGAKI, J; MURAKAMI, K; WANG, Y; CATALANO, R; QUON, D; CORDELL, B				ZHONG, ZY; HIGAKI, J; MURAKAMI, K; WANG, Y; CATALANO, R; QUON, D; CORDELL, B			SECRETION OF BETA-AMYLOID PRECURSOR PROTEIN INVOLVES MULTIPLE CLEAVAGE SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; SOLUBLE DERIVATIVES; TERMINAL FRAGMENTS; IDENTIFICATION; CELLS; BRAIN; BIOGENESIS; PEPTIDE	A major histopathological feature of Alzheimer's disease is deposits of a approximately 4-kDa beta-amyloid peptide derived by proteolytic processing from a precursor, the beta-amyloid precursor protein (beta-APP). Proteolytic cleavage of beta-APP within the approximately 4-kDa beta-amyloid domain permits the secretion of the amino-terminal portion of beta-APP while concomitantly producing a membrane bound approximately 9-kDa carboxyl-terminal fragment. We have characterized the proteolytic cleavage site for beta-APP secretion by amino acid sequence analysis of the approximately 9-kDa beta-APP carboxyl-terminal cleavage product produced by recombinant and native expression systems. Recombinant beta-APP was generated by a vaccinia virus expression system in CV-1 monkey fibroblasts; endogenous beta-APP was obtained using a fibroblast line derived from an individual with Down's syndrome. The sequences of both unlabeled and metabolically radiolabeled approximately 9-kDa fragment from CV-1 cells reveal that the major (60%) secretory cleavage site is after Lys16 of the beta-amyloid domain as reported previously; however, an additional cleavage site is seen after Phe19 (40%). Radiosequence analysis of the carboxyl-terminal fragment purified from Down's syndrome fibroblasts indicates cleavage sites after Phe19, Glu22, and Gly25 and not after Lys16. CV-1 cells expressing beta-APP mutants lacking 4 and 6 amino acids adjacent to Lys16 yielded approximately 9-kDa fragments with two identical cleavage sites, neither of which occurred after the retained Lys16 but were after Glu11 and His13. These data suggest that secretion of 6-APP involves multiple proteinases and that the composition of these proteinases may vary within different cell backgrounds.	SCIOS NOVA INC,2450 BAYSHORE PKWY,MT VIEW,CA 94043	Scios								ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GABUZDA D, 1991, J ACQ IMMUN DEF SYND, V4, P34; GANDY S, 1988, P NATL ACAD SCI USA, V85, P6218, DOI 10.1073/pnas.85.16.6218; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; LOWERY DE, 1991, J BIOL CHEM, V266, P19842; MANTLE D, 1990, J NEUROL SCI, V98, P13, DOI 10.1016/0022-510X(90)90178-P; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V179, P1670, DOI 10.1016/0006-291X(91)91767-7; MURPHY GM, 1990, PROG NEURO-PSYCHOPH, V14, P309, DOI 10.1016/0278-5846(90)90019-D; OVERLY CC, 1991, BIOCHEM BIOPH RES CO, V181, P513, DOI 10.1016/0006-291X(91)91218-2; PALMERT MR, 1989, P NATL ACAD SCI USA, V86, P6338, DOI 10.1073/pnas.86.16.6338; PASTERNACK JM, 1992, BIOCHEMISTRY-US, V31, P10936, DOI 10.1021/bi00159a038; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; RAMABHADRAN TV, 1993, J BIOL CHEM, V268, P2009; SAHASRABUDHE SR, 1992, J BIOL CHEM, V267, P25602; SAMBAMURTI K, 1992, J NEUROSCI RES, V33, P319, DOI 10.1002/jnr.490330216; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; WANG R, 1991, J BIOL CHEM, V266, P16960; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WOLF D, 1990, EMBO J, V9, P2079, DOI 10.1002/j.1460-2075.1990.tb07375.x	29	60	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					627	632						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276862				2022-12-27	WOS:A1994MR21900099
J	DAS, T; BAEK, KJ; GRAY, C; IM, MJ				DAS, T; BAEK, KJ; GRAY, C; IM, MJ			EVIDENCE THAT THE G(H) PROTEIN IS A SIGNAL MEDIATOR FROM ALPHA(1)-ADRENOCEPTOR TO A PHOSPHOLIPASE-C .2. PURIFICATION AND CHARACTERIZATION OF A G(H)-COUPLED 69-KDA PHOSPHOLIPASE-C AND RECONSTITUTION OF ALPHA(1)-ADRENOCEPTOR, G(H) FAMILY, AND PHOSPHOLIPASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; LIVER PLASMA-MEMBRANES; BOVINE BRAIN; ALPHA-1-ADRENERGIC RECEPTOR; RAT-LIVER; GUANINE-NUCLEOTIDE; ALPHA-SUBUNITS; KINASE-C; ACTIVATION; BINDING	Our studies on the alpha1-adrenoceptor signaling have demonstrated that the G(h) family is a signal mediator. We report here that a 69-kDa phospholipase C (PLC) is the effector in this signal pathway. The enzyme was isolated by dissociating a G(h7)-PLC complex which was induced in the bovine liver membranes incubating with (-)-epinephrine and GTP. The enzyme displayed a marked preference hydrolysis for phosphatidylinositol 4,5-bisphosphate over other phosphatidylinositides at micromolar calcium. Reconstitution of PLC with the alpha1-adrenoceptor and G(h) (G(h7)) into phospholipid vesicles resulted in a lowered Ca2+ requirement for the substrate hydrolysis in the presence of guanosine 5'-3-O-(thio)triphosphate (GTPgammaS) when the receptor was activated with the alpha1-agonist. The formation of inositol phosphate was hormone concentration dependent and reached maximal within 3 min which was faster than the formation in the presence of the alpha1-antagonist. An G(h7alpha) antibody co-immunoprecipitated 80-85% of phospholipase C activity in the presence of GTPgammaS, but not in the presence of GDP or buffer, showing the association of PLC with the alpha-subunit of G(h) family. Thus, our novel approaches to identify the effector involved in the alpha1-adrenoceptor signaling, as well as the reconstitution studies, substantially demonstrate that the alpha1-adrenoceptor-mediated transmembrane signaling involves the G(h) family and a 69-kDa PLC.	CLEVELAND CLIN FDN,RES INST,DEPT CARDIOVASC BIOL,FFB1 37,9500 EUCLID AVE,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NIGMS NIH HHS [GM45985] Funding Source: Medline; NINDS NIH HHS [NS19583] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019583] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAEHR W, 1982, J BIOL CHEM, V257, P6452; BAEK KJ, 1993, J BIOL CHEM, V268, P27390; BENNETT CF, 1987, J BIOL CHEM, V262, P13789; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; FEDER D, 1986, EMBO J, V5, P1509, DOI 10.1002/j.1460-2075.1986.tb04390.x; GONZALES RA, 1985, BIOCHEM J, V232, P799, DOI 10.1042/bj2320799; HO AK, 1987, J BIOL CHEM, V262, P11764; HOMMA Y, 1988, J BIOL CHEM, V263, P6592; IM MJ, 1990, J BIOL CHEM, V265, P18952; IM MJ, 1990, J BIOL CHEM, V265, P18944; IM MJ, 1992, J BIOL CHEM, V267, P8887; KATAN M, 1987, EUR J BIOCHEM, V168, P413, DOI 10.1111/j.1432-1033.1987.tb13435.x; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LLAHI S, 1992, J BIOL CHEM, V267, P3679; MARTIN KL, 1992, BIOCHEM BIOPH RES CO, V178, P679; MAY DC, 1988, BIOCHEMISTRY-US, V27, P4888, DOI 10.1021/bi00413a045; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P49, DOI 10.1016/0167-4889(91)90177-Y; MINNEMAN KP, 1988, PHARMACOL REV, V40, P87; NAKANISHI O, 1988, BIOCHEM J, V256, P453, DOI 10.1042/bj2560453; PITTNER RA, 1991, BIOCHEM J, V277, P371, DOI 10.1042/bj2770371; PRPIC V, 1984, J BIOL CHEM, V259, P1382; RANSNAS LA, 1992, BIOCHEM J, V283, P519, DOI 10.1042/bj2830519; REBECCHI MJ, 1987, J BIOL CHEM, V262, P12526; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; RYU SH, 1987, J BIOL CHEM, V262, P12511; RYU SH, 1986, BIOCHEM BIOPH RES CO, V141, P137, DOI 10.1016/S0006-291X(86)80345-X; SAWUTZ DG, 1987, MOL PHARMACOL, V32, P565; SCHWINN DA, 1991, MOL PHARMACOL, V40, P619; SUH PG, 1988, J BIOL CHEM, V263, P14497; TAKENAWA T, 1981, J BIOL CHEM, V256, P6769; TAYLOR GD, 1992, BIOCHEM BIOPH RES CO, V188, P1176, DOI 10.1016/0006-291X(92)91355-T; TAYLOR SJ, 1987, BIOCHEM J, V248, P791, DOI 10.1042/bj2480791; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THOMAS GMH, 1991, EMBO J, V10, P2507, DOI 10.1002/j.1460-2075.1991.tb07790.x; UHING RJ, 1986, J BIOL CHEM, V261, P2140; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WILSON KM, 1990, J BIOL CHEM, V265, P17601; WU DQ, 1992, J BIOL CHEM, V267, P25798; WU DQ, 1992, J BIOL CHEM, V267, P1811	41	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27398	27405						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262981				2022-12-27	WOS:A1993MM26200080
J	KARCHER, U; SCHRODER, H; HASLINGER, E; ALLMAIER, G; SCHREINER, R; WIELAND, F; HASELBECK, A; KONIG, H				KARCHER, U; SCHRODER, H; HASLINGER, E; ALLMAIER, G; SCHREINER, R; WIELAND, F; HASELBECK, A; KONIG, H			PRIMARY STRUCTURE OF THE HETEROSACCHARIDE OF THE SURFACE GLYCOPROTEIN OF METHANOTHERMUS-FERVIDUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAYER GLYCOPROTEINS; NMR-SPECTROSCOPY; SENSITIVITY; GLYCOSYLATION; METHANOGENS; OLIGOSACCHARIDES; BIOSYNTHESIS; PROTEINS; GLYCANS	The outer surface of the cells of the hyperthermophile Methanothermus fervidus is covered by crystalline glycoprotein subunits (S-layer). From the purified S-layer glycoprotein, a heterosaccharide was isolated. The heterosaccharide consists of D-3-O-methylmannose, D-mannose, and D-N-acetylgalactosamine in a molar ratio of 2:3:1 corresponding to a relative molecular mass of 1061.83 Da. 3-O-methylmannose could be partly replaced by 3-O-methylglucose. The primary structure of the glycan was revealed by methylation analysis, by plasma desorption mass spectrometry, and by high field NMR spectroscopy. The purified heterosaccharide is linked via N-acetylgalactosamine to an asparagine residue of the peptide moiety. The following structure is proposed for the heterosaccharide: alpha-D-3-O-MetManp-(1 --> 6)-alpha-D-3-O-MetManp-((1 --> 2)-alpha-D-Manp)3-(1 --> 4)-D-GalNAc.	UNIV ULM,ANGEW MIKROBIOL & MYKOL ABT,D-89069 ULM,GERMANY; BOEHRINGER MANNHEIM GMBH,D-82372 PENZBERG,GERMANY; UNIV ULM,ORGAN CHEM ABT 1,D-89069 ULM,GERMANY; UNIV VIENNA,INST ANALYT CHEM,A-1090 VIENNA,AUSTRIA; INST BIOCHEM 1,D-69120 HEIDELBERG,GERMANY	Ulm University; Ulm University; University of Vienna			Allmaier, Guenter/F-2604-2012					ALBERSHEIM PETER, 1967, CARBOHYD RES, V5, P340, DOI 10.1016/S0008-6215(00)80510-8; BALCH WE, 1979, MICROBIOL REV, V43, P260, DOI 10.1128/MMBR.43.2.260-296.1979; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BAX A, 1986, J MAGN RESON, V67, P565, DOI 10.1016/0022-2364(86)90395-1; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; Bergmeyer HU, 1974, METHODEN ENZYMATISCH; BOCK K, 1975, ACTA CHEM SCAND B, VB 29, P258, DOI 10.3891/acta.chem.scand.29b-0181; BROCKL G, 1991, EUR J BIOCHEM, V199, P147, DOI 10.1111/j.1432-1033.1991.tb16102.x; FAGUY DM, 1992, FEMS MICROBIOL LETT, V90, P129, DOI 10.1016/0378-1097(92)90616-V; GERWIG GJ, 1991, EUR J BIOCHEM, V196, P115, DOI 10.1111/j.1432-1033.1991.tb15793.x; HARTMANN E, 1989, ARCH MICROBIOL, V151, P274, DOI 10.1007/BF00413142; HASSID WZ, 1957, METHOD ENZYMOL, V3, P34, DOI 10.1016/S0076-6879(57)03345-5; HOFFMAN J, 1972, ACTA CHEM SCAND, V26, P661, DOI 10.3891/acta.chem.scand.26-0661; Horton D., 1969, AMINO SUGARS       A, VI, P1; Hough L., 1963, METHODS CARBOHYDRATE, V2, P203; Jansson P-E., 1976, CHEM COMMUN U STOCKH, V8, P1; KANDLER O, 1993, BIOCH ARCHAEA; KAWAMURA T, 1983, J BIOL CHEM, V258, P9514; KESSLER H, 1989, J MAGN RESON, V85, P1, DOI 10.1016/0022-2364(89)90314-4; KONIG H, 1980, H-S Z PHYSIOL CHEM, V361, P981; LECHNER J, 1989, ANNU REV BIOCHEM, V58, P173, DOI 10.1146/annurev.bi.58.070189.001133; Lennarz W.J., 1980, BIOCH GLYCOPROTEINS; LERNER L, 1986, J MAGN RESON, V69, P375, DOI 10.1016/0022-2364(86)90091-0; LIKHOSHERSTOV LM, 1990, CARBOHYD RES, V199, P67, DOI 10.1016/0008-6215(90)84093-A; Lindberg B., 1975, ADV CARBOHYD CHEM BI, V31, P185, DOI [10.1016/s0065-2318(08)60297-8, DOI 10.1016/S0065-2318(08)60297-8]; MENGELE R, 1992, J BIOL CHEM, V267, P8182; MESSNER P, 1992, ADV MICROB PHYSIOL, V33, P213, DOI 10.1016/S0065-2911(08)60218-0; Montreuil J, 1986, CARBOHYDRATE ANAL PR, P143; NIELSEN PF, 1988, BIOMED ENVIRON MASS, V17, P355, DOI 10.1002/bms.1200170503; NUSSER E, 1988, CRYSTALLINE BACTERIA, P21; OLDEN K, 1985, TRENDS BIOCHEM SCI, V10, P78, DOI 10.1016/0968-0004(85)90238-5; PARENTE JP, 1985, CARBOHYD RES, V141, P41, DOI 10.1016/S0008-6215(00)90753-5; PAUL G, 1986, J BIOL CHEM, V261, P1020; STETTER KO, 1981, ZBL BAKT MIK HYG I C, V2, P166, DOI 10.1016/S0721-9571(81)80038-5; SUMPER M, 1990, J BACTERIOL, V172, P7111, DOI 10.1128/jb.172.12.7111-7118.1990; Takasaki S, 1978, Methods Enzymol, V50, P50; TIPPER DJ, 1968, BIOCHEMISTRY-US, V7, P1441, DOI 10.1021/bi00844a029; WIELAND F, 1985, J BIOL CHEM, V260, P5180; WIELAND F, 1982, ZBL BAKT MIK HYG I C, V3, P161, DOI 10.1016/S0721-9571(82)80064-1	40	58	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26821	26826						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262914				2022-12-27	WOS:A1993MM26200003
J	STOLZ, B; HUBER, M; MARKOVICHOUSLEY, Z; ERNI, B				STOLZ, B; HUBER, M; MARKOVICHOUSLEY, Z; ERNI, B			THE MANNOSE TRANSPORTER OF ESCHERICHIA-COLI - STRUCTURE AND FUNCTION OF THE IIAB(MAN)-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE PHOSPHOTRANSFERASE SYSTEM; SIGNAL-TRANSDUCING PROTEIN; PHOSPHORYLATING SUBUNIT; PHOSPHOCARRIER PROTEIN; ENZYME-III; PERMEASE; EXPRESSION; OPERON; PHOSPHOENOLPYRUVATE; PURIFICATION	The mannose transporter of the bacterial phosphotransferase system consists of two transmembrane subunits (IIC(Man) and IID(Man)) and a hydrophilic subunit (IIAB(Man)). IIAB(Man) has two flexibly linked domains containing one phosphorylation site each and occurs as a dimer. Substrate transport is coupled to phosphorylation. The phosphoryl group is transferred from a phosphoryl carrier protein to His10 on IIA, hence to His175 on IIB and finally to the substrate. IIAB(Man) mutants were analyzed in vitro for complementation, negative dominance, cysteine cross-linking and reactivity. Conclusions: (i) His10, Trp12, Lys48, and Ser72 form a functional unit (phosphorylation site 1); (ii) His86 on the IIA domain and His175 on the IIB domain of the same subunit form a functional unit (phosphorylation site 2); (iii) phosphoryl transfer can occur between His10 and His86 of the same as well as of different subunits and His86 is necessary for this transfer; (iv) the subunits in the dimer are interdependent; (v) The phosphorylation site mutant H175C is highly reactive toward thiol reagents and it forms extensive homo- and heterocross-links with other surface-exposed cysteines. The phosphorylation site mutant H10C is 1000-fold less reactive. The two residues might be in complementary locations, His10 buried in a concave, His175 exposed on a convex surface.	UNIV BERN,INST BIOCHEM,FREIESTR 3,CH-3012 BERN,SWITZERLAND	University of Bern								AMSTERCHODER O, 1989, CELL, V58, P847, DOI 10.1016/0092-8674(89)90937-9; AMSTERCHODER O, 1992, SCIENCE, V257, P540; ATKINS PW, 1982, PHYSICAL CHEM; DEMEYER R, 1992, THESIS U MARBURG; ERNI B, 1985, J BIOL CHEM, V260, P5495; ERNI B, 1992, INT REV CYTOL, V137A, P127; ERNI B, 1989, J BIOL CHEM, V264, P18733; ERNI B, 1987, J BIOL CHEM, V262, P5238; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GENOVESIOTAVERNE JC, 1990, J MOL BIOL, V216, P515, DOI 10.1016/0022-2836(90)90379-Z; HERZBERG O, 1992, J BIOL CHEM, V267, P24819; KALLIS GB, 1980, J BIOL CHEM, V255, P261; LOLKEMA JS, 1993, BIOCHEMISTRY-US, V32, P1396, DOI 10.1021/bi00057a002; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; MARTINVERSTRAETE I, 1990, J MOL BIOL, V214, P657, DOI 10.1016/0022-2836(90)90284-S; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MEINS M, 1988, J BIOL CHEM, V263, P12986; MEINS M, 1993, J BIOL CHEM, V268, P11604; PAS HH, 1988, BIOCHEMISTRY-US, V27, P5835, DOI 10.1021/bi00416a002; PELTON JG, 1991, P NATL ACAD SCI USA, V88, P3479, DOI 10.1073/pnas.88.8.3479; POSTMA PW, 1985, MICROBIOL REV, V49, P232, DOI 10.1128/MMBR.49.3.232-269.1985; PRESPER KA, 1989, P NATL ACAD SCI USA, V86, P4052, DOI 10.1073/pnas.86.11.4052; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; ROOSSIEN FF, 1983, BIOCHIM BIOPHYS ACTA, V760, P185, DOI 10.1016/0304-4165(83)90141-1; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNETZ K, 1990, P NATL ACAD SCI USA, V87, P5074, DOI 10.1073/pnas.87.13.5074; SCHOLTE BJ, 1981, EUR J BIOCHEM, P51; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; Traut R., 1989, PROTEIN FUNCTION PRA, P101; VOGLER AP, 1988, MOL GEN GENET, V213, P175, DOI 10.1007/BF00333417; VOGLER AP, 1988, MOL MICROBIOL, V2, P719, DOI 10.1111/j.1365-2958.1988.tb00082.x; WENG QP, 1992, J BIOL CHEM, V267, P19529	33	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27094	27099						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262947				2022-12-27	WOS:A1993MM26200040
J	JACOB, R; BREWER, C; FRANSEN, JAM; NAIM, HY				JACOB, R; BREWER, C; FRANSEN, JAM; NAIM, HY			TRANSPORT, FUNCTION, AND SORTING OF LACTASE-PHLORHIZIN HYDROLASE IN MADIN-DARBY CANINE KIDNEY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; INFLUENZA-VIRUS HEMAGGLUTININ; PLASMA-MEMBRANE GLYCOPROTEIN; MDCK CELLS; INTRACELLULAR-TRANSPORT; PHLORHIZIN HYDROLASE; LACTOSE-INTOLERANCE; POLARIZED DELIVERY; O-GLYCOSYLATION; APICAL SURFACE	Lactase-phlorizin hydrolase (LPH), a small intestinal brush-border glycoprotein, is synthesized as a single chain precursor (pro-LPH, M(r) = 215,000-230,000) that undergoes cleavage to the final mature form (LPHm, M(r) = 160,000 in the human). In the human and pig small intestine as well as in the colon carcinoma cell line Caco-2, this cleavage takes place intracellularly prior to insertion into the brush-border membrane. To assess the role of proteolytic cleavage on the transport, function, and sorting of LPH a stable Madin-Darby canine kidney cell line was generated which expresses LPH (denoted as MDCK-ML). Biosynthetic labeling experiments demonstrated that the transport kinetics and posttranslational processing pattern of LPH in this cell line are similar to those in intestinal cells. Moreover, the enzymatic activity was found to be indistinguishable from that of brush-border LPH (LPHm). The sorting of LPH was studied by biosynthetic labeling of cells grown on filters followed by cell surface immunoprecipitation. Here, we could demonstrate that the cleaved LPHm molecule was predominantly found at the apical membrane, whereas complex glycosylated uncleaved pro-LPH (pro-LPHc) was targeted to both domains, the apical as well as the basolateral. In pulse-chase experiments at 20-degrees-C pro-LPH was arrested in the trans-Golgi network, and cleavage to LPHm did not take place. By contrast, when the chase temperature was raised to 37-degrees-C transport of pro-LPHc resumed, and cleavage to LPHm occurred. We conclude that the proteolytic cleavage of pro-LPHc to LPHm is a post-trans-Golgi network event and is most likely not implicated in the sorting of LPH by exposition of otherwise masked sorting elements.	HEINRICH HEINE UNIV,INST MICROBIOL,PROT SECRET GRP,UNIV STR 1,D-40225 DUSSELDORF,GERMANY; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; CATHOLIC UNIV NIJMEGEN,DEPT CELL BIOL & HISTOL,6500 HB NIJMEGEN,NETHERLANDS	Heinrich Heine University Dusseldorf; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Radboud University Nijmegen			Fransen, Jack/E-8924-2010; Jacob, Ralf/B-8163-2011	Fransen, Jack/0000-0002-0571-7639; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037547] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37547] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BULLER HA, 1987, J BIOL CHEM, V262, P17206; DAHLQVIST A, 1968, ANAL BIOCHEM, V22, P99, DOI 10.1016/0003-2697(68)90263-7; DANIELSEN EM, 1984, BIOCHEM BIOPH RES CO, V122, P82; FRANSEN JAM, 1991, J CELL BIOL, V115, P45, DOI 10.1083/jcb.115.1.45; FRANSEN JAM, 1985, EUR J CELL BIOL, V38, P6; FREUND JN, 1989, FEBS LETT, V248, P39, DOI 10.1016/0014-5793(89)80427-2; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; KLUMPERMAN J, 1991, J CELL SCI, V100, P339; LEBIVIC A, 1990, J CELL BIOL, V110, P1533, DOI 10.1083/jcb.110.5.1533; LISANTI MP, 1990, TRENDS BIOCHEM SCI, V15, P113, DOI 10.1016/0968-0004(90)90195-H; LOW SH, 1991, J BIOL CHEM, V266, P13391; MATLIN KS, 1984, J CELL BIOL, V99, P2131, DOI 10.1083/jcb.99.6.2131; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MATTER K, 1989, J BIOL CHEM, V264, P13131; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MISEK DE, 1984, CELL, V39, P537, DOI 10.1016/0092-8674(84)90460-4; MONTGOMERY RK, 1991, FASEB J, V5, P2824, DOI 10.1096/fasebj.5.13.1916106; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; NAIM HY, 1988, J BIOL CHEM, V263, P7242; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; NAIM HY, 1992, J BIOL CHEM, V267, P25494; NAIM HY, 1991, J BIOL CHEM, V266, P12313; NAIM HY, 1992, BIOCHEM J, V285, P13, DOI 10.1042/bj2850013; NAIM HY, 1993, DYN NUTR R, V3, P102; POWELL SK, 1991, NATURE, V353, P76, DOI 10.1038/353076a0; QUAN R, 1990, J BIOL CHEM, V265, P15882; RICHARDSON JCW, 1981, BIOCHIM BIOPHYS ACTA, V673, P26, DOI 10.1016/0304-4165(81)90307-X; RINDLER MJ, 1985, J CELL BIOL, V100, P136, DOI 10.1083/jcb.100.1.136; RODRIGUEZBOULAN E, 1984, J CELL BIOL, V98, P308, DOI 10.1083/jcb.98.1.308; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; Sambrook J, 1989, MOL CLONING LABORATO; SEBASTIO G, 1989, AM J HUM GENET, V45, P489; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; STERCHI EE, 1990, J CLIN INVEST, V86, P1329, DOI 10.1172/JCI114842; WESSELS HP, 1990, J CELL BIOL, V111, P2923, DOI 10.1083/jcb.111.6.2923; WITTE J, 1990, J CLIN INVEST, V86, P1338, DOI 10.1172/JCI114843; YEH KY, 1991, GASTROENTEROLOGY, V101, P312, DOI 10.1016/0016-5085(91)90005-6	39	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2712	2721						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300602				2022-12-27	WOS:A1994MV43200055
J	SHUE, GL; KOHTZ, DS				SHUE, GL; KOHTZ, DS			STRUCTURAL AND FUNCTIONAL-ASPECTS OF BASIC HELIX-LOOP-HELIX PROTEIN-FOLDING BY HEAT-SHOCK PROTEIN-90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; 2 CELLULAR PROTEINS; NUCLEOTIDE-SEQUENCE; GLUCOCORTICOID RECEPTOR; DIOXIN RECEPTOR; AH-RECEPTOR; GENE; ENHANCER; CLONING; ASSOCIATION	The assembly and folding of nascent Polypeptides are mediated in vivo by molecular chaperones, many of which are members of the heat-shock family of proteins. We have shown previously that heat-shock protein 90 (HSP90) folds an inactive fraction of a recombinant basic helix-loop-helix (bHLH) protein generated in Escherichia coli (MyoD) into its active conformation. We show here that HSP90 also folds another bHLH protein (E12) and heterodimers of E12/MyoD into their active conformations. By purifying inactive heterodimers of E12/MyoD and subsequently rendering them active in binding DNA by treatment with HSP90, we show that one folding step mediated by HSP90 occurs after oligomerization of the bHLH protein monomers. A series of deletion mutants is used to identify the 48-amino acid region of HSP90 that confers bHLH folding activity, which lies near the COOH terminus. This region is required for activation of DNA binding of MyoD and E12 homodimers and E12/MyoD heterodimers.	MT SINAI MED CTR,DEPT PATHOL,NEW YORK,NY 10029	Icahn School of Medicine at Mount Sinai					NHLBI NIH HHS [HL40659, HL43583] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL040659, R01HL043583] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLACKMAN RK, 1986, J MOL BIOL, V188, P499, DOI 10.1016/S0022-2836(86)80001-8; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CARSONJURICA MA, 1989, J STEROID BIOCHEM, V34, P1, DOI 10.1016/0022-4731(89)90060-5; CHAMBRAUD B, 1990, J BIOL CHEM, V265, P20686; COLE F, 1992, J CELL BIOCHEM, V50, P130, DOI 10.1002/jcb.240500204; CUENOUD B, 1993, SCIENCE, V259, P510, DOI 10.1126/science.8424173; DALMAN F, 1989, J BIOL CHEM, V264, P19816; DRAGON EA, 1987, MOL CELL BIOL, V7, P1271, DOI 10.1128/MCB.7.3.1271; FARRELLY FW, 1984, J BIOL CHEM, V259, P5745; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; GERMAN M, 1991, MOL ENDOCRINOL, V2, P292; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HOUSLEY PR, 1990, J BIOL CHEM, V265, P12778; LAI BT, 1984, MOL CELL BIOL, V4, P2802, DOI 10.1128/MCB.4.12.2802; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LIPSICH LA, 1982, MOL CELL BIOL, V2, P875, DOI 10.1128/MCB.2.7.875; MOORE SK, 1987, GENE, V56, P29, DOI 10.1016/0378-1119(87)90155-7; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; NISHIDA E, 1986, J BIOL CHEM, V261, P6033; OPPERMAN H, 1991, P NATL ACAD SCI USA, V78, P1067; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; REBBE NF, 1987, GENE, V53, P235, DOI 10.1016/0378-1119(87)90012-6; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZ ER, 1988, MOL ENDOCRINOL, V2, P756, DOI 10.1210/mend-2-8-756; SANCHEZ ER, 1987, J BIOL CHEM, V262, P6986; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SHANKOVICH R, 1992, MOL CELL BIOL, V12, P5059; SINGH H, 1989, BIOTECHNIQUES, V7, P252; THAYER MJ, 1993, P NATL ACAD SCI USA, V90, P6483, DOI 10.1073/pnas.90.14.6483; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WEICH H, 1992, NATURE, V358, P169; ZIEMIECKI A, 1986, BIOCHEM BIOPH RES CO, V138, P1298, DOI 10.1016/S0006-291X(86)80424-7	37	74	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2707	2711						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300601				2022-12-27	WOS:A1994MV43200054
J	CHESNEAU, V; PIEROTTI, AR; BARRE, N; CREMINON, C; TOUGARD, C; COHEN, P				CHESNEAU, V; PIEROTTI, AR; BARRE, N; CREMINON, C; TOUGARD, C; COHEN, P			ISOLATION AND CHARACTERIZATION OF A DIBASIC SELECTIVE METALLOENDOPEPTIDASE FROM RAT TESTES THAT CLEAVES AT THE AMINO-TERMINUS OF ARGININE RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCESSING ENZYME; SOMATOSTATIN-28 CONVERTASE; AMINOPEPTIDASE-B; MAMMALIAN TESTIS; MESSENGER-RNA; GENE ENCODES; BRAIN CORTEX; YEAST KEX2; EXPRESSION; CELLS	A metalloendopeptidase that selectively cleaves doublets of basic amino acids on the amino-terminal side of arginine residues was purified to homogeneity from rat testes and analyzed further. Two catalytically active forms with apparent relative molecular masses of 110,000 and 140,000 Da, respectively, were present in the purified preparation of the enzyme. Antibodies raised against the purified testis endopeptidase revealed by immunoblot both the 110- and 140-kDa forms in both rat testis and brain cortex extracts. The isolated enzyme was inhibited by metal chelators and divalent cations. Its activity, lost after preincubation with EDTA, was restored by low concentrations of Zn2+ and Mn2+, thus demonstrating the metallopeptidase nature of the enzyme. This endopeptidase also exhibited a high sensitivity to amastatin (100% inhibition at 20 muM), an aminopeptidase inhibitor. A substrate specificity study using physiologically important or synthetic peptides containing a processing dibasic site indicated that cleavage occurred selectively at the amino-terminal side of an arginine residue, independent of the nature of the basic doublet. The enzyme produced such a cleavage at the Arg-Lys doublet of somatostatin 28 (K(m) = 43 muM), at the Arg-Arg doublet of dynorphin A (K(m) = 6.45 muM) and atrial natriuretic factor (K(m) = 6.25 muM), and at the Lys-Arg doublet of preproneurotensin-(154-170) (K(m) = 17.3 muM). Moreover, cleavage efficiency was found to be higher for the larger substrates. The distinctive properties of this endopeptidase imply that this protein is a member of a novel class of proteolytic enzymes that may be involved in the endoproteolytic maturation of hormonal precursors.	UNIV PARIS 06, BIOCHEM SIGNAUX REGULATEURS CELLULAIRES & MOLEC LA, CNRS, URA 1682, F-75006 PARIS, FRANCE; CTR ETUD SACLAY, DEPT RECH IMAGERIE PHARMACOL & PHYSIOL, SERV PHARMACOL & IMMUNOL, F-91191 GIF SUR YVETTE, FRANCE; COLL FRANCE, BIOL CELLULE NEUROENDOCRINE GRP, URA 1115, F-75231 PARIS 05, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; PSL Research University Paris; College de France								AOYAGI T, 1978, J ANTIBIOT, V31, P636, DOI 10.7164/antibiotics.31.636; BOURDAIS J, 1990, BIOCHEM BIOPH RES CO, V170, P1263, DOI 10.1016/0006-291X(90)90530-Z; BRAKCH N, 1993, BIOCHEMISTRY-US, V32, P4925, DOI 10.1021/bi00069a029; BRAKCH N, 1993, EUR J BIOCHEM, V216, P39, DOI 10.1111/j.1432-1033.1993.tb18114.x; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CHEN CLC, 1984, P NATL ACAD SCI-BIOL, V81, P5672, DOI 10.1073/pnas.81.18.5672; DARBY NJ, 1990, BIOSCIENCE REP, V10, P1, DOI 10.1007/BF01116845; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; DOUGLASS J, 1987, ENDOCRINOLOGY, V120, P707, DOI 10.1210/endo-120-2-707; ERDOS EG, 1985, LAB INVEST, V52, P437; Frobert Y, 1992, Methods Mol Biol, V80, P65, DOI 10.1385/0-89603-204-3:65; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GERMAIN D, 1992, EUR J BIOCHEM, V204, P121, DOI 10.1111/j.1432-1033.1992.tb16613.x; GLUSCHANKOF P, 1984, P NATL ACAD SCI-BIOL, V81, P6662, DOI 10.1073/pnas.81.21.6662; GLUSCHANKOF P, 1987, NEUROCHEM RES, V12, P951, DOI 10.1007/BF00966318; GLUSCHANKOF P, 1987, J BIOL CHEM, V262, P9615; GOMEZ S, 1988, P NATL ACAD SCI USA, V85, P5468, DOI 10.1073/pnas.85.15.5468; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KEW D, 1990, P NATL ACAD SCI USA, V87, P9143, DOI 10.1073/pnas.87.23.9143; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KILPATRICK DL, 1987, P NATL ACAD SCI USA, V84, P5695, DOI 10.1073/pnas.84.16.5695; KILPATRICK DL, 1985, P NATL ACAD SCI USA, V82, P7467, DOI 10.1073/pnas.82.21.7467; KUO WL, 1993, ENDOCRINOLOGY, V132, P604, DOI 10.1210/en.132.2.604; LEPAGELEZIN A, 1991, J BIOL CHEM, V266, P1679; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; NISHINO N, 1979, BIOCHEMISTRY-US, V18, P4340, DOI 10.1021/bi00587a012; ORLOWSKI M, 1989, BIOCHEM J, V261, P951, DOI 10.1042/bj2610951; PANDEY KN, 1991, BIOCHEM BIOPH RES CO, V180, P437, DOI 10.1016/S0006-291X(05)81312-9; PEKARY AE, 1984, LIFE SCI, V34, P939, DOI 10.1016/0024-3205(84)90298-4; RHOLAM M, 1986, FEBS LETT, V207, P1, DOI 10.1016/0014-5793(86)80002-3; SEIDAH NG, 1992, MOL ENDOCRINOL, V6, P1559, DOI 10.1210/me.6.10.1559; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SUDA H, 1976, ARCH BIOCHEM BIOPHYS, V177, P196, DOI 10.1016/0003-9861(76)90429-X; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VAITUKAITIS J, 1971, J CLIN ENDOCR METAB, V33, P988, DOI 10.1210/jcem-33-6-988; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378	41	90	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2056	2061						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294457				2022-12-27	WOS:A1994MR98800077
J	DEV, IK; DALLAS, WS; FERONE, R; HANLON, M; MCKEE, DD; YATES, BB				DEV, IK; DALLAS, WS; FERONE, R; HANLON, M; MCKEE, DD; YATES, BB			MODE OF BINDING OF FOLATE ANALOGS TO THYMIDYLATE SYNTHASE - EVIDENCE FOR 2 ASYMMETRIC BUT INTERACTIVE SUBSTRATE-BINDING SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LACTOBACILLUS-CASEI; DIHYDROFOLATE-REDUCTASE; QUINAZOLINE ANTIFOLATE; CRYSTAL-STRUCTURE; SYNTHETASE; INHIBITORS; EXPRESSION; ENZYME; AFFINITY	Human thymidylate synthase is a polymeric protein composed of two subunits with identical primary structures. In this study we determined the binding affinities of 5,10-methylene tetrahydropteroyltetraglutamate (folate substrate) and a group of close structural folate analog inhibitors. Thymidylate synthase bound both mono and polyglutamylated folate substrates and analogs more tightly in the presence of deoxyuridylate. These results and product inhibition studies confirmed that the orders of substrate addition and product release from thymidylate synthase were similar for mono and polyglutamylated substrates. Equilibrium dialysis studies showed that the folate substrate in a ternary complex with deoxyuridylate bound to one of the subunits (site A) with a K(d) of 720 nm. The binding of the substrate to the second subunit (site B) was much weaker, and the K(d) could not be determined by this method. However, dissociation constants for each subunit could be measured for the folate analog inhibitors, and, depending on the inhibitor, the relative K(d) value for each subunit varied substantially. For example, formyl-5,8-dideazafolate and tetraglutamylated 10-propargyl-5,8-dideazafolate bound to both sites with similar K(d) values, whereas D1694Glu4 bound to subunit A with a higher affinity (K(d) = 1.0 nM) than to subunit B (K(d) = 30 nM). In contrast, 1843U89 (mono or diglutamylated form) had a much higher affinity for subunit B (K(d) approximately 1 nM) compared with subunit A (K(d) approximately 400 nM). Enzyme inhibition kinetic analyses showed that the K(i) values of 1843U89 were quite low (0.1 nM) and that the inhibition was noncompetitive. In contrast, the other folate analogs inhibited the enzyme via mixed inhibition (i.e. both the K(m) for the folate substrate and the V(max) were altered). We conclude that the two subunits of thymidylate synthase bind folate substrates and analogs differently and that the asymmetric binding of the ligands is the major factor that determines the inhibition kinetics of each folate analog inhibitor.			DEV, IK (corresponding author), BURROUGHS WELLCOME CO, DIV MOLEC GENET & MICROBIOL, RES TRIANGLE PK, NC 27709 USA.							AULL JL, 1974, J BIOL CHEM, V249, P1167; AULL JL, 1974, MICROCHEM J, V19, P210, DOI 10.1016/0026-265X(74)90076-9; BAPAT AR, 1983, J BIOL CHEM, V258, P4130; BEAUDETTE NV, 1977, ARCH BIOCHEM BIOPHYS, V179, P272, DOI 10.1016/0003-9861(77)90112-6; BEAUDETTE NV, 1980, ARCH BIOCHEM BIOPHYS, V200, P410, DOI 10.1016/0003-9861(80)90371-9; BOGNAR AL, 1987, J BIOL CHEM, V262, P12337; BOYER PD, 1977, STRUCTURE FUNCTION E, P261; CANTWELL BMJ, 1988, EUR J CANCER CLIN ON, V24, P733, DOI 10.1016/0277-5379(88)90307-0; CHENG YC, 1985, CANCER RES, V45, P598; CISNEROS R J, 1988, Drugs of the Future, V13, P859; DALLAS WS, 1992, J BACTERIOL, V174, P5961, DOI 10.1128/jb.174.18.5961-5970.1992; DANENBERG KD, 1979, J BIOL CHEM, V254, P4345; DANENBERG PV, 1978, BIOCHEMISTRY-US, V17, P4018, DOI 10.1021/bi00612a022; DARON HH, 1978, J BIOL CHEM, V253, P940; DAVISSON VJ, 1989, J BIOL CHEM, V264, P9145; DEV IK, 1984, J BIOL CHEM, V259, P1114; DEV IK, 1988, P NATL ACAD SCI USA, V85, P1472, DOI 10.1073/pnas.85.5.1472; DEV IK, 1989, J BIOL CHEM, V264, P19132; DOLNICK BJ, 1978, J BIOL CHEM, V253, P3563; DUCH DS, 1993, CANCER RES, V53, P810; FERONE R, 1986, J BIOL CHEM, V261, P6363; GALIVAN JH, 1976, BIOCHEMISTRY-US, V15, P356, DOI 10.1021/bi00647a018; GALIVAN JH, 1976, BIOCHEM BIOPH RES CO, V71, P527, DOI 10.1016/0006-291X(76)90819-6; GARVEY EP, 1987, J BIOL CHEM, V262, P9068; GHOSE C, 1990, CHEMISTRY AND BIOLOGY OF PTERIDINES 1989, P860; HARDY LW, 1987, SCIENCE, V235, P448, DOI 10.1126/science.3099389; HENDERSON PJ, 1973, BIOCHEM J, V135, P101, DOI 10.1042/bj1350101; HUANG CY, 1982, ANNU REV BIOCHEM, V51, P935, DOI 10.1146/annurev.bi.51.070182.004443; HUTCHISON CA, 1978, J BIOL CHEM, V253, P6551; JACKMAN AL, 1991, CANCER RES, V51, P5579; JONES TR, 1981, EUR J CANCER, V17, P11, DOI 10.1016/0014-2964(81)90206-1; KAMB A, 1992, BIOCHEMISTRY-US, V31, P12876, DOI 10.1021/bi00166a024; KEYOMARSI K, 1990, J BIOL CHEM, V265, P19163; LANGENBACH R, 1976, BIOCHIM BIOPHYS ACTA, V422, P295, DOI 10.1016/0005-2744(76)90140-6; LAPATPOLASKO L, 1990, BIOCHEMISTRY-US, V29, P9561, DOI 10.1021/bi00493a010; LAZDUNSKI M, 1972, CURRENT TOPICS CELLU, V6, P267; LEARY RP, 1975, J BIOL CHEM, V250, P4864; LOCKSHIN A, 1979, J BIOL CHEM, V254, P2285; LOCKSHIN A, 1981, BIOCHEM PHARMACOL, V30, P247, DOI 10.1016/0006-2952(81)90085-X; LORENSON MY, 1967, J BIOL CHEM, V242, P3332; LU YZ, 1984, BIOCHEMISTRY-US, V23, P6870, DOI 10.1021/bi00321a091; Maniatis T, 1982, MOL CLONING LABORATO, P312; MATTHEWS DA, 1990, J MOL BIOL, V214, P923, DOI 10.1016/0022-2836(90)90346-N; MATTHEWS DA, 1990, J MOL BIOL, V214, P937, DOI 10.1016/0022-2836(90)90347-O; MILLER SM, 1991, BIOCHEMISTRY-US, V30, P2600, DOI 10.1021/bi00224a006; MONTFORT WR, 1990, BIOCHEMISTRY-US, V29, P6964, DOI 10.1021/bi00482a004; MOORE MA, 1986, J BIOL CHEM, V261, P2745; NAKAGAWA TY, 1986, P NATL ACAD SCI USA, V83, P2007, DOI 10.1073/pnas.83.7.2007; PATTISHALL KH, 1976, J BIOL CHEM, V251, P7011; POGOLOTTI AL, 1986, J MED CHEM, V29, P478, DOI 10.1021/jm00154a009; RADPARVAR S, 1988, ARCH BIOCHEM BIOPHYS, V260, P342, DOI 10.1016/0003-9861(88)90458-4; ROBERTS D, 1966, BIOCHEMISTRY-US, V5, P3546, DOI 10.1021/bi00875a022; RODE W, 1979, J BIOL CHEM, V254, P1538; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTI DV, 1984, FOLATES PTERINS, P345; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCOTT RL, 1956, RECL TRAV CHIM PAY B, V75, P787, DOI 10.1002/recl.19560750711; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SPECTOR T, 1981, ANAL BIOCHEM, V115, P403, DOI 10.1016/0003-2697(81)90025-7; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAKEISHI K, 1985, NUCLEIC ACIDS RES, V13, P2035, DOI 10.1093/nar/13.6.2035; VARNEY MD, 1992, J MED CHEM, V35, P663, DOI 10.1021/jm00082a006; WAHBA AJ, 1961, J BIOL CHEM, V236, pPC11; WARD WHJ, 1992, BIOCHEM PHARMACOL, V43, P2029, DOI 10.1016/0006-2952(92)90646-Z; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	65	68	69	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1873	1882						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294436				2022-12-27	WOS:A1994MR98800051
J	DRAEGER, LJ; MULLEN, GP				DRAEGER, LJ; MULLEN, GP			INTERACTION OF THE BHLH-ZIP DOMAIN OF C-MYC WITH H1-TYPE PEPTIDES - CHARACTERIZATION OF HELICITY IN THE H1 PEPTIDES BY NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; SECONDARY STRUCTURE; PROTEIN; SEQUENCE; GENE; TRANSCRIPTION; SPECTROSCOPY; DAUGHTERLESS; SIMILARITIES; ONCOGENE	The carboxyl-terminal 92 residues of c-Myc-92 display site-specific DNA binding specificity for the consensus sequence 5'-CACCACGTGGTG-3' (Blackwell, T. K., Kretzner, L., Blackwood, E. M., Eisenman, R. N., and Weintraub, H. (1990) Science 250, 1149-1151). Size exclusion high pressure liquid chromatography analysis of the purified fusion protein, glutathione S-transferase-c-Myc-92, indicates that c-Myc-92 is tetrameric with a dissociation constant of <60 nM. Helix-1 (H1) and leucine zipper peptides from the basic-helix-loop-helix-zipper domain of c-Myc and Max were assayed as potential inhibitors of c-Myc-92 DNA binding. H1 peptides with substitutions that confer greater helicity are found to inhibit c-Myc-92 DNA binding. The mechanism of inhibition involves the cooperative binding of H1 peptides with tetrameric c-Myc-92 as determined by a spectrophotometric assay employing 2,4-dinitrophenyl-H1-F8A. NMR structural characterization reveals a correlation between helicity and inhibition. In a partially hydrophobic environment, H1-Mx (from Max) is a random coil, while H1-WT, H1-F8A, and H1-F8A,S6A (from c-Myc) display differing degrees of helicity. Structure determination on the basis of nuclear Overhauser effect data indicates that the H1-F8A helix is significantly more ordered than H1-WT. Analysis on the basis of the Max x-ray structure (Ferre-D'Amare, R., Prendergast, G. C., Ziff, E. B., and Burley, S. K. (1993) Nature 363, 38-45) suggests that H1 peptide binding to c-Myc-92 may occur through an alteration in the packing of helix-1 in c-Myc-92 or through an interaction with an exposed hydrophobic cluster of residues at each H1-H2 interface. This binding site for H1 peptides may be of significance in the interaction of c-Myc with proteins involved in transcriptional regulation.	UNIV WISCONSIN,DEPT CHEM,MILWAUKEE,WI 53211	University of Wisconsin System; University of Wisconsin Milwaukee								ALONSO MC, 1988, EMBO J, V7, P2585, DOI 10.1002/j.1460-2075.1988.tb03108.x; ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLAKE PR, 1991, BIOCHEMISTRY-US, V30, P10885, DOI 10.1021/bi00109a012; BRUNGER AT, 1992, XPLOR VERSION 3 MANU; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DEPINHO RA, 1987, GENE DEV, V1, P1311, DOI 10.1101/gad.1.10.1311; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HALAZONETIS TD, 1992, SCIENCE, V255, P464, DOI 10.1126/science.1734524; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LIU T, 1993, J BIOL CHEM, V268, P16309; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; STAROVASNIK MA, 1992, BIOCHEMISTRY-US, V31, P9891, DOI 10.1021/bi00156a006; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; WATT R, 1983, NATURE, V303, P725, DOI 10.1038/303725a0; WUTHRICH K, 1984, J MOL BIOL, V180, P715, DOI 10.1016/0022-2836(84)90034-2	28	42	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1785	1793						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294427				2022-12-27	WOS:A1994MR98800039
J	DROLET, M; BI, X; LIU, LF				DROLET, M; BI, X; LIU, LF			HYPERNEGATIVE SUPERCOILING OF THE DNA-TEMPLATE DURING TRANSCRIPTION ELONGATION IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOPOISOMERASE-I MUTANTS; COLI RNA-POLYMERASE; ESCHERICHIA-COLI; GYRASE INHIBITORS; RIBOSOMAL-RNA; PLASMID DNA; PBR322 DNA; REPLICATION; SPECIFICITY; INITIATION	Supercoiled plasmid DNAs with negative superhelicity several times higher than normal have been isolated from Escherichia coli topA mutants. The formation of these hypernegatively supercoiled plasmid DNAs is apparently induced by transcription. We show that hypernegatively supercoiled plasmid DNAs isolated from topA mutants contain R-loop(s). To study the mechanism of formation of hypernegatively supercoiled plasmid DNA, we have been able to reproduce hypernegatively supercoiled DNA in vitro using purified RNA polymerase and DNA gyrase. The formation of hypernegatively supercoiled plasmid DNA template in vitro is shown to require transcription elongation and is tightly linked to R-loop formation. We propose that one of the roles of topoisomerase I is to suppress R-loop formation during transcription elongation.			LIU, LF (corresponding author), UMDNJ,ROBERT WOOD JOHNSON MED SCH,DEPT PHARMACOL,675 HOES LANE,PISCATAWAY,NJ 08854, USA.		Drolet, Marc/M-1328-2019	Liu, Leroy/0000-0001-9396-763X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027731] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM27731] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRILL SJ, 1987, NATURE, V326, P414, DOI 10.1038/326414a0; BRILL SJ, 1988, CELL, V54, P403, DOI 10.1016/0092-8674(88)90203-6; CHAMPOUX JJ, 1975, BIOCHEMISTRY-US, V14, P307, DOI 10.1021/bi00673a017; COOK DN, 1992, P NATL ACAD SCI USA, V89, P10603, DOI 10.1073/pnas.89.22.10603; DINARDO S, 1982, CELL, V31, P43, DOI 10.1016/0092-8674(82)90403-2; DRLICA K, 1992, MOL MICROBIOL, V6, P425, DOI 10.1111/j.1365-2958.1992.tb01486.x; FLEISCHMANN G, 1984, P NATL ACAD SCI-BIOL, V81, P6958, DOI 10.1073/pnas.81.22.6958; FRANCO RJ, 1989, J BACTERIOL, V171, P6573, DOI 10.1128/jb.171.12.6573-6579.1989; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; GELLERT M, 1982, COLD SPRING HARB SYM, V47, P763; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; GILMOUR DS, 1986, CELL, V44, P1401; ITOH T, 1980, P NATL ACAD SCI-BIOL, V77, P2450, DOI 10.1073/pnas.77.5.2450; KAGUNI JM, 1984, J BIOL CHEM, V259, P8578; KOO HS, 1990, J BIOL CHEM, V265, P12300; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LOCKSHON D, 1983, NUCLEIC ACIDS RES, V11, P2999, DOI 10.1093/nar/11.10.2999; LODGE JK, 1989, J BACTERIOL, V171, P2181, DOI 10.1128/jb.171.4.2181-2187.1989; LYNCH AS, 1993, J BACTERIOL, V175, P1645, DOI 10.1128/JB.175.6.1645-1655.1993; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MULLER MT, 1985, EMBO J, V4, P1237, DOI 10.1002/j.1460-2075.1985.tb03766.x; OSTRANDER EA, 1990, SCIENCE, V249, P1261, DOI 10.1126/science.2399463; PARADA CA, 1989, J BIOL CHEM, V264, P15120; PRUSS GJ, 1985, J MOL BIOL, V185, P51, DOI 10.1016/0022-2836(85)90182-2; PRUSS GJ, 1986, P NATL ACAD SCI USA, V83, P8952, DOI 10.1073/pnas.83.23.8952; RAHMOUNI AR, 1992, J MOL BIOL, V223, P131, DOI 10.1016/0022-2836(92)90721-U; RAHMOUNI AR, 1989, SCIENCE, V246, P358, DOI 10.1126/science.2678475; RICHARDSON JP, 1975, J MOL BIOL, V98, P565, DOI 10.1016/S0022-2836(75)80087-8; ROSE KM, 1988, CHROMOSOMA, V96, P411, DOI 10.1007/BF00303034; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WU HY, 1991, J MOL BIOL, V219, P615, DOI 10.1016/0022-2836(91)90658-S; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8; ZHANG H, 1988, P NATL ACAD SCI USA, V85, P1060, DOI 10.1073/pnas.85.4.1060	34	110	111	3	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2068	2074						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294458				2022-12-27	WOS:A1994MR98800079
J	VERMA, AK; ENYEDI, A; FILOTEO, AG; PENNISTON, JT				VERMA, AK; ENYEDI, A; FILOTEO, AG; PENNISTON, JT			REGULATORY REGION OF PLASMA-MEMBRANE CA2+ PUMP - 28 RESIDUES SUFFICE TO BIND CALMODULIN BUT MORE ARE NEEDED FOR FULL AUTO-INHIBITION OF THE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+ PUMP; TRYPSIN PROTEOLYSIS; FUNCTIONAL DOMAINS; HUMAN-ERYTHROCYTES; CA-2+-ATPASE; CA2+-ATPASE; CLEAVAGE; PROTEINS	The Ca2+-pumping activity of constructs containing various portions of the putative 28-residue calmodulin-binding domain (C domain) of hPMCA4b were compared. As the length of the C domain in the pump increased, the pump's activity decreased and the ability of calmodulin to stimulate the activity increased. Study of the calmodulin dependence of activity showed that the construct containing all 28 residues of the C domain had a K1/2 for calmodulin equal to that of the complete molecule; the constructs containing less of the C domain interacted less strongly with calmodulin. On the other hand, incorporation of all 28 residues of the C domain did not decrease the activity of the pump (in the absence of calmodulin) as low as the activity of the complete molecule. This indicates that other segments of the molecule, further toward the COOH terminus, are also required for the degree of inhibition seen in the complete molecule.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,GUGGENHEIM 1642C,200 1ST ST SW,ROCHESTER,MN 55905	Mayo Clinic			Enyedi, Agnes/N-9742-2013	Enyedi, Agnes/0000-0002-7366-9376	NIGMS NIH HHS [GM 28835] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028835] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMO HP, 1992, BIOCHEM J, V285, P791, DOI 10.1042/bj2850791; BENAIM G, 1984, J BIOL CHEM, V259, P8471; CARAFOLI E, 1987, CALCIUM BINDING PROT, P78; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; ENYEDI A, 1991, J BIOL CHEM, V266, P8952; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; ENYEDI A, 1993, J BIOL CHEM, V268, P10621; JAMES P, 1988, J BIOL CHEM, V263, P2905; JAMES P, 1989, J BIOL CHEM, V264, P8289; JAMES PH, 1989, BIOCHEMISTRY-US, V28, P4253, DOI 10.1021/bi00436a020; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; SHULL GE, 1988, J BIOL CHEM, V263, P8646; VERMA AK, 1988, J BIOL CHEM, V263, P14152; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; WANG KKW, 1991, J BIOL CHEM, V266, P9078; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WANG KKW, 1988, ARCH BIOCHEM BIOPHYS, V267, P317, DOI 10.1016/0003-9861(88)90037-9; ZURINI M, 1984, J BIOL CHEM, V259, P618; ZVARITCH E, 1990, BIOCHEMISTRY-US, V29, P8070, DOI 10.1021/bi00487a012	19	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1687	1691						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294415				2022-12-27	WOS:A1994MR98800025
J	YAMASHITA, H; ICHIJO, H; GRIMSBY, S; MOREN, A; TENDIJKE, P; MIYAZONO, K				YAMASHITA, H; ICHIJO, H; GRIMSBY, S; MOREN, A; TENDIJKE, P; MIYAZONO, K			ENDOGLIN FORMS A HETEROMERIC COMPLEX WITH THE SIGNALING RECEPTORS FOR TRANSFORMING GROWTH-FACTOR-BETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BETA-1-SPECIFIC BINDING-PROTEINS; RGD-CONTAINING GLYCOPROTEIN; HUMAN ENDOTHELIAL-CELLS; HUMAN-PLATELETS; RAT GLOMERULI; IDENTIFICATION; EXPRESSION; COMPONENT; SEQUENCES; ANTIGEN	Human endoglin is a dimeric protein that binds transforming growth factor-beta (TGF-beta). A porcine cDNA clone for endoglin was obtained from a porcine uterus cDNA library. The deduced sequence of the primary translated product of endoglin consists of 643 amino acids with a high sequence identity (96%) to human endoglin in the transmembrane and intracellular domains, but with a lower sequence similarity (66%) in the extracellular domain. In contrast to human endoglin, porcine endoglin has no Arg-Gly-Asp tripeptide in its sequence. Antibodies, raised against a peptide corresponding to the intracellular domain of porcine endoglin, immunoprecipitated an 84-kDa protein under reducing condition and a 130-kDa protein under nonreducing condition in porcine aortic endothelial cells. Porcine endoglin bound TGF-beta1 and -beta3 efficiently, but TGF-beta2 less efficiently. Endoglin was found to be coimmunoprecipitated with TGF-beta receptors type I and/or II by the endoglin antibodies or by TGF-beta receptor II antibodies in the presence of ligand. Thus, endoglin and TGF-beta receptors I and/or II most likely formed a heteromeric receptor complex. Endoglin was phosphorylated on serine residue(s), which did not change after stimulation by TGF-beta1. These results revealed that endoglin is a phosphorylated protein which forms a heteromeric complex with signaling receptors for TGF-beta.			YAMASHITA, H (corresponding author), BIOMED CTR,LUDWIG INST CANC RES,BOX 595,S-75124 UPPSALA,SWEDEN.		Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X; Ichijo, Hidenori/0000-0002-5005-6438				BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BUHRING HJ, 1991, LEUKEMIA, V5, P841; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FROLIK CA, 1984, J BIOL CHEM, V259, P995; GOUGOS A, 1988, J IMMUNOL, V141, P1934; GOUGOS A, 1988, J IMMUNOL, V141, P1925; GOUGOS A, 1992, INT IMMUNOL, V4, P83, DOI 10.1093/intimm/4.1.83; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HIRAI R, 1992, EXP CELL RES, V201, P119, DOI 10.1016/0014-4827(92)90355-C; ICHIJO H, 1993, J BIOL CHEM, V268, P14505; JENNINGS JC, 1988, J CELL PHYSIOL, V137, P167, DOI 10.1002/jcp.1041370120; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LASTRES P, 1992, EUR J IMMUNOL, V22, P393, DOI 10.1002/eji.1830220216; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MACKAY K, 1990, J BIOL CHEM, V265, P9351; MACKAY K, 1992, J BIOL CHEM, V267, P11449; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MCKEEHAN WL, 1976, P NATL ACAD SCI USA, V73, P2023, DOI 10.1073/pnas.73.6.2023; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; MIYAZONO K, 1994, IN PRESS ADV IMMUNOL; MOREN A, 1992, BIOCHEM BIOPH RES CO, V189, P356, DOI 10.1016/0006-291X(92)91566-9; MOSES HL, 1985, CANCER CELL, V3, P65; OCONNELL PJ, 1992, CLIN EXP IMMUNOL, V90, P154; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; OLOFSSON A, 1992, J BIOL CHEM, V267, P19482; QUACKENBUSH EJ, 1986, J IMMUNOL, V136, P118; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	44	171	180	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1995	2001						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294451				2022-12-27	WOS:A1994MR98800069
J	SEKI, N; MUTA, T; ODA, T; IWAKI, D; KUMA, K; MIYATA, T; IWANAGA, S				SEKI, N; MUTA, T; ODA, T; IWAKI, D; KUMA, K; MIYATA, T; IWANAGA, S			HORSESHOE-CRAB (1,3)-BETA-D-GLUCAN-SENSITIVE COAGULATION FACTOR-G - A SERINE-PROTEASE ZYMOGEN HETERODIMER WITH SIMILARITIES TO BETA-GLUCAN-BINDING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TACHYPLEUS-TRIDENTATUS HEMOCYTES; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; CLOSTRIDIUM-THERMOCELLUM; BACILLUS-LICHENIFORMIS; LIMULUS-POLYPHEMUS; PROCLOTTING ENZYME; DNA-SEQUENCE; FACTOR-C; GENE	Horseshoe crab factor G is an intracellular serine protease zymogen that initiates the (1,3)-beta-D-glucan-sensitive hemolymph clotting pathway. Unlike other known serine protease zymogens, which are composed of a single subunit, factor G consists of two distinct subunits, alpha and beta, which are autocatalytically converted to active factor GBAR in the presence of (1,3)-beta-D-glucan. We have now cloned and sequenced cDNAs encoding both subunits of factor G. The subunits are derived from separate mRNA species and thus encoded by different genes. Subunit beta is a serine protease zymogen which consists of 278 residues with a calculated molecular mass of 30,846 Da; it exhibits homology to the serine protease domain of horseshoe crab factor B. Subunit alpha, on the other hand, is a new type of mosaic protein with intriguing features. The mature protein consists of 654 residues with a calculated molecular mass of 73,916 Da. The NH2-terminal portion of this subunit is similar to bacterial beta-1,3-glucanases. Its 126 amino acid COOH terminus exhibits a repetitive sequence having partial homology to xylanases. Between these regions are three repeating units of 47 amino acids, whose similarity to carbohydrate-binding proteins suggests that these may be the (1,3)-beta-D-glucan-binding domain(s) of factor G. Factor G, thus, is a structurally unique heterodimeric serine protease zymogen and as such may represent a new class of active defense proteins.	KYUSHU UNIV 33,GRAD SCH MED SCI,DEPT MOLEC BIOL,FUKUOKA 812,JAPAN; KYUSHU UNIV 33,FAC SCI,DEPT BIOL,FUKUOKA 812,JAPAN; KYOTO UNIV,FAC SCI,DEPT BIOPHYS,KYOTO 606,JAPAN	Kyushu University; Kyushu University; Kyoto University								ARMSTRONG PB, 1991, LIMULUS POLYPHEMUS I, P3; BORRISS R, 1990, MOL GEN GENET, V222, P278, DOI 10.1007/BF00633829; CHIHARA G, 1970, CANCER RES, V30, P2776; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DUMONT JN, 1966, J MORPHOL, V119, P181, DOI 10.1002/jmor.1051190206; DUVIC B, 1990, J BIOL CHEM, V265, P9327; GOSALBES MJ, 1991, J BACTERIOL, V173, P7705, DOI 10.1128/jb.173.23.7705-7710.1991; GREPINET O, 1988, J BACTERIOL, V170, P4582, DOI 10.1128/jb.170.10.4582-4588.1988; Halkier T, 1991, MECH BLOOD COAGULATI, P302; HASHIMOTO R, 1991, SEIKAGAKU, V63, P969; HERMODSON MA, 1973, BIOCHEMISTRY-US, V12, P3146, DOI 10.1021/bi00741a002; HOFEMEISTER J, 1986, GENE, V49, P177, DOI 10.1016/0378-1119(86)90278-7; HOJ PB, 1992, J BIOL CHEM, V267, P25059; IWANAGA S, 1993, CURR OPIN IMMUNOL, V5, P74, DOI 10.1016/0952-7915(93)90084-6; IWANAGA S, 1986, J PROTEIN CHEM, V5, P225; IWANAGA S, 1993, THROMBO RES, V68, P1; JULIUS D, 1983, CELL, V32, P839, DOI 10.1016/0092-8674(83)90070-3; KAKINUMA A, 1981, BIOCHEM BIOPH RES CO, V101, P434, DOI 10.1016/0006-291X(81)91278-X; LAMB FI, 1985, EUR J BIOCHEM, V148, P265, DOI 10.1111/j.1432-1033.1985.tb08834.x; LANZER M, 1992, EMBO J, V11, P1949, DOI 10.1002/j.1460-2075.1992.tb05248.x; LeGendre N., 1989, PRACTICAL GUIDE PROT, P52; LEVIN J, 1964, B JOHNS HOPKINS HOSP, V115, P265; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LLOBERAS J, 1991, EUR J BIOCHEM, V197, P337, DOI 10.1111/j.1432-1033.1991.tb15916.x; MEDFORD JI, 1991, PLANT CELL, V3, P359, DOI 10.1105/tpc.3.4.359; MORITA T, 1981, FEBS LETT, V129, P318, DOI 10.1016/0014-5793(81)80192-5; MURER EH, 1975, J CELL PHYSIOL, V86, P533, DOI 10.1002/jcp.1040860310; MURPHY N, 1984, NUCLEIC ACIDS RES, V12, P5355, DOI 10.1093/nar/12.13.5355; MUTA T, 1991, J BIOL CHEM, V266, P6554; MUTA T, 1993, J BIOL CHEM, V268, P21384; MUTA T, 1990, J BIOL CHEM, V265, P22426; NAKAMURA T, 1986, EUR J BIOCHEM, V154, P511, DOI 10.1111/j.1432-1033.1986.tb09427.x; NAKAMURA T, 1986, J BIOCHEM, V99, P847, DOI 10.1093/oxfordjournals.jbchem.a135545; NAKAMURA T, 1985, J BIOCHEM, V97, P1561, DOI 10.1093/oxfordjournals.jbchem.a135213; OCHIAI M, 1988, J BIOL CHEM, V263, P12056; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PLANAS A, 1992, FEBS LETT, V308, P141, DOI 10.1016/0014-5793(92)81262-K; SHARECK F, 1991, GENE, V107, P75, DOI 10.1016/0378-1119(91)90299-Q; SHEN SH, 1991, J BIOL CHEM, V266, P1058; SHIMOI H, 1992, J BIOL CHEM, V267, P25189; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; SMITH RH, 1985, J INVERTEBR PATHOL, V45, P272, DOI 10.1016/0022-2011(85)90103-X; SODERHALL K, 1988, INSECT BIOCHEM, V18, P323, DOI 10.1016/0020-1790(88)90045-5; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; Whistler R L, 1976, Adv Carbohydr Chem Biochem, V32, P235; YAHATA N, 1990, GENE, V86, P113, DOI 10.1016/0378-1119(90)90122-8; ZVERLOV VV, 1991, BIOCHEM BIOPH RES CO, V181, P507, DOI 10.1016/0006-291X(91)91217-Z	47	86	94	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1370	1374						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288603				2022-12-27	WOS:A1994MR22000093
J	BALAKIN, AG; LEMPICKI, RA; HUANG, GM; FOURNIER, MJ				BALAKIN, AG; LEMPICKI, RA; HUANG, GM; FOURNIER, MJ			SACCHAROMYCES-CEREVISIAE U14 SMALL NUCLEAR-RNA HAS LITTLE SECONDARY STRUCTURE AND APPEARS TO BE PRODUCED BY POSTTRANSCRIPTIONAL PROCESSING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-RIBOSOMAL-RNA; MOLECULAR-WEIGHT RNA; SMALL NUCLEOLAR RNA; REVERSE-TRANSCRIPTASE; PRIMER EXTENSION; MESSENGER-RNA; U3 SNRNA; BOX-C; YEAST; PROTEIN	Yeast U14 small nuclear (sn) RNA is required for normal processing of RNA. The sequence and folding properties of U14 were analyzed in the present study, with the aim of defining the structures of natural U14 subspecies and characterizing the folding properties of free U14 RNA. Natural U14 was determined to consist of four subspecies of 125-128 nucleotides, none containing a 5'-cap structure. Length heterogeneity occurs at both ends and is presumed to reflect post-transcriptional processing of U14 precursors. Results from nuclease and chemical probing revealed that U14 has surprisingly little secondary structure overall. Three essential sequence elements conserved among all U14 RNAs occur in regions that are largely single-stranded, i.e. box C, box D, and a 13-nucleotide segment complementary to 18 S rRNA, a non-essential 14-nucleotide sequence complementary to 18 S rRNA is also unpaired. Two non-conserved segments required for activity are part of a stably folded 32-base domain that is unique to yeast U14. Finally, a 5'-, 3'-stem shown earlier to be required for U14 accumulation appears to exist only in precursors to U14 and not in protein-free mature RNA. The implications of these results are discussed in terms of U14 synthesis and function.	UNIV MASSACHUSETTS, LEDERLE GRAD RES CTR, DEPT BIOCHEM & MOLEC BIOL, AMHERST, MA 01003 USA; UNIV MASSACHUSETTS, LEDERLE GRAD RES CTR, PROGRAM MOLEC & CELLULAR BIOL, AMHERST, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst			Lempicki, Richard A/E-1844-2012	Lempicki, Richard A/0000-0002-7059-409X	NIGMS NIH HHS [GM19351] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019351] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1990, NUCLEIC ACIDS RES, V18, P3035, DOI 10.1093/nar/18.10.3035; ALTMAN S, 1993, FASEB J, V7, P7, DOI 10.1096/fasebj.7.1.7916700; ARIS JP, 1991, METHOD ENZYMOL, V194, P735; BASERGA SJ, 1991, EMBO J, V10, P2645, DOI 10.1002/j.1460-2075.1991.tb07807.x; BRUCE AG, 1978, NUCLEIC ACIDS RES, V5, P3665, DOI 10.1093/nar/5.10.3665; DARR SC, 1992, TRENDS BIOCHEM SCI, V17, P178, DOI 10.1016/0968-0004(92)90262-8; FOURNIER MJ, 1993, TRENDS BIOCHEM SCI, V18, P131, DOI 10.1016/0968-0004(93)90020-N; GAUTHERET D, 1990, METHOD ENZYMOL, V183, P318; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; HUANG GM, 1992, MOL CELL BIOL, V12, P4456, DOI 10.1128/MCB.12.10.4456; HUGHES JMX, 1991, EMBO J, V10, P4231, DOI 10.1002/j.1460-2075.1991.tb05001.x; JARMOLOWSKI A, 1990, EMBO J, V9, P4503, DOI 10.1002/j.1460-2075.1990.tb07901.x; JONES EW, 1977, GENETICS, V85, P23; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KONDO K, 1992, J BIOL CHEM, V267, P16259; LEE WC, 1992, MOL CELL BIOL, V12, P3865, DOI 10.1128/MCB.12.9.3865; LEMPEREUR L, 1985, NUCLEIC ACIDS RES, V13, P8339, DOI 10.1093/nar/13.23.8339; LEVERETTE R, CELL, V71, P1215; LI HV, 1990, MOL CELL BIOL, V10, P1145, DOI 10.1128/MCB.10.3.1145; LI HV, 1992, EMBO J, V11, P683, DOI 10.1002/j.1460-2075.1992.tb05100.x; LIU J, 1990, NUCLEIC ACIDS RES, V18, P6565, DOI 10.1093/nar/18.22.6565; LUND E, 1992, SCIENCE, V255, P327, DOI 10.1126/science.1549778; Marzluff W. F., 1984, TRANSCRIPTION TRANSL, P89; MAXWELL ES, 1986, P NATL ACAD SCI USA, V83, P7261, DOI 10.1073/pnas.83.19.7261; MOAZED D, 1986, J MOL BIOL, V187, P399, DOI 10.1016/0022-2836(86)90441-9; MORRISSEY JP, 1993, MOL CELL BIOL, V13, P2469, DOI 10.1128/MCB.13.4.2469; MYSLINSKI E, 1990, SCIENCE, V247, P1213, DOI 10.1126/science.1690452; PARKER R, 1988, MOL CELL BIOL, V8, P3150, DOI 10.1128/MCB.8.8.3150; RIEDEL N, 1986, P NATL ACAD SCI USA, V83, P8097, DOI 10.1073/pnas.83.21.8097; RUSSELL ID, 1992, J CELL BIOL, V119, P737, DOI 10.1083/jcb.119.4.737; Sambrook J, 1989, MOL CLONING LABORATO; SCHIMMANG T, 1989, EMBO J, V8, P4015, DOI 10.1002/j.1460-2075.1989.tb08584.x; SEGAULT V, 1992, NUCLEIC ACIDS RES, V20, P3443, DOI 10.1093/nar/20.13.3443; SHANAB GM, 1991, NUCLEIC ACIDS RES, V19, P4891, DOI 10.1093/nar/19.18.4891; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; SHELNESS GS, 1985, J BIOL CHEM, V260, P8637; SINGH L, 1984, NUCLEIC ACIDS RES, V12, P5627, DOI 10.1093/nar/12.14.5627; SINGH R, 1989, P NATL ACAD SCI USA, V86, P8280, DOI 10.1073/pnas.86.21.8280; SOLLNERWEBB B, 1993, IN PRESS RIBOSOMAL R; TOLLERVEY D, 1991, EMBO J, V10, P573, DOI 10.1002/j.1460-2075.1991.tb07984.x; TRINHROHLIK Q, 1988, NUCLEIC ACIDS RES, V16, P6041, DOI 10.1093/nar/16.13.6041; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; TYCOWSKI TK, 1993, GENE DEV, V7, P1176; WISE JA, 1991, METHOD ENZYMOL, V194, P405; WYATT JR, 1991, BIOTECHNIQUES, V11, P764; ZAFARULLAH M, 1992, EUR J BIOCHEM, V204, P893, DOI 10.1111/j.1432-1033.1992.tb16709.x; ZAGORSKI J, 1988, MOL CELL BIOL, V8, P3282, DOI 10.1128/MCB.8.8.3282; ZUBENKO GS, 1980, GENETICS, V96, P137; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	50	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					739	746						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276877				2022-12-27	WOS:A1994MR21900116
J	SCHREIBER, RE; PROSSNITZ, ER; YE, RD; COCHRANE, CG; BOKOCH, GM				SCHREIBER, RE; PROSSNITZ, ER; YE, RD; COCHRANE, CG; BOKOCH, GM			DOMAINS OF THE HUMAN NEUTROPHIL N-FORMYL PEPTIDE RECEPTOR INVOLVED IN G-PROTEIN COUPLING - MAPPING WITH RECEPTOR-DERIVED PEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEINS; REAL-TIME ANALYSIS; PERTUSSIS TOXIN; REGULATORY PROTEIN; SYNTHETIC PEPTIDES; ALPHA-SUBUNIT; RHODOPSIN; LIGAND; TRANSDUCIN; FAMILY	Chemotactic signaling by the human neutrophil N-formyl peptide receptor requires its association with heterotrimeric G protein. Synthetic peptides and a fusion protein derived from the intracellular regions of the receptor were used to identify sites which interact with G protein. A peptide derived from the second intracellular loop (C12R), and peptides (F15R and S22L) and a fusion protein derived from the receptor's carboxyl terminus inhibited binding of anti-G(ialpha) antibody (R16,17) to G(ialpha) in a competitive enzyme-linked immunoassay, and antagonized pertussis-toxin catalyzed ADP-ribosylation of G(ialpha). C12R also inhibited G protein-dependent, high affinity ligand binding to the receptor and physical coupling of receptor to G protein. In contrast, a peptide consisting of the entire third loop of the N-formyl peptide receptor was totally inactive in these assays. Collectively, these data suggest that the second intracellular loop and the carboxyl-terminal tail are important for effective N-formyl peptide receptor/G protein coupling, but that the third intracellular loop is less important in coupling, unlike previous findings with other G protein-coupled receptor systems. The chemoattractant receptor family may rely on different structural determinants to interact with GTP-binding proteins.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute			Ye, Richard/ABF-2413-2020; Prossnitz, Eric R./B-4543-2008; Ye, Richard/O-5223-2016	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620; Prossnitz, Eric/0000-0001-9190-8302	NIGMS NIH HHS [GM39434, GM46572] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046572, R01GM039434] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOKOCH GM, 1988, J CELL BIOL, V106, P1927, DOI 10.1083/jcb.106.6.1927; BOKOCH GM, 1984, CELL, V39, P301, DOI 10.1016/0092-8674(84)90008-4; BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; BOKOCH GM, 1990, CURR TOP MEMBR TRANS, V35, P65; BOMMAKANTI RK, 1992, J BIOL CHEM, V267, P7576; BOMMAKANTI RK, 1992, CLIN RES, V40, pA352; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; CUPO JF, 1989, BIOCHIM BIOPHYS ACTA, V982, P31, DOI 10.1016/0005-2736(89)90170-3; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; FAY SP, 1991, BIOCHEMISTRY-US, V30, P5066, DOI 10.1021/bi00234a033; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; Hallet M. B., 1989, NEUTROPHIL CELLULAR, P1; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; KELLERMANN OK, 1982, METHOD ENZYMOL, V90, P459; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; MASTERS SB, 1986, PROTEIN ENG, V1, P47, DOI 10.1093/protein/1.1.47; MASUMOTO T, 1987, BIOCHEM BIOPH RES CO, V143, P489; MUNCH G, 1991, EUR J BIOCHEM, V198, P357, DOI 10.1111/j.1432-1033.1991.tb16023.x; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1992, J BIOL CHEM, V267, P7637; OMANN GM, 1987, PHYSIOL REV, V67, P285, DOI 10.1152/physrev.1987.67.1.285; PROBST WC, 1992, DNA CELL BIOL, V2, P1; PROSSNITZ ER, 1991, BIOCHEM BIOPH RES CO, V179, P471, DOI 10.1016/0006-291X(91)91394-R; PROSSNITZ ER, 1993, BIOCHEM J, V294, P581, DOI 10.1042/bj2940581; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHREIBER RE, 1993, J LEUKOCYTE BIOL, V53, P470, DOI 10.1002/jlb.53.4.470; SKLAR LA, 1984, J BIOL CHEM, V259, P5661; SKLAR LA, 1987, J BIOL CHEM, V262, P135; SKLAR LA, 1982, CYTOMETRY, V3, P161, DOI 10.1002/cyto.990030304; SNYDERMAN R, 1986, J LEUKOCYTE BIOL, V40, P785, DOI 10.1002/jlb.40.6.785; STRADER CD, 1989, FASEB J, V3; STROSBERG AD, 1991, EUR J BIOCHEM, V196, P1, DOI 10.1111/j.1432-1033.1991.tb15778.x; TAKEMOTO DJ, 1985, BIOCHEM J, V232, P669, DOI 10.1042/bj2320669; WEINGARTEN R, 1990, J BIOL CHEM, V265, P11044; WEISS ER, 1988, FASEB J, V2, P2841, DOI 10.1096/fasebj.2.13.3139484	40	68	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					326	331						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276814				2022-12-27	WOS:A1994MR21900056
J	SPACCIAPOLI, P; NOSSAL, NG				SPACCIAPOLI, P; NOSSAL, NG			A SINGLE MUTATION IN BACTERIOPHAGE-T4 DNA-POLYMERASE (A737V, TSL141) DECREASES ITS PROCESSIVITY AS A POLYMERASE AND INCREASES ITS PROCESSIVITY AS A 3' -] 5' EXONUCLEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC-ACID POLYMERASE; ESCHERICHIA-COLI; ACCESSORY PROTEINS; CB120 ANTIMUTATOR; BIOCHEMICAL BASIS; KLENOW FRAGMENT; REPLICATION; SITE; GENE; PURIFICATION	The bacteriophage T4 DNA polymerase mutant A737V (tsL141 and tsCB120) was originally characterized as temperature-sensitive for DNA replication and an antimutator for transition mutations. Its antimutator phenotype is suppressed by the L771F mutation (Reha-Krantz, L. J., Stocki, S., Nonay, R., and Maughan, C. (1989) J. Cell. Biochem. 13D, 140). We find that the A737V polymerase arrests much more frequently than the wild type when polymerizing on primed single-stranded DNA templates. Although the 3' --> 5' exonuclease of the mutant is indistinguishable from the wild type on single-stranded DNA, it is more active than the wild type on duplex DNA. In a single encounter with the primer, the wild type polymerase can incorporate more than 50 nucleotides. The processivity of the A737V polymerase is less than the wild type as a polymerase, but is greater than the wild type as an exonuclease. The L771F polymerase resembles the wild type in each of these properties, while the double mutant (A737V, L771F) is intermediate between the two single mutants. Kinetic studies of wild type T4 DNA polymerase (Capson, T. L., Peliska, J. A., Kaboord, B. F., Frey, M. W., Lively, C., Dahlberg, M., and Benkovic, S. J. (1992) Biochemistry 31, 10984-10994) suggest that DNA binds first to the polymerase active site, before adopting a configuration in which it can be hydrolyzed by the exonuclease. Within this framework, our studies suggest that DNA moves more readily from the polymerase- to the exonuclease-competent configuration on the A737V mutant polymerase, and that this movement is decreased by the compensating L771F mutation.	NIDDKD,MOLEC & CELLULAR BIOL LAB,ROOM 2A-19,BETHESDA,MD 20892; NIDDKD,BIOCHEM PHARMACOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ALBERTS BM, 1987, PHILOS T ROY SOC B, V317, P395, DOI 10.1098/rstb.1987.0068; BASU A, 1987, BIOCHEMISTRY-US, V26, P1704, DOI 10.1021/bi00380a032; BEAUCHAMP BB, 1988, P NATL ACAD SCI USA, V85, P2563, DOI 10.1073/pnas.85.8.2563; BLANCO L, 1992, GENE, V112, P139, DOI 10.1016/0378-1119(92)90316-H; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; CHARETTE MF, 1986, NUCLEIC ACIDS RES, V14, P3343, DOI 10.1093/nar/14.8.3343; COWART M, 1989, BIOCHEMISTRY-US, V28, P1975, DOI 10.1021/bi00431a004; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DEWAARD A, 1965, P NATL ACAD SCI USA, V54, P1241; DRAKE JW, 1969, NATURE, V221, P1128, DOI 10.1038/2211128a0; DRAKE JW, 1988, MOL GEN GENET, V214, P547, DOI 10.1007/BF00330493; DRAKE JW, 1968, COLD SPRING HARB SYM, V33, P339, DOI 10.1101/SQB.1968.033.01.039; DRAKE JW, 1970, P NATL ACAD SCI USA, V66, P823, DOI 10.1073/pnas.66.3.823; EPSTEIN RH, 1963, COLD SPRING HARB SYM, V28, P375, DOI 10.1101/SQB.1963.028.01.053; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; GAUSS P, 1983, P NATL ACAD SCI-BIOL, V80, P1669, DOI 10.1073/pnas.80.6.1669; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; GILLIN FD, 1975, BIOCHEM BIOPH RES CO, V64, P457, DOI 10.1016/0006-291X(75)90343-5; GILLIN FD, 1976, J BIOL CHEM, V251, P5219; GILLIN FD, 1976, J BIOL CHEM, V251, P5225; HERSHFIELD MS, 1973, J BIOL CHEM, V248, P1417; HINTON DM, 1985, J BIOL CHEM, V260, P2851; HOLLINGSWORTH HC, 1991, J BIOL CHEM, V266, P1888; HUANG CC, 1981, J BIOL CHEM, V256, P4087; JARVIS TC, 1991, J BIOL CHEM, V266, P1830; Joyce CM, 1991, CURR OPIN STRUC BIOL, V1, P123, DOI 10.1016/0959-440X(91)90020-T; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIN TC, 1987, P NATL ACAD SCI USA, V84, P7000, DOI 10.1073/pnas.84.20.7000; LO KY, 1976, J BIOL CHEM, V251, P2480; LO KY, 1976, J BIOL CHEM, V251, P2475; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACE DC, 1984, J MOL BIOL, V177, P313, DOI 10.1016/0022-2836(84)90459-5; MUZYCZKA N, 1972, J BIOL CHEM, V247, P7116; Nossal N.G., 1983, BACTERIOPHAGE T4, P71; NOSSAL NG, 1974, J BIOL CHEM, V249, P5668; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; NOSSAL NG, 1993, IN PRESS MOL BIOL BA; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; REDDY MK, 1992, J BIOL CHEM, V267, P14157; REHAKRANTZ LJ, 1993, J VIROL, V67, P60, DOI 10.1128/JVI.67.1.60-66.1993; REHAKRANTZ LJ, 1981, J MOL BIOL, V145, P677, DOI 10.1016/0022-2836(81)90309-0; REHAKRANTZ LJ, 1989, J VIROL, V63, P4762, DOI 10.1128/JVI.63.11.4762-4766.1989; REHAKRANTZ LJ, 1991, P NATL ACAD SCI USA, V88, P2417, DOI 10.1073/pnas.88.6.2417; REHAKRANTZ LJ, 1988, J MOL BIOL, V202, P711, DOI 10.1016/0022-2836(88)90552-9; REHAKRANTZ LJ, 1989, J CELL BIOL D, V13, P140; RIPLEY LS, 1983, MOL GEN GENET, V189, P113, DOI 10.1007/BF00326062; RIPLEY LS, 1990, ANNU REV GENET, V24, P189, DOI 10.1146/annurev.ge.24.120190.001201; RIPLEY LS, 1975, MOL GEN GENET, V141, P23, DOI 10.1007/BF00332376; ROTH AC, 1982, J BIOL CHEM, V257, P1267; RUSH J, 1990, J BIOL CHEM, V265, P4821; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SETO D, 1988, J BIOL CHEM, V263, P1494; SPACCIAPOLI P, J BIOL CHEM, V269, P447; SPICER EK, 1988, J BIOL CHEM, V263, P7478; TABOR S, 1990, J BIOL CHEM, V265, P8322; VENKATESAN M, 1982, J BIOL CHEM, V257, P2435; WURGLER SM, 1990, P NATL ACAD SCI USA, V87, P2740, DOI 10.1073/pnas.87.7.2740	60	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					438	446						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276833				2022-12-27	WOS:A1994MR21900074
J	TIAN, J; CHEN, JH; BANCROFT, C				TIAN, J; CHEN, JH; BANCROFT, C			EXPRESSION OF CONSTITUTIVELY ACTIVE G(S) ALPHA-SUBUNITS IN GH3 PITUITARY-CELLS STIMULATES PROLACTIN PROMOTER ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							THYROTROPIN-RELEASING-HORMONE; ADENYLYL CYCLASE; TRANSCRIPTION FACTOR; PHOSPHOLIPASE-C; GROWTH-HORMONE; G-PROTEIN; BINDING PROTEIN; PROXIMAL REGION; GENE; RECEPTOR	Although G protein alpha subunits are known to regulate such cellular functions as growth and enzymatic activity, the ability of these proteins to regulate target gene expression has not yet been directly investigated. Transient expression in GH3 pituitary cells of a target rat prolactin promoter-chloramphenicol acetyltransferase construct, (-1957)PRL-CAT, was increased by coexpressed constitutively active alpha(s) mutant Q227L-alpha(s) but not by wild-type alpha(s). Thus activated alpha(s) but not basal state alpha(s) can stimulate prolactin promoter activity. Q227L-alpha(s) also stimulated expression of construct (-187)PRL-CAT, showing that only the proximal prolactin promoter region is required for a response to activated alpha(s). The promoter specificity of the transcriptional influence of activated alpha(s) was demonstrated by the inability of either Q227L-alpha(s) or wild-type alpha(s) to stimulate expression of control target constructs containing either the rat growth hormone promoter or the thymidine kinase promoter. Previous studies have shown that the most proximal prolactin promoter binding site for the pituitary-specific transcription factor pit-1, site 1P, can act as an independent response element for either thyrotropin-releasing hormone or Ca2+. Two copies of site 1P conferred upon a heterologous metallothionein promoter a response to Q227L-alpha(s). This implies that site 1P can also serve as an independent response element for alpha(s) and suggests that pit-1 may be a mediator of the cellular regulation by alpha(s) of the prolactin promoter.	CUNY MT SINAI SCH MED,DEPT PHYSIOL & BIOPHYS,BOX 1218,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT BIOCHEM,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NCI NIH HHS [CA44998] Funding Source: Medline; NIDA NIH HHS [DA-07859] Funding Source: Medline; NIGMS NIH HHS [GM-36847] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036847] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007859] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ARAGAY AM, 1992, J BIOL CHEM, V267, P24983; BACHWICH D, 1992, MOL ENDOCRINOL, V6, P1175, DOI 10.1210/me.6.8.1175; CARILLO AJ, 1985, ENDOCRINOLOGY, V116, P202; CASTRILLO JL, 1989, SCIENCE, V243, P814, DOI 10.1126/science.2563596; COLEMAN DT, 1993, ENDOCRINOLOGY, V133, P2736, DOI 10.1210/en.133.6.2736; DAY RN, 1989, MOL ENDOCRINOL, V3, P3, DOI 10.1210/mend-3-1-3; DEMDEN MC, 1992, MOL ENDOCRINOL, V6, P581, DOI 10.1210/me.6.4.581; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; GRAEME M, 1993, TRENDS PHARMACOL SCI, V14, P239; HSIEH KP, 1992, MOL ENDOCRINOL, V6, P1673, DOI 10.1210/me.6.10.1673; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; JACKSON AE, 1988, MOL ENDOCRINOL, V2, P1139, DOI 10.1210/mend-2-11-1139; KEECH CA, 1992, MOL ENDOCRINOL, V6, P2059, DOI 10.1210/me.6.12.2059; KROLL SD, 1992, J BIOL CHEM, V267, P23183; LANDIS CA, 1990, J CLIN ENDOCR METAB, V71, P1416, DOI 10.1210/jcem-71-6-1416; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LIANG J, 1992, MOL ENDOCRINOL, V6, P885, DOI 10.1210/me.6.6.885; LUFKIN T, 1989, MOL ENDOCRINOL, V3, P559, DOI 10.1210/mend-3-3-559; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MATTERA R, 1989, SCIENCE, V243, P804, DOI 10.1126/science.2536957; MAURER RA, 1981, NATURE, V294, P94, DOI 10.1038/294094a0; MONTMAYEUR JP, 1993, MOL ENDOCRINOL, V7, P161, DOI 10.1210/me.7.2.161; MURDOCH GH, 1983, J BIOL CHEM, V258, P5329; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; PAN WT, 1990, J BIOL CHEM, V265, P7022; PAULSSEN RH, 1992, EUR J BIOCHEM, V204, P413, DOI 10.1111/j.1432-1033.1992.tb16651.x; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; WANG HL, 1992, EXP CELL RES, V203, P47, DOI 10.1016/0014-4827(92)90038-A; YAN GZ, 1991, MOL ENDOCRINOL, V5, P535, DOI 10.1210/mend-5-4-535; YAN GZ, 1991, MOL ENDOCRINOL, V5, P1488, DOI 10.1210/mend-5-10-1488; ZACHARY I, 1990, BIOCHEM BIOPH RES CO, V168, P1184, DOI 10.1016/0006-291X(90)91154-K	32	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					33	36						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276815				2022-12-27	WOS:A1994MR21900009
J	VANDORT, HM; LOW, PS; CORDES, KA; SCHOPFER, LM; SALHANY, JM				VANDORT, HM; LOW, PS; CORDES, KA; SCHOPFER, LM; SALHANY, JM			CALORIMETRIC EVIDENCE FOR ALLOSTERIC SUBUNIT INTERACTIONS ASSOCIATED WITH INHIBITOR BINDING TO BAND-3 TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN-ERYTHROCYTE-MEMBRANE; ANION TRANSPORT; KINETICS; EXCHANGE; TRANSITION; PROTEIN	A calorimetric endotherm occurring at 68-degrees-C (the C-transition) has been assigned previously to the integral domain of band 3 and was shown to be shifted to 78-degrees-C after covalent binding of 4,4'-diisothiocyanostilbene-2,2'-disulfonate (DIDS). In this study, we correlate the fractional appearance of the shifted C-transition with the fraction of DIDS bound to the band 3 monomer popuIation. Our results show a distinctly nonlinear correlation plot with the appearance of the shifted C-transition lagging behind DIDS labeling of the band 3 monomer population. The lag suggests that both monomers of a band 3 dimer must be labeled by DIDS in order for the shifted C-transition to appear at 78-degrees-C, implying that the thermal unfolding of the integral domain of band 3 is modulated by allosteric interactions between subunits. This is the first in situ structural evidence supporting ligand-mediated subunit interactions within a ''carrier''-type transporter protein oligomer.	UNIV NEBRASKA,MED CTR,VET ADM MED CTR,600 S 42ND ST,OMAHA,NE 68198; PURDUE UNIV,DEPT CHEM,W LAFAYETTE,IN 47907; UNIV NEBRASKA,MED CTR,DEPT BIOCHEM & MOLEC BIOL,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT INTERNAL MED,OMAHA,NE 68198	University of Nebraska System; University of Nebraska Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center				Low, Philip/0000-0001-9042-5528	NIGMS NIH HHS [GM 24417] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024417, R01GM024417] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AQUILA H, 1987, FEBS LETT, V212, P1, DOI 10.1016/0014-5793(87)81546-6; BRANDTS JF, 1977, BIOCHEMISTRY-US, V16, P3450, DOI 10.1021/bi00634a024; DAVIO SR, 1982, BIOCHEMISTRY-US, V21, P3585, DOI 10.1021/bi00258a009; EISINGER J, 1982, P NATL ACAD SCI-BIOL, V79, P408, DOI 10.1073/pnas.79.2.408; JANAS T, 1989, AM J PHYSIOL, V257, pC601, DOI 10.1152/ajpcell.1989.257.4.C601; JARDETZK.O, 1966, NATURE, V211, P969, DOI 10.1038/211969a0; JENNINGS ML, 1979, BIOCHIM BIOPHYS ACTA, V554, P498, DOI 10.1016/0005-2736(79)90387-0; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; SALHANY JM, 1981, J BIOL CHEM, V256, P1080; SALHANY JM, 1992, BIOCHEMISTRY-US, V31, P7301, DOI 10.1021/bi00147a014; SALHANY JM, 1978, BIOCHEMISTRY-US, V17, P3354, DOI 10.1021/bi00609a028; SALHANY JM, 1993, BIOCHEMISTRY-US, V32, P7413, DOI 10.1021/bi00080a011; SALHANY JM, 1992, PROGR CELL RES; SALHANY JM, 1990, ERYTHROCYTE, V3, P79; SCHOPFER LM, 1992, BIOCHEMISTRY-US, V31, P12610, DOI 10.1021/bi00165a010; SINGER SJ, 1977, J SUPRAMOL STR CELL, V6, P313, DOI 10.1002/jss.400060304; STEIN WD, 1990, CHANNELS CARRIERS PU, P127; WANG DN, 1993, EMBO J, V12, P2233, DOI 10.1002/j.1460-2075.1993.tb05876.x	19	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					59	61						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276856				2022-12-27	WOS:A1994MR21900016
J	ZHANG, K; MAX, EE; CHEAH, HK; SAXON, A				ZHANG, K; MAX, EE; CHEAH, HK; SAXON, A			COMPLEX ALTERNATIVE RNA SPLICING OF EPSILON-IMMUNOGLOBULIN TRANSCRIPTS PRODUCES MESSENGER-RNAS ENCODING 4 POTENTIAL SECRETED PROTEIN ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGE PRODUCTION; SINGLE GENE; B-CELLS; PATHWAYS; EXONS	In RNA from human IgE-producing lymphocytes, we previously discovered two alternatively spliced epsilon-immunoglobulin mRNA isoforms that encode a novel secreted form of IgE and a membrane-bound species. Further analysis using epsilon-specific reverse transcriptase polymerase chain reactions has elucidated several additional alternatively spliced species of epsilon mRNA. One RNA isoform is generated by splicing the CH4 exon to a novel distal splice acceptor site, forming an epsilon RNA species (designated CH4-M2'') that encodes a secreted epsilon protein 6 amino acids larger than the classic secreted epsilon protein. The other three novel epsilon RNAs are generated by splicing from within CH4 to a new exon structure (designated CH5) that is located between CH4 and the membrane exons. Since the three new mRNAs using CH5 share the same stop codon in CH5, they all encode the same novel protein, which is 10 amino acids shorter than the classic secreted epsilon heavy chain. The new alternatively spliced epsilon mRNAs reported here, in addition to the previously reported forms encoding membrane and larger secreted IgE, appear to reflect the normal splicing pattern in humans, as we have detected all these epsilon RNAs in all the human IgE-secreting cells and cell lines tested.	US FDA, CTR BIOL EVALUAT & RES, BETHESDA, MD 20892 USA	US Food & Drug Administration (FDA)	ZHANG, K (corresponding author), UNIV CALIF LOS ANGELES, SCH MED,DEPT MED,DIV CLIN IMMUNOL ALLERGY, HART & LOUISE LYON LAB, CTR HLTH SCI 52175, LOS ANGELES, CA 90024 USA.				NATIONAL CANCER INSTITUTE [R01CA030515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI015251, U01AI034567, U19AI034567, R01AI015251] Funding Source: NIH RePORTER; NCI NIH HHS [CA-30515] Funding Source: Medline; NIAID NIH HHS [AI-34567, AI-15251] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BREITBART RE, 1987, CELL, V49, P793, DOI 10.1016/0092-8674(87)90617-9; EARLY P, 1980, CELL, V20, P313, DOI 10.1016/0092-8674(80)90617-0; Hasemann CA, 1989, FUNDAMENTAL IMMUNOLO, P209; HELFMAN DM, 1986, MOL CELL BIOL, V6, P3582, DOI 10.1128/MCB.6.11.3582; HELLMAN L, 1993, EUR J IMMUNOL, V23, P159, DOI 10.1002/eji.1830230126; ISHIZAKA K, 1966, J IMMUNOL, V97, P75; MAX EE, 1982, CELL, V29, P691, DOI 10.1016/0092-8674(82)90185-4; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NOGUCHI T, 1986, J BIOL CHEM, V261, P3807; PENG C, 1992, J IMMUNOL, V148, P129; PERIASAMY M, 1984, J BIOL CHEM, V259, P3595; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAXON A, 1976, J IMMUNOL METHODS, V12, P285, DOI 10.1016/0022-1759(76)90050-8; SAXON A, 1991, J IMMUNOL, V147, P4000; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; THYPHRONITIS G, 1991, J IMMUNOL, V146, P1496; TRIMBLE RB, 1984, ANAL BIOCHEM, V141, P515, DOI 10.1016/0003-2697(84)90080-0; ZHANG K, 1992, J EXP MED, V176, P233, DOI 10.1084/jem.176.1.233; ZHANG K, 1991, J IMMUNOL, V146, P1836; ZORN AM, 1991, BIOTECHNIQUES, V11, P180	21	44	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					456	462						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276835				2022-12-27	WOS:A1994MR21900076
J	CHU, A; DINKOVA, A; DAVIN, LB; BEDGAR, DL; LEWIS, NG				CHU, A; DINKOVA, A; DAVIN, LB; BEDGAR, DL; LEWIS, NG			STEREOSPECIFICITY OF (+)-PINORESINOL AND (+)-LARICIRESINOL REDUCTASES FROM FORSYTHIA-INTERMEDIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE-EXTRACTS; ALCOHOL-DEHYDROGENASE; LIGNANS; BIOSYNTHESIS; PURIFICATION; COMPONENTS; LACTONE; BINDING; LIVER	Pinoresinol/lariciresinol reductase catalyzes the first known example of a highly unusual benzylic ether reduction in plants; its mechanism of hydride transfer is described. The enzyme was found in Forsythia intermedia and catalyzes the presumed regulatory branch-points in the pathway leading to benzylaryltetrahydrofuran, dibenzylbutane, dibenzylbutyrolactone, and aryltetrahydronaphthalene lignans. Using [7,7'-H-2(2)]-pinoresinol and [7,7'-H-2(3)]lariciresinol as substrates, the hydride transfers of the highly unusual reductase were demonstrated to be completely stereospecific (>99%). The incoming hydrides were found to take up the pro-R position at C-7' (and/or C-7) in lariciresinol and secoisolariciresinol, thereby eliminating the possibility of random hydride delivery to a planar quinone methide intermediate. As might be expected, the mode of hydride abstraction from NADPH was also stereospecific: using [4R-H-3] and [4S-H-3]NADPH, it was found that only the 4 pro-R hydrogen was abstracted for enzymatic hydride transfer.	WASHINGTON STATE UNIV,INST BIOL CHEM,PULLMAN,WA 99163	Washington State University				Dinkova-Kostova, Albena/0000-0003-0316-9859; Lewis, Norman/0000-0001-5742-032X; Davin, Laurence/0000-0002-3248-6485				Adlercreutz H., 1991, Nutrition, toxicity, and cancer., P137; ADLERCREUTZ H, 1984, GASTROENTEROLOGY, V86, P761; Ayres D.C., 1990, LIGNANS CHEM BIOL CH; BELMARES H, 1979, IND ENG CHEM PROD RD, V18, P220, DOI 10.1021/i360071a014; BIELLMANN JF, 1979, EUR J BIOCHEM, V102, P107, DOI 10.1111/j.1432-1033.1979.tb06268.x; BINNS AN, 1987, P NATL ACAD SCI USA, V84, P980, DOI 10.1073/pnas.84.4.980; BORRIELLO SP, 1985, J APPL BACTERIOL, V58, P37, DOI 10.1111/j.1365-2672.1985.tb01427.x; Bovey F. A., 1969, NUCLEAR MAGNETIC RES; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAVIN LB, 1992, PHYTOCHEMISTRY, V31, P3869, DOI 10.1016/S0031-9422(00)97544-7; DAVIN LB, 1992, RECENT ADV PHYTOCHEM, V26, P325; ELAKOVICH SD, 1985, J CHEM ECOL, V11, P27, DOI 10.1007/BF00987601; FAURE M, 1990, PHYTOCHEMISTRY, V29, P3773, DOI 10.1016/0031-9422(90)85329-E; FUJIMOTO H, 1982, MOKUZAI GAKKAISHI, V28, P555; Grisebach H., 1981, The biochemistry of plants. A comprehensive treatise. Volume 7. Secondary plant products., P457; GRISEBACH H, 1977, PYRIDINE NUCLEOTIDE, P458; HARMATHA J, 1984, BIOCHEM SYST ECOL, V12, P95, DOI 10.1016/0305-1978(84)90015-2; HATTORI M, 1986, CHEM PHARM BULL, V34, P3885; KAMIL WM, 1986, PHYTOCHEMISTRY, V25, P2093, DOI 10.1016/0031-9422(86)80072-3; KATAYAMA T, 1992, PHYTOCHEMISTRY, V31, P3875, DOI 10.1016/S0031-9422(00)97545-9; KATAYAMA T, 1993, PHYTOCHEMISTRY, V33, P581, DOI 10.1016/0031-9422(93)85452-W; KLISCHIES M, 1978, PHYTOCHEMISTRY, V17, P1523, DOI 10.1016/S0031-9422(00)94634-X; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LEWIS NG, 1990, ANNU REV PLANT PHYS, V41, P455, DOI 10.1146/annurev.pp.41.060190.002323; LEWIS NG, 1992, B LIAISON GROUPE POL, V16, P98; MANSELL RL, 1974, PHYTOCHEMISTRY, V13, P2427, DOI 10.1016/S0031-9422(00)86917-4; MARKKANEN T, 1981, DRUG EXP CLIN RES, V7, P711; MORAN RG, 1984, ANAL BIOCHEM, V138, P196, DOI 10.1016/0003-2697(84)90788-7; OSAWA T, 1985, AGR BIOL CHEM TOKYO, V49, P3351, DOI 10.1080/00021369.1985.10867272; OZAWA S, 1993, PHYTOCHEMISTRY, V32, P643, DOI 10.1016/S0031-9422(00)95149-5; PROCHASKA HJ, 1986, J BIOL CHEM, V261, P1372; RAHMAN MMA, 1990, PHYTOCHEMISTRY, V29, P1841, DOI 10.1016/0031-9422(90)85025-B; SAKAKIBARA A, 1987, HOLZFORSCHUNG, V41, P1, DOI 10.1515/hfsg.1987.41.1.1; SCHRODER HC, 1990, Z NATURFORSCH C, V45, P1215; SLESSOR KN, 1971, CAN J CHEMISTRY, V49, P2874, DOI 10.1139/v71-477; UMEZAWA T, 1991, J BIOL CHEM, V266, P10210; UMEZAWA T, 1990, BIOCHEM BIOPH RES CO, V171, P1008, DOI 10.1016/0006-291X(90)90784-K; UMEZAWA T, 1990, J CHEM SOC CHEM COMM, P1405, DOI 10.1039/c39900001405	38	68	71	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27026	27033						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262939				2022-12-27	WOS:A1993MM26200031
J	MENDELMAN, LV; NOTARNICOLA, SM; RICHARDSON, CC				MENDELMAN, LV; NOTARNICOLA, SM; RICHARDSON, CC			EVIDENCE FOR DISTINCT PRIMASE AND HELICASE DOMAINS IN THE 63-KDA GENE-4 PROTEIN OF BACTERIOPHAGE-T7 - CHARACTERIZATION OF A NUCLEOTIDE-BINDING SITE MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE 5'-TRIPHOSPHATASE ACTIVITY; DNA-POLYMERASE; DEOXYRIBONUCLEIC-ACID; ADENYLATE KINASE; ESCHERICHIA-COLI; PRIMER SYNTHESIS; STRAND SYNTHESIS; REPLICATION; ATP; PURIFICATION	Gene 4 of bacteriophage T7 encodes two co-linear proteins, the 56- and 63-kDa gene 4 proteins. The 56-kDa protein translocates 5' to 3' on single-stranded DNA using nucleotide hydrolysis for energy and is a helicase. The 63-kDa gene 4 protein catalyzes all of the activities of the 56-kDa gene 4 protein and, in addition, catalyzes the synthesis of oligoribonucleotides on single-stranded DNA. Two conserved residues in a putative nucleotide binding site of the 63-kDa gene 4 protein were mutated by substituting Val and Met for wild-type residues Gly and Lys, at positions 317 and 318, respectively. The mutant 63-kDa gene 4 protein lacks the ability to catalyze the hydrolysis of a nucleoside 5'-triphosphate in a single-stranded DNA-dependent reaction and inhibits nucleotide hydrolysis by wild-type gene 4 proteins. The mutant primase contains 0.4% of the primase activity of the 63-kDa gene 4 protein on M13 single-stranded DNA and 12% of the wild-type primase activity on an oligonucleotide with a single primase recognition site. Addition of wild-type 56-kDa gene 4 protein stimulates the mutant primase activity over 50-fold on M13 single-stranded DNA and 8-fold on oligonucleotides. This increase in primase activity correlates with an increase in the affinity of the mutant primase-wild-type helicase complex for single-stranded DNA template.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School					NIAID NIH HHS [AI-06045] Funding Source: Medline; PHS HHS [1F32 A108630-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI006045, R01AI006045] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARAI K, 1981, J BIOL CHEM, V256, P5260; ARAI KI, 1981, P NATL ACAD SCI-BIOL, V78, P707, DOI 10.1073/pnas.78.2.707; BERNSTEIN JA, 1988, J BIOL CHEM, V263, P14891; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; BROWN WC, 1989, J BIOL CHEM, V264, P6748; BURGERS PMJ, 1989, PROG NUCLEIC ACID RE, V37, P235; CALDER JM, 1990, NUCLEIC ACIDS RES, V18, P3573, DOI 10.1093/nar/18.12.3573; DODSON MS, 1991, P NATL ACAD SCI USA, V88, P1105, DOI 10.1073/pnas.88.4.1105; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; HINTON DM, 1987, J BIOL CHEM, V262, P10873; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; KORNBERG A, 1991, DNA REPLICATION, P275; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MATSON SW, 1985, J BIOL CHEM, V260, P2281; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MENDELMAN LV, 1992, P NATL ACAD SCI USA, V89, P10638, DOI 10.1073/pnas.89.22.10638; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; MILLER JH, 1987, METHOD ENZYMOL, V152, P163; NAKAI H, 1988, J BIOL CHEM, V263, P9818; NOTARNICOLA SM, 1993, J BIOL CHEM, V268, P27198; PATEL SS, 1992, J BIOL CHEM, V267, P15013; PATEL SS, 1993, J BIOL CHEM, V268, P10668; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; QIAN XQ, 1993, NATURE, V365, P277, DOI 10.1038/365277a0; ROMANO LJ, 1979, J BIOL CHEM, V254, P483; ROSENBERG AH, 1992, J BIOL CHEM, V267, P15005; SCHERZINGER E, 1977, EUR J BIOCHEM, V72, P543, DOI 10.1111/j.1432-1033.1977.tb11278.x; SCHERZINGER E, 1977, NUCLEIC ACIDS RES, V4, P4151, DOI 10.1093/nar/4.12.4151; SEKI T, 1979, NUCLEIC ACIDS RES, V7, P1603, DOI 10.1093/nar/7.6.1603; SHRIMANKAR P, 1992, J BACTERIOL, V174, P7689, DOI 10.1128/JB.174.23.7689-7696.1992; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1987, THESIS HARVARD U; TAGAYA M, 1987, J BIOL CHEM, V262, P8257; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; ZIEGELIN G, 1993, EMBO J, V12, P3703, DOI 10.1002/j.1460-2075.1993.tb06045.x	39	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27208	27213						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262962				2022-12-27	WOS:A1993MM26200057
J	HUFLEJT, ME; TURCK, CW; LINDSTEDT, R; BARONDES, SH; LEFFLER, H				HUFLEJT, ME; TURCK, CW; LINDSTEDT, R; BARONDES, SH; LEFFLER, H			L-29, A SOLUBLE LACTOSE-BINDING LECTIN, IS PHOSPHORYLATED ON SERINE-6 AND SERINE-12 IN-VIVO AND BY CASEIN KINASE-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE-T-ANTIGEN; TRANSCRIPTIONAL ACTIVATION; RIBONUCLEOPROTEIN COMPLEX; MAC-2 ANTIGEN; P53 PROTEIN; CELLS; LOCALIZATION; RECOGNITION; FIBROBLASTS; EXPRESSION	L-29, a mammalian soluble lactose-binding lectin, was previously shown to be phosphorylated in confluent 3T3 fibroblasts (Cowles, E. A., Agrwal, N., Anderson, R. L., and Wang, J. L. (1990) J. Biol. Chem. 265, 17706-17712), which contain a small amount of this protein. We have determined the site of phosphorylation on L-29, taking advantage of the abundance of L-29 (about 1% of total soluble cell protein) in confluent polarized Madin-Darby canine kidney (MDCK) cells. Approximately 15-20% of the L-29 is phosphorylated in these cells. Phosphoamino acid analysis showed phosphate incorporation only at serine. Analysis of chymotryptic and endoproteinase Asp-N-generated NH2-terminal fragments by Edman degradation showed that 90% of the phosphate was at Ser6 and 10% at Ser12. The sequence surrounding Ser6, which is conserved in all known L-29 sequences, indicated that this serine might be phosphorylated by casein kinase I or casein kinase II. Reaction of human recombinant L-29 with [gamma-P-32]ATP and each of these casein kinases showed that only casein kinase I catalyzed significant incorporation of P-32 into L-29; and, as with the L-29 from the MDCK cell extracts, most of the phosphate was incorporated at Ser6 and a small amount was incorporated at Ser12.	UNIV CALIF SAN FRANCISCO, LANGLEY PORTER NEUROPSYCHIAT INST, DEPT PSYCHIAT, BOX F-0984, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Leffler, Hakon/A-2416-2019	Huflejt, Malgorzata/0000-0002-2016-8367; Leffler, Hakon/0000-0003-4482-8945				BREITFELD PP, 1989, METHOD CELL BIOL, V32, P329; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; COWLES EA, 1990, J BIOL CHEM, V265, P17706; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; HAMANN KK, 1991, EXP CELL RES, V196, P82, DOI 10.1016/0014-4827(91)90458-7; HATHAWAY GM, 1983, METHOD ENZYMOL, V99, P317, DOI 10.1016/0076-6879(83)99067-5; HATHAWAY GM, 1983, METHOD ENZYMOL, V99, P308, DOI 10.1016/0076-6879(83)99066-3; HERRMANN J, 1993, J BIOL CHEM, V268, P26704; HO MK, 1982, J IMMUNOL, V128, P1221; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; LAING JG, 1988, BIOCHEMISTRY-US, V27, P5329, DOI 10.1021/bi00414a057; LEFFLER H, 1989, BIOCHEMISTRY-US, V28, P9222, DOI 10.1021/bi00449a039; LINDSTEDT R, 1993, J BIOL CHEM, V268, P11750; LOTZ MM, 1993, P NATL ACAD SCI USA, V90, P3466, DOI 10.1073/pnas.90.8.3466; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MILNE DM, 1992, ONCOGENE, V7, P1361; MOUTSATSOS IK, 1986, J CELL BIOL, V102, P477, DOI 10.1083/jcb.102.2.477; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; ODA Y, 1991, GENE, V99, P279; OROURKE RW, 1990, ONCOGENE, V5, P1829; PALEN E, 1991, BIOCHEMISTRY-US, V30, P5586, DOI 10.1021/bi00236a035; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROBERTSON MW, 1991, J IMMUNOL, V147, P3024; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; UMPHRESS JL, 1992, EUR J BIOCHEM, V203, P239, DOI 10.1111/j.1432-1033.1992.tb19852.x; WANG JL, 1992, BIOCHEM SOC T, V20, P269, DOI 10.1042/bst0200269; WOO HJ, 1990, J BIOL CHEM, V265, P7097	31	102	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26712	26718						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253806				2022-12-27	WOS:A1993MK42500102
J	BURMA, S; MUKHERJEE, B; JAIN, A; HABIB, S; HASNAIN, SE				BURMA, S; MUKHERJEE, B; JAIN, A; HABIB, S; HASNAIN, SE			AN UNUSUAL 30-KDA PROTEIN-BINDING TO THE POLYHEDRON GENE PROMOTER OF AUTOGRAPHA-CALIFORNICA NUCLEAR POLYHEDROSIS-VIRUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACULOVIRUS EXPRESSION VECTORS; RNA-POLYMERASE; TRANSCRIPTION; PHOSPHORYLATION; INITIATION; ACTIVATION; SITES; CELLS	Gel retardation assays-using nuclear extracts from the Autographa californica nuclear polyhedrosis virus-infected Sf21 (Spodoptera frugiperda) insect cell line revealed a host factor (polyhedrin promoter-binding protein or PPBP) that binds to the polyhedrin gene promoter. A hexanucleotide sequence (AATAAA) within the promoter is important for binding in association with neighboring elements, some of which are contributed by the sequence TAAGTATT present at the transcription start point. PPBP was affinity purified and appears to be an unusual DNA-binding protein with respect to its stability (binding was obtained at NaCl concentrations and temperatures ranging from 0.2 to 2 m and 0 to 65-degrees-C, respectively), high binding affinity (binding even in the absence of nonspecific DNA) with an apparent dissociation constant of approximately 3.7 x 10(-12) M, and high specificity (binding was unaffected in the presence of a 50,000 times excess of nonspecific DNA). From UV cross-linking and Southwestern analyses the molecular mass of PPBP was estimated to be approximately 30 kDa. PPBP is phosphorylated and may have a regulatory function because dephosphorylation abolished DNA binding activity. Differences in PPBP characteristics between nuclear extracts from Sf21 and from Bm5 (Bombyx mori) cell line suggested that additional factors may be involved in the interaction of PPBP with the polyhedrin promoter.			BURMA, S (corresponding author), NATL INST IMMUNOL,EUKARYOT GENE EXPRESS LAB,ARUNA ASAF ALI MARG,NEW DELHI 110067,INDIA.		HASNAIN, SEYED/C-1492-2009	Hasnain, Seyed/0000-0002-2967-0791				BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CARACAMO J, 1990, GENE DEV, V4, P1611; CHODOSH L, 1988, CURRENT PROTOCOLS MO, V2; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; HUH NE, 1990, J GEN VIROL, V71, P195, DOI 10.1099/0022-1317-71-1-195; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; JARVIS DL, 1992, RECOMBINANT DNA VACC, P265; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIAO XB, 1992, J MOL BIOL, V223, P857, DOI 10.1016/0022-2836(92)90248-I; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MARZLUFF WF, 1990, METHOD ENZYMOL, V181, P30; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MILLER DW, 1986, GENETIC ENG PRINCIPL, V8, P277; MILLER LK, 1989, BIOESSAYS, V11, P91, DOI 10.1002/bies.950110404; NAKHAI B, 1991, FEBS LETT, V283, P104, DOI 10.1016/0014-5793(91)80564-J; OOI BG, 1989, J MOL BIOL, V210, P721, DOI 10.1016/0022-2836(89)90105-8; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; OTTONELLO S, 1987, EMBO J, V6, P1921, DOI 10.1002/j.1460-2075.1987.tb02452.x; PAPAVASSILIOU AG, 1992, ANAL BIOCHEM, V203, P302, DOI 10.1016/0003-2697(92)90317-Z; PARTHUN MR, 1992, MOL CELL BIOL, V12, P4981, DOI 10.1128/MCB.12.11.4981; PASSARELLI AL, 1993, J VIROL, V67, P2149, DOI 10.1128/JVI.67.4.2149-2158.1993; PASSARELLI AL, 1993, J VIROL, V67, P3481, DOI 10.1128/JVI.67.6.3481-3488.1993; POSSEE R, 1991, VIROLOGY, V185, P299; POSSEE RD, 1987, NUCLEIC ACIDS RES, V15, P10233, DOI 10.1093/nar/15.24.10233; PUGH BF, 1992, J BIOL CHEM, V267, P679; RANKIN C, 1988, GENE, V70, P39, DOI 10.1016/0378-1119(88)90102-3; RAO MV, 1990, J BIOL CHEM, V265, P5617; RICE WC, 1986, VIRUS RES, V6, P155, DOI 10.1016/0168-1702(86)90047-X; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; ROELVINK PW, 1992, J GEN VIROL, V73, P1481, DOI 10.1099/0022-1317-73-6-1481; RUTBERG SE, 1992, NUCLEIC ACIDS RES, V20, P1815, DOI 10.1093/nar/20.7.1815; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; SRIDHAR P, 1993, FEBS LETT, V315, P282, DOI 10.1016/0014-5793(93)81179-4; SRIDHAR P, 1993, IN PRESS GENE AMST; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3; WILSON ME, 1987, J VIROL, V61, P661, DOI 10.1128/JVI.61.3.661-666.1987; YANG CL, 1991, VIRUS RES, V20, P251, DOI 10.1016/0168-1702(91)90079-B; YOUNG LS, 1991, SCIENCE, V252, P542, DOI 10.1126/science.1708526	41	45	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2750	2757						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300607				2022-12-27	WOS:A1994MV43200060
J	DESBOIS, C; HOGUE, DA; KARSENTY, G				DESBOIS, C; HOGUE, DA; KARSENTY, G			THE MOUSE OSTEOCALCIN GENE-CLUSTER CONTAINS 3 GENES WITH 2 SEPARATE SPATIAL AND TEMPORAL PATTERNS OF EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; MATRIX GLA-PROTEIN; CRYSTAL-GROWTH; BONE; INHIBITOR; STONES	Osteocalcin is the most abundant noncollagenous protein of bone. Here we report that the mouse genome contains an osteocalcin cluster composed of three genes arranged within a 23-kilobase span of genomic DNA. We named them osteocalcin gene 1 (OG1), osteocalcin gene 2 (OG2), and osteocalcin-related gene (ORG) in order from the 5' end to the 3' end of the cluster. Hybridization of polymerase chain reaction-amplified cDNAs with specific oligonucleotides and RNase protection assays showed that OG1 and OG2 are expressed only in bone, whereas ORG is transcribed in kidney but not in bone. Furthermore, during embryogenesis, OG1 and OG2 begin to be expressed at day 15.5, while ORG is transcribed as early as day 10.5. The protein encoded by ORG has a similar pattern of expression and identical structural features to nephrocalcin, a calcium-binding protein partially purified from kidney that plays a role in calcium reabsorption and in prevention of nephrolithiasis. The nephrocaicin gene has not been cloned in any species; we propose that ORG is the mouse nephrocalcin gene. The existence of several osteocalcin or osteocalcin-related sequences is not restricted to mouse but is present in every species we examined.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Morris, Christelle/M-8168-2014	Morris, Christelle/0000-0003-1575-4609	NIAMS NIH HHS [AR41059-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR041059] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CELESTE AJ, 1986, EMBO J, V5, P1885, DOI 10.1002/j.1460-2075.1986.tb04440.x; COE FL, 1992, NEW ENGL J MED, V327, P1141, DOI 10.1056/NEJM199210153271607; DEYL Z, 1980, H-S Z PHYSIOL CHEM, V361, P1767, DOI 10.1515/bchm2.1980.361.2.1767; FRASER JD, 1988, J BIOL CHEM, V263, P11033; HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990; JOHANNES FJ, 1992, TRENDS GENET, V8, P48; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LIAN J, 1989, P NATL ACAD SCI USA, V86, P1143, DOI 10.1073/pnas.86.4.1143; NAKAGAWA Y, 1987, J CLIN INVEST, V79, P1782, DOI 10.1172/JCI113019; NAKAGAWA Y, 1983, J BIOL CHEM, V258, P2594; OH Y, 1992, J BIOL CHEM, V267, P18498; POSER JW, 1980, J BIOL CHEM, V255, P8685; POSER JW, 1979, J BIOL CHEM, V254, P431; PRICE PA, 1982, P NATL ACAD SCI-BIOL, V79, P7734, DOI 10.1073/pnas.79.24.7734; ROMBERG RW, 1986, BIOCHEMISTRY-US, V25, P1176, DOI 10.1021/bi00353a035; RUGH R, 1990, MOUSE ITS REPRODUCTI, P216; TERMINE JD, 1980, CALCIFIED TISSUE INT, V31, P247, DOI 10.1007/BF02407188; TROUTT AB, 1992, P NATL ACAD SCI USA, V89, P9823, DOI 10.1073/pnas.89.20.9823	18	193	198	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1183	1190						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288580				2022-12-27	WOS:A1994MR22000066
J	LANCASTER, CA; TAYLORHARRIS, PM; SELF, AJ; BRILL, S; VANERP, HE; HALL, A				LANCASTER, CA; TAYLORHARRIS, PM; SELF, AJ; BRILL, S; VANERP, HE; HALL, A			CHARACTERIZATION OF RHOGAP - A GTPASE-ACTIVATING PROTEIN FOR RHO-RELATED SMALL GTPASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; BINDING PROTEIN; MOLECULAR-CLONING; CDC42HS PROTEIN; HUMAN HOMOLOG; GENE FAMILY; BCR GENE; RAS P21; IDENTIFICATION; PURIFICATION	GTPase-activating proteins or GAPs play an important role in signal transduction pathways regulated by GTP-binding proteins. In addition to acting as down-regulators of GTPases, there is growing evidence that they also act as effector molecules required for downstream signaling. PLC-beta1, the target protein regulated by the heterotrimeric GTPase Gq, has been shown to be a GAP, whereas rasGAP, a down-regulator of the small GTPase ras, may be required for ras-mediated signals. We have purified a GAP specific for the rho subfamily of small GTPases. Partial sequence analysis of rhoGAP has led to the identification of a family of related proteins which now includes bcr, chimaerin, p190, p85, and 3BP-1. We report here the isolation of a cDNA clone encoding human rhoGAP and the expression of recombinant protein. The full-length protein is 50 kDa and is ubiquitously expressed in mammalian cells. At least three members of the rho family are substrates for rhoGAP, rho, rac, and G25K/CDC42, and they each bind equally well to the protein. In vitro GTPase assays, however, reveal that G25K/CDC42 is the preferred substrate. RhoGAP contains a proline-rich sequence, suggesting that it is an SH3-binding protein.	INST CANC RES, CHESTER BEATTY LABS, LONDON SW3 6JB, ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK								ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ADAMS JM, 1992, ONCOGENE, V7, P611; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; CHUANG TH, 1993, J BIOL CHEM, V268, P775; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GARRETT MD, 1991, BIOCHEM J, V276, P833, DOI 10.1042/bj2760833; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HALL A, 1992, CELL, V69, P389, DOI 10.1016/0092-8674(92)90441-E; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1993, EMBO J, V12, P1915, DOI 10.1002/j.1460-2075.1993.tb05840.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HART MJ, 1991, J BIOL CHEM, V266, P20840; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KOZAK M, 1991, J BIOL CHEM, V266, P19867; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MANSER E, 1992, J BIOL CHEM, V267, P16025; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MITCHELL PJ, 1992, ONCOGENE, V7, P383; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MORII N, 1991, J BIOL CHEM, V266, P7646; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; UEDA T, 1990, J BIOL CHEM, V265, P9373; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138	45	140	142	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1137	1142						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288572				2022-12-27	WOS:A1994MR22000058
J	WONG, MH; OELKERS, P; CRADDOCK, AL; DAWSON, PA				WONG, MH; OELKERS, P; CRADDOCK, AL; DAWSON, PA			EXPRESSION CLONING AND CHARACTERIZATION OF THE HAMSTER ILEAL SODIUM-DEPENDENT BILE-ACID TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORDER MEMBRANE-VESICLES; XENOPUS-LAEVIS OOCYTES; TAUROCHOLATE TRANSPORT; FUNCTIONAL EXPRESSION; RAT; SYSTEM; SEQUENCE; KINETICS; ILEUM; ABSORPTION	Active uptake of bile acids from the lumen of the small intestine is mediated hy an ileal Na+-dependent bile acid transport system. To identify components of this transport system, an expression cloning strategy was employed to isolate a hamster ileal cDNA that exhibits bile, acid transport activity. By Northern blot analysis, mRNA for the cloned transporter was readily detected in ileum and kidney but was absent from liver and proximal small intestine. The transporter cDNA encoded a 348-amino acid protein with seven potential transmembrane domains and three possible N-linked glycosylation sites. The amino acid sequence was 35% identical and 63% similar to the rat liver Na+/bile acid cotransporter. After transfection into COS cells, the hamster cDNA transported taurocholate in a strict Na+-dependent fashion with an apparent K(m) of 33 muM. This taurocholate transport was inhibited by various bile acids but not by taurine or other organic anions. The Na+ dependence, saturability, and bile acid specificity of transport as well as the tissue specificity of mRNA expression strongly argue that the transporter cDNA characterized in this study is the Na+/bile acid cotransporter described previously in ileum.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED,DEPT INTERNAL MED, DIV GASTROENTEROL,MED CTR BLVD, WINSTON SALEM, NC 27157 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT COMPARAT MED, WINSTON SALEM, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center					NCRR NIH HHS [RR-05404] Funding Source: Medline; NHLBI NIH HHS [HL07115] Funding Source: Medline; NIDDK NIH HHS [DK08718, R29 DK047987] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F31DK008718, R29DK047987] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BARNARD JA, 1987, GASTROENTEROLOGY, V93, P925, DOI 10.1016/0016-5085(87)90553-1; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BOYER JL, 1992, ANNU REV PHYSIOL, V54, P415, DOI 10.1146/annurev.ph.54.030192.002215; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; CHANDLER CE, 1993, AM J PHYSIOL, V264, pG1118, DOI 10.1152/ajpgi.1993.264.6.G1118; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEGRIP WJ, 1982, METHOD ENZYMOL, V81, P197; DEGUCHI Y, 1990, J BIOL CHEM, V265, P21704; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIETSCHY JM, 1968, J LIPID RES, V9, P297; ERCOLANI L, 1988, J BIOL CHEM, V263, P15335; ESSER V, 1988, J BIOL CHEM, V263, P13282; FLIESLER SJ, 1985, P NATL ACAD SCI USA, V82, P1116, DOI 10.1073/pnas.82.4.1116; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HOFMANN AF, 1977, CLIN GASTROENTEROL, V6, P3; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRAG E, 1974, J CLIN INVEST, V53, P1686, DOI 10.1172/JCI107720; KRAMER W, 1992, BIOCHIM BIOPHYS ACTA, V1111, P93, DOI 10.1016/0005-2736(92)90278-T; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LACK L, 1961, AM J PHYSIOL, V200, P313, DOI 10.1152/ajplegacy.1961.200.2.313; LACK L, 1979, ENVIRON HEALTH PERSP, V33, P79, DOI 10.2307/3429075; LEWIS MC, 1990, AM J PHYSIOL, V259, pG233, DOI 10.1152/ajpgi.1990.259.2.G233; LIN MC, 1990, J BIOL CHEM, V265, P14986; MARCUS SN, 1991, GASTROENTEROLOGY, V100, P212; MULLINS JGL, 1992, BIOCHEM J, V285, P785, DOI 10.1042/bj2850785; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SCHIFF ER, 1972, J CLIN INVEST, V51, P1351, DOI 10.1172/JCI106931; SCHWENK M, 1983, EUR J BIOCHEM, V131, P387, DOI 10.1111/j.1432-1033.1983.tb07275.x; SORSCHER S, 1992, BIOCHEM BIOPH RES CO, V186, P1455, DOI 10.1016/S0006-291X(05)81570-0; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WEINBERG SL, 1986, J CLIN INVEST, V78, P44, DOI 10.1172/JCI112571; WEINER IM, 1964, AM J PHYSIOL, V207, P964; WILSON FA, 1979, BIOCHIM BIOPHYS ACTA, V554, P430, DOI 10.1016/0005-2736(79)90382-1; WILSON FA, 1974, BIOCHIM BIOPHYS ACTA, V363, P112, DOI 10.1016/0005-2736(74)90010-8; WILSON FA, 1981, AM J PHYSIOL, V241, pG83, DOI 10.1152/ajpgi.1981.241.2.G83; WILSON FA, 1981, J CLIN INVEST, V67, P1141, DOI 10.1172/JCI110128; WILSON FA, 1975, BIOCHIM BIOPHYS ACTA, V406, P280, DOI 10.1016/0005-2736(75)90010-3; WRIGHT E M, 1992, Current Opinion in Cell Biology, V4, P696, DOI 10.1016/0955-0674(92)90091-P; ZIMMERLI B, 1989, J PHARMACOL EXP THER, V250, P301	46	314	323	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1340	1347						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288599				2022-12-27	WOS:A1994MR22000089
J	ARUNACHALAM, U; MASSEY, V; MILLER, SM				ARUNACHALAM, U; MASSEY, V; MILLER, SM			MECHANISM OF P-HYDROXYPHENYLACETATE-3-HYDROXYLASE - A 2-PROTEIN ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARA-HYDROXYBENZOATE HYDROXYLASE; PHENOL HYDROXYLASE; HALF-REACTION; INTERMEDIATE; PURIFICATION	p-Hydroxyphenylacetate-3-hydroxylase purified from Pseudomonas putida is a two-protein enzyme requiring a flavoprotein and a coupling protein for productive hydroxylation (Arunachalam, U., Massey, V., and Vaidyanathan, C. S. (1992) J. Biol. Chem. 267,25848-25855). This paper presents information on the mechanism of the enzyme from absorbance and fluorescence stopped-flow studies. The reduction of the substrate-free flavoprotein by NADH was slow and was not altered by the presence of the coupling protein. In contrast, the coupling protein has a dramatic effect in the oxidative half-reaction. The flavoprotein when present alone, both in the absence and presence of the aromatic substrate, reacts in a second-order fashion with oxygen to form oxidized flavoprotein, with no indication of flavin-oxygen intermediates. However, an intermediate identified as the C4a-flavin hydroperoxide is stabilized when the flavoprotein-coupling protein complex reacts with oxygen in the absence of the aromatic substrate, p-hydroxyphenylacetate, and at least three flavin-oxygen intermediates, attributed to the anionic (I) and protonated (I*) forms of the flavin hydroperoxide and the hydroxyflavin (III), are formed in the oxidative half-reaction in the presence of the aromatic substrate. A reaction mechanism for the two-protein complex is proposed in which the aromatic substrate has little effect on the rate of reduction of the enzyme flavin but has strict control in the oxidative half-reaction. In this phase the flavin hydroperoxide is remarkably stable in the absence of the substrate but disappears rapidly upon encountering the aromatic substrate.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM011106, R01GM011106] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-11106] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RF, 1990, J BIOL CHEM, V265, P1952; ARUNACHALAM U, 1992, J BIOL CHEM, V267, P2584; Ballou D. P., 1984, FLAVINS FLAVOPROTEIN, P605; BEATY NB, 1980, J BIOL CHEM, V255, P3817; BEATY NB, 1981, J BIOL CHEM, V256, P4611; Bevington P. R., 1969, DATA REDUCTION ERROR, P235; BRISSETTE P, 1989, ANAL BIOCHEM, V181, P234, DOI 10.1016/0003-2697(89)90235-2; DETMER K, 1985, J BIOL CHEM, V260, P5998; ENTSCH B, 1991, J BIOL CHEM, V266, P17341; ENTSCH B, 1989, BIOCHIM BIOPHYS ACTA, V999, P313, DOI 10.1016/0167-4838(89)90014-9; ENTSCH B, 1974, BIOCHEM BIOPH RES CO, V57, P1018, DOI 10.1016/0006-291X(74)90798-0; ENTSCH B, 1976, J BIOL CHEM, V251, P2550; HOWELL LG, 1972, J BIOL CHEM, V247, P4340; HUSAIN M, 1979, J BIOL CHEM, V254, P6657; MAEDAYORITA K, 1993, J BIOL CHEM, V268, P4134; Massey V, 1990, FLAVINS FLAVOPROTEIN, P59; SCHOPFER LM, 1979, J BIOL CHEM, V254, P634; STRICKLAND S, 1973, J BIOL CHEM, V248, P2944; TAYLOR MG, 1990, J BIOL CHEM, V265, P13687; VERVOORT J, 1986, BIOCHEMISTRY-US, V25, P8062, DOI 10.1021/bi00372a040; WHITESTE.RH, 1970, BIOCHEM BIOPH RES CO, V38, P882, DOI 10.1016/0006-291X(70)90803-X	21	30	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					150	155						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276789				2022-12-27	WOS:A1994MR21900031
J	CLAGUE, MJ; URBE, S; ANIENTO, F; GRUENBERG, J				CLAGUE, MJ; URBE, S; ANIENTO, F; GRUENBERG, J			VACUOLAR ATPASE ACTIVITY IS REQUIRED FOR ENDOSOMAL CARRIER VESICLE FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ADP-RIBOSYLATION FACTOR; FUSION INVITRO; ENDOCYTIC PATHWAYS; CELLS; ACIDIFICATION; PROTEIN; BINDING; PH	A proton pump, the vacuolar ATPase, is known to generate the acidic lumenal environment of endosomes and lysosomes. We have investigated the role of the vacuolar ATPase in endocytic membrane traffic by combining electron microscopy in vivo with a cell-free assay that reconstitutes endosome fusion in vitro. Our observations show that inactivation of this proton pump with bafilomycin A1 has no significant effects on internalization or recycling back to the plasma membrane. However, early endosomes become highly tubular and endocytosed markers do not appear in late endosomes. Our data strongly suggest that, upon inactivation of the proton pump, the formation of a vesicular intermediate between early and late endosomes, which we term endosomal carrier vesicle, is impaired.	UNIV LIVERPOOL,DEPT PHYSIOL,POB 147,CROWN ST,LIVERPOOL L69 3BX,ENGLAND	University of Liverpool	CLAGUE, MJ (corresponding author), EUROPEAN MOLEC BIOL LAB,D-69012 HEIDELBERG,GERMANY.		Aniento, Fernando/G-9781-2015; Clague, Michael/A-7199-2008	Aniento, Fernando/0000-0003-3553-585X; Clague, Michael/0000-0003-3355-9479; Urbe, Sylvie/0000-0003-4735-9814				ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; ANIENTO F, 1993, IN PRESS J CELL BIOL; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CAIN CC, 1989, P NATL ACAD SCI USA, V86, P544, DOI 10.1073/pnas.86.2.544; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; EMANS N, 1993, J CELL BIOL, V120, P1357, DOI 10.1083/jcb.120.6.1357; FUCHS R, 1989, J BIOL CHEM, V264, P2212; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Griffiths G, 1991, Trends Cell Biol, V1, P5, DOI 10.1016/0962-8924(91)90047-D; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; GRUENBERG J, 1992, PROTEIN TARGETING PR, P187; HARFORD J, 1983, J BIOL CHEM, V258, P3191; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LUDWIG T, 1991, J CELL BIOL, V115, P1561, DOI 10.1083/jcb.115.6.1561; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Murphy R F, 1991, Trends Cell Biol, V1, P77, DOI 10.1016/0962-8924(91)90022-2; PARTON RG, 1989, J CELL BIOL, V109, P3259, DOI 10.1083/jcb.109.6.3259; PARTON RG, 1992, J CELL BIOL, V119, P123, DOI 10.1083/jcb.119.1.123; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; TOOZE J, 1991, J CELL BIOL, V115, P635, DOI 10.1083/jcb.115.3.635; YILLA M, 1993, J BIOL CHEM, V268, P19092; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; ZEUZEM S, 1992, P NATL ACAD SCI USA, V89, P6619, DOI 10.1073/pnas.89.14.6619	28	353	353	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					21	24						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276796				2022-12-27	WOS:A1994MR21900006
J	DOUGHERTY, BA; VANDERIJN, I				DOUGHERTY, BA; VANDERIJN, I			MOLECULAR CHARACTERIZATION OF HASA FROM AN OPERON REQUIRED FOR HYALURONIC-ACID SYNTHESIS IN GROUP A STREPTOCOCCI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCI; CAPSULE EXPRESSION; RHIZOBIUM-MELILOTI; SACCHAROMYCES-CEREVISIAE; SEQUENCE-ANALYSIS; CHITIN SYNTHESIS; S-CEREVISIAE; GENE; NODULATION; SYNTHASE	The mechanism by which group A streptococci produce the antiphagocytic hyaluronate (hyaluronic acid) capsule is incompletely understood. Enzymes known to be essential for synthesis of this polysaccharide include the membrane-associated hyaluronate synthase as well as those required for production of the substrate sugars UDP-N-acetylglucosamine and UDP-glucuronic acid. In this study, a Tn916 insertion that inactivates hyaluronate synthetic activity was localized to a gene designated hasA in the hyaluronic acid synthesis operon. This gene has recently been preliminarily identified as the group A streptococcal hyaluronate synthase. The DNA sequence and transcription start site of hasA were determined, and the predicted HasA protein was shown to have characteristics of a membrane protein. Amino acid sequence homology suggests that HasA is related to a family of proteins involved in polysaccharide production and cell differentiation. Finally, in addition to the loss of hyaluronate synthase activity, the hasA=Tn916 insertion was demonstrated to correlate with a loss of UDP-glucuronic acid dehydrogenase activity. These results suggest that the genes required for hyaluronate synthase activity and production of the UDP-glucuronic acid substrate are transcribed as a unit in group A streptococci.	WAKE FOREST UNIV, MED CTR, WINSTON SALEM, NC 27157 USA	Wake Forest University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007401] Funding Source: NIH RePORTER; NCI NIH HHS [CA12107] Funding Source: Medline; NHLBI NIH HHS [HL 30069] Funding Source: Medline; NIAID NIH HHS [T32-AI-07401] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUSTRIAN R, 1959, J EXP MED, V110, P585, DOI 10.1084/jem.110.4.585; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; AUYOUNG J, 1990, MOL MICROBIOL, V4, P197, DOI 10.1111/j.1365-2958.1990.tb00587.x; BOULNOIS GJ, 1990, CURR TOP MICROBIOL, V150, P1; BULAWA CE, 1986, CELL, V46, P213, DOI 10.1016/0092-8674(86)90738-5; BULAWA CE, 1992, MOL CELL BIOL, V12, P1764, DOI 10.1128/MCB.12.4.1764; BULAWA CE, 1991, NATURE, V353, P710, DOI 10.1038/353710b0; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CLEWELL DB, 1988, J BACTERIOL, V170, P3046, DOI 10.1128/jb.170.7.3046-3052.1988; DEANGELIS PL, 1993, J BIOL CHEM, V268, P14568; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOUGHERTY BA, 1993, J BIOL CHEM, V268, P7118; DOUGHERTY BA, 1992, J EXP MED, V175, P1291, DOI 10.1084/jem.175.5.1291; FARBER BF, 1990, J INFECT DIS, V161, P37, DOI 10.1093/infdis/161.1.37; FISCHETTI VA, 1971, J EXP MED, V133, P1105, DOI 10.1084/jem.133.5.1105; FISHER RF, 1992, NATURE, V357, P655, DOI 10.1038/357655a0; FOLEY MJ, 1959, J EXP MED, V110, P617, DOI 10.1084/jem.110.4.617; GLASER L, 1955, P NATL ACAD SCI USA, V41, P253, DOI 10.1073/pnas.41.5.253; HAMADA S, 1980, MICROBIOL REV, V44, P331, DOI 10.1128/MMBR.44.2.331-384.1980; Hirst GK, 1941, J EXP MED, V73, P493, DOI 10.1084/jem.73.4.493; HUANG TT, 1989, INFECT IMMUN, V57, P502, DOI 10.1128/IAI.57.2.502-506.1989; JACOBS TW, 1985, J BACTERIOL, V162, P469, DOI 10.1128/JB.162.2.469-476.1985; JAHNIG F, 1990, TRENDS BIOCHEM SCI, V15, P93, DOI 10.1016/0968-0004(90)90188-H; JOHN M, 1988, EMBO J, V7, P583, DOI 10.1002/j.1460-2075.1988.tb02850.x; JOHNSON BH, 1958, J INFECT DIS, V103, P135, DOI 10.1093/infdis/103.2.135; Kass EH, 1944, J EXP MED, V79, P319, DOI 10.1084/jem.79.3.319; KUYPERS JM, 1989, INFECT IMMUN, V57, P3058, DOI 10.1128/IAI.57.10.3058-3065.1989; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAPLACE F, 1989, FEMS MICROBIOL LETT, V65, P89, DOI 10.1016/0378-1097(89)90371-6; LEE CY, 1992, MOL MICROBIOL, V6, P1515, DOI 10.1111/j.1365-2958.1992.tb00872.x; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; LONG SR, 1989, ANNU REV GENET, V23, P483, DOI 10.1146/annurev.ge.23.120189.002411; LUDWIG W, 1985, J GEN MICROBIOL, V131, P543; MARKOVITZ A, 1959, J BIOL CHEM, V234, P2343; MARKOVITZ A, 1977, SURFACE CARBOHYDRATE, P415; MCCARTY M, 1990, MICROBIOLOGY, P525; MORRISON DA, 1990, MOL MICROBIOL, V4, P1143, DOI 10.1111/j.1365-2958.1990.tb00689.x; ROBBINS PW, 1967, SCIENCE, V158, P1536, DOI 10.1126/science.158.3808.1536; ROBERTS IS, 1989, BIOCHEM SOC T, V17, P462, DOI 10.1042/bst0170462; ROSA F, 1988, DEV BIOL, V129, P114, DOI 10.1016/0012-1606(88)90166-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHILLER JG, 1973, BIOCHIM BIOPHYS ACTA, V293, P1, DOI 10.1016/0005-2744(73)90369-0; Seastone CV, 1939, J EXP MED, V70, P361, DOI 10.1084/jem.70.4.361; SILVERMAN SJ, 1989, YEAST, V5, P459, DOI 10.1002/yea.320050605; SLACK MPE, 1981, LANCET, V2, P502; SMITH EE, 1961, J BIOL CHEM, V236, P2179; STGEME JW, 1991, INFECT IMMUN, V59, P1325, DOI 10.1128/IAI.59.4.1325-1333.1991; TRISCOTT MX, 1986, J BIOL CHEM, V261, P6004; VANDERIJN I, 1983, J BACTERIOL, V156, P1059, DOI 10.1128/JB.156.3.1059-1065.1983; VANDERIJN I, 1992, J BIOL CHEM, V267, P24302; WESSELS MR, 1991, P NATL ACAD SCI USA, V88, P8317, DOI 10.1073/pnas.88.19.8317; WHITNACK E, 1981, INFECT IMMUN, V31, P985, DOI 10.1128/IAI.31.3.985-991.1981; ZWAHLEN A, 1989, MICROB PATHOGENESIS, V7, P225, DOI 10.1016/0882-4010(89)90058-2	54	97	121	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					169	175						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276791				2022-12-27	WOS:A1994MR21900034
J	PARANANDI, MV; GUZZETTA, AW; HANCOCK, WS; ASWAD, DW				PARANANDI, MV; GUZZETTA, AW; HANCOCK, WS; ASWAD, DW			DEAMIDATION AND ISOASPARTATE FORMATION DURING IN-VITRO AGING OF RECOMBINANT TISSUE-PLASMINOGEN ACTIVATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CARBOXYL METHYLTRANSFERASE; HUMAN GROWTH-HORMONE; SUCCINIMIDE FORMATION; ASPARAGINYL RESIDUES; SPONTANEOUS DEGRADATION; BOVINE BRAIN; PEPTIDES; ASPARTYL; CALMODULIN; SEQUENCE	When incubated at pH 7.3, 37-degrees-C, human recombinant tissue plasminogen activator accumulated 0.77 mol of isoaspartate per mol of plasminogen activator over a 14-day period. Isoaspartate was detected by enzymatic transfer of H-3-labeled methyl groups from S-adenosyl-L-methionine in a reaction catalyzed by protein L-isoaspartyl methyltransferase. Analysis of tryptic peptides derived from aged plasminogen activator revealed that the two major sites of isoaspartate accumulation resulted from deamidation of Asn58 in the sequence -FNGG- and Asn77 in the sequence -GNSD-. Significant levels of isoaspartate also accumulated via deamidation of Asn37 in the sequence -CNSG-. All three sites occur in sequences predicted from studies with synthetic peptide to be unstable. All three sites appear to be on the surface of the protein, and all three occur in regions of the protein predicted to have higher than average chain mobility. These findings add support to the idea that sequence and flexibility play major roles in determining susceptibility to deamidation and peptide bond isomerization at Asn and Asp sites under mild conditions. These studies also illustrate the utility of enzymatic methylation for characterizing sites of deamidation in a large protein that contains numerous disulfide bonds and several sites of glycosylation.	UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717; GENENTECH INC,DEPT MED & ANALYT CHEM,S SAN FRANCISCO,CA 94080	University of California System; University of California Irvine; Roche Holding; Genentech					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029421] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-29421] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASWAD DW, 1984, J BIOL CHEM, V259, P714; ASWAD DW, 1990, ANN NY ACAD SCI, V613, P26, DOI 10.1111/j.1749-6632.1990.tb18145.x; Bornstein P, 1977, Methods Enzymol, V47, P132; CHIRPICH T, 1968, THESIS U CALIFORNIA; CHLOUPEK RC, 1989, J CHROMATOGR, V463, P375, DOI 10.1016/S0021-9673(01)84491-5; CLARKE S, 1987, INT J PEPT PROT RES, V30, P808, DOI 10.1111/j.1399-3011.1987.tb03390.x; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; GALLETTI P, 1988, BIOCHEMISTRY-US, V27, P1752, DOI 10.1021/bi00405a055; HENZEL WJ, 1989, J BIOL CHEM, V264, P15905; JOHNSON BA, 1987, J BIOL CHEM, V262, P12283; JOHNSON BA, 1993, J BIOL CHEM, V268, P6174; JOHNSON BA, 1987, J BIOL CHEM, V262, P5622; JOHNSON BA, 1991, ANAL BIOCHEM, V192, P384, DOI 10.1016/0003-2697(91)90553-6; JOHNSON BA, 1989, ARCH BIOCHEM BIOPHYS, V268, P276, DOI 10.1016/0003-9861(89)90589-4; JOHNSON BA, 1989, J BIOL CHEM, V264, P14262; JOHNSON BA, 1990, PROTEIN METHYLATION, P195; JONES BN, 1981, J LIQ CHROMATOGR, V4, P565, DOI 10.1080/01483918108059956; KOSSIAKOFF AA, 1988, SCIENCE, V240, P191, DOI 10.1126/science.3353715; LI C, 1992, P NATL ACAD SCI USA, V89, P9885, DOI 10.1073/pnas.89.20.9885; LIU DTY, 1992, TRENDS BIOTECHNOL, V10, P364, DOI 10.1016/0167-7799(92)90269-2; LIU DTY, 1992, TRENDS BIOTECHNOL, V10, P114, DOI 10.1016/0167-7799(92)90192-X; LOWENSON JD, 1990, J BIOL CHEM, V265, P3106; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACFARLANE DE, 1984, J BIOL CHEM, V259, P1357; MANNING MC, 1989, PHARM RES-DORDR, V6, P903, DOI 10.1023/A:1015929109894; MCFADDEN PN, 1987, P NATL ACAD SCI USA, V84, P2595, DOI 10.1073/pnas.84.9.2595; MURRAY ED, 1986, J BIOL CHEM, V261, P306; OTA IM, 1989, BIOCHEMISTRY-US, V28, P4020, DOI 10.1021/bi00435a058; OTA IM, 1990, PROTEIN METHYLATION, P179; PATEL K, 1990, PHARMACEUT RES, V7, P787, DOI 10.1023/A:1015999012852; POTTER SM, 1993, PROTEIN SCI, V2, P1648, DOI 10.1002/pro.5560021011; RAGONE R, 1989, PROTEIN ENG, V2, P497, DOI 10.1093/protein/2.7.497; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; TYLERCROSS R, 1991, J BIOL CHEM, V266, P22549; WRIGHT HT, 1991, PROTEIN ENG, V4, P283, DOI 10.1093/protein/4.3.283	36	71	72	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					243	253						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276801				2022-12-27	WOS:A1994MR21900045
J	RAMASWAMY, M; YEUNG, AT				RAMASWAMY, M; YEUNG, AT			SEQUENCE-SPECIFIC INTERACTIONS OF UVRABC ENDONUCLEASE WITH PSORALEN INTERSTRAND CROSS-LINKS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED DNA-STRUCTURE; ESCHERICHIA-COLI; (A)BC EXCINUCLEASE; EXCISION NUCLEASE; ENZYMATIC-PROPERTIES; PROTEIN COMPLEX; DAMAGED DNA; INCISION; BINDING; REPAIR	The nature of the Uvr protein-DNA complexes formed on psoralen-DNA interstrand cross-links was analyzed by DNase I footprinting and correlated with the incision efficiency of the UvrABC endonuclease on the cross-links of different DNA sequences. Our results indicate that the repair specificity is dependent on the DNA sequence and the psoralen orientation in the cross-link. On the strand that will be cut, a 30-nucleotide long UvrAB footprint with a DNase I hypersensitive site at the 11th nucleotide 5' to the lesion was observed and subsequently rearranged to a 22-nucleotide long UvrB-lesion footprint. On the strand that will not be cut, the UvrAB- lesion footprint had no 5' DNase I hypersensitive site and did not form the UvrB-lesion footprint. Although UvrABC incision requires the formation of UvrB-lesion complex on the strand which will be cut, the affinities of these complexes do not correlate with the incision efficiencies, suggesting that the overall reaction can be driven forward by a favorable next step such as UvrC incision. A study of the time-dependent interconversion of UvrAB-lesion complex to UvrB-lesion complex on a cross-link revealed a secondary recognition of the UvrB-lesion complex by UvrA2(B) proteins in vitro.	FOX CHASE CANC CTR,INST CANC RES,PHILADELPHIA,PA 19111	Fox Chase Cancer Center					NCI NIH HHS [CA06927] Funding Source: Medline; NCRR NIH HHS [RR05539] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELGUISEVALLADIER P, 1991, BIOCHEMISTRY-US, V30, P10091, DOI 10.1021/bi00106a005; BERTRANDBURGGRAF E, 1991, J MOL BIOL, V219, P27, DOI 10.1016/0022-2836(91)90854-Y; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; CIMINO GD, 1985, ANNU REV BIOCHEM, V54, P1151, DOI 10.1146/annurev.bi.54.070185.005443; GROSSMAN L, 1990, MUTAT RES, V236, P213, DOI 10.1016/0921-8777(90)90006-Q; JONES BK, 1988, P NATL ACAD SCI USA, V85, P8410, DOI 10.1073/pnas.85.22.8410; JONES BK, 1990, J BIOL CHEM, V265, P3489; KUMARESAN KR, 1992, BIOCHEMISTRY-US, V31, P6774, DOI 10.1021/bi00144a018; LIN JJ, 1992, J BIOL CHEM, V267, P17693; MAXAM A, 1980, METHOD ENZYMOL, V65, P498; MAZUR SJ, 1991, BIOCHEMISTRY-US, V30, P4432, DOI 10.1021/bi00232a009; MUNN MM, 1991, J BIOL CHEM, V266, P24748; OH EY, 1989, J BIOL CHEM, V264, P1336; OH EY, 1987, P NATL ACAD SCI USA, V84, P3638, DOI 10.1073/pnas.84.11.3638; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; ORREN DK, 1990, J BIOL CHEM, V265, P15796; ROCHE CJ, 1991, CHEM RES TOXICOL, V4, P311, DOI 10.1021/tx00021a009; RODRIGUEZ H, 1993, BIOCHEMISTRY-US, V32, P1759, DOI 10.1021/bi00058a009; RUBIN CM, 1980, NUCLEIC ACIDS RES, V8, P4613, DOI 10.1093/nar/8.20.4613; SAGE E, 1987, BIOCHEMISTRY-US, V26, P3307, DOI 10.1021/bi00386a010; Sambrook J, 1989, MOL CLONING LABORATO; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SEEBERG E, 1990, P NATL ACAD SCI USA, V87, P191, DOI 10.1073/pnas.87.1.191; SHI Q, 1992, J MOL BIOL, V226, P425, DOI 10.1016/0022-2836(92)90957-L; SNOWDEN A, 1991, J MOL BIOL, V220, P19, DOI 10.1016/0022-2836(91)90378-J; SONG PS, 1979, PHOTOCHEM PHOTOBIOL, V29, P1177, DOI 10.1111/j.1751-1097.1979.tb07838.x; TOMIC MT, 1987, SCIENCE, V238, P1722, DOI 10.1126/science.3686011; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; VANHOUTEN B, 1987, J BIOL CHEM, V262, P13180; VANHOUTEN B, 1986, P NATL ACAD SCI USA, V83, P8077; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; VEAUTE X, 1991, NUCLEIC ACIDS RES, V19, P5603, DOI 10.1093/nar/19.20.5603; VISSE R, 1992, J BIOL CHEM, V267, P6736; YEUNG AT, 1988, BIOCHEMISTRY-US, V27, P6332, DOI 10.1021/bi00417a020; YEUNG AT, 1988, NUCLEIC ACIDS RES, V16, P4539, DOI 10.1093/nar/16.10.4539; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P8535, DOI 10.1093/nar/14.21.8535; YEUNG AT, 1983, P NATL ACAD SCI-BIOL, V80, P6157, DOI 10.1073/pnas.80.20.6157; YEUNG AT, 1988, BIOCHEMISTRY-US, V27, P3204, DOI 10.1021/bi00409a012; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P6157	40	19	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					485	492						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276840				2022-12-27	WOS:A1994MR21900080
J	YING, WL; SEPPLORENZINO, L; CAI, KW; ALOISE, P; COLEMAN, PS				YING, WL; SEPPLORENZINO, L; CAI, KW; ALOISE, P; COLEMAN, PS			PHOTOAFFINITY-LABELING PEPTIDE-SUBSTRATES FOR FARNESYL-PROTEIN TRANSFERASE AND THE INTERSUBUNIT LOCATION OF THE ACTIVE-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; P21RAS FARNESYLTRANSFERASE; CATALYTIC COOPERATIVITY; ISOPRENOID MODIFICATION; PRENYLATED PROTEINS; ALPHA-SUBUNIT; RAT-BRAIN; GERANYLGERANYLTRANSFERASE; F1-ATPASE; SEQUENCE	-CAAX motif peptides, which are substrates for isoprenylation, were synthetically derivatized with the light-sensitive benzophenone (Bz) group in order to determine their potential use as catalytic site-directed covalent photocross-linking ligands for one of the enzymes catalyzing protein isoprenylation, farnesyl-protein transferase (FPTase). Bz-peptides could be synthesized with [H-3]benzophenone and possessed either one or two benzophenone groups located at or near the peptide's NH2 terminus (e.g. the mono-Bz probes Bz-ACVIM and Bz-LPCVVM, and the di-Bz derivatized probe Bz-GY(Bz)PCVVM, referred to as BZ2-GYPCVVM). Each type of derivatized peptide behaved as a substrate for farnesylation in vitro without irradiation, while under 366-nm irradiation each demonstrated covalent cross-linking ability as a catalytic site-directed photoaffinity ligand with tissue-purified or enriched but impure fractions from rat and bovine brain FPTase, as well as with a recombinant human FPTase variant, FPTase(betaalpha(t)) expressed in Escherichia coli. Without photoactivation, Bz-ACVIM yielded a K(d) of 37 nm for the cloned variant of human FPTase. Pseudo first-order photolytic inhibition of FPTase preparations with Bz-peptides, as well as protection from photoinactivation by unmodified -CAAX motif peptides, supported the capacity of these Bz-peptides to serve as co-substrates and their specificity for seeking the catalytic site of the enzyme. SDS-polyacrylamide gel electrophoresis analysis subsequent to photolysis indicated that the mono-Bz-derivatized peptides (e.g. [H-3]Bz-LPCVVM or [H-3]Bz-ACVIM) became covalently cross-linked preferentially to the approximately 49-kDa beta subunit of the alphabeta dimeric FPTase. The farnesyl-PP co-substrate bound equally well to unmodified and Bz-ACVIM-labeled enzyme. The di-Bz derivative, [H-3]Bz2-GYPCVVM, in contrast, revealed exclusive photocovalent cross-linking with a species of molecular mass approximately 95-97 kDa, indicating that both FPTase subunits were tethered together covalently by the di-Bz probe. Similar differential SDS-polyacrylamide gel electrophoresis cross-linking patterns were obtained with homogeneous FPTases as well as with partially purified rat or bovine brain enzyme preparations. The absence of nonspecific photolabeling of any proteins in the partially purified rat or bovine brain enzyme preparations other than FPTase independently attested to the high efficiency of photocross-linking of the FPTase, and the selective catalytic site-seeking ability of these Bz-derivatized peptide substrates, verifying their potential as structural probes for the active site domain on the enzyme. Results with the BZ2-GYPCVVM imply that the catalytic domain on FPTase is comprised of an interfacial cleft at the contact region between alpha and beta subunits, a domain that is shared by both -CAAX and farnesyl substrate moieties.	BOSTON BIOMED RES INST,METAB REGULAT LABS,BOSTON,MA 02114	Boston Biomedical Research Institute								ACKERMAN SH, 1987, J BIOL CHEM, V262, P13765; ADMON A, 1987, BIOCHEMISTRY-US, V26, P3193, DOI 10.1021/bi00385a038; ANDRES DA, 1993, J BIOL CHEM, V268, P1383; BLACK SD, 1992, BIOCHEM BIOPH RES CO, V186, P1437, DOI 10.1016/S0006-291X(05)81567-0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRAUN PE, 1991, J NEUROSCI RES, V30, P540, DOI 10.1002/jnr.490300311; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CHEN WJ, 1991, P NATL ACAD SCI USA, V88, P11368, DOI 10.1073/pnas.88.24.11368; Dorman G., 1993, CHEMTRACTS ORG CHEM, V6, P131; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P469, DOI 10.1016/0968-0004(90)90300-Z; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDSTEIN JL, 1991, J BIOL CHEM, V266, P15575; GORKA J, 1989, Peptide Research, V2, P376; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HORIUCHI H, 1991, J BIOL CHEM, V266, P16981; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KOHL NE, 1991, J BIOL CHEM, V266, P18884; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MANOLSON MF, 1985, J BIOL CHEM, V260, P2273; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; MOORES SL, 1991, J BIOL CHEM, V266, P14603; OMER CA, 1993, BIOCHEMISTRY-US, V32, P5167, DOI 10.1021/bi00070a028; PAL PK, 1990, J BIOL CHEM, V265, P14996; PAL PK, 1992, J BIOL CHEM, V267, P25003; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; REISS Y, 1990, Methods (Orlando), V1, P241, DOI 10.1016/S1046-2023(05)80323-8; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1991, J BIOL CHEM, V266, P10672; REISS Y, 1992, BIOCHEM SOC T, V20, P487, DOI 10.1042/bst0200487; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SEPPLORENZINO L, 1993, IN PRESS J NEUROCHEM; SHIRATAKI H, 1992, J BIOL CHEM, V267, P10946; STIMMEL JB, 1990, BIOCHEMISTRY-US, V29, P9651, DOI 10.1021/bi00493a021; VOGEL HJ, 1982, J BIOL CHEM, V257, P4834; WILLIAMS KP, 1993, J BIOL CHEM, V268, P5361; WILLIAMS N, 1982, J BIOL CHEM, V257, P2834; YANG ZB, 1993, PLANT PHYSIOL, V101, P667, DOI 10.1104/pp.101.2.667; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; YOKOYAMA K, 1993, J BIOL CHEM, V268, P4055	50	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					470	477						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276838				2022-12-27	WOS:A1994MR21900078
J	GOPALAKRISHNA, R; CHEN, ZH; GUNDIMEDA, U				GOPALAKRISHNA, R; CHEN, ZH; GUNDIMEDA, U			NITRIC-OXIDE AND NITRIC OXIDE-GENERATING AGENTS INDUCE A REVERSIBLE INACTIVATION OF PROTEIN-KINASE-C ACTIVITY AND PHORBOL ESTER BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-NITROSYLATION; REGULATORY DOMAIN; RAT-BRAIN; ACTIVATION; RECEPTOR; SYNTHASE; CELLS; LIPOPOLYSACCHARIDE; PHOSPHORYLATION; TRANSLOCATION	Since S-nitrosylation of protein thiols is one of the cellular regulatory mechanisms induced by nitric oxide (NO), and since protein kinase C (PKC) has critical thiol residues which influence its kinase activity, we have determined whether NO could regulate this enzyme. Initial studies were carried out with purified PKC and the NO-generating agent S-nitrosocysteine. This agent decreased phosphotransferase activity of PKC in a Ca2+- and oxygen-dependent manner with an IC50 of 75 muM. Phorbol ester binding was affected partially only at higher concentrations (>100 muM) of S-nitrosocysteine. This inactivation of PKC was blocked by the NO scavenger oxyhemoglobin or reversed by dithiothreitol. It is likely that NO initially induced an S-nitrosylation of vicinal thiols, which were then oxidized to form an intramolecular disulfide. Other NO-generating agents such as S-nitroso-N-acetylpenicillamine and sodium nitroprusside, as well as authentic NO gas, induced similar types of PKC modifications. In intact B16 melanoma cells treated with S-nitrosocysteine a rapid decrease in PKC activity in both cytosol and membrane was observed. Unlike in experiments with purified PKC, in intact cells treated with S-nitrosocysteine the phorbol ester binding also decreased to a rate equal to that of PKC activity. These modifications were readily reversed by treating the homogenates with dithiothreitol in test tubes or by removing the NO-generating source from intact cells. To determine whether the limited amounts of NO generated within the intact cells could induce this type of PKC modification, the macrophage cell line IC-21 was treated with lipopolysacharide and Ca2+ ionophore A23187 to induce the NO production. With an increase in generation of NO (3-12-h period) in these cells, a parallel and irreversible decrease in PKC activity and phorbol ester binding was observed. A specific inhibitor for NO synthase, N(G)-monomethyl-L-arginine, inhibited both the production of NO and PKC inactivation. In experiments using purified enzyme or intact cells there was no decrease in cAMP-dependent protein kinase activity. Conceivably, NO production for limited time induces a reversible inactivation of PKC due to the formation of a disulfide bridge(s), whereas the chronic production of NO could induce irreversible inactivation of PKC. The reversible or irreversible inactivations of PKC may in part influence NO-mediated cytoprotective or cytotoxic actions, respectively.			GOPALAKRISHNA, R (corresponding author), USC,SCH MED,DEPT PHARMACOL & NUTR,2025 ZONAL AVE,MMR-330,LOS ANGELES,CA 90033, USA.				NATIONAL CANCER INSTITUTE [R29CA047142] Funding Source: NIH RePORTER; NCI NIH HHS [CA47142] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BELL RM, 1991, J BIOL CHEM, V266, P4661; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; CLANCY RM, 1993, BIOCHEM BIOPH RES CO, V191, P847, DOI 10.1006/bbrc.1993.1294; CURRAN RD, 1991, FASEB J, V5, P2085, DOI 10.1096/fasebj.5.7.1707021; DIMMELER S, 1992, FEBS LETT, V315, P21; ETOH S, 1991, NEUROSCI LETT, V126, P119, DOI 10.1016/0304-3940(91)90533-Y; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GIRARD P, 1993, FEBS LETT, V320, P7, DOI 10.1016/0014-5793(93)81645-G; GOPALAKRISHNA R, 1992, FEBS LETT, V314, P149, DOI 10.1016/0014-5793(92)80962-G; GOPALAKRISHNA R, 1991, ARCH BIOCHEM BIOPHYS, V285, P382, DOI 10.1016/0003-9861(91)90377-U; GOPALAKRISHNA R, 1989, P NATL ACAD SCI USA, V86, P6758, DOI 10.1073/pnas.86.17.6758; GOPALAKRISHNA R, 1992, ANAL BIOCHEM, V206, P24, DOI 10.1016/S0003-2697(05)80006-5; GOPALAKRISHNA R, 1978, BIOCHEM MEDICA, V22, P70; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HORTELANO S, 1992, J BIOL CHEM, V267, P24937; HOUSEY GM, 1987, P NATL ACAD SCI USA, V84, P1065, DOI 10.1073/pnas.84.4.1065; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; JAKEN S, 1990, CANCER CELL-MON REV, V2, P401; KASS GEN, 1989, BIOCHEM J, V260, P499, DOI 10.1042/bj2600499; KHAN WA, 1993, J BIOL CHEM, V268, P5063; KIKKAWA U, 1987, FEBS LETT, V223, P212, DOI 10.1016/0014-5793(87)80291-0; KNOWLES RG, 1992, TRENDS BIOCHEM SCI, V17, P399, DOI 10.1016/0968-0004(92)90008-W; LANG D, 1991, BRIT J PHARMACOL, V104, P139, DOI 10.1111/j.1476-5381.1991.tb12398.x; LARSSON R, 1989, CANCER RES, V49, P5627; LEI SZ, 1992, NEURON, V8, P1087, DOI 10.1016/0896-6273(92)90130-6; LI LM, 1991, CANCER RES, V51, P2531; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NORONHADUTRA AA, 1993, FEBS LETT, V321, P59, DOI 10.1016/0014-5793(93)80621-Z; PALUMBO EJ, 1992, BIOCHEM BIOPH RES CO, V187, P1439, DOI 10.1016/0006-291X(92)90463-U; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; QUEST AFG, 1992, J BIOL CHEM, V267, P10193; RASMUSSEN H, 1987, FASEB J, V1, P177, DOI 10.1096/fasebj.1.3.3040504; ROGERS NE, 1992, BIOCHEM BIOPH RES CO, V189, P242, DOI 10.1016/0006-291X(92)91550-A; SEVERN A, 1992, BIOCHEM BIOPH RES CO, V188, P997, DOI 10.1016/0006-291X(92)91330-S; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P8087, DOI 10.1073/pnas.89.17.8087; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; TAKAI Y, 1981, BIOCHEM BIOPH RES CO, V101, P61, DOI 10.1016/S0006-291X(81)80010-1; VEDIA LM, 1992, J BIOL CHEM, V267, P24929; WINK DA, 1993, ARCH BIOCHEM BIOPHYS, V300, P115, DOI 10.1006/abbi.1993.1016	46	267	275	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27180	27185						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262958				2022-12-27	WOS:A1993MM26200053
J	MURPHY, BJ; ROSSIE, S; DEJONGH, KS; CATTERALL, WA				MURPHY, BJ; ROSSIE, S; DEJONGH, KS; CATTERALL, WA			IDENTIFICATION OF THE SITES OF SELECTIVE PHOSPHORYLATION AND DEPHOSPHORYLATION OF THE RAT-BRAIN NA+ CHANNEL ALPHA-SUBUNIT BY CAMP-DEPENDENT PROTEIN-KINASE AND PHOSPHOPROTEIN PHOSPHATASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE SODIUM-CHANNELS; RABBIT SKELETAL-MUSCLE; SOMATIC-CELL LINE; FUNCTIONAL MODULATION; XENOPUS-OOCYTES; EXPRESSION; NEURONS	Voltage-sensitive brain Na+ channels are regulated by cAMP-dependent protein kinase (cA-PK) and protein kinase C. Using synthetic peptides and protein microsequencing, we have determined that the a subunit of rat brain Na+ channel is selectively phosphorylated by cA-PK in vitro and in intact cells on 4 serine residues in the intracellular loop connecting homologous domains I and II. Ser-623 was most rapidly and extensively phosphorylated in vitro, whereas Ser-573, Ser-610, and Ser-687 were phosphorylated to lesser extents. In contrast, serine 687 was most extensively phosphorylated in mammalian cells transfected with the alpha subunit of type IIA Na+ channel in response to an increase in intracellular cAMP. Purified protein phosphatases dephosphorylated these sites selectively. Calcineurin rapidly and extensively dephosphorylated Ser-623 and also dephosphorylated Ser-573, Ser-610, and Ser-687 to lesser extents. Phosphatase 2A selectively dephosphorylated Ser-610. Together these results indicate that modulation of neuronal Na+ channel activity and therefore neuronal excitability by cAMP-dependent phosphorylation results from selective phosphorylation and dephosphorylation of four sites in the intracellular loop connecting homologous domains I and II of the alpha subunit.	PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	MURPHY, BJ (corresponding author), UNIV WASHINGTON, DEPT PHARMACOL, SJ-30, SEATTLE, WA 98195 USA.				NINDS NIH HHS [NS31221, NS15751] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031221, R29NS031221, R01NS015751] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.biochem.55.1.953; COHEN P, 1988, METHOD ENZYMOL, V159, P427; COHEN P, 1988, METHOD ENZYMOL, V159, P390; COSTA MRC, 1982, J BIOL CHEM, V257, P7918; COSTA MRC, 1984, CELL MOL NEUROBIOL, V4, P291, DOI 10.1007/BF00733592; COSTA MRC, 1984, J BIOL CHEM, V259, P8210; DOUCET JP, 1990, ANAL BIOCHEM, V190, P209, DOI 10.1016/0003-2697(90)90182-9; GERSHON E, 1992, J NEUROSCI, V12, P3743; GOLDIN AL, 1986, P NATL ACAD SCI USA, V83, P7503, DOI 10.1073/pnas.83.19.7503; GORDON D, 1988, BIOCHEMISTRY-US, V27, P7032, DOI 10.1021/bi00418a054; HARTSHORNE RP, 1984, J BIOL CHEM, V259, P1667; HUGANIR RL, 1984, P NATL ACAD SCI-BIOL, V81, P6968, DOI 10.1073/pnas.81.22.6968; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI M, 1992, NEURON, V8, P1151, DOI 10.1016/0896-6273(92)90135-Z; LOTAN I, 1990, FEBS LETT, V267, P25, DOI 10.1016/0014-5793(90)80279-R; Maizel JV, 1971, METHOD VIROL, V5, P179; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MURPHY BJ, 1992, J BIOL CHEM, V267, P16129; MUSZYNSKA G, 1986, BIOCHEMISTRY-US, V25, P6850, DOI 10.1021/bi00370a018; NAKAYAMA H, 1992, BIOCHIM BIOPHYS ACTA, V1175, P67, DOI 10.1016/0167-4889(92)90010-9; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; NUMANN R, 1991, SCIENCE, V254, P115, DOI 10.1126/science.1656525; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; ROSSIE S, 1987, J BIOL CHEM, V262, P12735; ROSSIE S, 1989, J BIOL CHEM, V264, P14220; ROSSIE S, 1987, J BIOL CHEM, V262, P17530; ROTMAN EI, 1992, J BIOL CHEM, V267, P16100; SCHACTER E, 1984, ANAL BIOCHEM, V138, P416; SCHEUER T, 1990, SCIENCE, V247, P854, DOI 10.1126/science.2154850; TALVENHEIMO JA, 1982, J BIOL CHEM, V257, P1868; WEST JW, 1992, NEURON, V8, P59, DOI 10.1016/0896-6273(92)90108-P	35	112	112	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27355	27362						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262976				2022-12-27	WOS:A1993MM26200075
J	TANABE, J; FUJITA, H; IWAMATSU, A; MOHRI, H; OHKUBO, T				TANABE, J; FUJITA, H; IWAMATSU, A; MOHRI, H; OHKUBO, T			FIBRONECTIN INHIBITS PLATELET-AGGREGATION INDEPENDENTLY OF RGD SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; VONWILLEBRAND-FACTOR-BINDING; STIMULATED HUMAN-PLATELETS; FIBRINOGEN BINDING; PLASMA FIBRONECTIN; PROTEOLYTIC FRAGMENTS; MONOCLONAL-ANTIBODY; THROMBIN; RECEPTOR; ADHESION	Fibronectin binds to platelet membrane glycoprotein (GP) IIb-IIIa in Arg-Gly-Asp (RGD)-dependent and -independent manners. We have isolated and characterized the 29-kDa dispase fragment of fibronectin. Binding of I-125-fibronectin to thrombin-stimulated platelets was inhibited by the 29-kDa fragment and the GRGDSPA peptide with IC50 values of 1.5 +/- 0.4 and 8.1 +/- 0.9 muM, respectively. The NH2-terminal sequence of this fragment gave this result: Ala-Val-Thr-Thr-Ile-Pro-Ala-Pro-Thr-Asp. This established the position of this peptide within fibronectin as beginning with the residue tentatively designated 1597. Neither the RGDS sequence nor the RGD-independent binding domain of fibronectin (Bowditch, R. D., Halloran, C. E., Aota, S., Obara, M., Plow, E. F., Yamada, K. M., and Ginsberg, M. H. (1991) J. Biol. Chem. 266, 23323-23328) was contained in this fragment. The 29-kDa fragment inhibited ADP-induced aggregation of platelets and binding of fibrinogen to activated platelets. The fragment bound to immobilized GPIIb-IIIa. The I-125-labeled 29-kDa fragment directly bound to thrombin-stimulated platelets with 98,000 +/- 4,600 molecules/platelet (K(d) = 4.6 +/- 0.5 x 10(-6) M). Direct binding was inhibited by the unlabeled 29-kDa fragment but was not blocked by either the GRGDSPA peptide or the monoclonal anti-GPIIb-IIIa antibody. These results indicate that the additional RGD-independent binding domain(s) to GPIIb-IIIa are present on fibronectin. This additional binding domain(s) on fibronectin may prevent thrombus formation by interfering with the interaction of fibrinogen with GPIIb-IIIa.	YOKOHAMA CITY UNIV,SCH MED,DEPT INTERNAL MED 1,3-9 FUKUURA,KANAZAWA KU,YOKOHAMA,KANAGAWA 232,JAPAN; KIRIN BREWERY,CENT LABS KEY TECHNOL,YOKOHAMA 236,JAPAN	Yokohama City University; Kirin Brewery Company Limited								AOYAMA H, 1988, J PROTEIN CHEM, V7, P191; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BERLINER S, 1988, J BIOL CHEM, V263, P7500; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; BOWDITCH RD, 1991, J BIOL CHEM, V266, P23323; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIXIT VM, 1985, P NATL ACAD SCI USA, V82, P3844, DOI 10.1073/pnas.82.11.3844; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FRACKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849; FUJITA H, 1992, JPN J THROMB HAEMOST, V3, P399; GARDNER JM, 1985, CELL, V42, P439, DOI 10.1016/0092-8674(85)90101-1; GARTNER TK, 1985, J BIOL CHEM, V260, P1891; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; GINSBERG MH, 1980, P NATL ACAD SCI-BIOL, V77, P1049, DOI 10.1073/pnas.77.2.1049; GINSBERG MH, 1986, FIBRONECTIN ITS ROLE, P86; HANDA M, 1986, J BIOL CHEM, V261, P2579; HOUDIJK WPM, 1985, BLOOD, V65, P598; HOUDIJK WPM, 1985, J CLIN INVEST, V75, P531, DOI 10.1172/JCI111729; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; KOUNS WC, 1992, BLOOD, V80, P2539; LOMBARDO VT, 1985, J CLIN INVEST, V76, P1950, DOI 10.1172/JCI112193; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MOHRI H, 1986, AM J HEMATOL, V22, P391, DOI 10.1002/ajh.2830220408; PARISE LV, 1985, J BIOL CHEM, V260, P698; PARISE LV, 1986, J BIOL CHEM, V261, P14011; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PIOTROWICZ RS, 1988, J CELL BIOL, V106, P1359, DOI 10.1083/jcb.106.4.1359; PLOW EF, 1985, BLOOD, V66, P26; PLOW EF, 1985, BLOOD, V66, P724; PLOW EF, 1981, J BIOL CHEM, V256, P9477; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; WALSH PN, 1977, BRIT J HAEMATOL, V36, P281, DOI 10.1111/j.1365-2141.1977.tb00649.x; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; ZUCKER MB, 1979, BLOOD, V54, P8	36	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27143	27147						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262952				2022-12-27	WOS:A1993MM26200046
J	FANTOZZI, DA; HAROOTUNIAN, AT; WEN, W; TAYLOR, SS; FERAMISCO, JR; TSIEN, RY; MEINKOTH, JL				FANTOZZI, DA; HAROOTUNIAN, AT; WEN, W; TAYLOR, SS; FERAMISCO, JR; TSIEN, RY; MEINKOTH, JL			THERMOSTABLE INHIBITOR OF CAMP-DEPENDENT PROTEIN-KINASE ENHANCES THE RATE OF EXPORT OF THE KINASE CATALYTIC SUBUNIT FROM THE NUCLEUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP; REGULATORY SUBUNIT; HEPATOMA-CELLS; PROGESTERONE-RECEPTOR; ELECTRON-MICROSCOPY; ESCHERICHIA-COLI; SKELETAL-MUSCLE; PORE COMPLEX; SITE-A; LOCALIZATION	The catalytic (C) subunit of cAMP-dependent protein kinase is inhibited by the regulatory (R) subunit and by a thermostable inhibitor (PKI). Both inhibitors also affect the intracellular distribution of the C subunit. Whether injected into the cytoplasm or into the nucleus, free C subunit can enter and exit the nucleus freely. After 30 min its distribution is identical and is independent of the initial site of injection. In contrast, when C is injected into the cytoplasm complexed with R or PKI, the complexes are restricted to the cytoplasm (1-3). However, unlike the R subunit, which is restricted to the cytoplasm like the holoenzyme, free PKI enters the nucleus rapidly following its injection into the cytoplasm. When holoenzyme is injected directly into the nucleus, it cannot exit and return to the cytoplasm. In contrast, nuclear injection of a C.PKI complex results in the rapid exit of the C subunit from the nucleus. In equilibrated cells previously injected with the C subunit, subsequent cytoplasmic injection of either PKI or type 1 R depletes the nucleus of C although PKI does so faster, consistent with its ability to enter the nucleus. Both inhibitors block the cAMP response element-regulated gene expression. Hence PKI may serve as a nuclear scavenger of C providing a mechanism not only for inhibition but also for subcellular localization in the presence of cAMP by restricting the access of the C subunit to the nucleus.	UNIV CALIF SAN DIEGO,DEPT MED,0613-K,9500 GILMAN DR,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT CHEM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR CANC,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego			Meinkoth, Judy L/G-2900-2010		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS027177, R01NS027177] Funding Source: NIH RePORTER; NINDS NIH HHS [NS27177] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; ALABDALY FA, 1989, ENDOCRINOLOGY, V124, P2901, DOI 10.1210/endo-124-6-2901; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; BROWNE CL, 1980, J CELL BIOL, V87, P336, DOI 10.1083/jcb.87.2.336; BUBIS J, 1988, J BIOL CHEM, V263, P9668; BUECHLER YJ, 1991, J BIOL CHEM, V266, P3491; BYUS CV, 1982, J CELL BIOL, V93, P727, DOI 10.1083/jcb.93.3.727; CHANDRAN UR, 1992, MOL ENDOCRINOL, V6, P837, DOI 10.1210/me.6.5.837; CLAIR T, 1987, FEBS LETT, V224, P377, DOI 10.1016/0014-5793(87)80488-X; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; EINCK L, 1984, J CELL BIOL, V98, P205, DOI 10.1083/jcb.98.1.205; FANTOZZI DA, 1992, J BIOL CHEM, V267, P16824; FLETCHER WH, 1986, J BIOL CHEM, V261, P5504; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; GIBBS CS, 1992, J BIOL CHEM, V267, P4806; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HANOVER JA, 1992, FASEB J, V6, P2288, DOI 10.1096/fasebj.6.6.1312045; HERBERG FW, 1993, IN PRESS PROTEIN ENG; HOFMANN F, 1980, J BIOL CHEM, V255, P1559; JUNGMANN RA, 1988, METHOD ENZYMOL, V159, P225; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; KREBS EG, 1986, ENZYMES, P3; KUETTEL MR, 1984, CELL BIOL INT REP, V8, P949, DOI 10.1016/0309-1651(84)90193-0; LANG I, 1986, J CELL BIOL, V102, P1183, DOI 10.1083/jcb.102.4.1183; LOHMANN SM, 1980, J BIOL CHEM, V255, P9985; MANDELL RB, 1990, J CELL BIOL, V111, P1775, DOI 10.1083/jcb.111.5.1775; MEIER UT, 1992, CELL, V70, P127; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MEINKOTH JL, 1992, J BIOL CHEM, V267, P13239; MILLER M, 1991, PHYSIOL REV, V71, P909, DOI 10.1152/physrev.1991.71.3.909; NEITZEL JJ, 1991, BIOCHEMISTRY-US, V30, P733, DOI 10.1021/bi00217a023; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; SARASWAT LD, 1988, METHOD ENZYMOL, P325; SLICE LW, 1989, J BIOL CHEM, V264, P20940; STACEY DW, 1984, EXP CELL RES, V154, P283, DOI 10.1016/0014-4827(84)90687-6; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; THOMAS J, 1991, J BIOL CHEM, V266, P10906; VANPATTEN SM, 1992, MOL ENDOCRINOL, V6, P2114, DOI 10.1210/me.6.12.2114; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WALSH DA, 1971, J BIOL CHEM, V246, P1977; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682; Zetterqvist O.Z., 1990, PEPTIDES PROTEIN PHO, P171; ZHAO LJ, 1988, CELL, V55, P1005, DOI 10.1016/0092-8674(88)90245-0; ZOLLER MJ, 1979, J BIOL CHEM, V254, P2408	51	81	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2676	2686						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300597				2022-12-27	WOS:A1994MV43200050
J	SEEDORF, U; SCHEEK, S; ENGEL, T; STEIF, C; HINZ, HJ; ASSMANN, G				SEEDORF, U; SCHEEK, S; ENGEL, T; STEIF, C; HINZ, HJ; ASSMANN, G			STRUCTURE-ACTIVITY STUDIES OF HUMAN STEROL CARRIER PROTEIN-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-TRANSFER PROTEIN; AMINO-ACID-SEQUENCE; GLUTATHIONE S-TRANSFERASE; RAT-LIVER; SECONDARY STRUCTURE; ESCHERICHIA-COLI; BOVINE LIVER; CHOLESTEROL; PURIFICATION; EXPRESSION	Recombinant human sterol carrier protein 2 (SCP2) variants were generated by site-directed mutagenesis and expression in Escherichia coli. The ability of the variants to stimulate microsomal conversion of 7-dehydrocholesterol to cholesterol (sterol carrier activity) and to transfer cholesterol and phosphatidylcholine from donor small unilamellar vesicles to acceptor membranes (cholesterol and phosphatidylcholine transfer activities) was compared with wild-type recombinant SCP2. Our results indicate that all measured activities of recombinant human pre-SCP2 (including the 20-amino acid leader sequence) and mature SCP2 were similar. Expressed glutathione S-transferase fusion proteins (GST-SCP2 and GST-pre-SCP2) possessed considerable activity, suggesting that steric obstruction at the amino terminus causes only minor inactivation. The effect of progressive removal of peptides from the carboxyl terminus showed that amino acids between Lys100 and Asn104 are essential for SCP2 activity. This conclusion was substantiated by the observation that replacing Asn104 with Asp or Ile caused considerable inactivation, whereas replacing Met105 with Leu had almost no effect. Since N-ethylmaleimide is known to inhibit SCP2 activity, substitutions were also introduced in the vicinity of Cys71. Whereas Val71 and Ser71 variants possessed wild-type activity, replacing Asp70 with Asn almost completely abolished SCP2 activity. Further, the importance of residues located close to the amino terminus was indicated by complete inactivation of a 10-amino-terminal amino acid deletion mutant and by replacing Leu20 with Glu. Circular dichroism results showed that Leu20 and Asp-70 may serve to stabilize the overall fold, whereas residue 104 appears to play a role in the specific lipid binding and/or transfer activity of SCP2.	UNIV MUNSTER, INST KLIN CHEM & LAB MED, ZENT LAB, D-48149 MUNSTER, GERMANY; UNIV MUNSTER, INST BIOCHEM, D-48149 MUNSTER, GERMANY; UNIV MUNSTER, INST PHYS CHEM, D-48149 MUNSTER, GERMANY	University of Munster; University of Munster; University of Munster	SEEDORF, U (corresponding author), UNIV MUNSTER, INST ARTERIOSKLEROSEFORSCH, DOMAGKSTR 3, D-48149 MUNSTER, GERMANY.							APPELKVIST EL, 1987, BIOSCIENCE REP, V7, P853, DOI 10.1007/BF01119476; BILLHEIMER JT, 1990, DNA CELL BIOL, V9, P154; BLOJ B, 1978, FEBS LETT, V96, P87, DOI 10.1016/0014-5793(78)81068-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BUTKO P, 1990, BIOCHEMISTRY-US, V29, P4070, DOI 10.1021/bi00469a007; CHANDERBHAN R, 1983, BIOCHEM BIOPH RES CO, V117, P702, DOI 10.1016/0006-291X(83)91654-6; CHANDERBHAN R, 1982, J BIOL CHEM, V257, P8928; CHANG S, 1979, MOL GEN GENET, V168, P111, DOI 10.1007/BF00267940; CHESTERTON CJ, 1968, J BIOL CHEM, V243, P1147; COLBEAU A, 1971, BIOCHIM BIOPHYS ACTA, V249, P462, DOI 10.1016/0005-2736(71)90123-4; CRAIN RC, 1980, BIOCHEMISTRY-US, V19, P1433, DOI 10.1021/bi00548a026; GADELLA TWJ, 1991, BIOCHEMISTRY-US, V30, P5555, DOI 10.1021/bi00236a031; GAVEY KL, 1981, J BIOL CHEM, V256, P2993; HABIG WH, 1974, P NATL ACAD SCI USA, V71, P3879, DOI 10.1073/pnas.71.10.3879; HE ZG, 1991, DNA CELL BIOL, V10, P559, DOI 10.1089/dna.1991.10.559; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JOHNSON KS, 1989, NATURE, V338, P585, DOI 10.1038/338585a0; KANDUTSCH AA, 1962, J BIOL CHEM, V237, P358; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDSTROMOLSSON B, 1986, BIOCHEM J, V238, P879; MONCECCHI D, 1991, J BIOL CHEM, V266, P9885; MORI T, 1991, P NATL ACAD SCI USA, V88, P4338, DOI 10.1073/pnas.88.10.4338; NOLAND BJ, 1980, J BIOL CHEM, V255, P4282; OSSENDORP BC, 1990, BIOCHEM BIOPH RES CO, V168, P631, DOI 10.1016/0006-291X(90)92367-9; OSSENDORP BC, 1992, FEBS LETT, V296, P179, DOI 10.1016/0014-5793(92)80374-P; OSSENDORP BC, 1991, EUR J BIOCHEM, V201, P233, DOI 10.1111/j.1432-1033.1991.tb16279.x; PASTUSZYN A, 1987, J BIOL CHEM, V262, P13219; POORTHUIS BJHM, 1981, BIOCHIM BIOPHYS ACTA, V665, P256, DOI 10.1016/0005-2760(81)90010-2; POORTHUIS BJHM, 1982, BIOCHIM BIOPHYS ACTA, V710, P99, DOI 10.1016/0005-2760(82)90195-3; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; PTITSYN OB, 1983, BIOPOLYMERS, V22, P15, DOI 10.1002/bip.360220105; REINHART MP, 1990, EXPERIENTIA, V46, P599, DOI 10.1007/BF01939699; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SCHROEDER F, 1990, J BIOL CHEM, V265, P151; SCHROEDER F, 1989, BIOCHEMISTRY-US, V28, P5992, DOI 10.1021/bi00440a041; SEEDORF U, 1991, J BIOL CHEM, V266, P630; SEEDORF U, 1993, GENE, V123, P165, DOI 10.1016/0378-1119(93)90120-R; SELTMAN H, 1985, BIOCHEM J, V230, P19, DOI 10.1042/bj2300019; SIEDEL J, 1983, METHOD ENZYMAT AN, V8, P139; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKAYAMA M, 1977, CLIN CHIM ACTA, V79, P93, DOI 10.1016/0009-8981(77)90465-X; TAN H, 1990, EUR J BIOCHEM, V190, P107, DOI 10.1111/j.1432-1033.1990.tb15552.x; THOMPSON SL, 1987, J BIOL CHEM, V262, P17420; TRZASKOS JM, 1983, BIOCHIM BIOPHYS ACTA, V751, P52, DOI 10.1016/0005-2760(83)90256-4; VAHOUNY GV, 1984, BIOCHEM BIOPH RES CO, V122, P509, DOI 10.1016/S0006-291X(84)80062-5; VAHOUNY GV, 1983, J BIOL CHEM, V258, P1731; VANAMERONGEN A, 1985, CHEM PHYS LIPIDS, V38, P195, DOI 10.1016/0009-3084(85)90067-2; VANAMERONGEN A, 1989, BIOCHIM BIOPHYS ACTA, V1004, P36, DOI 10.1016/0005-2760(89)90209-9; WESTERMAN J, 1985, BIOCHEM BIOPH RES CO, V127, P333, DOI 10.1016/S0006-291X(85)80163-7; WIRTZ KWA, 1990, EXPERIENTIA, V46, P592, DOI 10.1007/BF01939698; YAMAMOTO R, 1991, P NATL ACAD SCI USA, V88, P463, DOI 10.1073/pnas.88.2.463; ZILVERSMIT DB, 1976, METHODS MEMBRANE BIO, P211	53	56	57	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2613	2618						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300590				2022-12-27	WOS:A1994MV43200041
J	WAKIM, BT; ASWAD, GD				WAKIM, BT; ASWAD, GD			CA2+-CALMODULIN-DEPENDENT PHOSPHORYLATION OF ARGININE IN HISTONE-3 BY A NUCLEAR KINASE FROM MOUSE LEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT PHOSPHORYLATION; TREATED HELA-CELLS; PROTEIN-KINASE; CHROMATIN STRUCTURE; PURIFICATION; CALMODULIN; ACID; MITOSIS; CYCLE; DNA	A Ca2+-calmodulin dependent histone 3 kinase was partially purified from a low salt (150 mm NaCl) nuclear extract of mouse leukemia cells by calmodulin-Sepharose affinity chromatography. In vitro, the kinase activity transferred gamma-phosphate from ATP to histone 3 to form an acid-labile and alkaline-stable linkage. Under the assay conditions 1.8 mol of phosphate are incorporated per mol of histone 3. Upon modification of arginine residues with phenylglyoxal prior to phosphorylation, a considerable decrease in the amount of phosphate transferred to histone 3 was observed. Amino acid analysis revealed that H3 was phosphorylated on arginine residues. To identify the phosphorylated peptide(s), histone 3 was cleaved with cyanogen bromide prior to phosphorylation. The phosphorylated mixture was then separated by gel filtration high-performance liquid chromatography under denaturing conditions. Fragments I (N-terminal 10.3-kDa peptide) and III (C-terminal 1.7-kDa peptide) were both phosphorylated. Amino acid sequencing further revealed that the molar yields of 3 of the 4 arginines present in the phosphorylated cyanogen bromide fragment III were reduced by a factor of about 10 compared with the corresponding arginines from the unphosphorylated fragment. In the case of fragment I, 25 cycles of Edman degradation revealed that the recovery of only arginine 2 was reduced by a factor of 20. The putative phosphorylation sites are arginines 2, 128, 129, and 131. The sequence information offered an indirect evidence that these arginines were the sites of phosphorylation. The kinase described in this report represents a first member of a potentially important new class of kinases which are Ca2+-calmodulin dependent and which phosphorylate arginine.	LOYOLA UNIV,STRITCH SCH MED,DEPT MICROBIOL & IMMUNOL,MAYWOOD,IL 60153	Loyola University Chicago	WAKIM, BT (corresponding author), LOYOLA UNIV,STRITCH SCH MED,MACROMOLEC LAB,MAYWOOD,IL 60153, USA.							BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BOHMANN D, 1990, CANCER CELL-MON REV, V2, P337; Bonner J, 1968, METHODS ENZYMOL, V12, P3; BRADBURY EM, 1983, CIBA F SYMP, V93, P246; CHEN CC, 1977, BIOCHEMISTRY-US, V16, P4852, DOI 10.1021/bi00641a016; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GURLEY LR, 1974, J CELL BIOL, V60, P356, DOI 10.1083/jcb.60.2.356; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; HUANG JM, 1991, J BIOL CHEM, V266, P9023; HUEBNER VD, 1985, J BIOL CHEM, V260, P6106; HULTQUIS.DE, 1968, BIOCHIM BIOPHYS ACTA, V153, P329, DOI 10.1016/0005-2728(68)90078-9; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; KEITH CH, 1985, NATURE, V316, P848, DOI 10.1038/316848a0; KROLL DJ, 1991, J BIOL CHEM, V266, P7957; LEVYFAVATIER F, 1987, EUR J BIOCHEM, V166, P617, DOI 10.1111/j.1432-1033.1987.tb13558.x; LU KP, 1993, J CELL BIOL, V121, P621, DOI 10.1083/jcb.121.3.621; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MARKS DB, 1973, J BIOL CHEM, V248, P5660; MATTHEWS HR, 1978, EXP CELL RES, V111, P343, DOI 10.1016/0014-4827(78)90179-9; MATTHEWS HR, 1984, MOL CELL BIOCHEM, V59, P81; MEANS AR, 1991, PHARMACOL THERAPEUT, V50, P255, DOI 10.1016/0163-7258(91)90017-G; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NYGARD O, 1991, J BIOL CHEM, V266, P16425; SHIBATA K, 1990, EUR J BIOCHEM, V192, P87, DOI 10.1111/j.1432-1033.1990.tb19199.x; SHOEMAKER CB, 1980, J BIOL CHEM, V255, P1048; SHOEMAKER CB, 1978, J BIOL CHEM, V253, P5802; SIMPSON RT, 1978, NUCLEIC ACIDS RES, V5, P1109, DOI 10.1093/nar/5.4.1109; STEINER AW, 1980, J CHROMATOGR, V202, P263, DOI 10.1016/S0021-9673(00)81735-5; WAKIM BT, 1990, BIOCHEM BIOPH RES CO, V171, P84, DOI 10.1016/0006-291X(90)91359-Z; WEI YF, 1990, ANAL BIOCHEM, V190, P188, DOI 10.1016/0003-2697(90)90179-D; WEI YF, 1990, METHOD ENZYMOL, V200, P388; WHITLOCK JP, 1980, NATURE, V287, P74, DOI 10.1038/287074a0; WHITLOCK JP, 1983, J BIOL CHEM, V258, P1299	34	50	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2722	2727						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300603				2022-12-27	WOS:A1994MV43200056
J	GANDINO, L; LONGATI, P; MEDICO, E; PRAT, M; COMOGLIO, PM				GANDINO, L; LONGATI, P; MEDICO, E; PRAT, M; COMOGLIO, PM			PHOSPHORYLATION OF SERINE-985 NEGATIVELY REGULATES THE HEPATOCYTE GROWTH-FACTOR RECEPTOR KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR SCATTER FACTOR; TYROSINE PROTEIN-KINASE; MET HGF RECEPTOR; C-MET; INTRACELLULAR CALCIUM; SIGNAL TRANSDUCTION; TUMOR PROMOTERS; EGF RECEPTOR; INSULIN; AUTOPHOSPHORYLATION	The receptor for hepatocyte growth factor/scatter factor (HGF/SF) is an alphabeta tyrosine kinase of 190 kDa which mediates growth and motility in several cell types. We have previously shown that tyrosine autophosphorylation enhances the receptor kinase activity, while serine phosphorylation by protein kinase C or other Ca2+-dependent kinase(s) is inhibitory. We now identify Ser985 as the major phosphorylation site for the protein kinases responsible for such inhibition. Both phorbol esters or Ca2+ ionophore treatment induces phosphorylation of the same tryptic phosphopeptide corresponding to the sequence Leu983-Arg987 located in the juxtamembrane domain of the receptor beta chain. Purified protein kinase C phosphorylates in vitro a synthetic peptide (V14S) including Ser985. Trypsin digestion of the phosphorylated V14S generates a single phosphopeptide comigrating in reverse-phase high performance liquid chromatography with the tryptic peptide phosphorylated in vivo. Phorbol ester treatment of cultured cells inhibits the ligand-induced tyrosine autophosphorylation of the receptor. In vitro, Ser985 phosphorylation inhibits the receptor tyrosine kinase activity on exogenous substrates. Substitution of Ser985 by site-directed mutagenesis results in increased tyrosine phosphorylation of the receptor and abolishes down-modulation by protein kinase C. These data show that phosphorylation of Ser985 is a key mechanism for the negative regulation of HGF/SF receptor.	UNIV TURIN,SCH MED,DEPT BIOMED SCI & ONCOL,I-10126 TURIN,ITALY	University of Turin			Medico, Enzo/K-8497-2018	Medico, Enzo/0000-0002-3917-2438; Comoglio, Paolo/0000-0002-7056-5328				BARDELLI A, 1992, ONCOGENE, V7, P1973; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; COCHET C, 1984, J BIOL CHEM, V259, P2553; COMOGLIO PM, 1984, EMBO J, V3, P483, DOI 10.1002/j.1460-2075.1984.tb01834.x; COMOGLIO PM, 1993, HEPATOCYTE GROWTH FA, P131; COOPER CS, 1992, ONCOGENE, V7, P3; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; DAVIS RJ, 1984, J BIOL CHEM, V259, P8545; DIRENZO MF, 1993, ONCOGENE, V8, P219; DIRENZO MF, 1986, EUR J BIOCHEM, V158, P383; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FEARN JC, 1985, CELL, V40, P991, DOI 10.1016/0092-8674(85)90359-9; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FRIEDMAN B, 1989, P NATL ACAD SCI USA, V86, P812, DOI 10.1073/pnas.86.3.812; FRIEDMAN BA, 1984, P NATL ACAD SCI-BIOL, V81, P3034, DOI 10.1073/pnas.81.10.3034; GANDINO L, 1991, J BIOL CHEM, V266, P16098; GANDINO L, 1990, ONCOGENE, V5, P721; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; JACOBS S, 1983, P NATL ACAD SCI-BIOL, V80, P6211, DOI 10.1073/pnas.80.20.6211; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KLEIN HH, 1986, J BIOL CHEM, V261, P4691; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIVNEH E, 1988, MOL CELL BIOL, V8, P2302, DOI 10.1128/MCB.8.6.2302; MECKLINGHANSEN K, 1987, EMBO J, V6, P659, DOI 10.1002/j.1460-2075.1987.tb04805.x; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1991, ONCOGENE, V6, P553; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TEMPEST PR, 1986, FEBS LETT, V209, P357, DOI 10.1016/0014-5793(86)81142-5; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VERHEIJDEN GF, 1990, BIOCHEM J, V271, P215, DOI 10.1042/bj2710215; VILLAMORUZZI E, 1993, IN PRESS J BIOL CHEM, V268; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WEINMASTER G, 1986, EMBO J, V5, P69, DOI 10.1002/j.1460-2075.1986.tb04179.x; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YU KT, 1984, J BIOL CHEM, V259, P5277; YU KT, 1986, J BIOL CHEM, V261, P4715	61	124	128	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1815	1820						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294430				2022-12-27	WOS:A1994MR98800042
J	HEIDENREICH, O; BENSELER, F; FAHRENHOLZ, A; ECKSTEIN, F				HEIDENREICH, O; BENSELER, F; FAHRENHOLZ, A; ECKSTEIN, F			HIGH-ACTIVITY AND STABILITY OF HAMMERHEAD RIBOZYMES CONTAINING 2'-MODIFIED PYRIMIDINE NUCLEOSIDES AND PHOSPHOROTHIOATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ANTI-HIV-1 THERAPEUTIC AGENTS; SELF-CLEAVAGE REACTION; MESSENGER-RNA; CATALYTIC ACTIVITY; HIV-1 REPLICATION; MEDIATED CLEAVAGE; GENE-EXPRESSION; INVIVO; CELLS	The influence of chemical modifications on the catalytic activity and stability of a hammerhead ribozyme directed against the long terminal repeat RNA of the human immunodeficiency virus 1 was examined. Previous studies had shown that substitution of all pyrimidine nucleosides by their 2'-fluoro analogs led to an 8-fold decrease in catalytic efficiency in the cleavage reaction compared to the unmodified ribozyme (Heidenreich, O., and Eckstein, F. (1992) J. Biol. Chem. 267,1904-1909). It is shown here that replacement of the 2'-fluoro-2'-deoxyuridines in the conserved region of this ribozyme, positions 4 and 7, by 2'-amino-2'-deoxyuridines fully restores catalytic activity of the ribozyme. Ribozymes containing these 2'-modifications show an increased stability against RNases present in fetal calf serum and in cell culture supernatant. The stability is increased further by the incorporation of four terminal phosphorothioates as protection against 3'-exonucleases, the degree of which depends on the secondary structure of the ribozyme. Such ribozymes are stable in undiluted fetal calf serum for at least 24 h. The results clearly demonstrate the potential to design stable ribozymes without any loss of catalytic activity.	MAX PLANCK INST EXPTL MED, HERMANN REIN STR 3, D-37075 GOTTINGEN, GERMANY	Max Planck Society			Heidenreich, Olaf/AAP-5045-2021	Heidenreich, Olaf/0000-0001-5404-6483				BENSELER F, 1992, NUCLEOS NUCLEOT, V11, P1333, DOI 10.1080/07328319208021177; BRUENING G, 1989, METHOD ENZYMOL, V180, P546; BUZAYAN JM, 1990, NUCLEIC ACIDS RES, V18, P4447, DOI 10.1093/nar/18.15.4447; CAMERON FH, 1989, P NATL ACAD SCI USA, V86, P9139, DOI 10.1073/pnas.86.23.9139; CHEN CJ, 1992, NUCLEIC ACIDS RES, V20, P4581, DOI 10.1093/nar/20.17.4581; CODINGTON JF, 1964, J ORG CHEM, V29, P558, DOI 10.1021/jo01026a009; CONNOLLY BA, 1991, OLIGONUCLEOTIDES ANA, P155; COTTEN M, 1990, TRENDS BIOTECHNOL, V8, P174, DOI 10.1016/0167-7799(90)90168-W; COTTEN M, 1989, EMBO J, V8, P3861, DOI 10.1002/j.1460-2075.1989.tb08564.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DROPULIC B, 1992, J VIROL, V66, P1432; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; Eder P S, 1991, Antisense Res Dev, V1, P141; FEDOR MJ, 1990, P NATL ACAD SCI USA, V87, P1668, DOI 10.1073/pnas.87.5.1668; Fersht A., 1985, ENZYME STRUCTURE MEC; FOX JJ, 1963, J ORG CHEM, V28, P936, DOI 10.1021/jo01039a014; GOODCHILD J, 1992, NUCLEIC ACIDS RES, V20, P4607, DOI 10.1093/nar/20.17.4607; HAMPTON A, 1966, BIOCHEMISTRY-US, V5, P2076, DOI 10.1021/bi00870a040; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HEIDENREICH O, 1992, J BIOL CHEM, V267, P1904; HEIDENREICH O, 1993, FASEB J, V7, P90, DOI 10.1096/fasebj.7.1.7678566; HENDRY P, 1992, NUCLEIC ACIDS RES, V20, P5737, DOI 10.1093/nar/20.21.5737; HERTEL KJ, 1992, NUCLEIC ACIDS RES, V20, P3252, DOI 10.1093/nar/20.12.3252; HOMANN M, 1993, NUCLEIC ACIDS RES, V21, P2809, DOI 10.1093/nar/21.12.2809; KAWASAKI AM, 1993, J MED CHEM, V36, P831, DOI 10.1021/jm00059a007; KOIZUMI M, 1992, GENE, V117, P179, DOI 10.1016/0378-1119(92)90727-7; KRUG A, 1989, NUCLEOS NUCLEOT, V8, P1473, DOI 10.1080/07328318908048855; LANGE W, 1993, IN PRESS LEUKEMIA; LHUILLIER PJ, 1992, EMBO J, V11, P4411, DOI 10.1002/j.1460-2075.1992.tb05541.x; LI BFL, 1987, BIOCHEMISTRY-US, V26, P1086, DOI 10.1021/bi00378a015; LO KMS, 1992, VIROLOGY, V190, P176, DOI 10.1016/0042-6822(92)91203-7; OJWANG JO, 1992, P NATL ACAD SCI USA, V89, P10802, DOI 10.1073/pnas.89.22.10802; OLSEN DB, 1991, BIOCHEMISTRY-US, V30, P9735, DOI 10.1021/bi00104a024; Ortigao J F, 1992, Antisense Res Dev, V2, P129; PAOLELLA G, 1992, EMBO J, V11, P1913, DOI 10.1002/j.1460-2075.1992.tb05244.x; PERREAULT JP, 1990, NATURE, V344, P565, DOI 10.1038/344565a0; PIEKEN WA, 1991, SCIENCE, V253, P314, DOI 10.1126/science.1857967; ROSSI J J, 1992, Current Opinion in Biotechnology, V3, P3, DOI 10.1016/0958-1669(92)90117-2; ROSSI JJ, 1990, TRENDS BIOTECHNOL, V8, P179, DOI 10.1016/0167-7799(90)90169-X; ROSSI JJ, 1992, AIDS RES HUM RETROV, V8, P183, DOI 10.1089/aid.1992.8.183; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; RUFFNER DE, 1990, NUCLEIC ACIDS RES, V18, P6025, DOI 10.1093/nar/18.20.6025; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SAXENA SK, 1990, J BIOL CHEM, V265, P17106; SCANLON KJ, 1991, P NATL ACAD SCI USA, V88, P10591, DOI 10.1073/pnas.88.23.10591; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; SHAW JP, 1991, NUCLEIC ACIDS RES, V19, P747, DOI 10.1093/nar/19.4.747; SHIBAHARA S, 1989, NUCLEIC ACIDS RES, V17, P239, DOI 10.1093/nar/17.1.239; SHIMAYAMA T, 1993, NUCLEIC ACIDS RES, V21, P2605, DOI 10.1093/nar/21.11.2605; SINHA ND, 1984, NUCLEIC ACIDS RES, V12, P4539, DOI 10.1093/nar/12.11.4539; SIOUD M, 1992, J MOL BIOL, V223, P831, DOI 10.1016/0022-2836(92)90244-E; SIOUD M, 1991, P NATL ACAD SCI USA, V88, P7303, DOI 10.1073/pnas.88.16.7303; STEINECKE P, 1992, EMBO J, V11, P1525, DOI 10.1002/j.1460-2075.1992.tb05197.x; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; TANG JY, 1993, NUCLEIC ACIDS RES, V21, P2729, DOI 10.1093/nar/21.11.2729; TAYLOR NR, 1992, NUCLEIC ACIDS RES, V20, P4559, DOI 10.1093/nar/20.17.4559; TSUCHL T, 1993, P NATL ACAD SCI USA, V90, P6991; TSUJI H, 1992, EUR J CLIN CHEM CLIN, V30, P339; WEERASINGHE M, 1991, J VIROL, V65, P5531, DOI 10.1128/JVI.65.10.5531-5534.1991; WILLIAMS DM, 1991, BIOCHEMISTRY-US, V30, P4001, DOI 10.1021/bi00230a027; WILLIAMS DM, 1992, BIOCHEMISTRY-US, V89, P918; WOISARD A, 1992, J AM CHEM SOC, V114, P10072, DOI 10.1021/ja00051a056; YANG JH, 1992, BIOCHEMISTRY-US, V31, P5005, DOI 10.1021/bi00136a013; ZHENG X, 1993, J VIROL, V67, P1840, DOI 10.1128/JVI.67.4.1840-1847.1993; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	65	147	195	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2131	2138						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294467				2022-12-27	WOS:A1994MR98800088
J	PROCYSHYN, RM; REID, RE				PROCYSHYN, RM; REID, RE			A STRUCTURE-ACTIVITY STUDY OF CALCIUM AFFINITY AND SELECTIVITY USING A SYNTHETIC PEPTIDE MODEL OF THE HELIX-LOOP-HELIX CALCIUM-BINDING MOTIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL TROPONIN-C; SITE-III; MAGNESIUM BINDING; CRYSTAL-STRUCTURE; PARVALBUMIN; PROTEINS; RESOLUTION; CALMODULIN; MUSCLE; ACID	The acid pair hypothesis predicts the calcium affinity of the helix-loop-helix calcium-binding motif based on the number and location of acidic amino acid residues in chelating positions of the calcium-binding loop region. This study investigates the effects of the number and position of acidic residues in the loop region on calcium affinity and selectivity using 33-residue synthetic models of single helix-loop-helix calcium-binding motifs. Increasing the number of acidic residues in the octahedrally arranged chelating positions of the loop region from 3 to 4 by replacing an asparagine in the +y position with an aspartic acid increases the calcium affinity of the models between 2- and 38-fold. Differences in affinities are more pronounced in the models containing an x axis acid pair. The calcium affinities of peptide models containing 3 or 4 acidic residues in chelating positions of the loop region and an x axis acid pair are reduced when the residue in the +z position is changed from asparagine to serine. A similar reduction in calcium affinity occurs in the z axis acid paired peptides when the -x chelating residue is changed from serine to asparagine. Models with 3 acidic residues in chelating positions containing az axis acid pair have greater calcium affinity than comparable peptide models with an x axis acid pair. The presence of x or z axis acid pairs in comparable peptides containing 4 acidic residues in chelating positions does not greatly alter calcium affinity. Calcium selectivity resides in x axis acid paired peptides, whereas z axis acid paired peptides exhibit both magnesium-and calcium-induced structural changes. This ion selectivity may be explained by postulating that the z axis residue side chains produce the initial, rate-limiting interactions with the cation, causing hydration shell destabilization and initiating the subsequent ligand interactions.	UNIV BRITISH COLUMBIA,FAC PHARMACEUT SCI,DIV PHARMACEUT CHEM,2146 E MALL,VANCOUVER V6T 1Z3,BC,CANADA	University of British Columbia			Procyshyn, Ric/AAE-5499-2019	Procyshyn, Ric/0000-0002-4348-0855				AHMED FR, 1990, J MOL BIOL, V216, P127, DOI 10.1016/S0022-2836(05)80065-8; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BOGUTA G, 1988, J THEOR BIOL, V135, P63, DOI 10.1016/S0022-5193(88)80174-7; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; COLLINS JH, 1976, SOC EXP BIOL S, V30, P303; DECLERCQ JP, 1991, J MOL BIOL, V220, P1017, DOI 10.1016/0022-2836(91)90369-H; EIGEN M, 1961, ADVANCES CHEMISTRY C, P371; HAIECH J, 1979, BIOCHEMISTRY-US, V18, P2752, DOI 10.1021/bi00580a010; HAPAK RC, 1989, J BIOL CHEM, V264, P18751; HERZBERG O, 1985, BIOCHEMISTRY-US, V24, P5298, DOI 10.1021/bi00341a004; HUDSON D, 1988, J ORG CHEM, V53, P617, DOI 10.1021/jo00238a026; KOBAYASHI T, 1989, J BIOL CHEM, V264, P18247; KRETSINGER RH, 1976, COORDIN CHEM REV, V18, P29, DOI 10.1016/S0010-8545(00)82054-8; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; KUMAR VD, 1990, BIOCHEMISTRY-US, V29, P1404, DOI 10.1021/bi00458a010; LEHKY P, 1977, ANAL BIOCHEM, V82, P158, DOI 10.1016/0003-2697(77)90144-0; Lehn JM., 1973, STRUCT BONDING BERLI, V16, P1, DOI DOI 10.1017/BFB0004364; MARSDEN BJ, 1988, BIOCHEMISTRY-US, V27, P4198, DOI 10.1021/bi00411a043; MARSDEN BJ, 1990, BIOCHEM CELL BIOL, V68, P587, DOI 10.1139/o90-084; MATTHEWS BW, 1993, ANNU REV BIOCHEM, V62, P139, DOI 10.1146/annurev.bi.62.070193.001035; MOESCHLER HJ, 1980, EUR J BIOCHEM, V111, P73; NAGY B, 1978, J BIOL CHEM, V253, P5971; PERRIN DD, 1967, TALANTA, V14, P833, DOI 10.1016/0039-9140(67)80105-X; Potter J.D., 1977, CALCIUM BINDING PROT, P239; POTTER JD, 1975, J BIOL CHEM, V250, P4628; POTTER JD, 1977, BIOPHYS J, V17, P118; REID RE, 1987, BIOCHEMISTRY-US, V26, P6070, DOI 10.1021/bi00393a019; REID RE, 1987, INT J PEPT PROT RES, V30, P613; REID RE, 1990, J BIOL CHEM, V265, P5971; REID RE, 1980, J THEOR BIOL, V84, P401, DOI 10.1016/S0022-5193(80)80013-0; REID RE, 1981, J BIOL CHEM, V256, P2742; SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1; SEKHARUDU YC, 1988, PROTEIN ENG, V2, P139, DOI 10.1093/protein/2.2.139; SHAW GS, 1991, BIOCHEMISTRY-US, V30, P8339, DOI 10.1021/bi00098a009; SILLEN LG, 1971, SPECIAL PUBLICATION, V25, P452; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; Szebenyi DME, 1981, NATURE, V294, P327, DOI 10.1038/294327a0; VOGT HP, 1979, J THEOR BIOL, V76, P297, DOI 10.1016/0022-5193(79)90314-X; West TS, 1969, COMPLEXOMETRY EDTA R	39	53	54	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1641	1647						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294410				2022-12-27	WOS:A1994MR98800018
J	TAKAYAMA, K; MITCHELL, DH; DIN, ZZ; MUKERJEE, P; LI, C; COLEMAN, DL				TAKAYAMA, K; MITCHELL, DH; DIN, ZZ; MUKERJEE, P; LI, C; COLEMAN, DL			MONOMERIC RE LIPOPOLYSACCHARIDE FROM ESCHERICHIA-COLI IS MORE ACTIVE THAN THE AGGREGATED FORM IN THE LIMULUS AMEBOCYTE LYSATE ASSAY AND IN INDUCING EGR-1 MESSENGER-RNA IN MURINE PERITONEAL-MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTOXIN; DIFFERENTIATION; PROTEIN; GROWTH	Using the equilibrium dialysis apparatus, an aqueous suspension of predominantly aggregated Re lipopolysaccharide (ReLPS) from Escherichia coli D31 m4 (99.9% at 82.5 muM) can be processed to yield a solution of monomeric ReLPS at a saturation concentration of 77 ng/ml (3.4 x 10(-8) m). We compared the in vitro biological activities of these two physically distinct types of ReLPS preparations in two select assays, reaction in the Limulus amebocyte lysate (LAL) assay and induction of Egr-1 mRNA in macrophages. These assays were chosen for their rapid response times and relatively short incubation periods. The monomeric ReLPS was 179- and 1000-fold more active than the aggregated ReLPS preparation in the LAL assay and induction of Egr-1 mRNA by thioglycollate-elicited murine peritoneal macrophages, respectively. These results clearly showed that the monomeric ReLPS is the more active form. The lower biological activities of the aggregated ReLPS preparation might be due to the presence of a small amount of monomeric ReLPS (0.01-0.6%) produced during its preparation and the incubation periods in the biological assays. Thus, aggregated ReLPS may be relatively inactive.	UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BACTERIOL,MADISON,WI 53706; UNIV WISCONSIN,SCH PHARM,MADISON,WI 53706; UNIV COLORADO,HLTH SCI CTR,DIV INFECT DIS,DENVER,CO 80262; VET ADM MED CTR,INFECT DIS SECT,DENVER,CO 80220	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA)	TAKAYAMA, K (corresponding author), WILLIAM S MIDDLETON MEM VET ADM MED CTR,MYCOBACTERIOL RES LAB,2500 OVERLOOK TERRACE,MADISON,WI 53705, USA.		mukerjee, pasupati/A-7163-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036054] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-36054] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; COLEMAN DL, 1992, J IMMUNOL, V149, P3045; COOPER JF, 1971, J LAB CLIN MED, V78, P138; DIN ZZ, 1993, BIOCHEMISTRY-US, V32, P4579, DOI 10.1021/bi00068a014; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; LEVIN J, 1970, J LAB CLIN MED, V75, P903; LIU JW, 1991, J BIOL CHEM, V266, P5929; MORRISON DC, 1989, MICROB PATHOGENESIS, V7, P389, DOI 10.1016/0882-4010(89)90019-3; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; NOWOTNY A, 1983, BENEFICIAL EFFECTS E; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; ROTH RI, 1989, J LAB CLIN MED, V114, P306; SEYDEL U, 1993, IMMUNOBIOLOGY, V187, P191, DOI 10.1016/S0171-2985(11)80339-6; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TAKAYAMA K, 1990, J BIOL CHEM, V265, P14023; TOMASULO PA, 1977, J LAB CLIN MED, V89, P308	18	110	110	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2241	2244						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294481				2022-12-27	WOS:A1994MR98800102
J	DERIJKE, YB; VANBERKEL, TJC				DERIJKE, YB; VANBERKEL, TJC			RAT-LIVER KUPFFER AND ENDOTHELIAL-CELLS EXPRESS DIFFERENT BINDING-PROTEINS FOR MODIFIED LOW-DENSITY LIPOPROTEINS - KUPFFER CELLS EXPRESS A 95-KDA MEMBRANE-PROTEIN AS A SPECIFIC BINDING-SITE FOR OXIDIZED LOW-DENSITY LIPOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BOVINE SERUM-ALBUMIN; ATHEROSCLEROTIC LESIONS; CHOLESTEROL DEPOSITION; PLASMA-LIPOPROTEINS; SCAVENGER RECEPTORS; MACROPHAGE; INVIVO; METABOLISM; DEGRADATION; RECOGNITION	The liver is the major organ responsible for the uptake of oxidized low density lipoproteins (Ox-LDL) from the blood circulation with Kupffer cells as major cellular uptake site. Candidate binding proteins for Ox-LDL on membranes from Kupffer and endothelial liver cells were identified with ligand blots. Under nonreducing conditions, a major binding protein with an estimated molecular mass of 95 kDa and a minor stained protein of 220 kDa were detected on Kupffer cell membranes, while endothelial cell membranes expressed only a 220-kDa binding protein. Both the 95-kDa protein of Kupffer cell membranes and the 220-kDa protein of endothelial membranes displayed saturable binding of I-125-Ox-LDL with a K(d) of 15 and 5 mug/ml, respectively. LDL was a weak competitor for the binding of I-125-Ox-LDL to the 95-kDa protein, while the degree of competition appeared to be dependent on the oxidation grade of LDL with a complete competition with LDL oxidized for 20 h with 10 muM Cu2+. We conclude that the 95-kDa binding protein, highly concentrated on rat Kupffer cells, forms the most likely candidate for mediating the in vivo uptake of Ox-LDL from the blood circulation.	LEIDEN UNIV,LEIDEN AMSTERDAM CTR DRUG RES,DIV BIOPHARMACEUT,SYLVIUS LABS,2312 AV LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC			Van Berkel, Theo/ABD-7677-2021; de Rijke, Yolanda/AAQ-5497-2020					ARAI H, 1989, BIOCHEM BIOPH RES CO, V159, P1375, DOI 10.1016/0006-291X(89)92262-6; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BROWN MS, 1980, J SUPRAMOL STR CELL, V13, P67, DOI 10.1002/jss.400130107; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; DERIJKE YB, 1992, J LIPID RES, V33, P1315; DRESEL HA, 1985, EMBO J, V4, P1157, DOI 10.1002/j.1460-2075.1985.tb03754.x; DRESEL HA, 1987, EMBO J, V6, P319, DOI 10.1002/j.1460-2075.1987.tb04757.x; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FOGELMAN AM, 1980, P NATL ACAD SCI-BIOL, V77, P2214, DOI 10.1073/pnas.77.4.2214; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HAMPTON RY, 1988, J BIOL CHEM, V263, P14802; HORIUCHI S, 1985, J BIOL CHEM, V259, P53; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1979, J CLIN INVEST, V64, P743, DOI 10.1172/JCI109518; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; NAGELKERKE JF, 1983, J BIOL CHEM, V258, P2221; NAITO M, 1991, KUPFFER CELL F CELLS, V3, P497; OTTNAD E, 1990, BIOCHEM J, V265, P689, DOI 10.1042/bj2650689; OTTNAD E, 1992, BIOCHEM J, V281, P745, DOI 10.1042/bj2810745; OTTNAD E, 1993, 14 P ANN EUR C VASC, P90; PITAS RE, 1985, J CELL BIOL, V100, P103, DOI 10.1083/jcb.100.1.103; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; STANTON LW, 1992, J BIOL CHEM, V267, P22446; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Steinberg D., 1988, ATHEROSCLER REV, V18, P1; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; VANBERKEL TJC, 1982, BIOCHEM J, V208, P493, DOI 10.1042/bj2080493; WRIGHT SD, 1986, J EXP MED, V164, P1876, DOI 10.1084/jem.164.6.1876; YLAHERTTUALA S, 1991, J CLIN INVEST, V87, P1146, DOI 10.1172/JCI115111; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	37	72	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					824	827						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288634				2022-12-27	WOS:A1994MR22000011
J	PARK, IK; ROACH, P; BONDOR, J; FOX, SP; DEPAOLIROACH, AA				PARK, IK; ROACH, P; BONDOR, J; FOX, SP; DEPAOLIROACH, AA			MOLECULAR MECHANISM OF THE SYNERGISTIC PHOSPHORYLATION OF PHOSPHATASE INHIBITOR-2 - CLONING, EXPRESSION, AND SITE-DIRECTED MUTAGENESIS OF INHIBITOR-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT-SKELETAL-MUSCLE; GLYCOGEN-SYNTHASE KINASE-3; DEPENDENT PROTEIN PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE; SUBUNIT STRUCTURE; REGULATORY SUBUNIT; CATALYTIC SUBUNIT; SEQUENCE-ANALYSIS; IDENTIFICATION; ACTIVATION	Inhibitor-2 (I-2) is the regulatory subunit of the ATP-Mg-dependent phosphatase, a cytosolic form of type 1 protein phosphatase. Phosphorylation of 1-2 at Thr-72 by the protein kinase glycogen synthase kinase-3 (GSK-3) leads to activation of the enzyme. Casein kinase II action was shown to synergistically enhance phosphorylation and activation by GSK-3 (DePaoli-Roach, A. A. (1984) J. Biol. Chem. 259, 12144-12152). Rabbit skeletal muscle and liver I-2 cDNA clones have been isolated. Rabbit skeletal muscle cDNAs could be placed in two subtypes, differing in the length of the 3'-untranslated region. The coding sequence of 612 nucleotides was identical in the two skeletal muscle and the liver cDNAs and predicted a protein of 204 amino acids, consistent with analysis of the purified protein. Northern hybridization analysis indicated that the two mRNAs of 1.7 and 2.7 kilobase pairs were present in all rabbit tissues examined, except in liver, where only the larger transcript was detected, and in testis, where additional transcripts were present. Expression in Escherichia coli of wild-type and phosphorylation site mutants resulted in the production of I-2 polypeptides with apparent M(r) values of approximately 31,000 on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The inhibitory activity of the recombinant proteins was similar to that of native rabbit skeletal muscle I-2 and was unaffected by the substitution of alanine for the GSK-3 site (Thr-72) and for the casein kinase II sites (Ser-86 and Ser-120/121) or by substitution of glutamic acid and aspartic acid for Thr-72 and Ser-86. Recombinant wild-type I-2 and the Ala-120/121 mutant were phosphorylated synergistically by GSK-3 and casein kinase II. The Thr-72 and Ser-86 mutants, however, did not undergo this synergistic phosphorylation. Our studies indicate that Thr-72 is the only GSK-3 site and that Ser-86 is the casein kinase II site required for the potentiation of GSK-3 action. Furthermore, acidic residues cannot substitute for the phosphate group either in enhancing GSK-3 phosphorylation or in activating the phosphatase.	INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, 635 BARNHILL DR, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036569] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36569] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGOSTINIS P, 1987, FEBS LETT, V224, P385, DOI 10.1016/0014-5793(87)80489-1; ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; BALLOU LM, 1983, BIOCHEMISTRY-US, V22, P3393, DOI 10.1021/bi00283a014; BEULLENS M, 1992, J BIOL CHEM, V267, P16538; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUTIGAN DL, 1990, NATURE, V344, P74, DOI 10.1038/344074a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHEN P, 1973, EUR J BIOCHEM, V34, P1, DOI 10.1111/j.1432-1033.1973.tb02721.x; DePaoli-Roach A A, 1985, FEBS Lett, V183, P423; DEPAOLIROACH AA, 1983, J BIOL CHEM, V258, P702; DEPAOLIROACH AA, 1984, J BIOL CHEM, V259, P2144; DEPAOLIROACH AA, 1993, FASEB J, V7, pA1157; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; FIOL CJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P797, DOI 10.1016/0003-9861(88)90089-6; FIOL CJ, 1992, J CELL BIOCH A S, V16, P97; FISCHER EDMOND H., 1958, JOUR BIOL CHEM, V231, P65; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; GRUPPUSO PA, 1985, J BIOL CHEM, V260, P4288; GUBLER V, 1983, GENE, V25, P264; HEMMINGS BA, 1982, FEBS LETT, V150, P319, DOI 10.1016/0014-5793(82)80760-6; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HOLMES CFB, 1987, BIOCHIM BIOPHYS ACTA, V929, P208, DOI 10.1016/0167-4889(87)90178-9; HOLMES CFB, 1986, BIOCHIM BIOPHYS ACTA, V870, P408, DOI 10.1016/0167-4838(86)90248-7; HOLMES CFB, 1986, EUR J BIOCHEM, V155, P173, DOI 10.1111/j.1432-1033.1986.tb09473.x; HUANG FL, 1976, EUR J BIOCHEM, V70, P419, DOI 10.1111/j.1432-1033.1976.tb11032.x; HUBBARD MJ, 1989, EUR J BIOCHEM, V180, P457, DOI 10.1111/j.1432-1033.1989.tb14668.x; INGEBRITSEN TS, 1980, FEBS LETT, V119, P9, DOI 10.1016/0014-5793(80)80987-2; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAWRENCE JC, 1988, BIOCHEM BIOPH RES CO, V150, P197, DOI 10.1016/0006-291X(88)90505-0; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; Maniatis T., 1982, MOL CLONING; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; NEWGARD CB, 1986, P NATL ACAD SCI USA, V83, P8132, DOI 10.1073/pnas.83.21.8132; ORGAD S, 1987, EUR J BIOCHEM, V164, P31, DOI 10.1111/j.1432-1033.1987.tb10988.x; OYEN O, 1989, FEBS LETT, V246, P57, DOI 10.1016/0014-5793(89)80253-4; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; PONDAVEN P, 1987, EUR J BIOCHEM, V167, P135, DOI 10.1111/j.1432-1033.1987.tb13314.x; PUSKAS R, 1983, ARCH BIOCHEM BIOPHYS, V223, P503, DOI 10.1016/0003-9861(83)90615-X; RAMAKRISHNA S, 1990, BIOCHEMISTRY-US, V29, P7617, DOI 10.1021/bi00485a011; RECHSTEINER M, 1987, BIOCHEM BIOPH RES CO, V143, P194, DOI 10.1016/0006-291X(87)90649-8; ROACH P, 1985, J BIOL CHEM, V260, P6314; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SILVA OBD, 1987, FEBS LETT, V221, P415, DOI 10.1016/0014-5793(87)80966-3; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STALFORS P, 1985, EUR J BIOCHEM, V149, P295; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANG PM, 1991, J BIOL CHEM, V266, P15782; VANPATTEN SM, 1992, MOL ENDOCRINOL, V6, P2114, DOI 10.1210/me.6.12.2114; WALAAS SI, 1984, J NEUROSCI, V4, P84; WANG YH, 1991, P NATL ACAD SCI USA, V88, P2446, DOI 10.1073/pnas.88.6.2446; YANG SD, 1981, J BIOL CHEM, V256, P231; ZHANG WM, 1993, ARCH BIOCHEM BIOPHYS, V304, P219, DOI 10.1006/abbi.1993.1342; ZHANG ZJ, 1992, BIOCHEM BIOPH RES CO, V186, P1168, DOI 10.1016/0006-291X(92)90869-M	61	75	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					944	954						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288648				2022-12-27	WOS:A1994MR22000029
J	WU, KJ; WILSON, DR; SHIH, CH; DARLINGTON, GJ				WU, KJ; WILSON, DR; SHIH, CH; DARLINGTON, GJ			THE TRANSCRIPTION FACTOR HNF1 ACTS WITH C/EBP-ALPHA TO SYNERGISTICALLY ACTIVATE THE HUMAN ALBUMIN PROMOTER THROUGH A NOVEL DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; FUNCTIONAL COOPERATIVITY; GENE-EXPRESSION; MAMMALIAN-CELLS; GLUTAMINE-RICH; REPORTER GENE; SEQUENCE; ELEMENTS; INVITRO; DISTINCT	HNF1 and C/EBPalpha are transcription factors that bind to and trans-activate the human albumin gene proximal promoter. Various 5' deletions of the human albumin promoter were coupled to a luciferase reporter gene (alb-luc constructs) and co-electroporated with HNF1 and/or C/EBPalpha expression vectors into HeLa cells. Luciferase activities from co-electroporation of the HNF1 and C/EBPalpha expression vectors with the alb-luc constructs were approximately 10-fold greater than the sum of the activities achieved with HNF1 and C/EBPalpha alone. Analysis of COOH-terminal or internal deletions of the HNF1 expression vector revealed that the domain important for collaborative interaction with C/EBPalpha could be localized to a 157 amino acid region not previously described. This domain is proline and glutamine-rich and is highly homologous (66%) to a portion of vHNF1, an evolutionarily related gene first identified in dedifferentiated hepatoma cells. A construct linking the negatively charged activation domain of herpes simplex virus protein VP16 to the DNA-binding domain of HNF1 showed that it could also synergize with C/EBPalpha to trans-activate the human albumin gene promoter. Our studies delineate a domain in HNF1 important for synergistic activation with C/EBPalpha.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030; UNIV TEXAS,MED BRANCH,DEPT PATHOL,GALVESTON,TX 77550	Baylor College of Medicine; Baylor College of Medicine; University of Texas System; University of Texas Medical Branch Galveston			Wu, Kou-Juey/P-4654-2015; Shih, Chiaho/S-7017-2018		NIDDK NIH HHS [DK36089] Funding Source: Medline; NIGMS NIH HHS [GM32111] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032111] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHIU G, 1987, NUCLEIC ACIDS RES, V15, P1311; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DRIEVER W, 1989, NATURE, V342, P149, DOI 10.1038/342149a0; FOWLKES DM, 1984, P NATL ACAD SCI-BIOL, V81, P2313, DOI 10.1073/pnas.81.8.2313; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HARDWICK JM, 1992, J VIROL, V66, P5500, DOI 10.1128/JVI.66.9.5500-5508.1992; HERBOMEL P, 1989, MOL CELL BIOL, V9, P4750, DOI 10.1128/MCB.9.11.4750; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; JANSON L, 1990, P NATL ACAD SCI USA, V87, P4732, DOI 10.1073/pnas.87.12.4732; LAUGHON A, 1984, NATURE, V310, P25, DOI 10.1038/310025a0; LAWN RM, 1981, NUCLEIC ACIDS RES, V9, P6103, DOI 10.1093/nar/9.22.6103; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MILOS PM, 1992, GENE DEV, V6, P991, DOI 10.1101/gad.6.6.991; NICOSIA A, 1990, CELL, V61, P1225, DOI 10.1016/0092-8674(90)90687-A; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PEI DQ, 1991, MOL CELL BIOL, V11, P1480, DOI 10.1128/MCB.11.3.1480; PIRROTTA V, 1987, EMBO J, V6, P791, DOI 10.1002/j.1460-2075.1987.tb04821.x; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; RANEY AK, 1991, J VIROL, V65, P5774, DOI 10.1128/JVI.65.11.5774-5781.1991; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; REYCAMPOS J, 1991, EMBO J, V10, P1445, DOI 10.1002/j.1460-2075.1991.tb07665.x; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; SADOWSKI I, 1988, NATURE, V335, P559; SCHNEUWLY S, 1986, EMBO J, V5, P733, DOI 10.1002/j.1460-2075.1986.tb04275.x; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TRONCHE F, 1991, J MOL BIOL, V221, P31; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; URANO Y, 1986, J BIOL CHEM, V261, P3244; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WILSON DR, 1990, MOL CELL BIOL, V10, P6181, DOI 10.1128/MCB.10.12.6181; WU KJ, 1991, MOL CELL BIOL, V11, P4423, DOI 10.1128/MCB.11.9.4423	52	70	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1177	1182						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288579				2022-12-27	WOS:A1994MR22000065
J	GARRETT, RM; RAJAGOPALAN, KV				GARRETT, RM; RAJAGOPALAN, KV			MOLECULAR-CLONING OF RAT-LIVER SULFITE OXIDASE - EXPRESSION OF A EUKARYOTIC MO-PTERIN-CONTAINING ENZYME IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRATE REDUCTASE; MOLYBDENUM COFACTOR; NUCLEOTIDE-SEQUENCE; CDNA; GENE; DOMAINS; SITE	The cDNA encoding sulfite oxidase has been cloned from a rat liver cDNA library. The gene contains a single open reading frame of 1464 nucleotides encoding a protein of 488 amino acids. The deduced amino acid sequence contains a 22-residue amino-terminal presequence that may serve as a mitochondrial targeting signal. The amino acid sequence deduced from the cDNA shows significant similarity to those of sulfite oxidase from chicken liver and nitrate reductases from algal, fungal, and plant sources. Two cysteine residues are conserved in all of these proteins, and it is proposed that one or both of these cysteines serve as ligands to molybdenum. The gene has been expressed in Escherichia coli to a level equivalent to that observed in rat liver. The recombinant enzyme has been found to contain the molybdopterin form of the molybdenum cofactor and is active as determined by the sulfite dependent reduction of cytochrome c.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007031] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044283] Funding Source: NIH RePORTER; NIEHS NIH HHS [T32 ES07031] Funding Source: Medline; NIGMS NIH HHS [GM00091, GM44283] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBER MJ, 1990, J BIOL CHEM, V265, P20912; BELLISSIMO DB, 1988, THESIS DUKE U; BILOFSKY HS, 1988, NUCLEIC ACIDS RES, V16, P1861, DOI 10.1093/nar/16.5.1861; COHEN HJ, 1971, J BIOL CHEM, V246, P359; CRAMER SP, 1981, J AM CHEM SOC, V103, P7721, DOI 10.1021/ja00416a005; CRAMER SP, 1979, J AM CHEM SOC, V101, P2772, DOI 10.1021/ja00504a067; CRAWFORD NM, 1988, P NATL ACAD SCI USA, V85, P5006, DOI 10.1073/pnas.85.14.5006; CRAWFORD NM, 1986, P NATL ACAD SCI USA, V83, P8073, DOI 10.1073/pnas.83.21.8073; DANIELVEDELE F, 1989, GENE, V85, P371, DOI 10.1016/0378-1119(89)90430-7; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FRIEMANN A, 1991, MOL GEN GENET, V227, P97, DOI 10.1007/BF00260713; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; JOHNSON JL, 1991, J BIOL CHEM, V266, P12140; JOHNSON JL, 1974, J BIOL CHEM, V249, P5046; JOHNSON JL, 1976, J CLIN INVEST, V58, P543, DOI 10.1172/JCI108499; JOHNSTONE IL, 1990, GENE, V90, P181, DOI 10.1016/0378-1119(90)90178-T; KRAMER SP, 1987, J BIOL CHEM, V262, P16357; NEAME PJ, 1989, J BIOL CHEM, V264, P20894; OKOMATO PM, 1991, MOL GEN GENET, V227, P213; PATEMAN JA, 1964, NATURE, V201, P58, DOI 10.1038/201058a0; PROSSER IM, 1990, PLANT MOL BIOL, V15, P187, DOI 10.1007/BF00017743; Rajagopalan K.V., 1980, MOLYBDENUM MOLYBDENU, P241; RAJAGOPALAN KV, 1991, ADV ENZYMOL RAMB, V64, P215; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VAUCHERET H, 1989, PLANT MOL BIOL, V12, P597, DOI 10.1007/BF00036974; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x	27	67	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					272	276						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276806				2022-12-27	WOS:A1994MR21900049
J	KONG, H; ROEMER, SE; WAITEREES, PA; BENNER, JS; WILSON, GG; NWANKWO, DO				KONG, H; ROEMER, SE; WAITEREES, PA; BENNER, JS; WILSON, GG; NWANKWO, DO			CHARACTERIZATION OF BCGI, A NEW KIND OF RESTRICTION-MODIFICATION SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I DNA RESTRICTION; NUCLEOTIDE-SEQUENCE; RECOGNITION SEQUENCE; MODIFICATION ENZYMES; ANTICODON NUCLEASE; MODIFICATION GENES; CLONING; ENDONUCLEASE; EXPRESSION; PROTEINS	The BcgI restriction enzyme from Bacillus coagulans is unusual in that it cleaves on both sides of its recognition site, CGAN6TGC, releasing a fragment that includes the site and several bases on each side. We report the organization and nucleotide sequences of the genes for the BcgI restriction-modification system and the properties of the proteins that they encode. The system comprises two adjacent, similarly oriented genes. The proximal gene, bcgIA, codes for a 637-amino acid protein (molecular mass = 71.6 kDa) that resembles certain m6A-specific DNA-methyltransferases, particularly those that constitute the modification subunits of type I restriction-modification systems. The distal gene, bcgIB, codes for a 341-amino acid protein (molecular mass = 39.2 kDa) that resembles none of the sequences in the sequence data bases. The two genes overlap by several nucleotides. Alone, neither protein restricts or modifies DNA, but, together, they form a complex in the proportion A2B that does both. DNA binding assays showed that the DNA-protein complex can be formed only in the presence of both subunits, suggesting that the association of inactive subunits generates the active BcgI enzyme that can bind DNA and then either cleaves or methylates at target site.			KONG, H (corresponding author), NEW ENGLAND BIOLABS INC, BEVERLY, MA 01915 USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMITSUR M, 1992, EMBO J, V11, P3129, DOI 10.1002/j.1460-2075.1992.tb05385.x; BOCKLAGE H, 1991, NUCLEIC ACIDS RES, V19, P1007, DOI 10.1093/nar/19.5.1007; CAREY J, 1988, P NATL ACAD SCI USA, V85, P975, DOI 10.1073/pnas.85.4.975; Chandrasegaran S, 1988, STRUCTURE EXPRESSION, V1, P149; CHEN L, 1991, BIOCHEMISTRY-US, V30, P11018, DOI 10.1021/bi00110a002; CONRAD M, 1989, P NATL ACAD SCI USA, V86, P9707, DOI 10.1073/pnas.86.24.9707; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; ITO H, 1990, NUCLEIC ACIDS RES, V18, P3903, DOI 10.1093/nar/18.13.3903; JANULAITIS A, 1992, NUCLEIC ACIDS RES, V20, P6043, DOI 10.1093/nar/20.22.6043; JANULAITIS A, 1992, NUCLEIC ACIDS RES, V20, P6051, DOI 10.1093/nar/20.22.6051; KAWAKAMI B, 1991, AGR BIOL CHEM TOKYO, V55, P1553, DOI 10.1080/00021369.1991.10870835; KAWAKAMI B, 1990, AGR BIOL CHEM TOKYO, V54, P3227, DOI 10.1080/00021369.1990.10870493; KHORANA HG, 1961, J AM CHEM SOC, V83, P686, DOI 10.1021/ja01464a038; KONG H, 1993, Patent No. 5200336; KONG HM, 1993, NUCLEIC ACIDS RES, V21, P987, DOI 10.1093/nar/21.4.987; KRUGER DH, 1988, NUCLEIC ACIDS RES, V16, P3997; LANDRY D, 1989, GENE, V77, P1, DOI 10.1016/0378-1119(89)90353-3; LANDRY D, 1992, METHOD ENZYMOL, V216, P244; LINDER P, 1990, NUCLEIC ACIDS RES, V18, P7170, DOI 10.1093/nar/18.23.7170; LOENEN WAM, 1987, J MOL BIOL, V198, P159, DOI 10.1016/0022-2836(87)90303-2; LUNGU O, 1993, BIOTECHNIQUES, V14, P62; LUNNEN KD, 1988, GENE, V74, P25, DOI 10.1016/0378-1119(88)90242-9; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEISEL A, 1991, NUCLEIC ACIDS RES, V19, P3997, DOI 10.1093/nar/19.14.3997; PEIN CD, 1991, NUCLEIC ACIDS RES, V19, P5139, DOI 10.1093/nar/19.19.5139; PRICE C, 1989, J MOL BIOL, V205, P115, DOI 10.1016/0022-2836(89)90369-0; RIOZES G, 1991, DNA SEQUENCE, V2, P65; ROBERTS RJ, 1992, NUCLEIC ACIDS RES, V20, P2167, DOI 10.1093/nar/20.suppl.2167; SLATKO BE, 1987, NUCLEIC ACIDS RES, V15, P9781, DOI 10.1093/nar/15.23.9781; SMITH HO, 1990, P NATL ACAD SCI USA, V87, P826, DOI 10.1073/pnas.87.2.826; SMITH JD, 1972, J MOL BIOL, V63, P1, DOI 10.1016/0022-2836(72)90517-7; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SZYBALSKI W, 1991, GENE, V100, P13, DOI 10.1016/0378-1119(91)90345-C; TAO T, 1991, J BACTERIOL, V173, P1367, DOI 10.1128/jb.173.4.1367-1375.1991; TAYLOR JD, 1991, BIOCHEMISTRY-US, V30, P8743, DOI 10.1021/bi00100a005; THERIAULT G, 1985, NUCLEIC ACIDS RES, V13, P8441, DOI 10.1093/nar/13.23.8441; TOPAL MD, 1991, BIOCHEMISTRY-US, V30, P2006, DOI 10.1021/bi00221a038; VOVIS GF, 1975, J MOL BIOL, V95, P557, DOI 10.1016/0022-2836(75)90317-4; WAITEREES PA, 1991, J BACTERIOL, V173, P5207, DOI 10.1128/jb.173.16.5207-5219.1991; WILSON GG, 1992, METHOD ENZYMOL, V216, P259; WILSON GG, 1991, ANNU REV GENET, V25, P585, DOI 10.1146/annurev.ge.25.120191.003101; YUAN R, 1981, ANNU REV BIOCHEM, V50, P285, DOI 10.1146/annurev.bi.50.070181.001441; YUAN R, 1984, DNA METHYLATION BIOC, P11; ZEBALA JA, 1992, J BIOL CHEM, V267, P8097	45	47	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					683	690						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276869				2022-12-27	WOS:A1994MR21900107
J	PEREIRA, DS; DONALD, LJ; HOSFIELD, DJ; DUCKWORTH, HW				PEREIRA, DS; DONALD, LJ; HOSFIELD, DJ; DUCKWORTH, HW			ACTIVE-SITE MUTANTS OF ESCHERICHIA-COLI CITRATE SYNTHASE - EFFECTS OF MUTATIONS ON CATALYTIC AND ALLOSTERIC PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATE ANALOG INHIBITOR; DIRECTED MUTAGENESIS; ACETYL-COA; CRYSTAL-STRUCTURE; TERNARY COMPLEX; COENZYME-A; OXALOACETATE; GENE; BINDING; SEQUENCE	We report properties of five active site mutants of Escherichia coli citrate synthase, in which histidine 264, aspartate 362, and phenylalanine 383 were replaced by alanines, and arginines 387 and 407 by leucines. All mutants have much lower turnover numbers than wild type enzyme; the strongest effect was with the arginine 387 mutant, perhaps because the substrate, oxaloacetate, binds in a different orientation. The arginine 407 mutant has lost most of its ability to distinguish alpha-ketoglutarate, a competitive inhibitor, from oxaloacetate. The mutations of histidine 264 and aspartate 362 affect steady-state kinetics as would be anticipated from current models for citrate synthase catalysis, and resemble mutations of these residues, in pig heart and E. coli enzyme, reported by others. Mutations of residues 264,362, and 383 also affect allosteric properties. With the phenylalanine 383 mutant, acetyl-CoA saturation is strongly sigmoid, even in the presence of the activator, KCl, implying a marked shift of the allosteric equilibrium toward the T state. The histidine 264 mutant appears to be shifted toward R state and shows weaker binding of the allosteric inhibitor, NADH; thus this mutation also affects the allosteric site, 25-30 angstrom away.	UNIV MANITOBA,DEPT CHEM,WINNIPEG R3T 2N2,MANITOBA,CANADA	University of Manitoba								ALTER GM, 1990, BIOCHEMISTRY-US, V29, P7557, DOI 10.1021/bi00485a003; ANDERSON DH, 1989, BIOCHEM CELL BIOL, V67, P98, DOI 10.1139/o89-015; ANDERSON DH, 1988, J BIOL CHEM, V263, P2163; ANDERSON DH, 1991, BIOCHEM CELL BIOL, V69, P232, DOI 10.1139/o91-035; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; DANSON MJ, 1973, BIOCHEM J, V135, P513, DOI 10.1042/bj1350513; DAVID M, 1991, BIOCHEM J, V278, P225, DOI 10.1042/bj2780225; DONALD LJ, 1991, J BIOL CHEM, V266, P20709; DONALD LJ, 1989, J BACTERIOL, V171, P5542, DOI 10.1128/jb.171.10.5542-5550.1989; DUCKWORTH HW, 1982, CAN J BIOCHEM CELL B, V60, P1143, DOI 10.1139/o82-146; DUCKWORTH HW, 1976, BIOCHEMISTRY-US, V15, P108, DOI 10.1021/bi00646a017; FALOONA GR, 1969, BIOCHEMISTRY-US, V8, P4497, DOI 10.1021/bi00839a041; FUKUYA M, 1990, J BACTERIOL, V172, P2096; HANDFORD PA, 1988, BIOCHIM BIOPHYS ACTA, V953, P232, DOI 10.1016/0167-4838(88)90030-1; HEINZEN RA, 1991, GENE, V109, P63, DOI 10.1016/0378-1119(91)90589-4; KARPUSAS M, 1990, BIOCHEMISTRY-US, V29, P2213, DOI 10.1021/bi00461a002; KARPUSAS M, 1991, BIOCHEMISTRY-US, V30, P6024, DOI 10.1021/bi00238a028; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURZ LC, 1992, BIOCHEMISTRY-US, V31, P7899, DOI 10.1021/bi00149a022; KURZ LC, 1987, BIOCHEMISTRY-US, V26, P2623, DOI 10.1021/bi00383a032; KURZ LC, 1985, BIOCHEMISTRY-US, V24, P452, DOI 10.1021/bi00323a031; KURZ LC, 1992, BIOCHEMISTRY-US, V31, P7908, DOI 10.1021/bi00149a023; LIAO DI, 1991, BIOCHEMISTRY-US, V30, P6031, DOI 10.1021/bi00238a029; MAN WJ, 1991, BIOCHEM J, V280, P521, DOI 10.1042/bj2800521; MOLGAT GF, 1992, ARCH BIOCHEM BIOPHYS, V298, P238, DOI 10.1016/0003-9861(92)90118-G; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NER SS, 1983, BIOCHEMISTRY-US, V22, P5243, DOI 10.1021/bi00292a001; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; SCHENDEL FJ, 1992, APPL ENVIRON MICROB, V58, P335, DOI 10.1128/AEM.58.1.335-345.1992; SUTHERLAND KJ, 1990, EUR J BIOCHEM, V194, P839, DOI 10.1111/j.1432-1033.1990.tb19477.x; TALGOY MM, 1979, CAN J BIOCHEM CELL B, V57, P385, DOI 10.1139/o79-049; TALGOY MM, 1979, CAN J BIOCHEM CELL B, V57, P822, DOI 10.1139/o79-102; Weitzman P D, 1976, Curr Top Cell Regul, V10, P161; WIEGAND G, 1984, J MOL BIOL, V174, P205, DOI 10.1016/0022-2836(84)90373-5; WRIGHT JA, 1971, J BIOL CHEM, V246, P1689; WRIGHT JA, 1967, BIOCHEM BIOPH RES CO, V29, P34, DOI 10.1016/0006-291X(67)90536-0; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	37	33	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					412	417						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276829				2022-12-27	WOS:A1994MR21900070
J	DAMRON, DS; VANWAGONER, DR; MORAVEC, CS; BOND, M				DAMRON, DS; VANWAGONER, DR; MORAVEC, CS; BOND, M			ARACHIDONIC-ACID AND ENDOTHELIN POTENTIATE CA2+ TRANSIENTS IN RAT CARDIAC MYOCYTES VIA INHIBITION OF DISTINCT K+ CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; UNSATURATED FATTY-ACIDS; GUINEA-PIG ATRIA; SARCOPLASMIC-RETICULUM; VENTRICULAR MYOCYTES; SIGNAL TRANSDUCTION; TROPONIN-I; CALCIUM; CA-2+; ACTIVATION	The release of arachidonic acid by phospholipases in response to cell surface receptor activation may be an important step in the initiation of inotropic events in cardiac muscle. Endothelin has been shown to activate phospholipase A2 and release arachidonic acid in isolated rat hearts. Endothelin also has a positive inotropic effect in cardiac muscle, suggesting that endothelin increases Ca2+ influx or the amount of Ca2+ released from the sarcoplasmic reticulum. We used suspensions of adult rat ventricular myocytes loaded with fura-2/AM to compare the effects of arachidonic acid and endothelin on Ca2+ transients evoked by extracellular ATP. We showed recently (Damron, D. S., and Bond, M. (1993) Circ. Res. 72, 376-386) that pretreatment of cardiac myocytes with arachidonic acid significantly potentiated the amplitude of the ATP-triggered Ca2+ transient. We now report that endothelin also enhances the ATP-triggered Ca2+ transient and that the effect of the combination of maximal doses of endothelin and arachidonic acid is additive. Neither endothelin nor arachidonic acid was found to affect the size of the sarcoplasmic reticulum Ca2+ store. The potentiating effects of both arachidonic acid and endothelin were sensitive to inhibitors of protein kinase C. Endothelin was also found to stimulate phospholipase C but not phospholipase A2. Application of arachidonic acid to individual cardiac muscle cells resulted in inhibition of the transient outward K+ current, whereas application of endothelin inhibited the delayed rectifier current. These effects of arachidonic acid and endothelin were additive, and both effects could be blocked by the protein kinase C inhibitor, staurosporine. Similarly, staurosporine inhibited endothelin-induced increases in isometric contractions in ventricular papillary muscle. We conclude that arachidonic acid and endothelin may be involved in the modulation of inotropic activity in cardiac muscle by means of protein kinase C-dependent inhibition of two distinct K+ channels. This would result in a prolongation of action potential duration and thus an increase in Ca2+ influx across the sarcolemma.	CLEVELAND CLIN FDN,RES INST,DEPT CARDIOVASC BIOL,9500 EUCLID AVE,CLEVELAND,OH 44195	Cleveland Clinic Foundation			Van Wagoner, David R/C-6783-2008	Van Wagoner, David R/0000-0001-8250-9828	NHLBI NIH HHS [HL33713, HL08726, HL41883] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008726, R01HL041883, P50HL033713] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN IS, 1988, CIRC RES, V62, P524, DOI 10.1161/01.RES.62.3.524; ALTSCHULD R, 1980, J MOL CELL CARDIOL, V12, P1383, DOI 10.1016/0022-2828(80)90123-6; APKON M, 1988, P NATL ACAD SCI USA, V85, P8756, DOI 10.1073/pnas.85.22.8756; BERS DM, 1987, CAN J PHYSIOL PHARM, V65, P610, DOI 10.1139/y87-103; BOGOYEVITCH MA, 1993, CIRC RES, V72, P757, DOI 10.1161/01.RES.72.4.757; BROWN JH, 1985, CIRC RES, V57, P532, DOI 10.1161/01.RES.57.4.532; CAPOGROSSI MC, 1990, CIRC RES, V66, P1143, DOI 10.1161/01.RES.66.4.1143; CHRISTIE A, 1992, J PHYSIOL-LONDON, V445, P369, DOI 10.1113/jphysiol.1992.sp018929; DAMRON DS, 1993, CIRC RES, V72, P376, DOI 10.1161/01.RES.72.2.376; DAMRON DS, 1993, NEUROCHEM RES, V18, P1231, DOI 10.1007/BF00975040; DEYOUNG MB, 1989, AM J PHYSIOL, V257, pC750, DOI 10.1152/ajpcell.1989.257.4.C750; DORMAN RV, 1988, BRAIN RES BULL, V21, P445, DOI 10.1016/0361-9230(88)90157-8; EDES I, 1990, CIRC RES, V67, P394, DOI 10.1161/01.RES.67.2.394; FILEP JG, 1991, BIOCHEM BIOPH RES CO, V177, P171, DOI 10.1016/0006-291X(91)91964-E; FREEMAN EJ, 1990, NEUROCHEM RES, V15, P743, DOI 10.1007/BF00973656; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANSFORD RG, 1987, J PHYSIOL-LONDON, V390, P453, DOI 10.1113/jphysiol.1987.sp016711; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; ISHII K, 1992, BIOCHEM BIOPH RES CO, V184, P1484, DOI 10.1016/S0006-291X(05)80050-6; ISHIKAWA T, 1988, AM J PHYSIOL, V255, pH970, DOI 10.1152/ajpheart.1988.255.4.H970; KAKU T, 1991, AM J PHYSIOL, V260, pC635, DOI 10.1152/ajpcell.1991.260.3.C635; KELLY RA, 1990, J CLIN INVEST, V86, P1164, DOI 10.1172/JCI114822; KIM DH, 1990, CIRC RES, V67, P1040, DOI 10.1161/01.RES.67.4.1040; KOHL C, 1990, BRIT J PHARMACOL, V101, P829, DOI 10.1111/j.1476-5381.1990.tb14165.x; KRAMER BK, 1991, CIRC RES, V68, P269, DOI 10.1161/01.RES.68.1.269; LACERDA AE, 1988, NATURE, V335, P249, DOI 10.1038/335249a0; LESTER DS, 1991, BIOCHEM BIOPH RES CO, V179, P1522, DOI 10.1016/0006-291X(91)91745-X; LIMAS CJ, 1980, BIOCHEM BIOPH RES CO, V96, P1378, DOI 10.1016/0006-291X(80)90103-5; LINDEN DJ, 1989, J PHYSIOL-LONDON, V419, P95, DOI 10.1113/jphysiol.1989.sp017863; LYNCH MA, 1989, BIOESSAYS, V10, P85, DOI 10.1002/bies.950100212; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; MORAVEC CS, 1989, BIOCHEM BIOPH RES CO, V159, P14, DOI 10.1016/0006-291X(89)92397-8; MORAVEC CS, 1991, AM J PHYSIOL, V260, pH989, DOI 10.1152/ajpheart.1991.260.3.H989; MOVSESIAN MA, 1984, J BIOL CHEM, V259, P8029; MURAKAMI K, 1986, J BIOL CHEM, V261, P5424; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NOLAND TA, 1991, J BIOL CHEM, V266, P4974; OKUMURA K, 1988, J CARDIOVASC PHARM, V11, P651, DOI 10.1097/00005344-198806000-00004; PRASAD MR, 1991, BIOCHEM BIOPH RES CO, V174, P952, DOI 10.1016/0006-291X(91)91511-A; ROGERS TB, 1990, J BIOL CHEM, V265, P4302; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMONSON MS, 1990, J CLIN INVEST, V85, P790, DOI 10.1172/JCI114505; SIROIS MG, 1992, EUR J PHARMACOL, V214, P119, DOI 10.1016/0014-2999(92)90108-G; TAKASAGO T, 1991, J BIOCHEM-TOKYO, V109, P163, DOI 10.1093/oxfordjournals.jbchem.a123339; TEUTSCH I, 1987, EUR J PHARMACOL, V144, P363, DOI 10.1016/0014-2999(87)90389-X; VANWAGONER DR, 1993, CIRC RES, V72, P973, DOI 10.1161/01.RES.72.5.973; VENEMA RC, 1993, J BIOL CHEM, V268, P2705; VIGNE P, 1989, FEBS LETT, V249, P143, DOI 10.1016/0014-5793(89)80611-8; YOSHIDA K, 1992, P NATL ACAD SCI USA, V89, P6443, DOI 10.1073/pnas.89.14.6443; ZHENG JS, 1992, AM J PHYSIOL, V262, pC128, DOI 10.1152/ajpcell.1992.262.1.C128	53	81	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27335	27344						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262973				2022-12-27	WOS:A1993MM26200072
J	HEACOCK, DH; LIU, RQ; YU, CA; YU, L; DURHAM, B; MILLETT, F				HEACOCK, DH; LIU, RQ; YU, CA; YU, L; DURHAM, B; MILLETT, F			INTRACOMPLEX ELECTRON-TRANSFER BETWEEN RUTHENIUM-CYTOCHROME-C DERIVATIVES AND CYTOCHROME-C(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC CYTOCHROME-C1; BINDING; KINETICS; PROTEIN; COMPLEX; OXIDOREDUCTASE; SPHAEROIDES; PEROXIDASE; REDUCTION; OXIDASE	The reactions of a beef heart cytochrome c1 preparation containing the hinge protein with horse cytochrome c derivatives labeled at specific lysine amino groups with (dicarboxybipyridine)(bisbipyridine) ruthenium(II) (Ru(II)) were studied by flash photolysis. All of the ruthenium-cytochrome c derivatives formed complexes with cytochrome c1 in low ionic strength buffer (5 mm sodium phosphate, pH 7). Excitation of Ru(II) to Ru(II) with a 0.4-mus laser flash resulted in rapid electron transfer to the ferric heme group in cytochrome c, followed by electron transfer from the ferrous heme group of cytochrome c to the ferric heme group of cytochrome c1. The kinetic difference spectra displayed maxima at 546 nm and minima at 554 nm characteristic of electron transfer between the two cytochromes. The rate constants were independent of concentration at low ionic strength, indicating intracomplex electron transfer. The rate constants were 4,800, 6,800, 22,000, and 22,000 s-1 for cytochrome c derivatives modified at lysines 13, 27, 25, and 72, respectively. The observed rate constants were independent of ionic strength up to about 50 mm and then decreased progressively with further increases in ionic strength indicating dissociation of the complex. Second-order kinetics were observed at 310 mm ionic strength, with rate constants of 1.0 x 10(6), 1.6 x 10(7), 1.2 x 10(8), and 3.0 x 10(7) M-1 s-1 for the derivatives modified at lysines 13, 27, 25, and 72, respectively. The ionic strength dependence of the second-order rate constants is comparable to that involving native horse cytochrome c and is consistent with electron transfer reactions between oppositely charged proteins.	UNIV ARKANSAS,DEPT CHEM & BIOCHEM,115 CHEM BLDG,FAYETTEVILLE,AR 72701; OKLAHOMA STATE UNIV,DEPT BIOCHEM,STILLWATER,OK 74078	University of Arkansas System; University of Arkansas Fayetteville; Oklahoma State University System; Oklahoma State University - Stillwater					NCRR NIH HHS [RR07101] Funding Source: Medline; NIGMS NIH HHS [GM30721, GM20488] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030721, R01GM030721] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED AJ, 1978, BIOCHEMISTRY-US, V17, P2479, DOI 10.1021/bi00606a003; BERRY EA, 1985, COENZYME Q, P365; BROGER C, 1983, EUR J BIOCHEM, V131, P349, DOI 10.1111/j.1432-1033.1983.tb07269.x; CAPALDI RA, 1982, BIOCHIM BIOPHYS ACTA, V694, P291, DOI 10.1016/0304-4157(82)90009-0; CHIANG YL, 1976, J BIOL CHEM, V251, P29; CROFTS AR, 1986, J BIOENERG BIOMEMBR, V18, P437, DOI 10.1007/BF00743014; DURHAM B, 1989, BIOCHEMISTRY-US, V28, P8659, DOI 10.1021/bi00447a057; DUTTON PL, 1970, BIOCHEMISTRY-US, V9, P5077, DOI 10.1021/bi00828a006; GABELLINNI N, 1988, J BIOENERG BIOMEMBR, V18, P59; GEREN L, 1991, BIOCHEMISTRY-US, V30, P9450, DOI 10.1021/bi00103a009; GREEN DE, 1959, BIOCHIM BIOPHYS ACTA, V31, P34, DOI 10.1016/0006-3002(59)90436-6; GUTWENIGER HE, 1983, BIOCHEM BIOPH RES CO, V116, P272, DOI 10.1016/0006-291X(83)90411-4; HAHM S, 1992, BIOCHEMISTRY-US, V31, P3472, DOI 10.1021/bi00128a022; KIM CH, 1983, J BIOL CHEM, V258, P3543; KIM CH, 1987, J BIOL CHEM, V262, P8103; KIM CH, 1984, P NATL ACAD SCI-BIOL, V81, P2026, DOI 10.1073/pnas.81.7.2026; KONIG BW, 1980, BIOCHIM BIOPHYS ACTA, V621, P283, DOI 10.1016/0005-2795(80)90180-4; KONIG BW, 1980, FEBS LETT, V111, P395, DOI 10.1016/0014-5793(80)80835-0; KONIG BW, 1981, BIOCHIM BIOPHYS ACTA, V636, P9, DOI 10.1016/0005-2728(81)90069-4; LIU RQ, 1992, BIOPHYS J, V61, P193; MARGALIT R, 1973, EUR J BIOCHEM, V32, P492, DOI 10.1111/j.1432-1033.1973.tb02633.x; OCKERBLOOM NE, 1956, J AM CHEM SOC, V78, P267, DOI 10.1021/ja01583a004; PAN LP, 1990, BIOCHEMISTRY-US, V29, P3231, DOI 10.1021/bi00465a013; PAN LP, 1993, BIOCHEMISTRY-US, V32, P8492, DOI 10.1021/bi00084a014; PAN LP, 1988, BIOCHEMISTRY-US, V27, P7180, DOI 10.1021/bi00419a003; RIEDER R, 1980, J BIOL CHEM, V255, P4732; SCHROEDL NA, 1977, BIOCHEMISTRY-US, V16, P4961, DOI 10.1021/bi00642a003; SMITH HT, 1981, J BIOL CHEM, V256, P4984; SPECK SH, 1979, P NATL ACAD SCI USA, V76, P155, DOI 10.1073/pnas.76.1.155; STONEHUERNER J, 1985, J BIOL CHEM, V260, P5392; WAKABAYASHI S, 1982, J BIOCHEM, V91, P2077, DOI 10.1093/oxfordjournals.jbchem.a133901; WAKABAYASHI S, 1982, J BIOL CHEM, V257, P9335; WILLIE A, 1992, BIOCHEMISTRY-US, V31, P7237, DOI 10.1021/bi00147a005; WILLIE A, 1993, BIOCHEMISTRY-US, V32, P7519, DOI 10.1021/bi00080a025; YU CA, 1972, J BIOL CHEM, V247, P1012; YU CA, 1983, BIOCHIM BIOPHYS ACTA, V736, P226, DOI 10.1016/0005-2736(83)90288-2; YU CA, 1973, J BIOL CHEM, V248, P528; YU L, 1984, J BIOL CHEM, V259, P5752	38	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27171	27175						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262956				2022-12-27	WOS:A1993MM26200051
J	KAIKAUS, RM; SUI, ZH; LYSENKO, N; WU, NY; DEMONTELLANO, PRO; OCKNER, RK; BASS, NM				KAIKAUS, RM; SUI, ZH; LYSENKO, N; WU, NY; DEMONTELLANO, PRO; OCKNER, RK; BASS, NM			REGULATION OF PATHWAYS OF EXTRAMITOCHONDRIAL FATTY-ACID OXIDATION AND LIVER FATTY-ACID-BINDING PROTEIN BY LONG-CHAIN MONOCARBOXYLIC FATTY-ACIDS IN HEPATOCYTES - EFFECT OF INHIBITION OF CARNITINE PALMITOYLTRANSFERASE-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXISOMAL BETA-OXIDATION; HYDROGENATED FISH OIL; ISOLATED RAT-LIVER; ACYL-COA OXIDASE; NUCLEOTIDE-SEQUENCE; ACTIVATED RECEPTOR; GENE-EXPRESSION; INDUCTION; IDENTIFICATION; PROLIFERATORS	The regulation of the extramitochondrial fatty acid oxidation pathways located in the peroxisomes and the endoplasmic reticulum is not fully understood. Although both long-chain dicarboxylic fatty acids, which are poorly metabolized in hepatocytes, and non-beta-oxidizable fatty acid analogs induce peroxisomal beta-oxidation and liver fatty acid-binding protein (L-FABP) by a pretranslational mechanism, monocarboxylic long-chain fatty acids, which are rapidly esterified and oxidized, do not. To establish whether impaired utilization and, hence, sustained intracellular levels of monocarboxylic long-chain fatty acids increase their efficacy as inducers, the effect of oleic acid on cytochrome P-450 4A1, peroxisomal beta-oxidation, and L-FABP during inhibition of mitochondrial beta-oxidation was determined. In primary hepatocyte cultures, oleic acid had no inducing effect, but in the presence of 2-tetradecylglycidic acid (TDGA), an inhibitor of carnitine palmitoyltransferase I, it induced P-450 4A1, peroxisomal beta-oxidation, and L-FABP pretranslationally. An increase in peroxisomal beta-oxidation was also noted in the presence of etomoxir, another inhibitor of carnitine palmitoyltransferase 1. Exposure of hepatocytes to TDGA for 1 h led to an expected decrease in incorporation of radiolabel from [1-C-14]oleate into CO2 and water-soluble products. In contrast, long-term exposure to TDGA increased incorporation of [1-C-14]oleate into oxidation products, most likely due to an adaptive induction of peroxisomal beta-oxidation. Both acute and long-term exposure of hepatocytes to TDGA decreased incorporation of oleic acid into triglycerides, an effect that may have contributed to the intracellular accumulation of fatty acids. These results provide support for a mechanism by which long-chain fatty acids or specific metabolites, including long-chain acyl-CoA esters and long-chain dicarboxylic acids, act as signals in the induction of P-450 4A1, peroxisomal beta-oxidation, and L-FABP under conditions in which long-chain fatty acids accumulate due to impaired entry into the mitochondrial beta-oxidation pathway.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR LIVER,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	KAIKAUS, RM (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,BOX 0538,HSW 1120,3RD & PARNASSUS AVE,SAN FRANCISCO,CA 94143, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002056, R01DK032926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025515, R37GM025515] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-02056, DK-32926] Funding Source: Medline; NIGMS NIH HHS [GM-25515] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARSLAND A, 1990, BIOCHIM BIOPHYS ACTA, V1033, P176, DOI 10.1016/0304-4165(90)90009-L; BARDOT Z, 1993, BIOCHEM BIOPH RES CO, V1932, P37; BASS NM, 1988, INT REV CYTOL, V111, P143, DOI 10.1016/S0074-7696(08)61733-7; BASS NM, 1993, HEPATOLOGY, V18, pA125, DOI 10.1016/0270-9139(93)92029-Y; BISSELL DM, 1987, J CLIN INVEST, V79, P801, DOI 10.1172/JCI112887; BRANDES R, 1990, BIOCHIM BIOPHYS ACTA, V1034, P53, DOI 10.1016/0304-4165(90)90152-M; CABAUD PG, 1958, AM J CLIN PATHOL, V30, P234, DOI 10.1093/ajcp/30.3.234; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DISTEL RJ, 1992, J BIOL CHEM, V267, P5937; EACHO PI, 1988, BIOCHEM BIOPH RES CO, V157, P1148, DOI 10.1016/S0006-291X(88)80993-8; ENOCH T, 1986, MOL CELL BIOL, V6, P801, DOI 10.1128/MCB.6.3.801; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLATMARK T, 1988, BIOCHIM BIOPHYS ACTA, V962, P122, DOI 10.1016/0005-2760(88)90103-8; FOLCH J, 1957, J BIOL CHEM, V226, P497; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GRIMALDI PA, 1992, P NATL ACAD SCI USA, V89, P10930, DOI 10.1073/pnas.89.22.10930; HARDWICK JP, 1987, J BIOL CHEM, V262, P801; HERTZ R, 1985, BIOCHIM BIOPHYS ACTA, V836, P192, DOI 10.1016/0005-2760(85)90066-9; HEUBI JE, 1987, HEPATOLOGY, V7, P155, DOI 10.1002/hep.1840070130; IDE T, 1981, J BIOL CHEM, V256, P247; INTRASUKSRI U, 1991, BIOCHEM PHARMACOL, V4, P184; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KAIKAUS RM, 1993, J BIOL CHEM, V268, P9593; KAIKAUS RM, 1990, EXPERIENTIA, V46, P617, DOI 10.1007/BF01939701; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KIORPES TC, 1984, J BIOL CHEM, V259, P9750; LOCK EA, 1989, ANNU REV PHARMACOL, V29, P145; MA X, 1992, HEPATOLOGY, V16, pA450; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; MORTENSEN PB, 1992, BIOCHIM BIOPHYS ACTA, V1124, P71, DOI 10.1016/0005-2760(92)90128-I; MORTENSEN PB, 1982, BIOCHIM BIOPHYS ACTA, V710, P477, DOI 10.1016/0005-2760(82)90132-1; NILSSON A, 1987, BIOCHIM BIOPHYS ACTA, V920, P114, DOI 10.1016/0005-2760(87)90250-5; OSMUNDSEN H, 1991, BIOCHIM BIOPHYS ACTA, V1085, P141, DOI 10.1016/0005-2760(91)90089-Z; SALAH AEA, 1987, BIOCHEM PHARMACOL, V36, P4307; SCHULZ H, 1987, LIFE SCI, V40, P1443, DOI 10.1016/0024-3205(87)90375-4; SKORIN C, 1992, BIOCHEM J, V281, P561, DOI 10.1042/bj2810561; SKORVE J, 1990, BIOCHEM PHARMACOL, V40, P2005, DOI 10.1016/0006-2952(90)90230-I; SWEETSER DA, 1986, J BIOL CHEM, V261, P5553; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; TUTWILER GF, 1979, J BIOL CHEM, V254, P2935; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WOLF HPO, 1990, NEW ANTIDIABETIC DRU, P217	43	51	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26866	26871						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262919				2022-12-27	WOS:A1993MM26200009
J	SEKIMOTO, T; MATSUYAMA, T; FUKUI, T; TANIZAWA, K				SEKIMOTO, T; MATSUYAMA, T; FUKUI, T; TANIZAWA, K			EVIDENCE FOR LYSINE-80 AS GENERAL BASE CATALYST OF LEUCINE DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; DEPENDENT GLUTAMATE-DEHYDROGENASE; COMPLETE NUCLEOTIDE-SEQUENCE; BACILLUS-STEAROTHERMOPHILUS; NAD(P)+-DEPENDENT DEHYDROGENASES; PHENYLALANINE DEHYDROGENASE; BOVINE ENZYME; CLONING; PHOSPHATE; LIVER	To elucidate the functional role of the lysyl residue highly conserved in NAD(P)+-dependent amino acid dehydrogenases, Lys-80 of leucine dehydrogenase from Bacillus stearothermophilus has been mutated into Ala, Arg, or Gln. All of the mutant enzymes had markedly reduced activities in the oxidative deamination, whereas the Michaelis constants for substrate and coenzyme did not change significantly upon the mutation, except for a 10-30-fold increase in K(m) values for alpha-keto-iso-caproate in the Ala and Gln mutants. The pH profiles of kinetic parameters of the mutants considerably differed from those of the wild type, in which two ionizable groups with pK(a) values of 8.9 and 10.7 must be unprotonated for catalysis and protonated for substrate binding, respectively. Combined with the analyses of solvent isotope effect and inhibition by substrate analogs, these results unequivocally show that the epsilon-amino group of Lys-80 participates in catalysis as a general base, assisting the nucleophilic attack of a water molecule to the substrate alpha-carbon atom. Furthermore, the Ala mutant was markedly stimulated by primary amines depending on the pK(a) and molecular volume, suggesting that in the Ala mutant the added amines can partially replace the general base function of Lys-80 in the wild type enzyme.	OSAKA UNIV,INST SCI & IND RES,IBARAKI,OSAKA 567,JAPAN	Osaka University								BAKER PJ, 1992, PROTEINS, V12, P75, DOI 10.1002/prot.340120109; BLUMENTHAL KM, 1975, J BIOL CHEM, V250, P3644; BROWN A, 1973, BIOCHEMISTRY-US, V12, P4367, DOI 10.1021/bi00746a011; Cleland W W, 1979, Methods Enzymol, V63, P103; Cleland W W, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P273; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; HABERLAND ME, 1980, J BIOL CHEM, V255, P7984; JENCKS WP, 1968, HDB BIOCH MOL BIOL, P150; JULLIARD JH, 1979, J BIOL CHEM, V254, P3427; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURODA SI, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00456a025; LILLEY KS, 1991, BIOCHIM BIOPHYS ACTA, V1080, P191, DOI 10.1016/0167-4838(91)90001-G; LILLEY KS, 1992, EUR J BIOCHEM, V207, P533, DOI 10.1111/j.1432-1033.1992.tb17079.x; MATSUYAMA T, 1992, J BIOCHEM-TOKYO, V112, P258, DOI 10.1093/oxfordjournals.jbchem.a123887; MCPHERSON MJ, 1983, NUCLEIC ACIDS RES, V11, P5257, DOI 10.1093/nar/11.15.5257; MCPHERSON MJ, 1988, PROTEIN ENG, V2, P147, DOI 10.1093/protein/2.2.147; MOON K, 1973, J BIOL CHEM, V248, P3082; MOON K, 1972, P NATL ACAD SCI USA, V69, P1380, DOI 10.1073/pnas.69.6.1380; MOYE WS, 1985, J BIOL CHEM, V260, P8502; NAGATA S, 1988, BIOCHEMISTRY-US, V27, P9056, DOI 10.1021/bi00425a026; OHSHIMA T, 1978, J BIOL CHEM, V253, P5719; OHSHIMA T, 1985, ARCH MICROBIOL, V141, P407, DOI 10.1007/BF00428857; OKAZAKI N, 1988, GENE, V63, P337, DOI 10.1016/0378-1119(88)90537-9; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; PISZKIEWICZ D, 1971, BIOCHEMISTRY-US, V10, P4544, DOI 10.1021/bi00800a031; RIFE JE, 1980, BIOCHEMISTRY-US, V19, P2328, DOI 10.1021/bi00552a008; SANDER F, 1977, P NATL ACAD SCI USA, V74, P5463; SINGH N, 1993, J BIOL CHEM, V268, P21; SMITH HB, 1991, BIOCHEMISTRY-US, V30, P5172, DOI 10.1021/bi00235a009; SODA K, 1971, BIOCHEM BIOPH RES CO, V44, P931, DOI 10.1016/0006-291X(71)90801-1; TAKADA H, 1991, J BIOCHEM-TOKYO, V109, P371, DOI 10.1093/oxfordjournals.jbchem.a123388; TONEY MD, 1989, SCIENCE, V243, P1485, DOI 10.1126/science.2538921; VALLE F, 1984, GENE, V27, P193, DOI 10.1016/0378-1119(84)90140-9; WOOTTON JC, 1974, P NATL ACAD SCI USA, V71, P4361, DOI 10.1073/pnas.71.11.4361; ZINK MW, 1962, ARCH BIOCHEM BIOPHYS, V99, P72, DOI 10.1016/0003-9861(62)90245-X	35	48	50	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27039	27045						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262941				2022-12-27	WOS:A1993MM26200033
J	OHNAKA, K; TAKAYANAGI, R; NISHIKAWA, M; HAJI, M; NAWATA, H				OHNAKA, K; TAKAYANAGI, R; NISHIKAWA, M; HAJI, M; NAWATA, H			PURIFICATION AND CHARACTERIZATION OF A PHOSPHORAMIDON-SENSITIVE ENDOTHELIN-CONVERTING ENZYME IN PORCINE AORTIC ENDOTHELIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIG ENDOTHELIN-1; CATHEPSIN-D; METALLOPROTEINASE INHIBITOR; CELLS; CONVERSION; PROTEINS; INVIVO; ELECTROPHORESIS; IDENTIFICATION; SUPPRESSES	An enzyme that catalyzes the conversion of big endothelin-1 to endothelin-1, designated as endothelin-converting enzyme, was solubilized with Lubrol PX from the membrane fraction of porcine aortic endothelium and was purified by sequential chromatography on DEAE-agarose, Ricinus communis agglutinin 120-agarose, peanut agglutinin-agarose, Mono Q, and TSK G3000SW(XL) columns. Approximately 12,000-fold purification of the membrane fraction enzyme was achieved. The purified enzyme had a very narrow neutral pH optimum and was inhibited by EDTA, 1, 10-phenanthroline, phosphoramidon, and low concentrations of some divalent cations (Cu2+, Zn2+, Co2+, Fe2+) but not by thiorphan. Addition of Zn2+ was most effective for the restoration of the EDTA-inactivated enzyme. The purified enzyme showed the highest affinity for big endothelin-1 among big endothelin isopeptides, and the K(m) for big endothelin-1 and the corresponding V(max) for endothelin-1 formation were 3.3 +/- 0.3 muM and 0.41 +/- 0.02 mumol/min/mg of protein, respectively. The carboxyl-terminal sequence from His27 to Gly34 and Trp21 was essential for recognition by this enzyme, while the presence of the amino-terminal loop structure reduced the hydrolysis rate. The purified enzyme showed an isoelectric point of 4.1. The molecular mass was estimated to be 131 kDa by sucrose density gradient centrifugation, and a value of 120 kDa was obtained by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, indicating that endothelin-converting enzyme is a monomeric glycoprotein.	KYUSHU UNIV, FAC MED,DEPT INTERNAL MED 3,MAINASHI 3-1-1, HIGASHI KU, FUKUOKA 812, JAPAN; FUJISAWA PHARMACEUT CO LTD, EXPLORATORY RES LABS, TSUKUBA, IBARAKI 30026, JAPAN	Kyushu University; Astellas Pharmaceuticals								AHN K, 1992, P NATL ACAD SCI USA, V89, P8606, DOI 10.1073/pnas.89.18.8606; ANDREWS P, 1965, BIOCHEM J, V96, P595, DOI 10.1042/bj0960595; CUSHMAN DW, 1971, BIOCHEM PHARMACOL, V20, P1637, DOI 10.1016/0006-2952(71)90292-9; DAS M, 1975, J BIOL CHEM, V250, P6762; DENG YL, 1992, J BIOCHEM, V111, P346, DOI 10.1093/oxfordjournals.jbchem.a123760; FUKURODA T, 1990, BIOCHEM BIOPH RES CO, V172, P390, DOI 10.1016/0006-291X(90)90685-G; HAGA T, 1977, J BIOL CHEM, V252, P5776; IKEGAWA R, 1990, BIOCHEM BIOPH RES CO, V171, P669, DOI 10.1016/0006-291X(90)91198-2; IKEGAWA R, 1990, BIOCHEM BIOPH RES CO, V167, P860, DOI 10.1016/0006-291X(90)92104-8; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; KASHIWABARA T, 1989, FEBS LETT, V247, P73, DOI 10.1016/0014-5793(89)81243-8; KON V, 1989, J CLIN INVEST, V83, P1762, DOI 10.1172/JCI114079; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MASAOKA H, 1989, LANCET, V2, P1402; MATSUMURA Y, 1990, FEBS LETT, V272, P166, DOI 10.1016/0014-5793(90)80475-X; MATSUMURA Y, 1990, BIOCHEM BIOPH RES CO, V167, P203, DOI 10.1016/0006-291X(90)91751-D; MATSUMURA Y, 1990, EUR J PHARMACOL, V185, P103, DOI 10.1016/0014-2999(90)90216-S; MATSUMURA Y, 1991, BIOCHEM BIOPH RES CO, V178, P531, DOI 10.1016/0006-291X(91)90140-3; MCMAHON EG, 1991, P NATL ACAD SCI USA, V88, P703, DOI 10.1073/pnas.88.3.703; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OHNAKA K, 1990, BIOCHEM BIOPH RES CO, V168, P1128, DOI 10.1016/0006-291X(90)91146-J; OHNAKA K, 1992, BIOCHEM BIOPH RES CO, V185, P611, DOI 10.1016/0006-291X(92)91668-G; OHNAKA K, 1991, J CARDIOVASC PHARM, V17, pS17, DOI 10.1097/00005344-199100177-00006; OKADA K, 1991, BIOCHEM BIOPH RES CO, V180, P1019, DOI 10.1016/S0006-291X(05)81167-2; OKADA K, 1990, BIOCHEM BIOPH RES CO, V171, P1192, DOI 10.1016/0006-291X(90)90811-Z; ORLEANSJUSTE PD, 1990, BIOCHEM PHARMACOL, V39, pR21, DOI 10.1016/0006-2952(90)90419-L; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SAWAMURA T, 1990, BIOCHEM BIOPH RES CO, V172, P883, DOI 10.1016/0006-291X(90)90758-F; SAWAMURA T, 1991, BIOCHEM BIOPH RES CO, V174, P779, DOI 10.1016/0006-291X(91)91485-U; SAWAMURA T, 1990, BIOCHEM BIOPH RES CO, V169, P1138, DOI 10.1016/0006-291X(90)92014-Q; SAWAMURA T, 1990, BIOCHEM BIOPH RES CO, V168, P1230, DOI 10.1016/0006-291X(90)91160-T; SHIELDS PP, 1991, BIOCHEM BIOPH RES CO, V177, P1006, DOI 10.1016/0006-291X(91)90638-N; TAKADA J, 1991, BIOCHEM BIOPH RES CO, V176, P860, DOI 10.1016/S0006-291X(05)80265-7; TAKAOKA M, 1990, BIOCHEM BIOPH RES CO, V173, P1218, DOI 10.1016/S0006-291X(05)80916-7; TASHEVA B, 1983, ANAL BIOCHEM, V129, P98, DOI 10.1016/0003-2697(83)90057-X; WATANABE T, 1990, NATURE, V344, P114, DOI 10.1038/344114a0; WATANABE T, 1991, CIRC RES, V69, P370, DOI 10.1161/01.RES.69.2.370; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; WUWONG JR, 1990, BIOCHEM BIOPH RES CO, V171, P1291, DOI 10.1016/0006-291X(90)90826-9; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	41	124	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26759	26766						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253812				2022-12-27	WOS:A1993MK42500109
J	FONG, TM; YU, H; CASCIERI, MA; UNDERWOOD, D; SWAIN, CJ; STRADER, CD				FONG, TM; YU, H; CASCIERI, MA; UNDERWOOD, D; SWAIN, CJ; STRADER, CD			THE ROLE OF HISTIDINE-265 IN ANTAGONIST BINDING TO THE NEUROKININ-1 RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTANCE-P ANTAGONIST; MOLECULAR CHARACTERIZATION; FUNCTIONAL CDNA; POTENT; PEPTIDES; NEURONS	Previous studies suggested that the antagonist binding site in the neurokinin-1 receptor is composed of phylogenetically conserved residues, while phylogenetically divergent residues affect the conformation of the binding site. To test this hypothesis, we investigated the role of conserved residues in antagonist binding. Histidine 197 in the human receptor was found to interact with CP-96,345 but not RP67580. In addition, a nearby residue, histidine 265 of the human receptor, is required for the binding of RP67580 but not CP-96,345 or substance P. The interaction between residue 265 and RP67580 is consistent with a hydrogen bonding interaction. Analysis of several analogs of CP-96,345 revealed that histidine 265 of the human receptor is in proximity to the substituted benzyl moiety of CP-96,345, and can interact with other analogs of CP-96,345. In contrast to the human neurokinin-1 receptor, both histidine 197 and histidine 265 in the rat neurokinin-1 receptor appear to interact with both CP96,345 and RP67580. These results support a conformational difference between the antagonist binding sites of the rat and human neurokinin-1 receptors and provide a model for examining specific interactions between antagonists and the receptor.	MERCK SHARP & DOHME LTD, DEPT MOLEC SYST, RAHWAY, NJ 07065 USA; MERCK SHARP & DOHME LTD, NEUROSCI RES CTR, HARLOW CM20 2PT, ESSEX, ENGLAND	Merck & Company; Merck & Company	FONG, TM (corresponding author), MERCK SHARP & DOHME LTD, DEPT MOLEC PHARMACOL & BIOCHEM, MAIL CODE 80M-213, POB 2000, RAHWAY, NJ 07065 USA.							BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; CASCIERI MA, 1992, MOL PHARMACOL, V42, P458; DE KONINCK Y, 1991, P NATL ACAD SCI USA, V88, P11344, DOI 10.1073/pnas.88.24.11344; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; FONG TM, 1993, NATURE, V362, P350; GARRET C, 1991, P NATL ACAD SCI USA, V88, P10208, DOI 10.1073/pnas.88.22.10208; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; HELKE CJ, 1990, FASEB J, V4, P1606, DOI 10.1096/fasebj.4.6.1969374; HERSHEY AD, 1990, SCIENCE, V247, P958, DOI 10.1126/science.2154852; IVERSEN LL, 1987, TOP MED CHEM, V65, P1; LOWE JA, 1992, J MED CHEM, V35, P2591, DOI 10.1021/jm00092a009; NAKANISHI S, 1991, ANNU REV NEUROSCI, V14, P123, DOI 10.1146/annurev.ne.14.030191.001011; PEYRONEL JF, 1992, BIOORG MED CHEM LETT, V2, P37, DOI 10.1016/S0960-894X(00)80650-2; REGOLI D, 1989, PHARMACOLOGY, V38, P1, DOI 10.1159/000138512; SACHAIS BS, 1993, J BIOL CHEM, V268, P2319; SCHMIDT AW, 1992, EUR J PHARMACOL, V215, P351, DOI 10.1016/0014-2999(92)90057-B; SNIDER RM, 1991, SCIENCE, V251, P435, DOI 10.1126/science.1703323; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; SWAIN CJ, 1993, IN PRESS BIOORG MED; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	21	79	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2728	2732						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300604				2022-12-27	WOS:A1994MV43200057
J	MALMBERG, RL; CELLINO, ML				MALMBERG, RL; CELLINO, ML			ARGININE DECARBOXYLASE OF OATS IS ACTIVATED BY ENZYMATIC CLEAVAGE INTO 2 POLYPEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE DECARBOXYLASE	Oat arginine decarboxylase is synthesized as a 66-kDa proenzyme, but the soluble enzyme is found in oats as a complex of 42- and 24-kDa polypeptide fragments, both derived from the 66-kDa precursor. We report here that this proteolytic cleavage is the result of a processing enzyme, distinct from arginine decarboxylase itself, that leads to activation of the arginine decarboxylase. The proteolysis is resistant to a standard set of protease inhibitors, but is inhibited by high concentrations of Zn2+, as is the activation of arginine decarboxylase. Agmatine, putrescine, spermidine, and spermine, as well as the arginine decarboxylase inhibitor difluoromethylarginine, each had no effect on the reaction. Oat arginine decarboxylase is thus similar to some other amino acid decarboxylases in requiring a proteolytic cleavage for activation; however, it differs in that the other examples are auto-catalytic self-processing.			MALMBERG, RL (corresponding author), UNIV GEORGIA,DEPT BOT,ATHENS,GA 30602, USA.			Malmberg, Russell/0000-0002-7448-5034				BELL E, 1990, MOL GEN GENET, V224, P431, DOI 10.1007/BF00262438; BITONTI AJ, 1987, BIOCHEM J, V242, P69, DOI 10.1042/bj2420069; Brandford M.M., 1976, ANAL BIOCHEM, V72, P248; COHN MS, 1977, J BIOL CHEM, V252, P8212; HIATT AC, 1986, J BIOL CHEM, V261, P1293; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY R, 1980, METHOD ENZYMOL, V65, P367; MALMBERG RL, 1992, PLANT PHYSIOL, V100, P146, DOI 10.1104/pp.100.1.146; PIKE CS, 1972, PLANT PHYSIOL, V49, P521, DOI 10.1104/pp.49.4.521; RECSEI PA, 1993, P NATL ACAD SCI USA, V80, P973; STANLEY BA, 1989, J BIOL CHEM, V264, P21073; STOREY RD, 1986, PHYTOCHEMISTRY, V25, P2701; TIBURCIO AF, 1986, PLANT PHYSIOL, V82, P375, DOI 10.1104/pp.82.2.375; VIERSTRA RD, 1984, PLANTA, V160, P521, DOI 10.1007/BF00411140; YOUNG ND, 1984, PLANT PHYSIOL, V76, P331, DOI 10.1104/pp.76.2.331	15	57	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2703	2706						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300600				2022-12-27	WOS:A1994MV43200053
J	CREPALDI, T; PRAT, M; GIORDANO, S; MEDICO, E; COMOGLIO, PM				CREPALDI, T; PRAT, M; GIORDANO, S; MEDICO, E; COMOGLIO, PM			GENERATION OF A TRUNCATED HEPATOCYTE GROWTH-FACTOR RECEPTOR IN THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; PRE-GOLGI DEGRADATION; MET PROTO-ONCOGENE; C-MET; SCATTER FACTOR; BREFELDIN-A; EPITHELIAL-CELLS; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; PEST HYPOTHESIS	The hepatocyte growth factor (HGF) receptor (p190MET) is a tyrosine kinase composed of two disulfide-linked chains, alpha of 50 kDa and beta of 145 kDa. We have previously described an isoform (p140MET) containing a beta chain of 85 kDa, lacking the cytoplasmic kinase domain. The two receptor variants originate by post-translational processing of a common single-chain precursor of 170 kDa (Pr170). In the endoplasmic reticulum a fraction of Pr170 is cleaved at the cytosolic side generating an intermediate product of 120 kDa (Pr120). This molecule 1) is already detectable after 15 min of pulse labeling, 2) contains high mannose-branched oligosaccharides, and 3) accumulates upon treatments inhibiting the export from the endoplasmic reticulum. A second cleavage, occurring after 30 min of chase in the trans-Golgi network, converts the single-chain precursors Pr170 and Pr120 into the mature heterodimers p190MET and p140MET This process is inhibited by brefeldin A treatment. Conditions leading to Pr170 accumulation in the endoplasmic reticulum, such as receptor overexpression, induce kinase activation and overproduction of Pr120. Conversely, cells expressing a kinase-defective HGF receptor lack the truncated isoform. The proteolytic cleavage of the cytoplasmic domain may thus represent a safety mechanism aimed at preventing ligand-independent intracellular activation of the HGF receptor kinase.			CREPALDI, T (corresponding author), UNIV TURIN,SCH MED,DEPT BIOMED SCI & ONCOL,C M DAZEGLIO 52,I-10126 TURIN,ITALY.		Giordano, Silvia/J-9858-2018; crepaldi, tiziana/AAY-7207-2020; Medico, Enzo/K-8497-2018	Giordano, Silvia/0000-0003-1854-1086; crepaldi, tiziana/0000-0003-3410-947X; Medico, Enzo/0000-0002-3917-2438; Comoglio, Paolo/0000-0002-7056-5328				AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; BARDELLI A, 1992, ONCOGENE, V7, P1973; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BASU A, 1989, MOL CELL BIOL, V9, P671, DOI 10.1128/MCB.9.2.671; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHAN AML, 1988, ONCOGENE, V2, P593; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; CHEN C, 1988, J CELL BIOL, V107, P2149, DOI 10.1083/jcb.107.6.2149; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FURLONG RA, 1991, J CELL SCI, V100, P173; GANDINO L, 1991, J BIOL CHEM, V266, P16098; GANDINO L, 1994, J BIOL CHEM, V269, P1815; GANDINO L, 1990, ONCOGENE, V5, P721; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LOETSCHER P, 1991, J BIOL CHEM, V266, P11213; LONGATI P, 1993, IN PRESS ONCOGENE, V8; MARK MR, 1993, IN PRESS J BIOL CHEM, V268; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MONDINO A, 1991, MOL CELL BIOL, V11, P6084, DOI 10.1128/MCB.11.12.6084; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; ROSEN EM, 1990, INVAS METAST, V10, P49; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TEMPEST PR, 1988, BRIT J CANCER, V58, P3, DOI 10.1038/bjc.1988.150; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEBER W, 1984, SCIENCE, V224, P294, DOI 10.1126/science.6324343; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973; ZABRECKY JR, 1991, J BIOL CHEM, V266, P1716	63	44	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1750	1755						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294424				2022-12-27	WOS:A1994MR98800034
J	FAYOS, BE; BARTLES, JR				FAYOS, BE; BARTLES, JR			REGULATION OF HEPATOCYTIC GLYCOPROTEIN SIALYLATION AND SIALYLTRANSFERASES BY PEROXISOME PROLIFERATORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; PLASMA-MEMBRANE PROTEINS; GAL-BETA-1->3(4)GLCNAC ALPHA-2->3 SIALYLTRANSFERASE; RAT-LIVER; TRANSCRIPTIONAL REGULATION; LINKED OLIGOSACCHARIDES; SIALIC-ACID; EXPRESSION; GENE; GLYCOSYLATION	Short-term dietary exposure of rats to a representative member of each of the three classes of peroxisome proliferators was found to elicit: (i) 71-80 and 66-75% reductions in the specific activities of the hepatic beta-galactoside alpha2,6- and alpha2,3-sialyltransferases, respectively; (ii) a 67-69% reduction in the level of hepatic beta-galactoside alpha2,6-sialyltransferase protein; and (iii) 41-46 and 6-28% reductions in the levels of the hepatic beta-galactoside alpha2,6- and alpha2,3-sialyltransferase mRNAs, respectively. These changes were found to correlate with a reduction in the sialylation of the N-linked glycans of a prototypical hepatocytic sialoglycoconjugate, the integral plasma membrane glycoprotein CE9, as was evident through: (i) a decrease in apparent molecular mass, (ii) a conversion to a more basic distribution of isoelectric points, and (iii) 56-72 and 33-44% decreases in the ability to bind lectins specific for sialic acid in alpha2,3- and alpha2,6-linkage, respectively. When assessed by labeling semithin frozen sections of liver tissue with a fluorescent lectin specific for alpha2,6-linked sialic acid, the reduced sialylation observed for CE9 was found to extend to other hepatocytic glycoconjugates in the livers of peroxisome proliferator-treated rats.	NORTHWESTERN UNIV,SCH MED,DEPT CELL MOLEC & STRUCT BIOL,WARD BLDG,303 E CHICAGO AVE,CHICAGO,IL 60611	Northwestern University				Bartles, James/0000-0002-7056-3875	NCI NIH HHS [CA53997] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053997] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BARTLES JR, 1985, J CELL BIOL, V100, P1126, DOI 10.1083/jcb.100.4.1126; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BARTLES JR, 1991, DEV BIOL, V143, P258, DOI 10.1016/0012-1606(91)90076-F; BARTLES JR, 1990, CANCER RES, V50, P669; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EDLUND C, 1986, CHEM-BIOL INTERACT, V57, P255, DOI 10.1016/0009-2797(86)90001-3; GROLLMAN EF, 1993, J BIOL CHEM, V268, P3604; HARTREE AS, 1992, BIOCHEM J, V287, P665, DOI 10.1042/bj2870665; HAWKINS JM, 1987, DRUG METAB REV, V18, P441, DOI 10.3109/03602538708994130; HUBBARD AL, 1985, J CELL BIOL, V100, P1115, DOI 10.1083/jcb.100.4.1115; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; NEHME CL, 1993, J CELL BIOL, V120, P6587; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; RAO MS, 1987, CARCINOGENESIS, V8, P631; REDDY JK, 1983, CRC CR REV TOXICOL, V12, P1, DOI 10.3109/10408448309029317; REDDY JK, 1986, TRENDS PHARMACOL SCI, V7, P438, DOI 10.1016/0165-6147(86)90416-5; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SHAH S, 1992, J BIOL CHEM, V267, P10652; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; WANG WC, 1988, J BIOL CHEM, V263, P4576; WANG XC, 1990, J BIOL CHEM, V265, P17849; WANG XC, 1989, J BIOL CHEM, V264, P1854; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13845; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; WEN DX, 1992, J BIOL CHEM, V267, P21011	36	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2151	2157						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294470				2022-12-27	WOS:A1994MR98800091
J	KWON, OS; CHURCHICH, JE				KWON, OS; CHURCHICH, JE			INTERACTION OF 70-KDA HEAT-SHOCK COGNATE PROTEIN WITH PEPTIDES AND MYOINOSITOL MONOPHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEINS; BINDING; CLATHRIN; PURIFICATION; ATPASE; HSP70	Fluorescence techniques have been used to investigate the interaction of bovine 70-kDA heat shock cognate protein (Hsc 70) with small molecular weight peptides and myo-inositol monophosphatase. The emission properties of Hsc 70 remain invariant upon addition of ATP. The results of steady-state fluorescence indicate that the tryptophan residues of Hsc 70 are exposed to the rapidly relaxing aqueous solvent. Binding of residues 1-20 of ribonuclease A (RNase S-peptide) to Hsc 70 causes protein fluorescence quenching which was used to determine a dissociation constant K(d) = 2.7 muM for the binary Hsc 70.RNase S-peptide complex. The octapeptide corresponding to the NH2-terminal portion of sickle cell hemoglobin recognizes Hsc 70 and binds with a K(d) = 9.3 muM. Binding of RNase S-peptide to Hsc 70 produces a small enhancement of ATPase activity. Unfolded myoinositol monophosphatase, tagged with the fluorescent probe 5-[2-(2-iodoacetamido)ethylamino]-1-naphthalenesulfonic acid, recognizes Hsc 70; the formation of a stable complex was detected by steady-state emission anisotropy measurements. The rate and extent of recovery of catalytic activity of unfolded myo-inositol monophosphatase is not influenced by Hsc 70. It is suggested that interaction of Hsc 70 with unfolded proteins in the cell may be able to delay the formation of misfolded structures.			KWON, OS (corresponding author), UNIV TENNESSEE,DEPT BIOCHEM,KNOXVILLE,TN 37996, USA.							BAIS R, 1975, ANAL BIOCHEM, V63, P271, DOI 10.1016/0003-2697(75)90215-8; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BIERZYNSKI A, 1982, P NATL ACAD SCI-BIOL, V79, P2470, DOI 10.1073/pnas.79.8.2470; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEMCHENKO AP, 1982, BIOPHYS CHEM, V15, P101, DOI 10.1016/0301-4622(82)80022-7; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GALLEY WC, 1970, P NATL ACAD SCI USA, V67, P1116, DOI 10.1073/pnas.67.3.1116; GEE NS, 1988, BIOCHEM J, V249, P880; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KWON OS, 1993, J BIOL CHEM, V268, P7912; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEWIS MJ, 1985, EMBO J, V4, P3137, DOI 10.1002/j.1460-2075.1985.tb04056.x; MAZURENKO YT, 1970, OPT SPEKTROSK, V28, P905; MEEK JL, 1988, BIOCHEM BIOPH RES CO, V156, P143, DOI 10.1016/S0006-291X(88)80816-7; MILARSKI KL, 1989, J CELL BIOL, V109, P1947, DOI 10.1083/jcb.109.5.1947; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; RICHARDS FM, 1959, J BIOL CHEM, V234, P1459; ROTHMAN JE, 1986, CELL, V46, P5, DOI 10.1016/0092-8674(86)90852-4; ROTHMAN JE, 1986, NATURE, V322, P209, DOI 10.1038/322209a0; SADIS S, 1990, BIOCHEMISTRY-US, V29, P8199, DOI 10.1021/bi00488a001; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHMID SL, 1985, J BIOL CHEM, V260, P10050; STEVENSON MA, 1990, MOL CELL BIOL, V10, P1234, DOI 10.1128/MCB.10.3.1234; WASYLEWSKI Z, 1992, EUR J BIOCHEM, V206, P235, DOI 10.1111/j.1432-1033.1992.tb16921.x	29	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					266	271						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276805				2022-12-27	WOS:A1994MR21900048
J	OPOKU, J; SIMONS, SS				OPOKU, J; SIMONS, SS			ABSENCE OF INTRAMOLECULAR DISULFIDES IN THE STRUCTURE AND FUNCTION OF NATIVE RAT GLUCOCORTICOID RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; SITE-DIRECTED MUTAGENESIS; STEROID-BINDING; DEXAMETHASONE 21-MESYLATE; BOND FORMATION; SULFHYDRYL-GROUPS; REDOX REGULATION; PROTEIN; CYSTEINES; DOMAIN	The presence of intramolecular disulfides in different functional states of the native glucocorticoid receptor in the absence of added oxidants has been examined on nonreducing SDS-polyacrylamide gels. Possible disulfides were trapped by the reaction of thiols in crude receptor solutions with methyl methanethiolsulfonate or iodoacetamide. The presence of diffuse bands at lower molecular weights than either the fully reduced or the thiol-blocked species for both the intact 98-kDa receptor and the 42-kDa chymotryptic fragment was diagnostic of an intramolecular disulfide(s) that had undergone thiol-disulfide rearrangements. However, both the rearrangements and the formation of intramolecular disulfides were found to occur only with denatured receptors during gel analysis. It appears that the thiols normally complexed with zinc in the zinc fingers may be recruited for disulfide bond formation. Finally, even when a documented intramolecular disulfide was formed in solutions of the native protein, thiol-disulfide rearrangements did not occur. The tertiary structure of the receptor is thus constituted in a manner that not only limits the formation of disulfides but also prevents the usually facile rearrangements of disulfide bond-containing structures to receptor forms that may have greatly reduced activity. Therefore, although intramolecular disulfide bonds may be of transitory importance, the structural or functional changes of native glucocorticoid receptors that are associated with steroid binding, activation, and dissociation of heat shock protein 90 neither involve nor require the formation or reduction of stable intramolecular disulfides.	NIDDK,LMCB,STEROID HORMONES SECT,BLDG 8,RM B2A-07,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BLICQ S, 1988, BIOCHEMISTRY-US, V27, P8436, DOI 10.1021/bi00422a021; BODWELL JE, 1984, BIOCHEMISTRY-US, V23, P1392, DOI 10.1021/bi00302a009; BRESNICK EH, 1988, BIOCHEMISTRY-US, V27, P2866, DOI 10.1021/bi00408a030; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CAVANAUGH AH, 1990, BIOCHEMISTRY-US, V29, P996, DOI 10.1021/bi00456a023; CHAKRABORTI PK, 1990, ENDOCRINOLOGY, V127, P2530, DOI 10.1210/endo-127-5-2530; CHAKRABORTI PK, 1992, J BIOL CHEM, V267, P11366; CLARKE J, 1993, BIOCHEMISTRY-US, V32, P4322, DOI 10.1021/bi00067a022; EISEN LP, 1985, J BIOL CHEM, V260, P1805; EWBANK JJ, 1991, NATURE, V350, P518, DOI 10.1038/350518a0; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; FISER A, 1992, FEBS LETT, V302, P117, DOI 10.1016/0014-5793(92)80419-H; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GRANBERG JP, 1977, ENDOCRINOLOGY, V100, P1160; GRIPPO JF, 1985, J BIOL CHEM, V260, P93; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HOECK W, 1989, J BIOL CHEM, V264, P14396; HUTCHISON KA, 1991, J BIOL CHEM, V266, P10505; JACOBSON BL, 1991, J BIOL CHEM, V266, P5220; KOSEN PA, 1992, BIOCHEMISTRY-US, V31, P5705, DOI 10.1021/bi00140a004; LANDGRAF W, 1991, J BIOL CHEM, V266, P16305; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MATSUMURA M, 1989, SCIENCE, V243, P792, DOI 10.1126/science.2916125; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MAYADAS TN, 1992, P NATL ACAD SCI USA, V89, P3531, DOI 10.1073/pnas.89.8.3531; MCBRIDE AA, 1992, P NATL ACAD SCI USA, V89, P7531, DOI 10.1073/pnas.89.16.7531; MESHINCHI S, 1990, J BIOL CHEM, V265, P11643; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MILLER NR, 1988, J BIOL CHEM, V263, P15217; OCONNOR TR, 1993, J BIOL CHEM, V268, P9063; OSHIMA H, 1992, MOL ENDOCRINOL, V6, P416, DOI 10.1210/me.6.3.416; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; REICHMAN ME, 1984, BIOCHEMISTRY-US, V23, P5376, DOI 10.1021/bi00317a042; ROTHWARF DM, 1992, P NATL ACAD SCI USA, V89, P7944, DOI 10.1073/pnas.89.17.7944; SEVERNE Y, 1988, EMBO J, V7, P2503, DOI 10.1002/j.1460-2075.1988.tb03097.x; SILVA CM, 1989, J BIOL CHEM, V264, P6638; SIMONS SS, 1987, J BIOL CHEM, V262, P9676; SIMONS SS, 1990, J BIOL CHEM, V265, P1938; SIMONS SS, 1987, J BIOL CHEM, V262, P9669; SIMONS SS, 1989, J BIOL CHEM, V264, P14493; SIMONS SS, 1981, P NATL ACAD SCI-BIOL, V78, P3541, DOI 10.1073/pnas.78.6.3541; SINGH R, 1991, J ORG CHEM, V56, P2332, DOI 10.1021/jo00007a018; SPANJAARD RA, 1993, MOL ENDOCRINOL, V7, P12, DOI 10.1210/me.7.1.12; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TANIYAMA Y, 1991, J BIOL CHEM, V266, P6456; TIENRUNGROJ W, 1987, J BIOL CHEM, V262, P6992; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783	50	15	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					503	510						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276843				2022-12-27	WOS:A1994MR21900082
J	RANKIN, S; ROZENGURT, E				RANKIN, S; ROZENGURT, E			PLATELET-DERIVED GROWTH-FACTOR MODULATION OF FOCAL ADHESION KINASE (P125FAK) AND PAXILLIN TYROSINE PHOSPHORYLATION IN SWISS 3T3 CELLS - BELL-SHAPED DOSE-RESPONSE AND CROSS-TALK WITH BOMBESIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-GAMMA; PDGF RECEPTOR; SIGNAL TRANSDUCTION; ONCOGENIC TRANSFORMATION; SH3 DOMAINS; PROTEIN; ASSOCIATION; BINDING; VASOPRESSIN; STIMULATION	In the present study, we have identified several proteins in Swiss 3T3 cells that are phosphorylated on tyrosine in response to platelet-derived growth factor (PDGF) and exhibit an unusual bell-shaped dose-response curve with a maximum at 5 ng/ml platelet-derived growth factor (PDGF). These proteins include two that are associated with focal adhesions, namely the focal adhesion kinase (p125FAK), a novel cytosolic tyrosine kinase, and paxillin. At low concentrations of PDGF (1-5 ng/ml), these proteins are the predominant tyrosine-phosphorylated species. At 30 ng/ml PDGF, however, there was no stimulation of their phosphorylation over control levels. In contrast, tyrosine phosphorylation of previously described substrates of the PDGF receptor tyrosine kinase, namely the p21ras GTPase-activating protein, p120, phosphatidyl inositol 3' kinase, and phospholipase Cgamma exhibited sigmoidal dose-response curves with PDGF and were all efficiently phosphorylated on tyrosine at 30 ng/ml PDGF. Cytochalasin D, which disrupts the actin cytoskeleton, completely inhibited the tyrosine phosphorylation of p125FAK and paxillin by PDGF. Examination of the actin cytoskeleton after stimulation of cells with different concentrations of PDGF revealed that at 5 ng/ml PDGF, actin appears in stress fibers and in membrane ruffles, while at 30 ng/ml, PDGF disrupts the actin cytoskeleton. Bombesin stimulates actin stress fiber formation with no evidence of disruption of stress fibers at high concentrations. When cells were stimulated with bombesin (10 nm) in the presence of 30 ng/ml PDGF, however, the actin cytoskeleton was completely disrupted. Further, the tyrosine phosphorylation of both p125FAK and paxillin induced by bombesin (10 nm) was completely prevented when cells were stimulated with bombesin in the presence of 30 ng/ml PDGF. We propose that the inhibitory limb in the bell-shaped dose-response curve of PDGF and the novel cross-talk between PDGF and bombesin on tyrosine phosphorylation may be explained by the ability of PDGF at 30 ng/ml to disrupt the actin cytoskeleton.	IMPERIAL CANC RES FUND,POB 123,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND	Cancer Research UK								ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BOCKUS BJ, 1984, EXP CELL RES, V153, P186, DOI 10.1016/0014-4827(84)90460-9; BOWENPOPE DF, 1989, J BIOL CHEM, V264, P2502; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; DOWNING JR, 1991, ONCOGENE, V6, P607; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; FORCE T, 1991, J BIOL CHEM, V266, P6650; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HEIDARAN MA, 1991, J BIOL CHEM, V266, P20232; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HERMAN B, 1985, J CELL BIOL, V100, P1031, DOI 10.1083/jcb.100.4.1031; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KELLY JD, 1991, J BIOL CHEM, V266, P8987; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MELLSTROM K, 1988, EXP CELL RES, V177, P347, DOI 10.1016/0014-4827(88)90468-5; MELLSTROM K, 1983, J MUSCLE RES CELL M, V4, P589, DOI 10.1007/BF00712117; MIURA Y, 1993, J BIOL CHEM, V268, P501; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SIEFERT RA, 1989, J BIOL CHEM, V264, P8771; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TURNER CE, 1993, J CELL SCI, V105, P637; TURNER CE, 1991, J CELL BIOL, V115, P201, DOI 10.1083/jcb.115.1.201; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WESTERMARK B, 1991, CANCER RES, V51, P5087; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WOODS A, 1988, COLLAGEN REL RES, V8, P155; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	64	315	316	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					704	710						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276872				2022-12-27	WOS:A1994MR21900110
J	ROBERTS, RC; SPANGLER, C; HELINSKI, DR				ROBERTS, RC; SPANGLER, C; HELINSKI, DR			CHARACTERISTICS AND SIGNIFICANCE OF DNA-BINDING ACTIVITY OF PLASMID STABILIZATION PROTEIN PARD FROM THE BROAD-HOST-RANGE PLASMID RK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; SITE-SPECIFIC RECOMBINATION; F-PLASMID; AGROBACTERIUM-TUMEFACIENS; ESCHERICHIA-COLI; SYSTEM; REGION; PARTITION; SEQUENCE; LOCUS	A region of the plasmid RK2 has been shown to stabilize plasmid replicons in a broad host-range manner. This region encodes two divergently transcribed operons: parCBA and parDE. The parCBA operon specifies a multimer resolution system, while the parDE operon alone is capable of stabilizing an RK2-derived minireplicon under defined growth conditions in several different Gram-negative bacteria. The observed autoregulation of the parDE operon is most likely the result of ParD protein binding within the PparDE region. The characteristics of ParD binding to this region and the role of such binding in plasmid stabilization were examined with purified ParD protein. The results indicate that the binding of a single dimer of ParD protein to the promoter region most likely blocks interaction of RNA polymerase holoenzyme with the promoter. DNase I protection experiments indicate that ParD binds to a discrete sequence of 48 base pairs in length. While the binding of ParD to PparDE is essential for proper regulation of expression of the ParD and ParE proteins in vivo, the analyses of binding properties of mutant ParD proteins suggest that binding to this region does not play a direct role in plasmid stabilization.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI007194] Funding Source: NIH RePORTER; NIAID NIH HHS [AIO7194] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABELES AL, 1985, J MOL BIOL, V185, P261, DOI 10.1016/0022-2836(85)90402-4; Brand L., 1967, METHODS ENZYMOL, P776, DOI [10.1016/S0076-6879(67)11091-4, DOI 10.1016/S0076-6879(67)11091-4]; Cantor CR, 1980, BIOPHYSICAL CHEM 2, P461; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; DAVIS TL, 1992, MOL MICROBIOL, V6, P1981, DOI 10.1111/j.1365-2958.1992.tb01371.x; DODD HM, 1987, J GEN MICROBIOL, V133, P2031; EBERL L, 1992, MOL MICROBIOL, V9, P1969; FUNNELL BE, 1988, J BACTERIOL, V170, P954, DOI 10.1128/JB.170.2.954-960.1988; GALLIE DR, 1987, J MOL BIOL, V193, P465, DOI 10.1016/0022-2836(87)90260-9; GARNIER T, 1987, MOL MICROBIOL, V1, P371, DOI 10.1111/j.1365-2958.1987.tb01944.x; GERDES K, 1986, J MOL BIOL, V190, P269, DOI 10.1016/0022-2836(86)90001-X; GERDES K, 1990, New Biologist, V2, P946; GERLITZ M, 1990, J BACTERIOL, V172, P6194, DOI 10.1128/jb.172.11.6194-6203.1990; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRINTER NJ, 1989, PLASMID, V22, P203, DOI 10.1016/0147-619X(89)90003-6; GUEST CR, 1991, BIOCHEMISTRY-US, V30, P8759, DOI 10.1021/bi00100a007; HELSBERG M, 1986, J BACTERIOL, V165, P1043, DOI 10.1128/jb.165.3.1043-1045.1986; HIRAGA S, 1992, ANNU REV BIOCHEM, V61, P283; JAFFE A, 1985, J BACTERIOL, V163, P841; JAYARAM M, 1985, MOL CELL BIOL, V5, P2466, DOI 10.1128/MCB.5.9.2466; Kittell B. L., 1993, BACTERIAL CONJUGATIO, P223, DOI 10.1007/978-1-4757-9357-4_8; KUES U, 1989, MICROBIOL REV, V53, P491; KUSUKAWA N, 1987, MOL GEN GENET, V208, P365, DOI 10.1007/BF00328125; LANE D, 1987, MOL GEN GENET, V207, P406, DOI 10.1007/BF00331608; MARTIN KA, 1987, P NATL ACAD SCI USA, V84, P8544, DOI 10.1073/pnas.84.23.8544; MILLER CA, 1990, CELL, V62, P127, DOI 10.1016/0092-8674(90)90246-B; MORRISSEY TH, 1981, ANAL BIOCHEM, V43, P177; NORDSTROM K, 1989, ANNU REV GENET, V23, P37, DOI 10.1146/annurev.genet.23.1.37; ROBERTS RC, 1990, J BACTERIOL, V172, P6204, DOI 10.1128/jb.172.11.6204-6216.1990; ROBERTS RC, 1992, J BACTERIOL, V174, P8119, DOI 10.1128/JB.174.24.8119-8132.1992; Sambrook J, 1989, MOL CLONING LABORATO; SAURUGGER PN, 1986, J BIOTECHNOL, V4, P333, DOI 10.1016/0168-1656(86)90047-7; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TABUCHI A, 1988, J MOL BIOL, V202, P511, DOI 10.1016/0022-2836(88)90282-3; Thomas CM, 1989, PROMISCUOUS PLASMIDS, P1; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4	38	47	50	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27109	27117						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262949				2022-12-27	WOS:A1993MM26200042
J	SCHMALIX, W; BANDLOW, W				SCHMALIX, W; BANDLOW, W			THE ETHANOL-INDUCIBLE YAT1 GENE FROM YEAST ENCODES A PRESUMPTIVE MITOCHONDRIAL OUTER CARNITINE ACETYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; RAT-LIVER; CHOLINE-ACETYLTRANSFERASE; BINDING PROTEIN; PALMITOYLTRANSFERASE; CLONING; SYSTEM; SEQUENCES; CDNA; DNA	The gene YAT1 from Saccharomyces cerevisiae encodes a protein of 688 amino acids which displays significant sequence similarity to vertebrate L-carnitine acyltransferases and yeast inner mitochondrial L-carnitine acetyltransferase. Steady state levels of the respective mRNA are low during growth on glucose or galactose, derepressed on glycerol, and significantly induced when ethanol or acetate are the only carbon sources. The YAT1 promotor region confers the identical carbon source dependence also on the expression of beta-galactosidase when cloned 5' to the Escherichia coli lacZ-coding region. An antiserum directed against a beta-galactosidase/Yat1p fusion protein recognizes a protein of 78-kDa molecular mass in the mitochondrial fraction from yeast. In vitro translated Yat1p, which lacks a cleavable presequence, binds to mitochondria in a protease-sensitive location in a standard in vitro import assay. Deletion of the single copy gene in a haploid yeast strain yields no obvious phenotype with any carbon source. Carnitine acetyltransferase activities of intact mitochondria from a YAT1 deletion mutant are slightly lower than wild type, but are approximately alike in lysed mitochondria from mutant and control cells. Thus, the novel gene is nonessential and likely to code for a minor mitochondial outer carnitine acetyltransferase.	UNIV ULM, INST PATHOL & FORENS MED, W-7900 ULM, GERMANY; UNIV MUNICH, MOLEC BIOL LAB, D-80937 MUNICH, GERMANY; UNIV MUNICH, INST GENET & MICROBIOL, D-80938 MUNICH, GERMANY	Ulm University; University of Munich; University of Munich								ADOLPHUS, 1983, EMBO J, V2, P1765, DOI 10.1002/j.1460-2075.1983.tb01655.x; BARKER WC, 1983, ATLAS PROTEIN SEQUEN, V7; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3018; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; BERRARD S, 1987, P NATL ACAD SCI USA, V84, P9280, DOI 10.1073/pnas.84.24.9280; BIEBER LL, 1972, ANAL BIOCHEM, V50, P509, DOI 10.1016/0003-2697(72)90061-9; BIEBER LL, 1983, ENZYMES, V16, P627; BURGLIN TR, 1987, EMBO J, V6, P2617, DOI 10.1002/j.1460-2075.1987.tb02552.x; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; CHASE JFA, 1970, BIOCHEM J, V116, P713, DOI 10.1042/bj1160713; CHATTERJEE B, 1988, BIOCHEMISTRY-US, V27, P9000, DOI 10.1021/bi00425a018; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DAUM G, 1982, J BIOL CHEM, V257, P3028; DOBSON MJ, 1982, NUCLEIC ACIDS RES, V10, P2625, DOI 10.1093/nar/10.8.2625; EINERHAND AWC, 1991, EUR J BIOCHEM, V200, P113, DOI 10.1111/j.1432-1033.1991.tb21056.x; ENTIAN KD, 1992, TRENDS BIOCHEM SCI, V17, P506, DOI 10.1016/0968-0004(92)90341-6; GANCEDO JM, 1992, EUR J BIOCHEM, V206, P297, DOI 10.1111/j.1432-1033.1992.tb16928.x; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOPPEL CH, 1985, ENZYMES BIOL MEMBR, V2, P139; HYMAN LE, 1991, MOL CELL BIOL, V11, P2004, DOI 10.1128/MCB.11.4.2004; ITOH N, 1986, P NATL ACAD SCI USA, V83, P4081, DOI 10.1073/pnas.83.11.4081; KELLER GA, 1991, J CELL BIOL, V114, P893, DOI 10.1083/jcb.114.5.893; KISPAL G, 1993, J BIOL CHEM, V268, P1824; KUNAU WH, 1988, BIOCHEM SOC T, V16, P418, DOI 10.1042/bst0160418; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEMIRE BD, 1989, J BIOL CHEM, V264, P20206; MAGDOLEN V, 1992, FEBS LETT, V299, P267, DOI 10.1016/0014-5793(92)80129-5; MAGDOLEN V, 1988, MOL CELL BIOL, V8, P5108, DOI 10.1128/MCB.8.12.5108; Maniatis T., 1982, MOL CLONING; MIYAZAWA S, 1983, J BIOCHEM-TOKYO, V93, P453, DOI 10.1093/oxfordjournals.jbchem.a134199; MULLER G, 1989, BIOCHEMISTRY-US, V28, P9957; MURTHY MSR, 1987, P NATL ACAD SCI USA, V84, P378, DOI 10.1073/pnas.84.2.378; NICHOLSON DW, 1988, PROTEIN TRANSFER ORG, P677; OZASA H, 1983, J BIOCHEM-TOKYO, V94, P543, DOI 10.1093/oxfordjournals.jbchem.a134385; PANDE SV, 1980, J BIOL CHEM, V255, P2994; RAMSAY RR, 1976, EUR J BIOCHEM, V69, P299, DOI 10.1111/j.1432-1033.1976.tb10886.x; RODEL G, 1985, J BACTERIOL, V161, P7; RUSSO P, 1991, EMBO J, V10, P563, DOI 10.1002/j.1460-2075.1991.tb07983.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIKORSKI RS, 1989, GENETICS, V122, P19; SKONECZNY M, 1988, EUR J BIOCHEM, V174, P297, DOI 10.1111/j.1432-1033.1988.tb14097.x; TRUMBLY RJ, 1992, MOL MICROBIOL, V6, P15, DOI 10.1111/j.1365-2958.1992.tb00832.x; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WOELTJE KF, 1990, J BIOL CHEM, V265, P10720; WOELTJE KF, 1990, J BIOL CHEM, V265, P10714; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	53	66	71	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27428	27439						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262985				2022-12-27	WOS:A1993MM26200084
J	HIGH, S; MARTOGLIO, B; GORLICH, D; ANDERSEN, SSL; ASHFORD, AJ; GINER, A; HARTMANN, E; PREHN, S; RAPOPORT, TA; DOBBERSTEIN, B; BRUNNER, J				HIGH, S; MARTOGLIO, B; GORLICH, D; ANDERSEN, SSL; ASHFORD, AJ; GINER, A; HARTMANN, E; PREHN, S; RAPOPORT, TA; DOBBERSTEIN, B; BRUNNER, J			SITE-SPECIFIC PHOTOCROSS-LINKING REVEALS THAT SEC61P AND TRAM CONTACT DIFFERENT REGIONS OF A MEMBRANE-INSERTED SIGNAL SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; UNNATURAL AMINO-ACIDS; TRANSFER-RNA PHES; PROTEIN TRANSLOCATION; RECOGNITION PARTICLE; POLYPEPTIDE TRANSLOCATION; NASCENT PREPROLACTIN; NONNATURAL RESIDUES; ER MEMBRANE; YEAST	A chemically charged amber suppressor TRNA was used to introduce the photoactivatable amino acid (Tmd)Phe at a selected position within the signal sequence of the secretory protein preprolactin. This allowed the interactions of the NH2-terminal, the central, and the COOH-terminal regions of the signal Sequence to be investigated during insertion into the membrane of the endoplasmic reticulum (ER). We found that different regions of the nascent chains were photocross-linked to different ER proteins. The TRAM protein (translocating chain-associating membrane protein) contacts the NH2-terminal region of the signal sequence while the mammalian Sec61p contacts the hydrophobic core of the signal sequence and regions COOH-terminal of this. These results suggest that the ER translocation complex is composed of heterologous protein subunits which contact distinct regions of nascent polypeptides during their membrane insertion.	SWISS FED INST TECHNOL, CH-8092 ZURICH, SWITZERLAND; MAX DELBRUCK CTR MOLEC MED, W-1115 BERLIN, GERMANY; HUMBOLDT UNIV BERLIN, INST BIOCHEM, O-1040 BERLIN, GERMANY	Swiss Federal Institutes of Technology Domain; ETH Zurich; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin	HIGH, S (corresponding author), EUROPEAN MOLEC BIOL LAB, POSTFACH 102209, MEYERHOFSTR 1, W-6900 HEIDELBERG, GERMANY.		Hartmann, Enno/C-5687-2013; Andersen, Søren S. L./O-1915-2017; Görlich, Dirk/B-8296-2017	Andersen, Søren S. L./0000-0002-3625-1640; Görlich, Dirk/0000-0002-4343-5210; High, Stephen/0000-0002-4532-8152				BAIN JD, 1991, BIOCHEMISTRY-US, V30, P5411, DOI 10.1021/bi00236a013; BAIN JD, 1992, NATURE, V356, P537, DOI 10.1038/356537a0; BAIN JD, 1989, J AM CHEM SOC, V111, P8013, DOI 10.1021/ja00202a052; BAIN JD, 1991, J ORG CHEM, V56, P4615, DOI 10.1021/jo00015a011; BALDINI G, 1988, BIOCHEMISTRY-US, V27, P7951, DOI 10.1021/bi00420a054; BRUCE AG, 1982, BIOCHEMISTRY-US, V21, P855, DOI 10.1021/bi00534a007; BRUNNER J, 1980, J BIOL CHEM, V255, P3313; CHUNG HH, 1993, SCIENCE, V259, P806, DOI 10.1126/science.8430333; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; ELLMAN J, 1991, METHOD ENZYMOL, V202, P301; ELLMAN JA, 1992, SCIENCE, V255, P197, DOI 10.1126/science.1553546; ELLMAN JA, 1992, J AM CHEM SOC, V114, P7959, DOI 10.1021/ja00046a080; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; GREEN N, 1992, J CELL BIOL, V116, P597, DOI 10.1083/jcb.116.3.597; HAEUPTLE MT, 1986, NUCLEIC ACIDS RES, V14, P1427, DOI 10.1093/nar/14.3.1427; HECKLER TG, 1984, BIOCHEMISTRY-US, V23, P1468, DOI 10.1021/bi00302a020; HIGH S, 1993, J CELL BIOL, V121, P743, DOI 10.1083/jcb.121.4.743; HIGH S, 1992, BIOESSAYS, V14, P535, DOI 10.1002/bies.950140807; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; HIGH S, 1992, MEMBRANE BIOGENESIS, V22, P105; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; MENDEL D, 1992, SCIENCE, V256, P1798, DOI 10.1126/science.1615324; MUSCH A, 1992, CELL, V69, P343, DOI 10.1016/0092-8674(92)90414-8; NASSAL M, 1984, J AM CHEM SOC, V106, P7540, DOI 10.1021/ja00336a038; NOREN CJ, 1990, NUCLEIC ACIDS RES, V18, P83, DOI 10.1093/nar/18.1.83; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; PAYNE RC, 1987, BIOCHEMISTRY-US, V26, P3197, DOI 10.1021/bi00385a039; PEZZUTO JM, 1980, J BIOL CHEM, V255, P865; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; RAPOPORT TA, 1990, TRENDS BIOCHEM SCI, V15, P355, DOI 10.1016/0968-0004(90)90076-N; ROBERTSON SA, 1991, J AM CHEM SOC, V113, P2722, DOI 10.1021/ja00007a055; ROESSER JR, 1989, BIOCHEMISTRY-US, V28, P5185, DOI 10.1021/bi00438a041; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SIEGEL V, 1988, CELL, V52, P39, DOI 10.1016/0092-8674(88)90529-6; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WIEDMANN M, 1989, FEBS LETT, V257, P263, DOI 10.1016/0014-5793(89)81549-2	49	127	127	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26745	26751						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253810				2022-12-27	WOS:A1993MK42500107
J	GAIRE, M; MAGBANUA, Z; MCDONNELL, S; MCNEIL, L; LOVETT, DH; MATRISIAN, LM				GAIRE, M; MAGBANUA, Z; MCDONNELL, S; MCNEIL, L; LOVETT, DH; MATRISIAN, LM			STRUCTURE AND EXPRESSION OF THE HUMAN GENE FOR THE MATRIX METALLOPROTEINASE MATRILYSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHEUMATOID SYNOVIAL FIBROBLASTS; COLLAGENASE GENE; HUMAN STROMELYSIN; IV COLLAGENASE; CHROMOSOMAL LOCALIZATION; PHORBOL INDUCTION; MESSENGER-RNA; GROWTH-FACTOR; PROMOTER; TRANSIN	Matrilysin, a member of the matrix metalloproteinase family, is structurally different from the other matrix metalloproteinases by virtue of the absence of a conserved COOH-terminal protein domain. In addition, matrilysin mRNA is regulated in a specific and distinct manner in normal and malignant tissues. Analysis of the genomic structure of the human matrilysin gene revealed that the organization of the first five exons is highly conserved among the different members of the matrix metalloproteinase family, but that matrilysin contains an atypical sixth exon. The promoter region of the matrilysin gene has several features that are conserved among several other matrix metalloproteinase family members, including the presence of TATA, AP-1, and PEA3 elements. Comparison of the expression of the human matrilysin promoter with rat stromelysin promoter/chloramphenicol acetyltransferase constructs in HeLa cells revealed that constructs containing AP-1 and PEA3 elements respond similarly to epidermal growth factor and tumor promoter (12-O-tetradecanoylphorbol-13-acetate) induction, but that the addition of upstream stromelysin sequences results in an increased transcriptional activity not observed with upstream matrilysin sequences. The similarities and differences observed between the promoters of matrilysin and the other metalloproteinases may provide insights into the molecular mechanisms that regulate the expression of this family of enzymes as a whole and the factors that distinguish the expression patterns of individual family members.	VANDERBILT UNIV,DEPT CELL BIOL,NASHVILLE,TN 37232; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO VET AFFAIRS MED CTR,DEPT MED,SAN FRANCISCO,CA 94121	Vanderbilt University; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center					NCI NIH HHS [CA46843] Funding Source: Medline; NIDDK NIH HHS [DK39776] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046843] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK039776, R01DK039776] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; BANYAI L, 1991, FEBS LETT, V282, P23, DOI 10.1016/0014-5793(91)80436-7; BASSETT P, 1909, NATURE, V348, P699; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREATHNACH R, 1987, NUCLEIC ACIDS RES, V15, P1139, DOI 10.1093/nar/15.3.1139; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; BUTTICE G, 1991, NUCLEIC ACIDS RES, V19, P3723, DOI 10.1093/nar/19.13.3723; CASE JP, 1990, J IMMUNOL, V145, P3755; CHUA CC, 1985, J BIOL CHEM, V260, P5213; COLLIER IE, 1991, GENOMICS, V9, P429, DOI 10.1016/0888-7543(91)90408-7; COLLIER IE, 1988, SANGMJ, V263, P10711; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; LAFYATIS R, 1990, MOL ENDOCRINOL, V4, P973, DOI 10.1210/mend-4-7-973; MARTI HP, 1992, BIOCHEM J, V285, P899, DOI 10.1042/bj2850899; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MATRISIAN LM, 1991, AM J MED SCI, V302, P157, DOI 10.1097/00000441-199109000-00008; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1678; MATTEI MG, 1990, ONCOGENE, V5, P151; MCONNELL S, 1991, MOL CARCINOG, V4, P527; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MURPHY G, 1992, J BIOL CHEM, V267, P9612; MURPHY GJP, 1991, FEBS LETT, V289, P4, DOI 10.1016/0014-5793(91)80895-A; PAJOUH MS, 1991, J CANCER RES CLIN, V117, P144, DOI 10.1007/BF01613138; PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V176, P633, DOI 10.1016/S0006-291X(05)80231-1; QUANTIN B, 1989, BIOCHEMISTRY-US, V28, P5327, DOI 10.1021/bi00439a004; QUINONES S, 1989, J BIOL CHEM, V264, P8339; RODGERS WH, 1993, AM J OBSTET GYNECOL, V168, P253, DOI 10.1016/S0002-9378(12)90922-9; Roth P., 1990, NUCLEIC ACIDS RES, V18, P5009; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO SD, 1992, J BIOL CHEM, V267, P4664; SIRUM KL, 1989, BIOCHEMISTRY-US, V28, P8691, DOI 10.1021/bi00448a004; SIRUMCONNOLLY K, 1991, NUCLEIC ACIDS RES, V19, P335, DOI 10.1093/nar/19.2.335; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WOESSNER JF, 1988, J BIOL CHEM, V263, P16918	51	232	242	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2032	2040						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294454				2022-12-27	WOS:A1994MR98800074
J	RAVICHANDRAN, KS; BURAKOFF, SJ				RAVICHANDRAN, KS; BURAKOFF, SJ			THE ADAPTER PROTEIN SHC INTERACTS WITH THE INTERLEUKIN-2 (IL-2) RECEPTOR UPON IL-2 STIMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SIGNAL TRANSDUCTION; TYROSINE KINASES; BETA-SUBUNIT; ACTIVATION; REGION; CHAIN; IDENTIFICATION; ASSOCIATION; BINDING; DOMAIN	Binding of interleukin-2 (IL-2) to the IL-2 receptor (IL-2R) stimulates Src family kinases, tyrosine phosphorylation of several proteins, conversion of Ras to its active GTP-bound form, and eventually c-fos, c-jun, and c-myc induction. The IL-2Rbeta chain plays a crucial role in IL-2R signaling. Within the cytoplasmic domain of the beta chain, a region essential for mitogenesis and another involved in binding the Src family kinase Lck have been defined. The beta chain itself is tyrosine-phosphorylated upon IL-2 stimulation. Since the adapter protein Shc acts upstream of Ras and is involved in T cell receptor-mediated Ras activation, we examined the role of Shc in IL-2 signaling. Shc was found to be tyrosine-phosphorylated upon IL-2 stimulation in CTLL-20 cells. After its phosphorylation, Shc interacted with another adapter protein, Grb2, and, via Grb2, with the Ras GTP/GDP exchange factor mSOS. After IL-2 stimulation, Shc also associated with the IL-2Rbeta chain. Thus, during IL-2 signaling, the interaction of Shc with the IL-2Rbeta chain and its simultaneous association with Grb2 and mSOS may couple IL-2R stimulation to Ras signaling.	HARVARD UNIV, SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL, 44 BINNEY ST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School			Ravichandran, Kattur Soundarapandian/AAG-7319-2019	Ravichandran, Kattur Soundarapandian/0000-0003-2397-461X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017258] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-17258] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FUNG MR, 1991, J IMMUNOL, V147, P1253; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALTZMAN EM, 1988, J BIOL CHEM, V263, P6956; SATOH T, 1992, J BIOL CHEM, V267, P25423; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAKESHITA T, 1990, INT IMMUNOL, V2, P477, DOI 10.1093/intimm/2.5.477; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	23	133	136	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1599	1602						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294403				2022-12-27	WOS:A1994MR98800009
J	FOURNIER, L; WHITFIELD, JF; SCHWARTZ, JL; BEGINHEICK, N				FOURNIER, L; WHITFIELD, JF; SCHWARTZ, JL; BEGINHEICK, N			CYCLIC-AMP TRIGGERS LARGE [CA2+](I) OSCILLATIONS IN GLUCOSE-STIMULATED BETA-CELLS FROM OB OB MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC B-CELLS; BURSTING ELECTRICAL-ACTIVITY; SENSITIVE K+ CHANNELS; CYTOSOLIC FREE CA-2+; INSULIN RELEASE; ADENOSINE-MONOPHOSPHATE; ABNORMAL REGULATION; MOUSE ISLETS; ION CHANNELS; CAMP LEVELS	The modulation of intracellular free calcium concentration ([Ca2+]i) by cAMP was compared in pancreatic beta-cells of lean (+/+) and obese (ob/ob) mice. Neither forskolin nor 8-bromo-cAMP significantly affected basal [Ca2+]i in unstimulated lean and obese mouse beta-cells. In obese, but not in lean mouse beta-cells, adding forskolin or 8-bromo-cAMP during the glucose-induced [Ca2+]i response triggered external Ca2+-dependent [Ca2+]i oscillations with a duration of 5-11 s and a frequency of 2.3-4.8 min-1. The induction of oscillations by cAMP required both a stimulatory glucose concentration and membrane depolarization. (S(p))-cAMPS, did induce oscillations in lean mouse beta-cells. However, these oscillations were different from those seen in obese mouse beta-cells and required higher concentrations of (S(p))-cAMPS. The inducibility of fast oscillations in obese mouse beta-cells indicates hypersensitivity of these cells to cAMP, and suggests an abnormal behavior of K+ and/or Ca2+ channels.	UNIV OTTAWA,DEPT BIOCHEM,OTTAWA K1H 8M5,ONTARIO,CANADA; NATL RES COUNCIL CANADA,INST BIOL SCI,CELL SYST SECT,OTTAWA K1A 0R6,ONTARIO,CANADA; NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,MONTREAL,PQ,CANADA	University of Ottawa; National Research Council Canada; National Research Council Canada								BLACK M, 1986, BIOCHEM J, V238, P863, DOI 10.1042/bj2380863; BLACK MA, 1988, AM J PHYSIOL, V255, pE833, DOI 10.1152/ajpendo.1988.255.6.E833; EDDLESTONE GT, 1985, AM J PHYSIOL, V248, pC145, DOI 10.1152/ajpcell.1985.248.1.C145; FOURNIER L, 1992, J MEMBRANE BIOL, V129, P267; FOURNIER LA, 1993, AM J PHYSIOL, V246, pC1458; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; GRAPENGIESSER E, 1991, J BIOL CHEM, V266, P12207; GRAPENGIESSER E, 1989, ARCH BIOCHEM BIOPHYS, V268, P404, DOI 10.1016/0003-9861(89)90602-4; GYLFE E, 1988, J BIOL CHEM, V263, P5044; HELLMAN B, 1991, NUTRIENT REGULATION, P213; HENQUIN JC, 1984, ENDOCRINOLOGY, V115, P1125, DOI 10.1210/endo-115-3-1125; HENQUIN JC, 1983, BIOCHEM BIOPH RES CO, V112, P614, DOI 10.1016/0006-291X(83)91508-5; HENQUIN JC, 1990, PFLUG ARCH EUR J PHY, V416, P568, DOI 10.1007/BF00382691; HILL RS, 1987, DIABETES, V36, P440, DOI 10.2337/diabetes.36.4.440; HOLZ GG, 1993, NATURE, V361, P362, DOI 10.1038/361362a0; HUGHES SJ, 1989, MOL CELL ENDOCRINOL, V65, P35, DOI 10.1016/0303-7207(89)90162-7; KUKULJAN M, 1991, J MEMBRANE BIOL, V119, P187, DOI 10.1007/BF01871418; LEVITAN IB, 1988, ANNU REV NEUROSCI, V11, P119, DOI 10.1146/annurev.neuro.11.1.119; LEVITAN IB, 1985, J MEMBRANE BIOL, V87, P177, DOI 10.1007/BF01871217; MALAISSE WJ, 1984, ENDOCRINOLOGY, V115, P2015, DOI 10.1210/endo-115-5-2015; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; PRENTKI M, 1987, FEBS LETT, V220, P103, DOI 10.1016/0014-5793(87)80884-0; RAJAN AS, 1989, DIABETES, V38, P874, DOI 10.2337/diabetes.38.7.874; ROE MW, 1993, J BIOL CHEM, V268, P9953; RORSMAN P, 1985, ACTA PHYSIOL SCAND, V125, P639, DOI 10.1111/j.1748-1716.1985.tb07766.x; RORSMAN P, 1991, NATURE, V349, P77, DOI 10.1038/349077a0; ROSARIO LM, 1985, Q J EXP PHYSIOL CMS, V70, P137, DOI 10.1113/expphysiol.1985.sp002885; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; SEINO S, 1992, P NATL ACAD SCI USA, V89, P584, DOI 10.1073/pnas.89.2.584; SMITH PA, 1989, NATURE, V342, P550, DOI 10.1038/342550a0; SUSSMAN KE, 1987, DIABETES, V36, P571, DOI 10.2337/diabetes.36.5.571; VALDEOLMILLOS M, 1989, FEBS LETT, V259, P19, DOI 10.1016/0014-5793(89)81484-X; VELASCO JM, 1988, FEBS LETT, V231, P366, DOI 10.1016/0014-5793(88)80851-2; WIEDENKELLER DE, 1983, ENDOCRINOLOGY, V113, P2311, DOI 10.1210/endo-113-6-2311; YANEY GC, 1992, MOL ENDOCRINOL, V6, P2143, DOI 10.1210/me.6.12.2143	35	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1120	1124						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288569				2022-12-27	WOS:A1994MR22000055
J	GOETZL, EJ; SHAMES, RS; YANG, JH; BIRKE, FW; LIU, YF; ALBERT, PR; AN, SZ				GOETZL, EJ; SHAMES, RS; YANG, JH; BIRKE, FW; LIU, YF; ALBERT, PR; AN, SZ			INHIBITION OF HUMAN HL-60 CELL RESPONSES TO CHEMOTACTIC FACTORS BY ANTISENSE MESSENGER-RNA DEPLETION OF G-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; PITUITARY-CELLS; RECEPTORS; BINDING; LEUKOTRIENE-B4; PEPTIDE; IDENTIFICATION; ACTIVATION; SUBUNITS; AFFINITY	Chemotactic factors bound to receptors of the seven-transmembrane domain family signal leukocytes through associated guanine nucleotide-binding (G) proteins. Human leukocytes of the HL-60 line, which express G protein-coupled receptors for leukotriene B4 (LTB4) and N-formyl-methionyl-leucyl-phenylalanine (fMLP) after differentiation with vitamin D3 and transforming growth factor-beta, were transfected with expression plasmids containing antisense-oriented cDNAs encoding the alpha-chains of G(o), G(i1), G(i2), and G(i3). Antisense mRNA for G(o) and G(i2) alpha-chains suppressed by over 80% the level of the respective G protein. G(o)-deficient HL-60 cells had depressed functional and intracellular calcium responses to LTB4 and fMLP, but no alterations in the responses of cyclic adenosine 3',5'-monophosphate (cAMP). In contrast, HL-60 cells deficient in G(i2) lost only responses of the intracellular concentration of cAMP. Antisense mRNA suppression of distinct G proteins thus may delineate some transductional requirements for cellular responses.	UNIV CALIF SAN FRANCISCO,DEPT MOLEC IMMUNOL,SAN FRANCISCO,CA 94143; MCGILL UNIV,DEPT PHARMACOL & THERAPEUT,MONTREAL H3G 1Y6,QUEBEC,CANADA	University of California System; University of California San Francisco; McGill University	GOETZL, EJ (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,UB8B,BOX 0711,533 PARNASSUS AVE,SAN FRANCISCO,CA 94143, USA.		Albert, Paul/E-4804-2010	Albert, Paul/0000-0002-1809-3554	NHLBI NIH HHS [HL 31809] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031809] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; ARAGAY AM, 1992, J BIOL CHEM, V267, P24983; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; DIDSBURY JR, 1987, FEBS LETT, V21, P160; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EASON MG, 1992, J BIOL CHEM, V267, P15795; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDMAN DW, 1986, J IMMUNOL, V136, P4631; GOLDMAN DW, 1985, J EXP MED, V162, P145, DOI 10.1084/jem.162.1.145; GOLDMAN DW, 1984, J EXP MED, V159, P1027, DOI 10.1084/jem.159.4.1027; JONES DT, 1987, J BIOL CHEM, V262, P14241; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KOO C, 1983, J CLIN INVEST, V72, P748, DOI 10.1172/JCI111045; KRAUSE KH, 1985, J CLIN INVEST, V76, P1348, DOI 10.1172/JCI112109; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAW SF, 1993, J BIOL CHEM, V268, P10721; LAW SF, 1991, J BIOL CHEM, V266, P17885; LLEDO PM, 1992, NEURON, V8, P455, DOI 10.1016/0896-6273(92)90273-G; MUKAI H, 1992, J BIOL CHEM, V267, P16237; MURRAYWHELAN R, 1992, J BIOL CHEM, V267, P2960; OKUMA Y, 1992, J BIOL CHEM, V267, P14826; SCHEPERS TM, 1992, J BIOL CHEM, V267, P159; SHERMAN JW, 1992, J CELL BIOCHEM, V48, P367, DOI 10.1002/jcb.240480405; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986	25	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					809	812						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288630				2022-12-27	WOS:A1994MR22000007
J	SUEN, CS; YEN, PM; CHIN, WW				SUEN, CS; YEN, PM; CHIN, WW			IN-VITRO TRANSCRIPTIONAL STUDIES OF THE ROLES OF THE THYROID-HORMONE (T(3)) RESPONSE ELEMENTS AND MINIMAL PROMOTERS IN T(3)-STIMULATED GENE-TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; X-RECEPTOR; FUNCTIONAL-CHARACTERIZATION; AUXILIARY PROTEIN; ENHANCES BINDING; RXR-BETA; RAT; DNA; SITE; TRANSACTIVATION	Thyroid hormone receptors (TRs) are ligand-dependent nuclear transcription factors that are encoded by two different genes, TRalpha and TRbeta, and bind to thyroid hormone response elements (TREs) in the promoters of thyroid hormone (T3)-regulated genes. Retinoid X receptors (RXRs), major members of the thyroid hormone receptor auxiliary proteins, have recently been shown to enhance the binding of TRs to TREs. We previously showed that TPs extracted from rat pituitary GH3 cells retain ligand (T3) and DNA binding specificity and stimulate rat growth hormone (rGH) promoter activity in a cell-free in vitro transcription system. In this report, we have studied further how T3 activates endogenous TRs and stimulates transcription from different TRE-containing promoters. We found that T3 (10(-8) M) selectively stimulates transcription (rom rGH-TRE- and TREpal-, but not ME-TRE- and F2-TRE-, containing templates in which these TREs are linked in front of the rGH minimal promoter containing only the TATA box binding protein, but not any other proximal binding protein, sequence. In contrast, only the TREpal/AdML template, in which TREpal oligonucleotide was linked in front of the adenovirus major late gene (AdML) minimal promoter, was stimulated by T3. Electrophoretic mobility shift assay (EMSA) demonstrates that endogenous TR complexes specifically bind to either natural or idealized TRE (rGH-TRE, TREpal, ME-TRE, and F2-TRE) oligonucleotides. To further understand these receptor-DNA complexes formed on various TREs, isoform-specific anti-receptor antisera (TRalpha, TRbeta1, TRbeta2, and RXRbeta) were added in the EMSA. These antisera differentially supershifted TR.DNA complexes formed on the TREs. These data suggest either that endogenous TR isoforms and RXRbeta may form different complexes on the various TREs or that TR.RXR complexes have distinct conformations when bound to the various TREs. Taken together, these data suggest that particular TREs in which specific TR.RXR complexes are formed and different minimal promoters may provide specificity in T3-mediated transcriptional stimulation of gene expression.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	SUEN, CS (corresponding author), BRIGHAM & WOMENS HOSP,HOWARD HUGHES MED INST,DEPT MED,DIV GENET,GW THORN RES BLDG,BOSTON,MA 02115, USA.		Yen, Paul M/V-9857-2019	Yen, Paul/0000-0002-3790-8114				BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BERKENSTAM A, 1992, CELL, V69, P401, DOI 10.1016/0092-8674(92)90443-G; BRENT GA, 1989, J BIOL CHEM, V264, P178; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; BURNSIDE J, 1989, J BIOL CHEM, V264, P6886; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; DARLING DS, 1989, MOL ENDOCRINOL, V3, P1359, DOI 10.1210/mend-3-9-1359; DAVIS KD, 1993, ENDOCRINOLOGY, V132, P1469, DOI 10.1210/en.132.4.1469; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; HALLENBECK PL, 1993, J BIOL CHEM, V268, P3825; HERMANN T, 1992, MOL ENDOCRINOL, V6, P1153, DOI 10.1210/me.6.7.1153; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LAZAR MA, 1990, J CLIN INVEST, V86, P1777, DOI 10.1172/JCI114906; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MADER S, 1993, J BIOL CHEM, V268, P591; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; SAMBROOK KJ, 1989, MOL CLONING LABORATO; SAMUELS HH, 1988, J CLIN INVEST, V81, P957, DOI 10.1172/JCI113449; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SIMON MC, 1990, P NATL ACAD SCI USA, V87, P513, DOI 10.1073/pnas.87.2.513; STUNNENBERG HG, 1993, BIOESSAYS, V15, P309, DOI 10.1002/bies.950150504; SUEN CS, 1993, MOL CELL BIOL, V13, P1719, DOI 10.1128/MCB.13.3.1719; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; WOOD WM, 1989, J BIOL CHEM, V264, P14840; YE ZS, 1988, J BIOL CHEM, V263, P7821; YEN PM, 1992, J BIOL CHEM, V267, P3565; YEN PM, 1992, ENDOCRINOLOGY, V130, P1539, DOI 10.1210/en.130.3.1539; YEN PM, 1992, J BIOL CHEM, V267, P23248; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	42	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1314	1322						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288596				2022-12-27	WOS:A1994MR22000086
J	BOEKHOFF, I; INGLESE, J; SCHLEICHER, S; KOCH, WJ; LEFKOWITZ, RJ; BREER, H				BOEKHOFF, I; INGLESE, J; SCHLEICHER, S; KOCH, WJ; LEFKOWITZ, RJ; BREER, H			OLFACTORY DESENSITIZATION REQUIRES MEMBRANE TARGETING OF RECEPTOR KINASE MEDIATED BY BETA-GAMMA-SUBUNITS OF HETEROTRIMERIC G-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MUSCARINIC ACETYLCHOLINE-RECEPTORS; LIGHT-DEPENDENT PHOSPHORYLATION; SIGNAL TRANSDUCTION; RHODOPSIN; ISOPRENYLATION; KINETICS; FAMILY; CILIA	Olfaction is mediated by G protein-coupled receptors. In isolated rat olfactory cilia, odorants such as citralva stimulate a burst of cAMP, which peaks in 50 ms and returns almost to base-line level within 150 ms in the continuing presence of odorant. This desensitization is mediated by the cAMP dependent protein kinase and a specialized G protein-coupled receptor kinase originally termed betaARK2BAR (GRK3). In vitro experiments suggest that the prenylated betagamma-subunits of heterotrimeric G proteins target the cytosolic betaARK1 (GRK2) enzyme to its membrane bound receptor substrate by binding to sites in its carboxyl terminus. Here we demonstrate that odorants stimulate translocation of GRK3 from cytosol to membranes in isolated rat olfactory cilia. We introduced a glutathione S-transferase-GRK3ct fusion protein, containing the carboxyl-terminal 222 amino acid residues of GRK3, which includes the betagamma binding site, or a 28-amino acid peptide derived therefrom, into permeabilized cilia preparations. These reagents block odorant-mediated enzyme translocation and desensitization while markedly attenuating odorant-stimulated phosphorylation of olfactory proteins. These findings suggest that betaggamma-subunits may physiologically regulate a G protein-coupled receptor kinase and that enzyme translocation may be a general and required feature of the activity of some members of this enzyme family.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MED,BOX 3821,DURHAM,NC 27710; UNIV HOHENHEIM,DEPT ZOOPHYSIOL,D-70593 STUTTGART,GERMANY; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; University Hohenheim; Duke University; Howard Hughes Medical Institute			Lefkowitz, Robert/AAW-2649-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adam G., 1968, STRUCTURAL CHEM MOL, P198; ANHOLT RRH, 1986, J NEUROSCI, V6, P1962; ARRIZA JL, 1992, J NEUROSCI, V12, P4045; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BOEKHOFF I, 1992, P NATL ACAD SCI USA, V89, P11983, DOI 10.1073/pnas.89.24.11983; BOEKHOFF I, 1992, P NATL ACAD SCI USA, V89, P471, DOI 10.1073/pnas.89.2.471; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breer H, 1992, Curr Opin Neurobiol, V2, P439, DOI 10.1016/0959-4388(92)90177-M; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; DAWSON TM, 1993, SCIENCE, V259, P825, DOI 10.1126/science.8381559; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; INGLESE J, 1992, J BIOL CHEM, V267, P1422; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; KAMEYAMA K, 1993, J BIOL CHEM, V268, P7753; KIM CM, 1993, J BIOL CHEM, V268, P15412; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; LAMB TD, 1992, TRENDS NEUROSCI, V15, P291, DOI 10.1016/0166-2236(92)90079-N; LEFKOWITZ RJ, 1990, TRENDS PHARMACOL SCI, V11, P190, DOI 10.1016/0165-6147(90)90113-M; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; REED RR, 1992, NEURON, V8, P205, DOI 10.1016/0896-6273(92)90287-N; SCHLEICHER S, 1993, P NATL ACAD SCI USA, V90, P1420, DOI 10.1073/pnas.90.4.1420; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; STEINER AL, 1972, J BIOL CHEM, V247, P1114; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032	32	95	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					37	40						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276821				2022-12-27	WOS:A1994MR21900010
J	HART, MJ; EVA, A; ZANGRILLI, D; AARONSON, SA; EVANS, T; CERIONE, RA; ZHENG, Y				HART, MJ; EVA, A; ZANGRILLI, D; AARONSON, SA; EVANS, T; CERIONE, RA; ZHENG, Y			CELLULAR-TRANSFORMATION AND GUANINE-NUCLEOTIDE EXCHANGE ACTIVITY ARE CATALYZED BY A COMMON DOMAIN ON THE DBL ONCOGENE PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GTP-BINDING PROTEIN; MOLECULAR-CLONING; ACTIVATING PROTEIN; ESCHERICHIA-COLI; CDC42HS PROTEIN; RAS; YEAST; GENE; IDENTIFICATION; POLARITY	The dbl oncogene product contains a 238-amino acid domain, which is shared by an expanding family of growth regulatory proteins. These include the Saccharomyces cerevisiae cell division cycle protein, CDC24, the breakpoint cluster region protein, the ect2 and vav oncogene products, and the brain GDP-releasing factor for Ras. Previous studies have provided evidence that oncogenic Dbl or an associated protein stimulates GDP dissociation from the human species (Hs) homolog of CDC42. We show here that Dbl specifically complexes with the GDP-bound forms of CDC42Hs and RhoA, but not Rac1 or TC10, and that this specificity correlates with the ability of Dbl to act as a GDP-releasing factor. Small deletions throughout the Dbl domain, which inactivate transformation, eliminated the ability of Dbl to stimulate GDP dissociation, whereas deletions outside of this domain did not impair either function. Finally, the Dbl domain itself, when expressed and purified as a recombinant protein, was shown to stimulate GDP dissociation from purified, recombinant CDC42Hs. These findings establish that a minimal unit on Dbl that is critical to its transforming function directly regulates GDP-GTP exchange activity.	CORNELL UNIV,DEPT PHARMACOL,ITHACA,NY 14853; CORNELL UNIV,DEPT BIOCHEM & CELL & MOLEC BIOL,ITHACA,NY 14853; NCI,BETHESDA,MD 20892; ONYX PHARMACEUT,RICHMOND,CA 94806	Cornell University; Cornell University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Zheng, Yi/J-7235-2015; Eva, Alessandra/J-8268-2016	Zheng, Yi/0000-0001-7089-6074; Eva, Alessandra/0000-0003-2949-078X; Hart, Matthew/0000-0002-2683-480X	NIGMS NIH HHS [GM47458] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047458] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVA A, 1987, ONCOGENE, V1, P355; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANI G, 1992, ONCOGENE, V7, P229; GRAZIANI G, 1989, ONCOGENE, V4, P823; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HART MJ, 1991, J BIOL CHEM, V266, P20840; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KOLAND JG, 1990, BIOCHEM BIOPH RES CO, V166, P90, DOI 10.1016/0006-291X(90)91915-F; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; RON D, 1991, NEW BIOL, V3, P372; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SLOAT BR, 1990, J CELL BIOL, V111, P143; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STACEY DW, 1991, ONCOGENE, V6, P2297; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286; ZHENG Y, 1993, J BIOL CHEM, V268, P24629	28	281	292	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					62	65						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276860				2022-12-27	WOS:A1994MR21900017
J	VANHORN, DJ; MYERS, MG; BACKER, JM				VANHORN, DJ; MYERS, MG; BACKER, JM			DIRECT ACTIVATION OF THE PHOSPHATIDYLINOSITOL 3'-KINASE BY THE INSULIN-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RAT HEPATOMA-CELLS; TYROSINE KINASE; 3-KINASE ACTIVITY; SIGNAL TRANSMISSION; GROWTH-FACTOR; INTACT RAT; PHOSPHORYLATION; EXPRESSION; IRS-1; STIMULATION	We have previously shown that phosphatidylinositol (PtdIns) 3'-kinase is activated by the binding of proteins or peptides containing the phosphorylated motif Y(P)XXM. In the present study, we examine interactions between PtdIns 3'-kinase and the human insulin receptor, which contains a C-terminal phosphorylation site in the sequence Y1322THM. Partially purified insulin receptors bound tightly to bacterial fusion proteins containing the N- or C-terminal SH2 domains from PtdIns 3'-kinase regulatory subunit (p85). In contrast, a mutant insulin receptor, truncated by 43 amino acids at the C terminus (IR(DELTACT)), bound poorly to the SH2 domains; these mutant receptors have normal kinase activity but lack the Y1322THM motif. Similarly, incubation with wild-type receptors increased the activity of immunopurified PtdIns 3'-kinase, whereas incubation with IR(DELTACT) receptors did not affect PtdIns 3'-kinase activity. Activation of PtdIns 3'-kinase by the wild-type receptor was mimicked by a tyrosyl phosphopeptide derived from the insulin receptor C terminus and containing the Y1322THM motif; non-phosphorylated peptide did not affect activity. Thus, the insulin receptor C terminus activates PtdIns 3'-kinase in vitro by binding to the SH2 domains of the 85-kDa regulatory subunit. These data support the hypothesis that binding of tyrosyl-phosphorylated receptors to p85 SH2 domains is a general mechanism for PtdIns 3'-kinase activation, and they suggest that direct interactions between the insulin receptor and PtdIns 3'-kinase may provide an alternative pathway for the activation of this enzyme by insulin.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOLEC PHARMACOL, 1300 MORRIS PK AVE, BRONX, NY 10461 USA; BRIGHAM & WOMENS HOSP, JOSLIN DIABET CTR, DEPT MED, DIV RES, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA	Yeshiva University; Albert Einstein College of Medicine; Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School					NIDDK NIH HHS [DK-44541] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044541] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1989, J BIOL CHEM, V264, P1694; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1993, J BIOL CHEM, V268, P8204; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FEENER EP, 1993, J BIOL CHEM, V268, P11256; FOLLI F, 1992, J BIOL CHEM, V267, P22171; HERRERA R, 1988, J BIOL CHEM, V263, P5560; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KAPELLER R, 1991, MOL ENDOCRINOL, V5, P769, DOI 10.1210/mend-5-6-769; KELLY KL, 1992, J BIOL CHEM, V267, P3423; KELLY KL, 1993, J BIOL CHEM, V268, P4391; MYERS MG, 1991, J BIOL CHEM, V266, P10616; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANAYOTOU G, 1992, EMBO J, V11, P4261, DOI 10.1002/j.1460-2075.1992.tb05524.x; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITE MF, 1988, J BIOL CHEM, V263, P2969; YONEZAWA K, 1992, J BIOL CHEM, V267, P440; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	36	109	114	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					29	32						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276809				2022-12-27	WOS:A1994MR21900008
J	ZHANG, JZ; REDMAN, CM				ZHANG, JZ; REDMAN, CM			ROLE OF INTERCHAIN DISULFIDE BONDS ON THE ASSEMBLY AND SECRETION OF HUMAN FIBRINOGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN FIBRINOGEN; ELECTRON-MICROSCOPY; MOLECULAR-STRUCTURE; CHAIN; IDENTIFICATION; DOMAINS; MODEL; CELLS	The cysteines involved in joining the 2 half-molecules of fibrinogen and also those located on either side of the alpha-helical coiled-coil region, were substituted, by site-directed mutagenesis, with serine. Fibrinogen assembly and secretion were determined in transiently transfected COS cells. Our studies indicate that in order to assemble the 2 half-molecules into a dimer, it is not sufficient to only have the disulfide linkages which keep the 2 half-molecules intact. The disulfide rings which flank the coil-coiled region also play important roles in dimer assembly. Intact interchain disulfide linkages at the NH2-terminal end of the coiled-coil region are essential for assembly of the 2 half-molecules. Disruption of these disulfide rings leads to the formation and secretion of half-molecules. Disruption of the interchain disulfide rings at the COOH-terminal end of the coiled-coil region allows dimer formation, but the 6-chain molecule which is assembled is not secreted. Disruption of both disulfide rings at either end of the coiled-coil region disallows assembly of half-molecules and of dimeric fibrinogen.	NEW YORK BLOOD CTR,LINDSLEY F KIMBALL RES INST,NEW YORK,NY 10021	New York Blood Center					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037457] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37457] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARNHART MI, 1962, P SOC EXP BIOL MED, V110, P734; BINNIE CG, 1993, BIOCHEMISTRY-US, V32, P107, DOI 10.1021/bi00052a015; BLOMBACK B, 1972, ANN NY ACAD SCI, V202, P77, DOI 10.1111/j.1749-6632.1972.tb16323.x; BLOMBACK B, 1968, NATURE, V218, P130, DOI 10.1038/218130a0; BLOMBACK B, 1974, THROMB RES, V4, P55, DOI 10.1016/0049-3848(74)90203-5; BLOMBACK B, 1976, THROMB RES, V8, P639, DOI 10.1016/0049-3848(76)90245-0; BOUMA H, 1978, THROMB RES, V713, P557; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DANISHEFSKY K, 1990, BIOCHIM BIOPHYS ACTA, V1048, P202, DOI 10.1016/0167-4781(90)90057-9; DOOLITTLE RF, 1978, J MOL BIOL, V120, P311, DOI 10.1016/0022-2836(78)90070-0; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; FARRELL DH, 1991, BIOCHEMISTRY-US, V30, P9414, DOI 10.1021/bi00103a004; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; HALL CE, 1959, J BIOPHYS BIOCHEM CY, V5, P11, DOI 10.1083/jcb.5.1.11; HARTWIG R, 1991, J BIOL CHEM, V266, P6578; HENSCHEN A, 1983, ANN NY ACAD SCI, V408, P28, DOI 10.1111/j.1749-6632.1983.tb23232.x; HENSCHEN A, 1964, ARK KEMI, V22, P355; HOEPRICH PD, 1983, BIOCHEMISTRY-US, V22, P2049, DOI 10.1021/bi00278a003; HUANG SM, 1993, J BIOL CHEM, V268, P8919; HUANG SM, 1993, BIOCHEM BIOPH RES CO, V190, P488, DOI 10.1006/bbrc.1993.1074; IWANAGA S, 1967, BIOCHIM BIOPHYS ACTA, V147, P606, DOI 10.1016/0005-2795(67)90025-6; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MOSESSON MW, 1981, J MOL BIOL, V153, P695, DOI 10.1016/0022-2836(81)90414-9; MURAKAWA M, 1993, THROMB HAEMOSTASIS, V69, P351; PROCYK R, 1992, BIOCHEMISTRY-US, V31, P2273, DOI 10.1021/bi00123a009; RAO SPS, 1991, J MOL BIOL, V222, P89, DOI 10.1016/0022-2836(91)90739-S; ROY SN, 1991, J BIOL CHEM, V266, P4758; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; UU S, 1984, J BIOL CHEM, V259, P10574; WEISEL JW, 1981, NATURE, V289, P263, DOI 10.1038/289263a0; YU S, 1987, THROMB RES, V46, P281, DOI 10.1016/0049-3848(87)90290-8; YU S, 1983, J BIOL CHEM, V258, P3407; YU S, 1986, SCHEME INTRACELLULAR, P665; ZHANG JZ, 1992, J BIOL CHEM, V267, P21727; ZHANG JZ, 1993, J BIOL CHEM, V268, P11278; ZHANG JZ, 1992, MOL BIOL CELL, V3, pA113	36	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					652	658						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276866				2022-12-27	WOS:A1994MR21900103
J	BRESLIN, MB; LINDBERG, I; BENJANNET, S; MATHIS, JP; LAZURE, C; SEIDAH, NG				BRESLIN, MB; LINDBERG, I; BENJANNET, S; MATHIS, JP; LAZURE, C; SEIDAH, NG			DIFFERENTIAL PROCESSING OF PROENKEPHALIN BY PROHORMONE CONVERTASE-1(3) AND CONVERTASE-2 AND FURIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE REQUIREMENTS; VONWILLEBRAND-FACTOR; BETA-ENDORPHIN; GENE ENCODES; EXPRESSION; CELL; KEX2; RAT; IDENTIFICATION; CLEAVAGE	Recombinant vaccinia virus vectors were used to coexpress mouse prohormone convertase 1 (mPC1), mPC2, or human furin together with human proenkephalin in GH4C1 cells (rat pituitary somatomammotrophs) to examine the proteolytic processing of proenkephalin by these enzymes. Radioimmunoassays performed on high pressure gel permeation size-fractionated extracts obtained from GH4C1 cells and corresponding conditioned media revealed distinct profiles of immunoreactivity for products generated by each enzyme. PC1 produced intermediate sized processing products (3-10 kDa); the major immunoreactive enkephalin-containing species observed eluted at the positions of peptide B, the 5.3-kDa fragment, and free Leu5-enkephalin. PC2 exhibited a more complete processing profile. The major immunoreactive enkephalins produced were free Met5-enkephalin-Arg-Phe, free Met5-enkephalin-Arg-Gly-Leu, free Leu5-enkephalin, and free Met5-enkephalin. Thus PC2 appears to be more capable of generating active opioid units from proenkephalin than is PC1. Finally, furin cleaved proenkephalin to generate peptide B, an unidentified peak between the 18- and 5.3-kDa fragments, and a small amount of the 5.3-kDa fragment. Radiosequencing data verified that the production of the 5.3-kDa fragment by PC1 occurred as a result of a Lys-Lys cleavage. The ability of PC1 to cleave proenkephalin (but not proopiomelanocortin) at a Lys-Lys site implies that the structural context of the paired basic cleavage site may be more important in the determination of cleavage specificity than the particular pair of basic residues at the site.	LOUISIANA STATE UNIV, MED CTR, DEPT BIOCHEM & MOLEC BIOL, 1901 PERDIDO ST, NEW ORLEANS, LA 70112 USA; CLIN RES INST MONTREAL, JA DESEVE LAB, MONTREAL H2W 1R7, QUEBEC, CANADA	Louisiana State University System; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal			Seidah, Nabil/I-3596-2013; Lindberg, Iris/Q-3825-2019	Seidah, Nabil/0000-0001-6503-9342; 	NATIONAL INSTITUTE ON DRUG ABUSE [R56DA005084, R01DA005084] Funding Source: NIH RePORTER; NIDA NIH HHS [R56 DA005084, R01 DA005084] Funding Source: Medline; PHS HHS [05084] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BIRCH NP, 1986, FEBS LETT, V197, P173, DOI 10.1016/0014-5793(86)80321-0; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; DANDEKAR S, 1982, P NATL ACAD SCI-BIOL, V79, P1017, DOI 10.1073/pnas.79.4.1017; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; GIRAUD P, 1981, NEUROPEPTIDES, V1, P237, DOI 10.1016/0143-4179(81)90002-0; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; Hutton JC, 1990, CURR OPIN CELL BIOL, V2, P1131, DOI 10.1016/0955-0674(90)90167-D; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; LINDBERG I, 1983, LIFE SCI, V33, P5, DOI 10.1016/0024-3205(83)90430-7; LINDBERG I, 1991, ENDOCRINOLOGY, V128, P1849, DOI 10.1210/endo-128-4-1849; LINDBERG I, 1986, J BIOL CHEM, V261, P6317; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; MARRIOTT D, 1992, MOL ENDOCRINOL, V6, P1441, DOI 10.1210/me.6.9.1441; MATHIS JP, 1992, ENDOCRINOLOGY, V131, P2287, DOI 10.1210/en.131.5.2287; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; MOCCHETTI I, 1984, EUR J PHARMACOL, V106, P427, DOI 10.1016/0014-2999(84)90734-9; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; NAKAYAMA K, 1991, J BIOCHEM, V109, P803, DOI 10.1093/oxfordjournals.jbchem.a123461; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; REHEMTULLA A, 1992, BLOOD, V79, P2349; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; SCHAFER MKH, 1993, NEUROSCIENCE, V13, P1258; SCHALKEN JA, 1987, J CLIN INVEST, V80, P1545, DOI 10.1172/JCI113240; SEIDAH NG, 1992, MOL ENDOCRINOL, V6, P1559, DOI 10.1210/me.6.10.1559; SEIDAH NG, 1978, P NATL ACAD SCI USA, V75, P3153, DOI 10.1073/pnas.75.7.3153; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; SONDERS M, 1984, BIOCHEM BIOPH RES CO, V122, P892, DOI 10.1016/0006-291X(84)91174-4; THOMAS G, 1988, BIOCHIMIE, V70, P89, DOI 10.1016/0300-9084(88)90163-0; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; UDENFRIEND S, 1983, ARCH BIOCHEM BIOPHYS, V221, P309, DOI 10.1016/0003-9861(83)90149-2; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; WATANABE T, 1992, J BIOL CHEM, V267, P8270; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; YANAGITA M, 1992, FEBS LETT, V311, P55, DOI 10.1016/0014-5793(92)81366-T; YI Z, 1993, J BIOL CHEM, V268, P5615; ZHOU A, 1993, J BIOL CHEM, V268, P1763	44	140	142	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27084	27093						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262946				2022-12-27	WOS:A1993MM26200039
J	FILHOL, O; CHAMBAZ, EM; GILL, GN; COCHET, C				FILHOL, O; CHAMBAZ, EM; GILL, GN; COCHET, C			EPIDERMAL GROWTH-FACTOR STIMULATES A PROTEIN-TYROSINE KINASE WHICH IS SEPARABLE FROM THE EPIDERMAL GROWTH-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF RECEPTOR; TRANSCRIPTION FACTOR; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; SH3 DOMAINS; PHOSPHORYLATION; ASSOCIATION; CELLS; SRC; TERMINUS	The intrinsic protein tyrosine kinase activity of the epidermal growth factor (EGF) receptor is necessary for ligand-induced signaling. To determine whether cellular protein tyrosine kinases are substrates for EGF-activated receptors, phosphotyrosine-containing proteins were isolated from EGF-treated cells and assayed for tyrosine kinase activity using peptide substrates. A tyrosine kinase activity that is distinct from the EGF receptor was adsorbed to monoclonal anti-phosphotyrosine antibody columns and eluted with phenyl phosphate. Near-maximal tyrosine phosphorylation of this kinase occurred within 1 min of cell stimulation with an ED50 for EGF of 2.5 nM. The kinase was deactivated by incubation with purified CD45 tyrosine phosphatase in vitro, but activity could be restored by incubation with purified EGF receptor and Mn2+ ATP. These results suggest a cascade of tyrosine kinase signaling analogous to well characterized serine/threonine kinase cascades.	CEN,DBMS,BRCE,INSERM,U244,F-38041 GRENOBLE,FRANCE; UNIV CALIF SAN DIEGO,DEPT MED,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093	Institut National de la Sante et de la Recherche Medicale (Inserm); University of California System; University of California San Diego			Filhol-Cochet, Odile/I-3962-2016	Filhol, Odile/0000-0003-1964-7958; Cochet, Claude/0000-0002-1772-4270	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK013149, R01DK013149] Funding Source: NIH RePORTER; NIDDK NIH HHS [DDK 13149] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CAMPOSGONZALEZ R, 1992, J BIOL CHEM, V267, P14535; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COCHET C, 1991, J BIOL CHEM, V266, P637; DECKER SJ, 1992, J BIOL CHEM, V267, P1104; DICKSON B, 1992, NATURE, V360, P603; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GILL GN, 1984, J BIOL CHEM, V259, P7755; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEE CY, 1977, ARCH BIOCHEM BIOPHYS, V178, P8, DOI 10.1016/0003-9861(77)90165-5; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; OLIVIER JP, 1993, SCIENCE, V260, P315; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SELVA E, 1993, J BIOL CHEM, V268, P2250; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WEDEGAERTNER PB, 1992, ARCH BIOCHEM BIOPHYS, V292, P273, DOI 10.1016/0003-9861(92)90079-C; ZACHARY I, 1991, J BIOL CHEM, V266, P24126	35	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26978	26982						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262933				2022-12-27	WOS:A1993MM26200024
J	FURUCHI, T; AIKAWA, K; ARAI, H; INOUE, K				FURUCHI, T; AIKAWA, K; ARAI, H; INOUE, K			BAFILOMYCIN-A(1), A SPECIFIC INHIBITOR OF VACUOLAR-TYPE H+-ATPASE, BLOCKS LYSOSOMAL CHOLESTEROL TRAFFICKING IN MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; NIEMANN-PICK DISEASE; HAMSTER OVARY CELLS; INTRACELLULAR-TRANSPORT; C FIBROBLASTS; FOAM CELLS; METABOLISM; ACCUMULATION; DEGRADATION	Certain steroids having an oxo group at the C-17 or C-20 position such as pregnenolone and dehydroisoandrosterone inhibit the cholesterol transport from lysosomes to other cellular sites. Taking advantage of the fact that the inhibition is reversed upon removal of the steroids, we studied the factors that control the cholesterol transport from lysosomes to other cellular sites in macrophages. Macrophages that accumulated unesterified cholesterol in their lysosomes were prepared by incubating cells with liposomes containing cholesterol and phosphatidylserine in the presence of a steroid inhibitor. These cells were chased by means of steroid washout, and then the effects of various pharmacological agents on the subsequent metabolism of cholesterol were examined. When the cells were chased in the absence of the agents, some of the cholesterol was converted to cholesteryl esters in the cells, and others were desorbed into the medium as unesterified forms, suggesting recovery of lysosomal cholesterol trafficking. Among the agents tested, bafilomycin A1, a specific inhibitor of vacuolar-type H+-ATPase, completely blocked both cholesterol esterification and cholesterol desorption at 10 nm. Moreover, agents that neutralize the lysosomal proton gradient, such as ammonium chloride and chloroquine, also reduced both of the processes. Fluorescent microscopic examination of bafilomycin A1-treated cells revealed extensive filipin-cholesterol staining of perinuclear lysosomes. From these data, we conclude that acidic pH is required for the efflux of cholesterol from lysosomes to other cellular sites.	UNIV TOKYO,FAC PHARMACEUT SCI,DEPT HLTH CHEM,HONGO 7-3-1,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BROWN MS, 1979, J CELL BIOL, V82, P597, DOI 10.1083/jcb.82.3.597; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; CADIGAN KM, 1990, J CELL BIOL, V110, P295, DOI 10.1083/jcb.110.2.295; DAHL NK, 1992, J BIOL CHEM, V267, P4889; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GERRITY RG, 1981, AM J PATHOL, V103, P181; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; KOVAL M, 1990, J CELL BIOL, V111, P429, DOI 10.1083/jcb.111.2.429; KRUTH HS, 1986, J BIOL CHEM, V261, P6769; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; LISCUM L, 1987, J BIOL CHEM, V262, P17002; LISCUM L, 1992, J LIPID RES, V33, P1239; LISCUM L, 1990, BIOCHIM BIOPHYS ACTA, V1045, P40, DOI 10.1016/0005-2760(90)90201-8; LISCUM L, 1989, J BIOL CHEM, V264, P11796; LUKACS GL, 1991, J BIOL CHEM, V266, P24540; NISHIKAWA K, 1993, BIOCHIM BIOPHYS ACTA, V1169, P257; NISHIKAWA K, 1990, J BIOL CHEM, V265, P5226; PENTCHEV PG, 1985, P NATL ACAD SCI USA, V82, P8247, DOI 10.1073/pnas.82.23.8247; SCHAFFNER T, 1980, AM J PATHOL, V100, P57; SOKOL J, 1988, J BIOL CHEM, V263, P3411	23	79	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27345	27348						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262974				2022-12-27	WOS:A1993MM26200073
J	JIANG, XC; MASUCCIMAGOULAS, L; MAR, J; LIN, M; WALSH, A; BRESLOW, JL; TALL, A				JIANG, XC; MASUCCIMAGOULAS, L; MAR, J; LIN, M; WALSH, A; BRESLOW, JL; TALL, A			DOWN-REGULATION OF MESSENGER-RNA FOR THE LOW-DENSITY-LIPOPROTEIN RECEPTOR IN TRANSGENIC MICE CONTAINING THE GENE FOR HUMAN CHOLESTERYL ESTER TRANSFER PROTEIN - MECHANISM TO EXPLAIN ACCUMULATION OF LIPOPROTEIN-B PARTICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID TRANSFER PROTEIN; APOLIPOPROTEIN-E; PLASMA; METABOLISM; TRANSCRIPTION; HAMSTER; RABBIT; LIVER; RATES	To evaluate the effects of cholesteryl ester transfer protein (CETP) on apoB-containing lipoproteins, we analyzed plasma lipoproteins from three different lines of human CETP transgenic mice, with plasma CETP concentration ranging from low (1.5 mug/ml) to high levels (8.5 mug/ml). With increasing CETP concentration, very low density lipoprotein and low density lipoprotein (LDL) cholesteryl ester (CE) and apoB were progressively increased, and high density lipoprotein CE was decreased. To investigate the mechanism of accumulation of lipoproteins containing apoB (lipoprotein B), the abundance of hepatic LDL receptor mRNA was determined. LDL receptor mRNA was reduced as a result of CETP expression, with maximum repression to about 48% of the level of non-transgenic mice. Among the different lines of CETP transgenic mice there was an inverse relationship between plasma CETP concentration and hepatic LDL receptor mRNA abundance (r = -0.94, p < 0.01). CETP expression also led to increased cholesterol and cholesteryl ester content in liver and to decreased abundance of mRNAs encoding 3-hydroxy-3-methylglutaryl-coenzyme A reductase and 7-alpha-hydroxylase. Thus, CETP expression results in increased cholesteryl ester concentration in very low density lipoprotein and LDL, probably reflecting both CE transfer from high density lipoprotein and accumulation of lipoprotein B particles. The accumulation of lipoprotein B particles results from CETP-mediated down-regulation of liver LDL receptors, possibly due to enhanced return of cholesterol to the liver.	COLUMBIA UNIV,DEPT MED,DIV MOLEC MED,NEW YORK,NY 10032; ROCKEFELLER UNIV,BIOCHEM GENET & METAB LAB,NEW YORK,NY 10021	Columbia University; Rockefeller University			Tall, Alan/AAT-8528-2021; Breslow, Jan L/B-7544-2008		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006, R01HL033714, R01HL043165] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43165, HL-21006, HL-33714] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGELLON LB, 1991, J BIOL CHEM, V266, P10796; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Bachorik P S, 1986, Methods Enzymol, V129, P78; CARR TP, 1993, CLIN BIOCHEM, V26, P39, DOI 10.1016/0009-9120(93)90015-X; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; FORBES WR, 1985, ARTERIOSCLEROSIS, V5, P283; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GROENER JEM, 1989, BIOCHIM BIOPHYS ACTA, V1002, P93, DOI 10.1016/0005-2760(89)90070-2; HA YC, 1982, COMP BIOCHEM PHYS B, V71, P265, DOI 10.1016/0305-0491(82)90252-8; INAZU A, 1990, NEW ENGL J MED, V323, P1234, DOI 10.1056/NEJM199011013231803; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; JIANG XC, 1992, J CLIN INVEST, V90, P1290, DOI 10.1172/JCI115993; JIANG XC, 1991, J BIOL CHEM, V266, P4631; KANE JP, 1980, P NATL ACAD SCI-BIOL, V77, P2465, DOI 10.1073/pnas.77.5.2465; KELZ HR, 1982, J BIOL CHEM, V257, P8061; KESNIEMI YA, 1983, J CLIN INVEST, V71, P950; KOIZUMI J, 1991, ATHEROSCLEROSIS, V90, P189, DOI 10.1016/0021-9150(91)90114-I; MAHLEY RW, 1983, BIOCHIM BIOPHYS ACTA, V737, P197, DOI 10.1016/0304-4157(83)90001-1; MARCEL YL, 1990, J CLIN INVEST, V85, P10, DOI 10.1172/JCI114397; MAROTTI KR, 1992, ARTERIOSCLER THROMB, V12, P736, DOI 10.1161/01.ATV.12.6.736; MCPHERSON R, 1991, ARTERIOSCLER THROMB, V11, P476, DOI 10.1161/01.ATV.11.3.476; MENZEL HJ, 1983, ARTERIOSCLEROSIS, V3, P310, DOI 10.1161/01.ATV.3.4.310; MOULIN P, 1992, J LIPID RES, V33, P1817; QUIG DW, 1986, BIOCHIM BIOPHYS ACTA, V879, P171, DOI 10.1016/0005-2760(86)90100-1; QUINET E, 1991, J CLIN INVEST, V87, P1559, DOI 10.1172/JCI115169; QUINET EM, 1990, J CLIN INVEST, V85, P357, DOI 10.1172/JCI114446; RUDLING M, 1992, J LIPID RES, V33, P493; RUDLING M, 1993, J CLIN INVEST, V91, P2796, DOI 10.1172/JCI116522; SEHAYEK E, 1991, J CLIN INVEST, V88, P553, DOI 10.1172/JCI115339; SPADY DK, 1985, P NATL ACAD SCI USA, V82, P4526, DOI 10.1073/pnas.82.13.4526; SPADY DK, 1985, J LIPID RES, V26, P465; SPADY DK, 1983, P NATL ACAD SCI-BIOL, V80, P3499, DOI 10.1073/pnas.80.11.3499; TALL A, 1987, J CLIN INVEST, V79, P1217, DOI 10.1172/JCI112940; TALL AR, 1986, J LIPID RES, V27, P361; WEINTRAUB MS, 1987, J CLIN INVEST, V80, P1571, DOI 10.1172/JCI113243; WHITLOCK ME, 1989, J CLIN INVEST, V84, P129, DOI 10.1172/JCI114132; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210	37	92	93	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27406	27412						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262982				2022-12-27	WOS:A1993MM26200081
J	LOBSANOV, YD; GITT, MA; LEFFLER, H; BARONDES, SH; RINI, JM				LOBSANOV, YD; GITT, MA; LEFFLER, H; BARONDES, SH; RINI, JM			X-RAY CRYSTAL-STRUCTURE OF THE HUMAN DIMERIC S-LAC LECTIN, L-14-II, IN COMPLEX WITH LACTOSE AT 2.9-ANGSTROM RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDE-BINDING LECTIN; CARBOHYDRATE-RECOGNITION DOMAINS; AMINO-ACID-SEQUENCE; VERTEBRATE LECTINS; MAC-2 ANTIGEN; PROTEIN; SPECIFICITY; LAMININ; FAMILY; SITE	S-Lac lectins are a family of soluble lactose-binding animal lectins, some of which have been implicated in modulating cell-cell and cell-matrix interactions through specific carbohydrate-mediated recognition. We report here the x-ray crystal structure of a representative member of this family, the human dimeric S-Lac lectin, L-14-II, in complex with lactose, at 2.9-angstrom resolution. The two-fold symmetric dimer is made up of two extended anti-parallel beta-sheets, which associate in a beta-sandwich motif. Remarkably, the L-14-II monomer shares not only the same topology, but a very similar beta-sheet structure with that of the leguminous plant lectins, suggesting a conserved structure-function relationship. Carbohydrate binding by L-14-II was found to involve protein residues that are very highly conserved among all S-Lac lectins. These residues map to a single DNA exon, suggesting a carbohydrate binding cassette common to all S-Lac lectins.	UNIV TORONTO,INST MOLEC GENET,TORONTO M5S 1A8,ONTARIO,CANADA; RUSSIAN ACAD SCI,INST MOLEC GENET,MOSCOW 123182,RUSSIA; UNIV TORONTO,DEPT MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV CALIF SAN FRANCISCO,LANGLEY PORTER NEUROPSYCHIAT INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MOLEC GENET,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143	University of Toronto; Russian Academy of Sciences; University of Toronto; University of Toronto; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Leffler, Hakon/A-2416-2019	Leffler, Hakon/0000-0003-4482-8945				ABBOTT WM, 1991, J BIOL CHEM, V266, P5552; AHMED H, 1990, BIOCHEMISTRY-US, V29, P5315, DOI 10.1021/bi00474a015; BARONDES SH, 1984, SCIENCE, V223, P1259, DOI 10.1126/science.6367039; BRUNGER AT, 1992, X PLOR MANJUAL VERSI; CERRA RF, 1985, J BIOL CHEM, V260, P10474; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; CHILDS RA, 1990, J BIOL CHEM, V265, P20770; Colin Hughes R., 1992, CURR OPIN STRUC BIOL, V2, P687, DOI 10.1016/0959-440X(92)90202-I; COOPER DNW, 1991, J CELL BIOL, V115, P1437, DOI 10.1083/jcb.115.5.1437; DIAZ CL, 1989, NATURE, V338, P579, DOI 10.1038/338579a0; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; EINSPAHR H, 1986, J BIOL CHEM, V261, P6518; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GITT MA, 1986, P NATL ACAD SCI USA, V83, P7603, DOI 10.1073/pnas.83.20.7603; GITT MA, 1992, J BIOL CHEM, V267, P10601; GITT MA, 1991, BIOCHEMISTRY-US, V30, P82, DOI 10.1021/bi00215a013; GRITZMACHER CA, 1992, BIOCHEMISTRY-US, V31, P9533, DOI 10.1021/bi00155a004; HARRISON FL, 1991, J CELL SCI, V100, P9; HIRABAYASHI J, 1992, J BIOL CHEM, V267, P15485; HIRABAYASHI J, 1991, J BIOL CHEM, V266, P23648; HIRABAYASHI J, 1987, J BIOCHEM-TOKYO, V101, P775, DOI 10.1093/jb/101.3.775; HSU DK, 1992, J BIOL CHEM, V267, P14167; IMBERTY A, 1993, ADV BIOPH C, V0003; JIA SH, 1988, J BIOL CHEM, V263, P6009; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; LAING JG, 1989, J BIOL CHEM, V264, P1907; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LEE RT, 1991, J BIOL CHEM, V266, P4810; LEE RT, 1990, J BIOL CHEM, V265, P7864; LEFFLER H, 1986, J BIOL CHEM, V261, P119; LEFFLER H, 1989, BIOCHEMISTRY-US, V28, P9222, DOI 10.1021/bi00449a039; LEVI G, 1981, J BIOL CHEM, V256, P5735; LOBSANOV YD, 1993, J MOL BIOL, V233, P553, DOI 10.1006/jmbi.1993.1533; MARSCHAL P, 1992, J BIOL CHEM, V267, P12942; MASSA SM, 1993, BIOCHEMISTRY-US, V32, P260, DOI 10.1021/bi00052a033; ODA Y, 1993, J BIOL CHEM, V268, P5929; ODA Y, 1991, GENE, V99, P279; QUIOCHO FA, 1989, PURE APPL CHEM, V61, P1293, DOI 10.1351/pac198961071293; RINI JM, 1993, J BIOL CHEM, V268, P10126; ROSENBERG IM, 1993, J BIOL CHEM, V268, P12393; SATO S, 1992, J BIOL CHEM, V267, P6983; SOLOMON JC, 1991, CARBOHYD RES, V213, P293, DOI 10.1016/S0008-6215(00)90616-5; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WOO HJ, 1990, J BIOL CHEM, V265, P7097; ZHOU Q, 1990, ARCH BIOCHEM BIOPHYS, V281, P27, DOI 10.1016/0003-9861(90)90408-Q	49	275	288	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27034	27038						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262940				2022-12-27	WOS:A1993MM26200032
J	NOTARNICOLA, SM; RICHARDSON, CC				NOTARNICOLA, SM; RICHARDSON, CC			THE NUCLEOTIDE-BINDING SITE OF THE HELICASE-PRIMASE OF BACTERIOPHAGE-T7 - INTERACTION OF MUTANT AND WILD-TYPE PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID REPLICATION INVITRO; NUCLEOSIDE 5'-TRIPHOSPHATASE ACTIVITY; T7 DEOXYRIBONUCLEIC-ACID; DNAB GENE-PRODUCT; ESCHERICHIA-COLI; PHYSICAL-PROPERTIES; PRIMER SYNTHESIS; EXCISION REPAIR; RNA PRIMER; 4 PROTEIN	The helicase and primase activities of bacteriophage T7 are distributed between the 56- and 63-kDa gene 4 proteins. The 63-kDa protein catalyzes both helicase and primase activities. The 56-kDa gene 4 protein lacks the 63 amino acids at the N terminus of the colinear 63-kDa protein and catalyzes only helicase activity. Helicase activity is dependent on the hydrolysis of a nucleoside 5'-triphosphate. Sequence analysis reveals a single ''A-type'' nucleoside 5'-triphosphate binding site near the center of each gene 4 protein. We have examined the essential role of nucleoside triphosphate hydrolysis both in vivo and in vitro by using site-directed mutagenesis to alter the conserved, adjacent Gly and Lys residues within this nucleotide binding site. The mutant gene 4 proteins, expressed from plasmids carrying the cloned genes, do not complement a T7 phage lacking gene 4. Moreover, the mutations are dominant-lethal: they block productive infection by wild-type T7 phage. A nucleotide binding site mutant 56-kDa gene 4 protein, purified to homogeneity from cells over-expressing the gene, binds but lacks the ability to hydrolyze nucleotides and cannot bind to single-stranded DNA. Consequently, this mutant gene 4 protein also lacks helicase activity. The mutant gene 4 proteins inhibit the nucleotide hydrolysis activity of wild-type gene 4 proteins in a stoichiometric manner. The apparent inhibition constant (K(i) = 22 +/- 4.5 nM) of this interaction may reflect the gene 4 oligomer dissociation constant in the presence of nucleotide and single-stranded DNA. Analysis of the inhibition reaction indicates that this is a linear mixed-type inhibition, indicating that the mutant protein binds the wild-type protein to form an inactive complex on single-stranded DNA. Furthermore, the mutant 56-kDa gene 4 protein has the same affinity for both the wild-type 63- and 56-kDa gene 4 proteins, suggesting that there is no preference for the formation of homo-oligomeric complexes. The ability of the mutant proteins to inhibit the activity of the wild-type gene 4 proteins indicates that nucleotide hydrolysis is coordinated and cooperative among the members of the gene 4 protein complex as it binds and translocates on single-stranded DNA.			NOTARNICOLA, SM (corresponding author), HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA.				NIAID NIH HHS [AI-06045] Funding Source: Medline; PHS HHS [1 F32 A108630-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI006045, R01AI006045] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM KI, 1984, BIOCHEMISTRY-US, V23, P1176, DOI 10.1021/bi00301a023; ARAI K, 1981, J BIOL CHEM, V256, P5247; BERNSTEIN JA, 1988, J BIOL CHEM, V263, P14891; BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; FUJIYAMA A, 1981, P NATL ACAD SCI-BIOL, V78, P903, DOI 10.1073/pnas.78.2.903; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; HABER LT, 1991, EMBO J, V10, P2707, DOI 10.1002/j.1460-2075.1991.tb07815.x; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; HILL J, 1979, ANN BOT-LONDON, V43, P449, DOI 10.1093/oxfordjournals.aob.a085655; HUBER HE, 1988, J BIOL CHEM, V263, P13549; HUBER HE, 1988, CANCER CELL, V6, P11; KIM YT, 1992, J BIOL CHEM, V267, P15032; KOLODNER R, 1977, P NATL ACAD SCI USA, V74, P1525, DOI 10.1073/pnas.74.4.1525; KOLODNER R, 1978, J BIOL CHEM, V253, P566; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; MARSZALEK J, 1992, J BIOL CHEM, V267, P19334; MATSON SW, 1985, J BIOL CHEM, V260, P2281; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MENDELMAN LV, 1992, P NATL ACAD SCI USA, V89, P10638, DOI 10.1073/pnas.89.22.10638; MENDELMAN LV, 1993, J BIOL CHEM, V268, P27208; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; MILLER H, 1987, METHOD ENZYMOL, V152, P145; NAKAI H, 1986, J BIOL CHEM, V261, P5217; NAKAI H, 1988, J BIOL CHEM, V263, P9831; PATEL SS, 1992, J BIOL CHEM, V267, P15013; PATEL SS, 1993, J BIOL CHEM, V268, P10668; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4043; ROMANO LJ, 1979, J BIOL CHEM, V254, P476; ROSENBERG AH, 1992, J BIOL CHEM, V267, P15005; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHERZINGER E, 1977, EUR J BIOCHEM, V72, P543, DOI 10.1111/j.1432-1033.1977.tb11278.x; SEELEY TW, 1989, P NATL ACAD SCI USA, V86, P6577, DOI 10.1073/pnas.86.17.6577; SEGEL IH, 1976, BIOCH CALCULATIONS, P246; SHRIMANKAR P, 1992, J BACTERIOL, V174, P7689, DOI 10.1128/JB.174.23.7689-7696.1992; SOKOLOV BP, 1990, NUCLEIC ACIDS RES, V18, P3671, DOI 10.1093/nar/18.12.3671; STUDIER FW, 1969, VIROLOGY, V39, P562, DOI 10.1016/0042-6822(69)90104-4; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; THIAGALINGAM S, 1991, J BIOL CHEM, V266, P11395; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; ZAVITZ KH, 1992, J BIOL CHEM, V267, P6933	56	60	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27198	27207						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262961				2022-12-27	WOS:A1993MM26200056
J	CHA, JH; CHO, YJ; WHITAKER, RD; CARRELL, HL; GLUSKER, JP; KARPLUS, PA; BATT, CA				CHA, JH; CHO, YJ; WHITAKER, RD; CARRELL, HL; GLUSKER, JP; KARPLUS, PA; BATT, CA			PERTURBING THE METAL SITE IN D-XYLOSE ISOMERASE - EFFECT OF MUTATIONS OF HIS-220 ON ENZYME STABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-ISOMERASE; ACTINOPLANES-MISSOURIENSIS; STREPTOMYCES-RUBIGINOSUS; DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; MECHANISM; REFINEMENT; BINDING; ARTHROBACTER; RESOLUTION	The histidine residue at position 220 in the Streptomyces rubiginosus D-xylose isomerase is conserved in all D-xylose isomerases. The three-dimensional structure of D-xylose isomerase reveals that His-220 is part of the octahedral coordination sphere of M2, one of two metal ions (Mn2+) in the active site. This work describes the effects of replacing His-220 with Ser, Glu, Asn, and Lys. The consequences of these amino acid substitutions on enzyme activity, thermostability, and structure were analyzed by kinetic, denaturation, and crystallographic methods. The k(cat) values for H220S, H220N, and H220E are only 0.3-0.5% of the wild-type values, and the K(m) for each of these mutant enzymes increased by 30-40-fold over the wild-type value. The mutant enzyme H220K did not exhibit any measurable activity. Thermal denaturation studies (T(m) values) indicate that the H220S and H220N mutant enzymes are approximately 58-degrees-C less stable than the wild-type enzyme, whereas H220E and H220K are 13-24-degrees-C less stable than the wild-type enzyme. To analyze the molecular basis for this decreased thermostability, the crystal structures of the H220S, H220N, and H220E mutant enzymes complexed with Mn2+ have been determined at 1.95, 1.90, and 1.75 angstrom, respectively. In the H220S structure, a water molecule effectively replaces the Nepsilon-2 atom of the imidazole ring of His-220 and mediates the interaction between Mn2+ at the M2 site and Ser-220. A similar water-mediated interaction between the metal ion and Asn-220 is observed in H220N. No direct or water-mediated interactions between the carboxyl group of Glu-220 and the metal are observed in H220E. Whereas octahedral coordination is maintained for the metal at the M2 site in H220S and H220N, a pentahedral coordination with the metal at the M2 site is observed in H220E. Metal activation measurements support the observation that metal binding is perturbed and is responsible for thermal lability of His-220 mutants.	CORNELL UNIV,DEPT FOOD SCI,413 STOCKING HALL,ITHACA,NY 14853; CORNELL UNIV,MICROBIOL SECT,ITHACA,NY 14853; CORNELL UNIV,SECT BIOCHEM & CELL & MOLEC BIOL,ITHACA,NY 14853; FOX CHASE CANC CTR,INST CANC RES,PHILADELPHIA,PA 19111	Cornell University; Cornell University; Cornell University; Fox Chase Cancer Center				Karplus, Paul/0000-0001-8725-6292	NCI NIH HHS [CA-10925] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA010925] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATT CA, 1990, P NATL ACAD SCI USA, V87, P618, DOI 10.1073/pnas.87.2.618; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1990, XPLOR VERSION 2 1; CALLENS M, 1988, BIOCHEM J, V250, P285, DOI 10.1042/bj2500285; CARRELL HL, 1984, J BIOL CHEM, V259, P3230; CARRELL HL, 1989, P NATL ACAD SCI USA, V86, P4440, DOI 10.1073/pnas.86.12.4440; COLLYER CA, 1990, P NATL ACAD SCI USA, V87, P1362, DOI 10.1073/pnas.87.4.1362; COLLYER CA, 1990, J MOL BIOL, V212, P211, DOI 10.1016/0022-2836(90)90316-E; DANNO G-I, 1970, Agricultural and Biological Chemistry, V34, P1805; DISCHE Z, 1951, J BIOL CHEM, V192, P583; FARBER GK, 1987, PROTEIN ENG, V1, P459, DOI 10.1093/protein/1.6.459; FARBER GK, 1989, BIOCHEMISTRY-US, V28, P7289, DOI 10.1021/bi00444a022; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; HENRICK K, 1987, PROTEIN ENG, V1, P467, DOI 10.1093/protein/1.6.467; HENRICK K, 1989, J MOL BIOL, V208, P129, DOI 10.1016/0022-2836(89)90092-2; JENKINS J, 1992, BIOCHEMISTRY-US, V31, P5449, DOI 10.1021/bi00139a005; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KNOSSOW M, 1986, ACTA CRYSTALLOGR B, V42, P627, DOI 10.1107/S0108768186097628; LAMBEIR AM, 1992, BIOCHEMISTRY-US, V31, P5459, DOI 10.1021/bi00139a006; MRABET NT, 1992, BIOCHEMISTRY-US, V31, P2239, DOI 10.1021/bi00123a005; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; STITES WE, 1991, J MOL BIOL, V221, P7, DOI 10.1016/0022-2836(91)80195-Z; TENEYCK LF, 1977, ACTA CRYSTALLOGR A, V33, P486, DOI 10.1107/S0567739477001211; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; VOLKIN DB, 1989, BIOTECHNOL BIOENG, V33, P1104, DOI 10.1002/bit.260330905; WHITLOW M, 1991, PROTEINS, V9, P153, DOI 10.1002/prot.340090302; WONG HC, 1991, J BACTERIOL, V173, P6849, DOI 10.1128/jb.173.21.6849-6858.1991	30	32	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2687	2694						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300598				2022-12-27	WOS:A1994MV43200051
J	HILL, BC				HILL, BC			MODELING THE SEQUENCE OF ELECTRON-TRANSFER REACTIONS IN THE SINGLE TURNOVER OF REDUCED, MAMMALIAN CYTOCHROME-C-OXIDASE WITH OXYGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLASH-PHOTOLYSIS; ROOM-TEMPERATURE; FLOW-FLASH; HEME-A; INTERMEDIATE; DIOXYGEN; COPPER; CUA; EQUILIBRIUM; ACTIVATION	Single-turnover studies of the reaction of reduced cytochrome oxidase with oxygen has led to a mechanistic model that specifies a linear sequence of electron transfer from cytochrome c to O2 via the four redox active metals of mitochondrial cytochrome oxidase. Fully reduced oxidase initially forms a dioxygen adduct within which two electrons are transferred at a rate of 6 x 10(4) s-1 to form a peroxy adduct. This two-electron step results in single-electron oxidation of cytochrome a3 and cytochrome a. Cytochrome a is then re-reduced by Cu(A) in an intramolecular reaction. Subsequent reoxidation of cytochrome a occurs at a rate nearly 100-fold slower than its initial oxidation. Oxidation of Cu(B) in this sequence has been the most difficult to determine and here is specified as the third electron transfer step. This reaction sequence is unchanged in the presence of tightly bound cytochrome c, although cytochrome c is rapidly oxidized via Cu(A) and cytochrome a. The linear model advanced here has Cu(A) as the acceptor of electrons from cytochrome c, with cytochrome a serving as a bridge to deliver electrons from Cu(A) (and cytochrome c) to the binuclear center, cytochrome a3-Cu(B).	UNIV CALGARY, DEPT BIOL SCI, DIV BIOCHEM, CALGARY T2N 1N4, ALBERTA, CANADA	University of Calgary								BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BLACKMORE RS, 1991, J BIOL CHEM, V266, P19245; BOELENS R, 1982, BIOCHIM BIOPHYS ACTA, V682, P264, DOI 10.1016/0005-2728(82)90107-4; BRUDVIG GW, 1984, J BIOL CHEM, V259, P1001; BRUNORI M, 1983, EMBO J, V2, P2025, DOI 10.1002/j.1460-2075.1983.tb01695.x; CHANCE B, 1977, P NATL ACAD SCI USA, V74, P4777, DOI 10.1073/pnas.74.11.4777; CLORE GM, 1980, BIOCHEM J, V185, P139, DOI 10.1042/bj1850139; DOCKTER ME, 1978, J BIOL CHEM, V253, P311; EINARSDOTTIR O, 1992, P NATL ACAD SCI USA, V89, P6934, DOI 10.1073/pnas.89.15.6934; FERREIRARAJABI L, 1989, BIOCHEMISTRY-US, V28, P8028, DOI 10.1021/bi00446a009; GOODMAN G, 1985, BIOCHEMISTRY-US, V24, P2310, DOI 10.1021/bi00330a028; GRAY HB, 1989, BIOCHEMISTRY-US, V28, P7499, DOI 10.1021/bi00445a001; GREENWOO.C, 1967, J BIOL CHEM, V242, P1782; GREENWOOD C, 1983, BIOCHEM J, V215, P303, DOI 10.1042/bj2150303; HAN S, 1990, P NATL ACAD SCI USA, V87, P8408, DOI 10.1073/pnas.87.21.8408; HILL BC, 1983, BIOCHEM J, V215, P659, DOI 10.1042/bj2150659; HILL BC, 1991, J BIOL CHEM, V266, P2219; HILL BC, 1993, BIOCHEM BIOPH RES CO, V192, P665, DOI 10.1006/bbrc.1993.1466; HILL BC, 1986, BIOCHIM BIOPHYS ACTA, V853, P91, DOI 10.1016/0304-4173(86)90006-6; HOLM L, 1987, EMBO J, V6, P2819, DOI 10.1002/j.1460-2075.1987.tb02578.x; KORNBLATT JA, 1990, BIOCHEMISTRY-US, V29, P9370, DOI 10.1021/bi00492a010; KUBOYAMA M, 1972, J BIOL CHEM, V247, P6375; LAURAEUS M, 1991, EUR J BIOCHEM, V197, P699, DOI 10.1111/j.1432-1033.1991.tb15961.x; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MORGAN JE, 1989, BIOCHEMISTRY-US, V28, P6975, DOI 10.1021/bi00443a030; NILSSON T, 1990, FEBS LETT, V260, P45, DOI 10.1016/0014-5793(90)80062-N; OLIVEBERG M, 1991, BIOCHEMISTRY-US, V30, P7053, DOI 10.1021/bi00243a003; OLIVEBERG M, 1992, BIOCHEMISTRY-US, V31, P3560, DOI 10.1021/bi00129a002; ORII Y, 1984, J BIOL CHEM, V259, P7187; ORII Y, 1988, ANN NY ACAD SCI, V550, P105, DOI 10.1111/j.1749-6632.1988.tb35327.x; ORII Y, 1992, BIOCHEM BIOPH RES CO, V182, P1264, DOI 10.1016/0006-291X(92)91868-Q; PAN LP, 1993, BIOCHEMISTRY-US, V32, P8492, DOI 10.1021/bi00084a014; SANTANA M, 1992, J BIOL CHEM, V267, P10225; SHAPLEIGH JP, 1992, P NATL ACAD SCI USA, V89, P4786, DOI 10.1073/pnas.89.11.4786; VAROTSIS C, 1993, P NATL ACAD SCI USA, V90, P237, DOI 10.1073/pnas.90.1.237; VAROTSIS C, 1990, BIOCHEMISTRY-US, V29, P7357, DOI 10.1021/bi00484a001; WIKSTROM M, 1992, J BIOL CHEM, V267, P10266; WRIGGLESWORTH JM, 1984, BIOCHEM J, V217, P715, DOI 10.1042/bj2170715	38	112	114	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2419	2425						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300568				2022-12-27	WOS:A1994MV43200015
J	LI, BY; RAMAKRISHNAN, S				LI, BY; RAMAKRISHNAN, S			RECOMBINANT HYBRID TOXIN WITH DUAL ENZYMATIC-ACTIVITIES - POTENTIAL USE IN PREPARING HIGHLY EFFECTIVE IMMUNOTOXINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICIN-A-CHAIN; DIPHTHERIA-TOXIN; PSEUDOMONAS EXOTOXIN; ESCHERICHIA-COLI; MONOCLONAL-ANTIBODIES; PROTEIN-SYNTHESIS; FRAGMENT-A; DOMAIN-II; EXPRESSION; CELLS	Bacterial toxins and ribosomal inhibitory proteins isolated from plants are used to prepare tumor-specific cytotoxic conjugates. The ability of these conjugates to kill tumor cells depends on binding, internalization, translocation to cytoplasm, and translation inhibition. Modulation of any one of these processes can improve cytotoxicity. Since bacterial and plant toxins act at a distinct step in translation, a combination of their activities could be more effective. Therefore, a chimeric protein was prepared by genetically fusing the coding region of the ricin A chain (RTA) and the fragment A of diphtheria toxin (DTA). The hybrid protein (RTA-DTA) expressed in bacteria retained the N-glycosidase activity of the RTA and ADP-ribosylation activity of the DTA. The hybrid toxin was more potent than the ricin A chain (11-fold) and the diphtheria toxin (50-fold) in inhibiting cell-free translation. Immunotoxin made with the hybrid toxin was about 100- and 1000-fold more effective than RTA or DTA conjugate, respectively, in inhibiting tumor cell growth in vitro. These results indicate that the hybrid toxin with dual activities could be useful in preparing potent immunotoxins with better anti-tumor cell activity.	UNIV MINNESOTA, DEPT PHARMACOL, 3-249 MILLARD HALL, 435 DELAWARE ST SE, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities					NCI NIH HHS [CA 48068] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048068] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBIERI JT, 1987, INFECT IMMUN, V55, P1647, DOI 10.1128/IAI.55.7.1647-1651.1987; BJORN MJ, 1985, CANCER RES, V45, P1214; BLUM JS, 1991, J BIOL CHEM, V266, P22091; CASELLAS P, 1984, J BIOL CHEM, V259, P9359; CHAUDHARY VK, 1988, P NATL ACAD SCI USA, V85, P2939, DOI 10.1073/pnas.85.9.2939; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COBB PW, 1992, SEMIN HEMATOL, V29, P6; ENDO Y, 1987, J BIOL CHEM, V262, P8128; FRANKEL A, 1989, MOL CELL BIOL, V9, P415, DOI 10.1128/MCB.9.2.415; GILL DM, 1971, J BIOL CHEM, V246, P1492; GLUCK A, 1992, J MOL BIOL, V226, P411, DOI 10.1016/0022-2836(92)90956-K; GREENFIELD L, 1987, SCIENCE, V238, P536, DOI 10.1126/science.3498987; GRIFFIN TW, 1992, J IMMUNOTHER, V11, P12, DOI 10.1097/00002371-199201000-00002; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; JANSEN B, 1993, LEUKEMIA, V7, P290; JOHNSON VG, 1991, INTRACELLULAR TRAFFI; KATZIN BJ, 1991, PROTEINS, V10, P251, DOI 10.1002/prot.340100309; LEWIN B, 1990, GENES, V4, P156; LI BY, 1992, PROTEIN EXPRES PURIF, V3, P386, DOI 10.1016/S1046-5928(05)80040-3; MAY MJ, 1989, EMBO J, V8, P301, DOI 10.1002/j.1460-2075.1989.tb03377.x; MITAMURA T, 1992, J CELL BIOL, V118, P1389, DOI 10.1083/jcb.118.6.1389; MURPHY JR, 1985, CURR TOP MICROBIOL, V118, P235; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; NICHOLLS PJ, 1992, GENETICALLY ENG TOXI, P339; OLSNES S, 1973, BIOCHEMISTRY-US, V12, P3121, DOI 10.1021/bi00740a028; PASTAN I, 1992, ANNU REV BIOCHEM, V61, P331, DOI 10.1146/annurev.bi.61.070192.001555; PEARSON JW, 1989, CANCER RES, V49, P3562; PIRKER R, 1989, CANCER RES, V49, P4791; PRIOR TI, 1992, BIOCHEMISTRY-US, V31, P3555, DOI 10.1021/bi00129a001; RAMAKRISHNAN S, 1992, ANNU REV PHARMACOL, V32, P579; RAMAKRISHNAN S, 1984, SCIENCE, V223, P58, DOI 10.1126/science.6318313; RAMAKRISHNAN S, 1989, CANCER RES, V49, P613; RUTENBER E, 1991, PROTEINS, V10, P240, DOI 10.1002/prot.340100308; STROM TB, 1991, ANN NY ACAD SCI, V636, P233, DOI 10.1111/j.1749-6632.1991.tb33455.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUNG C, 1991, J BIOL CHEM, V266, P14159; UCHIDA T, 1973, J BIOL CHEM, V248, P3845; UCKUN FM, 1993, LEUKEMIA, V7, P341; VANDEURS B, 1986, J CELL BIOL, V102, P37, DOI 10.1083/jcb.102.1.37; VANOOSTERHOUT YVJM, 1992, CANCER RES, V52, P5921; VITETTA ES, 1986, J IMMUNOL, V136, P1880; VIVETTA ES, 1990, J CLIN IMMUNOL, V1, pS15; WILLIAMS DP, 1990, J BIOL CHEM, V265, P11885; YAMAIZUMI M, 1982, P NATL ACAD SCI-BIOL, V79, P461, DOI 10.1073/pnas.79.2.461	45	14	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2652	2658						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300596				2022-12-27	WOS:A1994MV43200047
J	NAGASHIMA, KVP; MATSUURA, K; OHYAMA, S; SHIMADA, K				NAGASHIMA, KVP; MATSUURA, K; OHYAMA, S; SHIMADA, K			PRIMARY STRUCTURE AND TRANSCRIPTION OF GENES ENCODING B870 AND PHOTOSYNTHETIC REACTION-CENTER APOPROTEINS FROM RUBRIVIVAX-GELATINOSUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIUM RHODOPSEUDOMONAS-VIRIDIS; REACTION CENTER POLYPEPTIDES; CAPSULATUS-PUF OPERON; AMINO-ACID SEQUENCE; RHODOBACTER-CAPSULATUS; RHODOCYCLUS-GELATINOSUS; MESSENGER-RNA; RHODOSPIRILLUM-RUBRUM; CYTOCHROME SUBUNIT; SUPEROPERONAL ORGANIZATION	We determined the nucleotide sequence of the puf operon of Rubrivivax gelatinosus formerly called Rdodocyclus gelatinosus), a photosynthetic bacterium belonging to the beta subclass of purple bacteria (proteobacteria). The operon contains two unknown open reading frames (ORFs) in addition to five photosynthetic genes which have been reported in species belonging to the alpha subclass. These genes include pufB, -A, -L, -M, and -C coding for the beta and alpha subunits of the B870 light-harvesting protein and for the L, M, and cytochrome subunits of the reaction center complex, respectively. One (ORF1) of the two unknown ORFs locates immediately upstream of pufB, while the other (ORF2) locates between pufB and pufA. The deduced product of ORF1 is a small basic protein composed of 41 amino acids that did not show homology with any other proteins reported to date. The deduced product of ORF2 was composed of 74 amino acids having a hydrophobic region able to span the membrane and showed homology with the beta subunit of B870. The deduced amino acid sequence of the cytochrome subunit of the reaction center of R. gelatinosus had significant deletions in the possible attachment site to the M subunit compared with that of Rhodopseudomonas viridis. This is consistent with the facilitated dissociation of this subunit observed with detergent treatment in R. gelatinosus. Analysis of RNA from R. gelatinosus showed that the puf operon of this bacterium has two transcripts; the major one is 1 kilobase in length and the minor one is 4 kilobase in length. These two transcripts have the same 5;'-end, and their stoichiometry appeared to be controlled by a putative hairpin structure between pufA and pufL.			NAGASHIMA, KVP (corresponding author), TOKYO METROPOLITAN UNIV,FAC SCI,DEPT BIOL,MINAMIOSAWA 1-1,HACHIOJI,TOKYO 19203,JAPAN.		Nagashima, Kenji V. P./M-2208-2017	Nagashima, Kenji V. P./0000-0002-4526-6625				AGALIDIS I, 1992, BIOCHIM BIOPHYS ACTA, V1098, P201, DOI 10.1016/S0005-2728(05)80337-8; AGALIDIS I, 1990, PHOTOSYNTH RES, V23, P249, DOI 10.1007/BF00034855; ARMSTRONG GA, 1989, MOL GEN GENET, V216, P254, DOI 10.1007/BF00334364; BAUER C, 1993, TRENDS GENET, V9, P56, DOI 10.1016/0168-9525(93)90188-N; BAUER CE, 1991, MOL GEN GENET, V228, P433, DOI 10.1007/BF00260637; BAUER CE, 1988, P NATL ACAD SCI USA, V85, P7074, DOI 10.1073/pnas.85.19.7074; BELANGER G, 1988, J BIOL CHEM, V263, P7639; BELANGER G, 1988, J BIOL CHEM, V263, P7632; BERARD J, 1986, J BIOL CHEM, V261, P82; BLANKENSHIP RE, 1992, PHOTOSYNTH RES, V33, P91, DOI 10.1007/BF00039173; BRUNISHOLZ RA, 1985, BIOL CHEM H-S, V366, P87, DOI 10.1515/bchm3.1985.366.1.87; CLARK WG, 1984, J BACTERIOL, V157, P945, DOI 10.1128/JB.157.3.945-948.1984; COOMBER SA, 1990, MOL MICROBIOL, V4, P977, DOI 10.1111/j.1365-2958.1990.tb00670.x; DAVIS J, 1988, J BACTERIOL, V170, P320, DOI 10.1128/jb.170.1.320-329.1988; DEISENHOFER J, 1989, EMBO J, V8, P2149, DOI 10.1002/j.1460-2075.1989.tb08338.x; FARCHAUS JW, 1990, J BACTERIOL, V172, P977, DOI 10.1128/jb.172.2.977-985.1990; FARCHAUS JW, 1992, EMBO J, V11, P2779, DOI 10.1002/j.1460-2075.1992.tb05345.x; FUKUSHIMA A, 1988, BIOCHIM BIOPHYS ACTA, V933, P399, DOI 10.1016/0005-2728(88)90074-6; HOSHINO Y, 1985, AGR BIOL CHEM TOKYO, V49, P3331, DOI 10.1080/00021369.1985.10867265; INOUYE S, 1983, EMBO J, V2, P87, DOI 10.1002/j.1460-2075.1983.tb01386.x; KILEY PJ, 1987, J BACTERIOL, V169, P742, DOI 10.1128/jb.169.2.742-750.1987; KLUG G, 1987, EMBO J, V6, P3515, DOI 10.1002/j.1460-2075.1987.tb02677.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE JK, 1992, J BACTERIOL, V174, P1158, DOI 10.1128/jb.174.4.1158-1171.1992; LEE JK, 1989, J BIOL CHEM, V264, P19354; LEE JK, 1992, J BACTERIOL, V174, P1146, DOI 10.1128/jb.174.4.1146-1157.1992; LIEBETANZ R, 1991, MOL MICROBIOL, V5, P1459, DOI 10.1111/j.1365-2958.1991.tb00792.x; LILBURN TG, 1992, BIOCHIM BIOPHYS ACTA, V1100, P160; MATSUURA K, 1988, FEBS LETT, V237, P21, DOI 10.1016/0014-5793(88)80163-7; MICHEL H, 1986, EMBO J, V5, P1149, DOI 10.1002/j.1460-2075.1986.tb04340.x; NAGASHIMA KVP, 1993, PHOTOSYNTH RES, V36, P185, DOI 10.1007/BF00033037; NAGASHIMA KVP, 1992, RES PHOTOSYNTHESIS, V1, P365; NITSCHKE W, 1992, BIOCHIM BIOPHYS ACTA, V1100, P49; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; REZNIKOFF WS, 1985, ANNU REV GENET, V19, P355, DOI 10.1146/annurev.ge.19.120185.002035; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SGANGA MW, 1992, CELL, V68, P945, DOI 10.1016/0092-8674(92)90037-D; STANSSENS P, 1986, CELL, V44, P711, DOI 10.1016/0092-8674(86)90837-8; TAYLOR DP, 1983, J BACTERIOL, V154, P580, DOI 10.1128/JB.154.2.580-590.1983; TICHY HV, 1989, J BACTERIOL, V171, P4914, DOI 10.1128/jb.171.9.4914-4922.1989; TICHY HV, 1991, EMBO J, V10, P2949, DOI 10.1002/j.1460-2075.1991.tb07845.x; UILDIZ FH, 1992, MOL MICROBIOL, V6, P2683; WAYNE LG, 1987, INT J SYST BACTERIOL, V37, P463, DOI 10.1099/00207713-37-4-463; WEYER KA, 1987, BIOCHEMISTRY-US, V26, P2909, DOI 10.1021/bi00384a036; WEYER KA, 1987, EMBO J, V6, P2197, DOI 10.1002/j.1460-2075.1987.tb02490.x; WIESSNER C, 1990, J BACTERIOL, V172, P2877, DOI 10.1128/jb.172.6.2877-2887.1990; WILLIAMS JC, 1984, P NATL ACAD SCI-BIOL, V81, P7303, DOI 10.1073/pnas.81.23.7303; WILLIAMS JC, 1983, P NATL ACAD SCI-BIOL, V80, P6505, DOI 10.1073/pnas.80.21.6505; YILDIZ FH, 1991, J BACTERIOL, V173, P4163, DOI 10.1128/jb.173.13.4163-4170.1991; YOUNG DA, 1989, MOL GEN GENET, V218, P1, DOI 10.1007/BF00330558; YOUVAN DC, 1984, CELL, V37, P949, DOI 10.1016/0092-8674(84)90429-X; ZHU YS, 1986, P NATL ACAD SCI USA, V83, P7613, DOI 10.1073/pnas.83.20.7613; ZHU YS, 1986, J BIOL CHEM, V261, P366; ZSEBO KM, 1984, CELL, V37, P937, DOI 10.1016/0092-8674(84)90428-8; ZUBER H, 1991, CHLOROPHYLLS, P627	56	44	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2477	2484						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300574				2022-12-27	WOS:A1994MV43200023
J	JOSHI, B; YAN, RQ; RHOADS, RE				JOSHI, B; YAN, RQ; RHOADS, RE			IN-VITRO SYNTHESIS OF HUMAN PROTEIN-SYNTHESIS INITIATION FACTOR-4-GAMMA AND ITS LOCALIZATION ON 43-S AND 48-S INITIATION-COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-BINDING-PROTEIN; MESSENGER-RNA TRANSLATION; AMINO-ACID-SEQUENCE; WHEAT-GERM; KINASE-C; PHOSPHORYLATION; EIF-4F; IDENTIFICATION; INVOLVEMENT; RECOGNITION	The rate of protein synthesis is controlled in a large number of physiological situations at the stage of 48 S initiation complex formation, a phase that involves the recruitment of mRNA to the 40 S ribosomal subunit. This process is mediated by the eukaryotic initiation factor-4 (eIF-4) group of translation initiation factors consisting of eIF-4E, eIF-4A, eIF-4B, and eIF-4gamma. In order to develop a new tool to study this process, we have produced radiolabeled eIF-4gamma by in vitro transcription and translation. Despite the fact that eIF-4gamma is predicted from the cDNA sequence to be 154 kDa, the major synthetic product migrated on SDS-polyacrylamide gel electrophoresis at 205 kDa. Although this is similar to the migration of the fastest polypeptide of authentic eIF-4gamma (approximately 206 kDa), no products were found to co-migrate with the slowest forms of authentic eIF-4gamma (210-220 kDa), suggesting that these forms derive from extensive modification of the initial polypeptide. The in -vitro product also formed a complex with eIF-4E, as judged by its ability to bind to m7GTP-Sepharose. Sucrose gradient sedimentation studies demonstrated that eIF-4gamma was present on both 43 and 48 S initiation complexes but not 80 S complexes. This supports a model in which free eIF-4E binds to mRNA followed by binding of the eIF-4E-mRNA complex to a 43 S initiation complex already containing eIF-4gamma.	LOUISIANA STATE UNIV, MED CTR, DEPT BIOCHEM & MOLEC BIOL, 1501 KINGS HIGHWAY, SHREVEPORT, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport				Yan, Riqiang/0000-0001-7195-7617	NIGMS NIH HHS [GM20818] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMSON RD, 1988, J BIOL CHEM, V263, P6016; BROWNING KS, 1987, J BIOL CHEM, V262, P11228; CHAUCHEREAU A, 1991, J BIOL CHEM, V266, P18280; CLEMENS M, 1987, TRANSLATION TRANSCRI, P277; COLE JA, 1988, J CELL BIOL, V107, pA547; DUNCAN R, 1987, J BIOL CHEM, V262, P380; EDERY I, 1983, J BIOL CHEM, V258, P1398; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; GRASSER FA, 1991, J VIROL, V65, P3779; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; HIREMATH LS, 1989, J BIOL CHEM, V264, P1132; JACKSON RJ, 1991, NATURE, V353, P14, DOI 10.1038/353014a0; JOSHI B, 1991, BIOCHEM SOC T, V19, P282; JOSHI B, 1992, THESIS U SUSSEX BRIG; JOSHIBARVE S, 1990, J BIOL CHEM, V265, P2979; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LAX S, 1985, P NATL ACAD SCI USA, V82, P330, DOI 10.1073/pnas.82.2.330; LICHTENBERGKRAAG B, 1990, J STRUCT BIOL, V105, P46, DOI 10.1016/1047-8477(90)90097-V; MCMULLIN EL, 1988, BIOCHEM BIOPH RES CO, V153, P925; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MORLEY SJ, 1991, J BIOL CHEM, V266, P4669; NIELSEN DA, 1986, NUCLEIC ACIDS RES, V14, P5936, DOI 10.1093/nar/14.14.5936; PARIS J, 1991, GENE DEV, V5, P1697, DOI 10.1101/gad.5.9.1697; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; RHOADS RE, 1993, PROG NUCLEIC ACID RE, V46, P183, DOI 10.1016/S0079-6603(08)61022-3; RHOADS RE, 1991, TRANSLATION EUKARYOT, P109; RYCHLIK W, 1987, P NATL ACAD SCI USA, V84, P945, DOI 10.1073/pnas.84.4.945; SAFER B, 1989, EUR J BIOCHEM, V186, P1, DOI 10.1111/j.1432-1033.1989.tb15169.x; SAFER B, 1978, J BIOL CHEM, V253, P3384; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; SONENBERG N, 1990, CURR TOP MICROBIOL, V161, P23; THACH RE, 1992, CELL, V68, P177, DOI 10.1016/0092-8674(92)90461-K; TUAZON PT, 1989, J BIOL CHEM, V264, P2773; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WEBB NR, 1984, BIOCHEMISTRY-US, V23, P177, DOI 10.1021/bi00297a001; YAN RQ, 1992, J BIOL CHEM, V267, P23226	43	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2048	2055						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294456				2022-12-27	WOS:A1994MR98800076
J	LEUNG, KY; BETTS, JC; XU, L; NABEL, GJ				LEUNG, KY; BETTS, JC; XU, L; NABEL, GJ			THE CYTOPLASMIC DOMAIN OF THE INTERLEUKIN-1 RECEPTOR IS REQUIRED FOR NUCLEAR FACTOR-KAPPA-B SIGNAL-TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN IMMUNODEFICIENCY VIRUS; NECROSIS-FACTOR-ALPHA; IL-1 RECEPTOR; T-CELLS; EXPRESSION; CLONING; ACTIVATION; PROTEIN	Interleukin-1 (IL-1) plays a central role in mediating immune and inflammatory responses. Binding of IL-1 to the type I 80-kDa receptor results in generation of intracellular signals and activation of the transcription factor NF-kappaB. However, the nature of the signals required to generate NF-kappaB binding activity remains unclear. In this paper, we show that NF-kappaB1 (p50) and RelA (p65) were specifically translocated to the nucleus following activation of intact type I IL-1 receptor (IL-1R). The C-terminal region of the type I IL-1R is required for this effect, and deletion of its cytoplasmic domain abrogates the activation of NF-kappaB by IL-1. These results provide evidence that IL-1 modulates the activity of NF-kappaB through the type I IL-1 receptor and identifies a domain required for signal transduction to this specific transcription factor.	UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,DEPT INTERNAL MED,1150 W MED CTR DR,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT BIOL CHEM,ANN ARBOR,MI 48109	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029179] Funding Source: NIH RePORTER; NIAID NIH HHS [AI29179] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIRD TA, 1986, NATURE, V324, P263, DOI 10.1038/324263a0; CURTIS BM, 1989, P NATL ACAD SCI USA, V86, P3045, DOI 10.1073/pnas.86.9.3045; DOWER SK, 1986, NATURE, V324, P266, DOI 10.1038/324266a0; FREIMUTH WW, 1989, J IMMUNOL, V143, P3064; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GUIDA S, 1992, GENE, V111, P239, DOI 10.1016/0378-1119(92)90693-J; HEGUY A, 1991, CELL GROWTH DIFFER, V2, P311; KRASNOW SW, 1991, CYTOKINE, V3, P372, DOI 10.1016/1043-4666(91)90040-K; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; Sambrook J., 1989, MOL CLONING LABORATO, P31; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SLACK J, 1993, J BIOL CHEM, V268, P2513; ZHANG L, 1994, IN PRESS CYTOKINE	23	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1579	1582						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294399				2022-12-27	WOS:A1994MR98800004
J	KIMURA, K; SAIJO, M; UI, M; ENOMOTO, T				KIMURA, K; SAIJO, M; UI, M; ENOMOTO, T			GROWTH STATE-DEPENDENT AND CELL CYCLE-DEPENDENT FLUCTUATION IN THE EXPRESSION OF 2 FORMS OF DNA TOPOISOMERASE-II AND POSSIBLE SPECIFIC MODIFICATION OF THE HIGHER MOLECULAR-WEIGHT FORM IN THE M-PHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; MITOTIC CHROMOSOMES; LEUKEMIA-CELLS; PHORBOL ESTER; PHOSPHORYLATION; PROLIFERATION; CONDENSATION; LOCALIZATION; EXTRACTS; INVITRO	The fluctuations in the expression of two forms of DNA topoisomerase II, p170 and p180, were examined by immunoblotting during the transition of the growth state and the cell cycle in Swiss 3T3 cells. The level of p170 expression was higher during the exponentially growing phase than in the stationary phase, and the level of p180 did not appear to change when the cells changed the growth state. When quiescent cells were stimulated with serum, the p170 level began to increase at 12 h and reached a maximal level at 24-28 h, corresponding to the G2 phase. In contrast, the level of p180 was almost constant during the cell cycle, and the p180 band became obscure when the number of mitotic cells increased. Immunoblotting of the samples prepared from metaphase-synchronized HeLa cells did not have a p180 band, but did exhibit a band with a higher molecular weight. This band increased and p180 decreased in parallel with the increase in the number of mitotic cells. When the cells exited from the M phase, p180 reappeared and the higher molecular weight band disappeared.	UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; ACKERMAN P, 1988, J BIOL CHEM, V263, P12653; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; AUSTIN CA, 1990, FEBS LETT, V266, P115, DOI 10.1016/0014-5793(90)81520-X; AUSTIN CA, 1993, BIOCHIM BIOPHYS ACTA, V1172, P283, DOI 10.1016/0167-4781(93)90215-Y; BAE YS, 1988, P NATL ACAD SCI USA, V85, P2076, DOI 10.1073/pnas.85.7.2076; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; BRILL SJ, 1987, NATURE, V326, P414, DOI 10.1038/326414a0; CAPRANICO G, 1992, BIOCHIM BIOPHYS ACTA, V1132, P43, DOI 10.1016/0167-4781(92)90050-A; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; CHARRON M, 1990, BIOCHEMISTRY-US, V29, P9531, DOI 10.1021/bi00493a006; CHOW KC, 1987, MOL CELL BIOL, V7, P3119, DOI 10.1128/MCB.7.9.3119; CHUNG TDY, 1989, P NATL ACAD SCI USA, V86, P9431, DOI 10.1073/pnas.86.23.9431; DEVORE RF, 1992, CANCER RES, V52, P2156; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DRAKE FH, 1987, J BIOL CHEM, V262, P16739; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; DUGUET M, 1983, NUCLEIC ACIDS RES, V11, P1059, DOI 10.1093/nar/11.4.1059; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; FAIRMAN R, 1988, BIOCHEMISTRY-US, V27, P560, DOI 10.1021/bi00402a009; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; HECK MMS, 1986, J CELL BIOL, V103, P2569, DOI 10.1083/jcb.103.6.2569; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; HECK MMS, 1989, J BIOL CHEM, V264, P15161; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HSIANG YH, 1988, CANCER RES, V48, P3230; JENKINS JR, 1992, NUCLEIC ACIDS RES, V20, P5587, DOI 10.1093/nar/20.21.5587; KROLL DJ, 1991, J BIOL CHEM, V266, P7957; MARKOVITS J, 1987, CANCER RES, V47, P2050; NEGRI C, 1992, EXP CELL RES, V200, P452, DOI 10.1016/0014-4827(92)90195-E; NELSON WG, 1987, CANCER RES, V47, P3246; NELSON WG, 1986, NATURE, V322, P187, DOI 10.1038/322187a0; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; ROTTMANN M, 1987, EMBO J, V6, P3939, DOI 10.1002/j.1460-2075.1987.tb02735.x; SAHYOUN N, 1986, P NATL ACAD SCI USA, V83, P1603, DOI 10.1073/pnas.83.6.1603; SAIJO M, 1990, BIOCHEMISTRY-US, V29, P583, DOI 10.1021/bi00454a036; SAIJO M, 1992, BIOCHEMISTRY-US, V31, P359, DOI 10.1021/bi00117a007; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SULLIVAN DM, 1986, BIOCHEMISTRY-US, V25, P2248, DOI 10.1021/bi00356a060; TAKANO H, 1991, CANCER RES, V51, P3951; TAUDOU G, 1984, FEBS LETT, V176, P431, DOI 10.1016/0014-5793(84)81212-0; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839; ZINI N, 1992, EXP CELL RES, V200, P460, DOI 10.1016/0014-4827(92)90196-F	50	94	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1173	1176						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288578				2022-12-27	WOS:A1994MR22000064
J	PELUFFO, RD; ROSSI, RC; GARRAHAN, PJ; REGA, AF				PELUFFO, RD; ROSSI, RC; GARRAHAN, PJ; REGA, AF			LOW-AFFINITY ACCELERATION OF THE PHOSPHORYLATION REACTION OF THE NA,K-ATPASE BY ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(NA++K+)-ATPASE; NA+,K+-ATPASE; BINDING; SODIUM; POTASSIUM; KINETICS; KIDNEY; K+	The maximum rate of phosphorylation (r(m)) of a highly purified Na,K-ATPase from red outer medulla of pig kidney was measured at 25-degrees-C as a function of ATP concentration in media with Mg2+, Na+, and no K+. When r(m) was plotted as a function of the concentration of ATP a biphasic response was observed with a hyperbolic component of high affinity (K(m) = 15.7 +/-2.6 muM) and low velocity ((r(m))max = 460 +/- 40 nmol of P(i)/(mg of protein . s)) plus a parabolic component which showed no saturation up to 1000 muM ATP, concentration at which r(m) was 1768.1 +/- 429.6 nmol P(i)/(mg protein.s) (mean +/- S.E.; n = 3). This low affinity effect of ATP on the rate of phosphorylation disappeared when the Na,K-ATPase underwent turnover in medium without K+ suggesting that, like superphosphorylation (Peluffo, R. D., Garrahan, P. J., and Rega, A. F. (1992) J. Biol. Chem. 267, 6596-660 1), it required the enzyme to be at rest. This property of the Na,K-ATPase was not predicted by the Albers-Post reaction scheme. The observed behavior of the enzyme could be simulated by a scheme that involves a resting enzyme (E(r)) functionally different from E1 or E2, which is able to bind three molecules of ATP, one with high and two with low affinity, and that after phosphorylation is converted into the phosphointermediates that are generally considered to participate in the reaction cycle described by Albers and Post.			PELUFFO, RD (corresponding author), FAC FARM & BIOQUIM BUENOS AIRES, INST QUIM & FISICOQUIM BIOL, JUNIN 956, RA-1113 BUENOS AIRES, ARGENTINA.							CAMPOS M, 1992, BIOCHIM BIOPHYS ACTA, V1105, P51, DOI 10.1016/0005-2736(92)90161-E; DAWSON RMC, 1969, DATA BIOCH RES, P426; ESMANN M, 1988, METHOD ENZYMOL, V156, P105; FERDINAND W, 1966, BIOCHEM J, V98, P278, DOI 10.1042/bj0980278; FROEHLICH JP, 1991, SOC GEN PHY, V46, P227; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; JENSEN J, 1984, J PHYSIOL-LONDON, V346, P219, DOI 10.1113/jphysiol.1984.sp015018; JENSEN J, 1983, BIOCHIM BIOPHYS ACTA, V731, P282, DOI 10.1016/0005-2736(83)90020-2; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; KARLISH SJD, 1978, BIOCHIM BIOPHYS ACTA, V527, P115, DOI 10.1016/0005-2744(78)90261-9; KLODOS I, 1985, SODIUM PUMP, P383; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARDH S, 1977, J BIOL CHEM, V252, P633; MARDH S, 1974, BIOCHIM BIOPHYS ACTA, V350, P473, DOI 10.1016/0005-2744(74)90523-3; NORBY JG, 1971, BIOCHIM BIOPHYS ACTA, V233, P104, DOI 10.1016/0005-2736(71)90362-2; PELUFFO RD, 1992, J BIOL CHEM, V267, P6596; ROSSI RC, 1989, BIOCHIM BIOPHYS ACTA, V981, P85, DOI 10.1016/0005-2736(89)90085-0; ROSSI RC, 1993, J BIOL CHEM, V268, P12579; ROSSI RC, 1985, SODIUM PUMP, P443; SKOU JC, 1983, BIOCHIM BIOPHYS ACTA, V746, P101, DOI 10.1016/0167-4838(83)90016-X; SUZUKI K, 1987, J BIOL CHEM, V262, P11752	21	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1051	1056						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288560				2022-12-27	WOS:A1994MR22000045
J	QIN, J; LAMAR, GN; DOU, Y; ADMIRAAL, SJ; IKEDASAITO, M				QIN, J; LAMAR, GN; DOU, Y; ADMIRAAL, SJ; IKEDASAITO, M			H-1-NMR STUDY OF THE SOLUTION MOLECULAR AND ELECTRONIC-STRUCTURE OF ENGINEERED DISTAL MYOGLOBIN HIS(64)(E7) VAL VAL(68)(E11) HIS DOUBLE MUTANT - COORDINATION OF HIS(64)(E11) AT THE 6TH POSITION IN BOTH LOW-SPIN AND HIGH-SPIN STATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; SPERM WHALE MYOGLOBIN; FERRIC MYOGLOBIN; LIGAND-BINDING; HEME-PROTEINS; 1.6-A RESOLUTION; ESCHERICHIA-COLI; BOUND LIGAND; X-RAY; H-1-NMR	A genetically engineered human myoglobin (Mb) in which the distal His, His64(E7), and the distal Val, Val68(E11), are replaced by Val and His, respectively, has been expressed in Escherichia coli, for the purpose of assessing the potential role of a Ell residue in providing a hydrogen bond donor to the coordinated ligand. Molecular modeling indicates that such an interaction is possible. The H-1 NMR spectrum of the ferric form of the double mutant Mb exhibits large hyperfine shifts and strong paramagnetic relaxation for which the temperature dependence of the hyperfine shifts reveals a thermal equilibrium between a low-spin and high-spin state (70, 30% at 25-degrees-C, respectively). Standard sequence specific two-dimensional (2D) NMR assignments of the E and F helical backbones allow the identification of the peptide protons for the proximal His93(F8) and substituted distal His68(Ell). Steady-state nuclear Overhauser effect from these peptide protons locate strongly hyperfine shifted His93(F8) and His68(Ell) side chain protons which dictate that both the imidazole rings are coordinated to the iron. 2D bond correlation and one-dimensional and 2D dipolar correlation experiments locate and assign the resonances for the heme. The pattern of the heme contact shifts in both the low-spin and high-spin state, together with the nature of the temperature dependence of the His93(F8) and His68(E11) resonances, establish that the two His are ligated in the high-spin as well as low-spin forms. The pattern of heme methyl hyperfine shifts in the low-spin state, and the smaller hyperfine shifts for His68(E11) as compared to His93(F8) in the high-spin state, indicate that the axial bond to the distal His68(Ell) is weakened or strained as compared with that for the proximal His93(F8) in both spin states. This weak ligation originates from a tilted iron-His'' bond, the only conformation in which His'' can place its imidazole group sufficiently close to bind to the heme iron in the conventional Mb folding. Not only do these results support the belief that distal His is indispensable for the control of the ligand binding in Mb and hemoglobin, but also reveal the significance of the evolution that the stereochemical disposition of both His64 and Val68 are unique and non-exchangeable for interacting with the bound ligand.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106	Case Western Reserve University	QIN, J (corresponding author), UNIV CALIF DAVIS,DEPT CHEM,DAVIS,CA 95616, USA.		Ikeda-Saito, Masao/A-5992-2008; Ikeda-Saito, Masao/K-2703-2015	Qin, Jun/0000-0002-2647-9270	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016087, R01HL016087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039492] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16087] Funding Source: Medline; NIGMS NIH HHS [GM39492] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLOCATELLI CT, 1993, BIOCHEMISTRY-US, V32, P6041; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN, P40; BAX A, 1984, 2 DIMENSIONAL NMR LI; BERTINI I, 1993, CHEM PHYS LETT, V203, P445, DOI 10.1016/0009-2614(93)85290-5; BERTINI I, 1980, NMR PARAMAGNETIC MOL; BOLOGNESI M, 1989, J MOL BIOL, V205, P529, DOI 10.1016/0022-2836(89)90224-6; BOLOGNESI M, 1990, J MOL BIOL, V213, P621, DOI 10.1016/S0022-2836(05)80249-9; BOLOGNESI M, 1982, J MOL BIOL, V158, P305, DOI 10.1016/0022-2836(82)90435-1; CARVER TE, 1991, BIOCHEMISTRY-US, V30, P4697, DOI 10.1021/bi00233a009; CASE DA, 1979, J MOL BIOL, V132, P343, DOI 10.1016/0022-2836(79)90265-1; CUTNELL JD, 1981, J AM CHEM SOC, V103, P3567, DOI 10.1021/ja00402a053; CUTRUZZOLA F, 1991, FEBS LETT, V282, P281, DOI 10.1016/0014-5793(91)80495-O; EGEBERG KD, 1990, BIOCHEMISTRY-US, V29, P9783, DOI 10.1021/bi00494a004; EMERSON SD, 1990, BIOCHEMISTRY-US, V29, P1545, DOI 10.1021/bi00458a028; EMERSON SD, 1990, BIOCHEMISTRY-US, V29, P1556, DOI 10.1021/bi00458a029; HORI H, 1971, BIOCHIM BIOPHYS ACTA, V251, P227, DOI 10.1016/0005-2795(71)90106-1; IIZUKA T, 1974, BIOCHIM BIOPHYS ACTA, V371, P1, DOI 10.1016/0005-2795(74)90148-2; IKEDASAITO M, 1991, J BIOL CHEM, V266, P23641; IKEDASAITO M, 1992, J BIOL CHEM, V267, P22843; JOHNSON KA, 1989, J MOL BIOL, V207, P459, DOI 10.1016/0022-2836(89)90269-6; KOTTALAM J, 1988, J AM CHEM SOC, V110, P7690, DOI 10.1021/ja00231a018; KURIYAN J, 1986, J MOL BIOL, V192, P123; La Mar G. N., 1979, PORPHYRINS, VIV, P61, DOI DOI 10.1016/B978-0-12-220104-2.50009-0; La Mar G.N, 1979, BIOL APPLICATIONS MA, P305; LAMAR GN, 1990, J BIOL CHEM, V265, P16173; LAMAR GN, 1984, J AM CHEM SOC, V106, P6395, DOI 10.1021/ja00333a050; LAMAR GN, 1983, BIOCHEMISTRY-US, V22, P6239, DOI 10.1021/bi00295a031; LECOMTE JTJ, 1985, BIOCHIM BIOPHYS ACTA, V829, P268, DOI 10.1016/0167-4838(85)90197-9; LEE KB, 1990, BIOCHEMISTRY-US, V29, P9623, DOI 10.1021/bi00493a017; MAYER A, 1974, J MOL BIOL, V86, P749, DOI 10.1016/0022-2836(74)90351-9; MORIKIS D, 1990, J BIOL CHEM, V265, P12143; PEYTON DH, 1991, BIOCHEM BIOPH RES CO, V175, P515, DOI 10.1016/0006-291X(91)91594-3; PHILLIPS SEV, 1981, NATURE, V292, P81, DOI 10.1038/292081a0; PHILLIPS SEV, 1980, J MOL BIOL, V142, P531, DOI 10.1016/0022-2836(80)90262-4; QIN J, 1992, J BIOMOL NMR, V2, P597, DOI 10.1007/BF02192849; QIN J, 1992, J MOL BIOL, V224, P891, DOI 10.1016/0022-2836(92)90456-T; RAJARATHNAM K, 1991, J AM CHEM SOC, V113, P7886, DOI 10.1021/ja00021a010; RAJARATHNAM K, 1992, J AM CHEM SOC, V114, P9048, DOI 10.1021/ja00049a042; RINGE D, 1984, BIOCHEMISTRY-US, V23, P2, DOI 10.1021/bi00296a001; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; Sambrook J, 1989, MOL CLONING LABORATO; SHULMAN RG, 1971, J MOL BIOL, V57, P93, DOI 10.1016/0022-2836(71)90121-5; SMERDON SJ, 1991, BIOCHEMISTRY-US, V30, P6252, DOI 10.1021/bi00239a025; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; UNGER SW, 1985, J MAGN RESON, V61, P448, DOI 10.1016/0022-2364(85)90185-4; VARADARAJAN R, 1989, BIOCHEMISTRY-US, V28, P3771, DOI 10.1021/bi00435a022; VARADARAJAN R, 1985, P NATL ACAD SCI USA, V82, P5681, DOI 10.1073/pnas.82.17.5681; WEBER PC, 1981, J BIOL CHEM, V256, P7702; WU JZ, 1991, BIOCHEMISTRY-US, V30, P2156, DOI 10.1021/bi00222a020; YAMAMOTO Y, 1989, BIOCHIM BIOPHYS ACTA, V996, P187, DOI 10.1016/0167-4838(89)90246-X; YU LPP, 1990, J AM CHEM SOC, V112, P9527, DOI 10.1021/ja00182a012; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	56	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1083	1090						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288565				2022-12-27	WOS:A1994MR22000050
J	SHAH, VK; ALLEN, JR; SPANGLER, NJ; LUDDEN, PW				SHAH, VK; ALLEN, JR; SPANGLER, NJ; LUDDEN, PW			IN-VITRO SYNTHESIS OF THE IRON-MOLYBDENUM COFACTOR OF NITROGENASE - PURIFICATION AND CHARACTERIZATION OF NIFB COFACTOR, THE PRODUCT OF NIFB PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE REDUCTION PROPERTIES; AZOTOBACTER-VINELANDII; KLEBSIELLA-PNEUMONIAE; MEMBRANE-PROTEINS; FIXATION; HOMOCITRATE; MUTANTS; GENES; IDENTIFICATION; DINITROGENASE	The requirement of NIFB activity for the biosynthesis of iron-molybedenum cofactor (FeMo-co) can be satisfied by the addition of the low molecular weight product of NIFB, termed NifB cofactor (NifB-co). NifB-co has been purified to homogeneity by a unique one-step method. Addition of NifB-co into the FeMo-co synthesis system generated nitrogenase activity of 27-32 nmol of ethylene formed/min/nmol of iron. Iron is the only metal detected in the NifB-co. NifB-co-dependent in vitro FeMo-co synthesis is absolutely dependent on the presence of molybdate, homocitrate and active NIFNE protein in the reaction mixture. The cofactor appears to be a small Fe-S cluster synthesized by NIFB, as a precursor of FeMo-co. NifB-co did not display any EPR signal at 4 K in 0-4000 gauss range. A solution of NifB-co is greenish-brown in color, similar to FeMo-co. NifB-co exhibits a broad absorbance between 400 and 700 nm with no distinctive peaks or shoulders. NifB-co is stable to repeated freeze-thaw cycles and is also stable in N-methylformamide, the solvent used for the isolation of FeMo-co. The NifB-co is stable to a 5-min heat treatment at 60-degrees-C. The cofactor is extremely O2-labile, with half-life of less then 15 s in air.	UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53706; UNIV WISCONSIN,COLL AGR & LIFE SCI,CTR STUDIES NITROGEN FIXAT,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [GM35332] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035332, R37GM035332] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RM, 1993, J BIOL CHEM, V268, P23670; BISHOP PE, 1990, ANNU REV PLANT PHYS, V41, P109; BISHOP PE, 1986, SCIENCE, V232, P92, DOI 10.1126/science.232.4746.92; BRIGLE KE, 1987, J BACTERIOL, V169, P1547, DOI 10.1128/jb.169.4.1547-1553.1987; BULEN WA, 1966, P NATL ACAD SCI USA, V56, P979, DOI 10.1073/pnas.56.3.979; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; BURGESS BK, 1990, CHEM REV, V90, P1377, DOI 10.1021/cr00106a002; CHANG YC, 1992, ANAL BIOCHEM, V205, P22, DOI 10.1016/0003-2697(92)90573-P; HAGEMAN RV, 1978, BIOCHEMISTRY-US, V17, P4117, DOI 10.1021/bi00613a002; HAGEMAN RV, 1978, P NATL ACAD SCI USA, V75, P2699, DOI 10.1073/pnas.75.6.2699; Hartzell C R, 1978, Methods Enzymol, V53, P54; HAWKES TR, 1984, BIOCHEM J, V217, P317, DOI 10.1042/bj2170317; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; HOOVER TR, 1989, BIOCHEMISTRY-US, V28, P2768, DOI 10.1021/bi00433a004; HOOVER TR, 1987, NATURE, V329, P855, DOI 10.1038/329855a0; IMPERIAL J, 1989, BIOCHEMISTRY-US, V28, P7796, DOI 10.1021/bi00445a040; IMPERIAL J, 1988, NITROGEN FIXATION 10, P128; JOERGER RD, 1986, J BACTERIOL, V168, P673, DOI 10.1128/jb.168.2.673-682.1986; JOERGER RD, 1988, J BACTERIOL, V170, P1475, DOI 10.1128/jb.170.4.1475-1487.1988; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; MACNEIL T, 1978, J BACTERIOL, V136, P253, DOI 10.1128/JB.136.1.253-266.1978; MADDEN MS, 1990, P NATL ACAD SCI USA, V87, P6517, DOI 10.1073/pnas.87.17.6517; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; NAGATANI HH, 1974, J BACTERIOL, V120, P697, DOI 10.1128/JB.120.2.697-701.1974; PAGANI S, 1991, FEBS LETT, V278, P151, DOI 10.1016/0014-5793(91)80105-C; PAGANI S, 1987, BIOCHEM J, V244, P485, DOI 10.1042/bj2440485; PAUSTIAN TD, 1989, P NATL ACAD SCI USA, V86, P6082, DOI 10.1073/pnas.86.16.6082; RAWLINGS J, 1978, J BIOL CHEM, V253, P1001; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; ROBINSON NC, 1984, BIOCHEMISTRY-US, V23, P6121, DOI 10.1021/bi00320a034; Shah V. K., 1980, Methods in Enzymology, V69, P792, DOI 10.1016/S0076-6879(80)69074-0; Shah V. K., 1988, Nitrogen fixation: Hundred years after. Proceedings of the 7th International Congress on Nitrogen Fixation, Koln (Cologne), FRG, March 13-20, 1988., P115; SHAH VK, 1972, BIOCHIM BIOPHYS ACTA, V256, P498, DOI 10.1016/0005-2728(72)90078-3; SHAH VK, 1973, BIOCHIM BIOPHYS ACTA, V305, P445, DOI 10.1016/0005-2728(73)90190-4; SHAH VK, 1978, BIOCHEM BIOPH RES CO, V81, P232, DOI 10.1016/0006-291X(78)91654-6; SHAH VK, 1986, P NATL ACAD SCI USA, V83, P1636, DOI 10.1073/pnas.83.6.1636; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; SHAH VK, 1973, BIOCHIM BIOPHYS ACTA, V292, P246, DOI 10.1016/0005-2728(73)90269-7; TREMBLAY GY, 1969, J MOL BIOL, V40, P65, DOI 10.1016/0022-2836(69)90296-4; YANG SS, 1982, J BIOL CHEM, V257, P8042; YOCH DC, 1966, J BACTERIOL, V92, P618, DOI 10.1128/JB.92.3.618-622.1966; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754	42	92	91	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1154	1158						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288575				2022-12-27	WOS:A1994MR22000061
J	MIURA, O; NAKAMURA, N; IHLE, JN; AOKI, N				MIURA, O; NAKAMURA, N; IHLE, JN; AOKI, N			ERYTHROPOIETIN-DEPENDENT ASSOCIATION OF PHOSPHATIDYLINOSITOL 3-KINASE WITH TYROSINE-PHOSPHORYLATED ERYTHROPOIETIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; FACTOR-I RECEPTOR; SIGNAL TRANSDUCTION; KINASE-ACTIVITY; EXPRESSION CLONING; CYTOPLASMIC REGION; BETA-RECEPTOR; SH2 DOMAINS; CELL-LINES; PROTEIN	Erythropoietin (Epo) regulates the proliferation and differentiation of erythroid precursors. The Epo receptor (EpoR) belongs to the cytokine receptor family and lacks a tyrosine kinase domain. However, Epo induces tyrosine phosphorylation of cellular substrates including the EpoR. To explore the functional significance of receptor tyrosine phosphorylation, we examined the possible interaction of the receptor with the 85-kDa regulatory subunit (p85) of phosphatidylinositol (PI) 3-kinase. After Epo stimulation, p85 was found to associate with the tyrosine-phosphorylated 72-kDa form of EpoR as well as a 92-kDa phosphotyrosyl protein, and PI 3-kinase activity was detectable in anti-EpoR immunoprecipitates. Anti-EpoR blotting of anti-p85 immunoprecipitates revealed that p85 binds specifically to the 72-kDa form of the EpoR and not to unphosphorylated 66- and 64-kDa forms. Association of p85 with the EpoR was Epo dose- and time-dependent and correlated with tyrosine phosphorylation of the receptor. Consistent with a role for tyrosine phosphorylation of the EpoR, PI 3-kinase did not associate with a mitogenically active receptor mutant that lacked tyrosine-phosphorylation sites in the carboxyl-terminal region. A recombinant fusion protein containing the carboxyl-terminal SH-2 domain of p85 was shown to bind to tyrosine-phosphorylated EpoR in vitro. Taken together, these results indicate that, following Epo stimulation, the EpoR recruits PI 3-kinase to the cell membrane by binding between the carboxyl-terminal SH-2 domain of p85 and the tyrosine-phosphorylated carboxyl-terminal region of the receptor. The association with PI 3-kinase is, however, not required for the growth signal transduction from the EpoR.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital	MIURA, O (corresponding author), TOKYO MED & DENT UNIV, DEPT INTERNAL MED 1, 1-5-45 YUSHIMA, BUNKYO KU, TOKYO 113, JAPAN.			Miura, Osamu/0000-0002-0981-3054				AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DAMEN J, 1992, BLOOD, V80, P1923; DANDREA AD, 1990, J CLIN INVEST, V86, P681, DOI 10.1172/JCI114763; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DANEM JE, 1993, BLOOD, V81, P3204; DECKER SJ, 1993, J BIOL CHEM, V268, P9176; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DUSANTERFOURT I, 1992, J BIOL CHEM, V267, P10670; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FUKUI Y, 1989, ONCOGENE RES, V4, P283; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; IHLE JN, 1990, INT J CELL CLONING, V8, P130, DOI 10.1002/stem.5530080712; IHLE JN, 1993, IN PRESS SEMIN IMMUN; ISFORT RJ, 1988, P NATL ACAD SCI USA, V85, P7982, DOI 10.1073/pnas.85.21.7982; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOURY MJ, 1992, EUR J BIOCHEM, V210, P649, DOI 10.1111/j.1432-1033.1992.tb17466.x; KRANTZ SB, 1991, BLOOD, V77, P419; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; LINNEKIN D, 1992, J BIOL CHEM, V267, P23993; LINNEKIN D, 1992, P NATL ACAD SCI USA, V89, P6237, DOI 10.1073/pnas.89.14.6237; MERIDA I, 1991, J IMMUNOL, V147, P2202; MERIDA I, 1993, J BIOL CHEM, V268, P6765; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIGLIACCIO G, 1989, J CELL BIOL, V109, P833, DOI 10.1083/jcb.109.2.833; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIURA O, 1993, BLOOD, V81, P1739; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; QUELLE DE, 1991, P NATL ACAD SCI USA, V88, P4801, DOI 10.1073/pnas.88.11.4801; QUELLE FW, 1991, J BIOL CHEM, V266, P609; QUELLE FW, 1992, J BIOL CHEM, V267, P17055; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; SHERR CJ, 1991, TRENDS GENET, V7, P398, DOI 10.1016/0168-9525(91)90263-P; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VENKITARAMAN AR, 1992, P NATL ACAD SCI USA, V89, P12083, DOI 10.1073/pnas.89.24.12083; VONSCHU P, 1993, SCIENCE, V260, P88; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706; YOUSSOUFIAN H, 1993, BLOOD, V81, P2223	67	127	127	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					614	620						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276859				2022-12-27	WOS:A1994MR21900097
J	WANG, MY; LIEHR, JG				WANG, MY; LIEHR, JG			IDENTIFICATION OF FATTY-ACID HYDROPEROXIDE COFACTORS IN THE CYTOCHROME P450-MEDIATED OXIDATION OF ESTROGENS TO QUINONE METABOLITES - ROLE AND BALANCE OF LIPID PEROXIDES DURING ESTROGEN-INDUCED CARCINOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-DEETHYLASE ACTIVITY; MALE SYRIAN-HAMSTERS; CUMENE HYDROPEROXIDE; RAT-LIVER; BENZO<A>PYRENE; ESTRADIOL; ENZYMES; DIETHYLSTILBESTROL; 7-ETHOXYRESORUFIN; CHROMATOGRAPHY	Lipid hydroperoxide-supported metabolic redox cycling between diethylstilbestrol (DES) or catecholestrogens and their corresponding quinones has been postulated previously to play a role in estrogen-induced toxicity and carcinogenesis. As part of an examination of this postulate, we investigated (a) the effectiveness of various lipid hydroperoxides as oxidants in microsome-mediated quinone formation, and (b) the dependence of DES oxidation to quinone on lipid hydroperoxide levels in liver and kidney of hamsters. Kinetic analyses of the lipid hydroperoxide-mediated conversion of DES to DES quinone revealed that of the peroxides tested (9Z,11E,13(S))- 13-hydroperoxyoctadecadien-1-oic acid was the most powerful oxidant (V(max) = 10.5 nmol min-1; K(m) = 21.3 muM) followed by (5(S),6E,8Z,11Z,14Z)-5-hydroperoxyeicosatetraen-1-oic acid (V(max) = 1.0 nmol min-1; K(m) 10.0 muM). The other pure fatty acid hydroperoxide isomers or mixtures had a lower affinity for the enzyme (K(m) values ranging from 23.1 to 130 muM) and/or lower maximal velocity (V(max) values ranging from 0.2 to 7.0 nmol min-1). Levels of Z,Z-dienestrol, which arises from spontaneous rearrangement of DES quinone, were not affected in liver of hamsters treated with estradiol implants for 9 days and an injection of 20 mg/kg DES but increased in kidney by 120% over levels observed in animals without implants (5.5 and 12.1 nmol/g of wet tissue, respectively). Z,Z-Dienestrol concentrations correlated directly with lipid hydroperoxide concentrations in liver and kidney of control and estradiol-treated hamsters. The increased conversion of DES to quinone in kidney compared with that in liver was catalyzed by comparable activities of cytochrome P450 IA, the enzyme family catalyzing this oxidation. These results demonstrated that theoxidation of DES to quinone was directly dependent on the lipid hydroperoxide levels in the organ of metabolic conversion in addition to the enzyme activity catalyzing this reaction. The elevated lipid hydroperoxide levels in kidney of estrogen-treated hamsters indicate enhanced estrogen quinone formation and therefore enhanced generation of free radicals by metabolic redox cycling of estrogens in this organ prior to the appearance of malignancy.	UNIV TEXAS,MED BRANCH,DEPT PHARMACOL & TOXICOL,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston					NCI NIH HHS [CA 43233] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043233, R37CA043233] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLAKE RC, 1981, J BIOL CHEM, V256, P2127; BLANK JA, 1987, MOL PHARMACOL, V32, P168; CAPDEVILA J, 1980, ARCH BIOCHEM BIOPHYS, V200, P186, DOI 10.1016/0003-9861(80)90345-8; CAVALIERI E, 1987, BIOCHEM PHARMACOL, V36, P435, DOI 10.1016/0006-2952(87)90347-9; CAVALIERI EL, 1988, BIOCHEM PHARMACOL, V37, P2173, DOI 10.1016/0006-2952(88)90578-3; COON MJ, 1987, J BIOSCIENCE, V11, P35, DOI 10.1007/BF02704655; DIGNAM JD, 1977, BIOCHEMISTRY-US, V16, P1116, DOI 10.1021/bi00625a014; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; GUSTAFSSON JA, 1976, FEBS LETT, V70, P276, DOI 10.1016/0014-5793(76)80774-0; HRYCAY EG, 1976, EUR J BIOCHEM, V61, P43, DOI 10.1111/j.1432-1033.1976.tb09995.x; Kappus H., 1985, OXIDATIVE STRESS, V40, P273, DOI [DOI 10.1016/B978-0-12-642760-8.50016-8, 10.1016/B978-0-12-642760-8.50016-8]; KLOTZ AV, 1984, ANAL BIOCHEM, V140, P138, DOI 10.1016/0003-2697(84)90144-1; LIEHR JG, 1986, J BIOL CHEM, V261, P6865; LIEHR JG, 1983, BIOCHEM PHARMACOL, V32, P3711, DOI 10.1016/0006-2952(83)90139-9; OHISHI N, 1985, BIOCHEM INT, V10, P205; OMURA T, 1964, J BIOL CHEM, V239, P2370; POHL RJ, 1980, ANAL BIOCHEM, V107, P150, DOI 10.1016/0003-2697(80)90505-9; ROY D, 1992, MOL CELL BIOCHEM, V110, P31, DOI 10.1007/BF02385003; ROY D, 1991, CANCER RES, V51, P3882; ROY D, 1988, J BIOL CHEM, V263, P3646; ROY D, 1989, CANCER RES, V49, P1475; ROY D, 1992, ARCH BIOCHEM BIOPHYS, V296, P450, DOI 10.1016/0003-9861(92)90596-O; ROY D, 1991, ARCH BIOCHEM BIOPHYS, V285, P331, DOI 10.1016/0003-9861(91)90368-S; TATEISHI T, 1987, EXP GERONTOL, V22, P103, DOI 10.1016/0531-5565(87)90045-3; TENG JI, 1985, J CHROMATOGR, V350, P445, DOI 10.1016/S0021-9673(01)93550-2; VAZ ADN, 1987, P NATL ACAD SCI USA, V84, P1172, DOI 10.1073/pnas.84.5.1172; VAZ ADN, 1989, OXYGEN RADICALS BIOL, P501; WINTER ML, 1991, J BIOL CHEM, V266, P14446; WONG AKL, 1986, BIOCHEM PHARMACOL, V35, P1583, DOI 10.1016/0006-2952(86)90128-0	29	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					284	291						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276808				2022-12-27	WOS:A1994MR21900051
J	MURASAWA, S; MATSUBARA, H; URAKAMI, M; INADA, M				MURASAWA, S; MATSUBARA, H; URAKAMI, M; INADA, M			REGULATORY ELEMENTS THAT MEDIATE EXPRESSION OF THE GENE FOR THE ANGIOTENSIN-II TYPE-1A RECEPTOR FOR THE RAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHEOCHROMOCYTOMA CELLS; NEGATIVE REGULATION; SUBTYPES; MECHANISMS; PROMOTER; TRANSCRIPTION; SEQUENCES; SKELETAL; ENHANCER; BRAIN	To analyze the mechanism of the cell type-specific expression of rat angiotensin II type 1a receptor (AT1a-R) gene, we isolated the 5'-portion of the gene and identified multiple positive and negative regulatory sequences that regulate its transcription. Primer extension and S1 mapping identified a transcriptional initiation site at 33 (position +1) base pairs (bp) down-stream of TATA sequence. The transcriptional activities of various 5'-deletion mutants of the AT1a-R gene upstream region, fused to the chloramphenicol acetyltransferase (CAT) gene, were examined using rat vascular smooth muscle cells (A10) and glial cells expressing AT1a-R mRNA predominantly or PC12 cells expressing AT2-R and very small amounts of AT1a-R mRNA. A 980-bp 5'-flanking sequence contained at least three positive elements, P1 (-560 to -489), P2 (-331 to -201), and P3 (-201 to -61). P1 and P3 were active in the tested three cells, and P2 was functional only in glial and PC12 cells. In addition to these positive elements, there was negative element, N1 (-489 to -331), which was active only in PC12 cells. These elements, when cotransfected with the AT1a-CAT fusion gene, had competitive effects against its promoter activity. The present study suggests the presence of multiple trans-acting factors that act on these positive and negative cis-acting elements and regulate the cell type-specific expression of the rat AT1a-R gene.	KANSAI MED UNIV,DEPT INTERNAL MED 2,FUMIZONO CHO 1,MORIGUCHI,OSAKA 570,JAPAN	Kansai Medical University								AUSUBEL FM, 1983, CURRENT PROTOCOL MOL; BALLA T, 1991, MOL PHARMACOL, V40, P401; BERNSTEIN KE, 1992, ENDOCR REV, V13, P381, DOI 10.1210/er.13.2.381; BOUVAGNET PF, 1987, MOL CELL BIOL, V7, P4377, DOI 10.1128/MCB.7.12.4377; DEGASPARO M, 1990, J CARDIOVASC PHARM, V16, pS31, DOI 10.1097/00005344-199016004-00008; DUDLEY DT, 1991, MOL PHARMACOL, V40, P360; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; IMLER JL, 1987, MOL CELL BIOL, V7, P2558, DOI 10.1128/MCB.7.7.2558; IWAI N, 1991, BIOCHEM BIOPH RES CO, V177, P299, DOI 10.1016/0006-291X(91)91982-I; LANGFORD K, 1992, BIOCHEM BIOPH RES CO, V183, P1025, DOI 10.1016/S0006-291X(05)80293-1; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; MATSUBARA H, 1990, CIRC RES, V66, P176, DOI 10.1161/01.RES.66.1.176; MATSUBARA H, 1991, J BIOL CHEM, V266, P13324; Miller J. H, 1972, EXPT MOL GENETICS; MIZUNO K, 1992, LIFE SCI, V51, P183; MUGLIA L, 1986, P NATL ACAD SCI USA, V83, P7653, DOI 10.1073/pnas.83.20.7653; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NIR U, 1986, P NATL ACAD SCI USA, V83, P3180, DOI 10.1073/pnas.83.10.3180; OBERMULLER N, 1991, NEUROSCI LETT, V132, P11, DOI 10.1016/0304-3940(91)90420-X; PEACH MJ, 1977, PHYSIOL REV, V57, P313, DOI 10.1152/physrev.1977.57.2.313; PUCELL AG, 1991, ENDOCRINOLOGY, V128, P1947, DOI 10.1210/endo-128-4-1947; Saneto RP., 1987, NEUROCHEMISTRY PRACT, P27; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SPETH RC, 1990, BIOCHEM BIOPH RES CO, V169, P997, DOI 10.1016/0006-291X(90)91993-3; SUMNERS C, 1991, P NATL ACAD SCI USA, V88, P7567, DOI 10.1073/pnas.88.17.7567; SUZUKI J, 1993, CIRC RES, V73, P439, DOI 10.1161/01.RES.73.3.439; TIMMERMANS PBMWM, 1991, TRENDS PHARMACOL SCI, V12, P55, DOI 10.1016/0165-6147(91)90498-H; WEBB ML, 1992, PEPTIDES, V13, P499, DOI 10.1016/0196-9781(92)90081-D; WHITEBREAD S, 1989, BIOCHEM BIOPH RES CO, V163, P284, DOI 10.1016/0006-291X(89)92133-5; WHITEBREAD SE, 1991, BIOCHEM BIOPH RES CO, V181, P1365, DOI 10.1016/0006-291X(91)92089-3	34	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26996	27003						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262935				2022-12-27	WOS:A1993MM26200027
J	TAKEUCHI, M; KURAMOCHI, S; FUSAKI, N; NADA, S; KAWAMURATSUZUKU, J; MATSUDA, S; SEMBA, K; TOYOSHIMA, K; OKADA, M; YAMAMOTO, T				TAKEUCHI, M; KURAMOCHI, S; FUSAKI, N; NADA, S; KAWAMURATSUZUKU, J; MATSUDA, S; SEMBA, K; TOYOSHIMA, K; OKADA, M; YAMAMOTO, T			FUNCTIONAL AND PHYSICAL INTERACTION OF PROTEIN-TYROSINE KINASES FYN AND CSK IN THE T-CELL SIGNALING SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-I; SRC FAMILY GENE; ANTIGEN RECEPTOR; ZETA-CHAIN; INTERLEUKIN-2 PRODUCTION; SH3 DOMAINS; C-SRC; TRANSDUCTION; ACTIVATION; EXPRESSION	The Src-like protein-tyrosine kinase Fyn is associated with T-cell antigen receptor. Transient expression of actively mutated Fyn, having Phe-528 instead of Tyr-528 or Thr-338 instead of Ile-338, in Jurkat T-cells stimulated the serum response element (SRE), 12-O-tetradecanoyl-phorbol-13-acetate response element, cyclic AMP response element, and c-fos promoter. The stimulation of SRE was particularly prominent not only with active Fyn but also with normal (wild-type) Fyn. SRE was also stimulated by both normal and active Lck. Furthermore, normal and active Fyn stimulated transcription from the IL-2 gene promoter when transfected cells were stimulated by concanavalin A plus 12-O-tetradecanoyl-phorbol-13-acetate Under the same conditions, Lck did not stimulate IL-2 promoter unless it was activated by mutation. Interestingly, a mutant Fyn, which has deletions within the SH2 region and so is able to transform chicken embryo fibroblasts, did not stimulate either the c-fos or IL-2 promoter, suggesting the importance of this region in T-cell signaling. Csk, which phosphorylates tyrosine residues in the negative regulatory sites of Src family kinases, down-regulated Fyn- and Lck-mediated stimulation of the serum response element and Fyn-mediated enhancement of IL-2 promoter activity. These data suggest that Fyn and Lck, whose activities are regulated by Csk, are involved in different phases of T-cell activation.	UNIV TOKYO,INST MED SCI,4-6-1 SHIROKANEDAI,MINATO KU,TOKYO 108,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,INST PROT RES,SUITA,OSAKA 565,JAPAN	University of Tokyo; Osaka University; Osaka University			Fusaki, Noemi/U-1628-2019					APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COOKE M P, 1989, New Biologist, V1, P66; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; FUJITA T, 1986, CELL, V46, P401, DOI 10.1016/0092-8674(86)90660-4; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KATAGIRI T, 1989, P NATL ACAD SCI USA, V86, P10064, DOI 10.1073/pnas.86.24.10064; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOYASU S, 1992, J BIOL CHEM, V267, P3375; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUO KX, 1992, MOL CELL BIOL, V12, P4724, DOI 10.1128/MCB.12.10.4724; MANGER B, 1985, J IMMUNOL, V135, P3669; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OHTA M, 1990, JPN J CANCER RES, V81, P440, DOI 10.1111/j.1349-7006.1990.tb02588.x; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; OSHEA JJ, 1991, P NATL ACAD SCI USA, V88, P1741, DOI 10.1073/pnas.88.5.1741; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SEMBA K, 1990, MOL CELL BIOL, V10, P3095, DOI 10.1128/MCB.10.6.3095; SEMBA K, 1990, GENES CANCER, P73; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; UCHIUMI F, 1992, MOL CELL BIOL, V12, P3784, DOI 10.1128/MCB.12.9.3784; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1989, P NATL ACAD SCI USA, V86, P6538, DOI 10.1073/pnas.86.17.6538	54	77	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27413	27419						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262983				2022-12-27	WOS:A1993MM26200082
J	ACHARYA, AS; BOBELIS, DJ; WHITE, SP				ACHARYA, AS; BOBELIS, DJ; WHITE, SP			ELECTROSTATIC MODIFICATION AT THE AMINO TERMINI OF HEMOGLOBIN-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-PROPERTIES; GLYCERALDEHYDE; CYANATE	The structural perturbations of the amino-terminal domains of hemoglobin A resulting from the carbamino adduct formation (a reversible in vivo electrostatic modification reaction) at Val-1(alpha) and Val-1(beta) is expected to be mimicked in the derivatives of HbA reductively alkylated at its alpha-amino terminus with aldehydes containing a negatively charged functional group at their distal end (double-headed reagents). Derivatives of HbA with galacturonic acid linked through alkylamino linkage either to Val-1(alpha) or Val-1(beta) (disubstituted derivatives) as well as to both Val-1(alpha) and Val-1(beta) (tetrasubsituted derivative) have been now prepared. All the three derivatives exhibit normal cooperativity but reduced O2 affinities. The functional consequence of the modification of HbA at its amino termini with D-galacuronic acid has been compared with that of the carboxymethylation of HbA at the same sites. This comparative study suggests that the stereochemistry of the carboxylate ion introduced into beta-cleft of Hb dictates the level of reduction in the O2 affinity of the molecule seen on derivatization. However such a unique stereochemistry of the carboxylate ion of the reagent does not appear to be crucial to lower oxygen affinity when the modification is at the amino terminus of the alpha-chain. The molecular modeling studies demonstrate that the carboxylate ion of the carbamino adduct at the amino terminus of the beta-chain as well as the carboxylate of carboxymethyl group at the same site are in a geometrical orientation that favors the formation of an intrachain ionic interaction with the epsilon-amino group of Lys-82(beta). On the other hand the stereochemistry of a carboxylate ion of galacuronic acid on Val-1(beta) appears to be appropriate to form either an intrachian salt bridge with epsilon-amino group of Ly2-82(beta) of the same chain (intrachain) or alternatively an interchain salt bridge involving the epsilon-amino group of Lys-82(beta) of the trans chain. We speculate that the latter, i.e. trans configuration is favored as a result of the potential of D-galacturonic acid bound to Val-1(beta) to form an additional hydrogen bond with trans His-143(beta).	DNX CORP, PRINCETON FORRESTAL CTR, PRINCETON, NJ 08540 USA	Princeton University	ACHARYA, AS (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MED, DIV HEMATOL, BRONX, NY 10461 USA.				NHLBI NIH HHS [HL-38665] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABOLA EE, 1987, PROTEIN DATA BANK CR, P107; ACHARYA AS, 1983, INT J PEPT PROT RES, V22, P78; ACHARYA AS, 1983, J BIOL CHEM, V258, P2296; ACHARYA AS, 1983, J BIOL CHEM, V258, P3761; ACHARYA AS, 1984, J BIOL CHEM, V259, P4372; ACHARYA AS, 1980, J BIOL CHEM, V255, P1406; ACHARYA AS, 1982, FED PROC, V41, P1174; ACHARYA AS, 1985, J BIOL CHEM, V260, P6039; Benesch R E, 1974, Adv Protein Chem, V28, P211, DOI 10.1016/S0065-3233(08)60231-4; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BUCCI E, 1965, J BIOL CHEM, V240, pP551; BUCCI E, 1989, J BIOL CHEM, V264, P6191; BUCCI E, 1981, METHOD ENZYMOL, V76, P527; CERAMI A, 1971, P NATL ACAD SCI USA, V68, P1180, DOI 10.1073/pnas.68.6.1180; DIDONATO A, 1983, J BIOL CHEM, V258, P1890; FANELLI AR, 1964, ADV PROTEIN CHEM, V19, P73, DOI 10.1016/S0065-3233(08)60189-8; FANTL WJ, 1987, J BIOL CHEM, V262, P12700; HO C, 1992, ADV PROTEIN CHEM, V43, P153, DOI 10.1016/S0065-3233(08)60555-0; KILMARTIN JV, 1973, PHYSIOL REV, V53, P836, DOI 10.1152/physrev.1973.53.4.836; KILMARTIN JV, 1969, NATURE, V222, P1243, DOI 10.1038/2221243a0; MANNING JM, 1991, ADV ENZYMOL RAMB, V64, P55; NIGEN AM, 1974, J BIOL CHEM, V249, P6611; PERUTZ MF, 1978, SCI AM, V239, P92, DOI 10.1038/scientificamerican1278-92; SEETHARAM R, 1986, J CELL BIOCHEM, V30, P87, DOI 10.1002/jcb.240300110; TENEYCK LF, 1976, J MOL BIOL, V100, P3, DOI 10.1016/S0022-2836(76)80029-0; [No title captured]	26	3	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2796	2804						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300612				2022-12-27	WOS:A1994MV43200066
J	UCHIDA, K; KAWAKISHI, S				UCHIDA, K; KAWAKISHI, S			IDENTIFICATION OF OXIDIZED HISTIDINE GENERATED AT THE ACTIVE-SITE OF CU,ZN-SUPEROXIDE DISMUTASE EXPOSED TO H2O2 - SELECTIVE GENERATION OF 2-OXO-HISTIDINE AT THE HISTIDINE-118	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE SUPEROXIDE-DISMUTASE; METAL-CATALYZED OXIDATION; HYDROGEN-PEROXIDE; FREE-RADICALS; DNA; INACTIVATION; PROTEINS; COPPER; FRAGMENTATION; CONVERSION	Inactivation of CuZn-superoxide dismutase (Cu,Zn-SOD) by its own reaction product H2O2 is a well-known phenomenon. Generation of the hydroxyl radical has been a matter of great concern, and the target molecule has been regarded as its own active site histidine residues, whose oxidized forms have not yet been identified (Hodgson, E.K., and Fridovich, I. (1975) Biochemistry 14, 5294-5299). Here we report on the identification of oxidized histidines generated at the active site of Cu,Zn-SOD by reaction with H2O2. When bovine erythrocyte Cu,Zn-SOD (0.5 mg/ml) was treated with 5 mm H2O2 in 50 mm sodium phosphate buffer (pH 7.2), histidine was significantly lost; however, except for a significant increase in aspartate and glutamate, nothing new appeared in the amino acid analysis of oxidized Cu,Zn-SOD. On the other hand, the hydrolysates of oxidized Cu,Zn-SOD involved an unknown product that was detectable by reverse-phase high performance liquid chromatography with electrochemical detection. The product was found to be identical to 2-oxo-histidine that had been discovered as the major oxidation product of histidine and its peptides treated with a copper/ascorbate-free radical generating system. The main product present in the hydrolysate of H2O2-treated Cu,Zn-SOD was 2-oxo-histidine. Approximately 0.66 mol/mol subunit was formed when Cu,Zn-SOD was treated with 5 mM H2O2 for 30 min. Both metal chelators and the hydroxyl radical scavengers only slightly inhibited the 2-oxo-histidine formation (10-39%), suggesting that the active species were produced mainly inside the ligands of the Cu2+ in the enzyme. Trypsin digestion of H2O2-treated Cu,Zn-SOD showed selective reactions at the sequences of Gly24-Lys67 and Thr114-Arg126, in that histidine residues locate at the active center. Two new products derived from those peptides appeared in the tryptic map. Amino acid analysis of both products demonstrated the loss of only histidine. One of them derived from Thr114-Arg126 contained an equimolar amount of 2-oxo-histidine, indicating that His-118 was converted selectively to 2-oxo-histidine; however, another product derived from Gly24-Lys67 contained only 0.085 mol of 2-oxo-histidine/mol of peptide, suggesting that the product is a mixture consisting of unidentified forms of oxidized histidine. Taken together, the present study provided direct evidence that 2-oxo-histidine was generated in the Cu,Zn-SOD exposed to H2O2 and that its generation was selective at histidine 118 of the active site of the enzyme.			UCHIDA, K (corresponding author), NAGOYA UNIV,SCH AGR,FOOD & BIODYNAM LAB,NAGOYA 46401,JAPAN.			Uchida, Koji/0000-0003-3894-5299				AMICI A, 1989, J BIOL CHEM, V264, P3341; BLECH DM, 1983, ARCH BIOCHEM BIOPHYS, V224, P579, DOI 10.1016/0003-9861(83)90245-X; BRAY RC, 1974, BIOCHEM J, V139, P43, DOI 10.1042/bj1390043; Floyd R A, 1986, Free Radic Res Commun, V1, P163, DOI 10.3109/10715768609083148; FLOYD RA, 1986, BIOCHEM BIOPH RES CO, V137, P841, DOI 10.1016/0006-291X(86)91156-3; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; GETZOFF ED, 1983, NATURE, V306, P287, DOI 10.1038/306287a0; HALLIWELL B, 1985, MOL ASPECTS MED, V8, P89, DOI 10.1016/0098-2997(85)90001-9; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849; KASAI H, 1987, CARCINOGENESIS, V8, P1959, DOI 10.1093/carcin/8.12.1959; KASAI H, 1986, ENVIRON HEALTH PERSP, V67, P111, DOI 10.2307/3430324; KATO Y, 1992, J BIOL CHEM, V267, P23646; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE RL, 1981, P NATL ACAD SCI-BIOL, V78, P2120, DOI 10.1073/pnas.78.4.2120; OOKAWARA T, 1992, J BIOL CHEM, V267, P18505; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; SALO DC, 1990, J BIOL CHEM, V265, P11919; SATO K, 1992, J BIOL CHEM, V267, P25371; SHIGENAGA MK, 1989, P NATL ACAD SCI USA, V86, P9697, DOI 10.1073/pnas.86.24.9697; STADTMAN ER, 1986, TRENDS BIOCHEM SCI, V11, P11, DOI 10.1016/0968-0004(86)90221-5; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; STEINMAN HM, 1974, J BIOL CHEM, V249, P7326; STEWART LC, 1987, BIOCHEMISTRY-US, V26, P5302, DOI 10.1021/bi00391a013; TAINER JA, 1983, NATURE, V306, P284, DOI 10.1038/306284a0; UCHIDA K, 1990, BIOCHEM BIOPH RES CO, V169, P265, DOI 10.1016/0006-291X(90)91463-3; UCHIDA K, 1990, ARCH BIOCHEM BIOPHYS, V283, P20, DOI 10.1016/0003-9861(90)90606-Y; UCHIDA K, 1986, BIOCHEM BIOPH RES CO, V138, P659, DOI 10.1016/S0006-291X(86)80547-2; UCHIDA K, 1989, BIOORG CHEM, V17, P334; YIM MB, 1993, J BIOL CHEM, V268, P4099	33	198	203	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2405	2410						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300566				2022-12-27	WOS:A1994MV43200013
J	CASEY, WM; GIBSON, KJ; PARKS, LW				CASEY, WM; GIBSON, KJ; PARKS, LW			COVALENT ATTACHMENT OF PALMITOLEIC ACID (C16-1 DELTA(9)) TO PROTEINS IN SACCHAROMYCES-CEREVISIAE - EVIDENCE FOR A 3RD CLASS OF ACYLATED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; ALPHA-SUBUNIT; TERMINUS; CELLS	Saccharomyces cerevisiae was used as a model system to characterize the covalent attachment of palmitoleic acid to proteins. Chemically synthesized cis-[9,10-H-3]hexadecenoic acid (palmitoleic acid) was used to demonstrate the attachment of this lipid species to at least six proteins (m = 122, 58, 45, 41, 31, and 17 kDa). The majority of the labeled proteins are distinct from those labeled with [H-3]palmitic acid (16:0). Based on the lability of the bond in the presence of methanolic KOH or hydroxylamine (pH 8), we propose that [H-3] palmitoleic acid is attached to proteins via a thioester linkage. The identity of the palmitoleic acid was established by C-18 reverse phase high performance thin layer chromatography and argentation thin layer chromatography analysis after the fatty acid was liberated from the proteins by either transesterification or saponification. Incorporation of [H-3]palmitoleic acid into proteins was only slightly inhibited (relative to [H-3] myristic acid) by the presence of cycloheximide, indicating that the attachment of [H-3]palmitoleic acid occurs post-translationally. This report is the first description of multiprotein acylation by a long chain unsaturated fatty acid.	DUPONT CO INC,EXPTL STN,WILMINGTON,DE 19880	DuPont	CASEY, WM (corresponding author), N CAROLINA STATE UNIV,DEPT MICROBIOL,RALEIGH,NC 27695, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037222] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 37222] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMES DE, 1963, J CHEM SOC, P775, DOI 10.1039/jr9630000775; BUSS JE, 1986, MOL CELL BIOL, V6, P116, DOI 10.1128/MCB.6.1.116; CASABIELL X, 1991, BIOCHEM J, V278, P679, DOI 10.1042/bj2780679; CASEY WM, 1993, BIOCHEM BIOPH RES CO, V193, P1297, DOI 10.1006/bbrc.1993.1766; CASEY WM, 1992, J BACTERIOL, V174, P7283, DOI 10.1128/jb.174.22.7283-7288.1992; CHEN ZQ, 1985, J VIROL, V56, P607, DOI 10.1128/JVI.56.2.607-612.1985; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JENIS DM, 1987, LEUKEMIA RES, V11, P935, DOI 10.1016/0145-2126(87)90139-1; KAUFMAN JF, 1984, J BIOL CHEM, V259, P7230; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIDER ME, 1991, J BIOL CHEM, V266, P4654; MAGEE AI, 1984, BIOCHIM BIOPHYS ACTA, V798, P156, DOI 10.1016/0304-4165(84)90298-8; MAGEE AI, 1985, EMBO J, V4, P1137, DOI 10.1002/j.1460-2075.1985.tb03751.x; MORRIS LJ, 1962, CHEM IND-LONDON, P1238; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; STRAUCH MA, 1992, MOL MICROBIOL, V6, P2909, DOI 10.1111/j.1365-2958.1992.tb01750.x; STUKEY JE, 1989, J BIOL CHEM, V264, P16537; TOWLER DA, 1988, ANN REV BIOCH, V57, P5382; VINCENZINI MT, 1983, INT J BIOCHEM, V15, P1283, DOI 10.1016/0020-711X(83)90220-3; WILCOX C, 1987, SCIENCE, V238, P1275, DOI 10.1126/science.3685978	23	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2082	2085						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294460				2022-12-27	WOS:A1994MR98800081
J	DESILVA, HV; LAUER, SJ; WANG, JJ; SIMONET, WS; WEISGRABER, KH; MAHLEY, RW; TAYLOR, JM				DESILVA, HV; LAUER, SJ; WANG, JJ; SIMONET, WS; WEISGRABER, KH; MAHLEY, RW; TAYLOR, JM			OVEREXPRESSION OF HUMAN APOLIPOPROTEIN-C-III IN TRANSGENIC MICE RESULTS IN AN ACCUMULATION OF APOLIPOPROTEIN-B48 REMNANTS THAT IS CORRECTED BY EXCESS APOLIPOPROTEIN-E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE-RICH LIPOPROTEINS; LOW-DENSITY LIPOPROTEINS; RELEASABLE LIVER LIPASE; AMINO-ACID SEQUENCE; A-I; HEPATIC-UPTAKE; APO-CIII; BONE-MARROW; GENE; RAT	Overexpression of human apolipoprotein (apo) C-III in the plasma of transgenic mice results in hypertriglyceridemia, with up to a 20-fold elevation in plasma triglyceride. Nearly all of the triglyceride accumulates in the d < 1.006 g/ml lipoprotein fraction, which consists predominantly of apoB48-containing particles having a low apoE:apoB48 ratio in contrast to normal mice. The transgenic and nontransgenic d < 1.006 g/ml lipoproteins are similar in size, and they are equivalent substrates for lipoprotein lipase in vitro. Total apoB100 levels are similar in transgenic and normal plasma, but apoB48 levels are increased in transgenic mice. The transgenic d < 1.006 g/ml particles are poor competitors for the binding of low density lipoproteins to the low density lipoprotein receptor in vitro, which is corrected by the addition of exogenous apoE. The rate of clearance of labeled chylomicron remnants in apoC-III-transgenic mice was about half that in nontransgenic mice. The lipoprotein alterations are accompanied by up to a 5-fold increase in circulating nonesterified fatty acids, which may be the cause of fatty livers and increased liver triglyceride production also observed in the transgenic mice. These observations indicate that the primary defect leading to hypertriglyceridemia in apoC-III overexpressers is an impaired clearance of apoB48 remnants due to apoE insufficiency. Therefore, transgenic mice that overexpressed human apoE were cross-bred with the apoC-III overexpressers. Transgenic progeny that produced both human apoE and human apoC-III had normal levels of plasma triglyceride and normal amounts of apoB48 remnants. Thus, our studies suggest that a function of apoC-III is to modulate the apoE-mediated clearance of lipoproteins, and that the concentration of apoC-III relative to apoE is a key determinant of triglyceride levels in plasma.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,POB 4191000,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [HL41633, HL37063, HL08416] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037063, F32HL008416, P01HL041633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; BREWER HB, 1974, J BIOL CHEM, V249, P4975; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; BROWN WV, 1972, BIOCHEM BIOPH RES CO, V46, P375; CURRY MD, 1980, BIOCHIM BIOPHYS ACTA, V617, P503, DOI 10.1016/0005-2760(80)90016-8; DESILVA HV, 1992, CIRCULATION, V86, P1; ELOVSON J, 1981, P NATL ACAD SCI-BIOL, V78, P157, DOI 10.1073/pnas.78.1.157; ELSHOURBAGY NA, 1986, J BIOL CHEM, V261, P1998; FEIGELSON E, 1961, J CLIN INVEST, V40, P2171, DOI 10.1172/JCI104443; GILMAN M, 1990, CURRENT PROTOCOLS MO, V1; GINSBERG HN, 1986, J CLIN INVEST, V78, P1287, DOI 10.1172/JCI112713; GOLDBERG IJ, 1982, J CLIN INVEST, V70, P1184, DOI 10.1172/JCI110717; GROSSER J, 1981, J LIPID RES, V22, P437; HAMILTON RL, 1968, 1968 P DEUEL C LIP T, P3; HUSSAIN MM, 1989, J BIOL CHEM, V264, P9571; HUSSAIN MM, 1989, J BIOL CHEM, V264, P17931; Innerarity T L, 1986, Methods Enzymol, V129, P542; INNERARITY TL, 1978, BIOCHEMISTRY-US, V17, P1440, DOI 10.1021/bi00601a013; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; JANSEN H, 1980, BIOCHEM BIOPH RES CO, V92, P53, DOI 10.1016/0006-291X(80)91518-1; KARATHANASIS SK, 1983, NATURE, V301, P718, DOI 10.1038/301718a0; KARATHANASIS SK, 1985, J LIPID RES, V26, P451; KASHYAP ML, 1981, J LIPID RES, V22, P800; KINNUNEN PKJ, 1976, FEBS LETT, V65, P354, DOI 10.1016/0014-5793(76)80145-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUER SJ, 1988, J BIOL CHEM, V263, P7277; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1982, MED CLIN N AM, V66, P375, DOI 10.1016/S0025-7125(16)31426-2; MAHLEY RW, 1983, BIOCHIM BIOPHYS ACTA, V737, P197, DOI 10.1016/0304-4157(83)90001-1; NORUM RA, 1982, NEW ENGL J MED, V306, P1513, DOI 10.1056/NEJM198206243062503; REES A, 1983, LANCET, V1, P444; SCHONFELD G, 1979, METABOLISM, V28, P1001, DOI 10.1016/0026-0495(79)90004-0; SHELBURNE F, 1980, J CLIN INVEST, V65, P652, DOI 10.1172/JCI109710; SHOULDERS CC, 1991, ATHEROSCLEROSIS, V87, P239, DOI 10.1016/0021-9150(91)90026-Y; SIMONET WS, 1991, ARTERIOSCLER THROMB, V11, pA1391; THUREN T, 1991, BIOCHIM BIOPHYS ACTA, V1083, P217, DOI 10.1016/0005-2760(91)90046-K; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANTOL A, 1980, BIOCHEM BIOPH RES CO, V94, P101, DOI 10.1016/S0006-291X(80)80193-8; VONECKARDSTEIN A, 1991, J CLIN INVEST, V87, P1724, DOI 10.1172/JCI115190; WANG CS, 1985, J CLIN INVEST, V75, P384, DOI 10.1172/JCI111711; WINDLER E, 1980, J BIOL CHEM, V255, P8303; WINDLER E, 1980, J BIOL CHEM, V255, P5475; WINDLER E, 1985, J LIPID RES, V26, P556	43	191	200	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2324	2335						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294490				2022-12-27	WOS:A1994MR98800114
J	IZZO, NJ; TULENKO, TN; COLUCCI, WS				IZZO, NJ; TULENKO, TN; COLUCCI, WS			PHORBOL ESTERS AND NOREPINEPHRINE DESTABILIZE ALPHA(1B)-ADRENERGIC RECEPTOR MESSENGER-RNA IN VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ALPHA-ADRENERGIC RECEPTOR; ALPHA-1-ADRENERGIC RECEPTOR; GENE-EXPRESSION; CALCIUM EFFLUX; STIMULATION; INCREASES; CA-2+; MECHANISMS; ACTIVATION	The mechanism by which norepinephrine (NE) down-regulates alpha1B-adrenergic receptor (alpha-AR) mRNA was studied in rabbit aortic smooth muscle cells. NE, phorbol esters, and bradykinin each decreased alpha-AR mRNA levels by 70-80%. The protein kinase C inhibitor (+)-1-5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride (H-7) abolished the effects of phorbol esters and NE and decreased basal mRNA levels by 52 +/- 3%. Neither ryanodine nor EGTA inhibited down-regulation of alpha-AR mRNA by NE. Actinomycin D caused alpha-AR mRNA level to decrease with a half-life of 3.2 +/- 0.4 h and blocked the effect of H-7 to decrease basal alpha-AR mRNA level. Both NE and phorbol esters increased the rate of alpha-AR mRNA degradation. In NE-desensitized cells, phorbol esters and bradykinin each caused the expected down-regulation of alpha-AR mRNA. The protein phosphatase inhibitor okadaic acid prolonged the normally transient effect of NE for at least 24 h. We conclude that protein kinase C exerts two opposing effects on alpha-AR mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a protein kinase C substrate and 2) a permissive effect on alpha-AR gene transcription.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOVASC, 75 FRANCIS ST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; MED COLL PENN, DEPT PHYSIOL, PHILADELPHIA, PA 19129 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Drexel University				Izzo, Nicholas/0000-0002-0196-2055; Colucci, Wilson/0000-0002-0576-9420	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008324, R01HL030496] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL08324, HL425309, HL30496] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER RW, 1985, HYPERTENSION, V7, P447, DOI 10.1161/01.HYP.7.3.447; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BLAES N, 1983, J CELL PHYSIOL, V116, P167, DOI 10.1002/jcp.1041160207; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; COLUCCI WS, 1986, P NATL ACAD SCI USA, V83, P1743, DOI 10.1073/pnas.83.6.1743; COLUCCI WS, 1981, CIRC RES, V48, P104, DOI 10.1161/01.RES.48.1.104; COLUCCI WS, 1986, CIRC RES, V58, P393, DOI 10.1161/01.RES.58.3.393; COLUCCI WS, 1985, MOL PHARMACOL, V27, P517; COLUCCI WS, 1988, BIOCHEM BIOPH RES CO, V156, P924, DOI 10.1016/S0006-291X(88)80932-X; COLUCCI WS, 1908, CLIN RES, V36, pA269; COTECCHIA S, 1985, LIFE SCI, V37, P2389, DOI 10.1016/0024-3205(85)90106-7; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; EXTON JH, 1988, FASEB J, V2, P2670, DOI 10.1096/fasebj.2.11.2456243; FISH RD, 1988, CIRC RES, V62, P1049, DOI 10.1161/01.RES.62.5.1049; GRIENDLING KK, 1986, J BIOL CHEM, V261, P5901; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HISAYAMA T, 1990, BRIT J PHARMACOL, V100, P677, DOI 10.1111/j.1476-5381.1990.tb14075.x; HU ZW, 1993, J BIOL CHEM, V268, P3610; HWANG KS, 1987, PFLUG ARCH EUR J PHY, V408, P343, DOI 10.1007/BF00581127; IZZO NJ, 1990, P NATL ACAD SCI USA, V87, P6268, DOI 10.1073/pnas.87.16.6268; LEE RT, 1988, J CLIN INVEST, V81, P431, DOI 10.1172/JCI113337; MAJESKY MW, 1990, J BIOL CHEM, V265, P1082; MINNEMAN KP, 1988, PHARMACOL REV, V40, P87; MORRIS GM, 1991, J BIOL CHEM, V266, P2233; NAKAKI T, 1990, MOL PHARMACOL, V37, P30; RASMUSSEN H, 1987, FASEB J, V1, P177, DOI 10.1096/fasebj.1.3.3040504; SEI CA, 1991, J BIOL CHEM, V266, P15910; TSUJIMOTO G, 1987, CIRC RES, V61, P86, DOI 10.1161/01.RES.61.1.86; WIKBERG JES, 1983, LIFE SCI, V33, P1409, DOI 10.1016/0024-3205(83)90824-X	30	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1705	1710						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294418				2022-12-27	WOS:A1994MR98800028
J	MANO, H; MORI, R; OZAWA, T; TAKEYAMA, K; YOSHIZAWA, Y; KOJIMA, R; ARAO, Y; MASUSHIGE, S; KATO, S				MANO, H; MORI, R; OZAWA, T; TAKEYAMA, K; YOSHIZAWA, Y; KOJIMA, R; ARAO, Y; MASUSHIGE, S; KATO, S			POSITIVE AND NEGATIVE REGULATION OF RETINOID X-RECEPTOR GENE-EXPRESSION BY THYROID-HORMONE IN THE RAT - TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL CONTROLS BY THYROID-HORMONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ESTROGEN RESPONSE ELEMENT; MESSENGER-RNA; ACID RECEPTORS; BETA; SUPERFAMILY; STABILITY; CLONING; MEDIATE; LIGAND; ALPHA	The 9-cis-retinoic acid receptors (RXRs), belonging to the members of the steroid/thyroid hormone receptor superfamily, act as auxiliary proteins, heterodimerizing with other nuclear receptors such as retinoic acid receptors (RARs), vitamin D receptor, thyroid hormone receptors, and peroxisome-proliferator activated receptor, thereby transactivating target genes in a ligand-dependent manner. We have previously reported that in the rat, thyroid hormone (TH) positively and negatively regulates the hepatic mRNA levels of RXRbeta and RXRgamma, respectively. In the present study, we have tried to elucidate the level at which TH regulates the gene expression of RXRbeta and RXRgamma in the rat. A RNA synthesis inhibitor (actinomycin D), but not a protein synthesis inhibitor (cycloheximide), blocked the induction of RXRbeta mRNA by TH. On the other hand, none of these drugs inhibited the decrease of RXRgamma mRNA levels caused by TH. Nuclear run-on assays showed that the transcription rate of the RXRbeta gene was positively regulated by TH, whereas the transcription of RXRgamma gene was not controlled by TH. Taken together, these results indicate that the gene expression of RXRbeta is positively regulated by TH at transcriptional level, while the negative regulation of the RXRgamma gene expression by TH may occur at a post-transcriptional level in intact rat. Thus, the RXR-mediated signal transductions may be modulated in part through TH control of the levels of RXRbeta and RXRgamma.	TOKYO UNIV AGR, FAC AGR, DEPT AGR CHEM, SETAGAYA KU, TOKYO 156, JAPAN	Tokyo University of Agriculture			Arao, Yukitomo/AAL-1665-2021	Arao, Yukitomo/0000-0003-1560-351X				ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BELLARD M, 1989, METHOD ENZYMOL, V170, P317; BODENNER DL, 1991, J BIOL CHEM, V266, P21666; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HALLENBECK PL, 1993, J BIOL CHEM, V268, P3825; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KATO S, 1992, BIOCHEM J, V286, P755, DOI 10.1042/bj2860755; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KRANE IM, 1991, MOL ENDOCRINOL, V5, P469, DOI 10.1210/mend-5-4-469; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MANO H, 1993, BIOCHEM BIOPH RES CO, V191, P943, DOI 10.1006/bbrc.1993.1308; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NIELSEN DA, 1990, MOL ENDOCRINOL, V4, P953, DOI 10.1210/mend-4-7-953; NINOMIYA Y, 1992, BIOCHEM BIOPH RES CO, V187, P1374, DOI 10.1016/0006-291X(92)90454-S; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; RIEGEL AT, 1987, MOL ENDOCRINOL, V1, P160, DOI 10.1210/mend-1-2-160; ROSEN ED, 1992, J BIOL CHEM, V267, P22010; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	28	67	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1591	1594						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294402				2022-12-27	WOS:A1994MR98800007
J	TILLOTSON, LG; WANG, TC; BRAND, SJ				TILLOTSON, LG; WANG, TC; BRAND, SJ			ACTIVATION OF GASTRIN TRANSCRIPTION IN PANCREATIC INSULINOMA CELLS BY A CACC PROMOTER ELEMENT AND A 70-KDA SEQUENCE-SPECIFIC DNA-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; GENE-TRANSCRIPTION; ISLET CELL; ENHANCER-BINDING; CONTROL REGION; GLUCAGON GENE; EXPRESSION; UPSTREAM; IDENTIFICATION; DOMAINS	Gastrin gene expression in the pancreatic islets is developmentally regulated and occurs largely during fetal life. Deletional analysis of transiently transfected rat insulinoma cells with gastrin 5'-flanking sequences in luciferase reporter genes demonstrated that the gastrin promoter sequence proximal to -111 base pairs (bp) contains the cis-regulatory elements necessary for maximal transcription. Mutational analysis identified the sequence CCCCACCCCA (-109 to -100 bp) as a positive cis-regulatory element (CACC) located 5' to a previously described negative element (-100 to -90 bp) and E-box positive element at -82 bp. Multimers of the CACC element in a heterologous promoter activated transcription independent of the other cis-regulatory elements. CACC binding proteins were purified from insulinoma cell nuclear extracts by cation exchange and affinity chromatography. Southwestern blot of nuclear extracts identified a 70-kDa CACC-binding protein. Mutational analysis of the CACC element showed a close correlation between DNA binding of this protein and transcriptional activation. Transcriptional activation by multimers of the CACC element in a heterologous promoter was detected in a variety of cell lines but was strongest in those of islet lineage. Likewise, the presence of the 70-kDa CACC-binding protein was found in many cell lines but was most abundant in the insulinoma cells. The CACC-binding protein has not been previously identified among the known pancreatic regulatory factors and may have an important role in the developmental expression of gastrin.	MASSACHUSETTS GEN HOSP, DEPT MED, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	TILLOTSON, LG (corresponding author), MASSACHUSETTS GEN HOSP, GASTROINTESTINAL UNIT, JACKSON 7, BOSTON, MA 02114 USA.				NIDDK NIH HHS [DK42147] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042147] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDRISANI OM, 1988, MOL CELL BIOL, V8, P1947, DOI 10.1128/MCB.8.5.1947; BACHWICH D, 1992, MOL ENDOCRINOL, V6, P1175, DOI 10.1210/me.6.8.1175; BARDRAM L, 1990, P NATL ACAD SCI USA, V87, P298, DOI 10.1073/pnas.87.1.298; BASSELDUBY R, 1992, MOL CELL BIOL, V12, P5024, DOI 10.1128/MCB.12.11.5024; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND SJ, 1984, NATURE, V309, P456, DOI 10.1038/309456a0; BRAND SJ, 1988, J BIOL CHEM, V263, P5341; BRAND SJ, 1988, J BIOL CHEM, V263, P16597; CROWE DT, 1989, MOL CELL BIOL, V9, P1784, DOI 10.1128/MCB.9.4.1784; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DEBOER E, 1988, EMBO J, V7, P4203, DOI 10.1002/j.1460-2075.1988.tb03317.x; DEMEDIUK BH, 1992, GASTROENTEROLOGY, V102, P728; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DONG JL, 1991, MOL ENDOCRINOL, V5, P1633, DOI 10.1210/mend-5-11-1633; DRUCKER DJ, 1987, J BIOL CHEM, V262, P15659; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; GODLEY JM, 1989, P NATL ACAD SCI USA, V86, P3036, DOI 10.1073/pnas.86.9.3036; GONG QH, 1991, MOL CELL BIOL, V11, P2558, DOI 10.1128/MCB.11.5.2558; GOODBOURN S, 1988, P NATL ACAD SCI USA, V85, P1447, DOI 10.1073/pnas.85.5.1447; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; HEITZ PU, 1977, DIABETES, V26, P632, DOI 10.2337/diabetes.26.7.632; ITO R, 1984, P NATL ACAD SCI-BIOL, V81, P4662, DOI 10.1073/pnas.81.15.4662; JARMAN AP, 1991, MOL CELL BIOL, V11, P4679, DOI 10.1128/MCB.11.9.4679; JOHNSON TM, 1993, J BIOL CHEM, V268, P464; JONES FS, 1990, P NATL ACAD SCI USA, V87, P6497, DOI 10.1073/pnas.87.17.6497; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KLEINERT H, 1990, EMBO J, V9, P711, DOI 10.1002/j.1460-2075.1990.tb08164.x; KRUSE F, 1988, MOL CELL BIOL, V8, P893, DOI 10.1128/MCB.8.2.893; LARSSON LI, 1976, NATURE, V262, P609, DOI 10.1038/262609a0; LEE SL, 1988, J BIOL CHEM, V263, P16604; LEVANKIM C, 1989, J BIOL CHEM, V264, P20407; MERCHANT JL, 1991, MOL CELL BIOL, V11, P2686, DOI 10.1128/MCB.11.5.2686; MERCHANT JL, 1993, GASTROENTEROLOGY, V104, P283; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOSS LG, 1988, MOL CELL BIOL, V8, P2620, DOI 10.1128/MCB.8.6.2620; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NOURBAKHSH M, 1993, EMBO J, V12, P451, DOI 10.1002/j.1460-2075.1993.tb05677.x; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; PHILIPPE J, 1987, J CLIN INVEST, V79, P351, DOI 10.1172/JCI112819; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SWIFT GH, 1989, GENE DEV, V3, P687, DOI 10.1101/gad.3.5.687; TAKAKI R, 1986, IN VITRO CELL DEV B, V22, P120; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; VONSOLINGE WW, 1993, GASTROENTEROLOGY, V104, P1099; WANG TC, 1990, J BIOL CHEM, V265, P8908; WANG TC, 1993, J CLIN INVEST, V92, P1349, DOI 10.1172/JCI116708; WHEELER MB, 1992, MOL CELL BIOL, V12, P3531, DOI 10.1128/MCB.12.8.3531; WIBORG O, 1984, P NATL ACAD SCI-BIOL, V81, P1067, DOI 10.1073/pnas.81.4.1067; YU CY, 1991, J BIOL CHEM, V266, P8907	58	22	22	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2234	2240						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294480				2022-12-27	WOS:A1994MR98800101
J	WEI, SQ; STADER, J				WEI, SQ; STADER, J			2 DISTINCT REGIONS OF THE LAMB SIGNAL SEQUENCE FUNCTION IN DIFFERENT STEPS IN EXPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING-PROTEIN; ESCHERICHIA-COLI; SECB; MUTATIONS; TRANSLOCATION; COMPETENCE; STABILITY; PROMOTES; PEPTIDE; INVIVO	The hydrophobic core of the Escherichia coli LamB signal sequence contains two structurally distinct regions. One region forms a helix in nonpolar environments, and the other is less structured. These regions seem to be of special importance for export, as judged by the magnitude of the defect caused by their mutational inactivation. To gain insight into the mechanistic importance of these two regions, we examined the ability of precursors to pass partially through the export pathway when each region is mutated. The results demonstrate that mutations in the helical and unstructured regions of the signal sequence block different steps in the export pathway.	UNIV MISSOURI,SCH BIOL SCI,KANSAS CITY,MO 64110	University of Missouri System; University of Missouri Kansas City					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043514] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43514] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMAN E, 1990, J BIOL CHEM, V265, P18154; BANKAITIS VA, 1984, J BIOL CHEM, V259, P2193; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BRIGGS MS, 1986, SCIENCE, V233, P206, DOI 10.1126/science.2941862; BRUCH MD, 1990, J BIOL CHEM, V265, P3851; BRUCH MD, 1989, BIOCHEMISTRY-US, V28, P8554, DOI 10.1021/bi00447a043; CLARK D, 1980, J BIOL CHEM, V255, P714; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; DECOCK H, 1992, MOL MICROBIOL, V6, P599; EMR SD, 1981, CELL, V23, P79, DOI 10.1016/0092-8674(81)90272-5; EMR SD, 1983, P NATL ACAD SCI-BIOL, V80, P4599, DOI 10.1073/pnas.80.15.4599; FIKES JD, 1990, J BIOL CHEM, V265, P3417; FIKES JD, 1987, J BACTERIOL, V169, P2345, DOI 10.1128/jb.169.6.2345-2351.1987; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GOTTESMAN S, 1990, METHOD ENZYMOL, V185, P119; HARDY SJS, 1991, SCIENCE, V251, P439, DOI 10.1126/science.1989077; KUMAMOTO CA, 1988, J BIOL CHEM, V263, P11554; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; RYAN JP, 1985, J BIOL CHEM, V260, P4832; STADER J, 1988, J BACTERIOL, V170, P1973, DOI 10.1128/jb.170.4.1973-1974.1988; STADER J, 1986, J BIOL CHEM, V261, P5075; THOM JR, 1988, J BACTERIOL, V170, P5654, DOI 10.1128/jb.170.12.5654-5661.1988; TRUN NJ, 1988, J BACTERIOL, V170, P5928, DOI 10.1128/jb.170.12.5928-5930.1988; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978	24	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1648	1653						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294411				2022-12-27	WOS:A1994MR98800019
J	CHU, G				CHU, G			CELLULAR-RESPONSES TO CISPLATIN - THE ROLES OF DNA-BINDING PROTEINS AND DNA-REPAIR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							HUMAN OVARIAN-CANCER; COMPLEMENTATION GROUP-E; ANTITUMOR DRUG CIS-DIAMMINEDICHLOROPLATINUM(II); XERODERMA-PIGMENTOSUM; CARCINOMA-CELLS; ACQUIRED-RESISTANCE; ANTICANCER DRUGS; CYTO-TOXICITY; DAMAGED DNA; GLUTATHIONE DEPLETION	The anticancer drug cisplatin provokes a complex response in the cell. A lethal dose of the drug kills cells primarily by forming DNA adducts, causing G2 arrest in the cell cycle, and then triggering apoptosis. A sublethal dose induces drug resistance by several mechanisms, including changes in drug uptake and efflux, glutathione and metallothionein levels, and DNA repair. Cisplatin-DNA adducts bind several cellular proteins, including some that enhance survival of the cell by mediating DNA repair and others that hasten its death by conferring sensitivity to the drug.			CHU, G (corresponding author), STANFORD UNIV, MED CTR, SCH MED, DEPT MED, STANFORD, CA 94305 USA.							ANDREWS PA, 1985, CANCER RES, V45, P6250; ANDREWS PA, 1989, EUR J CANCER CLIN ON, V25, P619, DOI 10.1016/0277-5379(89)90195-8; ANDREWS PA, 1990, CANCER CELL-MON REV, V2, P35; ANDREWS PA, 1988, CANCER RES, V48, P68; ANDREWS PA, 1987, CANCER CHEMOTH PHARM, V19, P149; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; BEHRENS BC, 1987, CANCER RES, V47, P414; BELLON SF, 1991, BIOCHEMISTRY-US, V30, P8026, DOI 10.1021/bi00246a021; BERNAL SD, 1990, MOL CELL BIOCHEM, V95, P61; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BROWN SJ, 1993, SCIENCE, V261, P603, DOI 10.1126/science.8342024; BRUHN SL, 1992, P NATL ACAD SCI USA, V89, P2307, DOI 10.1073/pnas.89.6.2307; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; CHU G, 1990, P NATL ACAD SCI USA, V87, P3324, DOI 10.1073/pnas.87.9.3324; CHU G, 1987, MOL BIOL MED, V4, P277; CHU G, 1993, CANCER, V72, P3707, DOI 10.1002/1097-0142(19931215)72:12<3707::AID-CNCR2820721224>3.0.CO;2-U; CICCARELLI RB, 1985, BIOCHEMISTRY-US, V24, P7533, DOI 10.1021/bi00347a005; DABHOLKAR M, 1992, J NATL CANCER I, V84, P1512, DOI 10.1093/jnci/84.19.1512; DEUCHARS KL, 1989, SEMIN ONCOL, V16, P156; DONAHUE BA, 1990, BIOCHEMISTRY-US, V29, P5872, DOI 10.1021/bi00476a032; Eastman A, 1991, Cancer Treat Res, V57, P233; EASTMAN A, 1988, BIOCHEMISTRY-US, V27, P4730, DOI 10.1021/bi00413a022; EASTMAN A, 1986, BIOCHEMISTRY-US, V25, P3912, DOI 10.1021/bi00361a026; FICHTINGERSCHEPMAN AMJ, 1985, BIOCHEMISTRY-US, V24, P707, DOI 10.1021/bi00324a025; FRAVAL HNA, 1978, MUTAT RES, V51, P121, DOI 10.1016/0027-5107(78)90014-3; FRAVAL HNA, 1979, CANCER RES, V39, P1793; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; HAMER D, 1986, ANNU REV BIOCHEM, V235, P3460; HAMILTON TC, 1985, BIOCHEM PHARMACOL, V34, P2583, DOI 10.1016/0006-2952(85)90551-9; HANSSON J, 1990, NUCLEIC ACIDS RES, V18, P35, DOI 10.1093/nar/18.1.35; HARDER HC, 1970, INT J CANCER, V6, P207, DOI 10.1002/ijc.2910060207; HOWLE JA, 1970, BIOCHEM PHARMACOL, V19, P2757, DOI 10.1016/0006-2952(70)90102-4; HUGHES EN, 1992, J BIOL CHEM, V267, P13520; HWANG BJ, 1993, BIOCHEMISTRY-US, V32, P1657, DOI 10.1021/bi00057a033; ISHIKAWA T, 1993, J BIOL CHEM, V268, P20116; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; KATAOKA H, 1991, BIOCHEM BIOPH RES CO, V175, P1139, DOI 10.1016/0006-291X(91)91684-5; KAWAI K, 1990, J BIOL CHEM, V265, P13137; KEENEY S, 1992, MUTAT RES, V273, P49, DOI 10.1016/0921-8777(92)90049-9; KELLEY SL, 1988, SCIENCE, V241, P1813, DOI 10.1126/science.3175622; KNOX RJ, 1986, CANCER RES, V46, P1972; LAI GM, 1988, BIOCHEM PHARMACOL, V37, P4597, DOI 10.1016/0006-2952(88)90325-5; LAI GM, 1989, JNCI-J NATL CANCER I, V81, P535, DOI 10.1093/jnci/81.7.535; LILLEY DMJ, 1992, NATURE, V357, P282, DOI 10.1038/357282a0; LIPPARD SJ, 1987, PURE APPL CHEM, V59, P731, DOI 10.1351/pac198759060731; LOH SY, 1992, BRIT J CANCER, V66, P1109, DOI 10.1038/bjc.1992.419; MANN SC, 1990, CANCER CHEMOTH PHARM, V25, P236, DOI 10.1007/BF00684878; MASUDA H, 1988, CANCER RES, V48, P5713; MCCLAY EF, 1992, CANCER RES, V52, P6790; MCCLAY EF, 1993, CANCER RES, V53, P1571; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X; PARKER RJ, 1991, J CLIN INVEST, V87, P772, DOI 10.1172/JCI115080; PATTERSON M, 1989, MOL CELL BIOL, V9, P5105, DOI 10.1128/MCB.9.11.5105; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; ROSENBERG B, 1965, NATURE, V205, P698, DOI 10.1038/205698a0; SANCAR GB, 1990, MUTAT RES, V236, P147, DOI 10.1016/0921-8777(90)90002-M; SCANLON KJ, 1991, PHARMACOL THERAPEUT, V52, P385, DOI 10.1016/0163-7258(91)90033-I; SCHILDER RJ, 1990, INT J CANCER, V45, P416, DOI 10.1002/ijc.2910450306; SEBASTIAN J, 1990, MOL CELL BIOL, V10, P4630, DOI 10.1128/MCB.10.9.4630; SHEIBANI N, 1989, BIOCHEMISTRY-US, V28, P3120, DOI 10.1021/bi00433a055; SHIRAKATA M, 1991, MOL CELL BIOL, V11, P4528, DOI 10.1128/MCB.11.9.4528; SORENSON CM, 1990, JNCI-J NATL CANCER I, V82, P749, DOI 10.1093/jnci/82.9.749; SORENSON CM, 1988, CANCER RES, V48, P6703; SZYMKOWSKI DE, 1992, P NATL ACAD SCI USA, V89, P10772, DOI 10.1073/pnas.89.22.10772; TAKAO M, 1993, NUCLEIC ACIDS RES, V21, P4111, DOI 10.1093/nar/21.17.4111; TEICHER BA, 1990, SCIENCE, V247, P1457, DOI 10.1126/science.2108497; TIMMERBOSSCHA H, 1992, BRIT J CANCER, V66, P227, DOI 10.1038/bjc.1992.249; TONEY JH, 1989, P NATL ACAD SCI USA, V86, P8328, DOI 10.1073/pnas.86.21.8328; VANDUIN M, 1986, CELL, V44, P913, DOI 10.1016/0092-8674(86)90014-0; WOLF CR, 1987, INT J CANCER, V39, P695, DOI 10.1002/ijc.2910390607; Wyllie A H, 1980, Int Rev Cytol, V68, P251; ZHEN WP, 1992, MOL CELL BIOL, V12, P3689, DOI 10.1128/MCB.12.9.3689	74	672	691	2	51	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					787	790						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288625				2022-12-27	WOS:A1994MR22000001
J	FUKAMI, K; ENDO, T; IMAMURA, M; TAKENAWA, T				FUKAMI, K; ENDO, T; IMAMURA, M; TAKENAWA, T			ALPHA-ACTININ AND VINCULIN ARE PIP(2)-BINDING PROTEINS INVOLVED IN SIGNALING BY TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-GAMMA; RAT EMBRYO FIBROBLASTS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; GROWTH-FACTOR; PROFILIN; BINDING; PHOSPHORYLATION; DIACYLGLYCEROL; ASSOCIATION; PLATELET	Western blot analysis of Balb/c 3T3 cell lysates by an antibody specific to phosphatidylinositol 4,5-bisphosphate (PIP2) showed that several proteins exist in a PIP2-bound form. Among them, two proteins, 100 and 115 kDa in molecular mass, were detected as PIP2 abundant proteins. These were identified as alpha-actinin and vinculin by their antibodies. In Balb/c 3T3 cells, alpha-actinin in the cytoskeleton contains PIP2, while alpha-actinin in cytosol does not. The levels of PIP2 bound to alpha-aetinin decrease in response to platelet-derived growth factor (PDGF). Similarly, PIP2 bound to vinculin is decreased upon stimulation with PDGF. By immunofluorescent staining, PIP2 was found to be present densely in the central areas around nuclei, microfilament bundles, and focal contacts, where alpha-actinin and vinculin are distributed. PDGF stimulation decreases the intensity of PIP2 staining in these areas. In this paper we suggest that tyrosine kinase-activated phospholipase C hydrolyzes PIP2 bound to alpha-actinin and vinculin, leading to the simultaneous generation of second messengers and reorganization of the cytoskeleton.	UNIV TOKYO,INST MED SCI,DEPT MOLEC ONCOL,MINATO KU,TOKYO 108,JAPAN; CHIBA UNIV,FAC SCI,DEPT BIOL,INAGE KU,CHIBA 263,JAPAN; UNIV TSUKUBA,INST BASIC MED SCI,DEPT PHARMACOL,TSUKUBA,IBARAKI 305,JAPAN	University of Tokyo; Chiba University; University of Tsukuba								AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ANDERSON RA, 1985, NATURE, V318, P295, DOI 10.1038/318295a0; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLANCHARD A, 1989, J MUSCLE RES CELL M, V10, P280, DOI 10.1007/BF01758424; BURN P, 1985, NATURE, V314, P469, DOI 10.1038/314469a0; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; EBASHI S, 1964, NATURE, V203, P645, DOI 10.1038/203645a0; ENDO T, 1982, BIOCHEM BIOPH RES CO, V107, P1467, DOI 10.1016/S0006-291X(82)80164-2; ENDO T, 1984, J CELL BIOL, V99, P2322, DOI 10.1083/jcb.99.6.2322; FERAMISCO JR, 1980, J CELL BIOL, V86, P608; FUKAMI K, 1988, P NATL ACAD SCI USA, V85, P9057, DOI 10.1073/pnas.85.23.9057; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; GENTRY LE, 1984, J VIROL, V51, P539, DOI 10.1128/JVI.51.2.539-546.1984; GOLDSCHMIDTCLERMONT PJ, 1991, CELL, V66, P419, DOI 10.1016/0092-8674(81)90002-7; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; ISENBERG G, 1991, J MUSCLE RES CELL M, V12, P136, DOI 10.1007/BF01774032; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LAZARIDES E, 1975, CELL, V6, P289, DOI 10.1016/0092-8674(75)90180-4; MACHESKY LM, 1990, CELL REGUL, V1, P937, DOI 10.1091/mbc.1.12.937; MALGOLIS B, 1988, CELL, V57, P1101; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MCBRIDE K, 1991, P NATL ACAD SCI USA, V88, P7111, DOI 10.1073/pnas.88.16.7111; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MELLSTROM K, 1983, J MUSCLE RES CELL M, V4, P589, DOI 10.1007/BF00712117; MIYATA H, 1989, J CELL BIOL, V109, P1519, DOI 10.1083/jcb.109.4.1519; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROHRSCHNEIDER LR, 1984, J VIROL, V51, P547, DOI 10.1128/JVI.51.2.547-552.1984; TOKUUE Y, 1991, EXP CELL RES, V197, P158, DOI 10.1016/0014-4827(91)90418-T; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912	41	184	184	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1518	1522						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288618				2022-12-27	WOS:A1994MR22000113
J	KUSTERS, R; BREUKINK, E; GALLUSSER, A; KUHN, A; DEKRUIJFF, B				KUSTERS, R; BREUKINK, E; GALLUSSER, A; KUHN, A; DEKRUIJFF, B			A DUAL ROLE FOR PHOSPHATIDYLGLYCEROL IN PROTEIN TRANSLOCATION ACROSS THE ESCHERICHIA-COLI INNER MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVELY CHARGED PHOSPHOLIPIDS; SIGNAL PEPTIDES; SECA-PROTEIN; ACIDIC PHOSPHOLIPIDS; PLASMA-MEMBRANE; MODEL MEMBRANES; PROCOAT PROTEIN; INITIAL STEPS; PHOE PROTEIN; M13 PROCOAT	The involvement of phosphatidylglycerol in the SecA-independent translocation of M13 procoat in Escherichia coli was demonstrated. Processing of procoat to mature coat protein was retarded when the level of phosphatidylglycerol was reduced. In vitro translocation experiments using inner membrane vesicles isolated from a strain with inducible synthesis of phosphatidylglycerol, showed that translocation of procoat and of a SecA-dependent procoat analog was proportional to the content of phosphatidylglycerol. Moreover, introduction of phosphatidylglycerol by means of a lipid transfer method into phosphatidylglycerol-depleted inner membrane vesicles, efficiently restored procoat translocation. The phosphatidylglycerol dependence in both the SecA-dependent and -independent translocation pathway indicates that phosphatidylglycerol plays a dual role in translocation. We suggest that besides membrane binding of SecA this lipid has a direct interaction with the M13 procoat in translocation across the inner membrane.	UNIV UTRECHT,CTR BIOMEMBRANES & LIPID ENZYMOL,DEPT BIOCHEM MEMBRANES,3584 CH UTRECHT,NETHERLANDS; UNIV UTRECHT,INST MOLEC BIOL & MED BIOTECHNOL,3584 CH UTRECHT,NETHERLANDS; UNIV KARLSRUHE,DEPT APPL MICROBIOL,W-7500 KARLSRUHE 1,GERMANY	Utrecht University; Utrecht University; Helmholtz Association; Karlsruhe Institute of Technology			Breukink, Eefjan/I-3039-2016	Breukink, Eefjan/0000-0002-7311-0660				BATENBURG AM, 1988, BIOCHEMISTRY-US, V27, P5678, DOI 10.1021/bi00415a043; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; BRIGGS MS, 1985, SCIENCE, V228, P1096, DOI 10.1126/science.3158076; BRIGGS MS, 1986, SCIENCE, V233, P206, DOI 10.1126/science.2941862; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CAMMACK KA, 1965, BIOCHEM J, V96, P671, DOI 10.1042/bj0960671; DEMEL RA, 1990, BIOCHIM BIOPHYS ACTA, V1027, P155, DOI 10.1016/0005-2736(90)90079-4; DEVRIJE GJ, 1990, MOL MICROBIOL, V4, P143; DEVRIJE T, 1987, BIOCHIM BIOPHYS ACTA, V900, P63, DOI 10.1016/0005-2736(87)90278-1; DEVRIJE T, 1988, NATURE, V334, P173, DOI 10.1038/334173a0; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FIDELIO GD, 1987, BIOCHEM J, V244, P295, DOI 10.1042/bj2440295; GALLUSSER A, 1990, EMBO J, V9, P2723, DOI 10.1002/j.1460-2075.1990.tb07459.x; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; HIKITA C, 1992, J BIOL CHEM, V267, P12375; INOUYE M, 1980, CRC CR REV BIOCH MOL, V7, P339, DOI 10.3109/10409238009105465; ITO K, 1980, J BIOL CHEM, V255, P2123; KUHN A, 1986, EMBO J, V5, P3681, DOI 10.1002/j.1460-2075.1986.tb04699.x; KUHN A, 1990, EMBO J, V9, P2385, DOI 10.1002/j.1460-2075.1990.tb07413.x; KUSTERS R, 1992, FEBS LETT, V308, P97, DOI 10.1016/0014-5793(92)81060-Y; KUSTERS R, 1991, J BIOL CHEM, V266, P8659; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; PHOENIX DA, 1993, J BIOL CHEM, V268, P17069; PHOENIX DA, 1993, FEBS LETT, V324, P113, DOI 10.1016/0014-5793(93)81543-9; POORTHUIS BJHM, 1983, METHOD ENZYMOL, V98, P592; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; VANDEENEN LLM, 1964, ADV LIPID RES, V2, P167; VANDERGOOT FG, 1993, EUR J BIOCHEM, V213, P217; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; WICKNER W, 1979, ANNU REV BIOCHEM, V48, P23, DOI 10.1146/annurev.bi.48.070179.000323; WOLFE PB, 1985, J BIOL CHEM, V260, P1836	36	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1560	1563						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288623				2022-12-27	WOS:A1994MR22000119
J	MURANTE, RS; HUANG, L; TURCHI, JJ; BAMBARA, RA				MURANTE, RS; HUANG, L; TURCHI, JJ; BAMBARA, RA			THE CALF 5'-EXONUCLEASE TO 3'-EXONUCLEASE IS ALSO AN ENDONUCLEASE WITH BOTH ACTIVITIES DEPENDENT ON PRIMERS ANNEALED UPSTREAM OF THE POINT OF CLEAVAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 DNA-POLYMERASES; SIMIAN VIRUS-40; REPLICATION; EPSILON; INVITRO; STRAND; DELTA	The catalytic activity of the calf thymus 5'- to 3'-exonuclease was measured on substrates consisting of two primers annealed adjacent to each other on a template. Exonucleolytic degradation of the downstream primer is very slow if the primers are separated by a gap of one nucleotide or if no upstream primer is present. When only a nick separates the primers, degradation is rapid. This suggests that the nuclease is designed to work with calf DNA polymerases such that synthesis from an upstream primer creates the favored nuclease substrate. Nuclease action then destroys the substrate, but it is regenerated by further polymerization. This process, termed nick translation, is necessary for both DNA replication and repair. lf the downstream primer has an unannealed 5'-region, that region is removed by an endonuclease activity residing in the same enzyme. Efficient endonuclease action also requires an upstream primer that is annealed such that its 3'-end is directly adjacent to the annealed region of the downstream primer. This reaction is likely to be important for removal of DNA segments that are damaged such that exonuclease cleavage of the damaged site is not possible.	UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,CTR CANC,ROCHESTER,NY 14642	University of Rochester; University of Rochester			Turchi, John J/B-5807-2015	Turchi, John J/0000-0001-5375-2992	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007102, R01GM024441] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32-GM07102, GM24441] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; HIBINO Y, 1991, BIOCHIM BIOPHYS ACTA, V1088, P305, DOI 10.1016/0167-4781(91)90068-W; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JOYCE CM, 1987, TRENDS BIOCHEM SCI, V12, P288, DOI 10.1016/0968-0004(87)90143-5; KELLY RB, 1969, NATURE, V224, P495, DOI 10.1038/224495a0; KORNBERG A, 1991, DNA REPLICATION, P533; LEHMAN IR, 1976, SCIENCE, V193, P963, DOI 10.1126/science.781842; LUNDQUIST RC, 1982, CELL, V31, P53, DOI 10.1016/0092-8674(82)90404-4; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; NETHANEL T, 1990, J VIROL, V64, P5912, DOI 10.1128/JVI.64.12.5912-5918.1990; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; SAMBROOK J, 1991, MOL CLONING LABORATO; SIEGAL G, 1992, P NATL ACAD SCI USA, V89, P9377, DOI 10.1073/pnas.89.20.9377; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; WEINBERG DH, 1989, P NATL ACAD SCI USA, V86, P9742, DOI 10.1073/pnas.86.24.9742	18	110	126	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1191	1196						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288581				2022-12-27	WOS:A1994MR22000067
J	LIN, GF; PEARSON, AE; SCAMURRA, RW; ZHOU, YL; BAARSCH, MJ; WEISS, DJ; MURTAUGH, MP				LIN, GF; PEARSON, AE; SCAMURRA, RW; ZHOU, YL; BAARSCH, MJ; WEISS, DJ; MURTAUGH, MP			REGULATION OF INTERLEUKIN-8 EXPRESSION IN PORCINE ALVEOLAR MACROPHAGES BY BACTERIAL LIPOPOLYSACCHARIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL CHEMOTACTIC FACTOR; TUMOR-NECROSIS-FACTOR; ATTRACTANT ACTIVATION PROTEIN-1; MESSENGER-RNA; GENE-EXPRESSION; BETA-THROMBOGLOBULIN; FACTOR-ALPHA; CYTOKINES; SEQUENCE; CELLS	Interleukin (IL)-8 is a macrophage-derived neutrophil chemotactic factor that plays an important role in the recruitment of neutrophils to inflammatory loci. Hence, expression of IL-8 by alveolar macrophages may be a significant factor in host defense in the lung and in the pathogenesis of pneumonia in swine. To initiate molecular studies of IL-8 regulation in pigs, we cloned IL-8 cDNA and examined the regulation of its mRNA in alveolar macrophages. The porcine IL-8 cDNA consists of 1491 base pairs including a coding region of 309 base pairs. The deduced amino acid sequence was 75 and 81% similar to human and rabbit IL-8, respectively. Resting macrophages contained low levels of IL-8 mRNA, which increased markedly after exposure to bacterial lipopolysaccharide (LPS). LPS induction of IL-8 was direct, not mediated through elevation of tumor necrosis factor or interleukin-1. The effect of LPS on IL-8 expression was dose dependent, and induction was observed at a concentration of 10 pg/ml. IL-8 mRNA expression was detectable within 0.5 h after stimulation with LPS, peaked at 3-6 h at about 30-fold higher levels than in resting cells, and was maintained for 24 h. Secreted IL-8, measured by neutrophil chemotaxis, was induced within 4 h by LPS, and accumulated in the media throughout the 24-h period. The mechanism of induction of IL-8 mRNA appeared to involve transcription and RNA processing. Nuclear run-on analysis showed that the IL-8 gene was actively transcribed in noninduced cells; upon stimulation with LPS, the rate of IL-8 transcription was increased about 4-fold. A single mature mRNA species was detected by primer extension analysis. The half-life of IL-8 mRNA transcripts in aveolar macrophages was approximately 2 h and did not change after LPS stimulation. The ability of LPS to induce IL-8 expression was suppressed by recombinant human IL-4 and dexamethasone in a concentration-dependent manner. These observations indicate that the expression of IL-8 is an early event in the sequelae to bacterial infection in the lung.	UNIV MINNESOTA,COLL VET MED,DEPT VET PATHOBIOL,1971 COMMONWEALTH AVE,ST PAUL,MN 55108	University of Minnesota System; University of Minnesota Twin Cities								BAARSCH MJ, 1991, J IMMUNOL METHODS, V140, P15, DOI 10.1016/0022-1759(91)90121-U; BAGGIOLINI M, 1992, INFLAMMATION BASIC P, P248; BEGG GS, 1978, BIOCHEMISTRY-US, V17, P1739, DOI 10.1021/bi00602a024; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHOI C S, 1991, Animal Biotechnology, V2, P97, DOI 10.1080/10495399109525752; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEUEL TF, 1977, P NATL ACAD SCI USA, V74, P2256, DOI 10.1073/pnas.74.6.2256; FARBER JM, 1990, P NATL ACAD SCI USA, V87, P5238, DOI 10.1073/pnas.87.14.5238; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOLDSTEIN RA, 1992, INFLAMMATION BASIC P, P1061; GOODMAN RB, 1991, J BIOL CHEM, V266, P8455; GREGORY H, 1988, BIOCHEM BIOPH RES CO, V151, P883, DOI 10.1016/S0006-291X(88)80364-4; HOLT JC, 1986, BIOCHEMISTRY-US, V25, P1988, DOI 10.1021/bi00356a023; HUETHER MJ, 1993, GENE, V129, P285, DOI 10.1016/0378-1119(93)90281-7; IGLESIAS G, 1989, ARCH VIROL, V104, P107, DOI 10.1007/BF01313812; KEITA K, 1991, J LEUKOCYTE BIOL, V50, P287; KOWALSKI J, 1989, MOL CELL BIOL, V9, P1946, DOI 10.1128/MCB.9.5.1946; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEONARD EJ, 1990, J IMMUNOL, V144, P1323; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; MULLER R, 1984, NATURE, V311, P433; NAKAMURA H, 1991, J BIOL CHEM, V266, P19611; NELSON RD, 1975, J IMMUNOL, V115, P1650; RANKIN JA, 1990, J CLIN INVEST, V86, P1556, DOI 10.1172/JCI114875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEIMER RP, 1989, ALLERGY PRINCIPLES P, P739; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; STANDIFORD TJ, 1990, J IMMUNOL, V145, P1435; STOKES DC, 1989, J INFECT DIS, V160, P52, DOI 10.1093/infdis/160.1.52; STRIETER RM, 1990, BIOCHEM BIOPH RES CO, V166, P886, DOI 10.1016/0006-291X(90)90893-R; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; SYLVESTER I, 1990, AM REV RESPIR DIS, V141, P683, DOI 10.1164/ajrccm/141.3.683; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WALZ A, 1987, BIOCHEM BIOPH RES CO, V149, P755, DOI 10.1016/0006-291X(87)90432-3; WOLPE SD, 1989, P NATL ACAD SCI USA, V86, P612, DOI 10.1073/pnas.86.2.612; YOKOTA T, 1988, IMMUNOL REV, V102, P138; YOSHIMURA T, 1991, J IMMUNOL, V146, P3483; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233; ZACHARIAE COC, 1991, J INVEST DERMATOL, V97, P593, DOI 10.1111/1523-1747.ep12481934; ZHOU YL, 1992, MOL IMMUNOL, V29, P965, DOI 10.1016/0161-5890(92)90135-K	47	72	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					77	85						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276881				2022-12-27	WOS:A1994MR21900020
J	LINDQVIST, L; KAISER, R; REEVES, PR; LINDBERG, AA				LINDQVIST, L; KAISER, R; REEVES, PR; LINDBERG, AA			PURIFICATION, CHARACTERIZATION, AND HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY ASSAY OF SALMONELLA GLUCOSE-1-PHOSPHATE CYTIDYLYLTRANSFERASE FROM THE CLONED RFBF GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPHIMURIUM; SEQUENCE	We report the purification and characterization of glucose-1-phosphate cytidylyltransferase, the first of five enzymes committed to biosynthesis of CDP-D-abequose from Salmonella enterica strain LT2. The purification was greatly facilitated by using a cloned rfbF gene encoding this enzyme. Pure enzyme was obtained by 64-fold enrichment in three chromatography steps. The NH2-terminal sequence of the purified enzyme was in agreement with the sequence predicted from the nucleotide sequence of the rfbF gene. The SDS-polyacrylamide gel electrophoresis estimated subunit M(r) of 31,000 agrees well with the M(r) of 29,035 calculated from the amino acid composition deduced from the nucleotide sequence of the rfbF gene. The glucose-1-phosphate cytidylyltransferase catalyzes a reversible bimolecular group transfer reaction and steady-state kinetic measurements, including product inhibition patterns, indicate that this reaction proceeds by a ''ping-pong'' type of mechanism. The K(m) values for CTP, alpha-D-glucose 1-phosphate, CDP-D-glucose, and pyrophosphate are 0.28, 0.64, 0.11, and 1.89 mM, respectively.	KAROLINSKA INST,DEPT CHEM 1,S-10401 STOCKHOLM 60,SWEDEN; UNIV SYDNEY,DEPT MICROBIOL,SYDNEY,NSW 2006,AUSTRALIA	Karolinska Institutet; University of Sydney	LINDQVIST, L (corresponding author), HUDDINGE HOSP,KAROLINSKA INST,DEPT CLIN BACTERIOL,S-14186 HUDDINGE,SWEDEN.		Reeves, Peter R/A-6064-2008	Reeves, Peter R/0000-0003-4479-7974				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMBHATT HN, 1988, J BACTERIOL, V170, P98; Cleland W. W, 1970, ENZYMES, V2, P1; GAREGG PJ, 1988, CARBOHYDRATE CHEM, P500; JIANG XM, 1991, MOL MICROBIOL, V5, P695, DOI 10.1111/j.1365-2958.1991.tb00741.x; MARUMO K, 1992, EUR J BIOCHEM, V204, P539, DOI 10.1111/j.1432-1033.1992.tb16665.x; MAYER RM, 1965, J BIOL CHEM, V240, P1900; NEUHARD J, 1976, J BACTERIOL, V126, P999, DOI 10.1128/JB.126.2.999-1001.1976; NIKAIDO H, 1967, P NATL ACAD SCI USA, V57, P1825, DOI 10.1073/pnas.57.6.1825; Plowman K. M., 1972, ENZYME KINETICS; REEVES PR, 1992, TRENDS GENET, V9, P17; ROMANA LK, 1991, BIOCHEM BIOPH RES CO, V174, P846, DOI 10.1016/0006-291X(91)91495-X; SANDERSON KE, 1983, MICROBIOL REV, V47, P410, DOI 10.1128/MMBR.47.3.410-453.1983; Segel I.H., 1975, ENZYME KINETICS; SHEU KFR, 1978, J BIOL CHEM, V253, P3378; TSUBOI KK, 1969, J BIOL CHEM, V244, P1008; WYK P, 1989, J BACTERIOL, V171, P5687, DOI 10.1128/jb.171.10.5687-5693.1989	17	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					122	126						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276783				2022-12-27	WOS:A1994MR21900026
J	MALLENDER, WD; VOSS, EW				MALLENDER, WD; VOSS, EW			CONSTRUCTION, EXPRESSION, AND ACTIVITY OF A BIVALENT BISPECIFIC SINGLE-CHAIN ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-SCATTERING; ESCHERICHIA-COLI; FLUORESCYL ANTIBODIES; TRICHODERMA-REESEI; IDIOTYPE FAMILY; IGG ANTIBODIES; STRANDED-DNA; FAB COMPLEX; MAB 4-4-20; PROTEINS	This report describes the design, construction, and expression of a bivalent bispecific single-chain antibody (SCA) protein in Escherichia coli. The bispecificity of the bivalent protein was based on two previously constructed monovalent single-chain antibody molecules possessing distinct specificities, SCA 4-4-20 (anti-fluorescein) and SCA 04-01 (anti-single-stranded DNA). A flexible linker, modeled after a secreted fungal cellulase protein, was incorporated as the interdomain linker covalently joining the two active sites. Bivalent bispecific SCA protein that accumulated in bacteria as insoluble inclusion bodies was harvested, denatured, refolded, and affinity-purified in vitro. Affinity-purified bivalent bispecific SCA showed nearly identical ligand binding properties at each site relative to the individual monovalent single-chain antibody prototype molecules. In both solid and solution phase binding assays, the bivalent bispecific single-chain antibody simultaneously bound both ligands (fluorescein and (dT)6). Construction of a model bivalent bispecific molecule provides a foundation for future assembly of similar molecules designed to identify parameters involved in enhanced binding of antibodies due to avidity and dual specificity.	UNIV ILLINOIS, DEPT MICROBIOL, 131 BURRILL HALL, 407 S GOODWIN AVE, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign								ABUJA PM, 1988, EUR BIOPHYS J BIOPHY, V15, P339, DOI 10.1007/BF00254721; BALLARD DW, 1984, J BIOL CHEM, V259, P3492; BATES RM, 1985, MOL IMMUNOL, V22, P871, DOI 10.1016/0161-5890(85)90072-0; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; BEDZYK WD, 1990, J BIOL CHEM, V265, P1861; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; CHEONG HS, 1990, BIOCHEM BIOPH RES CO, V173, P795; CONDRA JH, 1990, J BIOL CHEM, V265, P2292; CROTHERS DM, 1972, IMMUNOCHEMISTRY, V9, P341, DOI 10.1016/0019-2791(72)90097-3; CUMBER AJ, 1992, J IMMUNOL, V149, P120; DENZIN LK, 1992, J BIOL CHEM, V267, P8925; DENZIN LK, 1991, J BIOL CHEM, V266, P14095; DENZIN LK, IN PRESS MOL IMMUNOL; DUNCANEL F, 1993, BIOTECHNOLOGY, V11, P601; FREUND C, 1993, FEBS LETT, V320, P97, DOI 10.1016/0014-5793(93)80070-B; GLOCKSHUBER R, 1990, BIOCHEMISTRY-US, V29, P1362, DOI 10.1021/bi00458a002; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; HERRON JN, 1984, FLUORESCEIN HAPTEN I, P49; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; HUSTON JS, 1991, METHOD ENZYMOL, V203, P46; KOSTELNY SA, 1992, J IMMUNOL, V148, P1547; KRANZ DM, 1982, J BIOL CHEM, V257, P6987; KRANZ DM, 1981, MOL IMMUNOL, V18, P889, DOI 10.1016/0161-5890(81)90012-2; LACY MJ, 1989, J IMMUNOL METHODS, V116, P87, DOI 10.1016/0022-1759(89)90316-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE RL, 1982, BIOCHEMISTRY-US, V21, P2600, DOI 10.1021/bi00540a004; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MACLEAN JA, 1993, J IMMUNOL, V150, P1619; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; PACK P, 1992, BIOCHEMISTRY-US, V31, P1597; RUMBLEY CA, 1993, J BIOL CHEM, V268, P13667; SCANDELLA D, 1985, J CELL BIOCH B, V9, P203; SCHMUCK M, 1986, BIOTECHNOL LETT, V8, P397, DOI 10.1007/BF01026739; SMITH RA, 1983, APPL ENVIRON MICROB, V45, P586, DOI 10.1128/AEM.45.2.586-590.1983; SNIDER DP, 1992, J IMMUNOL, V148, P1163; STEVENS SY, 1993, J AM CHEM SOC, V115, P1585, DOI 10.1021/ja00057a059; SWINDLEHURST CA, 1991, BIOPHYS J, V59, P619, DOI 10.1016/S0006-3495(91)82277-9; TAKKINEN K, 1991, PROTEIN ENG, V4, P837, DOI 10.1093/protein/4.7.837; TETIN SY, 1993, BIOCHEMISTRY-US, V32, P9011, DOI 10.1021/bi00086a005; TETIN SY, 1992, BIOCHEMISTRY-US, V31, P12029, DOI 10.1021/bi00163a010; VOSS EW, 1989, FLUORESCENT BIOMOLOC, P249; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0; WATT RM, 1977, IMMUNOCHEMISTRY, V14, P533, DOI 10.1016/0019-2791(77)90308-1; WATT RM, 1978, IMMUNOCHEMISTRY, V15, P875, DOI 10.1016/0161-5890(78)90121-9; WEIDNER KM, 1992, J BIOL CHEM, V267, P10281; WEIDNER KM, 1993, MOL IMMUNOL, V30, P1003, DOI 10.1016/0161-5890(93)90125-U; WEIDNER KM, 1991, J BIOL CHEM, V266, P2513; WELS W, 1992, CANCER RES, V52, P6310; WU S, 1993, J IMMUNOL, V150, P2211; YOKOTA T, 1992, CANCER RES, V52, P3402	53	102	164	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					199	206						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276795				2022-12-27	WOS:A1994MR21900038
J	NUTTLEY, WM; BRADE, AM; EITZEN, GA; VEENHUIS, M; AITCHISON, JD; SZILARD, RK; GLOVER, JR; RACHUBINSKI, RA				NUTTLEY, WM; BRADE, AM; EITZEN, GA; VEENHUIS, M; AITCHISON, JD; SZILARD, RK; GLOVER, JR; RACHUBINSKI, RA			PAY4, A GENE REQUIRED FOR PEROXISOME ASSEMBLY IN THE YEAST YARROWIA-LIPOLYTICA, ENCODES A NOVEL MEMBER OF A FAMILY OF PUTATIVE ATPASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROBODY TARGETING SIGNAL; AMINO-ACID-SEQUENCE; SACCHAROMYCES-CEREVISIAE; CANDIDA-TROPICALIS; HANSENULA-POLYMORPHA; ZELLWEGER SYNDROME; DEFICIENT MUTANTS; PICHIA-PASTORIS; PROTEIN IMPORT; RAT-LIVER	PAY genes are required for peroxisome assembly in the yeast Yarrowia lipolytica. Here we characterize one mutant, pay4, and describe the cloning and sequencing of the PAY4 gene. The pay4 mutant shows no identifiable peroxisomes by biochemical and morphological criteria. The complementing PAY4 gene encodes a polypeptide, Pay4p, 1025 amino acids in length and having a predicted molecular mass of 112,258 Da. The predicted Pay4p sequence contains two putative ATP-binding domains and shows structural relationships to other potential ATP-binding proteins involved in biological processes as diverse as peroxisome biogenesis, vesicle-mediated protein transport, cell cycle control, and transcriptional regulation. These proteins all share a highly conserved stretch of approximately 175 amino acids that contains a consensus sequence for ATP binding. Pay4p shows sequence conservation with Pas1p and Pas5p, putative ATPases required for peroxisomal assembly in the yeasts Saccharomyces cerevisiae and Pichia pastoris, respectively. Pay4p, Pas1p, and Pas5p are presumably related members of a family of putative ATPases involved in peroxisome biogenesis. Pay4p is synthesized in low amounts in Y lipolytica cells grown in glucose, and there is a rapid and pronounced increase in the levels of Pay4p upon transfer of the cells to a medium containing oleic acid as the sole carbon source.	MCMASTER UNIV,DEPT BIOCHEM,1200 MAIN ST W,HAMILTON L8N 3Z5,ONTARIO,CANADA; UNIV GRONINGEN,ELECTRON MICROSCOPY LAB,9750 AA HAREN,NETHERLANDS	McMaster University; University of Groningen			Eitzen, Gary/D-3682-2009					AITCHISON JD, 1992, MOL MICROBIOL, V6, P3455, DOI 10.1111/j.1365-2958.1992.tb01780.x; AITCHISON JD, 1992, YEAST, V8, P721, DOI 10.1002/yea.320080905; AITCHISON JD, 1991, J BIOL CHEM, V266, P23197; ALEXSON SEH, 1985, J CELL BIOL, V101, P294, DOI 10.1083/jcb.101.1.294; Ausubel FM, 1988, MOL REPROD DEV; BAUDHUIN P, 1964, BIOCHEM J, V92, P179, DOI 10.1042/bj0920179; BLATTNER J, 1992, J CELL BIOL, V119, P1129, DOI 10.1083/jcb.119.5.1129; BORST P, 1989, BIOCHIM BIOPHYS ACTA, V1008, P1, DOI 10.1016/0167-4781(89)90163-2; BORST P, 1986, BIOCHIM BIOPHYS ACTA, V866, P179, DOI 10.1016/0167-4781(86)90044-8; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CIGAN AM, 1987, GENE, V59, P1; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; COHEN G, 1988, EUR J BIOCHEM, V176, P159; COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665; CREGG JM, 1990, YEAST, V6, P87, DOI 10.1002/yea.320060202; DAVIDOW LS, 1987, J BACTERIOL, V169, P4621, DOI 10.1128/jb.169.10.4621-4629.1987; DAVIDOW LS, 1985, CURR GENET, V10, P39, DOI 10.1007/BF00418492; DEHOOP MJ, 1992, BIOCHEM J, V286, P657, DOI 10.1042/bj2860657; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; FUJIKI Y, 1984, P NATL ACAD SCI-BIOL, V81, P7127, DOI 10.1073/pnas.81.22.7127; FUJIKI Y, 1986, J BIOL CHEM, V261, P5787; GAILLARDIN CM, 1973, ARCH MIKROBIOL, V92, P69, DOI 10.1007/BF00409513; GLEESON MA, 1988, YEAST, V4, P293, DOI 10.1002/yea.320040407; GOULD SJ, 1990, J CELL BIOL, V110, P27, DOI 10.1083/jcb.110.1.27; GOULD SJ, 1992, YEAST, V8, P613, DOI 10.1002/yea.320080805; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; HARTIG A, 1986, EUR J BIOCHEM, V160, P487, DOI 10.1111/j.1432-1033.1986.tb10065.x; HENIKOFF S, 1984, MOL CELL BIOL, V4, P1515, DOI 10.1128/MCB.4.8.1515; HESLOT H, 1992, MOL BIOL GENETIC ENG, P118; HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167; KAMIRYO T, 1984, MOL CELL BIOL, V4, P2136, DOI 10.1128/MCB.4.10.2136; KAMIRYO T, 1982, J BACTERIOL, V152, P269; KELLER GA, 1991, J CELL BIOL, V114, P893, DOI 10.1083/jcb.114.5.893; KOLLER KJ, 1987, NATURE, V325, P542, DOI 10.1038/325542a0; KOTTIG H, 1991, MOL GEN GENET, V232, P423; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; LIU H, 1992, J BACTERIOL, V174, P4943, DOI 10.1128/JB.174.15.4943-4951.1992; NEEDLEMAN RB, 1975, ANAL BIOCHEM, V64, P545, DOI 10.1016/0003-2697(75)90466-2; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; NUTTLEY WM, 1993, YEAST, V9, P507, DOI 10.1002/yea.320090506; NUTTLEY WM, 1990, J CELL SCI, V95, P463; OSUMI T, 1979, BIOCHEM BIOPH RES CO, V89, P580, DOI 10.1016/0006-291X(79)90669-7; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; SANGER F, 1977, P NATL ACAD SCI USA, V83, P6156; SANTOS MJ, 1988, SCIENCE, V239, P1536, DOI 10.1126/science.3281254; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHUTGENS RBH, 1986, EUR J PEDIATR, V144, P430, DOI 10.1007/BF00441734; SUBRAMANI S, 1992, J MEMBRANE BIOL, V125, P99; SUTTON A, 1985, MOL CELL BIOL, V5, P2770, DOI 10.1128/MCB.5.10.2770; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VANDERLEIJ I, 1992, J CELL BIOL, V119, P153, DOI 10.1083/jcb.119.1.153; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WATERHAM HR, 1992, YEAST, V8, P961, DOI 10.1002/yea.320081106; WIEBELL FF, 1992, NATURE, V359, P355; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; XUAN JW, 1990, MOL CELL BIOL, V10, P4795, DOI 10.1128/MCB.10.9.4795; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2; ZHANG H, 1988, NUCLEIC ACIDS RES, V16, P1220, DOI 10.1093/nar/16.3.1220; ZOELLER RA, 1989, J BIOL CHEM, V264, P21872	65	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					556	566						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276851				2022-12-27	WOS:A1994MR21900089
J	BENNETT, SE; SCHIMERLIK, MI; MOSBAUGH, DW				BENNETT, SE; SCHIMERLIK, MI; MOSBAUGH, DW			KINETICS OF THE URACIL-DNA GLYCOSYLASE INHIBITOR PROTEIN ASSOCIATION - UNG INTERACTION WITH UGI, NUCLEIC-ACIDS, AND URACIL COMPOUNDS .5.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BACILLUS-SUBTILIS; EXCISION REPAIR; N-GLYCOSIDASE; RAT-LIVER; PURIFICATION; BACTERIOPHAGE-PBS2; SEQUENCE; IDENTIFICATION; OVERPRODUCTION	The bacteriophage PBS2 uracil-DNA glycosylase inhibitor (Ugi) inactivates Escherichia coli uracil-DNA glycosylase (Ung) by forming an Ung.Ugi protein complex with 1:1 stoichiometry. Stability of the Ung.Ugi complex was demonstrated by the inability of free Ugi to exchange with Ugi bound in preformed complex. Ung was reacted with fluorescein 5-isothiocyanate to produce fluorescent-Ung (F-Ung), which retained full uracil-DNA glycosylase activity and susceptibility to Ugi inactivation. Addition of Ugi to F-Ung under steady-state conditions resulted in saturable (15%) fluorescence quenching at a F-Ung.Ugi ratio of 1:1.4. Dissociation constants determined for the F-Ung interaction with M13 DNA, uracil-containing DNA, and poly(U) equaled 600, 220, and 190 muM, respectively. While F-Ung associated with nucleic acid polymers was able to bind Ugi efficiently, F-Ung bound in the F-Ung.Ugi complex could no longer effectively bind nucleic acid. Stopped-flow kinetic analysis suggested the F-Ung/Ugi association was described by a two-step mechanism. The first step entailed a rapid pre-equilibrium distinguished by the dissociation constant K(d) = 1.3 muM. The second step led irreversibly to the formation of the final complex and was characterized by the rate constant k = 195 s-1. We infer Ugi inactivates Ung through the formation of an exceptionally stable protein-protein complex.	OREGON STATE UNIV,DEPT AGR CHEM,CORVALLIS,OR 97331; OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331; OREGON STATE UNIV,CTR ENVIRONM HLTH SCI,CORVALLIS,OR 97331	Oregon State University; Oregon State University; Oregon State University					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032823] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES00210] Funding Source: Medline; NIGMS NIH HHS [GM32823] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT SE, 1992, J BIOL CHEM, V267, P22512; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONE R, 1977, BIOCHEMISTRY-US, V16, P3194, DOI 10.1021/bi00633a024; CROSBY B, 1981, NUCLEIC ACIDS RES, V9, P5797, DOI 10.1093/nar/9.21.5797; DOMENA JD, 1985, BIOCHEMISTRY-US, V24, P7320, DOI 10.1021/bi00346a045; DOMENA JD, 1988, BIOCHEMISTRY-US, V27, P6742, DOI 10.1021/bi00418a015; DUDLEY B, 1992, J BIOL CHEM, V267, P11964; DUGGLEBY RG, 1984, COMPUT BIOL MED, V14, P447, DOI 10.1016/0010-4825(84)90045-3; DUNCAN BK, 1984, GENE, V28, P211, DOI 10.1016/0378-1119(84)90258-0; FRANKLIN WA, 1988, EMBO J, V7, P3617, DOI 10.1002/j.1460-2075.1988.tb03240.x; FRIEDBERG EC, 1975, J VIROL, V16, P315, DOI 10.1128/JVI.16.2.315-321.1975; Haugland R. P., 1983, EXCITED STATES BIOPO, P29; HAUGLAND RP, 1992, HDB FLUORESCENT PROB, P22; KARRAN P, 1981, BIOCHEMISTRY-US, V20, P6092, DOI 10.1021/bi00524a027; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDAHL T, 1977, J BIOL CHEM, V252, P3286; LINN S, 1981, CHROMOSOME DAMAGE RE, P97; MOSBAUGH DW, 1983, J BIOL CHEM, V258, P108; OLSEN LC, 1989, EMBO J, V8, P3121, DOI 10.1002/j.1460-2075.1989.tb08464.x; SAKUMI K, 1990, MUTAT RES, V236, P161, DOI 10.1016/0921-8777(90)90003-N; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; TIMMER RT, 1989, THESIS U TEXAS; TYE BK, 1978, P NATL ACAD SCI USA, V75, P233, DOI 10.1073/pnas.75.1.233; TYE BK, 1977, J MOL BIOL, V117, P293, DOI 10.1016/0022-2836(77)90128-0; VARSHNEY U, 1988, J BIOL CHEM, V263, P7776; VARSHNEY U, 1991, BIOCHEMISTRY-US, V30, P4055, DOI 10.1021/bi00230a033; WANG Z, 1989, J BIOL CHEM, V264, P1163; WANG ZG, 1988, J BACTERIOL, V170, P1082, DOI 10.1128/jb.170.3.1082-1091.1988; WANG ZG, 1991, GENE, V99, P31; WITTWER CU, 1989, BIOCHEMISTRY-US, V28, P780, DOI 10.1021/bi00428a055; WORRAD DM, 1988, J VIROL, V62, P4774, DOI 10.1128/JVI.62.12.4774-4777.1988	31	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26879	26885						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262921				2022-12-27	WOS:A1993MM26200011
J	MONTERO, M; GARCIASANCHO, J; ALVAREZ, J				MONTERO, M; GARCIASANCHO, J; ALVAREZ, J			INHIBITION OF THE CALCIUM STORE-OPERATED CALCIUM-ENTRY PATHWAY BY CHEMOTACTIC PEPTIDE AND BY PHORBOL ESTER DEVELOPS GRADUALLY AND INDEPENDENTLY ALONG DIFFERENTIATION OF HL-60 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMYELOCYTIC LEUKEMIA-CELLS; PROTEIN-KINASE-C; N-FORMYLMETHIONYL-LEUCYLPHENYLALANINE; HUMAN-NEUTROPHILS; POLYMORPHONUCLEAR LEUKOCYTES; TERMINAL DIFFERENTIATION; PLASMA-MEMBRANE; PHOSPHOLIPASE-D; CA-2+ INFLUX; ACTIVATION	N-Formyl-methionyl-leucyl-phenylalanine (fMLP) inhibited transiently the entry of Ca2+ and Mn2+ induced by emptying with thapsigargin the Ca2+ stores of HL60 cells differentiated toward granulocytes. Phorbol 12,13-dibutyrate (PDB) produced a permanent inhibition of this store-operated Ca2+ entry pathway (SOCP), suggesting that inhibition was due to protein phosphorylation mediated by protein kinase C (PKC). Inhibition by PDB was prevented by the PKC inhibitors staurosporin and chelerythrine. Inhibition by fMLP was prevented by chelerythrine but only partially by staurosporin. The characteristics of the inhibition were similar to those reported in human neutrophils (Montero, M., Alvarez, J., and Garcia-Sancho, J. (1993) J. Biol. Chem. 268, 13055-13061). Neither fMLP nor PDB inhibited significantly SOCP in undifferentiated HL60 cells. Single-cell [Ca2+]i measurements at different stages of differentiation showed that inhibition by fMLP and PDB developed independently, suggesting different inhibitory mechanisms. The simplest explanation would be that inhibition by fMLP takes place through activation of a protein kinase distinct from PKC and that the PDB-activated PKC isoform necessary to phosphorylate and inhibit SOCP is expressed only along differentiation. Additionally, inhibition by both fMLP and PDB developed gradually. At intermediate stages of differentiation, PDB was able to produce a partial and maintained inhibition and fMLP a partial and short-lived inhibition of SOCP.	UNIV VALLADOLID,FAC MED,DEPT BIOQUIM & BIOL MOLEC & FISIOL,E-47005 VALLADOLID,SPAIN	Universidad de Valladolid			Montero, Mayte/K-8212-2014; Alvarez, Javier/K-8210-2014; Garcia-Sancho, Javier/K-2975-2014	Montero, Mayte/0000-0001-7702-6653; Alvarez, Javier/0000-0003-0636-5521; Garcia-Sancho, Javier/0000-0003-4573-7930				ALONSOTORRE SR, 1993, BIOCHEM J, V289, P761, DOI 10.1042/bj2890761; ALVAREZ J, 1989, EUR J BIOCHEM, V183, P709, DOI 10.1111/j.1432-1033.1989.tb21102.x; ANDERSSON T, 1986, MOL PHARMACOL, V30, P437; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHABOT MC, 1992, BIOCHEM J, V286, P693, DOI 10.1042/bj2860693; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; DING JB, 1993, J BIOL CHEM, V268, P5234; FODER B, 1989, CELL CALCIUM, V10, P477, DOI 10.1016/0143-4160(89)90025-0; GELAS P, 1992, BIOCHEM J, V287, P67, DOI 10.1042/bj2870067; GLENNON MC, 1992, J BIOL CHEM, V267, P8230; GRINSTEIN S, 1992, J BIOL CHEM, V267, P18122; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAINES KA, 1991, J CELL BIOL, V114, P433, DOI 10.1083/jcb.114.3.433; HELFMAN DM, 1983, CANCER RES, V43, P2955; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HEYWORTH PG, 1986, BIOCHEM J, V239, P723, DOI 10.1042/bj2390723; HUBERMAN E, 1979, P NATL ACAD SCI USA, V76, P1293, DOI 10.1073/pnas.76.3.1293; KESSELS GCR, 1991, J BIOL CHEM, V266, P23152; KORCHAK HM, 1984, J BIOL CHEM, V259, P4070; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; MONTERO M, 1991, BIOCHEM J, V277, P73, DOI 10.1042/bj2770073; MONTERO M, 1992, BIOCHEM J, V288, P519, DOI 10.1042/bj2880519; MONTERO M, 1993, J BIOL CHEM, V268, P13055; NAKADATE T, 1988, BIOCHEM PHARMACOL, V37, P1541, DOI 10.1016/0006-2952(88)90016-0; NATH J, 1989, J BIOL CHEM, V264, P848; NIEDEL J, 1980, P NATL ACAD SCI-BIOL, V77, P1000, DOI 10.1073/pnas.77.2.1000; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; OHTSUKA T, 1990, J BIOL CHEM, V265, P15418; PERIANIN A, 1989, J BIOL CHEM, V264, P1005; POZZAN T, 1983, SCIENCE, V221, P1413, DOI 10.1126/science.6310757; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; REIBMAN J, 1988, J BIOL CHEM, V263, P6322; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; THOMPSON HL, 1993, BIOCHEM J, V290, P483, DOI 10.1042/bj2900483	35	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26911	26919						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262925				2022-12-27	WOS:A1993MM26200015
J	WALSETH, TF; AARHUS, R; KERR, JA; LEE, HC				WALSETH, TF; AARHUS, R; KERR, JA; LEE, HC			IDENTIFICATION OF CYCLIC ADP-RIBOSE-BINDING PROTEINS BY PHOTOAFFINITY-LABELING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM RELEASE CHANNEL; MUSCLE SARCOPLASMIC-RETICULUM; SEA-URCHIN EGGS; RYANODINE RECEPTOR; CA-2+ RELEASE; INOSITOL TRISPHOSPHATE; MOLECULAR-CLONING; METABOLITE; NAD+; CDNA	We have synthesized 8-azido-cyclic ADP-ribose (8N3-cADPR) and [P-32]8-azido-cyclic ADP-ribose ([P-32]8N3-cADPR) in order to characterize cyclic ADP-ribose(cADPR) binding sites in sea urchin egg homogenates. 8N3-cADPR was an antagonist of cADPR since it did not induce Ca2+ release from egg microsomes but did inhibit the ability of cADPR to do so. The effect of 8N3-cADPR was reversible and could be overcome by high concentrations of cADPR, suggesting that both were acting on the same site. This was supported by the fact that 9N3-cADPR effectively competed for [P-32]CADPR binding to microsomes. Reciprocally, binding of [P-32]8N3-CADPR could also be selectively displaced by cADPR and 8N3-cADPR, but not by ADP-ribose. These results indicate that 8N3-cADPR binds specifically to the cADPR-binding sites and inhibits cADPR from releasing Ca2+. Photolysis of microsomes preincubated with [P-32]8N3-CADPR resulted in specific labeling of proteins of 140 and 100 kDa, which could be prevented by 8N3-cADPR or nanomolar concentrations of cADPR, but not by micromolar concentrations of ADP-ribose, AMP, ADP, ATP, cyclic AMP or inositol 1,4,5-trisphosphate. Caffeine, an agonist of Ca2+-induced Ca2+ release, preferentially inhibited the labeling of the 100 kDa as compared to the 140-kDa protein. These results suggest that cADPR may not interact directly with the ryanodine receptor, but may instead, exert its effect through intermediate proteins.	UNIV MINNESOTA,DEPT PHYSIOL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities	WALSETH, TF (corresponding author), UNIV MINNESOTA,DEPT PHARMACOL,3-247 MILLARD HALL,MINNEAPOLIS,MN 55455, USA.		Lee, Hon Cheung/C-4329-2009; Walseth, Timothy F/F-9518-2010	Walseth, Timothy F/0000-0003-2558-7859	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA008131] Funding Source: NIH RePORTER; NICHD NIH HHS [HD17484] Funding Source: Medline; NIDA NIH HHS [DA08131] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AXELSON JT, 1981, ANAL BIOCHEM, V116, P357, DOI 10.1016/0003-2697(81)90371-7; CARTWRIGHT IL, 1976, NUCLEIC ACIDS RES, V3, P2331, DOI 10.1093/nar/3.9.2331; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; GALIONE A, 1992, TRENDS PHARMACOL SCI, V13, P304, DOI 10.1016/0165-6147(92)90096-O; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HALEY B, 1976, METHOD ENZYMOL, V46, P339; KOSHIYAMA H, 1991, J BIOL CHEM, V266, P16985; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1993, BIOCHIM BIOPHYS ACTA, V1164, P68, DOI 10.1016/0167-4838(93)90113-6; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; LEE HC, 1993, J BIOL CHEM, V268, P293; LEE HC, 1991, J BIOL CHEM, V266, P2276; MARIASH CN, 1982, ANAL BIOCHEM, V121, P388, DOI 10.1016/0003-2697(82)90498-5; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MCPHERSON SM, 1992, J CELL BIOL, V116, P1111, DOI 10.1083/jcb.116.5.1111; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; OTSU K, 1990, J BIOL CHEM, V265, P13472; PRESCOTT M, 1990, ANAL BIOCHEM, V184, P330, DOI 10.1016/0003-2697(90)90690-B; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAKESHIMA H, 1993, FEBS LETT, V322, P105, DOI 10.1016/0014-5793(93)81547-D; WALSETH TF, 1979, BIOCHIM BIOPHYS ACTA, V562, P11, DOI 10.1016/0005-2787(79)90122-9; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S; WANG JX, 1992, NATURE, V359, P739, DOI 10.1038/359739a0; ZAIDI NF, 1989, J BIOL CHEM, V264, P21737; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	36	100	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26686	26691						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253802				2022-12-27	WOS:A1993MK42500098
J	BECKERT, V; DETTMER, R; BERNHARDT, R				BECKERT, V; DETTMER, R; BERNHARDT, R			MUTATIONS OF TYROSINE-82 IN BOVINE ADRENODOXIN THAT AFFECT BINDING TO CYTOCHROME-P45011A1 AND CYTOCHROME-P45011B1 BUT NOT ELECTRON-TRANSFER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; CROSS-LINKING; ADRENOCORTICAL MITOCHONDRIA; CHEMICAL MODIFICATION; MOLECULAR-CLONING; DIRECT EXPRESSION; PRECURSOR FORM; REDUCTASE; COMPLEX	To understand the function of the unique tyrosine in position 82 of bovine adrenodoxin (Adx), which had been proposed to be involved in electron transfer from NADPH-dependent adrenodoxin reductase (AdR) to cytochrome P-450 enzymes and/or AdR binding by chemical modification studies (Taniguchi, T., and Kimura, T. (1975) Biochemistry 14, 5573-5578), the residue was replaced by phenylalanine, leucine, or serine. Unchanged absorption, CD, and electron spin resonance spectra as well as redox potentials indicate that the environment of the [2Fe-2S] cluster was not affected by the mutations. The V(max) values in cytochrome c reduction, P45011A1- and P45011B1-dependent activities were also not changed when using Y82F, Y82S, and Y82L Adx mutants as electron donor, demonstrating that tyrosine 82 is not involved in the intra- or intermolecular electron transfer. Replacement of tyrosine 82 did not affect AdR binding as shown by unchanged cytochrome c activity. There are, however, changes in K(m) values up to 4-fold when measuring the enzymatic activities of mutant Adx with P45011A1 and P45011B1. These changes differ in dependence on the P-450 (P45011A1 or P45011B1) used. The results suggest that mutation of tyrosine 82 either directly or indirectly (by inducing small conformational changes of the binding domain) affects the binding of cytochromes P-450.			BECKERT, V (corresponding author), MAX DELBRUCK CENTRUM MOLEK MED, ROBERT ROSSLE STR 10, D-13125 BERLIN, GERMANY.							ADMAN ET, 1973, J BIOL CHEM, V248, P3987; AKHREM AA, 1979, ACTA BIOL MED GER, V38, P257; CARTER CW, 1974, J BIOL CHEM, V249, P4212; CHASHCHIN VL, 1985, BIOCHIM BIOPHYS ACTA, V828, P313, DOI 10.1016/0167-4838(85)90313-9; COGHLAN VM, 1991, J BIOL CHEM, V266, P18606; COGHLAN VM, 1992, J BIOL CHEM, V267, P8932; DEBUS RJ, 1988, BIOCHEMISTRY-US, V27, P9071, DOI 10.1021/bi00426a001; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; FARVER O, 1987, BIOCHEMISTRY-US, V26, P7317, DOI 10.1021/bi00397a018; GEREN LM, 1984, J BIOL CHEM, V259, P2155; GREENFIELD NJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P246, DOI 10.1016/0167-4838(89)90042-3; HANUKOGLU I, 1980, J BIOL CHEM, V255, P3057, DOI 10.1016/S0021-9258(19)85851-9; HARA T, 1989, J BIOCHEM-TOKYO, V105, P601, DOI 10.1093/oxfordjournals.jbchem.a122711; HIWATASHI A, 1976, BIOCHEMISTRY-US, V15, P3082, DOI 10.1021/bi00659a023; HIWATASHI A, 1986, FEBS LETT, V209, P311, DOI 10.1016/0014-5793(86)81133-4; KIDO T, 1979, J BIOL CHEM, V254, P1806; Kimura T., 1968, STRUCTURE BONDING, V5, P1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAMBETH JD, 1983, J BIOL CHEM, V258, P5596; LAMBETH JD, 1980, J BIOL CHEM, V255, P4667; LAMBETH JD, 1979, J BIOL CHEM, V254, P7255; LAMBETH JD, 1985, J BIOL CHEM, V260, P8810; LAMBETH JD, 1984, J BIOL CHEM, V259, P25; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LIM BT, 1981, J BIOL CHEM, V256, P4400; MARG A, 1992, J MOL BIOL, V227, P945, DOI 10.1016/0022-2836(92)90235-C; MATOCHA MF, 1985, J BIOL CHEM, V260, P2259; MITTAL S, 1988, ARCH BIOCHEM BIOPHYS, V264, P383, DOI 10.1016/0003-9861(88)90303-7; NABI N, 1980, BIOCHEM BIOPH RES CO, V97, P680, DOI 10.1016/0006-291X(80)90318-6; OKAMURA T, 1985, P NATL ACAD SCI USA, V82, P5705, DOI 10.1073/pnas.82.17.5705; OMURA T, 1964, J BIOL CHEM, V239, P2379; PACKER EL, 1972, P NATL ACAD SCI USA, V69, P3278, DOI 10.1073/pnas.69.11.3278; PALIN MF, 1992, ARCH BIOCHEM BIOPHYS, V295, P126, DOI 10.1016/0003-9861(92)90497-K; PICADOLEONARD J, 1988, J BIOL CHEM, V263, P3240; PICADOLEONARD J, 1988, J BIOL CHEM, V263, P11016; PORTER TD, 1991, METHOD ENZYMOL, V206, P108; SAGARA Y, 1992, FEBS LETT, V300, P208, DOI 10.1016/0014-5793(92)80847-A; Sambrook J, 1989, MOL CLONING LABORATO; SLIGAR SG, 1979, BIOCHEM BIOPH RES CO, V90, P925, DOI 10.1016/0006-291X(79)91916-8; SLIGAR SG, 1976, P NATL ACAD SCI USA, V73, P1078, DOI 10.1073/pnas.73.4.1078; SUGANO S, 1989, ANAL BIOCHEM, V182, P327, DOI 10.1016/0003-2697(89)90603-9; TANIGUCHI T, 1975, BIOCHEMISTRY-US, V14, P5573, DOI 10.1021/bi00697a006; TANIGUCHI T, 1976, BIOCHEMISTRY-US, V15, P2849, DOI 10.1021/bi00658a023; TURKO IV, 1989, BIOCHIM BIOPHYS ACTA, V996, P37, DOI 10.1016/0167-4838(89)90091-5; UHLMANN H, 1992, BIOCHEM BIOPH RES CO, V188, P1131, DOI 10.1016/0006-291X(92)91349-U; USANOV SA, 1986, BIOORG KHIM+, V12, P185; USANOV SA, 1990, FRONTIERS BIOTRANSFO, P1	47	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2568	2573						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300585				2022-12-27	WOS:A1994MV43200035
J	KLOEK, AP; YANG, J; MATHEWS, FS; FRIEDEN, C; GOLDBERG, DE				KLOEK, AP; YANG, J; MATHEWS, FS; FRIEDEN, C; GOLDBERG, DE			THE TYROSINE-B10 HYDROXYL IS CRUCIAL FOR OXYGEN AVIDITY OF ASCARIS HEMOGLOBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CARBON-MONOXIDE; LIGAND-BINDING; KINETICS; SITE; AUTOOXIDATION; LEGHEMOGLOBIN; MYOGLOBIN; AFFINITY; SUUM	The parasitic nematode Ascaris suum has a gene encoding a two-domain hemoglobin with remarkable oxygen avidity. The strong interaction with oxygen is a consequence of a particularly slow oxygen off-rate. The single polypeptide chain consists of two domains, each of which can be expressed separately in Escherichia coli as a globin-like protein exhibiting oxygen binding characteristics comparable with the native molecule. Site-directed mutagenesis was performed on the gene segment encoding domain one. The E7 position, involved in forming a hydrogen bond with the liganded oxygen in vertebrate globins, is a glutamine in both Ascaris domains. Conversion of this residue to leucine or alanine produced a hemoglobin variant with an oxygen off-rate 5- or 60-fold faster than that of unaltered domain one. Replacement of the tyrosine B10 with either phenylalanine or leucine (as found in vertebrate globins) yielded hemoglobin mutants with oxygen off-rates 280- or 570-fold faster, approaching rates found with vertebrate myoglobins. The data suggest that the distal glutamine hydrogen bonds with the liganded oxygen and that the tyrosine B10 hydroxyl contributes an additional hydrogen bond that appears substantially responsible for the extreme oxygen avidity of Ascaris hemoglobin.	WASHINGTON UNIV, SCH MED,DEPT MOLEC MICROBIOL,BOX 8230, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOPHYS, ST LOUIS, MO 63110 USA; JEWISH HOSP ST LOUIS, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Barnes-Jewish Hospital					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007172] Funding Source: NIH RePORTER; NIAID NIH HHS [5T32AI07172] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLAXTER ML, 1993, PARASITOL TODAY, V9, P353, DOI 10.1016/0169-4758(93)90082-Q; CARVER TE, 1992, J BIOL CHEM, V267, P14443; DARAWSHE S, 1987, BIOCHEM J, V242, P689, DOI 10.1042/bj2420689; DAVENPORT HE, 1949, PROC R SOC SER B-BIO, V136, P271, DOI 10.1098/rspb.1949.0025; DAVENPORT HE, 1949, PROC R SOC SER B-BIO, V136, P255, DOI 10.1098/rspb.1949.0024; DEBAERE I, 1992, P NATL ACAD SCI USA, V89, P4638, DOI 10.1073/pnas.89.10.4638; Dickerson R.E., 1983, HEMOGLOBIN STRUCTURE; FRENKEL MJ, 1992, MOL BIOCHEM PARASIT, V50, P27, DOI 10.1016/0166-6851(92)90241-B; GIBSON QH, 1989, J BIOL CHEM, V264, P100; GIBSON QH, 1993, J BIOL CHEM, V268, P16993; GIBSON QH, 1965, PROC R SOC SER B-BIO, V163, P206, DOI 10.1098/rspb.1965.0067; GOODMAN M, 1988, J MOL EVOL, V27, P236, DOI 10.1007/BF02100080; IMAMURA T, 1972, J BIOL CHEM, V247, P521; KLOEK AP, 1993, GENE, V129, P215, DOI 10.1016/0378-1119(93)90271-4; KLOEK AP, 1993, J BIOL CHEM, V268, P17669; LEE HC, 1993, BIOCHEMISTRY-US, V32, P11500, DOI 10.1021/bi00094a005; MORRISON HG, 1993, BIOTECHNIQUES, V14, P454; NAGAI K, 1987, NATURE, V329, P858, DOI 10.1038/329858a0; OKAZAKI T, 1967, BIOCHIM BIOPHYS ACTA, V140, P258, DOI 10.1016/0005-2795(67)90466-7; PHILLIPS SEV, 1981, NATURE, V292, P81, DOI 10.1038/292081a0; SHERMAN DR, 1992, P NATL ACAD SCI USA, V89, P11696, DOI 10.1073/pnas.89.24.11696; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WITTENBE.BA, 1965, BIOCHIM BIOPHYS ACTA, V111, P485, DOI 10.1016/0304-4165(65)90058-9; WITTENBERG JB, 1972, J BIOL CHEM, V247, P527; WITTENBERG JB, 1986, J BIOL CHEM, V261, P3624	26	51	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2377	2379						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300562				2022-12-27	WOS:A1994MV43200008
J	MERLIE, JP; MUDD, J; CHENG, TC; OLSON, EN				MERLIE, JP; MUDD, J; CHENG, TC; OLSON, EN			MYOGENIN AND ACETYLCHOLINE-RECEPTOR ALPHA-GENE PROMOTERS MEDIATE TRANSCRIPTIONAL REGULATION IN RESPONSE TO MOTOR INNERVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-SUBUNIT GENE; MUSCLE-SPECIFIC ENHANCER; LIGHT CHAIN ENHANCER; MESSENGER-RNA LEVELS; PROTEIN-KINASE-C; SKELETAL-MUSCLE; ELECTRICAL-ACTIVITY; GAMMA-SUBUNIT; 5'-FLANKING REGION; UPSTREAM SEQUENCE	Several genes expressed in skeletal muscle are transcriptionally repressed by electrical activity arising from motor innervation and are rapidly induced following denervation. Among these are genes encoding the subunits of the nicotinic acetylcholine receptor (AChR) and the myogenic helix-loop-helix protein myogenin, which activates muscle-specific genes. To understand how electrical activity arising from motor innervation is converted into a transcriptional response, we have attempted to localize cis-acting sequences in the AChR alpha subunit and myogenin genes sufficient to direct activity-dependent transcription. Here we show that an 111-base pair and a 335-base pair region from the promoters of the AChR alpha subunit and myogenin genes, respectively, can confer activity-dependent regulation to a linked reporter gene in transgenic mice. The presence of binding sites for myogenic helix-loop-helix proteins in both of these regulatory regions is consistent with the hypothesis that these myogenic regulators serve as nuclear targets for the signaling cascade through which motor innervation leads to changes in gene transcription in skeletal muscle.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	Washington University (WUSTL); University of Texas System; UTMD Anderson Cancer Center								BALDWIN TJ, 1988, J CELL BIOL, V107, P2271, DOI 10.1083/jcb.107.6.2271; BASSELDUBY R, 1992, MOL CELL BIOL, V12, P5024, DOI 10.1128/MCB.12.11.5024; BESSEREAU JL, 1993, EMBO J, V12, P443, DOI 10.1002/j.1460-2075.1993.tb05676.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BUONANNO A, 1988, NATO ASI SER H, V32, P541; CANGIANO A, 1993, NEUROREGENERATION; Cannon WB, 1949, SUPERSENSITIVITY DEN; CHAHINE KG, 1992, DEVELOPMENT, V115, P213; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P6103, DOI 10.1128/MCB.11.12.6103; CHENG TC, 1992, J CELL BIOL, V119, P1649, DOI 10.1083/jcb.119.6.1649; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; CLOSE RI, 1972, PHYSIOL REV, V52, P129, DOI 10.1152/physrev.1972.52.1.129; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; DONOGHUE MJ, 1991, J CELL BIOL, V115, P423, DOI 10.1083/jcb.115.2.423; DONOGHUE MJ, 1992, CELL, V69, P67, DOI 10.1016/0092-8674(92)90119-W; DUCLERT A, 1991, NEUROREPORT, V2, P25, DOI 10.1097/00001756-199101000-00006; DUTTON EK, 1993, P NATL ACAD SCI USA, V90, P2040, DOI 10.1073/pnas.90.5.2040; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EDMONDSON DG, 1992, MOL CELL BIOL, V21, P1; EFTIMIE R, 1991, P NATL ACAD SCI USA, V88, P1349, DOI 10.1073/pnas.88.4.1349; ERNST H, 1991, MOL CELL BIOL, V11, P3735, DOI 10.1128/MCB.11.7.3735; GILMOUR BP, 1991, J BIOL CHEM, V266, P19871; GOLDMAN D, 1988, NEURON, V1, P329, DOI 10.1016/0896-6273(88)90081-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GUNDERSEN K, 1993, BIOTECHNIQUES, V14, P412; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HANLEY T, 1991, BIOTECHNIQUES, V10, P56; HUANG CF, 1992, NEURON, V9, P671, DOI 10.1016/0896-6273(92)90030-H; JIA HT, 1992, CELL MOL NEUROBIOL, V12, P241, DOI 10.1007/BF00712929; KLARSFELD A, 1989, NEURON, V2, P1229, DOI 10.1016/0896-6273(89)90307-3; KLARSFELD A, 1987, MOL CELL BIOL, V7, P951, DOI 10.1128/MCB.7.2.951; Langley JN, 1916, J PHYSIOL-LONDON, V50, P335; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LI L, 1992, MOL CELL BIOL, V12, P4478, DOI 10.1128/MCB.12.10.4478; MARTINOU JC, 1991, P NATL ACAD SCI USA, V88, P7669, DOI 10.1073/pnas.88.17.7669; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; MERLIE JP, 1989, NEURON, V2, P1295, DOI 10.1016/0896-6273(89)90067-6; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; NEVILLE CM, 1992, CELL MOL NEUROBIOL, V12, P511, DOI 10.1007/BF00711232; NUMBERGER M, 1991, EMBO J, V10, P2957, DOI 10.1002/j.1460-2075.1991.tb07846.x; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PHIVAN L, 1990, MOL CELL BIOL, V10, P2302, DOI 10.1128/MCB.10.5.2302; PIETTE J, 1989, EMBO J, V8, P687, DOI 10.1002/j.1460-2075.1989.tb03427.x; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; PRODY CA, 1991, J BIOL CHEM, V266, P22588; PRODY CA, 1992, NUCLEIC ACIDS RES, V20, P2367, DOI 10.1093/nar/20.9.2367; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; ROSENTHAL N, 1989, P NATL ACAD SCI USA, V86, P7780, DOI 10.1073/pnas.86.20.7780; SALMON AM, 1992, NEUROREPORT, V3, P973, DOI 10.1097/00001756-199211000-00006; SANES JR, 1991, DEVELOPMENT, V113, P1181; SCHMALBRUCK H, 1985, HDB MIKROSK ANAT, V11, P1; SIMON AM, 1992, DEVELOPMENT, V114, P545; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; TSAY HJ, 1989, J CELL BIOL, V108, P1523, DOI 10.1083/jcb.108.4.1523; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; WANG XM, 1990, EMBO J, V9, P783, DOI 10.1002/j.1460-2075.1990.tb08174.x; WANG Y, 1988, NEURON, V1, P527, DOI 10.1016/0896-6273(88)90183-3; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; WITZEMANN V, 1989, FEBS LETT, V242, P419, DOI 10.1016/0014-5793(89)80514-9; WITZEMANN V, 1991, FEBS LETT, V282, P259, DOI 10.1016/0014-5793(91)80490-T; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YUTZEY KE, 1990, MOL CELL BIOL, V10, P3934, DOI 10.1128/MCB.10.8.3934	68	60	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2461	2467						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300573				2022-12-27	WOS:A1994MV43200021
J	MOR, A; NICOLAS, P				MOR, A; NICOLAS, P			THE NH2-TERMINAL ALPHA-HELICAL DOMAIN 1-18 OF DERMASEPTIN IS RESPONSIBLE FOR ANTIMICROBIAL ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS; PEPTIDES; SKIN; MAGAININS; SEQUENCE; ANALOGS; FORMS; CDNA; PGLA	Dermaseptin, a 34-amino acid residue cationic peptide, was recently shown to inhibit the growth of pathogenic fungi responsible for severe opportunistic infections accompanying immunodeficiency syndrome and the use of immunosuppressive agents. To improve our understanding of the mechanism by which dermaseptin exerts its potent antimicrobial action, a series of either NH2- or COOH-terminally truncated analogs was synthesized. These analogs were evaluated for their ability to inhibit the growth of various pathogenic agents in culture medium. Dermaseptin exerted a lytic action upon bacteria, protozoa, yeasts, and filamentous fungi at micromolar concentrations. No inhibition of proliferation was observed with human KB cells, and dermaseptin did not lyse guinea pig lymphocytes or rabbit erythrocytes at doses up to 200 mug/ml. Shortening the peptide chain of dermaseptin to dermaseptin-(3-34) slightly reduced the activity of the peptide, while further reduction of the chain length to residues 14-34, 16-34, 20-34, and 28-34 yielded peptide derivatives devoid of antimicrobial activity. On the other hand, lengthening the peptide chain starting from residues 1-4 to residues 1-8 and 1-18 led to a progressive recovery of the activity of the parent molecule. Whereas the central core of dermaseptin (residues 10-19) was virtually inactive, alteration of the COOH-terminal carboxylic group of dermaseptin-(1-18) to a carboxamide yielded a peptide exhibiting enhanced antimicrobial potency, yet displaying even less in vitro toxicity compared with dermaseptin. Overall, the data indicate that molecular elements responsible for the exceptional antimicrobial potency of dermaseptin are to be traced to the NH2-terminal alpha-helical amphipathic segment spanning residues 1-18 of the molecule. Dermaseptin-(1-18)-NH2 may therefore he considered as a useful and highly tractable tool for identifying key features responsible for membrane permeabilization and as a starting point for the design of new therapeutic agents.	INST JACQUES MONOD,BIOACTIVAT PEPTIDES LAB,2 PL JUSSIEU,F-75251 PARIS 05,FRANCE	UDICE-French Research Universities; Universite Paris Cite			Nicolas, Pierre/C-7908-2009					BEVINS CL, 1990, ANNU REV BIOCHEM, V59, P395, DOI 10.1146/annurev.bi.59.070190.002143; BOMAN HG, 1981, TRENDS BIOCHEM SCI, V6, P306, DOI 10.1146/annurev.mi.41.100187.000535; CHUNG LA, 1992, BIOCHEMISTRY-US, V31, P6608, DOI 10.1021/bi00143a035; CRUCIANI RA, 1991, P NATL ACAD SCI USA, V88, P3792, DOI 10.1073/pnas.88.9.3792; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; DUCLOHIER H, 1989, BIOPHYS J, V56, P1017, DOI 10.1016/S0006-3495(89)82746-8; FINTER NB, 1969, J GEN VIROL, V5, P419, DOI 10.1099/0022-1317-5-3-419; GIBSON BW, 1986, J BIOL CHEM, V261, P5341; GIBSON BW, 1991, ACS SYM SER, P222; GIOVANNINI MG, 1987, BIOCHEM J, V243, P113, DOI 10.1042/bj2430113; HERNANDEZ C, 1992, EUR J CELL BIOL, V59, P414; LEHRER RI, 1991, CELL, V64, P229, DOI 10.1016/0092-8674(91)90632-9; MCLEAN LR, 1991, BIOCHEMISTRY-US, V30, P31, DOI 10.1021/bi00215a005; MOORE KS, 1991, J BIOL CHEM, V266, P19851; MOR A, 1991, BIOCHEMISTRY-US, V30, P8824, DOI 10.1021/bi00100a014; NICOLAS P, 1986, BIOCHEM BIOPH RES CO, V140, P565, DOI 10.1016/0006-291X(86)90769-2; NICOLAS P, 1992, M S-MED SCI, V8, P423, DOI 10.4267/10608/3158; POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017; RANA FR, 1991, BIOCHEMISTRY-US, V30, P5858, DOI 10.1021/bi00238a008; ROMEO D, 1988, J BIOL CHEM, V263, P9573; SCHWYZER R, 1986, BIOCHEMISTRY-US, V25, P6335, DOI 10.1021/bi00368a075; WILLIAMS RW, 1990, BIOCHEMISTRY-US, V29, P4490, DOI 10.1021/bi00470a031; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449; ZASLOFF M, 1988, P NATL ACAD SCI USA, V85, P910, DOI 10.1073/pnas.85.3.910	24	145	157	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1934	1939						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294443				2022-12-27	WOS:A1994MR98800059
J	PAK, M; WILLIS, IM; SCHULMAN, LH				PAK, M; WILLIS, IM; SCHULMAN, LH			ANALYSIS OF ACCEPTOR STEM BASE-PAIRING ON TRANSFER RNA(TRP) AMINOACYLATION AND FUNCTION IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATOR TRANSFER-RNA; ELONGATION-FACTOR-TU; FORMYLMETHIONINE TRANSFER-RNA; ESCHERICHIA-COLI; PROTEIN-SYNTHESIS; RECOGNITION; TRYPTOPHAN; IDENTITY; MUTANTS; SYNTHETASE	The role of acceptor stem base pairs in determining the identity of Escherichia coli tRNA(Trp) was examined by complementation of an E. coli strain containing a temperature-sensitive tRNA(Trp) gene (trpT(ts)) and by monitoring aminoacylation levels in vivo. All derivatives of tRNA(Trp) containing substitutions at the first 3 base pairs in the acceptor stem complemented the trpT(ts) mutation at the nonpermissive temperature (42-degrees-C). However, three acceptor stem derivatives (tRNA(Trp)/C1.G72, tRNA(Trp)/C2.G71, and tRNA(TrP)/A3 . U70) required overexpression for growth at 42-degrees-C. Northern analysis of these derivatives following acid/urea gel electrophoresis showed no defects in tRNA aminoacylation at the nonpermissive temperature. Instead, these tRNAs appear to be defective in translation. This was suggested by the weak opal suppressor activities of the corresponding tRNA(UCA)Trp derivatives. These results demonstrate that the three terminal acceptor stem base pairs do not contribute to the identity of tRNA(Trp). Substitution of the C1.A72 base pair in a methionine initiator tRNA containing the tryptophan anticodon and discriminator base (tRNA(CCA)fMet/G73) with A1.U72, the base pair found in tRNA(Trp), or G1.C72 resulted in the conversion of these tRNAs into tryptophan-inserting elongator tRNAs in vivo. However, changes to U1.A72 or C1.G72 in tRNA(CCA)fMet/G73 resulted in misaminoacylation and/or defects in translation. Our data indicate that the A1.U72 base pair is a context-dependent, negative identity element of tRNA(Trp).	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT DEV & MOLEC BIOL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT BIOCHEM, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine				Willis, Ian/0000-0001-6599-2395	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007128] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32GM07128] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOUTORIN AS, 1981, J MOL BIOL, V152, P593, DOI 10.1016/0022-2836(81)90271-0; CHATTAPADHYAY R, 1990, BIOCHEMISTRY-US, V29, P4263, DOI 10.1021/bi00470a001; EISENBERG SP, 1979, J BIOL CHEM, V254, P5562; EISENBERG SP, 1980, J BIOL CHEM, V255, P1128; FRANCKLYN C, 1992, SCIENCE, V255, P1121, DOI 10.1126/science.1546312; FRANCKLYN C, 1990, P NATL ACAD SCI USA, V87, P8655, DOI 10.1073/pnas.87.21.8655; HARRINGTON KM, 1993, BIOCHEMISTRY-US, V32, P7617, DOI 10.1021/bi00081a003; HIMENO H, 1989, NUCLEIC ACIDS RES, V17, P7855, DOI 10.1093/nar/17.19.7855; HIMENO H, 1991, NUCLEIC ACIDS RES, V19, P6379, DOI 10.1093/nar/19.23.6379; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; JAHN M, 1991, NATURE, V352, P258, DOI 10.1038/352258a0; JAKUBOWSKI H, 1984, J BACTERIOL, V158, P769, DOI 10.1128/JB.158.3.769-776.1984; JEKOWSKY E, 1977, J MOL BIOL, V114, P451, DOI 10.1016/0022-2836(77)90262-5; LEE CP, 1991, J BIOL CHEM, V266, P18012; MCCLAIN WH, 1988, SCIENCE, V240, P793, DOI 10.1126/science.2452483; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; NORMANLY J, 1990, J MOL BIOL, V213, P719, DOI 10.1016/S0022-2836(05)80258-X; NORMANLY J, 1989, ANNU REV BIOCHEM, V58, P1029, DOI 10.1146/annurev.bi.58.070189.005121; PAK M, 1992, BIOCHEMISTRY-US, V31, P3303, DOI 10.1021/bi00128a001; PALLANCK L, 1991, P NATL ACAD SCI USA, V88, P3872, DOI 10.1073/pnas.88.9.3872; PALLANCK L, 1992, TRANSFER RNA PROTEIN, P279; ROGERS MJ, 1992, P NATL ACAD SCI USA, V89, P3463, DOI 10.1073/pnas.89.8.3463; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SCHIMMEL P, 1989, BIOCHEMISTRY-US, V28, P2747, DOI 10.1021/bi00433a001; SCHOFIEL.P, 1968, BIOCHIM BIOPHYS ACTA, V155, P410, DOI 10.1016/0005-2787(68)90185-8; SCHULMAN LH, 1991, PROG NUCLEIC ACID RE, V41, P23; SEONG BL, 1989, J BIOL CHEM, V264, P6504; SEONG BL, 1987, P NATL ACAD SCI USA, V84, P8859, DOI 10.1073/pnas.84.24.8859; SMITH D, 1989, J MOL BIOL, V206, P503, DOI 10.1016/0022-2836(89)90497-X; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; VARSHNEY U, 1991, J BIOL CHEM, V266, P18018; WIKMAN FP, 1987, NUCLEIC ACIDS RES, V15, P5787, DOI 10.1093/nar/15.14.5787; YANOFSKY C, 1977, J MOL BIOL, V113, P663, DOI 10.1016/0022-2836(77)90229-7	33	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2277	2282						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294486				2022-12-27	WOS:A1994MR98800108
J	RAMCHANDRAN, R; SEN, GC; MISONO, K; SEN, I				RAMCHANDRAN, R; SEN, GC; MISONO, K; SEN, I			REGULATED CLEAVAGE-SECRETION OF THE MEMBRANE-BOUND ANGIOTENSIN-CONVERTING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-ALPHA; MESSENGER-RNAS; DIPEPTIDYL CARBOXYPEPTIDASE; EXPRESSION; RAT; TRANSCRIPTION; ISOENZYMES; MECHANISMS; PROTEINS; SEQUENCE	Angiotensin-converting enzyme (ACE) is an ectoprotein anchored in the plasma membrane through a hydrophobic domain near its carboxyl-terminal region. Mouse epithelial cells transfected with rabbit testicular ACE cDNA, synthesize, glycosylate, and secrete ACE by cleavage processing of its membrane-anchoring carboxyl-terminal region. Because the cleavage-secretion process is slow, the enzyme accumulates on the cell surface. We show that this process can be enhanced by treatment of cells with tumor-promoting phorbol esters leading to depletion of the cell surface enzyme. The cleavage processing occurs only after the protein has reached the cell surface and is not affected by disruption of the Golgi apparatus or the lysosomal compartments. The exact peptide bond cleaved has been identified by sequencing the amino-terminal residues of the purified COOH-terminal tail left in the cells after ACE is secreted and the carboxyl-terminal residues of secreted ACE. The cleavage occurs at a monobasic site between Arg-663 and Ser-664 generating the soluble enzyme and leaving a cell-bound protein of 74 residues. These results demonstrate the existence of cellular mechanisms that regulate the conversion of cell-bound ACE to a soluble enzyme.	CLEVELAND CLIN FDN,RES INST,DEPT CARDIOVASC BIOL,9500 EUCLID AVE,CLEVELAND,OH 44195; CLEVELAND CLIN FDN,RES INST,DEPT MOLEC BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation; Cleveland Clinic Foundation					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048258] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-48258] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERG T, 1986, J HISTOCHEM CYTOCHEM, V34, P753, DOI 10.1177/34.6.3009604; BERNSTEIN KE, 1989, J BIOL CHEM, V264, P11945; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; CUSHMAN DW, 1980, PROG MED CHEM, V17, P42; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; EHLERS MRW, 1991, P NATL ACAD SCI USA, V88, P1009, DOI 10.1073/pnas.88.3.1009; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; ELDORRY HA, 1982, P NATL ACAD SCI-BIOL, V79, P4295, DOI 10.1073/pnas.79.14.4295; ELDORRY HA, 1982, J BIOL CHEM, V257, P4128; ERDOS E. G., 1967, LIFE SCI, V6, P569, DOI 10.1016/0024-3205(67)90090-2; GIULIAN GG, 1983, ANAL BIOCHEM, V129, P277, DOI 10.1016/0003-2697(83)90551-1; Hayashi R, 1977, Methods Enzymol, V47, P84; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; HUANG EJ, 1990, CELL, V3, P349; HUBERT C, 1991, J BIOL CHEM, V266, P21985; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KUMAR RS, 1991, J BIOL CHEM, V266, P3854; KUMAR RS, 1989, J BIOL CHEM, V264, P16754; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; LU HS, 1991, J BIOL CHEM, V266, P8102; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; Patchett A A, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P1; ROGERS J, 1980, CELL, V20, P303, DOI 10.1016/0092-8674(80)90616-9; Safer R. L., 1981, BIOCH REGULATION BLO, P123; SEN I, 1993, J BIOL CHEM, V268, P25748; SKEGGS LT, 1956, J EXP MED, V103, P295, DOI 10.1084/jem.103.3.295; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; THEKKUMKARA TJ, 1992, NUCLEIC ACIDS RES, V20, P683, DOI 10.1093/nar/20.4.683; WEI L, 1991, J BIOL CHEM, V266, P5540	32	92	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2125	2130						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294466				2022-12-27	WOS:A1994MR98800087
J	SHEPARD, AR; ZHANG, WG; EBERHARDT, NL				SHEPARD, AR; ZHANG, WG; EBERHARDT, NL			2 CGTCA MOTIFS AND A GHF1/PIT1 BINDING-SITE MEDIATE CAMP-DEPENDENT PROTEIN KINASE-A REGULATION OF HUMAN GROWTH-HORMONE GENE-EXPRESSION IN RAT ANTERIOR-PITUITARY GC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3',5'-CYCLIC ADENOSINE-MONOPHOSPHATE; TRANS-ACTING FACTOR; CYCLIC-AMP; RESPONSIVE ELEMENT; THYROID-HORMONE; TRANSCRIPTION FACTOR; TUMOR-CELLS; 5'-FLANKING REGION; PROLACTIN GENE; DNA	We established the cis-acting elements which mediate cAMP responsiveness of the human growth hormone (hGH) gene in transiently transfected rat anterior pituitary tumor GC cells. Analysis of the intact hGH gene or hGH 5'-flanking DNA (5'-FR) coupled to the hGH cDNA or chloramphenicol acetyltransferase or luciferase genes, indicated that cAMP primarily stimulated hGH promoter activity. Cotransfection of a protein kinase A inhibitory protein cDNA demonstrated that the cAMP response was mediated by protein kinase A. Mutational analysis of the hGH promoter identified two core cAMP response element motifs (CGTCA) located at nucleotides -187/-183 (distal cAMP response element; dCRE) and -99/-95 (proximal cAMP response element; pCRE) and a pituitary-specific transcription factor (GHF1/Pit1) binding site at nucleotides -123/-112 (dGHF1) which were required for cAMP responsiveness. GHF1 was not a limiting factor, since overexpression of GHF1 in cotransfections increased basal but not forskolin induction levels. Gel shift analyses indicated that similar, ubiquitous, thermostable protein(s) specifically bound the pCRE and dCRE motifs. The CGTCA motif-binding factors were cAMP response element binding protein (CREB)/activating transcription factor-1 (ATF-1)-related, since the DNA-protein complex was competed by unlabeled CREB consensus oligonucleotide, specifically super-shifted by antisera to CREB and ATF-1 but not ATF-2, and was bound by purified CREB with the same relative binding affinity (pCRE < dCRE < CREB) and mobility as the GC nuclear extract. UV cross-linking and Southwestern blot analyses revealed multiple DNA-protein interactions of which almost-equal-to 100- and almost-equal-to 45-kDa proteins were predominant; the almost-equal-to 45-kDa protein may represent CREB. These results indicate that CREB/ATF-1-related factors act coordinately with the cell-specific factor GHF1 to mediate cAMP-dependent regulation of hGH-1 gene transcription in anterior pituitary somatotrophs.	MAYO CLIN & MAYO FDN,DEPT MED & BIOCHEM,ENDOCRINE RES UNIT,4-407 ALFRED,SMH,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT MOLEC BIOL,ROCHESTER,MN 55905; UNIV CALIF SAN FRANCISCO,HORMONE RES INST,SAN FRANCISCO,CA 94143	Mayo Clinic; Mayo Clinic; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041206] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41206] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDRISANI O, 1990, J BIOL CHEM, V265, P3212; BARINAGA M, 1985, NATURE, V314, P279, DOI 10.1038/314279a0; BARINAGA M, 1983, NATURE, V306, P84, DOI 10.1038/306084a0; BEIMLING P, 1992, ONCOGENE, V7, P257; BODNER M, 1987, CELL, V50, P267, DOI 10.1016/0092-8674(87)90222-4; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BOSHART M, 1990, CELL, V61, P905, DOI 10.1016/0092-8674(90)90201-O; BRENT GA, 1988, MOL ENDOCRINOL, V2, P792, DOI 10.1210/mend-2-9-792; CATTINI PA, 1986, J BIOL CHEM, V261, P3367; CATTINI PA, 1987, NUCLEIC ACIDS RES, V15, P1297, DOI 10.1093/nar/15.3.1297; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; COPP RP, 1989, MOL ENDOCRINOL, V3, P790, DOI 10.1210/mend-3-5-790; DANA S, 1989, MOL ENDOCRINOL, V3, P815, DOI 10.1210/mend-3-5-815; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DEWIT JR, 1987, MOL CELL BIOL, V7, P725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRUST DS, 1991, MOL ENDOCRINOL, V5, P1541, DOI 10.1210/mend-5-10-1541; EASTMAN A, 1987, BIOTECHNIQUES, V5, P731; FINK JS, 1988, P NATL ACAD SCI USA, V85, P6662, DOI 10.1073/pnas.85.18.6662; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GROVE JR, 1987, SCIENCE, V238, P530; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HOSHI T, 1988, SCIENCE, V240, P1652, DOI 10.1126/science.2454506; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KEECH CA, 1992, MOL ENDOCRINOL, V6, P2059, DOI 10.1210/me.6.12.2059; KOBIERSKI LA, 1991, P NATL ACAD SCI USA, V88, P10222, DOI 10.1073/pnas.88.22.10222; LEE TC, 1992, NUCLEIC ACIDS RES, V20, P140, DOI 10.1093/nar/20.1.140; LEFEVRE C, 1987, EMBO J, V6, P971, DOI 10.1002/j.1460-2075.1987.tb04847.x; LIANG J, 1992, MOL ENDOCRINOL, V6, P885, DOI 10.1210/me.6.6.885; LIU F, 1993, J BIOL CHEM, V268, P6714; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MEYER TE, 1993, ENDOCRINOLOGY, V132, P770, DOI 10.1210/en.132.2.770; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MILLER WL, 1983, ENDOCR REV, V4, P97, DOI 10.1210/edrv-4-2-97; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; NACHTIGAL MW, 1989, NUCLEIC ACIDS RES, V17, P4327, DOI 10.1093/nar/17.11.4327; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NICKEL BE, 1991, MOL CELL BIOCHEM, V106, P181; PEERS B, 1991, J BIOL CHEM, V266, P18127; PEERS B, 1992, EUR J BIOCHEM, V210, P53, DOI 10.1111/j.1432-1033.1992.tb17389.x; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; Sambrook J, 1989, MOL CLONING LABORATO; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; SUN PQ, 1992, MOL ENDOCRINOL, V6, P1858, DOI 10.1210/me.6.11.1858; VERRIJZER CP, 1991, EMBO J, V10, P3007, DOI 10.1002/j.1460-2075.1991.tb07851.x; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WAGONER PK, 1988, SCIENCE, V240, P1655, DOI 10.1126/science.2454507; WALKER MD, 1983, NATURE, V306, P557, DOI 10.1038/306557a0; ZHANG WG, 1992, J BIOL CHEM, V267, P15056; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	61	70	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1804	1814						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294429				2022-12-27	WOS:A1994MR98800041
J	ALAM, J; CAI, J; SMITH, A				ALAM, J; CAI, J; SMITH, A			ISOLATION AND CHARACTERIZATION OF THE MOUSE HEME OXYGENASE-1 GENE - DISTAL 5' SEQUENCES ARE REQUIRED FOR INDUCTION BY HEME OR HEAVY-METALS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BALB/C 3T3 CELLS; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATION; REGULATORY ELEMENTS; MAMMALIAN-CELLS; TUMOR PROMOTERS; HEPATOMA-CELLS; OXIDANT STRESS; NUCLEAR FACTOR; EXPRESSION	Mouse genomic fragments encoding heme oxygenase-1 (HO-1) were isolated from a recombinant lambda library by in situ plaque hybridization. The mouse HO-1 gene, approximately 7 kilobase pairs (kbp) in length, is organized into 5 exons and 4 introns. The primary structure of the exons and 1287 base pairs (bp) of the 5'-flanking region was determined. The deduced amino acid sequence of the mouse HO-1 gene is identical to that of p32, initially identified as a stress-induced protein in mouse BALBc/3T3 cells. A single, major transcription initiation site is utilized for constitutive and heme- or metal-induced expression of the HO-1 gene in mouse hepatoma (Hepa) cells. The transcriptional activity of the 5'-flanking region was examined by transient expression assays using the chloramphenicol acetyltransferase gene as the reporter gene. Basal promoter activity in several cell lines was localized to within 149 bp of the upstream sequence by deletion analysis. This proximal promoter region of the mouse HO-1 gene contains several sequence elements that are not only conserved in both the rat and human HO-1 genes but also resemble consensus binding sites of various transcription factors including AP-1, AP-4, C/EBP and c-Myc:Max/USF. Heavy metals activate HO-1 gene transcription and the rat gene contains a putative metal regulatory element (Muller, R. M., Taguchi, H., and Shibahara, S. (1987) J. Biol. Chem. 262,6795-6802) that is completely conserved in the mouse gene. Transient expression analyses, however, indicate that this sequence, which contains a core heptanucleotide, TGCACTC, identical to that of the strongest metal regulatory element of the mouse metallothionein-1 gene, is not responsive to Cd2+ or Zn2+. Stable transfection of constructs containing the entire mouse HO-1 gene and various portions of the 5'-flanking region into rat C6 glioma cells and simultaneous, quantitative analysis of the mouse and rat HO-1 mRNAs indicate that distal 5' sequences, between positions -3.5 and -12.5 kbp, are required for induction of mouse HO-1 gene transcription by both heme and heavy metals. A 5-7-fold difference in the levels of induction between stably integrated and transiently expressed mouse HO-1 gene constructs is observed in this cell line. An HO-1/CAT fusion gene, pMH09cat, containing the HO-1 proximal promoter and the 9-kbp upstream fragment, is not inducible in C6 cells, but is activated 11- and 12-fold by Cd2+ and heme, respectively, in Hepa cells, indicating tissue-specific variation in the activation mechanism. The active, inducer-dependent element(s) is located within a 268-bp fragment previously shown to mediate 12-O-tetradecanoylphorbol-13-acetate induction of the mouse HO-1 gene (Alam, J., and Zhining, D. (1992) J. Biol. Chem. 267,21894-21900). Chromosomal integration of the HO-1/CAT constructs is required for heme- or Cd2+-mediated activation in Hepa cells, suggesting a role for chromatin organization in the induction process.	LOUISIANA STATE UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,NEW ORLEANS,LA 70121; UNIV MISSOURI,SCH BIOL SCI,KANSAS CITY,MO 64110	Louisiana State University System; University of Missouri System; University of Missouri Kansas City	ALAM, J (corresponding author), ALTON OCHSNER MED FDN & OCHSNER CLIN,DEPT MOLEC GENET,1516 JEFFERSON HIGHWAY,NEW ORLEANS,LA 70121, USA.		Alam, Jawed/F-2596-2010	Alam, Jawed/0000-0001-6520-482X	NIDDK NIH HHS [DK-43135, DK-37463] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037463, R01DK043135] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM J, 1989, J BIOL CHEM, V264, P17637; ALAM J, 1992, J BIOL CHEM, V267, P16379; ALAM J, 1990, ANAL BIOCHEM, V188, P245, DOI 10.1016/0003-2697(90)90601-5; ALAM J, 1992, J BIOL CHEM, V267, P21894; ALAM J, 1989, J BIOL CHEM, V264, P6371; ALAM J, 1991, BIOTECHNIQUES, V10, P423; AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; APPLEGATE LA, 1991, CANCER RES, V51, P974; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CULLOTTA VC, 1989, MOL CELL BIOL, V9, P1376; EVANS CO, 1991, BIOCHEM J, V273, P659, DOI 10.1042/bj2730659; EWING JF, 1991, P NATL ACAD SCI USA, V88, P5364, DOI 10.1073/pnas.88.12.5364; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENE JJ, 1988, CURRENT PROTOCOLS MO; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HIWASA T, 1982, P NATL ACAD SCI-BIOL, V79, P1800, DOI 10.1073/pnas.79.6.1800; HIWASA T, 1986, CANCER RES, V46, P2474; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; ISHIKAWA K, 1992, BIOCHEM BIOPH RES CO, V182, P981, DOI 10.1016/0006-291X(92)91828-E; JACOB M, 1989, NUCLEIC ACIDS RES, V17, P2159, DOI 10.1093/nar/17.6.2159; KAGEYAMA H, 1988, CANCER RES, V48, P4795; KEYSE SM, 1990, MOL CELL BIOL, V10, P4967, DOI 10.1128/MCB.10.9.4967; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; LIN JHC, 1990, EUR J BIOCHEM, V192, P577, DOI 10.1111/j.1432-1033.1990.tb19263.x; Locker J, 1990, DNA Seq, V1, P3, DOI 10.3109/10425179009041342; Maines M.D., 1992, HEME OXYGENASE CLIN; Maxam A M, 1980, Methods Enzymol, V65, P499; MITANI K, 1990, BIOCHEM BIOPH RES CO, V166, P1429, DOI 10.1016/0006-291X(90)91026-O; MULLER RM, 1987, J BIOL CHEM, V262, P6795; NASCIMENTO ALTO, 1993, NUCLEIC ACIDS RES, V21, P1103, DOI 10.1093/nar/21.5.1103; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO M, 1989, J BIOL CHEM, V264, P10251; SATO M, 1990, EUR J BIOCHEM, V188, P231, DOI 10.1111/j.1432-1033.1990.tb15394.x; SHIBAHARA S, 1989, EUR J BIOCHEM, V179, P557, DOI 10.1111/j.1432-1033.1989.tb14583.x; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P7865, DOI 10.1073/pnas.82.23.7865; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; SMITH A, 1984, J BIOL CHEM, V259, P2049; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STUART GW, 1985, NATURE, V317, P828, DOI 10.1038/317828a0; TYRRELL RM, 1993, CARCINOGENESIS, V14, P761, DOI 10.1093/carcin/14.4.761; WEIL D, 1988, J BIOL CHEM, V263, P8561; YOSHIDA T, 1988, EUR J BIOCHEM, V171, P457, DOI 10.1111/j.1432-1033.1988.tb13811.x	56	145	147	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1001	1009						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288554				2022-12-27	WOS:A1994MR22000037
J	LONG, GJ; ROSEN, JF; SCHANNE, FAX				LONG, GJ; ROSEN, JF; SCHANNE, FAX			LEAD ACTIVATION OF PROTEIN-KINASE-C FROM RAT-BRAIN - DETERMINATION OF FREE CALCIUM, LEAD, AND ZINC BY F-19-NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							OSTEOBLASTIC BONE-CELLS; INTRACELLULAR CALCIUM; MAMMALIAN-TISSUES; HEAVY-METALS; BINDING; CA-2+; PURIFICATION; EXPOSURE; NMR; PHOSPHOLIPIDS	Lead (Pb2+) has been reported to activate calcium/phospholipid-dependent protein kinase C (PKC) at subnanomolar concentrations (Markovac, J., and Goldstein, G. W. (1988) Nature 334, 732-734); however, others have failed to find any Pb2+-induced activation of PKC (Murakami, K., Feng, G., and Chen, S. G. (1993) J. Pharmacol. Exp. Ther. 264, 757-761). In neither of these studies was the actual free Pb2+ or Ca2+ concentration measured. In this study, 1,2-bis(2-amino-5-fluorophenoxy)ethane N,N,N',N'-tetraacetic acid (5F-BAPTA) was used to buffer Pb2+ and Ca2+ concentrations in the PKC reaction mixture. The specific free ion concentrations of Pb2+ and Ca2+, as well as Zn2+ and other divalent cations contained in the PKC reaction mixtures, were determined by F-19 NMR spectroscopy. Using this approach to set and confirm the free Pb2+ and Ca2+ concentrations, we measured the Pb2+-dependent and the Ca2+-dependent activation of phosphotydylserine/diolein-dependent incorporation of P-32 from ATP into histone and endogenous acid precipitable proteins in the 100,000 x g supernatant from homogenized rat brain cortex. We found that free Pb2+ activates PKC in the range from 10(-11) to 10(-8) M, K(act) = 5.5 x 10(-11) m, while Ca2+ activates PKC in the range from 10(-8) to 10(-5) M, K(cat) = 2.56 x 10(-7) M. These findings clearly resolve the activation of PKC by subnanomolar concentrations of free Pb2+ from activation induced by Ca2+ or other divalent cations. Furthermore, it documents the utility of 5F-BAPTA as buffer and indicator when resolving the contributions of multiple divalent cations in biochemical processes.	MONTEFIORE MED CTR,ALBERT EINSTEIN COLL MED,DEPT PEDIAT,BRONX,NY 10467; MONTEFIORE MED CTR,ALBERT EINSTEIN COLL MED,DEPT PATHOL,BRONX,NY 10467	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004006, R37ES001060, R23ES004006, R01ES001060, R29ES006087] Funding Source: NIH RePORTER; NIEHS NIH HHS [R29-ES06087, ES01060, ES04006] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALKON DL, 1988, SCIENCE, V239, P998, DOI 10.1126/science.2830669; [Anonymous], 1988, NATURE EXTENT LEAD P; AUDESIRK G, 1985, PROG NEUROBIOL, V24, P199, DOI 10.1016/0301-0082(85)90006-1; AUDESIRK G, 1991, NEUROTOXICOLOGY, V12, P519; AZZI A, 1992, EUR J BIOCHEM, V208, P547, DOI 10.1111/j.1432-1033.1992.tb17219.x; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P115, DOI 10.1021/bi00375a017; BELLINGER D, 1987, NEW ENGL J MED, V316, P1037, DOI 10.1056/NEJM198704233161701; BERS DM, 1982, AM J PHYSIOL, V242, pC404, DOI 10.1152/ajpcell.1982.242.5.C404; BRESSLER JP, 1991, BIOCHEM PHARMACOL, V41, P479, DOI 10.1016/0006-2952(91)90617-E; Byers RK, 1943, AM J DIS CHILD, V66, P471; COHAN CS, 1987, J NEUROSCI, V7, P3588; CONNOR JA, 1986, P NATL ACAD SCI USA, V83, P6179, DOI 10.1073/pnas.83.16.6179; COOPER GP, 1984, NEUROTOXICOLOGY, V5, P247; DOWD TL, 1993, P SOC MAGN RESON MED, V1, P407; FULLMER CS, 1985, J BIOL CHEM, V260, P6816; HABERMANN E, 1983, ARCH TOXICOL, V54, P61, DOI 10.1007/BF00277816; HARRISON SM, 1987, BIOCHIM BIOPHYS ACTA, V925, P133, DOI 10.1016/0304-4165(87)90102-4; HUANG KP, 1988, J BIOL CHEM, V263, P14839; INOUE M, 1977, J BIOL CHEM, V252, P7610; IRITA K, 1991, INT J BIOCHEM, V23, P301, DOI 10.1016/0020-711X(91)90110-9; JAKEN S, 1987, P NATL ACAD SCI USA, V84, P4418, DOI 10.1073/pnas.84.13.4418; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; KLANN E, 1991, J BIOL CHEM, V266, P24253; KOSTIAL K, 1957, BRIT J PHARM CHEMOTH, V12, P219, DOI 10.1111/j.1476-5381.1957.tb00123.x; LONG GJ, 1990, TOXICOL APPL PHARM, V106, P270, DOI 10.1016/0041-008X(90)90246-Q; LONG GJ, 1991, CALCIFIED TISSUE INT, V50, P451; MANTON WI, 1984, BRIT J IND MED, V41, P313; MARKOVAC J, 1988, TOXICOL APPL PHARM, V96, P14, DOI 10.1016/0041-008X(88)90242-6; MARKOVAC J, 1988, NATURE, V334, P732; MAURER MC, 1992, BIOCHEMISTRY-US, V31, P7714, DOI 10.1021/bi00148a036; MCMICHAEL AJ, 1988, NEW ENGL J MED, V319, P468, DOI 10.1056/NEJM198808253190803; METCALFE JC, 1985, CELL CALCIUM, V6, P183, DOI 10.1016/0143-4160(85)90043-0; MINNEMA DJ, 1988, TOXICOL APPL PHARM, V92, P351, DOI 10.1016/0041-008X(88)90175-5; MURAKAMI K, 1993, J PHARMACOL EXP THER, V264, P757; MURAKAMI K, 1987, J BIOL CHEM, V262, P13902; POUNDS JG, 1984, NEUROTOXICOLOGY, V5, P295; POUNDS JG, 1982, TOXICOL APPL PHARM, V63, P389, DOI 10.1016/0041-008X(82)90268-X; RASMUSSEN H, 1986, NEW ENGL J MED, V314, P1094; RODRIGUEZPARIS JM, 1989, BIOCHEM BIOPH RES CO, V159, P495, DOI 10.1016/0006-291X(89)90020-X; SCHACTERLE GR, 1973, ANAL BIOCHEM, V51, P654, DOI 10.1016/0003-2697(73)90523-X; SCHANNE FAX, 1990, ENVIRON HEALTH PERSP, V84, P99, DOI 10.2307/3430710; SCHANNE FAX, 1989, BRAIN RES, V503, P308, DOI 10.1016/0006-8993(89)91680-6; SCHANNE FAX, 1989, P NATL ACAD SCI USA, V86, P5133, DOI 10.1073/pnas.86.13.5133; SCHANNE FAX, 1990, BIOCHIM BIOPHYS ACTA, V1054, P250, DOI 10.1016/0167-4889(90)90249-D; SCHANNE FAX, 1992, BIOCHIM BIOPHYS ACTA, V1180, P187, DOI 10.1016/0925-4439(92)90067-W; Schoenmakers T. J., 1992, BIOTECHNIQUES, V12, P876; SCHOENMAKERS TJM, 1992, BIOTECHNIQUES, V12, P870; SIMONS TJB, 1987, J NEUROCHEM, V48, P383, DOI 10.1111/j.1471-4159.1987.tb04105.x; SIMONS TJB, 1986, BRIT MED BULL, V42, P431, DOI 10.1093/oxfordjournals.bmb.a072162; SMITH GA, 1983, P NATL ACAD SCI-BIOL, V80, P7178, DOI 10.1073/pnas.80.23.7178; SPEIZER LA, 1989, J BIOL CHEM, V264, P5581; TAKAI Y, 1977, J BIOL CHEM, V252, P7603; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; WATSON JB, 1992, P NATL ACAD SCI USA, V89, P8581, DOI 10.1073/pnas.89.18.8581; ZIDOVETZKI R, 1992, BIOCHIM BIOPHYS ACTA, V1134, P261, DOI 10.1016/0167-4889(92)90185-E; 1985, CDC992230 US DEP HLT	57	140	144	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					834	837						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288636				2022-12-27	WOS:A1994MR22000014
J	YATSUNAMI, K; OHTSU, H; TSUCHIKAWA, M; HIGUCHI, T; ISHIBASHI, K; SHIDA, A; SHIMA, Y; NAKAGAWA, S; YAMAUCHI, K; YAMAMOTO, M; HAYASHI, N; WATANABE, T; ICHIKAWA, A				YATSUNAMI, K; OHTSU, H; TSUCHIKAWA, M; HIGUCHI, T; ISHIBASHI, K; SHIDA, A; SHIMA, Y; NAKAGAWA, S; YAMAUCHI, K; YAMAMOTO, M; HAYASHI, N; WATANABE, T; ICHIKAWA, A			STRUCTURE OF THE L-HISTIDINE DECARBOXYLASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-CELL-LINE; CHRONIC MYELOGENOUS LEUKEMIA; MASTOCYTOMA P-815 CELLS; EXPRESSION; RNA; DIFFERENTIATION; HYBRIDIZATION; TRANSCRIPTS; CHROMOSOME; FRAGMENTS	Two species of L-histidine decarboxylase (HDC) mRNA were found in the KU-812-F basophilic cell line, but only the 2.4-kilobase (kb) one encodes the functional HDC (Mamune-Sato, R., Yamauchi, K., Tanno, Y., Ohkawara, Y., Ohtsu, H., Katayose, D., Maeyama, K., Watanabe, T., Shibahara, S., and Takishima, T. (1992) Eur. J. Biochem. 209, 533-539). The 3.4-kb one encodes a truncated HDC protein and is also found in human leukemia-derived cell lines HEL and KCL-22. To clarify the mechanisms that regulate transcription of the HDC gene and generate the two species of mRNA, we have isolated genomic DNA clones coding for the HDC from human genomic libraries. Structural analysis of the isolated clones revealed that the human HDC gene is composed of 12 exons spanning approximately 24 kb. Genomic DNA blot analysis suggested that HDC is encoded by a single copy gene. The structural analysis also demonstrated that the heterogeneity of the HDC mRNA is caused by an insertion of the seventh intron sequence and alternative use of the splicing acceptor site at the 12th exon. The transcription start site of the HDC gene and the nucleotide sequences of the promoter and first exon regions were determined. We found a TATA-like sequence, a GC box, four CACC boxes, four GATA consensus sequences, and six leader-binding protein-1 binding motifs in the promoter region of the HDC gene.	TOHOKU UNIV,SCH MED,DEPT PHARMACOL 1,SEIRYO MACHI 2-1,AOBA KU,SENDAI,MIYAGI 980,JAPAN; TOHOKU UNIV,SCH MED,DEPT INTERNAL MED 1,SENDAI,MIYAGI 980,JAPAN; KYOTO UNIV,FAC PHARMACEUT SCI,DEPT BUSINESS ADM,KYOTO 606,JAPAN; JAPAN TOBACCO INC,PHARMACEUT BASIC RES LABS,YOKOHAMA 236,JAPAN	Tohoku University; Tohoku University; Kyoto University; Japan Tobacco Inc.			Yamauchi, Kohei/N-2749-2016; Yamamoto, Masayuki/A-4873-2010	Yamamoto, Masayuki/0000-0002-9073-9436				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Beaven M A, 1978, Monogr Allergy, V13, P1; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BURLAND WL, 1982, PHARM HISTAMINE RECE, P436; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIULLA TA, 1988, ANAL BIOCHEM, V174, P485, DOI 10.1016/0003-2697(88)90047-4; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; ELSHOLTZ HP, 1986, SCIENCE, V234, P1552, DOI 10.1126/science.3491428; ENDO K, 1993, IN PRESS BR J HAEMAT; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUKUDA T, 1987, BLOOD, V70, P612; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; JOSEPH DR, 1990, P NATL ACAD SCI USA, V87, P733, DOI 10.1073/pnas.87.2.733; KAHLSON G, 1968, PHYSIOL REV, V48, P155, DOI 10.1152/physrev.1968.48.1.155; KAWAI H, 1992, BIOCHIM BIOPHYS ACTA, V1133, P172, DOI 10.1016/0167-4889(92)90066-K; KOEFFLER HP, 1978, SCIENCE, V200, P1153, DOI 10.1126/science.306682; KUBONISHI I, 1983, International Journal of Cell Cloning, V1, P105; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MAEYAMA K, 1988, BIOCHEM BIOPH RES CO, V151, P1402, DOI 10.1016/S0006-291X(88)80518-7; MAMUNESATO R, 1992, EUR J BIOCHEM, V209, P533, DOI 10.1111/j.1432-1033.1992.tb17317.x; Maniatis T., 1982, MOL CLONING; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MEINKOTH J, 1984, ANAL BIOCHEM, V138, P267, DOI 10.1016/0003-2697(84)90808-X; MINOWADA J, 1977, J NATL CANCER I, V59, P83, DOI 10.1093/jnci/59.1.83; OHKUBO T, 1985, LEUKEMIA RES, V9, P921, DOI 10.1016/0145-2126(85)90314-5; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVANY A, 1988, BIOCHEM INT, V16, P559; SAVANY A, 1982, BIOCHEM J, V205, P405, DOI 10.1042/bj2050405; SHIGA K, 1990, P NATL ACAD SCI USA, V87, P3594, DOI 10.1073/pnas.87.9.3594; SULLIVAN PM, 1991, J BIOL CHEM, V266, P143; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WATANABE T, 1982, ADV HISTAMINE RES, P93; YAMAMOTO J, 1990, FEBS LETT, V276, P214, DOI 10.1016/0014-5793(90)80545-T; YAMAMOTO M, 1985, P NATL ACAD SCI USA, V82, P3702, DOI 10.1073/pnas.82.11.3702; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; YAMAUCHI K, 1990, NUCLEIC ACIDS RES, V18, P5891, DOI 10.1093/nar/18.19.5891; YATSUNAMI K, 1993, AGENTS ACTIONS, V38, pC155, DOI 10.1007/BF01996445; YU CY, 1991, J BIOL CHEM, V266, P8907; Zahnow C A, 1991, DNA Seq, V1, P395, DOI 10.3109/10425179109020795; ZON LI, 1991, J BIOL CHEM, V266, P22948	42	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1554	1559						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288622				2022-12-27	WOS:A1994MR22000118
J	HAZARD, AL; SENIOR, AE				HAZARD, AL; SENIOR, AE			DEFECTIVE ENERGY COUPLING IN DELTA-SUBUNIT MUTANTS OF ESCHERICHIA-COLI F1F0-ATP SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ATP SYNTHASE; B UNCF-PROTEIN; ADENOSINE-TRIPHOSPHATASE; CRYOELECTRON MICROSCOPY; ELECTRON-MICROSCOPY; GAMMA-SUBUNIT; PROTON-ATPASE; ALPHA-SUBUNIT; H+-ATPASE; FACTOR-I	Membrane vesicles from 13 strains carrying mutations in the C-terminal region of the delta-subunit of Escherichia coli F1F0-ATP synthase were characterized in respect to ATPase activity, ATP-driven proton-pumping, dicyclohexylcarbodiimide sensitivity of ATPase, and oxidative phosphorylation. The salient finding was that energy-coupling between F1 and F0 sectors of the enzyme is impaired by several of the mutations. The deltaG150N mutant appeared completely uncoupled in vitro. The data emphasize the role of the C-terminal region of delta-subunit in integration of the proton conduction machinery in F0 with the three F1 catalytic sites. It is suggested that the C-terminal region of delta-subunit, speculatively located in the central region of the alpha3beta3 hexagon, acts functionally at the interface between the helical domain of the stalk and the F1 subunits to relay conformational signals which alter the affinities of the catalytic sites for substrates and products.			HAZARD, AL (corresponding author), UNIV ROCHESTER,MED CTR,DEPT BIOCHEM,ROCHESTER,NY 14642, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025349, R37GM025349] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 25349] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1993, EMBO J, V12, P1775, DOI 10.1002/j.1460-2075.1993.tb05825.x; AGGELER R, 1992, J BIOL CHEM, V267, P21355; BIANCHET M, 1991, J BIOL CHEM, V266, P21197; BOEKEMA EJ, 1990, BIOCHIM BIOPHYS ACTA, V1020, P49, DOI 10.1016/0005-2728(90)90092-I; BOEKEMA EJ, 1988, BIOCHIM BIOPHYS ACTA, V933, P365, DOI 10.1016/0005-2728(88)90044-8; BOEKEMA EJ, 1992, BIOCHIM BIOPHYS ACTA, V1098, P131, DOI 10.1016/S0005-2728(05)80328-7; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG TM, 1974, J BIOL CHEM, V249, P1090; COX GB, 1984, BIOCHIM BIOPHYS ACTA, V768, P201, DOI 10.1016/0304-4173(84)90016-8; CROSS RL, 1981, ANNU REV BIOCHEM, V50, P681, DOI 10.1146/annurev.bi.50.070181.003341; DUNCAN TM, 1985, J BIOL CHEM, V260, P4901; ENGELBRECHT S, 1990, BIOCHIM BIOPHYS ACTA, V1015, P379, DOI 10.1016/0005-2728(90)90072-C; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FRAGA D, 1989, J BIOL CHEM, V264, P6796; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4717, DOI 10.1021/bi00437a031; GOGOL EP, 1987, FEBS LETT, V219, P274, DOI 10.1016/0014-5793(87)80234-X; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; HAZARD AL, J BIOL CHEM, V269; HERTZBERG EL, 1974, BIOCHEM BIOPH RES CO, V58, P178, DOI 10.1016/0006-291X(74)90908-5; ISSARTEL JP, 1991, BIOCHEMISTRY-US, V30, P4726, DOI 10.1021/bi00233a013; JOSHI S, 1992, J BIOL CHEM, V267, P12860; JOUNOUCHI M, 1992, ARCH BIOCHEM BIOPHYS, V292, P376, DOI 10.1016/0003-9861(92)90005-H; LEE RSF, 1992, ARCH BIOCHEM BIOPHYS, V297, P334, DOI 10.1016/0003-9861(92)90681-L; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCKEN U, 1990, BIOCHEMISTRY-US, V29, P5339; LUNARDI J, 1988, P NATL ACAD SCI USA, V85, P8958, DOI 10.1073/pnas.85.23.8958; MAGGIO MB, 1988, J BIOL CHEM, V263, P4619; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P10987, DOI 10.1021/bi00109a025; MENDELHARTVIG J, 1991, BIOCHIM BIOPHYS ACTA, V1060, P115, DOI 10.1016/S0005-2728(05)80126-4; MILLER MJ, 1989, J BIOL CHEM, V264, P305; MOSHER ME, 1985, J BIOL CHEM, V260, P4807; NALIN CM, 1985, BIOCHEMISTRY-US, V24, P2318, DOI 10.1021/bi00330a029; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; PERLIN DS, 1985, ARCH BIOCHEM BIOPHYS, V236, P603, DOI 10.1016/0003-9861(85)90664-2; REENSTRA WW, 1980, BIOCHEMISTRY-US, V19, P1, DOI 10.1021/bi00542a001; SENIOR AE, 1979, BIOCHEM J, V180, P111, DOI 10.1042/bj1800111; SENIOR AE, 1992, ARCH BIOCHEM BIOPHYS, V297, P340, DOI 10.1016/0003-9861(92)90682-M; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SHAPIRO AB, 1990, J BIOL CHEM, V265, P4340; SHAPIRO AB, 1988, J BIOL CHEM, V263, P14160; SHIN K, 1992, J BIOL CHEM, V267, P20835; TURINA P, 1993, J BIOL CHEM, V268, P6978; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; WEBER J, 1993, J BIOL CHEM, V268, P20126; WILKENS S, 1992, ARCH BIOCHEM BIOPHYS, V299, P105, DOI 10.1016/0003-9861(92)90250-Z; WISE JG, 1985, BIOCHEMISTRY-US, V24, P6949, DOI 10.1021/bi00345a030	48	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					427	432						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276831				2022-12-27	WOS:A1994MR21900072
J	ROY, S; OVERTON, O; REDMAN, C				ROY, S; OVERTON, O; REDMAN, C			OVEREXPRESSION OF ANY FIBRINOGEN CHAIN BY HEP G2-CELLS SPECIFICALLY ELEVATES THE EXPRESSION OF THE OTHER 2 CHAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENTARY DEOXYRIBONUCLEIC-ACID; PHASE PLASMA-PROTEINS; BETA-CHAIN; TRANSCRIPTIONAL REGULATION; ALPHA-CHAIN; GLUCOCORTICOIDS; DEXAMETHASONE; STIMULATION; DEGRADATION; SEQUENCES	Earlier studies showed that overexpression of Bbeta fibrinogen chains, by transfection of Hep G2 cells with Bbeta cDNA, specifically enhanced the synthesis of all three fibrinogen chains (Roy, S. N., Mukhopadhyay, G., and Redman, C. M. (1990) J. Biol. Chem. 265, 6389-6393). To determine whether overexpression of any of the three component chains of fibrinogen affects the synthesis of the other two chains, we developed stable Hep G2 cell lines transfected with individual fibrinogen chain cDNAs. As a control, cells were also transfected with expression vector, which did not contain fibrinogen cDNA. Transfection with any fibrinogen cDNA increased the synthesis of all three fibrinogen chains but not of other plasma proteins. Hep G2 cells transfected with Bbeta cDNA produced 3-4-fold more fibrinogen than control cells, and cells transfected with Aalpha or gamma cDNA made about 2-fold more fibrinogen. Northern blot analyses showed that levels of all 3 fibrinogen mRNAs were increased and were highest in Hep G2-Bbeta cells. Nuclear run-on transcription assays demonstrated that increased expression of the chains was due to increased transcriptional activity. These studies show that transcription of the three fibrinogen chains is tightly linked, and increased expression of any chain specifically leads to increased synthesis of the other two chains.	NEW YORK BLOOD CTR,LINDSLEY F KIMBALL RES INST,310 E 67 ST,NEW YORK,NY 10021	New York Blood Center					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037457] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 37457] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUMANN H, 1987, J IMMUNOL, V139, P4122; BLOMBACK B, 1972, ANN NY ACAD SCI, V202, P77, DOI 10.1111/j.1749-6632.1972.tb16323.x; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; CHUNG DW, 1983, BIOCHEMISTRY-US, V22, P3244, DOI 10.1021/bi00282a032; CHUNG DW, 1983, BIOCHEMISTRY-US, V22, P3250, DOI 10.1021/bi00282a033; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; Crabtree G. R., 1987, MOL BASIS BLOOD DISE, P631; CRABTREE GR, 1982, J BIOL CHEM, V257, P7277; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; FU YP, 1992, BIOCHEMISTRY-US, V31, P11968, DOI 10.1021/bi00163a002; GEIGER T, 1988, EUR J IMMUNOL, V18, P712; GRAHAM FL, 1973, VIROLOGY, V52, P684; GRIENINGER G, 1978, P NATL ACAD SCI USA, V75, P5506, DOI 10.1073/pnas.75.11.5506; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HENRY I, 1984, AM J HUM GENET, V36, P760; HENSCHEN A, 1983, ANN NY ACAD SCI, V408, P28, DOI 10.1111/j.1749-6632.1983.tb23232.x; HUBER P, 1990, J BIOL CHEM, V265, P5695; KANT JA, 1985, P NATL ACAD SCI USA, V82, P2344, DOI 10.1073/pnas.82.8.2344; KANT JA, 1983, P NATL ACAD SCI-BIOL, V80, P3953, DOI 10.1073/pnas.80.13.3953; MANIATIS T, 1982, MOL CLONING LABORATO, P188; MARINKOVIC S, 1989, J IMMUNOL, V142, P808; MORGAN JG, 1988, MOL CELL BIOL, V8, P2628, DOI 10.1128/MCB.8.6.2628; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; NESBITT JE, 1991, BIOCHIM BIOPHYS ACTA, V1089, P88, DOI 10.1016/0167-4781(91)90089-5; NICKERSON JM, 1981, P NATL ACAD SCI USA, V78, P300; OTTO JM, 1987, J CELL BIOL, V105, P1067, DOI 10.1083/jcb.105.3.1067; RIXON MW, 1983, BIOCHEMISTRY-US, V22, P3237, DOI 10.1021/bi00282a031; ROY S, 1992, J BIOL CHEM, V267, P23151; ROY SN, 1991, J BIOL CHEM, V266, P4758; ROY SN, 1990, J BIOL CHEM, V265, P6389; YU S, 1984, J BIOL CHEM, V259, P574; YU S, 1983, J BIOL CHEM, V258, P3407; YU S, 1986, SCHEME INTRACELLULAR, V4, P665; ZHANG JZ, 1992, J BIOL CHEM, V267, P21727	36	35	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					691	695						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276870				2022-12-27	WOS:A1994MR21900108
J	CHEEK, TR; MORETON, RB; BERRIDGE, MJ; STAUDERMAN, KA; MURAWSKY, MM; BOOTMAN, MD				CHEEK, TR; MORETON, RB; BERRIDGE, MJ; STAUDERMAN, KA; MURAWSKY, MM; BOOTMAN, MD			QUANTAL CA2+ RELEASE FROM CAFFEINE-SENSITIVE STORES IN ADRENAL CHROMAFFIN CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; BULLFROG SYMPATHETIC NEURONS; CALCIUM RELEASE; INOSITOL 1,4,5-TRISPHOSPHATE; CA-2+ RELEASE; SKELETAL-MUSCLE; LUMINAL CA2+; INTRACELLULAR STORES; RYANODINE RECEPTOR; CHANNEL	In populations of fura-2-loaded chromaffin cells, caffeine caused a concentration-dependent increase in the intracellular Ca2+ concentration ([Ca2+]i), in the presence or absence of external Ca2+ ([Ca2+]o), that was saturable, reversible, and inhibited in a use-dependent fashion by ryanodine. These data confirm that caffeine mobilizes Ca2+ from the ryanodine-sensitive intracellular stores in chromaffin cells. In nominally Ca2+-free medium, sustained stimulation of cell populations or single cells with low caffeine concentrations failed to completely empty the caffeine-sensitive stores. In each case, there was a transient [Ca2+]i elevation, but a subsequent challenge with a higher caffeine concentration evoked a further [Ca2+]i rise, indicating that Ca2+ stores within individual cells were heterogeneous in their sensitivities to caffeine and that caffeine-induced Ca2+ release was quantal. The heterogeneous sensitivity was also demonstrated using ryanodine; pretreatment of cell populations with increasing caffeine concentrations with a constant ryanodine concentration, caused a dose-dependent irreversible inhibition of the response to the subsequent addition of a maximal caffeine concentration. We conclude that, within single chromaffin cells, intracellular Ca2+ stores are heterogeneous in their sensitivity to caffeine and the fraction of Ca2+ stores mobilized by caffeine increases in direct proportion to the caffeine concentration.	MERRELL DOW PHARMACEUT INC, RES INST, CINCINNATI, OH 45215 USA	Dow Chemical Company	CHEEK, TR (corresponding author), UNIV CAMBRIDGE, DEPT ZOOL, AFRC, MOLEC SIGNALLING LAB, DOWNING ST, CAMBRIDGE CB2 3EJ, ENGLAND.		Bootman, Martin/AAB-3330-2019	Bootman, Martin/0000-0002-6447-3451				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; BURGOYNE RD, 1989, NATURE, V342, P72, DOI 10.1038/342072a0; CHEEK TR, 1990, FEBS LETT, V266, P91, DOI 10.1016/0014-5793(90)81514-O; CHEEK TR, 1991, BIOCHEM J, V275, P697, DOI 10.1042/bj2750697; CHEEK TR, 1993, J CELL SCI, V105, P913; ELLISMAN MH, 1990, NEURON, V5, P135, DOI 10.1016/0896-6273(90)90304-X; ENDO M, 1985, CURR TOP MEMBR TRANS, V25, P181; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FILL M, 1988, TRENDS NEUROSCI, V11, P453, DOI 10.1016/0166-2236(88)90198-1; FRIEL DD, 1992, J PHYSIOL-LONDON, V450, P217, DOI 10.1113/jphysiol.1992.sp019125; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; HENZI V, 1992, NEUROSCIENCE, V46, P251, DOI 10.1016/0306-4522(92)90049-8; HIGASHIDA H, 1986, FEBS LETT, V208, P283, DOI 10.1016/0014-5793(86)81033-X; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INO M, 1989, J GEN PHYSIOL, V94, P363, DOI 10.1085/jgp.94.2.363; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; KUBA K, 1980, J PHYSIOL-LONDON, V298, P251, DOI 10.1113/jphysiol.1980.sp013079; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LIPSCOMBE D, 1988, NEURON, V1, P355, DOI 10.1016/0896-6273(88)90185-7; LIU PS, 1991, J NEUROCHEM, V56, P172, DOI 10.1111/j.1471-4159.1991.tb02577.x; MALGAROLI A, 1990, J BIOL CHEM, V265, P3005; MARRION NV, 1992, J PHYSIOL-LONDON, V445, P515, DOI 10.1113/jphysiol.1992.sp018937; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MISSIAEN L, 1992, J BIOL CHEM, V267, P22961; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MISSIAEN L, 1992, J PHYSIOL-LONDON, V455, P623, DOI 10.1113/jphysiol.1992.sp019319; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MORETON RB, 1991, CELLULAR NEUROBIOLOG, P205; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NAGASAKI K, 1984, J BIOCHEM-TOKYO, V96, P1769, DOI 10.1093/oxfordjournals.jbchem.a135009; NELSON TE, 1990, FEBS LETT, V263, P292, DOI 10.1016/0014-5793(90)81396-6; NUNN DL, 1992, MOL PHARMACOL, V41, P115; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; ONDRIAS K, 1990, CIRC RES, V67, P1167, DOI 10.1161/01.RES.67.5.1167; OSULLIVAN AJ, 1989, EMBO J, V8, P401, DOI 10.1002/j.1460-2075.1989.tb03391.x; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; ROBINSON IM, 1991, J NEUROCHEM, V56, P1587, DOI 10.1111/j.1471-4159.1991.tb02055.x; ROUSSEAU E, 1987, AM J PHYSIOL, V253, pC364, DOI 10.1152/ajpcell.1987.253.3.C364; ROUSSEAU E, 1988, ARCH BIOCHEM BIOPHYS, V267, P75, DOI 10.1016/0003-9861(88)90010-0; SALAMA G, 1992, CELL CALCIUM, V13, P635, DOI 10.1016/0143-4160(92)90074-3; SCHNEIDER MF, 1988, J PHYSIOL-LONDON, V405, P727, DOI 10.1113/jphysiol.1988.sp017358; STAUDERMAN KA, 1991, J BIOL CHEM, V266, P19150; STAUDERMAN KA, 1991, BIOCHEM J, V278, P643, DOI 10.1042/bj2780643; TAYLOR CW, 1991, PHARMACOL THERAPEUT, V51, P97, DOI 10.1016/0163-7258(91)90043-L; TAYLOR CW, 1990, BIOCHEM J, V266, P189, DOI 10.1042/bj2660189; THAYER SA, 1988, J NEUROSCI, V8, P4089; THAYER SA, 1988, MOL PHARMACOL, V34, P664; TREGEAR RT, 1991, P ROY SOC B-BIOL SCI, V243, P263, DOI 10.1098/rspb.1991.0040; TSHIPAMBA M, 1993, J CELL PHYSIOL, V155, P96, DOI 10.1002/jcp.1041550113; WITCHER DR, 1991, J BIOL CHEM, V266, P11144	58	79	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27076	27083						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262945				2022-12-27	WOS:A1993MM26200038
J	HUANG, ZF; WUN, TC; BROZE, GJ				HUANG, ZF; WUN, TC; BROZE, GJ			KINETICS OF FACTOR-XA INHIBITION BY TISSUE FACTOR PATHWAY INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT-BINDING INHIBITORS; MOLECULAR-WEIGHT-DEPENDENCE; COAGULATION INHIBITOR; PROTHROMBINASE COMPLEX; FACTOR-VII; ADENOSINE-DEAMINASE; EXTRINSIC PATHWAY; BLOOD-COAGULATION; ANTI-THROMBIN; SLOW-BINDING	Tissue factor pathway inhibitor is a multivalent, Kunitz-type proteinase inhibitor. It directly inhibits factor Xa and, in a factor Xa-dependent fashion, produces feedback inhibition of the factor VIIa/tissue factor catalytic complex which is responsible for the initiation of coagulation. Human recombinant TFPI (rTFPI) produced in Escherichia coli was used to define the kinetic constants describing the human factor Xa:TFPI interaction. The inactivation of factor Xa by E. coli-rTFPI is indistinguishable from that of rTFPI produced in mammalian SK-hepatoma cells, suggesting that post-translational modifications such as glycosylation and phosphorylation do not play a major role in the inhibitory process. The slow, tight-binding inhibition of factor Xa follows the scheme: [GRAPHICS] Where the enzyme (E) and inhibitor (I) form an initial, immediate collision complex (EI) that then isomerizes slowly to a tightened final EI complex. In the absence of other additions, the initial K(i) (=k2/k1) and final K(i) for the inhibition of factor Xa by E. coli-rTFPI are 1.24 nM and 26.4 pM, respectively. In the presence of calcium ions (5 mM) the interaction between factor Xa and rTFPI is substantially weaker, with a K(i) of 42.7 nM and K(i) of 85.2 pM. The addition of other components of the prothrombinase complex produces enhanced factor Xa inhibition predominantly through an effect on the initial K(i). In the presence of calcium ions and saturating concentrations of phospholipids and factor Va, the K(i) and K(i) for factor Xa inactivation are 2.04 nM and 52.3 pm. The enhancing effect of heparin on the inhibitory process is concentration dependent and exhibits an optimum, reminiscent of the ''template'' model for heparin's acceleration of thrombin and factor IXa inhibition by antithrombin III. At optimal concentrations, the major mechanism of heparin action is also a reduction in the K(i) of the initial encounter complex between factor Xa and rTFPI.	WASHINGTON UNIV, JEWISH HOSP ST LOUIS,MED CTR,DIV HEMATOL ONCOL, 216 S KINGSHIGHWAY BLVD, ST LOUIS, MO 63110 USA; MONSANTO CO, CHESTERFIELD, MO 63198 USA	Barnes-Jewish Hospital; Washington University (WUSTL); Monsanto					NHLBI NIH HHS [HL-34462] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034462] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTONINI E, 1983, BIOPOLYMERS, V22, P363, DOI 10.1002/bip.360220147; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; BROZE GJ, 1988, BLOOD, V71, P335; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; CASU B, 1981, BIOCHEM J, V197, P599, DOI 10.1042/bj1970599; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; CHA S, 1976, BIOCHEM PHARMACOL, V25, P1561; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2187, DOI 10.1016/0006-2952(75)90051-9; CHA S, 1976, BIOCHEM PHARMACOL, V25, P2695, DOI 10.1016/0006-2952(76)90259-8; CHASE T, 1970, METHOD ENZYMOL, V19, P20; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; DAY KC, 1990, BLOOD, V76, P1538; DAY KC, 1992, THROMB RES, V68, P369, DOI 10.1016/0049-3848(92)90095-R; ELLIS V, 1986, BIOCHEM J, V238, P329, DOI 10.1042/bj2380329; GIRARD TJ, 1990, BIOCHEM J, V270, P621, DOI 10.1042/bj2700621; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; HASKEL EJ, 1991, CIRCULATION, V84, P821, DOI 10.1161/01.CIR.84.2.821; HIGGINS DL, 1985, J BIOL CHEM, V260, P3604; HIGUCHI DA, 1992, BLOOD, V79, P1712; HOLMER E, 1981, BIOCHEM J, V193, P395, DOI 10.1042/bj1930395; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; KRISTENSEN HI, 1992, THROMB HAEMOSTASIS, V68, P310; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; LONGSTAFF C, 1991, BIOCHEMISTRY-US, V30, P979, DOI 10.1021/bi00218a014; MANN KG, 1990, BLOOD, V76, P1; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; NESHEIM ME, 1984, J BIOL CHEM, V259, P1447; NESHEIM ME, 1981, J BIOL CHEM, V256, P9874; NORDFANG O, 1991, BIOCHEMISTRY-US, V30, P10371, DOI 10.1021/bi00107a002; NOVOTNY WF, 1991, BLOOD, V78, P387; OLSON ST, 1993, IN PRESS SEMIN THROM; OOSTA GM, 1981, P NATL ACAD SCI-BIOL, V78, P829, DOI 10.1073/pnas.78.2.829; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; OWEN BA, 1990, BIOCHEMISTRY-US, V29, P9412, DOI 10.1021/bi00492a015; PALMIER MO, 1992, THROMB HAEMOSTASIS, V68, P33; RICH DH, 1980, BIOCHEM PHARMACOL, V29, P2205, DOI 10.1016/0006-2952(80)90199-9; SANDSET PM, 1988, THROMB RES, V50, P803, DOI 10.1016/0049-3848(88)90340-4; SILVERBERG SA, 1977, J BIOL CHEM, V252, P8481; SMITH PL, 1992, J BIOL CHEM, V267, P19140; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; THUNBERG L, 1979, BIOCHEM J, V181, P241, DOI 10.1042/bj1810241; WESSELSCHMIDT R, 1992, BLOOD, V79, P2004; WESSELSCHMIDT R, 1993, IN PRESS BLOOD COAGU; WUN TC, 1988, J BIOL CHEM, V263, P6001; ZUR M, 1980, J BIOL CHEM, V255, P5703	47	149	160	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26950	26955						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262929				2022-12-27	WOS:A1993MM26200020
J	KALAFATIS, M; MANN, KG				KALAFATIS, M; MANN, KG			ROLE OF THE MEMBRANE IN THE INACTIVATION OF FACTOR-VA BY ACTIVATED PROTEIN-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-V; BOVINE FACTOR-V; THROMBIN-CATALYZED ACTIVATION; HUMAN FACTOR-VIII; FACTOR-XA; PHOSPHOLIPID-VESICLES; BLOOD-COAGULATION; BINDING-SITE; PROTHROMBIN ACTIVATION; A1/A3-C1-C2 DIMER	Bovine factor Va inactivation by activated protein C (APC) was evaluated in the presence and absence of phospholipid vesicles and protein S. Following a 30-min incubation with APC (10 nM), membrane-bound factor Va (200 nM) is completely inactivated, whereas in the absence of phospholipid vesicles, after a 2-h incubation, the cofactor retains 60% of its initial co-factor activity. The complete loss of activity of membrane-bound factor Va is associated with the appearance of M(r) 40,000, 28,000, and 20,000 fragments derived from the heavy chain of the cofactor which correspond to cleavage at Arg306, Arg505, and Arg662. In the absence of a lipid bilayer, cleavage at Arg505 and Arg662 results in a cofactor with reduced activity. No difference is observed in the cleavage of the light chain of the cofactor by APC in the presence or absence of phospholipid vesicles. The rate of the cleavage of factor Va heavy chain at Arg306, Arg505, and Arg662 as well as the rate of the membrane-bound cofactor inactivation by APC were enhanced in the presence of protein S. Our data demonstrate that the anionic lipid-dependent cleavage of factor Va by APC at Arg306 is required for the complete inactivation of the cofactor.	UNIV VERMONT,COLL MED,DEPT BIOCHEM,GIVEN BLDG,HLTH SCI COMPLEX,BURLINGTON,VT 05405	University of Vermont					NHLBI NIH HHS [R37 HL34575, T32 HL07594, P01 HL46703] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007594, P01HL046703, R37HL034575] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAJAJ SP, 1973, J BIOL CHEM, V248, P7729; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BLOMBACK B, 1972, ANN NY ACAD SCI, V202, P77, DOI 10.1111/j.1749-6632.1972.tb16323.x; CHURCH WR, 1984, P NATL ACAD SCI-BIOL, V81, P6934, DOI 10.1073/pnas.81.22.6934; CHURCH WR, 1988, BLOOD, V72, P1911; COMP PC, 1984, J CLIN INVEST, V74, P2082, DOI 10.1172/JCI111632; CUTSFORTH GA, 1991, THROMB HAEMOSTASIS, V65, P858; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; ESMON CT, 1979, J BIOL CHEM, V254, P964; ESMON NL, 1982, J BIOL CHEM, V257, P859; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FOSTER WB, 1983, J BIOL CHEM, V258, P3970; Gomori G, 1942, J LAB CLIN MED, V27, P955; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; GUINTO ER, 1992, J BIOL CHEM, V267, P2971; HALEY PE, 1989, J BIOL CHEM, V264, P16303; HELDEBRANT CM, 1973, J BIOL CHEM, V248, P7149; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; JANE SM, 1989, J CLIN INVEST, V83, P222, DOI 10.1172/JCI113862; KALAFATIS M, 1993, METHOD ENZYMOL, V222, P224; KALAFATIS M, 1993, BLOOD, V81, P704; KALAFATIS M, 1990, J BIOL CHEM, V265, P21580; KALAFATIS M, 1992, CIRCULATION, V86, P1857; KALOUSEK F, 1975, FEBS LETT, V50, P382, DOI 10.1016/0014-5793(75)80533-3; KANE WH, 1988, BLOOD, V71, P539; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; KISIEL W, 1979, J CLIN INVEST, V64, P761, DOI 10.1172/JCI109521; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P5824, DOI 10.1021/bi00645a029; KISIEL W, 1901, METHOD ENZYMOL, V80, P320; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P9684; KRISHNASWAMY S, 1989, J BIOL CHEM, V264, P3160; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1991, J BIOL CHEM, V266, P11317; LUCKOW EA, 1989, BIOCHEMISTRY-US, V28, P2348, DOI 10.1021/bi00431a055; Lundblad R L, 1976, Methods Enzymol, V45, P156; MALHOTRA OP, 1985, J BIOL CHEM, V260, P279; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANNUCCI PM, 1986, THROMB HAEMOSTASIS, V55, P440; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MONKOVIC DD, 1990, BIOCHEMISTRY-US, V29, P1118, DOI 10.1021/bi00457a004; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NESHEIM ME, 1982, J BIOL CHEM, V257, P1443; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; NESHEIM ME, 1983, J BIOL CHEM, V258, P5386; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NESHEIM ME, 1980, METHOD ENZYMOL, V80, P243; ODEGAARD B, 1987, J BIOL CHEM, V262, P11233; OMAR MN, 1987, J BIOL CHEM, V262, P9750; ORTEL TL, 1992, J BIOL CHEM, V267, P4189; PITTMAN DD, 1988, P NATL ACAD SCI USA, V85, P2429, DOI 10.1073/pnas.85.8.2429; PRYZDIAL ELG, 1991, J BIOL CHEM, V266, P8969; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; TRACY PB, 1983, J BIOL CHEM, V258, P662; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; WALKER FJ, 1981, J BIOL CHEM, V256, P1128; WALKER FJ, 1990, J BIOL CHEM, V265, P1484; WALKER FJ, 1980, J BIOL CHEM, V255, P5521; XUE JC, 1993, BIOCHEMISTRY-US, V32, P5917, DOI 10.1021/bi00073a026	63	91	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27246	27257						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262965				2022-12-27	WOS:A1993MM26200061
J	RUPP, K; BIRNBACH, U; LUNDSTROM, J; VAN, PN; SOLING, HD				RUPP, K; BIRNBACH, U; LUNDSTROM, J; VAN, PN; SOLING, HD			EFFECTS OF CABP2, THE RAT ANALOG OF ERP72, AND OF CABP1 ON THE REFOLDING OF DENATURED REDUCED PROTEINS - COMPARISON WITH PROTEIN DISULFIDE-ISOMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; BINDING	It has been shown previously that CaBP2, the rat analog of the murine protein ERp72, and CaBP1, the rat analogue of the hamster protein P5, represent members of the protein disulfide isomerase (PDI) family and are able to catalyze the reduction of insulin in the presence of various reductants (Nguyen Van et al., 1993). We have now examined the abilities of CaBP2 and CaBP1 to catalyze the renaturation of denatured reduced model proteins. Both CaBP2 and CaBP1 catalyzed the reappearance of the biological activity of the denatured reduced F(ab) fragment of a monoclonal anti-human creatine phosphokinase antibody. The reaction rate was positively correlated with the amount of CaBP2 or CaBP1 and dependent on the GSH/GSSG ratio (maximum at GSH/GSSG = 1). Peptide prolyl-cis,trans-isomerase (PPI), which catalyzed some renaturation on its own, showed synergistic effects with PDI, CaBP2, and CaBP1. No synergistic effects could be observed when the combinations CaBP2 + PDI, CaBP1 + PDI, or CaBP2 + CaBP1 were tested. Variation of [Ca2+] between 0 and 1 mM did not have any effect on the rate or amount of renaturation catalyzed by CaBP2, CaBP1, or PDI, nor were these parameters affected by the simultaneous presence of BiP or grp94. Both CaBP2 and CaBP1 catalyzed also the renaturation of denatured reduced ribonuclease AIII in a way that depended on the amounts of CaBP2 or CaBP1 and on the redox potential of the redox system used (GSH/GSSG or CSH/CSSC). PPI alone had no effect on the rate of RNase AIII renaturation and did not significantly affect renaturation catalyzed by PDI, CaBP2, or CaBP1. PDI showed a moderate but significant synergism with CaBP2, and a strong synergism with CaBP1. The results indicate that both CaBP2 and CaBP1 can catalyze the formation of disulfide bonds and protein disulfide isomerization and may thus be involved in the folding of nascent proteins in the secretory pathway. This does not exclude the possibility of additional functions of these proteins in the pre-Golgi compartments.	UNIV GOTTINGEN,ZENTRUM INNERE MED,KLIN BIOCHEM ABT,ROBERT KOCH STR 40,W-3400 GOTTINGEN,GERMANY; KAROLINSKA INST,DEPT BIOCHEM,S-10401 STOCKHOLM 60,SWEDEN	University of Gottingen; Karolinska Institutet								CHAUDHURI MM, 1992, BIOCHEM J, V281, P645, DOI 10.1042/bj2810645; CUHNER J, 1991, BIOTECHNOLOGY, V9, P157; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; FREEDMAN RB, 1989, BIOCHEM SOC SYMP, V55, P167; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FREEDMAN RB, 1984, TRENDS BIOCHEM SCI, V9, P438, DOI 10.1016/0968-0004(84)90152-X; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LAMBERT N, 1983, BIOCHEM J, V213, P225, DOI 10.1042/bj2130225; LANG K, 1988, NATURE, V331, P453, DOI 10.1038/331453a0; LEWIS MJ, 1985, J BIOL CHEM, V260, P3050; LIN LN, 1988, BIOCHIM BIOPHYS ACTA, V956, P256, DOI 10.1016/0167-4838(88)90142-2; LYLES M, 1991, BIOCHEMISTRY-US, V39, P613; MAZARELLA R, 1990, J BIOL CHEM, V265, P1094; NOIVA R, 1991, J BIOL CHEM, V266, P19645; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; SCHENG S, 1987, J BIOL CHEM, V262, P11221; SCHUNBRUNNER E, 1992, P NATL ACAD SCI USA, V89, P4510; VAN PN, 1989, J BIOL CHEM, V264, P17494; VANNGUYEN P, 1993, EUR J BIOCHEM, V213, P789; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800	23	77	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2501	2507						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300576				2022-12-27	WOS:A1994MV43200026
J	WINKLER, E; KLINGENBERG, M				WINKLER, E; KLINGENBERG, M			EFFECT OF FATTY-ACIDS ON H+ TRANSPORT ACTIVITY OF THE RECONSTITUTED UNCOUPLING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN-ADIPOSE-TISSUE; NUCLEOTIDE-BINDING; PURINE NUCLEOTIDES; MITOCHONDRIA; MECHANISM; CONDUCTANCE; ACTIVATION; SITE	A detailed study on the activation of H+ transport by reconstituted uncoupling proteins from brown adipose tissue is given, including the influence of chain lengths and of other structural modifications, concentration dependence, and the influence of nucleotides. Uncoupling protein was reconstituted with phosphatidylcholine in such a way as to keep H+ transport with endogenous fatty acids at a minimum. Using excess of polystyrene beads on reconstitution avoided the complications arising from the use of albumin. Both DELTApsi-driven H+ uptake and H+ efflux systems are used by changing the polarity. Fatty acids stimulate H+ uptake up to 6-fold and H+ efflux more than 10-fold. There is no competition between the inhibition by nucleotides (GTP) and fatty acids. Also, the binding of GTP and ATP is not affected. Only fatty acids starting from Cs activate, reaching a maximum at C-14. However, unsaturated homologous of C18 (oleic, linoleic, etc.) are fully active. Hydrophilic substitutions by hydroxyl, CO2H, bromo, doxyl groups also permit good activation, probably due to improved uptake into the lipid phase. The hydrophobic moiety exhibits a low specificity. Blockage of carboxyl by esterification abolishes the activation. Maximum activation requires high total concentrations of 200-300 muM. The distribution of fatty acids between proteoliposomes and solution was determined. The activation mode of fatty acids is discussed either as regulatory activators or as cofactors in H+ translocation involving their carboxyl groups. Two alternatives are considered, namely that the fatty acids carboxyl group is at the translocation center or in the channel facilitating H+ transfer to the constituent H+-translocating carboxyl groups.	UNIV MUNICH,INST PHYS BIOCHEM,GOETHESTR 33,W-8000 MUNICH 2,GERMANY	University of Munich								Bernardi G, 1971, METHOD ENZYMOL, V22, P325; BUTT HJ, 1989, EMBO J, V8, P1657, DOI 10.1002/j.1460-2075.1989.tb03556.x; CUNNINGHAM SA, 1986, EUR J BIOCHEM, V157, P415, DOI 10.1111/j.1432-1033.1986.tb09683.x; GOODMAN DS, 1958, J AM CHEM SOC, V80, P3892, DOI 10.1021/ja01548a024; GUTKNECHT J, 1987, P NATL ACAD SCI USA, V84, P6443, DOI 10.1073/pnas.84.18.6443; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; HEATON GM, 1978, EUR J BIOCHEM, V82, P515, DOI 10.1111/j.1432-1033.1978.tb12045.x; JEZEK P, 1990, J BIOL CHEM, V265, P19303; JEZEK P, 1990, J LIPID MED, V2, P89; KATIYAR SS, 1991, BIOCHEM BIOPH RES CO, V175, P1104, DOI 10.1016/0006-291X(91)91679-7; KLINGENBERG M, 1988, BIOCHEMISTRY-US, V27, P781, DOI 10.1021/bi00402a044; KLINGENBERG M, 1986, METHOD ENZYMOL, V126, P498; KLINGENBERG M, 1985, EMBO J, V4, P3087, DOI 10.1002/j.1460-2075.1985.tb04049.x; KLINGENBERG M, 1990, TRENDS BIOCHEM SCI, V15, P108, DOI 10.1016/0968-0004(90)90194-G; KOPECKY J, 1987, EUR J BIOCHEM, V164, P687, DOI 10.1111/j.1432-1033.1987.tb11181.x; LIN CS, 1982, BIOCHEMISTRY-US, V21, P2950, DOI 10.1021/bi00541a023; LOCKE RM, 1982, EUR J BIOCHEM, V129, P373, DOI 10.1111/j.1432-1033.1982.tb07060.x; LOCKE RM, 1982, EUR J BIOCHEM, V129, P381, DOI 10.1111/j.1432-1033.1982.tb07061.x; NICHOLLS DG, 1979, BIOCHIM BIOPHYS ACTA, V549, P1, DOI 10.1016/0304-4173(79)90016-8; RIAL E, 1983, EUR J BIOCHEM, V137, P197, DOI 10.1111/j.1432-1033.1983.tb07815.x; ROONEY EK, 1983, BIOCHIM BIOPHYS ACTA, V728, P159, DOI 10.1016/0005-2736(83)90467-4; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; SMITH R, 1973, P NATL ACAD SCI USA, V70, P289, DOI 10.1073/pnas.70.2.289; SOBER HA, 1970, HDB CHEM, pE13; STRIELEMAN PJ, 1985, J BIOL CHEM, V260, P3402; WELLS MA, 1969, METHOD ENZYMOL, V14, P178; WINKLER E, 1992, EUR J BIOCHEM, V203, P295, DOI 10.1111/j.1432-1033.1992.tb19859.x; WINKLER E, 1992, EUR J BIOCHEM, V207, P135, DOI 10.1111/j.1432-1033.1992.tb17030.x	28	162	164	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2508	2515						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300577				2022-12-27	WOS:A1994MV43200027
J	BORST, DW; BETLEY, MJ				BORST, DW; BETLEY, MJ			PROMOTER ANALYSIS OF THE STAPHYLOCOCCAL ENTEROTOXIN-A GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; MESSENGER-RNA; AUREUS; TRANSCRIPTION; SEQUENCES; TOXIN; INITIATION; PLASMIDS	The promoter region of the staphylococcal enterotoxin A (SEA) gene (sea) of Staphylococcus aureus was localized by primer extension analysis in conjunction with in vitro mutagenesis. The 5'-end of sea mRNA was located 86 base pairs upstream of the translational initiation codon. A DNA region with good agreement with canonical promoter sequences was observed beginning 8 base pairs upstream of the apparent transcriptional start site. Analysis of a series of progressive deletions of upstream DNA revealed that no DNA upstream of the putative -35 region was required for transcription of sea (determined by primer extension analysis) or for SEA production as detected by Western immunoblot analysis. Deletion mutants extending into the -35 region or mutants containing nucleotide substitutions in the -10 region both showed dramatic reductions in SEA production and transcription of sea. Analysis of a deletion mutant in which 59 base pairs between the transcriptional and translational start sites were deleted revealed slightly increased levels of SEA production.	UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007215] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM07215] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL JG, 1987, CURRENT PROTOCOLS MO; BAYLES KW, 1989, J BACTERIOL, V171, P4799, DOI 10.1128/jb.171.9.4799-4806.1989; Bergdoll M.S., 1983, STAPHYLOCOCCI STAPHY, V2, P559; BETLEY MJ, 1985, SCIENCE, V229, P185, DOI 10.1126/science.3160112; BETLEY MJ, 1988, J BACTERIOL, V170, P34, DOI 10.1128/jb.170.1.34-41.1988; BETLEY MJ, 1992, CHEM IMMUNOL, V55, P1; Betley MJ, 1990, MOL BIOL STAPHYLOCOC, P327; BORST DW, 1994, IN PRESS INFECT IMMU, V64; CZOP JK, 1974, INFECT IMMUN, V9, P229, DOI 10.1128/IAI.9.2.229-235.1974; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GASKILL ME, 1988, J BIOL CHEM, V263, P6276; GRAVES MC, 1986, J BIOL CHEM, V261, P1409; HARLEY CB, 1987, NUCLEIC ACIDS RES, V15, P2343, DOI 10.1093/nar/15.5.2343; HOLMBERG SD, 1984, JAMA-J AM MED ASSOC, V251, P487, DOI 10.1001/jama.251.4.487; HUFNAGLE WO, 1991, INFECT IMMUN, V59, P2126, DOI 10.1128/IAI.59.6.2126-2134.1991; IORDANESCU S, 1975, J BACTERIOL, V124, P597; KARLS R, 1989, NUCLEIC ACIDS RES, V17, P3927, DOI 10.1093/nar/17.10.3927; KREISWIRTH BN, 1983, NATURE, V305, P709, DOI 10.1038/305709a0; MAHMOOD R, 1990, J BIOL CHEM, V265, P4652; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MORAN CP, 1982, MOL GEN GENET, V186, P339, DOI 10.1007/BF00729452; NOLETO AL, 1982, J FOOD PROTECT, V45, P1096, DOI 10.4315/0362-028X-45.12.1096; NOVICK RP, 1972, J MOL BIOL, V68, P285, DOI 10.1016/0022-2836(72)90214-8; NOVICK RP, 1963, J GEN MICROBIOL, V33, P121, DOI 10.1099/00221287-33-1-121; NOVICK RP, 1979, PLASMID, V2, P109, DOI 10.1016/0147-619X(79)90010-6; OTERO A, 1990, APPL ENVIRON MICROB, V56, P555, DOI 10.1128/AEM.56.2.555-559.1990; REGASSA LB, 1991, INFECT IMMUN, V59, P955, DOI 10.1128/IAI.59.3.955-962.1991; SANDLER P, 1988, J MOL BIOL, V203, P905, DOI 10.1016/0022-2836(88)90116-7; TREMAINE MT, 1993, INFECT IMMUN, V61, P356, DOI 10.1128/IAI.61.1.356-359.1993	30	15	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1883	1888						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294437				2022-12-27	WOS:A1994MR98800052
J	PACIFICI, RE; THOMASON, AR				PACIFICI, RE; THOMASON, AR			HYBRID TYROSINE KINASE CYTOKINE RECEPTORS TRANSMIT MITOGENIC SIGNALS IN RESPONSE TO LIGAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EPIDERMAL GROWTH-FACTOR; MURINE ERYTHROPOIETIN RECEPTOR; CELL-SURFACE RECEPTORS; EGF RECEPTOR; EXTRACELLULAR DOMAIN; EXPRESSION CLONING; PROTEINS; TRANSDUCTION; SUPERFAMILY; COMPLEX	While much is known about the mechanisms by which members of the receptor tyrosine kinase family effect mitogenic signal transduction, much less is known about such mechanisms for members of the hematopoietic cytokine receptor family. In an effort to determine the extent to which the signal transduction mechanisms of these two receptor families may be related, we constructed and tested interfamily hybrid receptors. Two hybrid receptors consisting of the ligand-binding domain of the epidermal growth factor receptor (EGFR) fused to the transmembrane and cytoplasmic domains of the erythropoietin receptor (EPOR), as well as the parental EPOR or EGFR, were introduced into interleukin-3-dependent 32D cells. Part of the EPOR extracellular region containing a conserved WSXWS amino acid motif was present in one of the hybrid receptors but not in the other. Cells expressing EGFR grew only poorly in response to EGF, whereas cells expressing either of the EGFR/EPOR hybrid receptors or EPOR grew robustly in epidermal growth factor or erythropoietin, respectively. This is the first demonstration of a chimera between these two unrelated receptor families that responds to ligand stimulation. The results indicate that the mechanisms by which receptor tyrosine kinases and cytokine receptors propagate mitogenic signals are sufficiently similar to allow interchange of their ligand binding domains and that generation of an efficient mitogenic signal by a cytokine receptor depends primarily on its cytoplasmic and/or transmembrane regions.	AMGEN INC, DEPT MOLEC BIOL, AMGEN CTR, 14-1-B-220, THOUSAND OAKS, CA 91320 USA	Amgen								BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BERNARD O, 1987, P NATL ACAD SCI USA, V84, P2125, DOI 10.1073/pnas.84.8.2125; CHAN KY, 1991, INVEST OPHTH VIS SCI, V32, P3209; CHIBA T, 1993, NATURE, V362, P646, DOI 10.1038/362646a0; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DUAN DSR, 1991, J BIOL CHEM, V266, P413; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HELDIN CH, 1991, TRENDS BIOCHEM SCI, V16, P450, DOI 10.1016/0968-0004(91)90175-U; HIGUCHI R, 1989, PCR PROTOCOLS GUIDE, P177; Hsuan J J, 1989, Prog Growth Factor Res, V1, P23, DOI 10.1016/0955-2235(89)90039-2; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; IHLE JN, 1981, J IMMUNOL, V126, P2184; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMERS R, 1991, METHOD ENZYMOL, V198, P225; LEV S, 1990, MOL CELL BIOL, V10, P6064, DOI 10.1128/MCB.10.11.6064; LIN CR, 1984, SCIENCE, V224, P843, DOI 10.1126/science.6326261; LIN FK, 1985, P NATL ACAD SCI USA, V82, P7580, DOI 10.1073/pnas.82.22.7580; LONGMORE GD, 1991, CELL, V67, P1089, DOI 10.1016/0092-8674(91)90286-8; MAYEUX P, 1991, J BIOL CHEM, V266, P23380; NEUMANN D, 1993, J BIOL CHEM, V268, P13639; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; QUELLE DE, 1992, MOL CELL BIOL, V12, P4533; SAWYER ST, 1989, J BIOL CHEM, V264, P13343; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEEDORF K, 1991, J BIOL CHEM, V266, P12424; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TARTARE S, 1991, J BIOL CHEM, V266, P9900; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; YAN H, 1991, SCIENCE, V252, P561, DOI 10.1126/science.1850551; ZIDOVETZKI R, 1981, P NATL ACAD SCI-BIOL, V78, P6981, DOI 10.1073/pnas.78.11.6981	41	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1571	1574						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294397				2022-12-27	WOS:A1994MR98800002
J	ROBERTS, JD; IZUTA, S; THOMAS, DC; KUNKEL, TA				ROBERTS, JD; IZUTA, S; THOMAS, DC; KUNKEL, TA			MISPAIR-SPECIFIC, SITE-SPECIFIC, AND STRAND-SPECIFIC ERROR RATES DURING SIMIAN VIRUS-40 ORIGIN-DEPENDENT REPLICATION IN-VITRO WITH EXCESS DEOXYTHYMIDINE TRIPHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SV40 DNA-REPLICATION; INITIATION; FIDELITY; EXTRACTS; REPAIR	We have measured the fidelity of leading and lagging strand DNA replication in HeLa cell extracts. Providing an excess of one dNTP in reactions induces replication errors consistent with misincorporation of that dNTP. With excess dTTP, both substitutions and single-nucleotide frameshifts are induced. Error distribution is nonrandom; reproducible hot spots for a substitution and a frameshift error are observed. Measurements with two vectors having the origin of replication on opposite sides of the mutational target demonstrate that error rates for G.dTTP and C.dTTP mispairs depend on whether the strand is replicated as the leading or lagging strand. Also, the two hot spots are only observed in one origin-target orientation. Replication reactions reconstituted from two fractions derived from extracts are 3-fold less accurate, but the error specificity with excess dTTP is similar to that with extracts. This suggests that the processes responsible for the nonrandom error rates are not lost as a result of fractionation. Furthermore, the reconstituted system is devoid of mismatch repair activity. Thus, mismatch repair is not responsible for the mispair-, site-, and strand-specific differences observed.	NIEHS,MOLEC GENET LAB,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Kunkel, Thomas A./D-5088-2019	Kunkel, Thomas A./0000-0002-9900-1788				EDENBERG HJ, 1975, ANNU REV GENET, V9, P245, DOI 10.1146/annurev.ge.09.120175.001333; HALLIDAY JA, 1990, ENVIRON MOL MUTAGEN, V16, P143, DOI 10.1002/em.2850160303; HAUSER J, 1988, MOL CELL BIOL, V8, P3267, DOI 10.1128/MCB.8.8.3267; HAY RT, 1982, CELL, V28, P767, DOI 10.1016/0092-8674(82)90056-3; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; KELLY TJ, 1988, J BIOL CHEM, V263, P17889; Kornberg A., 1992, DNA REPLICATION; LI JJ, 1985, MOL CELL BIOL, V5, P1238, DOI 10.1128/MCB.5.6.1238; LINN S, 1991, CELL, V66, P185, DOI 10.1016/0092-8674(91)90608-2; MILLER JK, 1986, P NATL ACAD SCI USA, V83, P1026, DOI 10.1073/pnas.83.4.1026; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; ROBERTS JD, 1993, BIOCHEMISTRY-US, V32, P4083, DOI 10.1021/bi00066a033; ROBERTS JD, 1991, P NATL ACAD SCI USA, V88, P3465, DOI 10.1073/pnas.88.8.3465; ROBERTS JD, 1988, P NATL ACAD SCI USA, V85, P7064, DOI 10.1073/pnas.85.19.7064; ROBERTS JD, 1993, METHODS MOL GENET, V2, P295; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; WOLD MS, 1989, J BIOL CHEM, V264, P2801; WOLD MS, 1988, CANCER CELL, V6, P133	23	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1711	1717						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294419				2022-12-27	WOS:A1994MR98800029
J	VAN HELVOORT, A; VANT HOF, W; RITSEMA, T; SANDRA, A; VAN MEER, G				VAN HELVOORT, A; VANT HOF, W; RITSEMA, T; SANDRA, A; VAN MEER, G			CONVERSION OF DIACYLGLYCEROL TO PHOSPHATIDYLCHOLINE ON THE BASOLATERAL SURFACE OF EPITHELIAL (MADIN-DARBY CANINE KIDNEY) CELLS - EVIDENCE FOR THE REVERSE ACTION OF A SPHINGOMYELIN SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CULTURED FIBROBLASTS; INTRACELLULAR-TRANSPORT; PLASMA-MEMBRANE; GOLGI-APPARATUS; PHOSPHATIDIC-ACID; RAT-LIVER; METABOLISM; SPHINGOLIPIDS; CERAMIDE	When N-6[7-nitro-2,1,3-benzoxadiazol-4-yl]aminohexanoyl-phosphatidic acid (C6-NBD-PA) is inserted into the plasma membrane of fibroblasts, it is metabolized by the cells to C6-NBD-diacylglycerol (DG), -triacylglycerol, -phosphatidylcholine (PC), and -phosphatidylethanolamine (PE) (Pagano, R. E., Longmuir, K. J., and Martin, O. C. (1983) J. Biol. Chem. 258, 2034-2040). In Madin-Darby canine kidney (MDCK) cells incubated at 10-degrees-C with C6-NBD-PA, up to 70% of the newly synthesized C6-NBD-PC but no Co-NBD-PE could be depleted from the basolateral cell surface by the addition of bovine serum albumin to the medium. Preincubation of the cells with [H-3]choline for 2 h at 37-degrees-C prior to C6-NBD-PA addition at 10-degrees-C labeled non-depletable C6-NBD-PC with a specific activity of >10 times that of the depletable C6-NBD-PC on the basolateral cell surface, indicating that the latter had not been synthesized by the CDP-choline pathway. C6-NBD-DG could substitute for C6-NBD-PA as substrate for both intracellular and surface C6-NBD-PC synthesis. In addition, C6-NBD-PC synthesis on the cell surface was independent of the location of the C6-NBD-chain on the 1- or 2-position, indicating that the reaction occurred by transfer of phosphorylcholine. Using C6-NBD-ceramide, C6-NBD-sphingomyelin (SM) synthesis also was discovered on the basolateral but not on the apical cell surface. The conversion of PC plus ceramide to DG and SM on the basolateral MDCK cell surface suggests that,the synthesis of C6-NBD-PC on this surface occurred via the reverse reaction of a SM synthase. Indeed, the surface C6-NBD-PC synthesis was reduced to 40-50% by addition of C6-NBD-ceramide or hydrolysis of cell surface SM by exogenous neutral sphingomyelinase. Since DG activates protein kinase C and ceramide indirectly inhibits,this kinase but activates other kinase(s) and phosphatase(s), the phosphocholine transferase at the cell surface may have a regulatory role in signal transduction.	UNIV UTRECHT, SCH MED,DEPT CELL BIOL,AZU H02314, HEIDELBERGLAAN 100, 3584 CX UTRECHT, NETHERLANDS; UNIV IOWA, COLL MED, DEPT ANAT, IOWA CITY, IA 52242 USA	Utrecht University; University of Iowa			van Meer, Gerrit/AAH-1560-2021; van Helvoort, Ardy/U-7549-2019	van Helvoort, Ardy/0000-0002-3585-0676; van Meer, Gerrit/0000-0002-5976-6436	FOGARTY INTERNATIONAL CENTER [F06TW001534] Funding Source: NIH RePORTER; FIC NIH HHS [F06 TW 01534] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		DAO HNT, 1991, ANAL BIOCHEM, V196, P46; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; FRIES E, 1986, BIOCHEM J, V237, P33, DOI 10.1042/bj2370033; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; HAMPTON RY, 1989, SCIENCE, V246, P1050, DOI 10.1126/science.2555921; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HJELMSTAD RH, 1991, BIOCHEMISTRY-US, V30, P1731, DOI 10.1021/bi00221a001; JECKEL D, 1990, FEBS LETT, V261, P155, DOI 10.1016/0014-5793(90)80659-7; KALLEN KJ, 1993, BIOCHIM BIOPHYS ACTA, V1166, P305, DOI 10.1016/0005-2760(93)90111-L; KAPLAN MR, 1985, J CELL BIOL, V101, P441, DOI 10.1083/jcb.101.2.441; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; KOLSENICK R, 1992, TRENDS CELL BIOL, V2, P232; KOVAL M, 1991, BIOCHIM BIOPHYS ACTA, V1082, P113, DOI 10.1016/0005-2760(91)90184-J; KUDOH T, 1983, BIOCHIM BIOPHYS ACTA, V754, P82, DOI 10.1016/0005-2760(83)90084-X; LIPSKY NG, 1985, J CELL BIOL, V100, P27, DOI 10.1083/jcb.100.1.27; LISCOVITCH M, 1992, TRENDS BIOCHEM SCI, V17, P393, DOI 10.1016/0968-0004(92)90007-V; MALGAT M, 1986, J LIPID RES, V27, P251; MARGGRAF WD, 1984, BIOCHIM BIOPHYS ACTA, V793, P346, DOI 10.1016/0005-2760(84)90248-0; MARTIN OC, 1986, ANAL BIOCHEM, V159, P101, DOI 10.1016/0003-2697(86)90313-1; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; PAGANO RE, 1981, J CELL BIOL, V91, P872, DOI 10.1083/jcb.91.3.872; PAGANO RE, 1985, J BIOL CHEM, V260, P1909; PAGANO RE, 1983, J BIOL CHEM, V258, P2034; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SLEIGHT RG, 1984, J CELL BIOL, V99, P742, DOI 10.1083/jcb.99.2.742; SPENCE MW, 1983, J BIOL CHEM, V258, P8595; ULLMAN MD, 1974, J BIOL CHEM, V249, P1506; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; van Meer G, 1993, CURR OPIN CELL BIOL, V5, P661, DOI 10.1016/0955-0674(93)90137-F; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10344; VANTHOF W, 1990, J CELL BIOL, V111, P977, DOI 10.1083/jcb.111.3.977; VANTHOF W, 1992, BIOCHEM J, V283, P913, DOI 10.1042/bj2830913; VOELKER DR, 1982, BIOCHEMISTRY-US, V21, P2753, DOI 10.1021/bi00540a027; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73	36	79	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1763	1769						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294425				2022-12-27	WOS:A1994MR98800036
J	GIFFIN, W; TORRANCE, H; SAFFRAN, H; MACLEOD, HL; HACHE, RJG				GIFFIN, W; TORRANCE, H; SAFFRAN, H; MACLEOD, HL; HACHE, RJG			REPRESSION OF MOUSE MAMMARY-TUMOR VIRUS TRANSCRIPTION BY A TRANSCRIPTION FACTOR COMPLEX - BINDING OF INDIVIDUAL COMPONENTS TO SEPARATED DNA STRANDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; NEGATIVE REGULATORY ELEMENT; ZINC-FINGER PROTEIN; T-CELLS; C-MYC; INDUCIBLE PROMOTER; RESPONSIVE ELEMENT; HORMONE RECEPTORS; SINGLE-STRAND; FACTOR OTF-1	Expression of mouse mammary tumor virus in T lymphocytes appears to be required for accession of horizontally transmitted virus to the mammary gland. Further, deletions in the long terminal repeat which relax constraints on viral transcription promote T cell lymphoma. We have identified a polypurine transcriptional repressor element (NRE1) that is deleted from viruses that induce T cell lymphoma. NRE1 binding activity in nuclear extracts proved to be related to a growth inhibitory activity that represses c-myc expression in mature B cells. Mobility shift, DNA footprinting, and UV cross-linking identified three factors that interacted preferentially with double-stranded NRE1 or the separated single strands. NRE1 binding factor (NBF) (80 kDa) bound double and upper strand NRE1, apparently in concert with NRE1 associated factor (NAF) (95 kDa), which interacted directly with DNA only on the upper strand. NRE1 lower strand binding factor (NLF) (50 kDa) cross-linked specifically to lower strand NRE1. On sucrose gradients NBF, NAF, and NLF binding activities cosedimented at 8 S, implying an in vitro association of the 50-, 80-, and 95-kDa factors which precedes DNA binding. Therefore, NRE1 appears to be the site of action of a complex transcriptional repressor comprised of at least three factors that interact differentially with each DNA strand to repress steroid hormone-induced transcription of mouse mammary tumor virus in T cells.	UNIV OTTAWA,OTTAWA CIVIC HOSP,LOEB INST MED RES,DEPT MED,OTTAWA K1Y 4E9,ONTARIO,CANADA; UNIV OTTAWA,OTTAWA CIVIC HOSP,LOEB INST MED RES,DEPT BIOCHEM,OTTAWA K1Y 4E9,ONTARIO,CANADA	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute								ACHAORBEA H, 1991, NATURE, V350, P203; ALLAN GF, 1991, J BIOL CHEM, V266, P5905; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; BALL JK, 1988, J VIROL, V62, P2985, DOI 10.1128/JVI.62.8.2985-2993.1988; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRAKKE MK, 1970, ANAL BIOCHEM, V38, P56, DOI 10.1016/0003-2697(70)90155-7; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; BUETTI E, 1989, NUCLEIC ACIDS RES, V17, P3065, DOI 10.1093/nar/17.8.3065; CATO ACB, 1987, EMBO J, V6, P363, DOI 10.1002/j.1460-2075.1987.tb04763.x; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHALEPAKIS G, 1988, CELL, V53, P371, DOI 10.1016/0092-8674(88)90157-2; CHOI YW, 1991, NATURE, V350, P203, DOI 10.1038/350203a0; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUDLEY JP, 1986, J VIROL, V57, P385, DOI 10.1128/JVI.57.1.385-388.1986; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FOX KR, 1988, NUCLEIC ACIDS RES, V16, P2063, DOI 10.1093/nar/16.5.2063; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; GARCIABLANCO MA, 1989, GENE DEV, V3, P1866; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GOLOVKINA TV, 1992, CELL, V69, P637, DOI 10.1016/0092-8674(92)90227-4; GOUILLEUX F, 1991, NUCLEIC ACIDS RES, V19, P1563, DOI 10.1093/nar/19.7.1563; GRAYHACK EJ, 1992, MOL CELL BIOL, V12, P3573, DOI 10.1128/MCB.12.8.3573; GRODY WW, 1982, ENDOCR REV, V3, P141, DOI 10.1210/edrv-3-2-141; Hache R J, 1991, Receptor, V1, P217; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; HSU CLL, 1988, J VIROL, V62, P4644, DOI 10.1128/JVI.62.12.4644-4652.1988; JANSENDURR P, 1992, NUCLEIC ACIDS RES, V20, P1243, DOI 10.1093/nar/20.6.1243; KAKKIS E, 1988, NUCLEIC ACIDS RES, V16, P77, DOI 10.1093/nar/16.1.77; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KAKKIS E, 1987, P NATL ACAD SCI USA, V84, P7031, DOI 10.1073/pnas.84.20.7031; KALFF M, 1990, NATURE, V344, P360, DOI 10.1038/344360a0; KENNEDY GC, 1992, P NATL ACAD SCI USA, V89, P11498, DOI 10.1073/pnas.89.23.11498; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; KUO WL, 1988, J VIROL, V62, P2394, DOI 10.1128/JVI.62.7.2394-2402.1988; LANNIGAN DA, 1989, P NATL ACAD SCI USA, V86, P863, DOI 10.1073/pnas.86.3.863; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; LEE JW, 1991, J BIOL CHEM, V266, P24101; LEFEBVRE P, 1991, MOL CELL BIOL, V11, P2529, DOI 10.1128/MCB.11.5.2529; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCCORMICK L, 1992, J VIROL, V66, P3435, DOI 10.1128/JVI.66.6.3435-3447.1992; MINK S, 1990, NUCLEIC ACIDS RES, V18, P2017, DOI 10.1093/nar/18.8.2017; MORLEY KL, 1987, NUCLEIC ACIDS RES, V15, P6973, DOI 10.1093/nar/15.17.6973; NUSSE R, 1988, TRENDS GENET, V4, P291, DOI 10.1016/0168-9525(88)90172-2; PARTHUN MR, 1992, MOL CELL BIOL, V12, P4981, DOI 10.1128/MCB.12.11.4981; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PRATT WB, 1990, PROG CLIN BIOL RES, V322, P119; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; RINGOLD GM, 1975, CELL, V6, P299, DOI 10.1016/0092-8674(75)90181-6; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; SCHUURING E, 1990, ONCOGENE, V5, P459; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SPITKOVSKY DD, 1992, NUCLEIC ACIDS RES, V20, P797, DOI 10.1093/nar/20.4.797; SQUARTINI F, 1970, CANCER RES, V30, P2069; STARK HC, 1992, P NATL ACAD SCI USA, V89, P2180, DOI 10.1073/pnas.89.6.2180; STERN S, 1991, GENE DEV, V5, P2555, DOI 10.1101/gad.5.12b.2555; STEWART TA, 1988, MOL CELL BIOL, V8, P473, DOI 10.1128/MCB.8.1.473; TANAKA H, 1991, P NATL ACAD SCI USA, V88, P5393, DOI 10.1073/pnas.88.12.5393; THEUNISSEN HJM, 1989, J VIROL, V63, P3466, DOI 10.1128/JVI.63.8.3466-3471.1989; TSUBURA A, 1988, CANCER RES, V48, P6555; UCKER DS, 1984, J BIOL CHEM, V259, P7416; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; VANOOYEN A, 1990, J VIROL, V64, P4043; WILKISON WO, 1990, J BIOL CHEM, V265, P477; WOODLAND DL, 1991, NATURE, V349, P529, DOI 10.1038/349529a0; YAGIL G, 1991, CRIT REV BIOCHEM MOL, V26, P475, DOI 10.3109/10409239109086791; YANAGAWA S, 1991, J VIROL, V65, P526, DOI 10.1128/JVI.65.1.526-531.1991; YANAGAWA SI, 1993, J VIROL, V67, P112, DOI 10.1128/JVI.67.1.112-118.1993; YANAGAWA SI, 1990, J VIROL, V64, P2474, DOI 10.1128/JVI.64.6.2474-2483.1990	78	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1449	1459						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288611				2022-12-27	WOS:A1994MR22000104
J	MAKINO, N; MOCHIZUKI, Y; BANNAI, S; SUGITA, Y				MAKINO, N; MOCHIZUKI, Y; BANNAI, S; SUGITA, Y			KINETIC-STUDIES ON THE REMOVAL OF EXTRACELLULAR HYDROGEN-PEROXIDE BY CULTURED FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIXED-FUNCTION OXIDATION; GLUTATHIONE-PEROXIDASE; DT-DIAPHORASE; RAT-LIVER; CATALASE; SYSTEMS; HEPATOCYTES; METABOLISM; PATHWAY; QUINONE	To investigate the function of antioxidant enzymes in intact cells, we examined the removal of extracellular H2O2 by cultured fibroblasts (IMR-90). H2O2 concentration dependence of the reaction rate was interpreted as that the process involves two kinetically different reactions (referred to as reactions 1 and 2). Reaction 1 was characterized by a relatively low K(m) value (about 40 muM), and reaction 2 by linear dependence of the rate up to 500 muM H2O2. The magnitude of reaction 1 was reduced by treatment of the cells with diethyl maleate or 6-aminonicotinamide, while reaction 2 was inhibited by 3-amino1, 2,4-triazole treatment. It was concluded that reactions 1 and 2 are principally due to GSH peroxidase and catalase, respectively. The values of kinetic parameters were estimated by curve-fitting, and it was inferred that 80 to 90% of H2O2 is decomposed by GSH peroxidase at H2O2 concentrations lower than 10 muM. The contribution of catalase increases with the increase in H2O2 concentration. The intact cells showed a low catalase activity (about 15%), as compared with the activity found in the solubilized cells. The low catalase activity was ascribed to the latency of the enzyme caused by localization in peroxisomes. Fibroblasts also removed intracellular H2O2 generated by menadione. Treatment with diethyl maleate greatly impaired the H2O2-removing capability and caused H2O2 efflux into the medium.			MAKINO, N (corresponding author), UNIV TSUKUBA, INST BASIC MED SCI, DIV BIOCHEM, TSUKUBA, IBARAKI 305, JAPAN.							AIKAWA J, 1991, P NATL ACAD SCI USA, V88, P10084, DOI 10.1073/pnas.88.22.10084; AWASTHI YC, 1975, J BIOL CHEM, V250, P5144; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; COHEN G, 1963, BIOCHEMISTRY-US, V2, P1420, DOI 10.1021/bi00906a038; DEDUVE C, 1966, PHYSIOL REV, V46, P323, DOI 10.1152/physrev.1966.46.2.323; DRAPER NR, 1966, APPLIED REGRESSION A, P273; EGGLESTON LV, 1974, BIOCHEM J, V138, P425, DOI 10.1042/bj1380425; ERICKSON RR, 1976, BIOCHEM PHARMACOL, V25, P1501, DOI 10.1016/0006-2952(76)90068-X; FISCHKOFF S, 1975, J GEN PHYSIOL, V65, P663, DOI 10.1085/jgp.65.5.663; FLOHE L, 1972, H-S Z PHYSIOL CHEM, V353, P987, DOI 10.1515/bchm2.1972.353.1.987; FLOHE L, 1971, H-S Z PHYSIOL CHEM, V352, P1401, DOI 10.1515/bchm2.1971.352.2.1401; GAETANI GF, 1989, BLOOD, V73, P334; IYANAGI T, 1990, FREE RADICAL RES COM, V8, P259, DOI 10.3109/10715769009053359; IYANAGI T, 1969, BIOCHIM BIOPHYS ACTA, V172, P370, DOI 10.1016/0005-2728(69)90133-9; IYANAGI T, 1970, BIOCHIM BIOPHYS ACTA, V216, P282, DOI 10.1016/0005-2728(70)90220-3; JONES DP, 1981, ARCH BIOCHEM BIOPHYS, V210, P505, DOI 10.1016/0003-9861(81)90215-0; KAUFFMAN FC, 1977, BIOCHEM J, V166, P583, DOI 10.1042/bj1660583; KAYE CI, 1975, J LAB CLIN MED, V86, P422; LIND C, 1982, ARCH BIOCHEM BIOPHYS, V216, P178, DOI 10.1016/0003-9861(82)90202-8; NELDER JA, 1965, COMPUT J, V7, P308, DOI 10.1093/comjnl/7.4.308; NICHOLLS P, 1972, BIOCHIM BIOPHYS ACTA, V279, P306, DOI 10.1016/0304-4165(72)90147-X; OLOUGHLIN MA, 1980, RADIAT RES, V84, P477, DOI 10.2307/3575486; POWIS G, 1979, PHARMACOL THERAPEUT, V7, P297, DOI 10.1016/0163-7258(79)90033-0; RAIVIO KO, 1981, BIOCHIM BIOPHYS ACTA, V678, P51, DOI 10.1016/0304-4165(81)90046-5; RUSH GF, 1986, TOXICOL APPL PHARM, V85, P324, DOI 10.1016/0041-008X(86)90339-X; Schonbaum G. R., 1976, ENZYMES, V13, P363, DOI [10.1016/S1874-6047(08)60245-0, DOI 10.1016/S1874-6047(08)60245-0]; SIES H, 1975, EUR J BIOCHEM, V57, P503, DOI 10.1111/j.1432-1033.1975.tb02325.x; THURMAN RG, 1973, EUR J BIOCHEM, V38, P73, DOI 10.1111/j.1432-1033.1973.tb03035.x; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TRIBBLE DL, 1990, BIOCHEM PHARMACOL, V39, P729, DOI 10.1016/0006-2952(90)90152-B; VANVELDHOVEN P, 1983, BIOCHEM J, V210, P685, DOI 10.1042/bj2100685; WILLIAMS DC, 1976, ANAL CHEM, V48, P1003, DOI 10.1021/ac60371a025; WINKLER BS, 1986, EXP EYE RES, V43, P829, DOI 10.1016/S0014-4835(86)80013-6; YAMASHOJI S, 1991, BIOCHIM BIOPHYS ACTA, V1059, P99, DOI 10.1016/S0005-2728(05)80191-4	34	109	113	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1020	1025						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288557				2022-12-27	WOS:A1994MR22000040
J	PILLINGER, MH; VOLKER, C; STOCK, JB; WEISSMANN, G; PHILIPS, MR				PILLINGER, MH; VOLKER, C; STOCK, JB; WEISSMANN, G; PHILIPS, MR			CHARACTERIZATION OF A PLASMA MEMBRANE-ASSOCIATED PRENYLCYSTEINE-DIRECTED ALPHA-CARBOXYL METHYLTRANSFERASE IN HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; LAMIN-B; SACCHAROMYCES-CEREVISIAE; TERMINAL METHYLATION; ALKALINE-PHOSPHATASE; CAAX MOTIF; SUBUNIT; CELLS; LOCALIZATION; MATURATION	Signal transduction in human neutrophils requires prenylcysteine-directed carboxyl methylation of ras-related low molecular weight GTP-binding proteins. We now report the subcellular localization and characterization of a neutrophil prenylcysteine alpha carboxyl methyltransferase. The highest carboxyl methyltransferase activity copurified with biotinylated neutrophil surface membranes, supporting a plasma membrane localization of the enzyme. Neutrophil nuclear fractions contained little or no methyltransferase activity. Methyltransferase activity was detergent-sensitive but could be reconstituted by removal of detergent in the presence of phosphatidyl choline and an anionic phospholipid. N-Acetyl-S-trans,trans-farnesyl-L-cysteine (AFC) and N-acetyl-S-all-trans-geranylgeranyl-L-cysteine (AGGC) were effective substrates for neutrophil prenylcysteine-directed methyltransferase; V(max) values for AFC and AGGC (16.4 and 22.1 pmol of methylated/mg protein/min, respectively) are among the highest yet reported. Although both GTPgammaS and the chemoattractant fMet-Leu-Phe stimulated methylation of ras-related proteins, neither affected methylation of AFC. These data suggest that neutrophil plasma membranes contain a phospholipid-dependent, prenylcysteine-directed carboxyl methyltransferase of relatively high specific activity that modifies ras-related protein substrates in the GTP-bound, activated state.	NYU MED CTR,SCH MED,DEPT MED,DIV RHEUMATOL,550 1ST AVE,NEW YORK,NY 10016; PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544; PRINCETON UNIV,DEPT CHEM,PRINCETON,NJ 08544	New York University; Princeton University; Princeton University			Weissmann, Gerald/N-5273-2015	Weissmann, Gerald/0000-0002-4285-4552; Pillinger, Michael/0000-0003-3168-1542; Mark, Philips/0000-0002-1179-8156	NIAID NIH HHS [AI-20980] Funding Source: Medline; NIAMS NIH HHS [AR-07176-18] Funding Source: Medline; NIGMS NIH HHS [GM-8309] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008309] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABO A, 1992, SCIENCE, V353, P668; AMUR SG, 1986, J NEUROSCI RES, V16, P367, DOI 10.1002/jnr.490160204; Aronson N N Jr, 1974, Methods Enzymol, V31, P90; BACKLUND PS, 1992, J BIOL CHEM, V267, P18432; BACKLUND PS, 1968, J BIOL CHEM, V263, P15864; BOKOCH GM, 1990, CURRENT TOPICS MEMBR, P65; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BUONO BJ, 1989, J CELL PHYSL, V141, P636; CHELSKY D, 1985, BIOCHEMISTRY-US, V24, P6651, DOI 10.1021/bi00344a053; CHELSKY D, 1989, J BIOL CHEM, V264, P7637; CHELSKY D, 1987, J BIOL CHEM, V262, P4303; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DECHATELET LR, 1970, BIOCHEM MED METAB B, V4, P61, DOI 10.1016/0006-2944(70)90103-1; DIDSBURY JR, 1990, BIOCHEM BIOPH RES CO, V171, P804, DOI 10.1016/0006-291X(90)91217-G; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HRYCYNA CA, 1992, J BIOL CHEM, V267, P10457; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; HUZOORAKBAR, 1991, J BIOL CHEM, V266, P4387; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LONG WK, 1987, J VIROL, V61, P221, DOI 10.1128/JVI.61.1.221-224.1987; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MANCOCK JF, 1989, CELL, V57, P1167; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; PHILIPS MR, 1991, J BIOL CHEM, V266, P1289; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; PIKE MC, 1978, P NATL ACAD SCI USA, V75, P3928, DOI 10.1073/pnas.75.8.3928; ROSEN CL, 1992, J CELL BIOL, V117, P617, DOI 10.1083/jcb.117.3.617; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SENGELOV H, 1992, J BIOL CHEM, V267, P14912; SERHAN CN, 1983, BIOCHIM BIOPHYS ACTA, V762, P420, DOI 10.1016/0167-4889(83)90007-1; SERHAN CN, 1982, BIOCHEM BIOPH RES CO, V107, P951, DOI 10.1016/0006-291X(82)90615-5; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SMOLEN JE, 1982, TRENDS PHARMACOL SCI, V3, P483, DOI 10.1016/0165-6147(82)91247-0; SNYDERMAN R, 1988, INFLAMMATION BASIC P, P309; SOBOTKABRINER C, 1992, J BIOL CHEM, V267, P12116; STEPHENSON RC, 1992, J BIOL CHEM, V267, P13314; STEPHENSON RC, 1990, J BIOL CHEM, V265, P16248; VOLKER C, 1990, Methods (Orlando), V1, P283, DOI 10.1016/S1046-2023(05)80329-9; VOLKER C, 1991, FEBS LETT, V295, P189, DOI 10.1016/0014-5793(91)81415-5; VOLKER C, 1991, J BIOL CHEM, V266, P21515; Zucker-Franklin D, 1988, ATLAS BLOOD CELLS FU	47	62	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1486	1492						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288614				2022-12-27	WOS:A1994MR22000108
J	FARRELL, DH; THIAGARAJAN, P				FARRELL, DH; THIAGARAJAN, P			BINDING OF RECOMBINANT FIBRINOGEN MUTANTS TO PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA FIBRINOGEN; GLYCOPROTEIN-IIB-IIIA; HUMAN-BLOOD PLATELETS; GAMMA-CHAIN; ALPHA-CHAIN; VONWILLEBRAND-FACTOR; AGGREGATION; FIBRONECTIN; RECOGNITION; INTEGRINS	Platelet aggregation is mediated by the interaction of fibrinogen with platelet membrane glycoprotein IIb-IIIa, a member of the integrin family (integrin alpha(IIb)beta3). Three different binding sites on fibrinogen for IIb-IIIa have been proposed, two RGD-containing sequences in the a chain and one dodecapeptide sequence at the carboxyl terminus of they chain. However, recent evidence shows that mutations in either of the a chain sequences have no effect on platelet aggregation, whereas the substitution of a variant gamma chain (gamma') for the gamma chain results in a major reduction in platelet aggregation activity. The present investigation demonstrates that the gamma' chain shows decreased binding to IIb-IIIa as measured by direct binding experiments. In addition, adhesion studies indicate that the binding of both stimulated and unstimulated platelets to immobilized fibrinogens is mediated primarily through the gamma chain carboxyl terminus. Furthermore, a peptide corresponding to the carboxyl terminus of the gamma chain inhibits fibrinogen binding and platelet adhesion, whereas a peptide corresponding to the carboxyl terminus of the gamma' chain is significantly less inhibitory. These data show that the defective platelet aggregation activity of the fibrinogen gamma' chain is due to decreased binding to platelet glycoprotein IIb-IIIa.	UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,DIV HEMATOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040860, R01HL016919] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-16919, HL-40860] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMRANI DL, 1988, BLOOD, V72, P919; BEACHAM DA, 1992, J BIOL CHEM, V267, P3409; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; CHERESH DA, 1989, CELL, V16, P427; CHERNY RC, 1993, J BIOL CHEM, V268, P9725; CHUNG DW, 1984, BIOCHEMISTRY-US, V23, P4232, DOI 10.1021/bi00313a033; DEMPFLE CE, 1987, THROMB RES, V46, P19, DOI 10.1016/0049-3848(87)90203-9; DOOLITTLE RF, 1978, J MOL BIOL, V120, P311, DOI 10.1016/0022-2836(78)90070-0; DOOLITTLE RF, 1979, NATURE, V280, P464, DOI 10.1038/280464a0; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FARRELL DH, 1991, BIOCHEMISTRY-US, V30, P9414, DOI 10.1021/bi00103a004; FORNACE AJ, 1984, P NATL ACAD SCI USA, V259, P12826; FRANCIS CW, 1980, J BIOL CHEM, V255, P5599; GARTNER TK, 1993, IN PRESS THROMB RES; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; HAVERSTICK DM, 1985, BLOOD, V66, P946; HAWIGER J, 1989, BIOCHEMISTRY-US, V28, P2909, DOI 10.1021/bi00433a024; HENSCHEN A, 1980, PROTIDES BIOL FLUIDS, V28, P51; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KAZAL LA, 1963, P SOC EXP BIOL MED, V113, P989; KIEFFER N, 1991, J CELL BIOL, V113, P451, DOI 10.1083/jcb.113.2.451; KIRSCHBAUM NE, 1992, BLOOD, V79, P2643; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; KUYAS C, 1990, THROMB HAEMOSTASIS, V63, P439; LASZ EC, 1993, BIOCHEM BIOPH RES CO, V190, P118, DOI 10.1006/bbrc.1993.1019; LINDON JN, 1986, BLOOD, V68, P355; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MARKWELL MAK, 1978, BIOCHEMISTRY-US, V17, P4807, DOI 10.1021/bi00615a031; MARTINEZ J, 1974, J CLIN INVEST, V53, P600, DOI 10.1172/JCI107595; MATTHIAS FR, 1975, THROMB RES, V7, P861, DOI 10.1016/0049-3848(75)90089-4; MCKEE PA, 1966, ARCH BIOCHEM BIOPHYS, V116, P271, DOI 10.1016/0003-9861(66)90033-6; NIEWIAROWSKI S, 1977, BLOOD, V49, P635; PEERSCHKE EIB, 1987, BLOOD, V69, P950; PEERSCHKE EIB, 1986, BLOOD, V67, P385; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; WOLFENSTEINTODEL C, 1980, P NATL ACAD SCI-BIOL, V77, P5069, DOI 10.1073/pnas.77.9.5069	40	143	146	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					226	231						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276798				2022-12-27	WOS:A1994MR21900042
J	TAMAI, K; LI, K; UITTO, J				TAMAI, K; LI, K; UITTO, J			IDENTIFICATION OF A DNA-BINDING PROTEIN (KERATINOCYTE TRANSCRIPTIONAL PROTEIN-1) RECOGNIZING A KERATINOCYTE-SPECIFIC REGULATORY ELEMENT IN THE 230-KDA BULLOUS PEMPHIGOID ANTIGEN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENT GENES; BASEMENT-MEMBRANE ZONE; FACTOR AP-2; ENHANCER ELEMENTS; CDNA CLONING; HUMAN-SKIN; I KERATIN; EXPRESSION; SEQUENCE; CONSERVATION	We have recently cloned and characterized the entire human 230-kDa bullous pemphigoid antigen gene, which is expressed at a relatively high level in the basal keratinocytes. A putative AP2 binding sequence (KRE2), identified in the position -1786 to -1778, was cloned in front of a heterologous thymidine kinase chloramphenicol acetyltransferase construct, and transient transfections of normal human keratinocytes indicated a marked enhancement of the promoter activity. Normal human keratinocyte nuclear extracts contained a protein, designated as keratinocyte transcriptional protein-1 (KTP-1), which complexed with the KRE2 oligomer when examined by gel mobility shift assays. This protein was not detected in human skin fibroblast or HeLa cell nuclear extracts that did, however, contain AP2. UV cross-linking studies and Southwestern analyses suggested that KTP-1 binds to DNA as a single polypeptide of approximately 110 kDa. These data suggest that KTP-1 is a DNA-binding protein clearly distinct from AP2, and this protein may be responsible for the basal keratinocyte-specific expression of the bullous pemphigoid antigen gene.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,JEFFERSON INST MOLEC MED,DEPT DERMATOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,JEFFERSON INST MOLEC MED,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University					NIAMS NIH HHS [T32-AR07561, P01-AR38923] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007561, P01AR038923] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BLESSING M, 1987, EMBO J, V6, P567, DOI 10.1002/j.1460-2075.1987.tb04792.x; BOOTH BA, 1980, BIOCHIM BIOPHYS ACTA, V607, P145, DOI 10.1016/0005-2787(80)90228-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; DIAZ LA, 1990, J CLIN INVEST, V86, P1088, DOI 10.1172/JCI114812; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; GIUDICE GJ, 1991, J CLIN INVEST, V87, P734, DOI 10.1172/JCI115054; GIUDICE GJ, 1992, J INVEST DERMATOL, V99, P243, DOI 10.1111/1523-1747.ep12616580; HOPKINSON SB, 1992, J INVEST DERMATOL, V99, P264, DOI 10.1111/1523-1747.ep12616615; HUFF CA, 1993, J BIOL CHEM, V268, P377; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JOHNSON LD, 1985, P NATL ACAD SCI USA, V82, P1896, DOI 10.1073/pnas.82.7.1896; JORDON RE, 1967, J AMER MED ASSOC, V200, P751, DOI 10.1001/jama.200.9.751; JORDON RE, 1971, ARCH DERMATOL, V103, P486, DOI 10.1001/archderm.103.5.486; KRIEG TM, 1985, J BIOL CHEM, V260, P5867; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; LERSCH R, 1989, MOL CELL BIOL, V9, P3685, DOI 10.1128/MCB.9.9.3685; LEVER WF, 1965, PEMPHIGUS PEMPHIGOID, P75; LI K, 1991, J BIOL CHEM, V266, P24064; LI KH, 1993, J BIOL CHEM, V268, P8825; LI KH, 1992, J INVEST DERMATOL, V99, P258, DOI 10.1111/1523-1747.ep12616611; MARCHUK D, 1985, P NATL ACAD SCI USA, V82, P1609, DOI 10.1073/pnas.82.6.1609; MARCHUK D, 1984, CELL, V39, P491, DOI 10.1016/0092-8674(84)90456-2; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOLL R, 1982, DIFFERENTIATION, V23, P170, DOI 10.1111/j.1432-0436.1982.tb01280.x; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MUTASIM DF, 1985, J INVEST DERMATOL, V84, P47, DOI 10.1111/1523-1747.ep12274684; Sambrook J, 1989, MOL CLONING LABORATO; SAWAMURA D, 1990, GENOMICS, V8, P722, DOI 10.1016/0888-7543(90)90261-R; SAWAMURA D, 1991, J INVEST DERMATOL, V96, P908, DOI 10.1111/1523-1747.ep12475433; SAWAMURA D, 1991, J BIOL CHEM, V266, P17784; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SNAPE AM, 1991, DEVELOPMENT, V113, P283; SNAPE AM, 1990, DEVELOPMENT, V109, P157; STANLEY JR, 1983, J CELL BIOL, V96, P1809, DOI 10.1083/jcb.96.6.1809; STANLEY JR, 1989, J CLIN INVEST, V83, P1443, DOI 10.1172/JCI114036; STANLEY JR, 1981, CELL, V24, P897, DOI 10.1016/0092-8674(81)90115-X; Sun TT, 1984, CANCER CELLS, V1, P169; TAMAI K, 1993, J CLIN INVEST, V92, P814, DOI 10.1172/JCI116655; TANAKA T, 1991, J BIOL CHEM, V266, P12555; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TYNER AL, 1985, P NATL ACAD SCI USA, V82, P4683, DOI 10.1073/pnas.82.14.4683; UITTO J, 1992, J CLIN INVEST, V90, P687, DOI 10.1172/JCI115938; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WESTGATE GE, 1985, J INVEST DERMATOL, V84, P218, DOI 10.1111/1523-1747.ep12265229; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557	51	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					493	502						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276841				2022-12-27	WOS:A1994MR21900081
J	WILLIMANN, TE; TRUEB, B				WILLIMANN, TE; TRUEB, B			IDENTIFICATION OF FUNCTIONAL ELEMENTS AND RECONSTITUTION OF THE ALPHA-1(VI) COLLAGEN PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEINS; VI COLLAGEN; TRANSCRIPTION INITIATION; MAMMALIAN NUCLEI; GENE-EXPRESSION; CELLS; FIBROBLASTS; SUBUNIT; CLONING; DNA	To gain insight into the regulatory mechanisms of collagen VI synthesis we have characterized the cis-acting elements of the chicken alpha1(VI) collagen promoter. Footprinting experiments with nuclear extracts from chicken embryos revealed three distinct elements, designated A, B, and C, that were protected from DNase I digestion. The nuclear proteins that interact with the three sites were identified by gel retardation assays in combination with the use of various oligonucleotide competitors as well as specific antibodies raised against well characterized transcription factors. Site A was found to be a target for transcriptional activator AP1, whereas sites B and C were shown to be recognized each by two distinct nuclear proteins which belong to the Spl multigene family. To address the question whether the three sites alone are able to direct transcription, a minipromoter construct was created in which the sequences of sites A, B, and C were placed in front of a reporter gene. After transfection into chicken fibroblasts, this construct exhibited a high relative promoter activity when compared to a large genomic fragment containing the basic alpha1(VI) collagen promoter. Thus, the three sites are sufficient to induce transcription of this gene.			WILLIMANN, TE (corresponding author), SWISS FED INST TECHNOL, BIOCHEM 1 LAB, CH-8092 ZURICH, SWITZERLAND.		Trueb, Beat/AAL-9621-2020	Trueb, Beat/0000-0001-8684-6856				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANTEQUERA F, 1989, CELL, V58, P509, DOI 10.1016/0092-8674(89)90431-5; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BONALDO P, 1993, MATRIX, V13, P223, DOI 10.1016/S0934-8832(11)80006-5; CARTER WG, 1982, J BIOL CHEM, V257, P13805; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HATAMOCHI A, 1989, J BIOL CHEM, V264, P3494; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOLLER E, 1992, EUR J BIOCHEM, V208, P769, DOI 10.1111/j.1432-1033.1992.tb17246.x; KOLLER E, 1991, NUCLEIC ACIDS RES, V19, P485, DOI 10.1093/nar/19.3.485; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAR JH, 1988, J CELL BIOL, V107, P573, DOI 10.1083/jcb.107.2.573; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; Sambrook J, 1989, MOL CLONING LABORATO; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SCHREIER T, 1988, BIOCHEM J, V253, P381, DOI 10.1042/bj2530381; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; Timpl R., 1987, STRUCTURE FUNCTION C, P105, DOI [10.1016/B978--0--12--481280-2.50008---8, DOI 10.1016/B978--0--12--481280-2.50008---8]; TRUEB B, 1989, J BIOL CHEM, V264, P136; TRUEB B, 1985, J CELL BIOL, V100, P638, DOI 10.1083/jcb.100.2.638; TRUEB B, 1986, EMBO J, V5, P2815, DOI 10.1002/j.1460-2075.1986.tb04573.x; VALLE PL, 1993, J CELL BIOL, V121, P1173, DOI 10.1083/jcb.121.5.1173; WESTIN G, 1988, NUCLEIC ACIDS RES, V16, P5771, DOI 10.1093/nar/16.13.5771	36	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					332	338						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276816				2022-12-27	WOS:A1994MR21900057
J	MCLEAN, JR; KRISHNAKUMAR, S; ODONNELL, JM				MCLEAN, JR; KRISHNAKUMAR, S; ODONNELL, JM			MULTIPLE MESSENGER-RNAS FROM THE PUNCH LOCUS OF DROSOPHILA-MELANOGASTER ENCODE ISOFORMS OF GTP CYCLOHYDROLASE-I WITH DISTINCT N-TERMINAL DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; ADRENAL-MEDULLA; NITRIC-OXIDE; BIOSYNTHESIS; TETRAHYDROBIOPTERIN; GENE; PURIFICATION; SEQUENCE; ENZYME; CELLS	The GTP cyclohydrolase I gene of Drosophila melanogaster, the Punch locus, encodes alternative transcripts of 1.7 and 1.75 kilobases (kb). These transcripts are differentially expressed throughout Drosophila development. cDNA clones representing these transcripts, corresponding genomic regions and polymerase chain reaction-amplified primer extensions of the 5' ends of the RNAs were sequenced. Both RNAs contain five exons and derive from primary transcripts that extend over approximately 8 and 4 kb for the 1.7- and 1.75-kb RNAs, respectively. Their 5'-most exons are unique and spliced onto common 3' exons. The cDNAs each contain a single long open reading frame, which can be translated into a polypeptide of 273 amino acids for the 1.7-kb mRNA and 308 amino acids for the 1.75-kb mRNA. The unique exons confer distinct N-terminal domains to each predicted protein. Sequence comparisons reveal that the drosophila GTP cyclohydrolase isoforms encoded by the multiple transcripts are highly similar to GTP cyclohydrolases from humans, rodents, and bacteria, with one significant exception. The N-terminal domains encoded by the transcript-specific 5' exons cannot be aligned with the N termini of any other GTP cyclohydrolases. These domains are predicted to confer distinct physical characteristics to the alternate isoforms, and it is hypothesized that they aid in regulating the expression of the enzyme in diverse cellular environments.	UNIV ALABAMA,DEPT BIOL SCI,TUSCALOOSA,AL 35487; CARNEGIE MELLON UNIV,DEPT BIOL SCI,PITTSBURGH,PA 15213	University of Alabama System; University of Alabama Tuscaloosa; Carnegie Mellon University					NIGMS NIH HHS [GM26757, GM08067] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026757] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUDONIA MM, 1981, P NATL ACAD SCI-BIOL, V78, P2703, DOI 10.1073/pnas.78.5.2703; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BABITZKE P, 1992, J BACTERIOL, V174, P2059, DOI 10.1128/JB.174.7.2059-2064.1992; CAVERNER DR, 1991, NUCLEIC ACIDS RES, V19, P1385; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOLLNICK P, 1990, P NATL ACAD SCI USA, V87, P8726, DOI 10.1073/pnas.87.22.8726; GOLUMBESKI GS, 1991, GENE DEV, V5, P2060, DOI 10.1101/gad.5.11.2060; HARADA T, 1993, SCIENCE, V260, P1507, DOI 10.1126/science.8502995; HATAKEYAMA K, 1989, J BIOL CHEM, V264, P21660; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HUBER C, 1990, CHEMISTRY AND BIOLOGY OF PTERIDINES 1989, P473; KATZENMEIER G, 1991, BIOL CHEM H-S, V372, P991, DOI 10.1515/bchm3.1991.372.2.991; LOVENBERG W, 1967, SCIENCE, V155, P217, DOI 10.1126/science.155.3759.217; MACKAY WJ, 1983, GENETICS, V105, P35; MACKAY WJ, 1985, GENETICS, V111, P885; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MCLEAN JR, 1990, GENETICS, V126, P1007; MILSTIEN S, 1990, CHEMISTRY AND BIOLOGY OF PTERIDINES 1989, P505; MIWA S, 1985, ARCH BIOCHEM BIOPHYS, V239, P234, DOI 10.1016/0003-9861(85)90831-8; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; NOMURA T, 1993, BIOCHEM BIOPH RES CO, V191, P523, DOI 10.1006/bbrc.1993.1249; ODONNELL JM, 1989, DEV GENET, V10, P273, DOI 10.1002/dvg.1020100316; ODONNELL JM, 1993, CHEM BIOL PTERIDINES; REYNOLDS ER, 1987, DEV BIOL, V123, P430, DOI 10.1016/0012-1606(87)90401-5; REYNOLDS ER, 1988, GENETICS, V119, P609; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOEDON G, 1989, EUR J BIOCHEM, V178, P627, DOI 10.1111/j.1432-1033.1989.tb14491.x; SCHOEDON G, 1987, EUR J BIOCHEM, V166, P303, DOI 10.1111/j.1432-1033.1987.tb13515.x; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TANAKA K, 1989, P NATL ACAD SCI USA, V86, P5864, DOI 10.1073/pnas.86.15.5864; TOGARI A, 1992, BIOCHEM BIOPH RES CO, V187, P359, DOI 10.1016/S0006-291X(05)81501-3; VIVEROS OH, 1981, SCIENCE, V213, P349, DOI 10.1126/science.7017928; WEISBERG EP, 1986, J BIOL CHEM, V261, P1453; WERNER ER, 1990, J BIOL CHEM, V265, P3189; WERNERFELMAYER G, 1991, FASEB J, V5, pA1672; ZIEGLER I, 1987, UNCONJUGATED PTERINS, P169	42	39	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27191	27197						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262960				2022-12-27	WOS:A1993MM26200055
J	OLIVIER, AR; PARKER, PJ				OLIVIER, AR; PARKER, PJ			BOMBESIN, PLATELET-DERIVED GROWTH-FACTOR, AND DIACYLGLYCEROL INDUCE SELECTIVE-MEMBRANE ASSOCIATION AND DOWN-REGULATION OF PROTEIN-KINASE-C ISOTYPES IN SWISS 3T3-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN-RELEASING-HORMONE; 3T3 CELLS; SIGNAL TRANSDUCTION; PHORBOL ESTERS; PHOSPHATIDYLCHOLINE HYDROLYSIS; RAT FIBROBLASTS; DNA-SYNTHESIS; GH4C1 CELLS; ACTIVATION; EPSILON	Swiss 3T3 cells contain protein kinase C (PKC) isotypes alpha, delta, epsilon and zeta (Olivier, A. R., and Parker, P. J. (1992) J. Cell. Physiol. 152, 240-244). Acute stimulation of quiescent cells with the neuropeptide bombesin decreases the mobility of PKC-delta and PKC-epsilon on SDS-polyacrylamide gels. These slower migrating forms of PKC-delta and PKC-epsilon rapidly (within 1 s) and selectively are found associated with the Triton X-100-soluble membrane fraction. No change in the mobility or distribution of PKC-alpha or PKC-zeta is detected. Long-term treatment of cells with bombesin induces selective membrane association and down-regulation of PKC-delta and PKC-epsilon (decreasing 70 and 65%, respectively). No change in the long-term distribution of PKC-alpha and PKC-zeta was detected. Bombesin did, however, increase PKC-alpha protein levels by 60% compared to control cells. PKC-zeta levels remained unchanged. Both the shift in mobility and down-regulation of PKC-delta and PKC-epsilon were only induced by mitogenic doses of bombesin. The potent mitogen platelet-derived growth factor induced similar effects on the PKC isotypes delta and epsilon. PKC-alpha and PKC-zeta levels were unaffected. Repeated doses of the synthetic diglyceride 1-oleoyl-2-acetyl-sn-glycerol induced PKC-delta and PKC-epsilon down-regulation and stimulated the cells to divide. Again PKC-alpha and PKC-zeta levels were unaffected. These results show a correlation between the membrane association and down-regulation of PKC-delta and PKC-epsilon and the entry of cells into S phase.			OLIVIER, AR (corresponding author), IMPERIAL CANC RES FUND,PROT PHOSPHORYLAT LAB,POB 123,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.		Parker, Peter j/D-5192-2013	parker, peter/0000-0002-6218-2933				AIHARA H, 1991, P NATL ACAD SCI USA, V88, P11062, DOI 10.1073/pnas.88.24.11062; AKITA Y, 1990, BIOCHEM BIOPH RES CO, V172, P184, DOI 10.1016/S0006-291X(05)80191-3; BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BORNER C, 1992, J BIOL CHEM, V267, P12900; BORNER C, 1992, J BIOL CHEM, V267, P12892; COOK SJ, 1990, BIOCHEM J, V265, P617, DOI 10.1042/bj2650617; COOK SJ, 1991, CELL SIGNAL, V3, P273, DOI 10.1016/0898-6568(91)90055-Y; HA KS, 1993, J BIOL CHEM, V268, P10534; ISSANDOU M, 1989, BIOCHEM BIOPH RES CO, V163, P201, DOI 10.1016/0006-291X(89)92121-9; KILEY S, 1990, J BIOL CHEM, V265, P15704; KILEY SC, 1991, J BIOL CHEM, V266, P23761; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH KL, 1991, J BIOL CHEM, V266, P3215; LEIBERSPERGER H, 1990, J BIOL CHEM, V265, P16108; MARAIS RM, 1991, METHOD ENZYMOL, V200, P234; MITCHELL FE, 1989, BIOCHEM J, V261, P131, DOI 10.1042/bj2610131; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; MUIR JG, 1987, J CELL PHYSIOL, V130, P382, DOI 10.1002/jcp.1041300311; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; OLIVIER AR, 1992, BIOCHEM SOC T, V20, P603, DOI 10.1042/bst0200603; OLIVIER AR, 1991, EUR J BIOCHEM, V200, P805, DOI 10.1111/j.1432-1033.1991.tb16248.x; OLIVIER AR, 1992, J CELL PHYSIOL, V152, P240, DOI 10.1002/jcp.1041520204; ORMEROD MG, 1990, FLOW CYTOMETRY; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PETTITT TR, 1993, BIOCHEM J, V289, P487, DOI 10.1042/bj2890487; PLEVIN R, 1991, BIOCHEM J, V279, P559, DOI 10.1042/bj2790559; ROZENGURT E, 1984, P NATL ACAD SCI-BIOL, V81, P5748, DOI 10.1073/pnas.81.18.5748; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0	40	101	102	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2758	2763						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300608				2022-12-27	WOS:A1994MV43200061
J	FRICK, DN; WEBER, DJ; GILLESPIE, JR; BESSMAN, MJ; MILDVAN, AS				FRICK, DN; WEBER, DJ; GILLESPIE, JR; BESSMAN, MJ; MILDVAN, AS			DUAL DIVALENT-CATION REQUIREMENT OF THE MUTT DGTPASE - KINETIC AND MAGNETIC-RESONANCE STUDIES OF THE METAL AND SUBSTRATE COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE; NUCLEOSIDE TRIPHOSPHATASE; MUTATOR GENE; NMR; IDENTIFICATION; PURIFICATION; PROTEINS; EXCHANGE; ENZYME	Kinetic analyses of both the Mn2+- and Mg2+-activated hydrolysis of dGTP by MutT show the requirement for two divalent cations. Whereas Mn2+ supports a 20-fold lower k(cat) (0.19 s-1) than Mg2+ (4.0 s-1), the K(m) of Mn2+.dGTP (6.3 mum) is 45-fold lower than that of Me2+.dGTP (284 mum). Adenosine 5'-(alpha,beta-methylenetriphosphate) (AMPCPP) is a linear competitive inhibitor with respect to dGTP with a K(i) for Mn2+.AMPCPP (42 muM) which is 57-fold lower than the K(i) of Mg2+.AMPCPP (2.4 mm). Such tightening suggests that a metal-bridge E.M2+.NTP.M2+ complex is the catalytically active species. The 12 dissociation constants describing the quaternary MutT.M2+.AMPCPP.M2+ complex were evaluated for both Mn2+ and Mg2+, using EPR and NMR methods. MutT binds a single Mn2+ with a K(d) of 130 +/- 40 muM in reasonable agreement with the kinetically determined activator constant of Mn2+ of 230 +/- 72 muM. The MutT.AMPCPP complex binds two Mn2+ ions, the weaker of which has a K(d) of 16 +/- 2 muM in agreement with the kinetically determined K(m)Mn2+ of 26 +/- 10 muM. MutT.Mn2+ binds Mn2+.AMPCPP with K(d) of 16 +/- 4 muM, whereas MutT alone binds Mn2+.AMPCPP with a K(d) of 135 +/- 30 muM. The 17-fold enhanced paramagnetic effect of Mn2+ on the longitudinal relaxation rate of water protons found with the binary MutT.Mn2+ complex decreases to 4.7-fold upon binding of AMPCPP and to 8.7-fold upon binding of Mn2+.AMPCPP, further supporting a metal-bridge MutT.M2+.NTP.M2+ complex. By competition with Mn2+ MutT binds Mg2+ at one site with a K(d) of 7.5 mM, and MutT.AMPCPP binds Mg2+ at two sites, the weaker of which has a K(d) of 0.9 mm. These values are comparable to the kinetically determined K(a)Mg of 15 +/- 7 mM and K(m)Mg of 1.7 +/- 0.7 mM, respectively. Studies with the racemic, substitution-inert beta,gamma-bidentate tetraamminecobalt (III)-beta,gamma-phosphate-ATP (Co3+(NH3)4ATP) complex show that MutT slowly hydrolyzes only the A stereoisomer but requires Mg2+ or Mn2+ to do so, confirming a dual metal ion requirement.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,725 N WOLFE ST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins University			Weber, David J/B-5349-2011; Gillespie, Joel/GXW-0158-2022	Weber, David J/0000-0002-8824-1110; Gillespie, Joel/0000-0002-5075-1609; Frick, David/0000-0002-2434-7223	NIDDK NIH HHS [DK 28616] Funding Source: Medline; NIGMS NIH HHS [GM18649, 5-T32-GM07231] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK028616, R01DK028616] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007231] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEYGUNAWARDANA C, 1993, 1993 ENC C ST LOUIS, P94; ADAMS H, 1965, METHOD ENZYMAT AN, P575; AKIYAMA M, 1989, P NATL ACAD SCI USA, V86, P3949, DOI 10.1073/pnas.86.11.3949; ARMSTRONG RN, 1979, BIOCHEMISTRY-US, V18, P1230, DOI 10.1021/bi00574a018; BERMAN KM, 1970, J BIOL CHEM, V245, P5309; BHATNAGAR SK, 1990, J BACTERIOL, V172, P2802, DOI 10.1128/jb.172.5.2802-2803.1990; BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; BULLIONIS LC, 1993, THESIS J HOPKINS U B; CARR HY, 1954, PHYS REV, V94, P630, DOI 10.1103/PhysRev.94.630; CLELAND WW, 1979, ADV INORG BIOCHEM, P163; COHN M, 1954, NATURE, V173, P1090, DOI 10.1038/1731090b0; CORNELIUS RD, 1978, BIOCHEMISTRY-US, V17, P3279, DOI 10.1021/bi00609a016; CORNELIUS RD, 1988, INORG CHEM, V16, P2799; DAWSON RMC, 1986, DATA BIOCH RES, P413; DIXON M, 1964, ENZYMES, P438; FOWLER RG, 1992, MUTAT RES, V284, P307, DOI 10.1016/0027-5107(92)90015-T; FRICK DN, 1993, FASEB J, V7, pA1064; GRANOT J, 1980, J BIOL CHEM, V255, P931; GRANOT J, 1979, FEBS LETT, V103, P265, DOI 10.1016/0014-5793(79)81342-3; KAY LE, 1990, J MAGN RESON, V89, P496, DOI 10.1016/0022-2364(90)90333-5; KAZIRO Y, 1959, J BIOCHEM-TOKYO, V46, P1523, DOI 10.1093/oxfordjournals.jbchem.a126949; KOFRON JL, 1988, BIOCHEMISTRY-US, V27, P4781, DOI 10.1021/bi00413a030; LI TM, 1978, J BIOL CHEM, V253, P3918; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; MERRITT EA, 1978, BIOCHEMISTRY-US, V17, P3274, DOI 10.1021/bi00609a015; MICHAELS G, 1978, J BIOL CHEM, V253, P7656; Mildvan A S, 1972, Methods Enzymol, V26, P654; MILDVAN AS, 1963, BIOCHEMISTRY-US, V2, P910, DOI 10.1021/bi00905a003; MILDVAN AS, 1966, J BIOL CHEM, V241, P1178; MILDVAN AS, 1970, ENZYMES, V2, P446; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; SERPERSU EH, 1986, BIOCHEMISTRY-US, V25, P68, DOI 10.1021/bi00349a011; SHIOTA T, 1969, BIOCHEMISTRY-US, V8, P5022, DOI 10.1021/bi00840a052; SWITZER RL, 1971, J BIOL CHEM, V246, P2447; SY J, 1973, P NATL ACAD SCI USA, V70, P306, DOI 10.1073/pnas.70.2.306; TREFFERS HP, 1954, P NATL ACAD SCI USA, V40, P1064, DOI 10.1073/pnas.40.11.1064; WEBER DJ, 1992, J BIOL CHEM, V267, P16939; WEBER DJ, 1993, FASEB J, V7, pA1289; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274	40	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1794	1803						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294428				2022-12-27	WOS:A1994MR98800040
J	NGAI, SM; SONNICHSEN, FD; HODGES, RS				NGAI, SM; SONNICHSEN, FD; HODGES, RS			PHOTOCHEMICAL CROSS-LINKING BETWEEN NATIVE RABBIT SKELETAL TROPONIN-C AND BENZOYLBENZOYL-TROPONIN-I INHIBITORY PEPTIDE, RESIDUES 104-115	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; NUCLEAR-MAGNETIC-RESONANCE; MUSCLE-CONTRACTION; BIOLOGICAL-ACTIVITY; SYNTHETIC PEPTIDES; REGULATORY DOMAIN; CRYSTAL-STRUCTURE; CALCIUM-BINDING; REGION; TROPOMYOSIN	The troponin I (TnI) inhibitory region (residues 104-115) was synthesized with alpha-C-14-labeled Gly-104 and a covalently linked benzoylbenzoyl (BB) moiety at the N terminus to yield a photoactivatable radioactive peptide (BBIp). BBIp was cross-linked to rabbit skeletal muscle troponin C (TnC) to locate the binding site on TnC. The TnC/BBIp mixture was subjected to photolysis in aqueous buffer at pH 7.5 in the presence or absence of Ca2+. A covalent (1:1) cross-linked protein-peptide complex (TnC.BBIp) was isolated in both cases. The cross-linked complex was digested with trypsin, and the peptide fragments were separated by reversed-phase high performance liquid chromatography. The radioactive cross-linked peptide was isolated and further characterized by peptide sequencing and mass spectrometry before and after cyanogen bromide cleavage. The results indicated that Met-155 of TnC was cross-linked to the BB moiety of BBIp in either the presence or absence of Ca2+. The biological activity of both the BBIp peptide and the cross-linked TnC.BBIp complex was studied and a model of the TnC-inhibitory peptide complex was derived using molecular dynamic and energy minimization calculations.	UNIV ALBERTA, DEPT BIOCHEM, EDMONTON T6G 2H7, ALBERTA, CANADA; UNIV ALBERTA, MRC CANADA, PROT STRUCT & FUNCT GRP, EDMONTON T6G 2H7, ALBERTA, CANADA; UNIV ALBERTA, PROT ENGN NETWORK CTR EXCELLENCE, EDMONTON T6G 2H7, ALBERTA, CANADA	University of Alberta; University of Alberta; University of Alberta			Sönnichsen, Frank D/D-8408-2011; Ngai, Sai Ming/S-4898-2018	Sönnichsen, Frank D/0000-0002-4539-3755; Ngai, Sai Ming/0000-0002-4484-2483				BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BLECHNER SL, 1992, BIOCHEMISTRY-US, V31, P11326, DOI 10.1021/bi00161a010; BURKE TWL, 1991, HIGH PERFORMANCE LIQ, P643; CACHIA PJ, 1986, BIOCHEMISTRY-US, V25, P3553, DOI 10.1021/bi00360a013; CACHIA PJ, 1983, BIOCHEMISTRY-US, V22, P4145, DOI 10.1021/bi00286a024; CACHIA PJ, 1985, CALMODULIN ANTAGONIS, P63; Campbell A P, 1989, Adv Exp Med Biol, V255, P195; CAMPBELL AP, 1991, BIOCHEM CELL BIOL, V69, P674, DOI 10.1139/o91-101; CAMPBELL AP, 1991, J MOL BIOL, V222, P405, DOI 10.1016/0022-2836(91)90219-V; CHEUNG HC, 1991, BIOCHEMISTRY-US, V30, P5238, DOI 10.1021/bi00235a018; CHONG PCS, 1982, J BIOL CHEM, V257, P1667; CHONG PCS, 1981, J BIOL CHEM, V256, P5071; CHONG PCS, 1983, FEBS LETT, V153, P372, DOI 10.1016/0014-5793(83)80646-2; CHONG PCS, 1982, J BIOL CHEM, V257, P2549; DALGARNO DC, 1982, FEBS LETT, V150, P54, DOI 10.1016/0014-5793(82)81303-3; DRABIKOWSKI W, 1985, EUR J BIOCHEM, V151, P17, DOI 10.1111/j.1432-1033.1985.tb09063.x; Ebashi S, 1968, Prog Biophys Mol Biol, V18, P123, DOI 10.1016/0079-6107(68)90023-0; GARIEPY J, 1983, FEBS LETT, V160, P1, DOI 10.1016/0014-5793(83)80924-7; GOODSELL DS, 1990, PROTEINS, V8, P195, DOI 10.1002/prot.340080302; GRABAREK Z, 1992, J MUSCLE RES CELL M, V13, P383, DOI 10.1007/BF01738034; GRABAREK Z, 1986, J BIOL CHEM, V261, P608; GREASER ML, 1971, J BIOL CHEM, V246, P4226; HARTSHOR.DJ, 1968, BIOCHEM BIOPH RES CO, V31, P647, DOI 10.1016/0006-291X(68)90610-4; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HITCHCOCK SE, 1975, EUR J BIOCHEM, V52, P255, DOI 10.1111/j.1432-1033.1975.tb03993.x; HODGES R S, 1988, Peptide Research, V1, P19; HODGES RS, 1991, HIGH PERFORMANCE LIQ, P773; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KOBAYASHI T, 1991, J BIOL CHEM, V266, P13746; KRETSINGER RH, 1986, J INORG BIOCHEM, V28, P289, DOI 10.1016/0162-0134(86)80093-9; LAN JQ, 1989, BIOCHEMISTRY-US, V28, P7380, DOI 10.1021/bi00444a035; LAPORTE DC, 1980, BIOCHEMISTRY-US, V19, P3814, DOI 10.1021/bi00557a025; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LESZYK J, 1988, BIOCHEMISTRY-US, V27, P6983, DOI 10.1021/bi00418a047; LESZYK J, 1990, BIOCHEMISTRY-US, V29, P299, DOI 10.1021/bi00453a041; LESZYK J, 1987, BIOCHEMISTRY-US, V26, P7035, DOI 10.1021/bi00396a027; MANT CT, 1987, CHROMATOGRAPHIA, V24, P565, DOI 10.1007/BF02688546; NGAI SM, 1992, J BIOL CHEM, V267, P15715; PARKER JMR, 1984, J PROTEIN CHEM, V3, P465, DOI 10.1007/BF01025065; PATO MD, 1981, J BIOL CHEM, V256, P593; PERRY SV, 1973, COLD SPRING HARB SYM, V37, P251, DOI 10.1101/SQB.1973.037.01.035; POTTER JD, 1974, BIOCHEMISTRY-US, V13, P2697, DOI 10.1021/bi00710a007; RICHMOND TJ, 1984, J MOL BIOL, V178, P63, DOI 10.1016/0022-2836(84)90231-6; ROSENFELD SS, 1985, J BIOL CHEM, V260, P252; SCHAUB MC, 1969, BIOCHEM J, V115, P993, DOI 10.1042/bj1150993; SHRAKE A, 1973, J MOL BIOL, V79, P351, DOI 10.1016/0022-2836(73)90011-9; SLUPSKY CM, 1992, PROTEIN SCI, V1, P1595, DOI 10.1002/pro.5560011207; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Strynadka NCJ, 1991, CURR OPIN STRUC BIOL, V1, P905, DOI 10.1016/0959-440X(91)90085-8; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; SWENSON CA, 1992, BIOCHEMISTRY-US, V31, P3420, DOI 10.1021/bi00128a017; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; TALBOT JA, 1979, J BIOL CHEM, V254, P3720; TALBOT JA, 1981, J BIOL CHEM, V256, P2374; TALBOT JA, 1981, J BIOL CHEM, V256, P2798; TAO T, 1986, BIOCHEMISTRY-US, V25, P7633, DOI 10.1021/bi00371a054; VANEYK JE, 1991, BIOCHEMISTRY-US, V30, P9974, DOI 10.1021/bi00105a023; VANEYK JE, 1988, J BIOL CHEM, V263, P1726; VANEYK JE, 1987, BIOCHEM CELL BIOL, V65, P982; WANG CLA, 1987, J BIOL CHEM, V262, P9636; WANG ZY, 1990, J BIOL CHEM, V265, P4953; WEBER K, 1969, J BIOL CHEM, V244, P4406; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WEEKS RA, 1978, BIOCHEM J, V173, P449, DOI 10.1042/bj1730449; WILKINSON JM, 1975, BIOCHEM J, V149, P493, DOI 10.1042/bj1490493; WILKINSON JM, 1978, NATURE, V271, P31, DOI 10.1038/271031a0; YAGI K, 1967, BIOCHEM BIOPH RES CO, V29, P331, DOI 10.1016/0006-291X(67)90458-5; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	69	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2165	2172						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294472				2022-12-27	WOS:A1994MR98800093
J	WINITZ, S; GUPTA, SK; QIAN, NX; HEASLEY, LE; NEMENOFF, RA; JOHNSON, GL				WINITZ, S; GUPTA, SK; QIAN, NX; HEASLEY, LE; NEMENOFF, RA; JOHNSON, GL			EXPRESSION OF A MUTANT G(I2) ALPHA-SUBUNIT INHIBITS ATP AND THROMBIN STIMULATION OF CYTOPLASMIC PHOSPHOLIPASE-A(2)-MEDIATED ARACHIDONIC-ACID RELEASE INDEPENDENT OF CA2+ AND MITOGEN-ACTIVATED PROTEIN-KINASE REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; GTP-BINDING PROTEINS; SWISS 3T3 CELLS; PROMOTING PHORBOL ESTERS; PHOSPHOLIPASE-C; PERTUSSIS TOXIN; PHOSPHOINOSITIDE HYDROLYSIS; TYROSINE PHOSPHORYLATION; SIGNALING PATHWAYS; RABBIT PLATELETS	The 85-kDa cytoplasmic phospholipase A2 (cPLA2) is the major hormone and growth factor-regulated enzyme that catalyzes release of arachidonic acid in mammalian cells. Activation of cPLA2 requires elevation of intracellular Ca2+ and the phosphorylation of the cPLA2 enzyme by mitogen-activated protein (MAP) kinase. Down-regulation of protein kinase C by phorbol esters or pertussis toxin catalyzed ADP-ribosylation of G(i) proteins inhibits thrombin and ATP receptor-stimulated MAP kinase and arachidonic acid release, indicating that functional protein kinase C and G(i) proteins are required for G protein regulation of arachidonic acid release. A mutant Galpha(i2) subunit having Gly203 mutated to Thr (alpha(i2)G203T) inhibited thrombin and ATP receptor stimulation of arachidonic acid release independent of adenylyl cyclase inhibition, Ca2+ mobilization, and MAP kinase activation. Overexpression of the wild-type alpha(i2) polypeptide or the inactive mutant alpha(i2)G204A (Gly204 mutated to Ala) polypeptide had no effect on thrombin or ATP receptor stimulation of arachidonic acid release. The phenotype observed with expression of the mutant alpha(i2)G203T polypeptide defines a role for G(i2) in the control of cPLA2 activity and subsequent arachidonic acid release in addition to the regulation of intracellular Ca2+ levels and MAP kinase activity.	UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262; UNIV COLORADO,SCH MED,DEPT MED,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	JOHNSON, GL (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,1400 JACKSON ST,DENVER,CO 80206, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871, R01DK039902] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030324, R37GM030324] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37871, DK39902] Funding Source: Medline; NIGMS NIH HHS [GM30324] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOKOCH GM, 1984, CELL, V39, P301, DOI 10.1016/0092-8674(84)90008-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHAREST R, 1985, BIOCHEM J, V227, P79, DOI 10.1042/bj2270079; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CONKLIN BR, 1988, P NATL ACAD SCI USA, V85, P8698, DOI 10.1073/pnas.85.22.8698; CURRIE S, 1992, J BIOL CHEM, V267, P6056; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRONICH JH, 1988, J BIOL CHEM, V263, P16645; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; GUPTA SK, 1992, MOL BIOL CELL, V3, P123, DOI 10.1091/mbc.3.1.123; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HADLEY JS, 1988, BIOMED ENVIRON MASS, V15, P175, DOI 10.1002/bms.1200150309; HEASLEY LE, 1989, MOL PHARMACOL, V35, P331; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; HUNG DT, 1992, J BIOL CHEM, V267, P20831; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3625; JURNAK F, 1990, CELL, V60, P525, DOI 10.1016/0092-8674(90)90652-U; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KAJIYAMA Y, 1990, BIOCHEM J, V270, P69, DOI 10.1042/bj2700069; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOWNDES JM, 1991, J BIOL CHEM, V266, P14193; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MURAYAMA T, 1990, J BIOL CHEM, V265, P4290; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; OSAWA S, 1991, J BIOL CHEM, V266, P4673; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; PARIS S, 1986, EMBO J, V5, P55, DOI 10.1002/j.1460-2075.1986.tb04177.x; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; TAKUWA N, 1991, J BIOL CHEM, V266, P14237; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TEITELBAUM I, 1990, J BIOL CHEM, V265, P4218; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; WEISS BA, 1991, J BIOL CHEM, V266, P2126; WU DQ, 1992, J BIOL CHEM, V267, P1811; XING MZ, 1992, J BIOL CHEM, V267, P25966; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	52	110	110	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1889	1895						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294438				2022-12-27	WOS:A1994MR98800053
J	SEN, M; MARSH, L				SEN, M; MARSH, L			NONCONTIGUOUS DOMAINS OF THE ALPHA-FACTOR RECEPTOR OF YEASTS CONFER LIGAND SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MATING-TYPE; SIGNAL TRANSDUCTION; PHEROMONE RECEPTOR; KLUYVERI; BINDING; PROTEIN; CELLS; STE2; GENE	The Saccharomyces cerevisiae alpha-factor receptor has a 3400-fold higher affinity for the S. cerevisiae alpha-factor peptide (c-alpha-f) than for the Saccharomyces kluyveri alpha-factor peptide (k-alpha-f) as determined by competition for [H-3]c-alpha-f binding. The S. kluyveri alpha-factor receptor has an approximately 2-fold higher affinity for k-alpha-f than for c-alpha-f. The S. kluyveri receptor gene (k-STE2) is incompletely regulated by S. cerevisiae mating type and poorly expressed on the surface of an S. cerevisiae mating type a strain. A chimeric receptor (c/kl) with amino acid residues 1-45 derived from S. cerevisiae and amino acid residues 46-427 from S. kluyveri exhibits the binding specificity of the S. kluyveri receptor. However, chimeric receptors containing residues 1-168 (c/k2) or 1-250 (c/k3) from S. cerevisiae and the remainder from the S. kluyveri receptor exhibit specificities similar to one another, but intermediate between the parent S. cerevisiae and S. kluyveri receptors. The relative ability of c-alpha-f and k-alpha-f to induce growth arrest in strains expressing chimeric receptors parallels relative affinity. Thus, two noncontiguous domains that include putative extracellular loops 1 and 3 and associated transmembrane segments, but exclude the extracellular NH2 terminus and loop 2, appear to contribute to alpha-factor receptor ligand specificity. COOH-terminal regions of the S. kluyveri receptor appear to confer a desensitization defect when expressed in S. cerevisiae. The S. cerevisiae receptor truncated at residue 296 retains ligand specificity for growth arrest.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,1300 MORRIS PARK AVE,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine					NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018738, R37AI018738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043365] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA13330] Funding Source: Medline; NIAID NIH HHS [AI18738] Funding Source: Medline; NIGMS NIH HHS [GM43365] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BLUMER KJ, 1990, P NATL ACAD SCI USA, V87, P4363, DOI 10.1073/pnas.87.11.4363; BURKHOLDER AC, 1985, NUCLEIC ACIDS RES, V13, P8463, DOI 10.1093/nar/13.23.8463; DIETZEL C, 1987, CELL, V50, P1000; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EGELMITANI M, 1987, NUCLEIC ACIDS RES, V15, P6303, DOI 10.1093/nar/15.15.6303; FINDLAY JBC, 1986, BIOCHEM J, V238, P625, DOI 10.1042/bj2380625; FUJIMURA H, 1982, ARCH MICROBIOL, V132, P225, DOI 10.1007/BF00407955; HAGEN DC, 1986, P NATL ACAD SCI USA, V83, P1418, DOI 10.1073/pnas.83.5.1418; HARTIG A, 1986, MOL CELL BIOL, V6, P2106, DOI 10.1128/MCB.6.6.2106; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HIRAGA K, 1991, J GEN MICROBIOL, V137, P1; HISATOMI T, 1988, CURR GENET, V13, P25, DOI 10.1007/BF00365752; JENNESS DD, 1986, MOL CELL BIOL, V6, P318, DOI 10.1128/MCB.6.1.318; JI I, 1991, J BIOL CHEM, V266, P13076; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KONOPKA JB, 1991, CELL REGUL, V2, P439, DOI 10.1091/mbc.2.6.439; KONOPKA JB, 1988, CELL, V54, P609, DOI 10.1016/S0092-8674(88)80005-9; KURJAN J, 1992, ANNU REV BIOCHEM, V61, P1097; MALONEYHUSS K, 1992, J MOL BIOL, V225, P859, DOI 10.1016/0022-2836(92)90406-A; MARSH L, 1988, P NATL ACAD SCI USA, V85, P3855, DOI 10.1073/pnas.85.11.3855; MARSH L, 1991, ANNU REV CELL BIOL, V7, P699, DOI 10.1146/annurev.cellbio.7.1.699; MARSH L, 1992, MOL CELL BIOL, V12, P3959, DOI 10.1128/MCB.12.9.3959; MARSH L, 1988, COLD SPRING HARB SYM, V53, P557, DOI 10.1101/SQB.1988.053.01.064; MCCULLOUGH J, 1979, J BACTERIOL, V138, P146, DOI 10.1128/JB.138.1.146-154.1979; MCPHERSON GA, 1983, COMPUT PROG BIOMED, V17, P107, DOI 10.1016/0010-468X(83)90031-4; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; NAKAYAMA N, 1985, EMBO J, V4, P2643, DOI 10.1002/j.1460-2075.1985.tb03982.x; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; RATHS SK, 1988, J BIOL CHEM, V263, P17333; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; Rose MD., 1990, METHODS YEAST GENETI; SAKURAI A, 1984, FEBS LETT, V166, P339, DOI 10.1016/0014-5793(84)80108-8; Sambrook J, 1989, MOL CLONING LABORATO; SMAMA P, 1993, J BIOL CHEM, V268, P4625; Sprague G F Jr, 1990, Adv Genet, V27, P33; WEINER JL, 1993, J BIOL CHEM, V268, P8070; XIE YB, 1990, J BIOL CHEM, V265, P21411; ZOLLER MJ, 1987, METHOD ENZYMOL, V154, P329	40	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					968	973						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288649				2022-12-27	WOS:A1994MR22000032
J	CHOI, OH; ADELSTEIN, RS; BEAVEN, MA				CHOI, OH; ADELSTEIN, RS; BEAVEN, MA			SECRETION FROM RAT BASOPHILIC RBL-2H3 CELLS IS ASSOCIATED WITH DIPHOSPHORYLATION OF MYOSIN LIGHT-CHAINS BY MYOSIN LIGHT-CHAIN KINASE AS WELL AS PHOSPHORYLATION BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-CELLS; TYROSINE PHOSPHORYLATION; IGE RECEPTOR; HISTAMINE-RELEASE; MAST-CELLS; SIGNAL TRANSDUCTION; PLATELET MYOSIN; PHOSPHOLIPASE C-GAMMA-1; ANTIGEN STIMULATION; SYNERGISTIC SIGNALS	The phosphorylation of myosin light chains and heavy chains by protein kinase C is known to be temporally correlated with Ca2+-dependent secretion of granules from RBL-2H3 cells (Ludowyke, R. I., Peleg, I., Beaven, M. A., and Adelstein, IL S. (1989) J. Biol. Chem. 264, 12492-12501). We now report that whereas myosin light chains are predominantly monophosphorylated by the Ca2+/calmodulin-dependent myosin light chain kinase at serine 19 in unstimulated cells, stimulation of RBL-2H3 cells with antigen or other stimulants causes additional phosphorylation of myosin light chains by myosin light chain kinase at threonine 18, as well as by protein kinase C at serine 1 or serine 2. This diphosphorylation at serine 19 and threonine 18 by myosin light chain kinase and the monophosphorylation by protein kinase C is correlated with the rate and extent of degranulation. Secretion occurs whenever phosphorylation by both enzymes is stimulated by antigen or by the combination of low concentrations of A23187 (50 nM) and phorbol 12-myristate 13-acetate (20 nM). These phosphorylations appear to be closely associated with exocytosis in RBL-2H3 cells. Thus, phosphorylation, as well as secretion, can be blocked by the kinase inhibitors KT5926 and ML-7. More specifically, phorbol ester alone induces phosphorylation of myosin light chains by protein kinase C exclusively, but fails to induce secretion until accompanied by low concentrations of A23187, which activates myosin light chain kinase. Conversely, selective suppression of phosphorylation by protein kinase C (with Ro31-7549 in antigen-stimulated cells) suppresses degranulation, thereby indicating a requirement for protein kinase C.	NHLBI,MOLEC CARDIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	CHOI, OH (corresponding author), NHLBI,CHEM PHARMACOL LAB,BLDG 10,RM 8N108,BETHESDA,MD 20892, USA.			Adelstein, Robert/0000-0002-8683-2144				ALBER G, 1991, J BIOL CHEM, V266, P22613; ALI H, 1989, J IMMUNOL, V143, P2626; APGAR JR, 1991, CELL REGUL, V2, P181, DOI 10.1091/mbc.2.3.181; APGAR JR, 1991, J CELL BIOL, V112, P1157, DOI 10.1083/jcb.112.6.1157; BEAVEN MA, 1987, J CELL BIOL, V105, P1129, DOI 10.1083/jcb.105.3.1129; BEAVEN MA, 1988, PROG ALLERGY, V42, P123; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BENHAMOU M, 1992, IMMUNOL TODAY, V13, P195, DOI 10.1016/0167-5699(92)90152-W; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BIRCH KA, 1992, J CELL BIOL, V118, P1501, DOI 10.1083/jcb.118.6.1501; CONRICODE KM, 1989, BIOCHIM BIOPHYS ACTA, V1003, P36, DOI 10.1016/0005-2760(89)90095-7; CONTI MA, 1991, BIOCHEMISTRY-US, V30, P966, DOI 10.1021/bi00218a012; CUNHAMELO JR, 1989, J IMMUNOL, V143, P2617; DANIEL JL, 1992, METHOD ENZYMOL, V215, P78; EGELHOFF TT, 1991, J CELL BIOL, V112, P677, DOI 10.1083/jcb.112.4.677; EISEMAN E, 1992, NATURE, V355, P78; ELLIOTT LH, 1990, BIOCHEM BIOPH RES CO, V171, P148, DOI 10.1016/0006-291X(90)91369-4; GRUCHALLA RS, 1990, J IMMUNOL, V144, P2334; HUANG FL, 1989, J BIOL CHEM, V264, P4238; IKEBE M, 1989, BIOCHEMISTRY-US, V28, P8750, DOI 10.1021/bi00448a011; ITOH K, 1992, BIOCHIM BIOPHYS ACTA, V1136, P52, DOI 10.1016/0167-4889(92)90084-O; ITOH K, 1992, BIOCHIM BIOPHYS ACTA, V1133, P286, DOI 10.1016/0167-4889(92)90049-H; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; KATAKAMI Y, 1984, BIOCHEM BIOPH RES CO, V121, P573, DOI 10.1016/0006-291X(84)90220-1; KILEY SC, 1990, MOL ENDOCRINOL, V4, P59, DOI 10.1210/mend-4-1-59; KITANI S, 1992, BIOCHEM BIOPH RES CO, V183, P48, DOI 10.1016/0006-291X(92)91607-R; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; LO TN, 1987, J BIOL CHEM, V262, P4141; LUDOWYKE RI, 1989, J BIOL CHEM, V264, P12492; METZGER H, 1992, J IMMUNOL, V149, P1477; NAKABAYASHI H, 1991, FEBS LETT, V294, P144, DOI 10.1016/0014-5793(91)81362-C; NAKANISHI S, 1990, MOL PHARMACOL, V37, P482; NISHIKAWA M, 1984, J BIOL CHEM, V259, P8808; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OLIVER JM, 1988, PROG ALLERGY, V42, P195; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PARK DJ, 1991, J BIOL CHEM, V266, P24237; PFEIFFER JR, 1985, J CELL BIOL, V101, P2145, DOI 10.1083/jcb.101.6.2145; SAGIEISENBERG R, 1987, IMMUNOLOGY, V61, P203; SAITOH M, 1987, J BIOL CHEM, V262, P7796; SCHOLEY JM, 1980, NATURE, V287, P233, DOI 10.1038/287233a0; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; SPUDICH A, 1990, J CELL BIOL, V111, P425; STEPHAN V, 1992, J BIOL CHEM, V267, P5434; TESHIMA R, 1989, MOL IMMUNOL, V26, P641; WYSOLMERSKI RB, 1991, AM J PHYSIOL, V261, pC32, DOI 10.1152/ajpcell.1991.261.1.C32; YAMADA K, 1992, J IMMUNOL, V149, P1031; YU KT, 1991, J BIOL CHEM, V266, P22564	49	86	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					536	541						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276847				2022-12-27	WOS:A1994MR21900086
J	LOETSCHER, M; GEISER, T; OREILLY, T; ZWAHLEN, R; BAGGIOLINI, M; MOSER, B				LOETSCHER, M; GEISER, T; OREILLY, T; ZWAHLEN, R; BAGGIOLINI, M; MOSER, B			CLONING OF A HUMAN 7-TRANSMEMBRANE DOMAIN RECEPTOR, LESTR, THAT IS HIGHLY EXPRESSED IN LEUKOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; NEUTROPHIL-ACTIVATING PEPTIDE-2; NEUROPEPTIDE-Y RECEPTOR; HUMAN INTERLEUKIN-8 RECEPTOR; ANGIOTENSIN-II RECEPTOR; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; RESPIRATORY BURST; CYTOKINE FAMILY; HIGH-AFFINITY	Several chemotactic agonists including interleukin-8 (IL-8) and related cytokines have been shown to activate and attract leukocytes via seven-transmembrane domain, GTP-binding protein-coupled receptors. A cDNA clone, LESTR, encoding a protein of 352 amino acids, corresponding to a novel receptor of this type, was isolated from a human blood monocyte cDNA library. The sequence of the deduced protein, LESTR (leukocyte-derived seven-transmembrane domain receptor), has 92.6% identity with that of a recently reported bovine neuropeptide Y (NPY) receptor, boLCR1 (Rimland, J., Xin, W., Sweetnam, P., Saijoh, K., Nestler, E. J., and Duman, R. S. (1991) Mol. Pharmacol. 40, 869-875). LESTR, however, is more similar (>34%) to the IL-8 receptors, IL-SR, and IL-8R2, than to several NPY receptors of different origin (<20%). In the monocyte library, LESTR cDNA fragments were about 20 times as frequent as cDNA coding for IL-8R, and IL-8R2, and much higher levels of LESTR- than IL-8R-specific mRNA were found in human blood neutrophils and lymphocytes. LESTR transcripts, by contrast, were low or undetectable in several neuroblastoma cell lines that are widely used to study NPY functions. Transfected cells expressing high levels of LESTR mRNA did not bind radiolabeled NPY, IL-8, NAP-2, GROalpha, PF4, IP10, MCP-1, MCP-3, MIP-1alpha, HC14,I309, RANTES, C3a, or LTB4. NPY also failed to bind to neutrophils, monocytes, and lymphocytes, to elicit responses in vitro such as Ca2+ changes, shape change, chemotaxis, enzyme release, and the respiratory burst, and to induce leukocyte accumulation upon injection in rats and rabbits. Although the ligand for LESTR could not be identified among a large number of chemotactic cytokines, the high expression in white blood cells and the marked sequence relation to IL-8R1 and IL-8R2 suggest that LESTR may function in the activation of inflammatory cells.	PHARMA RES CIBA GEIGY, CH-4002 BASEL, SWITZERLAND; UNIV BERN, DEPT VET PATHOL, CH-3000 BERN, SWITZERLAND	University of Bern	LOETSCHER, M (corresponding author), UNIV BERN, THEODOR KOCHER INST, POB 99, CH-3000 BERN 9, SWITZERLAND.			Moser, Bernhard/0000-0002-4354-4572				ALLEN JM, 1990, ANN NY ACAD SCI, V611, P1; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BECKMANN MP, 1991, BIOCHEM BIOPH RES CO, V179, P784, DOI 10.1016/0006-291X(91)91885-G; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; DACEY RG, 1974, ANTIMICROB AGENTS CH, V6, P437, DOI 10.1128/AAC.6.4.437; EVA C, 1990, FEBS LETT, V271, P81, DOI 10.1016/0014-5793(90)80377-U; GEISER T, 1993, J BIOL CHEM, V268, P15419; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GORDON EA, 1990, J NEUROCHEM, V55, P506, DOI 10.1111/j.1471-4159.1990.tb04164.x; HERZOG H, 1992, P NATL ACAD SCI USA, V89, P5794, DOI 10.1073/pnas.89.13.5794; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; IWAI N, 1992, FEBS LETT, V298, P257, DOI 10.1016/0014-5793(92)80071-N; KASSIS S, 1987, J BIOL CHEM, V262, P3429; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KERNEN P, 1991, J CLIN INVEST, V87, P2012, DOI 10.1172/JCI115230; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUNA P, 1992, J IMMUNOL, V149, P636; LARHAMMAR D, 1992, J BIOL CHEM, V267, P10935; LI XJ, 1992, J BIOL CHEM, V267, P9; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; MEYERHOF W, 1991, DNA CELL BIOL, V10, P689, DOI 10.1089/dna.1991.10.689; MICHEL MC, 1991, TRENDS PHARMACOL SCI, V12, P389, DOI 10.1016/0165-6147(91)90610-5; MOSER B, 1991, J BIOL CHEM, V266, P10666; MOSER B, 1993, BIOCHEM J, V294, P285, DOI 10.1042/bj2940285; MURPHY PM, 1992, J BIOL CHEM, V267, P7637; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; RIMLAND J, 1991, MOL PHARMACOL, V40, P869; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHUMACHER C, 1992, P NATL ACAD SCI USA, V89, P10542, DOI 10.1073/pnas.89.21.10542; Sneath P.H.A., 1973, NUMERICAL TAXONOMY; SREEDHARAN SP, 1991, P NATL ACAD SCI USA, V88, P4986, DOI 10.1073/pnas.88.11.4986; THOMAS KM, 1991, J BIOL CHEM, V266, P14839; VANRIPER G, 1993, J EXP MED, V177, P851, DOI 10.1084/jem.177.3.851; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0; WALZ A, 1991, J LEUKOCYTE BIOL, V50, P279, DOI 10.1002/jlb.50.3.279; WANG JM, 1993, J EXP MED, V177, P699, DOI 10.1084/jem.177.3.699; WESTON K, 1986, J MOL BIOL, V192, P177, DOI 10.1016/0022-2836(86)90359-1; WYMANN MP, 1987, ANAL BIOCHEM, V165, P371, DOI 10.1016/0003-2697(87)90284-3; YOSHIMURA T, 1990, J IMMUNOL, V145, P292	57	379	424	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					232	237						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276799				2022-12-27	WOS:A1994MR21900043
J	HEDBOM, E; HEINEGARD, D				HEDBOM, E; HEINEGARD, D			BINDING OF FIBROMODULIN AND DECORIN TO SEPARATE SITES ON FIBRILLAR COLLAGENS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL INTERSTITIAL PROTEOGLYCANS; DERMATAN SULFATE PROTEOGLYCAN; ELECTRON-MICROSCOPY; FIBRONECTIN; PROTEIN; CARTILAGE; TENDON; GLYCOSAMINOGLYCANS; FIBROBLASTS; INHIBITION	The small proteoglycans, decorin, fibromodulin, bi-glycan, and lumican, represent a family of structurally related but genetically distinct molecules present in many types of connective tissues. Fibromodulin and decorin interact with collagens I and II (Hedbom, E., and Heinegard, D. (1989) J. Biol. Chem. 264, 6898-6905). These interactions have been characterized further by using native radiolabeled components from fibroblast cultures and nonlabeled proteoglycans purified from guanidine hydrochloride extracts of bovine tendon. Binding of metabolically labeled macromolecules to collagen I was measured in an assay based on precipitation of collagen fibrils formed in vitro. Among a large number of secreted fibroblast products, decorin and fibromodulin represented the vast majority of the collagen binding components. These molecules showed poor binding to denatured collagen, in contrast to fibronectin, which was also present in the medium. Decorin and fibromodulin bind to different sites on collagen I fibrils, since the binding of either radiolabeled component could be competed for only by the corresponding nonlabeled proteoglycan. Similarly, these proteoglycans showed binding to separate sites on collagen II. Binding of isolated fibromodulin and decorin to collagens in solution was measured in a solid-phase inhibition assay. Each of the proteoglycans interacted with triple helical molecules, but not with denatured collagen chain constituents or fragments. For fibromodulin, the data indicated an average of one binding site per collagen I molecule (K(d) = 9.9 nM). The data on decorin indicated additional interactions, some apparently mediated by the dermatan sulfate side chain. The results suggest that the small proteoglycans bind to distinct triple helical sites, apparently differing from several other similar structures within each collagen molecule.			HEDBOM, E (corresponding author), LUND UNIV, DEPT PHYSIOL CHEM, POB 94, S-22100 LUND, SWEDEN.							ANTONOPO.CA, 1967, BIOCHIM BIOPHYS ACTA, V148, P158, DOI 10.1016/0304-4165(67)90291-7; ANTONOPOULOS CA, 1991, J BIOL CHEM, V266, P16859; AXELSSON I, 1978, BIOCHEM J, V169, P517, DOI 10.1042/bj1690517; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; BORNSTEIN P, 1965, SCIENCE, V148, P1353, DOI 10.1126/science.148.3675.1353; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; BRUCKNER P, 1985, P NATL ACAD SCI USA, V82, P2608, DOI 10.1073/pnas.82.9.2608; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; ENGVALL E, 1978, J EXP MED, V147, P1584, DOI 10.1084/jem.147.6.1584; FRANSSON LA, 1982, J BIOL CHEM, V257, P6333; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEINEGARD D, 1986, J BIOL CHEM, V261, P3866; HEINEGARD D, 1989, FASEB J, V3, P2042, DOI 10.1096/fasebj.3.9.2663581; HEINEGARD D, 1985, BIOCHEM J, V230, P181, DOI 10.1042/bj2300181; Heinegard Dick, 1993, P189; Kielty Cay M., 1993, P103; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWANDOWSKA K, 1987, J CELL BIOL, V105, P1443, DOI 10.1083/jcb.105.3.1443; MILLER EJ, 1987, METHOD ENZYMOL, V144, P3; MILLER EJ, 1972, BIOCHEMISTRY-US, V11, P4903, DOI 10.1021/bi00776a005; MORGELIN M, 1988, BIOCHEM J, V253, P175; MORGELIN M, 1989, J BIOL CHEM, V264, P12080; OBRINK B, 1973, EUR J BIOCHEM, V33, P387, DOI 10.1111/j.1432-1033.1973.tb02695.x; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; PAN TC, 1992, P NATL ACAD SCI USA, V89, P6565, DOI 10.1073/pnas.89.14.6565; PLAAS AHK, 1990, J BIOL CHEM, V265, P20634; PRINGLE GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1405, DOI 10.1177/38.10.1698203; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHMIDT G, 1987, J CELL BIOL, V104, P1683, DOI 10.1083/jcb.104.6.1683; SCHMIDT G, 1991, BIOCHEM J, V280, P411, DOI 10.1042/bj2800411; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; SCOTT JE, 1981, BIOCHEM J, V197, P213, DOI 10.1042/bj1970213; STEGEMAN.H, 1967, CLIN CHIM ACTA, V18, P267, DOI 10.1016/0009-8981(67)90167-2; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VOGEL KG, 1985, J BIOL CHEM, V260, P9298; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; WARD NP, 1987, BIOCHEM J, V242, P761, DOI 10.1042/bj2420761; WIGHT TN, 1991, CELL BIOL EXTRACELLU, P45, DOI DOI 10.1007/978-1-4615-3770-0_3	40	268	274	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27307	27312						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262971				2022-12-27	WOS:A1993MM26200068
J	KRAMER, RM; ROBERTS, EF; MANETTA, JV; HYSLOP, PA; JAKUBOWSKI, JA				KRAMER, RM; ROBERTS, EF; MANETTA, JV; HYSLOP, PA; JAKUBOWSKI, JA			THROMBIN-INDUCED PHOSPHORYLATION AND ACTIVATION OF CA2+-SENSITIVE CYTOSOLIC PHOSPHOLIPASE-A(2) IN HUMAN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ARACHIDONOYL-HYDROLYZING PHOSPHOLIPASE-A2; MACROPHAGE CELL-LINE; PROSTAGLANDIN-E2 PRODUCTION; THROMBOXANE BIOSYNTHESIS; STIMULATED PLATELETS; RABBIT PLATELETS; MESANGIAL CELLS; ACID RELEASE; CALCIUM	Receptor-mediated activation of human platelets by thrombin initiates a series of rapid biochemical events that include activation of phospholipase A2 to liberate arachidonic acid for further conversion to thromboxane A2. The identity of the phospholipase A2 involved has not been clear. Here we show by immunochemical analysis that human platelets contain significant amounts (60 ng/10(9) platelets) of the recently identified Ca2+-sensitive cytosolic phospholipase A2 (cPLA2). Metabolic labeling of human platelets with P-33i revealed that the extent of phosphorylation of cPLA2 was greatly increased after thrombin treatment. Upon stimulation of platelets with thrombin, cPLA2 exhibits enhanced catalytic activity, as well as a change in its electrophoretic and chromatographic properties compared with cPLA2 in resting platelets. These alterations of cPLA2 are reversed by treatment with phosphatase, demonstrating that they are the consequence of thrombin-stimulated phosphorylation. Thrombin-induced phosphorylation and activation of cPLA2 is rapid (half-maximal by 1 min at 1 unit/10(9) platelets) and dose-dependent. Agonist-induced phosphorylation of cPLA2 is more sensitive to thrombin than the generation of thromboxane A2, suggesting that it may be an early event in the sequence of steps leading to the mobilization and further metabolism of arachidonic acid. By comparing the functional properties of cPLA2 from control versus thrombin-stimulated platelets, we found that while activated cPLA2 exhibits the same Ca2+ requirement and apparent substrate affinity (K(m)), its catalytic activity (V(max)) is increased compared with control cPLA2. We conclude that 1) cPLA2 is likely to play an important role in agonist-induced mobilization of arachidonic acid and 2) thrombin elicits rapid and full activation of cPLA2 not only by promoting a rise in cytosolic free Ca2+ but also by inducing phosphorylation of cPLA2 thereby improving its catalytic activity.			KRAMER, RM (corresponding author), ELI LILLY & CO, LILLY RES LAB, INDIANAPOLIS, IN 46285 USA.							AXELROD J, 1990, BIOCHEM SOC T, V18, P503, DOI 10.1042/bst0180503; BONVENTRE JV, 1988, J CLIN INVEST, V82, P168, DOI 10.1172/JCI113566; BONVENTRE JV, 1990, J BIOL CHEM, V265, P4934; BRASS LF, 1990, PROGR HEMOSTASIS THR, P127; BROEKMAN MJ, 1986, J LIPID RES, V27, P884; BROOKS RC, 1989, J BIOL CHEM, V264, P20147; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; DAWSON RMC, 1985, BIOCHEM J, V230, P61, DOI 10.1042/bj2300061; DEYKIN D, 1979, PROSTAGLANDINS, V18, P19, DOI 10.1016/S0090-6980(79)80019-2; DHAR A, 1993, BRIT J HAEMATOL, V84, P1, DOI 10.1111/j.1365-2141.1993.tb03018.x; DIEZ E, 1990, J BIOL CHEM, V265, P14654; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FERRELL JE, 1989, J BIOL CHEM, V264, P20723; GODING JW, 1986, MONOCLONAL ANTIBODIE, P83; GRONICH JH, 1988, J BIOL CHEM, V263, P16645; HALENDA SP, 1989, BIOCHEMISTRY-US, V28, P7356, DOI 10.1021/bi00444a031; HARA S, 1991, J BIOCHEM, V110, P163, DOI 10.1093/oxfordjournals.jbchem.a123550; HARDINGER SA, 1991, BIOORG MED CHEM LETT, V1, P79, DOI 10.1016/S0960-894X(01)81097-0; HAWIGER J, 1989, METHOD ENZYMOL, V169, P191; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; INSEL PA, 1991, BIOCHEM SOC T, V19, P329, DOI 10.1042/bst0190329; JAKUBOWSKI JA, 1988, ARTERIOSCLEROSIS, V8, P436, DOI 10.1161/01.ATV.8.4.436; JAKUBOWSKI JA, 1985, BRIT J HAEMATOL, V60, P635, DOI 10.1111/j.1365-2141.1985.tb07467.x; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KIM DK, 1988, J BIOCHEM-TOKYO, V104, P492, DOI 10.1093/oxfordjournals.jbchem.a122496; KRAMER RM, 1986, BIOCHIM BIOPHYS ACTA, V878, P394, DOI 10.1016/0005-2760(86)90248-1; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRAMER RM, 1987, BIOCHEM J, V248, P779, DOI 10.1042/bj2480779; KRAMER RM, 1993, J LIPID MEDIATOR, V6, P209; KRAMER RM, 1988, BIOCHIM BIOPHYS ACTA, V959, P269, DOI 10.1016/0005-2760(88)90200-7; KRAMER RM, 1982, J BIOL CHEM, V257, P6844; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KROLL MH, 1989, BLOOD, V74, P1181; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LESLIE CC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P261, DOI 10.1016/0005-2760(90)90129-L; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOEB LA, 1986, J BIOL CHEM, V261, P467; MCINTYRE TM, 1987, J BIOL CHEM, V262, P15370; MUELLER HW, 1983, LIPIDS, V18, P814, DOI 10.1007/BF02534641; MURAKAMI M, 1991, FEBS LETT, V294, P247, DOI 10.1016/0014-5793(91)81440-J; MURAYAMA T, 1990, J BIOL CHEM, V265, P4290; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; NOZAWA Y, 1991, BIOCHIM BIOPHYS ACTA, V1082, P219, DOI 10.1016/0005-2760(91)90197-P; PARKER J, 1987, J BIOL CHEM, V262, P5385; PATRONO C, 1992, TRENDS CARDIOVAS MED, V2, P15, DOI 10.1016/1050-1738(92)90039-U; POLLOCK WK, 1986, BIOCHEM BIOPH RES CO, V139, P308, DOI 10.1016/S0006-291X(86)80114-0; PURDON AD, 1987, BIOCHIM BIOPHYS ACTA, V920, P205, DOI 10.1016/0005-2760(87)90096-8; RITTENHOUSE SE, 1984, BIOCHEM BIOPH RES CO, V123, P393, DOI 10.1016/0006-291X(84)90426-1; RITTENHOUSESIMM.S, 1981, PLATELETS BIOL PATHO, V2, P349; RITTENHOUSESIMMONS S, 1977, J CLIN INVEST, V60, P495, DOI 10.1172/JCI108801; SAMIEI M, 1993, BIOCHIM BIOPHYS ACTA, V1176, P287, DOI 10.1016/0167-4889(93)90057-V; SATO T, 1992, J BIOCHEM-TOKYO, V112, P756, DOI 10.1093/oxfordjournals.jbchem.a123971; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; SMITH WL, 1991, PHARMACOL THERAPEUT, V49, P153, DOI 10.1016/0163-7258(91)90054-P; WERY JP, 1991, NATURE, V352, P79, DOI 10.1038/352079a0; WHATLEY RE, 1989, J BIOL CHEM, V264, P6325; WIGHTMAN PD, 1982, J BIOL CHEM, V257, P6650; WIJKANDER J, 1991, EUR J BIOCHEM, V202, P873, DOI 10.1111/j.1432-1033.1991.tb16445.x; ZUPAN LA, 1992, J BIOL CHEM, V267, P8707	64	190	191	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26796	26804						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253817				2022-12-27	WOS:A1993MK42500114
J	QUINTO, I; RUOCCO, MR; BALDASSARRE, F; MALLARDO, M; DRAGONETTI, E; SCALA, G				QUINTO, I; RUOCCO, MR; BALDASSARRE, F; MALLARDO, M; DRAGONETTI, E; SCALA, G			THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 LONG TERMINAL REPEAT IS ACTIVATED BY MONOFUNCTIONAL AND BIFUNCTIONAL DNA ALKYLATING-AGENTS IN HUMAN-LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; NF-KAPPA-B; CELL NUCLEAR-PROTEIN; TRANS-ACTIVATION; BINDING-PROTEIN; TRANSCRIPTIONAL REGULATION; TRANSACTIVATING REGION; INDUCED EXPRESSION; GENE-EXPRESSION; PHORBOL ESTER	The activation of the human immunodeficiency virus, type 1 (HIV-1) by the DNA alkylating agents ethyl methanesulfonate, methyl methanesulfonate, and mitomycin C was observed in human B lymphocytes transiently transfected with plasmids in which the HIV-1 long terminal repeat (LTR) directed the expression of the bacterial chloramphenicol acetyltransferase gene. Deletion of the two NF-kappaB-binding sites of LTR abolished the HIV-1 activation induced by the three mutagens, while deletion of the three Sp1-binding sites slightly reduced it. Electrophoretic mobility shift assays revealed an increased binding to the kappaB sites of HIV-1 LTR in the nuclear extracts of human B lymphocytes upon mutagen treatment, while binding to Sp1 sites was unaffected. The TAR region was also involved in the mutagen- mediated activation of HIV-1 LTR inasmuch as a small deletion in the TAR sequence (nucleotides +34 to +37) greatly decreased the induction of HIV-1 expression. Moreover, an enhanced binding activity to the TAR DNA sequence (nucleotides +24 to +47) was observed in nuclear extracts of mutagen-treated lymphocytes. Thus, both the enhancer and the 5'-untranslated region of HIV-1 functionally cooperate in the mutagen-mediated induction of HIV-1 expression.	UNIV REGGIO CALABRIA,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY	Universita Mediterranea di Reggio Calabria	QUINTO, I (corresponding author), UNIV FEDERICO 2,DIPARTIMENTO BIOCHIM & BIOTECNOL MED,VIA S PANSINI 5,I-80131 NAPLES,ITALY.		SCALA, GIUSEPPE/A-3280-2009	MALLARDO, Massimo/0000-0002-4001-3856; QUINTO, Ileana/0000-0001-8212-8515				ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; [Anonymous], 1985, DNA REPAIR; DAVIS MG, 1987, P NATL ACAD SCI USA, V84, P8642, DOI 10.1073/pnas.84.23.8642; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; FRANZA BR, 1987, NATURE, V330, P391, DOI 10.1038/330391a0; GARCIA JA, 1987, EMBO J, V6, P3761, DOI 10.1002/j.1460-2075.1987.tb02711.x; GARCIA JA, 1989, EMBO J, V8, P765, DOI 10.1002/j.1460-2075.1989.tb03437.x; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; GATIGNOL A, 1989, P NATL ACAD SCI USA, V86, P7828, DOI 10.1073/pnas.86.20.7828; GAYNOR R, 1989, P NATL ACAD SCI USA, V86, P4858, DOI 10.1073/pnas.86.13.4858; GENDELMAN HE, 1986, P NATL ACAD SCI USA, V83, P9759, DOI 10.1073/pnas.83.24.9759; GIMBLE JM, 1988, J VIROL, V62, P4104, DOI 10.1128/JVI.62.11.4104-4112.1988; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HARRICH D, 1989, J VIROL, V63, P2585, DOI 10.1128/JVI.63.6.2585-2591.1989; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; JAKOBOVITS A, 1988, MOL CELL BIOL, V8, P2555, DOI 10.1128/MCB.8.6.2555; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; JOSHI B, 1992, VACCINES 92 : MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P247; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; KAUFMAN JD, 1987, MOL CELL BIOL, V7, P3759, DOI 10.1128/MCB.7.10.3759; KORNER M, 1990, BIOCHEM J, V265, P547, DOI 10.1042/bj2650547; LEONARD J, 1989, J VIROL, V63, P4919, DOI 10.1128/JVI.63.11.4919-4924.1989; LIN CS, 1990, P NATL ACAD SCI USA, V87, P36, DOI 10.1073/pnas.87.1.36; MAEKAWA T, 1989, J BIOL CHEM, V264, P14591; MALIM MH, 1989, J VIROL, V63, P3213, DOI 10.1128/JVI.63.8.3213-3219.1989; MALLON R, 1990, J VIROL, V64, P6282, DOI 10.1128/JVI.64.12.6282-6285.1990; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; MORREY JD, 1991, J VIROL, V65, P5045, DOI 10.1128/JVI.65.9.5045-5051.1991; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PARROTT C, 1991, J VIROL, V65, P1414, DOI 10.1128/JVI.65.3.1414-1419.1991; POLI G, 1990, J EXP MED, V172, P151, DOI 10.1084/jem.172.1.151; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; ROSENBERG ZF, 1991, FASEB J, V5, P2382, DOI 10.1096/fasebj.5.10.1676689; ROUNSEVILLE MP, 1992, J VIROL, V66, P1688, DOI 10.1128/JVI.66.3.1688-1694.1992; ROY S, 1991, J VIROL, V65, P632, DOI 10.1128/JVI.65.2.632-640.1991; SCALA G, 1993, J VIROL, V67, P2853, DOI 10.1128/JVI.67.5.2853-2861.1993; SCALA G, 1990, J EXP MED, V172, P61, DOI 10.1084/jem.172.1.61; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHELINE CT, 1991, GENE DEV, V5, P2508, DOI 10.1101/gad.5.12b.2508; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; TONGSTARKSEN SE, 1987, P NATL ACAD SCI USA, V84, P6845, DOI 10.1073/pnas.84.19.6845; TONGSTARKSEN SE, 1989, J IMMUNOL, V142, P702; VALERIE K, 1990, New Biologist, V2, P712; VALERIE K, 1988, NATURE, V333, P78, DOI 10.1038/333078a0; WU F, 1991, GENE DEV, V5, P2128, DOI 10.1101/gad.5.11.2128; WU FK, 1988, EMBO J, V7, P2117, DOI 10.1002/j.1460-2075.1988.tb03051.x	56	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26719	26724						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253807				2022-12-27	WOS:A1993MK42500103
J	BEC, G; KERJAN, P; WALLER, JP				BEC, G; KERJAN, P; WALLER, JP			RECONSTITUTION IN-VITRO OF THE VALYL-TRANSFER RNA SYNTHETASE-ELONGATION FACTOR (EF) 1-BETA-GAMMA-DELTA COMPLEX - ESSENTIAL ROLES OF THE NH2-TERMINAL EXTENSION OF VALYL-TRANSFER RNA-SYNTHETASE AND OF THE EF-1-DELTA SUBUNIT IN COMPLEX-FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOACYL-TRANSFER-RNA; FACTOR-I; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; RABBIT LIVER; FACTOR-1-BETA; ARTEMIA; PROTEIN; BINDING; SITES	Valyl-tRNA synthetase from mammalian cells is isolated exclusively as a complex with elongation factor (EF) 1H (the ''heavy'' form of eukaryotic EF-1, composed of subunits alpha, beta, gamma, and delta). In a previous study, the 140-kDa valyl-tRNA synthetase subunit dissociated from the purified rabbit liver complex was shown to display hydrophobic properties, unlike the corresponding yeast cytoplasmic enzyme of 125 kDa (Bec, G., and Waller, J.-P. (1989) J. Biol. Chem. 264, 21138-21143). Compared to the sequence of yeast cytoplasmic valyl-tRNA synthetase, that of the human enzyme displays an NH2-terminal extension of approximately 200 amino acid residues that bears strong sequence similarity to the NH2-terminal moiety of EF-1gamma (Hsieh, S. L., and Campbell, R. D. (1991) Biochem. J. 278, 809-816). We now show that this NH2-terminal extension can be selectively excised by elastase treatment of the isolated rabbit valyl-tRNA synthetase, without impairing catalytic activity. To examine the role of the NH2-terminal extension of mammalian valyl-tRNA synthetase in complex formation and to identify the subunit(s) of EF-1H responsible for binding the enzyme, reconstitution experiments were undertaken. Native or truncated valyl-tRNA synthetases were incubated with the isolated EF-1 subunits betagamma and delta, either separately or in combination, and the ensuing products were analyzed by chromatography on DEAE-Sepharose FF and Superose 6. The results demonstrate that the NH2-terminal extension of valyl-tRNA synthetase is required for complex formation and that the enzyme-binding site(s) resides on the EF-1delta subunit. Moreover, although the EF-1betagamma binary complex does not bind valyl-tRNA synthetase, it is nevertheless required for assembly of a complex of defined quaternary structure by preventing the formation of high molecular weight aggregates generated in the presence of EF-1delta alone.	CNRS, LAB ENZYMOL, F-91198 GIF SUR YVETTE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay								BEC G, 1989, J BIOL CHEM, V264, P21131; BEC G, 1989, J BIOL CHEM, V264, P21138; BRANDS JHGM, 1986, EUR J BIOCHEM, V155, P167, DOI 10.1111/j.1432-1033.1986.tb09472.x; CHATTON B, 1988, J BIOL CHEM, V263, P52; CORMIER P, 1993, NUCLEIC ACIDS RES, V21, P743, DOI 10.1093/nar/21.3.743; CORMIER P, 1991, NUCLEIC ACIDS RES, V19, P6644, DOI 10.1093/nar/19.23.6644; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; HATTORI S, 1983, J BIOCHEM-TOKYO, V94, P79, DOI 10.1093/oxfordjournals.jbchem.a134357; HATTORI S, 1982, J BIOCHEM-TOKYO, V92, P173, DOI 10.1093/oxfordjournals.jbchem.a133914; HECK JD, 1988, J BIOL CHEM, V263, P868; HSIEH SL, 1991, BIOCHEM J, V278, P809, DOI 10.1042/bj2780809; Iwasaki K, 1979, Methods Enzymol, V60, P657; JANSSEN G, 1990, RIBOSOMES PROTEIN SY, P61; JANSSEN GMC, 1988, J BIOL CHEM, V263, P1773; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORBER B, 1988, EUR J BIOCHEM, V174, P155, DOI 10.1111/j.1432-1033.1988.tb14076.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAESSEN GDF, 1986, FEBS LETT, V208, P77, DOI 10.1016/0014-5793(86)81536-8; MAESSEN GDF, 1987, FEBS LETT, V223, P181, DOI 10.1016/0014-5793(87)80532-X; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; MIRANDE M, 1982, J BIOL CHEM, V257, P1049; MORALES J, 1992, NUCLEIC ACIDS RES, V20, P4091, DOI 10.1093/nar/20.15.4091; MOTORIN YA, 1991, EUR J BIOCHEM, V201, P325, DOI 10.1111/j.1432-1033.1991.tb16289.x; MOTORIN YA, 1988, FEBS LETT, V238, P262, DOI 10.1016/0014-5793(88)80492-7; SANDERS J, 1992, NUCLEIC ACIDS RES, V20, P5907, DOI 10.1093/nar/20.22.5907; SANDERS J, 1991, NUCLEIC ACIDS RES, V19, P4551, DOI 10.1093/nar/19.16.4551; SANDERS J, 1993, BIOCHIM BIOPHYS ACTA, V1174, P87, DOI 10.1016/0167-4781(93)90097-W; SHEU GT, 1992, NUCLEIC ACIDS RES, V20, P5849, DOI 10.1093/nar/20.21.5849; VANDAMME H, 1991, EUR J BIOCHEM, V197, P505, DOI 10.1111/j.1432-1033.1991.tb15938.x; VANDAMME HTF, 1990, BIOCHIM BIOPHYS ACTA, V1050, P241, DOI 10.1016/0167-4781(90)90174-Z; VANDAMME HTF, 1992, EUR J BIOCHEM, V207, P1025; VANHEMERT FJ, 1983, FEBS LETT, V157, P289, DOI 10.1016/0014-5793(83)80563-8; VENEMA RC, 1991, J BIOL CHEM, V266, P12574; VILALTA A, 1993, GENE, V123, P181, DOI 10.1016/0378-1119(93)90122-J	35	78	85	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2086	2092						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294461				2022-12-27	WOS:A1994MR98800082
J	MULLIS, KG; KORNFELD, RH				MULLIS, KG; KORNFELD, RH			CHARACTERIZATION AND IMMUNOLOCALIZATION OF BOVINE N-ACETYLGLUCOSAMINE-1-PHOSPHODIESTER ALPHA-N-ACETYLGLUCOSAMINIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; BREFELDIN-A; RECOGNITION MARKER; MEMBRANE-PROTEINS; CIS-GOLGI; PHOSPHORYLATION; CELLS; PURIFICATION; ER; REDISTRIBUTION	N-Acetylglucosamine-1-phosphodiester alpha-N-acetyl-glucosaminidase (phosphodiester alpha-GlcNAcase) has been purified 3,000-fold from bovine liver and its kinetic properties determined as described in the previous report (Mullis, K. G., Huynh, M., and Kornfeld, R. (1993) J. Biol. Chem. 269,1718-1726). This report describes the hydrodynamic and lectin binding properties of phosphodiester alpha-GlcNAcase as well as its intracellular localization. The molecular weight of phosphodiester alpha-GlcNAcase is 204,950, as determined from density gradient centrifugation in D2O and H2O glycerol gradients and gel filtration. Enzymatically active enzyme migrates on sodium dodecyl sulfate-polyacrylamide gel electrophoresis with a molecular weight of 129,000, consistent with native phosphodiester alpha-GlcNAcase being a dimer. The lectin binding properties of phosphodiester alpha-GlcNAcase indicate that it contains sialylated species of both complex type N-linked oligosaccharides and O-linked oligosaccharides. In immunofluorescence studies phosphodiester alpha-GlcNAcase shows a perinuclear, Golgi localization in Vero cells as does the mid-Golgi marker alpha-mannosidase II. After exposure of the Vero cells to brefeldin A, phosphodiester alpha-GlcNAcase assumes an endoplasmic reticulum staining pattern. In contrast, in cells costained with the trans-Golgi marker wheat germ agglutinin, the wheat germ agglutinin marker assumed an endosomal network appearance after exposure to brefeldin A. These findings indicate that phosphodiester alpha-GlcNAcase is normally located within the Golgi stack, separate from the trans-Golgi and trans-Golgi network stained by wheat germ agglutinin.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOPHYS,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NCI NIH HHS [CA08759] Funding Source: Medline; NHLBI NIH HHS [T32-HLO7088] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA008759, R37CA008759] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007088] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERS GK, 1967, J BIOL CHEM, V242, P3237; BENYOSEPH Y, 1986, BIOCHEM J, V235, P883, DOI 10.1042/bj2350883; CLARKE S, 1975, J BIOL CHEM, V250, P5459; GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159; GONATAS JO, 1989, J BIOL CHEM, V264, P646; HARLOW E, 1988, ANTIBODIES LABORATOR; HENDRICKS LC, 1991, J BIOL CHEM, V266, P17559; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZZARINO DA, 1988, J BIOL CHEM, V263, P10118; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MOREMEN KW, 1985, J BIOL CHEM, V260, P6654; MULLIS KG, 1992, ANAL BIOCHEM, V205, P200, DOI 10.1016/0003-2697(92)90424-6; MULLIS KG, 1993, J BIOL CHEM, V269, P1718; RADONS J, 1990, BIOL CHEM H-S, V371, P567, DOI 10.1515/bchm3.1990.371.2.567; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; SADLER JE, 1979, J BIOL CHEM, V254, P4434; SAMPATH D, 1992, J BIOL CHEM, V267, P4440; SCHWEIZER A, 1991, J CELL BIOL, V113, P45, DOI 10.1083/jcb.113.1.45; TULSIANI DRP, 1988, J BIOL CHEM, V263, P5408; WALKER DH, 1988, BIOCHEMISTRY-US, V27, P6504, DOI 10.1021/bi00417a046; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; YUAN L, 1987, J CELL BIOL, V105, P215, DOI 10.1083/jcb.105.1.215	24	8	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1727	1733						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294421				2022-12-27	WOS:A1994MR98800031
J	OKUBO, K; KANG, DC; HAMASAKI, N; JENNINGS, ML				OKUBO, K; KANG, DC; HAMASAKI, N; JENNINGS, ML			RED-BLOOD-CELL BAND-3 - LYSINE-539 AND LYSINE-851 REACT WITH THE SAME H2DIDS (4,4'-DIISOTHIOCYANODIHYDROSTILBENE-2,2'-DISULFONIC ACID) MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE-MEMBRANES; ANION-TRANSPORT PROTEIN; SITE-DIRECTED MUTAGENESIS; PREDOMINANT TRANSMEMBRANE POLYPEPTIDE; PHOSPHATE BINDING-SITE; CROSS-LINKING; EXCHANGE PROTEIN; XENOPUS-LAEVIS; LOCALIZATION; SEQUENCE	The band 3 protein of the red blood cell membrane catalyzes anion exchange that is inhibited by the stilbenedisulfonate derivative H2DIDS (4,4'-diisothiocyanodihydrostilbene-2,2'-disulfonic acid). There is one H2DIDS binding site per 95,000-Da band 3 polypeptide. The single bound H2DIDS molecule can react covalently with 2 different lysine residues. The 2 lysines that react covalently with H2DIDS have been localized directly by sequencing fragments of human band 3 from cells labeled with [H-3]H2DIDS. The most rapid covalent reaction is with Lys-539, in agreement with site-directed mutagenesis studies. The slower reaction is with Lys-851, which is known to be the primary site of binding of another anion transport inhibitor, pyridoxal phosphate (Kawano et al., 1988). These results indicate that the protein is folded to bring these 2 residues into close enough proximity to react covalently with the same H2DIDS molecule. In addition to defining the residues that react with H2DIDS, these studies have also defined new in situ proteolytic cleavage sites in band 3.	KYUSHU UNIV,SCH MED,DEPT CLIN CHEM & LAB MED,FUKUOKA 812,JAPAN; UNIV TEXAS,MED BRANCH,DEPT PHYSIOL & BIOPHYS,GALVESTON,TX 77550	Kyushu University; University of Texas System; University of Texas Medical Branch Galveston	OKUBO, K (corresponding author), FUKUOKA UNIV,SCH MED,DEPT CLIN CHEM & LAB MED,FUKUOKA 81401,JAPAN.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026861] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 26861] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTEL D, 1989, EMBO J, V8, P3601, DOI 10.1002/j.1460-2075.1989.tb08533.x; BARTEL D, 1989, BIOCHIM BIOPHYS ACTA, V985, P355, DOI 10.1016/0005-2736(89)90427-6; BROCK CJ, 1983, BIOCHEM J, V213, P577, DOI 10.1042/bj2130577; CABANTCHIK ZI, 1974, J MEMBRANE BIOL, V15, P207, DOI 10.1007/BF01870088; CABANTCHIK ZI, 1992, AM J PHYSIOL, V262, pC803, DOI 10.1152/ajpcell.1992.262.4.C803; CABANTCHIK ZI, 1975, J BIOL CHEM, V250, P5130; DRICKAMER LK, 1976, J BIOL CHEM, V251, P5115; DRICKAMER LK, 1978, J BIOL CHEM, V253, P7242; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; GARCIA AM, 1989, J BIOL CHEM, V264, P19607; HAMASAKI N, 1983, EUR J BIOCHEM, V132, P531, DOI 10.1111/j.1432-1033.1983.tb07394.x; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; IDEGUCHI H, 1982, EUR J BIOCHEM, V125, P665, DOI 10.1111/j.1432-1033.1982.tb06734.x; JENNINGS ML, 1985, J BIOL CHEM, V260, P5472; JENNINGS ML, 1984, BIOCHEMISTRY-US, V23, P6432, DOI 10.1021/bi00321a024; JENNINGS ML, 1982, J BIOL CHEM, V257, P7554; JENNINGS ML, 1986, J BIOL CHEM, V261, P9002; JENNINGS ML, 1984, J BIOL CHEM, V259, P4652; JENNINGS ML, 1979, BIOCHIM BIOPHYS ACTA, V554, P498, DOI 10.1016/0005-2736(79)90387-0; JENNINGS ML, 1981, BIOCHEMISTRY-US, V20, P7118, DOI 10.1021/bi00528a011; JENNINGS ML, 1989, ANION TRANSPORT PROT, P59; KAMPMANN L, 1982, J MEMBRANE BIOL, V70, P199, DOI 10.1007/BF01870563; KANG D, 1992, J BIOL CHEM, V267, P19211; KAWANO Y, 1986, J BIOCHEM-TOKYO, V100, P191, DOI 10.1093/oxfordjournals.jbchem.a121692; KAWANO Y, 1988, J BIOL CHEM, V263, P8232; KAY MMB, 1991, FASEB J, V5, P109, DOI 10.1096/fasebj.5.1.1991578; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPKE S, 1976, J MEMBRANE BIOL, V29, P147, DOI 10.1007/BF01868957; LOW PS, 1986, BIOCHIM BIOPHYS ACTA, V864, P145, DOI 10.1016/0304-4157(86)90009-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUX SE, 1989, P NATL ACAD SCI USA, V86, P9089, DOI 10.1073/pnas.86.23.9089; OKUBO K, 1991, J BIOL CHEM, V266, P16420; PASSOW H, 1986, REV PHYSIOL BIOCH P, V103, P61; REITHMEIER RAF, 1979, J BIOL CHEM, V254, P3054; STECK TL, 1978, BIOCHEMISTRY-US, V17, P1216, DOI 10.1021/bi00600a013; STECK TL, 1976, BIOCHEMISTRY-US, V15, P1154, DOI 10.1021/bi00650a030; TANNER MJA, 1988, BIOCHEM J, V256, P703, DOI 10.1042/bj2560703; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WOOD PG, 1992, J MEMBRANE BIOL, V127, P139; WOOD PG, 1992, BAND 3 PROTEINS ANIO, P325	42	139	142	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1918	1926						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294441				2022-12-27	WOS:A1994MR98800057
J	SZALLASI, Z; SMITH, CB; PETTIT, GR; BLUMBERG, PM				SZALLASI, Z; SMITH, CB; PETTIT, GR; BLUMBERG, PM			DIFFERENTIAL REGULATION OF PROTEIN-KINASE-C ISOZYMES BY BRYOSTATIN-1 AND PHORBOL 12-MYRISTATE 13-ACETATE IN NIH 3T3 FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE EPIDERMAL-CELLS; CARCINOMA-CELLS; ESTER; BINDING; JUN; PHOSPHORYLATION; ACTIVATION; MODULATION; HL-60; AP-1	Bryostatin 1 and phorbol 12-myristate 13-acetate (PMA) are both potent activators of protein kinase C (PKC), although in many systems bryostatin 1 induces only a subset of the responses to PMA and blocks those which it does not induce. We report here that in NIH 3T3 fibroblasts PMA showed similar potencies for translocating PKC isozymes alpha, delta, and epsilon to the Triton X-100-soluble and -insoluble fractions and for the down-regulation of the three isozymes. Bryostatin 1 was slightly more potent than PMA for translocating PKCalpha and was more potent than PMA for down-regulating it. Bryostatin 1 was markedly more potent than PMA for translocating PKCdelta but showed a biphasic dose-response curve for down-regulating this isozyme. 1-10 nm bryostatin 1 down-regulated PKCdelta to a similar extent as PMA; lower (10-100 pm) or, unexpectedly, higher (100 nm to 1 muM) doses of bryostatin 1 caused either no or reduced down-regulation. Moreover, these high (100 nm to 1 muM) doses of bryostatin 1 inhibited the down-regulation of PKCdelta by 1 muM PMA when coapplied. Bryostatin 1 caused translocation of PKCepsilon with slightly higher potency than PKCdelta, but there was no protection of this isozyme at any of the doses examined. Bryostatin 1 induced a long-term increase in c-Jun level. The dose-response curve for bryostatin 1 was biphasic, with maximal induction at 1-10 nM bryostatin 1, coincident with the maximal down-regulation of PKCdelta. We conclude that bryostatin 1 showed substantially different regulation for PKCalpha, PKCdelta, and PKCepsilon, whereas PMA distinguished only weakly between these isozymes.	NCI, CELLULAR CARCINOGENESIS LAB, BETHESDA, MD 20892 USA; ARIZONA STATE UNIV, CANC RES INST, TEMPE, AZ 85287 USA; ARIZONA STATE UNIV, DEPT CHEM, TEMPE, AZ 85287 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe				Szallasi, Zoltan/0000-0001-5395-7509				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BASU A, 1992, CANCER RES, V52, P3119; BLUMBERG PM, 1991, MOL CARCINOGEN, V4, P339, DOI 10.1002/mc.2940040502; BLUMBERG PM, 1992, ALFRED BENZON SYMP S, V33, P273; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; DALE IL, 1989, INT J CANCER, V43, P158, DOI 10.1002/ijc.2910430129; DELLAQUILA ML, 1987, CANCER RES, V47, P6006; KAZANIETZ MG, 1992, J BIOL CHEM, V267, P20878; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KENNEDY MJ, 1992, CANCER RES, V52, P1278; KRAFT AS, 1988, J BIOL CHEM, V263, P8437; KRAFT AS, 1986, P NATL ACAD SCI USA, V83, P1334, DOI 10.1073/pnas.83.5.1334; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEWIN NE, 1992, BIOCHEM PHARMACOL, V43, P2007, DOI 10.1016/0006-2952(92)90644-X; MURAMATSU MA, 1989, MOL CELL BIOL, V9, P831, DOI 10.1128/MCB.9.2.831; NELSESTUEN GL, 1991, J BIOENERG BIOMEMBR, V23, P43; OLIVIER AR, 1992, J CELL PHYSIOL, V152, P240, DOI 10.1002/jcp.1041520204; PETTIT GR, 1982, J AM CHEM SOC, V104, P6846, DOI 10.1021/ja00388a092; SAKO T, 1987, CANCER RES, V47, P5445; SHARKEY NA, 1985, CANCER RES, V45, P19; SHARKIS SJ, 1989, ANN NY ACAD SCI, V554, P59, DOI 10.1111/j.1749-6632.1989.tb22409.x; SHERMAN ML, 1990, J BIOL CHEM, V265, P3320; SREDNI B, 1990, IMMUNOLOGY, V70, P473; WARREN BS, 1988, CANCER RES, V48, P5984; WAYS DK, 1992, CANCER RES, V52, P5604	27	237	255	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2118	2124						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294465				2022-12-27	WOS:A1994MR98800086
J	ANDERSSON, M; OSTMAN, A; WESTERMARK, B; HELDIN, CH				ANDERSSON, M; OSTMAN, A; WESTERMARK, B; HELDIN, CH			CHARACTERIZATION OF THE RETENTION MOTIF IN THE C-TERMINAL PART OF THE LONG SPLICE FORM OF PLATELET-DERIVED GROWTH-FACTOR A-CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR-PERMEABILITY FACTOR; SIMIAN SARCOMA-VIRUS; FACTOR PDGF; FACTOR RECEPTORS; B-CHAIN; KINASE ACTIVATION; GOLGI-COMPLEX; CDNA; EXPRESSION; GENE	Platelet-derived growth factor (PDGF) A-chain is found in two different splice variants; the long A-chain variant differs from the short one in that it contains a stretch of basic amino acid residues in the C-terminal part that mediates retention of the growth factor inside the producer cell and to the cell matrix. By analyzing mutants in which different amino acid residues in the retention motif had been changed to alanine residues, we found that the total positive charge of the sequence is of importance for the function of the retention motif. Moreover, we showed that retention also occurs if only one of the polypeptides in the PDGF dimer carries the retention motif. Surface iodination and competition with a peptide having the sequence of the retention motif revealed that the long A-chain variant, in contrast to the short A-chain variant, is localized on the outside of the cells and is also associated to the cell matrix. The association is likely to be mediated partially through heparan sulfate proteoglycans since treatment of matrix with heparitinase released the long A-chain variant.	UNIV HOSP UPPSALA,DEPT PATHOL,S-75185 UPPSALA,SWEDEN	Uppsala University; Uppsala University Hospital	ANDERSSON, M (corresponding author), BIOMED CTR,LUDWIG INST CANC RES,BOX 595,S-75124 UPPSALA,SWEDEN.							ANDERSSON M, 1992, J BIOL CHEM, V267, P11260; BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BETSHOLTZ C, 1990, NATURE, V344, P299, DOI 10.1038/344299a0; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BONTHRON DT, 1988, P NATL ACAD SCI USA, V85, P1492, DOI 10.1073/pnas.85.5.1492; BYWATER M, 1988, MOL CELL BIOL, V8, P2753, DOI 10.1128/MCB.8.7.2753; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FORSBERG K, 1993, P NATL ACAD SCI USA, V90, P393, DOI 10.1073/pnas.90.2.393; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HELDIN CH, 1993, TRANSPLANT P, V25, P2072; JOSEPHS SF, 1984, SCIENCE, V223, P487, DOI 10.1126/science.6318322; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KELLY JL, 1993, J CELL BIOL, V121, P1153, DOI 10.1083/jcb.121.5.1153; KHACHIGIAN LM, 1992, J BIOL CHEM, V267, P1660; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAROCHELLE WJ, 1991, GENE DEV, V5, P1191, DOI 10.1101/gad.5.7.1191; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAGLIONE D, 1993, ONCOGENE, V8, P925; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; OSTMAN A, 1991, CELL REGUL, V2, P503, DOI 10.1091/mbc.2.7.503; OSTMAN A, 1988, J BIOL CHEM, V263, P16202; OSTMAN A, 1992, J CELL BIOL, V118, P509, DOI 10.1083/jcb.118.3.509; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; Pollock RA, 1992, GROWTH FACTORS, V7, P267, DOI 10.3109/08977199209046409; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; ROBBINS KC, 1985, EMBO J, V4, P1783, DOI 10.1002/j.1460-2075.1985.tb03851.x; ROBBINS KC, 1983, NATURE, V305, P605, DOI 10.1038/305605a0; RORSMAN F, 1988, MOL CELL BIOL, V8, P571, DOI 10.1128/MCB.8.2.571; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; STEIN J, 1991, ONCOGENE, V6, P601; THYBERG J, 1990, J CELL SCI, V97, P219; TRUETT MA, 1985, DNA-J MOLEC CELL BIO, V4, P333, DOI 10.1089/dna.1985.4.333; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	41	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					926	930						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288645				2022-12-27	WOS:A1994MR22000026
J	CHARLEMAGNE, D; ORLOWSKI, J; OLIVIERO, P; RANNOU, F; SAINTEBEUVE, C; SWYNGHEDAUW, B; LANE, LK				CHARLEMAGNE, D; ORLOWSKI, J; OLIVIERO, P; RANNOU, F; SAINTEBEUVE, C; SWYNGHEDAUW, B; LANE, LK			ALTERATION OF NA,K-ATPASE-SUBUNIT MESSENGER-RNA AND PROTEIN-LEVELS IN HYPERTROPHIED RAT-HEART	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(NA+ + K+)-ATPASE; SPONTANEOUSLY HYPERTENSIVE RATS; MYOSIN HEAVY-CHAIN; CARDIAC-HYPERTROPHY; BETA-SUBUNIT; CATALYTIC SUBUNIT; THYROID-HORMONE; GENE-EXPRESSION; BINDING-SITES; SARCOPLASMIC-RETICULUM	To determine if an altered expression of the Na,K-ATPase alpha isoform genes is responsible for an observed increase in cardiac glycoside sensitivity in compensatory hypertrophy, we performed Northern and slot blot analyses of RNA and specific immunological detection of Na,K-ATPase isoforms in rat hearts from normal and pressure overload-treated animals induced by abdominal aortic constriction. During the early phase of hypertrophy, the only alteration is a decrease in the alpha2 mRNA isoform. In the compensated hypertrophied heart, the levels of the predominant alpha1 isoform (mRNA and protein) and the beta1 subunit mRNA are unchanged. In contrast, the alpha2 isoform (mRNA and protein) is decreased by 35% and up to 61-64% in mild (<55%) and severe (>55%) hypertrophy, respectively. The alpha3 isoform (mRNA and protein), which is extremely Iow in adult heart, is increased up to 2-fold during hypertrophy but accounts for only congruent-to 5% of the total alpha isoform mRNA. These findings demonstrate that, in cardiac hypertrophy, the three a isoforms of the Na,K-ATPase are independently regulated and that regulation occurs at a pretranslational level. The pattern of expression in hypertrophied adult heart is similar to that of the neonatal heart where the inverse regulation between the alpha2 and alpha3 ouabain high affinity isoforms has been reported. This suggests that distinct regulatory mechanisms controlling Na,K-ATPase isoform expression may, at least in part, be involved in the sensitivity to cardiac glycosides.	UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT PHARMACOL & CELL BIOPHYS,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	CHARLEMAGNE, D (corresponding author), HOP LARIBOISIERE,INSERM,U127,41 BD CHAPELLE,F-75475 PARIS 10,FRANCE.			Orlowski, John/0000-0001-7371-175X				ACKERMANN U, 1990, FEBS LETT, V269, P105, DOI 10.1016/0014-5793(90)81130-G; ADAMS RJ, 1982, NATURE, V296, P167, DOI 10.1038/296167a0; AKERA T, 1990, CALCIUM HEART, P299; Aronson RS., 1991, J CARDIOVASC ELECTR, V2, P249, DOI 10.1111/j.1540-8167.1991.tb01323.x; BLACK FM, 1991, J CLIN INVEST, V88, P1581, DOI 10.1172/JCI115470; CHARLEMAGNE D, 1987, J BIOL CHEM, V262, P8941; CHARLEMAGNE D, 1986, J BIOL CHEM, V261, P185; CHEVALIER B, 1989, PFLUG ARCH EUR J PHY, V414, P311, DOI 10.1007/BF00584632; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIRILLO M, 1984, CLIN SCI, V67, P535, DOI 10.1042/cs0670535; CUTILLETTA AF, 1975, J MOL CELL CARDIOL, V7, P767, DOI 10.1016/0022-2828(75)90042-5; DELABASTIE D, 1990, CIRC RES, V66, P554, DOI 10.1161/01.RES.66.2.554; ERDMANN E, 1980, BIOCHEM PHARMACOL, V29, P3219, DOI 10.1016/0006-2952(80)90295-6; FELSENFELD DP, 1988, J BIOL CHEM, V263, P10932; GENY B, 1982, BIOCHIM BIOPHYS ACTA, V692, P345, DOI 10.1016/0005-2736(82)90383-2; GWATHMEY JK, 1985, CIRC RES, V57, P836, DOI 10.1161/01.RES.57.6.836; HERRERA VLM, 1987, J CELL BIOL, V105, P1855, DOI 10.1083/jcb.105.4.1855; HERRERA VLM, 1988, SCIENCE, V241, P221, DOI 10.1126/science.2838907; HICKERSON TW, 1988, MEMBRANE BIOPHYSICS, V3, P223; HOROWITZ B, 1990, J BIOL CHEM, V265, P14308; IZUMO S, 1987, J CLIN INVEST, V79, P1970; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; KAMITANI T, 1992, CIRC RES, V71, P1457, DOI 10.1161/01.RES.71.6.1457; LEE SW, 1983, HYPERTENSION, V5, P682, DOI 10.1161/01.HYP.5.5.682; LELIEVRE LG, 1986, AM J PHYSIOL, V250, pH923, DOI 10.1152/ajpheart.1986.250.6.H923; LOMPRE AM, 1991, CIRC RES, V69, P1380, DOI 10.1161/01.RES.69.5.1380; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCCHESI PA, 1991, J BIOL CHEM, V266, P9327; MANSIER P, 1982, NATURE, V300, P535, DOI 10.1038/300535a0; MELIKIAN J, 1991, J MEMBRANE BIOL, V119, P171, DOI 10.1007/BF01871416; MERCADIER JJ, 1989, AM J PHYSIOL, V257, pH979, DOI 10.1152/ajpheart.1989.257.3.H979; MOALIC JM, 1993, CARDIOVASC RES, V27, P231, DOI 10.1093/cvr/27.2.231; NAUDIN V, 1991, FEBS LETT, V285, P135, DOI 10.1016/0014-5793(91)80743-M; NOEL F, 1984, BIOCHEM PHARMACOL, V33, P47, DOI 10.1016/0006-2952(84)90369-1; NOGUCHI S, 1990, J BIOL CHEM, V265, P15991; ORLOWSKI J, 1990, J BIOL CHEM, V265, P3462; ORLOWSKI J, 1988, J BIOL CHEM, V263, P10436; REIBEL DK, 1986, AM J PHYSIOL, V250, pH1, DOI 10.1152/ajpheart.1986.250.1.H1; SCHWARTZ K, 1992, AM J PHYSIOL, V262, pR364, DOI 10.1152/ajpregu.1992.262.3.R364; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; SHYJAN AW, 1990, J BIOL CHEM, V265, P5166; SWEADNER KJ, 1979, J BIOL CHEM, V254, P6060; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; SWEADNER KJ, 1992, J BIOL CHEM, V267, P769; URAYAMA O, 1989, J BIOL CHEM, V264, P8271; VORNANEN M, 1987, BASIC RES CARDIOL, V82, P82, DOI 10.1007/BF01907056; WALLICK ET, 1980, ARCH BIOCHEM BIOPHYS, V202, P442, DOI 10.1016/0003-9861(80)90448-8; WERDAN K, 1984, BIOCHEM PHARMACOL, V33, P1873, DOI 10.1016/0006-2952(84)90542-2; WIBO M, 1991, CIRC RES, V68, P662, DOI 10.1161/01.RES.68.3.662; YOUNG RM, 1987, BIOCHEM BIOPH RES CO, V145, P52, DOI 10.1016/0006-291X(87)91286-1; ZAHLER R, 1992, P NATL ACAD SCI USA, V89, P99, DOI 10.1073/pnas.89.1.99	52	96	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1541	1547						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288620				2022-12-27	WOS:A1994MR22000116
J	DAILEY, HA; SELLERS, VM; DAILEY, TA				DAILEY, HA; SELLERS, VM; DAILEY, TA			MAMMALIAN FERROCHELATASE - EXPRESSION AND CHARACTERIZATION OF NORMAL AND 2 HUMAN PROTOPORHYRIC FERROCHELATASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROPOIETIC PROTOPORPHYRIA; SACCHAROMYCES-CEREVISIAE; LIVER-TRANSPLANTATION; BOVINE PROTOPORPHYRIA; MOUSE FERROCHELATASE; MOLECULAR-CLONING; SKIN FIBROBLASTS; GENE; PURIFICATION; DISEASE	Ferrochelatase (EC 4.99.1.1) catalyzes the terminal step in the heme biosynthetic pathway, the insertion of ferrous iron into protoporphyrin IX. Herein we report the expression, purification, and characterization of the mature processed form of human and mouse ferrochelatase in Escherichia coli JM109. Metal analysis of the recombinant normal human ferrochelatase reveals that there are approximately 2 iron atoms/molecule of enzyme. This, along with the presence of spectral absorbance near 320 nm, is strongly suggestive that recombinant mammalian ferrochelatase as expressed in E. coli may contain an iron sulfur cluster. Two human protoporphyric ferrochelatases, F417S and M267I, were also expressed and characterized. The M267I mutant possesses the same K(m) and V(max) as the normal enzyme but exhibits increased thermolability when compared with normal human ferrochelatase. The F417S mutant has less than 2% of the normal activity. Since the Phe --> Ser substitution in this mutation is both chemically and structurally significant, three single amino acid substitutions (Lys, Tyr, and Trp) were engineered and characterized. None of these resulted in a protein with wild type activity. Additionally the carboxyl-terminal 10-amino acid segment, which contains Phe-417, from the yeast sequence was substituted, but this construct had no activity. Elimination of the carboxyl-terminal 30 amino acid residues (which include Phe-417) results in a protein the same length as the bacterial ferrochelatases, but it is an inactive enzyme.	UNIV GEORGIA,CTR METALLOENZYME STUDIES,ATHENS,GA 30602	University System of Georgia; University of Georgia	DAILEY, HA (corresponding author), UNIV GEORGIA,DEPT MICROBIOL,ATHENS,GA 30602, USA.				NIDDK NIH HHS [R56 DK032303, DK 32303, DK 35898] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035898, R01DK032303] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BLOOMER JR, 1976, LANCET, V2, P226; BLOOMER JR, 1975, AM J MED, V58, P869, DOI 10.1016/0002-9343(75)90644-0; BLOOMER JR, 1989, GASTROENTEROLOGY, V97, P188, DOI 10.1016/0016-5085(89)91434-0; BLOOMER JR, 1987, J BIOL CHEM, V262, P667; BONKOWSKY HL, 1975, J CLIN INVEST, V56, P1139, DOI 10.1172/JCI108189; BOTTOMLEY SS, 1975, J LAB CLIN MED, V86, P126; BOULECHFAR S, 1993, GENOMICS, V16, P645, DOI 10.1006/geno.1993.1242; BRENNER DA, 1991, P NATL ACAD SCI USA, V88, P849, DOI 10.1073/pnas.88.3.849; BRENNER DA, 1992, AM J HUM GENET, V50, P1203; CAMADRO JM, 1988, J BIOL CHEM, V263, P11675; CARTER P, 1971, ANAL BIOCHEM, V40, P450, DOI 10.1016/0003-2697(71)90405-2; Dailey H. A., 1990, BIOSYNTHESIS HEME CH, P123; DAILEY HA, 1977, J BACTERIOL, V129, P815, DOI 10.1128/JB.129.2.815-820.1977; DAILEY HA, 1989, BIOCHIM BIOPHYS ACTA, V999, P7, DOI 10.1016/0167-4838(89)90021-6; DAILEY HA, 1983, J BIOL CHEM, V258, P1453; DAILEY HA, 1986, METHOD ENZYMOL, V123, P401; de Goeij A F, 1975, Eur J Clin Invest, V5, P397; ELDRIDGE MG, 1992, PROTEIN SCI, V1, P271; FRUSTACI JM, 1992, J BACTERIOL, V174, P4223, DOI 10.1128/JB.174.13.4223-4229.1992; HANSSON M, 1992, J BACTERIOL, V174, P8081, DOI 10.1128/JB.174.24.8081-8093.1992; HARBIN BM, 1985, BIOCHEMISTRY-US, V24, P366, DOI 10.1021/bi00323a019; HERBERT A, 1991, GASTROENTEROLOGY, V100, P1753, DOI 10.1016/0016-5085(91)90680-J; JONES MS, 1969, BIOCHEM J, V113, P507, DOI 10.1042/bj1130507; KARR SR, 1988, BIOCHEM J, V254, P799, DOI 10.1042/bj2540799; LABBEBOIS R, 1990, J BIOL CHEM, V265, P7278; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMORIL J, 1991, BIOCHEM BIOPH RES CO, V181, P594, DOI 10.1016/0006-291X(91)91231-Z; Lavallee DK, 1988, MECH PRINCIPLES ENZY, P279; MATHEWSROTH MM, 1987, ARCH DERMATOL, V123, P429, DOI 10.1001/archderm.123.4.429; MIYAMOTO K, 1991, J MOL BIOL, V219, P393, DOI 10.1016/0022-2836(91)90180-E; NAKAHASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P748, DOI 10.1016/S0006-291X(05)80099-3; NAKAHIGASHI K, 1991, P NATL ACAD SCI USA, V88, P10520, DOI 10.1073/pnas.88.23.10520; PAJOT P, 1976, EUR J BIOCHEM, V63, P263, DOI 10.1111/j.1432-1033.1976.tb10228.x; PROULX KL, 1993, PROTEIN SCI, V2, P1092, DOI 10.1002/pro.5560020703; RUTH GR, 1977, SCIENCE, V198, P199, DOI 10.1126/science.905823; STRAKA JG, 1991, J BIOL CHEM, V266, P24637; TAKETANI S, 1990, J BIOL CHEM, V265, P19377; TUTOIS S, 1991, J CLIN INVEST, V88, P1730, DOI 10.1172/JCI115491	39	61	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					390	395						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276824				2022-12-27	WOS:A1994MR21900066
J	FIGUEIREDOPEREIRA, ME; YU, B; WILK, S				FIGUEIREDOPEREIRA, ME; YU, B; WILK, S			DISSOCIATION AND REASSOCIATION OF THE BOVINE PITUITARY MULTICATALYTIC PROTEINASE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE NEUTRAL ENDOPEPTIDASE; RAT SKELETAL-MUSCLE; REVERSIBLE ACTIVATION; PROTEASE; PURIFICATION; LIVER; SPECIFICITY; PROSOMES; CASEIN; LATENT	The eukaryotic multicatalytic proteinase complex (proteasome) is a high molecular mass enzyme which contains 13-15 nonidentical subunits of similar size (molecular masses of 21-31 kDa), but differing widely in net charge (isoelectric points ranging from 3 to 10). At least four catalytic components termed chyriotrypsin-like, trypsin-like, peptidylglutamyl peptide-hydrolyzing, and caseinolytic are associated with the proteinase. The catalytic nature of the components is unknown, since sequences of cloned subunits bear no homology to known proteinases and proteolytically active subunits have not been isolated. Analysis of the relationship between structure and catalytic function would be greatly facilitated if a means for reversibly dissociating and reassociating the proteinase were available. We provide the first evidence of reassembly of dissociated multicatalytic proteinase complex into a functional molecule. Incubation with the organic mercurial, p-chloromercuribenzoic acid disrupts in a concentration-dependent manner the quaternary structure of the enzyme, leading to formation of a heterogeneous population of subunits. Dissociation of the complex coincides with progressive loss of chymotrypsin-like, trypsin-like, and peptidylglutamyl peptide hydrolyzing activities. The caseinolytic activity of the residual undissociated enzyme is markedly activated. Exposure of the dissociated enzyme to dithiothreitol restores the catalytic profile and reassociates the enzyme. Evidence for catalytically active subcomplexes was not obtained indicating that structural integrity may be necessary for expression of all defined activities.	CUNY MT SINAI SCH MED,DEPT PHARMACOL,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NIMH NIH HHS [MH-00350] Funding Source: Medline; NINDS NIH HHS [NS-29936] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH000350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029936] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAUMEISTER W, 1988, FEBS LETT, V241, P239, DOI 10.1016/0014-5793(88)81069-X; CARDOZO C, 1992, BIOCHEMISTRY-US, V31, P7373, DOI 10.1021/bi00147a023; DAHLMANN B, 1985, BIOCHEM J, V228, P161, DOI 10.1042/bj2280161; DJABALLAH H, 1992, EUR J BIOCHEM, V209, P629, DOI 10.1111/j.1432-1033.1992.tb17329.x; HOAGLAND VD, 1967, J BIOL CHEM, V242, P4341; KOPP F, 1993, J MOL BIOL, V229, P14, DOI 10.1006/jmbi.1993.1003; KOPP F, 1986, BIOCHIM BIOPHYS ACTA, V872, P253, DOI 10.1016/0167-4838(86)90278-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADSEN NB, 1956, J BIOL CHEM, V223, P1055; MCGUIRE MJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P181, DOI 10.1016/0167-4838(89)90078-2; NOTHWANG HG, 1992, EUR J BIOCHEM, V207, P621, DOI 10.1111/j.1432-1033.1992.tb17089.x; NOTHWANG HG, 1992, BIOCHEM J, V287, P733, DOI 10.1042/bj2870733; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORLOWSKI M, 1989, BIOCHEMISTRY-US, V28, P9270, DOI 10.1021/bi00450a006; OZAKI M, 1992, J BIOL CHEM, V267, P21678; PEREIRA ME, 1992, J BIOL CHEM, V267, P7949; RIVETT AJ, 1985, J BIOL CHEM, V260, P2600; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; STRACK PR, 1992, INT J BIOCHEM, V24, P887, DOI 10.1016/0020-711X(92)90093-G; TAMAOKI T, 1967, J MOL BIOL, V23, P35, DOI 10.1016/S0022-2836(67)80065-2; TANAKA K, 1992, NEW BIOL, V4, P173; TANAKA K, 1989, BIOCHEM BIOPH RES CO, V158, P548, DOI 10.1016/S0006-291X(89)80084-1; TANAKA K, 1986, J BIOL CHEM, V261, P5197; TANAKA K, 1989, J BIOCHEM-TOKYO, V106, P495, DOI 10.1093/oxfordjournals.jbchem.a122880; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEITMAN D, 1992, J BIOL CHEM, V267, P6977; WILK S, 1980, J NEUROCHEM, V35, P1172, DOI 10.1111/j.1471-4159.1980.tb07873.x; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x; YU B, 1991, J BIOL CHEM, V266, P17396; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	31	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					621	626						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276861				2022-12-27	WOS:A1994MR21900098
J	HUANG, N; WANG, D; HEPPEL, LA				HUANG, N; WANG, D; HEPPEL, LA			ROLE OF ADENOSINE 3'/5'-MONOPHOSPHATE-DEPENDENT PROTEIN-KINASE AND CAMP LEVELS IN ATP-DEPENDENT MITOGENESIS IN SWISS 3T3-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP ACCUMULATION; TRANSDUCTION PATHWAYS LEAD; ARACHIDONIC-ACID RELEASE; NERVE GROWTH-FACTOR; 3T3 CELLS; EXTRACELLULAR ATP; DNA-SYNTHESIS; PROSTAGLANDIN SYNTHESIS; STIMULATED MITOGENESIS; MAMMALIAN-CELLS	To investigate the role of cAMP-dependent protein kinase (PKA) and cAMP levels in ATP-dependent mitogenesis, Swiss 3T3 cells were transfected with an expression vector coding for (i) a mutated regulatory subunit of PKA (PKA mutant) or (ii) a yeast low K(m) cAMP phosphodiesterase gene (PDE mutant). The PKA mutant showed 70% reduced PKA activity. Phosphodiesterase activity increased 2.5-fold in the PDE mutant, leading to a great reduction of cAMP levels stimulated by ATP and other cAMP-increasing agents. The mitogenic responses of PKA and PDE mutants to insulin, epidermal growth factor, or 12-O-tetradecanoylphorbol-13-acetate were not significantly changed. However, the further stimulation by ATP, ADP, and adenosine 5'-(beta,gamma-imido)triphosphate in the presence of these growth factors was reduced by >80%. Mitogenic effect of prostaglandin E2, forskolin, cholera toxin, or adenosine was inhibited in both mutants. The mitogenic stimulation by dibutyryl cAMP, which is resistant to phosphodiesterase, was inhibited in the PKA mutant, but not in the PDE mutant. A partial reduction of platelet-derived growth factor- or bombesin-stimulated mitogenesis, which involves protein kinase C as well as the cAMP signal, was observed in the mutants. These genetic results confirm pharmacological data on the role of PKA and cAMP levels in mitogenesis due to ATP and other growth factors.	CORNELL UNIV, BIOCHEM MOLEC & CELL BIOL SECT, ITHACA, NY 14853 USA	Cornell University					NATIONAL CANCER INSTITUTE [R01CA058518] Funding Source: NIH RePORTER; NCI NIH HHS [5 RO1 CA58518] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM I, 1985, J BIOL CHEM, V260, P3934; BEAVO JA, 1974, P NATL ACAD SCI USA, V71, P3580, DOI 10.1073/pnas.71.9.3580; BULGAKOV R, 1983, BIOCHIM BIOPHYS ACTA, V756, P56, DOI 10.1016/0304-4165(83)90024-7; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; BURCH RM, 1989, J CELL PHYSIOL, V139, P29, DOI 10.1002/jcp.1041390106; CAMPAGNE MMV, 1990, J BIOL CHEM, V265, P5840; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; CORRELL LA, 1989, J BIOL CHEM, V264, P16672; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; FELDER CC, 1989, J BIOL CHEM, V264, P20356; GIL J, 1991, J CELL BIOL, V113, P943, DOI 10.1083/jcb.113.4.943; GINTY DD, 1991, J BIOL CHEM, V266, P15325; HABENICHT AJR, 1981, J BIOL CHEM, V256, P2329; HOOK VYH, 1982, BIOCHEM BIOPH RES CO, V106, P1364, DOI 10.1016/0006-291X(82)91264-5; HUANG NN, 1993, J BIOL CHEM, V268, P10789; HUANG NN, 1991, J CELL PHYSIOL, V146, P483, DOI 10.1002/jcp.1041460320; HUANG NN, 1989, P NATL ACAD SCI USA, V86, P7904, DOI 10.1073/pnas.86.20.7904; MILLAR JBA, 1988, J CELL PHYSIOL, V137, P214, DOI 10.1002/jcp.1041370203; MOOLENAAR WH, 1992, REV PHYSIOL BIOCH P, V119, P47; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; ROZENGURT E, 1981, P NATL ACAD SCI-BIOL, V78, P4392, DOI 10.1073/pnas.78.7.4392; ROZENGURT E, 1982, EXP CELL RES, V139, P71, DOI 10.1016/0014-4827(82)90319-6; ROZENGURT E, 1983, J CELL PHYSIOL, V116, P379, DOI 10.1002/jcp.1041160316; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1983, CELL, V34, P265, DOI 10.1016/0092-8674(83)90157-5; SCHECTERSON LC, 1991, MOL ENDOCRINOL, V5, P170, DOI 10.1210/mend-5-2-170; SCHUBERT D, 1978, NATURE, V273, P718, DOI 10.1038/273718a0; WANG D, 1990, BIOCHEM BIOPH RES CO, V166, P251, DOI 10.1016/0006-291X(90)91938-O; WANG DJ, 1991, J CELL PHYSIOL, V146, P473, DOI 10.1002/jcp.1041460319; WANG DJ, 1992, J CELL PHYSIOL, V153, P221, DOI 10.1002/jcp.1041530202; ZACHARY I, 1990, BIOCHEM BIOPH RES CO, V168, P1184, DOI 10.1016/0006-291X(90)91154-K; ZURIER RB, 1988, EXP CELL RES, V176, P155, DOI 10.1016/0014-4827(88)90129-2	33	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					548	555						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276849				2022-12-27	WOS:A1994MR21900088
J	SU, Y; VARUGHESE, KI; XUONG, NH; BRAY, TL; ROCHE, DJ; WHITELEY, JM				SU, Y; VARUGHESE, KI; XUONG, NH; BRAY, TL; ROCHE, DJ; WHITELEY, JM			THE CRYSTALLOGRAPHIC STRUCTURE OF A HUMAN DIHYDROPTERIDINE REDUCTASE NADH BINARY COMPLEX EXPRESSED IN ESCHERICHIA-COLI BY A CDNA CONSTRUCTED FROM ITS RAT HOMOLOG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; BINDING; PROTEIN; BACTERIOPHAGE-T4; PHENYLKETONURIA; DEFICIENCY	A human dihydropteridine reductase (EC 1.6.99.10) has been created from a rat cDNA clone by a single five-oligonucleotide mutagenesis reaction and expressed in good yield in Escherichia coli. The enzyme has been purified to homogeneity, and kinetic identity to the naturally occurring enzyme has been proven. Crystallization has also been achieved, and the crystal structure was solved using 2.5 angstrom data that was refined to an R value of 16.9%. The structure described in this report represents the first complete structural characterization of this important human enzyme.	UNIV CALIF SAN DIEGO, DEPT BIOL, 9500 GILMAN DR, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA; SCRIPPS RES INST, DEPT EXPTL & MOLEC MED, LA JOLLA, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Research Institute					NCI NIH HHS [CA 11778] Funding Source: Medline; NCRR NIH HHS [RR01644] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA011778] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001644] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALBER T, 1987, BIOCHEMISTRY-US, V26, P3754, DOI 10.1021/bi00387a002; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CAMBILLAU C, 1987, J MOL GRAPHICS, V5, P174, DOI 10.1016/0263-7855(87)80024-3; CHAUVIN MM, 1979, CAN J BIOCHEM CELL B, V57, P178, DOI 10.1139/o79-022; Cleland W W, 1979, Methods Enzymol, V63, P103; DAHL HHM, 1987, NUCLEIC ACIDS RES, V15, P1921, DOI 10.1093/nar/15.5.1921; FIRGAIRA FA, 1987, METHOD ENZYMOL, V142, P116; FROMM M, 1982, Journal of Molecular and Applied Genetics, V1, P457; GRIMSHAW CE, 1992, J BIOL CHEM, V267, P15334; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KAUFMAN S, 1975, NEW ENGL J MED, V293, P785, DOI 10.1056/NEJM197510162931601; KAUFMAN S, 1985, FOLATES PTERINS, V2, P252; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIND KE, 1973, EUR J BIOCHEM, V33, P67, DOI 10.1111/j.1432-1033.1973.tb02655.x; LOCKYER J, 1987, P NATL ACAD SCI USA, V84, P3329, DOI 10.1073/pnas.84.10.3329; Maniatis T., 1982, MOL CLONING; MATTHEWS DA, 1986, J BIOL CHEM, V261, P3891; MATTHEWS DA, 1991, ARCH BIOCHEM BIOPHYS, V287, P234, DOI 10.1016/0003-9861(91)90412-C; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; SCRIVER CR, 1980, NEW ENGL J MED, V303, P1394, DOI 10.1056/NEJM198012113032404; SHAHBAZ M, 1987, J BIOL CHEM, V262, P16412; SHARP PM, 1988, NUCLEIC ACIDS RES, V16, P8207, DOI 10.1093/nar/16.17.8207; SHIMAN R, 1985, FOLATES PTERINS, V2, P179; SMOOKER PM, 1993, 10TH INT S CHEM BIOL; STRAUCH MA, 1989, EMBO J, V8, P1615, DOI 10.1002/j.1460-2075.1989.tb03546.x; VARUGHESE KI, 1992, P NATL ACAD SCI USA, V89, P6080, DOI 10.1073/pnas.89.13.6080; WEBBER S, 1978, J BIOL CHEM, V253, P6724; XUONG NH, 1985, ACTA CRYSTALLOGR B, V41, P267, DOI 10.1107/S0108768185002105	31	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26836	26841						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262916				2022-12-27	WOS:A1993MM26200005
J	CREUWELS, LAJM; DEMEL, RA; VANGOLDE, LMG; BENSON, BJ; HAAGSMAN, HP				CREUWELS, LAJM; DEMEL, RA; VANGOLDE, LMG; BENSON, BJ; HAAGSMAN, HP			EFFECT OF ACYLATION ON STRUCTURE AND FUNCTION OF SURFACTANT PROTEIN-C AT THE AIR-LIQUID INTERFACE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG SURFACTANT; SP-B; MONOMOLECULAR LAYERS; PRECURSOR; LIPOPEPTIDE; ORIENTATION; MEMBRANES; BILAYER; BOVINE	Pulmonary surfactant protein C (SP-C) is a small hydrophobic peptide that is palmitoylated on 2 adjacent cysteine residues. SP-C enhances the adsorption of phospholipids into a monolayer. The function of the acylation is not clear yet. The experiments described in this article were carried out in order to investigate the function of SP-C acylation in (protein-catalyzed) lipid monolayer formation, and in bilayer interactions. Palmitoylated and nonpalmitoylated human recombinant SP-C were used. In addition, a nonacylated SP-C with a Cys --> Ser mutation was included in these studies. In Wilhelmy plate experiments using negatively charged, protein-containing phospholipid monolayers and negatively charged vesicles, CaCl2 was required to obtain a maximal insertion rate of lipids into the monolayer. If the negatively charged phospholipids in the monolayer were replaced by neutral phospholipids, CaCl2 was only required to show a maximal SP-C-catalyzed insertion rate (if the molecule is palmitoylated, but not if nonpalmitoylated proteins were added). In pressure area measurements, the palmitoylated protein showed a different change in pressure as a function of the surface area, as compared with the nonpalmitoylated proteins. Circular dichroism experiments showed that all three proteins had a high content of alpha-helix. All three proteins showed a preferential orientation at the air-water interface, but the palmitoylated protein has an orientation which is more parallel to the monolayer than that of the nonpalmitoylated proteins. It is concluded that acylation of SP-C alters structural and physical properties of this protein.	UNIV UTRECHT,VET BIOCHEM LAB,3508 TD UTRECHT,NETHERLANDS; UNIV UTRECHT,CTR BIOMEMBRANES & LIPID ENZYMOL,3508 TD UTRECHT,NETHERLANDS; SCIOS,MT VIEW,CA 94043	Utrecht University; Utrecht University; Scios			Haagsman, Henk P/F-8919-2010					CRONAN JE, 1981, P NATL ACAD SCI-BIOL, V78, P5440, DOI 10.1073/pnas.78.9.5440; CURSTEDT T, 1990, P NATL ACAD SCI USA, V87, P2985, DOI 10.1073/pnas.87.8.2985; HAAGSMAN HP, 1991, ANNU REV PHYSIOL, V53, P441, DOI 10.1146/annurev.physiol.53.1.441; JOHANSSON J, 1991, FEBS LETT, V281, P119, DOI 10.1016/0014-5793(91)80373-B; KELLER A, 1992, AM J RESP CELL MOL, V6, P601, DOI 10.1165/ajrcmb/6.6.601; KELLER A, 1991, BIOCHEM J, V277, P493, DOI 10.1042/bj2770493; LIS LJ, 1982, BIOPHYS J, V37, P657; OOSTERLAKENDIJKSTERHUIS MA, 1992, BIOCHIM BIOPHYS ACTA, V1110, P45, DOI 10.1016/0005-2736(92)90292-T; OOSTERLAKENDIJKSTERHUIS MA, 1991, BIOCHEMISTRY-US, V30, P10965, DOI 10.1021/bi00109a022; OOSTERLAKENDIJKSTERHUIS MA, 1991, BIOCHEMISTRY-US, V30, P8276, DOI 10.1021/bi00247a024; PASTRANA B, 1991, BIOCHEMISTRY-US, V30, P10058, DOI 10.1021/bi00105a033; PEREZGIL J, 1992, BIOPHYS J, V63, P197, DOI 10.1016/S0006-3495(92)81582-5; PHIZACKERLEY PJR, 1979, BIOCHEM J, V183, P731, DOI 10.1042/bj1830731; ROBERTSON B, 1992, PULMONARY SURFACTANT; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHIFFER K, 1993, BIOCHEMISTRY-US, V32, P590, DOI 10.1021/bi00053a026; STULTS JT, 1991, AM J PHYSIOL, V261, pL118, DOI 10.1152/ajplung.1991.261.2.L118; TAKAHASHI A, 1986, BIOCHEM BIOPH RES CO, V135, P527, DOI 10.1016/0006-291X(86)90026-4; VANDENBUSSCHE G, 1992, EUR J BIOCHEM, V203, P201, DOI 10.1111/j.1432-1033.1992.tb19848.x; VOORHOUT WF, 1993, INPRESS MICROSC RES; VORBROKER DK, 1992, BIOCHIM BIOPHYS ACTA, V1105, P161, DOI 10.1016/0005-2736(92)90175-L; WARR RG, 1987, P NATL ACAD SCI USA, V84, P7915, DOI 10.1073/pnas.84.22.7915	22	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26752	26758						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253811				2022-12-27	WOS:A1993MK42500108
J	HORIGOME, K; BULLOCK, ED; JOHNSON, EM				HORIGOME, K; BULLOCK, ED; JOHNSON, EM			EFFECTS OF NERVE GROWTH-FACTOR ON RAT PERITONEAL MAST-CELLS - SURVIVAL PROMOTION AND IMMEDIATE-EARLY GENE INDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; MESSENGER-RNA; PHEOCHROMOCYTOMA CELLS; HISTAMINE-SECRETION; TRK PROTOONCOGENE; NONNEURONAL CELLS; DE-GRANULATION; KIT LIGAND; C-FOS; FIBROBLASTS	Purified rat peritoneal mast cells in vitro die over a period of 2-6 days in conventional serum-containing medium. As mast cells die, they become pyknotic and undergo DNA fragmentation suggestive of an apoptotic process. Treatment of in vitro mast cells with nerve growth factor (NGF) greatly retards and reduces the death of mast cells (EC50 approximately 1 nM), with no effect on mast cell proliferation. Other neurotrophins have no such effect. NGF also induces the immediate early genes c-fos and NGFI-A with a similar dose dependence. In contrast to the secretagogue activity of NGF, neither the survival-promoting effect nor immediate early gene induction requires lysophosphatidylserine. The ability of NGF to promote mast cell survival is cell density-dependent and appears to be primarily because of induction of the synthesis and/or secretion of an autocrine survival factor by stimulated mast cells. These results suggest that the previously observed effects of NGF on mast cell numbers in vivo may in part be because of enhanced survival and that NGF may be an important mediator of mast cell function in normal and pathological states.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,660 S EUCLID AVE,BOX 8103,ST LOUIS,MO 63110	Washington University (WUSTL)								AGELL N, 1988, P NATL ACAD SCI USA, V85, P3693, DOI 10.1073/pnas.85.11.3693; ALOE L, 1977, BRAIN RES, V133, P358, DOI 10.1016/0006-8993(77)90772-7; ALOE L, 1988, J NEUROIMMUNOL, V18, P1, DOI 10.1016/0165-5728(88)90129-4; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARKER PA, 1993, J BIOL CHEM, V268, P15150; BOCCHINI V, 1969, P NATL ACAD SCI USA, V64, P787, DOI 10.1073/pnas.64.2.787; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRUNI A, 1982, FEBS LETT, V138, P190, DOI 10.1016/0014-5793(82)80438-9; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAYMAN HN, 1985, IMMUNOL TODAY, V6, P192; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; COSTA JJ, 1993, MAST CELL HLTH DIS, P443; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; EISEMAN E, 1992, NATURE, V355, P78; FENTON EL, 1970, EXP CELL RES, V59, P383, DOI 10.1016/0014-4827(70)90645-2; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GALLI SJ, 1990, LAB INVEST, V62, P5; GALLI SJ, 1993, AM J PATHOL, V142, P965; GAMBLE HJ, 1961, NATURE, V189, P766, DOI 10.1038/189766a0; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; HAMAGUCHI Y, 1987, J EXP MED, V165, P268, DOI 10.1084/jem.165.1.268; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; Hefti F, 1993, Adv Pharmacol, V24, P239, DOI 10.1016/S1054-3589(08)60939-4; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEUMANN R, 1987, J CELL BIOL, V104, P1623, DOI 10.1083/jcb.104.6.1623; HORIGOME K, 1993, J BIOL CHEM, V268, P14881; ISFORT R, 1988, J BIOL CHEM, V263, P19203; JOHNSON EM, 1993, ANNU REV NEUROSCI, V16, P31, DOI 10.1146/annurev.ne.16.030193.000335; JOHNSON EM, 1980, SCIENCE, V210, P916, DOI 10.1126/science.7192014; JOHNSON MD, 1989, ARCH PATHOL LAB MED, V113, P1263; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KEEGAN AD, 1991, EMBO J, V10, P3675, DOI 10.1002/j.1460-2075.1991.tb04935.x; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEVIMONTALCINI R, 1960, P NATL ACAD SCI USA, V46, P384, DOI 10.1073/pnas.46.3.384; LEVISCHAFFER F, 1986, P NATL ACAD SCI USA, V83, P6485, DOI 10.1073/pnas.83.17.6485; LEVISCHAFFER F, 1991, IMMUNOLOGY, V72, P174; LEVISCHAFFER F, 1985, J IMMUNOL, V135, P3454; LINDHOLM D, 1988, J BIOL CHEM, V263, P16348; MATSUDA H, 1991, J EXP MED, V174, P7, DOI 10.1084/jem.174.1.7; MATSUOKA I, 1991, J NEUROSCI, V11, P3165; MAZUREK N, 1986, FEBS LETT, V198, P315, DOI 10.1016/0014-5793(86)80428-8; Meininger C J, 1992, Semin Cancer Biol, V3, P73; MILBRANDT J, 1986, P NATL ACAD SCI USA, V83, P4789, DOI 10.1073/pnas.83.13.4789; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; NIELSEN EH, 1981, CELL TISSUE RES, V216, P635; OLSSON Y, 1971, ACTA NEUROL SCAND, V47, P357, DOI 10.1111/j.1600-0404.1971.tb07490.x; PEARCE FL, 1986, J PHYSIOL-LONDON, V372, P379, DOI 10.1113/jphysiol.1986.sp016014; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; PRYOR JC, 1992, NEUR ABSTR, V18, P950; RICCARDI V M, 1989, Neurofibromatosis, V2, P292; RICCARDI VM, 1987, ARCH DERMATOL, V123, P1011, DOI 10.1001/archderm.123.8.1011; RUOSS SJ, 1991, J CLIN INVEST, V88, P493, DOI 10.1172/JCI115330; Sambrook J, 1989, MOL CLONING LABORATO; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHWARTZ LB, 1993, MAST CELL HLTH DIS, P219; SEELDRAYERS PA, 1992, J NEUROIMMUNOL, V35, P239; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SLUTSKY B, 1987, EXP CELL RES, V168, P63, DOI 10.1016/0014-4827(87)90416-2; SNIDER WD, 1989, ANN NEUROL, V26, P489, DOI 10.1002/ana.410260402; SULLIVAN TJ, 1975, J IMMUNOL, V114, P1473; TAKAGI M, 1992, J IMMUNOL, V148, P3446; TAKAGI M, 1989, J EXP MED, V170, P233, DOI 10.1084/jem.170.1.233; TSAI M, 1991, P NATL ACAD SCI USA, V88, P6382, DOI 10.1073/pnas.88.14.6382; TSUJI K, 1990, BLOOD, V75, P421; VALENT P, 1991, Progress in Growth Factor Research, V3, P27, DOI 10.1016/0955-2235(91)90011-R; VIGE X, 1991, MOL PHARMACOL, V40, P186; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	72	134	137	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2695	2702						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300599				2022-12-27	WOS:A1994MV43200052
J	VERHEY, KJ; BIRNBAUM, MJ				VERHEY, KJ; BIRNBAUM, MJ			A LEU-LEU SEQUENCE IS ESSENTIAL FOR COOH-TERMINAL TARGETING SIGNAL OF GLUT4 GLUCOSE-TRANSPORTER IN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CYTOPLASMIC DOMAIN; INSULIN; PROTEIN; IDENTIFICATION; LOCALIZATION; ADIPOCYTES; ISOFORMS; RECEPTOR; SURFACE; GOLGI	In the insulin-responsive tissues, muscle and adipose, the GLUT4 glucose transporter isoform accounts for most of the increase in hexose flux in response to hormone. In these cell types, as well as in fibroblasts transfected with cDNAs encoding the transporters, GLUT1 and GLUT4 are sorted to different subcellular locations. In the latter, GLUT1 is found primarily at the cell surface whereas GLUT4 localizes to the interior of the cell in a perinuclear distribution. The construction and analysis of chimeras of these two transporter isoforms have allowed identification of the COOH-terminal 30 amino acids as a critical sorting signal for differential localization of the transporters. In this study, we show that 2 residues present in the GLUT4 COOH terminus, Leu-489 and Leu-490, are critical for the intracellular sequestration of this isoform in NIH3T3 cells.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School				Birnbaum, Morris/0000-0001-9972-8680	NIDDK NIH HHS [R01 DK39519] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039519] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLARD WJ, 1985, J BIOL CHEM, V260, P8668; ASANO T, 1992, J BIOL CHEM, V267, P19636; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; CZECH MP, 1993, J CELL BIOL, V123, P127, DOI 10.1083/jcb.123.1.127; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; HANEY PM, 1991, J CELL BIOL, V114, P689, DOI 10.1083/jcb.114.4.689; HOPKINS CR, 1992, TRENDS BIOCHEM SCI, V17, P27, DOI 10.1016/0968-0004(92)90423-7; HUDSON AW, 1993, J CELL BIOL, V122, P579, DOI 10.1083/jcb.122.3.579; HUDSON AW, 1992, J CELL BIOL, V116, P785, DOI 10.1083/jcb.116.3.785; HURTLEY SM, 1992, TRENDS BIOCHEM SCI, V17, P2, DOI 10.1016/0968-0004(92)90414-5; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LUZIO JP, 1993, TRENDS BIOCHEM SCI, V18, P395, DOI 10.1016/0968-0004(93)90097-7; MARSHALL B, 1993, DIABETES, V42, pA13; MORI S, 1991, J BIOL CHEM, V266, P21158; PIPER RC, 1992, J CELL BIOL, V117, P729, DOI 10.1083/jcb.117.4.729; PIPER RC, 1993, J CELL BIOL, V121, P1221, DOI 10.1083/jcb.121.6.1221; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; SHIN JY, 1991, J BIOL CHEM, V266, P10658; VAUX D, 1992, Trends in Cell Biology, V2, P189, DOI 10.1016/0962-8924(92)90232-C; VEGA MA, 1991, J BIOL CHEM, V266, P16269; VERHEY KJ, 1993, J CELL BIOL, V123, P137, DOI 10.1083/jcb.123.1.137; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	29	113	119	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2353	2356						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300557				2022-12-27	WOS:A1994MV43200002
J	MUELLER, SG; SCHRAW, WP; RICHMOND, A				MUELLER, SG; SCHRAW, WP; RICHMOND, A			MELANOMA GROWTH-STIMULATORY ACTIVITY ENHANCES THE PHOSPHORYLATION OF THE CLASS-II INTERLEUKIN-8 RECEPTOR IN NONHEMATOPOIETIC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING PEPTIDE-1 INTERLEUKIN-8; COLONY FORMATION INVITRO; HUMAN-NEUTROPHILS; INFLAMMATORY PROTEINS; PROGENITOR CELLS; PLASMA-MEMBRANES; LYMPHOCYTES-T; EXPRESSION; PROLIFERATION; MONOCYTES	The class II IL-8 receptor (IL-8R) binds both melanoma growth stimulatory activity (MGSA) and IL-8 with high affinity. Reverse transcriptase polymerase chain reaction demonstrates that the class II IL-8R mRNA, which has previously been detected only in cells of hematopoietic lineage, is also expressed in non-hematopoietic cell types shown to respond to MGSA or IL-8. To study the signaling mechanism by MGSA through the class II IL-8R in non-hematopoietic cells, this receptor was overexpressed in the 3ASubE human placental and the 293 human kidney cell lines. Membrane preparations of the class II IL-8R expressing 3ASubE transfectants exhibited a 2.3 +/- 0.2-fold increase in GTPgammaS-35 binding, which was sensitive to pertussis toxin, in response to MGSA treatment (0.2 muM). This MGSA response was not observed in cells transfected with the parental expression vector. In vivo phosphorylation studies demonstrated that the class II IL-8R was basally phosphorylated in the untreated transfectants, and MGSA (5 nM) treatment markedly enhanced the phosphorylation of this receptor. The MGSA-induced receptor phosphorylation was both time and concentration dependent and could be mimicked by treatment with the calcium ionophore A23187. Phosphoamino acid analysis indicated that the MGSA-induced receptor phosphorylation was on serine residue(s), suggesting that a serine kinase is activated in response to MGSA binding to the class II IL-8R in non-hematopoietic cells.	VANDERBILT UNIV, DEPT MED DERMATOL, NASHVILLE, TN 37232 USA; DEPT VET AFFAIRS MED CTR, NASHVILLE, TN 37232 USA	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	MUELLER, SG (corresponding author), VANDERBILT UNIV, DEPT CELL BIOL, NASHVILLE, TN 37232 USA.			RICHMOND, ANN/0000-0002-9580-900X	NCI NIH HHS [CA 34590] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R23CA034590, R01CA034590] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; BACON KB, 1990, BIOCHEM BIOPH RES CO, V169, P1099, DOI 10.1016/0006-291X(90)92008-N; BALENTIEN E, 1991, ONCOGENE, V6, P1115; BORDONI R, 1990, J CELL BIOCHEM, V44, P207, DOI 10.1002/jcb.240440403; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROXMEYER HE, 1990, BLOOD, V76, P1110; BROXMEYER HE, 1989, J EXP MED, V170, P1583, DOI 10.1084/jem.170.5.1583; CERRETTI DP, 1993, MOL IMMUNOL, V30, P359; CHENG QC, 1992, J IMMUNOL, V148, P451; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; DERYNCK R, 1990, BIOCHEMISTRY-US, V29, P10225, DOI 10.1021/bi00496a011; DJEU JY, 1990, J IMMUNOL, V144, P2205; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; GIERSCHIK P, 1991, EUR J BIOCHEM, V197, P725, DOI 10.1111/j.1432-1033.1991.tb15964.x; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HOON DSB, 1991, CANCER RES, V51, P2002; HORUK R, 1993, J BIOL CHEM, V268, P541; HOWE PH, 1989, BIOCHEM J, V261, P879, DOI 10.1042/bj2610879; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; KRUEGER G, 1990, J INVEST DERMATOL, V94, P545; KUPPER RW, 1992, BIOCHEM J, V282, P429, DOI 10.1042/bj2820429; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEE J, 1992, J BIOL CHEM, V267, P16283; LIU JH, 1992, J INFECT DIS, V166, P1089; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; RICHMOND A, 1986, J CELL PHYSIOL, V129, P375, DOI 10.1002/jcp.1041290316; ROLLINS BJ, 1991, MOL CELL BIOL, V11, P3125, DOI 10.1128/MCB.11.6.3125; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SAMANTA AK, 1990, J BIOL CHEM, V265, P183; Sambrook J, 1989, MOL CLONING LABORATO; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHRODER JM, 1990, J EXP MED, V171, P1091, DOI 10.1084/jem.171.4.1091; SIBLEY DR, 1984, J BIOL CHEM, V259, P9742; SPRENGER H, 1993, J IMMUNOL, V150, pA126; STRIETER RM, 1992, AM J PATHOL, V141, P1279; THELEN M, 1988, FASEB J, V2, P2702, DOI 10.1096/fasebj.2.11.2840318; TUSCHIL A, 1992, J INVEST DERMATOL, V99, P294, DOI 10.1111/1523-1747.ep12616634; UNEMORI EN, 1993, J BIOL CHEM, V268, P1338; WALZ A, 1991, J LEUKOCYTE BIOL, V50, P279, DOI 10.1002/jlb.50.3.279	47	61	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1973	1980						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294449				2022-12-27	WOS:A1994MR98800066
J	SWEENEY, HL; STRACESKI, AJ; LEINWAND, LA; TIKUNOV, BA; FAUST, L				SWEENEY, HL; STRACESKI, AJ; LEINWAND, LA; TIKUNOV, BA; FAUST, L			HETEROLOGOUS EXPRESSION OF A CARDIOMYOPATHIC MYOSIN THAT IS DEFECTIVE IN ITS ACTIN INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; HEAVY-CHAIN GENE; SKELETAL-MUSCLE; MOLECULAR-BASIS; MUTATIONS; MOTILITY; ASSAY	A point mutation in the heavy chain of cardiac myosin, resulting in replacement of an arginine (Arg) with glutamine (Gln), has been linked to hypertrophic cardiomyopathy in humans (Geisterfer-Lowrance, A. A. T., Kass, S., Tanigawa, G., Vosberg, H.-P., McKenna, W., Seidman, J. G., and Seidman, C. E. (1990) Cell 62, 999-1006). To determine the functional impact of this mutation, baculovirus-driven coexpression of myosin heavy and light chains has been developed. The Arg-403 --> Gln mutation resulted in cardiac myosin with normal ATPase activity in the absence of actin. However, in the presence of actin, ATPase activity was greatly reduced (V(max) decreased > 3.5-fold and K(app) increased >3-fold). In vitro motility was reduced nearly 5-fold by this single amino acid mutation. Thus, Arg-403 likely contributes to an important interaction at the actin interface of myosin. Replacement, of Arg-403 with Gln leads to decreased rate(s) of transition within the actin-myosin crossbridge cycle. In humans, this mutation will result in decreased power output per unit area of cardiac muscle, likely providing a stimulus for hypertrophy.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine	SWEENEY, HL (corresponding author), UNIV PENN,SCH MED,DEPT PHYSIOL,37TH ST & HAMILTON WALK,PHILADELPHIA,PA 19104, USA.		Sweeney, H Lee/F-1862-2010	LEINWAND, LESLIE/0000-0003-1470-4810				BOTTOMLEY RC, 1975, BIOCHEM J, V149, P365, DOI 10.1042/bj1490365; BRZESKA H, 1989, J BIOL CHEM, V264, P19340; CUDA G, 1993, J CLIN INVEST, V91, P2861, DOI 10.1172/JCI116530; EPSTEIN ND, 1992, CIRCULATION, V86, P345, DOI 10.1161/01.CIR.86.2.345; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; GRANDMONTLEBLANC A, 1977, CAN J BIOCHEM CELL B, V55, P949, DOI 10.1139/o77-142; HASEMANN CA, 1990, P NATL ACAD SCI USA, V87, P3942, DOI 10.1073/pnas.87.10.3942; HENKEL RD, 1988, ANAL BIOCHEM, V169, P312, DOI 10.1016/0003-2697(88)90290-4; HOH JFY, 1976, BIOCHEM J, V157, P87, DOI 10.1042/bj1570087; HOMSHER E, 1992, AM J PHYSIOL, V262, pC714, DOI 10.1152/ajpcell.1992.262.3.C714; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; MARGOSSIAN SS, 1985, J BIOL CHEM, V260, P3747; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MCNALLY EM, 1989, J MOL BIOL, V210, P665, DOI 10.1016/0022-2836(89)90141-1; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; UMEMOTO S, 1990, J BIOL CHEM, V265, P14864; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; WATKINS H, 1992, NEW ENGL J MED, V326, P1108, DOI 10.1056/NEJM199204233261703; WEEDS AG, 1971, J MOL BIOL, V61, P701, DOI 10.1016/0022-2836(71)90074-X	25	180	183	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1603	1605						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294404				2022-12-27	WOS:A1994MR98800010
J	AIRD, WC; PARVIN, JD; SHARP, PA; ROSENBERG, RD				AIRD, WC; PARVIN, JD; SHARP, PA; ROSENBERG, RD			THE INTERACTION OF GATA-BINDING PROTEINS AND BASAL TRANSCRIPTION FACTORS WITH GATA BOX-CONTAINING CORE PROMOTERS A MODEL OF TISSUE-SPECIFIC GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; DNA-BINDING; TATA BOX; ACCURATE TRANSCRIPTION; INITIATION; INVITRO; REPRESSOR; ELEMENTS; YEAST; ACTIVATION	The core promoters of the rat platelet factor 4 (PF4), mouse erythropoietin and chicken beta globin genes contain a GATA motif in place of the consensus TATAAA site. In the case of the PF4 gene, this site has been shown to play a critical role in restricting transcription to the megakaryocyte lineage. In order to understand the mechanism of tissue specificity, we investigated the function of the GATA box-containing promoters in vitro. Our studies show that the TATA-binding protein of TFIID is required for initiation of transcription from the GATA box-containing promoters. GATA-1 interacts with the core promoter GATA motif and inhibits generation of preinitiation complexes. The functional significance of the inhibition of preinitiation complexes is supported by in vitro transcription assays in which transcription from the PF4 and erythropoietin core promoters is suppressed by GATA-1. We also demonstrate that GATA-2 inhibits initiation of transcription from the PF4 core promoter. Based on these results, we propose a model in which repression of PF4 expression in nonmegakaryocytes is mediated, in part, by competition between GATA-binding proteins and basal factors for the core promoter.	MIT, DEPT BIOL, E25-229, 77 MASSACHUSETTS AVE, CAMBRIDGE, MA 02139 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA	Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center			Parvin, Jeffrey D/C-8955-2009		NATIONAL CANCER INSTITUTE [P30CA014051, P01CA042063] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL039753] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-14051, P01-CA42063] Funding Source: Medline; NHLBI NIH HHS [HL39753] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARTHEW RW, 1988, J BIOL CHEM, V263, P17128; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; DOSTATNI N, 1991, GENE DEV, V5, P1657, DOI 10.1101/gad.5.9.1657; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FONG TC, 1992, GENE DEV, V6, P521, DOI 10.1101/gad.6.4.521; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; KAUFMAN PD, 1991, P NATL ACAD SCI USA, V88, P2613, DOI 10.1073/pnas.88.7.2613; KIM CG, 1990, MOL CELL BIOL, V10, P5958, DOI 10.1128/MCB.10.11.5958; LEE ME, 1990, J BIOL CHEM, V265, P10446; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MARTIN DIK, 1989, NATURE, V338, P435, DOI 10.1038/338435a0; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P2289, DOI 10.1073/pnas.87.6.2289; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; PETERSON MG, 1991, NATURE, V354, P369; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAHUEL C, 1992, EMBO J, V11, P4095, DOI 10.1002/j.1460-2075.1992.tb05502.x; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; RAVID K, 1991, P NATL ACAD SCI USA, V88, P1521, DOI 10.1073/pnas.88.4.1521; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P5814, DOI 10.1073/pnas.89.13.5814; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650	36	77	77	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					883	889						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288642				2022-12-27	WOS:A1994MR22000021
J	CARROLL, MP; MAY, WS				CARROLL, MP; MAY, WS			PROTEIN KINASE-C-MEDIATED SERINE PHOSPHORYLATION DIRECTLY ACTIVATES RAF-1 IN MURINE HEMATOPOIETIC-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; TYROSINE PHOSPHORYLATION; MAP KINASE; INTERLEUKIN-2 RECEPTOR; GROWTH-FACTORS; ERYTHROPOIETIN; EXPRESSION; FAMILY; IDENTIFICATION; PROTOONCOGENE	We have previously found that Raf-1, which is activated by hematopoietic growth factors in association with phosphorylation, is required for hematopoietic cell proliferation. Recently, 12-O-tetradecanoylphorbol 13-acetate has been found to mediate Raf-l phosphorylation, suggesting that protein kinase C (PKC) may be involved in the Raf-l activation mechanism(s). Since PKC can be activated by hematopoietic growth factors, it was investigated as a potential ''Raf-l kinase-kinase.'' Results demonstrate that bryostatin 1, a pharmacologic activator of PKC, induces activation of Raf-l in FDC-P1 cells. PKC inhibitors H7 and staurosporine block both bryostatin 1- and interleukin-3-mediated Raf-l phosphorylation and FDC-P1 cell proliferation. Additionally, an antisense c-raf oligodeoxyribonucleotide specifically inhibits bryostatin 1-mediated proliferation, indicating a necessary role for Raf-l in PKC signaling. Purified PKC can phosphorylate Raf-l serine residues to high stoichiometry in vitro. Comparative phosphopeptide maps localize two PKC phosphorylation sites to Raf-l phosphopeptides isolated from hematopoietic growth factor- or bryostatin 1-stimulated cells. The sites of PKC-mediated Raf-l phosphorylation are deduced to be Ser497 and Ser619. Furthermore, PKC-mediated serine phosphorylation is sufficient to activate the enzymatic function of Raf-l in vitro. These findings demonstrate that activated PKC can promote hematopoietic cell growth by regulating the enzymatic activity of Raf-1 through direct serine phosphorylation.	JOHNS HOPKINS ONCOL CTR, 424 N BOND ST, BALTIMORE, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine					NCI NIH HHS [CA 01679, CA 44649, CA 47993] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA001679, R01CA044649, R01CA047993] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS PD, 1992, J BIOL CHEM, V267, P13135; ADUNYAH SE, 1991, J BIOL CHEM, V266, P5670; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DURONIO V, 1989, BIOCHEM BIOPH RES CO, V164, P804, DOI 10.1016/0006-291X(89)91530-1; FARRAR WL, 1989, J BIOL CHEM, V264, P12562; FIELDS AP, 1989, J BIOL CHEM, V264, P21896; GOMEZCAMBRONERO J, 1989, P NATL ACAD SCI USA, V86, P3569, DOI 10.1073/pnas.86.10.3569; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOGANS BB, 1988, J CELL PHYSIOL, V137, P346, DOI 10.1002/jcp.1041370219; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; ISFORT RJ, 1988, P NATL ACAD SCI USA, V85, P7982, DOI 10.1073/pnas.85.21.7982; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; MAY WS, 1993, IN PRESS C INSERM, V229; METCALF D, 1991, SCIENCE, V254, P529, DOI 10.1126/science.1948028; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; OKUDA K, 1992, BLOOD, V79, P2880; ORR JW, 1992, J BIOL CHEM, V267, P15263; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; QUELLE FW, 1991, J BIOL CHEM, V266, P609; SETH A, 1991, J BIOL CHEM, V266, P23521; SHERR CJ, 1990, BLOOD, V75, P1; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; SOZERI O, 1992, ONCOGENE, V7, P2259; SPANGLER R, 1991, J BIOL CHEM, V266, P681; SUMMERS MD, 1988, MANUAL METHODS BACUL, P10; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; ZOLLER MJ, 1979, J BIOL CHEM, V254, P8363	47	205	209	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1249	1256						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288587				2022-12-27	WOS:A1994MR22000076
J	MIZUNO, K; INOUE, H; HAGIYA, M; SHIMIZU, S; NOSE, T; SHIMOHIGASHI, Y; NAKAMURA, T				MIZUNO, K; INOUE, H; HAGIYA, M; SHIMIZU, S; NOSE, T; SHIMOHIGASHI, Y; NAKAMURA, T			HAIRPIN LOOP AND 2ND KRINGLE DOMAIN ARE ESSENTIAL SITES FOR HEPARIN-BINDING AND BIOLOGICAL-ACTIVITY OF HEPATOCYTE GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; C-MET PROTOONCOGENE; RAT PLATELETS; MOLECULAR-CLONING; DISULFIDE BONDS; SCATTER FACTOR; APPLE DOMAINS; EXPRESSION; IDENTIFICATION; GENE	Hepatocyte growth factor (HGF) has a strong affinity for heparin. About one fourth of HGF secreted from MRC-5 human embryonic lung fibroblast cells was found to be associated with heparin and heparan sulfate proteoglycan on the cell surface and extracellular matrix. To identify heparin-binding sites within the HGF molecule, we constructed variously deleted mutant HGFs and examined their binding ability to an immobilized heparin column. Native HGF and mutant HGFs, including d-K1 (deletion of the first kringle domain), d-K3 (deletion of the third kringle domain), d-K4 (deletion of the fourth kringle domain), d-beta (deletion of beta-chain), and HK1K2 (consisting of the N-terminal hairpin loop and the first two kringle domains), tightly bound to a heparin column, but d-H (deletion of the N-terminal hairpin loop) and d-K2 (deletion of the second kringle domain) markedly decreased binding ability to the column. These observations suggest that the N-terminal hairpin loop and the second kringle domain are essential for the heparin-binding of HGF. The finding that HK1K2 competed the binding of I-125-HGF to immobilized heparin provided additional evidence that the N-terminal half of HGF alpha-chain is the principal heparin-binding site. The hairpin loop in HGF possesses a cluster of basic amino acid residues and a highly positive net charge, when compared with hairpin loop structures in the other proteins, plasminogen and HGF-like protein. The second kringle domain in HGF has the basic amino acid cluster in the central region. Thus, it is likely that the basic clusters in these domains cooperatively contribute to the binding of HGF to the anionic heparin or heparan sulfate molecule.	TOYOBO CO LTD,PHARMACEUT RES CTR,OTSU 52002,JAPAN; OSAKA UNIV,SCH MED,BIOMED RES CTR,SUITA,OSAKA 565,JAPAN; KYUSHU UNIV,FAC SCI,DEPT CHEM,FUKUOKA 812,JAPAN	Toyobo Co., Ltd; Osaka University; Kyushu University	MIZUNO, K (corresponding author), KYUSHU UNIV,FAC SCI,DEPT BIOL,FUKUOKA 812,JAPAN.		Mizuno, Kensaku/G-8631-2015	Nose, Takeru/0000-0001-9771-7267				BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; DEGEN SJF, 1991, BIOCHEMISTRY-US, V30, P9781, DOI 10.1021/bi00104a030; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; HIGUCHI O, 1991, BIOCHEM BIOPH RES CO, V176, P599, DOI 10.1016/S0006-291X(05)80226-8; HIGUCHI O, 1992, FEBS LETT, V301, P282, DOI 10.1016/0014-5793(92)80257-H; ISHIKI Y, 1992, HEPATOLOGY, V16, P1227, DOI 10.1016/0270-9139(92)90019-6; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LIU KX, 1992, AM J PHYSIOL, V263, pG642, DOI 10.1152/ajpgi.1992.263.5.G642; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; LOTTENBERG R, 1981, METHOD ENZYMOL, V80, P341; MASUMOTO A, 1991, BIOCHEM BIOPH RES CO, V174, P90, DOI 10.1016/0006-291X(91)90489-T; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V181, P691, DOI 10.1016/0006-291X(91)91246-9; MATSUMOTO K, 1992, P NATL ACAD SCI USA, V89, P3800, DOI 10.1073/pnas.89.9.3800; Matsumoto K, 1993, HEPATOCYTE GROWTH FA, P225; MATSUMOTO K, 1992, Critical Reviews in Oncogenesis, V3, P27; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2056, DOI 10.1021/bi00222a008; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2050, DOI 10.1021/bi00222a007; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MIZUNO K, 1992, BIOCHEM BIOPH RES CO, V189, P1631, DOI 10.1016/0006-291X(92)90264-L; MIZUNO K, 1993, HEPATOCYTE GROWTH FA, P1; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NAKAMURA T, 1991, Progress in Growth Factor Research, V3, P67, DOI 10.1016/0955-2235(91)90014-U; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; OKIGAKI M, 1992, BIOCHEMISTRY-US, V31, P9555, DOI 10.1021/bi00155a007; PETERSEN TE, 1990, J BIOL CHEM, V265, P6104; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUSSELL WE, 1984, J CELL PHYSIOL, V119, P183, DOI 10.1002/jcp.1041190207; SEKI T, 1991, GENE, V102, P213; SEKI T, 1990, BIOCHEM BIOPH RES CO, V172, P321, DOI 10.1016/S0006-291X(05)80212-8; SHIMAMOTO A, 1993, IN PRESS FEBS LETT; STEPHENS RW, 1992, BIOCHEMISTRY-US, V31, P7572, DOI 10.1021/bi00148a019; TAJIMA H, 1992, EXP CELL RES, V202, P423, DOI 10.1016/0014-4827(92)90095-P; TAJIMA H, 1992, J BIOCHEM-TOKYO, V111, P401, DOI 10.1093/oxfordjournals.jbchem.a123769; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	42	114	124	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1131	1136						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288571				2022-12-27	WOS:A1994MR22000057
J	RYABOVA, L; VOLIANIK, E; KURNASOV, O; SPIRIN, A; WU, Y; KRAMER, FR				RYABOVA, L; VOLIANIK, E; KURNASOV, O; SPIRIN, A; WU, Y; KRAMER, FR			COUPLED REPLICATION-TRANSLATION OF AMPLIFIABLE MESSENGER-RNA - A CELL-FREE PROTEIN-SYNTHESIS SYSTEM THAT MIMICS VIRAL-INFECTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							Q-BETA-REPLICASE; NUCLEOTIDE-SEQUENCE; RECOMBINANT-RNA; MOLECULE; EVOLUTION	Amplifiable messenger RNAs (Wu, Y., Zhang, D. Y., and Kramer, F. R. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 11769-11773) were used as templates in coupled replication-translation reactions. These amplifiable mRNAs contained a preselected messenger sequence embedded within the sequence of MDV-1 RNA, which is a small, naturally occurring template for Qbeta replicase. When these recombinant mRNAs were incubated in vitro in reactions that contained both an Escherichia coli cell-free translation system and Qbeta replicase, the encoded protein was synthesized more efficiently than in corresponding reactions that did not contain Qbeta replicase. Moreover, when coupled replication-translation reactions were carried out in a continuous-flow format (Spirin, A. S., Baranov, V. I., Ryabova, L. A., Ovodov, S. Yu., and Alakhov, Yu. B. (1988) Science 242, 1162-1164), the synthesis of biologically active protein continued for a prolonged period. The results suggest that the mechanism of replication and translation in coupled reactions is similar to the mechanism by which Qbeta phage genomic RNA is simultaneously replicated and translated in Qbeta-infected E. coli: protein synthesis occurs on nascent RNA strands; many more sense strands are synthesized than antisense strands; and the integrity of the messenger sequence is preserved because a relatively small number of antisense strands serve as master templates for the synthesis of new messenger strands.	RUSSIAN ACAD SCI,INST PROT RES,142292 PUSHCHINO,RUSSIA; PUBL HLTH RES INST CITY NEW YORK INC,DEPT MOLEC GENET,NEW YORK,NY 10016	Russian Academy of Sciences				Ryabova, Lyubov/0000-0003-1989-203X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043521] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43521] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANERJEE AK, 1969, J MOL BIOL, V45, P181, DOI 10.1016/0022-2836(69)90098-9; BIEBRICHER CK, 1987, COLD SPRING HARB SYM, V52, P299, DOI 10.1101/SQB.1987.052.01.035; BILLETER MA, 1966, J BIOL CHEM, V241, P4750; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CHEN HZ, 1983, METHOD ENZYMOL, V101, P674; CHETVERIN AB, 1991, J MOL BIOL, V222, P3, DOI 10.1016/0022-2836(91)90729-P; DOBKIN C, 1979, BIOCHEMISTRY-US, V18, P2038, DOI 10.1021/bi00577a030; DOMINGO E, 1978, CELL, V13, P735, DOI 10.1016/0092-8674(78)90223-4; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; HARUNA I, 1965, P NATL ACAD SCI USA, V54, P1189, DOI 10.1073/pnas.54.4.1189; HARUNA I, 1965, SCIENCE, V150, P884, DOI 10.1126/science.150.3698.884; HODGES WM, 1987, ANAL BIOCHEM, V160, P65, DOI 10.1016/0003-2697(87)90614-2; HOTHAMIGLEWSKI B, 1968, NATURE, V219, P700, DOI 10.1038/219700a0; KACIAN DL, 1972, P NATL ACAD SCI USA, V69, P3038, DOI 10.1073/pnas.69.10.3038; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIZARDI PM, 1988, BIO-TECHNOL, V6, P1197, DOI 10.1038/nbt1088-1197; MIELE EA, 1983, J MOL BIOL, V171, P281, DOI 10.1016/0022-2836(83)90094-3; MILLS DR, 1975, P NATL ACAD SCI USA, V72, P4252, DOI 10.1073/pnas.72.11.4252; MILLS DR, 1973, SCIENCE, V180, P916, DOI 10.1126/science.180.4089.916; MOROZOV IY, 1993, P NATL ACAD SCI USA, V90, P9325, DOI 10.1073/pnas.90.20.9325; MUNISHKIN AV, 1991, J MOL BIOL, V221, P463, DOI 10.1016/0022-2836(91)80067-5; MUNISHKIN AV, 1988, NATURE, V333, P473, DOI 10.1038/333473a0; NISHIHARA T, 1983, J BIOCHEM, V93, P669, DOI 10.1093/jb/93.3.669; PRIANO C, 1987, COLD SPRING HARB SYM, V52, P321, DOI 10.1101/SQB.1987.052.01.037; SCHAFFNER W, 1977, J MOL BIOL, V117, P877, DOI 10.1016/S0022-2836(77)80004-1; SPIRIN AS, 1988, SCIENCE, V242, P1162, DOI 10.1126/science.3055301; SPIRIN AS, 1991, FRONTIERS BIOPROCESS, V2, P31; WU Y, 1992, P NATL ACAD SCI USA, V89, P11769, DOI 10.1073/pnas.89.24.11769	28	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1501	1505						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288616				2022-12-27	WOS:A1994MR22000110
J	BLUML, K; MUTSCHLER, E; WESS, J				BLUML, K; MUTSCHLER, E; WESS, J			IDENTIFICATION OF AN INTRACELLULAR TYROSINE RESIDUE CRITICAL FOR MUSCARINIC RECEPTOR-MEDIATED STIMULATION OF PHOSPHATIDYLINOSITOL HYDROLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; 3RD CYTOPLASMIC LOOP; ACETYLCHOLINE-RECEPTOR; LIGAND-BINDING; DOMAINS; GS; SELECTIVITY; ACTIVATION; SUBTYPES; DELINEATION	Several lines of evidence suggest that the N-terminal portion of the third cytoplasmic loop (i3) of muscarinic and other G protein-coupled receptors is of pivotal importance for G protein recognition and activation. The present study was designed to identify specific amino acids within this domain required for muscarinic receptor-induced activation of G proteins mediating stimulation of phosphatidylinositol (PI) hydrolysis. Among the five mammalian muscarinic receptors (m1-m5), only the m1, m3, and m5 receptors are efficiently coupled to this second messenger pathway. Initially, we created a series of rat m3 receptor mutants in which short segments in the N terminus of the i3 loop were replaced with the corresponding m2 receptor sequences. The effect of these substitutions on m3 receptor-mediated stimulation of PI hydrolysis was studied in transiently transfected COS-7 cells. We found that a stretch of 4 amino acids (Arg252-Ile253-Tyr254-Lys255) located at the beginning of the i3 domain of the m3 muscarinic receptor is critically involved in receptor-mediated stimulation of PI hydrolysis. Further mutational analysis of this 4-amino acid segment by single amino acid substitutions demonstrated that only Tyr254 is essential for efficient activation of the PI pathway. This tyrosine residue is conserved among all PI-coupled muscarinic receptors as well as in many other biogenic amine and glycoprotein hormone receptors, suggesting that it may also play an important functional role in other G protein-coupled receptors.	NIDDKD,BIOORGAN CHEM LAB,BLDG 8A,RM B1A-09,BETHESDA,MD 20892; UNIV FRANKFURT,W-6000 FRANKFURT,GERMANY	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Goethe University Frankfurt								ARDEN JR, 1992, BIOCHEM BIOPH RES CO, V188, P1111, DOI 10.1016/0006-291X(92)91346-R; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEUNG AH, 1992, MOL PHARMACOL, V41, P1061; CHEUNG AH, 1991, FEBS LETT, V279, P277, DOI 10.1016/0014-5793(91)80167-2; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DORJE F, 1991, J PHARMACOL EXP THER, V256, P727; Higuchi R., 1989, PCR TECHNOLOGY, P61; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SHAPIRO RA, 1989, BIOCHEMISTRY-US, V28, P8946, DOI 10.1021/bi00448a039; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRADER CD, 1987, J BIOL CHEM, V262, P16439; WESS J, 1989, FEBS LETT, V258, P133, DOI 10.1016/0014-5793(89)81633-3; WESS J, 1990, MOL PHARMACOL, V38, P517; WESS J, 1990, MOL PHARMACOL, V38, P872; WESS J, 1993, TRENDS PHARMACOL SCI, V14, P308, DOI 10.1016/0165-6147(93)90049-P; WONG SKF, 1990, J BIOL CHEM, V265, P6219	27	56	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					402	405						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276826				2022-12-27	WOS:A1994MR21900068
J	COURTY, Y; ROSINSKICHUPIN, I; ROUGEON, F				COURTY, Y; ROSINSKICHUPIN, I; ROUGEON, F			A NEW PROLINE-RICH PROTEIN-PRECURSOR EXPRESSED IN THE SALIVARY-GLANDS OF THE RAT IS ENCODED BY A GENE HOMOLOGOUS TO THE GENE CODING FOR THE PROHORMONE-LIKE PROTEIN SMR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBMANDIBULAR-GLAND; MULTIGENE FAMILIES; SUBMAXILLARY-GLAND; STREPTOCOCCUS-GORDONII; SEQUENCES; GLYCOPROTEINS; ORGANIZATION; PEPTIDES; ADHESION	A gene encoding a prohormone-like protein, (SMR1) has previously been characterized and shown to be expressed in the rat submandibular glands under androgenic control (Rosinski-Chupin, I., Tronik, D., and Rougeon, F. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 8553-8557). This gene, now named VCS-alpha1, belongs to a multigene family (Rosinski-Chupin, I., and Rougeon, F. (1990) DNA Cell Biol. 9, 553-559). We now describe the structure and the expression of a second member (VCS-beta1) of this family. The two genes differ principally in the protein-coding region, therefore we have named these related genes VCS (variable coding sequence). Genomic clones containing the VCS-beta1 gene were obtained by screening a lambdaEMBL3 library with a probe corresponding to the VCS-alpha1 cDNA. The nucleotide sequence of VCS-beta1 predicted a structure containing three exons. This structure, confirmed by sequencing a BCS-beta1 cDNA obtained by reverse polymerase chain reaction, is identical to the organization of the VCS-alpha1 gene. Comparison of the VCS-beta1 and VCS-alpha1 genomic sequences indicates regions of hemology which are unevenly distributed, suggesting a differential evolution of some areas (particularly the third exon) of the VCS genes. The VCS-beta1 cDNA codes for a proline-rich protein precursor named PR-Vbeta1 (148 amino acids, 39.2% proline, 10.8% glycine) and characterized by a secretory signal-peptide and three repeats of a unit rich in proline residues surrounded by two clusters of potential endoprotease cleavage sites. mRNA coding for PR-Vbeta1 was detected in the submandibular-sublingual gland complex of male and female rats. PR-Vbeta1 is homologous to the proline-rich peptide B isolated from human saliva (Isemura, S., Saitoh, E., and Sanada, K. (1979) J. Biochem. (Tokyo) 86, 79-86) and to the submandibular proline-rich protein precursor MSG1 of the mouse (D. Tronik-Le Roux, M. Senorale-Pose, and F. Rougeon, manuscript in preparation). Our observations provide evidence that in addition to the known proline-rich protein genes, there is, in rodent and probably human genomes, another class of genes coding for salivary proline-rich proteins. The high conservation of various sites for bacterial collagenases localized in the repeat region of PR-Vbeta1, MSG1, and PRP-B suggest a protective function of these proteins in the oral cavity.	INST PASTEUR, DEPT IMMUNOL,CNRS,UNITE GENET & BIOCHIM DEV, URA 361,25 RUE DR ROUX, F-75724 PARIS 15, FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris				Courty, Yves/0000-0003-3694-8517				ANN DK, 1987, J BIOL CHEM, V262, P3958; BARKA T, 1980, J HISTOCHEM CYTOCHEM, V28, P836, DOI 10.1177/28.8.7003006; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BENNICK A, 1982, MOL CELL BIOCHEM, V45, P83; BENNICK A, 1983, BIOCHEM J, V213, P11, DOI 10.1042/bj2130011; BOULIKAS T, 1992, J MOL EVOL, V35, P156, DOI 10.1007/BF00183227; CARLSON DM, 1988, BIOCHIMIE, V70, P1689, DOI 10.1016/0300-9084(88)90304-5; CARLSON DM, 1991, PROG NUCLEIC ACID RE, V41, P1; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLEMENTS S, 1985, J BIOL CHEM, V260, P3471; COOPER LF, 1991, J BIOL CHEM, V266, P3532; DICKINSON DP, 1988, MOL BIOL EVOL, V6, P80; DURET L, 1993, NUCLEIC ACIDS RES, V21, P2315, DOI 10.1093/nar/21.10.2315; FICKETT JW, 1982, NUCLEIC ACIDS RES, V10, P5303, DOI 10.1093/nar/10.17.5303; GIBBONS RJ, 1991, INFECT IMMUN, V59, P2948, DOI 10.1128/IAI.59.9.2948-2954.1991; GILLECECASTRO BL, 1991, J BIOL CHEM, V266, P17358; HEINRICH G, 1987, J BIOL CHEM, V262, P5262; HOLT S C, 1991, Critical Reviews in Oral Biology and Medicine, V2, P177; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; ISEMURA S, 1979, J BIOCHEM-TOKYO, V86, P79; KAUFFMAN DL, 1991, BIOCHEMISTRY-US, V30, P3351, DOI 10.1021/bi00228a001; KEIL B, 1992, SPECIFICITY PROTEOLY, P193; KIM HS, 1993, MAMM GENOME, V4, P3, DOI 10.1007/BF00364656; KOZAK M, 1992, CRIT REV BIOCHEM MOL, V27, P385, DOI 10.3109/10409239209082567; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; LYONS KM, 1988, GENETICS, V120, P267; LYONS KM, 1988, GENETICS, V120, P255; MAEDA N, 1985, J BIOL CHEM, V260, P1123; MAYRAND D, 1985, CAN J MICROBIOL, V31, P134, DOI 10.1139/m85-026; MEHANSHO H, 1983, P NATL ACAD SCI-BIOL, V80, P3948, DOI 10.1073/pnas.80.13.3948; MIRELS L, 1987, J BIOL CHEM, V262, P7289; MORI M, 1992, ACTA HISTOCHEM CYTOC, V25, P325, DOI 10.1267/ahc.25.325; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; OPPENHEIM FG, 1988, J BIOL CHEM, V263, P7472; PANTHIER JJ, 1983, EMBO J, V2, P675, DOI 10.1002/j.1460-2075.1983.tb01483.x; PUGSLEY AP, 1989, PROTEIN TARGETING, P45; ROSINSKICHUPIN I, 1988, P NATL ACAD SCI USA, V85, P8553, DOI 10.1073/pnas.85.22.8553; ROSINSKICHUPIN I, 1990, J BIOL CHEM, V265, P10709; ROSINSKICHUPIN I, 1990, DNA CELL BIOL, V9, P553, DOI 10.1089/dna.1990.9.553; STINSON MW, 1992, INFECT IMMUN, V60, P2598, DOI 10.1128/IAI.60.7.2598-2604.1992; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; ZIEMER MA, 1984, J BIOL CHEM, V259, P475	42	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					520	527						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276845				2022-12-27	WOS:A1994MR21900084
J	GALLAGHER, MJ; BLUMENTHAL, KM				GALLAGHER, MJ; BLUMENTHAL, KM			IMPORTANCE OF THE UNIQUE CATIONIC RESIDUES ARGININE-12 AND LYSINE-49 IN THE ACTIVITY OF THE CARDIOTONIC POLYPEPTIDE ANTHOPLEURIN-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; XANTHOGRAMMICA HEART STIMULANT; POTENTIAL NA+ IONOPHORE; SEA-ANEMONE TOXIN; H-1-NMR ASSIGNMENTS; SECONDARY STRUCTURE; SODIUM-CHANNEL; PHARMACOLOGICAL PROPERTIES; STICHODACTYLA-HELIANTHUS; SCORPION TOXIN	Sea anemone toxins are potentially important tools for understanding the pharmacology of voltage-sensitive sodium channels. We have previously described a bacterial expression system capable of producing large amounts of one such toxin, anthopleurin B (ApB), which delays channel repolarization (Gallagher, M. J., and Blumenthal K. M. (1992) J. Biol. Chem. 267,13958-13963). It has been suggested that cationic residues are a major determinant of anemone toxin binding. In this paper, we describe characterization of three mutants at each of two unique cationic sites of ApB, Arg-12 and Lys-49. The activities of all mutants on cardiac and neuronal sodium channels have been compared with that of wild-type ApB. Mutation of Lys-49 has relatively minor effects on toxicity, whereas the mutant R12A, but not R12S or R12K, is severely impaired. These results indicate that cationic residues per se are not absolutely required at either position, but that polar side chains at position 12 contribute significantly to binding affinity. Furthermore, Arg-12 appears to be involved in the toxin's ability to discriminate between neuronal and cardiac sodium channels.	UNIV CINCINNATI,DEPT MICROBIOL,CINCINNATI,OH 45267; UNIV CINCINNATI,DEPT BIOCHEM,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	GALLAGHER, MJ (corresponding author), UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET,CINCINNATI,OH 45267, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041543] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-41543] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALSEN C, 1983, FED PROC, V42, P101; BERGMAN C, 1976, BIOCHIM BIOPHYS ACTA, V455, P173, DOI 10.1016/0005-2736(76)90162-0; BLAIR RW, 1978, J PHARMACOL EXP THER, V207, P271; CATTERALL WA, 1976, J BIOL CHEM, V251, P5528; CATTERALL WA, 1981, MOL PHARMACOL, V20, P533; CATTERALL WA, 1978, J BIOL CHEM, V253, P7393; CATTERALL WA, 1977, J BIOL CHEM, V252, P8660; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; Cleland W W, 1979, Methods Enzymol, V63, P103; DONAHUE LM, 1991, DEV BIOL, V147, P415, DOI 10.1016/0012-1606(91)90299-I; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FOGH RH, 1989, BIOCHEMISTRY-US, V28, P1826, DOI 10.1021/bi00430a060; FRELIN C, 1984, MOL PHARMACOL, V26, P70; GALLAGHER MJ, 1992, J BIOL CHEM, V267, P13958; GOULD AR, 1991, EUR J BIOCHEM, V206, P641; GROSS GJ, 1985, EUR J PHARMACOL, V110, P271, DOI 10.1016/0014-2999(85)90223-7; HOWELL ML, 1989, J BIOL CHEM, V264, P15268; KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8; KEM WR, 1989, BIOCHEMISTRY-US, V28, P3483, DOI 10.1021/bi00434a050; KODAMA I, 1981, BRIT J PHARMACOL, V72, P239; MABBUTT BC, 1990, EUR J BIOCHEM, V187, P555, DOI 10.1111/j.1432-1033.1990.tb15337.x; Maniatis T., 1982, MOL CLONING; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; NELSON PG, 1973, NATURE-NEW BIOL, V246, P124; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; NORTON RS, 1991, TOXICON, V29, P1051, DOI 10.1016/0041-0101(91)90205-6; NORTON TR, 1976, J PHARM SCI, V65, P1368, DOI 10.1002/jps.2600650927; NORTON TR, 1981, FED PROC, V40, P21; REIMER NS, 1985, J BIOL CHEM, V260, P8690; RENAUD JF, 1986, EUR J PHARMACOL, V120, P161, DOI 10.1016/0014-2999(86)90536-4; ROGART RB, 1989, P NATL ACAD SCI USA, V73, P4055; ROMEY G, 1976, P NATL ACAD SCI USA, V73, P4055, DOI 10.1073/pnas.73.11.4055; SCHWEITZ H, 1981, BIOCHEMISTRY-US, V20, P5245, DOI 10.1021/bi00521a023; SHIBATA S, 1978, J PHARMACOL EXP THER, V205, P683; TANAKA M, 1977, BIOCHEMISTRY-US, V16, P204, DOI 10.1021/bi00621a007; WIDMER H, 1988, EUR J BIOCHEM, V171, P177, DOI 10.1111/j.1432-1033.1988.tb13774.x; ZENG D, 1993, IN PRESS 1993 SOC NE	37	42	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					254	259						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276803				2022-12-27	WOS:A1994MR21900046
J	MAUVIEL, A; LAPIERE, JC; HALCIN, C; EVANS, CH; UITTO, J				MAUVIEL, A; LAPIERE, JC; HALCIN, C; EVANS, CH; UITTO, J			DIFFERENTIAL CYTOKINE REGULATION OF TYPE-I AND TYPE-VII COLLAGEN GENE-EXPRESSION IN CULTURED HUMAN DERMAL FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; NECROSIS-FACTOR-ALPHA; MESSENGER-RNA LEVELS; HUMAN SYNOVIAL-CELLS; EPIDERMOLYSIS-BULLOSA; TRANSCRIPTIONAL ACTIVATION; EPIDERMAL-KERATINOCYTES; STIMULATES COLLAGENASE; LEUKOREGULIN; SKIN	Type VII collagen is the major component of anchoring fibrils in the cutaneous basement membrane zone. In this study, we have examined the effects of various cytokines on the expression of types I and VII collagen genes in dermal fibroblasts in culture. The pro-inflammatory cytokines, interleukin-1alpha (IL-1alpha), interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), and leukoregulin (LR) strongly elevated (approximately 5-9-fold) type VII collagen mRNA levels, as measured by Northern blot hybridizations. These effects were also observed at the protein level by indirect immunofluorescence using a monoclonal antibody specific for type VII collagen. By contrast, IL-1beta had only a slight stimulatory effect (approximately 2-fold) on type I collagen gene expression, while TNF-alpha and LR markedly reduced type I collagen mRNA steady-state levels. Interestingly, IL-1, TNF-alpha and LR had additive effects with transforming growth factor-beta (TGF-beta) on type VII collagen gene expression, whereas they counteracted the up-regulatory effect of TGF-beta on type I collagen gene expression. Thus, our data indicate that the modulation of type I and type VII collagen gene expression by cytokines involves different regulatory pathways.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL,DEPT DERMATOL,233 S 10TH ST, RM 450, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, DEPT BIOCHEM & MOLEC BIOL, PHILADELPHIA, PA 19107 USA; NCI, TUMOR BIOL SECT, BIOL LAB, BETHESDA, MD 20892 USA	Jefferson University; Jefferson University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			MAUVIEL, Alain/F-6251-2013	Mauviel, Alain/0000-0002-0438-2793	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007561, P01AR038923] Funding Source: NIH RePORTER; NIAMS NIH HHS [P01-AR38923, T32-AR07561] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRENNER D, 1989, NATURE, V348, P661; BURGESON RE, 1990, ANN NY ACAD SCI, V580, P32, DOI 10.1111/j.1749-6632.1990.tb17915.x; CHIRGWIN J, 1979, BIOCHEMISTRY-US, V18, P5293; CHU ML, 1985, J BIOL CHEM, V260, P2315; CONCA W, 1989, J CLIN INVEST, V83, P1753, DOI 10.1172/JCI114077; DAYER JM, 1985, J EXP MED, V162, P2163, DOI 10.1084/jem.162.6.2163; DAYER JM, 1986, J CLIN INVEST, V77, P645, DOI 10.1172/JCI112350; DAYER JM, 1976, P NATL ACAD SCI USA, V73, P945, DOI 10.1073/pnas.73.3.945; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; EVANS CH, 1989, ANAL BIOCHEM, V177, P358, DOI 10.1016/0003-2697(89)90066-3; FINE JD, 1991, J AM ACAD DERMATOL, V24, P119, DOI 10.1016/0190-9622(91)70021-S; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; HEINO J, 1990, BIOCHEM J, V271, P827, DOI 10.1042/bj2710827; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KONIG A, 1991, J INVEST DERMATOL, V96, P803, DOI 10.1111/1523-1747.ep12474424; KONIG A, 1992, J CELL BIOL, V117, P679, DOI 10.1083/jcb.117.3.679; LI KH, 1993, J BIOL CHEM, V268, P8825; MAUVIEL A, 1993, WOUNDS, V5, P137; MAUVIEL A, 1991, J INVEST DERMATOL, V96, P243, DOI 10.1111/1523-1747.ep12462185; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; MAUVIEL A, 1992, J CELL BIOCHEM, V50, P53, DOI 10.1002/jcb.240500110; MAUVIEL A, 1992, BIOCHEM J, V284, P629, DOI 10.1042/bj2840629; MAUVIEL A, 1992, J BIOL CHEM, V267, P5644; OH SP, IN PRESS P NATL ACAD; PALLER AS, 1985, J INVEST DERMATOL, V82, P215; PARENTE MG, 1991, P NATL ACAD SCI USA, V88, P6931, DOI 10.1073/pnas.88.16.6931; RYYNANEN J, 1991, BIOCHEM BIOPH RES CO, V180, P673, DOI 10.1016/S0006-291X(05)81118-0; RYYNANEN J, 1992, J CLIN INVEST, V89, P163, DOI 10.1172/JCI115557; SAKAI LY, 1986, J CELL BIOL, V103, P1577, DOI 10.1083/jcb.103.4.1577; Uitto J, 1992, Exp Dermatol, V1, P2, DOI 10.1111/j.1600-0625.1992.tb00065.x; UITTO J, 1992, J CLIN INVEST, V90, P687, DOI 10.1172/JCI115938; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VARGA J, 1987, BIOCHEM BIOPH RES CO, V147, P1282, DOI 10.1016/S0006-291X(87)80209-7; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; WOODLEY DT, 1985, BIOCHEM BIOPH RES CO, V130, P1267, DOI 10.1016/0006-291X(85)91751-6	36	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					25	28						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276802				2022-12-27	WOS:A1994MR21900007
J	MIURA, Y; KAWABATA, S; IWANAGA, S				MIURA, Y; KAWABATA, S; IWANAGA, S			A LIMULUS INTRACELLULAR COAGULATION INHIBITOR WITH CHARACTERISTICS OF THE SERPIN SUPERFAMILY - PURIFICATION, CHARACTERIZATION, AND CDNA CLONING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRAB TACHYPLEUS-TRIDENTATUS; AMINO-ACID-SEQUENCE; SERINE-PROTEASE ZYMOGEN; PLASMINOGEN-ACTIVATOR INHIBITOR; FACTOR-C; TRYPSIN-INHIBITOR; HEMOCYTES; HEMOLYMPH; POLYPHEMUS; AMEBOCYTES	A limulus intracellular coagulation inhibitor, designated LICI, was isolated from hemocytes of the Japanese horseshoe crab (Tachypleus tridentatus), using three steps of chromatography, including dextran sulfate-Sepharose CL-6B, Sephacryl S-200, and Mono S. LICI is a single-chain glycoprotein with an apparent M(r) = 48,000 estimated by SDS-polyacrylamide gel electrophoresis. It blocks the amidolytic activities of Limulus lipopolysaccharide-sensitive serine protease, factor CBAR, by forming a covalent 1:1 complex with the protease. The second-order rate constant for inhibition of factor CBAR was 2.5 x 10(6) m-1 s-1 at 37-degrees-C. LICI also inhibited human alpha-thrombin, rat salivary kallikrein, bovine plasmin, and trypsin but not Limulus clotting enzyme, Limulus factor BBAR, bovine factor Xa, human factor XIa, human tissue plasminogen activator, human urokinase, chymotrypsin, elastase, and papain. Glycosaminoglycans such as heparin and heparan sulfate had no effect on the inhibitory activity. A cDNA coding for LICI was isolated from a hemocyte cDNA library. The open reading frame of the 1,257-base pair cDNA codes for the mature protein of 394 amino acids, of which 223 residues were confirmed by amino acid sequence analysis. LICI shows significant sequence identities to members of the serpin superfamily, such as human plasminogen activator inhibitor type 2 (40%) and human monocyte/neutrophil elastase inhibitor (39%). LICI contains a putative reactive site, -Arg-Ser-, at the corresponding position present in several inhibitors of the serpin superfamily. The subcellular localization, determined using an anti-LICI polyclonal antibody, indicated that LICI colocates with the Limulus serine protease zymogens in large granules in the hemocyte.	KYUSHU UNIV 33,FAC SCI,DEPT BIOL,FUKUOKA 812,JAPAN; KYUSHU UNIV 33,GRAD SCH MED SCI,DEPT MOLEC BIOL,FUKUOKA 812,JAPAN	Kyushu University; Kyushu University			Miura, Yoshiki/U-8875-2019	Miura, Yoshiki/0000-0002-7596-0482				AKETAGAWA J, 1986, J BIOL CHEM, V261, P7357; BJORK I, 1986, PROTEINASE INHIBITOR, P489; Brehelin M., 1986, P36; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; CHASE T, 1970, METHOD ENZYMOL, V19, P20; DONOVAN MA, 1991, J BIOL CHEM, V266, P2121; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; EVANS DL, 1992, BIOCHEMISTRY-US, V31, P12629, DOI 10.1021/bi00165a013; HARLOW E, 1989, ANTIBODIES LABORATOR, P471; HASHIMOTO N, 1985, J BIOCHEM, V97, P1347, DOI 10.1093/oxfordjournals.jbchem.a135187; HEUSSEN C, 1984, J BIOL CHEM, V259, P1635; JESTY J, 1979, J BIOL CHEM, V254, P44; JOSLIN G, 1991, J BIOL CHEM, V266, P11282; KANOST MR, 1989, J BIOL CHEM, V264, P965; KATO H, 1987, J BIOCHEM, V102, P1389, DOI 10.1093/oxfordjournals.jbchem.a122185; KATO H, 1980, J BIOCHEM-TOKYO, V88, P183; KAWABATA S, 1985, J BIOCHEM-TOKYO, V67, P1073; KAWABATA SI, 1988, EUR J BIOCHEM, V172, P17, DOI 10.1111/j.1432-1033.1988.tb13849.x; KURACHI K, 1981, METHOD ENZYMOL, V80, P211; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LEVIN J, 1964, B JOHNS HOPKINS HOSP, V115, P265; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MINETTI CASA, 1991, J BIOL CHEM, V266, P20773; MIURA Y, 1992, J BIOCHEM-TOKYO, V112, P476, DOI 10.1093/oxfordjournals.jbchem.a123924; MIYATA T, 1984, J BIOL CHEM, V259, P8924; MORITA T, 1981, FEBS LETT, V129, P318, DOI 10.1016/0014-5793(81)80192-5; MUTA T, 1991, J BIOL CHEM, V266, P6554; NAKAMURA T, 1986, EUR J BIOCHEM, V154, P511, DOI 10.1111/j.1432-1033.1986.tb09427.x; NAKAMURA T, 1987, J BIOCHEM, V101, P1297, DOI 10.1093/oxfordjournals.jbchem.a121994; NAKAMURA T, 1986, J BIOCHEM, V99, P847, DOI 10.1093/oxfordjournals.jbchem.a135545; NAKAMURA T, 1985, J BIOCHEM, V97, P1561, DOI 10.1093/oxfordjournals.jbchem.a135213; NGUYEN NY, 1986, J BIOL CHEM, V261, P456; Ornberg R.L., 1979, Progress in Clinical and Biological Research, V29, P125; OUIGLEY JP, 1983, J BIOL CHEM, V258, P7903; Petersen TE, 1979, PHYSL INHIBITORS BLO, P43; REMOLDODONNELL E, 1992, P NATL ACAD SCI USA, V89, P5635, DOI 10.1073/pnas.89.12.5635; Sambrook J, 1989, MOL CLONING LABORATO; SASAKI T, 1991, EUR J BIOCHEM, V202, P255, DOI 10.1111/j.1432-1033.1991.tb16370.x; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SHIGENAGA T, 1993, J BIOCHEM-TOKYO, V114, P307, DOI 10.1093/oxfordjournals.jbchem.a124173; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; Stormer L., 1952, Journal of Paleontology, V26, P630; TAKAGI H, 1990, J BIOCHEM, V108, P372, DOI 10.1093/oxfordjournals.jbchem.a123208; TOH Y, 1991, CELL TISSUE RES, V266, P137, DOI 10.1007/BF00678720; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; YE RD, 1987, J BIOL CHEM, V262, P3718	49	75	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					542	547						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276848				2022-12-27	WOS:A1994MR21900087
J	COWAN, DB; WEISEL, RD; WILLIAMS, WG; MICKLE, DAG				COWAN, DB; WEISEL, RD; WILLIAMS, WG; MICKLE, DAG			IDENTIFICATION OF OXYGEN RESPONSIVE ELEMENTS IN THE 5'-FLANKING REGION OF THE HUMAN GLUTATHIONE-PEROXIDASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROPOIETIN GENE; DNA-BINDING PROTEINS; YEAST HAP1 ACTIVATOR; ENZYME-ACTIVITIES; OXIDATIVE STRESS; MAMMALIAN-CELLS; DIRECT CLONING; PCR PRODUCTS; SEQUENCE; EXPRESSION	The -1389 to +588 region of the human genomic glutathione peroxidase gene (hgpx1) was amplified using the polymerase chain reaction. This DNA fragment was cloned and sequenced, and various deletion constructs derived from the hgpx1 5'-flanking region were fused to the chloramphenicol acetyltransferase gene. These reporter genes were analyzed in transient transfection assays using primary cultured human ventricular cardiomyocytes obtained from patients with tetralogy of Fallot. Two distinct regions upstream from the transcription start site, which was determined using S1 nuclease analysis, were identified to be responsive to the oxygen tension in culture (pO2 values of 150 or 40 mm Hg). Methylation interference footprinting assays revealed proteins closely apposed to two sequences located at -1232 to -1213 and -282 to -275. We have designated these oxygen responsive elements ORE1 and ORE2, respectively. Gel mobility shift assays using double-stranded oligonucleotides corresponding to each site have demonstrated the formation of specific complexes using both cultured human cardiomyocyte and HeLa nuclear extracts. ORE1 and ORE2 bind disparate proteins with equal precision as bound complexes could be competed away with identical sequences but not with either the other ORE or an unrelated sequence. Insertion of these oxygen responsive elements into a reporter gene governed by a SV40 promoter similarly regulated chloramphenicol acetyltransferase activity according to the oxygen tension in culture.	UNIV TORONTO,TORONTO HOSP,DEPT CLIN BIOCHEM,EATON WING S 3-404A,200 ELIZABETH ST,TORONTO M5G 2C4,ON,CANADA; UNIV TORONTO,TORONTO HOSP,CTR CARDIOVASC RES,TORONTO M5G 2C4,ON,CANADA; UNIV TORONTO,TORONTO HOSP,DIV CARDIOVASC SURG,TORONTO M5G 2C4,ON,CANADA; UNIV TORONTO,HOSP SICK CHILDREN DIV CARDIOVASC,TORONTO M5G 2C4,ON,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Williams, William Galbraith/AAF-2104-2019	Cowan, Douglas/0000-0002-6309-2737				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; AGRON PG, 1993, P NATL ACAD SCI USA, V90, P3506, DOI 10.1073/pnas.90.8.3506; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BALDWIN AS, 1988, CURRENT PROTOCOLS MO; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHADA S, 1990, GENOMICS, V6, P268, DOI 10.1016/0888-7543(90)90566-D; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; CHU FF, 1993, J BIOL CHEM, V268, P2571; CLERCH LB, 1993, J CLIN INVEST, V91, P499, DOI 10.1172/JCI116228; COWAN DB, 1992, J MOL CELL CARDIOL, V24, P423, DOI 10.1016/0022-2828(92)93196-Q; COWAN DB, 1991, BIOCHEM J, V274, P687, DOI 10.1042/bj2740687; DELNIDO PJ, 1988, J THORAC CARDIOV SUR, V95, P223; DIAMOND AM, 1992, GENE, V122, P377, DOI 10.1016/0378-1119(92)90230-M; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FUCHS O, 1990, BIOMED BIOCHIM ACTA, V49, pS47; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENE JJ, 1988, CURRENT PROTOCOLS MO; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARABIN AL, 1990, J APPL PHYSIOL, V69, P328, DOI 10.1152/jappl.1990.69.1.328; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; HO YS, 1992, FEBS LETT, V301, P5, DOI 10.1016/0014-5793(92)80198-P; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; JONOT L, 1992, AM J RESPIR CELL MOL, V6, P107; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KINGSTON RE, 1988, CURRENT PROTOCOLS MO; KURATA H, 1992, FEBS LETT, V312, P10, DOI 10.1016/0014-5793(92)81400-G; LI RK, 1989, J MOL CELL CARDIOL, V21, P567, DOI 10.1016/0022-2828(89)90822-5; LI RK, 1992, J TISS CULT METHODS, V14, P93; MABLY JD, 1993, J BIOL CHEM, V268, P476; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MCBRIDE O W, 1988, Biofactors, V1, P285; MOSCOW JA, 1992, J BIOL CHEM, V267, P5949; MULLENBACH GT, 1987, NUCLEIC ACIDS RES, V15, P5484, DOI 10.1093/nar/15.13.5484; MULLENBACH GT, 1988, PROTEIN ENG, V2, P239, DOI 10.1093/protein/2.3.239; PALMER M, 1989, RED BOOK B S, V7; PFEIFER K, 1989, CELL, V56, P291, DOI 10.1016/0092-8674(89)90903-3; PFEIFER K, 1987, CELL, V49, P19, DOI 10.1016/0092-8674(87)90751-3; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; RISTER M, 1976, J CLIN INVEST, V58, P1174, DOI 10.1172/JCI108570; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P707; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; Sambrook J, 1989, MOL CLONING LABORATO; SELA S, 1993, NEPHRON, V63, P199; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SPALLHOLZ JE, 1991, PEROXIDASES CHEM BIO, V1, P259; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; SUKENAGA Y, 1987, NUCLEIC ACIDS RES, V15, P7198; TEOH KH, 1992, J THORAC CARDIOV SUR, V104, P159; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; WEBSTER KA, 1987, MOL CELL BIOCHEM, V77, P19; WEBSTER KA, 1992, J MOL CELL CARDIOL, V24, P741, DOI 10.1016/0022-2828(92)93388-Z; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869; ZITOMER RS, 1992, MICROBIOL REV, V56, P1	54	107	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26904	26910						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262924				2022-12-27	WOS:A1993MM26200014
J	JOLY, A; EDWARDS, PA				JOLY, A; EDWARDS, PA			EFFECT OF SITE-DIRECTED MUTAGENESIS OF CONSERVED ASPARTATE AND ARGININE RESIDUES UPON FARNESYL DIPHOSPHATE SYNTHASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYROPHOSPHATE SYNTHETASE; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; CAROTENOID BIOSYNTHESIS; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; CATALYTIC SITE; GENE; PRENYLTRANSFERASE; IDENTIFICATION	All polyprenyl synthases catalyze the condensation of the allylic substrate, isopentenyl diphosphate, with a specific homoallylic diphosphate substrate. Polyprenyl synthases from Homo sapiens, Ratus rattus, Escherichia coli, Saccharomyces cerevisiae, Neurospora crassa, and Erwinia herbicola contain two conserved ''aspartate-rich domains'' (Ashby, M. N., and Edwards, P.A. (1992) J. Biol. Chem. 267, 4128-4136). In order to determine the importance of these domains in catalysis, the conserved aspartates or arginines in domains I and II of rat farnesyl diphosphate synthase were individually mutated to glutamate or lysine, respectively. The putative ''active site'' arginine (Brems, D. N., Breunger, E., and Rilling, H. C. (1981) Biochemistry 20, 3711-3718) was mutated to lysine. Each mutant enzyme was overexpressed in E. coli and purified to apparent homogeneity. Detailed kinetic analyses of the wild type and mutant enzymes indicated that mutagenesis of Asp104, Asp107, Arg112, Arg113, and Asp243 resulted in a decreased V(max) of approximately 1000-fold compared to wild type. However, no significant change in the K(m) values for either the isopentenyl diphosphate or geranyl diphosphate substrate were observed. The results strongly suggest that these amino acids, and to a lesser extent Asp244, are involved in either the condensation of isopentenyl diphosphate and geranyl diphosphate to form farnesyl diphosphate and/or the release of the farnesyl diphosphate product from farnesyl diphosphate synthase. The conservation of these amino acid residues in different enzymes from several species suggests that these domains play a similar role in other polyprenyl synthases.	UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	JOLY, A (corresponding author), UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90024, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30568] Funding Source: Medline; NIGMS NIH HHS [GM 21326] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON MS, 1989, J BIOL CHEM, V264, P19176; ARMSTRONG GA, 1989, MOL GEN GENET, V216, P254, DOI 10.1007/BF00334364; ARMSTRONG GA, 1990, P NATL ACAD SCI USA, V87, P9975, DOI 10.1073/pnas.87.24.9975; ASHBY MN, 1992, J BIOL CHEM, V267, P4128; ASHBY MN, 1989, J BIOL CHEM, V264, P635; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; BARNARD GF, 1981, BIOCHIM BIOPHYS ACTA, V661, P87, DOI 10.1016/0005-2744(81)90086-3; BARNARD GF, 1980, BIOCHIM BIOPHYS ACTA, V617, P169, DOI 10.1016/0005-2760(80)90160-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREMS DN, 1981, BIOCHEMISTRY-US, V20, P3711, DOI 10.1021/bi00516a007; BREMS DN, 1979, BIOCHEMISTRY-US, V18, P860, DOI 10.1021/bi00572a019; CARATTOLI A, 1991, J BIOL CHEM, V266, P5854; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; EBERHARDT NL, 1975, J BIOL CHEM, V250, P863; FUJISAKI S, 1986, J BIOCHEM-TOKYO, V99, P1327, DOI 10.1093/oxfordjournals.jbchem.a135600; FUJISAKI S, 1990, J BIOCHEM-TOKYO, V108, P995, DOI 10.1093/oxfordjournals.jbchem.a123327; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOODMAN DS, 1960, J LIPID RES, V1, P286; HOLLOWAY PW, 1967, BIOCHEM J, V104, P57, DOI 10.1042/bj1040057; ITAKURA K, 1984, ANNU REV BIOCHEM, V53, P323; JENNINGS SM, 1991, P NATL ACAD SCI USA, V88, P6038, DOI 10.1073/pnas.88.14.6038; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOVICS FM, 1981, BIOCHEMISTRY-US, V20, P1893, DOI 10.1021/bi00510a027; LASKOVICS FM, 1979, J BIOL CHEM, V254, P9458; Maniatis T., 1982, MOL CLONING; MARRERO PF, 1992, J BIOL CHEM, V267, P21873; MATH SK, 1992, P NATL ACAD SCI USA, V89, P6761, DOI 10.1073/pnas.89.15.6761; PISZKIEWICZ D, 1977, KINETICS CHEM ENZYME, P79; Poulter C. D., 1981, BIOSYNTHESIS ISOPREN, V1, P161; POULTER CD, 1990, ACCOUNTS CHEM RES, V23, P70, DOI 10.1021/ar00171a003; REED BC, 1975, BIOCHEMISTRY-US, V14, P50, DOI 10.1021/bi00672a009; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGEL IH, 1975, ENZYME KINETICS, P18; STREET IP, 1990, BIOCHEMISTRY-US, V29, P7531, DOI 10.1021/bi00484a023; TERUYA JH, 1990, MOL CELL BIOL, V10, P2315, DOI 10.1128/MCB.10.5.2315; WILKIN DJ, 1990, J BIOL CHEM, V265, P4607; YEH LS, 1977, ARCH BIOCHEM BIOPHYS, V183, P718, DOI 10.1016/0003-9861(77)90405-2	38	135	149	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26983	26989						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262934				2022-12-27	WOS:A1993MM26200025
J	KREBS, JF; IPPOLITO, JA; CHRISTIANSON, DW; FIERKE, CA				KREBS, JF; IPPOLITO, JA; CHRISTIANSON, DW; FIERKE, CA			STRUCTURAL AND FUNCTIONAL IMPORTANCE OF A CONSERVED HYDROGEN-BOND NETWORK IN HUMAN CARBONIC ANHYDRASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC MECHANISM; HYDROPHOBIC POCKET; MACROMOLECULAR STRUCTURES; PROTEIN-STRUCTURE; ESCHERICHIA-COLI; PROTON-TRANSFER; BINDING; HYDRATION; ZINC; BUFFER	Amino acid substitutions at Thr199 of human carbonic anhydrase II (CAII) (Thr199 --> Ser, Ala, Val, and Pro) were characterized to investigate the importance of a conserved hydrogen bonding network. The three-dimensional structures of azide-bound and sulfate-bound T199V CAIIs were determined by x-ray crystallographic methods at 2.25 and 2.4 angstrom, respectively (final crystallographic R factors are 0.173 and 0.174, respectively). The CO2 hydrase activities of T199S and T199P variants suggest that the side chain methyl and backbone amino functionalities stabilize the transition state by almost-equal-to 0.4 and 0.8 kcal/mol, respectively. The side chain hydroxyl group causes: stabilization of zinc-hydroxide relative to zinc-water (pK(a) increases almost-equal-to 2 units); stabilization of the transition state for bicarbonate dehydration relative to the CAII.HCO3- complex (almost-equal-to 5 kcal/mol); and destabilization of the CAII.HCO3- complex (almost-equal-to 0.8 kcal/mol). An inverse correlation between log(k(cat)CO2/K(M)) and the pk(a) of zinc-water (r = 0.95, slope = -1) indicates that the hydrogen bonding network stabilizes the chemical transition state and zinc-hydroxide similarly. These data are consistent with the hydroxyl group of Thr199 forming a hydrogen bond with the transition state and a non-hydrogen-bonded van der Waals contact with CAII.HCO3-.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; UNIV PENN,DEPT CHEM,PHILADELPHIA,PA 19104	Duke University; University of Pennsylvania					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045614, T32GM008275, R01GM040602, R29GM040602, R29GM045614] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40602, GM08275, GM45614] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER RS, 1991, BIOCHEMISTRY-US, V30, P11064, DOI 10.1021/bi00110a008; ALEXANDER RS, 1993, BIOCHEMISTRY-US, V32, P1510, DOI 10.1021/bi00057a015; ARMSTRONG JM, 1966, J BIOL CHEM, V241, P5137; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; CHRISTIANSON DW, 1989, J AM CHEM SOC, V111, P6412, DOI 10.1021/ja00198a065; DURBIN RM, 1986, SCIENCE, V232, P1127, DOI 10.1126/science.3704639; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; EPSTEIN DM, 1992, BIOCHEMISTRY-US, V31, P11216, DOI 10.1021/bi00160a036; ERIKSSON AE, 1988, PROTEINS, V4, P274, DOI 10.1002/prot.340040406; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; FERSHT AR, 1987, TRENDS BIOCHEM SCI, V12, P301, DOI 10.1016/0968-0004(87)90146-0; FIERKE CA, 1989, BIOCHEMISTRY-US, V28, P478, DOI 10.1021/bi00428a011; FIERKE CA, 1991, BIOCHEMISTRY-US, V30, P11054, DOI 10.1021/bi00110a007; GANDOUR RD, 1981, BIOORG CHEM, V10, P169, DOI 10.1016/0045-2068(81)90020-1; GLASOE PK, 1960, J PHYS CHEM-US, V64, P188, DOI 10.1021/j100830a521; GROVES JT, 1985, INORG CHEM, V24, P2715, DOI 10.1021/ic00212a001; HAKANSSON K, 1992, J MOL BIOL, V227, P1192, DOI 10.1016/0022-2836(92)90531-N; HAKANSSON K, 1992, J MOL BIOL, V228, P1212, DOI 10.1016/0022-2836(92)90327-G; HAKANSSON K, 1992, THESIS U LUND SWEDEN; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HEWETTEMMETT D, 1991, CARBONIC ANHYDRASES; HUDSON RF, 1974, CHEM REACTIVITY REAC; IPPOLITO JA, 1993, BIOCHEMISTRY-US, V32, P9901, DOI 10.1021/bi00089a005; IPPOLITO JA, 1990, J MOL BIOL, V215, P457, DOI 10.1016/S0022-2836(05)80364-X; JACOB O, 1990, J AM CHEM SOC, V112, P8692, DOI 10.1021/ja00180a009; JENCKS WP, 1986, J AM CHEM SOC, V108, P479, DOI 10.1021/ja00263a019; JENCKS WP, 1987, ADV CHEM, V215, P155; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONSSON BH, 1976, FEBS LETT, V64, P310, DOI 10.1016/0014-5793(76)80317-1; KANNAN KK, 1977, FEBS LETT, V73, P115, DOI 10.1016/0014-5793(77)80028-8; KHALIFAH RG, 1971, J BIOL CHEM, V246, P2561; KIMURA E, 1990, J AM CHEM SOC, V112, P5805, DOI 10.1021/ja00171a020; KREBS JF, 1991, BIOCHEMISTRY-US, V30, P9153, DOI 10.1021/bi00102a005; KREBS JF, 1993, J BIOL CHEM, V268, P948; KREBS JF, 1993, BIOCHEMISTRY-US, V32, P4496, DOI 10.1021/bi00068a004; LIANG JY, 1990, P NATL ACAD SCI USA, V87, P3675, DOI 10.1073/pnas.87.10.3675; LIANG JY, 1987, BIOCHEMISTRY-US, V26, P5293, DOI 10.1021/bi00391a012; LIANG ZW, 1993, EUR J BIOCHEM, V211, P821, DOI 10.1111/j.1432-1033.1993.tb17614.x; LINDAHL M, 1992, ACTA CRYSTALLOGR B, V48, P281, DOI 10.1107/S0108768191013757; LINDAHL M, 1993, PROTEINS, V15, P177, DOI 10.1002/prot.340150207; LINDSKOG S, 1984, J MOL CATAL, V23, P357, DOI 10.1016/0304-5102(84)80021-8; LOGRASSO PV, 1993, BIOCHEMISTRY-US, V32, P5786, DOI 10.1021/bi00073a010; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MARTIN RB, 1976, J INORG NUCL CHEM, V38, P511, DOI 10.1016/0022-1902(76)80294-1; MERZ KM, 1990, J MOL BIOL, V214, P799, DOI 10.1016/0022-2836(90)90333-H; MERZ KM, 1991, J AM CHEM SOC, V113, P406, DOI 10.1021/ja00002a004; NAIR SK, 1993, EUR J BIOCHEM, V213, P507, DOI 10.1111/j.1432-1033.1993.tb17788.x; NAIR SK, 1993, BIOCHEMISTRY-US, V32, P4506, DOI 10.1021/bi00068a005; NAIR SK, 1991, J BIOL CHEM, V266, P17320; OSBORNE WRA, 1975, ANAL BIOCHEM, V64, P297, DOI 10.1016/0003-2697(75)90434-0; Pocker Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P149; ROWLETT RS, 1982, J AM CHEM SOC, V104, P6737, DOI 10.1021/ja00388a043; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schowen R. L., 1977, ISOTOPE EFFECTS ENZY, P64; SEGEL IH, 1975, ENZYME KINETICS, P34; SILLEN LG, 1964, STABILITY CONSTANTS, P61; SILVERMAN DN, 1988, ACCOUNTS CHEM RES, V21, P30, DOI 10.1021/ar00145a005; SOLA M, 1992, J AM CHEM SOC, V114, P869, DOI 10.1021/ja00029a010; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; STEIGEMANN W, 1974, THESIS M PLANCK I BI; STEINER H, 1975, EUR J BIOCHEM, V59, P253, DOI 10.1111/j.1432-1033.1975.tb02449.x; TU CK, 1982, BIOCHEMISTRY-US, V21, P6353, DOI 10.1021/bi00268a006; TU CK, 1990, BIOCHEMISTRY-US, V29, P6400, DOI 10.1021/bi00479a009; TU CK, 1989, BIOCHEMISTRY-US, V28, P7913, DOI 10.1021/bi00445a054; XUE YF, 1993, PROTEINS, V17, P93, DOI 10.1002/prot.340170112; XUE YF, 1993, PROTEINS, V15, P80, DOI 10.1002/prot.340150110	68	88	89	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27458	27466						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262987				2022-12-27	WOS:A1993MM26200087
J	MORAD, I; CHAPMANSHIMSHONI, D; AMITSUR, M; KAUFMANN, G				MORAD, I; CHAPMANSHIMSHONI, D; AMITSUR, M; KAUFMANN, G			FUNCTIONAL EXPRESSION AND PROPERTIES OF THE TRANSFER RNA(LYS)-SPECIFIC CORE ANTICODON NUCLEASE ENCODED BY ESCHERICHIA-COLI-PRRC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLONING VECTORS; DNA; RESTRICTION; PLASMID; PHAGE; GENE; BACTERIOPHAGE-T4; CONSTRUCTION; DERIVATIVES; FUSIONS	Escherichia coli carrying the optional locus prr harbor a latent, tRNA(Lys)-specific anticodon nuclease, activated by the product of phage T4 stp. Anticodon nuclease latency is ascribed to the masking of prrC, implicated with the enzymatic activity, by flanking, type Ic DNA restriction modification genes (prrA, B&D-hsdM, S&R). Overexpression of plasmid-borne prrC elicited anticodon nuclease activity in uninfected E. coli. In vitro, the prrC-coded core activity was indifferent to a synthetic Stp polypeptide, GTP, ATP, and endogenous DNA, effectors that synergistically activate the latent enzyme. Several facts suggested that PrrC is highly labile in the absence of the masking proteins. The core activity decayed with t1/2 below 1 min at 30-degrees-C, and the PrrC portion of a fusion protein was unstable. Moreover, expression of prrC from its own promoter at low plasmid copy number did not allow detection of core activity. Yet, it sufficed for establishment of a latent, T4-inducible enzyme when complemented by the masking Hsd proteins, which were provided by another replicon. Interaction between the antagonistic components of latent anticodon nuclease was also demonstrated immunochemically. The coupling of anticodon nuclease with a DNA restriction modification system may serve to ward off its inadvertent toxicity and maintain it as an antiviral contingency.	TEL AVIV UNIV,DEPT BIOCHEM,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University								ABDULJABBAR M, 1984, J VIROL, V51, P522; AMITSUR M, 1987, EMBO J, V6, P2499, DOI 10.1002/j.1460-2075.1987.tb02532.x; AMITSUR M, 1989, EMBO J, V8, P2411, DOI 10.1002/j.1460-2075.1989.tb08371.x; AMITSUR M, 1992, EMBO J, V11, P3129, DOI 10.1002/j.1460-2075.1992.tb05385.x; BALBAS P, 1986, GENE, V50, P3, DOI 10.1016/0378-1119(86)90307-0; BICKLE TA, 1987, ESCHERICHIA COLI SAL, P692; CAMI B, 1978, NUCLEIC ACIDS RES, V5, P2381, DOI 10.1093/nar/5.7.2381; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHAPMAN D, 1988, J MOL BIOL, V99, P373; CHURCHWARD G, 1984, GENE, V31, P165, DOI 10.1016/0378-1119(84)90207-5; DAVID M, 1982, VIROLOGY, V123, P480, DOI 10.1016/0042-6822(82)90284-7; DAVID M, 1982, P NATL ACAD SCI-BIOL, V79, P7097, DOI 10.1073/pnas.79.23.7097; DEPEW RE, 1974, J VIROL, V13, P888, DOI 10.1128/JVI.13.4.888-897.1974; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; HARLOW E, 1988, ANTIBODIES; INNIS MA, 1990, PROTOCOLS GUIDE METH; KAUFMANN G, 1986, J MOL BIOL, V188, P15, DOI 10.1016/0022-2836(86)90476-6; LEVITZ R, 1990, EMBO J, V9, P1383, DOI 10.1002/j.1460-2075.1990.tb08253.x; LINDER P, 1990, NUCLEIC ACIDS RES, V18, P7170, DOI 10.1093/nar/18.23.7170; LIU JD, 1989, J BACTERIOL, V171, P1254, DOI 10.1128/jb.171.3.1254-1261.1989; PRICE C, 1987, EUR J BIOCHEM, V167, P111, DOI 10.1111/j.1432-1033.1987.tb13310.x; RUNNELS JM, 1982, J MOL BIOL, V154, P273, DOI 10.1016/0022-2836(82)90064-X; Sambrook J, 1989, MOL CLONING LABORATO; SIROTKIN K, 1978, J MOL BIOL, V123, P221, DOI 10.1016/0022-2836(78)90322-4; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SNYDER L, 1976, P NATL ACAD SCI USA, V73, P3098, DOI 10.1073/pnas.73.9.3098; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WAY JC, 1984, GENE, V32, P369, DOI 10.1016/0378-1119(84)90012-X; Wiberg J. S., 1983, BACTERIOPHAGE T4, P193; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	30	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26842	26849						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262917				2022-12-27	WOS:A1993MM26200006
J	WEIGEL, PH; OKA, JA				WEIGEL, PH; OKA, JA			REGULATION OF ASIALOGLYCOPROTEIN RECEPTOR ACTIVITY BY A NOVEL INACTIVATION REACTIVATION CYCLE - RECEPTOR REACTIVATION IN PERMEABLE RAT HEPATOCYTES IS MEDIATED BY FATTY ACYL COENZYME-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; MEMBRANE-BOUND ENZYMES; EUKARYOTIC PROTEINS; TRANSPORT VESICLES; GOLGI CISTERNAE; COA; ENDOCYTOSIS; QUANTITATION; DEGRADATION; MACROPHAGES	We previously reported that a subpopulation of asialoglycoprotein receptors (ASGP-Rs), designated State 2 ASGP-Rs, can be inactivated in digitonin-permeabilized hepatocytes in the absence of cytosol by a process that is temperature- and ATP-dependent (Medh, J. D., and Weigel, P. H. (1991) J. Biol. Chem. 266, 8771-8778). Here we show that these inactivated ASGP-Rs are reactivated by the sole addition of fatty acyl-CoA. Of the derivatives tested (acyl chain length 4-18), palmitoyl-CoA was the most effective, although stearoyl-CoA (C18) and myristoyl-CoA (C14) were also active. Lauroyl-CoA (C12) was about half as effective as palmitoyl-CoA, and decanoyl-CoA (C10) and butyl-CoA (C4) were inactive. ASGP-R reactivation did not take place in the presence of free palmitate and coenzyme A, but did occur if low levels of ATP were also added to drive palmitoyl-CoA synthesis by the permeable cells. Addition of ATP after ASGP-R reactivation with palmitoyl-CoA again resulted in a rapid inactivation of these receptors. The extent and rate of this second ASGP-R inactivation process were proportional to ATP concentration; half-maximal effects occurred at approximately 0.5 mM ATP. ATP also rapidly reversed the ASGP-R reactivation seen with the other fatty acyl-CoAs. The results demonstrate the existence of a previously unrecognized pathway that regulates the activity of the ASGP-R population responsible for the majority of ligand endocytosis and processing in hepatocytes. This novel receptor inactivation/reaction cycle could ensure the high efficiency of segregating ligand and receptor during endocytosis and receptor recycling.			WEIGEL, PH (corresponding author), UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77555, USA.				NIGMS NIH HHS [GM 49695, GM 30218] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049695, R01GM030218] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKKEN AM, 1992, BIOCHEM J, V288, P763, DOI 10.1042/bj2880763; BOLDT DH, 1987, J CELL PHYSIOL, V132, P331, DOI 10.1002/jcp.1041320219; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRECHER P, 1983, MOL CELL BIOCHEM, V57, P3; CLARKE BL, 1985, J BIOL CHEM, V260, P128; CLARKE BL, 1987, J BIOL CHEM, V262, P17384; COLEMAN RA, 1992, BIOCHIM BIOPHYS ACTA, V1125, P203, DOI 10.1016/0005-2760(92)90046-X; CONSTANTINIDES PP, 1985, J BIOL CHEM, V260, P7573; DALET C, 1982, ANAL BIOCHEM, V122, P119, DOI 10.1016/0003-2697(82)90259-7; DAS AK, 1992, J BIOL CHEM, V267, P9724; DAS AK, 1992, J BIOL CHEM, V267, P9731; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; GREENSPAN P, 1984, J BIOL CHEM, V259, P1703; ITO M, 1987, BIOCHIM BIOPHYS ACTA, V922, P287; MCABEE DD, 1987, J BIOL CHEM, V262, P1942; MEDH JD, 1991, J BIOL CHEM, V266, P8771; OLSON EN, 1988, PROG LIPID RES, V27, P177, DOI 10.1016/0163-7827(88)90012-4; PATHAK RK, 1988, J CELL BIOL, V106, P1831, DOI 10.1083/jcb.106.6.1831; PEREZGIL J, 1990, MOL CELL BIOCHEM, V94, P167, DOI 10.1007/BF00214123; PFANNER N, 1990, J CELL BIOL, V110, P955, DOI 10.1083/jcb.110.4.955; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; POWELL GL, 1985, FED PROC, V44, P81; POWELL GL, 1981, J BIOL CHEM, V256, P2740; SAMUELSON AC, 1988, AM J PHYSIOL, V254, P829; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; SEGLEN PO, 1973, EXP CELL RES, V82, P391, DOI 10.1016/0014-4827(73)90357-1; SHEPHERD VL, 1990, J IMMUNOL, V145, P1530; SMITH RH, 1986, ARCH BIOCHEM BIOPHYS, V244, P357, DOI 10.1016/0003-9861(86)90124-4; STAHL P, 1986, J CLIN INVEST, V77, P657, DOI 10.1172/JCI112359; TOLLESHAUG H, 1981, J BIOL CHEM, V256, P6526; VENTURA MA, 1987, EXP CELL RES, V170, P290, DOI 10.1016/0014-4827(87)90307-7; WEIGEL PH, 1982, J BIOL CHEM, V257, P1201; WEIGEL PH, 1983, ANAL BIOCHEM, V133, P437, DOI 10.1016/0003-2697(83)90106-9; WEIGEL PH, 1983, J BIOL CHEM, V258, P5089; WEIGEL PH, 1984, J BIOL CHEM, V259, P1150; WEIGEL PH, 1992, MECH CONTROL GLYCOCO, P421; [No title captured]	38	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27186	27190						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262959				2022-12-27	WOS:A1993MM26200054
J	LOYER, P; GLAISE, D; CARIOU, S; BAFFET, G; MEIJER, L; GUGUENGUILLOUZO, C				LOYER, P; GLAISE, D; CARIOU, S; BAFFET, G; MEIJER, L; GUGUENGUILLOUZO, C			EXPRESSION AND ACTIVATION OF CDK-1 AND CDK-2 AND CYCLINS IN THE CELL-CYCLE PROGRESSION DURING LIVER-REGENERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDC2 PROTEIN-KINASE; TRANSCRIPTION FACTOR E2F; XENOPUS EGG EXTRACTS; FISSION YEAST; S-PHASE; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; TYROSINE PHOSPHORYLATION; REGULATED EXPRESSION; HISTONE-H1 KINASE	In normal adult liver, hepatocytes are arrested in G0, and they rapidly respond to a mass loss by a definite number of divisions. Thus, taking advantage of the in vivo regenerative capacity of the liver following partial hepatectomy, we have analyzed both expression and activation of p34cdc2 (= cdk1) and p33cdk2 through the cell cycle, particularly during the long lasting G1 phase and in the G1/S transition. While p33cdk2 is constantly expressed during the cell cycle, p34cdc2 is completely absent in resting hepatocytes and remains unexpressed for up to 20 h after partial hepatectomy, a time period corresponding to the G1 phase and G1/S transition, and then accumulates in the S, G2, and M phases. No histone H1 kinase activity is detected during the G1 phase, while two peaks of p34cdc2 kinase activity are observed during the S and M phases and only one peak of p33cdk2 kinase activity in the S phase. p34cdc2 forms complexes with both cyclins A and B while p33cdk2 is associated with cyclin A only. Surprisingly, cyclins E and D1 are present in resting liver and with modest variation throughout the cell cycle. Taken together, our data provide evidence that the pattern of G1-associated proteins in hepatocytes during liver regeneration is distinct from that described in other cell types.	STN BIOL,CNRS,F-29680 ROSCOF,FRANCE	Centre National de la Recherche Scientifique (CNRS)	LOYER, P (corresponding author), HOP PONTCHAILLOU,UNITE RECH HEPATOL,INSERM,U49,F-35033 RENNES,FRANCE.		Baffet, Georges/I-2574-2015; LOYER, Pascal/K-1838-2019; Baffet, Georges/M-1583-2016	LOYER, PASCAL/0000-0002-5656-2673; , laurent/0000-0003-3511-4916				AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; AKHURST RJ, 1989, DIFFERENTIATION, V40, P36, DOI 10.1111/j.1432-0436.1989.tb00811.x; ANDREWS GK, 1982, J BIOL CHEM, V257, P5148; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; AZZI L, 1992, EUR J BIOCHEM, V203, P353, DOI 10.1111/j.1432-1033.1992.tb16557.x; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CLARKE PR, 1992, EMBO J, V11, P1751, DOI 10.1002/j.1460-2075.1992.tb05227.x; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FABRIKANT JI, 1968, J CELL BIOL, V36, P551, DOI 10.1083/jcb.36.3.551; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GRISHAM JW, 1962, CANCER RES, V22, P842; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HADWIGER JA, 1989, MOL CELL BIOL, V9, P6255; HAMAGUCHI JR, 1992, J CELL BIOL, V117, P1041, DOI 10.1083/jcb.117.5.1041; HAYLES J, 1986, EMBO J, V5, P3373, DOI 10.1002/j.1460-2075.1986.tb04653.x; Higgins GM, 1931, ARCH PATHOL, V12, P186; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P112; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; LU XP, 1992, J BIOL CHEM, V267, P2841; MARRACCINO RL, 1992, MOL BIOL CELL, V3, P389, DOI 10.1091/mbc.3.4.389; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MEIJER L, 1991, EMBO J, V10, P1545, DOI 10.1002/j.1460-2075.1991.tb07674.x; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RAYMONDJEAN M, 1983, BIOCHIM BIOPHYS ACTA, V741, P30, DOI 10.1016/0167-4781(83)90006-4; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; ROY LM, 1991, J CELL BIOL, V113, P507, DOI 10.1083/jcb.113.3.507; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THOMPSON NL, 1986, CANCER RES, V46, P3111; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	73	127	129	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2491	2500						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300575				2022-12-27	WOS:A1994MV43200025
J	ROBINSON, GLWG; PESHAVARIA, M; HENDERSON, E; SHIEH, SY; TSAI, MJ; TEITELMAN, G; STEIN, R				ROBINSON, GLWG; PESHAVARIA, M; HENDERSON, E; SHIEH, SY; TSAI, MJ; TEITELMAN, G; STEIN, R			EXPRESSION OF THE TRANSACTIVE FACTORS THAT STIMULATE INSULIN CONTROL ELEMENT-MEDIATED ACTIVITY APPEAR TO PRECEDE INSULIN GENE-TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; BETA-CELL LINES; II GENE; NEGATIVE REGULATION; ENDOCRINE PANCREAS; RIBONUCLEIC-ACID; ISLET HORMONES; ENHANCER; PROMOTER; MYOD	Cell type-specific expression of the major differentiated products of alpha (glucagon) and beta (insulin) cells are regulated by sequences found within their 5'-flanking region. Specific transcription of the insulin gene appears to be principally controlled by a single cis-acting DNA element, termed the insulin control element (ICE). The ICE activator acts in combination with other positive regulatory factors that interact within this region to generate the correct, cell type-specific expression. In the present study, we show that the ICE activator is not only present but is functionally active in the islet glucagon-producing alpha cell line, alphaTC6. Analysis of the expression of various transfected insulin enhancer expression plasmids demonstrated that the insulin enhancer is active in alphaTC6 cells, although at a lower level than in beta cells. The reduced transcription from these constructs appears to be a consequence of the lack of other essential positive regulator(s). The alphaTC6 cells were also shown to display neuronal-like properties. Since islet cells appear to evolve from an alpha-like precursor cell that transiently expresses neuronal cell markers, these results would indicate that the ICE activator factor is induced before transcription of the insulin gene in the developing islet.	VANDERBILT UNIV,MED CTR,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; SUNY HLTH SCI CTR,DEPT ANAT & CELL BIOL,BROOKLYN,NY 11203	Vanderbilt University; Baylor College of Medicine; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center			Shieh, Sheau-Yann/N-9512-2018	Shieh, Sheau-Yann/0000-0002-5351-4430; Teitelman, Gladys/0000-0003-0687-3032	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER; NIDDK NIH HHS [P60 DK20593] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BOAM DSW, 1990, J BIOL CHEM, V265, P8285; BUCCHINI D, 1986, P NATL ACAD SCI USA, V83, P2511, DOI 10.1073/pnas.83.8.2511; CAMPOSORTEGA JA, 1990, ANNU REV GENET, V24, P387; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRAPKIEWICZ NB, 1989, NUCLEIC ACIDS RES, V17, P6651, DOI 10.1093/nar/17.16.6651; CORDLE SR, 1991, MOL CELL BIOL, V11, P2881, DOI 10.1128/MCB.11.5.2881; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; CROWE DT, 1989, MOL CELL BIOL, V9, P1784, DOI 10.1128/MCB.9.4.1784; DEKRIJGER RR, 1992, DEV BIOL, V153, P368, DOI 10.1016/0012-1606(92)90121-V; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; GERMAN MS, 1992, MOL CELL BIOL, V12, P1777, DOI 10.1128/MCB.12.4.1777; GERMAN MS, 1991, MOL ENDOCRINOL, V5, P292, DOI 10.1210/mend-5-2-292; GITTES GK, 1992, P NATL ACAD SCI USA, V89, P1128, DOI 10.1073/pnas.89.3.1128; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GUNNING P, 1983, MOL CELL BIOL, V3, P854; HAMAGUCHI K, 1990, DIABETES, V39, P415, DOI 10.2337/diabetes.39.4.415; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HEINRICH G, 1984, ENDOCRINOLOGY, V115, P2176, DOI 10.1210/endo-115-6-2176; HERRERA PL, 1991, DEVELOPMENT, V113, P1257; HWUNG YP, 1990, MOL CELL BIOL, V10, P1784, DOI 10.1128/MCB.10.4.1784; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LUKINIUS A, 1992, DEV BIOL, V153, P376, DOI 10.1016/0012-1606(92)90122-W; NIR U, 1986, P NATL ACAD SCI USA, V83, P3180, DOI 10.1073/pnas.83.10.3180; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; OHLSSON H, 1991, MOL ENDOCRINOL, V5, P897, DOI 10.1210/mend-5-7-897; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; Peters A., 1991, FINE STRUCTURE NERVO; Pictet R., 1972, HDB PHYSIOLOGY     7, V1, P25; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SELDEN RF, 1986, NATURE, V321, P525, DOI 10.1038/321525a0; SHIEH SY, 1991, J BIOL CHEM, V266, P16708; STEINER DF, 1985, ANNU REV GENET, V19, P463, DOI 10.1146/annurev.ge.19.120185.002335; TAMKUN MM, 1991, FASEB J, V5, P332; TEITELMAN G, 1990, DEV BIOL, V142, P368, DOI 10.1016/0012-1606(90)90357-O; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; VILLAKOMAROFF L, 1978, P NATL ACAD SCI USA, V75, P3727, DOI 10.1073/pnas.75.8.3727; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WHELAN J, 1989, MOL CELL BIOL, V9, P3253, DOI 10.1128/MCB.9.8.3253; WHELAN J, 1990, MOL CELL BIOL, V10, P1564, DOI 10.1128/MCB.10.4.1564	47	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2452	2460						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300572				2022-12-27	WOS:A1994MV43200020
J	BAGAI, S; SARKAR, DP				BAGAI, S; SARKAR, DP			FUSION-MEDIATED MICROINJECTION OF LYSOZYME INTO HEPG2 CELLS THROUGH HEMAGGLUTININ NEURAMINIDASE-DEPLETED SENDAI VIRUS ENVELOPES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC ASIALOGLYCOPROTEIN RECEPTOR; ADULT-RAT LIVER; INSULIN MOLECULES; DRUG DELIVERY; PROTEINS; ANTIBODIES; GLYCOPROTEINS; DEGRADATION; LIPOSOMES; VESICLES	The potential of reconstituted Sendai viral envelopes containing only the fusion protein (F-virosomes) was evaluated for a targeted cytosolic delivery of lysozyme to human hepatoblastoma cells (HepG2) in culture. I-125-Lysozyme loaded into F-virosomes was used to monitor its fusion-mediated transfer to the HepG2 cells. Using fusion assay based on the transfer of water soluble probe, we have demonstrated the existence of aqueous connection between F-virosomes and target cells. Target specificity of the F-virosomes was ensured by the strong interaction between terminal 6-galactose moiety of F protein and the asialoglycoprotein receptor on the membrane of HepG2 cells. Incubation of the loaded F-virosomes with cells resulted in fusion-mediated injection, as inferred from the ability of cells to internalize lysozyme in the presence of azide (an inhibitor of the endocytotic process). Binding as well as fusion of the F-virosomes to HepG2 cells was solely mediated by the F protein. Introduction of I-125-lysozyme into the HepG2 cells was confirmed by selective accumulation of acid and antibody-precipitable radioactivity in the cytosolic compartment. The structural integrity of the internalized lysozyme was also assessed. The potential usefulness of F-virosomes with defined specificities as biological carrier for both in vitro and in vivo cytosolic delivery of macromolecules and drugs has been established.	UNIV DELHI S CAMPUS, DEPT BIOCHEM, BENITO JUAREZ ROAD, NEW DELHI 110021, INDIA	University of Delhi				Sarkar, Debi P/0000-0002-8886-8415				Aronson N N Jr, 1974, Methods Enzymol, V31, P90; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BAGAI S, 1993, J VIROL, V67, P3312, DOI 10.1128/JVI.67.6.3312-3318.1993; BAGAI S, 1993, FEBS LETT, V326, P183, DOI 10.1016/0014-5793(93)81787-Z; BAGAI S, 1993, IN PRESS BIOCH BIOPH; Bayer E A, 1980, Methods Biochem Anal, V26, P1; BIJSTERBOSCH MK, 1992, MOL PHARMACOL, V41, P404; BLUMENTHAL R, 1991, TRENDS BIOTECHNOL, V9, P41, DOI 10.1016/0167-7799(91)90013-8; BRODSKY FM, 1991, ANNU REV IMMUNOL, V9, P707; CHOPPIN PW, 1980, REV INFECT DIS, V2, P40; CITOVSKY V, 1985, J BIOL CHEM, V260, P2072; DASGUPTA P, 1985, BIOCHEM INT, V10, P327; DRAGSTEN PR, 1987, BIOCHIM BIOPHYS ACTA, V926, P270, DOI 10.1016/0304-4165(87)90213-3; ELLENS H, 1989, METHOD CELL BIOL, V31, P155; GITMAN AG, 1984, J BIOL CHEM, V259, P9813; GITMAN AG, 1985, P NATL ACAD SCI USA, V82, P7309, DOI 10.1073/pnas.82.21.7309; GITMAN AG, 1985, BIOCHEMISTRY-US, V24, P2762, DOI 10.1021/bi00332a025; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HSU MC, 1979, VIROLOGY, V95, P476, DOI 10.1016/0042-6822(79)90502-6; HUNTER W, 1978, HDB EXPT IMMUNOLOGY; KALTENBACH JP, 1958, EXP CELL RES, V15, P112, DOI 10.1016/0014-4827(58)90067-3; KANEDA Y, 1989, SCIENCE, V243, P375, DOI 10.1126/science.2911748; KANEDA Y, 1989, J BIOL CHEM, V264, P12126; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOYTER A, 1984, CIBA F SYMP, V103, P163; LOYTER A, 1991, MEMBRANE FUSION, P731; Markwell M A, 1981, Methods Enzymol, V72, P296; MARKWELL MAK, 1985, P NATL ACAD SCI USA, V82, P978, DOI 10.1073/pnas.82.4.978; NICOLSON GL, 1972, BIOCHIM BIOPHYS ACTA, V266, P543, DOI 10.1016/0005-2736(72)90109-5; NUSSBAUM O, 1984, VIROLOGY, V138, P185, DOI 10.1016/0042-6822(84)90344-1; Okada Y., 1988, TRANSPORT-VILNIUS, P297, DOI [10.1016/S0070-2161(08)60138-0, DOI 10.1016/S0070-2161(08)60138-0]; PERETZ H, 1974, J CELL BIOL, V63, P1, DOI 10.1083/jcb.63.1.1; RECHSTEINER M, 1984, CIBA F SYMP, V103, P181; REDDY R, 1992, J IMMUNOL, V148, P1585; SARKAR DP, 1989, J CELL BIOL, V109, P113, DOI 10.1083/jcb.109.1.113; SARKAR DP, 1988, MEMBRANE BIOCHEM, V7, P231, DOI 10.3109/09687688709029434; SCHEID A, 1977, VIROLOGY, V80, P54, DOI 10.1016/0042-6822(77)90380-4; SCHERPHOF GL, 1986, LIPIDS MEMBRANES PAS, P113; SCHWARTZ AL, 1984, CRC CR REV BIOCH MOL, V16, P207, DOI 10.3109/10409238409108716; SCHWARTZ AL, 1981, J BIOL CHEM, V256, P8878; SCHWARTZ AL, 1982, J BIOL CHEM, V257, P4230; SCHWARTZ AL, 1991, LIVER DISEASES TARGE, P3; SECHOY O, 1989, EXP CELL RES, V185, P122, DOI 10.1016/0014-4827(89)90042-6; SZOKA FC, 1991, MEMBRANE FUSION, P845; TAKENAKA A, 1989, INT J BIOCHEM, V21, P497; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAINSTEIN A, 1984, BIOCHIM BIOPHYS ACTA, V773, P181, DOI 10.1016/0005-2736(84)90081-6; YOSHIMA H, 1981, J BIOL CHEM, V256, P5355	49	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1966	1972						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294448				2022-12-27	WOS:A1994MR98800065
J	KLODOS, I; POST, RL; FORBUSH, B				KLODOS, I; POST, RL; FORBUSH, B			KINETIC HETEROGENEITY OF PHOSPHOENZYME OF NA,K-ATPASE MODELED BY UNMIXED LIPID PHASES - COMPETENCE OF THE PHOSPHOINTERMEDIATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(NA+ + K+)-ATPASE; SENSITIVE PHOSPHORYLATED INTERMEDIATE; PIG-KIDNEY; ATPASE ACTIVITY; NA+/K+-ATPASE; ADENOSINE-TRIPHOSPHATASE; SARCOPLASMIC-RETICULUM; MEMBRANE-VESICLES; OUTER MEDULLA; SODIUM-PUMP	Interconversion of phosphoenzyme resistant to K+ and sensitive to ADP (E1P) and phosphoenzyme resistant to ADP and sensitive to K+ (E2P) was studied in bovine brain and dog and pig kidney. The kinetics of dephosphorylation were observed by chasing phosphoenzyme formed from [P-32]ATP with unlabeled ATP with or without ADP or K+. Phosphorylation in 0.6-1.0 m NaCl produced mostly ADP-sensitive potassium-insensitive E1P. A potassium chase of this phosphoenzyme exposed its rate of conversion to potassium-sensitive ADP-insensitive E2P. At 20-degrees-C the rate constant was approximately 1 s-1. Simultaneous dilution of [NaCl] in the chase to 100 mm increased the constant to approximately 60 s-1, which probably qualifies E1P as an intermediate in Na,K-ATPase activity. Anions inhibited conversion according to a Hofmeister series. Na+ had no specific effect. At 0-degrees-C the rate constant was < 0.4 s-1, but downward jumps in [salt] produced an acceleration to > 1 s-1 for < 3 s followed by a return to the slow rate. The rapid rate would qualify E1P to participate in Na,K-ATPase activity if this rapid state participates in the normal reaction cycle. Phosphorylation in 0.02-0.1 m NaCl produced mostly E2P. Upward jumps in [NaCl] converted E2P to E1P equally rapidly and transiently. Oligomycin and high [salt] cooperated in stabilizing E1P. Jumps in [salt] greatly and transiently increased the rate of conversion of one form of the phosphoenzyme to the other. This extraordinary result required heterogeneous kinetics. A model is proposed based on control of enzyme conformation by changes in separate unmixed phases of the lipid of the membrane.	UNIV PENN, SCH MED, DEPT PHYSIOL, PHILADELPHIA, PA 19104 USA; YALE UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, NEW HAVEN, CT 06510 USA	University of Pennsylvania; Yale University	KLODOS, I (corresponding author), AARHUS UNIV, INST BIOPHYS, OLE WORMS ALLE 185, DK-8000 AARHUS, DENMARK.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031782] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-31782] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERS RW, 1967, ANNU REV BIOCHEM, V36, P727, DOI 10.1146/annurev.bi.36.070167.003455; ALMEIDA PFF, 1992, BIOCHEMISTRY-US, V31, P6739, DOI 10.1021/bi00144a013; ASKARI A, 1987, J BIOENERG BIOMEMBR, V19, P359, DOI 10.1007/BF00768539; ASTURIAS FJ, 1990, BIOPHYS J, V58, P205, DOI 10.1016/S0006-3495(90)82366-3; BIGELOW DJ, 1992, J BIOL CHEM, V267, P6952; BULTMANN T, 1991, BIOCHEMISTRY-US, V30, P5573, DOI 10.1021/bi00236a033; BURACK WR, 1993, BIOCHEMISTRY-US, V32, P583, DOI 10.1021/bi00053a025; FORBUSH B, 1982, J BIOL CHEM, V257, P2678; FORBUSH B, 1984, ANAL BIOCHEM, V140, P495, DOI 10.1016/0003-2697(84)90200-8; FORBUSH B, 1987, J BIOL CHEM, V262, P11104; FORBUSH B, 1991, SOC GEN PHY, V46, P211; FORTES PAG, 1984, J BIOL CHEM, V259, P1176; FROEHLICH JP, 1991, SOC GEN PHY, V46, P227; Glynn I M, 1988, Prog Clin Biol Res, V268A, P435; HARA Y, 1981, J BIOCHEM, V90, P923, DOI 10.1093/oxfordjournals.jbchem.a133580; HASENAUER J, 1993, J BIOL CHEM, V268, P3289; HAYASHI Y, 1989, BIOCHIM BIOPHYS ACTA, V983, P217, DOI 10.1016/0005-2736(89)90237-X; Hobbs A. S., 1985, SODIUM PUMP, P355; HOBBS AS, 1983, J BIOL CHEM, V258, P8163; HOBBS AS, 1980, J BIOL CHEM, V255, P5724; HOBBS AS, 1983, CURR TOP MEMBR TRANS, V19, P569; JENSEN J, 1984, J PHYSIOL-LONDON, V346, P219, DOI 10.1113/jphysiol.1984.sp015018; JENSEN J, 1983, BIOCHIM BIOPHYS ACTA, V731, P282, DOI 10.1016/0005-2736(83)90020-2; JENSEN J, 1992, BIOCHIM BIOPHYS ACTA, V1110, P81, DOI 10.1016/0005-2736(92)90297-Y; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; KLODOS I, 1981, BIOCHIM BIOPHYS ACTA, V643, P463, DOI 10.1016/0005-2736(81)90089-4; KLODOS I, 1975, ANAL BIOCHEM, V67, P397, DOI 10.1016/0003-2697(75)90311-5; KLODOS I, 1987, BIOCHIM BIOPHYS ACTA, V897, P302, DOI 10.1016/0005-2736(87)90426-3; Klodos I, 1988, Prog Clin Biol Res, V268A, P315; KLODOS I, 1991, SODIUM PUMP RECENT D, P327; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARDH S, 1975, BIOCHIM BIOPHYS ACTA, V391, P448, DOI 10.1016/0005-2744(75)90269-7; MARTIN DW, 1991, J GEN PHYSIOL, V98, P419, DOI 10.1085/jgp.98.2.419; MISRA M, 1990, J STRUCT BIOL, V105, P67, DOI 10.1016/1047-8477(90)90100-Q; MITCHELL DC, 1990, BIOCHEMISTRY-US, V29, P9143, DOI 10.1021/bi00491a007; Norby J G, 1988, Prog Clin Biol Res, V268A, P249; NORBY JG, 1971, BIOCHIM BIOPHYS ACTA, V233, P104, DOI 10.1016/0005-2736(71)90362-2; NORBY JG, 1983, J GEN PHYSIOL, V82, P725, DOI 10.1085/jgp.82.6.725; OTTOLENGHI P, 1975, BIOCHEM J, V151, P61, DOI 10.1042/bj1510061; PLESNER L, 1988, BIOCHIM BIOPHYS ACTA, V937, P63, DOI 10.1016/0005-2736(88)90227-1; PLESNER L, 1991, BIOCHIM BIOPHYS ACTA, V1076, P421, DOI 10.1016/0167-4838(91)90486-J; POST RL, 1991, SOC GEN PHY, V46, P201; POST RL, 1969, J GEN PHYSIOL, V54, pS306, DOI 10.1085/jgp.54.1.306; RAYNARD RS, 1991, AM J PHYSIOL, V260, pR916, DOI 10.1152/ajpregu.1991.260.5.R916; SANDERSON PW, 1991, BIOCHIM BIOPHYS ACTA, V1067, P43, DOI 10.1016/0005-2736(91)90024-3; SKRIVER E, 1992, J STRUCT BIOL, V108, P176, DOI 10.1016/1047-8477(92)90017-5; SUZUKI K, 1991, SODIUM PUMP RECENT D, P375; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; TANIGUCHI K, 1986, J BIOL CHEM, V261, P3272; TATULIAN SA, 1983, BIOCHIM BIOPHYS ACTA, V736, P189, DOI 10.1016/0005-2736(83)90283-3; WILLIS JS, 1978, AM J PHYSIOL, V235, pC159, DOI 10.1152/ajpcell.1978.235.5.C159; YAMAGUCHI M, 1983, J BIOL CHEM, V258, P5260; YODA A, 1982, MOL PHARMACOL, V22, P693; YODA S, 1986, J BIOL CHEM, V261, P1147; YODA S, 1987, J BIOL CHEM, V262, P103; ZAMPIGHI G, 1984, J CELL BIOL, V98, P1851, DOI 10.1083/jcb.98.5.1851	56	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1734	1743						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294422				2022-12-27	WOS:A1994MR98800032
J	XIE, HY; CLARKE, S				XIE, HY; CLARKE, S			PROTEIN PHOSPHATASE-2A IS REVERSIBLY MODIFIED BY METHYL ESTERIFICATION AT ITS C-TERMINAL LEUCINE RESIDUE IN BOVINE BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL METHYLATION; SIGNAL TRANSDUCTION; HUMAN-ERYTHROCYTES; METHYLTRANSFERASE; CALMODULIN; KINASES; TYPE-2A; REPAIR	We have recently described a novel protein carboxyl methylation system that results in the reversible modification of a 36-kDa polypeptide component of a 178-kDa protein in the cytosol of a variety of eucaryotic cells. This reaction, catalyzed by a cytosolic 40-kDa methyltransferase, results in the methyl esterification of the alpha-carboxyl group of the C-terminal leucine residue. We have now purified the major methylated 36-kDa polypeptide from bovine brain. N-terminal sequence analysis of a tryptic fragment of this polypeptide revealed identity to the catalytic subunit of protein phosphatase 2A. This enzyme exists in the cell predominantly as a trimeric 151-kDa native species containing the 36-kDa catalytic polypeptide that terminates in a leucine residue. We then fractionated bovine brain cytosolic extracts to separate the major phosphatase isoforms 2A1 and 2A2 and found that both could be methylated by a partially purified preparation of the methyltransferase. A synthetic C-terminal octapeptide based on the sequence of the 36-kDa catalytic subunit is neither a substrate nor an inhibitor of this methyltransferase, suggesting that this enzyme recognizes aspects of the tertiary and/or quaternary structure of the native phosphatase. Because this modification reaction is readily reversible in extracts, it may represent a novel strategy of the cell to modulate the function of this protein phosphatase.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	XIE, HY (corresponding author), UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR005554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026020, R37GM026020] Funding Source: NIH RePORTER; NCRR NIH HHS [RR05554] Funding Source: Medline; NIGMS NIH HHS [GM26020] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACKLUND PS, 1992, J BIOL CHEM, V267, P18632; BARTEN DM, 1990, LIFE SCI, V47, P81; BLACKSHEAR PJ, 1988, FASEB J, V2, P2957, DOI 10.1096/fasebj.2.14.2972578; BRAUTIGAN DL, 1988, METHOD ENZYMOL, V159, P339; CHELSKY D, 1985, BIOCHEMISTRY-US, V24, P6651, DOI 10.1021/bi00344a053; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CLARKE S, 1985, ANNU REV BIOCHEM, V54, P479, DOI 10.1146/annurev.bi.54.070185.002403; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, J BIOL CHEM, V264, P21435; ERICKSON AK, 1992, PREP BIOCHEM, V22, P257, DOI 10.1080/10826069208021375; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; GALLETTI P, 1988, BIOCHEMISTRY-US, V27, P1752, DOI 10.1021/bi00405a055; GUO H, 1993, J BIOL CHEM, V268, P11193; HRYCYNA CA, 1993, IN PRESS PHARM THER, V60; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; JOHNSON BA, 1987, J BIOL CHEM, V262, P12283; LADINO CA, 1990, MECH AGEING DEV, V55, P123, DOI 10.1016/0047-6374(90)90020-G; LI C, 1992, P NATL ACAD SCI USA, V89, P9885, DOI 10.1073/pnas.89.20.9885; OCONNOR CM, 1984, J BIOL CHEM, V259, P2570; PELECH S, 1985, EUR J BIOCHEM, V148, P245, DOI 10.1111/j.1432-1033.1985.tb08832.x; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; POT DA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P35, DOI 10.1016/0167-4889(92)90082-M; SIEGEL FL, 1985, ARCH BIOCHEM BIOPHYS, V237, P347, DOI 10.1016/0003-9861(85)90286-3; STOCK JB, 1992, J BIOL CHEM, V267, P19753; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; VOLKER C, 1991, J BIOL CHEM, V266, P21515; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; XIE H, 1990, Methods (Orlando), V1, P276, DOI 10.1016/S1046-2023(05)80328-7; XIE HY, 1993, J BIOL CHEM, V268, P13364	31	119	126	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1981	1984						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294450				2022-12-27	WOS:A1994MR98800067
J	BANGE, FC; VOGEL, U; FLOHR, T; KIEKENBECK, M; DENECKE, B; BOTTGER, EC				BANGE, FC; VOGEL, U; FLOHR, T; KIEKENBECK, M; DENECKE, B; BOTTGER, EC			IFP-35 IS AN INTERFERON-INDUCED LEUCINE-ZIPPER PROTEIN THAT UNDERGOES INTERFERON-REGULATED CELLULAR REDISTRIBUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNA-SYNTHETASE; MAJOR HISTOCOMPATIBILITY COMPLEX; DNA-BINDING PROTEINS; CHAIN RELEASE FACTOR; CLASS-II REGION; GAMMA-INTERFERON; IFN-GAMMA; MOLECULAR-CLONING; MESSENGER-RNA; GENE-EXPRESSION	We have isolated a new human cDNA, named IFP 35, whose expression is regulated by interferons (IFN). Induction of IFP 35 mRNA in HeLa cells by IFN is due, at least in part, to increased transcription. In response to IFN treatment, the expression of IFP 35 mRNA is seen in a wide range of different cell types, including fibroblasts, macrophages, and epithelial cells. The cDNA sequence encodes a 282-amino acid protein with a deduced molecular mass of 31,130 Da. In vitro translation of mRNA obtained by both in vitro transcription and hybrid selection resulted in the synthesis of a 35-kDa protein. Antisera raised against IFP 35 recognized a protein with an apparent molecular mass of 35 kDa in HeLa cells. Amino acid sequence analysis revealed a leucine zipper motif in an alpha-helical configuration at the extreme amino terminus of IFP 35. Notably IFP 35 is a unique novel leucine zipper protein in that it lacks a basic domain critical for DNA binding. IFP 35 can specifically form homodimers in vitro. Western blot analysis of fractionated cell extracts indicates increased nuclear localization following IFN treatment.	HANNOVER MED SCH,INST MED MIKROBIOL,D-30623 HANNOVER,GERMANY	Hannover Medical School; University of Hamburg; University Medical Center Hamburg-Eppendorf			Böttger, Erik C./F-6175-2011					ACKRILL AM, 1991, NUCLEIC ACIDS RES, V19, P591, DOI 10.1093/nar/19.3.591; Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; ARNHEITER H, 1988, EMBO J, V7, P1315, DOI 10.1002/j.1460-2075.1988.tb02946.x; BAHRAM S, 1991, P NATL ACAD SCI USA, V88, P10094, DOI 10.1073/pnas.88.22.10094; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BANGE FC, 1992, FEBS LETT, V300, P162, DOI 10.1016/0014-5793(92)80187-L; BAUERLE PA, 1988, CELL, V53, P211; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLANAR MA, 1988, P NATL ACAD SCI USA, V85, P4672, DOI 10.1073/pnas.85.13.4672; BOTTGER EC, 1988, IMMUNOGENETICS, V28, P215, DOI 10.1007/BF00345497; BOTTGER EC, 1988, BIOTECHNIQUES, V6, P650; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; BUWITT U, 1992, EMBO J, V11, P489, DOI 10.1002/j.1460-2075.1992.tb05079.x; CAPTEN HS, 1988, J BIOL CHEM, V263, P332; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COX PM, 1992, NUCLEIC ACIDS RES, V20, P4881, DOI 10.1093/nar/20.18.4881; DECKER T, 1989, EMBO J, V8, P2009, DOI 10.1002/j.1460-2075.1989.tb03608.x; DEMAEYER E, 1988, INTERFERONS OTHER RE, P91; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAN XD, 1989, MOL CELL BIOL, V9, P1922, DOI 10.1128/MCB.9.5.1922; FARBER JM, 1992, MOL CELL BIOL, V12, P1535, DOI 10.1128/MCB.12.4.1535; FARBER JM, 1990, P NATL ACAD SCI USA, V87, P5238, DOI 10.1073/pnas.87.14.5238; FLECKNER J, 1991, P NATL ACAD SCI USA, V88, P11520, DOI 10.1073/pnas.88.24.11520; FLOHR T, 1992, INFECT IMMUN, V60, P4418, DOI 10.1128/IAI.60.10.4418-4421.1992; FLOHR T, 1992, EUR J IMMUNOL, V22, P975, DOI 10.1002/eji.1830220415; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; GAUTAM S, 1992, J IMMUNOL, V148, P1725; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; JACOB CO, 1987, J EXP MED, V166, P798, DOI 10.1084/jem.166.3.798; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KOWARY K, 1991, MOL CELL BIOL, V11, P2451; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; MAGGI E, 1992, J IMMUNOL, V148, P2142; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERLIN G, 1983, P NATL ACAD SCI-BIOL, V80, P4904, DOI 10.1073/pnas.80.16.4904; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAKAMURA M, 1984, NATURE, V307, P381, DOI 10.1038/307381a0; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PFEFFERKORN ER, 1986, J INTERFERON RES, V6, P267, DOI 10.1089/jir.1986.6.267; REVEL M, 1986, TRENDS BIOCHEM SCI, V11, P166, DOI 10.1016/0968-0004(86)90134-9; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; RUBIN BY, 1991, J BIOL CHEM, V266, P24245; Sambrook J, 1989, MOL CLONING LABORATO; SAMUEL EC, 1984, P NATL ACAD SCI USA, V76, P515; SAUNDERS ME, 1985, EMBO J, V4, P1761, DOI 10.1002/j.1460-2075.1985.tb03848.x; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; STAEHELI P, 1986, CELL, V44, P147, DOI 10.1016/0092-8674(86)90493-9; STREHLOW I, 1992, NUCLEIC ACIDS RES, V20, P3865, DOI 10.1093/nar/20.15.3865; Tamm I, 1987, Interferon, V9, P13; VILCEK J, 1989, HDB EXPT PATHOLOGY, P3; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	65	63	67	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1091	1098						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288566				2022-12-27	WOS:A1994MR22000051
J	ELAZAR, Z; MAYER, T; ROTHMAN, JE				ELAZAR, Z; MAYER, T; ROTHMAN, JE			REMOVAL OF RAB GTP-BINDING PROTEINS FROM GOLGI MEMBRANES BY GDP DISSOCIATION INHIBITOR INHIBITS INTER-CISTERNAL TRANSPORT IN THE GOLGI STACKS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BOVINE BRAIN CYTOSOL; SMG P25A; VESICULAR TRANSPORT; MUTATIONAL ANALYSIS; REGULATORY PROTEIN; SYNAPTIC VESICLES; EXCHANGE PROTEIN; PURIFICATION; YEAST; SECRETION	Rab proteins are a family of Ras-like GTPases involved in intracellular membrane traffic. Rab GDI, a cytosolic protein which inhibits the dissociation of GDP from various Pab proteins, is required to maintain a pool of Rab proteins in the cytosol. We describe the purification of a cytosolic factor from bovine liver that inhibits intra-cisternal transport between the Golgi stacks. We identify this factor as a Rab GDI. Half-maximal inhibition of transport was observed in the presence of the same concentration of GDI that is required for removal of Rab proteins from the Golgi.			ELAZAR, Z (corresponding author), MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021, USA.			Mayer, Thomas/0000-0001-6954-2287				ARAKI S, 1990, J BIOL CHEM, V265, P13007; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BARLOWE C, 1993, J BIOL CHEM, V268, P873; BECKER J, 1991, EMBO J, V10, P785, DOI 10.1002/j.1460-2075.1991.tb08010.x; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; DENFERT C, 1992, EMBO J, V11, P4205, DOI 10.1002/j.1460-2075.1992.tb05514.x; DENFERT C, 1991, J CELL BIOL, V114, P663, DOI 10.1083/jcb.114.4.663; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; ELAZAR Z, 1993, IN PRESS J CELL BIOL; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GOUD B, 1991, Current Opinion in Cell Biology, V3, P626, DOI 10.1016/0955-0674(91)90033-U; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MORII N, 1991, J BIOL CHEM, V266, P7646; MUSHA T, 1992, J BIOL CHEM, V267, P9821; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; OKA T, 1991, J CELL BIOL, V114, P671, DOI 10.1083/jcb.114.4.671; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; ORCI L, 1991, CELL, V64, P1183; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SASAKI T, 1991, MOL CELL BIOL, V11, P2909, DOI 10.1128/MCB.11.5.2909; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STORM M, 1993, NATURE, V361, P736; UEDA T, 1991, BIOCHEMISTRY-US, V30, P909, DOI 10.1021/bi00218a005; ULIRICH O, 1993, J BIOL CHEM, V268, P18143; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VIELH E, 1989, NUCLEIC ACIDS RES, V17, P770; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WATERS MG, 1992, J CELL BIOL, V118, P1015, DOI 10.1083/jcb.118.5.1015; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	43	53	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					794	797						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288626				2022-12-27	WOS:A1994MR22000003
J	GARCIAHIGUERA, I; PENELA, P; MURGA, C; EGEA, G; BONAY, P; BENOVIC, JL; MAYOR, F				GARCIAHIGUERA, I; PENELA, P; MURGA, C; EGEA, G; BONAY, P; BENOVIC, JL; MAYOR, F			ASSOCIATION OF THE REGULATORY BETA-ADRENERGIC-RECEPTOR KINASE WITH RAT-LIVER MICROSOMAL-MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-DEPENDENT PHOSPHORYLATION; ROUGH ENDOPLASMIC-RETICULUM; G-PROTEIN; SUBCELLULAR-LOCALIZATION; SIGNAL TRANSDUCTION; COUPLED RECEPTORS; GOLGI MEMBRANES; GAMMA-SUBUNITS; TRANSLOCATION; AGONIST	Beta-adrenergic receptor kinase (betaARK) is a regulatory enzyme involved in the modulation of beta-adrenergic and other G protein-coupled receptors. lt has been described that betaARK is a cytosolic protein that transiently translocates to the plasma membrane in order to specifically phosphorylate agonist-occupied receptors. In this report, we used betaARK-specific antibodies to demonstrate that a significant amount of this kinase is present in rat liver microsomal membranes. BeatARK seems to be peripherally associated with the cytosolic side of microsomal membranes since it can be stripped from the membranes by mild salt treatment. Cell-free association experiments indicate that the interaction of betaARK is reversible, saturable, and strongly inhibited by protease or heat treatment of the microsomes, thus suggesting that betaARK interacts with a protein component of the microsomal membrane. Gradient fractionation studies indicate that the highest betaARK-specific activity co-migrates with endoplasmic reticulum enzymatic markers. Furthermore, indirect immunofluorescence and immunogold electron microscopy experiments performed in cultured cells using affinity-purified anti-betaARK antibodies are consistent with this subcellular localization pattern. Taken together, our data suggest that several betaARK pools (i.e. microsome-bound, plasma membrane-bound, and cytosolic) may exist inside the cell. Such results are in line with recent reports showing that proteins involved in plasma membrane signal transduction, such as heterotrimeric G proteins, are also associated with membranes of different intracellular organelles.	UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOLEC SEVERO OCHOA,E-28049 MADRID,SPAIN; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Jefferson University			Garcia-Higuera, Irene/L-5004-2014; Egea, Gustavo/I-2394-2014; Mayor, Federico/N-7644-2016; Murga, Cristina/E-1965-2014	Garcia-Higuera, Irene/0000-0001-6331-075X; Egea, Gustavo/0000-0001-5242-150X; Murga, Cristina/0000-0002-8964-4077; Mayor Menendez, Federico/0000-0003-1434-8449	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44944] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON NG, 1989, BIOCHEM J, V262, P867, DOI 10.1042/bj2620867; ARONIN N, 1992, J NEUROSCI, V12, P3435; ARRIZA JL, 1992, J NEUROSCI, V12, P4045; AUDIGIER Y, 1988, J BIOL CHEM, V263, P16352; BALCH W E, 1992, Current Biology, V2, P157, DOI 10.1016/0960-9822(92)90276-G; BANSKIN AR, 1991, CELL, V66, P685; Barr F A, 1992, Trends Cell Biol, V2, P91, DOI 10.1016/0962-8924(92)90001-4; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BENOVIC JL, 1986, NATURE, V321, P869, DOI 10.1038/321869a0; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BONAY P, 1991, EUR J BIOCHEM, V197, P229, DOI 10.1111/j.1432-1033.1991.tb15903.x; BONAY P, 1991, EUR J CELL BIOL, V202, P321; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GARCIAHIGUERA I, 1992, FEBS LETT, V302, P61, DOI 10.1016/0014-5793(92)80285-O; GEORGE DJ, 1992, J BIOL CHEM, V267, P24879; HAGA K, 1992, J BIOL CHEM, V267, P2222; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; KIM CM, 1993, J BIOL CHEM, V268, P15412; KIM CM, 1993, RECEPTOR, V3, P39; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LEWIS JM, 1991, CELL REGUL, V2, P1097, DOI 10.1091/mbc.2.12.1097; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Magee Tony, 1992, Trends in Cell Biology, V2, P318, DOI 10.1016/0962-8924(92)90172-J; MANDON EC, 1992, J BIOL CHEM, V267, P11144; MAYOR F, 1987, J BIOL CHEM, V262, P6468; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; NIGAM SK, 1989, J BIOL CHEM, V264, P16927; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; ROTH J, 1981, J HISTOCHEM CYTOCHEM, V29, P663, DOI 10.1177/29.5.6166664; ROTH J, 1982, TECHNIQUES IMMUNOCYT, V1, P107; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; TRAUB LM, 1991, J BIOL CHEM, V266, P24642; TRAUB LM, 1991, BIOCHEM J, V280, P171, DOI 10.1042/bj2800171; WHITEHEART SW, 1992, J BIOL CHEM, V267, P12239	48	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1348	1355						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288600				2022-12-27	WOS:A1994MR22000090
J	KITAGAWA, H; PAULSON, JC				KITAGAWA, H; PAULSON, JC			CLONING OF A NOVEL ALPHA-2,3-SIALYLTRANSFERASE THAT SIALYLATES GLYCOPROTEIN AND GLYCOLIPID CARBOHYDRATE GROUPS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAL-BETA-1->3(4)GLCNAC ALPHA-2->3 SIALYLTRANSFERASE; BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; NH2-TERMINAL SIGNAL ANCHOR; MOLECULAR-CLONING; RAT-LIVER; ENZYMATIC CHARACTERIZATION; DETERMINES EXPRESSION; HOMOLOGOUS SEQUENCES; MESSENGER-RNA	Sialyltransferases are a family of 10-12 enzymes that catalyze the transfer of sialic acid to carbohydrate groups of glycoproteins and glycolipids. Three sialyltransferase cDNAs have been cloned, revealing a highly conserved sialylmotif in the catalytic domain of these enzymes. Using a polymerase chain reaction-based approach, we cloned a 150-base pair fragment of a new sialylmotif from human placenta mRNA, which was then used as a probe to clone the complete coding sequence of the corresponding gene from a cDNA library. Like the other members of the sialyltransferase gene family cloned to date, the new cDNA coded for a protein predicted to have an NH2-terminal signal-anchor sequence and had the sialylmotif located in the center of the molecule. Comparison with the three other cloned sialyltransferases revealed extensive sequence homology that was not recognized earlier. Expression of a soluble recombinant form of the protein in COS-1 cells produced an active sialyltransferase, which used oligosaccharide, glycoprotein, and glycolipid acceptor substrates with terminal galactose in the Galbeta1,3GalNAc and Galbeta1, 4GlcNAc sequences but not the Galbeta1,3GlcNAc sequence. The sialylated products were sensitive to digestion with the Newcastle disease virus sialidase, which is specific for sialic acid-galactose linkages in the alpha2,3 linkage. The results suggest that this new member of the sialyltransferase gene family is the enzyme previously described as a glycolipid sialyltransferase activity (SAT-3), which forms the terminal sequences NeuAca-2,3Galbeta1,3GalNAc-R and NeuAcalpha2,3Galbeta1,4GlcNAc-R.	CYTEL CORP, 3525 JOHN HOPKINS CT, SAN DIEGO, CA 92121 USA; Scripps Res Inst, DEPT CHEM, SAN DIEGO, CA 92121 USA; SCRIPPS RES INST, DEPT MOLEC BIOL, SAN DIEGO, CA 92121 USA	Scripps Research Institute; Scripps Research Institute			Paulson, James/AAG-3565-2019; Kitagawa, Hiroshi/AAJ-1344-2020	Kitagawa, Hiroshi/0000-0002-9307-7079	NIGMS NIH HHS [GM27904] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027904] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASU M, 1982, J BIOL CHEM, V257, P2765; BASU M, 1987, METHOD ENZYMOL, V138, P575; BASU S C, 1991, Glycobiology, V1, P469, DOI 10.1093/glycob/1.5.469; Beyer T A, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P23; BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; COLLEY KJ, 1989, J BIOL CHEM, V264, P17619; DASGUPTA S, 1990, BIOCHIM BIOPHYS ACTA, V1036, P11, DOI 10.1016/0304-4165(90)90207-D; DEVRIES AL, 1970, J BIOL CHEM, V245, P2901; DRICKAMER K, 1993, GLYCOBIOLOGY, V3, P2, DOI 10.1093/glycob/3.1.2; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; GILLESPIE W, 1992, J BIOL CHEM, V267, P21004; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GRUNDMANN U, 1990, NUCLEIC ACIDS RES, V18, P667, DOI 10.1093/nar/18.3.667; HARDUINLEPERS A, 1993, J BIOL CHEM, V268, P14348; HOLMES EH, 1986, J BIOL CHEM, V261, P3737; HOMA FL, 1993, J BIOL CHEM, V268, P12609; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; KITAGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P375, DOI 10.1006/bbrc.1993.1830; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUROSAWA N, 1994, J BIOL CHEM, V269, P1402; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MELKERSONWATSON LJ, 1991, J BIOL CHEM, V266, P4448; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; NAKAMURA M, 1987, ANAL BIOCHEM, V166, P230, DOI 10.1016/0003-2697(87)90569-0; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; PAULSON JC, 1977, J BIOL CHEM, V252, P2363; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; REARICK JI, 1979, J BIOL CHEM, V254, P4444; RUSSO RN, 1990, J BIOL CHEM, V265, P3324; SADLER JE, 1979, J BIOL CHEM, V254, P4434; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SVENSSON EC, 1992, J BIOL CHEM, V267, P3466; VANDENEIJNDEN DH, 1981, J BIOL CHEM, V256, P3159; WANG XC, 1993, J BIOL CHEM, V268, P4355; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13845; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; WEN DX, 1992, J BIOL CHEM, V267, P21011; WEN DX, 1992, J BIOL CHEM, V267, P2512; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; YAMAMOTO F, 1990, J BIOL CHEM, V265, P1146; YOSHIMA H, 1981, J BIOL CHEM, V256, P8476	55	197	221	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1394	1401						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288606				2022-12-27	WOS:A1994MR22000097
J	MARANTO, AR				MARANTO, AR			PRIMARY STRUCTURE, LIGAND-BINDING, AND LOCALIZATION OF THE HUMAN TYPE-3 INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR EXPRESSED IN INTESTINAL EPITHELIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; RECONSTITUTED LIPID VESICLES; PLASMA-MEMBRANE; PERMEABILIZED ENTEROCYTES; TRISPHOSPHATE RECEPTOR; CALCIUM MOBILIZATION; RAT ENTEROCYTES; K+ CONDUCTANCE; CELLS; PHOSPHORYLATION	The second messenger, inositol 1,4,5-trisphosphate (InsP3) transduces many hormonal signals which regulate Ca2+-dependent processes in the intestinal epithelium. To study the receptors for InsP3 (InsP3Rs), which function as intracellular Ca2+ channels, cDNA clones encoding InSP3Rs were isolated from a human colon adenocarcinoma cell line, HT29. The majority of clones encoded the type 3 InsP3R, the product of the ITPR3 gene on chromosome 6, for which only a 147-amino-acid fragment was known previously (Ozcelik, T., Sudhof, T. C., and Francke, U. (1991) Cytogenet. Cell Genet. Abstr. 58, 1880; Sudhof, T. C., Newton, C. L., Archer, B. T., III, Ushkaryov, Y. A., and Mignery, G. A. (1991) EMBO J. 10, 3199-3206). The complete sequence of the type 3 InsP3R polypeptide (2,671 amino acids) is described here. Primary structure analysis indicates a pattern of conserved and variable regions which is characteristic of the InsP3R family. A 250-kDa protein (SDS-PAGE) which specifically binds InsP3 is immunoprecipitated by affinity-purified antibodies raised against a COOH-terminal fusion protein. Transient expression in COS-7 cells of a polypeptide comprising the NH2-terminal 750 amino acids establishes that the ligand-binding domain is localized to this region. Lysates from transfected COS-7 cells bind InSP3 with high affinity (K(d) = 151 nM) compared with other inositol phosphates (InsP3 >> Ins 1,3,4,5-P4 > InsP6 > Ins 1,4-P2 >> Ins 1-P). Immunocytochemical localization in the intestine reveals expression in crypt and villus epithelial cells, but not in cells of the lamina propria, submucosa, or muscularis layers. The subcellular distribution and appearance of staining is consistent with localization on the endoplasmic reticulum, with the highest concentration of staining occurring adjacent to the apical brush border of villus cells.			MARANTO, AR (corresponding author), TUFTS UNIV,ST ELIZABETHS HOSP,SCH MED,DEPT MED,736 CAMBRIDGE ST,BOSTON,MA 02135, USA.				NIDDK NIH HHS [DK44475, P30 DK34928] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928, R29DK044475] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOZOU JC, 1989, BIOCHEM J, V264, P871, DOI 10.1042/bj2640871; CHANG EB, 1990, LIFE SCI, V46, P1913, DOI 10.1016/0024-3205(90)90506-M; COHEN ME, 1990, P NATL ACAD SCI USA, V87, P8990, DOI 10.1073/pnas.87.22.8990; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; DICKINSON KEJ, 1992, EUR J PHARM-MOLEC PH, V225, P291, DOI 10.1016/0922-4106(92)90102-2; FERAMISCO JR, 1980, J BIOL CHEM, V255, P4240; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; Fogh J., 1975, HUMAN TUMOR CELLS IN, P115, DOI 10.1007/978-1-4757-1647-4_5; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; ILUNDAIN A, 1987, BIOCHIM BIOPHYS ACTA, V896, P113, DOI 10.1016/0005-2736(87)90363-4; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KHAN AA, 1992, P NATL ACAD SCI USA, V89, P2849, DOI 10.1073/pnas.89.7.2849; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBERHERR M, 1989, J BIOL CHEM, V264, P20403; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MATOVCIK LM, 1993, AM J PHYSIOL, V264, pC1029, DOI 10.1152/ajpcell.1993.264.4.C1029; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MORRIS AP, 1993, AM J PHYSIOL, V264, pC968, DOI 10.1152/ajpcell.1993.264.4.C968; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; OZCELIK T, 1991, CYTOGENET CELL GENET, V58, P1880; PINTO M, 1982, BIOL CELL, V44, P193; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; ROSS CA, 1992, P NATL ACAD SCI USA, V87, P3841; ROUSSET M, 1986, BIOCHIMIE, V68, P1035, DOI 10.1016/S0300-9084(86)80177-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEPULVEDA FV, 1987, PFLUG ARCH EUR J PHY, V408, P231, DOI 10.1007/BF02181464; SJOLANDER A, 1990, J BIOL CHEM, V265, P20976; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; SWANLJUNGCOLLINS H, 1992, J BIOL CHEM, V267, P3445; TAYLOR CW, 1991, PHARMACOL THERAPEUT, V51, P97, DOI 10.1016/0163-7258(91)90043-L; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANCORVEN EJJM, 1987, CELL CALCIUM, V8, P197, DOI 10.1016/0143-4160(87)90018-2; VELASCO G, 1986, BIOCHEM BIOPH RES CO, V139, P612, DOI 10.1016/S0006-291X(86)80034-1; WALTERS RJ, 1991, PFLUG ARCH EUR J PHY, V419, P537, DOI 10.1007/BF00370802; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; YADA T, 1989, J MEMBRANE BIOL, V112, P159, DOI 10.1007/BF01871277; YOSHIKAWA S, 1992, J BIOL CHEM, V267, P16613	53	160	164	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1222	1230						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288584				2022-12-27	WOS:A1994MR22000072
J	NAKSHATRI, H; CHAMBON, P				NAKSHATRI, H; CHAMBON, P			THE DIRECTLY REPEATED RG(G/T)TCA MOTIFS OF THE RAT AND MOUSE CELLULAR RETINOL-BINDING PROTEIN-II GENES ARE PROMISCUOUS BINDING-SITES FOR RAR, RXR, HNF-4, AND ARP-1 HOMO-HETERODIMER AND HETERODIMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID RESPONSE ELEMENT; HORMONE RECEPTOR SUPERFAMILY; TISSUE-SPECIFIC EXPRESSION; POLYMERASE CHAIN-REACTION; HUMAN ESTROGEN-RECEPTOR; THYROID-HORMONE; X-RECEPTOR; MOLECULAR-CLONING; VITAMIN-A; CRABP-I	We show here that the element which was previously characterized as a retinoid X receptor (RXR)-specific response element (RXRE) in the rat cellular retinol-binding protein II (CRBPII) gene is not conserved in the mouse gene. However, two conserved cis-acting elements (RE2 and RE3) located in the promoter region of the mouse and rat CRBPII genes mediate transactivation by retinoic acid receptors (RARs) and RXRs in transfected Cos-1, CV-1, and HeLa cells. The element RE3 which is the major retinoic acid (RA) response element also binds the transcription factors HNF-4 and ARP-1. HNF-4 constitutively activates the mouse CRBPII promoter, whereas ARP-1 represses the activation mediated by RARs, RXRs, and HNF-4. In contrast, RA has no effect on the activity of the mouse CRBPII promoter in the human colon carcinoma cell line CaCo-2 which constitutively expresses RARalpha, RARgamma, RXRalpha, HNF-4, and ARP-1, under conditions where the activity of the RARbeta2 gene promoter is readily induced by RA. Our results suggest that the CRBPII gene may not be RA-inducible in tissues expressing HNF-4 and ARP-1, and that the RA inducibility of the CRBPII gene promoter observed in transfection experiments reflects the promiscuous binding of RARs/RXRs to HNF-4 and ARP-1 response elements.	FAC MED STRASBOURG,INST CHIM BIOL,GENET MOLEC EUCARYOTES LAB,CNRS,INSERM,U184,11 RUE HUMANN,F-67085 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg				Nakshatri, Harikrishna/0000-0001-8876-0052				ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; ASTROM A, 1991, J BIOL CHEM, V266, P17662; BLOMHOFF R, 1990, SCIENCE, V250, P399, DOI 10.1126/science.2218545; BLOMHOFF R, 1991, PHYSIOL REV, V71, P952; BOYLAN JF, 1992, J BIOL CHEM, V267, P21486; BROCKES J, 1990, NATURE, V345, P766, DOI 10.1038/345766a0; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; BROOKS AR, 1991, J BIOL CHEM, V266, P7848; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CHYTIL F, 1991, RETINOIDS : 10 YEARS ON, P38; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; DE LUCA LM, 1991, FASEB J, V5, P2924; DEMMER LA, 1987, J BIOL CHEM, V262, P2458; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; FIORELLA PD, 1991, J BIOL CHEM, V266, P16572; GIGUERE V, 1990, P NATL ACAD SCI USA, V87, P6233, DOI 10.1073/pnas.87.16.6233; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LEHMANN JM, 1992, MOL CELL BIOL, V12, P2976, DOI 10.1128/MCB.12.7.2976; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEROY P, 1991, P NATL ACAD SCI USA, V88, P10138, DOI 10.1073/pnas.88.22.10138; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LEVIN MS, 1987, J BIOL CHEM, V262, P7118; LI E, 1986, P NATL ACAD SCI USA, V83, P5779, DOI 10.1073/pnas.83.16.5779; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACGREGOR TM, 1991, J BIOL CHEM, V267, P777; Maden M., 1991, SEMIN DEV BIOL, V2, P161; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MENDELSOHN C, 1992, DEV BIOL, V152, P50, DOI 10.1016/0012-1606(92)90155-A; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; MUNOZCANOVES P, 1990, J BIOL CHEM, V265, P20065; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; OGAMI K, 1990, J BIOL CHEM, V265, P9808; ONG DE, 1987, ARCH DERMATOL, V123, P1693, DOI 10.1001/archderm.123.12.1693; ONG DE, 1987, J BIOL CHEM, V262, P2729; ONG DE, 1988, J BIOL CHEM, V263, P5789; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; QUICK TC, 1990, BIOCHEMISTRY-US, V29, P11116, DOI 10.1021/bi00502a015; REUE K, 1988, J BIOL CHEM, V263, P6857; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; RUBERTE E, 1992, DEVELOPMENT, V115, P973; Sambrook J, 1989, MOL CLONING LABORATO; SAURAT JH, 1990, RETINOIDS 10 YEARS; SHERMAN MI, 1986, RETINOIDS CELL DIFFE; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; STONER CM, 1989, CANCER RES, V49, P1497; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SUMMERBELL D, 1990, TRENDS NEUROSCI, V13, P142, DOI 10.1016/0166-2236(90)90006-V; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; WEI LN, 1989, MOL ENDOCRINOL, V3, P454, DOI 10.1210/mend-3-3-454; WIDOM RL, 1991, MOL CELL BIOL, V11, P677, DOI 10.1128/MCB.11.2.677; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZANNIS VI, 1992, CURR OPIN LIPIDOL, V3, P96; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	76	129	131	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					890	902						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288643				2022-12-27	WOS:A1994MR22000022
J	NISHI, N; TANABE, H; OYA, H; URUSHIHARA, M; MIYANAKA, H; WADA, F				NISHI, N; TANABE, H; OYA, H; URUSHIHARA, M; MIYANAKA, H; WADA, F			IDENTIFICATION OF PROBASIN-RELATED ANTIGEN AS CYSTATHIONINE GAMMA-LYASE BY MOLECULAR-CLONING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; PROTEIN	We reported previously that a monoclonal antibody against probasin (rat prostatic secretory protein) recognizes a 40-kDa protein localized in rat liver and kidney. The protein (probasin-related antigen, PRB-RA) may participate in a specific differentiated function of these tissues. To clarify the molecular nature of PRB-RA, a series of cDNA clones coding for the protein were isolated from a rat liver expression library using an affinity-purified polyclonal antibody. The amino acid sequence deduced from the determined cDNA sequence included sequences identical with those of proteolytic fragments of PRB-RA, which covered about 70% of the deduced sequence. Northern blot hybridization of poly(A)+ RNA isolated from rat tissues showed the presence of predominant and minor mRNA species of about 2.0 and 4.3 kilobases, respectively, in the liver and kidney. A sequence homology search revealed that PRB-RA is almost completely identical to rat cystathionine gamma-lyase (cystathionase) and that it does not show overall homology with probasin. Three candidates for an epitope common to probasin and PRB-RA were found on close examination of the amino acid sequences of the two proteins. A synthetic peptide, TYFRRI, corresponding to one of the candidates, neutralized the reactivity of the anti-probasin monoclonal antibody to both probasin and PRB-RA on Western blot analysis. These results show that PRB-RA/cystathionase is neither structurally nor functionally related to probasin except for a common epitope and that cystathionase, a cystein-producing enzyme, is localized in urinary tubular epithelial cells in a highly restricted region of the kidney in addition to in liver parenchymal cells.	KAGAWA MED SCH,CTR RES EQUIPMENT,MIKI,KAGAWA 76107,JAPAN; GOVT INST RES INST,TAKAMATSU,KAGAWA 761,JAPAN	Kagawa University; National Institute of Advanced Industrial Science & Technology (AIST)	NISHI, N (corresponding author), KAGAWA MED SCH,DEPT ENDOCRINOL,MIKI,KAGAWA 76107,JAPAN.			Nishi, Nozomu/0000-0001-7050-3226				AWATA S, 1984, GANRYU AMINOSAN, V7, P407; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Drapeau G R, 1977, Methods Enzymol, V47, P189; ERICKSON PF, 1990, BIOCHEM J, V269, P335, DOI 10.1042/bj2690335; FLAVIN M, 1971, METHODS ENZYMOLOGY B, V17, P433; FULLMER CS, 1984, ANAL BIOCHEM, V142, P336, DOI 10.1016/0003-2697(84)90473-1; LU Y, 1992, BIOCHEM BIOPH RES CO, V189, P749, DOI 10.1016/0006-291X(92)92265-Y; MATUO Y, 1985, BIOCHEM BIOPH RES CO, V130, P293, DOI 10.1016/0006-291X(85)90416-4; MATUO Y, 1982, BIOCHEM BIOPH RES CO, V109, P334, DOI 10.1016/0006-291X(82)91725-9; NISHI N, 1992, BIOCHIM BIOPHYS ACTA, V1117, P47, DOI 10.1016/0304-4165(92)90161-M; NISHI N, 1991, BIOCHIM BIOPHYS ACTA, V1095, P268, DOI 10.1016/0167-4889(91)90110-J; PEVSNER J, 1988, SCIENCE, V241, P336, DOI 10.1126/science.3388043; Sambrook J, 1989, MOL CLONING LABORATO; SPENCE AM, 1989, P NATL ACAD SCI USA, V86, P7843, DOI 10.1073/pnas.86.20.7843; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359	15	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1015	1019						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288556				2022-12-27	WOS:A1994MR22000039
J	SANTALA, P; LARJAVA, H; NISSINEN, L; RIIKONEN, T; MAATTA, A; HEINO, J				SANTALA, P; LARJAVA, H; NISSINEN, L; RIIKONEN, T; MAATTA, A; HEINO, J			SUPPRESSED COLLAGEN GENE-EXPRESSION AND INDUCTION OF ALPHA-2-BETA-1-INTEGRIN-TYPE COLLAGEN RECEPTOR IN TUMORIGENIC DERIVATIVES OF HUMAN OSTEOGENIC-SARCOMA (HOS) CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-BETA; LAMININ-BINDING INTEGRIN; FIBRONECTIN RECEPTOR; ADHESION RECEPTORS; ALTERED GLYCOSYLATION; MONOCLONAL-ANTIBODY; ENDOTHELIAL-CELLS; MELANOMA-CELLS; ALPHA-SUBUNIT; VLA-2	Cell-matrix interactions and integrin-type cell adhesion receptors are involved in the regulation of tumor cell invasion and metastasis. We have analyzed the expression of matrix proteins and their cellular receptors in human osteosarcoma cells (HOS) and in their virally (KHOS-NP) and chemically (HOS-MNNG) transformed tumorigenic subclones. Transformation decreased dramatically the cellular mRNA levels of alpha1(I) collagen. Concomitantly with down-regulation of collagen mRNA levels the synthesis of the collagen receptor, alpha2beta1 integrin, was induced. No alpha2 integrin mRNA was found in HOS cells, suggesting that its expression was regulated most probably at the transcriptional level. 5-Azacytidine alone or combined with alpha2 integrin-stimulating cytokines, transforming growth factor-beta1, and interleukin-1beta, did not turn on the alpha2 integrin gene. In chemically transformed cells, however, alpha2 integrin expression could be regulated by cytokines. Thus, we suggest that HOS cells have a strong element, probably other than cell culture-generated de novo promoter methylation, suppressing alpha2 integrin expression and that this factor is lost in both chemical and viral transformation. Furthermore, the mechanism used by cytokines and malignant transformation to increase alpha2 integrin expression seems not to be identical. Other transformation-related changes in beta1 integrins were (i) reduction of the intracellular pool of precursor beta1 (in HOS-MNNG cells), leading to faster maturation rate of beta1 subunit and slower maturation rate of alpha subunits, and (ii) decreased electrophoretic mobility of both alpha and beta1 subunits. At the cellular level both chemical and viral transformation increased cell adhesion to type I collagen.	UNIV TURKU,DEPT MED BIOCHEM,MEDICITY RES LAB,KIINAMYLLYNKATU 10,SF-20520 TURKU 52,FINLAND; UNIV TURKU,DEPT PERIODONT,SF-20520 TURKU 52,FINLAND	University of Turku; University of Turku			Larjava, Hannu/GRO-4325-2022	Nissinen, Liisa/0000-0002-6743-6736; Vihinen, Pia/0000-0003-1763-5363; Maatta, Arto/0000-0003-3759-1310				ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; AKIYAMA SK, 1990, CANCER RES, V50, P1601; AKIYAMA SK, 1987, J BIOL CHEM, V262, P17536; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BIRKENMEIER TM, 1991, J BIOL CHEM, V266, P20544; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CERVELLA P, 1993, J BIOL CHEM, V268, P5148; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CHEN FA, 1991, J EXP MED, V173, P1111, DOI 10.1084/jem.173.5.1111; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V10, P5291; DEDHAR S, 1990, J CELL BIOL, V110, P481, DOI 10.1083/jcb.110.2.481; DEFILIPPI P, 1991, J CELL BIOL, V114, P855, DOI 10.1083/jcb.114.4.855; FELDINGHABERMANN B, 1992, J CLIN INVEST, V89, P2018, DOI 10.1172/JCI115811; GEHLSEN KR, 1988, J CELL BIOL, V106, P925, DOI 10.1083/jcb.106.3.925; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GRZESIAK JJ, 1992, J CELL BIOL, V117, P1109, DOI 10.1083/jcb.117.5.1109; HEINO J, 1989, J BIOL CHEM, V264, P21806; HEINO J, 1989, J BIOL CHEM, V264, P380; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; IGNOTZ RA, 1989, J BIOL CHEM, V264, P389; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; KANTOR RRS, 1987, J BIOL CHEM, V262, P15158; KLEIN CE, 1991, J INVEST DERMATOL, V96, P281, DOI 10.1111/1523-1747.ep12464485; KLEIN CE, 1991, J CELL BIOL, V115, P1427, DOI 10.1083/jcb.115.5.1427; KRAMER RH, 1991, CELL REGUL, V2, P805, DOI 10.1091/mbc.2.10.805; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LARJAVA H, 1993, J CLIN INVEST, V92, P1425, DOI 10.1172/JCI116719; MAKELA JK, 1988, NUCLEIC ACIDS RES, V16, P349, DOI 10.1093/nar/16.1.349; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; NIKKARI L, 1993, AM J PATHOL, V142, P1019; OZ OK, 1989, INT J CANCER, V44, P343, DOI 10.1002/ijc.2910440226; PISCHEL KD, 1987, J IMMUNOL, V138, P226; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; RHIM JS, 1977, INT J CANCER, V19, P505, DOI 10.1002/ijc.2910190411; ROSEN GD, 1991, P NATL ACAD SCI USA, V88, P4094, DOI 10.1073/pnas.88.10.4094; ROSSINO P, 1990, EXP CELL RES, V189, P100, DOI 10.1016/0014-4827(90)90262-9; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1992, BRIT J CANCER, V66, P239, DOI 10.1038/bjc.1992.250; SANTALA P, 1991, J BIOL CHEM, V266, P23505; SCHIRO JA, 1991, CELL, V67, P403, DOI 10.1016/0092-8674(91)90191-Z; SEKIGUCHI K, 1986, BIOCHEMISTRY-US, V25, P4936, DOI 10.1021/bi00365a032; SHELLEY CS, 1991, P NATL ACAD SCI USA, V88, P10525, DOI 10.1073/pnas.88.23.10525; SLACK JL, 1992, MOL CELL BIOL, V12, P4714, DOI 10.1128/MCB.12.10.4714; SONNENBERG A, 1988, J BIOL CHEM, V263, P14030; STAROS JV, 1986, ANAL BIOCHEM, V156, P220, DOI 10.1016/0003-2697(86)90176-4; SYMINGTON BE, 1989, J BIOL CHEM, V264, P13258; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; UZAN G, 1991, J BIOL CHEM, V266, P8932; VANDEWATER L, 1988, CANCER RES, V48, P5730; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; YLANNE J, 1989, INT J CANCER, V43, P1126, DOI 10.1002/ijc.2910430628; YNES RO, 1992, CELL, V69, P11	56	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1276	1283						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288590				2022-12-27	WOS:A1994MR22000080
J	YANG, MJ; TRUMPOWER, BL				YANG, MJ; TRUMPOWER, BL			DELETION OF QCR6, THE GENE ENCODING SUBUNIT 6 OF THE MITOCHONDRIAL CYTOCHROME BC1 COMPLEX, BLOCKS MATURATION OF CYTOCHROME-C1, AND CAUSES TEMPERATURE-SENSITIVE PETITE GROWTH IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTONMOTIVE Q-CYCLE; IRON-SULFUR PROTEIN; ELECTRON-TRANSFER; HINGE PROTEIN; RHODOSPIRILLUM-RUBRUM; ENERGY TRANSDUCTION; MUTATIONAL ANALYSIS; C OXIDOREDUCTASE; YEAST; UBIQUINOL	It was previously reported that disruption or deletion of QCR6, the nuclear gene encoding subunit 6 of the cytochrome bc1 complex, does not impair growth of yeast on non-fermentable carbon sources (Schoppink, P. J., Hemrika, W., Reyne, J. M., Grivell, L. A., and Berden, J. A. (1988) Eur. J. Biochem. 113, 115-122; Crivellone, M. D., Wu, M. M., and Tzagoloff, A. (1988) J. Biol. Chem. 262, 14323-14333; Schmitt, M. E., and Trumpower, B. L. (1990) J. Biol. Chem. 265,17005-17011). We have discovered that deletion of QCR6 results in a temperature-sensitive petite phenotype, manifested at 37-degrees-C, and that this phenotype can be masked by spontaneously arising suppressor mutations. Mitochondrial membranes from the deletion strain grown at 37-degrees-C lack ubiquinol-cytochrome c reductase activity, and optical spectra reveal an extensive decrease in cytochrome b absorption, but little or no decrease in cytochrome c1 absorption. lmmunoblots of mitochondrial membrane proteins from the deletion strain indicate that processing of cytochrome cl from intermediate to mature size is blocked coincident with the loss of subunit 6. This is the first example where mutation of a subunit within the bc1 complex blocks maturation of cytochrome c1.	DARTMOUTH COLL SCH MED, DEPT BIOCHEM, 7200 VAIL BLDG, HANOVER, NH 03755 USA	Dartmouth College					NIGMS NIH HHS [GM20379] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020379, R01GM020379] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BRANDT U, 1993, J BIOL CHEM, V268, P8387; CRIVELLONE MD, 1988, J BIOL CHEM, V263, P14323; GRAHAM LA, 1993, J BIOENERG BIOMEMBR, V25, P245, DOI 10.1007/BF00762586; GRAHAM LA, 1991, J BIOL CHEM, V266, P22485; Hanahan D., 1985, DNA CLONING; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; KIM CH, 1981, BIOCHEM BIOPH RES CO, V101, P607, DOI 10.1016/0006-291X(81)91302-4; KIM CH, 1990, FEBS LETT, V266, P78, DOI 10.1016/0014-5793(90)81511-L; KIM CH, 1987, J BIOL CHEM, V262, P8103; LEONARD K, 1981, J MOL BIOL, V149, P259, DOI 10.1016/0022-2836(81)90301-6; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; LJUNGDAHL PO, 1989, J BIOL CHEM, V264, P3723; MAJEWSKI C, 1990, MOL GEN GENET, V224, P373, DOI 10.1007/BF00262431; MUKAI K, 1986, J BIOCHEM-TOKYO, V100, P1165, DOI 10.1093/oxfordjournals.jbchem.a121820; NALECZ MJ, 1985, ARCH BIOCHEM BIOPHYS, V236, P619; NEEDLEMAN RB, 1975, ANAL BIOCHEM, V64, P545, DOI 10.1016/0003-2697(75)90466-2; NICHOLSON DW, 1989, J BIOL CHEM, V264, P10156; OHASHI A, 1982, J BIOL CHEM, V257, P3042; OHTA S, 1987, FEBS LETT, V226, P171, DOI 10.1016/0014-5793(87)80573-2; PHILLIPS JD, 1993, J BIOL CHEM, V268, P11727; ROBERTSON DE, 1993, BIOCHEMISTRY-US, V32, P1310, DOI 10.1021/bi00056a016; SCHMITT ME, 1990, J BIOL CHEM, V265, P17005; SCHMITT ME, 1991, J BIOL CHEM, V266, P14958; SCHOPPINK PJ, 1989, BIOCHIM BIOPHYS ACTA, V974, P192, DOI 10.1016/S0005-2728(89)80372-X; SCHOPPINK PJ, 1988, EUR J BIOCHEM, V173, P115, DOI 10.1111/j.1432-1033.1988.tb13974.x; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P102; VANLOON APGM, 1984, EMBO J, V3, P1039, DOI 10.1002/j.1460-2075.1984.tb01924.x; WAKABAYASHI S, 1982, J BIOCHEM, V91, P2077, DOI 10.1093/oxfordjournals.jbchem.a133901; WYNN RM, 1986, PHOTOSYNTH RES, V9, P181, DOI 10.1007/BF00029743; YANG XH, 1986, J BIOL CHEM, V261, P2282; YANG XH, 1988, J BIOL CHEM, V263, P11962	33	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1270	1275						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288589				2022-12-27	WOS:A1994MR22000079
J	BRAKENHOFF, JPJ; DEHON, FD; FONTAINE, V; TENBOEKEL, E; SCHOOLTINK, H; ROSEJOHN, S; HEINRICH, PC; CONTENT, J; AARDEN, LA				BRAKENHOFF, JPJ; DEHON, FD; FONTAINE, V; TENBOEKEL, E; SCHOOLTINK, H; ROSEJOHN, S; HEINRICH, PC; CONTENT, J; AARDEN, LA			DEVELOPMENT OF A HUMAN INTERLEUKIN-6 RECEPTOR ANTAGONIST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; IL-6 SIGNAL TRANSDUCER; STIMULATORY FACTOR-II; HIGH-AFFINITY BINDING; ESCHERICHIA-COLI; AMINO-ACIDS; SCANNING MUTAGENESIS; EXTRACELLULAR DOMAIN; BIOLOGICAL-ACTIVITY; INTERNAL DELETIONS	Neutralizing monoclonal antibodies specific for human interleukin-6 (IL-6) bind two distinct sites on the IL-6 protein (sites I and II). Their interference with IL-6 receptor binding suggested that site I is a receptor-binding site of IL-6, whereas site II is important for signal transduction. Mutagenesis of site II could therefore result in the isolation of IL-6 receptor antagonists. To test this hypothesis, a panel of IL-6 mutant proteins was constructed that did not bind to a site II-specific monoclonal antibody. One such site II mutant protein (with double substitution of Gln-160 with Glu and Thr-163 with Pro) was found to be an antagonist of human IL-6. It was inactive on human CESS cells, weakly active on human HepG2 cells, but active on mouse B9 cells. It could specifically antagonize the activity of wild-type IL-6 on CESS and HepG2 cells. The binding affinity of this variant for the 80-kDa IL-6 receptor was similar to that of wild-type IL-6. High affinity binding to CESS cells, however, was abolished, suggesting that the mutant protein is inactive because the complex of the 80-kDa IL-6 receptor and the mutant protein cannot associate with the signal transducer gp130. The human IL-6 antagonist protein may be potentially useful as a therapeutic agent.	RHEIN WESTFAL TH AACHEN,INST BIOCHEM,W-5100 AACHEN,GERMANY; INST PASTEUR,B-1180 BRUSSELS,BELGIUM	RWTH Aachen University	BRAKENHOFF, JPJ (corresponding author), NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,DEPT AUTOIMMUNE DIS,CENT LAB,1066 CX AMSTERDAM,NETHERLANDS.		Rose-John, Stefan/A-7998-2010	Rose-John, Stefan/0000-0002-7519-3279; Fontaine, Veronique/0000-0001-7588-5462				AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; ARCONE R, 1991, FEBS LETT, V288, P197, DOI 10.1016/0014-5793(91)81033-5; AREND WP, 1990, J CLIN INVEST, V85, P1694, DOI 10.1172/JCI114622; BAUER J, 1991, ANN HEMATOL, V62, P203, DOI 10.1007/BF01729833; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAKENHOFF JPJ, 1990, J IMMUNOL, V145, P561; BRAKENHOFF JPJ, 1987, J IMMUNOL, V139, P4116; BRAKENHOFF JPJ, 1989, J IMMUNOL, V143, P1175; BRAKENHOFF JPJ, 1992, SERONO S PUBLICATION, V88, P33; CALVO JC, 1983, BIOCHEM J, V212, P259, DOI 10.1042/bj2120259; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; COULIE PG, 1987, EUR J IMMUNOL, V17, P1435, DOI 10.1002/eji.1830171008; COULIE PG, 1989, EUR J IMMUNOL, V19, P2107, DOI 10.1002/eji.1830191121; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DALESSANDRO F, 1993, J BIOL CHEM, V268, P2149; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Dinarello C A, 1992, Eur Cytokine Netw, V3, P7; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; ELDERING E, 1988, J BIOL CHEM, V263, P11776; FONTAINE V, 1993, EUR J BIOCHEM, V211, P749, DOI 10.1111/j.1432-1033.1993.tb17605.x; FONTAINE V, 1991, GENE, V104, P227, DOI 10.1016/0378-1119(91)90254-9; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; Grau G E, 1990, Eur Cytokine Netw, V1, P203; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIRANO T, 1990, IMMUNOL TODAY, V11, P443, DOI 10.1016/0167-5699(90)90173-7; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KLEIN B, 1991, BLOOD, V78, P1198; KRUTTGEN A, 1990, FEBS LETT, V273, P95, DOI 10.1016/0014-5793(90)81059-W; KRUTTGEN A, 1990, FEBS LETT, V262, P323, DOI 10.1016/0014-5793(90)80219-9; LEEBEEK FWG, 1992, J BIOL CHEM, V267, P14832; LIU JW, 1992, J BIOL CHEM, V267, P16763; LUTTICKEN C, 1991, FEBS LETT, V282, P265, DOI 10.1016/0014-5793(91)80491-K; MACKIEWICZ A, 1992, J IMMUNOL, V149, P2021; PIETZKO D, 1993, J BIOL CHEM, V268, P4250; POUPART P, 1987, EMBO J, V6, P1219, DOI 10.1002/j.1460-2075.1987.tb02357.x; ROODMAN GD, 1992, J CLIN INVEST, V89, P46, DOI 10.1172/JCI115584; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; ROSEJOHN S, 1991, J BIOL CHEM, V266, P3841; SEHGAL PB, 1990, P SOC EXP BIOL MED, V195, P183; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; SNYERS L, 1990, P NATL ACAD SCI USA, V87, P2838, DOI 10.1073/pnas.87.7.2838; STRASSMANN G, 1992, J CLIN INVEST, V89, P1681, DOI 10.1172/JCI115767; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; TAGA T, 1987, J EXP MED, V166, P967, DOI 10.1084/jem.166.4.967; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; ZURAW BL, 1990, J BIOL CHEM, V265, P12664; ZURAWSKI SM, 1992, EMBO J, V11, P3905, DOI 10.1002/j.1460-2075.1992.tb05483.x	62	108	170	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					86	93						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276883				2022-12-27	WOS:A1994MR21900021
J	HARE, JF; TAYLOR, K; HOLOCHER, A				HARE, JF; TAYLOR, K; HOLOCHER, A			ENERGY-DEPENDENT PROTEIN-TRIACYLGLYCEROL INTERACTION IN A CELL-FREE SYSTEM FROM 3T3-L1 ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIACYLGLYCEROL ACYLTRANSFERASE; INTERACTION INVITRO; VESICLES; VIMENTIN; FUSION; LIPIDS; RECONSTITUTION	Triacylglycerol is synthesized from the precursors sn-1,2-diacylglycerol and palmitoyl-CoA in a reaction catalyzed by the microsomal enzyme diacylglycerol acyltransferase (EC 2.3.1.20). lsolated 3T3-L1 adipocyte microsomal vesicles from cells pulse-labeled with L-[S-35]methionine were found to release microsomal proteins into a low density form during the synthesis of triacylglycerol. The proteins released, which represent a subset of those present in the labeled microsomes, include a 62-kDa protein found in high concentration in mature fat droplets. The formation of the triacylglycerol-protein complexes was dependent on time and temperature, was not stimulated by cytosol, and required ATP as well as diacylglycerol and palmitoyl-CoA. Only nucleoside triphosphates and not non-hydrolyzable analogues could replace ATP in the reaction. Unlike the enzyme reaction that measures the synthesis of triacylglycerol, the formation of low density membrane is thus dependent on ATP hydrolysis as well as enzyme substrates. The newly formed, low density particles are selectively enriched in triacylglycerol synthesized during the reaction as well as that synthesized prior to the reaction. The cell-free system described thus appears to represent an early adipogenic event leading to the lipid vacuoles found in mature adipocytes.			HARE, JF (corresponding author), OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201, USA.							BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; BRAELL WA, 1987, P NATL ACAD SCI USA, V84, P1137, DOI 10.1073/pnas.84.5.1137; Cabral F, 1979, Methods Enzymol, V56, P602; COLEMAN R, 1976, J BIOL CHEM, V251, P4537; DAVEY J, 1985, CELL, V43, P643, DOI 10.1016/0092-8674(85)90236-3; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DULLEY JR, 1975, ANAL BIOCHEM, V64, P136, DOI 10.1016/0003-2697(75)90415-7; FABER JL, 1981, ARCH BIOCHEM BIOPHYS, V211, P312; FRANKE WW, 1987, CELL, V49, P131, DOI 10.1016/0092-8674(87)90763-X; FROST SC, 1985, J BIOL CHEM, V260, P2646; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; HAAGSMAN HP, 1982, J BIOL CHEM, V257, P593; Jarett L, 1974, Methods Enzymol, V31, P60; MAIZEL JV, 1969, FUNDAMENTAL TECHNIQU, P334; MULLOCK BM, 1989, J CELL BIOL, V108, P2093, DOI 10.1083/jcb.108.6.2093; NOVIKOFF AB, 1980, J CELL BIOL, V87, P180, DOI 10.1083/jcb.87.1.180; OZASA S, 1989, J LIPID RES, V30, P1759; PERIDES G, 1986, EUR J CELL BIOL, V41, P313; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; POLOKOFF MA, 1978, J BIOL CHEM, V253, P7173; SLAVIN BG, 1979, ANAT RECORD, V195, P63, DOI 10.1002/ar.1091950106; TRAUB P, 1986, J BIOL CHEM, V261, P558; TRAUB P, 1985, FEBS LETT, V193, P217, DOI 10.1016/0014-5793(85)80155-1; WOODMAN PG, 1986, J CELL BIOL, V103, P1829, DOI 10.1083/jcb.103.5.1829; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	25	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					771	776						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276882				2022-12-27	WOS:A1994MR21900121
J	HORDIJK, PL; VERLAAN, I; VANCORVEN, EJ; MOOLENAAR, WH				HORDIJK, PL; VERLAAN, I; VANCORVEN, EJ; MOOLENAAR, WH			PROTEIN-TYROSINE PHOSPHORYLATION-INDUCED BY LYSOPHOSPHATIDIC ACID IN RAT-1 FIBROBLASTS - EVIDENCE THAT PHOSPHORYLATION OF MAP KINASE IS MEDIATED BY THE GI-P21RAS PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; GTPASE-ACTIVATING PROTEIN; PHOSPHOLIPASE-C; P21(RAS) ACTIVATION; SIGNALING PATHWAYS; PHOSPHATIDIC-ACID; MESANGIAL CELLS; FOCAL ADHESIONS; GROWTH-FACTORS; ENDOTHELIN	Lysophosphatidic acid (LPA) is a platelet-derived phospholipid that serves as a mitogen for fibroblasts. LPA activates its own G protein-coupled receptor(s) leading to stimulation of phospholipase C and inhibition of adenylate cyclase. Furthermore, LPA rapidly activates p21ras through a pertussis toxin-sensitive pathway. In this study, we have examined LPA-induced protein tyrosine phosphorylation in Rat-1 fibroblasts. LPA action was compared with that of endothelin, which is a stronger activator of phospholipase C than LPA but fails to activate p21ras and to stimulate DNA synthesis in these cells. LPA and, more effectively, endothelin rapidly stimulate tyrosine phosphorylation of proteins of 110-130, 95, and 65-75 kDa. The effect of LPA is dose- and time-dependent, being half-maximal at 3-30 nm and peaking after 2-5 min. Among the 110-130-kDa group of phosphotyrosyl proteins is the 125-kDa ''focal adhesion kinase'' (p125FAK) but not the 120-kDa p21ras GTPase-activating protein. Furthermore, LPA, like epidermal growth factor, causes tyrosine phosphorylation and activation of the p42/p44 mitogen-activated protein (MAP) kinases, paralleling p21ras activation. In contrast, endothelin fails to phosphorylate MAP kinase. Treatment of the cells with pertussis toxin blocks LPA-induced MAP kinase phosphorylation without affecting the other tyrosine phosphorylations. The kinase inhibitor staurosporine (1 muM) blocks LPA-induced, but not epidermal growth factor-induced, activation of p21ras and MAP kinase, consistent with an intermediate protein kinase linking the LPA receptor to p21ras activation. The results support a model in which LPA-induced phosphorylation of MAP kinase is mediated by p21ras and tyrosine phosphorylation of the other substrates, including p125FAK, is associated with phospholipase C activation.	NETHERLANDS CANC INST,DIV CELLULAR BIOCHEM,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute				Hordijk, Peter/0000-0002-3348-078X				AKIYAMA T, 1991, METHOD ENZYMOL, V201, P362; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FALLON RJ, 1990, BIOCHEM BIOPH RES CO, V170, P1191, DOI 10.1016/0006-291X(90)90519-S; FORCE T, 1991, J BIOL CHEM, V266, P6650; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; JALINK K, 1993, P NATL ACAD SCI USA, V90, P1857, DOI 10.1073/pnas.90.5.1857; JALINK K, 1990, J BIOL CHEM, V265, P12232; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE CH, 1992, J BIOL CHEM, V267, P16044; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MOLLOY CJ, 1992, MOL CELL BIOL, V12, P3903, DOI 10.1128/MCB.12.9.3903; MOOLENAAR WH, 1991, CELL GROWTH DIFFER, V2, P359; MOOLENAAR WH, 1992, REV PHYSL BIOCH PHAR, V119, P48; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OFFERMANNS S, 1993, BIOCHEM J, V290, P27, DOI 10.1042/bj2900027; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; PLEVIN R, 1991, BIOCHEM J, V280, P609, DOI 10.1042/bj2800609; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SECRIST JP, 1990, J BIOL CHEM, V265, P20394; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THOMAS G, 1992, CELL, V68, P1; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TIGYI G, 1992, J BIOL CHEM, V267, P21360; TORTI M, 1992, J BIOL CHEM, V267, P8293; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1259; VANDERBEND RL, 1992, BIOCHEM J, V285, P235, DOI 10.1042/bj2850235; VANDERBEND RL, 1992, EMBO J, V11, P2495, DOI 10.1002/j.1460-2075.1992.tb05314.x; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	56	239	240	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					645	651						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276865				2022-12-27	WOS:A1994MR21900102
J	JIANG, HB; WANG, Y; KANOST, MR				JIANG, HB; WANG, Y; KANOST, MR			MUTUALLY EXCLUSIVE EXON USE AND REACTIVE CENTER DIVERSITY IN INSECT SERPINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ACTIVATOR INHIBITOR-1 GENE; PROTEINASE-INHIBITORS; MANDUCA-SEXTA; HEMOLYMPH; SEQUENCES	We have isolated 38 cDNA clones for serpins from a lepidopteran insect, Manduca sexta, and have found that they are identical in sequence, except for a region encoding the carboxyl-terminal 40-45 residues, which includes the reactive center. Among these clones, there are 11 variants of the reactive center region, each encoded by a different version of the ninth exon in the serpin gene. Thus, evolution of this insect serpin gene has resulted from duplication and sequence divergence of only the exon encoding the reactive site. Alternative pre-mRNA splicing then generates inhibitor diversity and the potential to regulate a variety of proteinases, using the same protein framework joined to different reactive site region cassettes.	KANSAS STATE UNIV AGR & APPL SCI, DEPT BIOCHEM, MANHATTAN, KS 66506 USA	Kansas State University			Jiang, Haobo/A-6519-2008	Jiang, Haobo/0000-0003-1357-1315; Kanost, Michael/0000-0002-6827-0061	NIGMS NIH HHS [GM41247, R37 GM041247] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041247, R29GM041247, R01GM041247] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBAS JA, 1993, MOL CELL BIOL, V13, P1433, DOI 10.1128/MCB.13.3.1433; BORRIELLO F, 1991, P NATL ACAD SCI USA, V88, P9417, DOI 10.1073/pnas.88.21.9417; BOSMA PJ, 1988, J BIOL CHEM, V263, P9129; BOSWELL DR, 1988, BIOESSAYS, V8, P83, DOI 10.1002/bies.950080209; BRUZDZINSKI CJ, 1990, J BIOL CHEM, V265, P2078; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; COLE KD, 1990, INSECT BIOCHEM, V20, P381, DOI 10.1016/0020-1790(90)90058-3; FENG DF, 1990, METHOD ENZYMOL, V183, P375; HILL RE, 1987, NATURE, V326, P96, DOI 10.1038/326096a0; Kanost M.R., 1990, P139; KANOST MR, 1989, J BIOL CHEM, V264, P965; KANOST MR, 1990, INSECT BIOCHEM, V20, P141, DOI 10.1016/0020-1790(90)90006-G; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; NARUMI H, 1993, EUR J BIOCHEM, V214, P181, DOI 10.1111/j.1432-1033.1993.tb17911.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI T, 1991, EUR J BIOCHEM, V202, P255, DOI 10.1111/j.1432-1033.1991.tb16370.x; SAVAKIS C, 1986, DEV BIOL, V114, P194, DOI 10.1016/0012-1606(86)90395-7; SMITH CWJ, 1989, CELL, V56, P749, DOI 10.1016/0092-8674(89)90678-8; SUGUMARAN M, 1993, PARASITES PATHOGENS, V1, P317; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; WRIGHT HT, 1993, J MOL EVOL, V36, P136, DOI 10.1007/BF00166249	22	54	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					55	58						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276850				2022-12-27	WOS:A1994MR21900015
J	MCENERY, MW; SNOWMAN, AM; SNYDER, SH				MCENERY, MW; SNOWMAN, AM; SNYDER, SH			THE ASSOCIATION OF ENDOGENOUS-G(OMICRON-ALPHA) WITH THE PURIFIED OMEGA-CONOTOXIN GVIA RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RAT SYMPATHETIC NEURONS; NUCLEOTIDE-BINDING PROTEIN; BETA-GAMMA-SUBUNITS; CALCIUM CHANNELS; N-TYPE; P-TYPE; REGULATORY PROTEINS; VOLTAGE DEPENDENCE; PERIPHERAL NEURONS; SYNAPTIC VESICLES	Modulation of the neuronal omega-conotoxin GVIA-sensitive N-type voltage-dependent calcium channel (VDCC) by neurotransmitters and guanine nucleotides suggests a dynamic interaction between activated G-protein a subunits and the N-type VDCC. Our previous report on the purification of the N-type VDCC (McEnery, M. W., Snowman, A. M., Sharp, A. H., Adams, M. E., and Snyder, S. H. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 11095-11099), has led us to investigate a possible association of CTXR with an endogenous G(alpha) subunit. The addition of the G-protein activator AlF4- modulated the I-125-CTX binding characteristics of the solubilized CTXR. Further immunological analyses employing G(alpha) subunit-specific antibodies to monitor the cofractionation of G(alpha) with I-125-CTX binding activity throughout the purification procedure indicate the selective recovery of G(oalpha) in the purified CTXR preparation, as neither G(salpha), G(ialpha), nor G(betagamma) could be detected. Furthermore, G(oalpha) associated with CTXR acted as a substrate for pertussis toxin-dependent ADP-ribosylation only upon the addition of exogenous G(betagamma) subunits. These results strongly indicate a high affinity complex between an activated G(oalpha) and CTXR maintained throughout biochemical purification of the I-125-CTX receptor.	JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; CASE WESTERN RESERVE SCH MED, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHARMACOL & MOLEC SCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PSYCHIAT, BALTIMORE, MD 21205 USA	Johns Hopkins University; Case Western Reserve University; Johns Hopkins University; Johns Hopkins University								ANWYL R, 1991, BRAIN RES REV, V16, P265, DOI 10.1016/0165-0173(91)90010-6; BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BEECH DJ, 1992, NEURON, V8, P97, DOI 10.1016/0896-6273(92)90111-P; BEGAMASCHI S, 1992, J NEUROCHEM, V59, P536; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BERNHEIM L, 1991, NEURON, V6, P859, DOI 10.1016/0896-6273(91)90226-P; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; BOLAND LM, 1993, J NEUROSCI, V13, P516; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; DELCOUR AH, 1993, SCIENCE, V259, P980, DOI 10.1126/science.8094902; DOLPHIN AC, 1990, ANNU REV PHYSIOL, V52, P243; ELMSLIE KS, 1992, J PHYSIOL-LONDON, V451, P229, DOI 10.1113/jphysiol.1992.sp019162; ELMSLIE KS, 1990, NEURON, V5, P75, DOI 10.1016/0896-6273(90)90035-E; EWALD DA, 1988, P NATL ACAD SCI USA, V85, P3633, DOI 10.1073/pnas.85.10.3633; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HAMILTON SL, 1991, J BIOL CHEM, V266, P19528; HARRISWARRICK RM, 1988, NEURON, V1, P27, DOI 10.1016/0896-6273(88)90206-1; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; HOLZ GG, 1986, NATURE, V319, P670, DOI 10.1038/319670a0; HUFF RM, 1985, J BIOL CHEM, V260, P864; IKEDA SR, 1991, J PHYSIOL-LONDON, V439, P181, DOI 10.1113/jphysiol.1991.sp018663; JONES SW, 1991, BIOPHYS J, V60, P502, DOI 10.1016/S0006-3495(91)82077-X; KASAI H, 1989, PFLUG ARCH EUR J PHY, V414, P145, DOI 10.1007/BF00580956; KASAI H, 1991, P NATL ACAD SCI USA, V88, P8855, DOI 10.1073/pnas.88.19.8855; KATADA T, 1986, J BIOL CHEM, V261, P8182; KOBAYASHI I, 1989, FEBS LETT, V257, P177, DOI 10.1016/0014-5793(89)81815-0; KOMURO H, 1992, NATURE, V257, P806; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; LLINAS R, 1992, TRENDS NEUROSCI, V15, P351, DOI 10.1016/0166-2236(92)90053-B; MACKIE K, 1992, P NATL ACAD SCI USA, V89, P3825, DOI 10.1073/pnas.89.9.3825; MAEDA N, 1989, BRAIN RES, V489, P21, DOI 10.1016/0006-8993(89)90004-8; MATHIE A, 1992, NEURON, V8, P907, DOI 10.1016/0896-6273(92)90205-R; MCCORMICK DA, 1989, P NATL ACAD SCI USA, V86, P8098, DOI 10.1073/pnas.86.20.8098; MCENERY MW, 1990, BIOPHYS J, V57, pA516; MCENERY MW, 1984, J BIOL CHEM, V259, P4642; MCENERY MW, 1991, P NATL ACAD SCI USA, V88, P11095, DOI 10.1073/pnas.88.24.11095; MCENERY MW, IN PRESS ANN NY ACAD; MCENERY MW, 1993, MOL CELLULAR BIOL PH, V7, P3; MCFADZEAN I, 1989, NEURON, V3, P177, DOI 10.1016/0896-6273(89)90030-5; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; MINTZ IM, 1993, NEURON, V10, P889, DOI 10.1016/0896-6273(93)90204-5; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; PLUMMER MR, 1991, J NEUROSCI, V11, P2339; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; SCHULTZ G, 1990, ANNU REV PHYSIOL, V52, P275, DOI 10.1146/annurev.ph.52.030190.001423; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STERNWEIS PC, 1982, J BIOL CHEM, V79, P4888; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; TAKAHASHI M, 1991, BRAIN RES, V551, P279, DOI 10.1016/0006-8993(91)90942-O; TAKEMURA M, 1989, NEUROSCIENCE, V32, P405, DOI 10.1016/0306-4522(89)90089-4; TAUSSIG R, 1992, NEURON, V8, P799, DOI 10.1016/0896-6273(92)90100-R; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; TURNER TJ, 1991, ANN NY ACAD SCI, V635, P497, DOI 10.1111/j.1749-6632.1991.tb36538.x; WAGNER JA, 1988, J NEUROSCI, V8, P3354; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WORLEY PF, 1986, P NATL ACAD SCI USA, V83, P4561, DOI 10.1073/pnas.83.12.4561; YATANI A, 1988, J BIOL CHEM, V263, P9887	65	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					5	8						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276842				2022-12-27	WOS:A1994MR21900002
J	TAYLOR, LK; SWANSON, KD; KERIGAN, J; MOBLEY, W; LANDRETH, GE				TAYLOR, LK; SWANSON, KD; KERIGAN, J; MOBLEY, W; LANDRETH, GE			ISOLATION AND CHARACTERIZATION OF A NERVE GROWTH FACTOR-REGULATED FOS KINASE FROM PC12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; MICROTUBULE-ASSOCIATED PROTEIN-2; TRK PROTOONCOGENE PRODUCT; C-FOS; SERUM STIMULATION; TYROSINE KINASES; PHOSPHORYLATION; ACTIVATION; TRANSCRIPTION; PC12-CELLS	Nerve growth factor (NGF) treatment of PC12 cells activates a protein kinase that phosphorylates c-Fos protein at a site near its C terminus, as well as a peptide corresponding to a C-terminal region of c-Fos (Taylor, L. K., Marshak, D. R., and Landreth, G. E. (1993) Proc. Natl. Acad. Sci. U. S. A. 90,368-372). This serine/threonine kinase, termed Fos kinase, has been purified >24,000-fold through five column steps to near homogeneity and is shown to be a 37-kDa protein as determined by SDS-polyacrylamide gel electrophoresis (PAGE) with a pI = 6.0. Fos kinase is distinguishable from previously characterized NGF-regulated kinases by its chromatographic behavior, its response to specific kinase inhibitors, and its substrate specificity. The concentration of NGF required to activate Fos kinase is consistent with signaling from the high affinity NGF receptor. Fos kinase phosphorylates c-Fos at its C terminus as indicated by competitive inhibition with a peptide corresponding to C-terminal phosphorylation sites and lack of phosphorylation of a C-terminal deletion mutant of c-Fos. Hyperphosphorylation of c-Fos in vivo, as detected by reduced electrophoretic mobility of c-Fos, is induced by the same ligands which activate Fos kinase. Moreover, Fos kinase phosphorylation of c-Fos in vitro results in a similar electrophoretic mobility shift, demonstrating that Fos kinase may be responsible for growth factor-stimulated alterations in mobility on SDS-PAGE and phosphorylation of this transcription factor. The ability of this unique growth factor-responsive kinase to phosphorylate c-Fos at its C terminus, a region essential for the transrepressive properties of c-Fos, suggests that Fos kinase may play a role in the regulation of the transcriptional repressive activity of c-Fos.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT NEUROL,ALZHEIMER RES LAB,E504,10900 EUCLID AVE,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT NEUROSCI,CLEVELAND,OH 44106; UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143	Case Western Reserve University; Case Western Reserve University; University of California System; University of California San Francisco					NIGMS NIH HHS [GM34908] Funding Source: Medline; NINDS NIH HHS [NS/AG10672, NS24054] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034908] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024054, F31NS010672] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABATE C, 1991, ONCOGENE, V6, P2179; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHENG HC, 1986, J BIOL CHEM, V261, P989; CURRAN T, 1986, P NATL ACAD SCI USA, V83, P8521, DOI 10.1073/pnas.83.22.8521; CURRAN T, 1984, CELL, V36, P259; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1987, METHOD ENZYMOL, V147, P207; GUIS D, 1990, MOL CELL BIOL, V10, P4243; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HEASLEY LE, 1989, MOL PHARMACOL, V35, P331; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; LANDRETH GE, 1990, J NEUROCHEM, V55, P514, DOI 10.1111/j.1471-4159.1990.tb04165.x; LONGO FM, 1990, CELL REGUL, V1, P189, DOI 10.1091/mbc.1.2.189; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MUTOH T, 1988, J BIOL CHEM, V263, P15853; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; Qui MS, 1991, NEURON, V7, P937, DOI [DOI 10.1016/0896-6273(91)90339-2, 10.1016/0896-6273(91)90339-2]; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; ROWLAND EA, 1987, J BIOL CHEM, V262, P7504; ROWLANDGAGNE E, 1990, J NEUROCHEM, V54, P424, DOI 10.1111/j.1471-4159.1990.tb01890.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SMITH AP, 1968, BIOCHEMISTRY-US, V7, P3259, DOI 10.1021/bi00849a032; SMITH DS, 1989, J NEUROCHEM, V53, P800, DOI 10.1111/j.1471-4159.1989.tb11776.x; TAYLOR LK, 1993, P NATL ACAD SCI USA, V90, P368, DOI 10.1073/pnas.90.2.368; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; WILSON T, 1988, EMBO J, V7, P4193, DOI 10.1002/j.1460-2075.1988.tb03316.x; WOODGETT J, 1992, METHOD ENZYMOL, V200, P564	46	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					308	318						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276812				2022-12-27	WOS:A1994MR21900054
J	BLUM, JH; STEVENS, TL; DEFRANCO, AL				BLUM, JH; STEVENS, TL; DEFRANCO, AL			ROLE OF THE MU IMMUNOGLOBULIN HEAVY-CHAIN TRANSMEMBRANE AND CYTOPLASMIC DOMAINS IN B-CELL ANTIGEN RECEPTOR EXPRESSION AND SIGNAL-TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TYROSINE PHOSPHORYLATION; LYMPHOCYTE-B; MEMBRANE IMMUNOGLOBULIN; GAMMA-CHAINS; NUCLEOTIDE-SEQUENCE; CA-2+ MOBILIZATION; PHOSPHOLIPASE-C; MESSENGER-RNA; KINASE-C; T-CELLS	Membrane immunoglobulins (mIg) serve as the recognition components of B lymphocyte antigen receptors. Binding of antigen to these receptors leads to dramatic effects on B cell growth and viability. We have examined the structural elements of mIgM that are involved in antigen receptor assembly and function. Expression of transfected wild-type mIgM in a B cell line led to assembly with the other two known components of the antigen receptor, Ig-alpha and Ig-beta, expression on the cell surface, and when cross-linked by anti-IgM antibodies, stimulation of signal transductin reactions, including tyrosine protein phosphorylation, inositol phosphate production, and increases in cytoplasmic calcium concentration. Replacement of the highly conserved COOH-terminal 41 amino acids of mIgM heavy chain (mu(m)) with the transmembrane and cytoplasmic domains of human CD8alpha resulted in a molecule which was expressed on the B cell surface at levels comparable to wild-type mIgM, but which did not form a complex with Ig-alpha or Ig-beta and did not stimulate any of the signaling reactions mentioned above. Replacement of the basic three-amino-acid cytoplasmic domain of mu(m) with a different but similarly charged sequence had no effect on cell-surface expression or signaling function. On the other hand, removal of the entire cytoplasmic domain resulted in a molecule which did not bind Ig-alpha and Ig-beta and which did not transduce signals. This effect is probably due to altered post-translational processing of this mutant molecule. Finally, a series of eight single-amino-acid substitutions in the transmembrane domain was constructed. Most of these resulted in the removal of hydroxyl groups from conserved residues postulated to be important for interactions with other components. Each of these mutant molecules was capable of transducing signals when cross-linked by anti-IgM, but one was partially defective. Since alteration of any single residue was not sufficient to disrupt signaling completely, the interactions required for signaling are likely to involve multiple residues, so that elimination of one hydroxyl group does not prevent the interaction. We propose that the cytoplasmic domain of mu(m) does not play a critical role in receptor function but that the transmembrane domain specifies interactions with other components, probably Ig-alpha and Ig-beta, required for proper antigen receptor signal transduction.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,GEORGE WILLIAMS HOOPER FDN,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NCI NIH HHS [CA09043] Funding Source: Medline; NIAID NIH HHS [AI20038] Funding Source: Medline; NIGMS NIH HHS [GM07618] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009043] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020038, R01AI020038, R56AI020038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007618] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESMARTINEZ JE, 1988, P NATL ACAD SCI USA, V85, P6919, DOI 10.1073/pnas.85.18.6919; BERNSTEIN KE, 1984, J IMMUNOL, V132, P490; BIJSTERBOSCH MK, 1985, CELL, V41, P999, DOI 10.1016/S0092-8674(85)80080-5; BOYD AW, 1981, J IMMUNOL, V126, P2466; BROWN AMC, 1987, DNA CLONING, V3, P189; BRUNSWICK M, 1991, P NATL ACAD SCI USA, V88, P1311, DOI 10.1073/pnas.88.4.1311; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMBIER J, 1988, P NATL ACAD SCI USA, V85, P6493, DOI 10.1073/pnas.85.17.6493; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CHENG HL, 1982, NATURE, V296, P410, DOI 10.1038/296410a0; COSTA TE, 1992, J EXP MED, V175, P1669, DOI 10.1084/jem.175.6.1669; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DEFRANCO A L, 1992, Current Biology, V2, P477; DORAI H, 1989, NUCLEIC ACIDS RES, V17, P6412, DOI 10.1093/nar/17.15.6412; DUBOIS PM, 1992, EUR J IMMUNOL, V22, P851, DOI 10.1002/eji.1830220333; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GROSSCHEDL R, 1984, CELL, V38, P647, DOI 10.1016/0092-8674(84)90259-9; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HOMBACH J, 1990, EUR J IMMUNOL, V20, P2795, DOI 10.1002/eji.1830201239; ISHIDA N, 1982, EMBO J, V1, P1117, DOI 10.1002/j.1460-2075.1982.tb01306.x; KOKUBU F, 1988, EMBO J, V7, P1979, DOI 10.1002/j.1460-2075.1988.tb03036.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANE PJL, 1990, J IMMUNOL, V144, P3684; LANE PJL, 1991, J IMMUNOL, V146, P715; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; LYNCH CJ, 1985, MOL PHARMACOL, V28, P93; MATSUUCHI L, 1992, P NATL ACAD SCI USA, V89, P3404, DOI 10.1073/pnas.89.8.3404; MITCHELL RN, 1991, J BIOL CHEM, V266, P8856; MIZUGUCHI J, 1986, J IMMUNOL, V137, P2162; MONROE JG, 1989, MOL IMMUNOL, V26, P593, DOI 10.1016/0161-5890(89)90041-2; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NORMENT AM, 1989, J IMMUNOL, V142, P3312; OI VT, 1980, J EXP MED, V151, P1260, DOI 10.1084/jem.151.5.1260; PADEH S, 1991, J CLIN INVEST, V87, P1114, DOI 10.1172/JCI115074; PAGE DM, 1991, J BIOL CHEM, V266, P5563; PAGE DM, 1988, J IMMUNOL, V140, P3717; PARIKH VS, 1991, J EXP MED, V174, P1103, DOI 10.1084/jem.174.5.1103; PARIKH VS, 1992, J EXP MED, V176, P1025, DOI 10.1084/jem.176.4.1025; PIKE BL, 1982, P NATL ACAD SCI-BIOL, V79, P2013, DOI 10.1073/pnas.79.6.2013; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; ROGERS J, 1981, CELL, V26, P19, DOI 10.1016/0092-8674(81)90029-5; ROGERS J, 1984, ADV IMMUNOL, V35, P39, DOI 10.1016/S0065-2776(08)60573-8; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; SCHENA M, 1988, US BIOCH EDITORIAL C, V15, P23; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SHAW AC, 1990, CELL, V63, P381, DOI 10.1016/0092-8674(90)90171-A; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; THOMPSON JA, 1987, BIOCHEMISTRY-US, V26, P743, DOI 10.1021/bi00377a014; TISCH R, 1988, P NATL ACAD SCI USA, V85, P6914, DOI 10.1073/pnas.85.18.6914; TYLER BM, 1982, P NATL ACAD SCI-BIOL, V79, P2008, DOI 10.1073/pnas.79.6.2008; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; WARNER NL, 1979, IMMUNOL REV, V48, P197, DOI 10.1111/j.1600-065X.1979.tb00304.x; WEBB CF, 1989, P NATL ACAD SCI USA, V86, P1977, DOI 10.1073/pnas.86.6.1977; WILLIAMS GT, 1990, J EXP MED, V171, P947, DOI 10.1084/jem.171.3.947; Word C J, 1989, Int Immunol, V1, P296, DOI 10.1093/intimm/1.3.296; WORD CJ, 1983, EMBO J, V2, P887, DOI 10.1002/j.1460-2075.1983.tb01518.x; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMAWAKIKATAOKA Y, 1982, P NATL ACAD SCI-BIOL, V79, P2623, DOI 10.1073/pnas.79.8.2623	60	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27236	27245						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262964				2022-12-27	WOS:A1993MM26200060
J	LUKA, S; SANJUAN, J; CARLSON, RW; STACEY, G				LUKA, S; SANJUAN, J; CARLSON, RW; STACEY, G			NOLMNO GENES OF BRADYRHIZOBIUM-JAPONICUM ARE CO-TRANSCRIBED WITH NODYABCSUIJ, AND NOLO IS INVOLVED IN THE SYNTHESIS OF THE LIPO-OLIGOSACCHARIDE NODULATION SIGNALS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; RHIZOBIUM-MELILOTI; HOST-SPECIFICITY; NOD GENES; STRAIN NGR234; EXPRESSION; FAMILY; RANGE; BRADYRHIZOBIUM-JAPONICUM-NODD1; MUTAGENESIS	A host-inducible lacZ fusion was mapped downstream of the nodYABCSUIJ operon in Bradyrhizobium japonicum strain USDA110. Sequencing of this region identified three novel genes, nolMNO. RNA dot blot analysis showed that nolO transcription is nodD1-dependent and that a polar mutation in nodS, located 5 kilobases upstream of nolO, blocks the transcription of nolO. Coupled with the host- inducible nature of nolO expression, these results indicate that nolMNO are part of a 9-kilobase operon, nodYABCSUIJnolMNO. The lipo-oligosaccharide nodulation signals produced by strains SL67(nolO-) and SL65(nolNO-) were purified, and their chemical structures were determined. In addition to the wild-type signal molecules, both mutants produced modified compounds that are not produced by the parent strain USDA110. The most prevalent difference observed was the absence of the 2-O-methylfucosyl residue from the mutant structures. In addition, metabolites were found in which the N-acetylglucosamine residue at the reducing end was glycosidically linked to glycerol. These alterations in the profiles of nodulation signals produced by strains SL67 and SL65 were accompanied by reduced nodulation efficiency on all hosts tested.	UNIV TENNESSEE,DEPT MICROBIOL,CTR LEGUME RES,KNOXVILLE,TN 37996; UNIV GEORGIA,COMPLEX CARBOHYDRATE RES CTR,ATHENS,GA 30602	University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture; University System of Georgia; University of Georgia				Sanjuan, Juan/0000-0002-6404-8754	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039583] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM39583] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANFALVI Z, 1988, MOL GEN GENET, V214, P420, DOI 10.1007/BF00330475; CARLSON RW, 1993, J BIOL CHEM, V268, P18372; DEVINE TE, 1990, THEOR APPL GENET, V80, P33, DOI 10.1007/BF00224012; FELLAY R, 1987, GENE, V52, P147, DOI 10.1016/0378-1119(87)90041-2; FESTL H, 1986, APPL ENVIRON MICROB, V52, P1190, DOI 10.1128/AEM.52.5.1190-1194.1986; FISHER RF, 1988, GENE DEV, V2, P282, DOI 10.1101/gad.2.3.282; GEELEN D, 1993, MOL MICROBIOL, V9, P145, DOI 10.1111/j.1365-2958.1993.tb01676.x; GERHOLD D, 1989, THESIS U TENNESSEE K; GOTTFERT M, 1990, MOL PLANT MICROBE IN, V3, P308, DOI 10.1094/MPMI-3-308; GOTTFERT M, 1992, MOL PLANT MICROBE IN, V5, P257, DOI 10.1094/MPMI-5-257; HALVERSON LJ, 1985, PLANT PHYSIOL, V77, P621, DOI 10.1104/pp.77.3.621; HENIKOFF S, 1988, P NATL ACAD SCI USA, V85, P6602, DOI 10.1073/pnas.85.18.6602; HONG GF, 1987, NUCLEIC ACIDS RES, V15, P9677, DOI 10.1093/nar/15.23.9677; KRISHNAN HB, 1992, MOL MICROBIOL, V6, P3321, DOI 10.1111/j.1365-2958.1992.tb02200.x; KUYKENDALL LD, 1976, APPL ENVIRON MICROB, V32, P511, DOI 10.1128/AEM.32.4.511-519.1976; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; LEWIN A, 1990, MOL PLANT MICROBE IN, V3, P317, DOI 10.1094/MPMI-3-317; LONG SR, 1989, CELL, V56, P203, DOI 10.1016/0092-8674(89)90893-3; Maniatis T., 1982, MOL CLONING; MESSING J, 1991, GENE, V100, P3, DOI 10.1016/0378-1119(91)90344-B; NIEUWKOOP AJ, 1987, J BACTERIOL, V169, P2631, DOI 10.1128/jb.169.6.2631-2638.1987; ROCHE P, 1991, J BIOL CHEM, V266, P10933; ROSTAS K, 1986, P NATL ACAD SCI USA, V83, P1757, DOI 10.1073/pnas.83.6.1757; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANJUAN J, 1992, P NATL ACAD SCI USA, V89, P8789, DOI 10.1073/pnas.89.18.8789; SCHLAMAN HRM, 1992, J BACTERIOL, V174, P5177, DOI 10.1128/JB.174.16.5177-5182.1992; SCHULTZE M, 1992, P NATL ACAD SCI USA, V89, P192, DOI 10.1073/pnas.89.1.192; SCHWEDOCK J, 1990, NATURE, V348, P644, DOI 10.1038/348644a0; SCHWEDOCK J, 1989, Molecular Plant-Microbe Interactions, V2, P181, DOI 10.1094/MPMI-2-181; SCOTT KF, 1986, NUCLEIC ACIDS RES, V14, P2905, DOI 10.1093/nar/14.7.2905; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SMIT G, 1992, J BIOL CHEM, V267, P310; SO JS, 1987, MOL GEN GENET, V207, P15, DOI 10.1007/BF00331485; SPAINK HP, 1991, NATURE, V354, P125, DOI 10.1038/354125a0; TRUCHET G, 1991, NATURE, V351, P670, DOI 10.1038/351670a0; VEST G, 1972, CROP SCI, V12, P692, DOI 10.2135/cropsci1972.0011183X001200050042x; WANG SP, 1990, MOL GEN GENET, V223, P329, DOI 10.1007/BF00265071; WANG SP, 1991, J BACTERIOL, V173, P3356, DOI 10.1128/jb.173.11.3356-3365.1991; York WS, 1985, METHOD ENZYMOL, P3, DOI DOI 10.1016/0076-6879(86)18062-1	39	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27053	27059						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262943				2022-12-27	WOS:A1993MM26200035
J	DOU, QP; ZHAO, SC; LEVIN, AH; WANG, J; HELIN, K; PARDEE, AB				DOU, QP; ZHAO, SC; LEVIN, AH; WANG, J; HELIN, K; PARDEE, AB			G1/S-REGULATED E2F-CONTAINING PROTEIN COMPLEXES BIND TO THE MOUSE THYMIDINE KINASE GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR E2F; CELL-CYCLE REGULATION; RETINOBLASTOMA PROTEIN; LABILE PROTEIN; DNA-BINDING; PRODUCT; EXPRESSION; GROWTH; PHASE; SITE	By performing DNase I footprint analysis, we had identified three distinct protein binding sequences (MT1, MT2, and MT3) located on the mouse thymidine kinase (TK) upstream promoter (Dou, Q.-P., Fridovich-Keil, J. L., and Pardee, A. B. (1991) Proc. Natl. Acad. Sci. U. S. A. 88,1157-1161). Here we report that MT2 includes an E2F-like binding site (GTTCGCGGGCAAA), as shown by the following evidence. (i) Mt2 bound specifically to an affinity-purified fusion human E2F protein. (ii) Both MT2 and an authentic E2F site (TTTCGCGCGCTTT) bound specifically to similar or identical nuclear protein complexes. (iii) Formation of both these DNA-protein complexes were cell cycle-dependent: a G0/G1 phase-specific complex (E2F.G0/G1) was replaced by an S phase-specific complex(es) (E2F.S), whereas ''free'' E2F increased after the G1/S transition. (iv) Pulse inhibition of protein synthesis with cycloheximide interchanged these complexes with similar kinetics. (v) When MT2-shifted E2F.G0/Gl, E2F.S, and free E2F were eluted and analyzed by Western blot assay using a specific antiserum to human E2F-1, two forms of murine E2F (62 and 66 kDa) were observed from all three complexes. The compositions of these MT2-bound complexes were also investigated. Studies using specific antibodies revealed that p107, a retinoblastoma-like protein, was present in both E2F.G0/G1 and E2F.S, whereas cyclin E.cyclin A.cdk2 were only present in E2F.S complex(es). These data suggest that removal of the p107-containing E2F.G0/Gl complex, a candidate repressor, from the MT2 site in late G1 may be essential for S phase-dependent transcription of the mouse TK gene.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CELL GROWTH & REGULAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, CTR CANC, BOSTON, MA 02129 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital			Helin, Kristian/HDM-8306-2022; Helin, Kristian/K-2526-2019	Helin, Kristian/0000-0003-1975-6097; Dou, Qingping/0000-0002-6465-1473	NATIONAL CANCER INSTITUTE [P01CA022427] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005526] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024571] Funding Source: NIH RePORTER; NCI NIH HHS [CA22427] Funding Source: Medline; NCRR NIH HHS [2 S07RR05526-28] Funding Source: Medline; NIGMS NIH HHS [GM24571] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BASERGA R, 1985, BIOL CELL REPRODUCTI, P134; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BRADLEY DW, 1990, P NATL ACAD SCI USA, V87, P9310, DOI 10.1073/pnas.87.23.9310; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAMPISI J, 1982, P NATL ACAD SCI-BIOL, V79, P436, DOI 10.1073/pnas.79.2.436; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COPPOCK DL, 1985, J CELL PHYSIOL, V124, P269, DOI 10.1002/jcp.1041240215; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOI QP, 1992, P NATL ACAD SCI USA, V89, P3256; DOU QP, 1991, P NATL ACAD SCI USA, V88, P1157, DOI 10.1073/pnas.88.4.1157; DOU QP, 1993, CANCER RES, V53, P1493; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; FRIDOVICHKEIL JL, 1993, CELL GROWTH DIFFER, V4, P679; FRIDOVICHKEIL JL, 1991, CELL GROWTH DIFFER, V2, P67; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KIM YK, 1992, J BIOL CHEM, V267, P2723; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LI LJ, 1993, P NATL ACAD SCI USA, V90, P3554, DOI 10.1073/pnas.90.8.3554; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MOSCOVITIS G, 1980, ANAL BIOCHEM, V101, P221, DOI 10.1016/0003-2697(80)90064-0; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NEVINS JR, 1992, SCIENCE, V258, P424; NEVINS JR, 1992, NATURE, V358, P375, DOI 10.1038/358375a0; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; WADE M, 1992, MOL CELL BIOL, V12, P4364, DOI 10.1128/MCB.12.10.4364; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578	49	94	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1306	1313						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288595				2022-12-27	WOS:A1994MR22000085
J	FENG, WC; SOUTHWOOD, CM; BIEKER, JJ				FENG, WC; SOUTHWOOD, CM; BIEKER, JJ			ANALYSES OF BETA-THALASSEMIA MUTANT-DNA INTERACTIONS WITH ERYTHROID KRUPPEL-LIKE FACTOR (EKLF), AN ERYTHROID CELL-SPECIFIC TRANSCRIPTION FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORPHOBILINOGEN DEAMINASE GENE; MURINE ERYTHROLEUKEMIA-CELLS; ZINC-BINDING DOMAINS; GLOBIN GENE; FACTOR-IIIA; FINGER PROTEIN; CONTROL REGION; PROMOTER; SEQUENCE; RECOGNITION	We describe functional tests and molecular modeling of erythroid Kruppel-like factor (EKLF) interactions with its DNA binding site. EKLF, a zinc finger-containing, erythroid-specific transcription factor, binds and transactivates from the CACCC element, an evolutionarily conserved DNA sequenee present within a large number of erythroid-specific promoters and enhancers. This DNA binding element is the site of naturally occurring point mutations that give rise to beta-thalassemia. We have directly tested whether CAC site point mutations (including two of the beta-thalassemia mutants) affect EKLF transactivation and DNA binding function. In vivo analyses demonstrate that EKLF is unable to transactivate a reporter plasmid that contains these mutations. In vitro analyses reveal a 40-100-fold decrease in binding affinity for these sites that accounts for the in vivo observations. The homology between the three EKLF and Zif268 zinc fingers and their conserved sequence-specific contaets to their target site allowed us to formulate a molecular model of the EKLF/CAC site complex, based primarily on energy minimization/refinement of the Zif268/DNA co-crystal structure. These models suggest that both specific and nonspecific hydrogen bonding play a critical role in the ability of EKLF to prefer binding to its cognate site. Analysis of sequence-specific contacts by EKLF to its target site within the beta-globin promoter verified the residues predicted to be important by the functional and modeling data. Together these results demonstrate that EKLF displays a strong discriminatory ability among potential DNA target sites consistent with the beta-thalassemia data. They also suggest that lack of EKLF binding to these sites may play a determining role in its phenotype, and they strengthen the evidence in favor of EKLFs proposed role in erythroid-specific transcriptional activation through the CACCC elements.	CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,BOX 1126,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT PHYSIOL & BIOPHYS,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT BIOCHEM,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD023250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046865] Funding Source: NIH RePORTER; NICHD NIH HHS [HD23250] Funding Source: Medline; NIDDK NIH HHS [DK46865] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P98; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; BERG JM, 1989, J AM CHEM SOC, V111, P3759, DOI 10.1021/ja00192a050; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; Berger S. L., 1987, GUIDE MOL CLONING TE; CARR MD, 1990, EUR J BIOCHEM, V188, P455, DOI 10.1111/j.1432-1033.1990.tb15423.x; CHARNAY P, 1985, MOL CELL BIOL, V5, P1498, DOI 10.1128/MCB.5.6.1498; COWIE A, 1988, MOL CELL BIOL, V8, P3122, DOI 10.1128/MCB.8.8.3122; DESJARLAIS JR, 1992, PROTEINS, V12, P101, DOI 10.1002/prot.340120202; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7345, DOI 10.1073/pnas.89.16.7345; DIAKUN GP, 1986, NATURE, V324, P698, DOI 10.1038/324698a0; DIERKS P, 1983, CELL, V32, P695, DOI 10.1016/0092-8674(83)90055-7; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FRAMPTON J, 1990, MOL CELL BIOL, V10, P3838, DOI 10.1128/MCB.10.7.3838; GONG QH, 1991, MOL CELL BIOL, V11, P2558, DOI 10.1128/MCB.11.5.2558; GUMUCIO DL, 1992, MOL CELL BIOL, V12, P4919, DOI 10.1128/MCB.12.11.4919; HANAS JS, 1989, NUCLEIC ACIDS RES, V17, P9861, DOI 10.1093/nar/17.23.9861; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; IKUTA T, 1991, P NATL ACAD SCI USA, V88, P10188, DOI 10.1073/pnas.88.22.10188; JACKSON PD, 1989, GENE DEV, V3, P1860, DOI 10.1101/gad.3.12a.1860; JACOBS GH, 1992, EMBO J, V11, P4507, DOI 10.1002/j.1460-2075.1992.tb05552.x; Kaptein R, 1991, CURR OPIN STRUC BIOL, V1, P63, DOI 10.1016/0959-440X(91)90013-J; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KLEVIT RE, 1990, PROTEINS, V7, P215, DOI 10.1002/prot.340070303; KLEVIT RE, 1991, SCIENCE, V253, P1367, DOI 10.1126/science.1896847; KLEVIT RE, 1991, SCIENCE, V253, P1395; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; KNOCHEL W, 1989, P NATL ACAD SCI USA, V86, P6097, DOI 10.1073/pnas.86.16.6097; KOCHOYAN M, 1991, BIOCHEMISTRY-US, V30, P3371, DOI 10.1021/bi00228a004; KULOZIK AE, 1991, BLOOD, V7, P2054; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; MANTOVANI R, 1988, NUCLEIC ACIDS RES, V16, P4299, DOI 10.1093/nar/16.10.4299; Maxam A M, 1980, Methods Enzymol, V65, P499; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MORTISHIRESMITH RJ, 1992, FEBS LETT, V296, P11, DOI 10.1016/0014-5793(92)80392-T; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; NEUHAUS D, 1990, FEBS LETT, V262, P179, DOI 10.1016/0014-5793(90)80184-K; OMICHINSKI JG, 1992, BIOCHEMISTRY-US, V31, P3907, DOI 10.1021/bi00131a004; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; ORKIN SH, 1982, NATURE, V296, P627, DOI 10.1038/296627a0; ORKIN SH, 1982, J BIOL CHEM, V259, P8679; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PARRAGA G, 1909, P NATL ACAD SCI USA, V87, P137; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PERKINS ND, 1989, NUCLEIC ACIDS RES, V17, P1299, DOI 10.1093/nar/17.4.1299; PHILIPSEN S, 1993, EMBO J, V12, P1077, DOI 10.1002/j.1460-2075.1993.tb05749.x; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; REDDY PMS, 1993, MOL CELL BIOL, V13, P1093, DOI 10.1128/MCB.13.2.1093; RHODES D, 1986, CELL, V46, P123, DOI 10.1016/0092-8674(86)90866-4; STRAUSS EC, 1992, MOL CELL BIOL, V12, P2135, DOI 10.1128/MCB.12.5.2135; STRAUSS EC, 1992, P NATL ACAD SCI USA, V89, P5809, DOI 10.1073/pnas.89.13.5809; STUVE LL, 1990, MOL CELL BIOL, V10, P972, DOI 10.1128/MCB.10.3.972; SUN JM, 1992, NUCLEIC ACIDS RES, V20, P6385, DOI 10.1093/nar/20.23.6385; THIESEN HJ, 1991, FEBS LETT, V283, P23, DOI 10.1016/0014-5793(91)80545-E; THIESEN HJ, 1991, BIOCHEM BIOPH RES CO, V175, P333, DOI 10.1016/S0006-291X(05)81239-2; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; VALLEE BL, 1991, P NATL ACAD SCI USA, V88, P999, DOI 10.1073/pnas.88.3.999; WATT P, 1990, NUCLEIC ACIDS RES, V18, P1339, DOI 10.1093/nar/18.6.1339; YU CY, 1991, J BIOL CHEM, V266, P8907; ZHANG QY, 1993, MOL CELL BIOL, V13, P2298, DOI 10.1128/MCB.13.4.2298	66	172	176	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1493	1500						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288615				2022-12-27	WOS:A1994MR22000109
J	HAMA, H; WILSON, TH				HAMA, H; WILSON, TH			REPLACEMENT OF ALANINE-58 BY ASPARAGINE ENABLES THE MELIBIOSE CARRIER OF KLEBSIELLA-PNEUMONIAE TO COUPLE SUGAR-TRANSPORT TO NA+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CATION SPECIFICITY; COTRANSPORT; SYSTEM; SITE; GENE	The melibiose carrier of Klebsiella pneumoniae couples sugar transport to H+ and Li+, while that of Escherichia coli uses Na+ besides the other two cation species (Hama and Wilson, 1992). We have shown that the K. pneumoniae melibiose carrier is capable of recognizing Na+ when the amino-terminal 81 residues are replaced by the corresponding region of the E. coli melibiose carrier (Hama and Wilson, 1993). In this amino-terminal region there are 5 residues that are not conserved between the two carriers. In this study, we changed each of the 5 residues of the K. pneumoniae carrier to the one in the E. coli carrier. The substitutions are Ile-36 --> Val, Val-43 --> Leu, Leu-54 --> Trp, Ala-58 --> Asn, and Cys-68 --> Ala. With four of the five mutants, Ile-36 --> Val, Val-43 --> Leu, Leu-54 --> Trp, and Cys-68 --> Ala, sugar accumulation was not affected by Na+. In striking contrast, melibiose and methyl-1-thio-beta-D-galactopyranoside accumulation was greatly stimulated by Na+ with the Ala-58 --> Asn, mutant. Furthermore, Na+ uptake coupled to downhill melibiose transport was observed with the Ala-58 --> Asn mutant. These results indicate that the Ala-58 --> Asn substitution enables the K. pneumoniae melibiose carrier to couple sugar transport to Na+. It is clear that the Asn-58 residue (Asn-54 in the E. coli carrier) is involved in Na+ recognition.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School					NIDDK NIH HHS [DK05736] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK005736, R01DK005736] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOTFIELD MC, 1988, J BIOL CHEM, V263, P12909; BOTFIELD MC, 1992, J BIOL CHEM, V267, P1818; DEVRIJ W, 1989, J BACTERIOL, V171, P1118, DOI 10.1128/jb.171.2.1118-1125.1989; DIMROTH P, 1987, MICROBIOL REV, V51, P320, DOI 10.1128/MMBR.51.3.320-340.1987; HAMA H, 1993, J BIOL CHEM, V268, P10060; HAMA H, 1992, J BIOL CHEM, V267, P18371; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KAMATA H, 1992, J BIOL CHEM, V267, P21650; KAWAKAMI T, 1988, J BIOL CHEM, V263, P14276; LOPILATO J, 1986, MOL GEN GENET, V205, P285, DOI 10.1007/BF00430440; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MARTINEZ E, 1988, GENE, V68, P159, DOI 10.1016/0378-1119(88)90608-7; POURCHER T, 1991, BIOCHEM BIOPH RES CO, V178, P1176, DOI 10.1016/0006-291X(91)91016-6; POURCHER T, 1993, J BIOL CHEM, V268, P3209; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TSUCHIYA T, 1985, ANN NY ACAD SCI, V456, P342, DOI 10.1111/j.1749-6632.1985.tb14884.x; TSUCHIYA T, 1978, MEMBRANE BIOCHEM, V2, P63, DOI 10.3109/09687687809063858; WILSON DM, 1992, J BACTERIOL, V174, P3083, DOI 10.1128/JB.174.9.3083-3086.1992; WILSON DM, 1987, BIOCHIM BIOPHYS ACTA, V904, P191, DOI 10.1016/0005-2736(87)90368-3; YAZYU H, 1984, J BIOL CHEM, V259, P4320; YAZYU H, 1985, J BACTERIOL, V162, P933, DOI 10.1128/JB.162.3.933-937.1985	21	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1063	1067						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288562				2022-12-27	WOS:A1994MR22000047
J	KUROSAWA, N; HAMAMOTO, T; LEE, YC; NAKAOKA, T; KOJIMA, N; TSUJI, S				KUROSAWA, N; HAMAMOTO, T; LEE, YC; NAKAOKA, T; KOJIMA, N; TSUJI, S			MOLECULAR-CLONING AND EXPRESSION OF GALNAC ALPHA-2,6-SIALYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE SUBMAXILLARY MUCIN; GALACTOSIDE ALPHA-2->3 SIALYTRANSFERASE; LINKED OLIGOSACCHARIDE CHAINS; SUB-MAXILLARY GLANDS; ENZYMATIC CHARACTERIZATION; CARBOHYDRATE STRUCTURES; SEQUENCE-ANALYSIS; SIALIC-ACID; SIALYLTRANSFERASE; PURIFICATION	cDNA clones encoding GalNAc alpha2,6-sialyltransferase (EC 2.4.99.3) have been isolated from chick embryo cDNA libraries using sequence information obtained from the conserved amino acid sequence of the previously cloned enzymes. The cDNA sequence included an open reading frame coding for 566 amino acids, and the deduced amino acid sequence showed 12% identity with that of Galbeta1,4GlcNAc alpha2,6-sialyltransferase from chick embryo. The primary structure of this enzyme suggested a putative domain structure, like that in other glycosyltransferases, consisting of a short NH2-terminal cytoplasmic domain, a signal-membrane anchor domain, a proteolytically sensitive stem region, and a large COOH-terminal active domain. The identity of this enzyme was confirmed by the construction of a recombinant sialyltransferase in which the NH2-terminal part (232 amino acid residues) was replaced with the immunoglobulin signal sequence. The expression of this recombinant in COS-7 cells resulted in secretion of a catalytically active and soluble form of the enzyme into the medium. The expressed enzyme exhibited activity toward only asialomucin and (asialo)fetuin, no significant activity being detected toward the other glycoprotein and glycolipid substrates tested. C-14-Sialylated glycols obtained from asialomucin re-sialylated with this enzyme were identical to NeuAcalpha2,6-GalNAc-ol and GlcNAcbeta1,3(NeuAca2,6) GalNAc-ol. Synthetic GalNAc-SerNAc also served as an acceptor for alpha2,6-sialylation. These results clearly showed that the expressed enzyme is GalNAc alpha2,6-sialyltransferase.	INST PHYS & CHEM RES,FRONTIER RES PROGRAM,WAKO,SAITAMA 35101,JAPAN	RIKEN				Kurosawa, Nobuyuki/0000-0002-1548-4541				ARCE A, 1966, ARCH BIOCHEM BIOPHYS, V116, P52, DOI 10.1016/0003-9861(66)90011-7; ARCE A, 1971, BIOCHEM J, V121, P483, DOI 10.1042/bj1210483; BAIROCH A, 1990, PROSITE DICT PROTEIN; BAST BJEG, 1992, J CELL BIOL, V116, P423, DOI 10.1083/jcb.116.2.423; BAUBICHONCORTAY H, 1986, CARBOHYD RES, V149, P209, DOI 10.1016/S0008-6215(00)90379-3; BERGH MLE, 1983, J BIOL CHEM, V258, P7430; Beyer T A, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P23; BOERSCHSUPAN ME, 1985, J EXP MED, V161, P1272, DOI 10.1084/jem.161.6.1272; BROCKHAUSEN I, 1990, BIOCHEMISTRY-US, V29, P10206, DOI 10.1021/bi00496a008; BROQUET P, 1991, INT J BIOCHEM, V23, P385, DOI 10.1016/0020-711X(91)90164-I; CARLSON DM, 1968, J BIOL CHEM, V243, P616; CORFIELD T, 1992, GLYCOBIOLOGY, V2, P509, DOI 10.1093/glycob/2.6.509; DALLOLIO F, 1990, GLYCOCONJUGATE J, V7, P301, DOI 10.1007/BF01073374; DEN H, 1970, J BIOL CHEM, V245, P6607; DEN H, 1975, J BIOL CHEM, V250, P739; DENNIS J, 1982, NATURE, V300, P274, DOI 10.1038/300274a0; DRICKAMER K, 1993, GLYCOBIOLOGY, V3, P2, DOI 10.1093/glycob/3.1.2; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FISHMAN PH, 1976, SCIENCE, V194, P906, DOI 10.1126/science.185697; GARCIAFERNANDEZ J, 1991, P NATL ACAD SCI USA, V88, P7338, DOI 10.1073/pnas.88.16.7338; GILLESPIE W, 1992, J BIOL CHEM, V267, P21004; GOVINDAN MV, 1990, MOL ENDOCRINOL, V4, P417, DOI 10.1210/mend-4-3-417; GRUNDLER G, 1984, LIEBIGS ANN CHEM, P1826; GRUNDMANN U, 1990, NUCLEIC ACIDS RES, V18, P667, DOI 10.1093/nar/18.3.667; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; Hamamoto T, 1993, Bioorg Med Chem, V1, P141, DOI 10.1016/S0968-0896(00)82111-2; HENRICH VC, 1990, NUCLEIC ACIDS RES, V18, P4143, DOI 10.1093/nar/18.14.4143; HODGMAN TC, 1989, COMPUT APPL BIOSCI, V5, P1; JOBLING SA, 1987, NATURE, V325, P622, DOI 10.1038/325622a0; JOZIASSE DH, 1985, J BIOL CHEM, V260, P4941; KAUFMAN B, 1968, J BIOL CHEM, V243, P5804; KIMBER SJ, 1989, BIOCHEM SOC T, V17, P23, DOI 10.1042/bst0170023; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; KUROSAWA N, 1994, IN PRESS EUR J BIOCH; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE YC, 1993, EUR J BIOCHEM, V216, P377, DOI 10.1111/j.1432-1033.1993.tb18155.x; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PAULSON JC, 1991, GLYCOCONJUGATE J, V8, P145; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; REARICK JI, 1979, J BIOL CHEM, V254, P4444; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Roos E, 1984, Biochim Biophys Acta, V738, P263; ROSENBERG A, 1992, J BIOL CHEM, V267, P10607; SADLER JE, 1979, J BIOL CHEM, V254, P4434; SADLER JE, 1979, J BIOL CHEM, V254, P5934; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAGE AV, 1990, EUR J BIOCHEM, V193, P837, DOI 10.1111/j.1432-1033.1990.tb19407.x; SAVAGE AV, 1990, EUR J BIOCHEM, V192, P427, DOI 10.1111/j.1432-1033.1990.tb19244.x; SCHNAAR R L, 1991, Glycobiology, V1, P477, DOI 10.1093/glycob/1.5.477; STRENBERG MJE, 1991, NATURE, V349, P111; Svennerholm L, 1980, Adv Exp Med Biol, V125, P533; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TSUJI T, 1986, CARBOHYD RES, V151, P391, DOI 10.1016/S0008-6215(00)90358-6; WASSARMAN PM, 1987, ANNU REV CELL BIOL, V3, P109, DOI 10.1146/annurev.cellbio.3.1.109; WEIGANDT H, 1967, J NEUROCHEM, V14, P671; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; WEN DX, 1992, J BIOL CHEM, V267, P21011	64	88	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1402	1409						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288607				2022-12-27	WOS:A1994MR22000098
J	MATTHEWS, G; SHENNAN, KIJ; SEAL, AJ; TAYLOR, NA; COLMAN, A; DOCHERTY, K				MATTHEWS, G; SHENNAN, KIJ; SEAL, AJ; TAYLOR, NA; COLMAN, A; DOCHERTY, K			AUTOCATALYTIC MATURATION OF THE PROHORMONE CONVERTASE PC2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; CONSTITUTIVE SECRETORY PATHWAY; MICROINJECTED XENOPUS OOCYTES; ESCHERICHIA-COLI; KEX2 PROTEASE; PRO-REGION; PROCESSING ENDOPROTEASES; PRECURSOR CLEAVAGE; SUBTILISIN-E; SEQUENCE	PC2 is a member of the eukaryotic family of subtilisin-like proteases, which is thought to participate in the processing of prohormones and proneuropeptides in neuroendocrine cells. PC2 is synthesized as a 69-kDa prepropolypeptide. The NH2-terminal signal sequence is removed during segregation within the endoplasmic reticulum, where glycosylation occurs to generate a 75-kDa propolypeptide. A combination of site-directed mutagenesis and a cell-free translation/translocation system from Xenopus eggs was used to investigate the processing of the pro-PC2 precursor. The 75-kDa polypeptide underwent slow cleavage after the sequence Arg-Lys-Lys-Arg84 to generate a 68-kDa mature enzyme. Cleavage was blocked when the tetrahasic sequence was deleted (PC2M3) or when the active site Asp142 Was changed to Asn (PC2M4). This latter observation suggested that cleavage of the 75-kDa propolypeptide to the mature 68-kDa enzyme was autocatalytic. Incubation of the PC2M4 mutant with the wild type PC2 precursor resulted in cleavage of both the wild type polypeptide and the catalytically inactive PC2M4 mutant. This indicates that cleavage could occur through an intermolecular reaction. The results also demonstrate that the novel Xenopus egg extract translation/translocation system represents a powerful cell-free method for studying proteolytic processing of propolypeptides.	UNIV BIRMINGHAM,SCH BIOCHEM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,DEPT MED,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham			Seal, Andrew/C-8550-2014	Seal, Andrew/0000-0003-3656-4054; Docherty, Kevin/0000-0001-6765-2060	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAIYLES EM, 1992, BIOCHEM J, V285, P391; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BIRCH NP, 1991, BIOCHEM BIOPH RES CO, V179, P1311, DOI 10.1016/0006-291X(91)91716-P; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CARTER P, 1987, SCIENCE, V237, P394, DOI 10.1126/science.3299704; CHRISTIE DL, 1991, J BIOL CHEM, V266, P15679; FABRE E, 1991, J BIOL CHEM, V266, P3782; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GERMAIN D, 1992, FEBS LETT, V299, P283, DOI 10.1016/0014-5793(92)80132-Z; GUEST PC, 1992, J BIOL CHEM, V267, P22401; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; Hutton JC, 1990, CURR OPIN CELL BIOL, V2, P1131, DOI 10.1016/0955-0674(90)90167-D; IKEMURA H, 1988, J BIOL CHEM, V263, P12959; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; MATTHEWS G, 1991, NUCLEIC ACIDS RES, V19, P6405, DOI 10.1093/nar/19.23.6405; MIZUNO K, 1989, BIOCHEM BIOPH RES CO, V159, P305, DOI 10.1016/0006-291X(89)92438-8; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; NEBES VL, 1991, J BIOL CHEM, V266, P22851; POWER SD, 1986, P NATL ACAD SCI USA, V83, P3096, DOI 10.1073/pnas.83.10.3096; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; REHEMTULLA A, 1992, P NATL ACAD SCI USA, V89, P8235, DOI 10.1073/pnas.89.17.8235; RHODES CJ, 1992, J BIOL CHEM, V267, P22719; SEIDAH NG, 1992, MOL ENDOCRINOL, V6, P1559, DOI 10.1210/me.6.10.1559; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHENNAN KIJ, 1991, J BIOL CHEM, V266, P24011; SHENNAN KIJ, 1991, FEBS LETT, V284, P277, DOI 10.1016/0014-5793(91)80703-6; SILEN JL, 1989, J BACTERIOL, V171, P1320, DOI 10.1128/jb.171.3.1320-1325.1989; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; STEINER D F, 1991, Current Biology, V1, P375, DOI 10.1016/0960-9822(91)90198-6; STEINER DF, 1992, J BIOL CHEM, V267, P23435; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; WATANABE T, 1992, J BIOL CHEM, V267, P8270; WILCOX CA, 1991, J CELL BIOL, V115, P297, DOI 10.1083/jcb.115.2.297; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; WONG SL, 1984, P NATL ACAD SCI-BIOL, V81, P1184, DOI 10.1073/pnas.81.4.1184; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	47	75	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					588	592						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276855				2022-12-27	WOS:A1994MR21900093
J	DAWSON, GW; HICK, AJ; BENNETT, RN; DONALD, A; PICKETT, JA; WALLSGROVE, RM				DAWSON, GW; HICK, AJ; BENNETT, RN; DONALD, A; PICKETT, JA; WALLSGROVE, RM			SYNTHESIS OF GLUCOSINOLATE PRECURSORS AND INVESTIGATIONS INTO THE BIOSYNTHESIS OF PHENYLALKYLGLUCOSINOCATES AND METHYLTHIOALKYLGLUCOSINOLATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BICOLOR L MOENCH; BRASSICA-CARINATA; METABOLITES; DHURRIN; PLANTS; NAPUS	The alkenyl and aromatic glucosinolates in oilseed rape (Brassica napus) are biosynthesized from chain-extended homologues of protein amino acids, including methionine and phenylalanine. Homologues of these two amino acids, homophenylalanine (2-amino-4-phenylbutyric acid) and dihomomethionine (2-amino-6-methylthiohexanoic acid) were synthesized both with and without a 1-C-14 label. Microsomal preparations from oilseed rape leaves were shown to contain enzyme systems which metabolize these compounds, with loss of (CO2)-C-14, and produce the aldoxime intermediates possible in the biosynthetic pathway utilizing homophenylalanine. These were characterized by comparison with authenticated synthetic compounds. Potential intermediates on the pathway between homophenylalanine and its corresponding aldoxime, the N-hydroxyamino- and the oximino acids, were synthesized and their possible role in the pathway investigated.	AFRC, INST ARABLE CROPS RES, ROTHAMSTED EXPTL STN, HARPENDEN AL5 2JQ, HERTS, ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research								AHMAD A, 1974, B CHEM SOC JPN, V47, P1819, DOI 10.1246/bcsj.47.1819; BALLINI R, 1992, TETRAHEDRON LETT, V33, P4835, DOI 10.1016/S0040-4039(00)61298-4; Blight M.M., 1989, Aspects of Applied Biology, V23, P329; BLIGHT MM, 1992, 8TH P INT S INS PLAN, P105; CHAPPLE CCS, 1988, PHYTOCHEMISTRY, V27, P3461, DOI 10.1016/0031-9422(88)80748-9; CHAPPLE CCS, 1990, PLANT PHYSIOL, V94, P1887, DOI 10.1104/pp.94.4.1887; DAWSON GW, 1989, PESTIC SCI, V27, P191, DOI 10.1002/ps.2780270209; ELLIOTT M, 1988, PESTIC SCI, V22, P231, DOI 10.1002/ps.2780220305; ETTLINGER MG, 1961, P NATL ACAD SCI USA, V47, P1875, DOI 10.1073/pnas.47.12.1875; ETTLINGER MG, 1956, J AM CHEM SOC, V78, P4172, DOI 10.1021/ja01597a090; FENWICK GR, 1983, CRC CR REV FOOD SCI, V18, P123, DOI 10.1080/10408398209527361; GLOVER JR, 1988, PHYTOCHEMISTRY, V27, P1345, DOI 10.1016/0031-9422(88)80190-0; HALKIER BA, 1991, P NATL ACAD SCI USA, V88, P487, DOI 10.1073/pnas.88.2.487; HALKIER BA, 1991, PLANT PHYSIOL, V96, P10, DOI 10.1104/pp.96.1.10; Hallahan D. L., 1992, Plant genetic manipulation for crop protection., P215; HARBORNE JB, 1991, PLANT DEFENSES MAMMA, P45; HAUGHN GW, 1991, PLANT PHYSIOL, V97, P217, DOI 10.1104/pp.97.1.217; JAIN JC, 1989, ANAL BIOCHEM, V178, P137, DOI 10.1016/0003-2697(89)90369-2; KINDL H, 1968, PHYTOCHEMISTRY, V7, P745, DOI 10.1016/S0031-9422(00)84827-X; KOCH B, 1992, ARCH BIOCHEM BIOPHYS, V292, P141, DOI 10.1016/0003-9861(92)90062-2; Larsen PO, 1981, BIOCH PLANT PRODUCTS, V7, P501; LUDWIGMULLER J, 1988, PHYSIOL PLANTARUM, V74, P240, DOI 10.1111/j.1399-3054.1988.tb00627.x; MEISTER A, 1957, METHOD ENZYMOL, V3, P404, DOI 10.1016/S0076-6879(57)03405-9; PORTER AJR, 1991, ANN APPL BIOL, V118, P461, DOI 10.1111/j.1744-7348.1991.tb05647.x; Renwick J.A.A., 1992, Chemoecology, V3, P33, DOI 10.1007/BF01261454; TRAYNIER RMM, 1991, J CHEM ECOL, V17, P1371, DOI 10.1007/BF00983770; VAUGHAN JG, 1976, BIOL CHEM CRUCIFERAE, P191	27	40	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27154	27159						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262954				2022-12-27	WOS:A1993MM26200048
J	DELLANO, JJM; JONES, W; SCHNEIDER, K; CHAIT, BT; MANNING, JM; RODGERS, G; BENJAMIN, LJ; WEKSLER, B				DELLANO, JJM; JONES, W; SCHNEIDER, K; CHAIT, BT; MANNING, JM; RODGERS, G; BENJAMIN, LJ; WEKSLER, B			BIOCHEMICAL AND FUNCTIONAL-PROPERTIES OF RECOMBINANT HUMAN SICKLE HEMOGLOBIN EXPRESSED IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S POLYMERIZATION; COVALENT BINDING; GLUTATHIONE; DEOXYHEMOGLOBIN	Previous studies had indicated that recombinant and natural human sickle hemoglobin had similar chemical properties (Martin de Llano, J. J., Schneewind, O., Stetler, G., and Manning, J. M. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 918-922). In the present study, additional biochemical and physiological characterization of some primary through quaternary structural features of recombinant sickle hemoglobin are described. The molecular weight of the purified recombinant sickle hemoglobin was identical to natural sickle hemoglobin as determined by mass spectrometry, thus excluding extensive post-translational modification in the yeast system. Carboxypeptidases A and B together catalyzed the release of COOH-terminal amino acids at the same rate for recombinant and natural hemoglobin S, consistent with identity in their primary and secondary structures in this region of the molecule. The tryptic peptide maps of natural and recombinant hemoglobins were practically indistinguishable, indicating the same internal protein sequences for recombinant and natural hemoglobins. As a probe of the secondary structure of recombinant sickle Hb, the reactivity of the SH group of Cys-93(beta) was investigated for the glutathione sickle hemoglobin adduct, which has significant anti-gelling and anti-sickling properties. The position of glutathione at Cys-93(beta) was established by direct mass spectrometric analysis of enzyme digests; reduction of this derivative to the unmodified chains was also observed by mass spectrometry and by isoelectric focusing. The oxygen equilibrium curves of recombinant and natural sickle hemoglobin at high protein concentration were superimposable with identical Hill coefficients of 3.3. The response of recombinant sickle hemoglobin to chloride with respect to a lowered oxygen affinity was identical to that of natural sickle hemoglobin. The gelation properties of recombinant and natural sickle hemoglobins were identical at the high hemoglobin concentrations that occur in the red cell. Therefore, the yeast expression system synthesizes a completely functional recombinant sickle hemoglobin with the same biochemical and physiological properties as natural sickle hemoglobin with respect to features characteristic of its primary through quaternary structures.	ROCKEFELLER UNIV,NEW YORK,NY 10021; NIDDKD,CHEM BIOL LAB,MOLEC HEMATOL UNIT,BETHESDA,MD 20892; MONTEFIORE MED CTR,BRONX,NY 10467; CORNELL UNIV,MED CTR,COLL MED,DIV HEMATOL,NEW YORK,NY 10021	Rockefeller University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Cornell University			Schneider, Klaus/N-6604-2014; de Llano, José Javier Martín/K-6610-2012	Schneider, Klaus/0000-0002-3068-8681; de Llano, José Javier Martín/0000-0001-5933-9592	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000862] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL018819, R01HL018819] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00862] Funding Source: Medline; NHLBI NIH HHS [HL-18819] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI K, 1993, J BIOL CHEM, V268, P21650; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P432, DOI 10.1002/rcm.1290031207; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P233, DOI 10.1002/rcm.1290030708; BEAVIS RC, 1990, ANAL CHEM, V62, P1836, DOI 10.1021/ac00216a020; BENESCH RE, 1978, ANAL BIOCHEM, V89, P162, DOI 10.1016/0003-2697(78)90737-6; BIRCHMEIER W, 1973, BIOCHEMISTRY-US, V12, P3667, DOI 10.1021/bi00743a015; BOOKCHIN RM, 1967, J BIOL CHEM, V242, P248; CRAESCU CT, 1986, J BIOL CHEM, V261, P4710; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; DELLANO JJM, 1993, P NATL ACAD SCI USA, V90, P918, DOI 10.1073/pnas.90.3.918; EDELSTEIN SJ, 1979, J MOL BIOL, V134, P851, DOI 10.1016/0022-2836(79)90491-1; GAREL MC, 1982, EUR J BIOCHEM, V123, P513; GAREL MC, 1986, J BIOL CHEM, V261, P4704; Herrick J.B., 1910, ARCH INTERN MED, V6, P517; HUISMAN THJ, 1987, J CHROMATOGR-BIOMED, V418, P277, DOI 10.1016/0378-4347(87)80012-9; INGRAM VM, 1956, NATURE, V178, P792, DOI 10.1038/178792a0; Manning J M, 1981, Methods Enzymol, V76, P159; PAULING L, 1949, SCIENCE, V110, P543, DOI 10.1126/science.110.2865.543; PERUTZ MF, 1980, J MOL BIOL, V138, P649, DOI 10.1016/S0022-2836(80)80022-2; WAGENBACH M, 1991, BIO-TECHNOL, V9, P57, DOI 10.1038/nbt0191-57; WELLEMS TE, 1979, J MOL BIOL, V135, P651, DOI 10.1016/0022-2836(79)90170-0; WILSON JB, 1990, HPLC BIOL MACROMOLEC, P457; WINTERBOURN C C, 1976, Hemoglobin, V1, P1, DOI 10.3109/03630267609031018; WISHNER BC, 1975, J MOL BIOL, V98, P179, DOI 10.1016/S0022-2836(75)80108-2; WODAK SJ, 1986, J BIOL CHEM, V261, P4717; XSRIVASTAVA SK, 1970, BIOCHEM J, V119, P353	27	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27004	27011						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262936				2022-12-27	WOS:A1993MM26200028
J	HAINO, M; HAYASHIDA, H; MIYATA, T; SHIN, EK; MATSUDA, F; NAGAOKA, H; MATSUMURA, R; TAKAISHI, S; FUKITA, Y; FUJIKURA, J; HONJO, T				HAINO, M; HAYASHIDA, H; MIYATA, T; SHIN, EK; MATSUDA, F; NAGAOKA, H; MATSUMURA, R; TAKAISHI, S; FUKITA, Y; FUJIKURA, J; HONJO, T			COMPARISON AND EVOLUTION OF HUMAN IMMUNOGLOBULIN-V(H) SEGMENTS LOCATED IN THE 3' 0.8-MEGABASE REGION - EVIDENCE FOR UNIDIRECTIONAL TRANSFER OF SEGMENTAL GENE-SEQUENCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; HEAVY-CHAIN PROMOTER; SYSTEMIC LUPUS-ERYTHEMATOSUS; CELL-TYPE SPECIFICITY; ANTI-DNA ANTIBODY; 2 MOUSE STRAINS; VARIABLE-REGION; VH-GENES; SOMATIC MUTATION; CONSERVED SEQUENCE	Nucleotide sequences of 64 V(H) segments within the 3' 0.8-megabase region of the human immunoglobulin germ line V(H) locus were compared with trace evolution of human V(H) segments. Based on alignment of the deduced amino acid sequences of 37 functional germ line V(H) segments, a phylogenetic tree was generated using the neighbor-joining method. The phylogenetic tree clearly supports the previous classification of human V(H) segments into six families, which correlate roughly with mouse V(H) families with varying conservation. The human V(H-III) family is most homologous to mouse V(H) segments, suggesting that members of the V(H-III) family may be conserved by some functional constraint. The 5'-flanking region of each family has a family-specific structure. The sequenced 64 V(H) segments include 31 pseudogenes, of which 24 were highly conserved. Unidirectional transfer of segmental sequences was identified within the V(H-III) and V(H-IV) families, providing clear examples of germ line gene conversion. Such gene conversion may contribute to conserve structures of pseudo-V(H) segments. Comparison of the V(H-IV) family members indicates that recent repeated duplications and frequent gene conversions are responsible for strong conservation of this family, although functional selection is not completely excluded.	KYOTO UNIV,CTR MOLEC BIOL & GENET,SAKYO KU,KYOTO 606,JAPAN; KYOTO UNIV,FAC SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 606,JAPAN	Kyoto University; Kyoto University	HAINO, M (corresponding author), KYOTO UNIV,FAC MED,DEPT MED CHEM,SAKYO KU,KYOTO 606,JAPAN.		Honjo, Tasuku/N-4470-2016; Matsuda, Fumihiko/B-9893-2009; Takaishi, Shigeo/AAS-3319-2021; Fujikura, Junji/AAR-2684-2020					AEBI M, 1987, CELL, V50, P237, DOI 10.1016/0092-8674(87)90219-4; BALLARD DW, 1986, P NATL ACAD SCI USA, V83, P9626, DOI 10.1073/pnas.83.24.9626; BECKER RS, 1990, CELL, V63, P987, DOI 10.1016/0092-8674(90)90502-6; BERMAN JE, 1988, EMBO J, V7, P727, DOI 10.1002/j.1460-2075.1988.tb02869.x; BOTHWELL ALM, 1981, CELL, V24, P625, DOI 10.1016/0092-8674(81)90089-1; BRODEUR PH, 1984, EUR J IMMUNOL, V14, P922, DOI 10.1002/eji.1830141012; COHEN JB, 1983, EMBO J, V2, P1795, DOI 10.1002/j.1460-2075.1983.tb01660.x; COHEN JB, 1983, EMBO J, V2, P2013, DOI 10.1002/j.1460-2075.1983.tb01693.x; CREWS S, 1981, CELL, V25, P59, DOI 10.1016/0092-8674(81)90231-2; DAVIDSON A, 1990, J CLIN INVEST, V85, P1401, DOI 10.1172/JCI114584; EATON S, 1987, P NATL ACAD SCI USA, V84, P7634, DOI 10.1073/pnas.84.21.7634; FALKNER FG, 1984, NATURE, V310, P71, DOI 10.1038/310071a0; FOSTER J, 1985, NATURE, V315, P423, DOI 10.1038/315423a0; GIVOL D, 1981, NATURE, V292, P426, DOI 10.1038/292426a0; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; HARTMAN AB, 1984, EMBO J, V3, P3023, DOI 10.1002/j.1460-2075.1984.tb02249.x; HAYASHIDA H, 1983, P NATL ACAD SCI-BIOL, V80, P2671, DOI 10.1073/pnas.80.9.2671; HOCH S, 1987, J IMMUNOL, V139, P1689; HONJO T, 1983, ANNU REV IMMUNOL, V1, P499, DOI 10.1146/annurev.iy.01.040183.002435; HONJO T, 1985, ANNU REV BIOCHEM, V54, P803, DOI 10.1146/annurev.bi.54.070185.004103; HUANG H, 1981, Journal of Molecular and Applied Genetics, V1, P93; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; Kabat EA, 1991, SEQUENCES PROTEINS I; KEMLER I, 1989, EMBO J, V8, P2001, DOI 10.1002/j.1460-2075.1989.tb03607.x; KLEINFIELD RW, 1989, J IMMUNOL, V142, P4483; KODAIRA M, 1986, J MOL BIOL, V190, P529, DOI 10.1016/0022-2836(86)90239-1; KOFLER R, 1988, J IMMUNOL, V140, P4031; KOFLER R, 1992, IMMUNOL REV, V128, P5, DOI 10.1111/j.1600-065X.1992.tb00830.x; LEE KH, 1987, J MOL BIOL, V195, P761, DOI 10.1016/0022-2836(87)90482-7; Logtenberg T, 1989, Int Immunol, V1, P362, DOI 10.1093/intimm/1.4.362; LOH DY, 1983, CELL, V33, P85, DOI 10.1016/0092-8674(83)90337-9; MATSUDA F, 1993, NAT GENET, V3, P88, DOI 10.1038/ng0193-88; MAYER R, 1990, BLOOD, V75, P1518; MIYATA T, 1980, P NATL ACAD SCI-BIOL, V77, P7328, DOI 10.1073/pnas.77.12.7328; MIYATA T, 1980, P NATL ACAD SCI-BIOL, V77, P2143, DOI 10.1073/pnas.77.4.2143; NEAR RI, 1984, P NATL ACAD SCI-BIOL, V81, P2167, DOI 10.1073/pnas.81.7.2167; OLLO R, 1983, NUCLEIC ACIDS RES, V11, P7887, DOI 10.1093/nar/11.22.7887; PARSLOW TG, 1984, P NATL ACAD SCI-BIOL, V81, P2650, DOI 10.1073/pnas.81.9.2650; PENNELL CA, 1989, EUR J IMMUNOL, V19, P2115, DOI 10.1002/eji.1830191122; Rathbun G.A., 1987, P85; RECHAVI G, 1982, P NATL ACAD SCI-BIOL, V79, P4405, DOI 10.1073/pnas.79.14.4405; RECHAVI G, 1983, P NATL ACAD SCI-BIOL, V80, P855, DOI 10.1073/pnas.80.3.855; REININGER L, 1988, EUR J IMMUNOL, V18, P1521, DOI 10.1002/eji.1830181008; Riblet R., 1987, P53; ROUDIER J, 1990, J IMMUNOL, V144, P1526; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SANZ I, 1989, J IMMUNOL, V142, P4054; SCHROEDER HW, 1990, INT IMMUNOL, V20, P41; SCHUTTE MEM, 1991, EUR J IMMUNOL, V21, P1115, DOI 10.1002/eji.1830210505; SHEN A, 1987, P NATL ACAD SCI USA, V84, P8563, DOI 10.1073/pnas.84.23.8563; SHIN EK, 1991, EMBO J, V10, P3641, DOI 10.1002/j.1460-2075.1991.tb04930.x; SIU G, 1987, J IMMUNOL, V138, P4466; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TUTTER A, 1991, J IMMUNOL, V147, P3215; VANES JH, 1991, J EXP MED, V173, P461, DOI 10.1084/jem.173.2.461; WINTER E, 1985, EMBO J, V4, P2861, DOI 10.1002/j.1460-2075.1985.tb04015.x	56	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2619	2626						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300591				2022-12-27	WOS:A1994MV43200042
J	DZIARSKI, R; GUPTA, D				DZIARSKI, R; GUPTA, D			HEPARIN, SULFATED HEPARINOIDS, AND LIPOTEICHOIC ACIDS BIND TO THE 70-KDA PEPTIDOGLYCAN LIPOPOLYSACCHARIDE RECEPTOR PROTEIN ON LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRITICAL MICELLE CONCENTRATIONS; PHOTOAFFINITY CROSS-LINKING; MURINE SPLENOCYTES; BACTERIAL LIPOPOLYSACCHARIDE; CHOLESTEROL DEPOSITION; MONOCLONAL-ANTIBODY; DEXTRAN SULFATE; LYMPHOID-CELLS; IDENTIFICATION; BLOOD	The same 70-kDa protein, present on the surface of mouse lymphocytes, served as the predominant binding site for heparin, heparinoids, and bacterial lipoteichoic acids, as well as peptidoglycan and lipopolysaccharides. This conclusion was supported by the following results: (a) all of these compounds photoaffinity cross-linked to one major 70-kDa 6.5-7.0 pI protein that co-migrated on two-dimensional polyacrylamide gel electrophoresis; (b) peptide maps of the 70-kDa proteins digested with chymotrypsin, subtilisin, protease V, or papain yielded the same peptides for heparin-, lipoteichoic acid-, peptidoglycan-, and lipopolysaccharide-binding proteins; (c) cross-linking of peptidoglycan, lipopolysaccharide, lipoteichoic acid, and heparin was competitively inhibited by the same compounds with the same order of potency, i.e. carboxyl-reduced sulfated heparin > peptidoglycan > pentosan polysulfate > heparin > chitin > dextran sulfate > trestatin sulfate > polyanetholesulfonate > fucoidan> beta-cyclodextrin tetradecasulfate > heparan sulfate > carrageenan lambda > lipoteichoic acids > Re-lipopolysaccharide > lipopolysaccharide > lipid A > polygalacturonic acid; and (d) cross-linking of each of these ligands was not inhibited by carboxyl-reduced heparin, dextran, beta-cyclodextrin, trestatin, carrageenan kappa, chondroitin 4-sulfate, chondroitin 6-sulfate, beta-D-glucan, carboxymethylcellulose, levan, alpha-D-mannan, and glycogen. The minimum size of the molecule that bound was 7-9 glycan residues, whereas, di- and trisaccharides did not bind. There was a logarithmic linear relationship between the strength of the binding and the length of the polymer (up to >1500 glycan residues), which indicates an avidity effect of the cooperative binding of one polymeric molecule to several receptor molecules on the cell surface. The 70-kDa receptor, therefore, has a broad, but limited specificity of binding for non-charged (peptidoglycan and chitin), highly negatively charged (heparin and heparinoids), and weakly negatively charged (lipoteichoic acids, lipopolysaccharides, and lipid A) ligands.			DZIARSKI, R (corresponding author), INDIANA UNIV, SCH MED, NW CTR MED EDUC, GARY, IN 46408 USA.				NIAID NIH HHS [AI28797] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028797] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN RA, 1986, BIOCHIM BIOPHYS ACTA, V882, P271, DOI 10.1016/0304-4165(86)90248-5; BEACHEY EH, 1977, INFECT IMMUN, V16, P649, DOI 10.1128/IAI.16.2.649-654.1977; BEACHEY EH, 1979, INFECT IMMUN, V23, P618, DOI 10.1128/IAI.23.3.618-625.1979; BHAKDI S, 1991, INFECT IMMUN, V59, P4614, DOI 10.1128/IAI.59.12.4614-4620.1991; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BUTLER T, 1977, INFECT IMMUN, V16, P449, DOI 10.1128/IAI.16.2.449-455.1977; CASU B, 1985, ADV CARBOHYD CHEM BI, V43, P51, DOI 10.1016/S0065-2318(08)60067-0; CHEN TY, 1990, J IMMUNOL, V145, P8; COURTNEY H, 1981, INFECT IMMUN, V32, P625, DOI 10.1128/IAI.32.2.625-631.1981; COURTNEY HS, 1986, INFECT IMMUN, V51, P414, DOI 10.1128/IAI.51.2.414-418.1986; DENTENER MA, 1993, J IMMUNOL, V150, P2885; DZIARSKI R, 1989, J IMMUNOL, V143, P356; DZIARSKI R, 1991, J BIOL CHEM, V266, P4713; DZIARSKI R, 1992, CELL IMMUNOL, V145, P100, DOI 10.1016/0008-8749(92)90316-H; DZIARSKI R, 1991, J BIOL CHEM, V266, P4719; DZIARSKI R, 1987, CELL IMMUNOL, V109, P231, DOI 10.1016/0008-8749(87)90307-8; Dziarski R, 1992, J Immunol, V148, P1590; DZIARSKI R, 1993, INT CONGR SER, V1020, P151; EDENS RE, 1992, J PHARM SCI, V81, P823, DOI 10.1002/jps.2600810821; ESPEVIK T, 1993, EUR J IMMUNOL, V23, P255, DOI 10.1002/eji.1830230140; FISCHER W, 1983, EUR J BIOCHEM, V133, P523, DOI 10.1111/j.1432-1033.1983.tb07495.x; FOLKMAN J, 1989, SCIENCE, V243, P1490, DOI 10.1126/science.2467380; FOMSGAARD A, 1990, J CLIN MICROBIOL, V28, P2627, DOI 10.1128/JCM.28.12.2627-2631.1990; FRANSSON LA, 1985, POLYSACCHARIDES, V3, P337; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GREEN SJ, 1992, J IMMUNOL, V149, P2069; HALLING JL, 1992, INFECT IMMUN, V60, P845, DOI 10.1128/IAI.60.3.845-852.1992; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; HU WL, 1990, BIOCHEMISTRY-US, V29, P535, DOI 10.1021/bi00454a030; IWASAKI H, 1989, J BACTERIOL, V171, P424, DOI 10.1128/jb.171.1.424-429.1989; JAQUES LB, 1979, SCIENCE, V206, P528, DOI 10.1126/science.386509; KNAUS HG, 1990, J BIOL CHEM, V265, P11156; KRIEGER M, 1993, J BIOL CHEM, V268, P4569; LEDERMAN S, 1989, J IMMUNOL, V143, P1149; LEI MG, 1988, J IMMUNOL, V141, P996; LEI MG, 1988, J IMMUNOL, V141, P1006; LEI MG, 1991, J IMMUNOL, V147, P1925; LEVY R, 1990, INFECT IMMUN, V58, P566, DOI 10.1128/IAI.58.2.566-568.1990; LINHARDT RJ, 1984, APPL BIOCHEM BIOTECH, V9, P41, DOI 10.1007/BF02798373; LOBB RR, 1986, ANAL BIOCHEM, V154, P1, DOI 10.1016/0003-2697(86)90487-2; LONCHAMPT MO, 1992, J CARDIOVASC PHARM, V20, pS145, DOI 10.1097/00005344-199204002-00041; LYNN WA, 1992, IMMUNOL TODAY, V13, P271, DOI 10.1016/0167-5699(92)90009-V; MATHISON JC, 1992, J IMMUNOL, V149, P200; MORRISON DC, 1976, IMMUNOCHEMISTRY, V13, P813, DOI 10.1016/0019-2791(76)90181-6; MORRISON DC, 1990, J INFECT DIS, V162, P1063, DOI 10.1093/infdis/162.5.1063; NAKAMURA T, 1988, J BIOL CHEM, V263, P16709; OFEK I, 1975, J EXP MED, V141, P990, DOI 10.1084/jem.141.5.990; PARISH CR, 1985, CELL IMMUNOL, V91, P201, DOI 10.1016/0008-8749(85)90044-9; PARISH CR, 1988, J IMMUNOL, V141, P3498; QURESHI N, 1988, J BIOL CHEM, V263, P11971; RABIN RL, 1993, J INFECT DIS, V168, P135, DOI 10.1093/infdis/168.1.135; ROEDER DJ, 1989, INFECT IMMUN, V57, P1054, DOI 10.1128/IAI.57.4.1054-1058.1989; RUPLEY JA, 1964, BIOCHIM BIOPHYS ACTA, V83, P245, DOI 10.1016/0926-6526(64)90001-1; SCHREIBER AB, 1985, P NATL ACAD SCI USA, V82, P6138, DOI 10.1073/pnas.82.18.6138; SMITH CIE, 1978, J IMMUNOL, V121, P823; SMITH JW, 1990, J BIOL CHEM, V265, P2168; SORENSEN P, 1986, J BIOL CHEM, V261, P9094; TARSITSUK D, 1990, J IMMUNOL, V144, P2665; THURN AL, 1986, J CELL PHYSIOL, V126, P352, DOI 10.1002/jcp.1041260305; TOTH CA, 1992, J LEUKOCYTE BIOL, V51, P466; VANLENTEN BJ, 1986, P NATL ACAD SCI USA, V83, P2704; WESSEL HP, 1990, CARBOHYD RES, V204, P131, DOI 10.1016/0008-6215(90)84028-S; WICKEN AJ, 1986, J BACTERIOL, V166, P72, DOI 10.1128/jb.166.1.72-77.1986; WOLLENWEBER HW, 1985, J BIOL CHEM, V260, P5068; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; YANNARIELLOBROWN J, 1992, J BIOL CHEM, V267, P20451	67	28	28	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2100	2110						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294463				2022-12-27	WOS:A1994MR98800084
J	HE, DY; YU, L; YU, CA				HE, DY; YU, L; YU, CA			UBIQUINONE BINDING DOMAINS IN BOVINE HEART MITOCHONDRIAL CYTOCHROME-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; IRON-SULFUR PROTEIN; C REDUCTASE COMPLEX; BEEF-HEART; BC1 COMPLEX; OXIDOREDUCTASE; INHIBITORS; SUBUNIT; RESISTANCE; ANTIMYCIN	Cytochrome b was identified as one of the ubiquinone-binding proteins in bovine heart mitochondrial ubiquinol-cytochrome c reductase by photoaffinity labeling using 3-azido-2-methyl-5-methoxy-6-(3,7-dimethyl[H-3]-octyl)-1,4-benzoquinone ([H-3]azido-Q). The [H-3]azido-Q-labeled cytochrome b protein was purified to homogeneity from the azido-Q-labeled ubiquinol-cytochrome c reductase by a procedure involving Triton X-100 and urea treatment, calcium phosphate column chromatography, acetone precipitation, decanoyl-N-methylglucamide-cholate extraction, and preparative sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Purified cytochrome b protein containing 0.5 mol of azido-Q/mol of protein was subjected to reductive carboxymethylation and succinylation prior to digestion by chymotrypsin. Two azido-Q-linked peptides with retention times of 47.1 and 49.0 min were obtained by high performance liquid chromatographic separation. Partial amino-terminal amino acid sequences of these two peptides were determined to be GATVI- and ALVADL-, indicating that these two chymotryptic peptides are from amino residues 142-155 and 326-336. Monospecific polyclonal antibodies against two synthetic ubiquinone-binding peptides, NH2-G-A-T-V-I-T-N-L-L-S-COOH (P-47) and NH2-W-A-L-V-A-D-L-L-T-L-T-W-I-COOH (P-49), were generated in rabbits and purified. Western blotting and enzyme-linked immunosorbent assays showed that the purified antibodies against P-47 reacted with cytochrome b-containing reductases and purified cytochrome b protein. Antibodies against P-47 inhibited activities of succinate-cytochrome c and ubiquinol-cytochrome c reductases only when they were incubated with phospholipid-depleted reductases prior to the replenishment with phospholipid. No inhibition was observed with incubation with phospholipid-containing reductases, indicating that this peptide involved in ubiquinone binding is buried in a phospholipid environment.	OKLAHOMA STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,NOBLE RES CTR 246,STILLWATER,OK 74078	Oklahoma State University System; Oklahoma State University - Stillwater					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030721, R01GM030721] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30721] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BORCHART U, 1986, FEBS LETT, V200, P81, DOI 10.1016/0014-5793(86)80515-4; BOWYER JR, 1982, FUNCTION QUINONES EN, P365; BRANDT U, 1993, J BIOL CHEM, V268, P8387; COLSON AM, 1993, J BIOENERG BIOMEMBR, V25, P210; DALDAL F, 1989, EMBO J, V8, P3951, DOI 10.1002/j.1460-2075.1989.tb08578.x; DEVRIES S, 1981, J BIOL CHEM, V256, P1996; DEVRIES S, 1982, BIOCHIM BIOPHYS ACTA, V681, P41, DOI 10.1016/0005-2728(82)90276-6; DIRAGO JP, 1988, J BIOL CHEM, V263, P12564; GENNIS RB, 1993, J BIOENERG BIOMEMBR, V25, P195, DOI 10.1007/BF00762582; GONZALEZHALPHEN D, 1991, J BIOL CHEM, V266, P3870; GONZALEZHALPHEN D, 1988, BIOCHEMISTRY-US, V27, P7021, DOI 10.1021/bi00418a053; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.biochem.54.1.1015; HILDRETH JEK, 1982, BIOCHEM J, V207, P363, DOI 10.1042/bj2070363; HOSOKAWA Y, 1989, J BIOL CHEM, V264, P13483; JENNER ER, 1973, Patent No. 3737516; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI LB, 1991, BIOCHIM BIOPHYS ACTA, V1057, P215, DOI 10.1016/S0005-2728(05)80104-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARRES CAM, 1977, BIOCHIM BIOPHYS ACTA, V462, P531, DOI 10.1016/0005-2728(77)90099-8; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; OHNISHI T, 1980, J BIOL CHEM, V255, P3278; PAUL KG, 1953, ACTA CHEM SCAND, V7, P1284, DOI 10.3891/acta.chem.scand.07-1284; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; USUI S, 1990, BIOCHEMISTRY-US, V29, P4618, DOI 10.1021/bi00471a017; USUI S, 1990, BIOCHEM BIOPH RES CO, V167, P575, DOI 10.1016/0006-291X(90)92063-6; Voller A., 1980, MANUAL CLIN IMMUNOLO, P359; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; VONJAGOW G, 1984, J BIOL CHEM, V259, P6318; VONJAGOW G, 1987, ADV MEMBRANE BIOCH B, P155; WAKABAYASHI S, 1980, BIOCHEM BIOPH RES CO, V97, P1548, DOI 10.1016/S0006-291X(80)80042-8; WAKABAYASHI S, 1985, J BIOL CHEM, V260, P337; WIDGER WR, 1984, P NATL ACAD SCI-BIOL, V81, P674, DOI 10.1073/pnas.81.3.674; YU CA, 1993, J BIOENERG BIOMEMBR, V25, P259, DOI 10.1007/BF00762587; YU CA, 1983, BIOCHIM BIOPHYS ACTA, V736, P226, DOI 10.1016/0005-2736(83)90288-2; YU CA, 1980, ARCH BIOCHEM BIOPHYS, V204, P59, DOI 10.1016/0003-9861(80)90007-7; YU L, 1985, J BIOL CHEM, V260, P963; YU L, 1982, J BIOL CHEM, V257, P2016; YUE WH, 1991, BIOCHEMISTRY-US, V30, P2303, DOI 10.1021/bi00223a002	41	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2292	2298						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294488				2022-12-27	WOS:A1994MR98800110
J	SWEDER, KS; HANAWALT, PC				SWEDER, KS; HANAWALT, PC			THE COOH TERMINUS OF SUPPRESSOR OF STEM-LOOP (SSL2/RAD25) IN YEAST IS ESSENTIAL FOR OVERALL GENOMIC EXCISION-REPAIR AND TRANSCRIPTION-COUPLED REPAIR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XERODERMA-PIGMENTOSUM; DNA-REPAIR; SACCHAROMYCES-CEREVISIAE; PREFERENTIAL REPAIR; COCKAYNES-SYNDROME; PYRIMIDINE DIMERS; RAD3 PROTEIN; DHFR GENE; HELICASE; HOMOLOG	We examined several yeast strains with different mutations in the essential SSL2 (Suppressor of Stem Loop, also called RAD25) gene for their ability to remove cyclobutane pyrimidine dimers. from expressed genes, and from the genome overall. The SSL2 protein has a high degree of amino acid sequence identity to the protein encoded by the human ERCC3 gene (Gulyas, K. D., and Donahue, T. F. (1992) Cell 69, 1031-0142). The mutant allele SSL2-XP encodes a protein resembling the mutated ERCC3 protein from UV-sensitive human cells belonging to xeroderma pigmentosum complementation group B and Cockayne's syndrome (CS) complementation group C (Weeda, G., van Ham, R. C. A., Vermeulen, W., Bootsma, D., van der Eb, A. J., and Hoeijmakers, J. H. J. (1990) Cell 62, 777-791; Gulyas and Donahue, 1992). The SSL2-XP allele confers UV sensitivity on yeast strain KG119. We found-that the biochemical basis for the UV sensitivity of KG119 is a complete deficiency in the removal of cyclobutane pyrimidine dimers from the overall genome as well as a deficiency in transcription-coupled repair. This is the first analysis of the DNA repair defect responsible for the UV sensitivity of cells carrying the SSL2-XP allele, and it documents the similarity of the defect to that associated with XP-B/CS-C, and the difference between this defect and that in cells belonging to CS complementation groups A and B.			SWEDER, KS (corresponding author), STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA.		Sweder, Kevin/GSM-7837-2022		NATIONAL CANCER INSTITUTE [R35CA044349] Funding Source: NIH RePORTER; NCI NIH HHS [CA44349] Funding Source: Medline; NIEHS NIH HHS [ES05521-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		[Anonymous], 1985, DNA REPAIR; BAILLY V, 1991, P NATL ACAD SCI USA, V88, P9712, DOI 10.1073/pnas.88.21.9712; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; Cleaver J. E., 1989, METABOLIC BASIS INHE, V2, P2949; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; LEADON SA, 1992, J BIOL CHEM, V267, P23175; LEHMANN AR, 1981, DNA REPAIR LABORATOR, V1, P471; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MOUNKES LC, 1992, CELL, V71, P925, DOI 10.1016/0092-8674(92)90389-T; NASMYTH KA, 1980, P NATL ACAD SCI-BIOL, V77, P2119, DOI 10.1073/pnas.77.4.2119; PARK E, 1992, P NATL ACAD SCI USA, V89, P11416, DOI 10.1073/pnas.89.23.11416; ROZA L, 1990, CANCER RES, V50, P1905; Sambrook J, 1989, MOL CLONING LABORATO; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SHERMAN F, 1986, LABORATORY COURSE MA; SMERDON MJ, 1990, NUCLEIC ACIDS RES, V18, P2045, DOI 10.1093/nar/18.8.2045; SMITH CA, 1990, ADV MUTAGENESIS RES, V1, P153; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; SWEDER KS, 1992, P NATL ACAD SCI USA, V89, P10696, DOI 10.1073/pnas.89.22.10696; TERLETH C, 1991, MUTAGENESIS, V6, P103, DOI 10.1093/mutage/6.2.103; THACH RE, 1992, CELL, V68, P177, DOI 10.1016/0092-8674(92)90461-K; WEEDA G, 1991, CARCINOGENESIS, V12, P2361, DOI 10.1093/carcin/12.12.2361; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U	26	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1852	1857						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294433				2022-12-27	WOS:A1994MR98800048
J	CHEN, WN; BLANC, J; LIM, L				CHEN, WN; BLANC, J; LIM, L			CHARACTERIZATION OF A PROMISCUOUS GTPASE-ACTIVATING PROTEIN THAT HAS A BCR-RELATED DOMAIN FROM CAENORHABDITIS-ELEGANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GENE ENCODES; GAP; RHO; RAS; ORGANIZATION; CLONING; REGION	Human breakpoint cluster region (bcr) gene product is a member of a group of GTPase-activating proteins that act exclusively on members of the Ras-related Rho subfamily. A complementary DNA was isolated from Caenorhabditis elegans that encoded a polypeptide of 1438 amino acid residues, CeGA-P, which contains a domain with sequence similarity to the COOH-terminal segment (GTPase-activating protein region) of Bcr and other known GTPase-activating proteins of the Rho subfamily. It also contains a ''pleckstrin homology'' motif, present in many signaling proteins including GTPase-activating proteins and nucleotide exchange factors. The Bcr-like domain of CeGAP exhibited activity not only on members of the C. elegans and human Rho subfamily but surprisingly also on C. elegans Ras protein (let-60), human Ras, and Rab3A. CeGA-P is therefore the first GTPase-activating protein acting on Ras-related proteins across different subfamilies. Together with the presence of the pleckstrin homology motif, our finding suggests a central and integrative role for CeGAP in a signaling pathway common to Ras and related proteins.	INST NEUROL, LONDON WC1N 1PJ, ENGLAND	University of London; University College London	CHEN, WN (corresponding author), NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, 10 KENT RIDGE CRESCENT, SINGAPORE 0511, SINGAPORE.			, Yang/0000-0002-6620-8897; Blanc, Julian/0000-0003-4331-5339				ADAMS JM, 1992, ONCOGENE, V7, P611; ADAMSON ED, 1987, DEVELOPMENT, V99, P449; AGNEL M, 1992, MOL CELL BIOL, V12, P5111, DOI 10.1128/MCB.12.11.5111; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHEN WI, 1993, J BIOL CHEM, V268, P320; CHEN WN, 1993, J BIOL CHEM, V268, P13280; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; HALL C, 1993, MOL CELL BIOL, V13, P4986, DOI 10.1128/MCB.13.8.4986; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	26	20	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					820	823						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288633				2022-12-27	WOS:A1994MR22000010
J	OKAMOTO, N; HORI, S; AKAZAWA, C; HAYASHI, Y; SHIGEMOTO, R; MIZUNO, N; NAKANISHI, S				OKAMOTO, N; HORI, S; AKAZAWA, C; HAYASHI, Y; SHIGEMOTO, R; MIZUNO, N; NAKANISHI, S			MOLECULAR CHARACTERIZATION OF A NEW METABOTROPIC GLUTAMATE-RECEPTOR MGLUR7 COUPLED TO INHIBITORY CYCLIC-AMP SIGNAL-TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG HIPPOCAMPUS; RETINAL BIPOLAR CELLS; G-PROTEIN; SYNAPTIC TRANSMISSION; ADENYLATE-CYCLASE; ACID; NEURONS; CONDUCTANCE; CORTEX; 2-AMINO-4-PHOSPHONOBUTYRATE	A cDNA clone for a new rat metabotropic glutamate receptor termed mGluR7 was isolated through polymerase chain reaction-mediated DNA amplification by using primer sequences conserved among the metabotropic receptor (mGluR) family and by the subsequent screening of a rat forebrain cDNA library. The cloned mGluR7 subtype consists of 915 amino acid residues and exhibits a structural architecture common to the mGluR family with a large extracellular domain preceding the seven putative membrane-spanning domains. mGluR7 shows the highest sequence similarity to mGluR4 and mGluR6 among the members of the mGluR family. Similar to mGluR4 and mGluR6, mGluR7 inhibits forskolin-stimulated cyclic AMP accumulation in response to agonist interaction and potently reacts with L-2-amino-4-phosphonobutyrate and L-serine-O-phosphate in Chinese hamster ovary cells transfected with the cloned cDNA. RNA blot and in situ hybridization analyses of mGluR7 mRNA indicated that it is widely expressed in many neuronal cells of the central nervous system and is thus different from the more limitedly expressed mGluR4 or mGluR6 mRNA. mGluR7 together with mGluR4 thus corresponds to the putative L-2-amino-4-phosphonobutyrate receptor which plays an important role in modulation of glutamate transmission in the central nervous system.	KYOTO UNIV,FAC MED,DEPT MORPHOL BRAIN SCI,SAKYO KU,KYOTO 606,JAPAN	Kyoto University	NAKANISHI, S (corresponding author), KYOTO UNIV,FAC MED,INST IMMUNOL,YOSHIDA,SAKYO KU,KYOTO 606,JAPAN.		Shigemoto, Ryuichi/E-3628-2013; Hayashi, Yasunori/AAF-1408-2019	Shigemoto, Ryuichi/0000-0001-8761-9444; Hayashi, Yasunori/0000-0002-7560-3004				ABE T, 1992, J BIOL CHEM, V267, P13361; ANSON J, 1987, BRIT J PHARMACOL, V91, P753, DOI 10.1111/j.1476-5381.1987.tb11273.x; ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; BASKYS A, 1991, J PHYSIOL-LONDON, V444, P687, DOI 10.1113/jphysiol.1991.sp018901; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BROWN AM, 1988, AM J PHYSIOL, V254, pH401, DOI 10.1152/ajpheart.1988.254.3.H401; CARTMELL J, 1993, BRIT J PHARMACOL, V108, pP268; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; COTMAN CW, 1986, J PHYSIOL-LONDON, V378, P403, DOI 10.1113/jphysiol.1986.sp016227; FORSYTHE ID, 1990, J PHYSIOL-LONDON, V429, P1; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; HEARN TJ, 1986, BRAIN RES, V379, P372, DOI 10.1016/0006-8993(86)90793-6; HOLZ GG, 1989, J NEUROSCI, V9, P657; HORI N, 1982, J NEUROPHYSIOL, V48, P1289, DOI 10.1152/jn.1982.48.6.1289; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KOERNER JF, 1981, BRAIN RES, V216, P192, DOI 10.1016/0006-8993(81)91288-9; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LANTHORN TH, 1984, BRAIN RES, V290, P174, DOI 10.1016/0006-8993(84)90750-9; LIPSCOMBE D, 1989, NATURE, V340, P639, DOI 10.1038/340639a0; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MILLER RF, 1986, TRENDS NEUROSCI, V9, P211, DOI 10.1016/0166-2236(86)90061-5; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAKAJIMA Y, 1993, J BIOL CHEM, V268, P11868; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NAWY S, 1991, NEURON, V7, P677, DOI 10.1016/0896-6273(91)90380-I; NAWY S, 1990, NATURE, V346, P269, DOI 10.1038/346269a0; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; POOK PCK, 1992, EXP PHYSIOL, V77, P529, DOI 10.1113/expphysiol.1992.sp003617; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOEPP DD, 1993, TRENDS PHARMACOL SCI, V14, P13, DOI 10.1016/0165-6147(93)90107-U; SCHOLZ KP, 1991, J PHYSIOL-LONDON, V435, P373, DOI 10.1113/jphysiol.1991.sp018515; SHIELLS RA, 1990, P ROY SOC B-BIOL SCI, V242, P91, DOI 10.1098/rspb.1990.0109; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; TANABE Y, 1993, J NEUROSCI, V13, P1372; TROMBLEY PQ, 1992, J NEUROSCI, V12, P2043; TROMBLEY PQ, 1990, J NEUROPHYSIOL, V64, P598, DOI 10.1152/jn.1990.64.2.598; UI M, 1984, TRENDS PHARMACOL SCI, V5, P277, DOI 10.1016/0165-6147(84)90444-9; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; YAMAMOTO C, 1983, EXP BRAIN RES, V51, P128	41	440	448	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1231	1236						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288585				2022-12-27	WOS:A1994MR22000073
J	YADA, T; SAKURADA, M; IHIDA, K; NAKATA, M; MURATA, F; ARIMURA, A; KIKUCHI, M				YADA, T; SAKURADA, M; IHIDA, K; NAKATA, M; MURATA, F; ARIMURA, A; KIKUCHI, M			PITUITARY ADENYLATE-CYCLASE ACTIVATING POLYPEPTIDE IS AN EXTRAORDINARILY POTENT INTRAPANCREATIC REGULATOR OF INSULIN-SECRETION FROM ISLET BETA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFUSED RAT PANCREAS; HYPOTHALAMIC PEPTIDE; OVINE HYPOTHALAMUS; RELEASE; CA-2+; CALCIUM; GLUCOSE; INCREASE; SINGLE; PACAP	Insulin secretion from pancreatic islets is controlled by peptides as well as by nutrients. We report here a novel, extraordinarily potent peptidergic regulation of insulin secretion. A 27-residue form of pituitary adenylate cyclase activating polypeptide (PACAP27) as low as 10(-14) to 10(-13) M stimulated insulin release from rat islets in a glucose-dependent manner. PACAP27 also increased cytosolic free Ca2+ concentration ([Ca2+]i) in islet beta-cells. Nitrendipine, a blocker of the L-type Ca2+ channel, abolished both [Ca2+]i and insulin responses. Vasoactive intestinal peptide, a peptide exhibiting 68% amino acid homology with PACAP, also increased [Ca2+]i in beta-cells but only at concentrations in the nanomolar range, indicating that PACAP27 is 4 logs more potent. A 38-residue form of the peptide (PACAP38) stimulated insulin release and increased beta-cell [Ca2+]i in a manner similar to that of PACAP27. PACAP-like immunoreactivity was demonstrated in pancreatic nerve fibers, islets, and capillaries. The results indicate that PACAP is a physiologically occurring peptide in pancreas and that PACAP, in a glucose-dependent manner, activates beta-cells presumably via a high affinity PACAP-selective receptor, raises [Ca2+]i by increasing the activity of L-type Ca2+ channels, and consequently stimulates insulin release. PACAP appears to be by far the most potent insulinotropic peptide known.	KAGOSHIMA UNIV,SCH MED,DEPT ANAT,KAGOSHIMA 890,JAPAN; ASAHI LIFE FDN,INST ADULT DIS,TOKYO 160,JAPAN; TULANE UNIV,HEBERT CTR,UNITED STATES JAPAN BIOMED RES LABS,BELLE CHASSE,LA 70037	Kagoshima University; Asahi Life Foundation; Tulane University	YADA, T (corresponding author), KAGOSHIMA UNIV,SCH MED,DEPT PHYSIOL,8-35-1 SAKURAGAOKA,KAGOSHIMA 890,JAPAN.							AMMALA C, 1993, NATURE, V363, P356, DOI 10.1038/363356a0; ARIMURA A, 1991, ENDOCRINOLOGY, V129, P2787, DOI 10.1210/endo-129-5-2787; ARIMURA A, 1992, REGUL PEPTIDES, V37, P287; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; CANNY BJ, 1992, ENDOCRINOLOGY, V130, P211, DOI 10.1210/en.130.1.211; FRIDOLF T, 1992, CELL TISSUE RES, V269, P275, DOI 10.1007/BF00319618; GOTH MI, 1992, ENDOCRINOLOGY, V130, P939, DOI 10.1210/en.130.2.939; GOTTSCHALL PE, 1990, ENDOCRINOLOGY, V127, P272, DOI 10.1210/endo-127-1-272; GRAHAM RC, 1966, J HISTOCHEM CYTOCHEM, V14, P291, DOI 10.1177/14.4.291; GRAPENGIESSER E, 1988, BIOCHEM BIOPH RES CO, V150, P419, DOI 10.1016/0006-291X(88)90537-2; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HACKER GW, 1988, J HISTOTECHNOL, V11, P213, DOI 10.1179/his.1988.11.4.213; ISOBE K, 1993, ENDOCRINOLOGY, V132, P1757, DOI 10.1210/en.132.4.1757; KAWAI K, 1992, LIFE SCI, V50, P257, DOI 10.1016/0024-3205(92)90332-J; KOVES K, 1989, J HISTOCHEM CYTOCHEM, V37, P903, DOI 10.1177/37.6.2723405; KOVES K, 1990, ENDOCRINOLOGY, V127, P264; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MIYATA A, 1990, BIOCHEM BIOPH RES CO, V170, P643, DOI 10.1016/0006-291X(90)92140-U; MOJSOV S, 1987, J CLIN INVEST, V79, P616, DOI 10.1172/JCI112855; MUNGAN Z, 1991, PEPTIDES, V12, P559, DOI 10.1016/0196-9781(91)90101-T; ORSKOV C, 1992, DIABETOLOGIA, V35, P701; PENNER R, 1988, J EXP BIOL, V139, P329; PIPELEERS D, 1982, P NATL ACAD SCI-BIOL, V79, P7322, DOI 10.1073/pnas.79.23.7322; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; RAUFMAN JP, 1991, REGUL PEPTIDES, V36, P121, DOI 10.1016/0167-0115(91)90200-Z; ROTH J, 1982, J HISTOCHEM CYTOCHEM, V30, P691, DOI 10.1177/30.7.7050239; SAKURADA M, 1993, ENDOCRINOLOGY, V132, P2659, DOI 10.1210/en.132.6.2659; SMITH PA, 1989, NATURE, V342, P550, DOI 10.1038/342550a0; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TATSUNO I, 1992, ENDOCRINOLOGY, V131, P73, DOI 10.1210/en.131.1.73; WARREN JB, 1991, EUR J PHARMACOL, V197, P131, DOI 10.1016/0014-2999(91)90511-N; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914; YADA T, 1992, CELL CALCIUM, V13, P69, DOI 10.1016/0143-4160(92)90031-M; YADA T, 1993, PEPTIDES, V14, P235, DOI 10.1016/0196-9781(93)90035-F; YADA T, 1989, J BIOL CHEM, V264, P2455; YADA T, 1993, IN PRESS ENDOCRINOLO	36	243	244	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1290	1293						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288592				2022-12-27	WOS:A1994MR22000082
J	YOSHIDA, S; OHYA, Y; GOEBL, M; NAKANO, A; ANRAKU, Y				YOSHIDA, S; OHYA, Y; GOEBL, M; NAKANO, A; ANRAKU, Y			A NOVEL GENE, STT4, ENCODES A PHOSPHATIDYLINOSITOL 4-KINASE IN THE PKC1 PROTEIN-KINASE PATHWAY OF SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN; CELL-CYCLE; SIGNAL TRANSDUCTION; YEAST; PURIFICATION; DNA; STAUROSPORINE; 3-PHOSPHATE; 3-KINASE; IDENTIFICATION	A staurosporine-sensitive mutation (stt1) in yeast has been found in the PKC1 gene that encodes a protein kinase C homologue (Yoshida, S., Ikeda, E., Uno, I., and Mitsuzawa, H. (1992) Mol. Gen. Genet. 231, 337-344). We report here another staurosporine-sensitive mutant, stt4, which shows very similar phenotypes to that of the stt1 mutant. The stt4 temperature-sensitive mutant arrests mostly in G2/M phase at 37-degrees-C, and the stt4 deletion mutant shows an osmoremedial phenotype. Staurosporine sensitivity of the stt4 mutant was suppressed by overexpression of PKC1/STT1, indicating genetic interaction between stt4 and pkc1/stt1. The nucleotide sequenee of STT4 predicts a hydrophilic protein composed of 1,900 amino acid residues, with 26% sequence identity to the yeast VPS34 gene product and 27% to the catalytic subunit of mammalian phosphatidylinositol (PI) 3-kinase, respectively. Cell homogenates of the stt4 deletion mutant show normal PI3-kinase activity but lack most of the PI4-kinase activity that is detected in the wild-type. We conclude that STT4 encodes a yeast PI4-kinase that functions in the PKC1 protein kinase pathway.	UNIV TOKYO,FAC SCI,DEPT BIOL,BUNKYO KU,TOKYO 113,JAPAN; INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202	University of Tokyo; Indiana University System; Indiana University-Purdue University Indianapolis			Nakano, Akihiko/G-4942-2014; Nakano, Akihiko/C-6185-2009; Nakano, Akihiko/A-6420-2016	Nakano, Akihiko/0000-0003-3635-548X; Nakano, Akihiko/0000-0003-3635-548X				AUGER KR, 1989, J BIOL CHEM, V264, P20181; BECKER GW, 1977, J BIOL CHEM, V252, P8684; BELUNIS CJ, 1988, J BIOL CHEM, V263, P18897; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; DAHL C, 1987, P NATL ACAD SCI USA, V84, P4012, DOI 10.1073/pnas.84.12.4012; ENDEMANN G, 1987, BIOCHEMISTRY-US, V26, P6845, DOI 10.1021/bi00395a039; FLANAGAN CA, 1992, J BIOL CHEM, V267, P24117; HAWKINS PT, 1993, J BIOL CHEM, V268, P3374; Henry S. A., 1982, MOL BIOL YEAST SACCH, P101; Herman Paul K., 1992, Trends in Cell Biology, V2, P363, DOI 10.1016/0962-8924(92)90048-R; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KAIBUCHI K, 1986, P NATL ACAD SCI USA, V83, P8172, DOI 10.1073/pnas.83.21.8172; KATO M, 1989, J BIOL CHEM, V264, P423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; LIPS DL, 1989, J BIOL CHEM, V264, P8759; MORISHITA T, 1991, J BACTERIOL, V173, P2406, DOI 10.1128/JB.173.7.2406-2408.1991; MORTIMER RK, 1985, MICROBIOL REV, V49, P181, DOI 10.1128/MMBR.49.3.181-213.1985; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; NAKANO H, 1987, J ANTIBIOT, V40, P706, DOI 10.7164/antibiotics.40.706; NICKELS JT, 1992, J BIOL CHEM, V267, P16297; NIKAWA J, 1987, J BIOL CHEM, V262, P4876; NISHIKAWA S, 1990, J BIOL CHEM, V265, P7440; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OGITA K, 1990, P NATL ACAD SCI USA, V87, P5011, DOI 10.1073/pnas.87.13.5011; OMURA S, 1977, J ANTIBIOT, V30, P275, DOI 10.7164/antibiotics.30.275; PERKINS DD, 1949, GENETICS, V34, P607; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMON AJ, 1991, P ROY SOC B-BIOL SCI, V243, P165, DOI 10.1098/rspb.1991.0027; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VOLLRATH D, 1988, P NATL ACAD SCI USA, V85, P6027, DOI 10.1073/pnas.85.16.6027; WADA Y, 1992, J BIOL CHEM, V267, P18665; WALSH JP, 1991, P NATL ACAD SCI USA, V88, P9184, DOI 10.1073/pnas.88.20.9184; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WINSTON F, 1983, METHOD ENZYMOL, V101, P211; YOSHIDA S, 1992, MOL GEN GENET, V231, P337, DOI 10.1007/BF00292700; YOSHIHISA T, 1989, BIOCHEM BIOPH RES CO, V163, P908, DOI 10.1016/0006-291X(89)92308-5	53	168	170	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1166	1171						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288577				2022-12-27	WOS:A1994MR22000063
J	FRITZ, TA; LUGEMWA, FN; SARKAR, AK; ESKO, JD				FRITZ, TA; LUGEMWA, FN; SARKAR, AK; ESKO, JD			BIOSYNTHESIS OF HEPARAN-SULFATE ON BETA-D-XYLOSIDES DEPENDS ON AGLYCONE STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE; DERMATAN SULFATE; GLYCOSAMINOGLYCAN BIOSYNTHESIS; N-SULFOTRANSFERASE; D-GALACTOSIDES; BREFELDIN-A; CARTILAGE; OLIGOSACCHARIDES; PROTEOGLYCAN; LOCALIZATION	We have reported that 3-estradiol-beta-D-xyloside-primes heparan sulfate synthesis in Chinese hamster ovary cells and that the proportion of heparan sulfate made rises with increasing concentration of xyloside (Lugemwa, F. N. and Esko, J. D. (1991) J. Biol. Chem. 266, 6674-6677). Using estradiol as a guide, we varied the structure of the aglycone and showed that beta-D-xylosides containing two fused aromatic rings efficiently prime heparan sulfate. Thus, 2-naphthol-beta-D-xyloside primed heparan sulfate at low dose (less-than-or-equal-to 10 muM) and the proportion of heparan sulfate increased with concentration (up to 50% of total glycosaminoglycan). Various ring additions and heterocyclic ring substitutions altered the efficiency of heparan sulfate priming, but had no effect on the overall level of glycosaminoglycan synthesis. Replacement of the bridging oxygen with sulfur (2-naphthalenethiol-beta-D-xyloside) increased the efficiency of heparan sulfate priming. Priming of heparan sulfate correlated with hydrophobicity of the xyloside, but several exceptions suggested that the chemical structure of the aglycone played an equally important role. Interestingly, the heparan sulfate chains generated on 2-naphthol-beta-D-xyloside showed a 2-fold decrease in the proportion of disaccharides containing 6-O-sulfate groups and a striking diminution in non-sulfated iduronic acid containing disaccharides compared to the chains attached to cellular proteoglycans. Thus, both the type of glycosaminoglycan made on a xyloside and its fine structure depends on the aglycone.	UNIV ALABAMA,SCH MED,DEPT BIOCHEM & MOLEC GENET,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH DENT,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NCI NIH HHS [CA46462] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046462] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAME KJ, 1991, J BIOL CHEM, V266, P10287; BAME KJ, 1989, J BIOL CHEM, V264, P8059; CHIOU CT, 1977, ENVIRON SCI TECHNOL, V11, P475, DOI 10.1021/es60128a001; Conchie J, 1963, METHODS CARBOHYDRATE, V2, P335; COSTER L, 1991, BIOCHEM J, V276, P533, DOI 10.1042/bj2760533; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; FRANSSON LA, 1991, GLYCOCONJUGATE J, V8, P108, DOI 10.1007/BF00731020; FRANSSON LA, 1992, GLYCOCONJUGATE J, V9, P45, DOI 10.1007/BF00731177; FREEZE HH, 1993, J BIOL CHEM, V268, P1618; GIBSON KD, 1977, BIOCHEM J, V162, P217, DOI 10.1042/bj1620217; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; GUO YC, 1988, ANAL BIOCHEM, V168, P54, DOI 10.1016/0003-2697(88)90009-7; HELFERICH B, 1962, CHEM BER-RECL, V95, P2616, DOI 10.1002/cber.19620951105; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Koenigs W, 1901, BER DTSCH CHEM GES, V34, P957, DOI 10.1002/cber.190103401162; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; LINDAHL U, 1973, J BIOL CHEM, V248, P7234; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUGEMWA FN, 1991, J BIOL CHEM, V266, P6674; OKAYAMA M, 1973, J BIOCHEM-TOKYO, V74, P1069; Pagano RE, 1990, CURR OPIN CELL BIOL, V2, P652, DOI 10.1016/0955-0674(90)90107-P; PAULSEN H, 1981, CHEM BER-RECL, V114, P3102, DOI 10.1002/cber.19811140916; PLANT AL, 1985, J CELL BIOL, V100, P1295, DOI 10.1083/jcb.100.4.1295; ROBINSON HC, 1975, BIOCHEM J, V148, P25, DOI 10.1042/bj1480025; ROBINSON HC, 1981, BIOCHEM J, V194, P575, DOI 10.1042/bj1940575; ROHRMANN K, 1985, EUR J BIOCHEM, V148, P463, DOI 10.1111/j.1432-1033.1985.tb08862.x; SCHWARTZ NB, 1974, P NATL ACAD SCI USA, V71, P4047, DOI 10.1073/pnas.71.10.4047; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SOBUE M, 1987, BIOCHEM J, V241, P591, DOI 10.1042/bj2410591; SPIRO RC, 1991, J CELL BIOL, V115, P1463, DOI 10.1083/jcb.115.5.1463; STEVENS RL, 1982, J BIOL CHEM, V257, P253; SUDHAKARAN PR, 1981, H-S Z PHYSIOL CHEM, V362, P39, DOI 10.1515/bchm2.1981.362.1.39; SUGUMARAN G, 1992, J BIOL CHEM, V267, P8802; UHLINHANSEN L, 1993, J BIOL CHEM, V268, P17370; VANAKEN T, 1986, METHOD ENZYMOL, V125, P27; WOLFROM ML, 1963, METHODS CARBOHYDRATE, V2, P341	37	126	126	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					300	307						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276811				2022-12-27	WOS:A1994MR21900053
J	MONACO, L; VICINI, E; CONTI, M				MONACO, L; VICINI, E; CONTI, M			STRUCTURE OF 2 RAT GENES-CODING FOR CLOSELY-RELATED ROLIPRAM-SENSITIVE CAMP PHOSPHODIESTERASES - MULTIPLE MESSENGER-RNA VARIANTS ORIGINATE FROM ALTERNATIVE SPLICING AND MULTIPLE START SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; DROSOPHILA DUNCE+ GENE; AMP PHOSPHODIESTERASE; HORMONAL-REGULATION; SEQUENCES; DNA; EXPRESSION; CLONING; CELLS; CHROMATOGRAPHY	The products of two phosphodiesterase (PDE) genes (ratPDE3/IVd and ratPDE4/IVb) are present in the rat Sertoli cell in culture, and their expression is under the control of the gonadotropin follicle-stimulating hormone (Swinnen, J. V., Tsikalas, K. E., and Conti, M. (1991) J. Biol. Chem. 266,18370-18377). To understand the basis of the sequence heterogeneity found in the 5'-region of the different cDNAs thus far characterized, the structure of the coding region of these two cAMP PDE genes was investigated. Analysis of five ratPDE3/IVd and ratPDE4/IVb genomic clones showed that the coding region of these genes expressed in the Sertoli cell is divided into 11 exons distributed over 35-45 kilobases of genomic DNA. The intron/exon boundaries agreed, with some exceptions, with the established consensus sequences and were located in the same position in the coding region of the two genes. Also present were similarities to the exon composition of the Drosophila melanogaster ''dunce'' gene, the ancestor of these mammalian cAMP PDEs. Multiple AUG codons and short open reading frames were present at the 5'-untranslated end of the ratPDE4/IVb mRNA, but not in the ratPDE3 mRNA. By using polymerase chain reaction amplification or Northern analysis, it was determined that at least two forms of ratPDE3/IVd mRNA are present in rat Sertoli and FRTL-5 thyroid cells, but not in the brain. These mRNA variants are generated by inclusion or removal of an intron sequence that produces a frameshift affecting the position of the initiation AUG codon. Both mRNA species were efficiently translated into cAMP PDE proteins with different molecular masses in a transient transfection assay in COS cells. Polymerase chain reaction amplification demonstrated that heterogeneity of ratPDE4/IVb mRNAs was present in the same location as in the ratPDE3/IVd mRNA. Two ratPDE4/IVb mRNAs with different 5'-ends were expressed in Sertoli and FRTL-5 cells and in the brain. This heterogeneity is caused by the presence of an intron promoter that controls the transcription of this mRNA in Sertoli and FRTL-5 cells, but not in the brain. Upstream exons and additional promoters are probably present and necessary to generate the brain-specific mRNAs. These findings demonstrate that the cAMP-specific PDE genes have complex structure and that cAMP PDE proteins with different amino termini are derived from these genes.	UNIV ROME, INST HISTOL & GEN EMBRYOL, I-00161 ROME, ITALY	Sapienza University Rome			Monaco, Lucia/A-4031-2010	Vicini, Elena/0000-0003-0399-0145	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020788] Funding Source: NIH RePORTER; NICHD NIH HHS [HD20788] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CN, 1986, P NATL ACAD SCI USA, V83, P9313, DOI 10.1073/pnas.83.24.9313; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; CONTI M, 1991, ENDOCR REV, V12, P218, DOI 10.1210/edrv-12-3-218; CONTI M, 1990, CYCLIC NUCLEOTIDE PH, P3; DAVIS RL, 1991, TRENDS GENET, V7, P224, DOI 10.1016/0168-9525(91)90369-2; DAVIS RL, 1989, P NATL ACAD SCI USA, V86, P3604, DOI 10.1073/pnas.86.10.3604; DEMAZANCOURT P, 1988, METHOD ENZYMOL, V159, P766; EPSTEIN PM, 1982, ARCH BIOCHEM BIOPHYS, V218, P119, DOI 10.1016/0003-9861(82)90327-7; EPSTEIN PM, 1984, ADV CYCLIC NUCL PROT, V16, P303; FAURE M, 1990, MOL CELL BIOL, V10, P1921, DOI 10.1128/MCB.10.5.1921; FISHER R, 1985, J BIOL CHEM, V260, P1223; FOUGIER S, 1986, BIOCHEM BIOPH RES CO, V138, P205, DOI 10.1016/0006-291X(86)90267-6; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; JIN SLC, 1992, J BIOL CHEM, V267, P18929; KINCAID RL, 1985, J BIOL CHEM, V260, P9009; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LIVI GP, 1990, MOL CELL BIOL, V10, P2678, DOI 10.1128/MCB.10.6.2678; MCLAUGHLIN MM, 1993, J BIOL CHEM, V268, P6470; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; QIU YH, 1991, J MOL BIOL, V222, P553, DOI 10.1016/0022-2836(91)90496-S; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STROOP SD, 1989, J BIOL CHEM, V264, P13718; SWINNEN JV, 1991, J BIOL CHEM, V266, P18370; SWINNEN JV, 1991, J BIOL CHEM, V266, P14383; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P8197, DOI 10.1073/pnas.86.21.8197; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P5325, DOI 10.1073/pnas.86.14.5325; TUCKER MM, 1981, J BIOL CHEM, V256, P9051; WEBER B, 1991, NUCLEIC ACIDS RES, V19, P6263, DOI 10.1093/nar/19.22.6263; WEIL D, 1990, MOL CELL BIOL, V10, P5865, DOI 10.1128/MCB.10.11.5865; WELCH JE, 1992, BIOL REPROD, V46, P1027, DOI 10.1095/biolreprod46.6.1027; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692	39	93	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					347	357						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276818				2022-12-27	WOS:A1994MR21900059
J	SPACCIAPOLI, P; NOSSAL, NG				SPACCIAPOLI, P; NOSSAL, NG			INTERACTION OF DNA-POLYMERASE AND DNA HELICASE WITHIN THE BACTERIOPHAGE-T4 DNA-REPLICATION COMPLEX - LEADING-STRAND SYNTHESIS BY THE T4 DNA-POLYMERASE MUTANT A737V (TSL141) REQUIRES THE T4 GENE-59 HELICASE ASSEMBLY PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCESSORY PROTEINS; RNA PRIMERS; TEMPLATE; INVITRO; ANTIMUTATOR; MECHANISMS; HOLOENZYME; MUTATOR; FORK	The bacteriophage T4 tsL141 (A737V) mutant in T4 DNA polymerase is temperature-sensitive for DNA replication and an antimutator for some types of mutations. In the accompanying paper (Spacciapoli, P., and Nossal, N. G. (1993) J. Biol. Chem. 269,438-446), we show that the purified A737V T4 DNA polymerase is less processive than the wild type enzyme as a polymerase, but is more processive as an exonuclease. The bacteriophage T4 multienzyme replication complex reconstituted with the A737V mutant polymerase is defective in both lagging and leading strand synthesis. On lagging strand templates, the A737V polymerase is stimulated by the gene 44/62 and 45 polymerase accessory proteins and the gene 32 DNA binding protein, but is still arrested at pause sites much more frequently than the wild type. In contrast to wild type T4 DNA polymerase, the A737V polymerase does not catalyze leading strand synthesis on a forked duplex template with the polymerase accessory proteins, 32 protein, and the gene 41 protein helicase. The A737V polymerase requires the T4 gene 59 helicase assembly protein, as well as the other proteins, to carry out this reaction. Each of these defects is suppressed by the intragenic L771F mutation that suppresses the antimutator phenotype of the A737V polymerase in vivo (Reha-Krantz, L. J., Stocki, S., Nonay, R., and Maughan, C. (1989) J. Cell. Biochem. 13D, 140).	NIDDKD,MOLEC & CELLULAR BIOL,BLDG 8,ROOM 2A-19,BETHESDA,MD 20892; NIDDKD,BIOCHEM PHARMACOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								Alberts B.M., 1971, METHODS ENZYMOL, V21, P198; ALBERTS BM, 1987, PHILOS T ROY SOC B, V317, P395, DOI 10.1098/rstb.1987.0068; BEDINGER P, 1989, J BIOL CHEM, V264, P16880; CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; CHA TA, 1989, J BIOL CHEM, V264, P12220; DRAKE JW, 1988, MOL GEN GENET, V214, P547, DOI 10.1007/BF00330493; DRAKE JW, 1968, COLD SPRING HARB SYM, V33, P339, DOI 10.1101/SQB.1968.033.01.039; EPSTEIN RH, 1963, COLD SPRING HARB SYM, V28, P375, DOI 10.1101/SQB.1963.028.01.053; GILLIN FD, 1976, J BIOL CHEM, V251, P5225; HACKER K, 1989, J CELL BIOCHEM, V13, P87; HAHN S, 1989, NUCLEIC ACIDS RES, V17, P6729, DOI 10.1093/nar/17.16.6729; HOLLINGSWORTH HC, 1991, J BIOL CHEM, V266, P1888; HUANG CC, 1981, J BIOL CHEM, V256, P4087; HUANG CC, 1981, NUCLEIC ACIDS RES, V9, P5587, DOI 10.1093/nar/9.21.5587; KREUZER KN, 1993, IN PRESS MOL BIOL BA; Nossal N.G., 1983, BACTERIOPHAGE T4, P71; NOSSAL NG, 1974, J BIOL CHEM, V249, P5668; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; NOSSAL NG, 1993, IN PRESS MOL BIOL BA; REHAKRANTZ LJ, 1989, J CELL BIOL D, V13, P140; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; RICHARDSON RW, 1990, UCLA SYM BI, V127, P247; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4732; RIPLEY LS, 1983, MOL GEN GENET, V189, P113, DOI 10.1007/BF00326062; ROTH AC, 1982, J BIOL CHEM, V257, P1267; SPACCIAPOLI P, J BIOL CHEM, V269, P438; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	29	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					447	455						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276834				2022-12-27	WOS:A1994MR21900075
J	SUGAWARA, A; YEN, PM; APRILETTI, JW; RIBEIRO, RCJ; SACKS, DB; BAXTER, JD; CHIN, WW				SUGAWARA, A; YEN, PM; APRILETTI, JW; RIBEIRO, RCJ; SACKS, DB; BAXTER, JD; CHIN, WW			PHOSPHORYLATION SELECTIVELY INCREASES TRIIODOTHYRONINE RECEPTOR HOMODIMER BINDING TO DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; RETINOID-X-RECEPTOR; INSULIN-STIMULATED PHOSPHORYLATION; PROTEIN-KINASE-C; RESPONSE ELEMENTS; AUXILIARY PROTEIN; TRANSCRIPTIONAL ACTIVITY; ENHANCES BINDING; ACID RECEPTORS; RAT-LIVER	Thyroid hormone receptors (TRs) are ligand-regulated transcription factors that bind to thyroid hormone response elements (TREs) as monomers and homodimers, and as heterodimers with nuclear proteins such as TR auxiliary proteins and retinoid X receptors. Recently, bacterially expressed human TRbeta-1 (hTRbeta-1) was shown to be phosphorylated in vitro by HeLa cytosolic extract. However, little is known about the consequences of phosphorylation on the nature of TR complexes. Therefore, we studied the effect of phosphorylation on TR binding to TREs. Bacterially expressed hTRbeta-1 was phosphorylated in vitro with ATP by HeLa cytosolic extract. The ratio of phosphoserine to phosphothreonine was approximately 5:1. We then analyzed phosphorylated hTRbeta-1 binding to several TREs by electrophoretic mobility shift assay. Phosphorylated hTRbeta-1 bound better as a homodimer to the TREs than hTRbeta-1 incubated with preheated cytosolic extract. Alkaline phosphatase treatment of the phosphorylated hTRbeta3-1 eliminated the enhanced homodimer binding to DNA. In contrast, phosphorylation did not affect TR/TR auxiliary protein or TR/retinoid X receptor heterodimer binding to DNA. Triiodothyronine decreased both phosphorylated and unphosphorylated hTRbeta-1 homodimer binding to several TREs, and the addition of okadaic acid did not alter this triiodothyronine effect. These results indicate that phosphorylation, in addition to ligand binding, modulates TR dimer binding to TREs. As such, it is possible that phosphorylation may also participate in TR-mediated regulation of transcription.	BRIGHAM & WOMENS HOSP,HOWARD HUGHES MED INST,DEPT PATHOL,BOSTON,MA 02115; UNIV CALIF SAN FRANCISCO,METAB RES UNIT,SAN FRANCISCO,CA 94143; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Harvard University; Harvard Medical School	SUGAWARA, A (corresponding author), BRIGHAM & WOMENS HOSP,HOWARD HUGHES MED INST,DEPT MED,DIV GENET,G W THORN RES BLDG,RM 905,BOSTON,MA 02115, USA.		Yen, Paul M/V-9857-2019	Sacks, David/0000-0003-3100-0735; Yen, Paul/0000-0002-3790-8114; Sugawara, Akira/0000-0003-4511-8101	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043682] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43682] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON ML, 1992, NUCLEIC ACIDS RES, V20, P4803, DOI 10.1093/nar/20.18.4803; APRILETTI JW, 1988, J BIOL CHEM, V263, P9409; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRENT G A, 1989, New Biologist, V1, P329; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GLINEUR C, 1989, ONCOGENE, V4, P1247; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; HAWKINS PT, 1983, BIOCHEM J, V210, P717, DOI 10.1042/bj2100717; HOLLOWAY JM, 1990, P NATL ACAD SCI USA, V87, P8160, DOI 10.1073/pnas.87.20.8160; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LIN KH, 1992, P NATL ACAD SCI USA, V89, P7737, DOI 10.1073/pnas.89.16.7737; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MINAKAMI S, 1965, BIOCHEM BIOPH RES CO, V18, P345, DOI 10.1016/0006-291X(65)90711-4; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; RANGARAJAN PN, 1992, MOL ENDOCRINOL, V6, P1451, DOI 10.1210/me.6.9.1451; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; SACKS DB, 1988, J BIOL CHEM, V263, P2377; SACKS DB, 1992, BIOCHEM J, V286, P211, DOI 10.1042/bj2860211; SUGAWARA A, 1993, ENDOCRINOLOGY, V133, P965, DOI 10.1210/en.133.3.965; YEN PM, 1992, J BIOL CHEM, V267, P3565; YEN PM, 1992, ENDOCRINOLOGY, V130, P1539, DOI 10.1210/en.130.3.1539; YEN PM, 1992, J BIOL CHEM, V267, P23248; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1991, NEW BIOL, V3, P169; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	43	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					433	437						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276832				2022-12-27	WOS:A1994MR21900073
J	TSCHANTZ, WR; SUNG, M; DELGADOPARTIN, VM; DALBEY, RE				TSCHANTZ, WR; SUNG, M; DELGADOPARTIN, VM; DALBEY, RE			A SERINE AND A LYSINE RESIDUE IMPLICATED IN THE CATALYTIC MECHANISM OF THE ESCHERICHIA-COLI LEADER PEPTIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROSOMAL SIGNAL PEPTIDASE; ACYL-ENZYME INTERMEDIATE; BETA-LACTAMASE; DIRECTED MUTAGENESIS; CLEAVAGE SITE; COAT PROTEIN; AMINO-ACIDS; PURIFICATION; MEMBRANE; PENICILLIN	We report that a thiol leader peptidase, produced by replacing the critical serine at position 90 with a cysteine residue, is enzymatically active. In contrast to the wild-type leader peptidase, the thiol enzyme can be inactivated with N-ethylmaleimide, a cysteine-specific reagent. This strongly suggests that the serine 90 is involved in catalysis and is located at the active site. Of the three conserved basic residues in the signal peptidase family, only lysine 145 appears to be critical for catalysis; when lysine 145 was mutated to an alanine residue, leader peptidase K145A protein was inactive both in vitro and in vivo. A control experiment showed that the K145A mutant competes with the wild-type leader peptidase for substrate binding, confirming that the K145A mutation did not cause a global conformational change. The data provides evidence that catalysis of leader peptidase is carried out by a serine-lysine dyad.	OHIO STATE UNIV, DEPT CHEM, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University								ADACHI H, 1991, J BIOL CHEM, V266, P3186; BAKER RK, 1987, BIOCHEMISTRY-US, V26, P8561, DOI 10.1021/bi00400a010; BLACK MT, 1992, BIOCHEM J, V282, P539, DOI 10.1042/bj2820539; BOEKE JD, 1980, J MOL BIOL, V144, P103, DOI 10.1016/0022-2836(80)90027-3; CITRI N, 1960, J BIOL CHEM, V235, P3454; COHEN SN, 1973, P NATL ACAD SCI USA, V70, P3240, DOI 10.1073/pnas.70.11.3240; DALBEY RE, 1985, J BIOL CHEM, V260, P5925; DALBEY RE, 1992, TRENDS BIOCHEM SCI, V17, P474, DOI 10.1016/0968-0004(92)90492-R; DALBEY RE, 1987, SCIENCE, V235, P783, DOI 10.1126/science.3544218; Dunn BM., 1989, PROTEOLYTIC ENZYMES, P57; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; FIKES JD, 1990, J BIOL CHEM, V265, P3417; FOLZ RJ, 1988, J BIOL CHEM, V263, P2070; GREENBURG G, 1989, J BIOL CHEM, V264, P15762; INADA T, 1989, J BACTERIOL, V171, P585, DOI 10.1128/jb.171.1.585-587.1989; ITO K, 1980, J BIOL CHEM, V255, P2123; Jackson R C, 1980, Ann N Y Acad Sci, V343, P391, DOI 10.1111/j.1749-6632.1980.tb47268.x; JOHNSTON S, 1985, GENE, V34, P137, DOI 10.1016/0378-1119(85)90121-0; KELLY JA, 1986, SCIENCE, V231, P1429, DOI 10.1126/science.3082007; KELLY JA, 1985, J BIOL CHEM, V260, P6449; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LIN LL, 1988, J BACTERIOL, V170, P2163, DOI 10.1128/jb.170.5.2163-2173.1988; LIN LL, 1989, J MOL BIOL, V210, P439, DOI 10.1016/0022-2836(89)90121-6; Maniatis T., 1982, MOL CLONING; NEURATH H, 1989, PROTEOLYTIC ENZYMES, P1; OGAWARA H, 1981, J BIOL CHEM, V256, P2649; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER A, 1991, EMBO J, V10, P247, DOI 10.1002/j.1460-2075.1991.tb07944.x; SHEN LM, 1991, BIOCHEMISTRY-US, V30, P11775, DOI 10.1021/bi00115a006; SLILATY SN, 1986, BIOCHEMISTRY-US, V25, P6866, DOI 10.1021/bi00370a020; SLILATY SN, 1987, P NATL ACAD SCI USA, V84, P3987, DOI 10.1073/pnas.84.12.3987; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; SUNG M, 1992, J BIOL CHEM, V267, P13154; VANDIJL JM, 1992, EMBO J, V11, P2819, DOI 10.1002/j.1460-2075.1992.tb05349.x; VANDIJL JM, 1990, MOL GEN GENET, V223, P233, DOI 10.1007/BF00265059; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WOLFE PB, 1982, J BIOL CHEM, V257, P7898; YADEAU JT, 1989, J BIOL CHEM, V264, P2928; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468; ZWIZINSKI C, 1980, J BIOL CHEM, V255, P7973; ZWIZINSKI C, 1981, J BIOL CHEM, V256, P3593	41	108	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27349	27354						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262975				2022-12-27	WOS:A1993MM26200074
J	ZHU, YJ; ALVARES, K; HUANG, Q; RAO, MS; REDDY, JK				ZHU, YJ; ALVARES, K; HUANG, Q; RAO, MS; REDDY, JK			CLONING OF A NEW MEMBER OF THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GENE FAMILY FROM MOUSE-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ACYL-COA OXIDASE; BETA-OXIDATION; FATTY-ACIDS; RAT-LIVER; MECHANISMS; IDENTIFICATION; SUPERFAMILY; CLOFIBRATE; INDUCTION	Peroxisome proliferators are postulated to elicit predictable pleiotropic responses in the liver by activating a peroxisome proliferator-activated receptor (PPAR). PPARs from mouse liver (mPPAR), rat liver (rPPAR), and Xenopus liver (xPPARgamma) have been cloned recently. We now report the cloning of a new member from mouse liver which we designate mPPARgamma. mPPARgamma cDNA contained an open reading frame encoding a 475-amino acid protein exhibiting 75% amino acid similarity to xPPARgamma, while it showed only 55% identity with mPPAR. The ligand-binding and DNA-binding domains are best conserved between mPPARgamma, mPPAR, and xPPARgamma. Like rPPAR, mPPARgamma is able to impart peroxisome proliferator responsiveness to the promoter of peroxisomal bifunctional gene, which encodes the second enzyme of the peroxisomal fatty acid beta-oxidation system. Northern blot analysis revealed high expression of mPPARgamma gene in mouse liver, kidney, and heart and low expression in the lung, testis, brain, skeletal muscle, and spleen. In mice treated with ciprofibrate, a peroxisome proliferator, a 2-fold increase in mPPARgamma mRNA was observed in the liver and kidney. The presence of two PPARs in the mouse liver suggests the possibility of multiple signaling pathways for the peroxisome proliferator-induced pleiotropic responses.	NORTHWESTERN UNIV,SCH MED,DEPT PATHOL,303 E CHICAGO AVE,CHICAGO,IL 60611	Northwestern University				Alvares, Keith/0000-0003-3710-4367	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023750, R01GM023750] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23750] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVARES K, 1990, P NATL ACAD SCI USA, V87, P5293, DOI 10.1073/pnas.87.14.5293; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; HASHIMOTO T, 1982, ANN NY ACAD SCI, V386, P5, DOI 10.1111/j.1749-6632.1982.tb21403.x; HESS R, 1965, NATURE, V208, P856, DOI 10.1038/208856a0; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LOCK EA, 1989, ANNU REV PHARMACOL, V29, P145; Maniatis T., 1982, MOL CLONING; MARCUS SL, 1993, P NATL ACAD SCI USA, V90, P5723, DOI 10.1073/pnas.90.12.5723; NEMALI MR, 1988, CANCER RES, V48, P5316; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; REDDY JK, 1983, CRC CR REV TOXICOL, V12, P1, DOI 10.3109/10408448309029317; REDDY JK, 1986, TRENDS PHARMACOL SCI, V7, P438, DOI 10.1016/0165-6147(86)90416-5; REDDY JK, 1975, SCIENCE, V190, P787, DOI 10.1126/science.1198095; REDDY JK, 1980, NATURE, V283, P397, DOI 10.1038/283397a0; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; REDDY JK, 1990, BIOCHEM SOC T, V18, P92, DOI 10.1042/bst0180092; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; ZHANG BW, 1993, J BIOL CHEM, V268, P12939; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541	26	339	354	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26817	26820						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262913				2022-12-27	WOS:A1993MM26200002
J	CHEN, J; ENGLE, SJ; SEILHAMER, JJ; TISCHFIELD, JA				CHEN, J; ENGLE, SJ; SEILHAMER, JJ; TISCHFIELD, JA			CLONING AND RECOMBINANT EXPRESSION OF A NOVEL HUMAN LOW-MOLECULAR-WEIGHT CA2+-DEPENDENT PHOSPHOLIPASE-A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MEMBRANE-ASSOCIATED PHOSPHOLIPASE-A2; RAT PLATELET PHOSPHOLIPASE-A2; PANCREATIC PHOSPHOLIPASE-A2; SUBCELLULAR-LOCALIZATION; HAMSTER HEART; PURIFICATION; SEQUENCE; FORMS; LUNG; PHOSPHATIDYLCHOLINE	Extensive biochemical studies of phospholipase A2s (PLA2s) over the last two decades indicate that there are likely to be several distinct PLA2 genes in mammals. Here we report the cloning of a 1-kilobase pair cDNA encoding a novel human low molecular weight PLA2. The cDNA appears to encode a 118-amino acid mature peptide (M(r) = 13,592) preceded by a 20-residue prepeptide. The deduced amino acid sequence encodes a protein that lacks one of the seven disulfide bridges found in similar PLA2s and, therefore, represents a class of enzymes distinct from the mammalian group I and group II enzymes. An RNA blot hybridized with the cDNA exhibited a putative 1.2-kilobase pair transcript in heart and, less abundantly, in lung, as well as multiple putative transcripts in placenta. When the cDNA was expressed using an Epstein-Barr virus-based vector in human 293s cells, PLA2 activity accumulated in the culture medium. Conditioned medium optimally hydrolyzed the phospholipids of [1-C-14]oleate-labeled Escherichia coli at neutral to alkaline pH with 10 mM or greater Ca2+. In assays done with individual substrates, L-alpha-1-palmitoyl-2-oleoyl phosphatidylcholine was more efficiently hydrolyzed than L-alpha-1-palmitoyl-2-arachidonyl phosphatidylcholine, L-alpha-1-palmitoyl-2-arachidonyl phosphatidylethanolamine, or L-alpha-1-stearoyl-2-arachidonyl phosphatidylinositol.	INDIANA UNIV, SCH MED,DEPT MED & MOLEC GENET,IB130, 975 W WALNUT ST, INDIANAPOLIS, IN 46202 USA; INCYTE PHARMACEUT INC, PALO ALTO, CA 94304 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Incyte			Chen, Ju/E-5579-2011	Tischfield, Jay/0000-0003-3217-8287				AARSMAN AJ, 1989, J BIOL CHEM, V264, P10008; BENNETT CF, 1990, BIOCHIM BIOPHYS ACTA, V1047, P271, DOI 10.1016/0005-2760(90)90526-4; CAO YZ, 1987, J BIOL CHEM, V262, P16927; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; Dennis EA, 1983, ENZYMES, P307; ELSBACH P, 1991, METHOD ENZYMOL, V197, P24; FRANSON RC, 1982, LUNG, V160, P275, DOI 10.1007/BF02719301; HEINRIKSON RL, 1991, METHOD ENZYMOL, V197, P201; HEINRIKSON RL, 1977, J BIOL CHEM, V252, P4913; HEVALAINEN TJ, 1993, INFLAMMATION, V17, P453; ISHIZAKI J, 1989, BIOCHEM BIOPH RES CO, V162, P1030, DOI 10.1016/0006-291X(89)90777-8; Johnson L K, 1990, Adv Exp Med Biol, V275, P17; JORDAN LM, 1992, J CHROMATOGR, V597, P299, DOI 10.1016/0021-9673(92)80124-D; KINGSTON RE, 1989, CURRENT PROTOCOLS MO; KOMADA M, 1989, J BIOCHEM-TOKYO, V106, P545, DOI 10.1093/oxfordjournals.jbchem.a122890; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KUSUNOKI C, 1990, BIOCHIM BIOPHYS ACTA, V1087, P95, DOI 10.1016/0167-4781(90)90127-N; LINDAHL M, 1989, BIOCHIM BIOPHYS ACTA, V1005, P282, DOI 10.1016/0005-2760(89)90050-7; MALFERTHEINER P, 1989, KLIN WOCHENSCHR, V67, P183, DOI 10.1007/BF01711350; MARSHALL LA, 1992, BIOCHEM PHARMACOL, V44, P1849, DOI 10.1016/0006-2952(92)90081-S; NALBONE G, 1985, J LIPID RES, V26, P104; ONO T, 1988, J BIOL CHEM, V263, P5732; PRUZANSKI W, 1990, ADV EXP MED BIOL, V279, P239; RORDORF G, 1991, J NEUROSCI, V11, P1829; SEILHAMER JJ, 1989, J BIOCHEM, V106, P38, DOI 10.1093/oxfordjournals.jbchem.a122815; SEILHAMER JJ, 1986, DNA-J MOLEC CELL BIO, V5, P519, DOI 10.1089/dna.1.1986.5.519; TAM SW, 1984, CAN J BIOCHEM CELL B, V62, P1269, DOI 10.1139/o84-161; UHL W, 1990, J TRAUMA, V30, P1285, DOI 10.1097/00005373-199010000-00015; VADAS P, 1986, LAB INVEST, V55, P391	30	213	217	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2365	2368						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300559				2022-12-27	WOS:A1994MV43200005
J	XU, PX; FUKUTA, M; TAKIYA, S; MATSUNO, K; XU, X; SUZUKI, Y				XU, PX; FUKUTA, M; TAKIYA, S; MATSUNO, K; XU, X; SUZUKI, Y			PROMOTER OF THE POU-M1/SGF-3 GENE INVOLVED IN THE EXPRESSION OF BOMBYX SILK GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POU-DOMAIN; TRANSCRIPTION FACTOR; FIBROIN GENE; DNA-BINDING; CELL IDENTITY; STEM-CELLS; INVITRO; DROSOPHILA; PIT-1; SITES	To characterize the transcription regulation of the POU-M1/SGF-3 gene, we have cloned a genomic DNA fragment encompassing the whole coding region and its flanking sequences. This gene does not contain any intron. The 5'-flanking region of the gene contains several interesting motifs, such as homeodomain-binding motifs, sequences resembling the transcriptional factor Sp1-binding site, and TGTTT motifs, but lacks some of the typical transcriptional regulatory sequences, such as TATA and CCAAT boxes. Transcriptional analysis of a series of deletion mutants of the gene in the nuclear extracts prepared from the middle silk gland of 2-day-old fifth instar larvae revealed the presence of multiple cis-regulatory elements located both upstream and downstream of the initiation site. One of these elements, the homeodomain-binding element, was identified to mediate negative regulation. By mobility shift assay using the POU-M1 specific antibodies, we found that this negative element interacts with the POU-M1/SGF-3. Transcription analysis in vitro using templates mutagenized in the PB region and one of the POU-M1 antibodies indicated that the PB region is an autoregulatory element responsible for SGF-3-dependent transcriptional repression.	NATL INST BASIC BIOL, MYODAIJI, OKAZAKI, AICHI 444, JAPAN; GRAD UNIV ADV STUDIES, OKAZAKI 444, JAPAN	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Graduate University for Advanced Studies - Japan			Takiya, Shigeharu/A-6439-2012					AKAM M, 1987, DEVELOPMENT, V101, P1; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ELSONLTZ HP, 1990, GENE DEV, V4, P43; Favaloro J, 1980, Methods Enzymol, V65, P718; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FUKUTA M, 1993, J BIOL CHEM, V268, P19471; HARA Y, 1992, P NATL ACAD SCI USA, V89, P3280, DOI 10.1073/pnas.89.8.3280; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HIROSE S, 1982, P NATL ACAD SCI-BIOL, V79, P7258, DOI 10.1073/pnas.79.23.7258; HIROSE S, 1985, J BIOL CHEM, V260, P557; HUI CC, 1990, J MOL BIOL, V213, P651, DOI 10.1016/S0022-2836(05)80253-0; HUI CC, 1992, P NATL ACAD SCI USA, V89, P167, DOI 10.1073/pnas.89.1.167; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LEBOWITZ JH, 1989, GENE DEV, V3, P1625, DOI 10.1101/gad.3.10.1625; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; MATHIS DJ, 1981, NATURE, V290, P310, DOI 10.1038/290310a0; MATSUNO K, 1990, NUCLEIC ACIDS RES, V18, P1853, DOI 10.1093/nar/18.7.1853; MATSUNO K, 1989, J BIOL CHEM, V264, P18707; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MONUKI ES, 1990, SCIENCE, V249, P1300, DOI 10.1126/science.1975954; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PERKINS KK, 1988, GENE DEV, V2, P1615, DOI 10.1101/gad.2.12a.1615; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; REGULSKI M, 1987, EMBO J, V6, P767, DOI 10.1002/j.1460-2075.1987.tb04819.x; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SCOTT MP, 1987, CELL, V51, P689, DOI 10.1016/0092-8674(87)90092-4; Shenk T, 1981, Curr Top Microbiol Immunol, V93, P25; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; SUZUKI Y, 1986, P NATL ACAD SCI USA, V83, P9522, DOI 10.1073/pnas.83.24.9522; Suzuki Y., 1990, MOL INSECT SCI, P83; TAKIYA S, 1990, EMBO J, V9, P489, DOI 10.1002/j.1460-2075.1990.tb08135.x; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	47	26	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2733	2742						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300605				2022-12-27	WOS:A1994MV43200058
J	JOUNEAUX, C; MALLAT, A; SERRADEILLEGAL, C; GOLDSMITH, P; HANOUNE, J; LOTERSZTAJN, S				JOUNEAUX, C; MALLAT, A; SERRADEILLEGAL, C; GOLDSMITH, P; HANOUNE, J; LOTERSZTAJN, S			COUPLING OF ENDOTHELIN B-RECEPTORS TO THE CALCIUM-PUMP AND PHOSPHOLIPASE-C VIA GS AND GQ IN RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEIN; BETA-GAMMA-SUBUNITS; SIGNAL TRANSDUCTION; GUANINE-NUCLEOTIDE; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PLASMA-MEMBRANES; ADENYLYL CYCLASE; ALPHA-SUBUNITS; CA-2+ PUMP; ACTIVATION	We have demonstrated in liver from male rats that both endothelin A (ET(A)) and ET(B) receptors coexist in equal proportion and that ET(A) receptors mediate a calcium-dependent activation of glycogenolysis. We describe here a sex difference in endothelin action in hepatocytes because, in female rats, 80% of the ET receptors are of ET(B) type and, accordingly, activation of glycogenolysis is an ET(B)-mediated process (EC50 = 0.03 pm). ET- 1 stimulation of glycogenolysis in female rats was consecutive to activation of phosphatidylinositol 4,5-bisphosphate hydrolysis (EC50 = 0.03 pm) and to inhibition of the calcium extrusion pump (IC50 = 0.03 pm) in plasma membranes, with ET-1 almost-equal-to sarafotoxin S6C almost-equal-to ET-3. Endothelin regulation of each effector was potentiated by GTPgammaS. ET-1 did not stimulate adenylyl cyclase activity. To identify the nature of the guanine nucleotide regulatory proteins (G protein(s)) coupling ET(B) receptors to each effector, we used antibodies against the COOH terminus of different G protein alpha subunits. Antibodies reactive with Gsalpha (RM) blocked ET-1 inhibition of the calcium pump, while they did not affect ET-1 stimulation of phospholipase C. Antibodies reactive with Gqalpha (QL) dose-dependently antagonized stimulation of phospholipase C by ET-1 and vasopressin, without affecting ET-1 inhibition of the calcium pump. Antibodies reactive with Gi1alpha/Gi2alpha (AS) had no effect on either system. We conclude that the calcium signal provoked by endothelins in hepatocyte is not only consecutive to activation of phospholipase C but also to inhibition of the plasma membrane calcium pump, each effector being coupled to ET(B) receptors by different G proteins, Gq, and Gs.	SANOFI RECH,BIOCHIM EXPLORATOIRE,F-31036 TOULOUSE,FRANCE; NIDDKD,MOLEC PATHOPHYSIOL BRANCH,BETHESDA,MD 20892	Sanofi-Aventis; Sanofi France; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	JOUNEAUX, C (corresponding author), HOP HENRI MONDOR,INSERM,U99,F-94010 CRETEIL,FRANCE.		Lotersztajn, Sophie/K-9160-2017	lotersztajn, Sophie/0000-0002-0053-7807				ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARAMORI I, 1992, J BIOL CHEM, V267, P12468; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CLOZEL M, 1992, BIOCHEM BIOPH RES CO, V186, P867, DOI 10.1016/0006-291X(92)90826-7; EGUCHI S, 1993, ENDOCRINOLOGY, V132, P524, DOI 10.1210/en.132.2.524; EMORI T, 1991, BIOCHEM BIOPH RES CO, V174, P228, DOI 10.1016/0006-291X(91)90510-E; GANDHI CR, 1992, BIOCHEM J, V287, P897, DOI 10.1042/bj2870897; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HILALDANDAN R, 1992, J BIOL CHEM, V267, P10620; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; JHON DY, 1993, J BIOL CHEM, V268, P6654; JOUNEAUX C, 1993, J BIOL CHEM, V268, P2368; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; LITOSCH I, 1989, BIOCHEM J, V261, P325, DOI 10.1042/bj2610325; LOTERSZTAJN S, 1990, J BIOL CHEM, V265, P9876; LOTERSZTAJN S, 1992, J BIOL CHEM, V267, P2375; LOTERSZTAJN S, 1990, TRANSMEMBRANE SIGNAL; MACRAE AD, 1992, TRENDS ENDOCRIN MET, V3, P153, DOI 10.1016/1043-2760(92)90164-V; MALLAT A, 1987, NATURE, V325, P620, DOI 10.1038/325620a0; MARIN P, 1991, J NEUROCHEM, V56, P1270, DOI 10.1111/j.1471-4159.1991.tb11421.x; MATTERA R, 1989, SCIENCE, V243, P804, DOI 10.1126/science.2536957; MCKENZIE RC, 1990, BIOCHEM J, V266, P817; PRPIC V, 1984, J BIOL CHEM, V259, P1382; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SCHUBERT B, 1989, SCIENCE, V245, P804; SERRADEILLEGAL C, 1991, J CLIN INVEST, V87, P133, DOI 10.1172/JCI114962; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SHETTY SS, 1993, BIOCHEM BIOPH RES CO, V191, P459, DOI 10.1006/bbrc.1993.1240; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SOKOLOVSKY M, 1991, TRENDS BIOCHEM SCI, V16, P261, DOI 10.1016/0968-0004(91)90100-A; SOKOLOVSKY M, 1992, J BIOL CHEM, V267, P20551; STUDER RK, 1982, J BIOL CHEM, V257, P7987; TAKUWA Y, 1990, J CLIN INVEST, V85, P653, DOI 10.1172/JCI114488; TAYLOR SJ, 1987, BIOCHEM J, V248, P791, DOI 10.1042/bj2480791; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; VIGNE P, 1990, J BIOL CHEM, V265, P6782; WILLIAMS DL, 1991, BIOCHEM BIOPH RES CO, V175, P556, DOI 10.1016/0006-291X(91)91601-8; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	43	73	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1845	1851						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294432				2022-12-27	WOS:A1994MR98800047
J	PAANANEN, K; KOVANEN, PT				PAANANEN, K; KOVANEN, PT			PROTEOLYSIS AND FUSION OF LOW-DENSITY-LIPOPROTEIN PARTICLES INDEPENDENTLY STRENGTHEN THEIR BINDING TO EXOCYTOSED MAST-CELL GRANULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; APOLIPOPROTEIN B-100; HEPARIN-BINDING; ATHEROSCLEROTIC LESIONS; ARTERIAL PROTEOGLYCANS; PERITONEAL-MACROPHAGES; MEDIATED UPTAKE; RABBIT AORTAS; DEGRADATION; IDENTIFICATION	Contact between low density lipoproteins (LDL) and exocytosed mast cell granules, the ''granule remnants,'' leads to binding of LDL to the granule remnants via ionic interactions between the apolipoprotein B-100 (apoB-100) component of LDL and the heparin proteoglycan component of the granule remnants. Upon incubation at 37-degrees-C, the heparin proteoglycan-bound apoB-100 is progressively proteolyzed by remnant chymase and carboxypeptidase A, which are also bound to the heparin proteoglycans. Thereupon, the LDL particles fuse, and their binding to the granule remnants strengthens, as defined by the decreased ability of NaCl to release LDL from the remnants. We now have examined separately the effects of proteolysis and fusion on LDL binding. Proteolysis without fusion was induced by lowering the incubation temperature to 15-degrees-C, and proteolysis-independent fusion was induced by treating granule remnant-bound LDL with sphingomyelinase in the presence of protease inhibitors. It was found that degradation of the heparin proteoglycan-bound apoB-100, even without accompanying particle fusion, increased the strength of LDL binding to the granule remnants, suggesting exposure of buried heparin binding regions of apoB-100. When such proteolyzed LDL particles were allowed to fuse, the strength of their binding to the granule remnants increased still further, probably because of an increase in the number of apoB-100 fragments in the enlarged particles. Proteolysis-independent fusion, induced by sphingomyelinase treatment of granule remnant-bound LDL, also increased the strength of binding. The results show that proteolytic degradation and fusion, the two modifications of granule remnant-bound LDL subsequent to action by chymase and carboxypeptidase A of the granule remnants, represent two separate mechanisms by which LDL particles become tightly bound to the heparin proteoglycans of exocytosed mast cell granules. Since the formation of an atheroma, the hallmark of atherosclerosis, is characterized by accumulation in the proteoglycan matrix of the arterial intima of extracellular lipid droplets resembling the fused LDL particles on the granule remnant surfaces, the modifications of LDL described in this study may provide a clue to the actual processes by which the lipid droplets are anchored to the arterial intima.	WIHURI RES INST, KALLIOLINNANTIE 4, SF-00140 HELSINKI, FINLAND	Wihuri Research Institute			Oorni, Katariina/G-2484-2011	Oorni, Katariina/0000-0002-9525-0250				BAGGIOLINI M, 1982, INT ARCH ALLER A IMM, V67, P219, DOI 10.1159/000233022; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CAMEJO G, 1991, BIOCHIM BIOPHYS ACTA, V1096, P253, DOI 10.1016/0925-4439(91)90013-Y; CAMEJO G, 1988, ARTERIOSCLEROSIS, V8, P368, DOI 10.1161/01.ATV.8.4.368; CAMEJO G, 1982, ADV LIPID RES, V19, P1; CARDIN AD, 1986, BIOCHEMISTRY-US, V25, P5258, DOI 10.1021/bi00366a041; CHAO FF, 1988, AM J PATHOL, V131, P73; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CHEN SH, 1986, J BIOL CHEM, V261, P2918; DECKELBAUM RJ, 1977, J BIOL CHEM, V252, P744; DECKELBAUM RJ, 1975, SCIENCE, V190, P392, DOI 10.1126/science.170681; FRANK JS, 1989, J LIPID RES, V30, P967; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GUYTON JR, 1990, EUR HEART J, V11, P20, DOI 10.1093/eurheartj/11.suppl_E.20; GUYTON JR, 1989, AM J PATHOL, V134, P705; GUYTON JR, 1985, ARTERIOSCLEROSIS, V5, P644, DOI 10.1161/01.ATV.5.6.644; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HIROSE N, 1987, BIOCHEMISTRY-US, V26, P5505, DOI 10.1021/bi00391a044; HOFF HF, 1991, ARTERIOSCLER THROMB, V11, P1209, DOI 10.1161/01.ATV.11.5.1209; HOFF HF, 1987, EXP MOL PATHOL, V46, P331, DOI 10.1016/0014-4800(87)90054-2; IVERIUS PH, 1972, J BIOL CHEM, V247, P2607; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; KOKKONEN JO, 1986, J BIOL CHEM, V261, P6067; KOKKONEN JO, 1989, J BIOL CHEM, V264, P10749; KOKKONEN JO, 1985, J BIOL CHEM, V260, P4756; KOKKONEN JO, 1987, BIOCHEM J, V241, P583, DOI 10.1042/bj2410583; KOKKONEN JO, 1989, ATHEROSCLEROSIS, V79, P213, DOI 10.1016/0021-9150(89)90126-3; KOVANEN PT, 1991, J BIOL CHEM, V266, P4430; KOVANEN PT, 1991, ANN MED, V23, P551, DOI 10.3109/07853899109150517; LAW SW, 1986, P NATL ACAD SCI USA, V83, P8142, DOI 10.1073/pnas.83.21.8142; LINDAHL U, 1979, BIOCHEM J, V182, P189, DOI 10.1042/bj1820189; LINDSTEDT KA, 1992, J LIPID RES, V33, P65; LOWRY OH, 1951, J BIOL CHEM, V193, P265; METCALFE DD, 1981, CRC CR REV IMMUNOL, V3, P23; RADDING CM, 1960, J CLIN INVEST, V39, P1560, DOI 10.1172/JCI104177; SCHWARTZ LB, 1984, PROG ALLERGY, V34, P271; STARY HC, 1990, EUR HEART J, V11, P3, DOI 10.1093/eurheartj/11.suppl_E.3; VIJAYAGOPAL P, 1981, J BIOL CHEM, V256, P8234; WEISGRABER KH, 1987, J BIOL CHEM, V262, P11097; WOODBURY RG, 1981, METHOD ENZYMOL, V80, P588; XU XX, 1991, J BIOL CHEM, V266, P24849; YANG CY, 1989, ARTERIOSCLEROSIS, V9, P96, DOI 10.1161/01.ATV.9.1.96; YURT RW, 1977, J BIOL CHEM, V252, P518	44	61	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2023	2031						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294453				2022-12-27	WOS:A1994MR98800073
J	KAWAGISHI, H; YAMAWAKI, M; ISOBE, S; USUI, T; KIMURA, A; CHIBA, S				KAWAGISHI, H; YAMAWAKI, M; ISOBE, S; USUI, T; KIMURA, A; CHIBA, S			2 LECTINS FROM THE MARINE SPONGE HALICHONDRIA-OKADAI - AN N-ACETYL-SUGAR-SPECIFIC LECTIN (HOL-I) AND AN N-ACETYLLACTOSAMINE-SPECIFIC LECTIN (HOL-II)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFICATION; GALACTOSIDASES; HEMAGGLUTININ; AGGLUTININ; POLYETHER; BINDING	Two lectins (HOL-I and HOL-II) were isolated from the marine sponge Halichondria okadai by affinity chromatography on a bovine submaxillary mucin (BSM)-Toyopearl and an acid-treated Sepharose 4B columns, respectively. In hemagglutination inhibition assays, GlcNAc, GalNAc, and their methyl glycosides were the most potent inhibitors among the monosaccharides tested against the HOL-I-mediated hemagglutination, suggesting that HOL-I can especially recognize the N-acetyl groups of the sugars. This N-acetyl specificity was supported by H-1 NMR analyses; the highest field-shifts of the signal of the N-acetyl group among all the signals in Me betaGlcNAc were observed in H-1 NMR spectra of mixtures of HOL-I and the sugar. Among the oligosaccharides tested, GlcNAcbeta1-->4(GlcNAcbeta1-->2)Manalpha1-O(CH2)2 CH3 was the most potent inhibitor, and the inhibitory potency of the oligosaccharide was 2(4) times greater than those of GlcNAc and GalNAc. On the other hand, N-acetyllactosamine (Galbeta1-->4GlcNAc) and its analogs were the strongest inhibitors toward HOL-II-induced hemagglutination. The agglutination was completely inert to Galbeta1-->3GlcNAc, Galbeta1-->6GlcNAc, Galbeta1-->3GalNAc, Galbeta1-4GalNAc, and Galbeta1-->6GalNAc. Furthermore, HOL-II exhibited no binding ability to BSM, asialo-BSM, fetuin, asialofetuin, alpha1-acid glycoprotein, and human transferrin. These results indicate that HOL-II strictly recognizes simple Galbeta1-->4GlcNAc unit.	HOKKAIDO UNIV,FAC AGR,DEPT APPL BIOSCI,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University	KAWAGISHI, H (corresponding author), SHIZUOKA UNIV,FAC AGR,DEPT APPL BIOL CHEM,OYA,SHIZUOKA 422,JAPAN.							BRETTING H, 1976, BIOCHEMISTRY-US, V15, P3228, DOI 10.1021/bi00660a011; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; ERRSON B, 1973, BIOCHIM BIOPHYS ACTA, V310, P446; HEDBYS L, 1989, GLYCOCONJUGATE J, V6, P161, DOI 10.1007/BF01050645; HIRATA Y, 1986, PURE APPL CHEM, V58, P701, DOI 10.1351/pac198658050701; KAMIYA H, 1990, NIPPON SUISAN GAKK, V56, P1159, DOI 10.2331/suisan.56.1159; KAMIYA H, 1986, B JPN SOC SCI FISH, V52, P2205; KAWAGISHI H, 1991, BIOCHIM BIOPHYS ACTA, V1076, P179, DOI 10.1016/0167-4838(91)90263-Y; KAWAGISHI H, 1990, BIOCHIM BIOPHYS ACTA, V1034, P247, DOI 10.1016/0304-4165(90)90045-X; KRONIS KA, 1982, BIOCHEMISTRY-US, V21, P3050, DOI 10.1021/bi00256a003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOTAN R, 1975, J BIOL CHEM, V250, P8518; PANDOLFINO ER, 1980, J BIOL CHEM, V225, P870; SAKAI K, 1992, J CARBOHYD CHEM, V11, P553, DOI 10.1080/07328309208016148; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; TACHIBANA K, 1981, J AM CHEM SOC, V103, P2469, DOI 10.1021/ja00399a082; UEMURA D, 1985, J AM CHEM SOC, V107, P4796, DOI 10.1021/ja00302a042; UMETSU K, 1993, ARCH BIOCHEM BIOPHYS, V301, P200, DOI 10.1006/abbi.1993.1133; USUI T, 1993, CARBOHYD RES, V244, P315, DOI 10.1016/0008-6215(83)85010-1; VAITH P, 1979, DEV COMP IMMUNOL, V3, P399, DOI 10.1016/S0145-305X(79)80037-3	20	55	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1375	1379						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288604				2022-12-27	WOS:A1994MR22000094
J	NISHIYORI, A; TASHIRO, H; KIMURA, A; AKAGI, K; YAMAMURA, K; MORI, M; TAKIGUCHI, M				NISHIYORI, A; TASHIRO, H; KIMURA, A; AKAGI, K; YAMAMURA, K; MORI, M; TAKIGUCHI, M			DETERMINATION OF TISSUE-SPECIFICITY OF THE ENHANCER BY COMBINATORIAL OPERATION OF TISSUE-ENRICHED TRANSCRIPTION FACTORS - BOTH HNF-4 AND C/EBP-BETA ARE REQUIRED FOR LIVER-SPECIFIC ACTIVITY OF THE ORNITHINE TRANSCARBAMYLASE ENHANCER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE SYNTHETASE-I; DNA-BINDING PROTEIN; NUCLEAR FACTOR-IV; GENE-EXPRESSION; TRANSGENIC MICE; LEUCINE ZIPPER; RAT-LIVER; CARBAMOYLTRANSFERASE GENE; RECEPTOR SUPERFAMILY; ACTIVATOR PROTEIN	The enhancer of the rat ornithine transcarbamylase gene is located 11 kilobases upstream from the transcription start site and has been shown to be hepatoma cell-specific. Using transgenic mice, we showed that this enhancer is capable of activating transcription in a liver-specific manner, inverting the tissue specificity of the homologous promoter that is by itself more active in the small intestine than in the liver. Transient transfection analysis with cultured hepatoma cells indicated that the enhancer activity resides in the approximately 110-base pair region containing four protein-binding sites, two for hepatocyte nuclear factor-4 (HNF-4) and two for CCAAT/enhancer binding protein (C/EBP), both of which are liver-selective transcription factors. Concatemerization of a region containing one HNF-4 and one C/EBP site led to reconstitution of the hepatoma cell-specific enhancer, and intactness of these two sites was strictly required for the enhancer activity. Furthermore, cotransfection experiments showed that both HNF-4 and C/EBPbeta are necessary, and neither alone sufficient, for activation of the reconstituted enhancer in nonhepatic cells. Requirement of combinatorial operation of at least two liver-enriched transcription factors for transcriptional activation successfully explains why these liver-selective but not strictly liver-specific factors can confer more restricted liver specificity on transcription of their target genes.	KUMAMOTO UNIV,SCH MED,DEPT MOLEC GENET,KUHONJI 4-24-1,KUMAMOTO 862,JAPAN; KUMAMOTO UNIV,SCH MED,INST MOLEC EMBRYOL & GENET,KUMAMOTO 862,JAPAN	Kumamoto University; Kumamoto University								AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BEEKMAN JM, 1991, NUCLEIC ACIDS RES, V19, P5371, DOI 10.1093/nar/19.19.5371; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; FROMENTAL C, 1988, CELL, V54, P943, DOI 10.1016/0092-8674(88)90109-2; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GERLINGER P, 1986, NUCLEIC ACIDS RES, V14, P6565, DOI 10.1093/nar/14.16.6565; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HAMMER RE, 1987, SCIENCE, V235, P53, DOI 10.1126/science.2432657; HAMMER RE, 1987, MOL CELL BIOL, V7, P2956, DOI 10.1128/MCB.7.8.2956; HOWELL BW, 1989, MOL CELL BIOL, V9, P2928, DOI 10.1128/MCB.9.7.2928; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JONES SN, 1990, J BIOL CHEM, V265, P14684; KIMURA A, 1993, J BIOL CHEM, V268, P11125; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MIYAZAKI J, 1989, GENE, V79, P269; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MULLER MM, 1988, EUR J BIOCHEM, V176, P485, DOI 10.1111/j.1432-1033.1988.tb14306.x; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; MURAKAMI T, 1989, DEV GENET, V10, P393, DOI 10.1002/dvg.1020100507; MURAKAMI T, 1990, MOL CELL BIOL, V10, P1180, DOI 10.1128/MCB.10.3.1180; PALMITER RD, 1991, P NATL ACAD SCI USA, V88, P478, DOI 10.1073/pnas.88.2.478; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; QI S-L, 1991, Methods in Molecular and Cellular Biology, V2, P119; RYALL JC, 1986, EUR J BIOCHEM, V156, P453, DOI 10.1111/j.1432-1033.1986.tb09603.x; SCHAFER BW, 1990, NATURE, V344, P454, DOI 10.1038/344454a0; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHERER SE, 1988, NUCLEIC ACIDS RES, V16, P1593, DOI 10.1093/nar/16.4.1593; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; TAKIGUCHI M, 1989, BIOESSAYS, V10, P163, DOI 10.1002/bies.950100506; TAKIGUCHI M, 1987, P NATL ACAD SCI USA, V84, P6136, DOI 10.1073/pnas.84.17.6136; TAKIGUCHI M, 1991, J BIOL CHEM, V266, P9186; TIAN JM, 1991, GENE DEV, V5, P2225, DOI 10.1101/gad.5.12a.2225; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VANOOIJ C, 1992, MOL CELL BIOL, V12, P3023, DOI 10.1128/MCB.12.7.3023; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; WRAIGHT C, 1985, EUR J BIOCHEM, V153, P239, DOI 10.1111/j.1432-1033.1985.tb09292.x; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807	61	83	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1323	1331						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288597				2022-12-27	WOS:A1994MR22000087
J	QABAR, AN; LIN, ZW; WOLF, FW; OSHEA, KS; LAWLER, J; DIXIT, VM				QABAR, AN; LIN, ZW; WOLF, FW; OSHEA, KS; LAWLER, J; DIXIT, VM			THROMBOSPONDIN-3 IS A DEVELOPMENTALLY-REGULATED HEPARIN-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET THROMBOSPONDIN; MATRIX PROTEIN; CELL-ADHESION; MOUSE EMBRYO; EXPRESSION; GENE; SEQUENCE; GLYCOPROTEIN; RECEPTOR; GROWTH	The thrombospondins (TSPs) are a growing family of cell surface and extracellular matrix molecules composed of multiple repeating elements. Thrombospondin 3 is a recently described member that possesses the calcium binding Type 3 repeats, has 4 epidermal growth factor receptor-like Type 2 repeats, a complete absence of the complement-like Type 1 repeats, and a distinct N terminus that has no significant homology to the other TSPs. Metabolic labeling and immunoprecipitation analysis of cells transfected with a TSP3 expression vector revealed it to be an oligomeric heparin binding protein present in both the cell layer and medium. Finally, a combination of in situ hybridization and immunocytochemistry demonstrated TSP3 to be expressed in a temporal and spatial manner during murine embryogenesis, especially in the gut, cartilage, lung, and central nervous system.	UNIV MICHIGAN, SCH MED, DEPT ANAT & CELL BIOL, ANN ARBOR, MI 48109 USA; BRIGHAM & WOMENS HOSP, DEPT PATHOL, DIV VASC SURG, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	University of Michigan System; University of Michigan; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	QABAR, AN (corresponding author), UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA.		Lawler, Jack/AAJ-1379-2020; dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NCI NIH HHS [CA58182] Funding Source: Medline; NHLBI NIH HHS [HL28749] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058182] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028749] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS J, 1993, CURR BIOL, V3, P188, DOI 10.1016/0960-9822(93)90270-X; ASCH AS, 1989, PROG HEMOST THROMB, V9, P157; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; BORNSTEIN P, 1993, GENOMICS, V15, P607, DOI 10.1006/geno.1993.1114; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; BROWNE PC, 1988, ARCH BIOCHEM BIOPHYS, V265, P534, DOI 10.1016/0003-9861(88)90158-0; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; FRAZIER WA, 1987, J CELL BIOL, V105, P625, DOI 10.1083/jcb.105.2.625; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; GUO NH, 1992, J BIOL CHEM, V267, P19349; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; LAHERTY CD, 1992, J BIOL CHEM, V267, P3274; LANCASTER CA, 1990, BIOCHEM BIOPH RES CO, V173, P1019, DOI 10.1016/S0006-291X(05)80888-5; LAWLER J, 1993, J CELL BIOL, V120, P1059, DOI 10.1083/jcb.120.4.1059; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LAWLER J, 1992, BIOCHEMISTRY-US, V31, P1173, DOI 10.1021/bi00119a029; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LAWLER J, 1986, BLOOD, V67, P1197; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; MCPHERSON J, 1981, J BIOL CHEM, V256, P1330; OLDBERG A, 1992, J BIOL CHEM, V267, P22346; OROURKE KM, 1992, J BIOL CHEM, V267, P24921; OSHEA KS, 1990, J CELL BIOL, V111, P2713, DOI 10.1083/jcb.111.6.2713; OSHEA KS, 1990, J CELL BIOL, V110, P1275, DOI 10.1083/jcb.110.4.1275; OSHEA KS, 1988, J CELL BIOL, V107, P2737, DOI 10.1083/jcb.107.6.2737; PROCHOWNIK EV, 1989, J CELL BIOL, V109, P843, DOI 10.1083/jcb.109.2.843; ROBERTS DD, 1986, J BIOL CHEM, V261, P6872; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SPEZIALE MV, 1990, J BIOL CHEM, V265, P17859; SUCHARD SJ, 1991, J IMMUNOL, V147, P651; SUN XJ, 1989, J BIOL CHEM, V264, P11288; TUCKER RP, 1993, DEVELOPMENT, V117, P347; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VOS HL, 1992, J BIOL CHEM, V267, P12192; WATSON MA, 1990, DEVELOPMENT, V110, P173; WOLF FW, 1990, GENOMICS, V6, P685, DOI 10.1016/0888-7543(90)90505-O; YABKOWITZ R, 1991, CANCER RES, V51, P3648	38	54	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1262	1269						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288588				2022-12-27	WOS:A1994MR22000078
J	DIXON, KH; LANPHER, BC; CHIU, J; KELLEY, K; COWAN, KH				DIXON, KH; LANPHER, BC; CHIU, J; KELLEY, K; COWAN, KH			A NOVEL CDNA RESTORES REDUCED FOLATE CARRIER ACTIVITY AND METHOTREXATE SENSITIVITY TO TRANSPORT DEFICIENT CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BINDING PROTEINS; TUMOR-CELLS; RECEPTOR; RESISTANCE; TOXICITY	Mammalian cells accumulate reduced folates and methotrexate, a folate antagonist, through the reduced-folate carrier (RFC) (Goldman, I. D., Lichtenstein, N. S., and Oliverio, V. T. (1968) J. Biol. Chem. 243, 5007-5017). This study describes the isolation and expression of a cDNA clone that restores RFC activity to human breast cancer cells defective in this transporter. The cDNA codes for a peptide (mRFC1) of 58 kDa, whose hydropathy plot, resembling those of mammalian sugar transporters, predicts that it may be a member of a superfamily of transporter genes. Transfection of methotrexate-resistant (MTX(R)) ZR-75-1 cells with an expression vector, pRFC1, that codes for this peptide restores their ability to accumulate methotrexate. Furthermore, transport of methotrexate into pRFC1-transfected cells is blocked by a 10-fold molar excess of the reduced folate, 5-formyltetrahydrofolic acid, but is unaffected by folic acid. The increase in methotrexate uptake that is observed in pRFC1-transfected MTX(R) ZR-75-1 cells reverses their resistance to this antitumor agent.			DIXON, KH (corresponding author), NCI, MED BRANCH, MED BREAST CANC SECT, BETHESDA, MD 20892 USA.							ANTONY AC, 1981, J BIOL CHEM, V256, P9684; CHELLO PL, 1977, CANCER RES, V37, P4297; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COWAN KH, 1984, J BIOL CHEM, V259, P793; DIXON KH, 1991, CANCER COMMUN-US, V3, P357, DOI 10.3727/095535491820873687; DIXON KH, 1992, J BIOL CHEM, V267, P24140; ELWOOD PC, 1986, J BIOL CHEM, V261, P5416; FAN JG, 1991, J BIOL CHEM, V266, P14862; FREISHEIM JH, 1989, ADV ENZYME REGUL, V29, P13, DOI 10.1016/0065-2571(89)90091-5; GOLDMAN ID, 1985, PHARMACOL THERAPEUT, V28, P77, DOI 10.1016/0163-7258(85)90083-X; GOLDMAN ID, 1968, J BIOL CHEM, V243, P5007; GRIFFITH J K, 1992, Current Opinion in Cell Biology, V4, P684, DOI 10.1016/0955-0674(92)90090-Y; GROGER R, 1989, GENE, V83, P3951; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HENDERSON GB, 1990, ANNU REV NUTR, V10, P319, DOI [10.1146/annurev.nutr.10.1.319, 10.1146/annurev.nu.10.070190.001535]; HENDERSON GB, 1988, J MEMBRANE BIOL, V101, P247, DOI 10.1007/BF01872839; HENDERSON GB, 1991, J BIOL CHEM, V266, P1641; HERBERT DN, 1991, CURR OPIN CELL BIOL, V3, P702; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOLM J, 1991, BIOCHEM J, V280, P267, DOI 10.1042/bj2800267; KAMEN BA, 1989, J CLIN INVEST, V84, P1379, DOI 10.1172/JCI114310; KAPLAN JH, 1993, J BIOL CHEM, V72, P13; KISLIUK RL, 1984, FOLATE ANTAGONISTS T, V1, P1; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MATHERLY LH, 1992, J BIOL CHEM, V267, P23253; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; Sambrook J, 1989, MOL CLONING LABORATO; SIROTNAK FM, 1987, NCI MONOGRAPHS, V5, P27; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; TRIPPETT T, 1992, BLOOD, V80, P1158; VANDERVEER LJ, 1989, LEUKEMIA RES, V13, P981, DOI 10.1016/0145-2126(89)90005-2; WEITMAN SD, 1992, CANCER RES, V52, P6708	35	211	217	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					17	20						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276792				2022-12-27	WOS:A1994MR21900005
J	JAULT, JM; ALLISON, WS				JAULT, JM; ALLISON, WS			HYSTERETIC INHIBITION OF THE BOVINE HEART MITOCHONDRIAL F1-ATPASE IS DUE TO SATURATION OF NONCATALYTIC SITES WITH ADP WHICH BLOCKS ACTIVATION OF THE ENZYME BY ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-SITES; BETA-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; CATALYTIC SITE; KINETIC MECHANISM; F1 ATPASE; IDENTIFICATION; 5'-TRIPHOSPHATASE; INACTIVATION; DIPHOSPHATE	Prior incubation of the bovine heart mitochondrial F1-ATPase depleted of endogenous nucleotides (nd-MF1) with saturating ADP in the presence or absence of Mg2+ induces inhibition of hydrolysis of 2 mM ATP or ITP. After incubation of nd-MF1 with free ADP, inhibition develops hysteretically which is characterized by an uninhibited initial rate which decelerates to an inhibited, steady-state rate. When prior incubation of nd-MF1 is performed with ADP in the presence of Mg2+, the enzyme is partially inhibited when diluted into assay medium and more extensive inhibition develops hysteretically during turnover. Correlation of binding of [C-14]ADP, in the presence or absence of Mg2+, with the extent of hysteretic inhibition induced suggests that maximal inhibition occurs when at least two noncatalytic sites are filled with ADP. Hysteretic inhibition is also induced by prior incubation of the enzyme with 2-N3-ADP. Prior incubation of nd-MF1 with increasing concentrations of 2-N3-[beta-P-32]ADP, in the presence or absence of Mg2+, increases the extent of induced inhibition which correlates with increasing derivatization of tyrosine beta368 following irradiation of loaded enzyme. This demonstrates that binding of ADP to noncatalytic sites is, in part, responsible for induction of hysteretic inhibition. After inducing inhibition by prior incubation with ADP, the steady-state kinetic behavior of nd-MF1 differs from that of uninhibited enzyme. Lineweaver-Burk plots of steady-state rates of inhibited enzyme as a function of ATP concentration are linear rather than biphasic which is observed for uninhibited enzyme. The composite results suggest that prior saturation of noncatalytic sites of nd-MF1 with ADP prevents activation of the enzyme by blocking the binding of ATP to these sites which is necessary to promote dissociation of inhibitory MgADP from a catalytic site.	UNIV CALIF SAN DIEGO,DEPT CHEM,LA JOLLA,CA 92093	University of California System; University of California San Diego			jault, jean-michel/G-2086-2012	jault, jean-michel/0000-0003-1743-2777	NIGMS NIH HHS [GM-16974] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON WS, 1986, METHOD ENZYMOL, V126, P741; ALLISON WS, 1992, J BIOENERG BIOMEMBR, V24, P469, DOI 10.1007/BF00762364; BAUBICHON H, 1981, BIOCHEM BIOPH RES CO, V100, P1032, DOI 10.1016/0006-291X(81)91927-6; BERDEN JA, 1991, BIOCHIM BIOPHYS ACTA, V1057, P151, DOI 10.1016/S0005-2728(05)80099-4; BULLOUGH DA, 1986, J BIOL CHEM, V261, P5722; BULLOUGH DA, 1988, J BIOL CHEM, V263, P14053; BULLOUGH DA, 1986, J BIOL CHEM, V261, P14171; CHERNYAK BV, 1992, ARCH BIOCHEM BIOPHYS, V295, P247, DOI 10.1016/0003-9861(92)90514-W; CROSS RL, 1987, P NATL ACAD SCI USA, V84, P5715, DOI 10.1073/pnas.84.16.5715; CROSS RL, 1982, J BIOL CHEM, V257, P2874; CROSS RL, 1988, J BIOENERG BIOMEMBR, V20, P395, DOI 10.1007/BF00762200; Czarnecki J, 1979, Methods Enzymol, V56, P642; CZARNECKI JJ, 1984, BIOCHIM BIOPHYS ACTA, V800, P41, DOI 10.1016/0304-4165(84)90092-8; DIPIETRO A, 1980, BIOCHEMISTRY-US, V19, P5671, DOI 10.1021/bi00566a002; DIPIETRO A, 1981, BIOCHEMISTRY-US, V20, P6312, DOI 10.1021/bi00525a005; DIPIETRO A, 1986, BIOCHIM BIOPHYS ACTA, V851, P283, DOI 10.1016/0005-2728(86)90136-2; DROBINSKAYA IY, 1985, FEBS LETT, V182, P419, DOI 10.1016/0014-5793(85)80346-X; ESCH FS, 1978, J BIOL CHEM, V253, P6100; FELLOUS G, 1984, BIOCHEMISTRY-US, V23, P5294, DOI 10.1021/bi00317a030; FITIN AF, 1979, BIOCHEM BIOPH RES CO, V86, P434, DOI 10.1016/0006-291X(79)90884-2; GARIN J, 1986, BIOCHEMISTRY-US, V25, P4431, DOI 10.1021/bi00363a039; GARRETT NE, 1975, J BIOL CHEM, V250, P6640; HARRIS DA, 1993, FEBS LETT, V316, P209, DOI 10.1016/0014-5793(93)81295-B; JAULT JM, 1993, J BIOL CHEM, V268, P1558; KALASHNIKOVA TY, 1988, EUR J BIOCHEM, V177, P213, DOI 10.1111/j.1432-1033.1988.tb14364.x; KNOWLES AF, 1972, J BIOL CHEM, V247, P6617; LARDY HA, 1975, J SUPRAMOL STR CELL, V3, P214, DOI 10.1002/jss.400030303; MELESE T, 1985, J BIOL CHEM, V260, P5398; MILGROM YM, 1990, J BIOL CHEM, V265, P18725; MILGROM YM, 1990, BIOCHIM BIOPHYS ACTA, V1020, P43, DOI 10.1016/0005-2728(90)90091-H; MILGROM YM, 1989, BIOCHIM BIOPHYS ACTA, V975, P50, DOI 10.1016/S0005-2728(89)80200-2; MILGROM YM, 1991, J BIOL CHEM, V266, P11551; MINKOV IB, 1979, BIOCHEM BIOPH RES CO, V89, P1300, DOI 10.1016/0006-291X(79)92150-8; MURATALIEV MB, 1991, BIOCHEMISTRY-US, V30, P8305, DOI 10.1021/bi00098a004; MURATALIEV MB, 1992, BIOCHEMISTRY-US, V31, P12885, DOI 10.1021/bi00166a025; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; SCHUSTER SM, 1975, J BIOL CHEM, V250, P7848; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; VASILYEVA EA, 1982, BIOCHEM J, V202, P15, DOI 10.1042/bj2020015; VASILYEVA EA, 1982, BIOCHEM J, V202, P9, DOI 10.1042/bj2020009; VOGEL PD, 1991, J BIOL CHEM, V266, P6101; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; YSERN X, 1988, J BIOENERG BIOMEMBR, V20, P423, DOI 10.1007/BF00762202; ZHUO SQ, 1992, J BIOL CHEM, V267, P12916	45	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					319	325						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276813				2022-12-27	WOS:A1994MR21900055
J	RAJENDRAN, VM; BINDER, HJ				RAJENDRAN, VM; BINDER, HJ			DIFFERENTIAL MODULATION OF NA-HCO3 COTRANSPORT AND NA-H EXCHANGE BY PH IN BASOLATERAL MEMBRANE-VESICLES OF RAT DISTAL COLON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOLIC-ACIDOSIS; ADAPTATION; ANTIPORTER; CELLS	This study was designed to investigate the function of intravesicular proton on two pH gradient-dependent transport processes, a novel Na-HCO3 cotransport and a Na-H exchange, that are present in basolateral membrane vesicles of rat distal colon. Increasing intravesicular proton concentration saturated Na-22 uptake via both Na-H exchange and Na-HCO3 cotransport; reduced the apparent K(m) for sodium for Na-H exchange from 94.9 to 35.6 mM, without alteration in the V(max); but enhanced the V(max) for Na-HCO3 cotransport from 4.3 to 11.7 nmol/mg protein.6 s, while not changing the K(m) for sodium. The effect of a 10-fold proton concentration gradient at two different absolute proton concentrations on both systems was also determined. Na-22 uptake via Na-HCO3 cotransport, but not via Na-H exchange, was enhanced at the higher proton concentration, indicating that the magnitude of the proton concentration gradient is primarily responsible for proton stimulation of Na-H exchange, whereas the absolute proton concentration is critical for proton enhancement of Na-HCO3 cotransport. These studies also demonstrate saturation of both transport systems as a function of intravesicular proton concentration without an exponential component. These results indicate that proton stimulated Na-H exchange and Na-HCO3 cotransport are regulated by distinct and separate mechanisms that may reflect their different cellular functions.	YALE UNIV,SCH MED,DEPT INTERNAL MED,333 CEDAR ST,NEW HAVEN,CT 06510	Yale University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK014669] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-14669] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIBA T, 1987, J CLIN INVEST, V80, P308, DOI 10.1172/JCI113074; ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; BIBER J, 1983, BIOCHIM BIOPHYS ACTA, V735, P1, DOI 10.1016/0005-2736(83)90255-9; BINDER HJ, 1986, AM J PHYSIOL, V251, pG382, DOI 10.1152/ajpgi.1986.251.3.G382; Binder HJ, 1991, LARGE INTESTINE PHYS, P141; DELCASTILLO JR, 1991, AM J PHYSIOL, V261, pG1005, DOI 10.1152/ajpgi.1991.261.6.G1005; FELIPE A, 1990, BIOCHIM BIOPHYS ACTA, V1029, P61, DOI 10.1016/0005-2736(90)90436-R; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MONTROSE MH, 1988, NA H EXCHANGE, P57; PREISIG PA, 1988, J CLIN INVEST, V82, P1445, DOI 10.1172/JCI113750; RAJENDRAN VM, 1993, AM J PHYSIOL, V264, pG874, DOI 10.1152/ajpgi.1993.264.5.G874; RAJENDRAN VM, 1991, J CLIN INVEST, V88, P1379, DOI 10.1172/JCI115444; RENNER EL, 1989, J CLIN INVEST, V83, P1225, DOI 10.1172/JCI114005; SOLEIMANI M, 1991, J CLIN INVEST, V88, P1135, DOI 10.1172/JCI115413; VILELLA S, 1992, PFLUG ARCH EUR J PHY, V420, P275, DOI 10.1007/BF00374459; WARNOCK DG, 1988, NA PLUS H PLUS EXCHA, P77; ZAMIR A, 1991, GASTROENTEROLOGY, V100, pA710	18	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					156	160						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276790				2022-12-27	WOS:A1994MR21900032
J	TAKAHASHI, M; TANZAWA, K; TAKAHASHI, S				TAKAHASHI, M; TANZAWA, K; TAKAHASHI, S			ADENOPHOSTINS, NEWLY DISCOVERED METABOLITES OF PENICILLIUM-BREVICOMPACTUM, ACT AS POTENT AGONISTS OF THE INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; TRISPHOSPHATE RECEPTOR; CALCIUM RELEASE; PLASMA-MEMBRANE; ANIMAL-TISSUES; RAT-BRAIN; CELL; BINDING; 1,3,4,5-TETRAKISPHOSPHATE; SOLUBILIZATION	Potent inositol 1,4,5-trisphosphate (IP3) receptor agonists, adenophostin A and B, were found from fungal products. In spite of the striking structural difference from IP3, adenophostins were found to inhibit [H]IP3 binding more potently than IP3: the K(i) values for adenophostin A and B were both calculated to be 0.18 nM, while that of IP3 was 15 nM. Adenophostins induced Ca2+ release both from cerebellar microsomes and from intracellular Ca2+ stores in permeabilized NG108-15 cells. Adenophostins at concentration as low as 1 nM produced a significant Ca2+ release from cerebellar microsomes, and their activities were 100-fold more potent than IP3. In addition, heparin, an IP3 receptor antagonist, completely blocked the Ca2+ releasing activity of adenophostins. Adenophostins were resistant to phosphorylation and dephosphorylation by IP3-metabolizing enzymes, thereby providing a possible explanation for their prolonged activities. Adenophostin also bound to plasma membrane IP3 receptor with a high affinity and inhibited [H-3]IP, binding to jurkat human T-cell plasma membranes: the IC50 value for adenophostin A was 0.95 nM. Adenophostin may prove to be a powerful tool for investigating the physiological properties of IP3 and its receptor.			TAKAHASHI, M (corresponding author), SANKYO CO LTD,FERMENTAT RES LABS,1-2-58 HIROMACHI,SHINAGAWA KU,TOKYO 140,JAPAN.							BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; CHADWICK CC, 1992, J BIOL CHEM, V267, P3473; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; EHRLICH BE, 1988, NATURE, V336, P583, DOI 10.1038/336583a0; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; HIGASHIDA H, 1986, NATURE, V323, P333, DOI 10.1038/323333a0; HIRATA M, 1989, J BIOL CHEM, V264, P20303; IRVINE RF, 1986, NATURE, V320, P631, DOI 10.1038/320631a0; IRVINE RF, 1984, BIOCHEM J, V222, P269, DOI 10.1042/bj2220269; JEAN T, 1986, J BIOL CHEM, V261, P6414; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KHAN AA, 1992, P NATL ACAD SCI USA, V89, P2849, DOI 10.1073/pnas.89.7.2849; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1991, J BIOL CHEM, V266, P2276; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MIYAWAKI A, 1990, NEURON, V5, P11, DOI 10.1016/0896-6273(90)90029-F; NAHORSKI SR, 1989, TRENDS PHARMACOL SCI, V10, P139, DOI 10.1016/0165-6147(89)90165-X; OGURA A, 1990, J BIOL CHEM, V265, P3577; PRESTWICH GD, 1991, J AM CHEM SOC, V113, P1822, DOI 10.1021/ja00005a055; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; STAUDERMAN KA, 1988, BIOCHEM J, V255, P667; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAKAHASHI M, 1993, IN PRESS J ANTIBIOT; TAKAHASHI S, IN PRESS J ANTIBIOT; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; THEIBERT AB, 1990, BIOCHEM J, V267, P441, DOI 10.1042/bj2670441; THEIBERT AB, 1991, P NATL ACAD SCI USA, V88, P3165, DOI 10.1073/pnas.88.8.3165; WORLEY PF, 1987, J BIOL CHEM, V262, P12132	37	205	206	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					369	372						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276820				2022-12-27	WOS:A1994MR21900062
J	ZHANG, CH; EVANS, T				ZHANG, CH; EVANS, T			DIFFERENTIAL REGULATION OF THE 2 XGATA-1 GENES DURING XENOPUS DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID TRANSCRIPTION FACTOR; BONE MORPHOGENETIC PROTEIN-4; HEMATOPOIETIC-CELLS; VENTRALIZING FACTOR; FACTOR GATA-1; EXPRESSION; LAEVIS; MESODERM; INDUCTION; PROMOTER	Xenopus laevis provides an established developmental system to study the regulation of cell lineage establishment and the generation of tissue-specific patterns of gene expression. We have isolated from Xenopus erythroid cell RNA two distinct cDNA clones encoding the xGATA-1 transcription factor. We have identified, in erythroid nuclear extracts, the sequence-specific DNA-binding protein they encode. By characterizing the expression patterns for RNA derived from two distinct homologues, we find that the two xGATA-1 genes are differentially regulated. The xGATA-1a mRNA predominates in embryos prior to terminal differentiation of erythroid cells, while the differentiated cells contain RNA derived predominantly from the xGATA-1b gene. Both proteins activate a target globin promoter in transient transfection assays. During early development, GATA-1 transcripts are localized to ventral regions of the embryo. GATA-1 should therefore provide a useful early marker for studying signalling pathways which result in the generation of ventral mesoderm. The differentially regulated genes may be distinct markers for targets of ventral mesoderm induction.	UNIV PITTSBURGH,DEPT BIOL SCI,LANGLEY HALL,PITTSBURGH,PA 15260	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044167] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44167] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DALE L, 1987, DEVELOPMENT, V99, P527; DALE L, 1992, DEVELOPMENT, V115, P573; EVANS T, 1991, MOL CELL BIOL, V11, P843, DOI 10.1128/MCB.11.2.843; EVANS T, 1990, ANNU REV CELL BIOL, V6, P95, DOI 10.1146/annurev.cellbio.6.1.95; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; JONES CM, 1992, DEVELOPMENT, V115, P639; KAU CL, 1983, J IMMUNOL, V131, P2262; KELLER RE, 1976, DEV BIOL, V51, P118, DOI 10.1016/0012-1606(76)90127-5; MAENO M, 1985, DEV BIOL, V110, P503, DOI 10.1016/0012-1606(85)90108-3; MAENO M, 1985, DEV GROWTH DIFFER, V27, P137; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; ORKIN SH, 1992, BLOOD, V80, P575; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; SCHWARTZBAUER G, 1992, NUCLEIC ACIDS RES, V20, P4429, DOI 10.1093/nar/20.17.4429; SIMON MC, 1993, P SOC EXP BIOL MED, V202, P115; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPOSI NM, 1992, P NATL ACAD SCI USA, V89, P6353, DOI 10.1073/pnas.89.14.6353; TRAINOR CD, 1990, NATURE, V343, P92, DOI 10.1038/343092a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10642, DOI 10.1073/pnas.88.23.10642	30	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					478	484						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276839				2022-12-27	WOS:A1994MR21900079
J	MENON, SD; QIN, SX; GUY, GR; TAN, YH				MENON, SD; QIN, SX; GUY, GR; TAN, YH			DIFFERENTIAL INDUCTION OF NUCLEAR NF-KAPPA-B BY PROTEIN PHOSPHATASE INHIBITORS IN PRIMARY AND TRANSFORMED HUMAN-CELLS - REQUIREMENT FOR BOTH OXIDATION AND PHOSPHORYLATION IN NUCLEAR TRANSLOCATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HUMAN-IMMUNODEFICIENCY-VIRUS; KINASE-C; TRANSCRIPTION FACTOR; SIGNAL TRANSDUCTION; OKADAIC ACID; HUMAN-FIBROBLASTS; FACTOR-ALPHA; ACTIVATION; BINDING	Phosphoseryl/threonyl protein phosphatase inhibitors, viz. okadaic acid and calyculin-A, failed to induce nuclear factor-kappaB (NF-kappaB) nuclear translocation in several primary human cells although a marked and rapid induction was observed in their simian virus 40 transformed counterparts. Inability to induce NF-kappaB cannot be due to a non-activatable system since NF-kappaB was strongly activated by tumor necrosis factor in all the five primary cell types tested. It is also unlikely that the differential induction was due to differential sensitivity of primary and transformed cells to phosphatase inhibitors as the intracellular phosphatase activities of both cell types were equally inhibited by these inhibitors. However, pretreatment with hydrogen peroxide or buthionine sulfoximine, chemicals known to directly or indirectly elevate the intracellular free-radical levels, enabled okadaic acid to induce nuclear translocation of NF-kappaB in primary cells. Conversely cysteine, an antioxidant and precursor of the free radical scavenger, glutathione, inhibited the induction of NF-kappaB by tumor necrosis factor in primary cells, and by okadaic acid or tumor necrosis factor in transformed cells. These data, taken together, suggest that free radical-dependent oxidation and protein phosphorylation are not independent modes of NF-kappaB induction, but are both required for the release of NF-kappaB from IkappaB. Furthermore, the differential induction of NF-kappaB nuclear translocation by okadaic acid in primary and transformed human cells, reported herein, reflects intrinsic differences in the intracellular oxidative state between the two groups of cells. The induction of NF-kappaB by tumor necrosis factor in primary cells suggests that this cytokine fulfills the requirement for oxidation, possibly by inducing the production of free radicals.	NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, 10 KENT RIDGE CRESCENT, SINGAPORE 0511, SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore								BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, COLD SPRING HARB SYM, V53, P789, DOI 10.1101/SQB.1988.053.01.089; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; CAO XM, 1992, J BIOL CHEM, V267, P12991; CHAN WK, 1990, NUCLEIC ACIDS RES, V18, P763, DOI 10.1093/nar/18.4.763; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHRISTIANSEN NO, 1988, FEBS LETT, V239, P195, DOI 10.1016/0014-5793(88)80915-3; COHEN P, 1991, METHOD ENZYMOL, V201, P389; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FRIEDL HP, 1989, FASEB J, V3, P2512, DOI 10.1096/fasebj.3.13.2806779; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GRILLI M, 1993, INT REV CYTOL, P143; GUESDON F, 1993, J BIOL CHEM, V268, P4236; GUY GR, 1991, J BIOL CHEM, V266, P14343; GUY GR, 1992, J BIOL CHEM, V267, P1846; GUY GR, 1993, J BIOL CHEM, V268, P2141; HALLIWELL B, 1989, FREE RADICAL BIO MED, P79; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; ISRAEL N, 1992, J IMMUNOL, V149, P3386; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; LANDGRAF W, 1991, J BIOL CHEM, V266, P16305; LINK E, 1992, J BIOL CHEM, V267, P239; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MEISTER A, 1992, CHEMTRACTS BIOCH MOL, V3, P75; MINERS JO, 1984, BIOCHEM PHARMACOL, V33, P2995, DOI 10.1016/0006-2952(84)90599-9; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; Schmitz M L, 1991, Trends Cell Biol, V1, P130, DOI 10.1016/0962-8924(91)90118-S; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; Schulze-Osthoff K, 1991, Trends Cell Biol, V1, P150, DOI 10.1016/0962-8924(91)90003-R; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCHUTZE S, 1990, J IMMUNOL, V144, P2604; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; SUGANUMA M, 1990, CANCER RES, V50, P3521; SWAIN JE, 1991, J NEUROBIOL, V22, P855, DOI 10.1002/neu.480220806; TANG BL, 1993, J CELL BIOL, V120, P325, DOI 10.1083/jcb.120.2.325; THEVENIN C, 1990, New Biologist, V2, P793; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328	50	91	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26805	26812						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253818				2022-12-27	WOS:A1993MK42500115
J	MURPHYULLRICH, JE; GURUSIDDAPPA, S; FRAZIER, WA; HOOK, M				MURPHYULLRICH, JE; GURUSIDDAPPA, S; FRAZIER, WA; HOOK, M			HEPARIN-BINDING PEPTIDES FROM THROMBOSPONDIN-1 AND THROMBOSPONDIN-2 CONTAIN FOCAL ADHESION-LABILIZING ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLATELET THROMBOSPONDIN; HUMAN-MELANOMA CELLS; ENDOTHELIAL-CELLS; SULFATED GLYCOLIPIDS; GENE FAMILY; I REPEATS; RECEPTOR; GROWTH; ATTACHMENT; EXPRESSION	The cell adhesion regulating extracellular matrix glycoprotein, thrombospondin (TSP), causes a loss of focal adhesion plaques from spread endothelial cells and fibroblasts. To localize the site on TSP that has focal adhesion-labilizing activity, we initially tested proteolytic fragments of TSP for activity. The heparin-binding fragment has significant focal adhesion-labilizing activity, whereas the nonheparin-binding 140-kDa fragment had no significant activity. These results were consistent with previous data that showed that both a monoclonal antibody to the heparin-binding domain of TSP (A2.5) and heparin neutralized TSP activity. Peptides from putative heparin binding sequences of the amino-terminal heparin-binding domain of TSP were synthesized and tested for their ability to cause loss of focal adhesions. The hep I peptide (amino acids 17-35) caused maximal loss of focal adhesions and was active at 0.1 muM, whereas peptide hep II (74-95) and peptide hep III (170-189) were inactive. The activity of the hep I peptide was neutralized by the addition of heparin and heparan sulfate but not by chondroitin sulfate. The basic amino acids in the hep I sequence appear to be required for focal adhesion-labilizing activity, because modification of the lysine residues at amino acids 24 and 32 rendered the peptide completely inactive. In addition, a peptide from the analogous sequence of mouse TSP 2, in which basic residues are conserved, was nearly as active as hep I from TSP1. These data show that the anti-adhesive activity of TSP is conserved in both TSP1 and TSP2 and that the active site is located in a 19-amino acid sequence in the heparin-binding domain of TSPs.	TEXAS A&M UNIV SYST, INST BIOSCI & TECHNOL, HOUSTON, TX 77030 USA; WASHINGTON UNIV, SCH MED, DEPT BIOL CHEM, ST LOUIS, MO 63110 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Washington University (WUSTL)	MURPHYULLRICH, JE (corresponding author), UNIV ALABAMA, DEPT PATHOL, DIV MOLEC & CELLULAR BIOL, G038 VOLKER HALL, BIRMINGHAM, AL 35294 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027712] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044575] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44575] Funding Source: Medline; NIADDK NIH HHS [AM-27087] Funding Source: Medline; NICHD NIH HHS [HD27712] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ACHARYA AS, 1984, J CHROMATOGR, V297, P37, DOI 10.1016/S0021-9673(01)89027-0; ASCH AS, 1991, J BIOL CHEM, V266, P1740; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; BAGAVANDOSS P, 1990, BIOCHEM BIOPH RES CO, V163, P56; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; BORNSTEIN P, 1991, P NATL ACAD SCI USA, V88, P8636, DOI 10.1073/pnas.88.19.8636; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Chiquet-Ehrismann R, 1991, CURR OPIN CELL BIOL, V3, P800, DOI 10.1016/0955-0674(91)90053-2; COUCHMAN JR, 1979, J CELL SCI, V39, P149; DIXIT VM, 1984, J BIOL CHEM, V259, P100; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; GALVIN NJ, 1985, J CELL BIOL, V101, P1434, DOI 10.1083/jcb.101.4.1434; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; IRUELAARISPE ML, 1991, P NATL ACAD SCI USA, V88, P5026, DOI 10.1073/pnas.88.11.5026; KAESBERG PR, 1989, J CLIN INVEST, V83, P994, DOI 10.1172/JCI113986; LABELL TL, 1992, GENOMICS, V12, P421, DOI 10.1016/0888-7543(92)90430-Z; LAHERTY CD, 1992, J BIOL CHEM, V267, P3274; LAWLER J, 1993, J CELL BIOL, V120, P1059, DOI 10.1083/jcb.120.4.1059; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LAWLER J, 1992, BIOCHEMISTRY-US, V31, P1173, DOI 10.1021/bi00119a029; LAWLER J, 1991, J BIOL CHEM, V266, P8039; MAJACK RA, 1986, P NATL ACAD SCI USA, V83, P9050, DOI 10.1073/pnas.83.23.9050; MOSHER DF, 1990, ANNU REV MED, V41, P85; MURPHYULLRICH JE, 1987, SEMIN THROMB HEMOST, V13, P343, DOI 10.1055/s-2007-1003510; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; MURPHYULLRICH JE, 1989, J CELL BIOL, V109, P1309, DOI 10.1083/jcb.109.3.1309; MURPHYULLRICH JE, 1988, J BIOL CHEM, V263, P6400; MURPHYULLRICH JE, 1987, J CELL BIOL, V105, P1603, DOI 10.1083/jcb.105.4.1603; MURPHYULLRICH JE, 1991, J CELL BIOL, V115, P1127, DOI 10.1083/jcb.115.4.1127; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; ROBERTS DD, 1988, CANCER RES, V48, P6785; ROBERTS DD, 1985, J BIOL CHEM, V260, P9405; ROBERTS DD, 1987, J CELL BIOL, V104, P131, DOI 10.1083/jcb.104.1.131; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; SILVERSTEIN RL, 1992, J BIOL CHEM, V267, P16607; SUN X, 1992, J CELL BIOL, V118, P693, DOI 10.1083/jcb.118.3.693; SUN XJ, 1989, J BIOL CHEM, V264, P11288; TARABOLETTI G, 1987, J CELL BIOL, V105, P2409, DOI 10.1083/jcb.105.5.2409; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; VOS HL, 1992, J BIOL CHEM, V267, P12192; YABKOWITZ R, 1989, J BIOL CHEM, V264, P10888; YABKOWITZ R, 1991, CANCER RES, V51, P3648	45	142	146	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26784	26789						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253815				2022-12-27	WOS:A1993MK42500112
J	TCHOU, J; MICHAELS, ML; MILLER, JH; GROLLMAN, AP				TCHOU, J; MICHAELS, ML; MILLER, JH; GROLLMAN, AP			FUNCTION OF THE ZINC-FINGER IN ESCHERICHIA-COLI FPG PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE; APURINIC APYRIMIDINIC SITES; POLY(ADP-RIBOSE) POLYMERASE; SUBSTRATE-SPECIFICITY; IONIZING-RADIATION; IMIDAZOLE RINGS; DAMAGED DNA; MUTAGENESIS; EXCISION; 8-HYDROXYGUANINE	Fpg protein of Escherichia coli cleaves duplex DNA containing the oxidatively damaged base 8-oxo-7,8-dihydroguanine (Tchou, J., Kasai, H., Shibutani, S., Chung, M.-H., Laval, J., Grollman, A. P., and Nishimura, S. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 4690-4694). This DNA repair enzyme contains one zinc atom/protein molecule (Boiteux, S., O'Connor, T. R., Lederer, F., Gougette, A., and Laval, J. (1990) J. Biol. Chem. 265, 3916-3922); its N-glycosylase and apurinic/apyrimidinic lyase activities are physically associated. Amino acid sequence analysis reveals a putative single zinc finger motif of the CC/CC type located near the carboxyl terminus. A gel mobility shift assay was used to assay binding of Fpg protein to a non-cleavable substrate analog, namely an oligodeoxynucleotide duplex containing a single tetrahydrofuran residue. High resolution hydroxyl radical DNA footprinting showed protection centered around the tetrahydrofuran residue. No footprint was observed on the complementary strand. To establish the role of COOH-terminal zinc finger in DNA binding and/or DNA cleavage, amino acid substitutions and an amber mutation were introduced at Cys-244 (C244S, C244H, C244A, and C244amber). In addition, a double amino acid substitution was generated at Cys-244 and Cys-247 (C244S/C247S). These mutant Fpg proteins lack DNA binding or cleavage activity, as tested in crude lysates of Escherichia coli. Wild type Fpg protein contains one zinc/protein molecule, whereas the mutant Fpg protein (C244S/C247S) lacks zinc, as measured by atomic absorption spectroscopy. This mutation did not significantly alter secondary structure, as assessed by circular dichroism spectroscopy. Our results suggest that Fpg protein utilizes its single COOH-terminal zinc finger motif in DNA binding.	UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	TCHOU, J (corresponding author), SUNY STONY BROOK,DEPT PHARMACOL SCI,STONY BROOK,NY 11794, USA.				NATIONAL CANCER INSTITUTE [R37CA017395, R01CA017395] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032184] Funding Source: NIH RePORTER; NCI NIH HHS [CA-17395] Funding Source: Medline; NIGMS NIH HHS [GM-32184, GM07518] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILLY V, 1989, BIOCHEM J, V262, P581, DOI 10.1042/bj2620581; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BODEPUDI V, 1991, NUCLEOS NUCLEOT NUCL, V10, P755, DOI 10.1080/07328319108046660; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; BOITEUX S, 1989, CARCINOGENESIS, V10, P1905, DOI 10.1093/carcin/10.10.1905; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREIMER LH, 1984, NUCLEIC ACIDS RES, V12, P6359, DOI 10.1093/nar/12.16.6359; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHETSANGA CJ, 1983, CARCINOGENESIS, V4, P997, DOI 10.1093/carcin/4.8.997; CHETSANGA CJ, 1979, NUCLEIC ACIDS RES, V6, P3673, DOI 10.1093/nar/6.11.3673; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; DOWD DR, 1990, J BIOL CHEM, V265, P3424; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; GRAVES RJ, 1992, J BIOL CHEM, V267, P14429; GROLLMAN AP, 1992, 7TH P CONV BIOM STER, V1, P165; IKEJIMA M, 1990, J BIOL CHEM, V265, P21907; JONES JS, 1988, NUCLEIC ACIDS RES, V16, P7119, DOI 10.1093/nar/16.14.7119; Kaptein R, 1991, CURR OPIN STRUC BIOL, V1, P63, DOI 10.1016/0959-440X(91)90013-J; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVAL J, 1990, MUTAT RES, V233, P73, DOI 10.1016/0027-5107(90)90152-T; MAZEN A, 1989, NUCLEIC ACIDS RES, V17, P4689, DOI 10.1093/nar/17.12.4689; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; MICHAELS ML, 1991, NUCLEIC ACIDS RES, V19, P3269; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; MYLES GM, 1991, BIOCHEMISTRY-US, V30, P3834, DOI 10.1021/bi00230a005; NAVARATNAM S, 1989, J BIOL CHEM, V264, P16067; OCONNOR TR, 1989, P NATL ACAD SCI USA, V86, P5222, DOI 10.1073/pnas.86.14.5222; RYDBERG B, 1991, P NATL ACAD SCI USA, V88, P6839, DOI 10.1073/pnas.88.15.6839; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; TCHOU J, 1993, MUTAT RES, V299, P277, DOI 10.1016/0165-1218(93)90104-L; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	42	89	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26738	26744						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253809				2022-12-27	WOS:A1993MK42500106
J	LEPLEY, RA; FITZPATRICK, FA				LEPLEY, RA; FITZPATRICK, FA			IRREVERSIBLE INACTIVATION OF 5-LIPOXYGENASE BY LEUKOTRIENE-A(4) CHARACTERIZATION OF PRODUCT INACTIVATION WITH PURIFIED ENZYME AND INTACT LEUKOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; HUMAN-NEUTROPHILS; BIOSYNTHESIS INHIBITOR; SOYBEAN LIPOXYGENASE; MEMBRANE ASSOCIATION; CELLS; TRANSLOCATION; PURIFICATION; HYDROLASE; SYNTHASE	We report that leukotriene A4, the electrophilic product of 5-lipoxygenase catalysis, irreversibly inactivates the enzyme. Leukotriene A4 inhibits 5-hydroxyeicosatetraenoic acid formation by human neutrophils and differentiated granulocytic HL-60 cells in a concentration-dependent manner with IC50 values = 22.4 +/- 2.5 and 29.0 +/- 8.0 muM, respectively. Recovery of cellular enzymatic activity is negligible (<6%) following inactivation. Leukotriene A4 inactivates cellular 5-lipoxygenase without inhibiting its translocation from the cytosol to the membrane, suggesting that it impairs catalysis without impairing formation of the complex between 5-lipoxygenase and its membrane-associated activating protein. Consistent with this, leukotriene A4 inactivates purified 5-lipoxygenase from human neutrophils, via saturable, pseudo first-order kinetics with a rate constant, k(i) = 0.14 min-1 and a dissociation constant, K(i) = 2.1 +/- 0.7 muM. Purified 5-lipoxygenase incubated with [H-3]arachidonic acid incorporated a radiolabeled species that was not removed by electrophoresis under reduced denaturing conditions. Preincubation with leukotriene A4 diminished the incorporation of radiolabeled material, consistent with irreversible modification of 5-lipoxygenase by its metastable product, leukotriene A4. This unusual product inactivation mechanism may contribute to the decline in 5-lipoxygenase activity observed during catalysis.			LEPLEY, RA (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL C236,DENVER,CO 80262, USA.				NHLBI NIH HHS [HLB PO1 34303] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHARONY D, 1987, PROSTAGLANDINS, V33, P85, DOI 10.1016/0090-6980(87)90307-8; CARRIER DJ, 1988, PROSTAG LEUKOTR ESS, V34, P27, DOI 10.1016/0952-3278(88)90021-X; CHARLESON S, 1992, MOL PHARMACOL, V41, P873; CHO KS, 1969, BIOCHEMISTRY-US, V8, P2827; COFFEY M, 1992, J BIOL CHEM, V267, P570; DENIS D, 1991, J BIOL CHEM, V266, P5072; EVANS JF, 1985, J BIOL CHEM, V260, P966; EVANS JF, 1992, FEBS LETT, V297, P139, DOI 10.1016/0014-5793(92)80345-H; GILLARD J, 1989, CAN J PHYSIOL PHARM, V67, P456, DOI 10.1139/y89-073; GOETZE AM, 1985, PROSTAGLANDINS, V29, P689, DOI 10.1016/0090-6980(85)90130-3; HARTEL B, 1982, EUR J BIOCHEM, V126, P353; HILGER RA, 1992, IMMUNOLOGY, V77, P408; JONES DA, 1991, J BIOL CHEM, V266, P23510; KARGMAN S, 1992, J CELL BIOL, V119, P1701, DOI 10.1083/jcb.119.6.1701; KARGMAN S, 1991, J BIOL CHEM, V266, P23745; KARGMAN S, 1989, J BIOL CHEM, V264, P13313; KIM MR, 1989, BIOCHEM BIOPH RES CO, V164, P1384, DOI 10.1016/0006-291X(89)91823-8; KITZ R, 1962, J BIOL CHEM, V237, P3245; LECOMTE M, 1990, J BIOL CHEM, V265, P5178; LUNDBERG U, 1981, FEBS LETT, V126, P127, DOI 10.1016/0014-5793(81)81050-2; MAAS RL, 1983, P NATL ACAD SCI-BIOL, V80, P2884, DOI 10.1073/pnas.80.10.2884; MULLIEZ E, 1987, BIOCHIM BIOPHYS ACTA, V916, P13, DOI 10.1016/0167-4838(87)90205-6; NARUMIYA S, 1981, J BIOL CHEM, V256, P9583; ORNING L, 1992, J BIOL CHEM, V267, P22733; PRESCOTT SM, 1984, J BIOL CHEM, V259, P7615; RAPAPORT S, 1984, EUR J BIOCHEM, V139, P573; RAPAPORT SM, 1979, EUR J BIOCHEM, V96, P545; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; ROUZER CA, 1990, J BIOL CHEM, V265, P1436; SAMUELSSON B, 1989, J BIOL CHEM, V264, P19469; SHIMIZU T, 1984, P NATL ACAD SCI-BIOL, V81, P689, DOI 10.1073/pnas.81.3.689; SHIMIZU T, 1986, P NATL ACAD SCI USA, V83, P4175, DOI 10.1073/pnas.83.12.4175; SMITH WL, 1972, J BIOL CHEM, V247, P1038; SOK DE, 1989, BIOCHEM BIOPH RES CO, V162, P1357, DOI 10.1016/0006-291X(89)90823-1; SUN FF, 1984, BIOCHIM BIOPHYS ACTA, V794, P56, DOI 10.1016/0005-2760(84)90297-2; TAYLOR L, 1983, J BIOL CHEM, V258, P6855; VANOS CPA, 1981, BIOCHIM BIOPHYS ACTA, V663, P177, DOI 10.1016/0005-2760(81)90204-6; WISEMAN JS, 1989, BIOCHEMISTRY-US, V28, P2106, DOI 10.1021/bi00431a021; WONG A, 1988, BIOCHEMISTRY-US, V27, P6763, DOI 10.1021/bi00418a018; YOUNG SK, 1990, AM J RESP CELL MOL, V2, P523, DOI 10.1165/ajrcmb/2.6.523	40	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2627	2631						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300592				2022-12-27	WOS:A1994MV43200043
J	PODLASEK, CA; SERIANNI, AS				PODLASEK, CA; SERIANNI, AS			F-19 AND C-13 NMR-STUDIES OF POLYOL METABOLISM IN FREEZE-TOLERANT PUPAE OF HYALOPHORA-CECROPIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; GALL FLY LARVA; EUROSTA-SOLIDAGINIS; INVIVO; GLYCEROL; 3-DEOXY-3-FLUORO-D-GLUCOSE; CRYOPROTECTANTS; MONOSACCHARIDES; YEAST; COLD	Sorbitol biosynthesis and regulation in freeze tolerant pupae of Hyalophora cecropia have been investigated as a function of temperature by F-19 and C-13 nuclear magnetic resonance (NMR) spectroscopy using several C-13-labeled and/or fluorine-substituted carbohydrates. 3-Deoxy-3-fluoro-D-glucose (3DFG) was metabolized to 3-deoxy-3-fluoro-D-sorbitol (3DFS), 3-deoxy-3-fluoro-D-fructose (3DFF), and 3-deoxy-3-fluoro-D-gluconic acid (3DFGA), indicating that the enzymes required for sorbitol biosynthesis and metabolism are active in H. cecropia at warm (22-degrees-C) and cold (4 and -10-degrees-C) temperatures. Two additional metabolites were produced when pupae were injected with either 3DFG, 3DFS, 3DFF, or 3-deoxy-3-fluoro-D-mannose (3DFM). One of these was identified as 3-deoxy-3-fluoro-D-mannitol (3DFML) by C-13 NMR using [1-C-13]3DFM and [1-C-13]3DFG as metabolic probes. H. cecropia pupae injected with D-glucose labeled with C-13 at C-1, C-2, or C-3 and subsequently analyzed by C-13 NMR clearly demonstrated the ability to generate sorbitol and fructose. In contrast, gas chromatography/mass spectrometric analysis of hemolymph failed to detect sorbitol in pupae reared under natural conditions (i.e. in the absence of injected enriched sugars). Thus, although H. cecropia pupae have the enzymic machinery to biosynthesize sorbitol, they do not appear to accumulate high steady-state concentrations of this polyol over the temperature range studied. The specificity of the enzymes involved in alditol biosynthesis in H. cecropia was examined by C-13 NMR with a wide range of aldoses enriched with C-13 at C-1. Pupae were capable of converting these sugars to their corresponding [1-C-13]alditols, indicating that nonspecific dehydrogenase(s), in addition to aldose reductase, is(are) involved in polyol biosynthesis in H. cecropia pupae.	UNIV NOTRE DAME, DEPT CHEM & BIOCHEM, NOTRE DAME, IN 46556 USA	University of Notre Dame					NIGMS NIH HHS [GM 33791] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033791] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGBANYO MY, 1983, THESIS U WINDSOR WIN; ANGELOTTI T, 1987, J AM CHEM SOC, V109, P4464, DOI 10.1021/ja00249a007; ANGYAL SJ, 1979, CARBOHYD RES, V73, P9, DOI 10.1016/S0008-6215(00)85471-3; Asahina E, 1966, LOW TEMP SCI B, V24, P25; BERKOWITZ BA, 1990, J BIOL CHEM, V265, P12417; BESSELL EM, 1973, BIOCHEM J, V131, P83, DOI 10.1042/bj1310083; BESSELL EM, 1972, BIOCHEM J, V128, P199, DOI 10.1042/bj1280199; BOCK K, 1983, ADV CARBOHYD CHEM BI, V41, P27, DOI 10.1016/S0065-2318(08)60055-4; BUCHANAN GW, 1983, CAN J BIOCHEM CELL B, V61, P1260, DOI 10.1139/o83-162; CROWE JH, 1983, ARCH BIOCHEM BIOPHYS, V220, P477, DOI 10.1016/0003-9861(83)90438-1; CSUK R, 1988, ADV CARBOHYD CHEM BI, V46, P73, DOI 10.1016/S0065-2318(08)60165-1; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FOSTER AB, 1972, METHODS CARBOHYDR CH, V6, P197; HAYES ML, 1982, J AM CHEM SOC, V104, P6760; Hochachka P.W., 1984, BIOCHEMICAL ADAPTATI, P355; KENT PW, 1971, TETRAHEDRON, V27, P3887, DOI 10.1016/S0040-4020(01)98250-X; KUKAL O, 1989, J COMP PHYSIOL B, V158, P661, DOI 10.1007/BF00693004; KUKAL O, 1988, J COMP PHYSIOL B, V158, P175, DOI 10.1007/BF01075831; KWEE IL, 1987, J NEUROCHEM, V49, P428, DOI 10.1111/j.1471-4159.1987.tb02883.x; PERLIN AS, 1956, CAN J CHEM, V34, P541, DOI 10.1139/v56-075; PODLASEK CA, 1992, 29TH SOC CRY M ITH, P136; RASMUSSEN JR, 1983, CARBOHYD RES, V116, P21, DOI 10.1016/S0008-6215(00)90949-2; ROMASCHIN A, 1977, CAN J BIOCHEM CELL B, V55, P369, DOI 10.1139/o77-051; RUDOLPH AS, 1985, CRYOBIOLOGY, V22, P367, DOI 10.1016/0011-2240(85)90184-1; SERIANNI AS, 1990, J CARBOHYD CHEM, V9, P513, DOI 10.1080/07328309008543851; STOREY KB, 1988, PHYSIOL REV, V68, P27, DOI 10.1152/physrev.1988.68.1.27; STOREY KB, 1984, EUR J BIOCHEM, V142, P591, DOI 10.1111/j.1432-1033.1984.tb08327.x; STOREY KB, 1981, J COMP PHYSIOL, V144, P183, DOI 10.1007/BF00802756; STORY JM, 1983, J COMP PHYSIOL, V149, P495, DOI 10.1007/BF00690008; THOMPSON SN, 1988, INSECT BIOCHEM, V18, P21, DOI 10.1016/0020-1790(88)90032-7; ZIEGLER R, 1975, NATURE, V254, P622, DOI 10.1038/254622a0; ZIEGLER R, 1985, NATURWISSENSCHAFTEN, V72, P206, DOI 10.1007/BF01195764	32	2	2	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2521	2528						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300579				2022-12-27	WOS:A1994MV43200029
J	NIGAM, SK; GOLDBERG, AL; HO, S; ROHDE, MF; BUSH, KT; SHERMAN, MY				NIGAM, SK; GOLDBERG, AL; HO, S; ROHDE, MF; BUSH, KT; SHERMAN, MY			A SET OF ENDOPLASMIC-RETICULUM PROTEINS POSSESSING PROPERTIES OF MOLECULAR CHAPERONES INCLUDES CA2+-BINDING PROTEINS AND MEMBERS OF THE THIOREDOXIN SUPERFAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; GLUCOSE-REGULATED PROTEINS; DISULFIDE ISOMERASE; SUBCELLULAR-DISTRIBUTION; HEAT-SHOCK; RAT-LIVER; T-CELL; ERP72; GENE; IDENTIFICATION	The major proteins in the lumen of the endoplasmic reticulum (ER) are thought to function in Ca2+ sequestration or as ''molecular chaperones' in the folding and assembly of membrane or secreted proteins. Based on the ability of many chaperones to bind selectively to unfolded proteins and to dissociate from them upon ATP hydrolysis, we developed an affinity chromatography method to isolate proteins with these characteristics from pancreatic or liver ER. Seven ER proteins bound selectively to denatured protein columns and were specifically eluted by ATP (10(-6) M) but not by a nonhydrolyzable ATP analog. These proteins were identified with antibodies and microsequencing as the ER chaperone BiP (grp78), grp94, calreticulin, a novel 46-kDa protein that binds azido-ATP, as well as three members of the thioredoxin superfamily: protein-disulfide isomerase, ERp72, and a previously reported 50-kDa protein (p50). This set of seven proteins bound to and was eluted with ATP from a variety of denatured proteins, including histone, gelatin, a fetoprotein, thyroglobulin, lysozyme, casein, and IgG. The release of grp94, protein-disulfide isomerase, ERp72, calreticulin, and p50 was stimulated by Ca2+ in the presence of ATP. These proteins thus appear to function as Ca2+-dependent chaperones, which may account for the Ca2+ and ATP requirement for protein folding in the ER.	HARVARD UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, 25 SHATTUCK ST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, DIV RENAL, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; AMGEN INC, THOUSAND OAKS, CA 91320 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Amgen					NIDDK NIH HHS [R01 DK44503-01A1] Funding Source: Medline; NIGMS NIH HHS [R01 GM46147] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046147] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; BARDWELL JCA, 1993, CELL, V74, P769, DOI 10.1016/0092-8674(93)90455-Y; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; CHAUDHURI MM, 1992, BIOCHEM J, V281, P645, DOI 10.1042/bj2810645; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DORNER AJ, 1990, J BIOL CHEM, V265, P22029; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FREEDMAN RB, 1989, BIOCHEM SOC SYMP, V55, P167; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI X, 1991, MOL CELL BIOL, V11, P3446, DOI 10.1128/MCB.11.7.3446; LODISH HF, 1990, J BIOL CHEM, V265, P10893; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LU XJ, 1992, BIOCHEMISTRY-US, V31, P4205, DOI 10.1021/bi00132a008; LYTTON J, 1992, Current Opinion in Cell Biology, V4, P220, DOI 10.1016/0955-0674(92)90036-C; MACER DRJ, 1988, J CELL SCI, V91, P61; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MCCAULIFFE DP, 1992, J BIOL CHEM, V267, P2557; MICHALAK M, 1992, BIOCH J, V285; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; NIGAM SK, 1990, J CELL BIOL, V111, P197, DOI 10.1083/jcb.111.1.197; NIGAM SK, 1990, P NATL ACAD SCI USA, V87, P1296, DOI 10.1073/pnas.87.4.1296; NIGAM SK, 1989, J BIOL CHEM, V264, P16927; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PETER F, 1992, J BIOL CHEM, V267, P10631; PORUCHYNSKY MS, 1991, J CELL BIOL, V114, P651, DOI 10.1083/jcb.114.4.651; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SHERMAN MY, 1992, NATURE, V357, P167, DOI 10.1038/357167a0; SHERMAN MY, 1991, J BACTERIOL, V173, P7249, DOI 10.1128/jb.173.22.7249-7256.1991; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; TASANEN K, 1992, J BIOL CHEM, V267, P11513; VAN PN, 1989, J BIOL CHEM, V264, P17494; WADA I, 1991, J BIOL CHEM, V266, P19599; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P4406, DOI 10.1021/bi00232a006	39	259	265	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1744	1749						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294423				2022-12-27	WOS:A1994MR98800033
J	PUTTAGUNTA, S; MATHUR, M; COWIN, P				PUTTAGUNTA, S; MATHUR, M; COWIN, P			STRUCTURE OF DSG1, THE BOVINE DESMOSOMAL CADHERIN GENE ENCODING THE PEMPHIGUS FOLIACEUS ANTIGEN - EVIDENCE OF POLYMORPHISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; CYTOPLASMIC DOMAIN; N-CADHERIN; XENOPUS EMBRYOS; FAMILY; UVOMORULIN; PROTEIN; GLYCOPROTEIN; JUNCTIONS; MOUSE	The cadherin superfamily of calcium-dependent cell-cell adhesion and recognition proteins can be categorized into a number of subsets on the basis of the distinct cytoplasmic sequences of their members. Currently these families include classical cadherins, desmogleins, desmocollins, protocadherins, and the products of the Drosophila genes FAT and Dachsous. Dsg1, the prototype of the desmoglein family, is a major component of epidermal desmosomes and the antigenic target of antibodies found in the sera of patients with the blistering disease, pemphigus foliaceus. In this study, we determined the organization of the bovine DSG1 gene. This gene consists of 15 exons distributed over >37.5 kilobases of genomic DNA. A comparison of DSG1 with genes encoding classical cadherins revealed a striking conservation of exon boundaries in regions encoding the ectodomain and to a more limited extent among those encoding the cytoplasmic domain. Polymorphism was found in a sequence of DSG1 encoding protein proximal to the external face of the plasma membrane. This region is topologically equivalent to a domain of classical cadherins that harbors epitopes recognized by adhesion-disrupting antibodies. We discuss these results with regard to the evolution of the cadherin superfamily and their implications for the definition of pemphigus epitopes.	NYU MED CTR,RONALD O PERELMAN DEPT DERMATOL,550 1ST AVE,NEW YORK,NY 10016; NYU MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016; NYU MED CTR,DEPT CELL BIOL,NEW YORK,NY 10016	New York University; New York University; New York University				Cowin, Pamela/0000-0002-1827-1154	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047429] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM47429] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; ATCHISON M, 1986, P NATL ACAD SCI USA, V83, P2300, DOI 10.1073/pnas.83.8.2300; BEUTNER EH, 1964, P SOC EXP BIOL MED, V117, P505; BLAKE CCF, 1985, INT REV CYTOL, V93, P149, DOI 10.1016/S0074-7696(08)61374-1; BUXTON RS, 1993, J CELL BIOL, V121, P481, DOI 10.1083/jcb.121.3.481; COHEN SM, 1983, J BIOL CHEM, V258, P2621; COLLINS JE, 1991, J CELL BIOL, V113, P381, DOI 10.1083/jcb.113.2.381; COWIN P, 1986, CELL, V46, P1063, DOI 10.1016/0092-8674(86)90706-3; COWIN P, 1983, NATURE, V302, P148, DOI 10.1038/302148a0; COWIN P, 1993, MOL BASIS MORPHOGENE, P49; CRAIK CS, 1982, NATURE, V299, P180, DOI 10.1038/299180a0; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; DAMSKY CH, 1983, CELL, V34, P455, DOI 10.1016/0092-8674(83)90379-3; DETRICK RJ, 1990, NEURON, V4, P493, DOI 10.1016/0896-6273(90)90108-R; DIAZ L, 1989, J AM ACAD DERMATOL, P657; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; EYRE RW, 1987, J EXP MED, V165, P1719, DOI 10.1084/jem.165.6.1719; FUJIMORI T, 1990, DEVELOPMENT, V110, P97; GALLIN W, 1986, P NATL ACAD SCI USA, V84, P2808; GALLIN WJ, 1986, P NATL ACAD SCI USA, V83, P8235, DOI 10.1073/pnas.83.21.8235; GEIGER B, 1983, DIFFERENTIATION, V23, P189; GEIGER B, 1990, MORPHOREGULATORY MOL, P55; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GIUDICE GJ, 1984, J CELL BIOCHEM, V26, P35, DOI 10.1002/jcb.240260104; GOODWIN L, 1990, BIOCHEM BIOPH RES CO, V173, P1224, DOI 10.1016/S0006-291X(05)80917-9; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; HATTA M, 1991, NUCLEIC ACIDS RES, V19, P4437, DOI 10.1093/nar/19.16.4437; HOOD L, 1975, ANNU REV GENET, V9, P305, DOI 10.1146/annurev.ge.09.120175.001513; HYAFIL F, 1980, CELL, V21, P927, DOI 10.1016/0092-8674(80)90456-0; ITOH M, 1991, J CELL BIOL, V115, P1449, DOI 10.1083/jcb.115.5.1449; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KLEIN H, 1988, RECOMBINATION GENE O, P384; KOCH PJ, 1990, EUR J CELL BIOL, V53, P1; KOCH PJ, 1991, EUR J CELL BIOL, V55, P200; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; MECHANIC S, 1991, P NATL ACAD SCI USA, V88, P4476, DOI 10.1073/pnas.88.10.4476; MELLOR AL, 1983, NATURE, V306, P792, DOI 10.1038/306792a0; MIYATANI S, 1992, DEV BIOL, V89, P8443; MOSCONA AA, 1963, P NATL ACAD SCI USA, V49, P742, DOI 10.1073/pnas.49.5.742; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; NILLES LA, 1991, J CELL SCI, V99, P809; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; ODA H, 1993, J CELL BIOL, V121, P1133, DOI 10.1083/jcb.121.5.1133; OGOU SI, 1983, J CELL BIOL, V97, P944, DOI 10.1083/jcb.97.3.944; OSAWA M, 1990, J CELL BIOL, V111, P1645; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; OZAWA M, 1991, MECH DEVELOP, V33, P49; PARKER AE, 1991, J BIOL CHEM, V266, P10438; PIEPENHAGEN PA, 1993, J CELL SCI, V104, P751; RINGWALD M, 1991, NUCLEIC ACIDS RES, V19, P6533, DOI 10.1093/nar/19.23.6533; RINGWALD M, 1987, EMBO J, V6, P3647, DOI 10.1002/j.1460-2075.1987.tb02697.x; RUPPERT S, 1984, NATURE, V308, P554, DOI 10.1038/308554a0; SAFELL JL, 1909, J CELL BIOL, V118, P663; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANO K, 1993, EMBO J, V12, P2249, DOI 10.1002/j.1460-2075.1993.tb05878.x; SORKIN BC, 1991, P NATL ACAD SCI USA, V88, P11545, DOI 10.1073/pnas.88.24.11545; SORKIN BC, 1988, P NATL ACAD SCI USA, V85, P7617, DOI 10.1073/pnas.85.20.7617; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEINBERG MS, 1962, P NATL ACAD SCI USA, V48, P1577, DOI 10.1073/pnas.48.9.1577; SUZUKI S, 1991, CELL REGUL, V2, P261, DOI 10.1091/mbc.2.4.261; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TRAUT TW, 1988, P NATL ACAD SCI USA, V85, P2944, DOI 10.1073/pnas.85.9.2944; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; VESTWEBER D, 1984, EXP CELL RES, V152, P169, DOI 10.1016/0014-4827(84)90241-6; WHEELER GN, 1991, P NATL ACAD SCI USA, V88, P4796, DOI 10.1073/pnas.88.11.4796	71	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1949	1955						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294446				2022-12-27	WOS:A1994MR98800062
J	ROBERTSON, DL; HILTON, S; WONG, KR; KOEPKE, A; BUCKLEY, JT				ROBERTSON, DL; HILTON, S; WONG, KR; KOEPKE, A; BUCKLEY, JT			INFLUENCE OF ACTIVE-SITE AND TYROSINE MODIFICATION ON THE SECRETION AND ACTIVITY OF THE AEROMONAS-HYDROPHILA LIPASE ACYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LECITHIN-CHOLESTEROL ACYLTRANSFERASE; OLIGONUCLEOTIDE-DIRECTED MUTAGENESIS; SUBSTRATE-SPECIFICITY; PURIFICATION; PHOSPHOLIPASE-A2; SALMONICIDA; ACTIVATION; EXPRESSION; MECHANISM; AEROLYSIN	Aeromonas sp. secrete a lipase/acyltransferase that shares several properties with the mammalian plasma enzyme lecithin:cholesterol acyltransferase. Reaction of the enzyme with tetranitromethane led to modification of 2 tyrosines and a nearly 80% decline in enzyme activity. Replacing Tyr230 with Phe altered the activity of the enzyme in the same way as did treatment with tetranitromethane. Unlike the wild type enzyme, which preferentially hydrolyzes the 2-position acyl chain of phosphatidylcholine, the Y230F mutant enzyme did not discriminate between the 1- and 2-positions of the phospholipid. Tyr230 may be necessary to correctly position phospholipid substrates at the active site. Several amino acids around the active site Ser16 of the lipase were also changed. Replacing Ser18 with Gly; bringing the enzyme' s sequence into line with the ''lipase consensus sequence,'' resulted in reduced secretion of the protein and complete loss of activity. Changing this serine to Val led to an inactive protein that was not secreted at all. Substituting Phe'' in the hydrophobic region of the consensus sequence with Ser also prevented secretion, although the mutant protein appeared to be active. The Aeromonas lipase may represent a distinct group of lipolytic enzymes which have a novel active site structure.	UNIV VICTORIA,DEPT BIOCHEM & MICROBIOL,POB 3055,VICTORIA V8W 3P6,BC,CANADA; MAX PLANCK INST MOLEK NEUROENDOKRINOL,W-3400 GOTTINGEN,GERMANY	University of Victoria; Max Planck Society								ANDERSSON H, 1991, P NATL ACAD SCI USA, V88, P9751, DOI 10.1073/pnas.88.21.9751; ARON L, 1978, J BIOL CHEM, V253, P7220; BERG OG, 1991, BIOCHEMISTRY-US, V30, P7283, DOI 10.1021/bi00243a034; BONELLI FS, 1989, J BIOL CHEM, V264, P14723; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; BUCKLEY JT, 1983, BIOCHEMISTRY-US, V22, P5490, DOI 10.1021/bi00293a006; BUCKLEY JT, 1982, J BIOL CHEM, V257, P3320; BUCKLEY JT, 1982, BIOCHEMISTRY-US, V21, P6699, DOI 10.1021/bi00269a013; BUCKLEY JT, 1990, BIOCHEM CELL BIOL, V68, P221, DOI 10.1139/o90-029; CHO HS, 1993, J BIOL CHEM, V268, P9238; DEREWENDA ZS, 1991, BIOCHEM CELL BIOL, V69, P842, DOI 10.1139/o91-125; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GREEN MJ, 1990, BIOCHEMISTRY-US, V29, P2177, DOI 10.1021/bi00460a031; HILTON S, 1990, BIOCHEMISTRY-US, V29, P9072, DOI 10.1021/bi00490a026; HILTON S, 1991, J BIOL CHEM, V266, P997; KUIPERS OP, 1990, BIOCHEMISTRY-US, V29, P6094, DOI 10.1021/bi00477a029; KUIPERS OP, 1989, PROTEIN ENG, V2, P467, DOI 10.1093/protein/2.6.467; MILLER JH, 1972, EXPT MOL GENETICS, P341; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; ROBERTSON DL, 1992, BIOCHEMISTRY-US, V31, P4974, DOI 10.1021/bi00136a009; Sambrook J, 1989, MOL CLONING LABORATO; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; SOKOLOVS.M, 1966, BIOCHEMISTRY-US, V5, P3582, DOI 10.1021/bi00875a029; SUBBAIAH PV, 1985, J BIOL CHEM, V260, P5308; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TABOR S, 1990, CURRENT PROTOCOLS MO, P1621; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANOORT MG, 1989, BIOCHEMISTRY-US, V28, P9278, DOI 10.1021/bi00450a007; WONG KR, 1989, J BACTERIOL, V171, P2523, DOI 10.1128/jb.171.5.2523-2527.1989	33	25	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2146	2150						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294469				2022-12-27	WOS:A1994MR98800090
J	SAKAI, J; HOSHINO, A; TAKAHASHI, S; MIURA, Y; ISHII, H; SUZUKI, H; KAWARABAYASI, Y; YAMAMOTO, T				SAKAI, J; HOSHINO, A; TAKAHASHI, S; MIURA, Y; ISHII, H; SUZUKI, H; KAWARABAYASI, Y; YAMAMOTO, T			STRUCTURE, CHROMOSOME LOCATION, AND EXPRESSION OF THE HUMAN VERY-LOW-DENSITY LIPOPROTEIN RECEPTOR GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL REGULATORY ELEMENT; CELL LINE THP-1; MESSENGER-RNA; LDL RECEPTOR; DNA; PROTEIN; PROMOTER; POLYMERASE; SEQUENCE; AMPLIFICATION	Isolation and characterization of cDNAs encoding human very low density lipoprotein (VLDL) receptor revealed the presence of two forms of the receptor: one consists of five domains that resemble the low density lipoprotein (LDL) receptor, and a variant form lacks an O-linked sugar domain. More than 96% of amino acids in the human and rabbit VLDL receptors are identical, whereas those in the LDL receptors are less conserved between the two species (76%). The human VLDL receptor gene contains 19 exons spanning approximately 40 kilobases. The exon-intron organization of the gene is almost the same as that of the LDL receptor gene, except for an extra exon that encodes an additional repeat in the ligand binding domain of the VLDL receptor. Analysis of DNA from human-rodent hybrid cells revealed that the gene is located on chromosome 9. Although the 5'-flanking region of the VLDL receptor gene contains two copies of a sterol regulatory element-1 like sequence, the levels of mRNA for the receptor in THP-1 human monocytic leukemia cells were unchanged by sterols. The 5'-untranslated region of the receptor mRNA contains a polymorphic triplet repeat found also in the fragile X syndrome gene.	TOHOKU UNIV,GENE RES CTR,1-1 TSUTSUMIDORI AMAMIYA,AOBA KU,SENDAI 981,JAPAN	Tohoku University				Sakai, Juro/0000-0003-4043-1035				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIS CG, 1986, J BIOL CHEM, V261, P2828; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HEMMI H, 1985, JPN J CANCER RES, V76, P345; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; IGGO R, 1989, P NATL ACAD SCI USA, V86, P6211, DOI 10.1073/pnas.86.16.6211; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KLOCK G, 1987, NATURE, V329, P734, DOI 10.1038/329734a0; KOVANEN PT, 1981, P NATL ACAD SCI-BIOL, V78, P1396, DOI 10.1073/pnas.78.3.1396; KUMABE T, 1992, NUCLEIC ACIDS RES, V20, P2598, DOI 10.1093/nar/20.10.2598; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LINDGREN V, 1985, P NATL ACAD SCI USA, V82, P8567, DOI 10.1073/pnas.82.24.8567; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; PELHAM HRB, 1982, CELL, V30, P517, DOI 10.1016/0092-8674(82)90249-5; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; RUSSELL DW, 1983, P NATL ACAD SCI-BIOL, V80, P7501, DOI 10.1073/pnas.80.24.7501; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEIDEREIT C, 1984, P NATL ACAD SCI-BIOL, V81, P3029, DOI 10.1073/pnas.81.10.3029; SMITH JR, 1990, J BIOL CHEM, V265, P2306; SMITH JR, 1988, J BIOL CHEM, V263, P18480; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; YAMAMOTO T, 1986, SCIENCE, V232, P1230, DOI 10.1126/science.3010466; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; 1993, CELL, V72, P971	44	255	263	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2173	2182						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294473				2022-12-27	WOS:A1994MR98800094
J	BENNETT, BD; COWLEY, S; JIANG, SX; LONDON, R; DENG, BJ; GRABAREK, J; GROOPMAN, JE; GOEDDEL, DV; AVRAHAM, H				BENNETT, BD; COWLEY, S; JIANG, SX; LONDON, R; DENG, BJ; GRABAREK, J; GROOPMAN, JE; GOEDDEL, DV; AVRAHAM, H			IDENTIFICATION AND CHARACTERIZATION OF A NOVEL TYROSINE KINASE FROM MEGAKARYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEGAKARYOBLASTIC CELL-LINE; C-KIT LIGAND; GROWTH-FACTOR; GENE-PRODUCT; SI-LOCUS; PROTEIN; EXPRESSION; SRC; RECEPTOR; DIFFERENTIATION	Protein-tyrosine kinases play pivotal roles in cell signal transduction. We have isolated a cDNA clone encoding a novel human intracytoplasmic tyrosine kinase, termed matk (megakaryocyte-associated tyrosine kinase). Expression of matk mRNA was predominantly found in cells of megakaryocytic lineage. The matk cDNA clone encodes a polypeptide of 527 amino acids and has closest sequence similarity to the csk tyrosine kinase. Sequence comparisons also indicate that matk contains src homology region 2 and 3 domains but lacks the NH2-terminal myristylation signal, the negative regulatory tyrosine (Tyr-527), and the autophosphorylation site (Tyr-416) corresponding to those found in src. Antibodies raised against the NH2 terminus of matk immunoprecipitated a 60-kDa protein from the CMK human megakaryocyte cell line. Expression of matk mRNA was up-regulated in megakaryocytic cells induced to differentiate by the phorbol ester. Based on its restriction in expression and its modulation during in vitro differentiation, it is likely that matk participates in signal transduction during megakaryocytopoiesis.	HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,DIV HEMATOL ONCOL,BOSTON,MA 02215; GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080	Harvard University; Harvard Medical School; Roche Holding; Genentech				Cowley, Sally/0000-0003-0297-6675; Avraham, Hava/0000-0002-7545-3640	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042112, P50HL033774] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43510, HL42112, HL33774] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; AVRAHAM H, 1992, BLOOD, V79, P365; AVRAHAM H, 1992, BLOOD, V80, P1679; AVRAHAM H, 1992, INT J CELL CLONING, V10, P70, DOI 10.1002/stem.5530100203; BENNETT BD, 1991, J BIOL CHEM, V266, P23060; BOKFALVI A, 1992, BLOOD, V80, P1905; BRAUNINGER A, 1992, GENE, V110, P205, DOI 10.1016/0378-1119(92)90649-A; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DEBILI N, 1992, BLOOD, V80, P3022; DYMECKI SM, 1992, J BIOL CHEM, V267, P4815; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; FURTH ME, 1987, ONCOGENE, V1, P47; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEGECK S, 1993, P NATL ACAD SCI USA, V90, P669; HOFFMAN R, 1989, BLOOD, V74, P1196; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KOMATSU N, 1989, BLOOD, V74, P42; KONOPKA JB, 1984, J VIROL, V51, P223, DOI 10.1128/JVI.51.1.223-232.1984; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3316; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBEAN MM, 1987, MOL CELL BIOL, V7, P2267; LONG MW, 1993, STEM CELLS, V11, P33, DOI 10.1002/stem.5530110107; MANIATIS T, 1992, MOL CLONING; MARU Y, 1990, ONCOGENE RES, V5, P199; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; PARTANEN J, 1991, ONCOGENE, V6, P2013; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SATO T, 1987, EXP HEMATOL, V15, P495; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TANAKA H, 1989, BRIT J HAEMATOL, V73, P18, DOI 10.1111/j.1365-2141.1989.tb00212.x; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YOUNG JC, 1984, J VIROL, V52, P913, DOI 10.1128/JVI.52.3.913-918.1984; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	50	86	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1068	1074						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288563				2022-12-27	WOS:A1994MR22000048
J	BERGSTEN, P; MOURA, AS; ATWATER, I; LEVINE, M				BERGSTEN, P; MOURA, AS; ATWATER, I; LEVINE, M			ASCORBIC-ACID AND INSULIN-SECRETION IN PANCREATIC-ISLETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-AMIDATING MONOOXYGENASE; BETA-CELL; VITAMIN-C; DEHYDROASCORBIC ACID; DIABETES-MELLITUS; HUMAN NEUTROPHILS; CHROMAFFIN CELLS; RAT PANCREAS; HUMAN-PLASMA; GLUCOSE	The effect of ascorbic acid on glucose-induced insulin release from single pancreatic islets was measured using a new, ultra-sensitive enzyme-linked immunosorbent insulin assay. Within 20 s ascorbic acid inhibited insulin secretion; inhibition was dose dependent and completely reversible. There was a 50% inhibition of the secretory response with 200 muM ascorbic acid and 90% inhibition with 400 muM ascorbic acid. The decrease in insulin secretion was recorded as a reduction of the amplitudes of the fast insulin transients, which give rise to the oscillatory nature of insulin secretion. The inhibition of glucose-induced insulin release by ascorbic acid was associated with hyperpolarization of the pancreatic beta-cell. Suppression of glucose-induced membrane depolarization was evident after 20 s, was dose dependent, and was completely reversible. The data here may provide the first explanation of why plasma ascorbate concentrations are tightly controlled.	NIDDKD,CELL BIOL & GENET LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ATWATER I, 1978, J PHYSIOL-LONDON, V278, P117, DOI 10.1113/jphysiol.1978.sp012296; ATWATER I, 1976, J PHYSIOL-PARIS, V72, P769; BALCKE P, 1984, ANN INTERN MED, V101, P344, DOI 10.7326/0003-4819-101-3-344; BERGSTEN P, 1993, DIABETES, V42, P670, DOI 10.2337/diabetes.42.5.670; BERGSTEN P, 1993, BIOCHEM BIOPH RES CO, V192, P1182, DOI 10.1006/bbrc.1993.1541; BERGSTEN P, 1984, ENDOCRINOLOGY, V114, P1854, DOI 10.1210/endo-114-5-1854; CHEN MS, 1983, DIABETES, V32, P1078, DOI 10.2337/diabetes.32.11.1078; DHARIWAL KR, 1991, AM J CLIN NUTR, V54, P712, DOI 10.1093/ajcn/54.4.712; DILIBERTO EJ, 1991, AM J CLIN NUTR, V54, pS1163, DOI 10.1093/ajcn/54.6.1163s; EIPPER BA, 1991, AM J CLIN NUTR, V54, pS1153, DOI 10.1093/ajcn/54.6.1153s; Friedman GJ, 1940, J CLIN INVEST, V19, P685, DOI 10.1172/JCI101171; GARDINER TW, 1985, BRAIN RES, V344, P181, DOI 10.1016/0006-8993(85)91207-7; GOODNER CJ, 1988, DIABETES, V37, P1316, DOI 10.2337/diabetes.37.10.1316; GRAPENGIESSER E, 1988, BIOCHEM BIOPH RES CO, V151, P1299, DOI 10.1016/S0006-291X(88)80503-5; HEDESKOV CJ, 1980, PHYSIOL REV, V60, P442, DOI 10.1152/physrev.1980.60.2.442; HELLMAN B, 1965, ANN NY ACAD SCI, V131, P541, DOI 10.1111/j.1749-6632.1965.tb34819.x; IRWIN MI, 1976, J NUTR, V106, P823; KITABCHI AE, 1967, NATURE, V215, P1385, DOI 10.1038/2151385a0; KNOTH J, 1987, J BIOL CHEM, V262, P14036; KOHNERT KD, 1979, MOL CELL ENDOCRINOL, V16, P205, DOI 10.1016/0303-7207(79)90027-3; LANG DA, 1979, NEW ENGL J MED, V301, P1023, DOI 10.1056/NEJM197911083011903; LEVINE M, 1985, VITAM HORM, V42, P1; LEVINE M, 1983, J BIOL CHEM, V258, P3111; LEVINE M, 1986, NEW ENGL J MED, V314, P892, DOI 10.1056/NEJM198604033141407; LIU TZ, 1982, CLIN CHEM, V28, P2225; MACKIN RB, 1987, GEN COMP ENDOCR, V67, P263, DOI 10.1016/0016-6480(87)90156-0; MALTESE JY, 1989, BIOCHEM BIOPH RES CO, V158, P244, DOI 10.1016/S0006-291X(89)80204-9; MCLENNAN S, 1988, DIABETES, V37, P359, DOI 10.2337/diabetes.37.3.359; MELETHIL S, 1986, INT J PHARM, V31, P83, DOI 10.1016/0378-5173(86)90216-4; ORAHILLY S, 1988, NEW ENGL J MED, V318, P1225, DOI 10.1056/NEJM198805123181902; OUAFIK LH, 1986, BIOCHEM BIOPH RES CO, V138, P179, DOI 10.1016/0006-291X(86)90263-9; PATTERSON JW, 1950, J BIOL CHEM, V183, P81; Piesse J. W., 1985, International Clinical Nutrition Review, V5, P110; Ralli EP, 1938, J CLIN INVEST, V17, P765, DOI 10.1172/JCI101006; RIVERS JM, 1987, ANN NY ACAD SCI, V498, P445, DOI 10.1111/j.1749-6632.1987.tb23780.x; SAUBERLICH HE, 1975, ANN NY ACAD SCI, V258, P438, DOI 10.1111/j.1749-6632.1975.tb29302.x; SCHARFMANN R, 1988, ENDOCRINOLOGY, V123, P1329, DOI 10.1210/endo-123-3-1329; SCOTT AM, 1981, DIABETOLOGIA, V21, P470; SOM S, 1981, METABOLISM, V30, P572, DOI 10.1016/0026-0495(81)90133-5; STANKOVA L, 1984, METABOLISM, V33, P347, DOI 10.1016/0026-0495(84)90197-5; STEIN HB, 1976, ANN INTERN MED, V84, P385, DOI 10.7326/0003-4819-84-4-385; TOGGENBURGER G, 1981, BIOCHIM BIOPHYS ACTA, V646, P433, DOI 10.1016/0005-2736(81)90312-6; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; WAND GS, 1985, METABOLISM, V34, P1044, DOI 10.1016/0026-0495(85)90077-0; WASHKO P, 1992, J BIOL CHEM, V267, P23568; WASHKO P, 1991, AM J CLIN NUTR, V54, pS1221, DOI 10.1093/ajcn/54.6.1221s; WASHKO PW, 1989, ANAL BIOCHEM, V181, P276, DOI 10.1016/0003-2697(89)90243-1; ZHOU A, 1991, DIABETOLOGIA, V34, P839, DOI 10.1007/BF00408361; ZHOU A, 1991, BIOCHEM J, V274, P739, DOI 10.1042/bj2740739	49	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1041	1045						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288558				2022-12-27	WOS:A1994MR22000043
J	HENSON, JW				HENSON, JW			REGULATION OF THE GLIAL-SPECIFIC JC VIRUS EARLY PROMOTER BY THE TRANSCRIPTION FACTOR-SP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; GENE-EXPRESSION; BRAIN-CELLS; PROTEIN; SP1; DNA; ENHANCER; SEQUENCES; SITES; MOUSE	The regulation of glial-specific JC virus early gene expression was addressed by functional dissection of a previously uncharacterized form of the JC virus promoter (MH-1). The MH-1 promoter directed 31-fold higher reporter gene expression in U87MG glioma cells than in HeLa cells in a transient transfection assay. Transfection of promoter constructs containing proximal or proximal plus upstream regions revealed that reporter gene expression was activated by both proximal and tandem repeat regions in glioma cells. The proximal region contains a guanine-rich sequence, the GA box, which was found to regulate the promoter, and was recognized specifically by the transcription factor Spl. The GA box is also present in the promoters of three glial-specific cellular genes. Together with paired AP-1 and NF-1 sites in the tandem repeats, the GA box is part of a motif that is conserved between several glial-specific promoters, and is thus a potential determinant of glial-specific gene expression. These results delineate the promoter regions required for activation of the MH-I JC virus promoter, suggest a new determinant of glial specificity, and establish a model for the investigation of combinatorial activation of a glial-specific viral promoter.			HENSON, JW (corresponding author), MASSACHUSETTS GEN HOSP,MOLEC NEUROONCOL LAB,BLDG 149,13TH ST,BOSTON,MA 02129, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001650] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 01650] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHMED S, 1990, J BIOL CHEM, V265, P13899; AMEMIYA K, 1992, J BIOL CHEM, V267, P14204; DEVINEBEACH K, 1990, J BIOL CHEM, V265, P13830; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FEIGENBAUM L, 1992, J VIROL, V66, P1176, DOI 10.1128/JVI.66.2.1176-1182.1992; GENCIC S, 1990, J NEUROSCI, V10, P117; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; HENSON J, 1992, ANN NEUROL, V32, P72, DOI 10.1002/ana.410320112; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KENNEY S, 1984, SCIENCE, V226, P1337, DOI 10.1126/science.6095453; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KINGSTON RE, 1991, CURRENT PROTOCOLS MO; KUMAR KU, 1993, J VIROL, V67, P572, DOI 10.1128/JVI.67.1.572-576.1993; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; MARTIN JD, 1985, J VIROL, V53, P306, DOI 10.1128/JVI.53.1.306-311.1985; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; TADA H, 1992, J VIROL, V66, P6885, DOI 10.1128/JVI.66.12.6885-6892.1992; TAMURA T, 1988, BIOCHEM BIOPH RES CO, V157, P419, DOI 10.1016/S0006-291X(88)80265-1; WEGNER M, 1993, P NATL ACAD SCI USA, V90, P4743, DOI 10.1073/pnas.90.10.4743	23	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1046	1050						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288559				2022-12-27	WOS:A1994MR22000044
J	WUYTACK, F; PAPP, B; VERBOOMEN, H; RAEYMAEKERS, L; DODE, L; BOBE, R; ENOUF, J; BOKKALA, S; AUTHI, KS; CASTEELS, R				WUYTACK, F; PAPP, B; VERBOOMEN, H; RAEYMAEKERS, L; DODE, L; BOBE, R; ENOUF, J; BOKKALA, S; AUTHI, KS; CASTEELS, R			A SARCO ENDOPLASMIC-RETICULUM CA2+-ATPASE 3-TYPE CA2+ PUMP IS EXPRESSED IN PLATELETS, IN LYMPHOID-CELLS, AND IN MAST-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG SMOOTH-MUSCLE; SARCOPLASMIC-RETICULUM; CA-2+-TRANSPORT ATPASE; PLASMA-MEMBRANE; CALCIUM-PUMP; CA-2+ PUMP; ISOFORM; PHOSPHOLAMBAN; CA-2+-ATPASE; ANTIBODIES	An organellar-type of Ca2+ pump formerly detected by means of its phosphoprotein intermediate in platelets and in lymphoid cells, and which runs in acid gels at 97 kDa, is now characterized as sarco/endoplasmic reticulum Ca2+ ATPase 3 (SERCA3). SERCA3 is co-expressed in these cells along with the housekeeping SERCA2b. This conclusion is based on the following observations. 1) Tryptic digestion the phosphoprotein intermediate of SERCA3 expressed in COS cells yields a phosphorylated fragment of about 80 kDa, which can be clearly distinguished from the 57-kDa fragments formed in the SERCA1 and SERCA2 pumps. This 80-kDa fragment comigrates with a similar phosphoprotein fragment previously observed in human platelets (Papp, B., Enyedi, A., Paszty, K., Kovacs, T., Sarkadi, B., Gardos, G., Wuytack, F., and Enouf, J. (1992) Biochem. J. 288, 297-302). 2) An antiserum directed against an NH2-terminal SERCA3-specific peptide (N89) reacts with SERCA3 expressed in COS cells and with the 97-kDa protein in rat platelets and the corresponding protein in human platelets. Likewise an antiserum against the rat SERCA3 terminus (C90) binds to SERCA3 expressed in COS cells and to the 97-kDa band in rat platelets, but it does not recognize the human platelet pump. In conformity with the predicted absence of the T1 tryptic cleavage site in SERCA3, the autophosphorylated aspartyl residue and the COOH-terminal epitope were co-localized on the 80-kDa fragment. 3) The co-expression of nearly equal levels of SERCA3 and SERCA2b messengers in human lymphoblastoid Jurkat cells and in proliferating rat mucosal mast cells was also demonstrated by reverse transcriptase polymerase chain reaction.	HOP LARIBOISIERE,INSERM,U348,F-75010 PARIS,FRANCE; THROMBOSIS RES INST,LONDON SW3 6LR,ENGLAND	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Thrombosis Research Institute	WUYTACK, F (corresponding author), CATHOLIC UNIV LEUVEN,FYSIOL LAB,CAMPUS GASTHUISBERG,HERESTR,B-3000 LOUVAIN,BELGIUM.		BOBE, Regis/F-4951-2016	BOBE, Regis/0000-0002-8225-9117; Papp, Bela/0000-0002-5025-3087				ANDERSEN JP, 1992, J BIOL CHEM, V267, P2767; ANDERSEN JP, 1986, J MEMBRANE BIOL, V93, P85, DOI 10.1007/BF01871021; BOBE R, 1994, J BIOL CHEM, V269, P1417; BURK SE, 1989, J BIOL CHEM, V264, P18561; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; DEJAEGERE S, 1993, BIOCHIM BIOPHYS ACTA, V1173, P2188; EGGERMONT JA, 1990, BIOCHEM J, V271, P649, DOI 10.1042/bj2710649; EGGERMONT JA, 1990, BIOCHEM J, V266, P901; ENOUF J, 1989, BIOCHEM J, V263, P547, DOI 10.1042/bj2630547; ENOUF J, 1992, BIOCHEM J, V286, P135, DOI 10.1042/bj2860135; GUNTESKIHAMBLIN AM, 1992, BIOCHEMISTRY-US, V31, P700; HACK N, 1988, BIOCHEM J, V250, P355, DOI 10.1042/bj2500355; HARLOW E, 1992, ANTIBODIES LABORATOR; JORGENSEN AO, 1988, CELL MOTIL CYTOSKEL, V9, P164, DOI 10.1002/cm.970090208; LYTTON J, 1988, J BIOL CHEM, V263, P15024; MACLENNAN DH, 1992, ANN NY ACAD SCI, V671, P1, DOI 10.1111/j.1749-6632.1992.tb43779.x; MISSIAEN L, 1992, INT ENCY PHARM THERA, V139, P347; PAPP B, 1992, BIOCHEM J, V288, P297, DOI 10.1042/bj2880297; PAPP B, 1993, BIOCHEM J, V295, P685, DOI 10.1042/bj2950685; PAPP B, 1991, J BIOL CHEM, V266, P14593; STEWART PS, 1976, J BIOL CHEM, V251, P712; VALANT PA, 1992, J MEMBRANE BIOL, V130, P63; VERBOOMEN H, 1992, BIOCHEM J, V286, P591, DOI 10.1042/bj2860591; WUYTACK F, 1989, BIOCHEM J, V257, P117, DOI 10.1042/bj2570117; WUYTACK F, 1989, BIOCHEM J, V264, P765, DOI 10.1042/bj2640765; WUYTACK F, 1992, J BIOENERG BIOMEMBR, V24, P285; ZUBRZYCKAGAARN E, 1984, J BIOENERG BIOMEMBR, V16, P441, DOI 10.1007/BF00743238	27	195	197	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1410	1416						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288608				2022-12-27	WOS:A1994MR22000099
J	YONESAKI, T				YONESAKI, T			THE PURIFICATION AND CHARACTERIZATION OF GENE-59 PROTEIN FROM BACTERIOPHAGE-T4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETIC-RECOMBINATION; UVSX-PROTEIN; AFFINITY-CHROMATOGRAPHY; DNA-REPLICATION; STRANDED-DNA; T4; SPECIFICITY; MUTATIONS; FILAMENTS; BINDING	Gene 59 of bacteriophage T4 is involved in genetic recombination and recombination-dependent DNA replication. We purified the protein encoded by gene 59 after cloning the gene in an expression vector. The molecular weight and the sequence of seven N-terminal amino acids of the protein were consistent with the nucleotide sequence of the gene (Hahn, S., Kruse, U., and Ruger, W. (1986) Nucleic Acids Res. 14, 9311-9327). The purified 59 protein appeared to be a monomer under nondenaturing conditions, and it bound to single-stranded DNA in preference to double-stranded DNA. The protein could bind to a 24-nucleotide-long single-stranded DNA molecule that had previously bound either 32 protein (single-stranded DNA-binding protein) or uvsY protein (enhancer of uvsX protein), but it would not bind to this DNA if it had previously bound uvsX protein (synaptase). The binding occurred rapidly with 32 protein-bound DNA and slowly with uvsY protein-bound DNA. Accordingly, 32 protein bound specifically to an agarose matrix containing immobilized 59 protein. The 41 protein (DNA helicase) also bound specifically to this agarose matrix.			YONESAKI, T (corresponding author), OSAKA UNIV,COLL GEN EDUC,DEPT BIOL,TOYONAKA,OSAKA 560,JAPAN.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024020, R01GM024020] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24020] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROKER TR, 1971, J MOL BIOL, V60, P131, DOI 10.1016/0022-2836(71)90453-0; CHA TA, 1988, CANCER CELL, V6, P1; CUNNINGHAM RP, 1977, VIROLOGY, V80, P67, DOI 10.1016/0042-6822(77)90381-6; CUPIDO M, 1980, MUTAT RES, V70, P131, DOI 10.1016/0027-5107(80)90152-9; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; FORMOSA T, 1984, COLD SPRING HARB SYM, V49, P363, DOI 10.1101/SQB.1984.049.01.043; FORMOSA T, 1986, J BIOL CHEM, V261, P6107; FREITAG N, 1988, J BIOL CHEM, V263, P19525; GRIFFITH J, 1985, J BIOL CHEM, V260, P4484; HAHN S, 1986, NUCLEIC ACIDS RES, V14, P9311, DOI 10.1093/nar/14.23.9311; HARRIS LD, 1989, J MOL BIOL, V206, P19, DOI 10.1016/0022-2836(89)90520-2; HASHIMOTO K, 1991, J BIOL CHEM, V266, P4883; KODADEK T, 1989, J BIOL CHEM, V264, P16451; LIU CC, 1981, J BIOL CHEM, V256, P2813; MINAGAWA T, 1978, VIROLOGY, V91, P222, DOI 10.1016/0042-6822(78)90371-9; MIZUUCHI K, 1982, CELL, V29, P357, DOI 10.1016/0092-8674(82)90152-0; MOSIG G, 1987, ANNU REV GENET, V21, P347, DOI 10.1146/annurev.ge.21.120187.002023; NEWPORT JW, 1981, J MOL BIOL, V145, P105, DOI 10.1016/0022-2836(81)90336-3; PRASHAD N, 1972, J MOL BIOL, V70, P617, DOI 10.1016/0022-2836(72)90562-1; SHAH DB, 1976, J VIROL, V17, P175, DOI 10.1128/JVI.17.1.175-182.1976; TOMIZAWA JI, 1966, J MOL BIOL, V21, P247, DOI 10.1016/0022-2836(66)90095-7; WAKEM LP, 1981, VIROLOGY, V112, P472; WU JR, 1984, J VIROL, V52, P1028, DOI 10.1128/JVI.52.3.1028-1031.1984; WU R, 1975, J VIROL, V16, P5, DOI 10.1128/JVI.16.1.5-16.1975; YONESAKI T, 1989, J BIOL CHEM, V264, P7814; YONESAKI T, 1987, GENETICS, V115, P219; YONESAKI T, 1985, EMBO J, V4, P3321, DOI 10.1002/j.1460-2075.1985.tb04083.x; YONESAKI T, 1984, Memoirs of the Faculty of Science Kyoto University Series of Biology, V9, P87	30	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1284	1289						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288591				2022-12-27	WOS:A1994MR22000081
J	CADENA, DL; CHAN, CL; GILL, GN				CADENA, DL; CHAN, CL; GILL, GN			THE INTRACELLULAR TYROSINE KINASE DOMAIN OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR UNDERGOES A CONFORMATIONAL CHANGE UPON AUTOPHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDUCED INTERNALIZATION; FACTOR EGF RECEPTOR; SELF-PHOSPHORYLATION; CARBOXYL TERMINUS; BINDING; DIMERIZATION; ACTIVATION; SITES; IDENTIFICATION; AGGREGATION	The intracellular portion of the epidermal growth factor receptor consists of a tyrosine kinase domain of approximately 290 amino acids and a COOH-terminal regulatory domain of approximately 230 amino acids that contains five sites of autophosphorylation. The effect of autophosphorylation on the conformation of the intracellular domain has been analyzed using gel filtration. Both phosphorylated and dephosphorylated forms of the intracellular domain exist as monomers and as dimers and appear to have an extended conformation. The Stokes' radii of phosphorylated monomers and dimers were larger than those of the dephosphorylated forms, indicating that the dephosphorylated form is more compact. These results indicate that a significant conformational change occurs in the intracellular portion of the epidermal growth factor receptor upon tyrosine autophosphorylation.	UNIV CALIF SAN DIEGO,SCH MED,DEPT MED 0650,9500 GILMAN DR,LA JOLLA,CA 92093	University of California System; University of California San Diego					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013149, R37DK013149, T32DK007044] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK13149, DK07044] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANALS F, 1992, BIOCHEMISTRY-US, V31, P4493, DOI 10.1021/bi00133a016; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHANG CP, 1991, J BIOL CHEM, V266, P23467; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COCHET C, 1988, J BIOL CHEM, V263, P3290; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERBERG FW, 1993, IN PRESS PROTEIN ENG; HSU CYJ, 1991, J BIOL CHEM, V266, P603; HSU CYJ, 1990, CELL GROWTH DIFFER, V1, P191; HSUAN JJ, 1989, BIOCHEM J, V262, P659, DOI 10.1042/bj2620659; HUBLER L, 1989, J BIOL CHEM, V264, P1558; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAX I, 1991, J BIOL CHEM, V266, P13828; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MCGLYNN E, 1992, EUR J BIOCHEM, V207, P265, DOI 10.1111/j.1432-1033.1992.tb17047.x; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WEDEGAERTNER PB, 1992, ARCH BIOCHEM BIOPHYS, V292, P273, DOI 10.1016/0003-9861(92)90079-C; WEDEGAERTNER PB, 1989, J BIOL CHEM, V264, P11346; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	30	70	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					260	265						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276804				2022-12-27	WOS:A1994MR21900047
J	CORRELL, CC; EDWARDS, PA				CORRELL, CC; EDWARDS, PA			MEVALONIC ACID-DEPENDENT DEGRADATION OF 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE IN-VIVO AND IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; STEROL-ENHANCED DEGRADATION; MEMBRANE-BOUND DOMAIN; ENDOPLASMIC-RETICULUM; REGULATED DEGRADATION; RAT-LIVER; BETA-GALACTOSIDASE; MOLECULAR-CLONING; MAMMALIAN-CELLS; COA REDUCTASE	The microsomal enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase is subject to rapid degradation when cells are incubated with sterols or mevalonic acid (MVA). It has been shown that this rapid degradation is dependent upon both a sterol and another MVA-derived metabolite (Nakanishi, M., Goldstein, J. L., and Brown, M. S. (1988) J. Biol. Chem. 258, 8929-8937). In the current study, inhibitors of the isoprene biosynthetic pathway were used to define further this mevalonic acid derivative involved in the accelerated degradation of HMG-CoA reductase. The accelerated degradation of HMG-CoA reductase in met-18b-2 cells, which is induced by the addition of MVA, was inhibited by the presence of the squalene synthase inhibitor, zaragozic acid/squalestatin, or the squalene epoxidase inhibitor, NB-598. Accelerated degradation of HMG-CoA reductase was observed when NB-598-treated cells were incubated with both MVA and sterols. In contrast, the addition of MVA and sterols to zaragozic acid/squalestatin-treated cells did not result in rapid enzyme degradation. This MVA- and sterol-dependent degradation of HMG-CoA reductase persisted in cells permeabilized with reduced streptolysin O. Finally, the selective degradation of HMG-CoA reductase was also observed in rat hepatic microsomes incubated in vitro in the absence of ATP and cytosol. We conclude that the MVA-derived component that is required for the accelerated degradation of HMG-CoA reductase is derived from farnesyl diphosphate and/or squalene in the isoprenoid biosynthetic pathway. We propose that this component has a permissive effect and does not, by itself, induce the degradation of HMG-CoA reductase. We also conclude that the degradation of HMG-CoA occurs in the endoplasmic reticulum, and, once the degradation of HMGCoA reductase has been initiated by MVA and sterols, all necessary components for the continued degradation of HMG-CoA reductase reside in the endoplasmic reticulum.	UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, 10833 LE CONTE AVE, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DIV CARDIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NHLBI NIH HHS [HL 30568] Funding Source: Medline; NIGMS NIH HHS [GM 07185] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANHERTHILGER G, 1989, METHOD CELL BIOL, V31, P63; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BAXTER A, 1992, J BIOL CHEM, V267, P11705; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHIN DJ, 1985, MOL CELL BIOL, V5, P634, DOI 10.1128/MCB.5.4.634; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; DAWSON MJ, 1992, J ANTIBIOT, V45, P614; EDWARDS PA, 1983, J BIOL CHEM, V258, P219; EDWARDS PA, 1983, J BIOL CHEM, V258, P7272; EDWARDS PA, 1977, J BIOL CHEM, V252, P1057; EDWARDS PA, 1991, BIOCH LIPIDS LIPOPRO, P383; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FAUST J, 1987, J BIOL CHEM, V262, P1996; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HORIE M, 1990, J BIOL CHEM, V265, P18075; JINGAMI H, 1987, J CELL BIOL, V104, P1693, DOI 10.1083/jcb.104.6.1693; JOLY A, 1991, CURR OPIN LIPIDOL, V2, P283; KIM CM, 1992, J BIOL CHEM, V267, P23113; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI AC, 1988, J LIPID RES, V29, P781; LISCUM L, 1985, J BIOL CHEM, V260, P522; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MEIGS TE, 1992, J BIOL CHEM, V267, P13547; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; NESS GC, 1986, BIOCHEM J, V233, P167, DOI 10.1042/bj2330167; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; PANINI SR, 1989, J BIOL CHEM, V264, P11044; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; ROITELMAN J, 1992, J BIOL CHEM, V267, P25264; ROSSER DSE, 1989, J BIOL CHEM, V264, P12653; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; SINENSKY M, 1983, J BIOL CHEM, V258, P8547; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; SPEAR DH, 1992, J BIOL CHEM, V267, P14462; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; WIKSTROM L, 1992, J BIOL CHEM, V267, P5	41	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					633	638						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276863				2022-12-27	WOS:A1994MR21900100
J	FIORE, MM; NEUENSCHWANDER, PF; MORRISSEY, JH				FIORE, MM; NEUENSCHWANDER, PF; MORRISSEY, JH			THE BIOCHEMICAL BASIS FOR THE APPARENT DEFECT OF SOLUBLE MUTANT TISSUE FACTOR IN ENHANCING THE PROTEOLYTIC ACTIVITIES OF FACTOR-VIIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-VII; ACTIVATED FACTOR-IX; BLOOD-COAGULATION; FACTOR-X; FACTOR-XII; DEPENDENT AUTOACTIVATION; ENZYMATIC-PROPERTIES; COFACTOR FUNCTION; HAGEMAN-FACTOR; FACTOR PATHWAY	Tissue factor (TF), an integral membrane protein, is the cofactor for the serine protease, coagulation factor VIIa (FVIIa). Previous studies of the isolated extracellular domain of TF (sTF) reported a k(cat) for factor X (FX) activation by the sTF-VIIa complex only 4% that of wild-type TF.VIIa and furthermore, a complete inability of sTF to support FVII autoactivation. We now report that in the presence of poly(L-lysine), sTF promoted both FX activation and FVII autoactivation, the latter with an apparent second-order rate constant higher than reported previously for wild-type TF in phospholipid vesicles. This led us to reexamine the cofactor ability of sTF, using high concentrations of phospholipid to promote nearly quantitative binding of sTF.VII(a) complexes to the phospholipid surface. Rate constants for the activation of FX or FVII by sTF.VIIa were similar to those of wild-type TF.VIIa, indicating that the apparent deficiency of sTF is largely attributable to kinetic consequences of relatively weak affinity of FVIIa (and sTF.VIIa) for phospholipid surfaces in these surface-dependent reactions, compared with TF being embedded in the membrane. This supports the notion that sTF recapitulates the protein-protein interactions of wild-type TF with high, and possibly full, catalytic activity. lt also provides a biochemical explanation for the specificity of our recently described, sTF-based clotting assay for plasma FVIIa.	OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,825 NE 13TH ST,OKLAHOMA CITY,OK 73104	Oklahoma Medical Research Foundation			Morrissey, James H./GLR-5645-2022; Morrissey, James H/H-4933-2011	Morrissey, James H/0000-0002-1570-1569	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008710, R01HL047014] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-47014, F32 HL-08710] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; Bevington P.R., 1969, DATA REDUCTION ERROR; CARSON SD, 1993, BLOOD COAGUL FIBRIN, V4, P281, DOI 10.1097/00001721-199304000-00010; FIORE MM, 1992, BLOOD, V80, P3127; GRIFFITH MJ, 1985, J CLIN INVEST, V75, P4, DOI 10.1172/JCI111694; HAPAK RC, 1991, FASEB J, V6, P330; HIGASHI S, 1992, J BIOL CHEM, V267, P17990; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P4189, DOI 10.1021/bi00638a009; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P26110; LAAKE K, 1974, THROMB RES, V5, P759, DOI 10.1016/0049-3848(74)90119-4; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; LUNDBLAD RL, 1982, THROMB RES, V25, P319, DOI 10.1016/0049-3848(82)90232-8; MANN KG, 1992, SEMIN HEMATOL, V29, P213; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MASYS DR, 1982, BLOOD, V60, P1143; MIMMS LT, 1981, BIOCHEMISTRY-US, V17, P2134; MORRISSEY JH, 1993, BLOOD, V81, P734; MORRISSEY JH, 1988, THROMB RES, V50, P481, DOI 10.1016/0049-3848(88)90197-1; NAKAGAKI T, 1991, BIOCHEMISTRY-US, V30, P10820; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NEMERSON Y, 1986, BIOCHEMISTRY-US, V25, P4020, DOI 10.1021/bi00362a006; NEMERSON Y, 1966, BIOCHEMISTRY-US, V5, P601, DOI 10.1021/bi00866a029; NEMERSON Y, 1973, P NATL ACAD SCI USA, V70, P310, DOI 10.1073/pnas.70.2.310; NEMERSON Y, 1985, THROMB RES, V40, P351, DOI 10.1016/0049-3848(85)90270-1; NEUENSCHWANDER PF, 1992, J BIOL CHEM, V267, P14477; NEUENSCHWANDER PF, 1993, J BIOL CHEM, V268, P21489; NEUENSCHWANDER PF, 1991, BLOOD S1, V78, P61; NEUENSCHWANDER PF, 1993, IN PRESS THROMB HAEM; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; PABORSKY LR, 1991, J BIOL CHEM, V266, P21911; PEDERSEN AH, 1990, J BIOL CHEM, V265, P16786; PEDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P9331, DOI 10.1021/bi00450a013; RADCLIFFE R, 1975, J BIOL CHEM, V250, P388; RAO LVM, 1988, P NATL ACAD SCI USA, V85, P6687, DOI 10.1073/pnas.85.18.6687; RAWALASHEIKH R, 1992, BLOOD, V79, P398; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; RUF W, 1991, J BIOL CHEM, V266, P2158; RUF W, 1991, J BIOL CHEM, V266, P15719; RUF W, 1991, J BIOL CHEM, V266, P16256; SELIGSOHN U, 1979, J CLIN INVEST, V64, P1056, DOI 10.1172/JCI109543; SHIGEMATSU Y, 1992, J BIOL CHEM, V267, P21329; SMALL DM, 1967, J LIPID RES, V8, P551; TANKERSLEY DL, 1984, BIOCHEMISTRY-US, V23, P273, DOI 10.1021/bi00297a016; TANS G, 1987, J BIOL CHEM, V262, P11308; TANS G, 1983, J BIOL CHEM, V258, P8215; WAXMAN E, 1992, BIOCHEMISTRY-US, V31, P3998, DOI 10.1021/bi00131a015; WAXMAN E, 1993, BIOCHEMISTRY-US, V32, P3005, DOI 10.1021/bi00063a011; YAMAMOTO M, 1992, J BIOL CHEM, V267, P19089	48	57	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					143	149						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276788				2022-12-27	WOS:A1994MR21900030
J	HYUN, SW; PARK, K; LEE, YS; LEE, YI; KIM, SJ				HYUN, SW; PARK, K; LEE, YS; LEE, YI; KIM, SJ			INHIBITION OF PROTEIN PHOSPHATASES ACTIVATES P4 PROMOTER OF THE HUMAN INSULIN-LIKE GROWTH FACTOR-II GENE THROUGH THE SPECIFIC PROMOTER ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR SUPPRESSOR WT1; HEPATITIS-B VIRUS; OKADAIC ACID; TRANSCRIPTION FACTOR; 3T3 CELLS; C-FOS; EXPRESSION; PHOSPHORYLATION; REPRESSION; SEQUENCES	To understand the transcriptional regulation of the human insulin-like growth factor II (IGF-II) gene, we examined the effects of okadaic acid, a potent in vitro inhibitor of protein phosphatases, on the activation of human IGF-II gene expression. Treatment of A-549 human lung adenocarcinoma cells with okadaic acid increased expression of the IGF-II mRNAs. Since the 4.8-kb mRNA is transcribed under the control of human IGF-II P4 promoter, we examined the P4 promoter element responsible for the okadaic acid-mediated transcriptional activation. Transfection of IGF-II P4 promoter-chloramphenicol acetyltransferase constructs demonstrated that the effects of okadaic acid on the induction of IGF-II gene expression are mediated through multiple promoter elements, including an Egr-1 consensus element. We have also shown that okadaic acid induced the expression of the transcription factor Egr-1. Moreover, by using a GAL4-Egr-1 fusion protein, we have directly demonstrated that okadaic acid positively regulates Egr-1 transcriptional activity in vivo. These results indicate that protein phosphatases play an-important role in the transcriptional regulation of the IGF-II.	KOREA INST SCI & TECHNOL, GENET ENGN RES INST, MOLEC GENET LAB, TAEJON 305606, SOUTH KOREA; NCI, CHEMOPREVENT, BETHESDA, MD 20892 USA; CATHOLIC MED UNIV, SEOUL 137040, SOUTH KOREA	Korea Institute of Science & Technology (KIST); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Catholic University of Korea								ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BOHMANN D, 1990, CANCER CELL-MON REV, V2, P337; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CARIANI E, 1991, HEPATOLOGY, V13, P644, DOI 10.1002/hep.1840130406; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DARVILLE CN, 1991, HEPATOLOGY, V13, P310, DOI 10.1002/hep.1840130217; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ERODI F, 1988, BIOCHEM BIOPH RES CO, V153, P156; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GILARDI P, 1984, NUCLEIC ACIDS RES, V12, P7877, DOI 10.1093/nar/12.20.7877; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HESCHELER J, 1988, PFLUG ARCH EUR J PHY, V412, P248, DOI 10.1007/BF00582504; HOLTHUIZEN P, 1990, BIOCHIM BIOPHYS ACTA, V1087, P341, DOI 10.1016/0167-4781(90)90010-Y; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIM RW, 1987, ONCOGENE, V1, P263; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; SARA VR, 1990, PHYSIOL REV, V70, P591, DOI 10.1152/physrev.1990.70.3.591; SASSA T, 1989, BIOCHEM BIOPH RES CO, V159, P939, DOI 10.1016/0006-291X(89)92199-2; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; TACHIBANA K, 1981, J AM CHEM SOC, V103, P2469, DOI 10.1021/ja00399a082; XI XF, 1988, J VIROL, V62, P3422	35	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					364	368						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276819				2022-12-27	WOS:A1994MR21900061
J	LIU, XJ; LAM, E				LIU, XJ; LAM, E			2 BINDING-SITES FOR THE PLANT TRANSCRIPTION FACTOR ASF-1 CAN RESPOND TO AUXIN TREATMENTS IN TRANSGENIC TOBACCO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OCTOPINE SYNTHASE ENHANCER; TISSUE-SPECIFIC EXPRESSION; WHEAT HISTONE GENES; REGULATED GENE; T-DNA; MESOPHYLL PROTOPLASTS; MESSENGER-RNAS; OCS-ELEMENT; PROTEIN; PROMOTER	The hormone, auxin, plays an important role, in the differentiation and growth of plant cells. A number of auxin-responsive genes have been characterized but until now minimal auxin-responsive cis-elements within these promoter regions have not been identified. Here we show that two related DNA sequences of 21 base pairs can respond to auxin treatment in transgenic tobacco. In contrast, treatments with cytokinin or abscisic acid do not cause any apparent increase in promoter activity of these cis-acting elements. These sequences are present in the promoter regions of the nopaline synthase gene from the T-DNA of Agrobacterium tumefaciens and the 35 S promoter from cauliflower mosaic virus. Both sequences have been shown to be binding sites for the tobacco transcription factor ASF-1. Pretreatment of leaves with cycloheximide does not inhibit the response to auxin treatment, suggesting that hormone sensitivity of these promoter elements does not involve de novo synthesis of ASF-1. In addition, promoter elements from some auxin-responsive plant genes can bind ASF-1 in vitro. Based on these results, we propose that transcriptional activation by ASF-1 may be modulated by auxin through modification of pre-existing factors. Our results also suggest a role for ASF-1 in mediating some of the effects of auxin in vivo.	RUTGERS UNIV,WAKSMAN INST MICROBIOL,CTR AGBIOTECH,PISCATAWAY,NJ 08854; RUTGERS UNIV,DEPT PLANT SCI,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University New Brunswick								AINLEY WM, 1988, J BIOL CHEM, V263, P10658; ALLIOTTE T, 1989, PLANT PHYSIOL, V89, P743, DOI 10.1104/pp.89.3.743; ALONI R, 1987, ANNU REV PLANT PHYS, V38, P179, DOI 10.1146/annurev.pp.38.060187.001143; AN GH, 1990, PLANT CELL, V2, P225, DOI 10.1105/tpc.2.3.225; BENFEY PN, 1989, EMBO J, V8, P2195, DOI 10.1002/j.1460-2075.1989.tb08342.x; BENFEY PN, 1990, EMBO J, V9, P1685, DOI 10.1002/j.1460-2075.1990.tb08292.x; BOUCHEZ D, 1989, EMBO J, V8, P4197, DOI 10.1002/j.1460-2075.1989.tb08605.x; CZARNECKA E, 1984, PLANT MOL BIOL, V3, P45, DOI 10.1007/BF00023415; ELLIS JG, 1987, EMBO J, V6, P3203, DOI 10.1002/j.1460-2075.1987.tb02636.x; FLUHR R, 1986, EMBO J, V5, P2063, DOI 10.1002/j.1460-2075.1986.tb04467.x; FRALEY RT, 1985, BIO-TECHNOL, V3, P629, DOI 10.1038/nbt0785-629; FRANCO AR, 1990, J BIOL CHEM, V265, P15845; FROMM H, 1991, MOL GEN GENET, V229, P181, DOI 10.1007/BF00272154; FROMM H, 1989, PLANT CELL, V1, P977, DOI 10.1105/tpc.1.10.977; GEE MA, 1991, PLANT CELL, V3, P419, DOI 10.1105/tpc.3.4.419; GREEN PJ, 1989, PLANT MOL BIOL MANUA, V3, P303; HAGEN G, 1991, PLANT MOL BIOL, V17, P567, DOI 10.1007/BF00040658; HAGEN G, 1989, New Biologist, V1, P19; JACOBS M, 1976, PLANT PHYSIOL, V58, P203, DOI 10.1104/pp.58.2.203; JEFFERSON RA, 1987, EMBO J, V6, P3901; KATAGIRI F, 1990, GENE DEV, V4, P1899, DOI 10.1101/gad.4.11.1899; KATAGIRI F, 1992, TRENDS GENET, V8, P22, DOI 10.1016/0168-9525(92)90020-5; KATAGIRI F, 1989, NATURE, V340, P727, DOI 10.1038/340727a0; KORBER H, 1991, EMBO J, V10, P3983, DOI 10.1002/j.1460-2075.1991.tb04973.x; Krikorian A. D., 1987, Plant hormones and their role in plant growth and development., P593; KUHLEMEIER C, 1989, PLANT CELL, V1, P471, DOI 10.1105/tpc.1.4.471; LAM E, 1989, P NATL ACAD SCI USA, V86, P7890, DOI 10.1073/pnas.86.20.7890; LAM E, 1990, J BIOL CHEM, V265, P9909; LAM E, 1990, SCIENCE, V248, P471, DOI 10.1126/science.2330508; LANGRIDGE WHR, 1989, P NATL ACAD SCI USA, V86, P3219, DOI 10.1073/pnas.86.9.3219; MCCLURE BA, 1989, PLANT CELL, V1, P229, DOI 10.1105/tpc.1.2.229; MIKAMI K, 1987, FEBS LETT, V223, P273, DOI 10.1016/0014-5793(87)80303-4; PALME K, 1991, MECH DEVELOP, V33, P97, DOI 10.1016/0925-4773(91)90076-I; Rubery P. H., 1987, Plant hormones and their role in plant growth and development., P341; TABATA T, 1989, SCIENCE, V245, P965, DOI 10.1126/science.2772648; TAKAHASHI Y, 1989, P NATL ACAD SCI USA, V86, P9279, DOI 10.1073/pnas.86.23.9279; TAKAHASHI Y, 1991, PLANT J, V1, P327, DOI 10.1046/j.1365-313X.1991.t01-2-00999.x; THEOLOGIS A, 1985, J MOL BIOL, V183, P53, DOI 10.1016/0022-2836(85)90280-3; TOKUHISA JG, 1990, PLANT CELL, V2, P215, DOI 10.1105/tpc.2.3.215; VANDERZAAL EJ, 1987, PLANT MOL BIOL, V10, P145, DOI 10.1007/BF00016152; VANDERZAAL EJ, 1991, PLANT MOL BIOL, V16, P983, DOI 10.1007/BF00016071; VANONCKELEN H, 1986, FEBS LETT, V198, P357, DOI 10.1016/0014-5793(86)80436-7	42	77	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					668	675						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276868				2022-12-27	WOS:A1994MR21900105
J	VANDYCK, L; PEARCE, DA; SHERMAN, F				VANDYCK, L; PEARCE, DA; SHERMAN, F			PIM1 ENCODES A MITOCHONDRIAL ATP-DEPENDENT PROTEASE THAT IS REQUIRED FOR MITOCHONDRIAL-FUNCTION IN THE YEAST SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LIVER-MITOCHONDRIA; DNA REPLICATION; GENE; PROTEINS; SEQUENCE; TRANSFORMATION; DEGRADATION; MAINTENANCE; NUCLEAR	The PIM1 nuclear gene in the yeast Saccharomyces cerevisiae encodes a mitochondrial ATP-dependent protease that exhibits over 30% identity with ATP-dependent protease La from Escherichia coli, Lon from Bacillus brevis, and one from Myxococcus xanthus. In addition, Pim1 is 1133 amino acids long and has a putative mitochondrial import signal in the N-terminal region. Enzymatic comparisons of normal PIM1+ and deficient pim1-A strains revealed that the ATP-dependent protease is located within the mitochondrial matrix. The pim1-A strains are unable to utilize nonfermentable substrates as the sole carbon source and are unable to maintain functional mitochondrial DNA, indicating that the Pim1 protease is required for mitochondrial function. PIM1 mRNA is constitutively expressed but is increased after thermal stress, suggesting that Pim1 may play a role in the heat shock response.	UNIV ROCHESTER, SCH MED & DENT, DEPT BIOCHEM, ROCHESTER, NY 14642 USA; UNIV CATHOLIQUE LOUVAIN, UNITE BIOCHIM PHYSIOL, B-1348 LOUVAIN, BELGIUM; UNIV ROCHESTER, SCH MED & DENT, DEPT BIOPHYS, ROCHESTER, NY 14642 USA	University of Rochester; Universite Catholique Louvain; University of Rochester					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM012702] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 12702] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMERIK A, 1988, SOV J BIOORG CHEM, V14, P408; AMERIK AY, 1991, FEBS LETT, V287, P211, DOI 10.1016/0014-5793(91)80053-6; BAIROCH A, 1990, PROSITE DICT PROTEIN; CHIN DT, 1988, J BIOL CHEM, V263, P11718; DESAUTELS M, 1982, P NATL ACAD SCI-BIOL, V79, P1869, DOI 10.1073/pnas.79.6.1869; DESAUTELS M, 1982, J BIOL CHEM, V257, P1673; DIFFLEY JFX, 1991, P NATL ACAD SCI USA, V88, P7864, DOI 10.1073/pnas.88.17.7864; GENGA A, 1986, J BIOL CHEM, V261, P9328; GILL RE, 1993, J BACTERIOL, V175, P4538, DOI 10.1128/JB.175.14.4538-4544.1993; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GREENLEAF AL, 1986, P NATL ACAD SCI USA, V83, P3391, DOI 10.1073/pnas.83.10.3391; HAHN S, 1988, MOL CELL BIOL, V8, P655, DOI 10.1128/MCB.8.2.655; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HEINEMEYER W, 1991, BIOCHEM SOC T, V19, P724, DOI 10.1042/bst0190724; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; ITO K, 1992, J BACTERIOL, V174, P2281, DOI 10.1128/JB.174.7.2281-2287.1992; KAO LR, 1993, P NATL ACAD SCI USA, V90, P5598, DOI 10.1073/pnas.90.12.5598; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KUTEJOVA E, 1993, FEBS LETT, V329, P47, DOI 10.1016/0014-5793(93)80190-6; LEONHARDT SA, 1993, MOL CELL BIOL, V13, P6304, DOI 10.1128/MCB.13.10.6304; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LUZIKOV VN, 1991, CELL BIOL REV, V25, P245; MEGRAW TL, 1993, J BIOL CHEM, V268, P12758; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Rivett AJ, 1990, CURR OPIN CELL BIOL, V2, P1143, DOI 10.1016/0955-0674(90)90168-E; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J, 1989, MOL CLONING LABORATO; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SHERMAN F, 1964, BIOCHIM BIOPHYS ACTA, V90, P1, DOI 10.1016/0304-4165(64)90113-8; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; THIERRY A, 1990, YEAST, V6, P521, DOI 10.1002/yea.320060609; TOJO T, 1993, J BACTERIOL, V175, P2271; VALENS M, 1991, BIOCHIMIE, V12, P1525; VANDYCK E, 1992, EMBO J, V11, P3421, DOI 10.1002/j.1460-2075.1992.tb05421.x; WATABE S, 1985, J BIOL CHEM, V260, P5511; WATABE S, 1993, J BIOCHEM-TOKYO, V113, P672, DOI 10.1093/oxfordjournals.jbchem.a124101; WATABE S, 1985, J BIOL CHEM, V260, P11498; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944	40	186	189	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					238	242						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276800				2022-12-27	WOS:A1994MR21900044
J	WITKOWSKI, A; WITKOWSKA, HE; SMITH, S				WITKOWSKI, A; WITKOWSKA, HE; SMITH, S			REENGINEERING THE SPECIFICITY OF A SERINE ACTIVE-SITE ENZYME - 2 ACTIVE-SITE MUTATIONS CONVERT A HYDROLASE TO A TRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHETASE; RAT MAMMARY-GLAND; THIOESTERASE-II; PEPTIDE ANTIBIOTICS; SEQUENCE-ANALYSIS; ESCHERICHIA-COLI; SYNTHASE; DOMAIN; PURIFICATION; BIOSYNTHESIS	Two residues are known to play important catalytic roles in fatty acyl-thioester hydrolase, thioesterase II: Ser-101, the site of a covalent acyl-enzyme intermediate, and His-237 which is within hydrogen bonding distance of Ser-101 and facilitates catalysis by increasing the nucleophilicity of this residue. In this study we have examined the effect of mutations at these two residues on the ability of the enzyme to function as a hydrolase and, in the presence of a thiol acceptor, as an acyltransferase. In the hydrolase reaction k(cat) values for the wild-type, H237R, S101C, and S101C, H237R thioesterase enzymes were 0.11, <0.002, 0.10, and <0.002 s-1, respectively, and at steady state, the proportion of each enzyme present as the covalent acyl-enzyme intermediate was 11, 91, 71, and 100%, respectively. In the acyltransferase reaction no activity could be detected for the wild-type or H237R enzymes but the specific activities of the S101C and S101C/H237R thioesterases were 170 and 1300 nmol/min/mg of protein, respectively. From this data we conclude the following: the wild-type enzyme functions exclusively as a hydrolase. The H237R mutant acts ineffectively as a hydrolase primarily because the deacylation reaction is drastically retarded. The S101C enzyme functions well as a hydrolase, even though the rate of deacylation is adversely affected, and this enzyme can also perform as an acyltransferase. Mutation of both catalytic residues leads to a complete loss of hydrolase activity and the S101C,H237R mutant functions as an effective acyltransferase exhibiting k(cat) values higher then those of the wild-type enzyme acting as a hydrolase. This study reveals that, with only two amino acid replacements, an enzyme capable of functioning exclusively as a hydrolase can be converted into an equally active enzyme performing solely as an acyltransferase.	CHILDRENS HOSP,OAKLAND RES INST,747 52ND ST,OAKLAND,CA 94609	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute				Witkowski, Andrzej/0000-0002-0442-4586	NCRR NIH HHS [RR-06505] Funding Source: Medline; NIDDK NIH HHS [DK-16073, DK-34400] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR006505] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016073, R01DK034400] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BEVITT DJ, 1992, EUR J BIOCHEM, V204, P39, DOI 10.1111/j.1432-1033.1992.tb16603.x; DERENOBALES M, 1980, ARCH BIOCHEM BIOPHYS, V205, P464, DOI 10.1016/0003-9861(80)90129-0; Dixon M., 1979, ENZYMES, P47; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; HARDIE DG, 1985, BIOCHIM BIOPHYS ACTA, V828, P380, DOI 10.1016/0167-4838(85)90320-6; KATZ E, 1977, BACTERIOL REV, V41, P449, DOI 10.1128/MMBR.41.2.449-474.1977; KLEINKAUF H, 1990, EUR J BIOCHEM, V192, P1, DOI 10.1111/j.1432-1033.1990.tb19188.x; KNUDSEN J, 1976, BIOCHEM J, V160, P683, DOI 10.1042/bj1600683; KRATZSCHMAR J, 1989, J BACTERIOL, V171, P5422; LIBERTINI L, 1976, FED PROC, V35, P1069; LIBERTINI LJ, 1978, J BIOL CHEM, V253, P1393; LIN CY, 1978, J BIOL CHEM, V253, P1954; LIPPMAN F, 1980, ADV MICROBIOL PHYSL, V21, P227; NAGGERT J, 1991, BIOCHEM J, V273, P787, DOI 10.1042/bj2730787; NAGGERT J, 1988, J BIOL CHEM, V263, P1146; PAZIRANDEH M, 1991, J BIOL CHEM, V266, P20946; RAIBAUD A, 1991, J BACTERIOL, V173, P4454, DOI 10.1128/JB.173.14.4454-4463.1991; RANDHAWA ZI, 1987, EUR J BIOCHEM, V162, P577, DOI 10.1111/j.1432-1033.1987.tb10678.x; ROGERS L, 1982, J BIOL CHEM, V157, P880; TAI MH, 1993, P NATL ACAD SCI USA, V90, P1852, DOI 10.1073/pnas.90.5.1852; WITKOWSKA HE, 1990, J BIOL CHEM, V265, P5662; WITKOWSKI A, 1991, EUR J BIOCHEM, V198, P571, DOI 10.1111/j.1432-1033.1991.tb16052.x; WITKOWSKI A, 1985, ARCH BIOCHEM BIOPHYS, V243, P420, DOI 10.1016/0003-9861(85)90518-1; WITKOWSKI A, 1991, J BIOL CHEM, V266, P18514; WITKOWSKI A, 1992, J BIOL CHEM, V267, P18488	26	56	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					379	383						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276823				2022-12-27	WOS:A1994MR21900064
J	GERWIG, GJ; KAMERLING, JP; VLIEGENTHART, JFG; MORAG, E; LAMED, R; BAYER, EA				GERWIG, GJ; KAMERLING, JP; VLIEGENTHART, JFG; MORAG, E; LAMED, R; BAYER, EA			THE NATURE OF THE CARBOHYDRATE-PEPTIDE LINKAGE REGION IN GLYCOPROTEINS FROM THE CELLULOSOMES OF CLOSTRIDIUM-THERMOCELLUM AND BACTEROIDES-CELLULOSOLVENS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULASE COMPLEX; CELLULOMONAS-FIMI; BINDING DOMAINS; GENE; ENDOGLUCANASE; SEQUENCE; CLONING; CHAINS	The cellulase complexes of two cellulolytic bacteria, Clostridium thermocellum and Bacteroides cellulosolvens, were subjected to extensive Pronase digestion. Glycopeptide fractions were isolated by gel permeation and fast protein liquid chromatography and analyzed by monosaccharide analysis, amino acid analysis, methylation analysis, and H-1 NMR spectroscopy. Alkaline boro-hydride-induced deglycosylation/amino acid conversion and periodate oxidation studies on the glycopeptide fraction of the C. thermocellum cellulosome demonstrated that the earlier established collection of carbohydrate moieties with 3-O-Me-D-GlcpNAc-alpha(1-->2)-[D-Galp-alpha(1-->3)]-D-Galf-alpha(1-->2)-D-Gal (where 3-O-Me-D-GlcpNAc is 3-O-methyl-N-acetylglucopyranosamine, Galp is galactopyranose, and Galf is galactofuranose) as the major component, is O-linked to threonine via galactopyranose. Using the same approach for the glycopeptide fraction of the cellulase complex of B. cellulosolvens, it was found that the reported collection of carbohydrate moieties with D-Galf-alpha(1-->3)-D-GlcpNAc-alpha(1-->2)-D-Galf-alpha(1-->2)-[D-Galf-beta(1-->3)]-D-Gal as the major component, is O-linked mainly to threonine and partly to serine via galactopyranose. In both species, the hydroxyamino-acid-bound galactopyranose residue has probably an alpha-configuration. The carbohydrate chains appear as clusters located in highly Thr/Pro-rich peptide regions of the glycoproteins. The results are consistent with the notion that the glycosylation sites are localized in linker sequences which connect the various binding domains of the noncatalytic S1 subunit of the cellulosome.	UNIV UTRECHT, BIJVOET CTR, DEPT BIOORGAN CHEM, POB 80075, 3508 TB UTRECHT, NETHERLANDS; TEL AVIV UNIV, GEORGE S WISE FAC LIFE SCI, IL-69978 TEL AVIV, ISRAEL; WEIZMANN INST SCI, DEPT BIOPHYS, IL-76100 REHOVOT, ISRAEL	Utrecht University; Tel Aviv University; Weizmann Institute of Science								ALLEN AK, 1978, BIOCHEM J, V171, P665, DOI 10.1042/bj1710665; BAYER EA, 1985, J BACTERIOL, V163, P552, DOI 10.1128/JB.163.2.552-559.1985; BEGUIN P, 1985, J BACTERIOL, V162, P102; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DEBAAIJ JA, 1986, SCI TOOLS, V33, P17; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FUJINO T, 1992, FEMS MICROBIOL LETT, V94, P165; GERWIG GJ, 1989, J BIOL CHEM, V264, P1027; GERWIG GJ, 1991, EUR J BIOCHEM, V196, P115, DOI 10.1111/j.1432-1033.1991.tb15793.x; GERWIG GJ, 1992, EUR J BIOCHEM, V205, P799, DOI 10.1111/j.1432-1033.1992.tb16844.x; GHANGAS GS, 1988, APPL ENVIRON MICROB, V54, P2521, DOI 10.1128/AEM.54.10.2521-2526.1988; GILBERT HJ, 1990, MOL MICROBIOL, V4, P759, DOI 10.1111/j.1365-2958.1990.tb00646.x; GILKES NR, 1991, MICROBIOL REV, V55, P303, DOI 10.1128/MMBR.55.2.303-315.1991; GILKES NR, 1988, J BIOL CHEM, V263, P10401; GREPINET O, 1986, NUCLEIC ACIDS RES, V14, P1791, DOI 10.1093/nar/14.4.1791; HESTRIN S, 1949, J BIOL CHEM, V180, P249; HONNAMI K, 1986, ARCH MICROBIOL, V145, P13, DOI 10.1007/BF00413021; Kamerling J. P., 1989, MASS SPECTROMETRY, P176; LAMED R, 1983, BIOTECHNOL BIOENG, P163; Lamed R., 1988, Biochemistry and genetics of cellulose degradation, P101; LAMED R, 1991, CURR MICROBIOL, V22, P27, DOI 10.1007/BF02106209; LAMED R, 1987, J BACTERIOL, V169, P3792, DOI 10.1128/jb.169.8.3792-3800.1987; LAMED R, 1988, ADV APPL MICROBIOL, V33, P1, DOI 10.1016/S0065-2164(08)70203-X; LAMPORT DTA, 1973, BIOCHEM J, V133, P125, DOI 10.1042/bj1330125; LECHNER J, 1989, ANNU REV BIOCHEM, V58, P173, DOI 10.1146/annurev.bi.58.070189.001133; MCGAVIN M, 1989, J BACTERIOL, V171, P3310, DOI 10.1128/jb.171.6.3310-3315.1989; MUIR L, 1970, J BIOL CHEM, V245, P502; MURRAY WD, 1986, LETT APPL MICROBIOL, V3, P69, DOI 10.1111/j.1472-765X.1986.tb01550.x; ONEILL G, 1986, GENE, V44, P325, DOI 10.1016/0378-1119(86)90197-6; POOLE DM, 1993, IN PRESS FEMS MICROB; Schauer R, 1978, Methods Enzymol, V50, P64; SUMPER M, 1990, J BACTERIOL, V172, P7111, DOI 10.1128/jb.172.12.7111-7118.1990; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; WARREN R A J, 1986, Proteins Structure Function and Genetics, V1, P335, DOI 10.1002/prot.340010407	34	75	79	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26956	26960						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262930				2022-12-27	WOS:A1993MM26200021
J	OLIVEIRA, MGD; ROGANA, E; ROSA, JC; REINHOLD, BB; ANDRADE, MH; GREENE, LJ; MARESGUIA, M				OLIVEIRA, MGD; ROGANA, E; ROSA, JC; REINHOLD, BB; ANDRADE, MH; GREENE, LJ; MARESGUIA, M			TYROSINE-151 IS PART OF THE SUBSTRATE ACTIVATION BINDING-SITE OF BOVINE TRYPSIN - IDENTIFICATION BY COVALENT LABELING WITH P-DIAZONIUMBENZAMIDINE AND KINETIC CHARACTERIZATION OF TYR-151-(P-BENZAMIDINO)-AZO-BETA-TRYPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARA-NITROANILIDE; SERINE PROTEASE; HYDROLYSIS; INHIBITION; ACID	Identification of the substrate activation site of beta-trypsin by a 1:1 reacton with p-diazoniumbenzamidine chloride was confirmed by spectral anaylsis. Proteolysis of Cm-p-benzamidino-azo-beta-trypsin provided peptides containing modified tyrosine residues. The major product, Ser-146 to Lys-156, which corresponded to labeling at Tyr-151, was recovered in 35% yield, and its structure was demonstrated by amino acid analysis, Edman degradation, and mass spectrometry. Yields of labeled Tyr-151, Tyr-39, and Tyr-172, identified by peptide analysis, were in the proportion of 100:7:3. Tyr-151-(p-benzamidino)-azo-beta-trypsin is permanently activated, but can be further activated by substrates. Values of k(cat), Ks', and k(cat) vary from two to three times the equivalent values for trypsin. Berenil (4,4'-diazoamino-bis-benzamidine), a parabolic competitive inhibitor of beta-trypsin, was a hyperbolic competitive inhibitor of azo-beta-trypsin. Thus, Tyr-151, part of subsite S'2, affects the catalytic process and, when modified covalently, permanently activates trypsin. Equilibrium binding with berenil supported the kinetic data obtained with substrates. This permits the integration of protein modification, kinetics, equilibrium binding, and crystallographic data to demonstrate a fine interaction between subsites S1-S3 and S'2 in trypsin and azo-beta-trypsin, resulting in subtle structural changes when the native enzyme is covalently modified at Tyr-151.	FED UNIV MINAS GERAIS,INST BIOL SCI,DEPT BIOCHEM & IMMUNOL,POB 2486,BR-31270540 BELO HORIZONT,MG,BRAZIL; USP,CTR INTERDEPT PROT CHEM,BR-14049900 RIBEIRAO PRET,SP,BRAZIL; USP,FAC MED RIBEIRAO PRETO,DEPT GYNECOL & OBSTET,BR-14049900 RIBEIRAO PRET,SP,BRAZIL; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Universidade de Sao Paulo; Universidade de Sao Paulo; Harvard University; Harvard T.H. Chan School of Public Health			OLIVEIRA, Maria Goreti A./AGP-5215-2022; Greene, Lewis J/L-6098-2017; Rosa, Jose C/A-1966-2013; de Alemida Oliveira, Maria Goreti/P-9332-2017	Greene, Lewis J/0000-0003-0144-9726; Rosa, Jose C/0000-0002-6917-0230; de Alemida Oliveira, Maria Goreti/0000-0001-5603-9471				ALONZO N, 1968, ANAL BIOCHEM, V23, P272, DOI 10.1016/0003-2697(68)90359-X; ANDRADE MHG, 1990, BRAZ J MED BIOL RES, V23, P1223; BAINES NJ, 1964, BIOCHEM J, V90, P470, DOI 10.1042/bj0900470; Bidlingmeyer BA, 1986, METHODS PROTEIN SEQU, P229; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; Bratton AC, 1939, J BIOL CHEM, V128, P537; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; CHRISTOVA E, 1982, ARCH BIOCHEM BIOPHYS, V218, P626, DOI 10.1016/0003-9861(82)90390-3; CRAIK CS, 1987, SCIENCE, V237, P909, DOI 10.1126/science.3303334; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; DIAS CLF, 1986, BRAZ J MED BIOL RES, V19, P11; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; ERLANGER BF, 1961, ARCH BIOCHEM BIOPHYS, V95, P271, DOI 10.1016/0003-9861(61)90145-X; FAIRCLOUGH GF, 1966, BIOCHEMISTRY-US, V5, P673, DOI 10.1021/bi00866a038; FUSHITANI K, 1988, J BIOL CHEM, V263, P6502; Hartley BS, 1971, ENZYMES, V3, P323; HESTRIN S, 1949, J BIOL CHEM, V180, P249; HUBER R, 1974, BAYER S, V5, P497; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; Inagami T, 1972, PROTEIN-STRUCT FUNCT, P1; JUNQUEIRA RG, 1990, BRAZ J MED BIOL RES, V23, P773; JUNQUEIRA RG, 1992, BRAZ J MED BIOL RES, V25, P873; KUNITZ M, 1947, J GEN PHYSIOL, V30, P291, DOI 10.1085/jgp.30.4.291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; MAGALHAESROCHA NM, 1980, ARCH BIOCHEM BIOPHYS, V200, P61, DOI 10.1016/0003-9861(80)90330-6; MARESGUIA M, 1981, J BIOL CHEM, V256, P1661; MARESGUIA M, 1965, J BIOL CHEM, V240, P1579; NAKATA H, 1970, BIOCHEM BIOPH RES CO, V41, P393, DOI 10.1016/0006-291X(70)90517-6; NAKATA H, 1972, J BIOCHEM-TOKYO, V72, P281, DOI 10.1093/oxfordjournals.jbchem.a129907; NIELSEN BL, 1984, ANAL BIOCHEM, V141, P311, DOI 10.1016/0003-2697(84)90047-2; RIORDAN JF, 1972, ENZYME STRUCTURE, V20, P521; ROSA JC, 1992, 21 M BRAZ SOC BIOCH, P12; RUHLMANN A, 1973, J MOL BIOL, V77, P417, DOI 10.1016/0022-2836(73)90448-8; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P100; SCHOELLMANN G, 1963, BIOCHEMISTRY-US, V2, P252, DOI 10.1021/bi00902a008; SCHROEDER DD, 1968, J BIOL CHEM, V243, P2943; SCHWERT GW, 1955, BIOCHIM BIOPHYS ACTA, V16, P571; SHAW ELLIOTT, 1965, BIOCHEMISTRY, V4, P2219, DOI 10.1021/bi00886a039; SOKOLOVS.M, 1966, BIOCHEMISTRY-US, V5, P3574, DOI 10.1021/bi00875a028; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; SPRANG S, 1987, SCIENCE, V237, P905, DOI 10.1126/science.3112942; STROUD RM, 1974, SCI AM, V231, P74, DOI 10.1038/scientificamerican0774-74; TABACHNICK M, 1959, J BIOL CHEM, V234, P1726; TRENHOLM HL, 1969, BIOCHEMISTRY-US, V8, P1741, DOI 10.1021/bi00832a057; TROWBRIDGE CG, 1963, BIOCHEMISTRY-US, V2, P843, DOI 10.1021/bi00904a037; TSUNEMATSU H, 1983, J BIOCHEM-TOKYO, V94, P123, DOI 10.1093/oxfordjournals.jbchem.a134320; VILLELA L, 1984, ARQ BIOL TECHNOL, V27, P281	49	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26893	26903						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262923				2022-12-27	WOS:A1993MM26200013
J	QIU, HW; KODADEK, T; GIEDROC, DP				QIU, HW; KODADEK, T; GIEDROC, DP			ZINC-FREE AND REDUCED T4 GENE-32 PROTEIN BINDS SINGLE-STRANDED-DNA WEAKLY AND FAILS TO STIMULATE UVSX-CATALYZED HOMOLOGOUS PAIRING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T4 GENE-32; MESSENGER-RNA; 32 PROTEIN; RECOMBINATION; DOMAIN; SITE; PURIFICATION; COMPLEX; REMOVAL	The functional role of Zn(II) binding by T4 gene 32 protein (gp32), a single-stranded DNA-binding protein, has been investigated by assessing the capacity of a well-characterized metal-free gp32 derivative to function in vitro as an accessory protein of T4 uvsX-catalyzed homologous pairing. Metal-free gp32 was prepared upon reaction of cysteine thiolates with methylmethanethiol-sulfonate to form the mixed disulfide Cys-SSCH3 or S-methylated species. Far and near ultraviolet circular dichroism spectroscopy suggest a moderate but easily detected change in the far UV region, accompanied by only a minor alteration in the near UV region, relative to the Zn(H)-containing protein. Restoration of the wild-type spectral features is accomplished upon the addition of 2 mM dithiothreitol and excess Zn(II) but not dithiothreitol alone. Unlike wild-type gp32, apo S-methylated gp32 shows weak binding to the recombination substrate, single-stranded M13mp19, and fails to stimulate homologous pairing with a linear M13mp19 duplex substrate by uvsX protein. Complete reactivation of the apo S-methylated protein as a recombination-accessory protein is achievable in situ in the presence of reducing agent and sufficient exogenous Zn(II), but not one or the other alone. Analogous results are obtained with S-methylated C166S (Cys166 --> Ser) gp32, revealing that only the metal-liganding cysteines participate in the reconstitution. These findings suggest that formation of the ZN(II) chelate is directly linked to single-stranded DNA binding and functional efficacy of gp32 in DNA metabolism.	TEXAS A&M UNIV,DEPT BIOCHEM & BIOPHYS,COLL STN,TX 77843; UNIV TEXAS,DEPT CHEM & BIOCHEM,AUSTIN,TX 78712	Texas A&M University System; Texas A&M University College Station; University of Texas System; University of Texas Austin			Giedroc, David/A-8608-2018	Giedroc, David/0000-0002-2342-1620	NIGMS NIH HHS [GM42569] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042569, R29GM042569] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; FORMOSA T, 1986, J BIOL CHEM, V261, P6107; GARDNER KH, 1991, BIOCHEMISTRY-US, V30, P11292, DOI 10.1021/bi00111a015; GIEDROC DP, 1991, BIOCHEMISTRY-US, V30, P8230, DOI 10.1021/bi00247a020; GIEDROC DP, 1987, BIOCHEMISTRY-US, V26, P5251, DOI 10.1021/bi00391a007; GIEDROC DP, 1986, P NATL ACAD SCI USA, V83, P8452, DOI 10.1073/pnas.83.22.8452; GIEDROC DP, 1992, BIOCHEMISTRY-US, V31, P765, DOI 10.1021/bi00118a018; GIEDROC DP, 1989, BIOCHEMISTRY-US, V28, P2410, DOI 10.1021/bi00432a011; GIEDROC DP, 1993, ENCY INORGANIC CHEM; HASHIMOTO K, 1991, J BIOL CHEM, V266, P4883; HATTMAN S, 1991, P NATL ACAD SCI USA, V88, P10027, DOI 10.1073/pnas.88.22.10027; HINTON DM, 1986, J BIOL CHEM, V261, P5663; HURLEY JM, 1993, J MOL BIOL, V229, P398, DOI 10.1006/jmbi.1993.1042; JIANG H, 1993, J BIOL CHEM, V268, P7904; Karpel R.L., 1990, BIOL NONSPECIFIC DNA, P103; KEATING KM, 1988, BIOCHEMISTRY-US, V27, P5240, DOI 10.1021/bi00414a044; KEATING KM, 1987, PROTEIN STRUCT FOLDI, V2, P35; KHAN R, 1992, J BIOL CHEM, V267, P6689; KODADEK T, 1988, J BIOL CHEM, V263, P9427; KODADEK T, 1990, J BIOL CHEM, V265, P20966; KRASSA KB, 1991, P NATL ACAD SCI USA, V88, P4010, DOI 10.1073/pnas.88.9.4010; LANDRO JA, 1993, P NATL ACAD SCI USA, V90, P2261, DOI 10.1073/pnas.90.6.2261; LOHMAN TM, 1986, J MOL BIOL, V187, P603, DOI 10.1016/0022-2836(86)90338-4; MCPHEETERS DS, 1988, J MOL BIOL, V201, P517, DOI 10.1016/0022-2836(88)90634-1; NADLER SG, 1990, J BIOL CHEM, V265, P10389; PAN T, 1989, BIOCHEMISTRY-US, V28, P8828, DOI 10.1021/bi00448a022; PAN T, 1990, BIOCHEMISTRY-US, V29, P9218, DOI 10.1021/bi00491a016; PARRAGA G, 1988, SCIENCE, V241, P1489, DOI 10.1126/science.3047872; SHAMOO Y, 1991, J BIOL CHEM, V266, P7967; SMITH DJ, 1975, BIOCHEMISTRY-US, V14, P766, DOI 10.1021/bi00675a019; TSANG SS, 1985, BIOCHEMISTRY-US, V24, P3226, DOI 10.1021/bi00334a023; VILLEMAIN JL, 1993, IN PRESS BIOCHEMISTR; YONESAKI T, 1989, J BIOL CHEM, V264, P7814	34	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2773	2781						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300610				2022-12-27	WOS:A1994MV43200063
J	TAKEDA, A; MAIZEL, AL; KITAMURA, K; OHTA, T; KIMURA, S				TAKEDA, A; MAIZEL, AL; KITAMURA, K; OHTA, T; KIMURA, S			MOLECULAR-CLONING OF THE CD45-ASSOCIATED 30-KDA PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CD45 PHOSPHOTYROSINE PHOSPHATASE; CELL ANTIGEN RECEPTOR; TYROSINE PHOSPHATASE; SIGNAL TRANSDUCTION; T-CELLS; KINASE; ACTIVATION; PHOSPHORYLATION; EXPRESSION; ANTIBODIES	CD45, a leukocyte-specific transmembrane protein tyrosine phosphatase, mediates signal transduction pathways critical for immune responses. However, the mechanism of CD45-mediated signal transduction and the identity of CD45-associated proteins have remained unclear. A CD45-associated 30-kDa phosphorylated protein (CD45-AP) was purified by virtue of its specific association with CD45, and its mouse cDNA was cloned by using the internal amino acid sequence information. In vitro translated CD45-AP bound specifically to CD45. CD45-AP appears to be leukocyte-specific and shares no significant homology with presently known sequences. The predicted sequence contains no consensus tyrosine phosphorylation sites or conserved sequences of GTP-binding proteins. CD45-AP may act as an adapter molecule for CD45-mediated signal transduction.	NCI, MOLEC CARCINOGENESIS LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	TAKEDA, A (corresponding author), BROWN UNIV, ROGER WILLIAMS, MED CTR, DEPT PATHOL, 825 CHALKSTONE AVE, PROVIDENCE, RI 02908 USA.			Ohta, Tomohiko/0000-0002-9700-7342	NATIONAL CANCER INSTITUTE [P30CA013943, R37CA045148] Funding Source: NIH RePORTER; NCI NIH HHS [CA 45148, P30 CA13943] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIKES M, 1973, J NATL CANCER I, V50, P347, DOI 10.1093/jnci/50.2.347; CLARK EA, 1989, IMMUNOL TODAY, V10, P225, DOI 10.1016/0167-5699(89)90257-0; ELLINGTON A, 1993, CURRENT PROTOCOLS MO, V2; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KORETZKY GA, 1993, J BIOL CHEM, V268, P8958; KORETZKY GA, 1993, FASEB J, V7, P420, DOI 10.1096/fasebj.7.5.8462784; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEDBETTER JA, 1988, P NATL ACAD SCI USA, V85, P8628, DOI 10.1073/pnas.85.22.8628; LESLEY J, 1984, CELL IMMUNOL, V83, P14, DOI 10.1016/0008-8749(84)90220-X; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P21551; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; OSTERGAARD HL, 1991, SCIENCE, V253, P1423, DOI 10.1126/science.1654595; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; SARMIENTO M, 1982, IMMUNOL REV, V68, P135, DOI 10.1111/j.1600-065X.1982.tb01063.x; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SCHRAVEN B, 1992, EUR J IMMUNOL, V22, P1857, DOI 10.1002/eji.1830220727; SHIROO M, 1992, EMBO J, V11, P4887, DOI 10.1002/j.1460-2075.1992.tb05595.x; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; TAKEDA A, 1992, J BIOL CHEM, V267, P16651; TAKEDA A, 1990, SCIENCE, V250, P676, DOI 10.1126/science.2146743; TELFER JC, 1991, SCIENCE, V254, P439, DOI 10.1126/science.1925604; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; TROWBRIDGE IS, 1991, J BIOL CHEM, V266, P23517; VOLAREVIC S, 1992, J EXP MED, V176, P835, DOI 10.1084/jem.176.3.835	32	41	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2357	2360						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300558				2022-12-27	WOS:A1994MV43200003
J	LITTLE, RG; KELNER, DN; LIM, E; BURKE, DJ; CONLON, PJ				LITTLE, RG; KELNER, DN; LIM, E; BURKE, DJ; CONLON, PJ			FUNCTIONAL DOMAINS OF RECOMBINANT BACTERICIDAL PERMEABILITY-INCREASING PROTEIN (RBPI(23))	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; LIPID-A; ANTIBACTERIAL PEPTIDES; BOVINE BRAIN; POLYMYXIN-B; BINDING; PURIFICATION; ENDOTOXIN; FRAGMENT; LIPOPOLYSACCHARIDES	The 23-kDa recombinant amino-terminal bactericidal/permeability increasing protein fragment (rBPI22) has all of the antibacterial and antiendotoxin properties of the holoprotein. In the current studies, we have identified multiple active domains within rBPI23 with chemical and proteolytic cleavage fragments and with synthetic overlapping peptides. We also demonstrate a novel, high affinity heparin binding property for rBPI23, in addition to its established bactericidal and lipopolysaccharide binding properties. Cleavage fragments and synthetic, overlapping peptides of rBPI23 were analyzed for inhibition of the lipopolysaccharide-induced Limulus amebocyte lysate reaction, for bactericidal activity, and for heparin binding. Three separate, active domains were identified in amino acid regions 17-45, 65-99, and 142-169. A single synthetic peptide (85-99) was bactericidal. These results indicate that rBPI23 is comprised of three separate functional domains which contribute to the high affinity interaction of rBPI23 with Gram-negative bacteria. The individual activity of each domain and the cooperative interaction among domains provide the basis for developing rBPI23 analogues with increased biologic efficacy.	XOMA CORP,DEPT ANALYT BIOCHEM,BERKELEY,CA 94710		LITTLE, RG (corresponding author), XOMA CORP,DEPT IMMUNOL,2910 7TH ST,BERKELEY,CA 94710, USA.							BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BJORK I, 1992, J BIOL CHEM, V267, P1976; BOMAN HG, 1989, FEBS LETT, V259, P103, DOI 10.1016/0014-5793(89)81505-4; BRADE L, 1987, INFECT IMMUN, V55, P2636, DOI 10.1128/IAI.55.11.2636-2644.1987; BRAY AM, 1991, J ORG CHEM, V56, P6659, DOI 10.1021/jo00023a035; BURD RS, 1992, IMMUNOTHERAPY GRAM N, P21; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; DANNER RL, 1989, ANTIMICROB AGENTS CH, V33, P1428, DOI 10.1128/AAC.33.9.1428; ELSBACH P, 1993, CURR OPIN IMMUNOL, V5, P103, DOI 10.1016/0952-7915(93)90088-A; ELSBACH P, 1988, INFLAMMATION BASIC P, P603; FLODGAARD H, 1991, EUR J BIOCHEM, V197, P535, DOI 10.1111/j.1432-1033.1991.tb15942.x; FRANK RW, 1990, J BIOL CHEM, V265, P18871; GAZZANOSANTORO H, 1992, INFECT IMMUN, V60, P4754, DOI 10.1128/IAI.60.11.4754-4761.1992; HOESS A, 1993, EMBO J, V12, P3351, DOI 10.1002/j.1460-2075.1993.tb06008.x; JIANG H, 1992, J EXP MED, V175, P1373, DOI 10.1084/jem.175.5.1373; KINI RM, 1989, INT J PEPT PROT RES, V34, P277; LANE DA, 1984, BIOCHEM J, V218, P725, DOI 10.1042/bj2180725; LEHRER RI, 1991, J IMMUNOL METHODS, V137, P167, DOI 10.1016/0022-1759(91)90021-7; LEHRER RI, 1991, CELL, V64, P229, DOI 10.1016/0092-8674(91)90632-9; MACIAG T, 1984, SCIENCE, V225, P932, DOI 10.1126/science.6382607; MARRA MN, 1990, J IMMUNOL, V144, P662; MORRISON DC, 1976, IMMUNOCHEMISTRY, V13, P813, DOI 10.1016/0019-2791(76)90181-6; OOI CE, 1987, J BIOL CHEM, V262, P14891; OOI CE, 1991, J EXP MED, V174, P649, DOI 10.1084/jem.174.3.649; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PLOUG M, 1989, ANAL BIOCHEM, V181, P33, DOI 10.1016/0003-2697(89)90390-4; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; RUSTICI A, 1993, SCIENCE, V259, P361, DOI 10.1126/science.8420003; SMITH RD, 1990, ANAL CHEM, V62, P882, DOI 10.1021/ac00208a002; STEINER H, 1988, BIOCHIM BIOPHYS ACTA, V939, P260, DOI 10.1016/0005-2736(88)90069-7; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; THOMAS KA, 1984, P NATL ACAD SCI-BIOL, V81, P357, DOI 10.1073/pnas.81.2.357; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; VAARA M, 1992, MICROBIOL REV, V56, P395, DOI 10.1128/MMBR.56.3.395-411.1992; WARREN HS, 1992, INFECT IMMUN, V60, P2506, DOI 10.1128/IAI.60.6.2506-2513.1992; WEISS J, 1982, ADV EXP MED BIOL, V141, P129; WEISS J, 1984, J IMMUNOL, V132, P3109; WEISS J, 1992, J CLIN INVEST, V90, P1122, DOI 10.1172/JCI115930; WEISS J, 1978, J BIOL CHEM, V253, P2664; YAYON A, 1991, MOL CELL BIOL, V12, P240; ZASLOFF M, 1988, P NATL ACAD SCI USA, V85, P910, DOI 10.1073/pnas.85.3.910	42	108	133	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1865	1872						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294435				2022-12-27	WOS:A1994MR98800050
J	RYTOMAA, M; KINNUNEN, PKJ				RYTOMAA, M; KINNUNEN, PKJ			EVIDENCE FOR 2 DISTINCT ACIDIC PHOSPHOLIPID-BINDING SITES IN CYTOCHROME-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTROSCOPY; MOLTEN-GLOBULE STATE; FERRICYTOCHROME-C; CONFORMATIONAL-CHANGES; CARDIOLIPIN BILAYERS; CHARGED INTERFACES; NMR MEASUREMENTS; APOCYTOCHROME-C; IONIC-STRENGTH; PROTON-NMR	Binding of cytochrome c (cyt c) to cardiolipin/phosphatidylcholine (CL/PC) and phosphatidylglycerol/PC (PG/PC) liposomes was studied at neutral pH utilizing fluorescence resonance energy transfer from a membrane-incorporated pyrene phospholipid derivative to the heme of cyt c. ATP in millimolar concentrations displaced nearly quantitatively cyt c from membranes containing 17.5 mol % CL or 30 mol % PG. Notably, increasing the acidic phospholipid/PC molar ratio in the liposomes progressively reduced the membrane detachment of cyt c by ATP, and practically no dissociation of cyt c from neat PG or CL liposomes was observed. Complete dissociation of cyt c from PG/PC liposomes was also produced by subsequently added NaCl. However, the concentration of salt required for half-maximal effect increased upon increasing the PG/PC molar ratio. At 0.1 m NaCl no binding of cyt c to neat PG liposomes was observed whereas the extent of membrane association of cyt c increased with increasing CL/PC molar ratios also in the presence of salt. This difference between CL and PG is attributed to the complex electrostatics of the former lipid resulting in its high affinity for protons. The above results can be rationalized in terms of two acidic phospholipid-binding sites in cyt c. The electrostatically interacting site is constituted by basic residues in cyt c and could be identical to the ATP-binding site (Craig, D. B., and Wallace, C. J. A. (1993) Protein Sci. 2, 966-976). In addition there should be another lipid-binding site in cyt c with a high affinity to protonated acidic phospholipids. Both sites appear to be available for lipid binding at neutral bulk pH.	UNIV HELSINKI,DEPT MED CHEM,POB 8,SILTAVUORENPENGER 10A,SF-00100 HELSINKI 10,FINLAND	University of Helsinki								BROWN LR, 1977, BIOCHIM BIOPHYS ACTA, V468, P389, DOI 10.1016/0005-2736(77)90290-5; CRAIG DB, 1991, BIOCHEM J, V279, P781, DOI 10.1042/bj2790781; CRAIG DB, 1993, PROTEIN SCI, V2, P966, DOI 10.1002/pro.5560020610; DEJONGH HHJ, 1990, BIOCHIM BIOPHYS ACTA, V1029, P105, DOI 10.1016/0005-2736(90)90442-Q; DEKRUIJFF B, 1980, BIOCHIM BIOPHYS ACTA, V602, P477, DOI 10.1016/0005-2736(80)90327-2; DEMEL RA, 1989, J BIOL CHEM, V264, P3988; DICKERSON RE, 1971, J BIOL CHEM, V246, P1511; FENG YQ, 1990, BIOCHEMISTRY-US, V29, P3505, DOI 10.1021/bi00466a012; FERGUSONMILLER S, 1976, J BIOL CHEM, V251, P1104; GOTO Y, 1991, J BIOCHEM-TOKYO, V109, P746, DOI 10.1093/oxfordjournals.jbchem.a123451; HAVERSTICK DM, 1989, BIOPHYS J, V55, P677, DOI 10.1016/S0006-3495(89)82866-8; HEIMBURG T, 1991, BIOCHEMISTRY-US, V30, P9084, DOI 10.1021/bi00101a025; HILDEBRANDT P, 1989, BIOCHEMISTRY-US, V28, P6710, DOI 10.1021/bi00442a026; HILDEBRANDT P, 1989, BIOCHEMISTRY-US, V28, P6722, DOI 10.1021/bi00442a027; ISRAELACHVILI JN, 1980, Q REV BIOPHYS, V13, P121, DOI 10.1017/S0033583500001645; JORI G, 1974, PHOTOCHEM PHOTOBIOL, V19, P337, DOI 10.1111/j.1751-1097.1974.tb06521.x; KAIHOVAARA P, 1991, BIOCHEMISTRY-US, V30, P8380, DOI 10.1021/bi00098a015; KIMELBERG HK, 1969, BIOCHEM BIOPH RES CO, V34, P784, DOI 10.1016/0006-291X(69)90248-4; KINNUNEN PKJ, 1993, FLUORESCENCE SPECTRO, P159; KOZARAC Z, 1988, FEBS LETT, V229, P372, DOI 10.1016/0014-5793(88)81159-1; KURODA Y, 1992, J MOL BIOL, V223, P1139, DOI 10.1016/0022-2836(92)90265-L; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MITCHELL P, 1983, FEBS LETT, V151, P167, DOI 10.1016/0014-5793(83)80063-5; MOENCH SJ, 1991, EUR J BIOCHEM, V197, P631, DOI 10.1111/j.1432-1033.1991.tb15953.x; MUGA A, 1991, BIOCHEMISTRY-US, V30, P7219, DOI 10.1021/bi00243a025; MUSTONEN P, 1987, BIOCHEMISTRY-US, V26, P2991, DOI 10.1021/bi00385a006; MUSTONEN P, 1993, J BIOL CHEM, V268, P1074; NICHOLLS P, 1974, BIOCHIM BIOPHYS ACTA, V346, P261, DOI 10.1016/0304-4173(74)90003-2; OHGUSHI M, 1983, FEBS LETT, V164, P21, DOI 10.1016/0014-5793(83)80010-6; QUINN PJ, 1969, BIOCHEM J, V115, P65, DOI 10.1042/bj1150065; RYTOMAA M, 1992, J BIOL CHEM, V267, P22243; SOUSSI B, 1990, BIOCHEM J, V265, P227, DOI 10.1042/bj2650227; SPECK SH, 1983, FEBS LETT, V164, P379, DOI 10.1016/0014-5793(83)80321-4; SPOONER PJR, 1991, BIOCHEMISTRY-US, V30, P3871, DOI 10.1021/bi00230a010; SPOONER PJR, 1991, BIOCHEMISTRY-US, V30, P3880, DOI 10.1021/bi00230a011; SPOONER PJR, 1992, BIOCHEMISTRY-US, V31, P10129, DOI 10.1021/bi00156a037; Trauble H., 1976, STRUCTURE BIOL MEMBR, P509; VANDERKOOI J, 1973, ARCH BIOCHEM BIOPHYS, V154, P219, DOI 10.1016/0003-9861(73)90052-0; VIK SB, 1981, P NATL ACAD SCI-BIOL, V78, P1456, DOI 10.1073/pnas.78.3.1456; VINCENT JS, 1986, J AM CHEM SOC, V108, P3551, DOI 10.1021/ja00273a001; VINCENT JS, 1987, BIOCHEMISTRY-US, V26, P2312, DOI 10.1021/bi00382a036; WALTHAM MC, 1986, BIOCHIM BIOPHYS ACTA, V862, P451, DOI 10.1016/0005-2736(86)90250-6; YU LP, 1990, BIOCHEMISTRY-US, V29, P2920, DOI 10.1021/bi00464a005	43	218	219	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1770	1774						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294426				2022-12-27	WOS:A1994MR98800037
J	THOMALE, J; HOCHLEITNER, K; RAJEWSKY, MF				THOMALE, J; HOCHLEITNER, K; RAJEWSKY, MF			DIFFERENTIAL FORMATION AND REPAIR OF THE MUTAGENIC DNA ALKYLATION PRODUCT O6-ETHYLGUANINE IN TRANSCRIBED AND NONTRANSCRIBED GENES OF THE RAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETHYL-N-NITROSOUREA; TRANSCRIPTIONALLY ACTIVE DNA; NUCLEOTIDE EXCISION REPAIR; COMPLEMENTATION GROUP-C; ALKALI-LABILE SITES; SELECTIVE REPAIR; BRAIN DNA; O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; ESCHERICHIA-COLI; HUMAN-CELLS	Intragenomic differences regarding the formation and repair of carcinogen-DNA adducts influence gene-specific mutational patterns and the cellular risk of malignant conversion. Using a newly developed, monoclonal antibody-based immunoaffinity method (Hochleitner, K., Thomale, J., Nikitin, A. Y., and Rajewsky, M. F. (1991) Nucleic Acids Res. 19, 4467-4472), it has become possible to quantitate the mutagenic DNA alkylation product O6-ethylguanine (O6-EtGua) at the level of single-copy genes. We have analyzed the formation and repair kinetics of O6-EtGua in DNA in relation to the transcriptional activity of selected genes in two isogenic rat hepatoma cell lines (Fao and H5) exposed to N-ethyl-N-nitrosourea. Whereas the frequency of O6-EtGua initially formed in the inactive immunoglobulin E gene was indistinguishable from the value for bulk DNA, the initial O6-EtGua/guanine molar ratio in the transcribed beta-actin gene was nearly three times higher. The overall elimination rates of O6-EtGua were the same for bulk DNA and the IgE gene sequence, i.e. rapid in Fao cells (68% removed within 20 min) and four times slower in H5 cells. Preferential repair was found in the transcribed gene: during the initial phase of elimination, the half-life of O6-EtGua in the beta-actin gene was three times shorter than in the IgE gene in Fao cells (5 versus 15 min) and 12 times shorter in H5 cells (20 min versus 4 h).	UNIV ESSEN GESAMTHSCH,SCH MED,INST CELL BIOL CANC RES,HUFELAND STR 55,D-45122 ESSEN,GERMANY	University of Duisburg Essen								BHANOT OS, 1992, NUCLEIC ACIDS RES, V20, P587, DOI 10.1093/nar/20.3.587; BOHR VA, 1991, CARCINOGENESIS, V12, P1983, DOI 10.1093/carcin/12.11.1983; BRONSTEIN SM, 1992, CANCER RES, V52, P2008; COX R, 1979, CANCER RES, V39, P2675; DESCHATRETTE J, 1979, SOMAT CELL GENET, V5, P697, DOI 10.1007/BF01542636; DOLAN ME, 1991, CARCINOGENESIS, V12, P2305, DOI 10.1093/carcin/12.12.2305; DUMENCO LL, 1993, SCIENCE, V259, P219, DOI 10.1126/science.8421782; FREI JV, 1975, CHEM-BIOL INTERACT, V10, P413, DOI 10.1016/0009-2797(75)90072-1; GEORGIADIS P, 1991, CANCER RES, V51, P5843; GOTH R, 1974, P NATL ACAD SCI USA, V71, P639, DOI 10.1073/pnas.71.3.639; HO L, 1989, MOL CELL BIOL, V9, P1594, DOI 10.1128/MCB.9.4.1594; HOCHLEITNER K, 1991, NUCLEIC ACIDS RES, V19, P4467, DOI 10.1093/nar/19.16.4467; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUH N, 1986, CARCINOGENESIS, V7, P435, DOI 10.1093/carcin/7.3.435; KANTOR GJ, 1990, MUTAT RES, V235, P171, DOI 10.1016/0921-8777(90)90071-C; LEDOUX SP, 1991, CANCER RES, V51, P775; LEDOUX SP, 1990, J BIOL CHEM, V265, P14875; LOVELESS A, 1969, NATURE, V223, P206, DOI 10.1038/223206a0; LU SJ, 1992, P NATL ACAD SCI USA, V89, P1001, DOI 10.1073/pnas.89.3.1001; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MILLIGAN JR, 1988, BIOCHEM BIOPH RES CO, V155, P14, DOI 10.1016/S0006-291X(88)81042-8; MULLER R, 1983, CANCER RES, V43, P2897; NEHLS P, 1985, MUTAT RES, V150, P13, DOI 10.1016/0027-5107(85)90096-X; NEHLS P, 1984, EMBO J, V3, P327, DOI 10.1002/j.1460-2075.1984.tb01806.x; NEHLS P, 1984, J CANCER RES CLIN, V108, P23, DOI 10.1007/BF00390969; NEHLS P, 1985, CANCER RES, V45, P1378; NIKITIN AY, 1991, P NATL ACAD SCI USA, V88, P9939, DOI 10.1073/pnas.88.22.9939; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; OKUMOTO DS, 1987, NUCLEIC ACIDS RES, V15, P10021, DOI 10.1093/nar/15.23.10021; PALOMBO F, 1992, J MOL BIOL, V223, P587, DOI 10.1016/0022-2836(92)90974-O; PEGG AE, 1982, P NATL ACAD SCI-BIOL, V79, P5162, DOI 10.1073/pnas.79.17.5162; PERERA FP, 1992, NATURE, V360, P256, DOI 10.1038/360256a0; RAJEWSKY MF, 1977, ORIGINS HUMAN CANCER, P709; RAJEWSKY MF, 1980, CARCINOGENESIS FUNDA, P207; RAJEWSKY MF, 1987, MOL MECHANISMS CARCI, P131; RICHARDSON FC, 1989, J BIOL CHEM, V264, P838; RICHARDSON KK, 1983, NUCLEIC ACIDS RES, V11, P8809, DOI 10.1093/nar/11.24.8809; RYAN AJ, 1986, CARCINOGENESIS, V7, P1497, DOI 10.1093/carcin/7.9.1497; SAMSON L, 1988, EMBO J, V7, P2261, DOI 10.1002/j.1460-2075.1988.tb03066.x; SATOH MS, 1988, J BIOL CHEM, V263, P6854; SENDOWSKI K, 1991, MUTAT RES, V250, P153, DOI 10.1016/0027-5107(91)90171-J; SINGER B, 1986, CANCER RES, V46, P4879; SKLAR R, 1981, NATURE, V289, P417, DOI 10.1038/289417a0; SMITH CA, 1990, ADV MUTAGENESIS RES, V1, P153; STEEN ML, 1984, J MOL BIOL, V177, P19, DOI 10.1016/0022-2836(84)90055-X; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; SWENBERG JA, 1984, P NATL ACAD SCI-BIOL, V81, P1692, DOI 10.1073/pnas.81.6.1692; TEO IA, 1983, CARCINOGENESIS, V4, P1075, DOI 10.1093/carcin/4.8.1075; TERLETH C, 1991, MUTAGENESIS, V6, P103, DOI 10.1093/mutage/6.2.103; THOMALE J, 1990, P NATL ACAD SCI USA, V87, P9883, DOI 10.1073/pnas.87.24.9883; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VONHOFE E, 1992, P NATL ACAD SCI USA, V89, P11199, DOI 10.1073/pnas.89.23.11199	52	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1681	1686						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294414				2022-12-27	WOS:A1994MR98800024
J	FRUEN, BR; MICKELSON, JR; SHOMER, NH; ROGHAIR, TJ; LOUIS, CF				FRUEN, BR; MICKELSON, JR; SHOMER, NH; ROGHAIR, TJ; LOUIS, CF			REGULATION OF THE SARCOPLASMIC-RETICULUM RYANODINE RECEPTOR BY INORGANIC-PHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE FIBERS; MALIGNANT HYPERTHERMIA; CALCIUM-RELEASE; CARDIAC-MUSCLE; MAMMALIAN SKELETAL; RABBIT SKELETAL; XENOPUS-LAEVIS; FATIGUE; CONTRACTION; CHANNEL	To better understand the mechanisms regulating myoplasmic Ca2+ during muscle activity, we have examined the effect of inorganic phosphate (P(i)) on the ryanodine receptor (RyR) Ca2+ release channel of the sarcoplasmic reticulum (SR). We report that P(i) at concentrations reached in exercising skeletal muscle (3-30 mM) produced a dose-dependent stimulation of ryanodine binding to skeletal muscle SR. Ryanodine binding was increased by 84% in the presence of 30 mM P(i) with half-maximal stimulation at 4 mM P(i). In contrast to its effect on skeletal muscle SR, ryanodine binding to cardiac muscle SR was not stimulated by P(i) (3-30 mM). Stimulation of ryanodine binding to skeletal muscle SR was maximal in the presence of micromolar Ca2+ and was associated with an increased affinity of the RyR for ryanodine (K(d) = 204 nM in the absence, versus 107 nM in the presence of 10 mM P(i)). P(i) (10 mM) also increased the rate of Ca2+ release from Ca-45(2+)-filled skeletal muscle SR vesicles by 50% in the presence of micromolar Ca2+. Conversely, arsenate and sulfate (10 mM) had no effect on either ryanodine binding or Ca2+-induced Ca2+ release, demonstrating the specificity of the P(i) effect. Single-channel recordings of purified skeletal muscle SR RyR incorporated into planar lipid bilayers showed that addition of 10 mM P(i) to the cis chamber increased the open probability of the channel by 91%. These results demonstrate that concentrations of P(i) which occur in vivo during exercise significantly stimuIate the in vitro activity of the skeletal muscle RyR Ca2+ release channel.	UNIV MINNESOTA, DEPT BIOCHEM, ST PAUL, MN 55108 USA; UNIV MINNESOTA, DEPT VET PATHOBIOL, ST PAUL, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities				Mickelson, James/0000-0001-6951-0234; Shomer, Nirah/0000-0003-2520-0108	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031382] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-31382] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN DG, 1989, J PHYSIOL-LONDON, V415, P433, DOI 10.1113/jphysiol.1989.sp017730; ALLEN DG, 1987, CIRC RES, V60, P153, DOI 10.1161/01.RES.60.2.153; ALVES EW, 1987, EUR J BIOCHEM, V166, P647, DOI 10.1111/j.1432-1033.1987.tb13562.x; CADY EB, 1989, J PHYSIOL-LONDON, V418, P311, DOI 10.1113/jphysiol.1989.sp017842; CHASE PB, 1988, BIOPHYS J, V53, P935, DOI 10.1016/S0006-3495(88)83174-6; COOKE R, 1985, BIOPHYS J, V48, P789, DOI 10.1016/S0006-3495(85)83837-6; DAWSON MJ, 1978, NATURE, V274, P861, DOI 10.1038/274861a0; ERVASTI JM, 1991, AM J PHYSIOL, V260, pC58, DOI 10.1152/ajpcell.1991.260.1.C58; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; GODT RE, 1989, J PHYSIOL-LONDON, V412, P155, DOI 10.1113/jphysiol.1989.sp017609; HAMILTON SL, 1989, ANAL BIOCHEM, V183, P31, DOI 10.1016/0003-2697(89)90167-X; KUSHMERICK MJ, 1992, P NATL ACAD SCI USA, V89, P7521, DOI 10.1073/pnas.89.16.7521; LAI FA, 1992, AM J PHYSIOL, V263, pC365, DOI 10.1152/ajpcell.1992.263.2.C365; LAI FA, 1988, NATURE, V331, P135; LAI FA, 1989, J BIOL CHEM, V264, P1677; LANNERGREN J, 1991, J PHYSIOL-LONDON, V434, P307; LEE JA, 1991, J PHYSIOL-LONDON, V433, P307, DOI 10.1113/jphysiol.1991.sp018427; MEISSNER G, 1992, MOL CELL BIOCHEM, V114, P119; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MEISSNER G, 1988, MOL CELL BIOCHEM, V82, P59; MICHALAK M, 1988, BIOCHIM BIOPHYS ACTA, V939, P587, DOI 10.1016/0005-2736(88)90106-X; MICKELSON JR, 1988, J BIOL CHEM, V263, P9310; MICKELSON JR, 1986, BIOCHIM BIOPHYS ACTA, V862, P318, DOI 10.1016/0005-2736(86)90234-8; MICKELSON JR, 1990, ARCH BIOCHEM BIOPHYS, V278, P251, DOI 10.1016/0003-9861(90)90255-W; MOORE SA, 1983, J BIOL CHEM, V258, P6266; NOSEK TM, 1990, AM J PHYSIOL, V259, pC933, DOI 10.1152/ajpcell.1990.259.6.C933; OTSU K, 1990, J BIOL CHEM, V265, P13472; ROUSSEAU E, 1986, BIOPHYS J, V50, P1009, DOI 10.1016/S0006-3495(86)83543-3; ROUSSEAU E, 1990, PFLUG ARCH EUR J PHY, V415, P645, DOI 10.1007/BF02583520; SHOMER NH, 1993, AM J PHYSIOL, V264, pC125, DOI 10.1152/ajpcell.1993.264.1.C125; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; SMITH JS, 1986, J GEN PHYSIOL, V88, P773; STRAND MA, 1993, BIOCHIM BIOPHYS ACTA, V1175, P319, DOI 10.1016/0167-4889(93)90224-D; WESTERBLAD H, 1991, J GEN PHYSIOL, V98, P615, DOI 10.1085/jgp.98.3.615; WESTERBLAD H, 1991, AM J PHYSIOL, V261, pC195, DOI 10.1152/ajpcell.1991.261.2.C195	36	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					192	198						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276794				2022-12-27	WOS:A1994MR21900037
J	GALEANO, NF; MILNE, R; MARCEL, YL; WALSH, MT; LEVY, E; NGUYEN, TD; GLEESON, A; ARAD, Y; WITTE, L; ALHAIDERI, M; RUMSEY, SC; DECKELBAUM, RJ				GALEANO, NF; MILNE, R; MARCEL, YL; WALSH, MT; LEVY, E; NGUYEN, TD; GLEESON, A; ARAD, Y; WITTE, L; ALHAIDERI, M; RUMSEY, SC; DECKELBAUM, RJ			APOPROTEIN-B STRUCTURE AND RECEPTOR RECOGNITION OF TRIGLYCERIDE-RICH LOW-DENSITY-LIPOPROTEIN (LDL) IS MODIFIED IN SMALL LDL BUT NOT IN TRIGLYCERIDE-RICH LDL OF NORMAL SIZE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SKIN FIBROBLASTS; APOLIPOPROTEIN-B; MONOCLONAL-ANTIBODIES; FATTY-ACIDS; HUMAN-PLASMA; BINDING; CELLS; HYPERTRIGLYCERIDEMIA; EXPRESSION; METABOLISM	We compared the effect of lipid composition and particle size of triglyceride-rich low density lipoprotein (LDL) upon apoprotein B conformation and binding to the LDL receptor. Three groups of triglyceride-rich LDL were studied: (a) LDL isolated from chronic hypertriglyceridemic individuals (HTG-LDL); (b) normal LDL made triglyceride-rich by in vitro incubation with triglyceride emulsion and the neutral lipid transfer protein (R-LDL); and (c) LDL from normolipidemic individuals made acutely hypertriglyceridemic by intravenous infusion of 10% Intralipid (IV-LDL). HTG-LDL was small and dense, whereas R-LDL and IV-LDL had normal size. HTG-LDL, but not R-LDL or IV-LDL, exhibited decreased binding to the LDL receptor on human skin fibroblasts in studies at 4-degrees-C and reduced degradation at 37-degrees-C. Apoprotein B conformation was assessed by circular dichroism and by analyzing the immunoreactivity of different monoclonal antibodies. HTG-LDL but not R-LDL or IV-LDL showed a change in the CD spectra and a consistent decrease in the immunoreactivity of monoclonal antibody 3F5 (2.5-fold) which recognizes an epitope adjacent to the receptor binding domain of apoprotein B. These findings suggest that in triglyceride-rich LDL, the relative content of neutral lipid in the core of LDL in the absence of changes in the size of the particle does not significantly affect apoprotein B conformation or its affinity for the LDL receptor.	COLUMBIA UNIV,DEPT PEDIAT,630 W 168TH ST,NEW YORK,NY 10032; COLUMBIA UNIV,DEPT MED,NEW YORK,NY 10032; COLUMBIA UNIV,INST HUMAN NUTR,NEW YORK,NY 10032; UNIV OTTAWA,INST HEART,LIPOPROT & ATHEROSCLEROSIS GRP,OTTAWA K1Y 4E9,ONTARIO,CANADA; BOSTON UNIV,MED CTR,INST BIOPHYS,BOSTON,MA 02118; UNIV MONTREAL,DEPT NUTR,MONTREAL H3T 1CS,PQ,CANADA	Columbia University; Columbia University; Columbia University; University of Ottawa; University of Ottawa Heart Institute; Boston University; Universite de Montreal					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000065] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040404, P50HL021006] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1RR0065] Funding Source: Medline; NHLBI NIH HHS [HL-21006, HL-40404] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGNANI G, 1991, ARTERIOSCLER THROMB, V11, P1021, DOI 10.1161/01.ATV.11.4.1021; ARAD Y, 1992, CIRCULATION, V86, P551; AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917; AVIRAM M, 1988, J BIOL CHEM, V263, P15416; AVIRAM M, 1988, J BIOL CHEM, V263, P16842; AVIRAM M, 1991, J BIOL CHEM, V266, P11567; AVIRAM M, 1993, J CLIN INVEST, V91, P1942, DOI 10.1172/JCI116413; AVIRAM M, 1989, ARTERIOSCLEROSIS, V9, P67, DOI 10.1161/01.ATV.9.1.67; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BAUDET MF, 1986, CLIN PHYSIOL BIOCH, V4, P173; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; Buege J A, 1978, Methods Enzymol, V52, P302; CASTELLI WP, 1990, ATHER REV, V21, P7; CHAIT A, 1984, BIOCHIM BIOPHYS ACTA, V795, P314, DOI 10.1016/0005-2760(84)90081-X; CHAPPELL DA, 1991, J BIOL CHEM, V266, P19296; CHAPPELL DA, 1992, J BIOL CHEM, V267, P270; DECKELBAUM RJ, 1984, ARTERIOSCLEROSIS, V4, P225, DOI 10.1161/01.ATV.4.3.225; DECKELBAUM RJ, 1982, J BIOL CHEM, V257, P6509; DECKELBAUM RJ, 1988, BIOCHIM BIOPHYS ACTA, V961, P233; DEGRAAF J, 1991, ARTERIOSCLER THROMB, V11, P298, DOI 10.1161/01.ATV.11.2.298; DEJAGER S, 1993, J LIPID RES, V34, P295; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; EISENBERG S, 1984, J CLIN INVEST, V74, P470, DOI 10.1172/JCI111444; GIBSON JC, 1983, J LIPID RES, V24, P886; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GRANOT E, 1985, BIOCHIM BIOPHYS ACTA, V833, P308, DOI 10.1016/0005-2760(85)90203-6; HIRAMATSU K, 1985, DIABETES, V34, P8, DOI 10.2337/diabetes.34.1.8; HURTCAMEJO E, 1990, J LIPID RES, V31, P1387; Innerarity T L, 1986, Methods Enzymol, V129, P542; INNERARITY TL, 1987, P NATL ACAD SCI USA, V84, P6919, DOI 10.1073/pnas.84.19.6919; KINOSHITA M, 1990, J LIPID RES, V31, P701; KLEINMAN Y, 1985, J CLIN INVEST, V75, P1796, DOI 10.1172/JCI111892; KLEINMAN Y, 1988, J LIPID RES, V29, P729; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; KRIEGER M, 1978, J BIOL CHEM, V253, P4093; KRIEGER M, 1979, J BIOL CHEM, V254, P3845; KUNITAKE ST, 1990, J BIOL CHEM, V265, P20739; LIMBIRD LE, 1986, CELL SURFACE RECEPTO, P51; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCEL YL, 1988, ARTERIOSCLEROSIS, V8, P832, DOI 10.1161/01.ATV.8.6.832; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MCKEONE BJ, 1993, J CLIN INVEST, V91, P1926, DOI 10.1172/JCI116411; MCNAMARA JR, 1987, ARTERIOSCLEROSIS, V7, P483, DOI 10.1161/01.ATV.7.5.483; MILNE R, 1989, J BIOL CHEM, V264, P19754; MILNE RW, 1983, ARTERIOSCLEROSIS, V3, P23, DOI 10.1161/01.ATV.3.1.23; NENSETER MS, 1992, ARTERIOSCLER THROMB, V12, P369, DOI 10.1161/01.ATV.12.3.369; NIGON F, 1991, J LIPID RES, V32, P1741; PATSCH JR, 1974, J LIPID RES, V15, P356; PEASE RJ, 1990, J BIOL CHEM, V265, P553; SCHONFELD G, 1979, J CLIN INVEST, V64, P1288, DOI 10.1172/JCI109584; SCHONFELD G, 1986, J LIPID RES, V27, P583; SHEN MMS, 1981, J LIPID RES, V22, P236; SHEPHERD J, 1985, ARTERIOSCLEROSIS, V5, P162, DOI 10.1161/01.ATV.5.2.162; SMITH JB, 1976, J LAB CLIN MED, V88, P167; TENG B, 1983, P NATL ACAD SCI-BIOL, V80, P6662, DOI 10.1073/pnas.80.21.6662; TENG B, 1985, J BIOL CHEM, V260, P5067; TIKKANEN MJ, 1983, J LIPID RES, V24, P1494; TILLEY L, 1988, J BIOL CHEM, V263, P17541; VAKAKIS N, 1983, BIOCHIM BIOPHYS ACTA, V751, P280, DOI 10.1016/0005-2760(83)90285-0; VEGA GL, 1986, ARTERIOSCLEROSIS, V6, P395, DOI 10.1161/01.ATV.6.4.395; WALSH MT, 1990, BIOCHEMISTRY-US, V29, P6250, DOI 10.1021/bi00478a020; WINDLER E, 1980, J BIOL CHEM, V255, P8303; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; YOUNG SG, 1987, J CLIN INVEST, V79, P1831, DOI 10.1172/JCI113025	64	147	150	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					511	519						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276844				2022-12-27	WOS:A1994MR21900083
J	OTTONELLO, S; SCITA, G; MANTOVANI, G; CAVAZZINI, D; ROSSI, GL				OTTONELLO, S; SCITA, G; MANTOVANI, G; CAVAZZINI, D; ROSSI, GL			RETINOL BOUND TO CELLULAR RETINOL-BINDING PROTEIN IS A SUBSTRATE FOR CYTOSOLIC RETINOIC ACID SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MICROSOMES; VITAMIN-A; PIGMENT-EPITHELIUM; SMALL-INTESTINE; BOVINE RETINA; ACYL-COA; METABOLISM; ESTERIFICATION; CELLS; DIFFERENTIATION	Retinol bound to cellular retinol-binding protein (CRBP) was found to be oxidized to retinoic acid by a soluble activity from calf liver. Cytosolic retinoic acid synthesis from retinol-CRBP was strictly dependent on the exogenous supply of either NAD or NADP. NAD-supported reactions carried out in the presence or in the absence of dimethyl sulfoxide yielded apparent K(m) and V(max) values for the retinol-CRBP complex of 3.5 +/- 0.6 muM, 611 +/- 49 pmol h-1 (mg of protein)-1, and 0.84 +/- 0.12 muM, 601 +/- 38 pmol h-1 (mg of protein)-1, respectively. The corresponding values for the oxidation of free retinol, dissolved in dimethyl sulfoxide, were 7.1 +/- 0.3 muM and 948 +/- 47 pmol h-1 (mg of protein)-1. Since the dissociation constant of the bovine retinol-CRBP complex is less than 10(-8) M, whereas the K(m) for retinol-CRBP is of the same order as the K(m) for free retinol, synthesis of retinoic acid from retinol-CRBP does not rely on prior dissociation of retinol. ApoCRBP proved to be a specific inhibitor of retinoic acid synthesis from CRBP-bound retinol. Its inhibitory effect was indistinguishable from the dilution of the radioactive retinol-CRBP substrate that was obtained by the addition of unlabeled holoCRBP. In contrast, the oxidation of CRBP-bound retinol was not inhibited by the addition of other retinoid binding proteins nor by the addition of either free retinol or retinol complexed with proteins distinct from CRBP. These results indicate that the protein moiety of holoCRBP is specifically recognized by the cytosolic enzyme system that catalyzes retinoic acid synthesis from CRBP-bound retinol.			OTTONELLO, S (corresponding author), UNIV PARMA,INST BIOCHEM SCI,I-43100 PARMA,ITALY.		Cavazzini, Davide/C-8154-2014; Scita, Giorgio/J-9670-2012	Cavazzini, Davide/0000-0002-1743-2390; Scita, Giorgio/0000-0001-7984-1889				Baginski ES, 1974, METH ENZYMOL; Bergmeyer HU., 1974, METHODS ENZYMATIC AN, P574, DOI [10.1016/B978-0-12-091302-2.50010-4, DOI 10.1016/B978-0-12-091302-2.50010-4]; BERMAN ER, 1980, BIOCHIM BIOPHYS ACTA, V630, P36, DOI 10.1016/0304-4165(80)90135-X; BERNI R, 1989, COMP BIOCHEM PHYS B, V94, P79, DOI 10.1016/0305-0491(89)90014-X; BLOMHOFF R, 1991, PHYSIOL REV, V71, P951, DOI 10.1152/physrev.1991.71.4.951; BOERMAN MHEM, 1991, J BIOL CHEM, V266, P22273; BRADFORD MM, 1976, ANAL BIOCHEM, V150, P273; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; CHYTIL F, 1984, RETINOIDS, V2, P89; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; COLANTUONI V, 1985, BIOCHEM BIOPH RES CO, V130, P431, DOI 10.1016/0006-291X(85)90435-8; COWAN SW, 1993, J MOL BIOL, V230, P1225, DOI 10.1006/jmbi.1993.1238; CROW JA, 1987, ARCH BIOCHEM BIOPHYS, V254, P372, DOI 10.1016/0003-9861(87)90113-5; DE LUCA LM, 1991, FASEB J, V5, P2924; DIETZ AA, 1967, ANAL BIOCHEM, V20, P246, DOI 10.1016/0003-2697(67)90030-9; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; ERIKSSON U, 1987, J CELL PHYSIOL, V133, P482, DOI 10.1002/jcp.1041330308; FIORELLA PD, 1991, J BIOL CHEM, V266, P16572; FUGATE RD, 1980, BIOCHIM BIOPHYS ACTA, V625, P28, DOI 10.1016/0005-2795(80)90105-1; Haq R, 1988, Biochem Biophys Res Commun, V156, P712, DOI 10.1016/S0006-291X(88)80901-X; HARRISON EH, 1987, J LIPID RES, V28, P973; HERR FM, 1992, BIOCHEMISTRY-US, V31, P6748, DOI 10.1021/bi00144a014; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; KAKKAD BP, 1988, J BIOL CHEM, V263, P12916; KIM CI, 1992, ARCH BIOCHEM BIOPHYS, V294, P388, DOI 10.1016/0003-9861(92)90700-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEO MA, 1984, ARCH BIOCHEM BIOPHYS, V234, P305, DOI 10.1016/0003-9861(84)90353-9; LEO MA, 1985, J BIOL CHEM, V260, P5228; LEO MA, 1987, ARCH BIOCHEM BIOPHYS, V259, P241, DOI 10.1016/0003-9861(87)90492-9; LEROY P, 1992, RETINOIDS NORMAL DEV, P7; NAPOLI JL, 1987, ARCH BIOCHEM BIOPHYS, V255, P95, DOI 10.1016/0003-9861(87)90298-0; NAPOLI JL, 1991, BIOMED PHARMACOTHER, V45, P131, DOI 10.1016/0753-3322(91)90101-X; NAPOLI JL, 1986, J BIOL CHEM, V261, P3592; NAPOLI JL, 1990, BIOCHIM BIOPHYS ACTA, V1034, P228, DOI 10.1016/0304-4165(90)90081-7; NAPOLI JL, 1990, METHOD ENZYMOL, V189, P470; NOY N, 1990, BIOCHEMISTRY-US, V29, P3878, DOI 10.1021/bi00468a012; Ong D, 1980, Methods Enzymol, V67, P288; ONG DE, 1987, J BIOL CHEM, V262, P2729; ONG DE, 1988, J BIOL CHEM, V263, P5789; OTTONELLO S, 1984, CURR EYE RES, V3, P1085, DOI 10.3109/02713688409000806; OTTONELLO S, 1987, J BIOL CHEM, V262, P3975; POSCH KC, 1992, J BIOL CHEM, V267, P19676; POSCH KC, 1991, BIOCHEMISTRY-US, V30, P6224, DOI 10.1021/bi00239a021; POSCH KC, 1989, ARCH BIOCHEM BIOPHYS, V274, P171, DOI 10.1016/0003-9861(89)90428-1; ROBERTS AB, 1980, ARCH BIOCHEM BIOPHYS, V199, P374, DOI 10.1016/0003-9861(80)90293-3; ROSS AC, 1993, FASEB J, V7, P317, DOI 10.1096/fasebj.7.2.8440409; ROSS AC, 1982, J BIOL CHEM, V257, P2453; SAARI JC, 1982, BIOCHIM BIOPHYS ACTA, V716, P266, DOI 10.1016/0304-4165(82)90277-X; SHIH TW, 1991, DRUG METAB DISPOS, V19, P332; SHINGLETON JL, 1989, BIOCHEMISTRY-US, V28, P9641, DOI 10.1021/bi00451a015; SIEGENTHALER G, 1990, METHOD ENZYMOL, V189, P530; SIEGENTHALER G, 1990, BIOCHEM J, V268, P371, DOI 10.1042/bj2680371; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; STUMP DG, 1991, J BIOL CHEM, V266, P4622; TAKASE S, 1979, P NATL ACAD SCI USA, V76, P2204, DOI 10.1073/pnas.76.5.2204; THALLER C, 1988, DEVELOPMENT, V103, P473; TIMMERS AMM, 1986, J LIPID RES, V27, P979; WEI LN, 1989, MOL ENDOCRINOL, V3, P454, DOI 10.1210/mend-3-3-454; WILLIAMS JB, 1985, P NATL ACAD SCI USA, V82, P4658, DOI 10.1073/pnas.82.14.4658; WOLF G, 1984, PHYSIOL REV, V64, P873, DOI 10.1152/physrev.1984.64.3.873; YANG N, 1991, P NATL ACAD SCI USA, V88, P3559, DOI 10.1073/pnas.88.9.3559; YOST RW, 1988, J BIOL CHEM, V263, P18693	62	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27133	27142						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262951				2022-12-27	WOS:A1993MM26200045
J	OZAWA, K; HAGIWARA, H; TANG, XR; SAKA, F; KITABAYASHI, I; SHIROKI, K; FUJINAGA, K; ISRAEL, A; GACHELIN, G; YOKOYAMA, K				OZAWA, K; HAGIWARA, H; TANG, XR; SAKA, F; KITABAYASHI, I; SHIROKI, K; FUJINAGA, K; ISRAEL, A; GACHELIN, G; YOKOYAMA, K			NEGATIVE REGULATION OF THE GENE FOR H-2K(B) CLASS-I ANTIGEN BY ADENOVIRUS 12-E1A IS MEDIATED BY A CAA REPEATED ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TRANSCRIPTIONAL CONTROL; TRANSFORMED-CELLS; MESSENGER-RNA; RETINOIC ACID; RAT-CELLS; E1A; EXPRESSION; PROMOTER; SEQUENCES	Both positive and negative regulatory elements responsive to the product of the adenovirus type 12 E1A gene are located in the promoter region of the gene for mouse H-2K(bm1) major histocompatibility complex (MHC) class I antigen (1). We have analyzed the negative regulatory element that is affected by E1A and identified a target CAA repeated motif, CAA(A)CAAA, within -1725 to -1705 and -1591 to -1568 in a 316-bp sequence located in the far upstream region of H-2K(b) promoter (-1837 to -1522; +1 refers to the cap site). The extent of cell surface expression of the MHC class 1 antigen was significantly decreased in the case of transfectants obtained by introducing an expression plasmid that included MHC class 1 cDNA with the CAA repeated element, as compared with that of a plasmid with mutated CAA repeats. We have also characterized the nuclear proteins that bind to this motif. The analysis of the effects of mutations during competition assays of in vivo and gel retardation competition assays demonstrated that the CAA repeated element is essential not only for E1A-dependent repression of transcription but also for the cell surface expression of the product of the mouse H-2K(b) class I gene, presumably through nuclear proteins that specifically bind to it.	INST PHYS & CHEM RES, TSUKUBA LIFE SCI CTR, 3-1-1 KOYADAI, TSUKUBA, IBARAKI 305, JAPAN; UNIV TOKYO, INST MED, TOKYO 108, JAPAN; SAPPORO UNIV, SCH MED, SAPPORO 060, JAPAN; INST PASTEUR, UNITE BIOL MOLEC GENE, F-75724 PARIS 15, FRANCE	RIKEN; University of Tokyo; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Kitabayashi, Issay/G-2204-2017	Kitabayashi, Issay/0000-0002-8409-0407				ACKIL AM, 1988, ONCOGENE, V3, P483; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BERK AJ, 1986, CANCER SURV, V5, P367; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COCHET M, 1986, IMMUNOGENETICS, V24, P267, DOI 10.1007/BF00364531; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EAGER KB, 1985, P NATL ACAD SCI USA, V82, P5525, DOI 10.1073/pnas.82.16.5525; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FLINT SJ, 1980, MOL BIOL TUMOR VIRUS, V2, P547; FRIED M, 1981, NUCLEIC ACIDS RES, V5, P3157; FRIEDMAN DJ, 1988, VIROLOGY, V165, P303, DOI 10.1016/0042-6822(88)90689-7; GALLIMORE PH, 1979, COLD SPRING HARB SYM, V44, P703, DOI 10.1101/SQB.1980.044.01.075; GE RW, 1992, J VIROL, V66, P6969, DOI 10.1128/JVI.66.12.6969-6978.1992; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1984, ADENOVIRUSES, P339; GRAND RJA, 1987, BIOCHEM J, V241, P25, DOI 10.1042/bj2410025; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; HEN R, 1986, NATURE, V321, P249, DOI 10.1038/321249a0; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; KATOH S, 1990, EMBO J, V9, P127, DOI 10.1002/j.1460-2075.1990.tb08088.x; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; KITABAYASHI I, 1992, EMBO J, V11, P167, DOI 10.1002/j.1460-2075.1992.tb05039.x; KRALLI A, 1992, J VIROL, V66, P6979, DOI 10.1128/JVI.66.12.6979-6988.1992; LERNARDO M, 1989, EMBO J, V8, P3351; LITTLE JW, 1986, CELL, V46, P1043; MAK S, 1979, VIROLOGY, V98, P456, DOI 10.1016/0042-6822(79)90568-3; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; MEIJER I, 1989, J VIROL, V63, P4039, DOI 10.1128/JVI.63.9.4039-4042.1989; MIYAZAKI J, 1986, P NATL ACAD SCI USA, V83, P9537, DOI 10.1073/pnas.83.24.9537; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; OZAWA K, 1990, NUCLEIC ACIDS RES, V18, P4185, DOI 10.1093/nar/18.14.4185; REYES AA, 1981, IMMUNOGENETICS, V14, P383, DOI 10.1007/BF00373318; REYES AA, 1982, P NATL ACAD SCI-BIOL, V79, P3270, DOI 10.1073/pnas.79.10.3270; ROEHM N, 1982, P NATL ACAD SCI USA, V79, P3270; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADA Y, 1985, VIROLOGY, V147, P413, DOI 10.1016/0042-6822(85)90143-6; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SCHULZE DH, 1983, P NATL ACAD SCI-BIOL, V80, P2007, DOI 10.1073/pnas.80.7.2007; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHIROKI K, 1992, J VIROL, V66, P1449, DOI 10.1128/JVI.66.3.1449-1457.1992; SHIROKI K, 1984, J VIROL, V50, P854, DOI 10.1128/JVI.50.3.854-863.1984; SOGAWA K, 1989, EUR J BIOCHEM, V181, P539, DOI 10.1111/j.1432-1033.1989.tb14757.x; STEIN R, 1984, MOL CELL BIOL, V4, P2792, DOI 10.1128/MCB.4.12.2792; STEINMETZ M, 1981, CELL, V24, P125, DOI 10.1016/0092-8674(81)90508-0; TIMMERS HTM, 1989, J VIROL, V63, P1470, DOI 10.1128/JVI.63.3.1470-1473.1989; VAESSEN RTMJ, 1986, EMBO J, V5, P335, DOI 10.1002/j.1460-2075.1986.tb04217.x; VAESSEN RTMJ, 1987, SCIENCE, V235, P1486, DOI 10.1126/science.3823900; VANDENELSEN P, 1982, GENE, V18, P175, DOI 10.1016/0378-1119(82)90115-9; VELCICH A, 1986, MOL CELL BIOL, V6, P4019, DOI 10.1128/MCB.6.11.4019; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; YAMASHITA T, 1982, Tumor Research, V17, P9; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7363, DOI 10.1073/pnas.84.21.7363; YOUNG KS, 1989, MOL CELL BIOL, V9, P3109, DOI 10.1128/MCB.9.7.3109; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	63	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27258	27268						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262966				2022-12-27	WOS:A1993MM26200062
J	SPERLING, P; LINSCHEID, M; STOCKER, S; MUHLBACH, HP; HEINZ, E				SPERLING, P; LINSCHEID, M; STOCKER, S; MUHLBACH, HP; HEINZ, E			IN-VIVO DESATURATION OF CIS-DELTA-9-MONOUNSATURATED TO CIS-DELTA-9,12-DIUNSATURATED ALKENYLETHER GLYCEROLIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SUSPENSION CULTURES; OLEOYL-PHOSPHATIDYLCHOLINE; ETHER GLYCEROLIPIDS; LINOLEIC-ACID; PLANT LIPIDS; FATTY-ACIDS; CHROMATOGRAPHY; RAPE; ALKYLGLYCEROLS; PHOSPHOLIPIDS	Plants convert lipid-bound cis-n-9 monoenoic to polyenoic fatty acid residues without involvement of corresponding CoA-thioesters. To provide additional evidence for this type of lipid-linked desaturation we incubated sn-1-O- and 2-O-(cis-9)octadecenylglycerol isomers with photoautotrophic cell cultures from tomato. After 14 days the fractions of phosphatidylcholine and monogalactosyldiacylglycerol were isolated and the incorporated glycerol ether backbones released by treatment with LiAlH4 (reduction of ester bonds) and short acid hydrolysis (cleavage of enol ether bonds). High performance liquid chromatography and mass spectroscopy of the products in appropriately derivatized form showed that the (cis-9)octadecenyl group in the sn-1 position of the phospholipid was nearly completely desaturated to a (cis-9,12)octadecadienyl residue having the same double bond arrangement as linoleic acid. In the galactolipid fraction the desaturation had progressed to octadecatrienyl residues. Similarly, the octadecenyl residue in the sn-2 position of the phospholipid was nearly completely desaturated to an octadecadienyl group. These results are unambiguous proof for lipid-linked desaturation by both microsomal and plastidial desaturase systems of plants.	UNIV HAMBURG,INST ALLGEMEINE BOT,OHNHORSTSTR 18,D-22609 HAMBURG,GERMANY; INST SPEKTROCHEM & ANGEW SPEKTROSKOPIE,D-44139 DORTMUND,GERMANY	University of Hamburg			Linscheid, Michael W/D-2125-2009; Linscheid, Michael/ABB-7808-2020	Linscheid, Michael W/0000-0002-8902-1734; 				BROWSE J, 1991, ANNU REV PLANT PHYS, V42, P467, DOI 10.1146/annurev.pp.42.060191.002343; Egge H., 1983, ETHER LIPIDS, P17, DOI [10.1016/B978-0-12-468780-6.50007-X, DOI 10.1016/B978-0-12-468780-6.50007-X]; ENOCH HG, 1976, J BIOL CHEM, V251, P5095; FRANCIS GW, 1981, CHEM PHYS LIPIDS, V29, P369, DOI 10.1016/0009-3084(81)90070-0; HEINZ E, 1977, H-S Z PHYSIOL CHEM, V358, P897, DOI 10.1515/bchm2.1977.358.2.897; HEINZ E, 1979, CHEM PHYS LIPIDS, V24, P265, DOI 10.1016/0009-3084(79)90032-X; HOLLOWAY PW, 1983, ENZYMES, V16, P63; HUSEMANN W, 1977, PHYSIOL PLANTARUM, V40, P77, DOI 10.1111/j.1399-3054.1977.tb01498.x; JONES AVM, 1980, BIOCHEM J, V190, P851, DOI 10.1042/bj1900851; KAUFMANN HP, 1971, CHEM PHYS LIPIDS, V6, P325, DOI 10.1016/0009-3084(71)90044-2; KESSELMEIER J, 1985, ANAL BIOCHEM, V144, P319, DOI 10.1016/0003-2697(85)90124-1; KONDO Y, 1981, BIOCHIM BIOPHYS ACTA, V665, P471, DOI 10.1016/0005-2760(81)90260-5; LALAGUNA F, 1908, J AM OIL CHEM SOC, V65, P1808; MARTIN BA, 1986, PLANT PHYSIOL, V81, P41, DOI 10.1104/pp.81.1.41; MYHER JJ, 1974, J LIPID RES, V15, P586; NORMAN HA, 1991, PHYTOCHEMISTRY, V30, P2217, DOI 10.1016/0031-9422(91)83617-T; POHL P, 1970, J CHROMATOGR, V49, P488, DOI 10.1016/S0021-9673(00)93664-1; PUGH EL, 1977, J BIOL CHEM, V252, P68; PUGH EL, 1979, LIPIDS, V14, P159, DOI 10.1007/BF02533867; ROUGHAN PG, 1982, ANNU REV PLANT PHYS, V33, P97, DOI 10.1146/annurev.pp.33.060182.000525; SCHMID HHO, 1967, BIOCHIM BIOPHYS ACTA, V144, P344, DOI 10.1016/0005-2760(67)90163-4; SCHMIDT H, 1993, BIOCHEM J, V289, P777, DOI 10.1042/bj2890777; SIEBERTZ HP, 1977, Z NATURFORSCH C, V32, P193; SLACK CR, 1979, BIOCHEM J, V179, P649, DOI 10.1042/bj1790649; SPERLING P, 1993, EUR J BIOCHEM, V213, P965, DOI 10.1111/j.1432-1033.1993.tb17841.x; STYMNE S, 1978, EUR J BIOCHEM, V90, P223, DOI 10.1111/j.1432-1033.1978.tb12594.x; SZOLDERITS G, 1991, BIOCHIM BIOPHYS ACTA, V1063, P197, DOI 10.1016/0005-2736(91)90371-E; VECHTEL B, 1992, PLANT CELL PHYSIOL, V33, P41; WEBER N, 1985, EUR J BIOCHEM, V146, P323, DOI 10.1111/j.1432-1033.1985.tb08656.x; WEBER N, 1984, APPL MICROBIOL BIOT, V20, P238, DOI 10.1007/BF00250632; WEBER N, 1983, PLANTA, V158, P111, DOI 10.1007/BF00397703; WEBER N, 1982, PLANTA, V155, P225, DOI 10.1007/BF00392720; WEBER N, 1987, FEBS LETT, V211, P225, DOI 10.1016/0014-5793(87)81441-2; YAMAMOTO K, 1991, LIPIDS, V26, P948, DOI 10.1007/BF02535982; YAMAMOTO K, 1991, CHEM PHYS LIPIDS, V60, P39, DOI 10.1016/0009-3084(91)90013-2	35	41	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26935	26940						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262928				2022-12-27	WOS:A1993MM26200018
J	ZHANG, ZJ; SNIDERMAN, AD; KALANT, D; VU, H; MONGE, JC; TAO, YZ; CIANFLONE, K				ZHANG, ZJ; SNIDERMAN, AD; KALANT, D; VU, H; MONGE, JC; TAO, YZ; CIANFLONE, K			THE ROLE OF AMINO-ACIDS IN APOB100 SYNTHESIS AND CATABOLISM IN HUMAN HEPG2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; PERFUSED-RAT-LIVER; AMBULATORY PERITONEAL-DIALYSIS; APOLIPOPROTEIN-B SECRETION; PROTEIN-SYNTHESIS; HEPATOMA-CELLS; ALBUMIN SYNTHESIS; MESSENGER-RNA; HEPATOCYTES; GENE	The object of this study was to examine the effects of extracellular amino acids on hepatic apoB100 metabolism using a transformed human liver cell line (HepG2) as a hepatocyte model. The data demonstrate that reduced extracellular amino acids resulted in marked increases in apoB100 concentrations in the medium (87 +/- 10% increase; p < 0.002). These data contrast with the effects of amino acids on secretion of total hepatic protein into the medium, which increased by 541 +/- 83% at 5.5 mg/ml amino acids compared to the low (0.5 mg/ml) amino acid medium (p < 0.01), pointing to a positive relationship between the concentration of amino acids in the medium and overall secretion of protein by the HepG2 cells. No significant effect of medium amino acid concentration on intracellular synthesis of cholesterol ester, cholesterol, triglyceride, or apoA1 secretion was evident. Amino acids also affected the activity of the low density lipoprotein pathway: at lower medium amino acid concentration, specific cell-associated radioactivity and cellular degradation were increased (117 +/- 24 and 233 +/- 13% at 0.5 versus 5.5 mg/ml amino acids, respectively). Pulse-chase analysis demonstrated that there was no difference in secretion efficiency of apoB (36 +/- 6 versus 46 +/- 8% in low versus high amino acid medium, respectively), but that the initial amount of [H-3]apoB synthesized was greater in the low amino acid medium (10.5 +/- 3.8 versus 5.7 +/- 1.7 x 10(3) dpm [H-3] apoB/mg of cell protein; p < 0.05). In contrast, the initial amount of [H-3]albumin synthesized was much greater in the high amino acid medium (26.6 +/- 5.0 versus 54.6 +/- 19.0 x 10(3) dpm [H-3]albumin/mg of cell protein in low versus high amino acid medium, respectively; p < 0.05). Slot blot analysis of apoB mRNA was 87 +/- 22% higher in lower amino acid medium as compared to the high amino acid medium (p < 0.01). These results demonstrate that amino acids have a profound negative regulatory effect on apoB synthesis and secretion and may shed light on the pathogenesis of some clinical dyslipidemias such as the increased plasma apoB levels in patients treated with continuous ambulatory peritoneal dialysis.	ROYAL VICTORIA HOSP, MCGILL UNIT PREVENT CARDIOVASC DIS, 687 PINE AVE W, MONTREAL H3A 1A1, QUEBEC, CANADA	McGill University; Royal Victoria Hospital								BERGSTROM J, 1990, CLIN SCI, V79, P331, DOI 10.1042/cs0790331; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRESLOW JL, 1985, P NATL ACAD SCI USA, V82, P6825; BRUNO M, 1989, KIDNEY INT, V35, P1189, DOI 10.1038/ki.1989.109; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIANFLONE K, 1992, ARTERIOSCLER THROMB, V12, P271, DOI 10.1161/01.ATV.12.3.271; CIANFLONE KM, 1990, J LIPID RES, V31, P2045; CIANFLONE KM, 1990, J CLIN INVEST, V85, P722, DOI 10.1172/JCI114497; DAVIS RA, 1980, J BIOL CHEM, V255, P2039; DIXON JL, 1991, J BIOL CHEM, V266, P5080; EAGLE H, 1959, SCIENCE, V130, P432, DOI 10.1126/science.130.3373.432; EVERSON WV, 1989, AM J PHYSIOL, V256, pC18, DOI 10.1152/ajpcell.1989.256.1.C18; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERNSTROM JD, 1979, AM J CLIN NUTR, V32, P1912, DOI 10.1093/ajcn/32.9.1912; FLAIM KE, 1982, J BIOL CHEM, V257, P2939; FLAIM KE, 1982, J BIOL CHEM, V257, P2932; FUKI IV, 1989, BIOCHIM BIOPHYS ACTA, V1001, P235, DOI 10.1016/0005-2760(89)90153-7; GOLDBERG ACK, 1977, KIDNEY INT, V12, P23, DOI 10.1038/ki.1977.75; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GROVE RI, 1991, J BIOL CHEM, V266, P18194; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HEVIA P, 1980, J NUTR, V110, P1231, DOI 10.1093/jn/110.6.1231; HUTSON SM, 1987, AM J PHYSIOL, V252, pE291, DOI 10.1152/ajpendo.1987.252.3.E291; JACKSON TK, 1990, J CLIN INVEST, V86, P1746, DOI 10.1172/JCI114900; KATAN MB, 1982, ATHEROSCLEROSIS, V43, P381, DOI 10.1016/0021-9150(82)90037-5; KOPPLE JD, 1982, AM J CLIN NUTR, V36, P395, DOI 10.1093/ajcn/36.3.395; KUROWSKA EM, 1991, J NUTR BIOCHEM, V2, P656, DOI 10.1016/0955-2863(91)90064-C; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARDEUX BR, 1987, J BIOL CHEM, V262, P14514; LEDFORD BE, 1985, EUR J BIOCHEM, V152, P611, DOI 10.1111/j.1432-1033.1985.tb09239.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCKENZIE IF, 1968, J CLIN INVEST, V47, P1685, DOI 10.1172/JCI105859; MONTOYA A, 1989, IN VITRO CELL DEV B, V25, P358; MORTIMORE GE, 1988, METHOD ENZYMOL, V166, P461; NASSET ES, 1969, P SOC EXP BIOL MED, V132, P1077, DOI 10.3181/00379727-132-34370; PULLINGER CR, 1989, J LIPID RES, V30, P1065; REMESY C, 1978, BIOCHEM J, V170, P321, DOI 10.1042/bj1700321; SHEN MMS, 1981, J LIPID RES, V22, P236; SNIDERMAN A, 1987, ATHEROSCLEROSIS, V65, P257, DOI 10.1016/0021-9150(87)90041-4; SORCITHOMAS M, 1991, J BIOL CHEM, V266, P18045; SPARKS JD, 1990, J BIOL CHEM, V265, P8854; THERIAULT A, 1992, BIOCHEM BIOPH RES CO, V186, P617, DOI 10.1016/0006-291X(92)90791-I; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WADE DP, 1988, EUR J BIOCHEM, V174, P213, DOI 10.1111/j.1432-1033.1988.tb14084.x; WHITE AL, 1992, J BIOL CHEM, V267, P15657; WURTMAN RJ, 1968, NEW ENGL J MED, V279, P171, DOI 10.1056/NEJM196807252790401; YAMAUCHI A, 1992, AM J PHYSIOL, V263, pC397, DOI 10.1152/ajpcell.1992.263.2.C397; YOUNG G A, 1991, Amino Acids (Vienna), V1, P183, DOI 10.1007/BF00806915; YOUNG GA, 1989, NEPHROL DIAL TRANSPL, V4, P285, DOI 10.1093/oxfordjournals.ndt.a091874; YOUNG SG, 1986, CLIN CHEM, V32, P1484	53	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26920	26926						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262926				2022-12-27	WOS:A1993MM26200016
J	FAINZILBER, M; KOFMAN, O; ZLOTKIN, E; GORDON, D				FAINZILBER, M; KOFMAN, O; ZLOTKIN, E; GORDON, D			A NEW NEUROTOXIN RECEPTOR-SITE ON SODIUM-CHANNELS IS IDENTIFIED BY A CONOTOXIN THAT AFFECTS SODIUM-CHANNEL INACTIVATION IN MOLLUSKS AND ACTS AS AN ANTAGONIST IN RAT-BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE-ENDING PARTICLES; SNAIL CONUS-STRIATUS; SCORPION TOXIN; BLASTOMA CELLS; BINDING; VENOM; LOCALIZATION; INHIBITION; PROTEIN	The peptide conotoxin TxVIA is selectively toxic to molluscs and slows sodium current inactivation in mollusc neurons. Here we show that TxVIA binds with high affinity to new sites on sodium channels in both mollusc and rat central nervous systems, despite its lack of toxicity to vertebrates. Furthermore, TxVIA protects from the toxic effects of Conus striatus toxin in rat brain. The TxVIA binding site differs from other neurotoxin receptor sites affecting sodium channel inactivation in that binding is not voltage-dependent and undergoes negative allosteric modulation by veratridine. TxVIA therefore represents a novel category of sodium channel probes, designated delta-conotoxins. TxVIA is shown to discriminate between sodium channels in different phyla by activity but not by binding, thus providing a lead for the study of structural elements affecting gating modes of sodium channels.	HEBREW UNIV JERUSALEM,SILBERMAN INST LIFE SCI,DEPT CELL & ANIM BIOL,IL-91904 JERUSALEM,ISRAEL; BEN GURION UNIV NEGEV,BEER SHEVA MENTAL HLTH CTR,IL-84105 BEER SHEVA,ISRAEL; BEN GURION UNIV NEGEV,DEPT BEHAV SCI,IL-84105 BEER SHEVA,ISRAEL	Hebrew University of Jerusalem; Ben Gurion University; Ben Gurion University				Fainzilber, Mike/0000-0001-8173-8557				BADEN DG, 1989, FASEB J, V3, P1807, DOI 10.1096/fasebj.3.7.2565840; BARHANIN J, 1981, J BIOL CHEM, V256, P5764; BROWN GB, 1986, J NEUROSCI, V6, P2064; CANNON SC, 1993, NEURON, V10, P317, DOI 10.1016/0896-6273(93)90321-H; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.biochem.55.1.953; CATTERALL WA, 1985, TOXICON, V23, P497, DOI 10.1016/0041-0101(85)90034-0; COURAUD F, 1984, HDB NATURAL TOXINS, V2, P659; DYER JR, 1993, NEUROBIOLOGY APLYSIA, P26; FAINZILBER M, 1992, TOXICON, V30, P465, DOI 10.1016/0041-0101(92)90543-E; FAINZILBER M, 1991, EUR J BIOCHEM, V202, P589, DOI 10.1111/j.1432-1033.1991.tb16412.x; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GONOI T, 1984, J NEUROSCI, V4, P2836; GONOI T, 1986, MOL PHARMACOL, V29, P347; GONOI T, 1987, MOL PHARMACOL, V32, P691; GORDON D, 1992, BIOCHEMISTRY-US, V31, P7622, DOI 10.1021/bi00148a025; GORDON D, 1993, FEBS LETT, V315, P125, DOI 10.1016/0014-5793(93)81147-R; GRAY WR, 1988, ANNU REV BIOCHEM, V57, P665, DOI 10.1146/annurev.bi.57.070188.003313; Hashimoto Y., 1973, Publications Seto Mar Biol Lab, V20, P703; HASSON A, 1993, EUR J NEUROSCI, V5, P56, DOI 10.1111/j.1460-9568.1993.tb00205.x; Hille B, 1984, IONIC CHANNELS EXCIT; HILLYARD DR, 1989, BIOCHEMISTRY-US, V28, P358, DOI 10.1021/bi00427a049; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P1207, DOI 10.1021/bi00600a011; KOBAYASHI J, 1982, BIOCHEM BIOPH RES CO, V105, P1389, DOI 10.1016/0006-291X(82)90941-X; KOFMAN O, 1993, PSYCHOPHARMACOLOGY, V110, P229, DOI 10.1007/BF02246978; OLIVERA BM, 1991, J BIOL CHEM, V266, P22067; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RAY R, 1978, J BIOL CHEM, V253, P7307; SATO C, 1992, BIOCHEM BIOPH RES CO, V186, P61, DOI 10.1016/S0006-291X(05)80775-2; SATO C, 1992, BIOCHEM BIOPH RES CO, V186, P1158, DOI 10.1016/0006-291X(92)90868-L; TAMKUN MM, 1981, MOL PHARMACOL, V19, P78; THOMSEN WJ, 1989, P NATL ACAD SCI USA, V86, P10161, DOI 10.1073/pnas.86.24.10161; WEILAND GA, 1981, LIFE SCI, V29, P313, DOI 10.1016/0024-3205(81)90324-6; WILLOW M, 1982, MOL PHARMACOL, V22, P627; ZLOTKIN E, 1987, ENDEAVOUR, V11, P168, DOI 10.1016/0160-9327(87)90280-8	35	112	119	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2574	2580						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300586				2022-12-27	WOS:A1994MV43200036
J	SCHUMANN, MA; RAFFIN, TA				SCHUMANN, MA; RAFFIN, TA			ACTIVATION OF A VOLTAGE-DEPENDENT CHLORIDE CURRENT IN HUMAN NEUTROPHILS BY PHORBOL 12-MYRISTATE 13-ACETATE AND FORMYL-METHIONYL-LEUCYL-PHENYLALANINE - THE ROLE OF PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC CALCIUM; MYRISTATE ACETATE; ION CHANNELS; CA-2+; CELLS; HETEROGENEITY; LYMPHOCYTES; CONDUCTANCE; EXOCYTOSIS; TRANSPORT	Calcium-activated, voltage-independent Cl- currents have been demonstrated in human neutrophils (Krause, K.-H., and Welsh, M. J. (1990) J. Clin. Invest. 85,491-498). The activation is mediated by calcium/calmodulin-dependent protein kinase and not by protein kinase C (PKC) (Schumann, M., Gardner, A. P., and Raffin, T. A. (1993) J. Biol. Chem. 268, 2134-2140). It is not known whether there are Ca2+-independent, voltage-dependent Cl- currents in these cells. Using K+-free solutions and patch-clamp recordings from human neutrophils, we separated the whole cell Cl- current. Base-line Cl- currents of unstimulated cells were small and displayed time and voltage independence; some showed voltage dependence. With a Ca2+-free pipette solution, bath-administered 1 muM phorbol 12-myristate 13-acetate (PMA) or 0.1 muM N-formyl-methionyl-leucyl-phenylalanine (fMLP) for 10 s induced augmented Cl- currents with voltage- and time-dependent outwardly rectifying properties. The threshold voltage of tail Cl- current activation was -69 mV. With a pipette solution containing 0.1 mm Ca2+, bath-administered 0.1 muM fMLP, 1 muM PMA, or 1 muM Ca2+ ionophore A23187 for 30 s induced augmented Cl- currents with voltage-independent properties. With intracellular application of 5 muM PKC inhibitor PKC(19-36), voltage-dependent Cl- currents were no longer activated by PMA or fMLP. Similar application of 5 muM PKC noninhibitory analog [Glu27]PKC(19-36) did not block PMA (or fMLP)-induced Cl- currents. These results indicate that, in addition to Ca2+-activated Cl- currents, human neutrophils have voltage-dependent Cl- currents which are regulated by PKC.	STANFORD UNIV,MED CTR,SCH MED,DIV PULM & CRIT CARE MED,STANFORD,CA 94305	Stanford University					NHLBI NIH HHS [HL455330] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGGIOLINI M, 1990, TRENDS BIOCHEM SCI, V15, P69, DOI 10.1016/0968-0004(90)90179-F; BELL RM, 1991, J BIOL CHEM, V266, P4661; BLOCK ML, 1990, SCIENCE, V247, P1090, DOI 10.1126/science.2309122; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; DAVIES EV, 1991, IMMUNOLOGY, V73, P228; DIVIRGILIO F, 1987, J BIOL CHEM, V262, P4574; DIVIRGILIO F, 1985, BIOCHEM J, V229, P361, DOI 10.1042/bj2290361; EGGLETON P, 1992, J LEUKOCYTE BIOL, V51, P617, DOI 10.1002/jlb.51.6.617; GAY JC, 1990, J LEUKOCYTE BIOL, V47, P49, DOI 10.1002/jlb.47.1.49; GRAY LS, 1986, J IMMUNOL, V136, P3032; GRINSTEIN S, 1989, PHYSIOL REV, V69, P417, DOI 10.1152/physrev.1989.69.2.417; GRINSTEIN S, 1992, AM J PHYSIOL, V263, pC78, DOI 10.1152/ajpcell.1992.263.1.C78; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HELFMAN DM, 1983, BIOCHEM BIOPH RES CO, V111, P847, DOI 10.1016/0006-291X(83)91376-1; HOGG JC, 1987, PHYSIOL REV, V67, P1249, DOI 10.1152/physrev.1987.67.4.1249; HUANG CK, 1989, MEMBRANE BIOCHEM, V8, P61, DOI 10.3109/09687688909082261; KAIBUCHI K, 1983, J BIOL CHEM, V258, P6701; KORCHAK HM, 1984, J BIOL CHEM, V259, P4076; KORCHAK HM, 1980, P NATL ACAD SCI-BIOL, V77, P2721, DOI 10.1073/pnas.77.5.2721; KRAUSE KH, 1990, J CLIN INVEST, V85, P491, DOI 10.1172/JCI114464; LEHRER RI, 1988, ANN INTERN MED, V109, P127, DOI 10.7326/0003-4819-109-2-127; LEW PD, 1984, J CELL BIOL, V99, P1212, DOI 10.1083/jcb.99.4.1212; LEW PD, 1986, J CELL BIOL, V102, P2197, DOI 10.1083/jcb.102.6.2197; LEW PD, 1990, AM REV RESPIR DIS, V141, P5127; MAJUMDAR S, 1991, J BIOL CHEM, V266, P9285; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MARKERT M, 1988, J LAB CLIN MED, V111, P577; MATTHEWS G, 1989, J PHYSIOL-LONDON, V418, P131, DOI 10.1113/jphysiol.1989.sp017831; MERRITT JE, 1993, BIOCHEM J, V289, P919, DOI 10.1042/bj2890919; MYERS JB, 1990, AM J PHYSIOL, V259, pC531, DOI 10.1152/ajpcell.1990.259.4.C531; NASMITH PE, 1987, J BIOL CHEM, V262, P13558; NISHIHIRA J, 1985, J IMMUNOL, V135, P3439; NISHIMOTO I, 1991, NEURON, V6, P547, DOI 10.1016/0896-6273(91)90057-7; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ROSOFF PM, 1988, J BIOL CHEM, V263, P19535; RYVES WJ, 1991, FEBS LETT, V288, P5, DOI 10.1016/0014-5793(91)80989-G; SCHUMANN MA, 1992, BIOCHEM BIOPH RES CO, V185, P531, DOI 10.1016/0006-291X(92)91657-C; SCHUMANN MA, 1993, J BIOL CHEM, V268, P2134; SCHWARZE W, 1984, PFLUG ARCH EUR J PHY, V402, P281, DOI 10.1007/BF00585511; SHAAFI RI, 1988, PROG ALLERGY, V42, P1; SIMCHOWITZ L, 1986, J GEN PHYSIOL, V88, P167, DOI 10.1085/jgp.88.2.167; SMALLWOOD JI, 1992, J LEUKOCYTE BIOL, V51, P84, DOI 10.1002/jlb.51.1.84; SUZUKI Y, 1980, J CLIN INVEST, V66, P1409, DOI 10.1172/JCI109994; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0	46	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2389	2398						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300564				2022-12-27	WOS:A1994MV43200011
J	THOMPSON, SA; HIGASHIYAMA, S; WOOD, K; POLLITT, NS; DAMM, D; MCENROE, G; GARRICK, B; ASHTON, N; LAU, K; HANCOCK, N; KLAGSBRUN, M; ABRAHAM, JA				THOMPSON, SA; HIGASHIYAMA, S; WOOD, K; POLLITT, NS; DAMM, D; MCENROE, G; GARRICK, B; ASHTON, N; LAU, K; HANCOCK, N; KLAGSBRUN, M; ABRAHAM, JA			CHARACTERIZATION OF SEQUENCES WITHIN HEPARIN-BINDING EGF-LIKE GROWTH-FACTOR THAT MEDIATE INTERACTION WITH HEPARIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; FIBROBLAST GROWTH; ESCHERICHIA-COLI; FACTOR FAMILY; CELL-SURFACE; SULFATE; IDENTIFICATION; PROTEIN; CONSTRUCTION; EXPRESSION	Heparin-binding (HB) epidermal growth factor (EGF)-like growth factor (HB-EGF), a member of the EGF protein family, is a potent mitogen for fibroblasts, smooth muscle cells, and keratinocytes that was initially identified as a secreted product of macrophage-like cells. HB-EGF and EGF appear to act on target cells utilizing the same receptor, but HB-EGF is distinguishable from EGF by its strong affinity for heparin. To facilitate studies of structure-function relationships in HB-EGF, a bacterial recombinant expression system was established that produced biologically active HB-EGF with the expected disulfide bonding pattern. Mutagenesis and protease digestion studies of the recombinant HB-EGF, coupled with heparin-binding analyses of synthetic peptides, indicated that the sequences within HB-EGF mediating its interaction with heparin are located primarily in a stretch of 21 amino acids characterized by a high content of lysine and arginine residues. Most of this heparin-binding domain lies in an amino-terminal region of HB-EGF that has no counterpart in EGF, but a portion of the 21-residue sequence extends into the EGF-like region of HB-EGF. In addition, the mutagenesis and synthetic peptide studies indicated that sequences in HB-EGF lying outside of the 21-residue stretch can also influence the interaction with heparin. Finally, a synthetic peptide derived from the 21-residue stretch was found to compete with HB-EGF for binding to Chinese hamster ovary cells, suggesting that the heparin-binding sequences in HB-EGF may also mediate the interaction of this factor with cell surface heparan sulfate proteoglycan.	SCIOS NOVA INC, 2450 BAYSHORE PKWY, Mountain View, CA 94043 USA; CHILDRENS HOSP MED CTR, DEPT SURG RES, BOSTON, MA 02115 USA; CHILDRENS HOSP MED CTR, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Scios; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA037392, R37CA037392] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R44GM046166, R43GM046166, R01GM047397] Funding Source: NIH RePORTER; NCI NIH HHS [CA37392] Funding Source: Medline; NIGMS NIH HHS [GM46166-01, GM47397] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM JA, 1993, BIOCHEM BIOPH RES CO, V190, P125, DOI 10.1006/bbrc.1993.1020; AMANN E, 1985, GENE, V40, P183, DOI 10.1016/0378-1119(85)90041-1; BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; BENNETT GN, 1978, J MOL BIOL, V121, P113, DOI 10.1016/S0022-2836(78)80001-1; BERNARD O, 1991, P NATL ACAD SCI USA, V88, P7625, DOI 10.1073/pnas.88.17.7625; BESNER G, 1990, CELL REGUL, V1, P811, DOI 10.1091/mbc.1.11.811; Besner GE, 1992, GROWTH FACTORS, V7, P289, DOI 10.3109/08977199209046411; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CLOSE TJ, 1982, GENE, V20, P305, DOI 10.1016/0378-1119(82)90048-8; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; COOK PW, 1992, IN VITRO CELL DEV-AN, V28A, P218; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KAMBER B, 1980, HELV CHIM ACTA, V63, P899, DOI 10.1002/hlca.19800630418; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KIMURA H, 1990, NATURE, V348, P257, DOI 10.1038/348257a0; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; MESRI EA, 1993, J BIOL CHEM, V268, P4853; Miller J. H., 1972, EXPT MOL GENETICS, P431; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; OSTMAN A, 1991, CELL REGUL, V2, P503, DOI 10.1091/mbc.2.7.503; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROGHANI M, 1992, J BIOL CHEM, V267, P22156; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SAKAGUCHI K, 1991, J BIOL CHEM, V266, P7270; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SAVAGE CR, 1973, J BIOL CHEM, V248, P7669; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHIPLEY GD, 1984, CANCER RES, V44, P710; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; TEMIZER DH, 1992, J BIOL CHEM, V267, P24892; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WINKLER ME, 1986, J BIOL CHEM, V261, P3838; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	47	145	158	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2541	2549						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300582				2022-12-27	WOS:A1994MV43200032
J	HONDA, Z; TAKANO, T; GOTOH, Y; NISHIDA, E; ITO, K; SHIMIZU, T				HONDA, Z; TAKANO, T; GOTOH, Y; NISHIDA, E; ITO, K; SHIMIZU, T			TRANSFECTED PLATELET-ACTIVATING-FACTOR RECEPTOR ACTIVATES MITOGEN-ACTIVATED PROTEIN (MAP) KINASE AND MAP KINASE KINASE IN CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; PHEOCHROMOCYTOMA PC12 CELLS; SIGNAL TRANSDUCTION; TYROSINE KINASE; GENE-EXPRESSION; PHOSPHORYLATION; RAS; FIBROBLASTS; INSULIN; CASCADE	The platelet-activating factor (PAF) was seen to potently activate mitogen-activated protein (MAP) kinase and MAP kinase kinase through the cloned guinea pig PAF receptor stably expressed in Chinese hamster ovary (CHO) cells. Both 42- and 44-kDa MAP kinases were activated and tyrosine-phosphorylated in response to PAF. The PAF receptor also triggered the production of inositol phosphates and the release of arachidonic acid and inhibited cyclic AMP accumulation. Differential inhibitory effects of pertussis toxin (PTX) on these signals suggested that the PAF receptor couples to both PTX-sensitive and -insensitive G proteins in CHO cells. MAP kinase and MAP kinase kinase activations were partially regulated by PTX-sensitive G proteins. The PAF receptor did not trigger any detectable increase in the GTP form of Ras under the conditions in which the human insulin receptor expressed in the same parent CHO cells potently increased the level. Since these agonists induced comparable MAP kinase activations through cognate receptors, Ras seems to play different roles in MAP kinase activation by the two different classes of receptors. The activation of MAP kinase by the cloned PAF receptor may explain part of the mechanisms underlying PAF-induced differentiation and proliferation in non-inflammatory cells.	UNIV TOKYO,FAC MED,DEPT BIOCHEM,7-3-1 BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC MED,DEPT INTERNAL MED & PHYS THERAPY,BUNKYO KU,TOKYO 113,JAPAN; KYOTO UNIV,INST VIRUS RES,DEPT GENET & MOLEC BIOL,SAKYO KU,KYOTO 60601,JAPAN	University of Tokyo; University of Tokyo; Kyoto University								AHN NG, 1990, J BIOL CHEM, V265, P11495; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BATZER NL, 1993, NATURE, V363, P85; BEHRENS TW, 1990, INT J IMMUNOPHARMACO, V12, P175, DOI 10.1016/0192-0561(90)90051-N; BENVENISTE J, 1972, J EXP MED, V136, P1356, DOI 10.1084/jem.136.6.1356; BIJSTERBOSCH MK, 1985, CELL, V41, P999, DOI 10.1016/S0092-8674(85)80080-5; BITO H, 1992, NEURON, V9, P285, DOI 10.1016/0896-6273(92)90167-C; BLANK ML, 1979, BIOCHEM BIOPH RES CO, V90, P1194, DOI 10.1016/0006-291X(79)91163-X; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COBB MH, 1983, J BIOL CHEM, V258, P2472; DEMOPOULOS CA, 1979, J BIOL CHEM, V254, P9355; DHAR A, 1991, J BIOL CHEM, V266, P18797; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOMEZCAMBRONERO J, 1991, J BIOL CHEM, V266, P6240; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HANAHAN DJ, 1987, ANN REV BIOCH, V55, P69; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HOSHI M, 1988, J BIOL CHEM, V263, P5396; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HWANG SB, 1988, J BIOL CHEM, V263, P3225; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KORNECKI E, 1988, SCIENCE, V260, P315; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEPRINCE C, 1991, LIPIDS, V26, P1204, DOI 10.1007/BF02536532; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MATSUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015; MUROYA K, 1992, ONCOGENE, V7, P277; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PELECH SL, 1988, DEV BIOL, V130, P28, DOI 10.1016/0012-1606(88)90410-1; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAMIEI M, 1993, BIOCHIM BIOPHYS ACTA, V1176, P287, DOI 10.1016/0167-4889(93)90057-V; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1992, J BIOL CHEM, V267, P24149; SEQUINTO SP, 1989, J NEUROSCI RES, V24, P558; SETH A, 1991, J BIOL CHEM, V266, P23521; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; SHIMIZU T, 1992, BIOCHEM PHARMACOL, V44, P1001; SHUKLA SD, 1992, FASEB J, V6, P2296, DOI 10.1096/fasebj.6.6.1312046; SHUKLA SD, 1991, LIPIDS, V26, P1028, DOI 10.1007/BF02536496; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SNYDER F, 1987, PLATELET ACTIVATING; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOBE K, 1991, J BIOL CHEM, V266, P24793; ULLRICH A, 1986, COLD SPRING HARB SYM, V51, P713, DOI 10.1101/SQB.1986.051.01.084; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VARGAFTIG BB, 1980, EUR J PHARMACOL, V65, P185, DOI 10.1016/0014-2999(80)90391-X; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	76	162	164	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2307	2315						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294489				2022-12-27	WOS:A1994MR98800112
J	LIU, YC; MATTHEWS, KS				LIU, YC; MATTHEWS, KS			TRP REPRESSOR MUTATIONS ALTER DNA COMPLEX STOICHIOMETRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; TRYPTOPHAN-SPECIFIC PERMEASE; GAMMA-DELTA RESOLVASE; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURE; OPERATOR DNA; BINDING; APOREPRESSOR; GENE; EXPRESSION	We have examined the interaction of a series of mutant trp repressors with various operator DNA sequences using gel retardation. Binding to 40 base pairs (bp) TrpEDCBA operator yielded patterns distinct from the wild-type protein for superrepressors EK13, EK18, and EK49, with a protein-DNA complex of higher stoichiometry (three dimers/operator) than observed for wild-type repressor (two dimers/operator). This higher stoichiometry complex may contribute to the enhanced binding affinity and higher protein-operator stability observed for the superrepressors. In contrast, DN46 displayed the same complexes characteristic of the wild-type protein, although the complex of a single dimer with operator was more prominent in the DN46 binding pattern than wild-type despite higher apparent affinity of this protein for TrpEDCBA operator than wild-type protein. The binding of AV77 was indistinguishable from the wild-type protein. Similar patterns to that found for TrpEDCBA were also observed for the 40-bp aroH operator and symmetrized derivatives of TrpEDCBA for these superrepressors. Binding of EK13, EK18, and EK49 superrepressors to half-site DNAs, composed of 20 bp of TrpEDCBA sequence coupled with 20 bp of lac operator sequence, yielded 2:1 complex as the primary product with no detectable 3:1 complex; thus, two half-sites appear to be required for generation of the 3:1 complex. Mutation in the tryptophan-binding site can also generate higher order complexes with TrpEDCBA DNA as demonstrated by the binding of VA58; the presence of 3:1 complex with this protein was also dependent on the presence of two half-sites. In addition to effects of sequence changes in the protein, the ligand employed can influence the binding pattern, as demonstrated for EK49 and VA58 using 5-methyl-tryptophan; the 3:1 complex is produced more prominently and at lower protein concentration for both mutants. It is apparent from these data that binding of the trp repressor to DNA is influenced by the operator sequence, the nature of the corepressor, as well as interactions (perhaps involving the N-terminal regions) that occur within and between the dimeric structure of this protein.	RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251	Rice University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022441] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22441] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARROWSMITH CH, 1989, BIOCHEMISTRY-US, V28, P3875, DOI 10.1021/bi00435a037; ARVIDSON DN, 1991, GENETICS, V128, P29; ARVIDSON DN, 1993, J BIOL CHEM, V268, P4362; ARVIDSON DN, 1986, J BIOL CHEM, V261, P238; BASS S, 1987, GENE DEV, V1, P565, DOI 10.1101/gad.1.6.565; BENHAR I, 1993, CELL, V72, P121, DOI 10.1016/0092-8674(93)90056-V; BENHAR I, 1992, MOL MICROBIOL, V6, P2777, DOI 10.1111/j.1365-2958.1992.tb01457.x; BENNETT GN, 1978, J MOL BIOL, V121, P179, DOI 10.1016/S0022-2836(78)80004-7; CAREY J, 1989, J BIOL CHEM, V264, P1941; CAREY J, 1991, J BIOL CHEM, V266, P24509; CAREY J, 1988, P NATL ACAD SCI USA, V85, P975, DOI 10.1073/pnas.85.4.975; FERNANDO T, 1992, BIOCHEMISTRY-US, V31, P3429, DOI 10.1021/bi00128a018; GRADDIS TJ, 1988, PROTEINS, V4, P173, DOI 10.1002/prot.340040304; GROVE CL, 1987, J BACTERIOL, V169, P2158, DOI 10.1128/jb.169.5.2158-2164.1987; GUNSALUS RP, 1980, P NATL ACAD SCI-BIOL, V77, P7117, DOI 10.1073/pnas.77.12.7117; HARAN TE, 1992, EMBO J, V11, P3021, DOI 10.1002/j.1460-2075.1992.tb05372.x; HE JJ, 1990, J BIOL CHEM, V265, P731; HEATWOLE VM, 1991, J BACTERIOL, V173, P3601, DOI 10.1128/jb.173.11.3601-3604.1991; HEATWOLE VM, 1992, J BACTERIOL, V174, P331, DOI 10.1128/jb.174.1.331-335.1992; HEATWOLE VM, 1991, J BACTERIOL, V173, P108, DOI 10.1128/jb.173.1.108-115.1991; HUGHES RE, 1990, CELL, V63, P1331, DOI 10.1016/0092-8674(90)90428-H; HURLBURT BK, 1992, NUCLEIC ACIDS RES, V20, P337, DOI 10.1093/nar/20.2.337; HURLBURT BK, 1990, J BIOL CHEM, V265, P7853; JOACHIMIAK A, 1983, P NATL ACAD SCI-BIOL, V80, P668, DOI 10.1073/pnas.80.3.668; KELLEY RL, 1985, P NATL ACAD SCI USA, V82, P483, DOI 10.1073/pnas.82.2.483; KLIG LS, 1988, J BIOL CHEM, V263, P243; KUMAMOTO AA, 1987, GENE DEV, V1, P556, DOI 10.1101/gad.1.6.556; LEPECQ JB, 1966, ANAL BIOCHEM, V17, P100, DOI 10.1016/0003-2697(66)90012-1; LIU YC, 1993, J BIOL CHEM, V268, P23239; LIU YC, 1991, THESIS RICE U HOUSTO; Maniatis T., 1982, MOL CLONING; MARMORSTEIN RQ, 1991, BIOCHEMISTRY-US, V30, P1141, DOI 10.1021/bi00218a036; MARMORSTEIN RQ, 1987, J BIOL CHEM, V262, P4922; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PALUH JL, 1986, NUCLEIC ACIDS RES, V14, P7851, DOI 10.1093/nar/14.20.7851; Sambrook J., 1989, MOL CLONING; SANDERSON MR, 1990, CELL, V63, P1323, DOI 10.1016/0092-8674(90)90427-G; SARSERO JP, 1991, J BACTERIOL, V173, P4133, DOI 10.1128/jb.173.13.4133-4143.1991; SCHEVITZ RW, 1985, NATURE, V317, P782, DOI 10.1038/317782a0; SUTTON CL, 1993, BIOCHEMISTRY-US, V32, P4225, DOI 10.1021/bi00067a009; WICK KL, 1991, J BIOL CHEM, V266, P6106; YANG WP, 1993, P NATL ACAD SCI USA, V90, P5796, DOI 10.1073/pnas.90.12.5796; YANOFSKY C, 1981, NUCLEIC ACIDS RES, V9, P6647, DOI 10.1093/nar/9.24.6647; ZHANG RG, 1987, NATURE, V327, P591, DOI 10.1038/327591a0	44	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1692	1698						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294416				2022-12-27	WOS:A1994MR98800026
J	LU, Q; LUDUENA, RF				LU, Q; LUDUENA, RF			IN-VITRO ANALYSIS OF MICROTUBULE ASSEMBLY OF ISOTYPICALLY PURE TUBULIN DIMERS - INTRINSIC DIFFERENCES IN THE ASSEMBLY PROPERTIES OF ALPHA-BETA-II, ALPHA-BETA-III, AND ALPHA-BETA-IV TUBULIN DIMERS IN THE ABSENCE OF MICROTUBULE-ASSOCIATED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; BRAIN TUBULIN; BOVINE BRAIN; COLCHICINE BINDING; MASS-SPECTROMETRY; PORCINE BRAIN; ISOTYPE; CHLAMYDOMONAS; PURIFICATION; EXPRESSION	Microtubule assembly of different beta tubulin isotypes in the presence of 4 m glycerol and 6 mm magnesium ion demonstrates significantly different characteristics. alphabetaII and alphabetaIV assembled faster and to a greater extent than did unfractionated phosphocellulose-purified tubulin (PC-tubulin). Microtubule assembly from alphabetaIII showed a distinctive delay in nucleation, proceeded at a slower rate than those of the other beta tubulin isotypes, and had the highest critical concentration. However, treatment of beta tubulin isotypes with subtilisin to remove the C-terminal domain of the tubulin dimer abolished these differences in microtubule assembly pattern and enhanced self-assembly. The kinetic analysis of microtubule elongation of different beta tubulin isotypes also showed significant differences. Elongation of alphabetaIII from microtubule seeds had a lower apparent K(alpha) and a lower apparent K(d) than did alphabetaII and alphabetaIV. The dynamic behaviors of different beta tubulin isotypes were qualitatively similar to each other and fit the dynamic instability model. However, microtubules formed from alphabetaIII appeared to be less dynamic than microtubules formed from other beta tubulin isotypes. Our results suggest that the betaIII isotype might have a different conformation than do the other beta tubulin isotypes. The distinctive nucleation and elongation behaviors of the alphabetaIII dimers demonstrated in vitro may have a significant influence on microtubule functions in vivo.			LU, Q (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA.				NCI NIH HHS [CA26376] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026376] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AIZAWA H, 1989, J BIOL CHEM, V264, P5885; ALEXANDER JE, 1991, P NATL ACAD SCI USA, V88, P4685, DOI 10.1073/pnas.88.11.4685; ALLEN C, 1974, J MOL BIOL, V90, P381, DOI 10.1016/0022-2836(74)90381-7; Avila J, 1990, MICROTUBULE PROTEINS, V1st; BANERJEE A, 1992, J BIOL CHEM, V267, P5625; BANERJEE A, 1990, J BIOL CHEM, V265, P1794; BANERJEE A, 1992, J BIOL CHEM, V267, P13335; BANERJEE A, 1991, J BIOL CHEM, V266, P1689; BARRA HS, 1974, BIOCHEM BIOPH RES CO, V60, P1384, DOI 10.1016/0006-291X(74)90351-9; BINDER LI, 1975, P NATL ACAD SCI USA, V72, P1122, DOI 10.1073/pnas.72.3.1122; Dustin P., 1984, MICROTUBULES; EDDE B, 1990, SCIENCE, V247, P83, DOI 10.1126/science.1967194; FARRELL KW, 1987, J CELL BIOL, V104, P1035, DOI 10.1083/jcb.104.4.1035; FELLOUS A, 1977, EUR J BIOCHEM, V78, P167, DOI 10.1111/j.1432-1033.1977.tb11726.x; HAVERCROFT JC, 1984, J CELL BIOL, V99, P1927, DOI 10.1083/jcb.99.6.1927; HERZOG W, 1977, P NATL ACAD SCI USA, V74, P1860, DOI 10.1073/pnas.74.5.1860; HIMES RH, 1976, P NATL ACAD SCI USA, V73, P4397, DOI 10.1073/pnas.73.12.4397; JOHNSON KA, 1977, J MOL BIOL, V117, P1, DOI 10.1016/0022-2836(77)90020-1; KRAUHS E, 1981, P NATL ACAD SCI-BIOL, V78, P4156, DOI 10.1073/pnas.78.7.4156; KRISTOFFERSON D, 1986, J CELL BIOL, V102, P1007, DOI 10.1083/jcb.102.3.1007; LHERNAULT SW, 1985, BIOCHEMISTRY-US, V24, P473, DOI 10.1021/bi00323a034; LOBERT S, 1992, ARCH BIOCHEM BIOPHYS, V296, P152, DOI 10.1016/0003-9861(92)90557-D; LOBERT S, 1993, CELL MOTIL CYTOSKEL, V25, P285; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU Q, 1991, Journal of Cell Biology, V115, p38A; LU Q, 1992, MOL BIOL CELL, V3, pA168; LUDUENA RF, 1982, BIOCHEMISTRY-US, V21, P4787, DOI 10.1021/bi00262a041; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MONTEIRO MJ, 1988, J MOL BIOL, V199, P439, DOI 10.1016/0022-2836(88)90616-X; PEYROT V, 1900, ARCH BICOH BIOPHYS, V279, P328; PIPERNO G, 1985, J CELL BIOL, V101, P2085, DOI 10.1083/jcb.101.6.2085; PONSTINGL H, 1981, P NATL ACAD SCI-BIOL, V78, P2757, DOI 10.1073/pnas.78.5.2757; RAYBIN D, 1975, BIOCHEM BIOPH RES CO, V65, P1088, DOI 10.1016/S0006-291X(75)80497-9; ROTHWELL SW, 1986, J CELL BIOL, V102, P619, DOI 10.1083/jcb.102.2.619; RUDIGER M, 1992, FEBS LETT, V308, P101, DOI 10.1016/0014-5793(92)81061-P; SCHACTERLE GR, 1973, ANAL BIOCHEM, V51, P654, DOI 10.1016/0003-2697(73)90523-X; SERRANO L, 1985, EUR J BIOCHEM, V153, P595, DOI 10.1111/j.1432-1033.1985.tb09342.x; SERRANO L, 1984, P NATL ACAD SCI-BIOL, V81, P5989, DOI 10.1073/pnas.81.19.5989; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SULLIVAN KF, 1986, P NATL ACAD SCI USA, V83, P4327, DOI 10.1073/pnas.83.12.4327; SULLIVAN KF, 1988, ANNU REV CELL BIOL, V4, P687, DOI 10.1146/annurev.cb.04.110188.003351; VILLASANTE A, 1986, MOL CELL BIOL, V6, P2409, DOI 10.1128/MCB.6.7.2409; ZHU NZ, 1992, MOL BIOL CELL, V3, pA50	43	72	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2041	2047						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294455				2022-12-27	WOS:A1994MR98800075
J	MIKI, T; MIKI, M; ORII, Y				MIKI, T; MIKI, M; ORII, Y			MEMBRANE POTENTIAL-LINKED REVERSED ELECTRON-TRANSFER IN THE BEEF-HEART CYTOCHROME-BC(1) COMPLEX RECONSTITUTED INTO POTASSIUM-LOADED PHOSPHOLIPID-VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITS PROTON TRANSLOCATION; RESPIRATORY-CHAIN; C REDUCTASE; Q-CYCLE; UBIQUINOL; OXIDASE; OXIDOREDUCTASE; MITOCHONDRIA; DICYCLOHEXYLCARBODIIMIDE; ORGANIZATION	The cytochrome bc1 complex purified from beef heart mitochondria was incorporated into potassium (K+)-loaded phospholipid vesicles by a cholate dialysis method to study the reverse reaction of electron transfer in the complex. The reduction of cytochrome b in the presence of sodium ascorbate was observed on addition of valinomycin to the K+-loaded proteoliposomes in a medium containing no external KCl; it was followed by the gradual oxidation. Nigericin accelerated the reoxidation of reduced cytochrome b, indicating that a K+ diffusion potential (negative inside) induced the reduction of cytochrome b. The extent of the cytochrome b reduction depended on the magnitude of the diffusion potential across the liposomal membranes, and its maximal reduction was attained at more than 210 mV of the diffusion potential. It was cytochrome b562 that was reduced during the establishment of the K+ diffusion potential in the presence of ascorbate, and about 90% of cytochrome b562 was estimated to be reduced. Antimycin A and myxothiazol inhibited the diffusion potential-induced reduction of cytochrome b562, and ubiquinone was proved to be essential for the reversed electron transfer. The K+ diffusion potential also induced the partial reduction of cytochrome b566 when cytochrome b562 had previously been reduced with ascorbate plus tetramethyl-p-phenylenediamine. These results were interpreted well based on the Q cycle scheme which assumed the energy-dependent reduction of ubiquinone at center o. Dicyclohexylcarbodiimide, which did not perturb the ability of proteoliposomes to generate the K+ diffusion potential, inhibited the energy-dependent reduction of cytochrome b562 without a significant loss in the catalytic activity of the complex. The half-inhibition was brought about by 200, mol of dicyclohexylcarbodiimide/mol of cytochrome c1. These results strongly suggest the coupling of a proton flow with the reversed electron transfer in the bc1 complex.	KYOTO UNIV,FAC MED,DEPT PUBL HLTH,YOSHIDAKONOE CHO,SAKYO KU,KYOTO 606,JAPAN; KINKI UNIV,FAC MED,DEPT HYG,SAYAMA,OSAKA 589,JAPAN	Kyoto University; Kindai University (Kinki University)								BEATTIE DS, 1982, J BIOL CHEM, V257, P14746; BRASSEUR R, 1988, J BIOL CHEM, V263, P12571; CASEY RP, 1979, BIOCHEM BIOPH RES CO, V87, P1044, DOI 10.1016/S0006-291X(79)80013-3; CATTELL KJ, 1971, BIOCHEM J, V125, P169, DOI 10.1042/bj1250169; DRACHEV LA, 1989, BIOCHIM BIOPHYS ACTA, V973, P189, DOI 10.1016/S0005-2728(89)80421-9; ESPOSTI MD, 1983, BIOCHIM BIOPHYS ACTA, V725, P349, DOI 10.1016/0005-2728(83)90209-8; FLATMARK T, 1973, BIOCHIM BIOPHYS ACTA, V325, P16, DOI 10.1016/0005-2728(73)90146-1; GLASER EG, 1984, BIOCHIM BIOPHYS ACTA, V766, P322, DOI 10.1016/0005-2728(84)90248-2; GOPHER A, 1980, J BIOENERG BIOMEMBR, V12, P349, DOI 10.1007/BF00748764; GUTWENIGER H, 1977, BIOCHIM BIOPHYS ACTA, V459, P216, DOI 10.1016/0005-2728(77)90023-8; HINKLE PC, 1967, J BIOL CHEM, V242, P5169; KONSTANTINOV AA, 1990, BIOCHIM BIOPHYS ACTA, V1018, P138, DOI 10.1016/0005-2728(90)90234-U; KONSTANTINOV AA, 1981, CHEMIOSMOTIC PROTON, P123; LEUNG KH, 1975, J BIOL CHEM, V250, P8467; LOWRY OH, 1951, J BIOL CHEM, V262, P8677; MIKI T, 1987, J BIOCHEM-TOKYO, V102, P199, DOI 10.1093/oxfordjournals.jbchem.a122033; MIKI T, 1986, J BIOCHEM-TOKYO, V100, P735, DOI 10.1093/oxfordjournals.jbchem.a121766; MIKI T, 1986, J BIOL CHEM, V261, P3915; MIKI T, 1990, BIOCHEMISTRY-US, V30, P230; MITCHELL P, 1975, FEBS LETT, V56, P1, DOI 10.1016/0014-5793(75)80098-6; Nelson B D, 1978, Methods Enzymol, V53, P80; OHNISHI T, 1989, J BIOL CHEM, V264, P735; Redfearn E. R., 1967, METHOD ENZYMOL, V10, P381, DOI [10.1016/0076-6879(67)10071-2, DOI 10.1016/0076-6879(67)10071-2]; RIESKE JS, 1971, ARCH BIOCHEM BIOPHYS, V145, P179, DOI 10.1016/0003-9861(71)90025-7; ROBERTSON DE, 1988, BIOCHIM BIOPHYS ACTA, V935, P273, DOI 10.1016/0005-2728(88)90223-X; SATO N, 1971, BIOCHIM BIOPHYS ACTA, V253, P88, DOI 10.1016/0005-2728(71)90236-2; SEMENOV AY, 1993, FEBS LETT, V321, P1, DOI 10.1016/0014-5793(93)80608-W; Slater E C, 1970, Nature, V226, P1248, DOI 10.1038/2261248a0; SLATER EC, 1973, OXIDASE RELATED REDO, V2, P823; SONE N, 1977, J BIOCHEM-TOKYO, V81, P519, DOI 10.1093/oxfordjournals.jbchem.a131485; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1981, BIOCHIM BIOPHYS ACTA, V639, P129, DOI 10.1016/0304-4173(81)90008-2; TSAI AL, 1987, J BIOL CHEM, V262, P8677; VONJAGOW G, 1986, J BIOENERG BIOMEMBR, V18, P157, DOI 10.1007/BF00743462; WANG YD, 1991, ARCH BIOCHEM BIOPHYS, V291, P363, DOI 10.1016/0003-9861(91)90147-B; WIKSTROM MK, 1973, BIOCHIM BIOPHYS ACTA, V301, P155; YU C, 1980, BIOCHIM BIOPHYS ACTA, V591, P409, DOI 10.1016/0005-2728(80)90172-3; YU CA, 1980, BIOCHEMISTRY-US, V19, P5715, DOI 10.1021/bi00566a008	38	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1827	1833						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294431				2022-12-27	WOS:A1994MR98800044
J	DONOVANPELUSO, M; GEORGE, LD; HASSETT, AC				DONOVANPELUSO, M; GEORGE, LD; HASSETT, AC			LIPOPOLYSACCHARIDE INDUCTION OF TISSUE FACTOR EXPRESSION IN THP-1 MONOCYTIC CELLS - PROTEIN-DNA INTERACTIONS WITH THE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR GENE; TRANSCRIPTIONAL ACTIVATION; THROMBOPLASTIN ACTIVITY; PROCOAGULANT RESPONSE; RNA; BINDING; MACROPHAGES; INITIATION; RECEPTOR; ENHANCER	Tissue factor, the cellular receptor for factor VII/VIIa, activates both the intrinsic and extrinsic pathways of blood coagulation. In this analysis we have used DNase I footprinting to map the sites of protein-DNA interaction along the promoter (-383 to +8) using nuclear extracts prepared from uninduced and lipopolysaccharide-induced THP-1 cells. We have identified six regions that interact with nuclear factors in both uninduced and induced extracts. Four footprints are contained within a region reported to confer base-line high level expression and lipopolysaccharide and serum induction. Two additional footprints map to a region reported to reduce basal transcription by 50%. The only qualitative change in the footprint pattern with uninduced and induced extracts is the appearance of two hypersensitive sites with uninduced extracts. In addition, changes in the level of protein- DNA binding are detected with only one probe by DNA mobility shift analysis. A combination of well characterized transcription factors (AP1), primarily lymphoid cell specific regulatory proteins (NF-kappaB- and/or Ets-1-related proteins), as well as additional, uncharacterized proteins appear to interact with these sequences. Our data suggest that post-translational modification of existing transcription factors, and not induction of new DNA-binding activity, mediates the lipopolysaccharide induction of tissue factor synthesis in THP-1 cells.			DONOVANPELUSO, M (corresponding author), UNIV PITTSBURGH,SCH MED,SCH MED,DEPT PATHOL,S709 SCAIFE HALL,PITTSBURGH,PA 15261, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR006009] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL045621] Funding Source: NIH RePORTER; NCRR NIH HHS [1 P41 RR06009] Funding Source: Medline; NHLBI NIH HHS [1R29HL45621-01A1] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1988, P NATL ACAD SCI USA, V85, P7462, DOI 10.1073/pnas.85.20.7462; BAUER KA, 1989, THROMB RES, V563, P425; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND K, 1991, MOL CELL BIOL, V11, P4732, DOI 10.1128/MCB.11.9.4732; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAUSS M, 1990, J BIOL CHEM, V265, P7078; CONKLING PR, 1988, BLOOD, V72, P128; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FROMENTAL C, 1988, CELL, V54, P943, DOI 10.1016/0092-8674(88)90109-2; FURIE B, 1988, CELL, V53, pA505; GREGORY SA, 1989, MOL CELL BIOL, V9, P2752, DOI 10.1128/MCB.9.6.2752; KEY NS, 1990, P NATL ACAD SCI USA, V87, P7095, DOI 10.1073/pnas.87.18.7095; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LYBERG T, 1981, BIOCHEM J, V194, P699, DOI 10.1042/bj1940699; LYBERG T, 1987, J CELL PHYSIOL, V132, P367, DOI 10.1002/jcp.1041320226; MACKMAN N, 1990, P NATL ACAD SCI USA, V87, P2254, DOI 10.1073/pnas.87.6.2254; MACKMAN N, 1989, BIOCHEMISTRY-US, V28, P1755, DOI 10.1021/bi00430a050; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; NAKAMURA S, 1989, THROMB HAEMOSTASIS, V62; ONEILL D, 1990, NUCLEIC ACIDS RES, V18, P1977, DOI 10.1093/nar/18.8.1977; TAYLOR FB, 1991, CIRC SHOCK, V33, P127; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TIPPING PG, 1989, ATHEROSCLEROSIS, V79, P237, DOI 10.1016/0021-9150(89)90129-9; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	30	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1361	1369						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288602				2022-12-27	WOS:A1994MR22000092
J	FURUKAWA, K; TAGAYA, M; TANIZAWA, K; FUKUI, T				FURUKAWA, K; TAGAYA, M; TANIZAWA, K; FUKUI, T			IDENTIFICATION OF LYS(277) AT THE ACTIVE-SITE OF ESCHERICHIA-COLI GLYCOGEN-SYNTHASE - APPLICATION OF AFFINITY LABELING COMBINED WITH SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-BINDING SITE; ADENOSINE DIPHOSPHOPYRIDOXAL; BACTERIAL GLYCOGEN; ADENYLATE KINASE; BETA-SUBUNIT; ADP-GLUCOSE; SEQUENCE; TETRAPHOSPHOPYRIDOXAL; TRIPHOSPHOPYRIDOXAL; BIOSYNTHESIS	Lys15 in Escherichia coli glycogen synthase, which is specifically labeled by adenosine diphosphopyridoxal, is mainly involved in binding of the substrate ADP-glucose (Furukawa, K., Tagaya, M., Tanizawa, K., and Fukui, T. (1993) J. Biol. Chem. 268, 23837-23842). We have found that the mutant glycogen synthase in which Lys15 is replaced by Gln via site-directed mutagenesis is inactivated by adenosine diphosphopyridoxal at concentrations higher than those required for the inactivation of the wild-type enzyme. ADP and ADP-glucose offered protective effects on inactivation, suggesting that the label binds to the ADP-glucose-binding site in the mutant enzyme. Sequence analysis of the labeled peptide revealed that the labeled residue is Lys277. This lysyl residue is conserved in maize starch synthase, which shows about 30% amino acid identity to E. coli glycogen synthase. Substitution of Gln for Lys277 by site-directed mutagenesis resulted in a 140-fold decrease in the k(cat) value with little changes in the K(m) values for ADP-glucose and glycogen. These results suggest that Lys277 at the active site participates in the catalytic reaction rather than binding of substrate. The present study shows the usefulness of the combined application of affinity labeling and site-directed mutagenesis.	OSAKA UNIV,INST SCI & IND RES,IBARAKI,OSAKA 567,JAPAN	Osaka University			Furukawa, Koji/L-6909-2018	Furukawa, Koji/0000-0002-5701-2497				AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNER MF, 1989, P NATL ACAD SCI USA, V86, P1443, DOI 10.1073/pnas.86.5.1443; FARKAS I, 1990, J BIOL CHEM, V265, P20879; FOX J, 1976, BIOCHEMISTRY-US, V15, P849, DOI 10.1021/bi00649a019; FURUKAWA K, 1993, J BIOL CHEM, V268, P23837; FURUKAWA K, 1990, J BIOL CHEM, V265, P2086; HERMODSON MA, 1973, BIOCHEMISTRY-US, V12, P3146, DOI 10.1021/bi00741a002; Higuchi R., 1989, PCR TECHNOLOGY, P61; IDA K, 1991, J BIOL CHEM, V266, P5424; KLOESGEN R B, 1986, Molecular and General Genetics, V203, P237; KUMAR A, 1986, J BIOL CHEM, V261, P6256; NOUMI T, 1987, J BIOL CHEM, V262, P7686; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAGAYA M, 1987, J BIOL CHEM, V262, P8257; TAGAYA M, 1985, J BIOL CHEM, V260, P6670; TAGAYA M, 1986, BIOCHEMISTRY-US, V25, P2958, DOI 10.1021/bi00358a034; TAGAYA M, 1988, FEBS LETT, V233, P347, DOI 10.1016/0014-5793(88)80457-5; TAGAYA M, 1993, MOL ASPECTS ENZYME C, P73; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; YAGAMI T, 1988, FEBS LETT, V229, P261, DOI 10.1016/0014-5793(88)81137-2	21	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					868	871						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288640				2022-12-27	WOS:A1994MR22000018
J	LEINGARTNER, A; HEISENBERG, CP; KOLBECK, R; THOENEN, H; LINDHOLM, D				LEINGARTNER, A; HEISENBERG, CP; KOLBECK, R; THOENEN, H; LINDHOLM, D			BRAIN-DERIVED NEUROTROPHIC FACTOR INCREASES NEUROTROPHIN-3 EXPRESSION IN CEREBELLAR GRANULE NEURONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NERVE GROWTH-FACTOR; FACTOR MESSENGER-RNA; FACTOR NGF SYNTHESIS; TYROSINE PROTEIN-KINASE; DIFFERENTIAL REGULATION; ASTROCYTES; RECEPTOR; CULTURES; INTERLEUKIN-1; INHIBITOR	Neurotrophin-3 (NT-3) is a member of the neurotrophin gene family and is highly expressed in the developing rat cerebellum. Here we show that brain-derived neurotrophic factor (BDNF) increased by approximately 10-fold the NT-3 mRNA levels in cultured cerebellar granule neurons isolated from postnatal rats, whereas nerve growth factor (NGF) and NT-3 itself had no effect. The effect of BDNF was additive to that of triiodothyronine (T3), which also increased NT-3 mRNA in these neurons. The drug K252a inhibited the BDNF-mediated stimulation of NT-3 expression, suggesting an involvement of trkB receptors. Nuclear run-on experiments showed that BDNF enhanced NT-3 transcription, whereas the stability of NT-3 mRNA remained unchanged. The data presented are the first demonstration that one neurotrophin regulates the expression of another and provide evidence that NT-3 production in granule neurons is regulated by both BDNF and T3.	MAX PLANCK INST PSYCHIAT, DEPT NEUROCHEM, AM KLOPFERSPITZ 18A, D-82152 MARTINSRIED, GERMANY; MAX PLANCK INST PSYCHIAT, DEPT NEUROBIOCHEM, D-82152 MARTINSRIED, GERMANY	Max Planck Society; Max Planck Society			Lindholm, Dan/B-3777-2014	Heisenberg, Carl-Philipp/0000-0002-0912-4566				BARBANY G, 1992, EUR J NEUROSCI, V4, P396, DOI 10.1111/j.1460-9568.1992.tb00888.x; BERG MM, 1992, J BIOL CHEM, V267, P13; BERZAGHI MD, 1993, J NEUROSCI, V13, P3818; CARMANKRZAN M, 1991, J NEUROCHEM, V56, P636, DOI 10.1111/j.1471-4159.1991.tb08197.x; CASTREN E, 1992, P NATL ACAD SCI USA, V89, P9444, DOI 10.1073/pnas.89.20.9444; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUSSAULT JH, 1987, ANNU REV PHYSIOL, V49, P321, DOI 10.1146/annurev.ph.49.030187.001541; ERNFORS P, 1991, NEURON, V7, P165, DOI 10.1016/0896-6273(91)90084-D; GALL CM, 1989, SCIENCE, V245, P758, DOI 10.1126/science.2549634; GOTZ R, 1992, EUR J BIOCHEM, V204, P745, DOI 10.1111/j.1432-1033.1992.tb16689.x; HEISENBERG CP, 1992, NEUROREPORT, V3, P685, DOI 10.1097/00001756-199208000-00008; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KOIZUMI S, 1988, J NEUROSCI, V8, P715; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LINDHOLM D, 1993, EUR J NEUROSCI, V5, P1455, DOI 10.1111/j.1460-9568.1993.tb00213.x; LINDHOLM D, 1988, J BIOL CHEM, V263, P16348; Lindholm D, 1990, Neuroreport, V1, P9; LINDHOLM D, 1993, J CELL BIOL, V122, P443, DOI 10.1083/jcb.122.2.443; LINDHOLM D, 1992, EUR J NEUROSCI, V4, P404, DOI 10.1111/j.1460-9568.1992.tb00889.x; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MATSUDA Y, 1988, NEUROSCI LETT, V87, P11, DOI 10.1016/0304-3940(88)90137-1; MATSUOKA I, 1991, J NEUROSCI, V11, P3165; ROCAMORA N, 1992, MOL BRAIN RES, V13, P27, DOI 10.1016/0169-328X(92)90041-9; ROCAMORA N, 1993, MOL BRAIN RES, V17, P1, DOI 10.1016/0169-328X(93)90065-W; SEGAL RA, 1992, NEURON, V9, P1041, DOI 10.1016/0896-6273(92)90064-K; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SPRANGER M, 1990, EUR J NEUROSCI, V2, P69, DOI 10.1111/j.1460-9568.1990.tb00382.x; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; TAPLEY P, 1992, ONCOGENE, V7, P371; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; YOSHIDA K, 1992, BRAIN RES, V569, P14, DOI 10.1016/0006-8993(92)90364-F; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x; ZAFRA F, 1991, P NATL ACAD SCI USA, V88, P10037, DOI 10.1073/pnas.88.22.10037; ZAFRA F, 1992, J NEUROSCI, V12, P4793	36	62	62	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					828	830						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288635				2022-12-27	WOS:A1994MR22000012
J	MOEHREN, G; GUSTAVSSON, L; HOEK, JB				MOEHREN, G; GUSTAVSSON, L; HOEK, JB			ACTIVATION AND DESENSITIZATION OF PHOSPHOLIPASE-D IN INTACT RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER PLASMA-MEMBRANES; PHOSPHATIDYLCHOLINE BREAKDOWN; PHOSPHATIDYLETHANOL FORMATION; PHORBOL ESTER; DIACYLGLYCEROL FORMATION; RAPID DESENSITIZATION; SIGNAL-TRANSDUCTION; ETHANOL TREATMENT; CELLS; ACCUMULATION	Activation of phospholipase D (PLD) by receptor-coupled stimuli (vasopressin, ATP), phorbol esters, and Ca2+ ionophores was studied in isolated rat hepatocytes, double labeled with [H-3]arachidonate and [C-14]stearate. Phosphatidylethanol (Peth) was formed when cells were stimulated in the presence of ethanol. The effect of combinations of agonists was not additive, indicating that the same PLD isozyme(s) were activated. With all agonists, the H-3- and C-14-specific radioactivity in Peth was higher than in any of the main phospholipid classes. The H-3/C-14 ratios of Peth and phosphatidylcholine (PC) were identical and differed from other phospholipid classes, indicating that the predominant PLD substrate was a PC pool labeled preferentially with radioactive fatty acids. Ethanol (50-300 mm) decreased the initial rate cif phosphatidic acid (PA) formation, but did not affect total PLD activity. Agonist-induced changes in steady state accumulation of PA or 1,2-diacylglycerol were also unaffected. A slow degradation of Peth (apparent t1/2 > 60 min) occurred after ethanol removal from cells prestimulated with vasopressin. The rate of degradation was unaffected by agonists that stimulate PLD. Thus, Peth formation is a suitable cumulative indicator for PLD activation in intact hepatocytes. Peth accumulation declined over a period of 5-20 min, depending on the agonist. The decline was not due to increased Peth degradation, or limitations in substrate supply to PLD, or enzyme inhibition by accumulated Peth. Instead, a homologous desensitization of PLD occurs with all agonists. This desensitization may involve the action of selective protein kinase C isozymes.	THOMAS JEFFERSON UNIV, DEPT PATHOL & CELL BIOL, 1020 LOCUST ST, PHILADELPHIA, PA 19107 USA; LUND UNIV, DEPT PSYCHIAT & NEUROCHEM, S-22009 LUND, SWEDEN	Jefferson University; Lund University				Hoek, Jan/0000-0001-7127-4218	NIAAA NIH HHS [AA08714, AA07215, AA07186] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008714, P50AA007186] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALLING C, 1983, FEBS LETT, V152, P24, DOI 10.1016/0014-5793(83)80474-8; ALLING C, 1984, BIOCHIM BIOPHYS ACTA, V793, P119, DOI 10.1016/0005-2760(84)90060-2; AUGERT G, 1989, J BIOL CHEM, V264, P2574; AUGERT G, 1989, J BIOL CHEM, V264, P21689; BALSINDE J, 1989, EUR J BIOCHEM, V186, P717, DOI 10.1111/j.1432-1033.1989.tb15265.x; BENTHIN G, 1985, BIOCHIM BIOPHYS ACTA, V835, P385, DOI 10.1016/0005-2760(85)90295-4; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCCKINO SB, 1987, FEBS LETT, V225, P201, DOI 10.1016/0014-5793(87)81157-2; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; COOK SJ, 1992, REV PHYSIOL BIOCH P, V119, P13; Eibl H, 1981, Methods Enzymol, V72, P632; EXTON JH, 1988, REV PHYSIOL BIOCH P, V111, P117; EXTON JH, 1991, MOL CELL BIOCHEM, V104, P81; GATALICA Z, 1993, BIOCHIM BIOPHYS ACTA, V1177, P87, DOI 10.1016/0167-4889(93)90162-I; GUSTAVSSON L, 1991, ANN NY ACAD SCI, V625, P438, DOI 10.1111/j.1749-6632.1991.tb33873.x; GUSTAVSSON L, 1987, BIOCHEM BIOPH RES CO, V142, P958, DOI 10.1016/0006-291X(87)91507-5; GUSTAVSSON L, 1994, J BIOL CHEM, V269, P849; GUSTAVSSON L, 1990, J NEUROCHEM, V54, P737, DOI 10.1111/j.1471-4159.1990.tb02313.x; Heller M, 1978, Adv Lipid Res, V16, P267; HIGASHI K, 1991, J BIOL CHEM, V266, P2178; HOEK HB, 1993, LAB INVEST, V69, P1; HOEK JB, 1992, FASEB J, V6, P2386, DOI 10.1096/fasebj.6.7.1563591; HOEK JB, 1987, J BIOL CHEM, V262, P682; Holub B J, 1978, Adv Lipid Res, V16, P1; HUANG CF, 1992, J BIOL CHEM, V267, P16859; HUANG CF, 1990, J BIOL CHEM, V265, P14858; HURST KM, 1990, BIOCHEM J, V272, P749, DOI 10.1042/bj2720749; IRVING HR, 1987, J BIOL CHEM, V262, P3440; KANFER JN, 1980, CAN J BIOCHEM CELL B, V58, P1370, DOI 10.1139/o80-186; KISS Z, 1990, J BIOL CHEM, V265, P7345; KISS Z, 1990, PROG LIPID RES, V29, P141, DOI 10.1016/0163-7827(90)90001-2; KOBAYASHI M, 1987, J NEUROCHEM, V48, P1597, DOI 10.1111/j.1471-4159.1987.tb05707.x; LYNCH CJ, 1985, J BIOL CHEM, V260, P2844; MACDONALD JIS, 1991, BIOCHIM BIOPHYS ACTA, V1084, P105, DOI 10.1016/0005-2760(91)90209-Z; MCKENZIE FR, 1992, J BIOL CHEM, V267, P22759; METZ SA, 1991, BIOCHEM PHARMACOL, V41, pR1, DOI 10.1016/0006-2952(91)90470-P; NAKAMURA K, 1984, ANAL BIOCHEM, V142, P406, DOI 10.1016/0003-2697(84)90484-6; OMODEOSALE F, 1991, BIOCHEMISTRY-US, V30, P2477, DOI 10.1021/bi00223a026; PAI JK, 1987, CARCINOGENESIS, V8, P173, DOI 10.1093/carcin/8.1.173; PITTNER RA, 1992, BIOCHIM BIOPHYS ACTA, V1133, P316, DOI 10.1016/0167-4889(92)90053-E; PLEIN P, 1992, BIOL CHEM H-S, V373, P151, DOI 10.1515/bchm3.1992.373.1.151; PLEVIN R, 1992, BIOCHEM J, V285, P759, DOI 10.1042/bj2850759; PREISS JE, 1987, METHOD ENZYMOL, V141, P294; ROBLESFLORES M, 1991, BIOCHIM BIOPHYS ACTA, V1094, P77, DOI 10.1016/0167-4889(91)90028-V; SHUKLA SD, 1991, LIFE SCI, V48, P851, DOI 10.1016/0024-3205(91)90031-6; SIDDIQUI RA, 1992, J BIOL CHEM, V267, P5755; STADDON JM, 1989, EUR J BIOCHEM, V179, P47, DOI 10.1111/j.1432-1033.1989.tb14519.x; TROYER DA, 1992, AM J PHYSIOL, V262, pF185, DOI 10.1152/ajprenal.1992.262.2.F185; WAKELAM MJO, 1986, NATURE, V323, P68, DOI 10.1038/323068a0; WANG P, 1991, J BIOL CHEM, V266, P14877	51	58	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					838	848						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288637				2022-12-27	WOS:A1994MR22000015
J	GUPTA, M; ZHU, CX; TSEDINH, YC				GUPTA, M; ZHU, CX; TSEDINH, YC			MUTATIONS OF VACCINIA VIRUS-DNA TOPOISOMERASE-I THAT STABILIZE THE CLEAVAGE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE TYROSINE; ESCHERICHIA-COLI; ANTITUMOR DRUGS; CAMPTOTHECIN; SPECIFICITY; EXPRESSION; MUTANTS; GENE; MUTAGENESIS; SUBSTRATE	Two mutations in vaccinia virus topoisomerase I, K167D and G226N, have been characterized. SOS induction was observed in Escherichia coli expressing vaccinia topoisomerase I with either one of these mutations. The mutant enzymes were purified to homogeneity and compared with the wild type enzyme for relaxation activity and the partial activities of substrate binding, site-specific DNA cleavage and DNA religation to determine the mechanism of SOS induction. The K167D mutant enzyme had reduced binding affinity for the DNA substrate with a K(app) that was 10-fold higher than wild type. Nevertheless, in reactions with high enzyme concentration, its substrate cleavage activity was 90% that of wild type. The G226N mutant enzyme had virtually wild type binding and cleavage activities. However, intermolecular religation by these two mutants were observed to be significantly reduced. The cleavage complexes formed with the K167D and G226N mutants were more stable to high salt than the wild type cleavable complex. We propose that these mutants in vivo induce the SOS response in E. coli due to the shift of topoisomerase cleavage-religation equilibrium towards cleavage and increased stability of the cleavage complex. The mutation thus has a similar effect as the topoisomerase-targeting inhibitors that turn topoisomerases into DNA damaging agents.	NYU,COLL MED,DEPT BIOCHEM & MOLEC BIOL,VALHALLA,NY 10595	New York University								ANDERSEN AH, 1991, J BIOL CHEM, V266, P9203; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CARON PR, 1993, MOLECULAR BIOLOGY OF DNA TOPOISOMERASES AND ITS APPLICATION CHEMOTHERAPY, P1; CHAMPOUX JJ, 1989, J BIOL CHEM, V264, P1010; DRLICA K, 1988, BIOCHEMISTRY-US, V27, P2253, DOI 10.1021/bi00407a001; FERNANDEZBEROS ME, 1992, J BACTERIOL, V174, P7059, DOI 10.1128/JB.174.21.7059-7062.1992; GILMOUR DS, 1987, MOL CELL BIOL, V7, P141, DOI 10.1128/MCB.7.1.141; GUPTA M, 1992, J BIOL CHEM, V267, P24177; HANIFORD DB, 1989, CELL, V59, P385, DOI 10.1016/0092-8674(89)90299-7; HAUNG WM, 1990, DNA TOPOLOGY ITS BIO, P265; HEITMAN J, 1991, GENE, V103, P1, DOI 10.1016/0378-1119(91)90383-M; HEITMAN J, 1990, EMBO J, V9, P3369, DOI 10.1002/j.1460-2075.1990.tb07538.x; HEITMAN J, 1987, J BACTERIOL, V169, P3243, DOI 10.1128/jb.169.7.3243-3250.1987; HOOPER DC, 1991, NEW ENGL J MED, V324, P384, DOI 10.1056/NEJM199102073240606; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; KENYON CJ, 1980, P NATL ACAD SCI-BIOL, V77, P2819, DOI 10.1073/pnas.77.5.2819; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; MORHAM SG, 1992, J BIOL CHEM, V267, P15984; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P6402, DOI 10.1021/bi00394a015; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; Schneider E, 1990, Adv Pharmacol, V21, P149, DOI 10.1016/S1054-3589(08)60342-7; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P3489, DOI 10.1073/pnas.86.10.3489; SHUMAN S, 1991, J BIOL CHEM, V266, P1796; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1992, J BIOL CHEM, V267, P8620; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1987, P NATL ACAD SCI USA, V84, P7478, DOI 10.1073/pnas.84.21.7478; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P9793, DOI 10.1073/pnas.86.24.9793; SMITH CL, 1983, P NATL ACAD SCI-BIOL, V80, P2510, DOI 10.1073/pnas.80.9.2510; SUCK D, 1986, NATURE, V321, P620, DOI 10.1038/321620a0; SVESTRUP JQ, 1991, J MOL BIOL, V222, P669; THOMSEN B, 1987, EMBO J, V6, P1817, DOI 10.1002/j.1460-2075.1987.tb02436.x; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WEISEMANN JM, 1984, J BACTERIOL, V160, P112, DOI 10.1128/JB.160.1.112-121.1984	39	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					573	578						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276853				2022-12-27	WOS:A1994MR21900091
J	KANDROR, K; PILCH, PF				KANDROR, K; PILCH, PF			IDENTIFICATION AND ISOLATION OF GLYCOPROTEINS THAT TRANSLOCATE TO THE CELL-SURFACE FROM GLUT4-ENRICHED VESICLES IN AN INSULIN-DEPENDENT FASHION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORTER-CONTAINING VESICLES; RAT ADIPOSE-CELLS; GLUCOSE-TRANSPORTER; SUBCELLULAR-DISTRIBUTION; PLASMA-MEMBRANE; ADIPOCYTES; PROTEINS; TISSUES; GLUT4	It has previously been shown that in fat cells, the intracellular reservoir of the glucose transporter isoform GLUT4 consists of a membrane vesicle population highly enriched in this transporter (approximately 15% of the protein content) that has a relatively simple protein pattern as revealed by SDS-polyacrylamide gel electrophoresis and silver staining (Zorzano, A., Wilkinson, W., Kotliar, N., Thoidis, G., Wadzinski, B. E., Ruoho, A. E., and Pilch, P. F. (1989) J. Biol. Chem. 264,12358-12363). Upon exposure of adipocytes to insulin, the cell-surface (plasma membrane) content of GLUT4 is dramatically enhanced, and this transporter appears to continually cycle from intracellular vesicles to the plasma membrane. To identify other proteins that may recycle in a similar fashion to GLUT4 and that may participate in the insulin-dependent alteration in the cellular location of GLUT4 and other membrane proteins, we performed immunoadsorption of GLUT4-enriched vesicles together with biotinylation of membranes using a cell-impermeant analog of biotin. We find that immunoadsorbed GLUT4-containing vesicles can be fractionated into Triton X-100-soluble and -insoluble fractions. The first includes three major glycoprotein components with molecular masses of 110, 160, and 230 kDa and a few minor polypeptides with lower molecular masses. A Triton X-100-resistant fraction consists of GLUT4 and an approximately 25-kDa protein. All three major Triton-soluble proteins (110, 160, and 230 kDa) isolated from the immunoimmobilized vesicles on wheat germ agglutinin-agarose are strongly biotinylated in an insulin-dependent fashion, i.e. they cycle to and from the cell surface in an apparently identical manner to GLUT4. Sequence analysis of two tryptic fragments from p160 reveals that it is a novel protein containing sequence with no homology to known proteins.			KANDROR, K (corresponding author), BOSTON UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02118 USA.			Pilch, Paul/0000-0003-1997-0499; Kandror, Konstantin/0000-0002-8601-9313	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030425] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK30425-11] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BURANT CF, 1991, RECENT PROG HORM RES, V47, P349; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CORMONT M, 1991, ENDOCRINOLOGY, V129, P3343, DOI 10.1210/endo-129-6-3343; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1993, J BIOL CHEM, V268, P9187; DELVECCHIO RL, 1991, J BIOL CHEM, V266, P13278; HARE JF, 1989, BIOCHEMISTRY-US, V28, P574, DOI 10.1021/bi00428a024; HARE JF, 1992, ARCH BIOCHEM BIOPHYS, V293, P416, DOI 10.1016/0003-9861(92)90414-R; HARE JF, 1990, BIOCHEMISTRY-US, V265, P21758; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JAMES DE, 1988, BIOCHEM J, V256, P725, DOI 10.1042/bj2560725; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JAMES DE, 1987, J BIOL CHEM, V262, P11817; JHUN BH, 1992, J BIOL CHEM, V267, P17710; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OKA Y, 1988, J BIOL CHEM, V263, P13432; RODBELL M, 1964, J BIOL CHEM, V239, P375; SHOELSON SE, 1993, J BIOL CHEM, V268, P4085; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; THOIDIS G, 1993, J BIOL CHEM, V268, P11691; YANG J, 1992, BIOCHEM J, V281, P809, DOI 10.1042/bj2810809; YANG J, 1993, J BIOL CHEM, V268, P4600; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	28	87	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					138	142						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276787				2022-12-27	WOS:A1994MR21900029
J	LAMA, J; PAUL, AV; HARRIS, KS; WIMMER, E				LAMA, J; PAUL, AV; HARRIS, KS; WIMMER, E			PROPERTIES OF PURIFIED RECOMBINANT POLIOVIRUS PROTEIN 3AB AS SUBSTRATE FOR VIRAL PROTEINASES AND AS COFACTOR FOR RNA-POLYMERASE 3D(POL)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; REPLICATION; EXPRESSION; PRECURSOR; POLYPEPTIDE; VPG; INITIATION; CLEAVAGE; INVITRO; CELLS	The poliovirus-specific polypeptide 3AB (B = VPg) was expressed in Escherichia coli and purified to near homogeneity. Corresponding to its known association with membranes in poliovirus-infected HeLa cells, 3AB expressed in E. coli was also membrane-associated, and it could be solubilized only in detergent-containing buffers. In soluble form, 3AB was resistant to digestion with the virus-specific proteinases 3C(pro) and 3CD(pro). However, it was cleaved by these enzymes to 3A and VPg when bound to the bacterial membranes, an observation suggesting that 3AB may deliver the genome-linked protein VPg to the membrane-associated poliovirus replication complex. The specific activity of 3CD(pro) in processing 3AB was significantly higher than that of 3C(pro). Soluble 3AB was found to stimulate nearly 100-fold poly(A)-dependent, primer-dependent poly(U) synthesis, catalyzed by purified poliovirus RNA polymerase 3D(pol). We propose that 3AB has a dual function in poliovirus genome replication: as a precursor for VPg, and as a co-factor for 3D(pol).	SUNY STONY BROOK, HLTH SCI CTR, SCH MED, DEPT MICROBIOL, STONY BROOK, NY 11794 USA; UNIV AUTONOMA MADRID, FAC CIENCIAS, CTR BIOL MOLEC SEVERO OCHOA, E-28049 MADRID, SPAIN	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Autonomous University of Madrid					NCI NIH HHS [CA-28146] Funding Source: Medline; NIAID NIH HHS [AI-15122] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015122, R01AI015122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDINO R, 1990, CELL, V63, P369, DOI 10.1016/0092-8674(90)90170-J; BERNSTEIN HD, 1988, J VIROL, V62, P2922, DOI 10.1128/JVI.62.8.2922-2928.1988; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; FLANEGAN JB, 1977, P NATL ACAD SCI USA, V74, P3677, DOI 10.1073/pnas.74.9.3677; GIACHETTI C, 1991, J VIROL, V65, P2647, DOI 10.1128/JVI.65.5.2647-2654.1991; GUINEA R, 1991, VIROLOGY, V185, P473, DOI 10.1016/0042-6822(91)90802-I; HARRIS KS, 1992, J VIROL, V66, P7481, DOI 10.1128/JVI.66.12.7481-7489.1992; Harris KS, 1990, SEMINARS VIROLOGY, V1, P323; HELLEN CUT, 1989, BIOCHEMISTRY-US, V28, P9881, DOI 10.1021/bi00452a001; HUANG KS, 1980, P NATL ACAD SCI-BIOL, V77, P323, DOI 10.1073/pnas.77.1.323; JABLONSKI SA, 1993, J VIROL, V67, P373, DOI 10.1128/JVI.67.1.373-381.1993; JORE J, 1988, J GEN VIROL, V69, P1627, DOI 10.1099/0022-1317-69-7-1627; KITAMURA N, 1981, NATURE, V291, P547, DOI 10.1038/291547a0; Kuhn R. J., 1987, The molecular biology of the positive strand RNA viruses, P17; LAMA J, 1992, J BIOL CHEM, V267, P15932; LAMA J, 1992, BIOCHEM BIOPH RES CO, V188, P972, DOI 10.1016/0006-291X(92)91327-M; LAWSON MA, 1992, VIROLOGY, V191, P309, DOI 10.1016/0042-6822(92)90193-S; Maniatis T., 1982, MOL CLONING; MOLLA A, 1993, J VIROL, V67, P5932, DOI 10.1128/JVI.67.10.5932-5938.1993; NICKLIN MJH, 1988, J VIROL, V62, P4586, DOI 10.1128/JVI.62.12.4586-4593.1988; RICHARDS OC, 1990, CURR TOP MICROBIOL, V161, P89; RUECKERT RR, 1984, J VIROL, V50, P957, DOI 10.1128/JVI.50.3.957-959.1984; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEMLER BL, 1981, P NATL ACAD SCI-BIOL, V78, P3464, DOI 10.1073/pnas.78.6.3464; SEMLER BL, 1982, CELL, V28, P405, DOI 10.1016/0092-8674(82)90358-0; TAKEDA N, 1986, J VIROL, V60, P43, DOI 10.1128/JVI.60.1.43-53.1986; TAKEGAMI T, 1983, VIROLOGY, V128, P33, DOI 10.1016/0042-6822(83)90316-1; TAKEGAMI T, 1983, P NATL ACAD SCI-BIOL, V80, P7447, DOI 10.1073/pnas.80.24.7447; TOBIN GJ, 1989, CELL, V59, P511, DOI 10.1016/0092-8674(89)90034-2; VANDYKE TA, 1980, J VIROL, V35, P732, DOI 10.1128/JVI.35.3.732-740.1980; WIMMER E, 1982, CELL, V28, P199, DOI 10.1016/0092-8674(82)90335-X; WIMMER E, 1993, ANNU REV GENET, V27, P353, DOI 10.1146/annurev.ge.27.120193.002033; WU SX, 1992, P NATL ACAD SCI USA, V89, P11136, DOI 10.1073/pnas.89.23.11136; YPMAWONG MF, 1988, VIROLOGY, V166, P265, DOI 10.1016/0042-6822(88)90172-9	34	104	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					66	70						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276867				2022-12-27	WOS:A1994MR21900018
J	MANABE, R; SAITO, T; KUMAZAKI, T; SAKAITANI, T; NAKATA, N; OCHIAI, H				MANABE, R; SAITO, T; KUMAZAKI, T; SAKAITANI, T; NAKATA, N; OCHIAI, H			MOLECULAR-CLONING AND THE COOH-TERMINAL PROCESSING OF GP64, A PUTATIVE CELL-CELL ADHESION PROTEIN OF THE CELLULAR SLIME-MOLD POLYSPHONDYLIUM-PALLIDUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-A GLYCOPROTEIN; AGGREGATING DICTYOSTELIUM CELLS; EUKARYOTIC MESSENGER-RNAS; MONOCLONAL-ANTIBODIES; MEMBRANE; DISCOIDEUM; SEQUENCE; SIGNAL; CHROMATOGRAPHY; RESOLUTION	The cellular slime mold Polysphondylium pallidum expresses a cell surface glycoprotein (referred to as gp64), which seems to be implicated in cell-cell adhesion. We identified a near full-length gp64 cDNA (1,104 base) upon screening a P. pallidum lambdagt11 library with a monoclonal antibody. The open reading frame encodes a protein of 320 amino acids with a molecular mass of 32,752 Da; the protein includes hydrophobic segments at both a NH2- and a COOH-terminal ends. By an Edman degradation analysis of S-pyridylethylated gp64 and its COOH-terminal peptide, it was found that the NH2- and COOH-terminal segments are both removed from the precursor protein of gp64. The COOH-terminal segment was isolated from a lysyl endopeptidase digest of gp64 by an affinity method. The COOH-terminal segment was identified at positions 266-279 in the primary sequence deduced from the cDNA sequence. The mature gp64 consisted of 279 amino acid residues and extremely rich in Cys residues (36 Cys/279 amino acids = 12.9%). Although there was already maximal accumulation of gp64 mRNA in vegetative cells, the protein reached a maximal level during aggregation stage, decreased, and then leveled off through the developmental cycle.	HOKKAIDO UNIV,FAC SCI,DEPT BIOL,SAPPORO,HOKKAIDO 060,JAPAN; HOKKAIDO UNIV,FAC PHARMACEUT SCI,DEPT BIOCHEM,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University; Hokkaido University								AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BIRD P, 1990, J BIOL CHEM, V265, P8420; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOZZARO S, 1981, EXP CELL RES, V134, P181, DOI 10.1016/0014-4827(81)90475-4; CARAS IW, 1989, J CELL BIOL, V108, P1387, DOI 10.1083/jcb.108.4.1387; DUSTIN ML, 1987, NATURE, V329, P846, DOI 10.1038/329846a0; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUCHS M, 1993, IN PRESS J COMPUTER; FUKUI Y, 1987, METHOD CELL BIOL, V28, P347; GERISCH G, 1980, CELL ADHESION MOTILI, P293; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HERMODSON MA, 1973, BIOCHEMISTRY-US, V12, P3146, DOI 10.1021/bi00741a002; HINTERMANN R, 1979, FEBS LETT, V108, P219, DOI 10.1016/0014-5793(79)81214-4; ISHIHARA A, 1987, P NATL ACAD SCI USA, V84, P1290, DOI 10.1073/pnas.84.5.1290; KAMBOJ RK, 1989, CELL, V59, P615, DOI 10.1016/0092-8674(89)90007-X; KIMMEL AR, 1983, NUCLEIC ACIDS RES, V11, P541, DOI 10.1093/nar/11.2.541; KIMMEL AR, 1982, DEV DICTYOSTELIUM DI, P234; KODUKULA K, 1993, J CELL BIOL, V120, P657, DOI 10.1083/jcb.120.3.657; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KUMAZAKI T, 1987, J BIOCHEM-TOKYO, V102, P1539, DOI 10.1093/oxfordjournals.jbchem.a122202; KUMAZAKI T, 1986, Proteins Structure Function and Genetics, V1, P100, DOI 10.1002/prot.340010115; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LODISH HF, 1977, DEV DIFFERENTIATION, P253; MANABE R, 1990, J BIOCHEM-TOKYO, V108, P852, DOI 10.1093/oxfordjournals.jbchem.a123292; MATSUNAGA T, 1987, SCAND J IMMUNOL, V25, P485, DOI 10.1111/j.1365-3083.1987.tb02220.x; MCCARTY KS, 1974, ANAL BIOCHEM, V61, P165, DOI 10.1016/0003-2697(74)90343-1; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MULLER K, 1979, EUR J BIOCHEM, V99, P419, DOI 10.1111/j.1432-1033.1979.tb13271.x; NODA M, 1987, J CELL BIOL, V105, P1671, DOI 10.1083/jcb.105.4.1671; NOEGEL A, 1986, EMBO J, V5, P1473, DOI 10.1002/j.1460-2075.1986.tb04384.x; OCHIAI H, 1990, ELECTROPHORESIS, V11, P856, DOI 10.1002/elps.1150111015; OHNO S, 1987, EXP CLIN IMMUNOGENET, V4, P181; POWLL SK, 1991, ANAL CHEM, V43, P880; SAITO T, 1993, EUR J BIOCHEM, V211, P147, DOI 10.1111/j.1432-1033.1993.tb19881.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAXENA A, 1987, MOL CELL BIOL, V7, P3409, DOI 10.1128/MCB.7.10.3409; SIU CH, 1987, J CELL BIOL, V105, P2523, DOI 10.1083/jcb.105.6.2523; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; STADLER J, 1989, EMBO J, V8, P371, DOI 10.1002/j.1460-2075.1989.tb03387.x; STEINEMANN C, 1979, FEBS LETT, V108, P379, DOI 10.1016/0014-5793(79)80568-2; THOMAS J, 1987, BIOPHYS J, V51, P522; TODA K, 1984, EUR J BIOCHEM, V140, P73, DOI 10.1111/j.1432-1033.1984.tb08068.x; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4	45	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					528	535						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276846				2022-12-27	WOS:A1994MR21900085
J	REAGAN, JD				REAGAN, JD			EXPRESSION CLONING OF AN INSECT DIURETIC HORMONE-RECEPTOR - A MEMBER OF THE CALCITONIN SECRETIN RECEPTOR FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MANDUCA-SEXTA; ACHETA-DOMESTICUS; MOLECULAR-CLONING; TOBACCO HORNWORM; IDENTIFICATION; PEPTIDE; PROTEIN	Insect diuretic hormones and their receptors regulate fluid and ion secretion and thus are attractive targets for the design of novel insect control agents. A complementary DNA clone encoding a corticotropin-releasing factor-related diuretic hormone receptor from the tobacco hornworm Manduca sexta was isolated by expression cloning in COS-7 cells. The receptor consists of 395 amino acids and contains seven putative transmembrane domains. The expressed receptor binds M. sexta diuretic hormone, as well as several related insect diuretic peptides with high affinity. Furthermore, each of these peptides stimulate adenylate cyclase in COS-7 cells transfected with the receptor. The M. sexta diuretic hormone receptor is homologous to the receptors for calcitonin, secretin, vasoactive intestinal peptide, parathyroid hormone, glucagon-like peptide 1, growth hormone-releasing hormone, pituitary adenylate cyclase-activating polypeptide, and glucagon. The M. sexta diuretic hormone receptor is the first nonmammalian member of this family to be identified.			REAGAN, JD (corresponding author), SANDOZ AGRO INC,DIV RES,PALO ALTO,CA 94304, USA.							AUDSLEY N, 1993, J EXP BIOL, V178, P231; BLACKBURN MB, 1991, BIOCHEM BIOPH RES CO, V181, P927, DOI 10.1016/0006-291X(91)92025-F; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; COAST GM, 1992, J EXP BIOL, V162, P331; DEKKER LV, 1992, FEBS LETT, V312, P195, DOI 10.1016/0014-5793(92)80934-9; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KATAOKA H, 1989, P NATL ACAD SCI USA, V86, P2976, DOI 10.1073/pnas.86.8.2976; KAY I, 1992, REGUL PEPTIDES, V42, P111, DOI 10.1016/0167-0115(92)90091-8; KAY I, 1991, BIOL CHEM H-S, V372, P505, DOI 10.1515/bchm3.1991.372.2.505; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEHMBERG E, 1991, BIOCHEM BIOPH RES CO, V179, P1036, DOI 10.1016/0006-291X(91)91923-Z; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; MAYO KE, 1992, MOL ENDOCRINOL, V6, P1734, DOI 10.1210/me.6.10.1734; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; PISEGNA PR, 1993, P NATL ACAD SCI USA, V90, P6345; REAGAN JD, 1993, ARCH INSECT BIOCHEM, V23, P135, DOI 10.1002/arch.940230305; Sambrook J, 1989, MOL CLONING LABORATO; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WRAY V, 1993, BIOCHEMISTRY-US, V32, P5832, DOI 10.1021/bi00073a016	25	105	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					9	12						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276884				2022-12-27	WOS:A1994MR21900003
J	CHEN, YP; FARACO, J; YIN, WS; GERMILLER, J; FRANCKE, U; BONADIO, J				CHEN, YP; FARACO, J; YIN, WS; GERMILLER, J; FRANCKE, U; BONADIO, J			STRUCTURE, CHROMOSOMAL LOCALIZATION, AND EXPRESSION PATTERN OF THE MURINE MAGP GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELASTIN-ASSOCIATED MICROFIBRILS; MESSENGER-RNAS; INSITU HYBRIDIZATION; FIBRILLIN; GLYCOPROTEIN; COMPONENT; TISSUES; MUTATION; PROTEIN; PROBES	The microfibril- associated glycoprotein (MAGP) was recently established as a discrete constituent of 10-nm microfibrils. We have characterized the primary structure of the mouse transcript, the structure and chromosomal localization of the murine gene, and the developmental pattern of gene expression. The transcript consists of 1,037 base pairs as determined by cDNA cloning, Northern blot analysis, S1 nuclease mapping, and primer extension mapping. Using a cDNA fragment as a probe, we isolated a single genomic clone that contained the entire mouse gene. Analysis of this clone indicated that Magp is fragmented into 9 exons, with the initiator Met codon located in exon 2. As determined by analysis of somatic cell hybrid lines and by fluorescence in situ hybridization, the mouse gene was mapped to chromosome 4 at a location corresponding to region D3-E1. Genomic sequence immediately upstream of the transcription start site was found to be GC-rich but lacked TATA or CCAAT boxes as well as other cis-acting motifs known to regulate transcription. Promoters of this type are usually found in genes that exhibit broad temporal and spatial patterns of expression. Consistent with this idea, the Magp transcript appeared to be the widespread product of mesenchymal/connective tissue cells throughout mouse development. This study presents the first comprehensive evaluation of microfibril gene expression during mammalian development.	UNIV MICHIGAN, DEPT PATHOL, MSRB I, RM 3510, 1150 W MED CTR DR, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, ORTHOPAED RES LABS, ORTHOPAED SURG SECT, ANN ARBOR, MI 48109 USA; STANFORD UNIV, MED CTR, SCH MED, DEPT GENET, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, SCH MED, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Stanford University; Howard Hughes Medical Institute; Stanford University								ARBEILLE BB, 1991, J HISTOCHEM CYTOCHEM, V39, P1367, DOI 10.1177/39.10.1940308; BRESSAN GM, 1993, J CELL BIOL, V121, P201, DOI 10.1083/jcb.121.1.201; CLEARY EG, 1983, INT REV CONNECT TISS, V10, P97; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; DIETZ HC, 1992, J CLIN INVEST, V89, P1674, DOI 10.1172/JCI115766; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FARACO J, 1993, AM J MED GENET, V47, P148; FISHER C, 1984, DEV BIOL, V102, P290, DOI 10.1016/0012-1606(84)90194-5; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GEORGE DL, 1980, CYTOGENET CELL GENET, V28, P217, DOI 10.1159/000131535; GIBSON MA, 1986, J BIOL CHEM, V261, P1429; GIBSON MA, 1989, J BIOL CHEM, V264, P4590; GIBSON MA, 1991, J BIOL CHEM, V266, P7596; GIBSON MA, 1987, IMMUNOL CELL BIOL, V65, P345, DOI 10.1038/icb.1987.39; GIBSON MA, 1993, AM J MED GENET, V47, P148; HOLBROOK KA, 1982, J CELL BIOL, V92, P387, DOI 10.1083/jcb.92.2.387; HORRIGAN SK, 1992, J BIOL CHEM, V267, P10087; KAINULAINEN K, 1992, P NATL ACAD SCI USA, V89, P5917, DOI 10.1073/pnas.89.13.5917; KAUFMAN MH, 1992, ATLAS MOUSE DEV, P145; KEENE DR, 1991, J HISTOCHEM CYTOCHEM, V39, P441, DOI 10.1177/39.4.2005373; KOBAYASHI R, 1989, J BIOL CHEM, V264, P17437; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; LOW FN, 1962, ANAT REC, V142, P131, DOI 10.1002/ar.1091420205; LUTZNER MA, 1985, JNCI-J NATL CANCER I, V75, P161; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; MILATOVICH A, 1991, GENOMICS, V11, P1040, DOI 10.1016/0888-7543(91)90030-I; PATTERSON E, 1989, J BIOL CHEM, V264, P10083; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; Ross R, 1977, Adv Exp Med Biol, V79, P7; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Sambrook J, 1989, MOL CLONING LABORATO; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; TSIPOURAS P, 1992, NEW ENGL J MED, V326, P905, DOI 10.1056/NEJM199204023261401; VRACKO R, 1990, J MOL CELL CARDIOL, V22, P749, DOI 10.1016/0022-2828(90)90087-I; YANGFENG TL, 1986, P NATL ACAD SCI USA, V83, P8679, DOI 10.1073/pnas.83.22.8679	38	25	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27381	27389						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262979				2022-12-27	WOS:A1993MM26200078
J	HO, KC; MARSCHKE, KB; TAN, JA; POWER, SGA; WILSON, EM; FRENCH, FS				HO, KC; MARSCHKE, KB; TAN, JA; POWER, SGA; WILSON, EM; FRENCH, FS			A COMPLEX RESPONSE ELEMENT IN INTRON-1 OF THE ANDROGEN-REGULATED 20-KDA PROTEIN GENE DISPLAYS CELL TYPE-DEPENDENT ANDROGEN RECEPTOR SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VENTRAL PROSTATE; MAMMARY-TUMOR VIRUS; GLUCOCORTICOID RECEPTOR; DNA-BINDING; TRANSCRIPTION FACTORS; MAMMALIAN-CELLS; 1ST INTRON; C-JUN; EXPRESSION; HORMONE	The androgen-regulated 20-kDa protein gene consists of four exons that code for a major secretory protein of rat ventral prostate. Analysis of its potential cis-acting transcriptional regulatory elements revealed that a large intron 1 region (In-1) had stronger androgen response element (ARE) activity than did the 5'-flanking DNA. In cotransfected CV1 cells, In-1 and its most active subfragment In-1c functioned as AREs but not glucocorticoid response elements (GRE). Nevertheless several ARE/GRE-like partial palindromic sequences are present in In-1c, and it bound both androgen receptors and glucocorticoid receptors in mobility shift assays. A cluster of three ARE/GRE-like sequences contained within a 39-base pair sequence of In-1c had both ARE and GRE activities when analyzed as an isolated oligonucleotide, suggesting that other elements within In-1c determined its ARE specificity. In addition to ARE/GRE-like sequences, In-1c contains putative response elements for the transcription factors AP1, CREB, AP2, OCT-1, C/EBP, and a number of inverted and direct repeats. The ARE specificity of In-1c observed in CV1 cells was diminished in PC3 and HeLa cells transiently cotransfected with an androgen receptor or glucocorticoid receptor expression vector together with an In-1c reporter vector; however, the ARE activity of In-1c was greater than its GRE activity in these cell lines. Interestingly, a 131-base pair subfragment of In-1c retained ARE specificity in all three cell lines.	UNIV N CAROLINA,REPROD BIOL LABS,CB 7500,MACNIDER BLDG,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PEDIAT,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOCHEM BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007315, R37HD004466, R01HD004466, P30HD018968] Funding Source: NIH RePORTER; NICHD NIH HHS [P30-HD18968, T32-HDQ7315, HD04466] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADLER AJ, 1991, MOL ENDOCRINOL, V5, P1587, DOI 10.1210/mend-5-11-1587; ADLER AJ, 1992, P NATL ACAD SCI USA, V89, P11660, DOI 10.1073/pnas.89.24.11660; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; BURLEIGH BD, 1980, MOL CELL ENDOCRINOL, V19, P183, DOI 10.1016/0303-7207(80)90021-0; CATO ACB, 1987, EMBO J, V6, P363, DOI 10.1002/j.1460-2075.1987.tb04763.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAESSENS F, 1989, BIOCHEM BIOPH RES CO, V164, P833, DOI 10.1016/0006-291X(89)91534-9; COLLINS S, 1988, FEBS LETT, V223, P173; DENISON SH, 1989, ENDOCRINOLOGY, V124, P1091, DOI 10.1210/endo-124-2-1091; DEVOS P, 1991, J BIOL CHEM, V266, P3439; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FREEDMAN LP, 1992, ENDOCR REV, V13, P129, DOI 10.1210/er.13.2.129; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; HARRIS SE, 1988, CELLULAR FACTORS DEV, P53; HO KC, 1992, J BIOL CHEM, V267, P12660; HO KC, 1989, BIOCHEMISTRY-US, V28, P6367, DOI 10.1021/bi00441a032; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; LANGE AJ, 1992, J BIOL CHEM, V267, P15673; LOCKER J, 1990, J DNA SEQUENCING MAP, V1, P3; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; LUND SD, 1991, MOL CELL BIOL, V11, P5426, DOI 10.1128/MCB.11.11.5426; MANIATIS T, 1982, MOL CLONING LABORATO, P353; MARSCHKE KB, 1993, NEW PERSPECTIVES END, V99, P41; MARTIKAINEN P, 1987, ENDOCRINOLOGY, V121, P604, DOI 10.1210/endo-121-2-604; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1866, DOI 10.1210/mend-4-12-1866; RATAJCZAK T, 1992, J BIOL CHEM, V267, P11111; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; RENNIE PS, 1989, MOL ENDOCRINOL, V3, P703, DOI 10.1210/mend-3-4-703; RHEE M, 1991, MOL ENDOCRINOL, V5, P564, DOI 10.1210/mend-5-4-564; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; SANGER F, 1977, P NATL ACAD SCI USA, V74, P560; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SIMONS SS, 1992, MOL ENDOCRINOL, V6, P995, DOI 10.1210/me.6.7.995; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; TAN JA, 1992, J BIOL CHEM, V267, P4456; Thompson T C, 1987, Prog Clin Biol Res, V239, P239; VERCAEREN I, 1992, ENDOCRINOLOGY, V131, P2496, DOI 10.1210/endo-131-6-2496; WILSON EM, 1976, J BIOL CHEM, V251, P5620; WINDERICKX J, 1990, MOL ENDOCRINOL, V4, P657, DOI 10.1210/mend-4-4-657; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YARBROUGH WG, 1990, J BIOL CHEM, V265, P8893; ZHANG HY, 1991, J BIOL CHEM, V266, P24332	54	56	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27226	27235						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262963				2022-12-27	WOS:A1993MM26200059
J	TAN, EC; LEUNG, T; MANSER, E; LIM, L				TAN, EC; LEUNG, T; MANSER, E; LIM, L			THE HUMAN ACTIVE BREAKPOINT CLUSTER REGION-RELATED GENE ENCODES A BRAIN PROTEIN WITH HOMOLOGY TO GUANINE-NUCLEOTIDE EXCHANGE PROTEINS AND GTPASE-ACTIVATING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MILLER-DIEKER SYNDROME; BCR-GENE; TYROSINE KINASE; NEUROFIBROMATOSIS GENE; MOLECULAR-CLONING; BINDING PROTEINS; C-ABL; IDENTIFICATION; PRODUCT; SEQUENCES	GTPase-activating proteins (GAPs) modulate the activity of the ras superfamily of proteins by converting active GTP-bound to inactive GDP-bound p21s. Employing a novel GAP overlay assay (Manser, E., Leung, T., Monfries, C., Teo, M., Hall, C., and Lim, L. (1992) J. Biol. Chem. 267, 16025-16028), we demonstrated a diversity of proteins with GAP activities in different tissues. Using a polymerase chain reaction strategy exploiting conserved residues in the GAP domains of n-chimaerin and the product of the breakpoint cluster region gene (BCR), we isolated a human brain 5.3-kilobase cDNA containing a 486-base pair region with complete identity to a previously reported active BCR-related (ABR) gene sequence on human chromosome 17. The brain cDNA encoded a 98-kDa protein (ABR) resembling BCR (68% identity), containing both the oncogene dbl-related domain at the N terminus and the GAP domain at the C terminus; however, it lacks the N-terminal BCR protein kinase domain. The ABR GAP domain expressed as an Escherichia coli fusion protein was active against Rac1 and Cdc42 of the rho subfamily. The ABR mRNA is highly enriched in the brain. ABR probably corresponds to the brain-enriched 100-kDa GAP for Rac and Cdc42Hs previously detected. The relationship of ABR to Miller-Dieker syndrome, a neurological disorder co-mapping to 17p13.3, is discussed.	INST NEUROL,LONDON WC1N 1PJ,ENGLAND	University of London; University College London	TAN, EC (corresponding author), NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,SINGAPORE 0511,SINGAPORE.		Tan, EC/W-6304-2019; Manser, Edward/ABD-2301-2020					BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; DHUT S, 1988, ONCOGENE, V3, P561; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DISILVESTRE D, 1990, NUCLEIC ACIDS RES, V18, P5924, DOI 10.1093/nar/18.19.5924; DOBYNS WB, 1991, AM J HUM GENET, V48, P584; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HARTWELL LH, 1973, GENETICS, V74, P267; HEISTERKAMP N, 1989, NUCLEIC ACIDS RES, V17, P8821, DOI 10.1093/nar/17.21.8821; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KWIATKOWSKI DJ, 1990, AM J HUM GENET, V46, P559; LEDBETTER SA, 1990, GENOMICS, V7, P264, DOI 10.1016/0888-7543(90)90549-A; LEUNG T, 1993, J BIOL CHEM, V268, P3813; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; MANSER E, 1992, J BIOL CHEM, V267, P16025; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MELO JV, 1993, BLOOD, V81, P158; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NOWELL PC, 1960, SCIENCE, V132, P1197; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; TIMMONS MS, 1989, ONCOGENE, V4, P559; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; ZIMAN M, 1991, MOL CELL BIOL, V11, P3537, DOI 10.1128/MCB.11.7.3537	39	55	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27291	27298						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262969				2022-12-27	WOS:A1993MM26200066
J	GUIDOT, DM; MCCORD, JM; WRIGHT, RM; REPINE, JE				GUIDOT, DM; MCCORD, JM; WRIGHT, RM; REPINE, JE			ABSENCE OF ELECTRON-TRANSPORT (RHO(0) STATE) RESTORES GROWTH OF A MANGANESE-SUPEROXIDE DISMUTASE-DEFICIENT SACCHAROMYCES-CEREVISIAE IN HYPEROXIA - EVIDENCE FOR ELECTRON-TRANSPORT AS A MAJOR SOURCE OF SUPEROXIDE GENERATION IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C OXIDASE; HEART-MITOCHONDRIA; HYDROGEN-PEROXIDE; POLYMORPHONUCLEAR LEUKOCYTES; LIPID-PEROXIDATION; ESCHERICHIA-COLI; RAT-LIVER; FERRITIN; UBIQUINONE; RADICALS	To address the possibility that electron transport is a biologically significant source of superoxide anion (O2 radical anion) during exposure to hyperoxia in vivo, we constricted Saccharomyces cerevisiae strains with selective disruptions in the gene encoding the mitochondrial manganese-containing superoxide dismutase (Mn-SOD) and/or genes encoding proteins critical for complexes in electron transport. We hypothesized that complete absence of electron transport would restore growth in hyperoxia to a Mn-SOD-deficient yeast. We found that yeast deficient in Mn-SOD activity failed to grow normally in hyperoxia (95% O2, 5% CO2). In contrast, Mn-SOD-deficient yeast with complete absence of electron transport (the Rho0 state) grew normally in hyperoxia. By comparison, Mn-SOD-deficient yeast which were deficient only in cytochrome-c-oxidase, the terminal step in electron transport, had only partially restored growth in hyperoxia. Our results indicate that electron transport is a major source of O2 radical anion in vivo, and that the principal site of this O2 radical anion production is proximal to the cytochrome-c-oxidase complex.			GUIDOT, DM (corresponding author), WEBB WARING INST BIOMED RES, BOX C322, 4200 E 9TH AVE, DENVER, CO 80262 USA.		McCord, Joe/GWU-8607-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL027353, K11HL002690] Funding Source: NIH RePORTER; NHLBI NIH HHS [K11-HL02690, P50-HL27353] Funding Source: Medline; PHS HHS [R01-45582] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BIEMOND P, 1984, J CLIN INVEST, V73, P1576, DOI 10.1172/JCI111364; BOLANN BJ, 1987, BIOCHEM J, V243, P55, DOI 10.1042/bj2430055; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; CUMSKY MG, 1985, P NATL ACAD SCI USA, V82, P2235, DOI 10.1073/pnas.82.8.2235; FREDERIKS WM, 1986, VIRCHOWS ARCH B, V51, P321, DOI 10.1007/BF02899041; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; IMLAY JA, 1991, J BIOL CHEM, V266, P6957; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JENNINGS RB, 1976, CIRC RES, V38, P80; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MCCORD JM, 1988, FREE RADICAL BIO MED, V5, P363, DOI 10.1016/0891-5849(88)90109-8; MCEWEN JE, 1985, J BACTERIOL, V161, P831, DOI 10.1128/JB.161.3.831-835.1985; NISHIDA T, 1987, BIOCHIM BIOPHYS ACTA, V890, P82, DOI 10.1016/0005-2728(87)90071-5; NOHL H, 1981, FEBS LETT, V123, P241, DOI 10.1016/0014-5793(81)80297-9; SALIN ML, 1974, J CLIN INVEST, V54, P1005, DOI 10.1172/JCI107816; THOMAS CE, 1985, J BIOL CHEM, V260, P3275; TURRENS JF, 1982, ARCH BIOCHEM BIOPHYS, V217, P401, DOI 10.1016/0003-9861(82)90518-5; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; VANLOON APGM, 1986, P NATL ACAD SCI USA, V83, P3820; WEFERS H, 1988, EUR J BIOCHEM, V174, P353, DOI 10.1111/j.1432-1033.1988.tb14105.x; WRIGHT RM, 1989, NUCLEIC ACIDS RES, V17, P1103, DOI 10.1093/nar/17.3.1103; ZHANG Y, 1990, J BIOL CHEM, V265, P16330	28	141	145	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26699	26703						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253804				2022-12-27	WOS:A1993MK42500100
J	LIN, CM; KIEBEREMMONS, T; VILLALOBOS, AP; FOSTER, MH; WAHLGREN, C; KLEYMAN, TR				LIN, CM; KIEBEREMMONS, T; VILLALOBOS, AP; FOSTER, MH; WAHLGREN, C; KLEYMAN, TR			TOPOLOGY OF AN AMILORIDE-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-H+ EXCHANGER; EPITHELIAL SODIUM-CHANNEL; MEMBRANE-VESICLES; ANTIBODY; ANALOGS; SITE; INHIBITION; ANTIGEN; LIGANDS; CLONING	Amiloride and structurally related compounds inhibit many transport proteins, enzymes, and drug or hormone receptors, although the topology of amiloride binding sites on these proteins has not been defined. We have previously raised and characterized a monoclonal antiamiloride antibody (mAb BA7.1) which is similar to epithelial Na+ channels in its specificity of binding of amiloride and amiloride analogs, suggesting that their amiloride binding sites may be similar in topology. mAb BA7.1 was used as a model system to analyze the three-dimensional conformation of an amiloride binding site. The photoactive amiloride analog 2'-methoxy-5'-nitro-benzamil specifically labeled the heavy chain of mAb BA7.1, suggesting that the heavy chain participates in amiloride binding. The nucleotide sequences of the variable regions of the heavy and light chains of mAb BA7.1 were determined and amino acid sequences deduced to analyze the structure of the amiloride binding site. A comparative modeling approach was used to construct a model of the amiloride binding domain of mAb BA7.1, and a docking procedure was used to place amiloride within this domain. The model indicated that planar aromatic amino acid residues form a pocket into which amiloride, a planar molecule, inserts. Constraints on amiloride binding predicted by this model correlated with the measured specificity of binding of amiloride analogs with mAb BA7.1. These results provide a potential guide for the identification of motifs or amino acid contact residues present within other amiloride-sensitive proteins.	WISTAR INST ANAT & BIOL, 3601 SPRUCE ST, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT MED, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT PHYSIOL, PHILADELPHIA, PA 19104 USA; VET ADM MED CTR, PHILADELPHIA, PA 19104 USA	The Wistar Institute; University of Pennsylvania; University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA)								BALL RG, 1991, SRRGB0091B MERCK SHA; BENOS DJ, 1980, J MEMBRANE BIOL, V56, P149, DOI 10.1007/BF01875966; BENOS DJ, 1987, J BIOL CHEM, V262, P10613; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; CHEETHAM JC, 1991, P NATL ACAD SCI USA, V88, P7968, DOI 10.1073/pnas.88.18.7968; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOTHIA C, 1992, J MOL BIOL, V227, P799, DOI 10.1016/0022-2836(92)90224-8; COOK JS, 1987, AM J PHYSIOL, V253, pC199, DOI 10.1152/ajpcell.1987.253.2.C199; CORNELISSE J, 1975, CHEM REV, V75, P353, DOI 10.1021/cr60296a001; COUNILLON L, 1992, AMILORIDE ITS ANALOG, P247; Counillon Laurent, 1992, Journal of General Physiology, V100, p20A; CUTHBERT AW, 1974, MOL PHARMACOL, V10, P880; CUTHBERT AW, 1981, ION TRANSPORT EPITHE, P181; DEGUCHI Y, 1990, J BIOL CHEM, V265, P21704; DESJARLAIS RL, 1986, J MED CHEM, V29, P2149, DOI 10.1021/jm00161a004; DESJARLAIS RL, 1988, J MED CHEM, V31, P722, DOI 10.1021/jm00399a006; GANAPATHY V, 1987, BIOCHEM J, V245, P473, DOI 10.1042/bj2450473; GARRITSEN A, 1991, J RECEPTOR RES, V11, P891, DOI 10.3109/10799899109064686; GARTY H, 1988, PHYSIOL REV, V68, P309, DOI 10.1152/physrev.1988.68.2.309; GRILLO FG, 1986, J BIOL CHEM, V261, P1120; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUILLAUME T, 1990, J IMMUNOL, V145, P1934; HAGGERTY JG, 1988, P NATL ACAD SCI USA, V85, P6797, DOI 10.1073/pnas.85.18.6797; HARLOW E, 1988, ANTIBODIES LABORATOR; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KACZOROWSKI GJ, 1985, BIOCHEMISTRY-US, V24, P1394, DOI 10.1021/bi00327a017; KIEBEREMMONS T, 1992, AIDS RES REV, V2, P65; KINSELLA JL, 1981, AM J PHYSIOL, V241, pF374, DOI 10.1152/ajprenal.1981.241.4.F374; KLEYMAN TR, 1986, AM J PHYSIOL, V250, pC165, DOI 10.1152/ajpcell.1986.250.1.C165; KLEYMAN TR, 1989, AM J PHYSIOL, V257, pC1135, DOI 10.1152/ajpcell.1989.257.6.C1135; KLEYMAN TR, 1988, SEMIN NEPHROL, V8, P242; KLEYMAN TR, 1991, J BIOL CHEM, V266, P3907; KLEYMAN TR, 1989, J BIOL CHEM, V264, P11995; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; LEVY S, 1987, GENE, V54, P167, DOI 10.1016/0378-1119(87)90484-7; LI JHY, 1987, J MEMBRANE BIOL, V95, P171, DOI 10.1007/BF01869162; LI JHY, 1984, J MEMBRANE BIOL, V76, P235; MARTIN ACR, 1991, METHOD ENZYMOL, V203, P121; NISONOFF A, 1991, J IMMUNOL, V147, P2429; OH Y, 1992, AMILORIDE ITS ANALOG, P41; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; PARK CS, 1983, AM J PHYSIOL, V245, pF716, DOI 10.1152/ajprenal.1983.245.6.F716; PARK CS, 1980, AM J PHYSIOL, V239, pF299, DOI 10.1152/ajprenal.1980.239.3.F299; PARK CS, 1983, AM J PHYSIOL, V245, pF707, DOI 10.1152/ajprenal.1983.245.6.F707; PEERCE BE, 1985, J BIOL CHEM, V260, P6026; PRIDE MW, 1992, P NATL ACAD SCI USA, V89, P11900, DOI 10.1073/pnas.89.24.11900; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; Sambrook J, 1989, MOL CLONING LABORATO; SARIBANSOHRABY S, 1986, AM J PHYSIOL, V250, pC175, DOI 10.1152/ajpcell.1986.250.2.C175; Simchowitz L., 1992, AMILORIDE ITS ANALOG, P9; SMITH RL, 1979, J AM CHEM SOC, V101, P191, DOI 10.1021/ja00495a032; STAUB O, 1992, J CELL BIOL, V119, P1497, DOI 10.1083/jcb.119.6.1497; SUDARSANAM S, 1992, J COMPUT AID MOL DES, V6, P223, DOI 10.1007/BF00123378; TAUB R, 1992, BIOCHEMISTRY-US, V31, P7431, DOI 10.1021/bi00148a001; THORNTON JM, 1991, NATURE, V354, P105, DOI 10.1038/354105a0; TOMIYAMA Y, 1992, J BIOL CHEM, V267, P18085; VAUX D, 1991, METHOD CELL BIOL, V34, P1; VENANZI CA, 1992, J MED CHEM, V35, P1643, DOI 10.1021/jm00087a022; VOSS EW, 1992, IMMUNOL INVEST, V21, P71, DOI 10.3109/08820139209069364; WANG D, 1991, Journal of the American Society of Nephrology, V2, P715; WERNER A, 1991, P NATL ACAD SCI USA, V88, P9608, DOI 10.1073/pnas.88.21.9608; WILLIAMS WV, 1988, P NATL ACAD SCI USA, V85, P6488, DOI 10.1073/pnas.85.17.6488; WILLIAMS WV, 1991, J BIOL CHEM, V266, P9241; WILLIAMS WV, 1991, J BIOL CHEM, V266, P5182; WILLIAMS WV, 1989, P NATL ACAD SCI USA, V86, P5537, DOI 10.1073/pnas.86.14.5537; Zanetti M, 1991, Immunol Ser, V55, P221	67	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2805	2813						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300613				2022-12-27	WOS:A1994MV43200067
J	KALFA, TA; THULL, JD; BUTKOWSKI, RJ; CHARONIS, AS				KALFA, TA; THULL, JD; BUTKOWSKI, RJ; CHARONIS, AS			TUBULOINTERSTITIAL NEPHRITIS ANTIGEN INTERACTS WITH LAMININ AND TYPE-IV COLLAGEN AND PROMOTES CELL-ADHESION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANES; BINDING-SITES; DOMAINS; FORMS	Tubulointerstitial nephritis (TIN) antigen has been recently identified as a novel basement membrane macromolecule. It consists of a single chain of 58 kDa and exhibits a restricted distribution. The interaction between TIN antigen and laminin or type IV collagen has been studied using solid-phase binding assays and found to be for both macromolecules specific, saturable, and with an affinity in the low micromolar range. In similar assays, TIN antigen did not interact with heparin. In turbidimetry assays, it was found that the presence of TIN antigen did not affect the polymerization of type IV collagen but had a concentration-dependent inhibitory effect on laminin polymerization and on preformed laminin polymers. TIN antigen was able to promote adhesion of epithelial cells derived from kidney tubules and of endothelial cells derived from aorta. The data suggest that TIN antigen may be a macromolecule of importance both for basement membrane ultrastructure and cellular adhesion.	UNIV MINNESOTA,SCH MED,DEPT LAB MED & PATHOL,BOX 609 UMHC,420 DELAWARE ST SE,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities				Kalfa, Theodosia/0000-0002-0426-9686; Charonis, Aristidis/0000-0001-9956-732X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043569, R01DK036007] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43569, DK 36007] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUMAILLEY M, 1987, J BIOL CHEM, V262, P11532; BUTKOWSKI RJ, 1990, J BIOL CHEM, V265, P21091; BUTKOWSKI RJ, 1991, KIDNEY INT, V40, P838, DOI 10.1038/ki.1991.283; CARLSSON R, 1981, P NATL ACAD SCI-BIOL, V78, P2403, DOI 10.1073/pnas.78.4.2403; HAVERTY TP, 1988, J CELL BIOL, V107, P1359, DOI 10.1083/jcb.107.4.1359; HERBST TJ, 1988, J CELL BIOL, V106, P1365, DOI 10.1083/jcb.106.4.1365; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; KOUZIKOLIAKOS K, 1989, J BIOL CHEM, V264, P17971; PAULSSON M, 1992, CRIT REV BIOCHEM MOL, V27, P93; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SKUBITZ APN, 1988, J BIOL CHEM, V263, P4861; TIMPL R, 1979, J BIOL CHEM, V254, P9933; TSILIBARY EC, 1988, J BIOL CHEM, V263, P19112; YURCHENCO PD, 1990, J BIOL CHEM, V265, P3981; YURCHENCO PD, 1992, J CELL BIOL, V117, P1119, DOI 10.1083/jcb.117.5.1119	15	29	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1654	1659						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294412				2022-12-27	WOS:A1994MR98800020
J	LAI, K; MCGRAW, P				LAI, K; MCGRAW, P			DUAL CONTROL OF INOSITOL TRANSPORT IN SACCHAROMYCES-CEREVISIAE BY IRREVERSIBLE INACTIVATION OF PERMEASE AND REGULATION OF PERMEASE SYNTHESIS BY INO2, INO4, AND OPI1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID BIOSYNTHESIS; MYO-INOSITOL-1-PHOSPHATE SYNTHASE; PHOSPHATIDYLSERINE SYNTHASE; COORDINATE REGULATION; STRUCTURAL GENE; YEAST; MEMBRANE; PROTEIN; TRANSFORMATION; ENCODES	Uptake of inositol by Saccharomyces cerevisiae is regulated through transcriptional control of the gene that encodes the major inositol permease, ITR1 (Nikawa, J., Tsukagoshi, Y., and Yamashita, S. (1991) J. Biol. Chem. 266, 11184-11191). ITR1 mRNA abundance decreases when cells are transferred from medium without inositol to medium with inositol. Here we demonstrate that the mechanism of transcriptional regulation of ITR1 is through the action of the INO2, INO4 and OPI1 genes. INO2 and INO4 are required for derepressed levels of ITR1 mRNA, and OPI1 is necessary for repression of transcript levels in response to inositol. The INO2, INO4, and OPI1 genes thus coordinate uptake of inositol to endogenous inositol biosynthesis and to phospholipid biosynthesis. Repression of transcription of ITR1 also requires ongoing synthesis of phosphatidylcholine, defining an additional link between synthesis of phospholipids and regulation of inositol uptake. Analysis showed that the INO1 gene, encoding a key enzyme in the inositol biosynthetic pathway, responded to decreases in permease activity with a graduated increase in the level of INO1 mRNA. We also found that, in addition to the transcriptional regulation, inositol permease activity is regulated by irreversible inactivation. Inactivation of the ITR1 permease occurs in response to the presence of inositol and involves a change in the functional half-life of the protein.	UNIV MARYLAND, DEPT BIOL SCI, BALTIMORE CTY CAMPUS, CATONSVILLE, MD 21228 USA	University System of Maryland; University of Maryland Baltimore County								AMASINO RM, 1986, ANAL BIOCHEM, V152, P304, DOI 10.1016/0003-2697(86)90413-6; BAILIS AM, 1987, MOL CELL BIOL, V7, P167, DOI 10.1128/MCB.7.1.167; BISSON LF, 1983, P NATL ACAD SCI-BIOL, V80, P1730, DOI 10.1073/pnas.80.6.1730; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; DEANJOHNSON M, 1989, J BIOL CHEM, V264, P1274; DONAHUE TF, 1981, J BIOL CHEM, V256, P7077; FISCHL AS, 1986, J BIOL CHEM, V261, P3178; FRIED HM, 1981, P NATL ACAD SCI-BIOL, V78, P238, DOI 10.1073/pnas.78.1.238; FRUEN BR, 1991, FEBS LETT, V295, P43, DOI 10.1016/0014-5793(91)81380-Q; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; GREENBERG ML, 1982, GENETICS, V100, P19; HENRY SA, 1977, J BACTERIOL, V130, P472, DOI 10.1128/JB.130.1.472-484.1977; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HOMANN MJ, 1987, J BACTERIOL, V169, P3276, DOI 10.1128/jb.169.7.3276-3280.1987; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; LISANTI MP, 1990, J MEMBRANE BIOL, V117, P1, DOI 10.1007/BF01871561; LOEWY BS, 1984, MOL CELL BIOL, V4, P2479, DOI 10.1128/MCB.4.11.2479; LOEWY BS, 1985, THESIS A EINSTEIN CO; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P1687, DOI 10.1093/nar/19.7.1687; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MCGRAW P, 1989, GENETICS, V122, P317; NIKAWA J, 1991, J BIOL CHEM, V266, P11184; NIKOLOFF DM, 1992, NUCLEIC ACIDS RES, V20, P3253, DOI 10.1093/nar/20.12.3253; PALTAUF F, 1992, MOL CELLULAR BIOL YE, V2, P415; PATTON JL, 1991, J BACTERIOL, V173, P3101, DOI 10.1128/JB.173.10.3101-3108.1991; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHULLER HJ, 1992, NUCLEIC ACIDS RES, V20, P5955, DOI 10.1093/nar/20.22.5955; STEINER S, 1969, P NATL ACAD SCI USA, V64, P1042, DOI 10.1073/pnas.64.3.1042; VOLLAND C, 1992, J BIOL CHEM, V267, P23767; WHITE MJ, 1991, J BIOL CHEM, V266, P863; WINEGRAD AI, 1987, DIABETES, V36, P396, DOI 10.2337/diab.36.3.396	34	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2245	2251						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294482				2022-12-27	WOS:A1994MR98800103
J	LECOMPTE, MF; BOUIX, G; MANN, KG				LECOMPTE, MF; BOUIX, G; MANN, KG			ELECTROSTATIC AND HYDROPHOBIC INTERACTIONS ARE INVOLVED IN FACTOR-VA BINDING TO MEMBRANES CONTAINING ACIDIC PHOSPHOLIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE FACTOR-V; COAGULATION FACTOR-V; HUMAN-PLATELETS; COMPLETE CDNA; FACTOR-XA; PROTHROMBIN; VESICLES; PHOSPHATIDYLSERINE; MONOLAYERS; SUBUNITS	The interaction of factor Va with phospholipid monolayers was studied using alternating current polarography. For these studies a hanging mercury drop electrode is positioned in contact with the monolayer at the air-monolayer interface. Factor Va introduced into the aqueous subphase beneath the monolayer caused alterations in the capacitance of the circuit. When factor Va was introduced beneath monolayers containing 13-25% mole fraction phosphatidylserine (PS), 87-75% mole fraction phosphatidylcholine (PC), a significant capacitance increase occurred, which is interpreted to be the result of the penetration of the factor Va molecules through the monolayer. No penetration or associated capacitance changes were observed with monolayers composed of pure PC or pure PS. Polarography experiments were also conducted with the electrode placed in the aqueous subphase to measure the binding of factor Va to pure PS monolayers. This approach has allowed detection of factor Va (at nm concentrations) adsorption to a pure PS monolayer. Thus the membrane adsorption process can be distinguished from factor Va penetration through the monolayer. These results suggest that there are two types of interaction of the factor Va molecule with PS-containing monolayers. The interaction with the PS component of the monolayer is essential for binding the factor Va (at nm concentrations) that occurs by surface adsorption. For mixed PC/PS monolayers, PS adsorption is followed by penetration bf the protein through the membrane.	UNIV VERMONT,DEPT BIOCHEM,BURLINGTON,VT 05405	University of Vermont	LECOMPTE, MF (corresponding author), DEPT GLYCOCONJUGUES & BIOMEMBRANES,PHARMACOL & TOXICOL FUNDAMENTALES LAB,CNRS,118 ROUTE NARBONNE,F-31062 TOULOUSE,FRANCE.				NHLBI NIH HHS [HL 46973] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046973] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ESMON CT, 1979, J BIOL CHEM, V254, P964; GIESEN PLA, 1991, J BIOL CHEM, V266, P1870; GUINTO ER, 1992, J BIOL CHEM, V267, P2971; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; JONES ME, 1986, BIOCHEMISTRY-US, V25, P567, DOI 10.1021/bi00351a009; KALAFATIS M, 1990, J BIOL CHEM, V265, P21580; KANE WH, 1986, P NATL ACAD SCI USA, V83, P6800, DOI 10.1073/pnas.83.18.6800; KRISHNASWAMY S, 1989, J BIOL CHEM, V264, P3160; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P26610; LECOMPTE MF, 1990, BIOELECTROCH BIOENER, V24, P13, DOI 10.1016/0302-4598(80)85002-1; LECOMPTE MF, 1984, J ELECTROANAL CHEM, V163, P345, DOI 10.1016/S0022-0728(84)80061-3; LECOMPTE MF, 1987, ACS SYM SER, V343, P103; LECOMPTE MF, 1987, J BIOL CHEM, V262, P1935; LECOMPTE MF, 1980, BIOCHEMISTRY-US, V19, P3434, DOI 10.1021/bi00556a005; LECOMPTE MF, 1988, J COLLOID INTERF SCI, V123, P259, DOI 10.1016/0021-9797(88)90242-1; LECOMPTE MF, 1980, BIOCHEMISTRY-US, V19, P3439, DOI 10.1021/bi00556a006; LECOMPTE MF, 1980, PROTIDES BIOL FLUIDS, V28, P277; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1981, BIOCHEMISTRY-US, V20, P28, DOI 10.1021/bi00504a005; MILETICH JP, 1978, J BIOL CHEM, V253, P6908; MOSESSON MW, 1990, J BIOL CHEM, V265, P8863; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4164, DOI 10.1021/bi00638a005; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NESHEIM ME, 1980, METHOD ENZYMOL, V80, P243; ORTEL TL, 1992, J BIOL CHEM, V267, P4189; ORTEL TL, 1992, BLOOD S1, V80, pA637; PRYZDIAL ELG, 1991, J BIOL CHEM, V266, P8969; PUSEY ML, 1982, BIOCHEMISTRY-US, V21, P5262, DOI 10.1021/bi00264a022; ROSING J, 1985, BLOOD, V65, P319; TRACY PB, 1983, P NATL ACAD SCI-BIOL, V80, P2380, DOI 10.1073/pnas.80.8.2380; TRACY PB, 1979, J BIOL CHEM, V254, P354; VANDEWAART P, 1983, BIOCHEMISTRY-US, V22, P2427, DOI 10.1021/bi00279a019	36	35	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1905	1910						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294440				2022-12-27	WOS:A1994MR98800055
J	PAJOVIC, S; JONES, VE; PROWSE, KR; BERGER, FG; BAUMANN, H				PAJOVIC, S; JONES, VE; PROWSE, KR; BERGER, FG; BAUMANN, H			SPECIES-SPECIFIC CHANGES IN REGULATORY ELEMENTS OF MOUSE HAPTOGLOBIN GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE PLASMA-PROTEINS; RAT ALPHA-1-ACID GLYCOPROTEIN; C-REACTIVE PROTEIN; GLUCOCORTICOID-RESPONSE ELEMENTS; 3 C/EBP ISOFORMS; T-KININOGEN GENE; TRANSCRIPTIONAL REGULATION; CYTOKINE-RESPONSE; HEPATOMA-CELLS; ETS ONCOGENE	Although expression of the haptoglobin (HP) as an acute phase reactant is evolutionarily conserved among mammals, there are differences among species with regard to the hormones required for stimulation. Using primary hepatocyte cultures, we show that in Mus caroli, as in rat, IL-1 and IL-6 are stimulatory, whereas in M. domesticus, as in humans, IL-1 response is diminished. In vivo, an acute inflammatory process increases hepatic HP expression in both mouse species up to 30-fold but minimally affects the low level HP expression in the lung. To define the species-specific differences in regulation, we isolated the hormone-responsive elements of the HP gene from the Mus species, M. domesticus, M. caroli, and M. saxicola. Functional studies in transfected hepatoma cells revealed an exceptionally strong dexamethasone response for all three murine HP gene elements. The IL-6 response was less prominent than in rat or human. A modest response to IL-1 was observed in M. caroli and M. saxicola. A mouse-specific insertion of a polypurine sequence led to a binding site for the PEA3 transcription factor in the HP gene promoter of M. domesticus and M. saxicola, but not M. caroli. The specific regulatory effects of glucocorticoid receptor, C/EBPbeta, and Ets proteins were documented by co-transfection.	ROSWELL PK CANC INST, DEPT MOLEC & CELLULAR BIOL, ELM & CARLTON ST, BUFFALO, NY 14263 USA; UNIV S CAROLINA, DEPT BIOL SCI, COLUMBIA, SC 29208 USA	Roswell Park Cancer Institute; University of South Carolina; University of South Carolina System; University of South Carolina Columbia					NCI NIH HHS [CA26122] Funding Source: Medline; NIDDK NIH HHS [DK33886] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033886] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAM T, 1992, J BIOL CHEM, V267, P5021; ANDERSON KP, 1989, NUCLEIC ACIDS RES, V17, P2835, DOI 10.1093/nar/17.7.2835; ARCONE R, 1988, NUCLEIC ACIDS RES, V16, P3195, DOI 10.1093/nar/16.8.3195; BAUMANN H, 1989, IN VITRO CELL DEV B, V25, P115; BAUMANN H, 1983, J CELL BIOL, V97, P866, DOI 10.1083/jcb.97.3.866; BAUMANN H, 1987, J IMMUNOL, V139, P4122; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BAUMANN H, 1990, MOL CELL BIOL, V10, P5967, DOI 10.1128/MCB.10.11.5967; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BAUMANN H, 1988, METHOD ENZYMOL, V163, P566; BAUMANN H, 1990, J BIOL CHEM, V265, P22275; BAUMANN H, 1983, J CELL BIOL, V97, P728, DOI 10.1083/jcb.97.3.728; BAUMANN H, 1991, J BIOL CHEM, V266, P20390; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENSI G, 1985, EMBO J, V4, P119, DOI 10.1002/j.1460-2075.1985.tb02325.x; BONHOMME F, 1984, BIOCHEM GENET, V22, P275, DOI 10.1007/BF00484229; BOWMAN BH, 1982, ADV HUM GENET, V12, P189; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CASTELL JV, 1988, FEBS LETT, V232, P347, DOI 10.1016/0014-5793(88)80766-X; CHAPMAN V, 1984, NATURE, V307, P284, DOI 10.1038/307284a0; CHEN HM, 1991, J BIOL CHEM, V266, P2946; EDBROOKE MR, 1989, MOL CELL BIOL, V9, P1908, DOI 10.1128/MCB.9.5.1908; FIELD LJ, 1984, MOL CELL BIOL, V4, P2321, DOI 10.1128/MCB.4.11.2321; GOTSCHLICH EC, 1989, ANN NY ACAD SCI, V557, P9; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HUBER P, 1990, J BIOL CHEM, V265, P5695; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KOJ A, 1993, ACUTE PHASE PROTEINS, P275; KOJ A, 1985, ACUTE PHASE RESPONSE, V5, P139; KUSHNER I, 1981, J LAB CLIN MED, V97, P739; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; KUSHNER I, 1987, DIS MARKERS, V5, P1; LABARCA C, 1977, P NATL ACAD SCI USA, V74, P4462, DOI 10.1073/pnas.74.10.4462; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MAEDA N, 1984, NATURE, V309, P131, DOI 10.1038/309131a0; MANN EA, 1991, J BIOL CHEM, V266, P16931; MARINKOVIC S, 1990, MOL CELL BIOL, V10, P1573, DOI 10.1128/MCB.10.4.1573; MARINKOVIC S, 1989, J IMMUNOL, V142, P808; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MORRONE G, 1988, J BIOL CHEM, V263, P12554; NATSUKA S, 1991, FEBS LETT, V291, P58, DOI 10.1016/0014-5793(91)81103-F; OLIVIERO S, 1989, EMBO J, V8, P1145, DOI 10.1002/j.1460-2075.1989.tb03485.x; OLIVIERO S, 1987, EMBO J, V6, P1905, DOI 10.1002/j.1460-2075.1987.tb02450.x; PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; POLI V, 1989, ANN NY ACAD SCI, V557, P297; PROWSE KR, 1988, MOL CELL BIOL, V8, P42, DOI 10.1128/MCB.8.1.42; PRUITT SC, 1989, GENE, V66, P121; PUTNAM FW, 1975, PLASMA PROTEIN STRUC, V2, P1; RON D, 1990, MOL CELL BIOL, V10, P4389, DOI 10.1128/MCB.10.8.4389; SHURBAJI MS, 1991, AM J CLIN PATHOL, V96, P238, DOI 10.1093/ajcp/96.2.238; THOMPSON S, 1992, CANCER LETT, V65, P115, DOI 10.1016/0304-3835(92)90154-N; WILLIAMS PM, 1991, MOL CELL BIOL, V11, P4959, DOI 10.1128/MCB.11.10.4959; WON KA, 1990, MOL CELL BIOL, V10, P3965, DOI 10.1128/MCB.10.8.3965; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	57	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2215	2224						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294478				2022-12-27	WOS:A1994MR98800099
J	FRAPPIER, L; GOLDSMITH, K; BENDELL, L				FRAPPIER, L; GOLDSMITH, K; BENDELL, L			STABILIZATION OF THE EBNA1-PROTEIN ON THE EPSTEIN-BARR-VIRUS LATENT ORIGIN OF DNA-REPLICATION BY A DNA LOOPING MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR ANTIGEN EBNA-1; PLASMID REPLICATION; INITIATOR PROTEIN; ENHANCER; BINDING; CELLS; SITES; ORIP; FORM	DNA replication from the Epstein-Barr virus latent origin of replication, oriP, is activated by Epstein-Barr nuclear antigen 1 (EBNA1). This activation involves the binding of EBNA1 dimers to multiple sites present in the two noncontiguous functional elements of oriP, the dyad symmetry element (DS) from which replication initiates, and the family of repeats (FR) enhancer element. EBNA1 complexes formed on the FR and DS elements of oriP interact by a DNA looping mechanism. This interaction requires EBNA1 sequences in addition to those required for DNA binding and dimerization. To map the EBNA1 sequences required for the efficient interaction of FR- and DS-bound EBNA1 complexes, we have overproduced in Escherichia coli and purified a series of EBNA1 N-terminal truncation mutants, all of which retain the DNA binding and dimerization domains. The results of electron microscopy and ligation-enhancement assays using these mutants indicated that EBNA1 sequences between amino acids 350 and 361 are required for the efficient interaction of FR- and DS-bound EBNA1 complexes. EBNA1-mediated FR-DS interactions were shown to stabilize EBNA1 binding to the DS element, while EBNA1-mediated DS-DS interactions did not. These results suggest that the stabilization of EBNA1 on the DS element, which occurs as a result of EBNA1-mediated oriP looping, may be important for the activation of DNA replication from the DS element.			FRAPPIER, L (corresponding author), MCMASTER UNIV,MOLEC VIROL & IMMUNOL PROGRAM,1200 MAIN ST W,HAMILTON L8N 3Z5,ONTARIO,CANADA.		Goldsmith, Kimberley/B-9107-2011	Goldsmith, Kimberley/0000-0002-0620-7868				ADAMS A, 1987, J VIROL, V61, P1743, DOI 10.1128/JVI.61.5.1743-1746.1987; AMBINDER RF, 1991, J VIROL, V65, P1466, DOI 10.1128/JVI.65.3.1466-1478.1991; CHATTORAJ DK, 1988, CELL, V52, P551, DOI 10.1016/0092-8674(88)90468-0; FRAPPIER L, 1991, P NATL ACAD SCI USA, V88, P10875, DOI 10.1073/pnas.88.23.10875; FRAPPIER L, 1991, J BIOL CHEM, V266, P7819; GAHN TA, 1989, CELL, V58, P527, DOI 10.1016/0092-8674(89)90433-9; GOLDSMITH K, 1993, J VIROL, V67, P3418, DOI 10.1128/JVI.67.6.3418-3426.1993; HEARING J, 1992, J VIROL, V66, P694, DOI 10.1128/JVI.66.2.694-705.1992; MATTHEWS KS, 1992, MICROBIOL REV, V56, P123, DOI 10.1128/MMBR.56.1.123-136.1992; MIDDLETON T, 1992, J VIROL, V66, P489, DOI 10.1128/JVI.66.1.489-495.1992; MIRON A, 1992, EMBO J, V11, P1205, DOI 10.1002/j.1460-2075.1992.tb05161.x; MUKHERJEE S, 1988, CELL, V52, P375, DOI 10.1016/S0092-8674(88)80030-8; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; REISMAN D, 1985, MOL CELL BIOL, V5, P1822, DOI 10.1128/MCB.5.8.1822; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; SHAH WA, 1992, J VIROL, V66, P3355, DOI 10.1128/JVI.66.6.3355-3362.1992; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SU W, 1991, P NATL ACAD SCI USA, V88, P10870, DOI 10.1073/pnas.88.23.10870; TARTOF KD, 1987, FOCUS, V9, P12; WYSOKENSKI DA, 1989, J VIROL, V63, P2657, DOI 10.1128/JVI.63.6.2657-2666.1989; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; YATES JL, 1991, J VIROL, V65, P483, DOI 10.1128/JVI.65.1.483-488.1991	22	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1057	1062						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288561				2022-12-27	WOS:A1994MR22000046
J	SANDSTROM, PA; TEBBEY, PW; VANCLEAVE, S; BUTTKE, TM				SANDSTROM, PA; TEBBEY, PW; VANCLEAVE, S; BUTTKE, TM			LIPID HYDROPEROXIDES INDUCE APOPTOSIS IN T-CELLS DISPLAYING A HIV-ASSOCIATED GLUTATHIONE-PEROXIDASE DEFICIENCY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR-NECROSIS-FACTOR; ARACHIDONIC-ACID; FACTOR-ALPHA; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; ACTIVATION; INFECTION; INDIVIDUALS; METABOLITES	8E5 is a chronically human immunodeficiency virus (HIV)-infected human T cell line, which we have previously shown to be extremely susceptible to hydrogen peroxide (H2O2)-induced apoptosis due to a HIV-associated catalase deficiency. Here we report that HIV gene expression additionally renders 8E5 cells 10-fold more sensitive than either uninfected A3.01 cells or HIV-infected but nonexpressing 8E5L cells to killing by 15-hydroperoxyeicosatetraenoic acid (15-HPETE), as well as several other hydroperoxy fatty acids. Whereas the viability of A3.01 and 8E5L cells was relatively unaffected by exposure to 10 muM 15-HPETE, similarly treated 8E5 cells underwent apoptosis, as demonstrated by morphological changes and the presence of fragmented DNA. The unique susceptibility of 8E5 cells was attributable to their inability to convert 15-HPETE to 15-hydroxyeicosatetraenoic acid (15-HETE) owing to a marked reduction in glutathione peroxidase activity. Since oxidized lipids have been reported to accumulate in oxidatively stressed, HIV-infected individuals, a HIV-associated glutathione peroxidase deficiency may contribute to the depletion of CD4 T cells that occurs in the acquired immune deficiency syndrome (AIDS).	E CAROLINA UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,GREENVILLE,NC 27858	University of North Carolina; East Carolina University								BARUCHEL S, 1992, J LEUKOCYTE BIOL, V52, P111, DOI 10.1002/jlb.52.1.111; BUHL R, 1993, J IMMUNOL, V150, P1019; BUTTKE TM, 1993, J IMMUNOL METHODS, V157, P233, DOI 10.1016/0022-1759(93)90092-L; CARLBERG I, 1985, METHOD ENZYMOL, V113, P484; CHANG DJ, 1992, BIOCHEM BIOPH RES CO, V188, P538, DOI 10.1016/0006-291X(92)91089-9; CHAUDHRI G, 1986, J IMMUNOL, V137, P2646; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; DROGE W, 1992, IMMUNOL TODAY, V13, P211, DOI 10.1016/0167-5699(92)90156-2; DWORKIN BM, 1988, BIOL TRACE ELEM RES, V15, P167, DOI 10.1007/BF02990135; FAUCI AS, 1991, ANN INTERN MED, V114, P678, DOI 10.7326/0003-4819-114-8-678; FLORES SC, 1993, P NATL ACAD SCI USA, V90, P7632, DOI 10.1073/pnas.90.16.7632; FLOYD RA, 1990, FASEB J, V4, P2587, DOI 10.1096/fasebj.4.9.2189775; FOLKS T, 1985, P NATL ACAD SCI USA, V82, P4539, DOI 10.1073/pnas.82.13.4539; FOLKS TM, 1986, J EXP MED, V164, P280, DOI 10.1084/jem.164.1.280; FUCHS J, 1991, MED HYPOTHESES, V36, P60, DOI 10.1016/0306-9877(91)90164-T; GENIS P, 1992, J EXP MED, V176, P1703, DOI 10.1084/jem.176.6.1703; GOUGEON ML, 1991, CR ACAD SCI III-VIE, V312, P529; GRAFF G, 1990, ANAL BIOCHEM, V188, P38, DOI 10.1016/0003-2697(90)90525-E; GREENSPAN HC, 1993, MED HYPOTHESES, V40, P85, DOI 10.1016/0306-9877(93)90133-B; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; Gunzler WA, 1985, CRC HDB METHODS OXYG, P285; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; HALLIWELL B, 1991, ARCH INTERN MED, V151, P29, DOI 10.1001/archinte.151.1.29; HALLIWELL B, 1984, BIOCHEM J, V210, P1; HARLAN JM, 1984, J CLIN INVEST, V73, P706, DOI 10.1172/JCI111263; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LEGRANDPOELS S, 1990, AIDS RES HUM RETROV, V6, P1389, DOI 10.1089/aid.1990.6.1389; LIN FB, 1992, CANCER RES, V52, P5282; MASUTANI H, 1992, AIDS RES HUM RETROV, V9, P1707; MATSUYAMA T, 1991, AIDS, V5, P1405, DOI 10.1097/00002030-199112000-00001; MATTHEWS N, 1987, IMMUNOLOGY, V62, P153; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; NATHAN CF, 1979, J EXP MED, V149, P100, DOI 10.1084/jem.149.1.100; OCHI H, 1992, ARCH BIOCHEM BIOPHYS, V294, P407, DOI 10.1016/0003-9861(92)90704-Z; REID T, 1991, J BIOL CHEM, V266, P16580; SANDSTROM PA, 1993, P NATL ACAD SCI USA, V90, P4708, DOI 10.1073/pnas.90.10.4708; SANDSTROM PA, 1993, IN PRESS AIDS RES HU; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; STAAL FJT, 1992, AIDS RES HUM RETROV, V8, P305, DOI 10.1089/aid.1992.8.305; STAAL FJT, 1993, AIDS RES HUM RETROV, V9, P299, DOI 10.1089/aid.1993.9.299; SUFFYS P, 1987, BIOCHEM BIOPH RES CO, V149, P735, DOI 10.1016/0006-291X(87)90429-3; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188; WAHL LM, 1989, P NATL ACAD SCI USA, V86, P621, DOI 10.1073/pnas.86.2.621; WONG GHW, 1991, P NATL ACAD SCI USA, V88, P4372, DOI 10.1073/pnas.88.10.4372; ZILLI D, 1992, BIOCHEM BIOPH RES CO, V188, P177, DOI 10.1016/0006-291X(92)92366-6	47	192	194	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					798	801						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288627				2022-12-27	WOS:A1994MR22000004
J	TAKAHASHI, S; WANG, JL; ROUSSEAU, DL; ISHIKAWA, K; YOSHIDA, T; HOST, JR; IKEDASAITO, M				TAKAHASHI, S; WANG, JL; ROUSSEAU, DL; ISHIKAWA, K; YOSHIDA, T; HOST, JR; IKEDASAITO, M			HEME-HEME OXYGENASE COMPLEX STRUCTURE OF THE CATALYTIC SITE AND ITS IMPLICATION FOR OXYGEN ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-TRYPTOPHAN 2,3-DIOXYGENASES; FERRIC APLYSIA MYOGLOBIN; CYTOCHROME-C PEROXIDASE; RAT-LIVER MICROSOMES; RESONANCE RAMAN; ELECTROMAGNETIC PROPERTIES; AXIAL COORDINATION; SPIN EQUILIBRIUM; IRON; PURIFICATION	Heme oxygenase, a central monooxygenase enzyme of the heme catabolism and the associated generation of carbon monoxide, forms a 1:1 stoichiometric complex with iron protoporphyrin IX, which is a prosthetic active center and at the same time the substrate of the enzyme. By using EPR, resonance Raman, and optical absorption spectroscopic techniques, we have determined the axial ligand coordination of the enzyme-heme complex. The ferric heme iron in the heme-enzyme complex at neutral pH is six-coordinate high spin, while at alkaline pH (pK(a) 7.6), the complex becomes low spin. Spectra of ferrous forms of the complex indicate that histidine serves as the iron proximal axial ligand and that the residue is in its neutral imidazole rather than its imidazolate protonation state. Thus, the active site of the heme-heme oxygenase complex has a myoglobin-like structure rather than an active site similar to the large cytochrome P-450 class of monooxygenases. As a consequence, the activated form of the heme-heme oxygenase complex, a peroxo intermediate, is different from that of the cytochrome P-450 monooxygenases, in which the activated form is an oxo intermediate. The overall catalytic mechanism is probably more closely related to that of other monooxygenases with myoglobin-like active sites, such as secondary amine monooxygenase.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA; AT&T BELL LABS, MURRAY HILL, NJ 07974 USA; YAMAGATA UNIV, SCH MED, DEPT BIOCHEM, YAMAGATA 99023, JAPAN	Case Western Reserve University; AT&T; Nokia Corporation; Nokia Bell Labs; Yamagata University			Ikeda-Saito, Masao/K-2703-2015; Ikeda-Saito, Masao/A-5992-2008		NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR005659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048714, R01GM039492] Funding Source: NIH RePORTER; NCRR NIH HHS [RR05659] Funding Source: Medline; NIGMS NIH HHS [GM39492, GM48714] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTA JA, 1989, J BIOL CHEM, V264, P20467; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BROWN SB, 1976, BIOCHEM SOC T, V4, P197, DOI 10.1042/bst0040197; BRUNE B, 1987, MOL PHARMACOL, V32, P497; CHO KC, 1981, BIOCHIM BIOPHYS ACTA, V668, P186, DOI 10.1016/0005-2795(81)90162-8; DASGUPTA S, 1989, J BIOL CHEM, V264, P654; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; EGEBERG KD, 1990, BIOCHEMISTRY-US, V29, P9783, DOI 10.1021/bi00494a004; GIACOMETTI GM, 1981, J MOL BIOL, V146, P363, DOI 10.1016/0022-2836(81)90393-4; HORI H, 1981, J BIOL CHEM, V256, P7849; IIZUKA T, 1969, BIOCHIM BIOPHYS ACTA, V194, P351, DOI 10.1016/0005-2795(69)90096-8; IKEDASAITO M, 1985, J BIOL CHEM, V260, P1688; IKEDASAITO M, 1992, J BIOL CHEM, V267, P22843; ISHIKAWA K, 1992, BIOCHEM BIOPH RES CO, V182, P981, DOI 10.1016/0006-291X(92)91828-E; JUNG C, 1991, BIOCHIM BIOPHYS ACTA, V1076, P130, DOI 10.1016/0167-4838(91)90229-S; Kitagawa T, 1988, BIOL APPL RAMAN SPEC, V3, P97; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MAINES MD, 1986, J BIOL CHEM, V261, P411; MAKINO R, 1980, J BIOL CHEM, V255, P1883; MANTHEY JA, 1986, J BIOL CHEM, V261, P6734; MCCOUBREY WK, 1993, ARCH BIOCHEM BIOPHYS, V302, P402, DOI 10.1006/abbi.1993.1231; MCCOUBREY WK, 1992, ARCH BIOCHEM BIOPHYS, V295, P13, DOI 10.1016/0003-9861(92)90481-B; MIEYAL JJ, 1976, J BIOL CHEM, V251, P3436; MORIKIS D, 1990, J BIOL CHEM, V265, P12143; MULLER RM, 1987, J BIOL CHEM, V262, P6795; NAGAI K, 1983, BIOCHEMISTRY-US, V22, P1305, DOI 10.1021/bi00274a048; NOGUCHI M, 1983, J BIOCHEM, V93, P1027, DOI 10.1093/oxfordjournals.jbchem.a134226; OCARRA P, 1975, PORPHYRINS METALLOPO, P123; Ortiz de Montellano PR, 1986, CYTOCHROME P450 STRU, P217; POULOS TL, 1988, ADV INORG BIOCHEM, V7, P1; ROTENBERG MO, 1991, ARCH BIOCHEM BIOPHYS, V290, P336, DOI 10.1016/0003-9861(91)90549-X; ROUSSEAU DL, 1989, J BIOL CHEM, V264, P7878; SITTER AJ, 1988, J BIOL CHEM, V263, P13032; SPIRO TG, 1979, J AM CHEM SOC, V101, P2648, DOI 10.1021/ja00504a027; SUZUKI T, 1992, BIOCHEM INT, V28, P887; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; UCHIDA K, 1983, J BIOL CHEM, V258, P2519; VARADARAJAN R, 1989, BIOCHEMISTRY-US, V28, P3771, DOI 10.1021/bi00435a022; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WILKS A, 1993, J INORG BIOCHEM, V51, P269; YONETANI T, 1972, J BIOL CHEM, V247, P2447; YONETANI T, 1987, J BIOL CHEM, V262, P9547; YOSHIDA T, 1991, EUR J BIOCHEM, V199, P729, DOI 10.1111/j.1432-1033.1991.tb16177.x; YOSHIDA T, 1978, J BIOL CHEM, V253, P4230; YOSHIDA T, 1989, BIOCHEM BIOPH RES CO, V163, P1086, DOI 10.1016/0006-291X(89)92332-2; YOSHIDA T, 1978, J BIOL CHEM, V253, P4224; YOSHIDA T, 1979, J BIOL CHEM, V254, P4487; YOSHIDA T, 1982, J BIOL CHEM, V257, P9345; YOSHINAGA T, 1982, J BIOL CHEM, V257, P7778	49	133	136	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1010	1014						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288555				2022-12-27	WOS:A1994MR22000038
J	FANDL, JP; TOBKES, NJ; MCDONALD, NQ; HENDRICKSON, WA; RYAN, TE; NIGAM, S; ACHESON, A; CUDNY, H; PANAYOTATOS, N				FANDL, JP; TOBKES, NJ; MCDONALD, NQ; HENDRICKSON, WA; RYAN, TE; NIGAM, S; ACHESON, A; CUDNY, H; PANAYOTATOS, N			CHARACTERIZATION AND CRYSTALLIZATION OF RECOMBINANT HUMAN NEUROTROPHIN-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; MOLECULAR-CLONING; ESCHERICHIA-COLI; FACTOR FAMILY; BRAIN; EXPRESSION; PROTEIN; MEMBER; PROLIFERATION; RECEPTOR	Neurotrophin-4 (NT-4) is the most recently discovered member of the neurotrophin family. We have expressed, refolded, and purified recombinant human NT-4 from Escherichia coli and compared it with recombinant human NT-4 secreted into the culture medium of baculovirus-infected insect cells. Both preparations were characterized and determined to be indistinguishable according to several biochemical criteria. Recombinant NT-4 from E. coli was crystallized in a form suitable for x-ray analysis, and characterization of these crystals indicated that NT-4 was present as a dimer within the asymmetric unit. NT-4 was active in promoting the survival of rat TrkB receptor-expressing fibroblasts, but was inactive on embryonic chicken sensory neurons, unlike the other members of the neurotrophin family and in contrast to the reported activities of partially purified NT-4.	REGENERON PHARMACEUT INC,TARRYTOWN,NY 10591; COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Regeneron; Columbia University; Columbia University; Howard Hughes Medical Institute								BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BOTHWELL MA, 1977, J BIOL CHEM, V252, P8532; BRUNGER AT, 1990, XPLOR MANUAL VERSION; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHAUDHARY T, 1993, 41ST P ASMS C MASS S; Creighton T E, 1986, Methods Enzymol, V131, P83; DAVIES AM, 1986, J NEUROSCI, V6, P1897; DICOU E, 1989, J NEUROSCI RES, V22, P13, DOI 10.1002/jnr.490220103; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P916; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HOBER S, 1992, BIOCHEMISTRY-US, V31, P1749, DOI 10.1021/bi00121a024; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HU GL, 1988, GENE, V70, P57; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KAISHO Y, 1990, FEBS LETT, V266, P187, DOI 10.1016/0014-5793(90)81536-W; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MASIAKOWSKI P, 1991, J NEUROCHEM, V57, P1003, DOI 10.1111/j.1471-4159.1991.tb08250.x; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; Miller J.H., 1972, EXPT MOL GENETICS; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NEGRO A, 1992, BIOCHEM BIOPH RES CO, V186, P1553, DOI 10.1016/S0006-291X(05)81584-0; NEGRO A, 1992, GENE, V110, P251, DOI 10.1016/0378-1119(92)90657-B; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; RADZIEJEWSKI C, 1992, BIOCHEMISTRY-US, V31, P4431, DOI 10.1021/bi00133a007; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; WLODAWER A, 1975, P NATL ACAD SCI USA, V72, P777, DOI 10.1073/pnas.72.3.777; YANG JT, 1986, METHOD ENZYMOL, V130, P208	38	39	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					755	759						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276879				2022-12-27	WOS:A1994MR21900118
J	PERIDES, G; SAFRAN, RM; DOWNING, LA; CHARNESS, ME				PERIDES, G; SAFRAN, RM; DOWNING, LA; CHARNESS, ME			REGULATION OF NEURAL CELL-ADHESION MOLECULE AND L1 BY THE TRANSFORMING GROWTH-FACTOR-BETA SUPERFAMILY - SELECTIVE EFFECTS OF THE BONE MORPHOGENETIC PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOGENIC PROTEIN-1; EXPRESSION; DIFFERENTIATION; PATTERN; GENE; EMBRYOGENESIS; RECEPTORS; BINDING; FAMILY; MOUSE	The transforming growth factor-beta (TGF-beta) superfamily plays a role in embryogenesis and regeneration. We have reported that osteogenic protein-1 (OP-1) promotes cell aggregation and induces the expression of the neural cell adhesion molecules N-CAM and L1 in proliferating neuroblastoma x glioma hybrid NG108-15 cells (Perides, G., Safran, R. M., Rueger, D. C., and Charness, M. E. (1992) Proc. Natl. Acad. Sci. U. S. A. 89,10326-10330; Perides, G., Hu, G., Rueger, D. C., and Charness, M. E. (1993) J. Biol. Chem. 268, 25197-25205). Here we show that the structurally homologous bone morphogenetic proteins (BMP) BMP-2 and BMP-4 are 10-50-fold more potent in these actions than the subfamily comprising BMP-5, BMP-6, and OP-1 (BMP-7). In contrast, members of the TGF-beta subfamily, activin-A, inhibin-A, and 29 additional growth factors and cytokines did not induce N-CAM. The addition of serum to cella growing in serum-free medium caused a concentration-dependent increase in N-CAM and Li expression; however, serum did not potentiate the induction of N-CAM and L1 by 40 ng/ml OP-1. These findings suggest the presence in NG108-15 cells of a BMP-2/BMP-4 receptor that discriminates subtle differences in structure among homologous members of the TGF-beta superfamily. An endogenous ligand for this receptor may be present in serum.	HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; DEPT VET AFFAIRS MED CTR,SPINAL CORD INJURY LAB,BOSTON,MA 02132; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT NEUROL,DIV NEUROL,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV NEUROL,PROGRAM NEUROSCI,BOSTON,MA 02115; DEPT VET AFFAIRS MED CTR,NEUROL SECT,BOSTON,MA 02132	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School				Charness, Michael/0000-0002-3301-8966	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006662] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA06662] Funding Source: Medline; NINDS NIH HHS [NS 13034] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; COULOMBE JN, 1993, NEURON, V10, P899, DOI 10.1016/0896-6273(93)90205-6; DOHERTY P, 1988, J CELL BIOL, V107, P333, DOI 10.1083/jcb.107.1.333; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; HIRN M, 1981, BRAIN RES, V214, P43; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; JIANG TX, 1993, DEV BIOL, V155, P545, DOI 10.1006/dbio.1993.1051; JONES CM, 1991, DEVELOPMENT, V111, P531; LEE SJ, 1991, P NATL ACAD SCI USA, V88, P4250, DOI 10.1073/pnas.88.10.4250; LEE YS, 1992, J BONE MINER RES, V7, P1435; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; LEPAGE T, 1992, DEVELOPMENT, V114, P147; LYLES JM, 1993, J NEUROSCI RES, V34, P273, DOI 10.1002/jnr.490340304; LYONS KM, 1990, DEVELOPMENT, V109, P833; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MCPHERRON AC, 1993, J BIOL CHEM, V268, P3444; MESSING RO, 1991, BRAIN RES, V565, P301, DOI 10.1016/0006-8993(91)91662-K; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; OZKAYNAK E, 1991, BIOCHEM BIOPH RES CO, V179, P116, DOI 10.1016/0006-291X(91)91342-A; OZKAYNAK E, 1992, J BIOL CHEM, V267, P25220; PARALKAR VM, 1992, J CELL BIOL, V119, P1721, DOI 10.1083/jcb.119.6.1721; PERIDES G, 1993, J BIOL CHEM, V268, P25197; PERIDES G, 1992, P NATL ACAD SCI USA, V89, P10326, DOI 10.1073/pnas.89.21.10326; ROSEN V, 1992, TRENDS GENET, V8, P97, DOI 10.1016/0168-9525(92)90063-A; ROUBIN R, 1990, J CELL BIOL, V111, P673, DOI 10.1083/jcb.111.2.673; SAMPATH TK, 1992, J BIOL CHEM, V267, P20352; SCHUBERT D, 1990, NATURE, V344, P868, DOI 10.1038/344868a0; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T	31	74	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					765	770						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276880				2022-12-27	WOS:A1994MR21900120
J	HENDERSON, BR; SEISER, C; KUHN, LC				HENDERSON, BR; SEISER, C; KUHN, LC			CHARACTERIZATION OF A 2ND RNA-BINDING PROTEIN IN RODENTS WITH SPECIFICITY FOR IRON-RESPONSIVE ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRITIN MESSENGER-RNA; TRANSFERRIN RECEPTOR EXPRESSION; UNTRANSLATED REGION; REGULATORY FACTOR; 5-AMINOLEVULINATE SYNTHASE; DEPENDENT REGULATION; CYTOSOLIC PROTEIN; GENE-REGULATION; SULFUR CLUSTER; PURIFICATION	Iron regulatory factor (IRF) is a cytoplasmic RNA-binding protein involved in regulating iron homeostasis. IRF controls expression of ferritin and transferrin receptor post-transcriptionally via specific binding to stem-loop iron-responsive elements (IREs) located in the untranslated regions of the respective mRNAs. We have confirmed by RNA band-shift analysis that a second IRE-protein complex observed in different rodent cell extracts is, like IRF, regulated by intracellular iron levels. This faster migrating complex appears to represent a specific interaction between the ferritin IRE and an iron-regulated protein that is distinct from IRF, as concluded from the following lines of evidence. First, UV cross-linking and partial digestion with different proteases revealed different peptide patterns for the two IRE-protein complexes. Second, antiserum raised against IRF peptides immunoprecipitated only authentic IRF and not the protein of the faster migrating complex, as determined by band-shift analysis. Following separation of the two IRE-binding proteins by ion-exchange chromatography, only the IRF-containing fraction reacted with the antibodies on Western blots. The second protein binds IREs with an affinity similar to that of IRF as demonstrated by competition with a ferritin IRE and related stem-loop RNAs. UV cross-linking experiments indicate that this second protein, tentatively named IRF(B), has a molecular mass of approximately 105 kDa. Analysis of mouse tissues revealed differences in the distribution of IRF and IRF(B). Whereas IRF protein and IRE binding activity were predominant in liver, intestine, and kidney, the IRF(B) protein(s) revealed highest binding activity in intestine and brain. Our data support the existence of two distinct iron-regulated IRE-binding proteins in rodents.	SWISS INST EXPTL CANC RES,CH BOVERESSES 155,CH-1066 EPALINGES,SWITZERLAND	Swiss Institute Experimental Cancer Research				Seiser, Christian/0000-0002-7046-9352				AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; BARTON HA, 1990, J BIOL CHEM, V265, P7000; BETTANY AJE, 1992, J BIOL CHEM, V267, P16531; CHURCHER MJ, 1993, J MOL BIOL, V230, P90, DOI 10.1006/jmbi.1993.1128; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HENTZE MW, 1987, P NATL ACAD SCI USA, V84, P6730, DOI 10.1073/pnas.84.19.6730; HIRLING H, 1992, NUCLEIC ACIDS RES, V20, P33, DOI 10.1093/nar/20.1.33; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KOELLER DM, 1989, P NATL ACAD SCI USA, V86, P3574, DOI 10.1073/pnas.86.10.3574; KUHN LC, 1992, J INORG BIOCHEM, V47, P183, DOI 10.1016/0162-0134(92)84064-T; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEIBOLD EA, 1992, ANNU REV NUTR, V12, P345, DOI 10.1146/annurev.nu.12.070192.002021; MAY BK, 1990, MOL BIOL MED, V7, P405; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MULLNER EW, 1992, EUR J BIOCHEM, V208, P597, DOI 10.1111/j.1432-1033.1992.tb17224.x; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; NEUPERT B, 1990, NUCLEIC ACIDS RES, V18, P51, DOI 10.1093/nar/18.1.51; PATINO MM, 1992, J BIOL CHEM, V267, P19011; PHILPOTT CC, 1991, NUCLEIC ACIDS RES, V19, P6333, DOI 10.1093/nar/19.22.6333; ROSEN CA, 1991, GENE EXPRESSION, V1, P85; ROTHENBERGER S, 1990, NUCLEIC ACIDS RES, V18, P1175, DOI 10.1093/nar/18.5.1175; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; ROUAULT TA, 1990, P NATL ACAD SCI USA, V87, P7958, DOI 10.1073/pnas.87.20.7958; Sambrook J, 1989, MOL CLONING LABORATO; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; YU Y, 1992, J BIOL CHEM, V267, P19005	34	152	152	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27327	27334						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262972				2022-12-27	WOS:A1993MM26200071
J	KIM, IY; VERES, Z; STADTMAN, TC				KIM, IY; VERES, Z; STADTMAN, TC			BIOCHEMICAL-ANALYSIS OF ESCHERICHIA-COLI SELENOPHOSPHATE SYNTHETASE MUTANTS - LYSINE-20 IS ESSENTIAL FOR CATALYTIC ACTIVITY AND CYSTEINE-17-19 FOR 8-AZIDO-ATP DERIVATIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; SELD GENE-PRODUCT; SELENOCYSTEINE SYNTHASE; SELENIUM METABOLISM; SEQUENCE; BINDING; 5-METHYLAMINOMETHYL-2-SELENOURIDINE; PURIFICATION; NUCLEOSIDE; EXPRESSION	A labile selenium donor compound, selenophosphate, is formed from selenide and ATP by selenophosphate synthetase. A cysteine residue (Cys-17) that is essential for catalytic activity of the enzyme (Kim, I. Y., Veres, Z., and Stadtman, T. C. (1992) J. Biol. Chem. 267, 19650-19654) is located in a glycine-rich segment near the N terminus of the protein. The possibility that this peptide sequence (HGAGCGCK) defines the ATP-binding site of the enzyme, as does a conserved ATP or GTP binding sequence (GXXXXGKS/T) found in several other proteins, was tested by site-specific mutagenesis. Thus His-13 and Gly-18 were changed to Asn and Val, respectively, and Lys-20 to Arg or Gln. Catalytic activity was markedly decreased by mutation of Lys-20 to Arg and abolished by mutation of Lys-20 to Gln. The mutation of Cys-19 and His-13 did not substantially alter the ATP K(m) and V(max) values, whereas the Gly-18 mutation resulted in a 4-fold increase in the ATP K(m) value compared with that of the wild type. ATP binding properties of the mutant enzymes were determined using Mn-[P-32]ATP or Mn-[C-14]ATP and gel filtration. Photoaffinity labeling of the proteins with [gamma-P-32]8-azido-ATP showed that all mutant enzymes could be labeled with the ATP analog except those in which Cys-17 or Cys-19 were replaced with serine.	NHLBI,BIOCHEM LAB,BLDG 3,RM 108,9000 ROCKVILLE PIKE,BETHESDA,MD 20892; HUNGARIAN ACAD SCI,CENT RES INST CHEM,H-1025 BUDAPEST,HUNGARY	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences								BAGNARA AS, 1972, ANAL BIOCHEM, V45, P24, DOI 10.1016/0003-2697(72)90004-8; Bock A, 1988, Biofactors, V1, P245; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; Czarnecki J, 1979, Methods Enzymol, V56, P642; FORCHHAMMER K, 1991, J BIOL CHEM, V266, P6318; FORCHHAMMER K, 1991, J BIOL CHEM, V266, P6324; HADDOCK BA, 1982, BIOCHEM SOC T, V10, P478, DOI 10.1042/bst0100478; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; JULIN DA, 1987, J BIOL CHEM, V262, P9044; KIM IY, 1992, J BIOL CHEM, V267, P19650; KRAMER GF, 1988, J BACTERIOL, V170, P736, DOI 10.1128/jb.170.2.736-743.1988; LEINFELDER W, 1988, J BACTERIOL, V170, P540, DOI 10.1128/jb.170.2.540-546.1988; LEINFELDER W, 1990, P NATL ACAD SCI USA, V87, P543, DOI 10.1073/pnas.87.2.543; LIU F, 1992, J BIOL CHEM, V267, P2388; PECK HD, 1957, J BACTERIOL, V73, P706, DOI 10.1128/JB.73.6.706-721.1957; PHILLIPS NFB, 1993, FASEB J, V7, pA1272; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SEEFELDT LC, 1992, J BIOL CHEM, V267, P6680; STADTMAN T C, 1989, Biofactors, V2, P35; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; VERES Z, 1992, P NATL ACAD SCI USA, V89, P2975, DOI 10.1073/pnas.89.7.2975; WITTWER AJ, 1986, ARCH BIOCHEM BIOPHYS, V248, P540, DOI 10.1016/0003-9861(86)90507-2; WITTWER AJ, 1984, BIOCHEMISTRY-US, V23, P4650, DOI 10.1021/bi00315a021	26	37	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27020	27025						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262938				2022-12-27	WOS:A1993MM26200030
J	TAM, LT; MANNING, D; COX, DJ; RIGGS, AF				TAM, LT; MANNING, D; COX, DJ; RIGGS, AF			THE HEMOGLOBINS OF THE BULLFROG, RANA-CATESBEIANA - DEOXYGENATION-LINKED ASSOCIATION OF TETRAMERIC COMPONENT-B AND COMPONENT-C TO FORM THE TRIMER BC(2) - SEDIMENTATION ANALYSIS AND OXYGEN EQUILIBRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CHAIN; COOPERATIVITY; BINDING	Hemolysates from the adult bullfrog, Rana catesbeiana, show an unusually high degree of cooperativity of oxygen binding with Hill coefficients greater than 4. The principal components of the tetrameric hemoglobin, B and C, do not show this high cooperativity when isolated, but it reappears when the components are mixed. Sedimentation velocity measurements show that the unusual behavior results from the mixed association of components B and C to form complexes larger than tetramers. Computer simulation of the sedimentation behavior of mixtures of deoxygenated B and C components shows that the gradient profiles can be satisfactorily described in terms of an equilibrium between the B and C tetramers and a BC2 trimer. The simplest model consistent with the results is the mixed association: B + C reversible BC and BC + C reversible BC2, with the second binding constant being higher than the first, indicating significant cooperativity. The extent of association is highest at low pH and low temperature. The dissociation of the B.C complex with low oxygen affinity to higher affinity B and C molecules during oxygenation results in greatly increased cooperativity of oxygen binding with higher Hill coefficients than possessed by either component alone in equilibria measured between 5 and 25-degrees-C and between pH 6 and 8.	UNIV TEXAS,DEPT ZOOL,AUSTIN,TX 78712; KANSAS STATE UNIV AGR & APPL SCI,DEPT BIOCHEM,MANHATTAN,KS 66506	University of Texas System; University of Texas Austin; Kansas State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035847] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35847] Funding Source: Medline; PHS HHS [22243] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; AGGARWAL SJ, 1969, J BIOL CHEM, V244, P2372; ATHA DH, 1979, J BIOL CHEM, V254, P2390; ATHA DH, 1982, HEMOGLOBIN OXYGEN BI, P269; BONAVENTURA J, 1968, J BIOL CHEM, V243, P980; BROYLES RH, 1981, HEMOGLOBINS DEV DIFF, P179; COBB JA, 1992, J BIOL CHEM, V267, P1183; Cox D. J, 1978, METHOD ENZYMOL, V48F, P212; COX DJ, 1981, PROTEIN PROTEIN INTE, P173; DeLoid G, 1984, THESIS KANSAS STATE; DOLMAN D, 1978, ANAL BIOCHEM, V87, P127, DOI 10.1016/0003-2697(78)90576-6; DORN AR, 1982, P NATL ACAD SCI-BIOL, V79, P5592, DOI 10.1073/pnas.79.18.5592; EDELSTEIN SJ, 1986, J MOL BIOL, V187, P277, DOI 10.1016/0022-2836(86)90234-2; EDSALL JT, 1958, BIOPHYS CHEM, V1, P452; ELLI R, 1970, COMP BIOCHEM PHYSIOL, V36, P163, DOI 10.1016/0010-406X(70)90662-6; GILBERT GA, 1959, PROC R SOC LON SER-A, V250, P377, DOI 10.1098/rspa.1959.0070; GILL SJ, 1979, J MOL BIOL, V130, P175, DOI 10.1016/0022-2836(79)90425-X; GILOL SJ, 1978, SCIENCE, V201, P362; HOLLAND RAB, 1993, OXYGEN TRANSPORT TIS, V15; KITCHEN H, 1964, SCIENCE, V144, P1237, DOI 10.1126/science.144.3623.1237; LYKKEBOE G, 1978, RESP PHYSIOL, V35, P119, DOI 10.1016/0034-5687(78)90017-8; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; SHIMIZU K, 1983, HEMOGLOBIN, V7, P15, DOI 10.3109/03630268309038399; SMITH DJ, 1993, J BIOL CHEM, V268, P26961; TAM LT, 1986, J BIOL CHEM, V261, P8290; TAM LT, 1984, J BIOL CHEM, V259, P2610; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4	27	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26972	26977						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262932				2022-12-27	WOS:A1993MM26200023
J	HUANG, L; TURCHI, JJ; WAHL, AF; BAMBARA, RA				HUANG, L; TURCHI, JJ; WAHL, AF; BAMBARA, RA			ACTIVITY OF CALF THYMUS DNA HELICASE-E ON CIS-DIAMMINEDICHLOROPLATINUM-(II)-DAMAGED DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; ANTITUMOR DRUG CIS-DIAMMINEDICHLOROPLATINUM(II); UVRABC EXCISION NUCLEASE; SACCHAROMYCES-CEREVISIAE; POLYMERASE-EPSILON; HUMAN-FIBROBLASTS; REPAIR; ADDUCTS; DELTA; IDENTIFICATION	Calf DNA helicase E (hel E) is a moderately processive, 3' to 5' helicase, active on nicked DNA, that we have proposed to have a role in DNA repair (Turchi, J. J., Murante, R. S., and Bambara, R. A. (1992) Nucleic Acids Res. 20, 6075-6080). Here we have examined its activity on a series of cis-diamminedichloroplatinum (II) (cis-DDP)-modified DNA substrates. Hel E was capable of efficiently displacing a primer strand containing, in an internal position, a cis-DDP-modified dGG. In a two-primer model system, calf DNA polymerase epsilon could successfully extend an upstream primer through a cis-DDP-modified downstream primer, to the end of the complementary template strand, in a reaction dependent on hel E. However, the translocation of hel E was blocked by cis-DDP modification of the template strand. Primer displacement was completely prevented if the modified site was located just upstream of the primer. The DNA-dependent ATPase activity of helicase E was also reduced by cis-DDP modification of the template DNA. Substrate competition experiments indicated that cis-DDP-modified DNA templates did not sequester hel E. Substrate titration experiments suggested that there is a short delay without ATP hydrolysis before dissociation of helicase E from cis-DDP-modified template sites. Interestingly, hel E could displace a primer if the cis-DDP modification was on the template within the annealed region. Possible explanations for this are discussed. Taken together, these results are consistent with the proposal that hel E participates in DNA repair by displacing segments of damaged DNA.	UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642; BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT GROWTH REGULAT,SEATTLE,WA 98121; UNIV ROCHESTER,SCH MED & DENT,CTR CANC,ROCHESTER,NY 14642	University of Rochester; Bristol-Myers Squibb; University of Rochester			Turchi, John J/B-5807-2015	Turchi, John J/0000-0001-5375-2992	NATIONAL CANCER INSTITUTE [P30CA011198, T32CA009363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024441] Funding Source: NIH RePORTER; NCI NIH HHS [CA11198, T32-CA09363] Funding Source: Medline; NIGMS NIH HHS [GM24441] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1985, DNA REPAIR; BECK DJ, 1985, NUCLEIC ACIDS RES, V13, P7395, DOI 10.1093/nar/13.20.7395; BROWN WC, 1989, J BIOL CHEM, V264, P6748; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; CALSOU P, 1992, NUCLEIC ACIDS RES, V20, P6363, DOI 10.1093/nar/20.23.6363; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; DIJT FJ, 1988, CANCER RES, V48, P6058; EASTMAN A, 1988, BIOCHEMISTRY-US, V27, P4730, DOI 10.1021/bi00413a022; EASTMAN A, 1983, BIOCHEMISTRY-US, V22, P3927, DOI 10.1021/bi00285a031; FICHTINGERSCHEPMAN AMJ, 1985, BIOCHEMISTRY-US, V24, P707, DOI 10.1021/bi00324a025; FOCHER F, 1989, NUCLEIC ACIDS RES, V17, P1805, DOI 10.1093/nar/17.5.1805; FRIEDBERG EC, 1988, MICROBIOL REV, V52, P70, DOI 10.1128/MMBR.52.1.70-102.1988; HAROSH I, 1989, J BIOL CHEM, V264, P20532; HOEIJMAKERS JHJ, 1991, J CELL SCI, V100, P687; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HUANG L, 1993, BIOCHEMISTRY-US, V32, P841, DOI 10.1021/bi00054a015; HUSAIN I, 1985, P NATL ACAD SCI USA, V82, P6774, DOI 10.1073/pnas.82.20.6774; JONES JC, 1991, J BIOL CHEM, V266, P7101; KESTI T, 1991, J BIOL CHEM, V266, P6336; LEE SH, 1991, J BIOL CHEM, V266, P22707; MARROT L, 1989, BIOCHEMISTRY-US, V28, P1454, DOI 10.1021/bi00430a005; MASUDA H, 1990, CANCER RES, V50, P1863; MASUDA H, 1988, CANCER RES, V48, P5713; NAEGELI H, 1993, BIOCHEMISTRY-US, V32, P613, DOI 10.1021/bi00053a029; NISHIDA C, 1988, J BIOL CHEM, V263, P501; REYNOLDS RJ, 1981, J BACTERIOL, V146, P692, DOI 10.1128/JB.146.2.692-704.1981; RICE JA, 1988, P NATL ACAD SCI USA, V85, P4158, DOI 10.1073/pnas.85.12.4158; Sambrook J, 1989, MOL CLONING LABORATO; SENGUPTA DJ, 1992, SCIENCE, V256, P1656, DOI 10.1126/science.256.5064.1656; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SIEGAL G, 1992, J BIOL CHEM, V267, P13629; SIEGAL G, 1992, J BIOL CHEM, V267, P3991; SVOBODA DL, 1993, J BIOL CHEM, V268, P1931; SZYMKOWSKI DE, 1992, P NATL ACAD SCI USA, V89, P10772, DOI 10.1073/pnas.89.22.10772; TURCHI JJ, 1992, NUCLEIC ACIDS RES, V20, P6075, DOI 10.1093/nar/20.22.6075; TURCHI JJ, 1992, BIOCHEMISTRY-US, V31, P9008, DOI 10.1021/bi00152a043; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WILCOX DR, 1981, J BACTERIOL, V148, P618, DOI 10.1128/JB.148.2.618-623.1981	38	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26731	26737						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253808				2022-12-27	WOS:A1993MK42500105
J	BOIX, E; NOGUES, MV; SCHEIN, CH; BENNER, SA; CUCHILLO, CM				BOIX, E; NOGUES, MV; SCHEIN, CH; BENNER, SA; CUCHILLO, CM			REVERSE TRANSPHOSPHORYLATION BY RIBONUCLEASE-A NEEDS AN INTACT P(2)-BINDING SITE - POINT MUTATIONS AT LYS-7 AND ARG-10 ALTER THE CATALYTIC PROPERTIES OF THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE PANCREATIC RIBONUCLEASE; ESCHERICHIA-COLI; ACTIVE-SITE; CRYSTAL-STRUCTURE; C-PEPTIDE; BINDING; ACID; RESIDUES; SUBSTITUTION; MUTAGENESIS	Bovine pancreatic ribonuclease A interacts with RNA along multiple binding subsites that essentially recognize the negatively charged phosphates of the substrate. This work gives additional strong support to the existence of the postulated phosphate-binding subsite p2 (Pares, X., Llorens, R., Arus, C., and Cuchillo, C. M. (1980) Eur. J. Biochem. 105, 571-579) and confirms the central role of Lys-7 and Arg-10 in establishing an electrostatic interaction with a phosphate group of the substrate. The effects of charge elimination by Lys-7 --> Gln (K7Q) and/or Arg-10 --> Gln (R10Q) substitutions in catalytic and ligand-binding properties of ribonuclease A have been studied. The values of K(m) for cytidine 2',3'-cyclic phosphate and cytidylyl-3',5'-adenosine are not altered but are significantly increased for poly(C). In all cases, k(cat) values are lower. Synthetic activity, i.e. the reversion of the transphosphorylation reaction, is reduced for K7Q and R10Q mutants and is practically abolished in the double mutant. Finally, the extent of the reaction of the mutants with 6-chloropurine-9-beta-D-ribofuranosyl 5'-monophosphate indicates that the phosphate ionic interaction in P2 is weakened. Thus, p2 modification alters both the catalytic efficiency and the extent of the processes in which an interaction of the phosphate group of the substrate or ligand with the p2-binding subsite is involved.	UNIV AUTONOMA BARCELONA, FAC CIENCIAS, DEPT BIOQUIM & BIOL MOLEC, E-08193 BARCELONA, SPAIN; UNIV AUTONOMA BARCELONA, INST BIOL FONAMENTAL VICENT VILLAR PALASI, E-08193 BARCELONA, SPAIN; SWISS FED INST TECHNOL, ORGAN CHEM LAB, CH-8092 ZURICH, SWITZERLAND; SWISS FED INST TECHNOL, DEPT PHARM, CH-8092 ZURICH, SWITZERLAND	Autonomous University of Barcelona; University of Barcelona; Autonomous University of Barcelona; Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich			Boix, Ester/B-9038-2012; Schein, Catherine H/A-1426-2012; Nogues, M. Victoria/H-6100-2015	Boix, Ester/0000-0003-1790-2142; Nogues, M. Victoria/0000-0002-7104-0961; Schein, Catherine/0000-0002-8290-2109				ALONSO J, 1986, ARCH BIOCHEM BIOPHYS, V246, P681, DOI 10.1016/0003-9861(86)90324-3; ARUS C, 1981, BIOCHIM BIOPHYS ACTA, V660, P117, DOI 10.1016/0005-2744(81)90116-9; BEINTEMA JJ, 1988, PROG BIOPHYS MOL BIO, V51, P165, DOI 10.1016/0079-6107(88)90001-6; BIRDSALL DL, 1992, J BIOL CHEM, V267, P22230; Blackburn P, 1982, ENZYMES, VXV, P317; BORKAKOTI N, 1983, EUR J BIOCHEM, V132, P89, DOI 10.1111/j.1432-1033.1983.tb07329.x; BRUNGER AT, 1985, P NATL ACAD SCI USA, V82, P8458, DOI 10.1073/pnas.82.24.8458; DAY AG, 1992, BIOCHEMISTRY-US, V31, P6390, DOI 10.1021/bi00143a005; DELLORENS R, 1989, PROTEIN ENG, V2, P417, DOI 10.1093/protein/2.6.417; FILIPPI B, 1987, MACROMOLECULAR BIORE, P147; GEORGALIS Y, 1992, J BIOL CHEM, V267, P10323; GUASCH A, 1989, J CHROMATOGR, V473, P281, DOI 10.1016/S0021-9673(00)91311-6; IRIE M, 1986, J BIOCHEM-TOKYO, V100, P1057, DOI 10.1093/oxfordjournals.jbchem.a121785; IRIE M, 1984, J BIOCHEM-TOKYO, V95, P751, DOI 10.1093/oxfordjournals.jbchem.a134666; ISOBE K, 1986, J BIOCHEM BIOPH METH, V12, P299, DOI 10.1016/0165-022X(86)90066-7; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCPHERSON A, 1986, J MOL BIOL, V189, P305, DOI 10.1016/0022-2836(86)90512-7; MOSSAKOWSKA DE, 1989, BIOCHEMISTRY-US, V28, P3843, DOI 10.1021/bi00435a033; NAMBIAR KP, 1987, EUR J BIOCHEM, V163, P67, DOI 10.1111/j.1432-1033.1987.tb10737.x; OSTERHOUT JJ, 1989, BIOCHEMISTRY-US, V28, P7059, DOI 10.1021/bi00443a042; OSTERMAN HL, 1979, BIOCHEMISTRY-US, V18, P1984, DOI 10.1021/bi00577a021; PARES X, 1991, ESSAYS BIOCHEM, V26, P89; PARES X, 1980, EUR J BIOCHEM, V105, P571, DOI 10.1111/j.1432-1033.1980.tb04534.x; PFLUMM MN, 1969, J BIOL CHEM, V244, P3973; RIBO M, 1991, STRUCTURE, MECHANISM AND FUNCTION OF RIBONUCLEASES, P157; RICHARDS FM, 1971, ENZYMES, V4, P647; RICHARDSON RM, 1988, BIOCHIM BIOPHYS ACTA, V953, P70, DOI 10.1016/0167-4838(88)90010-6; RICHARDSON RM, 1990, BIOCHEM J, V267, P593, DOI 10.1042/bj2670593; RINK H, 1984, NUCLEIC ACIDS RES, V12, P6369, DOI 10.1093/nar/12.16.6369; SCHEIN CH, 1992, BIOCHEM J, V283, P137, DOI 10.1042/bj2830137; SELA M, 1957, BIOCHIM BIOPHYS ACTA, V24, P229, DOI 10.1016/0006-3002(57)90186-5; STREHLOW KG, 1989, BIOCHEMISTRY-US, V28, P2130, DOI 10.1021/bi00431a025; STRICKLA.EH, 1972, BIOCHEMISTRY-US, V11, P3465, DOI 10.1021/bi00768a022; SUMMERS RG, 1989, J BIOL CHEM, V264, P20082; WLODAWER A, 1984, BIOL MACROMOL, P393; YAMANE K, 1988, J BIOL CHEM, V263, P19690	38	71	71	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2529	2534						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300580				2022-12-27	WOS:A1994MV43200030
J	FERNANDEZ, JA; GRIFFIN, JH				FERNANDEZ, JA; GRIFFIN, JH			A PROTEIN-S BINDING-SITE ON C4B-BINDING PROTEIN INVOLVES BETA-CHAIN RESIDUES 31-45	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE; IDENTIFICATION; COMPLEX; SUBUNIT; PLASMA; FORMS	C4b-binding protein (C4BP) down-regulates the anticoagulant cofactor activity of protein S in the protein C pathway since free protein S but not the protein S:C4BP complex is anticoagulantly active. To identify beta chain residues responsible for binding protein S, synthetic overlapping pentadecapeptides covering the entire 1-235 sequence were tested as inhibitors of complex formation. The peptide comprising residues 31-45 (VCIKGYHLVGKKTLF) from the first short consensus repeat domain inhibited the binding of C4BP to protein S with half-maximal inhibition at 20-45 muM, and studies suggested the sequence of YxLVG was crucial. Peptide beta(31-45) specifically inhibited the APC cofactor activity of purified protein S in Xa-1-stage coagulation assays with 50% inhibition at 15 muM peptide. Peptide beta(31-45) and related peptides such as beta(34-42) inhibited the binding of protein S to an antipeptide monoclonal antibody made against residues 420-434 of protein S (monoclonal antibody LJ-56). Polyclonal anti-beta(31-45) peptide antibodies inhibited complex formation. Dose-dependent binding studies showed that protein S bound directly to immobilized peptide beta(31-45). These results show that residues 31-45 of the C4BP beta chain provide a binding site for protein S, and they suggest that the C4BP beta chain residues 34-42 are located near residues 420-434 of protein S in the protein S:C4BP complex.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute			Fernandez, Jose A/A-3211-2008	Fernandez, Jose A/0000-0002-0804-1865; Griffin, John/0000-0002-4302-2547	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021544] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-21544] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHUNG LP, 1985, MOL IMMUNOL, V22, P427, DOI 10.1016/0161-5890(85)90127-0; DAHLBACK B, 1983, BIOCHEM J, V209, P857, DOI 10.1042/bj2090857; DAHLBACK B, 1983, BIOCHEM J, V209, P847, DOI 10.1042/bj2090847; DAHLBACK B, 1986, J BIOL CHEM, V261, P2022; FERNANDEZ JA, 1993, J BIOL CHEM, V268, P16788; GRIFFIN JH, 1992, BLOOD, V79, P3203; HEEB MJ, 1988, THROMB RES, V52, P33, DOI 10.1016/0049-3848(88)90038-2; HEEB MJ, 1993, J BIOL CHEM, V268, P2872; HESSING M, 1993, FEBS LETT, V317, P228, DOI 10.1016/0014-5793(93)81281-4; HESSING M, 1990, THROMB HAEMOSTASIS, V64, P245; HILLARP A, 1987, J BIOL CHEM, V262, P11300; HILLARP A, 1989, FEBS LETT, V259, P53, DOI 10.1016/0014-5793(89)81492-9; HILLARP A, 1990, P NATL ACAD SCI USA, V87, P1183, DOI 10.1073/pnas.87.3.1183; HILLARP A, 1988, J BIOL CHEM, V263, P12759; JANATOVA J, 1989, BIOCHEMISTRY-US, V28, P4754, DOI 10.1021/bi00437a036; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MESTERS RM, 1991, J BIOL CHEM, V266, P24514; NELSON RM, 1991, BIOCHEMISTRY-US, V30, P2384, DOI 10.1021/bi00223a013; SCHARFSTEIN J, 1978, J EXP MED, V148, P207, DOI 10.1084/jem.148.1.207; SCHWARZ HP, 1987, THROMB HAEMOSTASIS, V56, P382; SUZUKI K, 1988, J BIOL CHEM, V263, P17034; TAYLOR F, 1991, BLOOD, V78, P357, DOI 10.1182/blood.V78.2.357.357	22	30	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2535	2540						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300581				2022-12-27	WOS:A1994MV43200031
J	JI, ZS; FAZIO, S; LEE, YL; MAHLEY, RW				JI, ZS; FAZIO, S; LEE, YL; MAHLEY, RW			SECRETION-CAPTURE ROLE FOR APOLIPOPROTEIN-E IN REMNANT LIPOPROTEIN METABOLISM INVOLVING CELL-SURFACE HEPARAN-SULFATE PROTEOGLYCANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RECEPTOR-RELATED PROTEIN; CHOLESTEROL TRANSPORT; CHYLOMICRON REMNANTS; CULTURED-CELLS; MACROPHAGES; E3-LEIDEN; BINDING; HEPARINASE; CLEARANCE	To determine the impact of enhanced apolipoprotein (apo) E secretion on the mechanism of remnant lipoprotein uptake, rat hepatoma cells (McA-RH7777) were stably transfected with normal human apoE3 or receptor binding-defective apoE-Leiden. After a 2-h incubation, the human apoE secreted from the transfected hepatocytes was 10-12 times greater than the endogenous rat apoE. The apoE3-transfected cells bound and internalized rabbit beta-very low density lipoproteins (beta-VLDL) to a much greater degree than did apoE-Leiden-transfected cells and nontransfected cells. The apoE3-secreting cells displayed a 2-3.5-fold enhancement of cell-associated beta-VLDL compared to either the apoE-Leiden-transfected or nontransfected cells. Fluorescently labeled beta-VLDL were observed to concentrate within intracellular granules of the apoE3-transfected cells, presumably within endosomes and lysosomes. Furthermore, electron microscopy revealed that the apoE3-secreting cells displayed abundant beta-VLDL and chylomicron remnants on their cell surfaces and microvilli, in contrast to non-transfected or apoE-Leiden-secreting cells. Electron microscopy also revealed an abundance of chylomicron remnants within intracellular vesicles and multivesicular bodies of apoE3-transfected hepatocytes. Heparinase treatment (3 units/ml) completely abolished the increased association of beta-VLDL with apoE3-transfected cells but did not affect the limited association of beta-VLDL with apoE-Leiden-transfected or nontransfected cells. We established that the apoE3-enriched beta-VLDL were bound to cell surface heparan sulfate proteoglycans, as was the newly synthesized and secreted apoE3 (approximately 12% of the total secreted apoE3 was released by heparinase and suramin; 4% by heparin). In addition, reisolation of beta-VLDL by fast performance liquid chromatography after their incubation with exogenous apoE3, with medium from apoE3-secreting cells, or with the apoE3-secreting cells themselves revealed that the particles were enriched in apoE3 and displayed enhanced binding. These results suggest a secretion-capture role for apoE and indicate an important role for heparan sulfate proteoglycans on the cell surface for remnant lipoprotein metabolism.	UNIV CALIF SAN FRANCISCO, GLADSTONE INST CARDIOVASC DIS, CARDIOVASC RES INST, POB 419100, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, DEPT PATHOL, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [HL41633] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNON R, 1991, BIOCHIM BIOPHYS ACTA, V1085, P336, DOI 10.1016/0005-2760(91)90138-8; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; CHOI SSY, 1991, J CLIN INVEST, V88, P1173, DOI 10.1172/JCI115419; DEKNIJFF P, 1991, J CLIN INVEST, V88, P643, DOI 10.1172/JCI115349; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; FAZIO S, 1992, J BIOL CHEM, V267, P6941; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HAVEKES L, 1986, HUM GENET, V73, P157, DOI 10.1007/BF00291607; HIXSON JE, 1990, J LIPID RES, V31, P545; HUMPHRIES DE, 1989, METHOD ENZYMOL, V179, P428; HUSSAIN MM, 1989, J BIOL CHEM, V264, P9571; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; ISHIBASHI S, 1990, J BIOL CHEM, V265, P3040; JI ZS, 1993, J BIOL CHEM, V268, P10160; KHAN MY, 1991, ANAL BIOCHEM, V196, P373; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; LILLYSTAUDERMAN M, 1993, J LIPID RES, V34, P190; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mahley R. W., 1991, CURR OPIN LIPIDOL, V2, P170; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1989, METABOLIC BASIS INHE, V1, P1195; MOKUNO H, 1991, BIOCHIM BIOPHYS ACTA, V1082, P63; MULDER M, 1992, BIOCHEM BIOPH RES CO, V185, P582, DOI 10.1016/0006-291X(92)91664-C; NADER HB, 1987, P NATL ACAD SCI USA, V84, P3565, DOI 10.1073/pnas.84.11.3565; OWENS RT, 1991, ARTERIOSCLER THROMB, V11, P1752, DOI 10.1161/01.ATV.11.6.1752; RALL SC, 1986, METHOD ENZYMOL, V128, P273; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; SAXENA U, 1992, J CLIN INVEST, V89, P373, DOI 10.1172/JCI115595; SHIMANO H, 1991, BIOCHIM BIOPHYS ACTA, V1086, P245, DOI 10.1016/0005-2760(91)90166-F; WARDELL MR, 1989, J BIOL CHEM, V264, P21205; WEISGRABER KH, 1988, BIOCHEM BIOPH RES CO, V157, P1212, DOI 10.1016/S0006-291X(88)81003-9; WERNETTEHAMMOND ME, 1989, J BIOL CHEM, V264, P9094; WILLIAMS DL, 1985, J BIOL CHEM, V260, P2444; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; YANG VC, 1985, J BIOL CHEM, V260, P1849	41	198	201	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2764	2772						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300609				2022-12-27	WOS:A1994MV43200062
J	BALZI, E; WANG, M; LETERME, S; VANDYCK, L; GOFFEAU, A				BALZI, E; WANG, M; LETERME, S; VANDYCK, L; GOFFEAU, A			PDR5, A NOVEL YEAST MULTIDRUG-RESISTANCE CONFERRING TRANSPORTER CONTROLLED BY THE TRANSCRIPTION REGULATOR PDR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLEIOTROPIC DRUG-RESISTANCE; TRANSMEMBRANE CONDUCTANCE REGULATOR; SACCHAROMYCES-CEREVISIAE GENE; CYSTIC-FIBROSIS MUTATIONS; NUCLEOTIDE-BINDING FOLD; P-GLYCOPROTEIN; ATP-BINDING; HEAT-SHOCK; MDR1 GENE; DROSOPHILA-MELANOGASTER	The complete sequence of the pleiotropic drug resistance gene PDR5 from Saccharomyces cerevisiae is reported and analyzed. PDR5 encodes a 160-kDa protein with a predicted duplicated six membrane-span domain and a repeated putative ATP-binding domain. PDR5 shares this structural feature with the mammalian multidrug resistance pumps as well as the functional capacity of conferring resistance to various inhibitors upon amplification (Leppert, G., McDevitt, R., Falco, S. C., Van Dyk, T. K., Ficke, M. B., and Golin, J. (1990) Genetics 125, 13-20). The yeast PDR5 is thus a new member of the ABC (ATP-binding cassette) protein superfamily. Mutations in another yeast pleiotropic drug resistance gene, PDR1, encoding a putative transcription regulator (Balzi, E., Chen, W., Ulaszewski, S., Capieaux, E., and Goffeau, A. (1987) J. Biol. Chem. 262, 16871-16879), increase markedly the mRNA levels of the PDR5 and STE6 genes. The multidrug resistance mutations pdr1-3 and pdr1-6 also lead to considerable overexpression of the PDR5 plasma membrane protein.	UNIV CATHOLIQUE LOUVAIN, UNITE BIOCHIM PHYSIOL, PLACE CROIX DU SUD 2-20, B-1348 LOUVAIN, BELGIUM	Universite Catholique Louvain								AMES GF, 1992, FASEB J, V6, P2660, DOI 10.1096/fasebj.6.9.1377140; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BALZI E, 1987, J BIOL CHEM, V262, P16871; BALZI E, 1991, BIOCHIM BIOPHYS ACTA, V1073, P241, DOI 10.1016/0304-4165(91)90128-4; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; BRADLEY G, 1988, BIOCHIM BIOPHYS ACTA, V948, P87, DOI 10.1016/0304-419X(88)90006-6; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; CHEN WN, 1991, YEAST, V7, P305, DOI 10.1002/yea.320070313; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHIN KV, 1990, J BIOL CHEM, V265, P221; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DELAVEAU T, 1992, YEAST, V8, P761, DOI 10.1002/yea.320080909; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DEXTER D, 1993, IN PRESS GENETICS; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; DREESEN TD, 1988, MOL CELL BIOL, V8, P5206, DOI 10.1128/MCB.8.12.5206; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9; GARRIDO MD, 1988, EMBO J, V7, P1853, DOI 10.1002/j.1460-2075.1988.tb03018.x; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GOFFEAU A, 1993, FEBS LETT, V325, P112, DOI 10.1016/0014-5793(93)81425-Y; GOFFEAU A, 1988, METHOD ENZYMOL, V157, P528; GOMPELKLEIN P, 1990, CURR GENET, V18, P93, DOI 10.1007/BF00321122; GREENBERGER LM, 1987, J BIOL CHEM, V262, P13685; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; GUILFOILE PG, 1991, P NATL ACAD SCI USA, V88, P8553, DOI 10.1073/pnas.88.19.8553; HENIKOFF S, 1984, MOL CELL BIOL, V4, P1515, DOI 10.1128/MCB.4.8.1515; HERTLE K, 1991, CURR GENET, V19, P429, DOI 10.1007/BF00312733; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HUSSAIN M, 1991, GENE, V101, P149, DOI 10.1016/0378-1119(91)90238-7; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KANAZAWA S, 1988, MOL CELL BIOL, V8, P664, DOI 10.1128/MCB.8.2.664; KIOKA N, 1992, FEBS LETT, V301, P37, DOI 10.1016/0014-5793(92)80205-U; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPPERT G, 1990, GENETICS, V125, P13; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; MIYAUCHI S, 1992, BIOCHIM BIOPHYS ACTA, V1110, P144, DOI 10.1016/0005-2736(92)90351-L; MIYAZAKI M, 1992, BIOCHEM BIOPH RES CO, V187, P677, DOI 10.1016/0006-291X(92)91248-O; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; NASS G, 1976, MOL GEN GENET, V147, P39, DOI 10.1007/BF00337933; NUOFFER C, 1991, MOL CELL BIOL, V11, P27, DOI 10.1128/MCB.11.1.27; OHARE K, 1984, J MOL BIOL, V180, P437, DOI 10.1016/0022-2836(84)90021-4; OUELLETTE M, 1990, EMBO J, V9, P1027, DOI 10.1002/j.1460-2075.1990.tb08206.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PELHAM H, 1985, TRENDS GENET, V1, P31, DOI 10.1016/0168-9525(85)90012-5; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; PURNELLE B, 1991, YEAST, V7, P867, DOI 10.1002/yea.320070813; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; RAYMOND M, 1989, P NATL ACAD SCI USA, V86, P6488, DOI 10.1073/pnas.86.17.6488; REINSTEIN J, 1990, BIOCHEMISTRY-US, V29, P7451, DOI 10.1021/bi00484a014; RIORDAN JR, 1989, SCIENCE, V245, P1066; SAMBROOK J, 1989, MOL CLONING LABORATO, P758; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SARKADI B, 1992, J BIOL CHEM, V267, P2087; SAUER B, 1992, J MOL BIOL, V223, P911, DOI 10.1016/0022-2836(92)90252-F; Schinkel A H, 1991, Semin Cancer Biol, V2, P213; SCHNELL N, 1992, CURR GENET, V21, P269, DOI 10.1007/BF00351681; SERVOS J, 1993, MOL GEN GENET, V236, P214, DOI 10.1007/BF00277115; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; SILVER S, 1989, TRENDS BIOCHEM SCI, V14, P76, DOI 10.1016/0968-0004(89)90048-0; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; THOMAS PJ, 1993, J BIOENERG BIOMEMBR, V25, P11, DOI 10.1007/BF00768063; TIAN G, 1990, BIOCHEMISTRY-US, V29, P4296, DOI 10.1021/bi00470a006; TREZISE AEO, 1992, EMBO J, V11, P4291, DOI 10.1002/j.1460-2075.1992.tb05528.x; UMESONO K, 1988, J MOL BIOL, V203, P299, DOI 10.1016/0022-2836(88)90002-2; VAI M, 1991, J BIOL CHEM, V266, P12242; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	79	376	386	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2206	2214						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294477				2022-12-27	WOS:A1994MR98800098
J	JEONG, S; STEIN, A				JEONG, S; STEIN, A			DNA-SEQUENCE AFFECTS NUCLEOSOME ORDERING ON REPLICATING PLASMIDS IN TRANSFECTED COS-1 CELLS AND IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; CHROMATIN STRUCTURE; GENE-EXPRESSION; SV40 DNA; REGION; TRANSCRIPTION; MINICHROMOSOMES; ORIGIN; ENCAPSIDATION; INITIATION	Nucleosome ordering on a variety of replicating plasmids, assembled into chromatin in transfected COS-1 cells, was studied by micrococcal nuclease digestion of isolated nuclei. Generally, no more than three well defined multiples of a unit nucleosome repeat, which resembled the first three bands of the (187 +/- 5 base pair (bp)) cellular chromatin ladder, could be detected in constructs that contained a near-minimal SV40 replication origin. In contrast, constructs that additionally contained the SV40 early region exhibited significantly more regular nucleosome arrangements. In some cases, eight to nine multiples of a 203 +/- 5-bp repeat could be resolved. The presence of the SV40 early region was necessary for physiological nucleosome alignment over the SV40 late and ori regions, or onto adjacent pBR327 DNA. In an in vitro chromatin assembly system, using purified chicken erythrocyte histones plus polyglutamic acid, a portion of SV40 DNA became packaged into a highly ordered 200 +/- 5-bp nucleosome array, which encompassed the early region and extended for about 2800 bp. The data suggest that in the cell nucleus, nucleosome ordering on SV40 DNA might spread from sequences in the early region, close to where transcription terminates, probably as a consequence of histone H1-nucleosome interactions.	PURDUE UNIV, DEPT BIOL SCI, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus				Jeong, Shinwu/0000-0002-4847-813X	NIGMS NIH HHS [GM48341] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048341] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN J, 1980, P NATL ACAD SCI-BIOL, V77, P885, DOI 10.1073/pnas.77.2.885; AMBROSE C, 1986, P NATL ACAD SCI USA, V83, P3287, DOI 10.1073/pnas.83.10.3287; AMBROSE C, 1990, J MOL BIOL, V214, P875, DOI 10.1016/0022-2836(90)90342-J; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; BLASQUEZ V, 1986, J MOL BIOL, V191, P97, DOI 10.1016/0022-2836(86)90425-0; BLASQUEZ V, 1985, THESIS PURDUE U W LA; BLASQUEZ V, 1987, MOL ASPECTS PAPOVAVI, P219; CARTWRIGHT IL, 1988, ARCHITECTURE EUKARYO, P283; CEREGHINI S, 1984, EMBO J, V3, P1243, DOI 10.1002/j.1460-2075.1984.tb01959.x; COCAPRADOS M, 1982, J VIROL, V44, P603, DOI 10.1128/JVI.44.2.603-609.1982; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FREEMAN L A, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P165; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GRUSS C, 1992, BIOESSAYS, V14, P1, DOI 10.1002/bies.950140102; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P504, DOI 10.1016/0006-291X(73)90740-7; HSIEH CH, 1988, CELL, V52, P535, DOI 10.1016/0092-8674(88)90466-7; JEONG SW, 1991, J MOL BIOL, V222, P1131, DOI 10.1016/0022-2836(91)90597-Y; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cellbio.8.1.563; LAUDERDALE JD, 1993, BIOCHEMISTRY-US, V32, P489, DOI 10.1021/bi00053a013; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LOHR D, 1975, SCIENCE, V188, P165, DOI 10.1126/science.1090006; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; OPPENHEIM A, 1992, J VIROL, V66, P5320, DOI 10.1128/JVI.66.9.5320-5328.1992; OPPENHEIM A, 1989, GENE, V77, P79, DOI 10.1016/0378-1119(89)90361-2; PIENTA K J, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P355; POLJAK LG, 1987, BIOCHEMISTRY-US, V26, P295, DOI 10.1021/bi00375a041; POMMIER Y, 1990, J VIROL, V64, P419, DOI 10.1128/JVI.64.1.419-423.1990; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; ROSE SM, 1984, J BIOL CHEM, V259, P8534; ROSL F, 1991, MOL CARCINOGEN, V4, P248, DOI 10.1002/mc.2940040312; RUIZCARRILLO A, 1975, SCIENCE, V190, P117, DOI 10.1126/science.1166303; Sambrook J, 1989, MOL CLONING LABORATO; SARAGOSTI S, 1980, CELL, V20, P65, DOI 10.1016/0092-8674(80)90235-4; SHELTON ER, 1978, J MOL BIOL, V125, P491, DOI 10.1016/0022-2836(78)90312-1; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SOBERON X, 1980, GENE, V9, P287, DOI 10.1016/0378-1119(90)90328-O; STEIN A, 1989, METHOD ENZYMOL, V170, P585; STEIN A, 1987, J BIOL CHEM, V262, P3872; van Holde KE., 1989, SPRINGER SERIES MOL; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643; WOLFFE AP, 1991, J CELL SCI, V99, P201; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0	48	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2197	2205						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294476				2022-12-27	WOS:A1994MR98800097
J	JUNKER, J; SOMMER, JR; SAR, M; MEISSNER, G				JUNKER, J; SOMMER, JR; SAR, M; MEISSNER, G			EXTENDED JUNCTIONAL SARCOPLASMIC-RETICULUM OF AVIAN CARDIAC-MUSCLE CONTAINS FUNCTIONAL RYANODINE RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RELEASE CHANNEL COMPLEX; SKELETAL-MUSCLE; CALCIUM RELEASE; CA-2+; VESICLES; CHARGE; PROBE; CDNA	The ryanodine receptor (RYR)/Ca2+ release channel of avian cardiac muscle was localized by immunocytochemical techniques and biochemically characterized using isolated membrane and receptor protein fractions. Monoclonal antibody C3-33 raised against the canine cardiac RYR bound to the junctional sarcoplasmic reticulum of pigeon and finch hearts, both at peripheral couplings and at extended junctional sarcoplasmic reticulum (EJSR). Immunoblots of sarcoplasmic reticulum vesicles from pigeon and finch hearts showed this antibody recognized a single high molecular weight protein, which co-migrated with the canine M(r) 565,000 RYR/Ca2+ release channel polypeptide. The pigeon heart RYR bound [H-3]ryanodine with high affinity in a Ca2+-dependent manner, comparable to the canine cardiac RYR. Purification of the pigeon RYR yielded a 30 S protein complex, which bound the maximum calculated amount of [H-3]ryanodine ((440 +/- 60) pmol/mg protein), assuming one high affinity site/tetrameric 30 S RYR comprised of M(r) 565,000 polypeptides. Autoradiography of isolated finch cardiac myocytes indicated [H-3]ryanodine binding throughout the cells. These results suggest that avian heart contains a single population of RYRs, and thereby support the hypothesis that avian EJSR contains functional calcium release channels which, because of the absence of transverse tubules, can be located micrometers away from the surface membrane in avian heart.	UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599; CAMPBELL UNIV,SCH PHARM,BULES CREEK,NC 27506; DUKE UNIV,DEPT PATHOL,DURHAM,NC 27710; VET ADM MED CTR,DURHAM,NC 27705; UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; Campbell University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of North Carolina; University of North Carolina Chapel Hill					NHLBI NIH HHS [HL 12486] Funding Source: Medline; NIAMS NIH HHS [AR 18687] Funding Source: Medline; NINDS NIH HHS [NS 17479] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL012486] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR018687, R37AR018687] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017479] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIREY JA, 1993, BIOCHEMISTRY-US, V32, P5739, DOI 10.1021/bi00073a003; ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; ANDERSON K, 1989, J BIOL CHEM, V264, P1329; BENDUKIDZE Z, 1985, BASIC RES CARDIOL S1, V80, P513; BOSSEN EH, 1978, TISSUE CELL, V10, P773, DOI 10.1016/0040-8166(78)90062-9; CANNELL MB, 1987, SCIENCE, V238, P1419, DOI 10.1126/science.2446391; CHU A, 1990, MOL PHARMACOL, V37, P735; DOLBER PC, 1984, J ULTRA MOL STRUCT R, V87, P190, DOI 10.1016/S0022-5320(84)80078-7; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FRANZINI.C, 1970, J CELL BIOL, V47, P488, DOI 10.1083/jcb.47.2.488; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; GYORKE S, 1992, J PHYSIOL-LONDON, V457, P195; INUI M, 1987, J BIOL CHEM, V262, P15637; JORGENSEN AO, 1988, CIRC RES, V63, P1060, DOI 10.1161/01.RES.63.6.1060; JORGENSEN AO, 1993, J CELL BIOL, V120, P969, DOI 10.1083/jcb.120.4.969; JUNKER J, 1992, FASEB J, V6, pA1240; LAI FA, 1989, J BIOENERG BIOMEMBR, V21, P227, DOI 10.1007/BF00812070; LAI FA, 1992, AM J PHYSIOL, V263, pC365, DOI 10.1152/ajpcell.1992.263.2.C365; LAI FA, 1989, J BIOL CHEM, V264, P16776; MEISSNER G, 1989, J BIOL CHEM, V264, P1715; MEISSNER G, 1992, MOL CELL BIOCHEM, V114, P119; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; NOWYCKY MC, 1993, BIOPHYS J, V64, P77, DOI 10.1016/S0006-3495(93)81342-0; OTSU K, 1990, J BIOL CHEM, V265, P13472; RARDON DP, 1989, CIRC RES, V64, P779, DOI 10.1161/01.RES.64.4.779; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; SABBADINI RA, 1992, J BIOL CHEM, V267, P15475; SAR M, 1985, TECHNIQUES IMMUNOCYT, V3, P43; SCHNEIDER MF, 1981, ANNU REV PHYSIOL, V43, P507, DOI 10.1146/annurev.ph.43.030181.002451; Sommer J.R., 1979, HDB PHYSL 2, VVolume 1, P113; SOMMER JR, 1968, J CELL BIOL, V36, P497, DOI 10.1083/jcb.36.3.497; SOMMER JR, 1969, Z ZELLFORSCH MIK ANA, V98, P437, DOI 10.1007/BF00346685; SOMMER JR, 1991, ACTA PHYSIOL SCAND, V142, P5; STERN MD, 1992, BIOPHYS J, V63, P497, DOI 10.1016/S0006-3495(92)81615-6; Stumpf W E, 1975, Methods Enzymol, V36, P135	38	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1627	1634						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294409				2022-12-27	WOS:A1994MR98800016
J	NOLTA, KV; STECK, TL				NOLTA, KV; STECK, TL			ISOLATION AND INITIAL CHARACTERIZATION OF THE BIPARTITE CONTRACTILE VACUOLE COMPLEX FROM DICTYOSTELIUM-DISCOIDEUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-MICROSCOPY; LOCALIZATION; MEMBRANE; ASSOCIATION; ACIDOSOMES; PARAMECIUM; MYOSIN; ATPASE	The contractile vacuole complex serves to excrete excess cytosolic water from protists. In the amoeba, Dictyostelium discoideum, the organelle had a bipartite morphology: a large main vacuole (bladder) marked by lumenal alkaline phosphatase was surrounded by numerous satellite vacuoles (spongiomes). Bladders and spongiomes have now been purified for the first time. The spongiome membranes had a high density of surface projections identified as catalytically-active vacuolar proton pumps (V-H+-ATPase). Spongiomes were resolved from the pump-poor bladders by immunogold buoyant density shift with antibodies to the V-H+-ATPase; they contained little protein other than this pump. It appears that, following homogenization, most of the spongiome dissociated from bladders and populated the proton pump-rich membrane fraction called acidosomes. Isolated bladders were enriched >40-fold in alkaline phosphatase and phosphodiesterase, the activities of which were >85% latent. Bladders depleted of spongiomes bore several distinctive polypeptides; they also had an excess of the basepieces of the proton pump over the catalytic heads. Bladder membranes were also lipid-rich and had a distinctive lipid composition. We conclude that the contractile vacuole system in Dictyostelium is a complex of discrete, separable bladder and spongiome membranes. The V-H+-ATPase in the spongiome may catalyze the primary energy transduction step for pumping water out of the cytoplasm.	UNIV CALIF LOS ANGELES,DEPT BIOCHEM & MOLEC BIOL,920 E 58TH ST,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007183, R01GM047282] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42086] Funding Source: Medline; NIGMS NIH HHS [GM07183, R01GM47282] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARONSON S, 1974, J CELL SCI, V4, P1; AKBARIEH M, 1988, J PROTOZOOL, V35, P99, DOI 10.1111/j.1550-7408.1988.tb04085.x; ALLEN RD, 1990, J CELL SCI, V96, P469; ALLEN RD, 1988, J PROTOZOOL, V35, P63, DOI 10.1111/j.1550-7408.1988.tb04078.x; BAINES IC, 1990, J CELL BIOL, V111, P1895, DOI 10.1083/jcb.111.5.1895; BOWERS B, 1973, J CELL BIOL, V59, P784, DOI 10.1083/jcb.59.3.784; BOWERS B, 1968, J CELL BIOL, V39, P95, DOI 10.1083/jcb.39.1.95; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DECHASTELLIER C, 1978, J ULTRA MOL STRUCT R, V62, P220, DOI 10.1016/S0022-5320(78)80019-7; DSCHIDA WJ, 1992, J BIOL CHEM, V267, P18783; GILKES NR, 1977, BIOCHIM BIOPHYS ACTA, V464, P142, DOI 10.1016/0005-2736(77)90377-7; GINGELL D, 1982, J CELL SCI, V54, P287; GLOMP I, 1985, HISTOCHEMISTRY, V83, P251, DOI 10.1007/BF00953993; HEUSER J, 1993, J CELL BIOL, V121, P1311, DOI 10.1083/jcb.121.6.1311; HEYWOOD P, 1978, J CELL SCI, V31, P213; KANE PM, 1992, J EXP BIOL, V172, P93; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENHARD JM, 1992, J BIOL CHEM, V267, P1896; LINDER JC, 1979, J CELL BIOL, V83, P371, DOI 10.1083/jcb.83.2.371; LISANTI MP, 1990, TRENDS BIOCHEM SCI, V15, P113, DOI 10.1016/0968-0004(90)90195-H; MCKANNA JA, 1976, J ULTRA MOL STRUCT R, V54, P1, DOI 10.1016/S0022-5320(76)80002-0; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; NOLTA KV, 1993, J CELL SCI, V105, P849; NOLTA KV, 1991, J BIOL CHEM, V266, P18318; PADH H, 1991, J BIOL CHEM, V266, P12123; PADH H, 1989, J CELL BIOL, V108, P865, DOI 10.1083/jcb.108.3.865; PADH H, 1989, BIOCHIM BIOPHYS ACTA, V982, P271, DOI 10.1016/0005-2736(89)90064-3; PATTERSON DJ, 1980, BIOL REV, V55, P1, DOI 10.1111/j.1469-185X.1980.tb00686.x; PRUSCH RD, 1970, J CELL BIOL, V46, P431, DOI 10.1083/jcb.46.2.431; QUIVIGER B, 1978, J ULTRA MOL STRUCT R, V62, P228, DOI 10.1016/S0022-5320(78)80020-3; REINHART MP, 1987, J BIOL CHEM, V262, P9649; RIDDICK DH, 1968, AM J PHYSIOL, V215, P736, DOI 10.1152/ajplegacy.1968.215.3.736; VERKMAN AS, 1992, ANNU REV PHYSIOL, V54, P97, DOI 10.1146/annurev.physiol.54.1.97; ZEUTHEN T, 1992, BIOCHIM BIOPHYS ACTA, V1113, P229, DOI 10.1016/0304-4157(92)90040-H; ZHANG JM, 1992, J BIOL CHEM, V267, P9773; ZHU QL, 1992, J CELL BIOL, V118, P347, DOI 10.1083/jcb.118.2.347	36	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2225	2233						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294479				2022-12-27	WOS:A1994MR98800100
J	VAELLO, ML; RUIZGOMEZ, A; LERMA, J; MAYOR, F				VAELLO, ML; RUIZGOMEZ, A; LERMA, J; MAYOR, F			MODULATION OF INHIBITORY GLYCINE RECEPTORS BY PHOSPHORYLATION BY PROTEIN-KINASE-C AND CAMP-DEPENDENT PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED ION CHANNELS; NICOTINIC ACETYLCHOLINE-RECEPTOR; MOUSE SPINAL-CORD; FUNCTIONAL EXPRESSION; CHLORIDE CHANNELS; PRIMARY CULTURES; BETA-SUBUNIT; MUSCLE-CELLS; RAT-BRAIN; VARIANTS	Recent evidence has suggested a role for phosphorylation in the regulation of ligand-gated ion channels. We have recently shown (Ruiz-Gomez, A., Vaello, M., Valdivieso, F., and Mayor, F., Jr. (1991) J. Biol. Chem. 266, 559-566) that the inhibitory glycine receptor (GlyR) alpha subunit is phosphorylated in vitro by protein kinase C (PKC). In this report we further show that alpha subunits of the GlyR can also be phosphorylated by cAMP-dependent protein kinase (PKA) in an in vitro assay. Moreover, incubation of intact rat spinal cord neurons with specific PKC or PKA activators leads to increased phosphorylation of the GlyR alpha subunits, strongly suggesting a physiological role in its functional modulation. The role of protein phosphorylation in modulating GlyR channels was explored in Xenopus oocytes injected with poly (A)+ mRNA isolated from nervous tissue. The treatment of oocytes with phorbol esters or dibutyryl cAMP resulted in a decrease of an enhancement, respectively, of glycine-evoked currents. Our results show that the GlyR can be phosphorylated in vivo in response to activation of either PKC or PKA with opposite functional consequences, suggesting that neurotransmitters affecting the activity of such kinases could profoundly alter glycine-mediated neuronal signaling and modulate synaptic efficacy.	UNIV AUTONOMA MADRID, CSIC, CTR BIOL MOLEC SEVERO OCHOA, E-28049 MADRID, SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Ruiz-Gómez, Ana/H-2092-2015; Ruiz-Gomez, Ana/ABF-3079-2021; Mayor, Federico/N-7644-2016; Lerma, Juan/G-7907-2015	Ruiz-Gómez, Ana/0000-0002-1646-3072; Lerma, Juan/0000-0001-7838-5199; Mayor Menendez, Federico/0000-0003-1434-8449				Aprison MH, 1978, ADV NEUROCHEM, V3, P203; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BREWER GJ, 1989, BRAIN RES, V494, P65, DOI 10.1016/0006-8993(89)90144-3; CLARK EA, 1991, J NEUROCHEM, V57, P802, DOI 10.1111/j.1471-4159.1991.tb08222.x; GARCIACALVO M, 1989, BIOCHEMISTRY-US, V28, P6405, DOI 10.1021/bi00441a037; GOMEZ AR, 1989, BIOCHEM BIOPH RES CO, V160, P374, DOI 10.1016/0006-291X(89)91666-5; GRENNINGLOH G, 1990, NEURON, V4, P963, DOI 10.1016/0896-6273(90)90149-A; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; GRENNINGLOH G, 1990, EMBO J, V9, P771, DOI 10.1002/j.1460-2075.1990.tb08172.x; HOCH W, 1989, NEURON, V3, P339, DOI 10.1016/0896-6273(89)90258-4; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; JOHNSTON ME, 1989, J NEUROCHEM, V52, P75, DOI 10.1111/j.1471-4159.1989.tb10900.x; KUHSE J, 1990, NEURON, V5, P867, DOI 10.1016/0896-6273(90)90346-H; KUHSE J, 1990, J BIOL CHEM, V265, P22317; LAI Y, 1990, J BIOL CHEM, V265, P20839; LANGOSCH D, 1992, FEBS LETT, V298, P113, DOI 10.1016/0014-5793(92)80034-E; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; LERMA J, 1989, P NATL ACAD SCI USA, V86, P1708, DOI 10.1073/pnas.86.5.1708; LOTAN I, 1990, FEBS LETT, V267, P25, DOI 10.1016/0014-5793(90)80279-R; MALOSIO ML, 1991, J BIOL CHEM, V266, P2048; MALOSIO ML, 1991, EMBO J, V10, P2401, DOI 10.1002/j.1460-2075.1991.tb07779.x; MILES K, 1987, P NATL ACAD SCI USA, V84, P6591, DOI 10.1073/pnas.84.18.6591; MOSS SJ, 1992, J BIOL CHEM, V267, P14470; MOSS SJ, 1992, SCIENCE, V257, P661, DOI 10.1126/science.1323140; PFEIFFER F, 1982, J BIOL CHEM, V257, P9389; PILLER V, 1989, J BIOL CHEM, V264, P18824; PRIBILLA I, 1992, EMBO J, V11, P4305, DOI 10.1002/j.1460-2075.1992.tb05529.x; PRIOR P, 1992, NEURON, V8, P1161, DOI 10.1016/0896-6273(92)90136-2; RANSOM BR, 1977, J NEUROPHYSIOL, V40, P1132, DOI 10.1152/jn.1977.40.5.1132; RAYMOND LA, 1993, TRENDS NEUROSCI, V16, P147, DOI 10.1016/0166-2236(93)90123-4; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; ROSS A, 1988, J CELL BIOL, V107, P1139, DOI 10.1083/jcb.107.3.1139; ROSSIE S, 1987, J BIOL CHEM, V262, P12735; RUIZGOMEZ A, 1990, BIOCHEMISTRY-US, V29, P7033, DOI 10.1021/bi00482a012; RUIZGOMEZ A, 1991, J BIOL CHEM, V266, P559; SCHMIEDEN V, 1989, EMBO J, V8, P695, DOI 10.1002/j.1460-2075.1989.tb03428.x; SIGEL E, 1988, P NATL ACAD SCI USA, V85, P6192, DOI 10.1073/pnas.85.16.6192; SONG Y, 1990, NATURE, V348, P242, DOI 10.1038/348242a0; SONTHEIMER H, 1989, NEURON, V2, P1491, DOI 10.1016/0896-6273(89)90195-5; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; VAELLO ML, 1992, BIOCHEM BIOPH RES CO, V188, P813, DOI 10.1016/0006-291X(92)91129-E; VITORICA J, 1988, J NEUROSCI, V8, P615; WAGNER K, 1991, J BIOL CHEM, V266, P23784; WANG LY, 1993, SCIENCE, V259, P1173, DOI 10.1126/science.8382377	44	106	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2002	2008						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294452				2022-12-27	WOS:A1994MR98800070
J	GAN, ZR; LI, YP; CHEN, ZG; LEWIS, SD; SHAFER, JA				GAN, ZR; LI, YP; CHEN, ZG; LEWIS, SD; SHAFER, JA			IDENTIFICATION OF BASIC-AMINO-ACID RESIDUES IN THROMBIN ESSENTIAL FOR HEPARIN-CATALYZED INACTIVATION BY ANTITHROMBIN-III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; PRO-ARG CHLOROMETHYLKETONE; MOLECULAR-WEIGHT HEPARIN; HIGH-AFFINITY HEPARIN; FACTOR-XA; PROTEASE INACTIVATION; TRANSIENT KINETICS; CRYSTAL-STRUCTURE; BINDING; MECHANISM	The therapeutically important anticoagulant heparin catalyzes inactivation of thrombin by antithrombin III via formation of an intermediary ternary thrombin-heparin-antithrombin III complex that is subsequently converted to a stable thrombin-antithrombin III complex with the release of heparin. Point mutations at Arg-180, Arg-245, Lys-248, and Lys-252 in thrombin markedly reduced the efficiency of heparin catalysis by decreasing the stability of the ternary intermediate, whereas the inactivation of thrombin by antithrombin alone was not affected by these mutations. These results together with an analysis of the x-ray crystal structure of thrombin yielded a model for the thrombin-heparin interaction, wherein heparin forms salt linkages along a groove in thrombin defined by Lys-252, Lys-248, Arg-245, Arg-89, Arg-98, and Arg-180.	MERCK SHARP & DOHME LTD, DEPT BIOL CHEM, W POINT, PA 19486 USA	Merck & Company								BERESFORD CH, 1990, INT J BIOCHEM, V22, P121, DOI 10.1016/0020-711X(90)90172-Y; BJORK I, 1992, J BIOL CHEM, V267, P1976; BJORK I, 1989, HEPARIN CHEM BIOL PR, P229; BLOMBACK B, 1978, NATURE, V275, P501, DOI 10.1038/275501a0; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1992, PROTEIN SCI, V1, P426; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; Choay J, 1981, Ann N Y Acad Sci, V370, P644, DOI 10.1111/j.1749-6632.1981.tb29770.x; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; ESMON CT, 1986, ANN NY ACAD SCI, V485, P215, DOI 10.1111/j.1749-6632.1986.tb34583.x; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; GAN ZR, 1991, BIOCHEMISTRY-US, V30, P11694, DOI 10.1021/bi00114a013; GAN ZR, 1993, ARCH BIOCHEM BIOPHYS, V301, P228, DOI 10.1006/abbi.1993.1138; GRIFFITH MJ, 1983, P NATL ACAD SCI-BIOL, V80, P5460, DOI 10.1073/pnas.80.18.5460; HORNE A, 1992, BIOCHEMISTRY-US, V31, P2286, DOI 10.1021/bi00123a011; HOYER LW, 1981, J LAB CLIN MED, V97, P50; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; JORDAN RE, 1980, J BIOL CHEM, V255, P81; KISIEL W, 1979, J CLIN INVEST, V64, P761, DOI 10.1172/JCI109521; LAU HK, 1980, J BIOL CHEM, V255, P5885; NASKI MC, 1990, J BIOL CHEM, V265, P13484; NESHEIM ME, 1983, J BIOL CHEM, V258, P4708; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; OLSON ST, 1986, J BIOL CHEM, V261, P3151; OLSON ST, 1982, J BIOL CHEM, V257, P4891; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1991, J BIOL CHEM, V266, P6342; OLSON ST, 1981, J BIOL CHEM, V256, P1073; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1988, J BIOL CHEM, V263, P1698; OLSON ST, 1981, J BIOL CHEM, V256, P1065; POMERANTZ MW, 1978, BIOCHIM BIOPHYS ACTA, V535, P66, DOI 10.1016/0005-2795(78)90033-8; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; ROSENBERG RD, 1987, HEMOSTASIS THROMBOSI, P1373; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; SHAFER JA, 1988, CRIT REV CL LAB SCI, V26, P1; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2	41	127	127	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1301	1305						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288594				2022-12-27	WOS:A1994MR22000084
J	KHERA, PK; BLUMENTHAL, KM				KHERA, PK; BLUMENTHAL, KM			ROLE OF THE CATIONIC RESIDUES ARGININE-14 AND LYSINE-48 IN THE FUNCTION OF THE CARDIOTONIC POLYPEPTIDE ANTHOPLEURIN-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-ANEMONE TOXIN; NUCLEAR MAGNETIC-RESONANCE; RESISTANT NA+ CHANNELS; AMINO-ACID SEQUENCE; SECONDARY STRUCTURE; PHARMACOLOGICAL PROPERTIES; H-1-NMR ASSIGNMENTS; CARDIAC STIMULANT; AP-A; SULCATA	Polypeptide neurotoxins from sea anemones have been useful biological probes for sodium channel function. Cationic residues, specifically Arg-14, which is conserved in essentially all known sea anemone toxins, have been generally thought to be important determinants of their binding affinity and/or efficacy. In the present study, we have constructed site-directed mutants of the Anthopleura xanthogrammica toxin anthopleurin B (ApB) at Arg-14 and Lys-48 to characterize the roles played by these cationic residues in the biological activity of the toxin. Using a bacterial expression system developed in this laboratory, we have produced recombinant proteins having three substitutions at each of these positions. The proteins produced have been purified to homogeneity and have structures and conformational stabilities identical to wild-type ApB. We have assayed the mutants by determining their ability to enhance the veratridine-dependent uptake of sodium by both N1E-115 neuroblastoma cells and RT4-B cells, which express the cardiac/denervated skeletal muscle sodium channel. All mutants showed activities only slightly reduced from that of wild-type ApB, with the greatest reductions (4- and 6-fold) being observed for the mutants R14A and K48A, respectively. We conclude that contrary to results from chemical modification studies, Arg-14 is not essential for the biological activity of the toxin. Our data also indicate that Lys-48 plays a small but discernible role in the toxin-receptor interaction.	UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	University of Cincinnati					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041543] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-41543] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALSEN C, 1983, FED PROC, V42, P101; ALSEN C, 1976, N-S ARCH PHARMACOL, V295, P55, DOI 10.1007/BF00509773; BARHANIN J, 1981, J BIOL CHEM, V256, P5764; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARIELLO L, 1989, BIOCHEMISTRY-US, V28, P2484, DOI 10.1021/bi00432a020; CATTERALL WA, 1981, MOL PHARMACOL, V20, P533; CATTERALL WA, 1984, SCIENCE, V223, P653, DOI 10.1126/science.6320365; CATTERALL WA, 1977, J BIOL CHEM, V252, P8660; Cleland W W, 1979, Methods Enzymol, V63, P103; DONAHUE LM, 1991, DEV BIOL, V147, P415, DOI 10.1016/0012-1606(91)90299-I; FRELIN C, 1984, MOL PHARMACOL, V26, P70; GALLAGHER MJ, 1994, J BIOL CHEM, V269, P254; GALLAGHER MJ, 1992, J BIOL CHEM, V267, P13958; GOOLEY PR, 1986, BIOCHEMISTRY-US, V25, P2349, DOI 10.1021/bi00357a008; GOULD AR, 1990, EUR J BIOCHEM, V189, P145, DOI 10.1111/j.1432-1033.1990.tb15471.x; GROSS GJ, 1985, EUR J PHARMACOL, V110, P271, DOI 10.1016/0014-2999(85)90223-7; KOLKENBROCK HJ, 1983, 5TH P EUR S AN PLANT; MABBUTT BC, 1990, EUR J BIOCHEM, V187, P555, DOI 10.1111/j.1432-1033.1990.tb15337.x; MAHNIR VM, 1989, TOXICON, V27, P1075, DOI 10.1016/0041-0101(89)90001-9; NEWCOMB R, 1980, FRONTIERS PROTEIN CH, P539; NORTON RS, 1979, J BIOL CHEM, V254, P220; NORTON RS, 1991, TOXICON, V29, P1051, DOI 10.1016/0041-0101(91)90205-6; RAVENS U, 1976, N-S ARCH PHARMACOL, V296, P73, DOI 10.1007/BF00498842; REIMER NS, 1985, J BIOL CHEM, V260, P8690; RENAUD JF, 1986, EUR J PHARMACOL, V120, P161, DOI 10.1016/0014-2999(86)90536-4; ROMEY G, 1976, P NATL ACAD SCI USA, V73, P4055, DOI 10.1073/pnas.73.11.4055; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHWEITZ H, 1981, BIOCHEMISTRY-US, V20, P5245, DOI 10.1021/bi00521a023; SCRIABINE A, 1979, J CARDIOVASC PHARM, V1, P571, DOI 10.1097/00005344-197909000-00009; SHIBATA S, 1976, J PHARMACOL EXP THER, V199, P298; WIDMER H, 1988, EUR J BIOCHEM, V171, P177, DOI 10.1111/j.1432-1033.1988.tb13774.x; ZENG D, 1993, 1993 SOC NEUR ANN M	32	24	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					921	925						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288644				2022-12-27	WOS:A1994MR22000025
J	WENTHOLD, RJ; TRUMPY, VA; ZHU, WS; PETRALIA, RS				WENTHOLD, RJ; TRUMPY, VA; ZHU, WS; PETRALIA, RS			BIOCHEMICAL AND ASSEMBLY PROPERTIES OF GLUR6 AND KA2, 2 MEMBERS OF THE KAINATE RECEPTOR FAMILY, DETERMINED WITH SUBUNIT-SPECIFIC ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID BINDING-SITES; SELECTIVE GLUTAMATE RECEPTORS; HIGH-AFFINITY KAINATE; RAT-BRAIN; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; NERVOUS-SYSTEM; NMDA RECEPTOR; CHANNELS; AMPA	To examine subunit assembly and biochemical properties of two members of the kainate family of glutamate receptors (GluR), antibodies were made to synthetic peptides corresponding to the carboxyl termini of GluR6 and KA2. lmmunoblot analysis of membranes from human embryonic kidney cells transfected with glutamate receptor cDNAs showed that these antibodies are selective for their respective receptor subunit except that the antibody to GluR6 also recognizes GluR7, which is expected due to the sequence homology between the two subunits at the carboxyl terminus. In transfected cell membranes, immunoblot analysis with the antibody to GluR6 showed a major immunoreactive band at 118 kDa and minor bands at 103 and 28 kDa. The 103-kDa band appears to be a deglycosylated form of GluR6 since deglycosylation eliminates staining at 118 kDa and increases staining of the 103-kDa band. lmmunoblot analysis of KA2 transfected cell membranes shows a major band at 123 kDa and minor bands at 109 and 37 kDa. Deglycosylation converts the 123-kDa band into a 109-kDa. band. Analysis of brain tissues shows that both antibodies label single major bands which migrate at the same molecular masses as those from transfected cell membranes, 118 and 123 kDa for GluR6 and KA2, respectively. lmmunoprecipitation studies showed that antibodies to GluR6 and KA2 selectively immunoprecipitated [H-3]kainate binding activity, but not H-3-labeled alpha-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (AMPA) binding activity, from Triton X-100-solubilized rat brain membranes. Furthermore, each antibody co-immunoprecipitated GluR6 and KA2 from cells co-transfected with GluR6 and KA2 cDNAs and from detergent-solubilized rat brain membranes, indicating that these two subunits can coassemble into a molecular complex. Interestingly, GluR1 and GluR2, subunits of the AMPA receptor, also co-immunoprecipitated with GluR6 in cells co-transfected with GluR6 and GluR1 or GluR2 cDNAs. Such complexes appear to be present to a limited extent in the brain.			WENTHOLD, RJ (corresponding author), NIH,NATL INST DEAFNESS & COMMUN DIS,NEUROCHEM LAB,BLDG 36,RM 5D08,BETHESDA,MD 20892, USA.							BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; BETTLER B, 1992, NEURON, V8, P257, DOI 10.1016/0896-6273(92)90292-L; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; GASIC GP, 1992, ANNU REV PHYSIOL, V54, P507, DOI 10.1146/annurev.physiol.54.1.507; HAMPSON DR, 1987, J NEUROCHEM, V49, P1209, DOI 10.1111/j.1471-4159.1987.tb10012.x; HERB A, 1992, NEURON, V8, P775, DOI 10.1016/0896-6273(92)90098-X; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HUETTNER JE, 1990, NEURON, V5, P255, DOI 10.1016/0896-6273(90)90163-A; HUNTER C, 1990, J NEUROCHEM, V54, P118, DOI 10.1111/j.1471-4159.1990.tb13290.x; ISHII T, 1993, J BIOL CHEM, V268, P2836; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMELI H, 1992, FEBS LETT, V307, P139, DOI 10.1016/0014-5793(92)80753-4; MARTIN LJ, 1993, NEUROSCIENCE, V53, P327, DOI 10.1016/0306-4522(93)90199-P; MOLNAR E, 1993, NEUROSCIENCE, V53, P307, DOI 10.1016/0306-4522(93)90198-O; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MONAGHAN DT, 1986, NEUROCHEM RES, V11, P1073, DOI 10.1007/BF00965595; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; PATEL S, 1986, NEUROSCI LETT, V70, P301, DOI 10.1016/0304-3940(86)90569-0; PAULSON HL, 1991, J CELL BIOL, V113, P1371, DOI 10.1083/jcb.113.6.1371; PETRALIA RS, 1992, J COMP NEUROL, V318, P329, DOI 10.1002/cne.903180309; SAEDI MS, 1991, J CELL BIOL, V112, P1007, DOI 10.1083/jcb.112.5.1007; SAKIMURA K, 1992, NEURON, V8, P267, DOI 10.1016/0896-6273(92)90293-M; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SOMMER B, 1992, EMBO J, V11, P1651, DOI 10.1002/j.1460-2075.1992.tb05211.x; SOMMER B, 1992, TRENDS PHARMACOL SCI, V13, P291, DOI 10.1016/0165-6147(92)90088-N; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UNNERSTALL JR, 1983, EUR J PHARMACOL, V86, P361, DOI 10.1016/0014-2999(83)90185-1; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; WENTHOLD RJ, 1990, FEBS LETT, V276, P147, DOI 10.1016/0014-5793(90)80529-R; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0	37	106	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1332	1339						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288598				2022-12-27	WOS:A1994MR22000088
J	WOLINS, NE; DONALDSON, RP				WOLINS, NE; DONALDSON, RP			SPECIFIC BINDING OF THE PEROXISOMAL PROTEIN TARGETING SEQUENCE TO GLYOXYSOMAL MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-LOCALIZATION SEQUENCES; CASTOR-BEAN ENDOSPERM; ACYL-COA OXIDASE; ELECTRON-TRANSPORT; IMPORT RECEPTOR; SIGNAL; YEAST	It has been demonstrated that the carboxyl-terminal amino acid sequence, serine-lysine-leucine (SKL), is sufficient to direct a polypeptide to peroxisomes in vivo, and that this sequence is functional in plants, animals, and yeasts. Furthermore, many peroxisomal proteins have SKL carboxyl termini, including rat acyl-CoA oxidase. We have synthesized a I-125-peptide with the sequence of the last 12 amino acids of acyl-CoA oxidase, D-Tyr-HKHLKPLQSKL (SKLp), and used it to detect a receptor that recognizes SKL containing proteins targeted to glyoxysomes. SKLp binding to alkali-stripped glyoxysomal membranes was saturable and 80% of the binding could be displaced by 1 muM unlabeled SKLp or 8 mug/ml glyoxysomal matrix proteins. Very little specific binding was associated with endoplasmic reticulum or mitochondrial membranes. Specific binding was affected by the ionic composition of the medium; the binding was optimal at pH 6.5 and was inhibited by mono- and divalent cations. Scatchard analysis of SKLp binding to glyoxysomal membranes indicated that there were two binding sites with K(d) values of 160 and 1450 nM and abundances of 17 and 43 nmol/mg glyoxysomal membrane protein, respectively. Protease treatment of the alkali-stripped glyoxysomal membranes lowered the number of high affinity sites and destroyed all the low affinity sites. These results demonstrate, for the first time, that there is an integral membrane protein in glyoxysomes that has the characteristics of a receptor for protein import.	GEORGE WASHINGTON UNIV,DEPT BIOL SCI,WASHINGTON,DC 20052	George Washington University								ALANI AA, 1990, PLANT PHYSIOL, V94, P1842, DOI 10.1104/pp.94.4.1842; CHAPMAN KD, 1991, J CELL BIOL, V115, P995, DOI 10.1083/jcb.115.4.995; COOPER TG, 1969, J BIOL CHEM, V244, P3514; FANG TK, 1987, PLANTA, V172, P1, DOI 10.1007/BF00403023; FUJIKI Y, 1985, J BIOL CHEM, V260, P5603; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; KELLER GA, 1991, J CELL BIOL, V114, P893, DOI 10.1083/jcb.114.5.893; LUSTER DG, 1987, PLANT PHYSIOL, V85, P796, DOI 10.1104/pp.85.3.796; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; PFALLER R, 1987, EMBO J, V9, P2635; SANTOS MJ, 1988, J BIOL CHEM, V263, P10502; SILVER P, 1989, J CELL BIOL, V109, P983, DOI 10.1083/jcb.109.3.983; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; SPARACE SA, 1979, PLANT PHYSIOL, V63, P963, DOI 10.1104/pp.63.5.963; STOCHAJ U, 1992, J CELL BIOL, V117, P473, DOI 10.1083/jcb.117.3.473; SUBRAMANI S, 1992, J MEMBRANE BIOL, V125, P99; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; WALTON PA, 1992, MOL CELL BIOL, V12, P531, DOI 10.1128/MCB.12.2.531; WILSON DW, 1993, J BIOL CHEM, V268, P7465	20	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1149	1153						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288574				2022-12-27	WOS:A1994MR22000060
J	ETTINGER, RA; ISMAIL, R; DELUCA, HF				ETTINGER, RA; ISMAIL, R; DELUCA, HF			CDNA CLONING AND CHARACTERIZATION OF A VITAMIN-D(3) HYDROXYLASE-ASSOCIATED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-KIDNEY; 1,25-DIHYDROXYVITAMIN-D 24-HYDROXYLASE; SUBMITOCHONDRIAL LOCALIZATION; SUBCELLULAR-LOCALIZATION; ADRENAL-CORTEX; 25-HYDROXYCHOLECALCIFEROL; MITOCHONDRIA; METABOLISM; METHIONINE; ENZYMES	We previously reported the generation of monoclonal antibodies which immunoprecipitate a fraction of the total chick kidney 1,25-dihydroxyvitamin D3-24R-hydroxylase activity. These antibodies were used to screen a chick kidney lambdagt11 cDNA library resulting in the isolation of a full-length cDNA encoding a protein that is not the 1,25-dihydroxyvitamin D3-24R-hydroxylase but another protein we term the vitamin D3 hydroxylase-associated protein (VDHAP). The deduced amino acid sequence agreed with an NH2-terminal amino acid sequence from the isolated VDHAP. Gene and protein bank search did not identify homology to known sequences or functional domains in the VDHAP cDNA. VDHAP mRNA levels are not altered by conditions which either induce 1,25-dihydroxyvitamin D3-24R-hydroxylase activity (78-fold) or 25-hydroxyvitamin D3-1alpha-hydroxylase activity (30-fold). Northern analysis of poly(A)+ RNA from chick tissues revealed VDHAP only in kidney. Cellular fractionation experiments demonstrated that VDHAP and the 25-hydroxyvitamin D3-1alpha-hydroxylase are colocalized in the inner membrane of mitochondria. The VDHAP antibody immunoprecipitates 14% of the total 1,25-dihydroxyvitamin D3-24R-hydroxylase activity (7-fold over background) and immunoprecipitates 21% of the total 25-hydroxyvitamin D3-1alpha-hydroxylase activity (2-fold over background). VDHAP is a novel chick kidney-specific inner membrane protein of mitochondria, which associates with a fraction of the 1,25-dihydroxyvitamin D3-24R-hydroxylase and 25-hydroxyvitamin D3-1alpha-hydroxylase.	UNIV WISCONSIN, COLL AGR & LIFE SCI, DEPT BIOCHEM, 420 HENRY MALL, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison					NIDDK NIH HHS [DK-14881] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK014881] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM, 1992, CURRENT PROTOCOLS MO; BOISSEL JP, 1985, P NATL ACAD SCI USA, V82, P8448, DOI 10.1073/pnas.82.24.8448; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN AJ, 1987, ANAL BIOCHEM, V164, P424, DOI 10.1016/0003-2697(87)90514-8; BURGOSTRINIDAD M, 1990, ANAL BIOCHEM, V190, P102, DOI 10.1016/0003-2697(90)90141-U; BURGOSTRINIDAD M, 1992, J BIOL CHEM, V267, P3498; BURGOSTRINIDAD M, 1991, BIOCHIM BIOPHYS ACTA, V1078, P226, DOI 10.1016/0167-4838(91)90562-E; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CHEN KS, 1993, P NATL ACAD SCI USA, V90, P4543, DOI 10.1073/pnas.90.10.4543; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAME MC, 1986, BIOCHEMISTRY-US, V25, P4523, DOI 10.1021/bi00364a011; DeLuca HF, 1984, VITAMIN D BASIC CLIN, P1; DHANAKOTI SN, 1992, BIOCHEM J, V282, P369, DOI 10.1042/bj2820369; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; FRASER DR, 1970, NATURE, V228, P764, DOI 10.1038/228764a0; GARABEDIAN M, 1978, ENDOCRINOLOGY, V102, P1262, DOI 10.1210/endo-102-4-1262; GHAZARIAN JG, 1974, J BIOL CHEM, V49, P3026; GLOVER LA, 1992, BIOCHEM J, V284, P609, DOI 10.1042/bj2840609; GONZALEZ FJ, 1988, PHARMACOL REV, V40, P243; GRAY R, 1971, SCIENCE, V172, P1232, DOI 10.1126/science.172.3989.1232; GRAY RW, 1972, J BIOL CHEM, V247, P7528; GRIBSKOV M, 1988, COMPUT APPL BIOSCI, V4, P61; HARLOW E, 1988, ANTIBODIES LABORATOR; HART LE, 1984, J NUTR, V114, P2059, DOI 10.1093/jn/114.11.2059; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; KALRA J, 1974, J BIOL CHEM, V249, P3255; KNUTSON JC, 1974, BIOCHEMISTRY-US, V13, P1543, DOI 10.1021/bi00704a034; KOHN J, 1982, BIOCHEM BIOPH RES CO, V107, P878, DOI 10.1016/0006-291X(82)90604-0; KUMAR R, 1978, J BIOL CHEM, V253, P3804; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCHE JL, 1978, J AM CHEM SOC, V100, P2226, DOI 10.1021/ja00475a040; MITANI F, 1982, J HISTOCHEM CYTOCHEM, V30, P1066, DOI 10.1177/30.10.6813370; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; NEILANDS JB, 1955, METHOD ENZYMOL, V1, P449, DOI 10.1016/0076-6879(55)01074-4; NIMMOSMITH R, 1961, BIOCHIM BIOPHYS ACTA, V50, P166, DOI 10.1016/0006-3002(61)91074-5; OHYAMA Y, 1991, FEBS LETT, V278, P195, DOI 10.1016/0014-5793(91)80115-J; OHYAMA Y, 1991, J BIOL CHEM, V266, P8690; OKAMOTO Y, IN PRESS P SOC EXP B; OMDAHL J, 1971, BIOCHEMISTRY-US, V10, P2935, DOI 10.1021/bi00791a022; ORMEJOHNSON WH, 1969, J BIOL CHEM, V244, P6143; PFANNER N, 1987, J BIOL CHEM, V262, P14851; REEVE L, 1983, J BIOL CHEM, V258, P3615; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; SHINKI T, 1992, J BIOL CHEM, V267, P13757; SNOKE JE, 1956, J BIOL CHEM, V223, P271; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; SUGIYAMA T, 1975, FEBS LETT, V52, P145, DOI 10.1016/0014-5793(75)80658-2; TSUNASAWA S, 1985, J BIOL CHEM, V260, P5382; YAGO N, 1970, J BIOCHEM, V68, P775, DOI 10.1093/oxfordjournals.jbchem.a129414; YAN X, 1987, BIOCHEM CELL BIOL, V65, P673, DOI 10.1139/o87-089; YOSHIDA A, 1972, J BIOL CHEM, V247, P952; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	54	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					176	182						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276793				2022-12-27	WOS:A1994MR21900035
J	VANDEKLUNDERT, FAJM; JANSEN, HJ; BLOEMENDAL, H				VANDEKLUNDERT, FAJM; JANSEN, HJ; BLOEMENDAL, H			A PROXIMAL PROMOTER ELEMENT IN THE HAMSTER DESMIN UPSTREAM REGULATORY REGION IS RESPONSIBLE FOR ACTIVATION BY MYOGENIC DETERMINATION FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC ENHANCER; DNA-BINDING; SUBUNIT GENE; MYC HOMOLOGY; MYOD FAMILY; EXPRESSION; CELLS; TRANSCRIPTION; PROTEINS; DISTINCT	The muscle-specific intermediate filament protein desmin is up-regulated during skeletal muscle differentiation. When myoblasts leave the cell cycle and fusion into multinucleated myotubes starts, genes associated with myogenesis become activated. The activation is believed to be mediated by the muscle-specific determination factors. We present evidence that both MyoD and myogenin are able to activate the transcription of the hamster desmin gene. A proximal promoter fragment of 89 base pairs is sufficient for this transactivation process. The single E-box in this region is essential for desmin promoter activity in mouse C2 skeletal muscle cells and upon co-transfection of a myogenin expression vector also in human primary fibroblasts. Mutation of this MyoD binding site abrogates desmin transcription, and transactivation of the promoter no longer occurs. By using gel electrophoretic mobility shift assays, we were able to demonstrate that nuclear proteins from C2 muscle cells and myogenin/E12 glutathione S-transferase fusion proteins are able to bind to the functional E-box consensus sequence. A second E-box, situated in a more upstream regulatory region, which also binds to purified Helix-Loop-Helix proteins in vitro is only moderately affected by site-directed in vitro mutagenesis.			VANDEKLUNDERT, FAJM (corresponding author), CATHOLIC UNIV NIJMEGEN,FAC SCI,DEPT BIOCHEM,6500 HB NIJMEGEN,NETHERLANDS.			Jansen, Hans/0000-0002-8563-4146				BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOBER E, 1991, J CELL BIOL, V113, P1255, DOI 10.1083/jcb.113.6.1255; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CHOI J, 1990, P NATL ACAD SCI USA, V87, P7988, DOI 10.1073/pnas.87.20.7988; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; FINKEL T, 1993, J BIOL CHEM, V268, P5; FRENCH BA, 1991, MOL CELL BIOL, V11, P2439, DOI 10.1128/MCB.11.5.2439; FUJISAWASEHARA A, 1992, J BIOL CHEM, V267, P10031; GILMOUR BP, 1991, J BIOL CHEM, V266, P19871; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; KRIMPENFORT PJ, 1988, EMBO J, V7, P941, DOI 10.1002/j.1460-2075.1988.tb02899.x; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LI H, 1993, NUCLEIC ACIDS RES, V21, P335, DOI 10.1093/nar/21.2.335; LI ZL, 1991, J BIOL CHEM, V266, P6562; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAKATSUJI Y, 1992, MOL CELL BIOL, V12, P4384, DOI 10.1128/MCB.12.10.4384; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OTT MO, 1991, DEVELOPMENT, V111, P1097; PARI G, 1991, MOL CELL BIOL, V11, P4796, DOI 10.1128/MCB.11.9.4796; PIEPER FR, 1987, EMBO J, V6, P3611, DOI 10.1002/j.1460-2075.1987.tb02692.x; PIEPER FR, 1988, MOL BIOL REP, V13, P59, DOI 10.1007/BF00805640; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; PRODY CA, 1992, NUCLEIC ACIDS RES, V20, P2367, DOI 10.1093/nar/20.9.2367; QUAX W, 1984, P NATL ACAD SCI-BIOL, V81, P5970, DOI 10.1073/pnas.81.19.5970; QUAX W, 1985, CELL, V43, P327, DOI 10.1016/0092-8674(85)90038-8; RAMAEKERS FCS, 1983, AM J SURG PATHOL, V7, P381, DOI 10.1097/00000478-198306000-00010; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; Sambrook J, 1989, MOL CLONING LABORATO; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; VANDEKLUNDERT FAJM, 1992, GENE, V122, P337, DOI 10.1016/0378-1119(92)90223-C; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Wright WE, 1992, CURR OPIN GENET DEV, V2, P243, DOI 10.1016/S0959-437X(05)80280-1; YAFFE D, 1977, DIFFERENTIATION, V7, P159, DOI 10.1111/j.1432-0436.1977.tb01507.x; YUTZEY KE, 1992, NUCLEIC ACIDS RES, V20, P5105, DOI 10.1093/nar/20.19.5105	58	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					220	225						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276797				2022-12-27	WOS:A1994MR21900041
J	WANG, SY				WANG, SY			A RETINOIC ACID-INDUCIBLE GATA-BINDING PROTEIN BINDS TO THE REGULATORY REGION OF J6 SERPIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; MOUSE TERATOCARCINOMA CELLS; EMBRYONAL CARCINOMA-CELLS; 5' FLANKING REGION; RESPONSIVE ELEMENT; MESSENGER-RNA; CDNA CLONES; STEM-CELLS; DIFFERENTIAL EXPRESSION; ENDOTHELIAL-CELLS	Transcription of the J6 gene (a member of the serpin family) is induced in murine F9 teratocarcinoma cells 24-48 h after retinoic acid (RA) treatment. Previously, we have identified a region of the J6 5'-flanking region (-1050 to -738) that is involved in regulating transcription of this gene. In this report, we show that a RA-induced nuclear protein in the F9 cell extract recognizes the GAGATAG sequence which is repeated four times in this regulatory region of the J6 gene. The kinetics of RA induction of the GAGATAG-binding protein correlates with that of J6 mRNA, suggesting that the GAGATAG-binding protein may be involved in the transactivation of the J6 gene in RA-treated F9 cells. Competition experiments demonstrate further that the RA- induced GAGATAG-binding protein is related to the transcription factors GATA-1 and GATA-2. Furthermore, insertion of the RA regulatory region of the J6 gene into a thymidine kinase promotor/chloramphenicol acetyltransferase expression vector causes an increase in chloramphenicol acetyltransferase expression by 5-8-fold in human HeLa cells when co-transfected with human GATA-2 or GATA-3 expression vectors. This suggests that the J6 gene is likely to be transactivated by the GATA-2, GATA-3, or related transcription factor, which is activated by retinoic acid during F9 cell differentiation.			WANG, SY (corresponding author), SUNY ALBANY,DEPT BIOL SCI,ALBANY,NY 12222, USA.				NATIONAL CANCER INSTITUTE [R29CA044955] Funding Source: NIH RePORTER; NCI NIH HHS [R29CA44955] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; BRULET P, 1983, P NATL ACAD SCI-BIOL, V80, P5641, DOI 10.1073/pnas.80.18.5641; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CLARKE EP, 1991, J BIOL CHEM, V266, P17230; COLBERGPOLEY AM, 1985, NATURE, V314, P713, DOI 10.1038/314713a0; CROCE CM, 1981, P NATL ACAD SCI-BIOL, V78, P5754, DOI 10.1073/pnas.78.9.5754; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DUDLER R, 1984, CELL, V38, P391, DOI 10.1016/0092-8674(84)90494-X; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GALSON DL, 1988, MOL CELL BIOL, V8, P381, DOI 10.1128/MCB.8.1.381; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GUDAS LJ, 1990, ANN NY ACAD SCI, V580, P245, DOI 10.1111/j.1749-6632.1990.tb17933.x; HIRAYOSHI K, 1991, MOL CELL BIOL, V11, P4036, DOI 10.1128/MCB.11.8.4036; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; KURKINEN M, 1983, NUCLEIC ACIDS RES, V11, P6199, DOI 10.1093/nar/11.18.6199; LAROSA GJ, 1988, P NATL ACAD SCI USA, V85, P329, DOI 10.1073/pnas.85.2.329; LAROSA GJ, 1988, MOL CELL BIOL, V8, P3906, DOI 10.1128/MCB.8.9.3906; LEE ME, 1991, J BIOL CHEM, V266, P16188; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVINE RA, 1984, MOL CELL BIOL, V4, P2142, DOI 10.1128/MCB.4.10.2142; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARTIN CA, 1990, P NATL ACAD SCI USA, V87, P4804, DOI 10.1073/pnas.87.12.4804; MURPHY D, 1983, CELL, V35, P865, DOI 10.1016/0092-8674(83)90119-8; MURPHY SP, 1988, P NATL ACAD SCI USA, V85, P5587, DOI 10.1073/pnas.85.15.5587; NAGATA K, 1988, J BIOL CHEM, V263, P8344; NAGATA K, 1986, J CELL BIOL, V103, P223, DOI 10.1083/jcb.103.1.223; OSTAPCHUK P, 1986, P NATL ACAD SCI USA, V83, P8550, DOI 10.1073/pnas.83.22.8550; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; SCHIER AF, 1992, NATURE, V356, P804, DOI 10.1038/356804a0; SHERMAN MI, 1986, RETINOIDS CELL DIFFE; STACEY AJ, 1984, EMBO J, V3, P2279, DOI 10.1002/j.1460-2075.1984.tb02126.x; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SUMMERBELL D, 1990, TRENDS NEUROSCI, V13, P142, DOI 10.1016/0166-2236(90)90006-V; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; WANG SY, 1990, J BIOL CHEM, V265, P15818; WANG SY, 1985, DEV BIOL, V107, P75, DOI 10.1016/0012-1606(85)90377-X; WANG SY, 1992, J BIOL CHEM, V267, P15362; WANG SY, 1983, P NATL ACAD SCI-BIOL, V80, P5880, DOI 10.1073/pnas.80.19.5880; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; YANG YC, 1986, CELL, V47, P3, DOI 10.1016/0092-8674(86)90360-0; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	56	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					607	613						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276858				2022-12-27	WOS:A1994MR21900096
J	EISENSTEIN, RS; TUAZON, PT; SCHALINSKE, KL; ANDERSON, SA; TRAUGH, JA				EISENSTEIN, RS; TUAZON, PT; SCHALINSKE, KL; ANDERSON, SA; TRAUGH, JA			IRON-RESPONSIVE ELEMENT-BINDING PROTEIN - PHOSPHORYLATION BY PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRITIN MESSENGER-RNA; TRANSFERRIN RECEPTOR EXPRESSION; SULFUR CLUSTER; SUBSTRATE-SPECIFICITY; RABBIT RETICULOCYTES; CYTOSOLIC ACONITASE; REGULATORY PROTEIN; REPRESSOR PROTEIN; IRE-BP; TRANSLATION	The iron-responsive element-binding protein (IRE-BP) is a cytosolic RNA-binding protein that functions in the maintenance of iron homeostasis by post-transcriptionally regulating transferrin receptor and ferritin synthesis. Little is known concerning how factors other than iron may modulate the activity of this central regulator of cellular iron utilization. We present evidence indicating that phosphorylation of the IRE-BP by protein kinase C (PKC) could provide a mechanism for regulation of IRE-BP function. Purified rat liver IRE-BP was phosphorylated by PKC up to 1.3 mol of phosphate/mol of protein with Ser the modified amino acid. Ser was also the phosphoacceptor in the IRE-BP in intact cells. The K(m) of PKC for the IRE-BP was 0.4 muM. Tryptic phosphopeptide mapping identified one major phosphopeptide plus several other peptides with lesser amounts of phosphate. Synthetic peptides of the IRE-BP containing Ser 138 (site A) and Ser 711 (site B) were phosphorylated by PKC. In HL 60 cells, addition of phorbol 12-myristate 13-acetate (PMA) stimulated IRE-BP phosphorylation within 30 min and increased high affinity IRE RNA binding activity 2-fold. After 90 min, the level of phosphorylation had increased further, and high affinity IRE RNA binding activity had increased 3-fold above the control. Incorporation of [S-35]Met into immunoprecipitable IRE-BP was not altered in cells treated with PMA for 30 or 90 min. PMA also stimulated IRE-BP phosphorylation in rat fibroblasts. Taken together, our studies begin to define a novel mechanism by which hormones, growth factors, and other agents may regulate cellular iron utilization through specific phosphoregulation of the IRE-BP.	UNIV CALIF RIVERSIDE, DEPT BIOCHEM, RIVERSIDE, CA 92521 USA	University of California System; University of California Riverside	EISENSTEIN, RS (corresponding author), UNIV WISCONSIN, DEPT NUTR SCI, 1415 LINDEN DR, MADISON, WI 53706 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026738] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26738] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS ML, 1989, BIOCHIM BIOPHYS ACTA, V1012, P243, DOI 10.1016/0167-4889(89)90104-3; ANDREESEN R, 1984, BLUT, V49, P195, DOI 10.1007/BF00319822; BARTON HA, 1990, J BIOL CHEM, V265, P7000; BETTANY AJE, 1992, J BIOL CHEM, V267, P16531; BOMFORD AB, 1985, HEPATOLOGY, V5, P870, DOI 10.1002/hep.1840050528; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHAN LNL, 1992, J BIOL CHEM, V267, P8254; CHOU CC, 1986, MOL CELL BIOL, V6, P566, DOI 10.1128/MCB.6.2.566; CONSTABLE A, 1992, P NATL ACAD SCI USA, V89, P4554, DOI 10.1073/pnas.89.10.4554; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; DAVIS RJ, 1987, J BIOL CHEM, V262, P6832; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; EMERYGOODMAN A, 1993, NUCLEIC ACIDS RES, V21, P1457, DOI 10.1093/nar/21.6.1457; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GOESSLING LS, 1992, SCIENCE, V256, P670, DOI 10.1126/science.1316633; GOOSSEN B, 1990, EMBO J, V9, P4127, DOI 10.1002/j.1460-2075.1990.tb07635.x; HAILE DJ, 1989, MOL CELL BIOL, V9, P5055, DOI 10.1128/MCB.9.11.5055; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; Hathaway G M, 1979, Methods Enzymol, V60, P495; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HENTZE MW, 1991, NUCLEIC ACIDS RES, V19, P1739, DOI 10.1093/nar/19.8.1739; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HIRLING H, 1992, NUCLEIC ACIDS RES, V20, P33, DOI 10.1093/nar/20.1.33; HO PTC, 1989, CANCER RES, V49, P1989; HOUSE C, 1987, J BIOL CHEM, V262, P772; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; KAPTAIN S, 1991, P NATL ACAD SCI USA, V88, P10109, DOI 10.1073/pnas.88.22.10109; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KONIJN AM, 1981, BRIT J HAEMATOL, V49, P361, DOI 10.1111/j.1365-2141.1981.tb07238.x; Krebs EG, 1986, ENZYMES, V17, P3, DOI 10.1016/S1874-6047(08)60426-6; KUMAGAI N, 1987, J IMMUNOL, V139, P1391; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARRICK JW, 1979, J SUPRAMOL STR CELL, V11, P579, DOI 10.1002/jss.400110415; LAUBLE H, 1992, BIOCHEMISTRY-US, V31, P2735, DOI 10.1021/bi00125a014; LEIBOLD EA, 1992, ANNU REV NUTR, V12, P345, DOI 10.1146/annurev.nu.12.070192.002021; MELEFORS O, 1993, J BIOL CHEM, V268, P5974; MISKIMINS WK, 1986, J CELL BIOL, V103, P1781, DOI 10.1083/jcb.103.5.1781; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MUNRO HN, 1992, NUTRITION GENE EXPRE, P525; NEMANI R, 1989, J BIOL CHEM, V264, P15361; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PALEN E, 1987, J BIOL CHEM, V262, P3518; PALEN E, 1990, FEBS LETT, V274, P12, DOI 10.1016/0014-5793(90)81317-H; PALEN E, 1991, BIOCHEMISTRY-US, V30, P5586, DOI 10.1021/bi00236a035; PATINO MM, 1992, J BIOL CHEM, V267, P19011; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PHILPOTT CC, 1991, NUCLEIC ACIDS RES, V19, P6333, DOI 10.1093/nar/19.22.6333; PRODROMOU C, 1992, EUR J BIOCHEM, V204, P599, DOI 10.1111/j.1432-1033.1992.tb16673.x; ROGERS JT, 1990, J BIOL CHEM, V265, P14572; ROUAULT TA, 1992, BIOMETALS, V5, P131, DOI 10.1007/BF01061319; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; ROUAULT TA, 1990, P NATL ACAD SCI USA, V87, P7958, DOI 10.1073/pnas.87.20.7958; Schmitz M L, 1991, Trends Cell Biol, V1, P130, DOI 10.1016/0962-8924(91)90118-S; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; TAHARA SM, 1981, J BIOL CHEM, V256, P1558; TANG CK, 1992, J BIOL CHEM, V267, P24466; TEIXEIRA S, 1991, EUR J BIOCHEM, V202, P819, DOI 10.1111/j.1432-1033.1991.tb16438.x; TESTA U, 1989, J BIOL CHEM, V264, P13181; TESTA U, 1991, J BIOL CHEM, V266, P13925; THEIL EC, 1990, J BIOL CHEM, V265, P4771; TUAZON PT, 1989, J BIOL CHEM, V264, P2773; UMPHRESS JL, 1992, EUR J BIOCHEM, V203, P239, DOI 10.1111/j.1432-1033.1992.tb19852.x; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; VENEMA RC, 1991, J BIOL CHEM, V266, P5298; VINCENT JB, 1990, FASEB J, V4, P3009, DOI 10.1096/fasebj.4.12.2394317; YU Y, 1992, J BIOL CHEM, V267, P19005; ZHENG LM, 1992, ARCH BIOCHEM BIOPHYS, V299, P356, DOI 10.1016/0003-9861(92)90287-7; ZHENG LM, 1990, J BIOL CHEM, V265, P2814	75	116	117	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27363	27370						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262977				2022-12-27	WOS:A1993MM26200076
J	FUNK, CD; FURCI, L; FITZGERALD, GA; GRYGORCZYK, R; ROCHETTE, C; BAYNE, MA; ABRAMOVITZ, M; ADAM, M; METTERS, KM				FUNK, CD; FURCI, L; FITZGERALD, GA; GRYGORCZYK, R; ROCHETTE, C; BAYNE, MA; ABRAMOVITZ, M; ADAM, M; METTERS, KM			CLONING AND EXPRESSION OF A CDNA FOR THE HUMAN PROSTAGLANDIN-E RECEPTOR-EP(1) SUBTYPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG; SMOOTH-MUSCLE; CELL-LINE; AGONIST; PROTEIN	A functional cDNA clone coding for the human prostaglandin E receptor EP1 subtype has been isolated from a human erythroleukemia cell cDNA library probed by low-stringency hybridization using a polymerase chain reaction fragment of the human thromboxane receptor. The human EP1 receptor is comprised of 402 amino acids with a predicted molecular mass of 41,858 and has the topography common to all G-protein-coupled receptors with seven predicted transmembrane spanning domains. Prostaglandin (PG) E2 challenge of Xenopus oocytes injected with EP1 cDNA resulted in an increase in intracellular Ca2+. In addition, the rank order of potency for prostaglandins in competition for [H-3]PGE2 specific binding to membranes prepared from EP1 cDNA transfected COS cells was PGE2 > PGE1 > PGF2alpha > PGD2. Furthermore, the EP1 receptor-selective antagonists AH 6809 and SC19220 were more potent than the EP2 receptor-selective agonist butaprost in these competition binding assays. In summary, therefore, we have cloned the human EP1 receptor subtype which is functionally coupled to an increase in intracellular Ca2+.	MERCK FROST CTR THERAPEUT RES,DEPT PHARMACOL,POB 1005,POINTE CLAIRE,DORVAL H9R 4P8,PQ,CANADA; MERCK FROSST CTR THERAPEUT RES,DEPT MOLEC BIOL,DORVAL H9R 4P8,PQ,CANADA; VANDERBILT UNIV,MED CTR,SCH MED,DIV CLIN PHARMACOL,NASHVILLE,TN 37232	Merck & Company; Vanderbilt University			FitzGerald, Garret A/A-4222-2010; Funk, Colin D/A-9518-2010; Furci, Lucinda/I-8752-2012	Grygorczyk, Ryszard/0000-0002-9798-7651; Funk, Colin/0000-0001-7029-4233	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL002710, R01HL030400] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02710, HL30400] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BUNCE KT, 1987, GASTROENTEROLOGY, V92, P1332; Campbell W. B., 1990, PHARMACOL BASIS THER, P600; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN RA, 1985, PROSTAGLANDINS, V29, P363, DOI 10.1016/0090-6980(85)90096-6; COLEMAN RA, 1990, COMPREHENSIVE MED CH, V3, P643; Coleman RA, 1985, BRIT J PHARMACOL, V85, P273; Colman A., 1984, TRANSCRIPTION TRANSL, P49; DONG YJ, 1986, BRIT J PHARMACOL, V87, P97, DOI 10.1111/j.1476-5381.1986.tb10161.x; EGLEN RM, 1988, BRIT J PHARMACOL, V94, P591, DOI 10.1111/j.1476-5381.1988.tb11565.x; EHRENPREIS S, 1973, NATURE-NEW BIOL, V245, P280, DOI 10.1038/newbio245280a0; FREY EA, 1993, EUR J PHARM-MOLEC PH, V244, P239, DOI 10.1016/0922-4106(93)90149-4; GARDINER PJ, 1986, BRIT J PHARMACOL, V87, P45, DOI 10.1111/j.1476-5381.1986.tb10155.x; GILADI E, 1991, BIOTECHNIQUES, V10, P744; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HEDGVIST P, 1972, NEUROPHARMACOLOGY, V11, P177; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HONDA A, 1993, J BIOL CHEM, V268, P7759; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAWRENCE RA, 1992, BRIT J PHARMACOL, V105, P817, DOI 10.1111/j.1476-5381.1992.tb09063.x; LAWRENCE RA, 1992, BRIT J PHARMACOL, V105, P271, DOI 10.1111/j.1476-5381.1992.tb14245.x; LOUTTIT JB, 1992, 8TH INT C PROST REL; MCKENNIFF M, 1988, EUR J PHARMACOL, V153, P149, DOI 10.1016/0014-2999(88)90601-2; Sambrook J, 1989, MOL CLONING LABORATO; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641; TABILIO A, 1984, EMBO J, V3, P453, DOI 10.1002/j.1460-2075.1984.tb01827.x; WATABE A, 1993, J BIOL CHEM, V268, P20175; WATANABE T, 1991, BLOOD, V78, P2328	31	275	303	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26767	26772						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253813				2022-12-27	WOS:A1993MK42500110
J	GUM, JR; HICKS, JW; TORIBARA, NW; SIDDIKI, B; KIM, YS				GUM, JR; HICKS, JW; TORIBARA, NW; SIDDIKI, B; KIM, YS			MOLECULAR-CLONING OF HUMAN INTESTINAL MUCIN (MUC2) CDNA - IDENTIFICATION OF THE AMINO-TERMINUS AND OVERALL SEQUENCE SIMILARITY TO PREPRO-VON-WILLEBRAND FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON-CANCER METASTASIS; VON-WILLEBRAND FACTOR; SEA-URCHIN EMBRYOS; MESSENGER-RNAS; REPEATED DOMAINS; GLYCOPROTEINS; GENE; GLYCOSYLATION; PROTEIN; CELLS	Secretory mucins consist of a protein backbone that is catenated by disulfide bonds, heavily O-glycosylated, and packaged into storage granules prior to release from cells. In this paper, we identify and sequence cDNAs that encode the amino terminus of the MUC2 protein, a major form of mucin found in human intestines and airways. The protein sequence was found to contain a repetitive element of approximately 350 amino acids with considerable sequence similarity to the D domains of prepro-von Willebrand factor. A total of four of these D domains were found to be present in the MUC2 protein, three in the amino-terminal region, and one in the carboxyl-terminal region. Prepro-von Willebrand factor contains four D domains itself, and the overall positioning of the D domains in the two proteins is similar. Pre-pro-von Willebrand factor contains a 741 residue proprotein that has been implicated in both the disulfide-linked oligomerization of von Willebrand factor and its packaging into secretory vacuoles. A similar region is present in the MUC2 amino terminus sequence, suggesting that the mechanisms involved in the polymerization and packaging of MUC2 may parallel those already described for von Willebrand factor.	UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	GUM, JR (corresponding author), DEPT VET AFFAIRS MED CTR, GASTROINTESTINAL RES LAB 151M2, SAN FRANCISCO, CA 94121 USA.							ALLEN A, 1981, PHYSL GASTROINTESTIN, P627; BHARGAVA AK, 1990, P NATL ACAD SCI USA, V87, P6798, DOI 10.1073/pnas.87.17.6798; BONTHRON DT, 1986, NATURE, V324, P270, DOI 10.1038/324270a0; BRESALIER RS, 1991, J CLIN INVEST, V87, P1037, DOI 10.1172/JCI115063; BYRD JC, 1988, CANCER RES, V48, P6678; CONG NV, 1990, HUM GENET, V86, P167; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DEKKER J, 1991, BIOCHEM J, V277, P423, DOI 10.1042/bj2770423; DEKKER J, 1990, J BIOL CHEM, V265, P18116; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; GREEN F, 1987, GENE, V57, P101, DOI 10.1016/0378-1119(87)90181-8; GRIFFITHS B, 1990, ANN HUM GENET, V54, P277, DOI 10.1111/j.1469-1809.1990.tb00383.x; GUM JR, 1989, J BIOL CHEM, V264, P6480; GUM JR, 1992, AM J RESP CELL MOL, V7, P557, DOI 10.1165/ajrcmb/7.6.557; GUM JR, 1992, J BIOL CHEM, V267, P21375; HARDING SE, 1989, ADV CARBOHYD CHEM BI, V47, P345; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOFFMANN W, 1993, COMP BIOCHEM PHYS B, V105, P465, DOI 10.1016/0305-0491(93)90075-G; HOLMGREN A, 1984, METHOD ENZYMOL, V107, P295; JANY BH, 1991, J CLIN INVEST, V87, P77, DOI 10.1172/JCI115004; JOURNET AM, 1993, EUR J CELL BIOL, V60, P31; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LYNN DA, 1983, P NATL ACAD SCI-BIOL, V80, P2656, DOI 10.1073/pnas.80.9.2656; MAYADAS TN, 1991, ANN NY ACAD SCI, V614, P153, DOI 10.1111/j.1749-6632.1991.tb43700.x; MAYADAS TN, 1992, P NATL ACAD SCI USA, V89, P3531, DOI 10.1073/pnas.89.8.3531; MAYADAS TN, 1989, J BIOL CHEM, V264, P13497; Neutra M.R., 1987, PHYSL GASTROINTESTIN, V2, P975; PROBST JC, 1990, BIOCHEMISTRY-US, V29, P6240, DOI 10.1021/bi00478a018; ROSE MC, 1992, AM J PHYSIOL, V263, pL413, DOI 10.1152/ajplung.1992.263.4.L413; RUGGERI ZM, 1991, MAYO CLIN PROC, V66, P847, DOI 10.1016/S0025-6196(12)61204-X; SADLER JE, 1991, J BIOL CHEM, V266, P22777; SCHWARTZ B, 1992, INT J CANCER, V52, P60, DOI 10.1002/ijc.2910520113; SHELTONINLOES BB, 1986, BIOCHEMISTRY-US, V25, P3164, DOI 10.1021/bi00359a014; SHELTONINLOES BB, 1987, BIOCHEM BIOPH RES CO, V144, P657, DOI 10.1016/S0006-291X(87)80016-5; SHOGREN RL, 1986, BIOPOLYMERS, V25, P1505, DOI 10.1002/bip.360250809; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; THORNTON DJ, 1991, BIOCHEM J, V276, P667, DOI 10.1042/bj2760667; THORNTON DJ, 1990, BIOCHEM J, V265, P179, DOI 10.1042/bj2650179; TORIBARA NW, 1991, J CLIN INVEST, V88, P1005, DOI 10.1172/JCI115360; TSAI HSH, 1993, EUR J GASTROEN HEPAT, V5, P214, DOI 10.1097/00042737-199304000-00005; TYTGAT KM, 1993, EUR J GASTROEN HEPAT, V5, P119, DOI 10.1097/00042737-199303000-00001; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WAGNER DD, 1986, J CELL BIOL, V102, P1320, DOI 10.1083/jcb.102.4.1320; WAGNER DD, 1991, CELL, V64, P403, DOI 10.1016/0092-8674(91)90648-I; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; WISE RJ, 1988, CELL, V52, P229, DOI 10.1016/0092-8674(88)90511-9; XU GQ, 1992, J BIOL CHEM, V267, P5401; Yang H., 1992, ICASSP-92: 1992 IEEE International Conference on Acoustics, Speech and Signal Processing (Cat. No.92CH3103-9), P17, DOI 10.1109/ICASSP.1992.226287; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	49	396	402	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2440	2446						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300571				2022-12-27	WOS:A1994MV43200018
J	MCLEAN, BG; GREENE, EA; ZAMBRYSKI, PC				MCLEAN, BG; GREENE, EA; ZAMBRYSKI, PC			MUTANTS OF AGROBACTERIUM VIRA THAT ACTIVATE VIR GENE-EXPRESSION IN THE ABSENCE OF THE INDUCER ACETOSYRINGONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMEFACIENS VIRULENCE GENES; T-DNA TRANSFER; TRANSCRIPTIONAL ACTIVATOR; SIGNAL TRANSDUCTION; ESCHERICHIA-COLI; BINDING-PROTEIN; OMPR; PHOSPHORYLATION; OSMOREGULATION; MECHANISM	In the presence of inducer molecules produced by wounded plants, the VirA/VirG two-component positive regulatory system of Agrobacterium tumefaciens initiates transcription of virulence genes required for crown gall tumor formation. Exactly how this system enables the bacterium to respond to an environmental signal is not known, but phosphorylation of VirA and VirG plays a role. To analyze further the function of VirA, we chemically mutagenized the virA gene. Two mutants that activate vir transcription without the plant inducer acetosyringone were found; these mutants alter VirA function by distinct mechanisms. One mutant functions entirely independently of acetosyringone, whereas the activity of the second mutant is enhanced by acetosyringone. Both mutants function best at acid pH, but respond differently to specific monosaccharides that stimulate induction by wild-type VirA. Both mutant phenotypes are dominant over wild-type VirA, and both need the conserved histidine at the autophosphorylation site for strong inducer-independent vir transcription.	UNIV CALIF BERKELEY,DEPT PLANT BIOL,111 KOSHLAND HALL,BERKELEY,CA 94720	University of California System; University of California Berkeley					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014124] Funding Source: NIH RePORTER; NIGMS NIH HHS [F-32-GM14124] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIBA H, 1989, J BIOL CHEM, V264, P14090; ALBRIGHT LM, 1989, ANNU REV GENET, V23, P311, DOI 10.1146/annurev.ge.23.120189.001523; ANKENBAUER RG, 1990, J BACTERIOL, V172, P6442, DOI 10.1128/jb.172.11.6442-6446.1990; ANKENBAUER RG, 1991, MOL PLANT MICROBE IN, V4, P400, DOI 10.1094/MPMI-4-400; AOYAMA T, 1990, FEBS LETT, V263, P1, DOI 10.1016/0014-5793(90)80691-B; BINNS AN, 1988, ANNU REV MICROBIOL, V42, P575, DOI 10.1146/annurev.mi.42.100188.003043; CANGELOSI GA, 1990, P NATL ACAD SCI USA, V87, P6708, DOI 10.1073/pnas.87.17.6708; CHANG CH, 1992, J BACTERIOL, V174, P7033, DOI 10.1128/JB.174.21.7033-7039.1992; HAN DC, 1992, J BACTERIOL, V174, P7040, DOI 10.1128/JB.174.21.7040-7043.1992; HESS KM, 1991, P NATL ACAD SCI USA, V88, P7854, DOI 10.1073/pnas.88.17.7854; HUANG MW, 1990, J BACTERIOL, V172, P1814, DOI 10.1128/jb.172.4.1814-1822.1990; HUANG Y, 1990, J BACTERIOL, V172, P1142, DOI 10.1128/jb.172.2.1142-1144.1990; JIN SG, 1993, MOL MICROBIOL, V7, P555, DOI 10.1111/j.1365-2958.1993.tb01146.x; JIN SG, 1990, J BACTERIOL, V172, P4945, DOI 10.1128/jb.172.9.4945-4950.1990; JIN SG, 1990, J BACTERIOL, V172, P525, DOI 10.1128/jb.172.2.525-530.1990; JIN SG, 1990, J BACTERIOL, V172, P531, DOI 10.1128/jb.172.2.531-537.1990; JOUANIN L, 1985, MOL GEN GENET, V201, P370, DOI 10.1007/BF00331325; KANAMARU K, 1989, J BIOL CHEM, V264, P21633; KNAUF VC, 1982, PLASMID, V8, P45, DOI 10.1016/0147-619X(82)90040-3; LEE KH, 1992, P NATL ACAD SCI USA, V89, P8666, DOI 10.1073/pnas.89.18.8666; LEROUX B, 1987, EMBO J, V6, P849, DOI 10.1002/j.1460-2075.1987.tb04830.x; MELCHERS LS, 1989, EMBO J, V8, P1919, DOI 10.1002/j.1460-2075.1989.tb03595.x; MYERS RM, 1985, SCIENCE, V229, P242, DOI 10.1126/science.2990046; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PAZOUR GJ, 1990, J BACTERIOL, V172, P1241, DOI 10.1128/jb.172.3.1241-1249.1990; PAZOUR GJ, 1992, J BACTERIOL, V174, P4169, DOI 10.1128/jb.174.12.4169-4174.1992; PAZOUR GJ, 1990, NUCLEIC ACIDS RES, V18, P6909, DOI 10.1093/nar/18.23.6909; PAZOUR GJ, 1991, P NATL ACAD SCI USA, V88, P6941, DOI 10.1073/pnas.88.16.6941; POWELL BS, 1990, MOL MICROBIOL, V4, P2159, DOI 10.1111/j.1365-2958.1990.tb00577.x; ROITSCH T, 1990, J BACTERIOL, V172, P6054, DOI 10.1128/jb.172.10.6054-6060.1990; RUSSO FD, 1991, J MOL BIOL, V222, P567, DOI 10.1016/0022-2836(91)90497-T; SHIMODA N, 1990, P NATL ACAD SCI USA, V87, P6684, DOI 10.1073/pnas.87.17.6684; STACHEL SE, 1986, P NATL ACAD SCI USA, V83, P379, DOI 10.1073/pnas.83.2.379; STACHEL SE, 1985, NATURE, V318, P624, DOI 10.1038/318624a0; STACHEL SE, 1986, CELL, V46, P325, DOI 10.1016/0092-8674(86)90653-7; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; WINANS SC, 1989, J BACTERIOL, V171, P1616, DOI 10.1128/jb.171.3.1616-1622.1989; WINANS SC, 1986, P NATL ACAD SCI USA, V83, P8278, DOI 10.1073/pnas.83.21.8278; WINANS SC, 1992, MICROBIOL REV, V56, P12, DOI 10.1128/MMBR.56.1.12-31.1992; WINANS SC, 1988, J BACTERIOL, V170, P4047, DOI 10.1128/jb.170.9.4047-4054.1988; WOLFE AJ, 1993, P NATL ACAD SCI USA, V90, P1518, DOI 10.1073/pnas.90.4.1518; YANG Y, 1993, J MOL BIOL, V231, P335, DOI 10.1006/jmbi.1993.1286; ZAMBRYSKI PC, 1992, ANNU REV PLANT PHYS, V43, P465, DOI 10.1146/annurev.pp.43.060192.002341	43	29	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2645	2651						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300595				2022-12-27	WOS:A1994MV43200046
J	PANSEGRAU, W; SCHRODER, W; LANKA, E				PANSEGRAU, W; SCHRODER, W; LANKA, E			CONCERTED ACTION OF 3 DISTINCT DOMAINS IN THE DNA CLEAVING-JOINING REACTION CATALYZED BY RELAXASE (TRAI) OF CONJUGATIVE PLASMID-RP4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TRANSFER ORIGIN; AGROBACTERIUM-TUMEFACIENS; DIRECTED MUTAGENESIS; NUCLEOTIDE-SEQUENCE; NICK REGIONS; T-DNA; PROTEIN; RP4; TRANSFORMATION	The TraI protein of plasmid RP4 (IncPalpha) catalyzes a site- and strand-specific cleaving-joining reaction on form I or single-stranded DNA. Thus, TraI is one of the key components involved in the initiation and termination of horizontal DNA transfer by bacterial conjugation. Amino acid sequence comparison revealed three motifs in the TraI sequence conserved in relaxases from different origins. Site-directed mutagenesis of the traI structural gene and application of purified mutant TraI proteins for in vitro assays served to evaluate the functional importance of conserved amino acid residues. Two regions of TraI designated as motifs I and III are involved in catalyzing the cleaving-joining reaction. Motif I carries the tyrosine residue (Tyr-22), which covalently attaches TraI in a transesterification reaction to the 5' terminus of the cleaved DNA. Motif III contains one histidine residue (His-116) essential for relaxase activity and therefore proposed to activate the aromatic hydroxyl group of tyrosine 22 by proton abstraction. Exchange of a serine residue (Ser-74), located in motif II, against alanine prevents formation of stable relaxosomes but strongly enhances topoisomerase activity of the combination TraI/TraJ on form I oriT DNA. Motif II therefore might represent the DNA recognition domain of TraI. Our studies allowed us to establish a model of the interplay of three motifs located in the N-terminal region (amino acid positions 19-124) of TraI.	MAX PLANCK INST MOLEC GENET, ABT SCHUSTER, IHNESTR 73, D-14195 BERLIN, GERMANY; FREE UNIV BERLIN, INST BIOCHEM, D-14195 BERLIN, GERMANY	Max Planck Society; Free University of Berlin								ARGOS P, 1988, NUCLEIC ACIDS RES, V16, P9909, DOI 10.1093/nar/16.21.9909; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; BRENNER DG, 1985, EMBO J, V4, P561, DOI 10.1002/j.1460-2075.1985.tb03665.x; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; FERSHT AR, 1984, ENZYME STRUCTURE MEC, P405; FURSTE JP, 1989, P NATL ACAD SCI USA, V86, P1771, DOI 10.1073/pnas.86.6.1771; FURUYA N, 1991, J BACTERIOL, V173, P2231, DOI 10.1128/JB.173.7.2231-2237.1991; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HIRAYAMA T, 1988, MOL GEN GENET, V213, P229, DOI 10.1007/BF00339586; ILYINA TV, 1992, NUCLEIC ACIDS RES, V20, P3279, DOI 10.1093/nar/20.13.3279; IPPENIHLER KA, 1986, ANNU REV GENET, V20, P593, DOI 10.1146/annurev.ge.20.120186.003113; JAYASWAL RK, 1987, J BACTERIOL, V169, P5035, DOI 10.1128/jb.169.11.5035-5045.1987; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KOONIN EV, 1993, BIOSYSTEMS, V30, P241, DOI 10.1016/0303-2647(93)90074-M; LEE J, 1992, J MOL BIOL, V228, P1091, DOI 10.1016/0022-2836(92)90317-D; MENDIOLA MV, 1992, NUCLEIC ACIDS RES, V20, P3521, DOI 10.1093/nar/20.13.3521; Miller J. H., 1972, EXPT MOL GENETICS, P433; PANSEGRAU W, 1990, J BIOL CHEM, V265, P10637; PANSEGRAU W, 1993, P NATL ACAD SCI USA, V90, P11538, DOI 10.1073/pnas.90.24.11538; PANSEGRAU W, 1993, P NATL ACAD SCI USA, V90, P2925, DOI 10.1073/pnas.90.7.2925; PANSEGRAU W, 1990, P NATL ACAD SCI USA, V87, P6555, DOI 10.1073/pnas.87.17.6555; PANSEGRAU W, 1991, NUCLEIC ACIDS RES, V19, P3455, DOI 10.1093/nar/19.12.3455; PROJAN SJ, 1988, NUCLEIC ACIDS RES, V16, P2179, DOI 10.1093/nar/16.5.2179; ROHRER J, 1992, J BACTERIOL, V174, P6230, DOI 10.1128/JB.174.19.6230-6237.1992; Roychoudhury R, 1980, Methods Enzymol, V65, P43; Sambrook J, 1989, MOL CLONING LABORATO; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; VANMANSFELD ADM, 1986, NUCLEIC ACIDS RES, V14, P4229, DOI 10.1093/nar/14.10.4229; VANMANSFELD ADM, 1980, NATURE, V288, P561, DOI 10.1038/288561a0; VOGEL AM, 1992, J BACTERIOL, V174, P303, DOI 10.1128/jb.174.1.303-308.1992; WANG K, 1990, J BACTERIOL, V172, P4432, DOI 10.1128/jb.172.8.4432-4440.1990; WANG PZ, 1993, EMBO J, V12, P45, DOI 10.1002/j.1460-2075.1993.tb05630.x; WATERS VL, 1991, P NATL ACAD SCI USA, V88, P1456, DOI 10.1073/pnas.88.4.1456; Wilkins B, 1993, BACTERIAL CONJUGATIO, P105; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZIEGELIN G, 1989, J BIOL CHEM, V264, P11989; Ziegelin G, 1991, DNA Seq, V1, P303, DOI 10.3109/10425179109020786; ZIEGELIN G, 1992, J BIOL CHEM, V267, P17279; ZIEGELIN G, 1989, THESIS FREIE U BERLI	39	88	88	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2782	2789						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300611				2022-12-27	WOS:A1994MV43200064
J	SLUNT, HH; THINAKARAN, G; VONKOCH, C; LO, ACY; TANZI, RE; SISODIA, SS				SLUNT, HH; THINAKARAN, G; VONKOCH, C; LO, ACY; TANZI, RE; SISODIA, SS			EXPRESSION OF A UBIQUITOUS, CROSS-REACTIVE HOMOLOG OF THE MOUSE BETA-AMYLOID PRECURSOR PROTEIN (APP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; IDENTIFICATION; PEPTIDE; CELLS; CDNA	Alzheimer's disease is characterized by the presence of senile plaques comprised primarily of deposits of the beta-amyloid protein (Abeta) derived from larger amyloid precursor proteins (APP). We have identified a cDNA that encodes a 751-amino acid APP-like protein (designated APLP2) from the mouse that, with exception of the Abeta region, is highly homologous to APP. In situ hybridization and quantitative polymerase chain reaction reveal that APLP2 and APP mRNA are expressed in similar, if not identical, neuronal populations and at similar levels. APLP2 appears to mature through the same unusual secretory/cleavage pathway as APP. Furthermore, widely utilized antibodies generated against non-overlapping epitopes of APP do not discriminate between APP and APLP2. Although APLP2 cannot give rise to Abeta, its near identity to APP outside the Abeta domain confounds the interpretation of previous immunocytochemical and biochemical characterizations of APP biosynthesis and metabolism.	JOHNS HOPKINS UNIV,SCH MED,NEUROPATHOL LAB,558 ROSS RES BLDG,720 RUTLAND AVE,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Harvard University; Harvard Medical School			Tanzi, Rudolph/AAE-9622-2019; Lo, Amy C. Y./C-1195-2009	Tanzi, Rudolph/0000-0002-7032-1454; Lo, Amy C. Y./0000-0003-4239-6851	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS020471, P01NS020471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005146] Funding Source: NIH RePORTER; NIA NIH HHS [AG 05146] Funding Source: Medline; NINDS NIH HHS [NS 20471] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AUSUBELFM, 1987, CURRENT PROTOCOLS MO; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DESTROOPER B, 1991, BIOCHIM BIOPHYS ACTA, V1129, P141, DOI 10.1016/0167-4781(91)90231-A; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Goedert M, 1991, Curr Opin Neurobiol, V1, P441, DOI 10.1016/0959-4388(91)90067-H; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kim K., 1988, NEUROSCI RES COMMUN, V2, P121; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; MARTIN LJ, 1991, P NATL ACAD SCI USA, V88, P1461, DOI 10.1073/pnas.88.4.1461; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; RIDGWAY ND, 1992, J CELL BIOL, V116, P307, DOI 10.1083/jcb.116.2.307; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SISODIA SS, 1993, J NEUROSCI, V13, P3136; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SPRECHER CA, 1993, BIOCHEMISTRY-US, V32, P4481, DOI 10.1021/bi00068a002; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VIDAL F, 1992, BIOCHEM BIOPH RES CO, V189, P1336, DOI 10.1016/0006-291X(92)90220-F; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Wisniewski HM, 1973, PROGR NEUROPATHOLOGY, V2, P1; YAN YC, 1990, P NATL ACAD SCI USA, V87, P2405, DOI 10.1073/pnas.87.7.2405	34	307	311	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2637	2644						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300594				2022-12-27	WOS:A1994MV43200045
J	CIFUENTES, ME; DELANEY, T; REBECCHI, MJ				CIFUENTES, ME; DELANEY, T; REBECCHI, MJ			D-MYO-INOSITOL 1,4,5-TRISPHOSPHATE INHIBITS BINDING OF PHOSPHOLIPASE C-DELTA(1) TO BILAYER-MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; BACILLUS-CEREUS; STEREOCHEMICAL MECHANISM; G-PROTEINS; C-GAMMA; STIMULATION; PHOSPHORUS; ACTIVATION; SUBSTRATE; INVITRO	The binding of phosphoinositide-specific phospholipase C-delta1 (PLC-delta1) to bilayer membranes composed of phosphatidylcholine (PC) and phosphatidylinositol 4,5-bisphosphate (PIP2) was measured in the presence or absence of inositol phosphates. Binding was inhibited by the natural D-isomer of myo-inositol 1,4,5-trisphosphate (D-InsP3), but not by the L-isomer. The concentration Of D-InsP3 required to decrease binding by 50% was 5.4 +/- 0.5 muM. 1-(alpha-Glycerophosphoryl)-D-myo-inositol 4,5-bisphosphate and D-myo-inositol 2,4,5-trisphosphate were nearly as effective as D-Ins(1,4,5)P3. D-myo-inositol monophosphate with phosphate esterified at either positions 1 or 2 of the myo-inositol ring, had no significant effect on binding. D-myo-inositol 1,4-bisphosphate weakly inhibited the binding, whereas the 4,5-isomer was nearly as potent as D-InsP3. Neither ATP nor inorganic phosphate significantly affected binding. As expected, D-Ins(1,4,5)P3 but not L-Ins(1,4,5)P3 decreased the initial rate Of PIP2 hydrolysis in bilayer vesicles. The concentration required to decrease hydrolysis by 50% was 12.4 +/- 0.5 muM. A catalytic fragment of PLC-delta1 that lacks a domain necessary for high affinity PIP2 binding was prepared as previously described (Cifuentes, M. E., Honkanen, L., and Rebecchi, M. J. (1993) J. Biol. Chem. 268, 11586-11593). In contrast to the native enzyme, the rate Of PIP2 hydrolysis, catalyzed by the fragment, was not affected by D-Ins(1,4,5)P3. These data suggest that high affinity binding of the enzyme to PIP and processive catalysis, involve specific recognition of the 4- and 5-position phosphates of the inositol ring. Our results are consistent with feedback inhibition by the polar head group product, D-Ins(1,4,5)P3, at a step that precedes catalysis, namely interfacial recognition.	SUNY STONY BROOK, DEPT PHYSIOL & BIOPHYS, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook				Cifuentes-Pagano, Eugenia/0000-0002-2482-080X	NIGMS NIH HHS [GM-43422] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043422, R01GM043422] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRUZIK KS, 1992, BIOCHEMISTRY-US, V31, P5183, DOI 10.1021/bi00137a014; CHILVERS ER, 1990, BRIT J PHARMACOL, V99, P297, DOI 10.1111/j.1476-5381.1990.tb14698.x; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; CRUZRIVERA M, 1990, BIOCHIM BIOPHYS ACTA, V1042, P113, DOI 10.1016/0005-2760(90)90064-5; GRIFFITH OH, 1991, METHOD ENZYMOL, V197, P493; JAIN MK, 1989, BIOCHIM BIOPHYS ACTA, V1002, P127, DOI 10.1016/0005-2760(89)90281-6; KIM JW, 1990, J BIOL CHEM, V265, P3940; LEIGH AJ, 1992, BIOCHEMISTRY-US, V31, P8978, DOI 10.1021/bi00152a039; LIN G, 1990, BIOCHEMISTRY-US, V29, P2747, DOI 10.1021/bi00463a018; LUTTRELL BM, 1993, J BIOL CHEM, V268, P1521; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; PAWELCZYK T, 1993, BIOCHEM J, V291, P693, DOI 10.1042/bj2910693; POLOKOFF MA, 1988, J BIOL CHEM, V263, P11922; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; REBECCHI MJ, 1987, J BIOL CHEM, V262, P12526; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; WAHL MI, 1992, J BIOL CHEM, V267, P10447	21	99	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1945	1948						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294445				2022-12-27	WOS:A1994MR98800061
J	CREMERS, FPM; ARMSTRONG, SA; SEABRA, MC; BROWN, MS; GOLDSTEIN, JL				CREMERS, FPM; ARMSTRONG, SA; SEABRA, MC; BROWN, MS; GOLDSTEIN, JL			REP-2, A RAB ESCORT PROTEIN ENCODED BY THE CHOROIDEREMIA-LIKE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERANYLGERANYL TRANSFERASE; BINDING; CLONING; ENZYME; FAMILY; YPT1	Rab escort proteins (REPs) bind to newly synthesized Rab proteins and remain bound during and after the attachment of a geranylgeranyl (GG) group by the catalytic component of the Rab GG transferase. Transfer of the GG group is absolutely dependent on the participation of a REP. REP-1, the first characterized REP, is produced by a gene on the X chromosome that is defective in patients with choroideremia, a form of retinal degeneration. Cremers et al. (Cremers, F. P. M., Molloy, C. M., van de Pol, D. J. R., van den Hurk, J. A. J. M., Bach, I., Geurts van Kessel, A. H. M., and Ropers, H.-H. (1992) Hum. Mol. Genet. 1, 71-75) isolated a related gene designated choroideremia-like, which encodes a protein that closely resembles REP-1. In the current studies, we produced REP-1 and REP-2 by recombinant DNA methods and showed that both proteins were approximately equal in facilitating the attachment of GG groups to several Rab proteins, including Rab1A, Rab5A, and Rab6. However, REP-2 was only 25% as active as REP-1 in supporting GG attachment to Rab3A and Rab3D. The low activity toward Rab3A was increased to that of Rab1A when the COOH-terminal 12 amino acids of Rab3A were replaced with the corresponding residues of Rab1A. We suggest that REP-2 substitutes for the absent function of REP-1 in nonretinal cells of patients with choroideremia, thus preventing cellular dysfunction throughout the body. In the retina, REP-2 may be only partially effective, leading eventually to retinal degeneration and blindness.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,5323 HARRY HINES BLVD,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Seabra, Miguel C/M-3280-2013; Cremers, Frans/A-5625-2014; Seabra, Miguel/AAC-3099-2019	Seabra, Miguel C/0000-0002-6404-4892; Cremers, Frans/0000-0002-4954-5592; 	NHLBI NIH HHS [HL20948] Funding Source: Medline; NIGMS NIH HHS [GM08014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; CREMERS FPM, 1990, NATURE, V347, P674, DOI 10.1038/347674a0; Cremers Frans P. M., 1992, Human Molecular Genetics, V1, P71, DOI 10.1093/hmg/1.2.71; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; Glomset J. A., 1991, CURR OPIN LIPIDOL, V2, P118; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GROEBE DR, 1990, NUCLEIC ACIDS RES, V18, P4033, DOI 10.1093/nar/18.13.4033; GUAN K, 1992, ANAL BIOCHEM, V192, P262; Heckenlively JR, 1988, RETINITIS PIGMENTOSA, P176; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MERRY DE, 1992, P NATL ACAD SCI USA, V89, P2135, DOI 10.1073/pnas.89.6.2135; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; ROSSI G, 1991, NATURE, V351, P158, DOI 10.1038/351158a0; Sambrook J, 1989, MOL CLONING LABORATO; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	30	161	167	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2111	2117						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294464				2022-12-27	WOS:A1994MR98800085
J	MATOZAKI, T; SUZUKI, T; UCHIDA, T; INAZAWA, J; ARIYAMA, T; MATSUDA, K; HORITA, K; NOGUCHI, H; MIZUNO, H; SAKAMOTO, C; KASUGA, M				MATOZAKI, T; SUZUKI, T; UCHIDA, T; INAZAWA, J; ARIYAMA, T; MATSUDA, K; HORITA, K; NOGUCHI, H; MIZUNO, H; SAKAMOTO, C; KASUGA, M			MOLECULAR-CLONING OF A HUMAN TRANSMEMBRANE-TYPE PROTEIN-TYROSINE-PHOSPHATASE AND ITS EXPRESSION IN GASTROINTESTINAL CANCERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GASTRIC-CANCER; LEUKOCYTE-COMMON ANTIGEN; HUMAN-COLON CARCINOMA; P53 GENE-MUTATIONS; SIGNAL TRANSDUCTION; KINASE-ACTIVITY; FAMILY; ASSIGNMENT; SEQUENCE; MEMBER	To determine the expression of various protein-tyrosine phosphatases (PTPs) in human gastric cancers, cDNAs encoding conserved PTP domains were amplified by reverse transcriptase polymerase chain reaction from KATO-III cell mRNA and sequenced. Among 72 polymerase chain reaction clones, one of the cDNA sequences encoded a novel potential PTP (stomach cancer-associated PTP, SAP-I). The full length (3.9 kilo-bases) of the SAP-I cDNA was further isolated from the KATO-III cell cDNA library and the WiDr cell cDNA library. The predicted amino acid sequence of the SAP-1 cDNA showed that mature SAP-1 consisted of 1093 amino acids and a transmembrane-type PTP, which possessed a single PTP-conserved domain in the cytoplasmic region. The extracellular region of SAP-1 consisted of eight fibronectin type III-like structure repeats and contained multiple N-glycosylation sites. These data suggest that SAP-1 is structurally similar to HPTPbeta and that SAP-1 and HPTPbeta represent a subfamily of transmembrane-type PTPs. SAP-1 was mainly expressed in brain and liver and at a lower level in heart and stomach as a 4.2-kilobase mRNA, but it was not detected in pancreas or colon. In contrast, among cancer cell lines tested, SAP-1 was highly expressed in pancreatic and colorectal cancer cells. The bacterially expressed SAP-1 fusion protein had tyrosine-specific phosphatase activity. Immunoblotting with anti-SAP-1 antibody showed that SAP-1 is a 200-kDa protein. In addition, transient transfection of SAP-1 cDNA to COS cells resulted in the predominant expression of a 200-kDa protein recognized by anti-SAP-1 antibody. SAP-1 is mapped to chromosome 19 region q13.4 and might be related to carcinoembryonic antigen mapped to 19q13.2.	KYOTO PREFECTURAL UNIV MED,DEPT HYG,KAMIGYO KU,KYOTO 602,JAPAN	Kyoto Prefectural University of Medicine	MATOZAKI, T (corresponding author), KOBE UNIV,SCH MED,SCH MED,DEPT INTERNAL MED 2,KUSUNOKI CHO,CHUO KU,KOBE 650,JAPAN.							ADACHI M, 1992, CANCER RES, V52, P737; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BAKER SJ, 1990, CANCER RES, V50, P7717; BOLEN JB, 1987, ONCOGENE RES, V1, P149; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FISHER EH, 1991, SCIENCE, V253, P401; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9978; HANAFUSA H, 1987, ONCOGENES GROWTH CON, P100; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HIROHASHI S, 1991, CANCER CELL-MON REV, V3, P49; INAZAWA J, 1989, CYTOGENET CELL GENET, V52, P28, DOI 10.1159/000132833; INAZAWA J, 1991, GENOMICS, V10, P1075, DOI 10.1016/0888-7543(91)90202-P; KAMEDA T, 1990, CANCER RES, V50, P8002; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; MATOZAKI T, 1992, CANCER RES, V52, P4335; MATOZAKI T, 1992, BIOCHEM BIOPH RES CO, V182, P215, DOI 10.1016/S0006-291X(05)80133-0; NISHI M, 1991, CANCER GENET CYTOGEN, V54, P77, DOI 10.1016/0165-4608(91)90033-Q; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; Sambrook J, 1989, MOL CLONING LABORATO, P545; SANO T, 1991, CANCER RES, V51, P2936; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; TAKESHIMA E, 1991, JPN J CANCER RES, V82, P1428, DOI 10.1111/j.1349-7006.1991.tb01816.x; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; TROWBRIDGE IS, 1991, J BIOL CHEM, V266, P23517; UCHIDA T, 1993, J BIOL CHEM, V268, P11845; UCHIDA T, 1992, BIOCHEM BIOPH RES CO, V187, P332, DOI 10.1016/S0006-291X(05)81497-4; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VIGEGASPEQUIGNO.E, 1978, ANN GENET, V21, P122; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YAMANISHI K, 1992, J BIOL CHEM, V267, P17858; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4; YI T, 1991, BLOOD, V78, P222; ZANKE B, 1992, EUR J IMMUNOL, V22, P235, DOI 10.1002/eji.1830220134; ZENG XM, 1992, NATURE, V359, P336	49	68	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2075	2081						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294459				2022-12-27	WOS:A1994MR98800080
J	MCINTYRE, GF; GODBOLD, GD; ERICKSON, AH				MCINTYRE, GF; GODBOLD, GD; ERICKSON, AH			THE PH-DEPENDENT MEMBRANE ASSOCIATION OF PROCATHEPSIN-L IS MEDIATED BY A 9-RESIDUE SEQUENCE WITHIN THE PROPEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCES; MOUSE CATHEPSIN-D; DICTYOSTELIUM-DISCOIDEUM; HEPG2 CELLS; YEAST; PROTEINASE; NUCLEOTIDE; LYSOSOMES; CLONING; CDNA	The lysosomal proprotease procathepsin L binds to mouse fibroblast microsomal membranes at pH 5, but mature active cathepsin L does not (McIntyre, G. F., and Erickson, A. H. (1991) J. Biol. Chem. 266, 15438-15445). This binding is not dependent on N-linked carbohydrate as procathepsin L synthesized in cells treated with tunicamycin still shows pH-dependent membrane association. These results suggest that the propeptide (Thr18-Lys113) of the cysteine protease mediates its pH-dependent membrane association. Synthetic peptides containing either 24 or 9 residues from the N-terminal portion of the mouse procathepsin L propeptide inhibited the binding of mouse procathepsin L to microsomal membranes at pH 5. In contrast, the pH-dependent membrane association was not inhibited either by a scrambled version of the 24-residue peptide, in which 3 adjacent residues likely to be positively charged at pH 5 were dispersed, or by a second control peptide containing the 11 N-terminal residues from mature mouse cathepsin L. The 24-residue peptide chemically coupled to horseradish peroxidase bound to microsomes at pH 5, but not at pH 7. On ligand blots, the same conjugate bound specifically to a 43-kDa integral membrane protein, identifying the microsomal protein that mediates the proenzyme binding. The 9-residue propeptide sequence that inhibits the membrane association of procathepsin L at pH 5 resembles the vacuolar sorting sequences in the propeptides of yeast proteinase A and carboxypeptidase Y. This suggests that the membrane association of procathepsin L may play a role in the transport of the proenzyme to lysosomes, the vacuolar equivalent in mammalian cells.	UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill								AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; BURGE V, 1991, BIOCHEM J, V275, P797, DOI 10.1042/bj2750797; CARDELLI JA, 1986, J CELL BIOL, V102, P1264, DOI 10.1083/jcb.102.4.1264; CHAN SJ, 1986, P NATL ACAD SCI USA, V83, P7721, DOI 10.1073/pnas.83.20.7721; DIEDRICH JF, 1990, NUCLEIC ACIDS RES, V18, P7184, DOI 10.1093/nar/18.23.7184; DIMENT S, 1988, J BIOL CHEM, V263, P6901; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GAL S, 1988, BIOCHEM J, V253, P303, DOI 10.1042/bj2530303; GRUSBY MJ, 1990, NUCLEIC ACIDS RES, V18, P4008, DOI 10.1093/nar/18.13.4008; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; JOSEPH LJ, 1988, J CLIN INVEST, V81, P1621, DOI 10.1172/JCI113497; KARRER KM, 1993, P NATL ACAD SCI USA, V90, P3063, DOI 10.1073/pnas.90.7.3063; KING TP, 1978, BIOCHEMISTRY-US, V17, P1499, DOI 10.1021/bi00601a022; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KLIONSKY DJ, 1992, J BIOL CHEM, V267, P3416; LACOSTE CH, 1992, J BIOL CHEM, V267, P5942; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCINTYRE GF, 1991, J BIOL CHEM, V266, P15438; MCINTYRE GF, 1993, IN PRESS P NATL ACAD; MIERENDORF RC, 1985, J CELL BIOL, V100, P1777, DOI 10.1083/jcb.100.5.1777; PORTNOY DA, 1986, J BIOL CHEM, V261, P4697; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P4862; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P23586; SEEMAN P, 1967, J CELL BIOL, V32, P55, DOI 10.1083/jcb.32.1.55; TKACZ JS, 1975, BIOCHEM BIOPH RES CO, V65, P248, DOI 10.1016/S0006-291X(75)80086-6; VALLS LA, 1990, J CELL BIOL, V111, P361, DOI 10.1083/jcb.111.2.361; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7	29	77	78	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					567	572						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276852				2022-12-27	WOS:A1994MR21900090
J	RINALDICARMONA, M; PRABONNAUD, V; BOUABOULA, M; POINOTCHAZEL, C; CASELLAS, P; LEFUR, G; HERBERT, JM				RINALDICARMONA, M; PRABONNAUD, V; BOUABOULA, M; POINOTCHAZEL, C; CASELLAS, P; LEFUR, G; HERBERT, JM			REGULATION OF 5-HYDROXYTRYPTAMINE(2) (5-HT(2)) RECEPTOR EXPRESSION IN CULTURED RAT AORTIC SMOOTH-MUSCLE CELLS BY SR-46349B, A SELECTIVE 5-HT(2) RECEPTOR ANTAGONIST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; SEROTONIN BINDING-SITES; RAPID DESENSITIZATION; DOWN-REGULATION; AGONIST; CORTEX; BRAIN; HYDROLYSIS; RITANSERIN; LIGAND	Regulation of 5-hydroxytryptamine (5-HT2) receptor expression by SR 46349B, a potent and selective 5-HT2 receptor antagonist, was investigated in cultured rat aortic smooth muscle cells. Binding of [H-3]SR 46349B to rat vascular smooth muscle cells was time-dependent, reversible, and saturable. [H-3]SR 46349B bound to one class of specific binding sites with high affinity (K(D) = 1.3 +/- 0.3 nm; B(max) = 176 +/- 42 fmol/10(5) cells). Exposure of cells to a 1 muM concentration of the 5-HT2 agonist (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane ((+/-)-DOI) or the antagonist ketanserin led to a significant decrease in 5-HT2 receptor density as measured by [H-3]SR 46349B binding. In contrast, exposure of cells to 1 muM SR 46349B caused a marked increase in the maximal binding capacity of [H-3]SR 46349B, with a maximal effect at 24 h (73% increase). The affinity constant was not affected by prior exposure to (+/-)-DOI, ketanserin, or SR 46349B. Furthermore, exposure of cells to 1 muM (+/-)-DOI or ketanserin produced, 48 h later, a decrease in the ability of (+/-)-DOI to stimulate phosphoinositide turnover in the cells, whereas treatment with SR 46349B induced a significant stimulation of the 5-HT2 receptor-linked signal transduction. This effect occurred with no changes in the amount of 5-HT2 receptor mRNAs as measured by quantitative polymerase chain reaction. These results indicate that SR 46349B increases 5-HT2 receptor binding and functions without altering steady-state 5-HT2 mRNA levels in cultured rat aortic smooth muscle cells.	SANOFI RECH,195 ROUTE ESPAGNE,F-31036 TOULOUSE,FRANCE; SANOFI RECH,F-34184 MONTPELLIER 04,FRANCE	Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France								ANDREE TH, 1986, J NEUROCHEM, V46, P191, DOI 10.1111/j.1471-4159.1986.tb12944.x; BALL SG, 1985, J CARDIOVASC PHARM, V7, P120; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BLACKSHEAR MA, 1983, N-S ARCH PHARMACOL, V324, P125, DOI 10.1007/BF00497017; BLACKSHEAR MA, 1986, NEUROPHARMACOLOGY, V25, P1267, DOI 10.1016/0028-3908(86)90146-2; BOUABOULA M, 1992, J BIOL CHEM, V267, P21830; BUCKHOLTZ NS, 1988, LIFE SCI, V42, P2439, DOI 10.1016/0024-3205(88)90342-6; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; GOODWIN GM, 1984, BRIT J PHARMACOL, V83, P235, DOI 10.1111/j.1476-5381.1984.tb10140.x; HADCOCK JR, 1991, TRENDS NEUROSCI, V14, P242, DOI 10.1016/0166-2236(91)90124-D; IVINS KJ, 1991, J PHARMACOL EXP THER, V259, P423; JACOBS S, 1975, BIOCHEM BIOPH RES CO, V66, P687, DOI 10.1016/0006-291X(75)90564-1; JAZAYERI A, 1989, EUR J PHARMACOL, V169, P183, DOI 10.1016/0014-2999(89)90832-7; LEYSEN JE, 1989, EUR J PHARMACOL, V163, P145, DOI 10.1016/0014-2999(89)90409-3; LEYSEN JE, 1986, PSYCHOPHARMACOLOGY, V88, P434, DOI 10.1007/BF00178504; MCKENNA DJ, 1989, NEUROPSYCHOPHARMACOL, V2, P81, DOI 10.1016/0893-133X(89)90010-9; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY LD, 1990, BIOCHEMISTRY-US, V29, P10351, DOI 10.1021/bi00497a009; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; PAUL R, 1987, THROMB RES, V46, P793, DOI 10.1016/0049-3848(87)90071-5; PAUWELS PJ, 1988, NEUROCHEM INT, V13, P409, DOI 10.1016/0197-0186(88)90016-2; PAUWELS PJ, 1990, LIFE SCI, V47, P2009, DOI 10.1016/0024-3205(90)90435-T; PEROUTKA SJ, 1980, SCIENCE, V210, P88, DOI 10.1126/science.6251550; PRANZATELLI MR, 1991, BIOCHEM PHARMACOL, V42, P1099, DOI 10.1016/0006-2952(91)90294-F; PRITCHETT DB, 1988, EMBO J, V7, P4135, DOI 10.1002/j.1460-2075.1988.tb03308.x; RINALDICARMONA M, 1992, J PHARMACOL EXP THER, V262, P759; RINALDICARMONA M, 1993, MOL PHARMACOL, V43, P84; RINALDICARMONA M, 1993, EUR J PHARM-MOLEC PH, V246, P73, DOI 10.1016/0922-4106(93)90012-X; ROTH B, 1992, BIOL PSYCHIAT, V31, pA110; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; TWIST EC, 1990, BIOCHEM PHARMACOL, V39, P161, DOI 10.1016/0006-2952(90)90660-D	32	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					396	401						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276825				2022-12-27	WOS:A1994MR21900067
J	BAEK, KJ; DAS, T; GRAY, C; ANTAR, S; MURUGESAN, G; IM, MJ				BAEK, KJ; DAS, T; GRAY, C; ANTAR, S; MURUGESAN, G; IM, MJ			EVIDENCE THAT THE G(H) PROTEIN IS A SIGNAL MEDIATOR FROM ALPHA(1)-ADRENOCEPTOR TO A PHOSPHOLIPASE-C .1. IDENTIFICATION OF ALPHA(1)-ADRENOCEPTOR-COUPLED G(H) FAMILY AND PURIFICATION OF G(H7) FROM BOVINE HEART	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1-ADRENERGIC RECEPTOR SUBTYPES; MOLECULAR-CLONING; ALPHA-SUBUNITS; ADRENERGIC-RECEPTOR; BINDING-PROTEINS; CDNA; EXPRESSION; ACTIVATION; RECONSTITUTION; MEMBRANE	Our previous studies on alpha1-adrenoceptor-mediated signaling suggested that G(h) is a signal mediator. G(h) consists of a 74-kDa GTP-binding alpha-subunit and a 50-kDa beta-subunit. Studies using the alpha1-agonist-receptor-G-protein ternary complexes from various tissues and species revealed that the intensity (GTP-binding) of the [alpha-P-32]GTP-labeled proteins resulting from activating the alpha1-receptor was significantly attenuated by phentolamine. The molecular masses of GTP-binding proteins were 74 kDa in rat heart and liver, 77 kDa in dog heart, 78 kDa (G(h7alpha)) in bovine heart and liver, and 80 kDa in human heart. Supporting these observations, a specific antibody to G(h7alpha) not only recognized these GTP-binding proteins in the ternary complex preparations, but also co-immunoprecipitated alpha1-adrenoceptors, indicating a tight association of these GTP-binding proteins with the alpha1-adrenoceptor. These results also demonstrate that functional and structural similarities exist among these GTP-binding proteins. Additionally, one of the identified G-proteins (termed G(h7)) was purified from bovine heart. G(h7) consisted of the 78-kDa GTP-binding protein and a 50-kDa protein.	CLEVELAND CLIN FDN,RES INST,DEPT CARDIOVASC BIOL,FFB1-37,9500 EUCLID AVE,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NIGMS NIH HHS [GM45985] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045985] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEK KJ, 1993, J BIOL CHEM, V268, P27398; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; DOLHMAN H, 1991, ANN REV BIOCH, V60, P653; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HARRIS BA, 1985, SCIENCE, V229, P1274, DOI 10.1126/science.3839937; IM MJ, 1990, J BIOL CHEM, V265, P18952; IM MJ, 1990, J BIOL CHEM, V265, P18944; IM MJ, 1992, J BIOL CHEM, V267, P8887; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMASNEY JW, 1991, J BIOL CHEM, V266, P6365; LOMASNEY JW, 1990, P NATL ACAD SCI USA, V87, P5094, DOI 10.1073/pnas.87.13.5094; MAY DC, 1988, BIOCHEMISTRY-US, V27, P4888, DOI 10.1021/bi00413a045; MINNEMAN KP, 1988, PHARMACOL REV, V40, P87; MINNEMAN KP, 1988, MOL PHARMACOL, V33, P509; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; PEREZ DM, 1991, MOL PHARMACOL, V40, P876; PFEUFFER T, 1988, CURR TOP CELL REGUL, V29, P129; PRPIC V, 1984, J BIOL CHEM, V259, P1382; SCHWINN DA, 1990, J BIOL CHEM, V265, P8183; UHING RJ, 1986, J BIOL CHEM, V261, P2140; VOIGT MM, 1990, NUCLEIC ACIDS RES, V18, P1053, DOI 10.1093/nar/18.4.1053; WU DQ, 1992, J BIOL CHEM, V267, P25798; WU DQ, 1992, J BIOL CHEM, V267, P1811	26	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27390	27397						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262980				2022-12-27	WOS:A1993MM26200079
J	CAO, X; ROSS, FP; ZHANG, LM; MACDONALD, PN; CHAPPEL, J; TEITELBAUM, SL				CAO, X; ROSS, FP; ZHANG, LM; MACDONALD, PN; CHAPPEL, J; TEITELBAUM, SL			CLONING OF THE PROMOTER FOR THE AVIAN INTEGRIN BETA(3) SUBUNIT GENE AND ITS REGULATION BY 1,25-DIHYDROXYVITAMIN-D-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN INTESTINAL RECEPTOR; RETINOIC ACID; RESPONSE ELEMENTS; OSTEOCALCIN GENE; THYROID-HORMONE; CELL-ADHESION; EXPRESSION; IDENTIFICATION; DIFFERENTIATION; BINDING	We have cloned the promoter of the avian beta3 integrin gene. Using a probe comprising the 5'-untranslated region of an avian macrophage beta3 cDNA, characterized by 5' rapid amplification of cDNA ends, several clones were isolated from an avian genomic library. One major and one minor transcriptional start site were identified at +1 and -47 base pairs, respectively, with the latter coinciding with a consensus sequence of an initiator. DNA sequence analysis of 800 base pairs 5' of the transcriptional start site fails to reveal either a TATA or CAAT box. In addition to an initiator, the first 200 base pairs contain consensus sequences for the binding of AP-1 and SP-1. A 3.5-kilobase fragment located immediately upstream of the transcriptional start site exhibits functional promoter activity, and deletion analysis reveals both suppressor and enhancer elements. In light of our observation that 1,25-dihydroxyvitamin D3 (D3) accelerates beta3 transcription, we determined whether the avian beta3 promoter contains a vitamin D response element (VDRE). Transfected reporter constructs containing the first 1.5 kilobases upstream of the major beta3 transcriptional start site respond to D3 with enhanced luciferase activity. Analysis of this region reveals a classical VDRE consensus sequence, located at -756 to -770. The following observations support the hypothesis that this sequence represents a functional VDRE: 1) a 600-base pair genomic fragment or a 29-base pair oligomer, each containing the putative VDRE, respond to D3 when transfected into HD11 cells; 2) a 67-base pair DNA fragment derived from genomic DNA and containing the candidate beta3 VDRE specifically binds the vitamin D receptor-retinoid X receptor beta complex; and 3) avian osteoclast precursor-derived nuclear extracts bind to a synthetic oligomer containing the beta3 VDRE-like sequence and, in turn, are specifically displaced by unlabeled beta3 VDRE and anti-vitamin D receptor antibody.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT PATHOL & LAB MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,DIV RENAL,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Washington University (WUSTL); Washington University (WUSTL)				Teitelbaum, Steven/0000-0002-4054-6679	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR032788, R01AR042404] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR32788, AR42404] Funding Source: Medline; NIDCR NIH HHS [DE05413] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALBELDA SM, 1993, LAB INVEST, V68, P4; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BARSHAVIT Z, 1983, P NATL ACAD SCI-BIOL, V80, P5907, DOI 10.1073/pnas.80.19.5907; BEUG H, 1979, CELL, V18, P579; BIRKENMEIER TM, 1991, J BIOL CHEM, V266, P20544; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CERVELLA P, 1993, J BIOL CHEM, V268, P5148; CHIBA M, 1993, J BONE MINER RES, V8, pS144; CLOHISY DR, 1987, J BIOL CHEM, V262, P15922; DARWISH HM, 1992, P NATL ACAD SCI USA, V89, P603, DOI 10.1073/pnas.89.2.603; DEAN DC, 1987, P NATL ACAD SCI USA, V84, P1876, DOI 10.1073/pnas.84.7.1876; DEDHAR S, 1991, J BIOL CHEM, V266, P21846; DEFILIPPI P, 1991, J BIOL CHEM, V266, P7638; DEMAY MB, 1990, P NATL ACAD SCI USA, V87, P369, DOI 10.1073/pnas.87.1.369; DENICHILO MO, 1993, P NATL ACAD SCI USA, V90, P2517, DOI 10.1073/pnas.90.6.2517; FELDINGHABERMANN B, 1992, J CLIN INVEST, V89, P2018, DOI 10.1172/JCI115811; FREEDMAN LP, 1993, J CELL BIOCHEM, V51, P140, DOI 10.1002/jcb.240510205; GILL RK, 1993, P NATL ACAD SCI USA, V90, P2984, DOI 10.1073/pnas.90.7.2984; HICKSTEIN DD, 1992, P NATL ACAD SCI USA, V89, P2105, DOI 10.1073/pnas.89.6.2105; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KRISSANSEN GW, 1990, J BIOL CHEM, V265, P823; LAKONISHOK M, 1992, DEV BIOL, V152, P209, DOI 10.1016/0012-1606(92)90129-5; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LOPEZCABRERA M, 1993, J BIOL CHEM, V268, P1187; MACDONALD PN, 1991, J BIOL CHEM, V266, P18808; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; MEDHORA MM, 1993, J BIOL CHEM, V268, P1456; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; PERKINS SL, 1991, ENDOCRINOLOGY, V128, P303, DOI 10.1210/endo-128-1-303; PHILLIPS DR, 1988, BLOOD, V71, P831; PIKE JW, 1987, J BIOL CHEM, V262, P1305; PRANDINI MH, 1988, BIOCHEM BIOPH RES CO, V156, P595, DOI 10.1016/S0006-291X(88)80884-2; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; ROSEN GD, 1991, P NATL ACAD SCI USA, V88, P4094, DOI 10.1073/pnas.88.10.4094; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; ROSS FP, 1993, J BIOL CHEM, V268, P9901; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Sambrook J, 1989, MOL CLONING LABORATO; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHEPPARD D, 1992, J BIOL CHEM, V267, P17409; SIMPSON RU, 1982, P NATL ACAD SCI-BIOL, V79, P16, DOI 10.1073/pnas.79.1.16; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZIMRIN AB, 1990, J BIOL CHEM, V265, P8590	47	120	121	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27371	27380						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262978				2022-12-27	WOS:A1993MM26200077
J	ECCLESTON, JF; MOORE, KJM; MORGAN, L; SKINNER, RH; LOWE, PN				ECCLESTON, JF; MOORE, KJM; MORGAN, L; SKINNER, RH; LOWE, PN			KINETICS OF INTERACTION BETWEEN NORMAL AND PROLINE-12 RAS AND THE GTPASE-ACTIVATING PROTEINS, P120-GAP AND NEUROFIBROMIN - THE SIGNIFICANCE OF THE INTRINSIC GTPASE RATE IN DETERMINING THE TRANSFORMING ABILITY OF RAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 NEUROFIBROMATOSIS; ESCHERICHIA-COLI; GENE-PRODUCT; MOLECULAR SWITCH; CATALYTIC DOMAIN; NF1 GENE; GAP; P21; MECHANISM; CELLS	Single turnover and equilibrium binding measurements on the interaction of Gly-12 and Pro-12 Ras.GTP with the catalytic domains of the GTPase-activating proteins, p120-GAP and neurofibromin, have been made utilizing fluorescent 2'(3')O-(N-methylanthraniloyl)-nucleotides. These have enabled the equilibrium dissociation constants (K(d)) for their initial binding and the rate constants of the hydrolysis step to be measured. p120-GAP binds to both Ras proteins with a K(d) of 17 muM, whereas neurofibromin binds to both Ras proteins with a K(d) of 1 muM. Both p120-GAP and neurofibromin increased the rate constant of the GTP hydrolysis step of Pro-12 Ras, but the maximal activation at 30-degrees-C was 120-fold and 560-fold, as compared with 70,000- and 52,000-fold, with Gly-12 Ras. The affinity with which p120-GAP and neurofibromin binds to either Gly-12 or Pro-12 Ras protein was decreased dramatically by increasing ionic strength caused by addition of NaCl. The rate constant of the cleavage step of hydrolysis catalyzed by neuroribromin increases with increasing ionic strength, whereas that catalyzed by p120-GAP appears to be unaffected. The high ionic strength within the cell might result in a much lower overall GTPase-activating protein activity than is measured under conditions of low ionic strength in vitro, with p120-GA-P being more severely inhibited. The GTP hydrolysis rate of Pro-12 Ras is 2-fold faster than that of normal Ras. The low oncogenicity of Pro-12 ras is explained by a model in which the intrinsic rates of hydrolysis and exchange, as well as GTPase-activating protein- and exchange factor-stimulated rates, are determinants of the biological activity of Ras proteins in fibroblasts.	WELLCOME RES LABS,DEPT CELL BIOL,BECKENHAM BR3 3BS,KENT,ENGLAND	GlaxoSmithKline; Wellcome Research Laboratories	ECCLESTON, JF (corresponding author), NATL INST MED RES,DIV PHYS BIOCHEM,MILL HILL,LONDON NW7 1AA,ENGLAND.							ANTONNY B, 1991, BIOCHEMISTRY-US, V30, P8287, DOI 10.1021/bi00098a002; BAGSHAW CR, 1974, BIOCHEM J, V141, P351, DOI 10.1042/bj1410351; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BROWNBRIDGE GG, 1993, J BIOL CHEM, V268, P10914; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; COLBY WW, 1986, MOL CELL BIOL, V6, P730, DOI 10.1128/MCB.6.2.730; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Downward J, 1992, CURR OPIN GENET DEV, V2, P13, DOI 10.1016/S0959-437X(05)80315-6; ECCLESTON JF, 1991, BIOCHEM SOC T, V19, P432, DOI 10.1042/bst0190432; ECCLESTON JF, 1987, SPECTROPHOTOMETRY SP, P137; FUJITAYOSHIGAKI J, 1992, J PROTEIN CHEM, V11, P731, DOI 10.1007/BF01024974; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; HALL A, 1986, J BIOL CHEM, V261, P19636; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; JOHN J, 1989, J BIOL CHEM, V264, P13086; JOHN J, 1988, J BIOL CHEM, V263, P11792; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LOWE PN, 1991, J BIOL CHEM, V266, P1672; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MOORE KJM, 1993, BIOCHEMISTRY-US, V32, P7451, DOI 10.1021/bi00080a016; MOORE KJM, 1992, PHILOS T ROY SOC B, V336, P49, DOI 10.1098/rstb.1992.0043; NEAL SE, 1988, J BIOL CHEM, V263, P19718; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3562, DOI 10.1073/pnas.87.9.3562; REINSTEIN J, 1991, J BIOL CHEM, V266, P17700; RENSLAND H, 1991, BIOCHEMISTRY-US, V30, P11181, DOI 10.1021/bi00110a023; RICKETTS MH, 1988, MOL CELL BIOL, V8, P1460, DOI 10.1128/MCB.8.4.1460; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SATOH T, 1987, MOL CELL BIOL, V7, P4553, DOI 10.1128/MCB.7.12.4553; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SIGAL IS, 1987, ANTI-CANCER DRUG DES, V2, P107; SKINNER RH, 1991, J BIOL CHEM, V266, P14163; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WEBB MR, 1992, BIOCHEM J, V287, P555, DOI 10.1042/bj2870555; WIESMULLER L, 1992, J BIOL CHEM, V267, P10207; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P	48	93	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27012	27019						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262937				2022-12-27	WOS:A1993MM26200029
J	REHAKRANTZ, LJ; NONAY, RL				REHAKRANTZ, LJ; NONAY, RL			GENETIC AND BIOCHEMICAL-STUDIES OF BACTERIOPHAGE-T4 DNA-POLYMERASE 3'-]5'-EXONUCLEASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5' EXONUCLEASE ACTIVITY; AMINO-ACID; 3'-5' EXONUCLEASE; ESCHERICHIA-COLI; SPONTANEOUS MUTATION; SITE; REPLICATION; EXPRESSION; POLYMERIZATION; MUTAGENESIS	DNA polymerase exonucleolytic proofreading is important in attaining high fidelity DNA replication. One of the most well characterized proofreading activities is the 3'-->5'-exonuclease activity of bacteriophage T4 DNA polymerase. We have used genetic analyses and protein sequence comparisons to Escherichia coli DNA polymerase I to identify amino acids in the N-terminal region of T4 DNA polymerase that are required for exonucleolytic proofreading. Mutant DNA polymerases with amino acid substitutions D112A/E114A, D219A, or D324A reduced 3'-->5'-exonuclease activity 10(2)-10(4)-fold in various in vitro assays and decreased DNA replication fidelity in vivo. DNA replication activity was also reduced for the exonuclease-deficient DNA polymerases in vitro and in vivo. Reduction in DNA replication appeared to be due primarily to the interdependence of T4 DNA polymerase replication and proofreading activities; T4 DNA polymerase requires 3'-->5'-exonuclease activity to repair primer termini that are not suitable substrates for extension. Observations reported here provide further evidence in support of the proposal that DNA polymerases have distinct 3'-->5'-exonuclease and polymerase active sites.			REHAKRANTZ, LJ (corresponding author), UNIV ALBERTA,DEPT GENET,EDMONTON T6G 2E9,AB,CANADA.							BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BESSMAN MJ, 1977, J MOL BIOL, V116, P115, DOI 10.1016/0022-2836(77)90122-X; BLANCO L, 1992, GENE, V112, P139, DOI 10.1016/0378-1119(92)90316-H; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; GIBBS JS, 1991, MOL CELL BIOL, V11, P4786, DOI 10.1128/MCB.11.9.4786; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; KUNKEL TA, 1988, CELL, V53, P837, DOI 10.1016/S0092-8674(88)90189-4; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1992, J BIOL CHEM, V267, P18251; LIN TC, 1987, P NATL ACAD SCI USA, V84, P7000, DOI 10.1073/pnas.84.20.7000; MCPHEETERS DS, 1986, NUCLEIC ACIDS RES, V14, P5813, DOI 10.1093/nar/14.14.5813; MORRISON A, 1991, P NATL ACAD SCI USA, V88, P9473, DOI 10.1073/pnas.88.21.9473; MUZYCZKA N, 1972, J BIOL CHEM, V247, P7116; NEWPORT JW, 1980, MECHANISTIC STUDIES, V19, P485; NOSSAL NG, 1969, J BIOL CHEM, V244, P218; NOSSAL NG, 1971, J BIOL CHEM, V246, P5414; OLESON AE, 1964, J BIOL CHEM, V239, P2935; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PETRUSKA J, 1985, J BIOL CHEM, V260, P7533; REDDY MK, 1992, J BIOL CHEM, V267, P14157; REHAKRANTZ LJ, 1986, J MOL BIOL, V189, P261, DOI 10.1016/0022-2836(86)90508-5; REHAKRANTZ LJ, 1993, J VIROL, V67, P60, DOI 10.1128/JVI.67.1.60-66.1993; REHAKRANTZ LJ, 1989, J VIROL, V63, P4762, DOI 10.1128/JVI.63.11.4762-4766.1989; REHAKRANTZ LJ, 1991, P NATL ACAD SCI USA, V88, P2417, DOI 10.1073/pnas.88.6.2417; REHAKRANTZ LJ, 1988, J MOL BIOL, V202, P711, DOI 10.1016/0022-2836(88)90552-9; REHAKRANTZ LJ, 1984, GENETICS, V106, P335; ROZOVSKAYA T A, 1981, Molekulyarnaya Biologiya (Moscow), V15, P1205; SIMON M, 1991, EMBO J, V10, P2165, DOI 10.1002/j.1460-2075.1991.tb07751.x; SPICER EK, 1988, J BIOL CHEM, V263, P7478; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1989, J BIOL CHEM, V264, P6447; VENKATESAN M, 1982, J BIOL CHEM, V257, P2435; WANG Y, 1992, J VIROL, V66, P1814, DOI 10.1128/JVI.66.3.1814-1816.1992	40	72	79	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27100	27108						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262948				2022-12-27	WOS:A1993MM26200041
J	SAIKI, K; MOGI, T; HORI, H; TSUBAKI, M; ANRAKU, Y				SAIKI, K; MOGI, T; HORI, H; TSUBAKI, M; ANRAKU, Y			IDENTIFICATION OF THE FUNCTIONAL DOMAINS IN HEME-O SYNTHASE - SITE-DIRECTED MUTAGENESIS STUDIES ON THE CYOE GENE OF THE CYTOCHROME-BO OPERON IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AEROBIC RESPIRATORY-CHAIN; LOW-SPIN HEME; C-OXIDASE; TERMINAL OXIDASE; PARACOCCUS-DENITRIFICANS; UBIQUINOL OXIDASE; SUBUNIT-I; RHODOBACTER-SPHAEROIDES; QUINOL OXIDASE; PROTON PUMP	The cytochrome bo complex is a terminal ubiquinol oxidase in the aerobic respiratory chain of Escherichia coli and is encoded by the cyoABCDE operon. Recently, we have demonstrated that heme O at the high-spin heme-binding site is essential for redox-coupled proton pumping by the oxidase and suggested that the cyoE gene encodes a novel enzyme for heme O biosynthesis, protoheme IX farnesyltransferase (heme O synthase) (Saiki, K., Mogi, T., and Anraku, Y. (1992) Biochem. Biophys. Res. Commun. 189,1491-1497). This study was focused to define the catalytic domain(s) of the CyoE protein via a site-directed mutagenesis approach. We have individually substituted 40 amino acid residues including 22 invariant residues with alanines and found that 23 mutant oxidases were nonfunctional and exhibited a specific loss of the CO binding activity at the site of the high-spin heme. Characterizations of the purified D65A, Y120A, and W172A mutant oxidases, which represent the mutations of different topological domains, revealed that their defects are attributable to substitution of protoheme IX for heme O present in the high-spin heme-binding site. Based on the above observations, we suggest that the conserved amino acid residues present in the cytoplasmic loops II/III and IV/V are part of the catalytic center of heme O synthase.	UNIV TOKYO,GRAD SCH SCI,DEPT PLANT SCI,BUNKYO KU,TOKYO 113,JAPAN; OSAKA UNIV,FAC ENGN SCI,DEPT BIOPHYS ENGN,TOYONAKA,OSAKA 560,JAPAN; HIMEJI INST TECHNOL,FAC SCI,DEPT LIFE SCI,HYOGO 67812,JAPAN	University of Tokyo; Osaka University; University of Hyogo								ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P5730, DOI 10.1073/pnas.84.16.5730; ANRAKU Y, 1987, TRENDS BIOCHEM SCI, V12, P262, DOI 10.1016/0968-0004(87)90131-9; ANRAKU Y, 1988, ANNU REV BIOCHEM, V57, P101, DOI 10.1146/annurev.bi.57.070188.000533; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; AU DCT, 1985, J BACTERIOL, V161, P123, DOI 10.1128/JB.161.1.123-127.1985; BABCOCK GT, 1983, BIOCHEMISTRY-US, V22, P2314, DOI 10.1021/bi00279a002; BERATAN DN, 1991, SCIENCE, V252, P1285, DOI 10.1126/science.1656523; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; CAO J, 1992, J BIOL CHEM, V267, P24273; CARATTOLI A, 1991, J BIOL CHEM, V266, P5854; CASTOR LN, 1959, J BIOL CHEM, V234, P1587; CAUGHEY WS, 1975, J BIOL CHEM, V250, P7602; CHEPURI V, 1990, J BIOL CHEM, V265, P11185; CHEPURI V, 1990, J BIOL CHEM, V265, P12978; GENNIS RB, 1991, BIOCHIM BIOPHYS ACTA, V1058, P21, DOI 10.1016/S0005-2728(05)80260-9; GEORGIOU CD, 1988, J BACTERIOL, V170, P961, DOI 10.1128/jb.170.2.961-966.1988; GOLLUB EG, 1977, J BIOL CHEM, V252, P2846; HANSSON M, 1993, FEMS MICROBIOL LETT, V107, P121; HATA A, 1985, BIOCHIM BIOPHYS ACTA, V810, P62, DOI 10.1016/0005-2728(85)90206-3; HILL J, 1992, BIOCHEMISTRY-US, V31, P11435, DOI 10.1021/bi00161a023; ISHIZUKA M, 1992, EBEC SHORT REP, V7, P50; KITA K, 1982, J BIOL CHEM, V257, P7933; KITA K, 1984, J BIOL CHEM, V259, P3368; KITA K, 1984, J BIOL CHEM, V259, P3375; LEMIEUX LJ, 1992, J BIOL CHEM, V267, P2105; MARRERO PF, 1992, J BIOL CHEM, V267, P21873; MATSUSHITA K, 1992, J BACTERIOL, V174, P122, DOI 10.1128/jb.174.1.122-129.1992; MATSUSHITA K, 1984, BIOCHEMISTRY-US, V23, P4703, DOI 10.1021/bi00315a028; MINAGAWA J, 1992, J BIOL CHEM, V267, P2096; MINAGAWA J, 1990, J BIOL CHEM, V265, P11198; MINGHETTI KC, 1992, BIOCHEMISTRY-US, V31, P6917, DOI 10.1021/bi00145a008; MIYAMOTO K, 1991, J MOL BIOL, V219, P393, DOI 10.1016/0022-2836(91)90180-E; MULLER M, 1988, BIOCHEMISTRY-US, V27, P7546; NAKAMURA H, 1990, J BIOL CHEM, V265, P11193; NAKAMURA H, 1991, THESIS U TOKYO; NICHOLS BP, 1992, J BACTERIOL, V174, P5309, DOI 10.1128/JB.174.16.5309-5316.1992; NISHIMURA K, 1992, J BACTERIOL, V174, P5762, DOI 10.1128/JB.174.17.5762-.1992; NOBREGA MP, 1990, J BIOL CHEM, V265, P14220; ONDRIAS MR, 1980, BIOCHEM BIOPH RES CO, V93, P29, DOI 10.1016/S0006-291X(80)80241-5; PORRA RJ, 1993, FEBS LETT, V323, P31, DOI 10.1016/0014-5793(93)81442-3; PUUSTINEN A, 1989, FEBS LETT, V249, P163, DOI 10.1016/0014-5793(89)80616-7; PUUSTINEN A, 1991, P NATL ACAD SCI USA, V88, P6122, DOI 10.1073/pnas.88.14.6122; PUUSTINEN A, 1992, BIOCHEMISTRY-US, V31, P10363, DOI 10.1021/bi00157a026; PUUSTINEN A, 1991, BIOCHEMISTRY-US, V30, P3936, DOI 10.1021/bi00230a019; QUIRK PG, 1993, J BIOL CHEM, V268, P678; RAITIO M, 1987, EMBO J, V6, P2825, DOI 10.1002/j.1460-2075.1987.tb02579.x; SAIKI K, 1992, BIOCHEM BIOPH RES CO, V189, P1491, DOI 10.1016/0006-291X(92)90243-E; SALERNO JC, 1990, J BIOL CHEM, V265, P4364; SARASTE M, 1991, EUR J BIOCHEM, V195, P517, DOI 10.1111/j.1432-1033.1991.tb15732.x; SHAPLEIGH JP, 1992, P NATL ACAD SCI USA, V89, P4786, DOI 10.1073/pnas.89.11.4786; SHBY MN, 1992, J BIOL CHEM, V267, P4128; SIEBERT M, 1992, FEBS LETT, V307, P347, DOI 10.1016/0014-5793(92)80710-X; SINCLAIR P, 1967, BIOCHIM BIOPHYS ACTA, V143, P427, DOI 10.1016/0005-2728(67)90097-7; SONE N, 1991, FEBS LETT, V288, P154, DOI 10.1016/0014-5793(91)81024-3; SONE N, 1990, FEBS LETT, V262, P249, DOI 10.1016/0014-5793(90)80202-T; STEINRUCKE P, 1991, J BIOL CHEM, V266, P7676; SVENNSON B, 1992, EBEC SHORT REPORTS, V7, P36; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P6065, DOI 10.1021/bi00074a018; TZAGOLOFF A, 1990, EMBO J, V9, P2759, DOI 10.1002/j.1460-2075.1990.tb07463.x; UNO T, 1985, J BIOL CHEM, V260, P6755; VANDEROOST J, 1991, J BIOENERG BIOMEMBR, V23, P257, DOI 10.1007/BF00762221; WOODRUFF WH, 1991, P NATL ACAD SCI USA, V88, P2588, DOI 10.1073/pnas.88.6.2588; WU W, 1992, J AM CHEM SOC, V114, P1182, DOI 10.1021/ja00030a009	64	47	49	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26927	26934						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262927				2022-12-27	WOS:A1993MM26200017
J	SMITH, DJ; ZHU, H; KOLATKAR, PR; TAM, LT; BALDWIN, TO; ROE, BA; BROYLES, RH; RIGGS, AF				SMITH, DJ; ZHU, H; KOLATKAR, PR; TAM, LT; BALDWIN, TO; ROE, BA; BROYLES, RH; RIGGS, AF			THE HEMOGLOBINS OF THE BULLFROG, RANA-CATESBEIANA - THE CDNA-DERIVED AMINO-ACID-SEQUENCES OF THE ALPHA-CHAINS OF ADULT HEMOGLOBIN-B AND HEMOGLOBIN-C - THEIR ROLES IN DEOXYGENATION-INDUCED AGGREGATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; XENOPUS-LAEVIS; MESSENGER-RNA; BETA-CHAIN; OXYGEN; COOPERATIVITY; COMPONENT; PROTEINS; TADPOLE; BINDING	The adult bullfrog (Rana catesbeiana) has two major tetrameric hemoglobins, B and C, which share a common beta chain but have different alpha chains. Components B and C associate upon deoxygenation to form a complex of the form BC2, a trimer of tetramers that depends on contacts between the alpha(B) and alpha(C) chains. Nucleotide sequences of cDNA transcripts for these chains have been determined. Transcripts were identified by analysis of the amino acid compositions of the tryptic peptides of the components and by partial amino acid sequencing. These results, together with the amino acid sequence of the beta chain (Tam, L.-T., Gray, G. P., and Riggs, A. F. (1986) J. Biol. Chem. 261, 8290-8294), permit an analysis of the structures of the alpha2beta2 tetramers of hemoglobins B and C. Molecular modeling suggests possible residues at the alpha(B)-alpha(C) interfaces in the BC2 trimer and additional alpha(C)-alpha(C) contacts that would form a closed ring of six alpha chain subunits that would further stabilize the BC2 trimer. Phylogenetic analysis of the alpha(B) sequence suggests that it may be a ''tadpole'' chain, the temporal expression of which has shifted from larva to adult.	UNIV TEXAS,DEPT ZOOL,AUSTIN,TX 78712; UNIV TEXAS,DEPT CHEM & BIOCHEM,AUSTIN,TX 78712; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,OKLAHOMA CITY,OK 73190; UNIV OKLAHOMA,DEPT CHEM & BIOCHEM,NORMAN,OK 73019	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma - Norman				kolatkar, prasanna/0000-0003-4970-5944	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021764] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041878] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 21764] Funding Source: Medline; NIGMS NIH HHS [GM-05818, GM41878] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; AGGARWAL SJ, 1969, J BIOL CHEM, V244, P2372; AHERN E, 1976, FEBS LETT, V69, P99, DOI 10.1016/0014-5793(76)80662-X; Anson ML, 1930, J GEN PHYSIOL, V13, P469, DOI 10.1085/jgp.13.4.469; ATHA DH, 1979, J BIOL CHEM, V254, P3393; BALDWIN TO, 1974, J BIOL CHEM, V249, P6110; BANVILLE D, 1983, J BIOL CHEM, V258, P7924; BONAVENTURA J, 1967, SCIENCE, V158, P800, DOI 10.1126/science.158.3802.800-a; BROWN JR, 1966, BIOCHEM J, V101, P214, DOI 10.1042/bj1010214; Broyles R.H., 1981, P461; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU AH, 1981, J BIOL CHEM, V256, P1199; COBB JA, 1992, J BIOL CHEM, V267, P1183; CULVERT SJ, 1993, RESPIR PHYSL, V91, P99; DEWITT W, 1967, BIOCHEM BIOPH RES CO, V27, P236, DOI 10.1016/S0006-291X(67)80067-6; DINTZIS HM, 1961, P NATL ACAD SCI USA, V47, P247, DOI 10.1073/pnas.47.3.247; DORN AR, 1982, P NATL ACAD SCI-BIOL, V79, P5592, DOI 10.1073/pnas.79.18.5592; FAITH DP, 1991, SYST ZOOL, V40, P366, DOI 10.2307/2992329; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FERMI G, 1975, J MOL BIOL, V97, P237, DOI 10.1016/S0022-2836(75)80037-4; FISHER WK, 1977, AUST J BIOL SCI, V30, P487, DOI 10.1071/BI9770487; GAO J, 1989, SCIENCE, V244, P1069, DOI 10.1126/science.2727695; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; Hall FG, 1934, J PHYSIOL-LONDON, V83, P222, DOI 10.1113/jphysiol.1934.sp003223; Haurowitz F, 1930, H-S Z PHYSIOL CHEM, V186, P141, DOI 10.1515/bchm2.1930.186.4-6.141; HOLLAND RAB, 1988, RESP PHYSIOL, V73, P69, DOI 10.1016/0034-5687(88)90128-4; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; Jordan HE, 1923, J EXP MED, V38, P529, DOI 10.1084/jem.38.5.529; Jordan HE, 1923, AM J ANAT, V32, P155, DOI 10.1002/aja.1000320203; KAY RM, 1983, NUCLEIC ACIDS RES, V11, P1537, DOI 10.1093/nar/11.5.1537; KLEINSCHMIDT T, 1987, BIOL CHEM H-S, V368, P579; KNUTH A, 1979, ACTA HAEMATOL-BASEL, V61, P121, DOI 10.1159/000207643; MAEDA N, 1982, J BIOL CHEM, V257, P2806; Maniatis T., 1982, MOL CLONING; MANNING DR, 1984, BIOPHYS J, V45, pA368; MAPLES PB, 1986, DEV BIOL, V117, P337, DOI 10.1016/0012-1606(86)90303-9; MATSUURA MSA, 1989, J BIOL CHEM, V264, P5515; MCCARTHY EARL F., 1933, JOUR PHYSIOL, V80, P206, DOI 10.1113/jphysiol.1933.sp003083; Mccutcheon FH, 1936, J CELL COMPAR PHYSL, V8, P63, DOI 10.1002/jcp.1030080107; MCDONALD MJ, 1985, J MOL BIOL, V183, P105, DOI 10.1016/0022-2836(85)90284-0; McKinney ML, 1991, HETEROCHRONY EVOLUTI, P437; MOSS B, 1968, J MOL BIOL, V32, P481, DOI 10.1016/0022-2836(68)90336-7; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; PATIENT RK, 1983, J BIOL CHEM, V258, P8521; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; QUEEN C, 1984, NUCLEIC ACIDS RES, V12, P581, DOI 10.1093/nar/12.1Part2.581; RIGGS A, 1951, J GEN PHYSIOL, V35, P23, DOI 10.1085/jgp.35.1.23; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; Swofford David L., 1990, P411; TAM LT, 1986, J BIOL CHEM, V261, P8290; TAM LT, 1993, J BIOL CHEM, V268, P26972; TAM LT, 1984, J BIOL CHEM, V259, P2610; TIBBEN EA, 1991, RESP PHYSIOL, V84, P93, DOI 10.1016/0034-5687(91)90021-A; TRADER CD, 1966, J BIOL CHEM, V241, P357; YOKOTA E, 1984, J BIOL CHEM, V259, P4739	56	12	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26961	26971						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262931				2022-12-27	WOS:A1993MM26200022
J	HANSSON, L; BLACKBERG, L; EDLUND, M; LUNDBERG, L; STROMQVIST, M; HERNELL, O				HANSSON, L; BLACKBERG, L; EDLUND, M; LUNDBERG, L; STROMQVIST, M; HERNELL, O			RECOMBINANT HUMAN-MILK BILE SALT-STIMULATED LIPASE - CATALYTIC ACTIVITY IS RETAINED IN THE ABSENCE OF GLYCOSYLATION AND THE UNIQUE PROLINE-RICH REPEATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC CHOLESTEROL ESTERASE; BOVINE PAPILLOMA-VIRUS; CDNA CLONING; PREMATURE-INFANTS; LYSOPHOSPHOLIPASE; DIGESTION; IDENTITY; CALCIUM; GENE; FAT	Human milk bile salt-stimulated lipase ensures efficient utilization of triacylglycerol by breast-fed infants. Cloning and sequencing of cDNA have revealed that the peptide chain consists of 722 amino acid residues showing only little homology to typical lipases. The sequence is identical to that of pancreatic carboxylic-ester hydrolase. The COOH-terminal part contains 16 proline-rich repeats of 11 residues with O-linked carbohydrate. The only N-linked sugar chain is situated close to the active-site serine. Using C127 cells and a bovine papilloma virus vector, high and stable expression of full-length lipase and of several variants, obtained by site-directed mutagenesis, was achieved. The produced proteins were purified and further characterized. Variants lacking all, or all but two, repeats were active with similar specific activity and the same bile salt dependence as the native milk enzyme. Changing the asparagine necessary for N-glycosylation gave the same principal results. Active recombinant full-length lipase was also produced in a bacterial system. We conclude that neither glycosylation (N- or O-linked) nor the proline-rich repeats are essential for catalytic activity or bile salt activation of human milk bile salt-stimulated lipase.	UMEA UNIV,DEPT MED BIOCHEM & BIOPHYS,S-90187 UMEA,SWEDEN; UMEA UNIV,DEPT PEDIAT,S-90187 UMEA,SWEDEN; ASTRA HASSLE AB,PRECLIN RES & DEV,S-43183 MOLNDAL,SWEDEN	Umea University; Umea University	HANSSON, L (corresponding author), SYMBICOM AB,S-90124 UMEA,SWEDEN.							ABOUAKIL N, 1989, BIOCHIM BIOPHYS ACTA, V1002, P225, DOI 10.1016/0005-2760(89)90291-9; ATKINSON SA, 1981, J PEDIATR-US, V99, P617, DOI 10.1016/S0022-3476(81)80275-2; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BABA T, 1991, BIOCHEMISTRY-US, V30, P500, DOI 10.1021/bi00216a028; BERNBACK S, 1990, J CLIN INVEST, V85, P1221, DOI 10.1172/JCI114556; BJORKSTEN B, 1980, BRIT MED J, V201, P267; BLACKBERG L, 1983, FEBS LETT, V157, P337, DOI 10.1016/0014-5793(83)80571-7; BLACKBERG L, 1981, EUR J BIOCHEM, V116, P221, DOI 10.1111/j.1432-1033.1981.tb05322.x; BLACKBERG L, 1993, FEBS LETT, V323, P207, DOI 10.1016/0014-5793(93)81340-6; CHAPPELL JE, 1986, J PEDIATR-US, V108, P439, DOI 10.1016/S0022-3476(86)80893-9; FONTAINE RN, 1991, BIOCHEMISTRY-US, V30, P7008, DOI 10.1021/bi00242a028; FREDRIKZON B, 1978, PEDIATR RES, V12, P1048, DOI 10.1203/00006450-197811000-00004; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAMOSH M, 1986, FED PROC, V45, P1452; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HERNELL O, 1975, EUR J CLIN INVEST, V5, P267, DOI 10.1111/j.1365-2362.1975.tb02294.x; Hernell O., 1989, Textbook of gastroenterology and nutrition in infancy., P209; HERNELL O, 1991, ENCY HUMAN BIOL, V3, P47; HUI DY, 1990, FEBS LETT, V276, P131, DOI 10.1016/0014-5793(90)80525-N; KYGER EM, 1989, BIOCHEM BIOPH RES CO, V164, P1302, DOI 10.1016/0006-291X(89)91811-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUSKY M, 1984, CELL, V36, P391, DOI 10.1016/0092-8674(84)90232-0; NILSSON J, 1990, EUR J BIOCHEM, V192, P543, DOI 10.1111/j.1432-1033.1990.tb19259.x; Patton J.S., 1981, PHYSL GASTROINTESTIN, P1123; PAVLAKIS GN, 1983, P NATL ACAD SCI-BIOL, V80, P397, DOI 10.1073/pnas.80.2.397; REUE K, 1991, J LIPID RES, V32, P267; SARVER N, 1982, P NATL ACAD SCI-BIOL, V79, P7147, DOI 10.1073/pnas.79.23.7147; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WILLIAMSON S, 1978, ARCH DIS CHILD, V53, P555, DOI 10.1136/adc.53.7.555	30	72	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26692	26698						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253803				2022-12-27	WOS:A1993MK42500099
J	GRACE, ME; NEWMAN, KM; SCHEINKER, V; BERGFUSSMAN, A; GRABOWSKI, GA				GRACE, ME; NEWMAN, KM; SCHEINKER, V; BERGFUSSMAN, A; GRABOWSKI, GA			ANALYSIS OF HUMAN ACID BETA-GLUCOSIDASE BY SITE-DIRECTED MUTAGENESIS AND HETEROLOGOUS EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAUCHER DISEASE TYPE-1; HUMAN GLUCOCEREBROSIDASE GENE; BINDING-SITES; ACTIVE-SITE; MONOCLONAL-ANTIBODIES; CATALYTIC ACTIVITY; HETEROGENEITY; MUTATIONS; FIBROBLASTS; INVESTIGATE	Structure/function relationships of acid beta-glucosidase, the enzyme deficient in Gaucher disease, were evaluated by characterizing the proteins expressed from cDNAs encoding normal and mutant enzymes. Twenty-two Gaucher disease mutations or created mutations were expressed in Spodoptera frugiperda (Sf9) cells and analyzed for catalytic properties, stability, inhibitor binding, and modifier interactions. Many Gaucher disease mutations encoded highly disruptive amino acid substitutions (e.g. P289L and D409V) and produced severely compromised proteins with very reduced activity (k(cat) < 1% of normal) and/or stability. Six mutant enzymes had sufficient catalytic activity (k(cat) approximately 5-30% of normal) for extensive studies. The highly conservative substitutions, i.e. F216Y or S364T and V394L, led to severe, but selective, abnormalities of enzyme stability or large decreases in catalytic activity, respectively. The T323I, N370S, and V394L enzymes interacted abnormally with active site-directed inhibitors and localized these residues to the glycon binding region. Selected mutant enzymes were poorly activated by phosphatidylserine (V394L, L444P, and R463C) or by saposin C (L444P and T323I), indicating that the enzyme sites for interaction with these activators were within the carboxyl one-third of the enzyme. Substitutions of Ser, Glu, and/or Gly at residues Asp-443 and/or Asp-445 demonstrated important steric roles for these residues in the active site, but neither is the catalytic nucleophile. Together with previous studies, the present analyses provide an insight into the pathogenesis of Gaucher disease and the functional organization of acid beta-glucosidase.	CHILDRENS HOSP MED CTR, DIV HUMAN GENET, 3333 BURNET AVE, CINCINNATI, OH 45229 USA; CUNY MT SINAI SCH MED, DEPT MED & MOLEC GENET, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, DEPT PEDIAT, NEW YORK, NY 10029 USA	Cincinnati Children's Hospital Medical Center; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NIDDK NIH HHS [DK 36729] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036729] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AERTS JMFG, 1987, EUR J BIOCHEM, V163, P583, DOI 10.1111/j.1432-1033.1987.tb10907.x; AGMON V, 1993, IN PRESS BIOCH BIOPH; BARNEVELD RA, 1983, HUM GENET, V64, P227, DOI 10.1007/BF00279398; BERENT SL, 1981, ARCH BIOCHEM BIOPHYS, V208, P248, DOI 10.1016/0003-9861(81)90147-8; BERGFUSSMAN A, 1993, J BIOL CHEM, V268, P14861; BERGMANN JE, 1989, AM J HUM GENET, V44, P741; BEUTELR E, 1994, IN PRESS METABOLIC B; BEUTLER E, 1990, ANN HUM GENET, V54, P149, DOI 10.1111/j.1469-1809.1990.tb00371.x; BEUTLER E, 1993, GENOMICS, V15, P203, DOI 10.1006/geno.1993.1035; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; BRADY RO, 1965, BIOCHEM BIOPH RES CO, V18, P221, DOI 10.1016/0006-291X(65)90743-6; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CONZELMANN E, 1984, DEV NEUROSCI-BASEL, V6, P58, DOI 10.1159/000112332; DAHL N, 1990, AM J HUM GENET, V47, P275; Devine E A, 1982, Prog Clin Biol Res, V95, P511; DINUR T, 1986, P NATL ACAD SCI USA, V83, P1660, DOI 10.1073/pnas.83.6.1660; DINUR T, 1984, ANAL BIOCHEM, V136, P223, DOI 10.1016/0003-2697(84)90329-4; DINUR T, 1986, ENZYMES LIPID METABO, V2, P289; ERICKSON AH, 1985, J BIOL CHEM, V260, P4319; EYAL N, 1990, GENE, V96, P277, DOI 10.1016/0378-1119(90)90264-R; EYAL N, 1991, HUM GENET, V87, P328; FABBRO D, 1987, AM J HUM GENET, V40, P15; FABBRO D, 1991, J BIOL CHEM, V266, P15021; GATT S, 1966, J BIOL CHEM, V241, P3724; GEBLER JC, 1992, J BIOL CHEM, V267, P11126; GRABOWSKI GA, 1984, ARCH BIOCHEM BIOPHYS, V231, P144, DOI 10.1016/0003-9861(84)90371-0; GRABOWSKI GA, 1990, CRIT REV BIOCHEM MOL, V25, P385, DOI 10.3109/10409239009090616; GRABOWSKI GA, 1989, ENZYME, V41, P131, DOI 10.1159/000469068; GRABOWSKI GA, 1985, AM J MED GENET, V21, P529, DOI 10.1002/ajmg.1320210316; GRABOWSKI GA, 1986, J BIOL CHEM, V261, P8263; GRACE ME, 1990, BIOCHEM BIOPH RES CO, V168, P771, DOI 10.1016/0006-291X(90)92388-G; GRACE ME, 1990, J BIOL CHEM, V265, P6827; GRACE ME, 1991, AM J HUM GENET, V49, P646; GRAVES PN, 1988, DNA-J MOLEC CELL BIO, V7, P521, DOI 10.1089/dna.1.1988.7.521; GREENBERG P, 1990, BIOCHIM BIOPHYS ACTA, V1039, P12, DOI 10.1016/0167-4838(90)90220-A; HE GS, 1992, AM J HUM GENET, V51, P810; He Guo-Shun, 1992, Human Mutation, V1, P423, DOI 10.1002/humu.1380010513; HONG CM, 1990, DNA CELL BIOL, V9, P233, DOI 10.1089/dna.1990.9.233; HOROWITZ M, 1989, GENOMICS, V4, P87, DOI 10.1016/0888-7543(89)90319-4; Institute of Gaucher Disease, 2020, EP GAUCH DIS; KEMPTON JB, 1992, BIOCHEMISTRY-US, V31, P9961, DOI 10.1021/bi00156a015; LATHAM T, 1990, AM J HUM GENET, V47, P79; LATHAM TE, 1991, DNA CELL BIOL, V10, P15, DOI 10.1089/dna.1991.10.15; LEGLER G, 1990, ADV CARBOHYD CHEM BI, V48, P319, DOI 10.1016/S0065-2318(08)60034-7; LEINEKUGEL P, 1992, HUM GENET, V88, P513, DOI 10.1007/BF00219337; LOEB DD, 1989, NATURE, V340, P397, DOI 10.1038/340397a0; MATTHEWS REF, 1982, 4TH INT COMM TAX VIR; MUELLER OT, 1979, J BIOL CHEM, V254, P3521; OHASHI T, 1991, J BIOL CHEM, V266, P3661; ONEILL RR, 1989, P NATL ACAD SCI USA, V86, P5049, DOI 10.1073/pnas.86.13.5049; OSIECKINEWMAN K, 1987, BIOCHIM BIOPHYS ACTA, V915, P87, DOI 10.1016/0167-4838(87)90128-2; OSIECKINEWMAN K, 1988, ENZYME, V40, P173, DOI 10.1159/000469161; OSIECKINEWMAN KM, 1986, ENZYME, V35, P147, DOI 10.1159/000469336; OSIECKINEWMAN KO, 1987, THESIS CITY U NEW YO; PATTERSON MC, 1993, NEUROLOGY, V43, P1993, DOI 10.1212/WNL.43.10.1993; REIDHAAROLSON JF, 1990, BIOCHEMISTRY-US, V29, P7563, DOI 10.1021/bi00485a004; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; SANO A, 1988, J BIOL CHEM, V263, P19597; SIBILLE A, 1993, AM J HUM GENET, V52, P1094; SORGE J, 1985, P NATL ACAD SCI USA, V82, P7289, DOI 10.1073/pnas.82.21.7289; Summers M.D., 1987, TEXAS AGR EXPT STATI; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8749, DOI 10.1093/nar/13.24.8749; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; THEOPHILUS B, 1989, AM J HUM GENET, V45, P212; THEOPHILUS BDM, 1989, NUCLEIC ACIDS RES, V17, P7707, DOI 10.1093/nar/17.19.7707; TRIMBUR DE, 1992, J BIOL CHEM, V267, P10248; TSUJI S, 1988, P NATL ACAD SCI USA, V85, P2349, DOI 10.1073/pnas.85.7.2349; TSUJI S, 1987, NEW ENGL J MED, V316, P570, DOI 10.1056/NEJM198703053161002; WIGDERSON M, 1989, AM J HUM GENET, V44, P365; WILLEMSEN R, 1987, J NEUROL, V234, P44, DOI 10.1007/BF00314009; ZIMRAN A, 1989, LANCET, V2, P349; ZIMRAN A, 1990, J CLIN INVEST, V85, P219, DOI 10.1172/JCI114415	72	118	124	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2283	2291						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294487				2022-12-27	WOS:A1994MR98800109
J	KUBISESKI, TJ; GREEN, NC; BORHANI, DW; FLYNN, TG				KUBISESKI, TJ; GREEN, NC; BORHANI, DW; FLYNN, TG			STUDIES ON PIG ALDOSE REDUCTASE - IDENTIFICATION OF AN ESSENTIAL ARGININE IN THE PRIMARY AND TERTIARY STRUCTURE OF THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ALDEHYDE REDUCTASE; CRYSTAL-STRUCTURE; BINDING; LENS; MUSCLE; KIDNEY; SUPERFAMILY; EXPRESSION; MECHANISM	Reaction of pig muscle aldose reductase with phenylglyoxal resulted in the chemical modification of 2 arginine residues with accompanying loss of catalytic activity. The amino acid sequences of radioactive peptides resulting from the reaction of aldose reductase with [C-14]phenylglyoxal followed by tryptic digestion and high performance liquid chromatography separation allowed identification of the modified arginine residues as R268 and R293. In the presence of the coenzyme NADP+, R268 is protected from modification by phenylglyoxal, while R293 becomes hyper-reactive. Phenylglyoxal modification of aldose reductase is slowed 3-fold by the presence of the coenzyme analog ADPRP; however, both arginines are still modified. These chemical modification results are in complete accord with the previously determined crystal structures of human and porcine aldose reductase complexed with NADPH, NADP+, and ADPRP. These structures indicate that R268 is located at the adenosine binding site, salt bridged to the 2'-phosphate group of NADP(H) and ADPRP. Arginine 293 is near the surface of the enzyme and is part of the C-terminal loop. In the apoenzyme or the ADPRP complex, R293 is partially protected by loop 7; upon binding NADP(H), loop 7 folds down over the co-enzyme, thus exposing R293 to solvent. Our modification studies provide further evidence of the conformational change that occurs during the aldose reductase catalytic cycle.	QUEENS UNIV,DEPT BIOCHEM,KINGSTON K7L 3N6,ONTARIO,CANADA; BIOCRYST PHARMACEUT INC,BIRMINGHAM,AL 35244	Queens University - Canada				Borhani, David/0000-0002-8486-8792; Kubiseski, Terrance/0000-0001-9388-8608	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R43DK044789] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44789] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOHREN KM, 1989, J BIOL CHEM, V264, P9547; BOHREN KM, 1991, J BIOL CHEM, V266, P24031; BOHREN KM, 1993, ENZYMOLOGY MOL BIOL, V328, P267; BORHANI DW, 1992, J BIOL CHEM, V267, P24841; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANLANT G, 1981, EUR J BIOCHEM, V116, P505, DOI 10.1111/j.1432-1033.1981.tb05365.x; BRANLANT G, 1982, EUR J BIOCHEM, V129, P99, DOI 10.1111/j.1432-1033.1982.tb07026.x; CARPER D, 1987, FEBS LETT, V220, P209, DOI 10.1016/0014-5793(87)80905-5; CHANG GG, 1981, BIOCHIM BIOPHYS ACTA, V660, P341, DOI 10.1016/0005-2744(81)90179-0; CROMLISH JA, 1983, J BIOL CHEM, V258, P3583; DAVIDSON WS, 1979, J BIOL CHEM, V254, P3724; DIXON M, 1979, ENZYMES, P374; DOUGHTY CC, 1982, BIOCHIM BIOPHYS ACTA, V708, P358, DOI 10.1016/0167-4838(82)90449-6; FLYNN TG, 1986, METABOLISM, V35, P105, DOI 10.1016/0026-0495(86)90197-6; GRIMSHAW CE, 1990, BIOCHEMISTRY-US, V29, P9936, DOI 10.1021/bi00494a026; GRIMSHAW CE, 1990, BIOCHEMISTRY-US, V29, P9947, DOI 10.1021/bi00494a027; GRIMSHAW CE, 1989, BIOCHEMISTRY-US, V28, P5343, DOI 10.1021/bi00439a006; HALDER AB, 1985, OPHTHALMIC RES, V17, P185, DOI 10.1159/000265372; HYNDMAN DJ, 1986, THESIS QUEENS U KING; KUBISESKI TJ, 1992, J BIOL CHEM, V267, P6510; KUBISESKI TJ, 1993, ENZYMOLOGY MOL BIOL, V4, P259; LIU S, 1989, ARCH BIOCHEM BIOPHYS, V275, P112, DOI 10.1016/0003-9861(89)90355-X; MORJANA NA, 1989, J BIOL CHEM, V264, P2912; PENEFSKY SH, 1971, METHOD ENZYMOL, V56, P527; PETRASH JM, 1992, J BIOL CHEM, V267, P24833; PETRASH JM, 1993, ENZYMOLOGY MOL BIOL, V4, P289; RONDEAU JM, 1992, NATURE, V355, P469, DOI 10.1038/355469a0; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; TAKAHASHI K, 1968, J BIOL CHEM, V243, P6171; TARLE I, 1993, J BIOL CHEM, V268, P25687; VANDERJAGT DL, 1990, J BIOL CHEM, V265, P10912; WILSON DK, 1992, SCIENCE, V257, P81, DOI 10.1126/science.1621098	32	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2183	2188						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294474				2022-12-27	WOS:A1994MR98800095
J	KUSUKAWA, J; RAMACHANDRA, M; NAKANO, R; PADMANABHAN, R				KUSUKAWA, J; RAMACHANDRA, M; NAKANO, R; PADMANABHAN, R			PHOSPHORYLATION-DEPENDENT INTERACTION OF ADENOVIRUS PRETERMINAL PROTEIN WITH THE VIRAL ORIGIN OF DNA-REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SV40 T-ANTIGEN; RECOMBINANT VACCINIA VIRUS; NUCLEAR FACTOR-III; CASEIN KINASE-II; TERMINAL PROTEIN; BINDING PROTEIN; POLYMERASE-ALPHA; CELL-CYCLE; INSECT CELLS; HELA-CELLS	Adenovirus preterminal protein (pTP) exists as a heterodimer with the viral DNA polymerase (AdPol) and becomes covalently linked to a dCMP residue during initiation of DNA replication. The in vivo phosphorylation of pTP could he demonstrated when pTP is overproduced using recombinant vaccinia viruses, or by a large scale metabolic labeling of adenovirus 2 (Ad2)-infected HeLa cells. Phosphoserine was the only phosphoamino acid obtained by acid hydrolysis of P-32-labeled pTP immunoprecipitated from metabolically labeled HeLa cells infected with either Ad2 or recombinant vaccinia virus. Tryptic peptide maps of pTP expressed using recombinant vaccinia virus system in HeLa cells revealed that phosphorylation of pTP occurred on multiple sites. Dephosphorylation of pTP with calf intestinal alkaline phosphatase resulted in a significant decrease in its activity in the in vitro DNA replication initiation assays. Further characterization of the phosphatase-treated pTP indicated that although dephosphorylation did not affect its interaction with AdPol, the specific recognition of the DNA replication origin by pTP was significantly reduced as determined by gel electrophoresis-based DNA mobility shift assays.	UNIV KANSAS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, 3901 RAINBOW BLVD, KANSAS CITY, KS 66160 USA	University of Kansas; University of Kansas Medical Center				Ramachandra, Murali/0000-0003-4039-1491	NCI NIH HHS [CA33099] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; BINGER MH, 1982, J VIROL, V42, P488, DOI 10.1128/JVI.42.2.488-501.1982; BOSHER J, 1990, New Biologist, V2, P1083; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CHALLBERG MD, 1981, J VIROL, V38, P272, DOI 10.1128/JVI.38.1.272-277.1981; CHALLBERG MD, 1980, P NATL ACAD SCI-BIOL, V77, P5105, DOI 10.1073/pnas.77.9.5105; CHALLBERG MD, 1979, P NATL ACAD SCI USA, V76, P655, DOI 10.1073/pnas.76.2.655; CHEN M, 1990, J BIOL CHEM, V265, P18634; CHEN M, 1989, P NATL ACAD SCI USA, V86, P6116, DOI 10.1073/pnas.86.16.6116; CRIPPSWOLFMAN J, 1989, J BIOL CHEM, V264, P19478; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DOBBS L, 1990, VIROLOGY, V178, P43, DOI 10.1016/0042-6822(90)90377-4; DONALDSON RW, 1987, P NATL ACAD SCI USA, V84, P759, DOI 10.1073/pnas.84.3.759; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DUCEMAN BW, 1980, BIOCHEM J, V190, P781, DOI 10.1042/bj1900781; DURBAN E, 1985, EMBO J, V4, P2921, DOI 10.1002/j.1460-2075.1985.tb04024.x; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; ENOMOTO T, 1981, P NATL ACAD SCI-BIOL, V78, P6779, DOI 10.1073/pnas.78.11.6779; FANNING E, 1992, J VIROL, V66, P1289, DOI 10.1128/JVI.66.3.1289-1293.1992; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Green M, 1979, Methods Enzymol, V58, P425; HAY RT, 1989, BIOCHEM J, V258, P3, DOI 10.1042/bj2580003; HOSS A, 1990, J VIROL, V64, P4799; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; JENG YH, 1977, J VIROL, V22, P402, DOI 10.1128/JVI.22.2.402-411.1977; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JOUNG I, 1992, J VIROL, V66, P5788, DOI 10.1128/JVI.66.10.5788-5796.1992; KENNY MK, 1988, J BIOL CHEM, V263, P9809; KLEIN H, 1979, J BIOL CHEM, V254, P1051; KRANIAS EG, 1977, J BIOL CHEM, V252, P6750; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMAN IR, 1989, J BIOL CHEM, V264, P4265; LICHY JH, 1982, P NATL ACAD SCI-BIOL, V79, P5225, DOI 10.1073/pnas.79.17.5225; LINNE T, 1980, EUR J BIOCHEM, V103, P259, DOI 10.1111/j.1432-1033.1980.tb04310.x; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MCVEY D, 1993, J VIROL, V67, P5206, DOI 10.1128/JVI.67.9.5206-5215.1993; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MOHR IJ, 1987, EMBO J, V6, P153, DOI 10.1002/j.1460-2075.1987.tb04733.x; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORIN N, 1989, J VIROL, V63, P5228, DOI 10.1128/JVI.63.12.5228-5237.1989; MOSS B, 1991, SCIENCE, V252, P1662, DOI 10.1126/science.2047875; MUL YM, 1990, J VIROL, V64, P5510, DOI 10.1128/JVI.64.11.5510-5518.1990; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P6177, DOI 10.1073/pnas.80.20.6177; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P4266, DOI 10.1073/pnas.80.14.4266; NAKANO R, 1991, GENE, V105, P173, DOI 10.1016/0378-1119(91)90148-5; NASHEUER HP, 1991, J BIOL CHEM, V266, P7893; ONEILL EA, 1988, SCIENCE, V241, P1210, DOI 10.1126/science.3413485; PRIVES C, 1990, CELL, V61, P735, DOI 10.1016/0092-8674(90)90179-I; PRONK R, 1993, NUCLEIC ACIDS RES, V21, P2293, DOI 10.1093/nar/21.10.2293; PRUIJN GJM, 1986, NATURE, V322, P656, DOI 10.1038/322656a0; PRUIJN GJM, 1987, EMBO J, V6, P3771, DOI 10.1002/j.1460-2075.1987.tb02712.x; RAMACHANDRA M, 1993, J BIOL CHEM, V268, P17448; RAMACHANDRA M, 1993, J BIOL CHEM, V268, P442; REKOSH DMK, 1977, CELL, V11, P283, DOI 10.1016/0092-8674(77)90045-9; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; RONINSON I, 1980, BIOCHEM BIOPH RES CO, V94, P398, DOI 10.1016/S0006-291X(80)80234-8; ROOVERS DJ, 1993, J VIROL, V67, P265, DOI 10.1128/JVI.67.1.265-276.1993; ROSE KM, 1979, J BIOL CHEM, V254, P256; SASAGURI Y, 1987, VIROLOGY, V160, P389, DOI 10.1016/0042-6822(87)90010-9; SCHAACK J, 1990, GENE DEV, V4, P1197, DOI 10.1101/gad.4.7.1197; SCHNEIDER J, 1988, J VIROL, V62, P1598, DOI 10.1128/JVI.62.5.1598-1605.1988; SHU LM, 1987, VIROLOGY, V161, P520, DOI 10.1016/0042-6822(87)90146-2; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STILLMAN BW, 1981, CELL, V23, P497, DOI 10.1016/0092-8674(81)90145-8; STILLMAN BW, 1979, VIROLOGY, V93, P69, DOI 10.1016/0042-6822(79)90276-9; STUNNENBERG HG, 1988, NUCLEIC ACIDS RES, V16, P2431, DOI 10.1093/nar/16.6.2431; TAMANOI F, 1982, P NATL ACAD SCI-BIOL, V79, P2221, DOI 10.1073/pnas.79.7.2221; TEMPERLEY SM, 1992, EMBO J, V11, P761, DOI 10.1002/j.1460-2075.1992.tb05109.x; TEMPLETON DJ, 1992, MOL CELL BIOL, V12, P435, DOI 10.1128/MCB.12.2.435; Vishwanatha J K, 1989, Cancer Commun, V1, P345; WATSON CJ, 1990, NUCLEIC ACIDS RES, V18, P1167, DOI 10.1093/nar/18.5.1167; WIDES RJ, 1987, MOL CELL BIOL, V7, P864, DOI 10.1128/MCB.7.2.864; ZHAO LJ, 1991, NEW BIOL, V3, P1074; ZHAO LJ, 1988, CELL, V55, P1005, DOI 10.1016/0092-8674(88)90245-0; ZHAO LJ, 1991, GENE, V100, P147, DOI 10.1016/0378-1119(91)90360-N	82	8	8	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2189	2196						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294475				2022-12-27	WOS:A1994MR98800096
J	LAMBEAU, G; ANCIAN, P; BARHANIN, J; LAZDUNSKI, M				LAMBEAU, G; ANCIAN, P; BARHANIN, J; LAZDUNSKI, M			CLONING AND EXPRESSION OF A MEMBRANE-RECEPTOR FOR SECRETORY PHOSPHOLIPASES-A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CRYSTAL-STRUCTURE; MANNOSE RECEPTOR; TOXIC PHOSPHOLIPASES-A2; VENOM PHOSPHOLIPASE-A2; BINDING-PROTEIN; SKELETAL-MUSCLE; SNAKE-VENOM; IDENTIFICATION; RESOLUTION; SEQUENCE	Snake venom and mammalian secretory phospholipases A2 are structurally related enzymes that have been associated with several toxic (neurotoxicity, myotoxicity, etc.), pathological (inflammation, hypersensitivity, etc.), or physiological (contraction, proliferation, etc.) processes. We have previously shown that snake venom PLA2s have specific high affinity receptors. Here, we report the molecular cloning of one of these PLA2 receptors (molecular mass approximately 180 kDa), previously purified from rabbit skeletal muscle. It is a membrane protein with a N-terminal cysteine-rich domain, a fibronectin type II domain, eight repeats of a carbohydrate recognition domain, a unique transmembrane domain, and an intracellular C-terminal domain. The 1458-residue PLA2 receptor, expressed in transfected cells, binds svPLA2 with very high affinities (K(d) values approximately 10-20 pM). It also tightly binds the two structural types of msPLA2s, i.e. pancreatic PLA2 and synovial PLA2 (K(d) approximately 1-10 nM). This receptor might have a key role in normal and pathological actions of secretory PLA2s.	INST PHARMACOL MOLEC & CELLULAIRE,660 ROUTE LUCIOLES,F-06560 VALBONNE,FRANCE				Lambeau, Gerard/GRJ-5624-2022	Lambeau, Gerard/0000-0002-9239-518X				AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ARITA H, 1991, J BIOL CHEM, V266, P19139; BRUNIE S, 1985, J BIOL CHEM, V260, P9742; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; Dennis EA, 1983, ENZYMES, P307; DIJKSTRA BW, 1983, J MOL BIOL, V168, P163, DOI 10.1016/S0022-2836(83)80328-3; EZEKOWITZ RAB, 1991, NATURE, V351, P155, DOI 10.1038/351155a0; FRY MR, 1992, BIOL REPROD, V47, P751, DOI 10.1095/biolreprod47.5.751; GLASER KB, 1993, TRENDS PHARMACOL SCI, V14, P92, DOI 10.1016/0165-6147(93)90071-Q; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hawgood B., 1991, HDB NATURAL TOXINS R, V5, P3; HOLLAND DR, 1990, J BIOL CHEM, V265, P17649; KAMERLING JP, 1975, BIOCHEM J, V151, P491, DOI 10.1042/bj1510491; KANEMASA T, 1992, FEBS LETT, V303, P217, DOI 10.1016/0014-5793(92)80523-J; KINI RM, 1989, TOXICON, V27, P613, DOI 10.1016/0041-0101(89)90013-5; KRUSKAL BA, 1992, J EXP MED, V176, P1673, DOI 10.1084/jem.176.6.1673; KUIPERS OP, 1989, SCIENCE, V244, P82, DOI 10.1126/science.2704992; LAMBEAU G, 1990, J BIOL CHEM, V265, P9526; LAMBEAU G, 1989, J BIOL CHEM, V264, P11503; LAMBEAU G, 1991, FEBS LETT, V293, P29, DOI 10.1016/0014-5793(91)81145-X; LAMBEAU G, 1991, NEUROCHEM RES, V16, P651, DOI 10.1007/BF00965551; LENNARTZ MR, 1987, BIOCHEM J, V245, P705, DOI 10.1042/bj2450705; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MUKHERJEE AB, 1992, DNA CELL BIOL, V11, P233, DOI 10.1089/dna.1992.11.233; NAKAJIMA M, 1992, FEBS LETT, V309, P261, DOI 10.1016/0014-5793(92)80785-F; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PRUZANSKI W, 1991, IMMUNOL TODAY, V12, P143, DOI 10.1016/0167-5699(91)90077-7; PUIJK WC, 1977, BIOCHIM BIOPHYS ACTA, V492, P254, DOI 10.1016/0005-2795(77)90076-9; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; SOMMERS CD, 1992, EUR J PHARMACOL, V216, P87, DOI 10.1016/0014-2999(92)90213-N; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; VADAS P, 1989, AM J PATHOL, V134, P807; VADAS P, 1992, INFECT IMMUN, V60, P3928, DOI 10.1128/IAI.60.9.3928-3931.1992; VADAS P, 1986, LAB INVEST, V55, P391; VADAS P, 1981, NATURE, V293, P583, DOI 10.1038/293583a0; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WAITE M, 1987, HDB LIPID RES, V5, P111; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WERY JP, 1991, NATURE, V352, P79, DOI 10.1038/352079a0	40	262	269	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1575	1578						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294398				2022-12-27	WOS:A1994MR98800003
J	CATERINA, MJ; MILNE, JLS; DEVREOTES, PN				CATERINA, MJ; MILNE, JLS; DEVREOTES, PN			MUTATION OF THE 3RD INTRACELLULAR LOOP OF THE CAMP RECEPTOR, CAR1, OF DICTYOSTELIUM YIELDS MUTANTS IMPAIRED IN MULTIPLE SIGNALING PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; SITE-DIRECTED MUTAGENESIS; CYCLIC-AMP RECEPTOR; ADENYLATE-CYCLASE; SACCHAROMYCES-CEREVISIAE; ALPHA-SUBUNITS; LIGAND-BINDING; DISCOIDEUM; CELL; PROTEIN	Seven-membrane span receptors transduce a wide range of signals across the plasma membrane. One member of this family, the cAMP receptor, cAR1, of Dictyostelium, mediates some responses (eg. adenylyl cyclase activation, multicellular aggregation) which require G-proteins and others (e.g. Ca2+ influx, loss of ligand binding, cAR1 phosphorylation) which appear to be G-protein-independent. In this study, we randomly mutagenized the NH2-terminal eight amino acids of the third intracellular loop of cAR1 and examined the ability of these mutants to exhibit the three G-protein-independent responses listed above. Most mutants (classes I, II) exhibited wild-type or mildly defective responses. Several mutants (class III), however, were severely impaired in all three processes but not in cAMP binding. Furthermore, these mutants failed to couple productively with G-proteins and could not replace cAR1 in a car1- cell. For these reasons, we propose that class III mutations interfere with the formation of an ''active'' conformation of the receptor.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,520 WBSB,725 N WOLFE ST,BALTIMORE,MD 21205	Johns Hopkins University					PHS HHS [34933] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AU DC, 1989, BIOCHEMISTRY-US, V28, P2772, DOI 10.1021/bi00433a005; BONNER JT, 1982, DEV DICTYOSTELIUM DI, P1; BOYMARCOTTE E, 1984, MOL GEN GENET, V193, P406, DOI 10.1007/BF00382076; CATERINA MJ, 1991, FASEB J, V5, P3078, DOI 10.1096/fasebj.5.15.1743439; CHEUNG AH, 1989, MOL PHARMACOL, V34, P132; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; COUKELL MB, 1983, DEV GENET, V3, P283; COUKELL MB, 1990, J CELL SCI, V97, P649; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DEVREOTES P, 1987, METHOD CELL BIOL, V28, P299; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; DIXON RAF, 1987, NATURE, V326, P73, DOI 10.1038/326073a0; DOWD BF, 1988, J BIOL CHEM, V263, P15985; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; FRANKE J, 1977, P NATL ACAD SCI USA, V74, P2157, DOI 10.1073/pnas.74.5.2157; HADWIGER JA, 1991, P NATL ACAD SCI USA, V88, P8213, DOI 10.1073/pnas.88.18.8213; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; JACQUET M, 1988, MOL GEN GENET, V211, P441, DOI 10.1007/BF00425698; JOHNSON RL, 1991, BIOCHEMISTRY-US, V30, P6982, DOI 10.1021/bi00242a025; JOHNSON RL, 1992, J BIOL CHEM, V267, P4600; JOHNSON RL, 1993, GENE DEV, V7, P273, DOI 10.1101/gad.7.2.273; KESBEKE F, 1988, J CELL BIOL, V107, P521, DOI 10.1083/jcb.107.2.521; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KLEIN C, 1977, CELL, V10, P329, DOI 10.1016/0092-8674(77)90227-6; KLEIN C, 1979, J BIOL CHEM, V254, P2573; KLEIN P, 1987, J BIOL CHEM, V262, P358; KLEIN P, 1985, J BIOL CHEM, V260, P1757; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; KOSUGI S, 1992, J BIOL CHEM, V267, P24153; KUMAGAI A, 1991, J BIOL CHEM, V266, P1220; KUSPA A, 1992, P NATL ACAD SCI USA, V89, P8803, DOI 10.1073/pnas.89.18.8803; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILNE JL, 1991, J CELL BIOL, V112, P103, DOI 10.1083/jcb.112.1.103; MILNE JL, 1993, MOL BIOL CELL, V4, P283, DOI 10.1091/mbc.4.3.283; NAKAYAMA N, 1985, EMBO J, V4, P2643, DOI 10.1002/j.1460-2075.1985.tb03982.x; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; PUPILLO M, 1989, P NATL ACAD SCI USA, V86, P4892, DOI 10.1073/pnas.86.13.4892; PUPILLO M, 1992, MOL BIOL CELL, V3, P1229, DOI 10.1091/mbc.3.11.1229; RANDERATH E, 1965, ANAL BIOCHEM, V12, P83, DOI 10.1016/0003-2697(65)90145-4; SALAMON Y, 1979, ADV CYCLIC NUCL RES, V10, P35; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Sambrook J, 1989, MOL CLONING LABORATO; SAXE CL, 1993, GENE DEV, V7, P262, DOI 10.1101/gad.7.2.262; SAXE CL, 1992, DEV GENET, V12, P6; SNAARJAGALSKA BE, 1988, J BIOL CHEM, V263, P897; SUN TJ, 1990, J CELL BIOL, V110, P1549, DOI 10.1083/jcb.110.5.1549; SUN TJ, 1991, GENE DEV, V5, P572, DOI 10.1101/gad.5.4.572; VANHAASTERT PJM, 1987, J BIOL CHEM, V262, P7700; VANHAASTERT PJM, 1985, BIOCHIM BIOPHYS ACTA, V845, P254, DOI 10.1016/0167-4889(85)90184-3; VANHAASTERT PJM, 1984, BIOCHEM BIOPH RES CO, V124, P597, DOI 10.1016/0006-291X(84)91596-1; VANHAASTERT PJM, 1992, MOL BIOL CELL, V3, P603, DOI 10.1091/mbc.3.6.603; VAUGHAN RA, 1988, J BIOL CHEM, V263, P14538; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; WEINER JL, 1993, J BIOL CHEM, V268, P8070; WU LJ, 1991, BIOCHEM BIOPH RES CO, V179, P1141, DOI 10.1016/0006-291X(91)91690-E; YU SS, 1993, J BIOL CHEM, V268, P337; ZANOLARI B, 1992, CELL, V71, P755, DOI 10.1016/0092-8674(92)90552-N	59	74	74	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1523	1532						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288619				2022-12-27	WOS:A1994MR22000114
J	FRIMPONG, K; RODWELL, VW				FRIMPONG, K; RODWELL, VW			THE ACTIVE-SITE OF HAMSTER 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE RESIDES AT THE SUBUNIT INTERFACE AND INCORPORATES CATALYTICALLY ESSENTIAL ACIDIC RESIDUES FROM SEPARATE POLYPEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; BETA-METHYLGLUTARYL-COENZYME; NUCLEOTIDE-SEQUENCE; ARABIDOPSIS-THALIANA; ESCHERICHIA-COLI; RAT-LIVER; PURIFICATION; CLONING; YEAST; CDNA	We employed site-directed mutagenesis based on sequence comparisons and characterization of purified mutant enzymes to identify Glu558 and Asp766 of Syrian hamster 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (EC 1.1.1.34) as essential for catalysis. Mutant enzymes E558D, E558Q, and D766N had wild-type K(m) values for (S)-HMG-CoA and NADPH, but exhibited Iess than 0.5% of the wild-type catalytic activity. The inactive mutant polypeptides E558Q and D766N nevertheless can associate to generate an active enzyme. In vitro, 6% of the wild-type activity was observed when mutant polypeptides E558D and D766N were mixed in the absence of chaotropic agents. When mutant polypeptides E558Q and D766N were co-expressed in Escherichia coli, the resulting purified enzyme had 25% of wild-type activity. Hamster HMG-CoA reductase thus is a two-site, dimeric enzyme whose subunits associate to form an active site in which each monomer contributes at least one residue (e.g. Glu558 from one monomer and Asp766 from the other). The wild-type enzyme behaves as a dimer during size exclusion chromatography and has one HMG-CoA binding site per monomer. Syrian hamster HMG-CoA reductase thus appears to be a homodimer with two active sites which are located at the subunit interface.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047113] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47113] Funding Source: Medline; NIAID NIH HHS [AI 127713] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASSON ME, 1988, MOL CELL BIOL, V8, P3797, DOI 10.1128/MCB.8.9.3797; BASSON ME, 1986, P NATL ACAD SCI USA, V83, P5563, DOI 10.1073/pnas.83.15.5563; BEACH MJ, 1989, J BACTERIOL, V171, P2994, DOI 10.1128/jb.171.6.2994-3001.1989; BISCHOFF KM, 1992, BIOCHEM MED METAB B, V48, P149, DOI 10.1016/0885-4505(92)90060-C; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAELLES C, 1989, PLANT MOL BIOL, V13, P627, DOI 10.1007/BF00016018; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHEN HJ, 1990, J BIOL CHEM, V265, P4622; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; CHYE ML, 1991, PLANT MOL BIOL, V16, P567, DOI 10.1007/BF00023422; CORKEY BE, 1981, ANAL BIOCHEM, V118, P30, DOI 10.1016/0003-2697(81)90152-4; DARNAY BG, 1993, J BIOL CHEM, V268, P8429; DARNAY BG, 1992, J BIOL CHEM, V267, P15064; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DISTEFANO MD, 1990, BIOCHEMISTRY-US, V29, P2703, DOI 10.1021/bi00463a013; EDWARDS PA, 1985, J BIOL CHEM, V260, P278; ENDO A, 1992, J LIPID RES, V33, P1569; FERRER A, 1990, FEBS LETT, V266, P67, DOI 10.1016/0014-5793(90)81508-L; FRIMPONG K, 1993, PROTEIN EXPRES PURIF, V4, P337, DOI 10.1006/prep.1993.1044; GERTLER FB, 1988, MOL CELL BIOL, V8, P2713, DOI 10.1128/MCB.8.7.2713; GILL JF, 1985, J BIOL CHEM, V260, P9393; HSIAO KC, 1991, NUCLEIC ACIDS RES, V19, P2787, DOI 10.1093/nar/19.10.2787; JORDANSTARCK TC, 1989, J BIOL CHEM, V264, P17913; KLEINSEK DA, 1979, J BIOL CHEM, V254, P7591; LAM WL, 1992, J BIOL CHEM, V267, P5829; LARIMER FW, 1987, J BIOL CHEM, V262, P15327; LAWRENCE CM, 1993, BIOPHYS J, V64, pA350; LEARNED RM, 1989, P NATL ACAD SCI USA, V86, P2779, DOI 10.1073/pnas.86.8.2779; LEE SY, 1987, J BACTERIOL, V169, P3938, DOI 10.1128/jb.169.9.3938-3944.1987; LUSKEY KL, 1985, J BIOL CHEM, V260, P271; MAYER RJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P110, DOI 10.1016/0003-9861(88)90014-8; NESS GC, 1979, ARCH BIOCHEM BIOPHYS, V197, P493, DOI 10.1016/0003-9861(79)90272-8; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; QURESHI N, 1976, BIOCHEMISTRY-US, V15, P4185, DOI 10.1021/bi00664a009; RAJKOVIC A, 1989, P NATL ACAD SCI USA, V86, P8217, DOI 10.1073/pnas.86.21.8217; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKALNIK DG, 1985, DNA-J MOLEC CELL BIO, V4, P439, DOI 10.1089/dna.1985.4.439; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Teraoka H, 1979, Methods Enzymol, V59, P862; VELOSO D, 1981, BIOCHEMISTRY-US, V20, P887, DOI 10.1021/bi00507a036; WANG YL, 1990, J BIOL CHEM, V265, P21634; WOODWARD HD, 1988, J BIOL CHEM, V263, P18411; 1991, PROMEGA PROTOCOLS AP, P264; 1983, OLIGONUCLEOTIDE DIRE, P1	45	20	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1217	1221						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288583				2022-12-27	WOS:A1994MR22000071
J	OHMICHI, M; MATUOKA, K; TAKENAWA, T; SALTIEL, AR				OHMICHI, M; MATUOKA, K; TAKENAWA, T; SALTIEL, AR			GROWTH-FACTORS DIFFERENTIALLY STIMULATE THE PHOSPHORYLATION OF SHC PROTEINS AND THEIR ASSOCIATION WITH GRB2 IN PC-12 PHEOCHROMOCYTOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRK PROTOONCOGENE PRODUCT; SRC HOMOLOGY DOMAIN; SIGNAL TRANSDUCTION; TYROSINE KINASES; INSULIN-RECEPTOR; RAS; RAF-1; ACTIVATION; PHOSPHOLIPASE-C-GAMMA-1; MEMBRANE	Growth factor receptor tyrosine kinases can form stable associations with intracellular proteins that contain src homology (SH) 2 domains, including two proteins, Shc and Grb2, that are thought to lie upstream from the ras protooncogene in a signaling cascade. The phosphorylation and molecular associations of these proteins were evaluated in PC-12 pheochromocytoma cells treated with nerve growth factor (NGF), epidermal growth factor (EGF), and insulin. Both NGF and EGF stimulated the tyrosine phosphorylation of Shc proteins and their subsequent association with the receptors. In contrast, insulin had no effect on Shc phosphorylation, despite the expression of functional insulin receptors in these cells at levels comparable to those observed for NGF and EGF. NGF and EGF also induced the association of Shc proteins with a Grb2 fusion protein or endogenous Grb2, whereas insulin had no effect. All of the tyrosine-phosphorylated Shc proteins associated with the Grb2 fusion protein, although only about half of the endogenous She was phosphorylated in response to NGF or EGF. However, aH three hormones induced the association of several additional tyrosine phosphorylated proteins with Grb2, some of which also coprecipitated with antiserum against the 85-kDa subunit of phosphatidylinositol-3 kinase. Moreover, these growth factors stimulated the association of phosphatidylinositol-3 kinase activity with the Grb2 fusion protein, although this activity was not detected in anti-Shc immunoprecipitates. These results provide further evidence for the divergence of signaling pathways in insulin action, and suggest that Grb2 forms separate complexes with tyrosine-phosphorylated proteins in PC-12 cells.	UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48104; PARKE DAVIS & CO,DIV PHARMACEUT RES,DEPT SIGNAL TRANSDUCT,ANN ARBOR,MI 48105; UNIV TOKYO,INST MED SCI,DEPT MOLEC ONCOL,TOKYO 108,JAPAN; TOKYO METROPOLITAN GERIATR HOSP & INST GERONTOL,DEPT BIOSIGNAL RES,ITABASHI KU,TOKYO 173,JAPAN	University of Michigan System; University of Michigan; Pfizer; University of Tokyo			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; CARPENTER G, 1979, J BIOL CHEM, V254, P4884; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COUGHLIN SR, 1989, SCIENCE, V243, P1191; HATTORI S, 1992, J BIOL CHEM, V267, P20346; JAISWAL RK, 1993, J BIOL CHEM, V268, P7055; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOVACINA KS, 1990, J BIOL CHEM, V265, P1215; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1990, EMBO J, V9, P4357; MATHUDA Y, 1987, J BIOL CHEM, V262, P2832; MATSUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; OHMICHI M, 1993, ENDOCRINOLOGY, V133, P46, DOI 10.1210/en.133.1.46; OHMICHI M, 1991, J BIOL CHEM, V266, P14858; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; OHMICHI M, 1992, J BIOL CHEM, V267, P21601; OHMICHI M, 1992, J BIOL CHEM, V267, P14604; OHMICHI M, 1991, BIOCHEM BIOPH RES CO, V179, P217, DOI 10.1016/0006-291X(91)91357-I; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; SALTIEL AR, 1991, MOL CELL ENDOCRINOL, V81, pC197, DOI 10.1016/0303-7207(91)90198-2; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; THIES RS, 1989, J BIOL CHEM, V263, P8912; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHU GC, 1992, P NATL ACAD SCI USA, V89, P9559, DOI 10.1073/pnas.89.20.9559; ZHU GC, 1993, J BIOL CHEM, V268, P1775	39	78	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1143	1148						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288573				2022-12-27	WOS:A1994MR22000059
J	ENYEDI, A; VERMA, AK; HEIM, R; ADAMO, HP; FILOTEO, AG; STREHLER, EE; PENNISTON, JT				ENYEDI, A; VERMA, AK; HEIM, R; ADAMO, HP; FILOTEO, AG; STREHLER, EE; PENNISTON, JT			THE CA2+ AFFINITY OF THE PLASMA-MEMBRANE CA2+ PUMP IS CONTROLLED BY ALTERNATIVE SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CALMODULIN-BINDING	The plasma membrane Ca2+ pump is a calmodulin-regulated P-type ATPase that is an essential element in controlling intracellular Ca2+ concentration. Studies on the gene structure of this pump have revealed an alternate splice option that changes the structure of the calmodulin-binding domain. This change in the structure of the enzyme results in a reduced calmodulin affinity. Tests of the enzyme's activity in the presence of a high calmodulin concentration, approximating that found inside living cells, show that this reduced calmodulin affinity causes a reduced apparent affinity of the enzyme for Ca2+. This shift in the Ca2+ activation occurs in a Ca2+ concentration range crucial to cellular function and is probably the physiologically important consequence of the alternate splice.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905; SWISS FED INST TECHNOL,BIOCHEM LAB,CH-8092 ZURICH,SWITZERLAND	Mayo Clinic; ETH Zurich			Adamo, Hugo Pedro/ABB-8338-2021; Enyedi, Agnes/N-9742-2013	Adamo, Hugo Pedro/0000-0002-1712-8049; Enyedi, Agnes/0000-0002-7366-9376	NIGMS NIH HHS [GM 28835] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028835] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMO HP, 1992, BIOCHEM J, V285, P791, DOI 10.1042/bj2850791; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; ENYEDI A, 1991, J BIOL CHEM, V266, P8952; ENYEDI A, 1993, J BIOL CHEM, V268, P10621; GOUGH AH, 1993, J CELL BIOL, V121, P1095, DOI 10.1083/jcb.121.5.1095; HEIM R, 1992, J BIOL CHEM, V267, P24476; KEETON TP, 1993, J BIOL CHEM, V268, P2740; KESSLER F, 1992, BIOCHEMISTRY-US, V31, P11785, DOI 10.1021/bi00162a016; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; Penniston J T, 1980, Ann N Y Acad Sci, V356, P245, DOI 10.1111/j.1749-6632.1980.tb29615.x; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STAUFFER TP, 1993, J BIOL CHEM, V268, P25993; STREHLER EE, 1991, J MEMBRANE BIOL, V120, P1, DOI 10.1007/BF01868586	13	121	121	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					41	43						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276828				2022-12-27	WOS:A1994MR21900011
J	YENUSH, L; KUNDRA, V; WHITE, MF; ZETTER, BR				YENUSH, L; KUNDRA, V; WHITE, MF; ZETTER, BR			FUNCTIONAL DOMAINS OF THE INSULIN-RECEPTOR RESPONSIBLE FOR CHEMOTACTIC SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOGENOUS SUBSTRATE PHOSPHORYLATION; HUMAN INTERLEUKIN-8 RECEPTOR; TYROSINE KINASE-ACTIVITY; BC3H-1 MURINE MYOCYTES; GROWTH-FACTOR; JUXTAMEMBRANE REGION; BETA-SUBUNIT; PROTEIN; CELLS; AUTOPHOSPHORYLATION	The insulin receptor mediates a variety of cellular responses to insulin, including glucose transport, endocytosis, and cell proliferation. The role of the insulin receptor in mediating cellular motility has not, however, been extensively investigated. In this report, we demonstrate that chinese hamster ovary (CHO) cells that normally have low concentrations of insulin receptor display chemotaxis toward insulin after overexpression of the wild type human insulin receptor. Chemotaxis toward insulin proceeded through a pertussis toxin-sensitive pathway and required both tyrosine kinase activity and tyrosine autophosphorylation of the regulatory region of the beta-subunit. In contrast, the autophosphorylation sites in the carboxyl terminus of the receptor were not required for chemotactic activity. A mutation in the juxtamembrane region, which disabled tyrosine phosphorylation of the insulin receptor substrate-1 (IRS-1), also prevented the chemotactic response, suggesting a possible role for IRS-1 in chemotactic signaling. In the absence of insulin receptor, however, the presence of excess transfected IRS-1 was not sufficient to mediate chemotaxis toward insulin. These results demonstrate that the intact insulin receptor can stimulate a chemotactic signaling pathway and that this initial pathway more closely correlates with that for insulin-stimulated cell proliferation than for insulin-stimulated receptor endocytosis.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT SURG,300 LONGWOOD AVE,BOSTON,MA 02115; HARVARD UNIV,SCH MED,PROGRAM CELL & DEV BIOL,BOSTON,MA 02115; JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Joslin Diabetes Center, Inc.			Yenush, Lynne/J-8815-2014	Yenush, Lynne/0000-0001-8589-7002	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK038712, R01DK038712, R01DK043808, R55DK038712] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 38712, DK 43808] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1992, J BIOL CHEM, V267, P1367; BACKER JM, 1991, BIOCHEMISTRY-US, V30, P6366, DOI 10.1021/bi00240a003; BACKER JM, 1990, J BIOL CHEM, V265, P16450; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BEGUM N, 1993, J BIOL CHEM, V268, P7917; BOTWELL D, 1992, P NATL ACAD SCI USA, V89, P6511; Donahue WL, 1954, J PEDIATR, V45, P505; FEENER EP, 1993, J BIOL CHEM, V268, P11256; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; KNIGHT AB, 1981, P NATL ACAD SCI-BIOL, V78, P2554, DOI 10.1073/pnas.78.4.2554; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; LUTTRELL L, 1990, J BIOL CHEM, V265, P16873; LUTTRELL LM, 1988, J BIOL CHEM, V263, P6134; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; NALDINI L, 1991, ONCOGENE, V6, P501; OBERMAIERKUSSER B, 1989, J BIOL CHEM, V264, P9497; PIENTA KJ, 1991, CANCER SURV, V11, P255; ROTHENBERG PL, 1988, J BIOL CHEM, V263, P15546; SCHILLING EE, 1979, P NATL ACAD SCI USA, V76, P5877, DOI 10.1073/pnas.76.11.5877; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STRACKE ML, 1989, J BIOL CHEM, V264, P21544; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; ZETTER BR, 1980, NATURE, V285, P41, DOI 10.1038/285041a0	33	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					100	104						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276780				2022-12-27	WOS:A1994MR21900023
J	ZEGERS, I; HAIKAL, AF; PALMER, R; WYNS, L				ZEGERS, I; HAIKAL, AF; PALMER, R; WYNS, L			CRYSTAL-STRUCTURE OF RNASE T1 WITH 3'-GUANYLIC ACID AND GUANOSINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEAST-SQUARES REFINEMENT; 3-DIMENSIONAL STRUCTURE; MACROMOLECULAR STRUCTURES; GPN TRANSESTERIFICATION; SUBSITE INTERACTIONS; SUBSTRATE-BINDING; 1.9-A RESOLUTION; X-RAY; RIBONUCLEASE-T1; COMPLEX	A modified method for the synthesis and separation of endo and exo guanosine 2',3'-cyclophosphorothioate (cGPS) has been developed. The exo diastereoisomer has been co-crystallized with RNase T1. cGPS is known to be a RNase T1 inhibitor but is also a very slow substrate. It was hydrolyzed during the crystallization, leaving 3'-guanylic acid (3'-GMP) in the active site. As a guanosine was also found to be bound in a subsite, the enzyme contains the products of the reaction of guanylyl-3',5'-guanosine. The structure was refined to a resolution of 1.7 angstrom and yielded a final R value of 14.5%. In contrast to previous 3'-GMP complexes of RNase T1, the ribose phosphate moiety of the inhibitor is in contact with all the active site residues. The phosphate forms hydrogen bonds with Asn36, Tyr38, Arg77, His92, and with Asn49 from a symmetry-related molecule. The ribose 2'-OH is hydrogen-bonded to both Glu58 and His40. The interactions in the active site of the present structure are compared to those found in the 2'-GMP complex of RNase T1.	UNIV LONDON BIRKBECK COLL,DEPT CRYSTALLOG,LONDON WC1E 7HX,ENGLAND	University of London; Birkbeck University London	ZEGERS, I (corresponding author), VRIJE UNIV BRUSSELS,INST MOLEC BIOL,PAARDENSTR 65,B-1640 RHODE ST GENESE,BELGIUM.							ALTONA C, 1972, J AM CHEM SOC, V94, P8205, DOI 10.1021/ja00778a043; ARNI R, 1988, J BIOL CHEM, V263, P15358; DING JP, 1991, J BIOL CHEM, V266, P15128; ECKSTEIN F, 1972, BIOCHEMISTRY-US, V11, P3507, DOI 10.1021/bi00769a002; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; HEINEMANN U, 1982, NATURE, V299, P27, DOI 10.1038/299027a0; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; HILL C, 1983, TRENDS BIOCHEM SCI, V8, P364, DOI 10.1016/0968-0004(83)90363-8; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KOEPKE J, 1989, J MOL BIOL, V206, P475, DOI 10.1016/0022-2836(89)90495-6; KOSTREWA D, 1989, BIOCHEMISTRY-US, V28, P7592, DOI 10.1021/bi00445a014; LENZ A, 1991, J BIOL CHEM, V266, P7661; LENZ A, 1993, EUR J BIOCHEM, V211, P311, DOI 10.1111/j.1432-1033.1993.tb19900.x; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; NISHIKAWA S, 1987, BIOCHEMISTRY-US, V26, P8620, DOI 10.1021/bi00400a019; PACE CN, 1991, ANGEW CHEM INT EDIT, V30, P343, DOI 10.1002/anie.199103433; PLETINCKX J, 1993, IN PRESS BIOCHEMISTR; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SHERIFF S, 1987, J APPL CRYSTALLOGR, V20, P55, DOI 10.1107/S0021889887087132; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; STEYAERT J, 1991, BIOCHEMISTRY-US, V30, P8661, DOI 10.1021/bi00099a024; STEYAERT J, 1990, BIOCHEMISTRY-US, V29, P9064, DOI 10.1021/bi00490a025; STEYAERT J, 1991, BIOCHEMISTRY-US, V30, P8666, DOI 10.1021/bi00099a025; SUGIO S, 1985, FEBS LETT, V183, P115, DOI 10.1016/0014-5793(85)80966-2; SUGIO S, 1988, J BIOCHEM-TOKYO, V103, P354, DOI 10.1093/oxfordjournals.jbchem.a122274; SUSSMAN JL, 1977, ACTA CRYSTALLOGR A, V33, P800, DOI 10.1107/S0567739477001958; TAKAHASHI K, 1971, J BIOCHEM, V70, P945, DOI 10.1093/oxfordjournals.jbchem.a129724; Takahashi K., 1982, ENZYMES, V15, p435 468; WALZ FG, 1977, BIOCHEMISTRY-US, V16, P5509, DOI 10.1021/bi00644a018; ZEGERS I, 1992, BIOCHEMISTRY-US, V31, P11317, DOI 10.1021/bi00161a009	32	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					127	133						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276784				2022-12-27	WOS:A1994MR21900027
J	PENA, A; REDDY, CD; WU, SJ; HICKOK, NJ; REDDY, EP; YUMET, G; SOPRANO, DR; SOPRANO, KJ				PENA, A; REDDY, CD; WU, SJ; HICKOK, NJ; REDDY, EP; YUMET, G; SOPRANO, DR; SOPRANO, KJ			REGULATION OF HUMAN ORNITHINE DECARBOXYLASE EXPRESSION BY THE C-MYC.MAX PROTEIN COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEIN; DNA-BINDING; MYC PROTEIN; TRANSCRIPTIONAL ACTIVATION; NUCLEOTIDE-SEQUENCE; GENE; CELLS; MAX; GROWTH; DOMAINS	The presence of a CACGTG element within a region of the human ornithine decarboxylase (ODC) promoter located at -491 to -474 base pairs 5' to the start site of transcription suggested that the c-Myc.Max protein complex may play a role in the regulation of ODC expression during growth. Electrophoretic mobility shift assays and methylation interference analysis showed that the nuclei of WI-38 cells expressing ODC contained proteins that bound to this region of the ODC gene in a manner that correlated with growth-associated ODC expression. Also, use of antibodies against c-Myc and Max and purified recombinant c-Myc and Max protein in the electrophoretic mobility shift assay confirmed that these proteins can specifically bind this portion of the human ODC promoter. Transient transfection studies showed that increase in the level of c-Myc and/or Max led to a significant enhancement of expression of a human ODC promoter-CAT reporter construct. Moreover, treatment of actively growing WI-38 cells with an antisense oligomer to c-Myc reduced the amount of endogenous protein complex formed and the amount of endogenous ODC mRNA expressed. These studies show that the c-Myc.Max protein complex plays a role in the transcriptional regulation of human ODC in vivo.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS RES INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; THOMAS JEFFERSON UNIV,DEPT DERMATOL & BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University			Reddy, E. Premkumar/F-6233-2011		NCI NIH HHS [CA 10817, CA 56309] Funding Source: Medline; NIAMS NIH HHS [AR 40022] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA056309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR040022] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABRAHAMSEN MS, 1990, MOL CELL BIOL, V10, P5525, DOI 10.1128/MCB.10.10.5525; ABRAHAMSEN MS, 1992, J BIOL CHEM, V267, P18866; AUGENLICHT LH, 1974, EXP CELL RES, V8, P255; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BACON TA, 1991, ONCOGENE RES, V6, P21; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BERBERICH S, 1992, ONCOGENE, V7, P775; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRABANT M, 1988, P NATL ACAD SCI USA, V85, P2200, DOI 10.1073/pnas.85.7.2200; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CARTER R, 1991, ONCOGENE, V6, P229; COSENZA SC, 1988, J BIOL CHEM, V263, P12751; CRISTOFALO VJ, 1973, EXP CELL RES, V76, P419, DOI 10.1016/0014-4827(73)90394-7; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HALMEKYTO M, 1989, BIOCHEM BIOPH RES CO, V162, P528, DOI 10.1016/0006-291X(89)92029-9; HEBBY O, 1990, TRENDS BIOCHEM SCI, V15, P153; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HICKOK NJ, 1990, GENE, V93, P257, DOI 10.1016/0378-1119(90)90233-H; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HOLTTA E, 1989, GENE, V83, P125, DOI 10.1016/0378-1119(89)90410-1; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; KAHANA C, 1984, P NATL ACAD SCI-BIOL, V81, P3645, DOI 10.1073/pnas.81.12.3645; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATZ A, 1987, MOL CELL BIOL, V7, P2641, DOI 10.1128/MCB.7.7.2641; KATZ A, 1988, J BIOL CHEM, V263, P7604; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LU L, 1991, BIOCHEM J, V277, P671, DOI 10.1042/bj2770671; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MANZELLA JM, 1990, J BIOL CHEM, V265, P11817; MOSHIER JA, 1992, NUCLEIC ACIDS RES, V20, P2581, DOI 10.1093/nar/20.10.2581; OLSON EN, 1986, MOL CELL BIOL, V6, P2792, DOI 10.1128/MCB.6.8.2792; OWEN TA, 1990, J CELL PHYSIOL, V142, P137, DOI 10.1002/jcp.1041420117; OWEN TA, 1987, J BIOL CHEM, V262, P15111; PALVIMO JJ, 1991, NUCLEIC ACIDS RES, V19, P3921, DOI 10.1093/nar/19.14.3921; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1988, CANCER RES, V48, P759; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RAPPOLEE DA, 1989, J CELL BIOCHEM, V39, P1, DOI 10.1002/jcb.240390102; REDDY CD, 1992, ONCOGENE, V7, P2085; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SETH A, 1986, GENE, V42, P49, DOI 10.1016/0378-1119(86)90149-6; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TOSCANI A, 1987, ANAL BIOCHEM, V165, P309, DOI 10.1016/0003-2697(87)90274-0; WEN L, 1989, J BIOL CHEM, V264, P9016; WETTERS TV, 1989, MOL CELL BIOL, V9, P5484, DOI 10.1128/MCB.9.12.5484; WETTERS TV, 1989, NUCLEIC ACIDS RES, V17, P9843, DOI 10.1093/nar/17.23.9843; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	61	131	133	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27277	27285						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262968				2022-12-27	WOS:A1993MM26200064
J	TATE, CG; HENDERSON, PJF				TATE, CG; HENDERSON, PJF			MEMBRANE TOPOLOGY OF THE L-RHAMNOSE-H+ TRANSPORT PROTEIN (RHAT) FROM ENTEROBACTERIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BETA-LACTAMASE; CYTOPLASMIC MEMBRANE; GENE-PRODUCT; CLONING; PURIFICATION; INSERTION; SEQUENCE; VECTOR; EXPORT	The L-rhamnose-H+ symporter (RhaT) is a 344-amino acid integral membrane protein, found in many Enterobacteria, which couples the uptake of the sugar L-rhamnose with the inward movement of protons. Based on its hydropathy profile and the application of von Heijne's ''positive inside'' rule (von Heijne, G. (1992) J. Mol. Biol. 225, 487-494), a model of the L-rhamnose-H+ symport protein (RhaT) is proposed containing 10 transmembrane helices with the NH2 and COOH termini in the periplasm. This model was tested by the creation of random beta-lactamase (Bla) fusions. The data from 33 unique, randomly generated, RhaT-Bla fusions and from 5 site-specific fusions supported the proposed topology between transmembrane helices 2-10. However, the localization of the putative first hydrophilic loop and the NH2 terminus was not possible because the beta-lactamase fusions in this region were shown to be unreliable indicators of the topology of RhaT.	UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND; UNIV LEEDS,DEPT BIOCHEM & MOLEC BIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND	University of Cambridge; University of Leeds			Henderson, Peter JF/Q-1907-2018	Tate, Christopher/0000-0002-2008-9183; Henderson, Peter/0000-0002-9187-0938	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSSON H, 1992, J BIOL CHEM, V267, P1491; BALDOMA L, 1990, FEMS MICROBIOL LETT, V72, P103, DOI 10.1016/0378-1097(90)90353-R; BOWLER LD, 1989, MOL MICROBIOL, V3, P1277, DOI 10.1111/j.1365-2958.1989.tb00278.x; BROOMESMITH JK, 1986, GENE, V49, P341, DOI 10.1016/0378-1119(86)90370-7; BROOMESMITH JK, 1990, MOL MICROBIOL, V4, P1637, DOI 10.1111/j.1365-2958.1990.tb00540.x; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CROWE JS, 1991, NUCLEIC ACIDS RES, V19, P184, DOI 10.1093/nar/19.1.184; EDELMAN A, 1987, MOL MICROBIOL, V1, P101, DOI 10.1111/j.1365-2958.1987.tb00533.x; GARCIAMARTIN C, 1992, J GEN MICROBIOL, V138, P1109, DOI 10.1099/00221287-138-6-1109; GERMINO J, 1984, P NATL ACAD SCI-BIOL, V81, P4692, DOI 10.1073/pnas.81.15.4692; GRIFFITH J K, 1992, Current Opinion in Cell Biology, V4, P684, DOI 10.1016/0955-0674(92)90090-Y; HENDERSON PJF, 1986, METHOD ENZYMOL, V125, P387; KAMPFENKEL K, 1993, J BIOL CHEM, V268, P6050; KUHLBRANDT W, 1991, NATURE, V350, P130, DOI 10.1038/350130a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEWIS MJ, 1992, J BIOL CHEM, V267, P3482; LEWIS MJ, 1990, J BIOL CHEM, V265, P10541; Maniatis T., 1982, MOL CLONING; MOORE KE, 1987, J BIOL CHEM, V262, P8806; MUIRY JAR, 1993, BIOCHEM J, V290, P833, DOI 10.1042/bj2900833; MUIRY JAR, 1989, THESIS U CAMBRIDGE; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; Sambrook J, 1989, MOL CLONING LABORATO; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; TATE CG, 1992, J BIOL CHEM, V267, P6923; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; WANG RC, 1991, J MOL BIOL, V217, P441, DOI 10.1016/0022-2836(91)90748-U; WEINER JH, 1993, J BIOL CHEM, V268, P3238; WITHOLT B, 1976, ANAL BIOCHEM, V74, P160, DOI 10.1016/0003-2697(76)90320-1; WU JH, 1992, J BIOL CHEM, V267, P12570	34	17	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					26850	26857						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262918				2022-12-27	WOS:A1993MM26200007
J	ZIOBER, BL; VU, MP; WALEH, N; CRAWFORD, J; LIN, CS; KRAMER, RH				ZIOBER, BL; VU, MP; WALEH, N; CRAWFORD, J; LIN, CS; KRAMER, RH			ALTERNATIVE EXTRACELLULAR AND CYTOPLASMIC DOMAINS OF THE INTEGRIN-ALPHA-7 SUBUNIT ARE DIFFERENTIALLY EXPRESSED DURING DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMININ-BINDING INTEGRIN; CELL-ADHESION RECEPTORS; AMINO-ACID-SEQUENCE; MESSENGER-RNA; ALPHA-SUBUNIT; ONCOGENIC TRANSFORMATION; MEMBRANE GLYCOPROTEIN; FIBRONECTIN RECEPTOR; MOLECULAR-CLONING; EPITHELIAL-CELLS	Examination of cDNAs for the laminin-binding alpha7 integrin subunit identified two different sequences (designated X1 and X2) coding for the variable region between the III and IV homology repeat domains near the putative ligand-binding site. Sequencing of a mouse alpha7 genomic clone established that the X1 and X2 regions are derived by mutually exclusive alternative mRNA splicing. Reverse transcriptase-polymerase chain reaction analysis of alpha7 mRNA indicated that the X1 and X2 isoforms were present in equal amounts in mouse skeletal myoblasts and adult heart. However, in adult skeletal muscle, the X2 variant was exclusively expressed. Amino acid sequence homologies in the III/IV segment suggest that alpha3 and alpha6 are also alternatively spliced at this site. We identified alternatively spliced exons in a human alpha6 genomic clone that encode X1- and X2-like segments. Analysis of the alpha7 cytoplasmic domain indicated that this region was also alternatively spliced and like alpha3 and alpha6 could exist as the A or B form. In mouse skeletal and cardiac muscle the B form of alpha7 was strongly expressed. However, we identified alpha7A in neonate and adult skeletal muscle but not in cardiac tissue. High levels of alpha7A were detected in differentiating myotubes, but in proliferating myoblasts only the alpha7B isoform was present. These results indicate that alternative splicing of alpha7 mRNA is differentially regulated during development and generates variant integrin chains with structurally and presumably functionally unique ligand-binding and cytoplasmic domains.	UNIV CALIF SAN FRANCISCO, DEPT STOMATOL & ANAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA; SRI INT, MENLO PK, CA 94025 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; SRI International					NCI NIH HHS [CA51884, CA33834] Funding Source: Medline; NIDCR NIH HHS [DE10356] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051884, R01CA033834] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BRAY PF, 1990, J BIOL CHEM, V265, P9587; BROWN NH, 1989, CELL, V59, P185, DOI 10.1016/0092-8674(89)90880-5; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER HM, 1991, J CELL BIOL, V115, P843, DOI 10.1083/jcb.115.3.843; DECURTIS I, 1991, J CELL BIOL, V113, P405, DOI 10.1083/jcb.113.2.405; DEDHAR S, 1992, EXP CELL RES, V203, P270, DOI 10.1016/0014-4827(92)90064-F; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; ERLE DJ, 1991, AM J RESP CELL MOL, V5, P170, DOI 10.1165/ajrcmb/5.2.170; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GEHLSEN KR, 1989, J BIOL CHEM, V264, P19034; GEHLSEN KR, 1988, SCIENCE, V241, P1228, DOI 10.1126/science.2970671; GEORGEWEINSTEIN M, 1993, DEV BIOL, V156, P209, DOI 10.1006/dbio.1993.1071; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HIERCK BP, 1993, CELL ADHES COMMUN, V1, P1; HIRANO S, 1991, DEVELOPMENT, V113, P1007; HOGERVORST F, 1993, J CELL BIOL, V121, P179, DOI 10.1083/jcb.121.1.179; HOGERVORST F, 1991, EUR J BIOCHEM, V199, P425, DOI 10.1111/j.1432-1033.1991.tb16140.x; HOGERVORST F, 1993, J BIOL CHEM, V268, P18427; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRAMER RH, 1991, CELL REGUL, V2, P805, DOI 10.1091/mbc.2.10.805; KRAMER RH, 1989, J BIOL CHEM, V264, P15642; KRAMER RH, 1993, MOL CELLULAR ASPECTS, P239; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LANGUINO LR, 1992, J BIOL CHEM, V267, P7116; LEE EC, 1992, J CELL BIOL, V117, P671, DOI 10.1083/jcb.117.3.671; MANITIAS T, 1989, MOL CLONING LABORATO; MARINKOVICH MP, 1992, J CELL BIOL, V119, P695, DOI 10.1083/jcb.119.3.695; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; RAMOS DM, 1991, INVAS METAST, V11, P125; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW LM, 1990, J CELL BIOL, V110, P2167, DOI 10.1083/jcb.110.6.2167; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SMITH JW, 1990, J BIOL CHEM, V265, P12267; SONG WK, 1992, J CELL BIOL, V117, P643, DOI 10.1083/jcb.117.3.643; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; SUZUKI S, 1990, EMBO J, V9, P757, DOI 10.1002/j.1460-2075.1990.tb08170.x; TAKADA Y, 1991, J CELL BIOL, V115, P257, DOI 10.1083/jcb.115.1.257; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; TAMURA RN, 1991, P NATL ACAD SCI USA, V88, P10183, DOI 10.1073/pnas.88.22.10183; TSUJI T, 1990, J BIOL CHEM, V265, P7016; TSUJI T, 1991, J BIOCHEM-TOKYO, V109, P659, DOI 10.1093/oxfordjournals.jbchem.a123436; VANKUPPEVELT THMSM, 1989, P NATL ACAD SCI USA, V86, P5415; VONDERMARK H, 1991, J BIOL CHEM, V266, P23593; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651	61	133	136	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26773	26783						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253814				2022-12-27	WOS:A1993MK42500111
J	ARKHAMMAR, P; JUNTTIBERGGREN, L; LARSSON, O; WELSH, M; NANBERG, E; SJOHOLM, A; KOHLER, M; BERGGREN, PO				ARKHAMMAR, P; JUNTTIBERGGREN, L; LARSSON, O; WELSH, M; NANBERG, E; SJOHOLM, A; KOHLER, M; BERGGREN, PO			PROTEIN-KINASE-C MODULATES THE INSULIN SECRETORY PROCESS BY MAINTAINING A PROPER FUNCTION OF THE BETA-CELL VOLTAGE-ACTIVATED CA2+ CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE CA-2+ CONCENTRATION; RAT PANCREATIC-ISLETS; PHORBOL ESTER; SIGNAL TRANSDUCTION; PHOSPHOINOSITIDE HYDROLYSIS; INOSITOL TRISPHOSPHATE; CYTOPLASMIC CA-2+; K+ CHANNELS; LINE RINM5F; GLUCOSE	In the present study an attempt was made to further elucidate the molecular mechanisms whereby protein kinase C (PKC) modulates the beta-cell stimulus-secretion coupling. Regulation of Ca2+ channel activity, [Ca2+]i, and insulin release were investigated in both normal pancreatic mouse beta-cells and in similar beta-cells deprived of PKC activity. [Ca2+]i was measured with the intracellular fluorescent Ca2+ indicator fura-2 and the Ca2+ channel activity was estimated by the whole cell configuration of the patch-clamp technique. To reveal the various isoenzymes of PKC present in the mouse beta-cell, proteins were separated by one-dimensional gel electrophoresis and Western blotting was performed. The production of inositol phosphates was measured by ion-exchange chromatography and insulin release was measured radioimmunologically. Acute stimulation with the phorbol ester 12-O-tetradecanoylphorbol-13-acetate resulted in suppression of both the carbamylcholine-induced increase in [Ca2+]i and production of inositol 1,4,5-trisphosphate. Under these conditions the increase in [Ca2+]i in response to glucose was similar to that found in control cells. When beta-cells were deprived of PKC, by exposure to 200 nM 12-O-tetradecanoylphorbol-13-acetate for 24-48 h, there was an enhanced response to carbamylcholine. This response constituted increases in both the [Ca2+]i signal and production of inositol 1,4,5-trisphosphate. Interestingly, cells with down-regulated PKC activity responded more slowly to glucose stimulation, when comparing the initial increase in [Ca2+]i, than control cells. On the other hand, the maximal increase in [Ca2+]i was similar whether or not PKC was present. Moreover, PKC down-regulated cells exhibited a significant reduction of maximal whole cell Ca2+ currents, a finding that may explain the altered kinetics with regard to the [Ca2+]i increase in response to the sugar. Both the alpha and beta1 forms of the PKC isoenzymes were present in the mouse beta-cell and were also subjected to PKC down-regulation. Hence, either of these isoenzymes or both may be involved in the modulation of phospholipase C and Ca2+ channel activity. Since insulin release under physiological conditions is critically dependent on Ca2+-influx through the voltage-gated L-type Ca2+ channels, the kinetics of hormone release was expected to demonstrate a similar delay as that of the [Ca2+]i increase. Although not as pronounced, such a delay was indeed also observed in the onset of insulin release. There was, however, no effect on the total amounts of hormone released. The present study confirms that PKC has multiple roles and thereby interacts at different sites in the complex series of events constituting the beta-cell signal-transduction pathway. It is suggested that PKC may be tonically active and effective in the maintenance of the phosphorylation state of the voltage-gated L-type Ca2+ channel, enabling an appropriate function of this channel in the insulin secretory process.	KAROLINSKA INST, KAROLINSKA HOSP,ROLF LUFT CTR DIABET RES, DEPT ENDOCRINOL,BOX 60500, S-10401 STOCKHOLM 60, SWEDEN; UNIV UPPSALA, CTR BIOMED, DEPT MED CELL BIOL, S-75123 UPPSALA, SWEDEN; UNIV HOSP UPPSALA, DEPT PATHOL, S-75185 UPPSALA, SWEDEN	Karolinska Institutet; Karolinska University Hospital; Uppsala University; Uppsala University; Uppsala University Hospital			Welsh, Michael/AAF-8564-2020	Welsh, Michael/0000-0002-5467-9755; Berggren, Per-Olof/0000-0001-8991-413X				AMMALA C, 1991, NATURE, V353, P849, DOI 10.1038/353849a0; ARKHAMMAR P, 1987, J BIOL CHEM, V262, P5448; ARKHAMMAR P, 1989, BIOCHEM J, V264, P207, DOI 10.1042/bj2640207; ARKHAMMAR P, 1990, BIOCHEM J, V265, P203, DOI 10.1042/bj2650203; ARKHAMMAR P, 1989, BIOCHEM BIOPH RES CO, V159, P223, DOI 10.1016/0006-291X(89)92426-1; ARKHAMMAR P, 1986, BIOCHIM BIOPHYS ACTA, V887, P236, DOI 10.1016/0167-4889(86)90060-1; ASHCROFT FM, 1988, J PHYSIOL-LONDON, V400, P501, DOI 10.1113/jphysiol.1988.sp017134; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; BARROWMAN MM, 1986, FEBS LETT, V201, P137, DOI 10.1016/0014-5793(86)80586-5; BERGGREN PO, 1989, BIOCHEM BIOPH RES CO, V165, P416, DOI 10.1016/0006-291X(89)91086-3; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BEST L, 1983, BIOCHEM BIOPH RES CO, V116, P9, DOI 10.1016/0006-291X(83)90373-X; DIVIRGILIO F, 1986, J BIOL CHEM, V261, P32; DUNNE MJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P67, DOI 10.1016/0304-4157(91)90012-L; EFENDIC S, 1993, J INT MED, V229, P9; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HELLMAN B, 1965, ANN NY ACAD SCI, V131, P541, DOI 10.1111/j.1749-6632.1965.tb34819.x; HELLMAN B, 1975, ENDOCRINOLOGY, V97, P392, DOI 10.1210/endo-97-2-392; HII CST, 1987, BIOCHEM J, V246, P489, DOI 10.1042/bj2460489; KANATSUNA T, 1981, DIABETES, V30, P231, DOI 10.2337/diabetes.30.3.231; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KINDMARK H, 1992, FEBS LETT, V303, P85, DOI 10.1016/0014-5793(92)80483-W; LAGAST H, 1984, J CLIN INVEST, V73, P878, DOI 10.1172/JCI111284; LERNMARK A, 1974, DIABETOLOGIA, V10, P431, DOI 10.1007/BF01221634; LI GD, 1990, BIOCHEM J, V272, P637, DOI 10.1042/bj2720637; Martell A. E., 1974, CRITICAL STABILITY C, V2; MONACO ME, 1988, BIOCHEM BIOPH RES CO, V151, P717, DOI 10.1016/S0006-291X(88)80339-5; NILSSON T, 1987, BIOCHEM J, V248, P329, DOI 10.1042/bj2480329; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; ORELLANA SA, 1985, J BIOL CHEM, V260, P5236; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PETERRIESCH B, 1988, J CLIN INVEST, V81, P1154, DOI 10.1172/JCI113430; PETERSEN OH, 1990, NATURE, V344, P300, DOI 10.1038/344300c0; PFEILSCHIFTER J, 1989, BIOCHEM J, V262, P285, DOI 10.1042/bj2620285; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; REGAZZI R, 1990, J BIOL CHEM, V265, P15003; RICKARD JE, 1985, BIOCHEM J, V231, P623, DOI 10.1042/bj2310623; RORSMAN P, 1986, AM J PHYSIOL, V251, pC912, DOI 10.1152/ajpcell.1986.251.6.C912; SHEARMAN MS, 1989, PHARMACOL REV, V41, P211; SMITH PA, 1989, NATURE, V342, P550, DOI 10.1038/342550a0; Smith RM, 1974, CRITICAL STABILITY C, V1-6; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; VELASCO JM, 1989, Q J EXP PHYSIOL CMS, V74, P367, DOI 10.1113/expphysiol.1989.sp003280; VELASCO JM, 1988, FEBS LETT, V231, P366, DOI 10.1016/0014-5793(88)80851-2; VICENTINI LM, 1988, FEBS LETT, V228, P346, DOI 10.1016/0014-5793(88)80029-2; WELSH N, 1991, AUTOIMMUNITY, V9, P33, DOI 10.3109/08916939108997121; WOLLHEIM CB, 1986, ANN NY ACAD SCI, V488, P317; WOLLHEIM CB, 1988, EMBO J, V7, P2443, DOI 10.1002/j.1460-2075.1988.tb03090.x; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914; YADA T, 1989, J BIOL CHEM, V264, P2455; ZAWALICH W, 1983, BIOCHEM BIOPH RES CO, V117, P448, DOI 10.1016/0006-291X(83)91221-4; ZAWALICH W, 1987, DIABETES, V36, P426, DOI 10.2337/diabetes.36.4.426	55	91	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2743	2749						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300606				2022-12-27	WOS:A1994MV43200059
J	PEDRON, T; GIRARD, R; TURCO, SJ; CHABY, R				PEDRON, T; GIRARD, R; TURCO, SJ; CHABY, R			PHOSPHATIDYLINOSITOL-ANCHORED MOLECULES AND INDUCIBLE LIPOPOLYSACCHARIDE-BINDING SITES OF HUMAN AND MOUSE BONE-MARROW CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-A; LEISHMANIA-DONOVANI; HUMAN MONOCYTES; MACROPHAGES; BACTERIAL; LIPOPHOSPHOGLYCAN; DIFFERENTIATION; ENDOTOXIN; RECEPTOR; RELEASE	We have previously established that lipopolysaccharide (LPS) induces the expression of new specific LPS-binding sites (LpsR) in mouse bone marrow cells (BMC). We now show that exposure of human BMC to LPS elicits the production of both CD14 molecules (detectable with monoclonal antibody My4) and LpsR (detectable with fluorescein isothiocyanate-LPS). Pretreatment of stimulated human BMC with My4 inhibited the binding of fluorescein isothiocyanate-LPS. The stimulation of human BMC, but not mouse BMC, required the presence of serum. Other characteristics of mouse and human BMC examined were very similar. Their inducible LpsR interacted with the lipid moieties of LPS and Leishmania donovani lipophosphoglycan and with a soluble preparation of peptidoglycan. Moreover, mouse and human LpsR were susceptible to treatment with a phosphatidylinositol-specific phospholipase C (PI-PLC), thus suggesting that both are PI-anchored CD14 molecules. Neither LpsR appeared able to interact with a synthetic LPS antagonist (compound PPDm2) structurally related to the lipid region of LPS. However, PPDm2 blocked LPS-induced expression of LpsR in both BMC. Furthermore, in both species, pretreatment of BMC with PI-PLC did not prevent the cells from expressing LpsR in response to LPS. The results support the hypothesis that the elicited LpsR of mouse and human BMC is an inducible form of CD14, whereas the putative ''signaling LPS receptor'' of these cells is not CD14 or any other PI-anchored molecule.	UNIV PARIS 11,CNRS,URA 1116,EQUIPE ENDOTOXINES,BATIMENT 432,F-91405 ORSAY,FRANCE; INST PASTEUR,CNRS,URA 359,UNITE IMMUNOPHYSIOL MOLEC,F-75724 PARIS 15,FRANCE; UNIV KENTUCKY,MED CTR,DEPT BIOCHEM,LEXINGTON,KY 40536	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Kentucky								ADAM A, 1972, P NATL ACAD SCI USA, V69, P851, DOI 10.1073/pnas.69.4.851; ADEREM AA, 1986, J EXP MED, V164, P165, DOI 10.1084/jem.164.1.165; BALL ED, 1984, J CLIN INVEST, V73, P1072, DOI 10.1172/JCI111292; BRIGHAM KL, 1974, J CLIN INVEST, V54, P792, DOI 10.1172/JCI107819; BUCKINGH.RB, 1972, J CLIN INVEST, V51, P1186, DOI 10.1172/JCI106912; CARVER MA, 1991, J BIOL CHEM, V266, P10974; CHABY R, 1993, IN PRESS J IMMUNOL; CONZELMANN A, 1987, BIOCHEM J, V246, P605, DOI 10.1042/bj2460605; COSTELLO LC, 1992, J BIOL CHEM, V267, P8599; COUTURIER C, 1991, J IMMUNOL, V147, P1899; DASILVA RP, 1989, J IMMUNOL, V143, P617; DZIARSKI R, 1991, J BIOL CHEM, V266, P4719; FEIST W, 1989, IMMUNOBIOLOGY, V179, P293, DOI 10.1016/S0171-2985(89)80036-1; FERRERO E, 1993, P NATL ACAD SCI USA, V90, P2380, DOI 10.1073/pnas.90.6.2380; GIRARD R, 1993, J IMMUNOL, V150, P4504; GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490; GOYERT SM, 1986, J IMMUNOL, V137, P3909; GREISMAN SE, 1969, P SOC EXP BIOL MED, V131, P1154, DOI 10.3181/00379727-131-34059; HAMMERLING U, 1976, P NATL ACAD SCI USA, V73, P2008, DOI 10.1073/pnas.73.6.2008; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; HAZIOT A, 1988, J IMMUNOL, V141, P547; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HINSHAW LB, 1977, SURG GYNECOL OBSTET, V145, P1; JORDAN MM, 1964, P SOC EXP BIOL MED, V115, P455; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; LEI MG, 1988, J IMMUNOL, V141, P996; LOPPNOW H, 1986, EUR J IMMUNOL, V16, P1263, DOI 10.1002/eji.1830161013; MCCONVILLE MJ, 1991, J BIOL CHEM, V266, P15170; Morrison D C, 1979, Adv Immunol, V28, P293; MUNN DH, 1990, BLOOD, V75, P2042; NASU N, 1991, INT IMMUNOL, V3, P205, DOI 10.1093/intimm/3.2.205; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; PEDRON T, 1992, INT IMMUNOL, V4, P533, DOI 10.1093/intimm/4.4.533; PORATH J, 1967, NATURE, V215, P1491, DOI 10.1038/2151491a0; RUCO LP, 1978, J IMMUNOL, V121, P2035; SCHOFIELD L, 1993, J EXP MED, V177, P145, DOI 10.1084/jem.177.1.145; STUTZ PL, 1990, CELLULAR MOL ASPECTS, P129; TAHRIJOUTI MA, 1990, MOL IMMUNOL, V27, P763, DOI 10.1016/0161-5890(90)90085-E; TAHRIJOUTI MA, 1990, MOL IMMUNOL, V27, P751, DOI 10.1016/0161-5890(90)90084-D; TALAMASROHANA P, 1990, J IMMUNOL, V144, P4817; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; Tracey K J, 1990, Adv Surg, V23, P21; ULMER AJ, 1992, INFECT IMMUN, V60, P5145, DOI 10.1128/IAI.60.12.5145-5152.1992; WEERSINK AJL, 1993, J IMMUNOL, V150, P253; WESTPHAL O, 1952, Z NATURFORSCH B, V7, P148, DOI 10.1515/znb-1952-0303; WILSON ME, 1986, J IMMUNOL, V136, P4681; WORTHEN GS, 1988, J IMMUNOL, V140, P3553; WRIGHT SD, 1991, CURR OPIN IMMUNOL, V3, P83, DOI 10.1016/0952-7915(91)90082-C; WRIGHT SD, 1989, J EXP MED, V169, P175, DOI 10.1084/jem.169.1.175; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	50	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2426	2432						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300569				2022-12-27	WOS:A1994MV43200016
J	TURNBOW, MA; KELLER, SR; RICE, KM; GARNER, CW				TURNBOW, MA; KELLER, SR; RICE, KM; GARNER, CW			DEXAMETHASONE DOWN-REGULATION OF INSULIN-RECEPTOR SUBSTRATE-1 IN 3T3-L1 ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORT; PROTEIN; PHOSPHORYLATION; RESISTANCE; BINDING; CELLS; RAT	Insulin resistance resulting from prolonged exposure of intact animals or cultured cells to glucocorticoids is often attributed to postreceptor signaling defects. To better understand the specific effects of glucocorticoids on insulin signaling, we have characterized the effect of dexamethasone on the expression of an insulin signaling intermediate, the insulin receptor substrate-1 (IRS-1) in 3T3-L1 adipocytes. Addition of dexamethasone resulted in a 40-70% decline in steady-state IRS-1 protein over 24-48 h of treatment. Dexamethasone did not significantly change the degradation rate of IRS-1 protein but decreased the net rate of amino acid incorporation into IRS-1 by 87%. Between 1 and 2.5 h of treatment with dexamethasone, actinomycin D, or both drugs given simultaneously, the concentration of IRS-1 mRNA declined with a half-life of 0.7-1.0 h. However, after 4 h of dexamethasone treatment, IRS-1 mRNA concentrations stabilized at approximately 35% of the control level. The dexamethasone-induced decline in IRS-1 protein could be prevented by simultaneous administration of the glucocorticoid antagonist mifepristone, RU38486. These results suggest that in 3T3-L1 adipocytes the loss of IRS-1 protein after dexamethasone treatment can be accounted for chiefly by inhibition of the synthesis of IRS-1 mRNA.	DARTMOUTH COLL,SCH MED,DEPT BIOCHEM,HANOVER,NH 03755	Dartmouth College	TURNBOW, MA (corresponding author), TEXAS TECH UNIV,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,3601 4TH ST,LUBBOCK,TX 79430, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042816] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 42816] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU DT, 1990, BIOCHEM SOC T, V18, P1247, DOI 10.1042/bst0181247; FROST SC, 1985, J BIOL CHEM, V260, P2646; GARVEY WT, 1989, ENDOCRINOLOGY, V124, P2063, DOI 10.1210/endo-124-5-2063; GRUNFELD C, 1981, ENDOCRINOLOGY, V109, P1723, DOI 10.1210/endo-109-5-1723; GUILLAUMEGENTIL C, 1990, ENDOCRINOLOGY, V126, P1873, DOI 10.1210/endo-126-4-1873; HOECK W, 1989, J BIOL CHEM, V264, P14396; KELLER SR, 1993, BIOCHIM BIOPHYS ACTA, V1172, P323, DOI 10.1016/0167-4781(93)90222-Y; KELLER SR, 1991, J BIOL CHEM, V266, P12817; LAZAR G, 1986, BIOCHEM BIOPH RES CO, V134, P44, DOI 10.1016/0006-291X(86)90524-3; OLEFSKY JM, 1975, J CLIN INVEST, V56, P1499, DOI 10.1172/JCI108231; RICE KM, 1992, J BIOL CHEM, V267, P10163; RICE KM, 1993, BIOCHEM BIOPH RES CO, V190, P961, DOI 10.1006/bbrc.1993.1143; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TURNBOW MA, 1993, BIOTECHNIQUES, V15, P267; VANPUTTEN JPM, 1985, DIABETOLOGIA, V28, P445, DOI 10.1007/BF00280889; WAJNGOT A, 1992, P NATL ACAD SCI USA, V89, P6035, DOI 10.1073/pnas.89.13.6035; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0	19	76	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2516	2520						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300578				2022-12-27	WOS:A1994MV43200028
J	HIASA, H; DIGATE, RJ; MARIANS, KJ				HIASA, H; DIGATE, RJ; MARIANS, KJ			DECATENATING ACTIVITY OF ESCHERICHIA-COLI DNA GYRASE AND TOPOISOMERASE-I AND TOPOISOMERASE-III DURING ORIC AND PBR322 DNA-REPLICATION IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; ORIGIN; GENE; CHROMOSOME; ENZYME; TRANSCRIPTION; PURIFICATION; MECHANISM; SEQUENCES; CLONING	oriC and pBR322 DNA replication, reconstituted with purified replication proteins, has been used to study the functional activities of Escherichia coli topoisomerase I, DNA gyrase, and topoisomerase III during the final stages of DNA replication. In the oriC system, DNA gyrase-catalyzed decatenation of daughter DNA molecules was very inefficient, whereas topoisomerase III could catalyze complete decatenation. In the pBR322 DNA replication system, almost all the daughter DNA molecules could be decatenated by DNA gyrase alone in the absence of salt. Decatenation by DNA gyrase in the pBR322 system was completely inhibited, without a concomitant inhibition of DNA synthesis, by the addition of physiological concentrations of salt. Topoisomerase III, however, could decatenate all of the daughter DNA molecules in the pBR322 system, even in the presence of high concentrations of salt. A similar effect could not be observed in the oriC system, because the addition of salt inhibited DNA synthesis. Topoisomerase I was incapable of catalyzing decatenation under any conditions examined in either the oriC or pBR322 replication system. The addition of topoisomerase I to the replication systems resulted only in an inhibition of DNA synthesis.	UNIV MARYLAND, SCH PHARM, DEPT BIOMED CHEM, BALTIMORE, MD 21201 USA; UNIV MARYLAND, INST MED BIOTECHNOL, CTR MED BIOTECHNOL, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	HIASA, H (corresponding author), MEM SLOAN KETTERING CANC CTR, MOLEC BIOL PROGRAM, NEW YORK, NY 10021 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034558, R29GM048445, R01GM048445] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48445, GM34558] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; ASAI T, 1990, EMBO J, V9, P4065, DOI 10.1002/j.1460-2075.1990.tb07628.x; BLISKA JB, 1987, J MOL BIOL, V194, P205, DOI 10.1016/0022-2836(87)90369-X; BOHK HJ, 1983, GENE, V24, P265; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; DEPEW RE, 1978, J BIOL CHEM, V253, P511; DIGATE RJ, 1989, J BIOL CHEM, V264, P17924; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; DRLICA K, 1978, J MOL BIOL, V120, P145, DOI 10.1016/0022-2836(78)90061-X; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; HIGGINS NP, 1978, P NATL ACAD SCI USA, V75, P1773, DOI 10.1073/pnas.75.4.1773; HIGGINS NP, 1982, NUCLEIC ACIDS RES, V10, P6833, DOI 10.1093/nar/10.21.6833; ITOH T, 1979, COLD SPRING HARB SYM, V43, P409, DOI 10.1101/SQB.1979.043.01.047; KAGUNI JM, 1982, NATURE, V296, P623, DOI 10.1038/296623a0; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KATO J, 1992, J BIOL CHEM, V267, P25676; KATO JI, 1988, J BACTERIOL, V170, P3967, DOI 10.1128/jb.170.9.3967-3977.1988; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARIANS KJ, 1987, J BIOL CHEM, V262, P10362; MARIANS KJ, 1982, J BIOL CHEM, V257, P5656; MINDEN JS, 1986, J BIOL CHEM, V261, P1906; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MIZUUCHI K, 1978, P NATL ACAD SCI USA, V75, P5960, DOI 10.1073/pnas.75.12.5960; ORR E, 1979, MOL GEN GENET, V177, P103, DOI 10.1007/BF00267259; PARADA CA, 1991, J BIOL CHEM, V266, P18895; PENG H, 1993, P NATL ACAD SCI USA, V90, P8571, DOI 10.1073/pnas.90.18.8571; PENG H, 1993, IN PRESS J BIOL CHEM; RICHEY B, 1987, J BIOL CHEM, V262, P7157; STECK TR, 1984, CELL, V36, P1081, DOI 10.1016/0092-8674(84)90058-8; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; TOMIZAWA JI, 1974, P NATL ACAD SCI USA, V71, P2260, DOI 10.1073/pnas.71.6.2260; TSEDINH YC, 1988, J BIOL CHEM, V263, P15857; WANG JC, 1983, NUCLEIC ACIDS RES, V11, P1773, DOI 10.1093/nar/11.6.1773; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WU CA, 1992, J BIOL CHEM, V267, P4030; ZAVITZ KH, 1992, J BIOL CHEM, V267, P6933	39	106	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2093	2099						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294462				2022-12-27	WOS:A1994MR98800083
J	BOBE, R; BREDOUX, R; WUYTACK, F; QUARCK, R; KOVACS, T; PAPP, B; CORVAZIER, E; MAGNIER, C; ENOUF, J				BOBE, R; BREDOUX, R; WUYTACK, F; QUARCK, R; KOVACS, T; PAPP, B; CORVAZIER, E; MAGNIER, C; ENOUF, J			THE RAT PLATELET 97-KDA CA2+ATPASE ISOFORM IS THE SARCOENDOPLASMIC RETICULUM CA2+ATPASE-3 PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELL; MESSENGER-RNA; CALCIUM PUMPS; SARCOPLASMIC-RETICULUM; MEMBRANE-VESICLES; INTRACELLULAR MEMBRANES; CA-2+-ATPASE GENE; CA2+ PUMP; EXPRESSION; DISTINCT	We recently showed that human and rat platelets express two types of SERCAs (Sarco Endoplasmic Reticulum Ca2+ ATPases): a 100-kDa SERCA2b isoform and a 97-kDa SERCA isoform. Here, we explored the possibility that the rat 97-kDa isoform is identical to the SERCA3 protein. For this purpose, we first attempted to detect SERCA3 mRNA in rat platelet total RNA by reverse transcription-polymerase chain reaction using SERCA3-specific primers, and demonstrated the presence of this mRNA species by sequencing the amplification product. We then searched for a relationship between the expression of the SERCA3 mRNA and of the 97-kDa protein using either rat aortic smooth muscle cells, previously found not to express the 97-kDa SERCA isoform (negative model), or platelets of spontaneously hypertensive rats (SHR), which overexpress this isoform (overexpression model) but express the 100-kDa SERCA2b isoform normally. No expression of SERCA3 mRNA was detectable by analysis of smooth muscle cell RNA, but comparison by reverse transcription-polymerase chain reaction of the SERCA2b and SERCA3 mRNAs from the platelets of normotensive (Wistar-Kyoto, WKY) rats and SHR clearly demonstrated a 238 +/- 43% increase in the expression of the SERCA3 mRNA in SHR platelets only. Last, by comparative Western blotting of WKY rat and SHR platelet membranes using a recently developed polyclonal anti-SERCA3 antibody, we established that the 97-kDa SERCA and the SERCA3 protein are identical, as immunostaining of the 97-kDa protein revealed a 230 +/- 25% increase in the expression of this protein in SHR versus WKY rat platelets. It is concluded that the 97-kDa platelet SERCA isoform, which is up-regulated in SHR, is the SERCA3 protein. As far as we know, this constitutes the first demonstration of the actual presence of this Ca2+ ATPase isoform in normal cells, in addition to the artificial transfection systems.	CATHOLIC UNIV LEUVEN, FYSIOL LAB, B-3000 LOUVAIN, BELGIUM; NATL INST HAEMATOL & BLOOD TRANSFUS, H-1113 BUDAPEST, HUNGARY	KU Leuven	BOBE, R (corresponding author), HOP LARBOISIERE, INSERM, U348, F-75010 PARIS, FRANCE.		Kovács, Tünde/O-6020-2017; BOBE, Regis/F-4951-2016; Quarck, Rozenn/J-8067-2018	Kovács, Tünde/0000-0003-1064-2616; BOBE, Regis/0000-0002-8225-9117; Quarck, Rozenn/0000-0002-8293-6261; Papp, Bela/0000-0002-5025-3087				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURK SE, 1989, J BIOL CHEM, V264, P18561; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEAN WL, 1989, CELL CALCIUM, V10, P289, DOI 10.1016/0143-4160(89)90055-9; DEAN WL, 1982, J BIOL CHEM, V257, P4390; DEMETZ M, 1984, BIOCHIM BIOPHYS ACTA, V770, P159; DESMEDT H, 1991, J BIOL CHEM, V266, P7092; DJAFFAR I, 1991, THROMB RES, V62, P127, DOI 10.1016/0049-3848(91)90187-2; ENOUF J, 1988, J BIOL CHEM, V263, P13922; ENOUF J, 1992, BIOCHEM J, V286, P135, DOI 10.1042/bj2860135; ENOUF J, 1987, J BIOL CHEM, V262, P9293; ENYEDI A, 1986, J BIOL CHEM, V261, P9558; FISCHER TH, 1985, J BIOL CHEM, V260, P8996; FISCHER TH, 1987, BIOCHEMISTRY-US, V26, P8024, DOI 10.1021/bi00398a070; HACK N, 1986, BIOCHEM J, V233, P661, DOI 10.1042/bj2330661; JAVORS MA, 1982, BIOCHIM BIOPHYS ACTA, V691, P220, DOI 10.1016/0005-2736(82)90410-2; KASERGLANZMANN R, 1977, BIOCHIM BIOPHYS ACTA, V466, P429, DOI 10.1016/0005-2736(77)90336-4; KORCZAK B, 1988, J BIOL CHEM, V263, P4813; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPEUCH CJ, 1983, BIOCHIM BIOPHYS ACTA, V731, P456, DOI 10.1016/0005-2736(83)90041-X; LYTTON J, 1992, J BIOL CHEM, V267, P14483; MAGNIER C, 1992, J BIOL CHEM, V267, P15808; MARUYAMA K, 1989, CELL MOTIL CYTOSKEL, V14, P26, DOI 10.1002/cm.970140107; MENASHI S, 1984, BIOCHEM J, V222, P413, DOI 10.1042/bj2220413; NAGAI R, 1989, P NATL ACAD SCI USA, V86, P2966, DOI 10.1073/pnas.86.8.2966; NEWMAN PJ, 1988, J CLIN INVEST, V82, P739, DOI 10.1172/JCI113656; PAPP B, 1992, BIOCHEM J, V288, P297, DOI 10.1042/bj2880297; PAPP B, 1993, BIOCHEM J, V295, P685, DOI 10.1042/bj2950685; PAPP B, 1991, J BIOL CHEM, V266, P14593; ROBBLEE LS, 1973, J GEN PHYSIOL, V61, P462, DOI 10.1085/jgp.61.4.462; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; ROTH GJ, 1989, BIOCHEM BIOPH RES CO, V160, P705, DOI 10.1016/0006-291X(89)92490-X; SARKADI B, 1988, BIOCHIM BIOPHYS ACTA, V939, P40, DOI 10.1016/0005-2736(88)90044-2; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; WICKI AN, 1989, THROMB HAEMOSTASIS, V61, P448; WUYTACK F, 1994, J BIOL CHEM, V269, P1410; ZARAINHERZBERG A, 1990, J BIOL CHEM, V265, P4670	38	106	106	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1417	1424						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288609				2022-12-27	WOS:A1994MR22000100
J	CALKIN, PA; BARNES, EM				CALKIN, PA; BARNES, EM			GAMMA-AMINOBUTYRIC ACID-A [GABA(A)] AGONISTS DOWN-REGULATE GABA(A) BENZODIAZEPINE RECEPTOR POLYPEPTIDES FROM THE SURFACE OF CHICK CORTICAL-NEURONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBRAL NEURONS; COMPLEX; ACTIVATION; SUBUNITS; PROTEINS; EXPOSURE; CURRENTS; CELLS	The impermeant SH-cleavable reagent, I-125-labeled 3,3'-dithiopropionyl 1-sulfosuccinimidyl 1'-glycyltyrosine (DPSgt) and specific immunoprecipitation were used to quantitate gamma-aminobutyric acid-A (GABA(A)) receptor polypeptides with domains exposed on the surface of chick cortical neurons. The I-125 label incorporated into 50- and 53-kDa receptor subunits was completely removed by washing the cells with glutathione (GSH) buffer. A single dose of 100 muM GABA or GABA agonist was added to the neurons, and after 5 days in culture the cells were washed and labeled with I-125-DPSgt. This treatment with GABA or isoguvacine reduced the level of the receptor I-125-labeled subunits by 50-60%, while the reduction by 4,5,6,7-tetrahydroisoazolo[5,4-c]pyridin-3-ol was less than 17%. The subunit down-regulation by agonist was prevented by the GABA(A) antagonist 3alpha-hydroxy-16-imino-5beta-17-aza-androstan-11-one (R5135). Direct iodination of membranes isolated from treated cells revealed a similar loss of subunits, indicating that the down-regulated polypeptides are not retained intracellularly. Furthermore, the level of intracellular [H-3]flunitrazepam binding (per mg of protein) did not change significantly during chronic GABA treatment, while the fraction of intracellular binding rose from 7% to 15% of the total, owing to a decline in surface binding. The fate of the surface subunits during acute agonist exposure was examined by labeling intact neurons with I-125-DPSgt at 0-degrees-C, incubating with GABA for 2-4 h at 37-degrees-C and then washing with GSH buffer. Of the 50-53-kDa receptor peptides originally on the surface, 16 +/- 2% became protected from GSH during the 2-h GABA treatment. This sequestration was not found in cells incubated without GABA, with GABA + R5135, or with GABA at 0-degrees-C. A consistently lower level of sequestered subunits was recovered after a 4- versus 2-h GABA treatment at 37-degrees-C, suggesting polypeptide degradation. Overall, the results indicate that GABA(A) receptor sequestration and subsequent degradation play an important role in agonist-dependent down-regulation.	BAYLOR COLL MED, VERNA & MARRS MCLEAN DEPT BIOCHEM, HOUSTON, TX 77030 USA	Baylor College of Medicine					NIDDK NIH HHS [DK17436] Funding Source: Medline; NIMH NIH HHS [MH47715] Funding Source: Medline; NINDS NIH HHS [NS11535] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017436] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH047715] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS011535, P50NS011535] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BORDEN LA, 1988, MOL PHARMACOL, V34, P354; BORDEN LA, 1984, SCIENCE, V226, P857, DOI 10.1126/science.6093257; BRETSCHER MS, 1989, EMBO J, V8, P1341, DOI 10.1002/j.1460-2075.1989.tb03514.x; BUREAU M, 1990, MOL PHARMACOL, V37, P497; BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; CALKIN PA, 1992, T AM SOC NEUROCHEM, V23, P228; DELOREY TM, 1992, J BIOL CHEM, V267, P16747; FIRESTONE GL, 1990, METHOD ENZYMOL, V182, P688; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HABLITZ JJ, 1989, BRAIN RES, V501, P332, DOI 10.1016/0006-8993(89)90650-1; HEBEBRAND J, 1987, J NEUROCHEM, V48, P1103, DOI 10.1111/j.1471-4159.1987.tb05633.x; KANG I, 1991, BRIT J PHARMACOL, V103, P1285, DOI 10.1111/j.1476-5381.1991.tb09781.x; MALOTEAUX JM, 1987, EUR J PHARMACOL, V144, P173, DOI 10.1016/0014-2999(87)90517-6; MCCONAHEY P, 1980, IMMUNOCHEMICAL TEC A, V70, P210; MEHTA AK, 1992, MOL BRAIN RES, V16, P29, DOI 10.1016/0169-328X(92)90190-M; MISTRY DK, 1990, PFLUG ARCH EUR J PHY, V416, P454, DOI 10.1007/BF00370754; MONTPIED P, 1991, J BIOL CHEM, V266, P6011; NUMANN RE, 1984, NEUROSCI LETT, V47, P289, DOI 10.1016/0304-3940(84)90528-7; REID PA, 1990, NATURE, V346, P655, DOI 10.1038/346655a0; ROCA DJ, 1990, MOL PHARMACOL, V37, P37; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SIGEL E, 1983, J BIOL CHEM, V258, P6965; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TEHRANI MHJ, 1986, DEV BRAIN RES, V25, P91; TEHRANI MHJ, 1988, NEUROSCI LETT, V87, P288, DOI 10.1016/0304-3940(88)90463-6; TEHRANI MHJ, 1993, J NEUROCHEM, V60, P1755; TEHRANI MHJ, 1991, J NEUROCHEM, V57, P1307, DOI 10.1111/j.1471-4159.1991.tb08295.x; THAMPY KG, 1983, DEV BRAIN RES, V8, P101, DOI 10.1016/0165-3806(83)90161-X; TIMMONS TM, 1990, METHOD ENZYMOL, V182, P679; VITORICA J, 1988, J NEUROSCI, V8, P615; WEISS DS, 1988, J NEUROPHYSIOL, V59, P495, DOI 10.1152/jn.1988.59.2.495; WEISS DS, 1988, J NEUROPHYSIOL, V59, P514, DOI 10.1152/jn.1988.59.2.514; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	33	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1548	1553						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288621				2022-12-27	WOS:A1994MR22000117
J	DAILEY, TA; MEISSNER, P; DAILEY, HA				DAILEY, TA; MEISSNER, P; DAILEY, HA			EXPRESSION OF A CLONED PROTOPORPHYRINOGEN OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DIPHENYL ETHER HERBICIDES; PURIFICATION; OXIDATION; STEP; HEME; CHLOROPHYLL; ORGANELLES	The previously cloned hem Y gene of Bacillus subtilis (Hansson, M., and Hederstedt, L. (1992) J. Bacteriol. 174, 8081-8093) has been expressed in Escherichia coli. The expressed protein has been shown to be the penultimate enzyme of the heme biosynthetic pathway, protoporphyrinogen oxidase (EC 1.3.3.4) and, thus, the gene designation should be hem G. This represents the first report of the expression of a cloned protoporphyrinogen oxidase from any source. The enzyme is present in the soluble cytoplasmic fraction and is, thus, unlike all previously reported eukaryotic or prokaryotic protoporphyrinogen oxidases, which are membrane-bound. It utilizes molecular oxygen as a terminal electron acceptor, and protoporphyrinogen IX, mesoporphyrinogen IX, and coproporphyrinogen III serve as substrates. The diphenyl ether herbicide acifluorfen, which is a strong inhibitor of the eukaryotic enzyme, is only weakly inhibitory. The enzyme has a predicted molecular weight of 51,200, which corresponds well with molecular weight determination via high performance liquid chromatography and SDS-polyacrylamide gel electrophoresis. In addition the enzyme contains a putative dinucleotide binding region at the amino terminus, which is consistent with the previously demonstrated presence of a flavin moiety in the characterized mammalian enzymes.	UNIV GEORGIA,DEPT MICROBIOL,ATHENS,GA 30602; UNIV GEORGIA,CTR METALLOENZYME STUDIES,ATHENS,GA 30602; UNIV CAPE TOWN,SCH MED,CTR LIVER RES,DEPT MED,CAPE TOWN 7925,SOUTH AFRICA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University of Cape Town					NIDDK NIH HHS [DK 35898, DK 32303, R56 DK032303] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032303, R01DK035898] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akhtar M., 1991, BIOSYNTHESIS TETRAPY, P67; BRENNER DA, 1980, CLIN CHIM ACTA, V100, P259, DOI 10.1016/0009-8981(80)90275-2; Dailey H. A., 1990, BIOSYNTHESIS HEME CH, P123; DAILEY HA, 1987, BIOCHEMISTRY-US, V26, P2697, DOI 10.1021/bi00384a007; FERREIRA GC, 1988, BIOCHEM J, V250, P597, DOI 10.1042/bj2500597; HANSSON M, 1992, J BACTERIOL, V174, P8081, DOI 10.1128/JB.174.24.8081-8093.1992; JACOBS JM, 1987, BIOCHEM J, V244, P219, DOI 10.1042/bj2440219; JACOBS JM, 1992, J BIOCHEM TOXICOL, V7, P87, DOI 10.1002/jbt.2570070206; JACOBS JM, 1984, ARCH BIOCHEM BIOPHYS, V229, P312, DOI 10.1016/0003-9861(84)90157-7; JACOBS NJ, 1981, ARCH BIOCHEM BIOPHYS, V211, P305, DOI 10.1016/0003-9861(81)90458-6; KLEMM DJ, 1987, J BACTERIOL, V169, P5209, DOI 10.1128/jb.169.11.5209-5215.1987; Labbe-Bois R, 1990, BIOSYNTHESIS HEME CH, P235; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATRINGE M, 1989, BIOCHEM J, V260, P231, DOI 10.1042/bj2600231; PROULX KL, 1992, PROTEIN SCI, V1, P801, DOI 10.1002/pro.5560010612; SIEPKER LJ, 1987, BIOCHIM BIOPHYS ACTA, V913, P349, DOI 10.1016/0167-4838(87)90146-4; TABOR S, 1991, CURRENT PROTOCOLS MO; WIERENGA RK, 1983, J MOL BIOL, V167, P725, DOI 10.1016/S0022-2836(83)80106-5; WILSON K, 1990, CURRENT PROTOCOLS MO	19	73	92	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					813	815						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288631				2022-12-27	WOS:A1994MR22000008
J	BACIU, PC; ACASTER, C; GOETINCK, PF				BACIU, PC; ACASTER, C; GOETINCK, PF			MOLECULAR-CLONING AND GENOMIC ORGANIZATION OF CHICKEN SYNDECAN-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; HUMAN-LUNG FIBROBLASTS; ROUS-SARCOMA VIRUS; CELL-SURFACE; MEMBRANE PROTEOGLYCAN; CORE PROTEIN; SEQUENCE-ANALYSIS; GROWTH-FACTOR; RECEPTOR; INTEGRIN	We have cloned and determined the genomic organization of the core protein of the chicken transmembrane proteoglycan, syndecan-4. Identification of the initial cDNA was accomplished using polyclonal antibodies directed against the cytoplasmic domain of murine syndecan-1 core protein. The cDNA for chicken syndecan-4 encodes a putative core protein of 197 amino acids which consists of a 19-amino acid signal peptide, a 125-amino acid ectodomain, a 25-amino acid transmembrane domain, and a 28-amino acid cytoplasmic domain. The predicted molecular mass of the mature core protein is 19,639 daltons. The ectodomain of chicken syndecan-4 core protein contains three potential sites for glycosaminoglycan attachment, two sites for N-glycosylation, and lacks a dibasic protease cleavage site proximal to the membrane-spanning region found in other syndecan family members. Comparison of the complete amino acid sequence with human syndecan-4 (amphlican (David, G., van der Schueren, B., Marynen, P., Cassiman, J. J., and van den Berghe, H. (1992) J. Cell Biol. 118, 961-969)) and rat syndecan-4 (ryudocan (Kojima, T., Shworak, N. W., and Rosenberg, R. D. (1992) J. Biol. Chem. 267, 4870-4877)) indicates an overall identity of 58 and 56%, respectively, with a 91 and 92% identity in the highly conserved transmembrane and cytoplasmic domains. The core protein of chicken syndecan-4 synthesized by chicken cells is modified with heparan sulfate side chains yielding a proteoglycan with a molecular mass of >200 kDa in LMH cells (immortalized male leghorn LM strain hepatocytes) and primary skin fibroblasts. Syndecan-4 isolated from chondrocyte cultures runs as a diffuse band between 100 and 200 kDa. Northern analysis of chicken syndecan-4 indicates three messages with distinct sizes of 0.9, 1.3, and 2.9 kb and a wide mRNA tissue distribution. The chicken syndecan-4 gene is divided into 5 exons encoding distinct regions which contain the signal peptide, the glycosaminoglycan attachment sites, a small spacer of unknown function, the glycosylation sites and the transmembrane and cytoplasmic domains.	HARVARD UNIV, MASSACHUSETTS GEN HOSP,SCH MED, CUTANEOUS BIOL RES CTR,MAH E BLDG 149, 13TH ST, BOSTON, MA 02129 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital					NCI NIH HHS [T32 CA 09579] Funding Source: Medline; NICHD NIH HHS [HD 22050, HD 25938] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022050, P01HD025938] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA009579] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BENOIT R, 1982, P NATL ACAD SCI-BIOL, V79, P917, DOI 10.1073/pnas.79.3.917; BERNFIELD M, 1990, PHILOS T R SOC B, V327, P171, DOI 10.1098/rstb.1990.0052; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; BOURDON MA, 1986, J BIOL CHEM, V261, P2534; CAREY DJ, 1992, J CELL BIOL, V117, P191, DOI 10.1083/jcb.117.1.191; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; DAVID G, 1992, J CELL BIOL, V118, P961, DOI 10.1083/jcb.118.4.961; DESIMONE DW, 1988, J BIOL CHEM, V263, P5333; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOEGE K, 1987, J BIOL CHEM, V262, P17757; GOETINCK PF, 1987, J CELL BIOL, V105, P2403, DOI 10.1083/jcb.105.5.2403; GOETINCK PF, 1991, CURR TOP DEV BIOL, V25, P111; GOULD SE, 1992, P NATL ACAD SCI USA, V89, P3271, DOI 10.1073/pnas.89.8.3271; HINKES M T, 1991, Journal of Cell Biology, V115, p125A; HUBER S, 1988, J BIOL CHEM, V263, P752; KAWAGUCHI T, 1987, CANCER RES, V47, P4460; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KJELLEN L, 1981, P NATL ACAD SCI-BIOL, V78, P5371, DOI 10.1073/pnas.78.9.5371; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; KOKENYESI R, 1992, MOL BIOL CELL, V3, pA64; KOZAK M, 1982, J MOL BIOL, V156, P807, DOI 10.1016/0022-2836(82)90143-7; KUGELMAN LC, 1992, J INVEST DERMATOL, V99, P381, DOI 10.1111/1523-1747.ep12616092; MALI M, 1990, J BIOL CHEM, V265, P6884; MARYNEN P, 1989, J BIOL CHEM, V264, P7017; NISHIYAMA A, 1991, J CELL BIOL, V114, P359, DOI 10.1083/jcb.114.2.359; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; PACIFICI M, 1977, CELL, V11, P891, DOI 10.1016/0092-8674(77)90300-2; PIERCE A, 1992, J BIOL CHEM, V267, P3894; RAUCH U, 1992, J BIOL CHEM, V267, P19536; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SELDIN DC, 1985, J BIOL CHEM, V260, P1131; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; TAPLEY P, 1989, ONCOGENE, V4, P325; TOMINAGA S, 1988, FEBS LETT, V238, P315, DOI 10.1016/0014-5793(88)80503-9; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WARREN W, 1991, BIOTECHNIQUES, V10, P216; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	45	34	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					696	703						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276871				2022-12-27	WOS:A1994MR21900109
J	SANTRA, M; DANIELSON, KG; IOZZO, RV				SANTRA, M; DANIELSON, KG; IOZZO, RV			STRUCTURAL AND FUNCTIONAL-CHARACTERIZATION OF THE HUMAN DECORIN GENE PROMOTER - A HOMOPURINE-HOMOPYRIMIDINE S1 NUCLEASE-SENSITIVE REGION IS INVOLVED IN TRANSCRIPTIONAL CONTROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; DERMATAN SULFATE PROTEOGLYCAN; MESSENGER-RNA LEVELS; HUMAN-COLON-CARCINOMA; KI-RAS PROMOTER; EXTRACELLULAR-MATRIX; NEOPLASTIC MODULATION; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; BINDING PROTEINS	Decorin is a leucine-rich, chondroitin/dermatan sulfate proteoglycan which binds collagen and growth factors. We have recently completed the genomic organization of human decorin and discovered two alternatively spliced leader exons, designated exon Ia and Ib, in the 5'-untranslated region. Initial analysis of the sequences upstream to these two exons showed that promoter Ia contained only two GC boxes while promoter Ib contained a CAAT and two TATA boxes in close proximity to the transcription start site. To determine if these 5'-flanking sequences exhibited promoter activity, chimeric chloramphenicol acetyltransferase expression plasmids containing the promoter region of either exon Ia or Ib were transfected into HeLa and MG-63 osteosarcoma cells. The results showed that only the region flanking exon Ib was functional. In vitro transcription assay generated two transcripts of 92 and 82 base pairs (bp) indicating that both TATA boxes could be used. Using stepwise 5' deletion analysis we found that the minimum promoter region at -140 bp from the transcription start site, which contained only the CAAT and the two TATA boxes, exhibited strong promoter activity. When a larger construct containing an additional 800 bp of upstream region was tested, a significant increase in transcriptional activity was observed. Interestingly, this promoter region contained several putative binding sites for ubiquitous factors (AP1, AP5, and NF-kappaB) and for transforming growth factor-beta and a 150-bp homopurine/homopyrimidine element with several mirror repeats. When contained in a supercoiled plasmid, this sequence exhibited sensitivity to endonuclease S1, an enzyme that preferentially digests single-stranded DNA. Precise S1 mapping, obtained by direct sequencing of nine distinct Sl-generated clones, revealed that in all cases the borders of the sensitive sequence resided within the pur/pyr segment. We propose that this region of the promoter could adopt an intramolecular hairpin triplex structure in vivo and may play a role in the chromatin organization at the decorin gene locus. In addition, this region was able to up-regulate a minimal heterologous promoter in transient transfection assays. The results show that the structure of the decorin gene promoter is different from that of any other proteoglycan promoter characterized so far and indicate that the pur/pyr segment plays a role in the regulation of gene transcription.	THOMAS JEFFERSON UNIV, DEPT PATHOL & CELL BIOL, RM 249, JEFFERSON ALUMNI HALL, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, PHILADELPHIA, PA 19107 USA	Jefferson University; Jefferson University			Iozzo, Renato/AAS-1980-2020	Iozzo, Renato/0000-0002-5908-5112	NCI NIH HHS [CA-47282, CA-39481] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047282, R01CA039481] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMSON SR, 1992, BIOCHIM BIOPHYS ACTA, V1132, P225, DOI 10.1016/0167-4781(92)90019-V; ADANY R, 1991, BIOCHEM J, V276, P301, DOI 10.1042/bj2760301; ADANY R, 1990, J BIOL CHEM, V265, P11389; BALVAY L, 1993, BIOESSAYS, V15, P165, DOI 10.1002/bies.950150304; BASSOLS A, 1988, J BIOL CHEM, V263, P3039; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BEHREND EI, 1993, J BIOL CHEM, V268, P11172; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; BIGGIN MD, 1989, TRENDS GENET, V5, P377, DOI 10.1016/0168-9525(89)90173-X; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; BREUER B, 1990, BIOCHEM J, V269, P551, DOI 10.1042/bj2690551; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN IR, 1993, IN PRESS P NATL ACAD; DANIELSON KG, 1993, GENOMICS, V15, P146, DOI 10.1006/geno.1993.1022; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DODGE GR, 1991, GENOMICS, V10, P673, DOI 10.1016/0888-7543(91)90451-J; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FINER MH, 1987, J BIOL CHEM, V262, P13323; FISHER LW, 1991, J BIOL CHEM, V266, P14371; FISHER LW, 1993, DERMATAN SULPHATE PR, P103; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HEINO J, 1988, BIOCHEM J, V252, P309, DOI 10.1042/bj2520309; HINKES MT, 1993, J BIOL CHEM, V268, P11440; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; IBARAKI K, 1993, GENE, V130, P225, DOI 10.1016/0378-1119(93)90423-Z; IOZZO R V, 1982, Journal of Biological Chemistry, V257, P11135; IOZZO RV, 1993, EXPERIENTIA, V49, P447, DOI 10.1007/BF01923588; IOZZO RV, 1985, J BIOL CHEM, V260, P7464; IOZZO RV, 1989, J CELL BIOCHEM, V39, P355, DOI 10.1002/jcb.240390403; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JOHNSON AC, 1988, J BIOL CHEM, V263, P5693; KAHARI VM, 1991, J BIOL CHEM, V266, P10608; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOLLER E, 1991, NUCLEIC ACIDS RES, V19, P485, DOI 10.1093/nar/19.3.485; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LI W, 1992, ARCH BIOCHEM BIOPHYS, V296, P190, DOI 10.1016/0003-9861(92)90562-B; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; MCKEON C, 1984, J BIOL CHEM, V259, P6636; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; NICODEMUS CF, 1990, J BIOL CHEM, V265, P5889; PESTOV DG, 1991, NUCLEIC ACIDS RES, V19, P6527, DOI 10.1093/nar/19.23.6527; ROMARIS M, 1991, BIOCHIM BIOPHYS ACTA, V1093, P229, DOI 10.1016/0167-4889(91)90127-J; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SACCOMANNO CF, 1992, BIOTECHNIQUES, V13, P846; Sambrook J, 1989, MOL CLONING LABORATO; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; VETTER U, 1993, GENOMICS, V15, P161, DOI 10.1006/geno.1993.1023; VOGEL KG, 1987, COLLAGEN REL RES, V7, P105; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; VONIOZZO R, 1982, LAB INVEST, V47, P124; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YARON I, 1987, ARTHRITIS RHEUM, V30, P424, DOI 10.1002/art.1780300410; YOUNG MF, 1992, INT CONGR SER, V1002, P243; YOUNG MF, 1989, J BIOL CHEM, V264, P450	63	82	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					579	587						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276854				2022-12-27	WOS:A1994MR21900092
J	WEINANDER, R; ANDERSON, C; MORGENSTERN, R				WEINANDER, R; ANDERSON, C; MORGENSTERN, R			IDENTIFICATION OF N-ACETYLCYSTEINE AS A NEW SUBSTRATE FOR RAT-LIVER MICROSOMAL GLUTATHIONE TRANSFERASE - A STUDY OF THIOL LIGANDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-TRANSFERASES; ACTIVATION; SERIES; PURIFICATION; INHIBITORS; MECHANISM; RESIDUES; ANALOGS; SITE	N-Acetyl-L-cysteine serves as an efficient substrate for the rat liver microsomal glutathione transferase with 1-chloro-2,4-dinitrobenzene as second substrate (8.8 +/-0.37 mumol/min mg). The activity is actually higher than that obtained with glutathione (2-4 mumol/min mg). In examining the activity of liver subcellular fractions, no activity with N-acetyl-L-Cys could be detected in dialyzed or N-ethylmaleimide-treated (in order to remove endogenous glutathione) cytosol. The activity in rat liver microsomes was 0.11 +/- 0.007 mumol/min mg, which is accounted for by the content of microsomal glutathione transferase. Thus, N-acetyl-L-Cys can be used as a specific substrate for determining the conjugating activity of microsomal glutathione transferase. N-Acetyl-L-Cys was also shown to function as a substrate for the enzyme when other second substrates than 1-chloro-2,4-dinitrobenzene (with varying electrophilicity) are used. The pH dependence of microsomal glutathione transferase was studied. The k(cat)/K(m(1-chloro-2,4-dinitrobenzene)) was dependent on pH with an apparent pK(a) of 6, greater-than-or-equal-to 9, and greater-than-or-equal-to 8 with saturating glutathione, gamma-L-Glu-L-Cys, and N-acetyl-L-cysteine, respectively. Apparently the enzyme has the ability to lower the pK(a) of glutathione by 3 orders of magnitude. The k(cat)/K(m(thiol) did not vary appreciably with pH (except for N-acetyl-L-cysteine), indicating that no rate-determining deprotonation occurs on the enzyme itself between pH 5.5 and 9. The abilities of histidine-, lysine-, and arginine-selective reagents to inactivate the enzyme when N-acetyl-L-cysteine and gamma-L-Glu-L-Cys were used as substrates were investigated. The activity toward N-acetyl-L-cysteine was decreased considerably less after treatment with the arginine-selective reagent phenylglyoxal, as compared to the activity toward GSH andy-L-Glu-L-Cys. This indicates that an arginine makes contact with the gamma-L-Glu residue in GSH. With the other reagent/substrate combinations tested the enzyme was inactivated almost completely. The ability of microsomal glutathione transferase to stabilize the Meisenheimer complex formation between 1,3,5-trinitrobenzene and various glutathione analogues, including non-substrate thiols, has been examined. It is shown that, in general, substrates exhibited higher formation constants (approaching 50 mM-1) than non-substrates (4.5 +/- 1.7 mM-1, n = 7), whereas simpler thiols did not yield enzyme-bound complexes. The fact that the enzyme can stabilize Meisenheimer complexes from non-substrate thiol analogues of glutathione offers new possibilities for examining the substrate interactions of glutathione transferases.	UNIV STOCKHOLM,DEPT BIOCHEM,WALLENBERG LAB,BIOCHEM TOXICOL UNIT,S-10691 STOCKHOLM,SWEDEN	Stockholm University	WEINANDER, R (corresponding author), KAROLINSKA INST,INST ENVIRONM MED,DIV TOXICOL,BOX 210,S-17177 STOCKHOLM,SWEDEN.		Morgenstern, Ralf/GZH-0158-2022					ADANG AEP, 1988, BIOCHEM J, V255, P715; ADANG AEP, 1990, BIOCHEM J, V269, P47, DOI 10.1042/bj2690047; ANDERSSON C, 1990, BIOCHEM J, V272, P479, DOI 10.1042/bj2720479; ANDERSSON C, 1991, J BIOL CHEM, V266, P2076; ARMSTRONG RN, 1991, CHEM RES TOXICOL, V4, P131, DOI 10.1021/tx00020a001; BOYER TD, 1982, BIOCHEM J, V207, P57, DOI 10.1042/bj2070057; Chasseaud L F, 1979, Adv Cancer Res, V29, P175, DOI 10.1016/S0065-230X(08)60848-9; DEJONG JL, 1988, J BIOL CHEM, V263, P8430; ERNSTER L, 1962, J CELL BIOL, V15, P541, DOI 10.1083/jcb.15.3.541; GAN LH, 1977, AUST J CHEM, V30, P1475, DOI 10.1071/CH9771475; GRAMINSKI GF, 1989, BIOCHEMISTRY-US, V28, P6252, DOI 10.1021/bi00441a017; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HARGUS SJ, 1991, BIOCHEMISTRY-US, V30, P717, DOI 10.1021/bi00217a020; HARRIS JM, 1991, BIOCHEM J, V278, P137, DOI 10.1042/bj2780137; JUNG G, 1972, EUR J BIOCHEM, V24, P438, DOI 10.1111/j.1432-1033.1972.tb19704.x; KEEN JH, 1976, J BIOL CHEM, V251, P6183; KOHN MC, 1979, COMPUT BIOMED RES, V12, P461, DOI 10.1016/0010-4809(79)90032-6; LIU SX, 1992, J BIOL CHEM, V267, P4296; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MORGENSTERN R, 1989, BIOCHEM J, V260, P577, DOI 10.1042/bj2600577; MORGENSTERN R, 1983, FEBS LETT, V160, P264, DOI 10.1016/0014-5793(83)80979-X; MORGENSTERN R, 1982, EUR J BIOCHEM, V128, P243; MORGENSTERN R, 1983, EUR J BIOCHEM, V134, P591, DOI 10.1111/j.1432-1033.1983.tb07607.x; MORGENSTERN R, 1988, J BIOL CHEM, V263, P6671; Morgenstern R, 1985, REV BIOCHEM TOXICOL, V7, P67; MORGENSTERN R, 1988, GLUTATHIONE CONJUGAT, P157; MOSIALOU E, 1989, ARCH BIOCHEM BIOPHYS, V275, P289, DOI 10.1016/0003-9861(89)90375-5; MOSIALOU E, 1990, CHEM-BIOL INTERACT, V74, P275, DOI 10.1016/0009-2797(90)90044-N; PERSHT A, 1985, ENZYME STRUCTURE MEC; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; STOLE E, 1991, J BIOL CHEM, V266, P17850	31	36	36	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					71	76						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276873				2022-12-27	WOS:A1994MR21900019
J	MERRILL, AH; VANECHTEN, G; WANG, E; SANDHOFF, K				MERRILL, AH; VANECHTEN, G; WANG, E; SANDHOFF, K			FUMONISIN-B(1) INHIBITS SPHINGOSINE (SPHINGANINE) N-ACYLTRANSFERASE AND DE-NOVO SPHINGOLIPID BIOSYNTHESIS IN CULTURED NEURONS IN-SITU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HAMSTER OVARY CELLS; PORCINE SUBMAXILLARY-GLANDS; GROWTH-FACTOR RECEPTOR; LONG-CHAIN BASES; FUSARIUM-MONILIFORME; SERINE PALMITOYLTRANSFERASE; RAT-LIVER; PHOSPHATIDATE PHOSPHOHYDROLASE; GLUCOSYLCERAMIDE SYNTHESIS	Fumonisins, mycotoxins produced by Fusarium moniliforme and a number of other fungi, cause neuronal degeneration, liver and renal toxicity, cancer, and other injury to animals. Recent work with rat hepatocytes (Wang, E., Norred, W. P., Bacon, C. W., Riley, R. T., and Merrill, A. H., Jr. (1991) J. Biol. Chem. 266, 14486-14490) found that fumonisins block sphingosine biosynthesis by inhibiting the conversion of sphinganine to dihydroceramides, which precedes introduction of the 4,5-trans-double bond of sphingosine. The current study utilized mouse cerebellar neurons in culture to evaluate how this affects the distribution of newly synthesized ceramides among different complex sphingolipids. Fumonisin B1 inhibited ceramide synthase in mouse brain microsomes with a competitive-like kinetic behavior with respect to both sphinganine and stearoyl-CoA. Fumonisin B1 inhibited sphingolipid biosynthesis in cultured cerebellar neurons in situ as reflected by accumulation of free sphinganine, a reduction in the mass of total sphingolipids, reductions in the incorporation of [C-14]serine into glucosylceramide, lactosylceramide, sphingomyelin, and gangliosides (G(M1), G(D3), G(D1a), G(D1b), G(T1b), and G(Q1b)), and inhibition of the incorporation of [C-14]galactose and [H-3]sphinganine into complex sphingolipids. Dose-response studies revealed that the labeling of sphingomyelin (IC50 of 0.7 muM) was more sensitive to inhibition by fumonisin B1 than was glycolipid formation (IC50 of approximately 7 muM) in these cells. A similar effect was seen when beta-fluoroalanine was added to inhibit the activity of serine palmitoyltransferase, the first enzyme of the pathway. The inhibition of complex sphingolipid synthesis was reversible, and nearly normal labeling profiles were obtained 48 h after removing the mycotoxin. These studies establish that fumonisin B1 inhibits de novo sphingolipid biosynthesis by neuronal cells and, moreover, that limiting ceramide synthesis differentially affects the formation of sphingomyelin versus glycosphingolipids.	UNIV BONN,INST ORGAN CHEM & BIOCHEM,W-5300 BONN 1,GERMANY	University of Bonn	MERRILL, AH (corresponding author), EMORY UNIV,SCH MED,DEPT BIOCHEM,4113 ROLLINS RES CTR,ATLANTA,GA 30322, USA.			Merrill, Alfred/0000-0002-6673-968X	NIGMS NIH HHS [GM33369] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033369] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEZUIDENHOUT SC, 1988, J CHEM SOC CHEM COMM, P743, DOI 10.1039/c39880000743; COSTE H, 1985, BIOCHIM BIOPHYS ACTA, V814, P1, DOI 10.1016/0005-2736(85)90412-2; COSTE H, 1986, BIOCHIM BIOPHYS ACTA, V858, P6, DOI 10.1016/0005-2736(86)90285-3; FAUCHER M, 1988, J BIOL CHEM, V263, P5319; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; GAVER RC, 1966, J AM CHEM SOC, V88, P3643, DOI 10.1021/ja00967a032; GELDERBLOM WCA, 1991, CARCINOGENESIS, V12, P1247, DOI 10.1093/carcin/12.7.1247; GELDERBLOM WCA, 1988, CARCINOGENESIS, V9, P1405, DOI 10.1093/carcin/9.8.1405; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; Harrison L R, 1990, J Vet Diagn Invest, V2, P217; HOEKSTRA D, 1992, BIOCHIM BIOPHYS ACTA, V1113, P277, DOI 10.1016/0304-4157(92)90002-R; IGARASHI Y, 1989, BIOCHEMISTRY-US, V28, P6796, DOI 10.1021/bi00443a002; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; JECKEL D, 1990, FEBS LETT, V261, P155, DOI 10.1016/0014-5793(90)80659-7; KALLEN KJ, 1993, BIOCHEM J, V289, P307, DOI 10.1042/bj2890307; KRIEK NPJ, 1981, ONDERSTEPOORT J VET, V48, P129; LAVIE Y, 1990, J BIOL CHEM, V265, P3868; LIN M, 1980, GENETIC ENV FACTORS, P139; MANDON EC, 1991, EUR J BIOCHEM, V198, P667, DOI 10.1111/j.1432-1033.1991.tb16065.x; MANDON EC, 1992, J BIOL CHEM, V267, P11144; Marasas W. F. O., 1982, CANCER ESOPHAGUS, V1, P29; MARASAS WFO, 1984, INT J CANCER, V34, P383, DOI 10.1002/ijc.2910340315; MARASAS WFO, 1988, ONDERSTEPOORT J VET, V55, P197; MARASAS WFO, 1984, TOXIGENIC FUSARIUM S; MEDLOCK KA, 1988, BIOCHEM BIOPH RES CO, V157, P232, DOI 10.1016/S0006-291X(88)80037-8; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1993, ADV LIPID RES, V26, P215; MERRILL AH, 1993, ADV LIPID RES, V25, P1; MERRILL AH, 1983, BIOCHIM BIOPHYS ACTA, V754, P284, DOI 10.1016/0005-2760(83)90144-3; MERRILL AH, 1992, METHOD ENZYMOL, V209, P427; MERRILL AH, 1986, J BIOL CHEM, V261, P3764; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; MORELL P, 1970, J BIOL CHEM, V245, P342; MULLMANN TJ, 1991, J BIOL CHEM, V266, P2013; NORRED WP, 1992, MYCOPATHOLOGIA, V117, P73, DOI 10.1007/BF00497281; OISHI K, 1990, J BIOL CHEM, V265, P70; ONG DE, 1973, J BIOL CHEM, V248, P3884; RILEY RT, 1993, TOXICOL APPL PHARM, V118, P105, DOI 10.1006/taap.1993.1015; ROSS PF, 1990, APPL ENVIRON MICROB, V56, P3225, DOI 10.1128/AEM.56.10.3225-3226.1990; ROTHER J, 1992, BIOCHEM BIOPH RES CO, V189, P14, DOI 10.1016/0006-291X(92)91518-U; SCHWARZMANN G, 1987, METHOD ENZYMOL, V138, P318; SLIFE CW, 1989, J BIOL CHEM, V264, P10371; STEVENS VL, 1990, BIOCHIM BIOPHYS ACTA, V1051, P37, DOI 10.1016/0167-4889(90)90171-9; STOFFEL W, 1974, H-S Z PHYSIOL CHEM, V355, P911, DOI 10.1515/bchm2.1974.355.2.911; STOFFEL W, 1970, H-S Z PHYSIOL CHEM, V351, P635, DOI 10.1515/bchm2.1970.351.1.635; STOFFEL W, 1969, H-S Z PHYSIOL CHEM, V350, P1233, DOI 10.1515/bchm2.1969.350.2.1233; SYDENHAM EW, 1991, J AGR FOOD CHEM, V39, P2014, DOI 10.1021/jf00011a028; SYDENHAM EW, 1990, J AGR FOOD CHEM, V38, P285, DOI 10.1021/jf00091a064; VALSECCHI M, 1993, J NEUROCHEM, V60, P193, DOI 10.1111/j.1471-4159.1993.tb05837.x; VANECHTEN G, 1989, J NEUROCHEM, V52, P207; VANECHTEN G, 1990, J BIOL CHEM, V265, P9333; VOSS KA, 1990, MYCOPATHOLOGIA, V112, P81, DOI 10.1007/BF00436503; WANG E, 1991, J BIOL CHEM, V266, P14486; WEDEGAERTNER PB, 1989, J BIOL CHEM, V264, P11346; YANG CS, 1980, CANCER RES, V40, P2633; YOO HS, 1992, TOXICOL APPL PHARM, V114, P9, DOI 10.1016/0041-008X(92)90090-F; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	62	322	324	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27299	27306						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262970				2022-12-27	WOS:A1993MM26200067
J	FELGNER, JH; KUMAR, R; SRIDHAR, CN; WHEELER, CJ; TSAI, YJ; BORDER, R; RAMSEY, P; MARTIN, M; FELGNER, PL				FELGNER, JH; KUMAR, R; SRIDHAR, CN; WHEELER, CJ; TSAI, YJ; BORDER, R; RAMSEY, P; MARTIN, M; FELGNER, PL			ENHANCED GENE DELIVERY AND MECHANISM STUDIES WITH A NOVEL SERIES OF CATIONIC LIPID FORMULATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED DNA-TRANSFECTION; MAMMALIAN-CELLS; DIPALMITOYLPHOSPHATIDYLCHOLINE VESICLES; ANTISENSE OLIGONUCLEOTIDES; EFFICIENT TRANSFECTION; PHOSPHOLIPID-VESICLES; ENDOTHELIAL-CELLS; EXPRESSION INVIVO; PROKARYOTIC GENE; LIPOSOME REAGENT	The application of cationic liposome reagents has advanced DNA and mRNA transfection research in vitro, and data are accumulating which show their utility for in vivo gene transfer. However, chemical structure-activity data leading to a better mechanistic understanding of their biological activity is still limited. Most of the cationic lipid reagents in use today for this application are formulated as liposomes containing two lipid species, a cationic amphiphile and a neutral phospholipid, typically dioleoylphosphatidylethanolamine (DOPE). The studies reported here examine the effects of some systematic chemical structural changes in both of these lipid components. Cationic and neutral phospholipids were formulated together as large multilamellar vesicles (MLV) or small sonicated unilamellar vesicles (SUV) in water, and each formulation was assayed quantitatively in 96-well microtiter plates under 64 different assay conditions using COS.7 cells and an RSV-beta-galactosidase expression plasmid. The cationic lipid molecules used for these studies were derived from a novel series of 2,3-dialkyloxypropyl quaternary ammonium compounds containing a hydroxyalkyl moiety on the quaternary amine. A homologous series of dioleylalkyl (C18:1) compounds containing increasing hydroxyalkyl chain lengths on the quaternary amine were synthesized, formulated with 50 mol % DOPE, and assayed for transfection activity. The order of efficacy was ethyl > propyl > butyl > pentyl > 2,3-dioleyloxypropyl-1-trimethyl ammonium bromide (DOTMA). DOTMA, which is commercially available under the trademark Lipofectin Reagent, lacks a hydroxyalkyl moiety on the quaternary amine. A homologous series of hydroxyethyl quaternary ammonium derivatives with different alkyl chain substitutions were synthesized, formulated with 50 mol % DOPE, and assayed in the transfection assay. The order of transfection efficacy was dimyristyl (di-C14:0) > dioleyl (di-C18:1) > dipalmityl (di-C16:0) > disteryl (di-C18:0). The addition of 100 muM chloroquine in the transfection experiment enhanced the activity of the dioleyl compound by 4-fold and decreased the activity of the dimyristyl compound by 70%. For each of the compounds and formulations examined in this report, large multilamellar vesicles (MLV; diameter 300-700 nm) were more active than small unilamellar vesicles (SUV; diameter 50-100 nm). The neutral phospholipid requirements for transfection activity in COS.7 cells with these cationic lipid molecules were examined. Cationic vesicles formulated with 50 mol % dioleoylphosphatidylethanolamine (DOPE) were 2-5-fold more active than formulations with 50 mol % dioleoylphosphatidylcholine or formulations without any neutral lipid, and the level of DOPE required for optimal activity was 50 mol %. The differences between DOPE and dioleoylphosphatidylcholine were associated with differences in titratability of the primary ethanolamine and choline moieties on these two phospholipid molecules. DOPE analogs were studied for their transfection enhancing activity. Analogs with increasing acyl chain saturation were progressively less active than unsaturated analogs; analogs with increasing numbers of methyl or methylene groups added to the primary amine were also progressively less active. The lysophosphatidylethanolamine analogs examined neither enhanced nor inhibited the activity of these reagents. These results have implications regarding the design of new cationic and neutral lipid molecules for use in the development of improved cationic lipid gene delivery vectors.	VICAL INC,9373 TOWNE CTR DR,SAN DIEGO,CA 92121									BEHR JP, 1989, P NATL ACAD SCI USA, V86, P6982, DOI 10.1073/pnas.86.18.6982; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; BRIGHAM KL, 1989, AM J MED SCI, V298, P278, DOI 10.1097/00000441-198910000-00013; BRIGHAM KL, 1989, AM J RESP CELL MOL, V1, P95, DOI 10.1165/ajrcmb/1.2.95; BURGER HJ, 1992, P NATL ACAD SCI USA, V89, P2145, DOI 10.1073/pnas.89.6.2145; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; DEBS RJ, 1990, J BIOL CHEM, V265, P10189; DEMENEIX B A, 1991, International Journal of Developmental Biology, V35, P481; DUZGUNES N, 1989, BIOCHEMISTRY-US, V28, P9179, DOI 10.1021/bi00449a033; Duzgunes N, 1985, Subcell Biochem, V11, P195; EIBL H, 1979, BIOPHYS CHEM, V10, P261, DOI 10.1016/0301-4622(79)85015-2; FARHOOD H, 1992, BIOCHIM BIOPHYS ACTA, V1111, P239, DOI 10.1016/0005-2736(92)90316-E; FELGNER JH, 1993, IN PRESS PROTOCOLS C; Felgner P L, 1989, Proc West Pharmacol Soc, V32, P115; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FELGNER PL, 1983, BIOCHEMISTRY-US, V22, P1670, DOI 10.1021/bi00276a023; FELGNER PL, 1989, NATURE, V337, P387, DOI 10.1038/337387a0; FELGNER PL, 1981, BIOCHEMISTRY-US, V20, P2168, DOI 10.1021/bi00511a015; FELGNER PL, 1990, ADV DRUG DELIVERY RE, V5, P167; GAO X, 1991, BIOCHEM BIOPH RES CO, V179, P280, DOI 10.1016/0006-291X(91)91366-K; GRUNER SM, 1987, LIPOSOMES BIOPHYSICS, P1; HOLT CE, 1990, NEURON, V4, P203, DOI 10.1016/0896-6273(90)90095-W; ISRAELACHVILI JN, 1977, BIOCHIM BIOPHYS ACTA, V470, P185, DOI 10.1016/0005-2736(77)90099-2; JIAO SS, 1992, EXP NEUROL, V115, P400, DOI 10.1016/0014-4886(92)90205-5; LEGENDRE JY, 1993, P NATL ACAD SCI USA, V90, P893, DOI 10.1073/pnas.90.3.893; LEGENDRE JY, 1992, PHARMACEUT RES, V9, P1235, DOI 10.1023/A:1015836829670; LEVENTIS R, 1990, BIOCHIM BIOPHYS ACTA, V1023, P124, DOI 10.1016/0005-2736(90)90017-I; LICHTENBERG D, 1982, BIOCHIM BIOPHYS ACTA, V684, P277, DOI 10.1016/0005-2736(82)90017-7; LICHTENBERG D, 1981, BIOCHEMISTRY-US, V20, P3462, DOI 10.1021/bi00515a024; LIM CS, 1991, CIRCULATION, V83, P2007, DOI 10.1161/01.CIR.83.6.2007; LITZINGER DC, 1992, BIOCHIM BIOPHYS ACTA, V1113, P201, DOI 10.1016/0304-4157(92)90039-D; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; MULLER SR, 1990, DNA CELL BIOL, V9, P221, DOI 10.1089/dna.1990.9.221; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; NABEL EG, 1992, P NATL ACAD SCI USA, V89, P5157, DOI 10.1073/pnas.89.11.5157; Nabel G. J., 1992, HUM GENE THER, V3, P399; ONO T, 1990, NEUROSCI LETT, V117, P259, DOI 10.1016/0304-3940(90)90673-W; PHILIP R, 1993, J BIOL CHEM, V268, P16087; PINNADUWAGE P, 1989, BIOCHIM BIOPHYS ACTA, V985, P33, DOI 10.1016/0005-2736(89)90099-0; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; Sambrook J, 1989, MOL CLONING LABORATO; SIEGEL DP, 1986, BIOPHYS J, V49, P1155, DOI 10.1016/S0006-3495(86)83744-4; Silvius J.R., 1982, LIPID PROTEIN INTERA; STAMATATOS L, 1988, BIOCHEMISTRY-US, V27, P3917, DOI 10.1021/bi00411a005; STRIBLING R, 1992, P NATL ACAD SCI USA, V89, P11277, DOI 10.1073/pnas.89.23.11277; WALKER C, 1992, P NATL ACAD SCI USA, V89, P7915, DOI 10.1073/pnas.89.17.7915; WEISS B, 1989, J VIROL, V63, P5310, DOI 10.1128/JVI.63.12.5310-5318.1989; YAO SN, 1991, P NATL ACAD SCI USA, V88, P8101, DOI 10.1073/pnas.88.18.8101; YOSHIMURA K, 1992, NUCLEIC ACIDS RES, V20, P3233, DOI 10.1093/nar/20.12.3233; ZHOU XH, 1991, BIOCHIM BIOPHYS ACTA, V1065, P8, DOI 10.1016/0005-2736(91)90003-Q; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073	51	1151	1336	5	155	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 28	1994	269	4					2550	2561						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MV432	8300583				2022-12-27	WOS:A1994MV43200033
J	LEE, JSC; EDELMAN, AM				LEE, JSC; EDELMAN, AM			A PROTEIN ACTIVATOR OF CA2+-CALMODULIN-DEPENDENT PROTEIN KINASE-IA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN KINASE; RAT-BRAIN; AUTOPHOSPHORYLATION; PURIFICATION; CALCIUM; PHOSPHORYLATION; BINDING; IB	A protein activator of Ca2+-calmodulin-dependent protein kinase la (CaM kinase Ia) was purified to near homogeneity from pig brain. In the final step of purification, sucrose density gradient centrifugation, CaM kinase la activating activity correlated with the presence of a approximately 52-kDa protein band detected by SDS-polyacrylamide gel electrophoresis. Comparison of this value with estimations of its molecular mass under nondenaturing conditions indicated that CaM kinase Ia activator is a slightly asymmetric monomer. After removal of endogenous CaM kinase la activator, the activity of CaM kinase la was 2% of its activity in the presence of a maximally stimulating concentration (15 nM) of the purified activator. In its activated state, CaM kinase Ia retained complete dependence of its activity upon Ca2+-CaM. The activation of CaM kinase la was rapid (t1/2 < 1 min) and required the combined presence of CaM kinase Ia activation Ca2+-CaM, and MgATP. Similarly, in addition to MgATP, the phosphorylation of CaM kinase Ia required CaM kinase la activator and Ca2+-CaM. CaM kinase la activator was capable of Ca2+-dependent binding to CaM-Sepharose. The requirement of the combined presence of CaM kinase la activator, Ca2+-CaM, and MgATP for both the activation and phosphorylation of CaM kinase la is discussed in terms of potential mechanisms for CaM kinase la activation.	SUNY BUFFALO,DEPT PHARMACOL & THERAPEUT,102 FARBER HALL,BUFFALO,NY 14214	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NINDS NIH HHS [NS24738] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS024738, R01NS024738] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campbell A.K, 1983, INTRACELLULAR CALCIU; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; CZERNIK AJ, 1987, P NATL ACAD SCI USA, V84, P7518, DOI 10.1073/pnas.84.21.7518; DAVIS TN, 1992, CELL, V71, P557, DOI 10.1016/0092-8674(92)90590-9; DEREMER MF, 1992, J BIOL CHEM, V267, P13460; DEREMER MF, 1992, J BIOL CHEM, V267, P13466; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EDELMAN AM, 1992, MOL BRAIN RES, V14, P27, DOI 10.1016/0169-328X(92)90006-W; EDELMAN AM, 1985, J BIOL CHEM, V260, P1275; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P11309; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HASHIMOTO Y, 1987, J BIOL CHEM, V262, P8051; KENNEDY MB, 1987, CALCIUM CELL FUNCTIO, V7, P62; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LOU LL, 1986, P NATL ACAD SCI USA, V83, P9497, DOI 10.1073/pnas.83.24.9497; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MIYANO O, 1992, J BIOL CHEM, V267, P1198; MOCHIZUKI H, 1993, J BIOL CHEM, V268, P9143; MOEREMANS M, 1985, ANAL BIOCHEM, V145, P315, DOI 10.1016/0003-2697(85)90368-9; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NARIN AC, 1985, ANNU REV BIOCHEM, V54, P931; Pickett-Gies CA., 1986, ENZYMES, V17, P395; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; Sherman M R, 1975, Methods Enzymol, V36, P211; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; STULL JT, 1986, ENZYMES, V17, P113; TEO TS, 1973, J BIOL CHEM, V248, P588; WALSH DA, 1968, J BIOL CHEM, V243, P3763; WORTHINGTON CC, 1988, WORTHINGTON MANUAL E; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	34	86	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					2158	2164						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294471				2022-12-27	WOS:A1994MR98800092
J	OTTESON, EW; WELCH, WH; KOZEL, TR				OTTESON, EW; WELCH, WH; KOZEL, TR			PROTEIN-POLYSACCHARIDE INTERACTIONS - A MONOCLONAL-ANTIBODY SPECIFIC FOR THE CAPSULAR POLYSACCHARIDE OF CRYPTOCOCCUS-NEOFORMANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEROTYPE-A; 3-DIMENSIONAL STRUCTURE; ENZYMATIC AMPLIFICATION; HYPERVARIABLE REGIONS; ANTIGEN COMPLEX; FLUORESCENCE; BINDING; SPECTROSCOPY; DNA; GLUCURONOXYLOMANNAN	Monoclonal antibodies that react with the capsular polysaccharide, termed glucuronoxylomannan (GXM), of Cryptococcus neoformans have potential roles in the diagnosis, monitoring of disease progress, and immunotherapy of cryptococcosis. Monoclonal antibody 439 reacts with cryptococcal GXM of all four serotypes. A molecular model of the Fab fragment of monoclonal antibody 439 was constructed from the amino acid sequence and a template antibody molecule, Fab 4-4-20. A tryptophan is present on the surface between light chain CDR3 and heavy chain CDR3 in the putative binding site. This tryptophan residue proved to be a reporter group, and a fluorescence study of Fab 439 was performed to analyze the interaction between cryptococcal GXM and Fab 439. Binding of the polysaccharide enhanced the intrinsic fluorescence and caused a blue shift in the emission maximum, indicating that the environment of a tryptophan changes from a polar to less polar environment. This is consistent with the loss of water from the binding site caused by the binding of antigen. This interpretation was confirmed by acrylamide quenching, which showed that 1 less tryptophan was exposed to solvent in the Fab-GXM complex than in free Fab. Fluorescence titration was used to determine binding and dissociation constants (K(D)). The apparent K(D) values for serotypes A-C were approximately the same; the K(D) for serotype D GXM was 5-11-fold greater. De-O-acetylation of serotype A GXM produced a 31-fold increase in the K(D), indicating that the O-acetyl groups are important, but not essential, for binding. Carboxyl groups appear to be essential for strong binding because the K(D) for carboxyl-reduced GXM was so large that it could not be determined.	UNIV NEVADA,DEPT MICROBIOL,RENO,NV 89557; UNIV NEVADA,DEPT BIOCHEM,RENO,NV 89557; UNIV NEVADA,CELL & MOLEC BIOL PROGRAM,RENO,NV 89557	Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); University of Nevada Reno					NIAID NIH HHS [AI31696, AI14209] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI014209, U01AI031696, R01AI014209] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABOLA EE, 1987, PROTEIN DATA BANK CR, P107; AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BHATTACHARJEE AK, 1979, MOL IMMUNOL, V16, P531, DOI 10.1016/0161-5890(79)90081-6; BHATTACHARJEE AK, 1981, CARBOHYD RES, V95, P237, DOI 10.1016/S0008-6215(00)85580-9; BHATTACHARJEE AK, 1979, CARBOHYD RES, V73, P183, DOI 10.1016/S0008-6215(00)85488-9; BHATTACHARJEE AK, 1980, CARBOHYD RES, V82, P103, DOI 10.1016/S0008-6215(00)85524-X; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BLOOMFIELD N, 1963, P SOC EXP BIOL MED, V114, P64, DOI 10.3181/00379727-114-28586; CASADEVALL A, 1992, J IMMUNOL METHODS, V154, P27, DOI 10.1016/0022-1759(92)90209-C; CHERNIAK R, 1988, CARBOHYD RES, V172, P113, DOI 10.1016/S0008-6215(00)90846-2; CHERNIAK R, 1980, MOL IMMUNOL, V17, P1025, DOI 10.1016/0161-5890(80)90096-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; COULTER A, 1983, J IMMUNOL METHODS, V59, P199, DOI 10.1016/0022-1759(83)90031-5; CYGLER M, 1991, SCIENCE, V253, P442, DOI 10.1126/science.1713710; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DIAMOND RD, 1974, ANN INTERN MED, V80, P176, DOI 10.7326/0003-4819-80-2-176; DIVITA G, 1991, BIOCHEMISTRY-US, V30, P3256, DOI 10.1021/bi00227a013; DROMER F, 1987, INFECT IMMUN, V55, P749, DOI 10.1128/IAI.55.3.749-752.1987; ECKERT TF, 1987, INFECT IMMUN, V55, P1895, DOI 10.1128/IAI.55.8.1895-1899.1987; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; EFTINK MR, 1987, BIOCHIM BIOPHYS ACTA, V916, P343, DOI 10.1016/0167-4838(87)90179-8; EVANS EE, 1953, J BACTERIOL, V65, P571, DOI 10.1128/JB.65.5.571-577.1953; Fersht AR., 1977, ENZYME STRUCTURE MEC; GADE W, 1991, J CLIN MICROBIOL, V29, P1616, DOI 10.1128/JCM.29.8.1616-1619.1991; GHIRON CA, 1990, BIOCHIM BIOPHYS ACTA, V1041, P311, DOI 10.1016/0167-4838(90)90290-V; GLAUDEMANS CPG, 1971, METHODS CARBOHYDR CH, V3, P145; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; JOLLEY ME, 1974, CARBOHYD RES, V33, P377, DOI 10.1016/S0008-6215(00)82819-0; JONES KN, 1965, METHODS CARBOHYDR CH, V5, P445; Kabat EA, 1992, SEQUENCES PROTEINS I; KOVACS JA, 1985, ANN INTERN MED, V103, P533, DOI 10.7326/0003-4819-103-4-533; KOZEL TR, 1982, J IMMUNOL, V129, P1675; KOZEL TR, 1988, J IMMUNOL METHODS, V107, P53, DOI 10.1016/0022-1759(88)90008-7; KOZEL TR, 1984, INFECT IMMUN, V43, P879, DOI 10.1128/IAI.43.3.879-886.1984; Kwon-Chung J.K., 1992, MED MYCOL; LADOKHIN AS, 1991, BIOCHEMISTRY-US, V30, P10200, DOI 10.1021/bi00106a018; LAWS WR, 1992, METHOD ENZYMOL, V210, P448; MELHUISH WH, 1961, J PHYS CHEM-US, V65, P229, DOI 10.1021/j100820a009; MUKHERJEE J, 1992, INFECT IMMUN, V60, P4534, DOI 10.1128/IAI.60.11.4534-4541.1992; MUKHERJEE J, 1993, J EXP MED, V177, P1105, DOI 10.1084/jem.177.4.1105; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; NASHED EM, 1990, J BIOL CHEM, V265, P20699; NEMECZ G, 1991, J BIOL CHEM, V266, P17112; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PADLAN EA, 1988, P NATL ACAD SCI USA, V85, P6885, DOI 10.1073/pnas.85.18.6885; PIGAULT C, 1990, BIOCHIM BIOPHYS ACTA, V1037, P106, DOI 10.1016/0167-4838(90)90108-R; RAYCHAUDHURI G, 1985, MOL IMMUNOL, V22, P1009, DOI 10.1016/0161-5890(85)90104-X; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANFORD JE, 1990, INFECT IMMUN, V58, P1919, DOI 10.1128/IAI.58.6.1919-1923.1990; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELIK RM, 1987, AIDS, V1, P175; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; SPIROPULU C, 1989, INFECT IMMUN, V57, P3240, DOI 10.1128/IAI.57.10.3240-3242.1989; STEINBUCH M, 1969, ARCH BIOCHEM BIOPHYS, V134, P279, DOI 10.1016/0003-9861(69)90285-9; TAYLOR RL, 1972, BIOCHEMISTRY-US, V11, P1383, DOI 10.1021/bi00758a009; TURNER SH, 1992, CARBOHYD RES, V233, P205, DOI 10.1016/S0008-6215(00)90932-7; VALENZUELA CF, 1992, J BIOL CHEM, V267, P8238; WILSON DE, 1968, P SOC EXP BIOL MED, V127, P820, DOI 10.3181/00379727-127-32812	62	22	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1858	1864						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294434				2022-12-27	WOS:A1994MR98800049
J	SANCHEZ, A; ROBBINS, J				SANCHEZ, A; ROBBINS, J			UNPROCESSED MYOGENIN TRANSCRIPTS ACCUMULATE DURING MOUSE EMBRYOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MUSCLE REGULATORY GENE; BINDING PROTEINS; EXPRESSION; DIFFERENTIATION; MYOD; MYC; RNA; INACTIVATION; NEUROGENESIS; MYOBLASTS	The gene myogenin encodes a helix-loop-helix protein whose function is critical to the integrity of the mammalian myogenic cascade. In vitro, the expression of this gene immediately precedes terminal differentiation, as measured by the synthesis of those proteins that make up the contractile apparatus. However, during mammalian development, expression of myogenin and the appearance of sarcomeres are separated by at least 1 week. The observation that early embryos (10.5 days post coitum) do not possess myogenin protein despite the fact that transcripts are detected (Cusella-De Angelis et al. (1992) J. Cell Biol. 116, 1243-1255), suggests the possibility of post-transcriptional regulation. Using polymerase chain reaction and in situ analyses, we report here that the mouse embryo accumulates a significant pool of unprocessed myogenin RNA in the developing somites (10.5 days post coitum). These results indicate that post-transcriptional regulation of myogenin may occur at the RNA processing level.	CHILDRENS HOSP RES FDN,DEPT PEDIAT,DIV MOLEC CARDIOVASC BIOL,TCHRF,RM 3057,3333 BURNET AVE,CINCINNATI,OH 45229	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046826, P01HL022619, P01HL041496] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL22619, HL41496, HL46826] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSONI S, 1991, DEVELOPMENT, V112, P1041; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOBER E, 1991, J CELL BIOL, V113, P1255, DOI 10.1083/jcb.113.6.1255; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRUNETTI A, 1990, J BIOL CHEM, V265, P5960; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; CRONMILLER C, 1994, MOL GENETICS SEX DET, P171; CUSELLADEANGELIS MG, 1992, J CELL BIOL, V116, P1243, DOI 10.1083/jcb.116.5.1243; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DOLLE P, 1990, CELL, V60, P809, DOI 10.1016/0092-8674(90)90095-V; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HORABIN JI, 1993, MOL CELL BIOL, V13, P1408, DOI 10.1128/MCB.13.3.1408; LYONS GE, 1990, J CELL BIOL, V111, P1465, DOI 10.1083/jcb.111.4.1465; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RASTINEJAD F, 1993, CELL, V72, P903, DOI 10.1016/0092-8674(93)90579-F; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; Rugh R, 1990, MOUSE; SANCHEZ A, 1991, J BIOL CHEM, V266, P22419; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	31	10	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 21	1994	269	3					1587	1590						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR988	8294401				2022-12-27	WOS:A1994MR98800006
J	GALLOWAY, AM; LIUZZI, M; PATERSON, MC				GALLOWAY, AM; LIUZZI, M; PATERSON, MC			METABOLIC PROCESSING OF CYCLOBUTYL PYRIMIDINE DIMERS AND (6-4) PHOTOPRODUCTS IN UV-TREATED HUMAN-CELLS - EVIDENCE FOR DISTINCT EXCISION-REPAIR PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRADIMER PHOSPHODIESTER LINKAGE; COMPLEMENTATION GROUP-C; XERODERMA-PIGMENTOSUM; ENZYMATIC ANALYSIS; HUMAN-FIBROBLASTS; DNA-REPAIR; ISOMERIC TRITHYMIDYLATES; MICROCOCCUS-LUTEUS; MYC GENE; DAMAGE	A new nuclease digestion assay was developed to elucidate the human excision-repair system operating on cyclobutyl pyrimidine dimers and (6-4) photoproducts. We analyzed lesions that accumulated in excised oligonucleotide fragments during incubation of UV-treated cultured fibroblasts. (6-4) photoproducts were removed intact, whereas excised cyclobutyl dimers often contained ruptured interpyrimidine phosphodiester bonds, raising the possibility that the intradimer backbone-cleavage reaction may help promote the bypass of unexcised dimers by the DNA replication or RNA transcription machinery. Cell strains representing eight different inherited forms of the cancer-prone skin disease xeroderma pigmentosum (XP) were generally found to exhibit characteristic abilities to excise the two classes of photolesions, ranging from total deficiency in groups A and G to normal proficiency in the variant. The capacity of any given XP group to act on one class of photoproducts in no way predicted its ability to act on the other. Finally, in those XP strains displaying significant levels of dimer removal, the ratio of intact-versus-modified dimers was normal, implying that rupture of the intradimer backbone linkage occurs independently of subsequent excision-repair reactions. Our data indicate that cyclobutyl dimers and (6-4) photoproducts are processed by distinct nucleotide-excision-repair pathways in human cells.	CROSS CANC INST, MOLEC ONCOL PROGRAM, EDMONTON T6G 1Z2, ALBERTA, CANADA; UNIV ALBERTA, DEPT GENET, ALBERTA T6G 2Z3, AB, CANADA; UNIV ALBERTA, DEPT ONCOL, DEPT ONCOL, ALBERTA T6G 2Z3, AB, CANADA; UNIV ALBERTA, DEPT BIOCHEM, ALBERTA T6G 2Z3, AB, CANADA	University of Alberta; University of Alberta; University of Alberta; University of Alberta								BOHR VA, 1987, CANCER RES, V47, P6426; BRASH DE, 1982, NATURE, V298, P189, DOI 10.1038/298189a0; BRASH DE, 1987, P NATL ACAD SCI USA, V84, P3782, DOI 10.1073/pnas.84.11.3782; BUHL SN, 1972, INT J RADIAT BIOL RE, V22, P417, DOI 10.1080/09553007214551301; Carrier W. L., 1971, METHODS ENZYMOLOGY D, V21, P230; Cleaver J. E., 1989, METABOLIC BASIS INHE, V2, P2949; CLEAVER JE, 1991, PHOTOCHEM PHOTOBIOL, V54, P393, DOI 10.1111/j.1751-1097.1991.tb02033.x; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; EHMANN UK, 1978, BIOPHYS J, V22, P249, DOI 10.1016/S0006-3495(78)85487-3; FRANKLIN WA, 1982, J BIOL CHEM, V257, P13535; HIRAMOTO T, 1989, J INVEST DERMATOL, V93, P703, DOI 10.1111/1523-1747.ep12319907; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; KANTOR GJ, 1990, MUTAT RES, V235, P171, DOI 10.1016/0921-8777(90)90071-C; LABELLE M, 1982, PHOTOCHEM PHOTOBIOL, V36, P319, DOI 10.1111/j.1751-1097.1982.tb04381.x; LIUZZI M, 1992, J BIOL CHEM, V267, P22421; LIUZZI M, 1989, J BIOL CHEM, V264, P6355; MCWHINNEY C, 1990, NUCLEIC ACIDS RES, V18, P1233, DOI 10.1093/nar/18.5.1233; MITCHELL DL, 1984, PHOTOCHEM PHOTOBIOL, V40, P735; MITCHELL DL, 1988, PHOTOCHEM PHOTOBIOL, V48, P51; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; MULLENDERS LHF, 1984, MUTAT RES, V141, P75, DOI 10.1016/0165-7992(84)90014-9; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PATERSON MC, 1987, J CELL SCI, P161; PATERSON MC, 1973, MUTAT RES, V19, P245, DOI 10.1016/0027-5107(73)90083-3; PATERSON MC, 1992, ADP RIBOSYLATION REA, P97; REARDON JT, 1991, NUCLEIC ACIDS RES, V19, P4623, DOI 10.1093/nar/19.17.4623; ROZA L, 1990, CANCER RES, V50, P1905; SAMBROOK S, 1989, MOL CLONING LABORATO; SANCAR A, 1993, PHOTOCHEM PHOTOBIOL, V57, P905, DOI 10.1111/j.1751-1097.1993.tb09233.x; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SETLOW RB, 1969, P NATL ACAD SCI USA, V64, P1035, DOI 10.1073/pnas.64.3.1035; SIBGHATULLAH, 1990, BIOCHEMISTRY-US, V29, P5711, DOI 10.1021/bi00476a011; SMITH PJ, 1982, PHOTOCHEM PHOTOBIOL, V36, P333, DOI 10.1111/j.1751-1097.1982.tb04383.x; SPENCER CA, 1991, ADV CANCER RES, V56, P1; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; VASSILEV L, 1990, MOL CELL BIOL, V10, P4899, DOI 10.1128/MCB.10.9.4899; WANG SY, 1967, BIOCHEM BIOPH RES CO, V29, P543, DOI 10.1016/0006-291X(67)90519-0; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WEINFELD M, 1989, J BIOL CHEM, V264, P6364; WEINFELD M, 1986, BIOCHEMISTRY-US, V25, P2656, DOI 10.1021/bi00357a055; ZELLE B, 1979, MUTAT RES, V62, P363, DOI 10.1016/0027-5107(79)90091-5	42	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					974	980						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288650				2022-12-27	WOS:A1994MR22000033
J	GUSTAVSSON, L; MOEHREN, G; TORRESMARQUEZ, ME; BENISTANT, C; RUBIN, R; HOEK, JB				GUSTAVSSON, L; MOEHREN, G; TORRESMARQUEZ, ME; BENISTANT, C; RUBIN, R; HOEK, JB			THE ROLE OF CYTOSOLIC CA2+, PROTEIN-KINASE-C, AND PROTEIN KINASE-A IN HORMONAL-STIMULATION OF PHOSPHOLIPASE-D IN RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT PERITONEAL NEUTROPHILS; PHOSPHATIDYLCHOLINE HYDROLYSIS; D ACTIVATION; CA-2+-MOBILIZING HORMONES; INTRACELLULAR CALCIUM; DEPENDENT ACTIVATION; ENDOTHELIAL-CELLS; RESPIRATORY BURST; PHORBOL ESTER; CALPHOSTIN-C	Ca2+-dependent and protein kinase C-dependent mechanisms of phospholipase D (PLD) activation were studied in rat hepatocytes by measuring phosphatidylethanol (Peth) formation in the presence of ethanol. Stimulation of Peth formation by 12-O-tetradecanoylphorbol 13-acetate (TPA), vasopressin, or A23187 was inhibited by multiple protein kinase C inhibitors or by protein kinase C down-regulation, indicating that this enzyme is involved in the action of all these agents. A controlled elevation of the cytosolic Ca2+ concentration ([Ca2+]cyt) over the range of 0.1-2.0 muM activated Peth formation in the absence of other agonists. Staurosporin potentiated Ca2+-induced Peth formation by shifting the [Ca2+]cyt dose-response curve to the left. Other protein kinase C inhibitors (calphostin C, bisindolylmaleimide) inhibited Ca2+-mediated Peth formation, but this inhibition was reduced in staurosporin-treated cells. Okadaic acid potentiated PLD activation by TPA, but suppressed PLD activation by elevated [Ca2+]cyt. Desensitization of TPA-induced PLD activity did not affect PLD activation by Ca2+. These data indicate that [Ca2+]cyt and protein kinase C control distinct pathways of PLD activation, but the Ca2+-mediated pathway is suppressed by a staurosporin-sensitive protein kinase. Both mechanisms contribute to vasopressin-induced Peth formation in intact hepatocytes. Activation of protein kinase A enhanced vasopressin-induced Peth formation, but not TPA-stimulated or Ca2+-stimulated Peth formation. Protein kinase A acted by enhancing hormonal Ca2+ mobilization, rather than by directly activating PLD, and thereby shifted the balance of Ca2+-dependent and protein kinase C-dependent activation mechanisms of PLD in intact cells.	THOMAS JEFFERSON UNIV, DEPT PATHOL & CELL BIOL, PHILADELPHIA, PA 19107 USA; LUND UNIV, DEPT PSYCHIAT & NEUROCHEM, S-22009 LUND, SWEDEN; INSA, INSERM, UNITE 205, CHIM BIOL LAB, F-69621 VILLEURBANNE, FRANCE	Jefferson University; Lund University; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National des Sciences Appliquees de Lyon - INSA Lyon			Benistant, Christine/M-5771-2018	Hoek, Jan/0000-0001-7127-4218	NIAAA NIH HHS [AA07215, AA08714, AA07186] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA007186, R01AA008714] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOCCKINO SB, 1987, FEBS LETT, V225, P201, DOI 10.1016/0014-5793(87)81157-2; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOURGOIN S, 1992, CELL SIGNAL, V4, P487; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; DEWALD B, 1989, BIOCHEM J, V264, P879, DOI 10.1042/bj2640879; ELMOATASSIM C, 1992, J BIOL CHEM, V267, P23664; EXTON JH, 1992, CIBA F SYMP, V164, P36; EXTON JH, 1991, MOL CELL BIOCHEM, V104, P81; GENY B, 1992, BIOCHEM J, V284, P531, DOI 10.1042/bj2840531; GOPALAKRISHNA R, 1992, FEBS LETT, V314, P149, DOI 10.1016/0014-5793(92)80962-G; GUSTAVSSON L, 1987, BIOCHEM BIOPH RES CO, V142, P958, DOI 10.1016/0006-291X(87)91507-5; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HIGASHI K, 1991, J BIOL CHEM, V266, P2178; HUANG CF, 1992, J BIOL CHEM, V267, P16859; HUANG CF, 1990, J BIOL CHEM, V265, P17468; KANAHO Y, 1992, J BIOL CHEM, V267, P23554; KANAHO Y, 1992, J IMMUNOL, V149, P622; KANOH H, 1992, J NEUROCHEM, V59, P1786, DOI 10.1111/j.1471-4159.1992.tb11011.x; KASZKIN M, 1992, BIOCHEM J, V287, P51, DOI 10.1042/bj2870051; KESSELS GCR, 1991, J BIOL CHEM, V266, P23152; KISS Z, 1990, J BIOL CHEM, V265, P7345; KISS Z, 1990, PROG LIPID RES, V29, P141, DOI 10.1016/0163-7827(90)90001-2; KOBAYASHI M, 1987, J NEUROCHEM, V48, P1597, DOI 10.1111/j.1471-4159.1987.tb05707.x; LASSEGUE B, 1991, BIOCHEM J, V276, P19, DOI 10.1042/bj2760019; LAVIE Y, 1990, FEBS LETT, V277, P7, DOI 10.1016/0014-5793(90)80796-L; LIN PY, 1992, EUR J BIOCHEM, V207, P163, DOI 10.1111/j.1432-1033.1992.tb17033.x; LISCOVITCH M, 1991, CELL REGUL, V2, P1011, DOI 10.1091/mbc.2.12.1011; MARTIN TW, 1989, BIOCHEM BIOPH RES CO, V165, P319, DOI 10.1016/0006-291X(89)91072-3; MARTINSON EA, 1990, J BIOL CHEM, V265, P22282; MATTINGLY RR, 1992, FEBS LETT, V296, P225, DOI 10.1016/0014-5793(92)80385-T; MOEHREN G, 1994, J BIOL CHEM, V269, P838; NIGAM S, 1992, BIOCHIM BIOPHYS ACTA, V1135, P301, DOI 10.1016/0167-4889(92)90235-4; PACHTER JA, 1992, J BIOL CHEM, V267, P9826; PAI JK, 1991, CELL REGUL, V2, P897, DOI 10.1091/mbc.2.11.897; PERIANIN A, 1993, FEBS LETT, V315, P33, DOI 10.1016/0014-5793(93)81127-L; PIROTTON S, 1990, J CELL PHYSIOL, V142, P449, DOI 10.1002/jcp.1041420303; PITTNER RA, 1990, BIOCHIM BIOPHYS ACTA, V1043, P211, DOI 10.1016/0005-2760(90)90298-C; PITTNER RA, 1991, BIOCHEM J, V277, P371, DOI 10.1042/bj2770371; PLEIN P, 1992, BIOL CHEM H-S, V373, P151, DOI 10.1515/bchm3.1992.373.1.151; PLEVIN R, 1991, BIOCHEM J, V279, P559, DOI 10.1042/bj2790559; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; SHUKLA SD, 1991, LIFE SCI, V48, P851, DOI 10.1016/0024-3205(91)90031-6; SIDDIQUI RA, 1992, J BIOL CHEM, V267, P5755; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10344; WANG P, 1991, J BIOL CHEM, V266, P14877; WONG K, 1992, BIOCHEM J, V283, P499, DOI 10.1042/bj2830499; WU H, 1992, BIOCHEMISTRY-US, V31, P3370, DOI 10.1021/bi00128a010	54	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					849	859						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288638				2022-12-27	WOS:A1994MR22000016
J	TEZUKA, K; TEZUKA, Y; MAEJIMA, A; SATO, T; NEMOTO, K; KAMIOKA, H; HAKEDA, Y; KUMEGAWA, M				TEZUKA, K; TEZUKA, Y; MAEJIMA, A; SATO, T; NEMOTO, K; KAMIOKA, H; HAKEDA, Y; KUMEGAWA, M			MOLECULAR-CLONING OF A POSSIBLE CYSTEINE PROTEINASE PREDOMINANTLY EXPRESSED IN OSTEOCLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCES; BOVINE CATHEPSIN-S; BONE-RESORPTION; RAT-LIVER; COLLAGENOLYTIC CATHEPSIN; RABBIT SPLEEN; CDNA; DEGRADATION; NUCLEOTIDE; HOMOLOGY	Osteoclasts are multinucleate giant cells playing key roles in bone resorption. These cells solubilize mineralized bone matrix by means of acid and protease action; however, the precise mechanism of this process is not well known. Recently, we succeeded in the isolation of pure osteoclasts from rabbit bones and constructed a cDNA library. Using a differential screening procedure, two genes expressed predominantly in osteoclasts compared with spleen cells were isolated (Tezuka, K., Sato, T., Kamioka, H., Nijweide, P. J., Tanaka, K., Matsuo, T., Ohta, M., Kurihara, N., Hakeda, Y., and Kumegawa, M. (1992) Biochem. Biophys. Res. Commun. 186, 911-917). One of them, OC-2, was found to encode a possible cysteine proteinase structurally related to cathepsins L and S. By in situ hybridization, OC-2 was confirmed to be expressed in osteoclasts in vivo. By Northern blot analysis, OC-2 was highly and preferentially expressed in osteoclasts compared with other tissues such as kidney, liver, spleen, and lung. The predominant expression of OC-2 in osteoclasts may suggest that OC-2 encodes a protein, possibly a cysteine proteinase, that plays an important role in osteoclastic bone resorption.	MEIKAI UNIV,SCH DENT,DEPT ORAL ANAT,KEYAKIDAI 1-1,SAKADO,SAITAMA 35002,JAPAN; TAISHO PHARMACEUT CO LTD,RES CTR,DEPT APPL BIOL,OMIYA,SAITAMA 330,JAPAN; ST MARIANNA UNIV,SCH MED,DEPT INTERNAL MED,KAWASAKI,KANAGAWA 213,JAPAN; UNIV TOKUSHIMA,SCH DENT,DEPT ORTHODONT,TOKUSHIMA 770,JAPAN	Meikai University; Taisho Pharmaceutical Holdings Co Ltd; Saint Marianna University; Tokushima University			Tezuka, Ken-ichi/B-3836-2012; Kamioka, Hiroshi/B-2476-2011					BARON R, 1989, ANAT RECORD, V224, P317, DOI 10.1002/ar.1092240220; BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210; BURLEIGH MC, 1974, BIOCHEM J, V137, P387, DOI 10.1042/bj1370387; CHAN SJ, 1986, P NATL ACAD SCI USA, V83, P7721, DOI 10.1073/pnas.83.20.7721; DELAISSE JM, 1987, BONE, V8, P305, DOI 10.1016/8756-3282(87)90007-X; DELAISSE JM, 1991, BIOCHEM J, V279, P167, DOI 10.1042/bj2790167; DUFOUR E, 1987, BIOCHEMISTRY-US, V26, P5689, DOI 10.1021/bi00392a017; ETHERINGTON DJ, 1972, BIOCHEM J, V127, P685, DOI 10.1042/bj1270685; ETHERINGTON DJ, 1987, COLLAGEN REL RES, V7, P185; EVANS P, 1978, EUR J BIOCHEM, V83, P87, DOI 10.1111/j.1432-1033.1978.tb12071.x; EVERTS V, 1988, CALCIFIED TISSUE INT, V43, P172, DOI 10.1007/BF02571316; EVERTS V, 1992, J CELL PHYSIOL, V150, P221, DOI 10.1002/jcp.1041500202; FUCHS R, 1989, NUCLEIC ACIDS RES, V17, P9471, DOI 10.1093/nar/17.22.9471; GAL S, 1988, BIOCHEM J, V253, P303, DOI 10.1042/bj2530303; ISHIDOH K, 1987, FEBS LETT, V226, P33, DOI 10.1016/0014-5793(87)80545-8; ISHIDOH K, 1987, FEBS LETT, V223, P69, DOI 10.1016/0014-5793(87)80511-2; JOSEPH LJ, 1988, J CLIN INVEST, V81, P1621, DOI 10.1172/JCI113497; KIRSCHKE H, 1989, BIOCHEM J, V264, P467, DOI 10.1042/bj2640467; KIRSCHKE H, 1982, BIOCHEM J, V201, P367, DOI 10.1042/bj2010367; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KURIHARA N, 1989, BLOOD, V74, P1295; MACIEWICZ RA, 1987, COLLAGEN REL RES, V7, P295; MACIEWICZ RA, 1988, BIOCHEM J, V256, P433, DOI 10.1042/bj2560433; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; RIFKIN BR, 1991, BIOCHEM BIOPH RES CO, V179, P63, DOI 10.1016/0006-291X(91)91334-9; RITONJA A, 1991, FEBS LETT, V283, P329, DOI 10.1016/0014-5793(91)80620-I; SHI GP, 1992, J BIOL CHEM, V267, P7258; TAKEISHI K, 1982, J BIOCHEM-TOKYO, V92, P1173, DOI 10.1093/oxfordjournals.jbchem.a134033; TAKIO K, 1983, P NATL ACAD SCI-BIOL, V80, P3666, DOI 10.1073/pnas.80.12.3666; TEZUKA K, 1992, BIOCHEM BIOPH RES CO, V186, P911, DOI 10.1016/0006-291X(92)90832-6; TROEN BR, 1987, BIOCHEM J, V246, P731, DOI 10.1042/bj2460731; UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WIEDERANDERS B, 1992, J BIOL CHEM, V267, P13708; WIEDERANDERS B, 1991, FEBS LETT, V286, P189, DOI 10.1016/0014-5793(91)80971-5; YOKOUCHI Y, 1991, DEVELOPMENT, V113, P431	37	317	341	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 14	1994	269	2					1106	1109						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR220	8288568				2022-12-27	WOS:A1994MR22000053
J	CHRISTIANSEN, K; WESTERGAARD, O				CHRISTIANSEN, K; WESTERGAARD, O			CHARACTERIZATION OF INTRAMOLECULAR AND INTERMOLECULAR DNA LIGATION-MEDIATED BY EUKARYOTIC TOPOISOMERASE-I - ROLE OF BIPARTITE DNA INTERACTION IN THE LIGATION PROCESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; TYPE-1 TOPOISOMERASE; BINDING SEQUENCE; CLEAVAGE INVITRO; RAT-LIVER; SV40 DNA; SITES; CAMPTOTHECIN; CHROMATIN; BREAKAGE	The capacity of eukaryotic topoisomerase I to catalyze intra- and intermolecular DNA strand transfer via a two-step cleavage/ligation reaction was investigated by use of purified enzyme and defined DNA substrates. Topoisomerase I-mediated cleavage requires separate interaction with a duplex region encompassing the cleavage site (region A) and a duplex region located on the side holding the 5'-OH end generated by cleavage (region B). Cleaved topoisomerase 1-DNA complexes containing enzyme covalently attached at internal and terminal positions were employed to characterize the intra- and intermolecular ligation reactions. Enzyme attached covalently at an internal position of a partially single-stranded DNA molecule is able to catalyze ligation of a complementary dinucleotide within region A in the absence of interaction with region B. Moreover, the dinucleotide confines the minimal DNA acceptor for intramolecular ligation. Topoisomerase I attached covalently to DNA at a terminal position can ligate the cleaved strand to heterologous duplex DNA regardless of sequence, whereas ligation does not proceed with single-stranded DNA. When these features are considered together with the observation that intermolecular ligation is inhibited by 1 m NaCl, it suggests that the reaction requires bipartite DNA interaction. A model is proposed that relates the bipartite DNA binding of eukaryotic topoisomerase I to the catalytic functions.	AARHUS UNIV, DEPT MOLEC BIOL, CF MOLLERS ALLE, BLDG 130, DK-8000 AARHUS, DENMARK	Aarhus University								ANDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P6237, DOI 10.1021/bi00441a015; BAUER WR, 1993, P NATL ACAD SCI USA, V90, P833, DOI 10.1073/pnas.90.3.833; BEEN MD, 1981, P NATL ACAD SCI-BIOL, V78, P2883, DOI 10.1073/pnas.78.5.2883; BEEN MD, 1984, NUCLEIC ACIDS RES, V12, P3097, DOI 10.1093/nar/12.7.3097; BEEN MD, 1984, J MOL BIOL, V180, P515, DOI 10.1016/0022-2836(84)90025-1; BJORNSTI MA, 1989, CANCER RES, V49, P6318; BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; BRILL SJ, 1988, CELL, V54, P403, DOI 10.1016/0092-8674(88)90203-6; BROWN T, 1985, NATURE, V315, P604, DOI 10.1038/315604a0; BUSK H, 1987, NATURE, V327, P638, DOI 10.1038/327638a0; CAMILLONI G, 1989, P NATL ACAD SCI USA, V86, P3080, DOI 10.1073/pnas.86.9.3080; CASERTA M, 1989, NUCLEIC ACIDS RES, V17, P8462; CHRISTIANSEN K, 1993, J BIOL CHEM, V268, P9690; CHRISTIANSEN K, 1987, J MOL BIOL, V193, P517, DOI 10.1016/0022-2836(87)90264-6; CHRISTIANSEN K, 1993, ALFRED BENZON SYMP S, V35, P361; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; Der Garabedian P A, 1991, Biochemistry, V30, P9940, DOI 10.1021/bi00105a018; EDWARDS KA, 1982, NUCLEIC ACIDS RES, V10, P2565, DOI 10.1093/nar/10.8.2565; FRANK R, 1979, NUCLEIC ACIDS RES, V6, P2069, DOI 10.1093/nar/6.6.2069; HALLIGAN BD, 1982, J BIOL CHEM, V257, P3995; KIRKEGAARD K, 1984, COLD SPRING HARB SYM, V49, P411, DOI 10.1101/SQB.1984.049.01.047; KRASNOW MA, 1982, J BIOL CHEM, V257, P2687; KROGH S, 1991, NUCLEIC ACIDS RES, V19, P1235, DOI 10.1093/nar/19.6.1235; NESS PJ, 1988, J MOL BIOL, V200, P127, DOI 10.1016/0022-2836(88)90338-5; OSHEROFF N, 1989, PHARMACOL THERAPEUT, V41, P223, DOI 10.1016/0163-7258(89)90108-3; PILCH DS, 1990, P NATL ACAD SCI USA, V87, P1942, DOI 10.1073/pnas.87.5.1942; PRELL B, 1980, EUR J BIOCHEM, V108, P389, DOI 10.1111/j.1432-1033.1980.tb04734.x; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1992, J BIOL CHEM, V267, P16755; STEVNSNER T, 1989, J BIOL CHEM, V264, P10110; SVEJSTRUP JQ, 1991, J MOL BIOL, V222, P669, DOI 10.1016/0022-2836(91)90503-X; SVEJSTRUP JQ, 1990, J BIOL CHEM, V265, P12529; THOMSEN B, 1987, EMBO J, V6, P1817, DOI 10.1002/j.1460-2075.1987.tb02436.x; TSEDINH YC, 1986, J BIOL CHEM, V261, P931; VOSBERG HP, 1985, CURR TOP MICROBIOL, V114, P19; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x	38	60	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					721	729						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276874				2022-12-27	WOS:A1994MR21900113
J	HAZARD, AL; SENIOR, AE				HAZARD, AL; SENIOR, AE			MUTAGENESIS OF SUBUNIT-DELTA FROM ESCHERICHIA-COLI F1F0-ATP SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; SENSITIVITY-CONFERRING PROTEIN; B UNCF-PROTEIN; ADENOSINE-TRIPHOSPHATASE; ELECTRON-MICROSCOPY; NUCLEOTIDE-SEQUENCE; H+-ATPASE; CRYOELECTRON MICROSCOPY; DIRECTED MUTAGENESIS; MEMBRANE ATTACHMENT	In Escherichia coli, the F1 sector of the F1F0-ATP synthase is connected to the membrane-embedded F0 sector by a narrow stalk, thought to be formed by subunits delta and b. Mutagenic analysis was used here to study the structure and function of subunit delta. First, random mutations in the protein were generated by bisulfite mutagenesis. Two single missense mutations causing impaired growth by oxidative phosphorylation were found, namely deltaA149T and deltaG150D. Both occur at the conserved C-terminal region, which has been suggested previously to be functionally important. Two techniques were applied to study the C-terminal region in greater detail. Cassette mutagenesis was used to randomly mutate the sequence from delta145 to delta167, and residues delta4,149 and deltaG150 were specifically mutated by site-directed mutagenesis to obtain multiple substitutions at each position. Fifteen of the residues between delta145 and delta167 were mutated. None was found to be absolutely essential for function. However, the properties of the mutants obtained, which included partial impairment of growth by oxidative phosphorylation, temperature sensitivity, and specific structural requirements at residues deltaA149 and deltaG150, confirmed that this region is important for enzyme function. Based on these studies, and on secondary and tertiary structure predictions, a model for subunit delta and its orientation in F1F0-ATP synthase is proposed.			HAZARD, AL (corresponding author), UNIV ROCHESTER,MED CTR,DEPT BIOCHEM,ROCHESTER,NY 14642, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025349, R37GM025349] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25349] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1993, EMBO J, V12, P1775, DOI 10.1002/j.1460-2075.1993.tb05825.x; BECKERS G, 1992, BIOCHIM BIOPHYS ACTA, V1101, P97, DOI 10.1016/0167-4838(92)90473-Q; BLACKLOW SC, 1991, BIOCHEMISTRY-US, V30, P8470, DOI 10.1021/bi00098a026; BOEKEMA EJ, 1986, BIOCHIM BIOPHYS ACTA, V851, P353, DOI 10.1016/0005-2728(86)90071-X; BOEKEMA EJ, 1992, BIOCHIM BIOPHYS ACTA, V1098, P131, DOI 10.1016/S0005-2728(05)80328-7; COX GB, 1984, BIOCHIM BIOPHYS ACTA, V768, P201, DOI 10.1016/0304-4173(84)90016-8; DECKERSHEBESTR G, 1992, J BIOL CHEM, V267, P12634; DOWNIE JA, 1981, J BACTERIOL, V145, P200, DOI 10.1128/JB.145.1.200-210.1981; DUNN SD, 1992, J BIOL CHEM, V267, P7630; DUPUIS A, 1983, BIOCHEMISTRY-US, V22, P5951, DOI 10.1021/bi00294a039; ENGELBRECHT S, 1990, BIOCHIM BIOPHYS ACTA, V1015, P379, DOI 10.1016/0005-2728(90)90072-C; ENGELBRECHT S, 1991, Z NATURFORSCH C, V46, P759; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; GIBSON F, 1977, BIOCHEM J, V162, P665, DOI 10.1042/bj1620665; GIZA PE, 1981, GENE, V15, P331, DOI 10.1016/0378-1119(81)90176-1; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4717, DOI 10.1021/bi00437a031; GOGOL EP, 1987, FEBS LETT, V219, P274, DOI 10.1016/0014-5793(87)80234-X; HAZARD AL, J BIOL CHEM, V269, P427; HERMES JD, 1990, P NATL ACAD SCI USA, V87, P696, DOI 10.1073/pnas.87.2.696; HERMOLIN J, 1983, J BIOL CHEM, V258, P4550; HILL DE, 1987, METHOD ENZYMOL, V155, P558; JANS DA, 1985, J BACTERIOL, V162, P420, DOI 10.1128/JB.162.1.420-426.1985; JOSHI S, 1992, J BIOL CHEM, V267, P12860; JOUNOUCHI M, 1992, ARCH BIOCHEM BIOPHYS, V292, P376, DOI 10.1016/0003-9861(92)90005-H; KIMURA T, 1990, J BIOL CHEM, V265, P6079; LUCKEN U, 1990, BIOCHEMISTRY-US, V29, P5339; MABUCHI K, 1981, BIOCHEM BIOPH RES CO, V102, P172, DOI 10.1016/0006-291X(81)91504-7; MAGGIO MB, 1988, J BIOL CHEM, V263, P4619; Maniatis T., 1982, MOL CLONING; MCCARTHY JEG, 1988, J BIOENERG BIOMEMBR, V20, P19, DOI 10.1007/BF00762136; MENDELHARTVIG J, 1991, BIOCHIM BIOPHYS ACTA, V1060, P115, DOI 10.1016/S0005-2728(05)80126-4; Miller J.H., 1972, EXPT MOL GENETICS; PANCIC PG, 1991, FEBS LETT, V280, P387, DOI 10.1016/0014-5793(91)80338-4; PARSONAGE D, 1987, J BIOL CHEM, V262, P8022; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; PERLIN DS, 1985, ARCH BIOCHEM BIOPHYS, V236, P603, DOI 10.1016/0003-9861(85)90664-2; PORTER ACG, 1985, J BIOL CHEM, V260, P8182; RAO R, 1988, J BIOL CHEM, V263, P15957; RASMUSSEN OF, 1992, BIOCHEM J, V285, P881, DOI 10.1042/bj2850881; SENIOR AE, 1979, BIOCHEM J, V180, P111, DOI 10.1042/bj1800111; SENIOR AE, 1983, BIOCHIM BIOPHYS ACTA, V726, P81, DOI 10.1016/0304-4173(83)90001-0; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SMITH JB, 1977, BIOCHEMISTRY-US, V16, P306, DOI 10.1021/bi00621a023; STEFFENS K, 1987, J BIOL CHEM, V262, P5866; STERNWEIS PC, 1977, BIOCHEMISTRY-US, V16, P4020, DOI 10.1021/bi00637a013; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; WAGNER R, 1988, FEBS LETT, V230, P109, DOI 10.1016/0014-5793(88)80652-5; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WALKER JE, 1982, NATURE, V298, P867, DOI 10.1038/298867a0	51	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					418	426						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276830				2022-12-27	WOS:A1994MR21900071
J	ZHU, BT; EZELL, EL; LIEHR, JG				ZHU, BT; EZELL, EL; LIEHR, JG			CATECHOL-O-METHYLTRANSFERASE-CATALYZED RAPID O-METHYLATION OF MUTAGENIC FLAVONOIDS - METABOLIC INACTIVATION AS A POSSIBLE REASON FOR THEIR LACK OF CARCINOGENICITY IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LIVER; QUERCETIN; RAT; ESTROGENS; RUTIN; INHIBITION; ACTIVATION; HAMSTERS; CANCER; CELLS	Quercetin is highly mutagenic in vitro, yet is not carcinogenic when administered chronically at large doses to rodents for 12 months. We hypothesized that catechol-O-methyltransferase-catalyzed O-methylation of quercetin and other mutagenic catechol-containing flavonoids may provide an efficient inactivation in vivo and may therefore prevent tumor induction by these flavonoids. After one intraperitoneal administration of 50 mg/kg quercetin to hamsters, a urinary ether extract contained 2% quercetin and 97% 3'-O-methylquercetin. When the urine was treated first with bea-glucuronidase and sulfatase, 13% quercetin and 87% 3'-O-methylquercetin were recovered. Quercetin was rapidly O-methylated by either porcine liver or hamster kidney catechol-O-methyltransferase, with K(m) values of 6.1 and 6.9 muM and V(max) values of 14,870 and 200 pmol/mg of protein/min, respectively. S-Adenosyl-L-homocysteine exhibited a potent feedback inhibition of the catechol-O-methyltransferase-catalyzed O-methylation of quercetin by a competitive mechanism with respect to S-adenosyl-L-methionine and by a competitive plus noncompetitive mechanism with respect to the substrate. A comparison of the O-methylation rates and kinetic characteristics (K(m), V(max), and V(max)/K(m)) demonstrated that rates of O-methylation of quercetin and fisetin were up to three orders of magnitude higher than those of catechol estrogens and catecholamines. In conclusion, the rapid metabolic inactivation of mutagenic flavonoids catalyzed by catechol-O-methyltransferase may be a major reason for the lack of their carcinogenic activities in vivo.	UNIV TEXAS, MED BRANCH, DEPT PHARMACOL & TOXICOL, J-31, GALVESTON, TX 77555 USA; UNIV TEXAS, MED BRANCH, DEPT HUMAN BIOCHEM & GENET, GALVESTON, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston					NATIONAL CANCER INSTITUTE [R37CA043233, R01CA043233] Funding Source: NIH RePORTER; NCI NIH HHS [CA 43233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; AXELROD J, 1966, PHARMACOL REV, V18, P95; AXELROD J, 1965, J PHARMACOL EXP THER, V149, P16; AZELROD J, 1971, J PHARMACOL EXP THER, V176, P650; BACHUR NR, 1978, CANCER RES, V38, P1745; BALL P, 1972, EUR J BIOCHEM, V26, P560, DOI 10.1111/j.1432-1033.1972.tb01799.x; BALL P, 1990, AM J OBSTET GYNECOL, V163, P2163, DOI 10.1016/0002-9378(90)90558-O; BALL P, 1972, J CLIN ENDOCR METAB, V34, P736, DOI 10.1210/jcem-34-4-736; BJELDANES LF, 1977, SCIENCE, V197, P577, DOI 10.1126/science.327550; BOOTH AN, 1956, J BIOL CHEM, V223, P251; BOOTH AN, 1958, J BIOL CHEM, V230, P661; Borchardt R T, 1981, Methods Enzymol, V77, P267; BROWN JP, 1979, MUTAT RES, V66, P223, DOI 10.1016/0165-1218(79)90083-1; BROWN JP, 1977, BIOCHEM SOC T, V5, P1489, DOI 10.1042/bst0051489; CZECZOT H, 1990, MUTAT RES, V240, P209, DOI 10.1016/0165-1218(90)90060-F; DAS NP, 1973, BIOCHEM J, V136, P903, DOI 10.1042/bj1360903; DESCHNER EE, 1991, CARCINOGENESIS, V12, P1193, DOI 10.1093/carcin/12.7.1193; EICH G, 1982, J AM CHEM SOC, V104, P3731, DOI 10.1021/ja00377a036; FULLER RW, 1984, J PHARM PHARMACOL, V36, P419, DOI 10.1111/j.2042-7158.1984.tb04416.x; GRIFFITHS LA, 1972, ANGIOLOGICA, V9, P162; GRIFFITHS LA, 1972, BIOCHEM J, V128, P901, DOI 10.1042/bj1280901; GRIFFITHS LA, 1972, BIOCHEM J, V130, P141, DOI 10.1042/bj1300141; GROSSMAN MH, 1992, LIFE SCI, V50, P473, DOI 10.1016/0024-3205(92)90386-4; GUGLER R, 1975, EUR J CLIN PHARMACOL, V9, P229, DOI 10.1007/BF00614022; HIRONO I, 1981, CANCER LETT, V13, P15, DOI 10.1016/0304-3835(81)90081-1; ITO N, 1989, JPN J CANCER RES, V80, P317, DOI 10.1111/j.1349-7006.1989.tb02313.x; KATO R, 1983, CARCINOGENESIS, V4, P1301, DOI 10.1093/carcin/4.10.1301; Kuhnau J, 1976, World Rev Nutr Diet, V24, P117; LIEHR JG, 1986, J BIOL CHEM, V261, P6865; LIEHR JG, 1990, FREE RADICAL BIO MED, V8, P415, DOI 10.1016/0891-5849(90)90108-U; MACGREGOR JT, 1978, MUTAT RES, V54, P297, DOI 10.1016/0165-1161(78)90020-1; MACGREGOR JT, 1979, TOXICOL APPL PHARM, V48, pA47; MARUTA A, 1979, GANN, V70, P273; MORINO K, 1982, CARCINOGENESIS, V3, P93, DOI 10.1093/carcin/3.1.93; MULDER GJ, 1984, DRUGS NUTRITIENTS IN, P119; NAGAO M, 1981, ENVIRON MUTAGEN, V3, P401, DOI 10.1002/em.2860030402; NIKODEJEVIC B, 1970, J PHARMACOL EXP THER, V174, P83; ROY D, 1988, J BIOL CHEM, V263, P3646; Saito D, 1980, Teratog Carcinog Mutagen, V1, P213; SASAKI S, 1985, HDB PROTON NMR SPECT, V5, P97; SUGIMURA T, 1977, P JPN ACAD B-PHYS, V53, P194, DOI 10.2183/pjab.53.194; THOR H, 1982, J BIOL CHEM, V257, P2419; UENO I, 1983, JPN J EXP MED, V53, P41; UMEZAWA K, 1977, TOXICOL LETT, V1, P175; VERMA AK, 1988, CANCER RES, V48, P5754; ZHU BT, 1993, ENDOCRINOLOGY, V132, P577, DOI 10.1210/en.132.2.577; ZHU BT, 1993, ARCH BIOCHEM BIOPHYS, V304, P248, DOI 10.1006/abbi.1993.1346	47	217	221	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	1994	269	1					292	299						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MR219	8276810				2022-12-27	WOS:A1994MR21900052
J	TAKEUCHI, K; IRWIN, DM; GALLUP, M; SHINBROT, E; KAI, H; STEWART, CB; BASBAUM, C				TAKEUCHI, K; IRWIN, DM; GALLUP, M; SHINBROT, E; KAI, H; STEWART, CB; BASBAUM, C			MULTIPLE CDNA SEQUENCES OF BOVINE TRACHEAL LYSOZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLOBIN LOCUS; STOMACH LYSOZYMES; IMMUNOCYTOCHEMICAL LOCALIZATION; GENE; RUMINANTS; EXPRESSION; EVOLUTION; TISSUES; ORGANIZATION; CONVERGENCE	The principal role of lysozyme is to prevent bacterial invasion at body surfaces. We are interested in how lysozyme is regulated at the surface of the respiratory tract, where the serous gland cell is regarded as the primary cellular source of this enzyme. Since the cow genome contains at least 10 lysozyme-like genes, our objective was to determine which of them are expressed in the cow tracheal gland serous cell. By screening tracheal cDNA libraries with a probe constructed from the cDNA encoding stomach lysozyme 2, we obtained 3 lysozyme cDNAs: 5a (1023 base pairs (bp)), 7a (1060 bp), and 14d (1249 bp). cDNA 7a corresponds to a previously reported gene (showing sequence identity to the stomach 2 lysozyme gene), whereas cDNAs 5a and 14d correspond to lysozyme genes not previously reported. Northern blot analysis of cow tracheal RNA showed lysozyme mRNAs of three distinct lengths. Based on hybridization with probes specific for each cDNA, we determined that the longest transcript corresponded to cDNA 5a, the shortest to 7a, and the intermediate-length transcript to 14d. Cultured cow tracheal gland serous cell RNA, reverse transcribed and amplified by the polymerase chain reaction with primers common to all three cDNAs, yielded a product that hybridized to oligonucleotide probes specific for all three cDNAs but most strongly to that for 5a. These results indicate that multiple lysozyme mRNAs are expressed in the cow trachea and that the lysozyme encoded by cDNA 5a is the major form expressed in the tracheal gland serous cell. This serous cell lysozyme is predicted to differ importantly in structure from both 7a and 14d lysozymes, with an arginine:lysine ratio almost 10-fold higher. The sequence differences may underlie functional differences, including variable resistance to proteolysis and variable affinity for large polyanions (e.g. mucins) found in the respiratory tract lumen.	UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO M5G 1L5,ONTARIO,CANADA; SUNY ALBANY,DEPT BIOL SCI,ALBANY,NY 12222	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Toronto; State University of New York (SUNY) System; State University of New York (SUNY) Albany			Shinbrot, Eve/V-2784-2019	Shinbrot, Eve/0000-0002-8879-3150; Irwin, David/0000-0001-6131-4933	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL24136] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOAT TF, 1977, PEDIATR RES, V11, P977, DOI 10.1203/00006450-197709000-00009; BOWES D, 1977, THORAX, V32, P163, DOI 10.1136/thx.32.2.163; BUTTLE DJ, 1990, SCAND J CLIN LAB INV, V50, P509, DOI 10.3109/00365519009089165; CASTANON MJ, 1988, GENE, V66, P223, DOI 10.1016/0378-1119(88)90359-9; CROSS M, 1988, P NATL ACAD SCI USA, V85, P6232, DOI 10.1073/pnas.85.17.6232; DOBSON DE, 1984, J BIOL CHEM, V259, P1607; DORING G, 1983, J INFECT DIS, V147, P744, DOI 10.1093/infdis/147.4.744; FERAMISCO JR, 1982, J BIOL CHEM, V257, P1024; FINKBEINER WE, 1986, IN VITRO CELL DEV B, V22, P561, DOI 10.1007/BF02623514; Fleming A, 1922, P R SOC LOND B-CONTA, V93, P306, DOI 10.1098/rspb.1922.0023; HAMMER MF, 1987, J MOL EVOL, V24, P272, DOI 10.1007/BF02111240; HANKE PD, 1988, MOL CELL BIOL, V8, P3591, DOI 10.1128/MCB.8.9.3591; IRWIN DM, 1992, ANIM GENET, V23, P193, DOI 10.1111/j.1365-2052.1992.tb00131.x; IRWIN DM, 1989, J BIOL CHEM, V264, P11387; IRWIN DM, 1989, IMMUNE RESPONSE TO STRUCTURALLY DEFINED PROTEINS : THE LYSOZYME MODEL, P73; IRWIN DM, 1992, J MOL EVOL, V35, P355; IZZO P, 1988, EUR J BIOCHEM, V174, P569, DOI 10.1111/j.1432-1033.1988.tb14136.x; JOLLES J, 1990, J MOL EVOL, V30, P370, DOI 10.1007/BF02101891; JOLLES J, 1989, J MOL EVOL, V28, P528, DOI 10.1007/BF02602933; JOLLES P, 1984, J BIOL CHEM, V259, P1617; JUAREGUIADELL J, 1975, ANAL BIOCHEM, V69, P468; KLOCKARS M, 1975, J HISTOCHEM CYTOCHEM, V23, P932, DOI 10.1177/23.12.1104708; KLOCKARS M, 1974, J HISTOCHEM CYTOCHEM, V22, P139, DOI 10.1177/22.3.139; KONSTAN MW, 1982, EXP LUNG RES, V3, P175, DOI 10.3109/01902148209063291; KYLE H, 1990, J APPL PHYSIOL, V68, P135, DOI 10.1152/jappl.1990.68.1.135; LEWIS CE, 1990, IMMUNOLOGY, V69, P402; LI QL, 1991, GENOMICS, V9, P488, DOI 10.1016/0888-7543(91)90415-B; MASON DY, 1975, J CLIN PATHOL, V28, P124, DOI 10.1136/jcp.28.2.124; MASSON P, 1973, SPUTUM, V438, P412; PETERS CWB, 1989, EUR J BIOCHEM, V182, P507, DOI 10.1111/j.1432-1033.1989.tb14857.x; PRIEUR DJ, 1986, COMP BIOCHEM PHYS B, V85, P349, DOI 10.1016/0305-0491(86)90011-8; PUCHELLE E, 1987, European Journal of Respiratory Diseases Supplement, V71, P117; SAMUELSON LC, 1990, MOL CELL BIOL, V10, P2513, DOI 10.1128/MCB.10.6.2513; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SPENCE SE, 1985, NUCLEIC ACIDS RES, V13, P2171, DOI 10.1093/nar/13.6.2171; SPICER SS, 1977, LAB INVEST, V36, P282; STEWART CB, 1987, COLD SPRING HARB SYM, V52, P891, DOI 10.1101/SQB.1987.052.01.097; SWANSON KW, 1991, J MOL EVOL, V33, P418, DOI 10.1007/BF02103133	39	17	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1993	268	36					27440	27446						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MM262	8262986				2022-12-27	WOS:A1993MM26200085
J	ATKINSON, YH; GOGOLINEWENS, KJ; HOUNSELL, EF; DAVIES, MJ; BRANDON, MR; SEAMARK, RF				ATKINSON, YH; GOGOLINEWENS, KJ; HOUNSELL, EF; DAVIES, MJ; BRANDON, MR; SEAMARK, RF			CHARACTERIZATION OF PLACENTATION-SPECIFIC BINUCLEATE CELL GLYCOPROTEINS POSSESSING A NOVEL CARBOHYDRATE - EVIDENCE FOR A NEW FAMILY OF PREGNANCY-ASSOCIATED MOLECULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; CARCINOEMBRYONIC ANTIGEN; STRUCTURAL DETERMINANTS; POLYACRYLAMIDE GELS; SUGAR CHAINS; PROTEINS; SHEEP; BETA-1-GLYCOPROTEIN; IDENTIFICATION; IMPLANTATION	The ovine binucleate cell-specific glycoproteins recognized by the monoclonal antibody SBU-3 first appear at the initiation of placentation, and their expression continues throughout gestation. These placenta-specific proteins have not been detected in any other adult or fetal sheep tissues and are specific to the materno-fetal interface. The SBU-3 monoclonal antibody recognizes the carbohydrate epitope common to a group of proteins ranging in molecular mass from 30 to 200 kDa whose function during pregnancy remains undefined. The biochemical properties of these uniquely expressed glycoproteins were investigated by analyzing both the carbohydrate and protein portion of the molecules. Analysis of phytohemagglutinin and concanavalin A binding to electrophoretically separated SBU-3 proteins revealed that the major proteins between 40 and 70 kDa bind phytohemagglutinin. In contrast, concanavalin A bound only to minor proteins in the SBU-3 glycoprotein preparation. Analysis of the carbohydrate conjugated to the SBU-3 glycoproteins revealed that the major chains are sialylated O-linked and complex partially sialylated multiple antennary N-linked chains. The presence of N-glycolylneuraminic acid in an N-linked structure indicates the unique nature of this carbohydrate epitope. The differential binding to phytohemagglutinin and concanavalin A provided a method for further purification and characterization of the major protein components with monoclonal antibody immunoaffinity-purified SBU-3 proteins being further separated by concanavalin A-Sepharose chromatography. Microsequence analysis of the major non-concanavalin A-binding proteins (69, 62, and 57 kDa) revealed partial homology to ovine and bovine pregnancy-associated glycoprotein and rabbit pepsinogen F. Immunoblot analysis of the SBU-3 proteins showed cross-reactivity with polyclonal antisera directed against ovine placental-associated glycoprotein and pregnancy-specific glycoprotein B. These results suggest that together these glycoproteins represent members of a binucleate cell-derived family of pregnancy-associated molecules in the ruminant placenta.	UNIV MELBOURNE,SCH VET SCI,CTR ANIM BIOTECHNOL,PARKVILLE,VIC 3052,AUSTRALIA; CLIN RES CTR,GLYCOCONJUGATES SECT,HARROW HA1 3UJ,MIDDX,ENGLAND	University of Melbourne	ATKINSON, YH (corresponding author), UNIV ADELAIDE,DEPT OBSTET & GYNAECOL,ADELAIDE,SA 5001,AUSTRALIA.		Hounsell, Elizabeth F/C-5177-2008					ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; BOHN H, 1971, ARCH GYNAKOL, V210, P440, DOI 10.1007/BF01628222; CHAI WG, 1992, EUR J BIOCHEM, V207, P973, DOI 10.1111/j.1432-1033.1992.tb17132.x; CHAUDHURI TR, 1987, PREP BIOCHEM, V17, P93, DOI 10.1080/00327488708062478; CORFIELD AP, 1982, SIALIC ACIDS CHEM ME, P5; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1230; ENDO T, 1988, J BIOCHEM-TOKYO, V103, P182, DOI 10.1093/oxfordjournals.jbchem.a122228; ENDO Y, 1979, J BIOCHEM-TOKYO, V85, P669; FENDERSON BA, 1984, J EXP MED, V160, P1591, DOI 10.1084/jem.160.5.1591; GOGOLINEWENS KJ, 1986, PLACENTA, V7, P243, DOI 10.1016/S0143-4004(86)80162-X; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; HIGASHI H, 1977, BIOCHEM BIOPH RES CO, V79, P388, DOI 10.1016/0006-291X(77)90169-3; HORNE CHW, 1976, EXPERIENTIA, V32, P1197, DOI 10.1007/BF01927624; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; KAWASAKI T, 1976, J BIOL CHEM, V251, P1296; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CS, 1986, J REPROD FERTIL, V78, P653; LYNCH R A, 1992, Biology of Reproduction, V46, P73; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORGAN G, 1987, J CELL SCI, V88, P503; MURRAY FA, 1978, BIOL REPROD, V19, P15, DOI 10.1095/biolreprod19.1.15; PAXTON RJ, 1987, P NATL ACAD SCI USA, V84, P920, DOI 10.1073/pnas.84.4.920; Reimers TJ, 1985, BIOL REPROD S1, V32, P65; SEGERSON E C, 1988, Journal of Animal Science, V66, P420; SMITH PL, 1992, J BIOL CHEM, V267, P19140; TAKAMOTO M, 1989, J BIOCHEM-TOKYO, V105, P742, DOI 10.1093/oxfordjournals.jbchem.a122738; TAKAMOTO M, 1989, J BIOCHEM-TOKYO, V106, P228, DOI 10.1093/oxfordjournals.jbchem.a122837; TAKASAKI S, 1980, J BIOCHEM-TOKYO, V88, P1587, DOI 10.1093/oxfordjournals.jbchem.a133133; TATARINOV Y S, 1970, Byulleten' Eksperimental'noi Biologii i Meditsiny, V69, P66; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WASSARMAN PM, 1987, ANNU REV CELL BIOL, V3, P109, DOI 10.1146/annurev.cellbio.3.1.109; WATANABE S, 1988, BIOCHEM BIOPH RES CO, V152, P762, DOI 10.1016/S0006-291X(88)80103-7; WATANABE S, 1988, J BIOL CHEM, V263, P2049; WOODING FBP, 1992, PLACENTA, V13, P101, DOI 10.1016/0143-4004(92)90025-O; XIE SC, 1991, P NATL ACAD SCI USA, V88, P10247, DOI 10.1073/pnas.88.22.10247; YAMASHITA K, 1983, J BIOL CHEM, V258, P4753; ZOLI AP, 1991, BIOL REPROD, V45, P1, DOI 10.1095/biolreprod45.1.1	38	49	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1993	268	35					26679	26685						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	MK425	8253801				2022-12-27	WOS:A1993MK42500097
